program 2 0 1 4 book Pre-meeting Courses: Friday, November 14 Saturday, November 15, 2014 Annual Scientific Sessions: Saturday, November 15 Wednesday, November 19, 2014 Exhibits: Sunday, November 16 Tuesday, November 18, 2014
IMPORTANT LOCATIONS ACR Office... 260; Telephone: (617) 954-3940 Attendee Lounge... Ballroom Lobby Business Center... Level 1: North Lobby Career Connection... Exhibit Hall A: Discovery Center (Booth #731) Child Care.... Call for Location; Telephone: (617) 954-3451 Coat/Baggage Check.... Level 1: Northeast Lobby A (near 154) Concierge Center... Level 1: North Lobby Discovery Center.... Exhibit Hall A (Booth #731) Exhibit Hall... Exhibit Hall A First Aid... Level 1: North Lobby Foundation Booth... Exhibit Hall A: Discovery Center (Booth #731) Foundation Donors Lounge.... Boardroom (Suite 201) Hotel Reservations... Exhibit Level: Registration Industry-Supported Symposia Information... Level 1: North Lobby Innovation Theater.................................. Exhibit Hall A (Booths #139 and #1401) Lost and Found... ACR Office (260) Membership Booth... Exhibit Level: Registration Newsroom.... 252; Telephone: (617) 954-3943 Nursing Mothers Room... 162-A Overflow Rooms.... 109, 204 and 259 Poster Hall.... Exhibit Hall B Prayer Room... 106 Recharge Areas... Attendee Lounge, Technology Center and Wi-Fi Way Registration... Exhibit Level: East Registration Restaurant Reservations.............................. Level 1: North Lobby Ribbon Distribution... Exhibit Level: Registration Shuttle Bus... Level 1 (near 156) Simple Tasks... Exhibit Hall A: Discovery Center (Booth #731) Speaker Ready Room... 206 Technology Center... Level 1: North Lobby Visitor Information... Level 1: North Lobby Wheelchairs... Order through ScootAround, Inc.; Telephone: (888) 441-7575 Wi-Fi Way... Exhibit Hall A Special Needs If you require special arrangements, please contact the ACR Office (260); Telephone: (617) 954-3940. Emergency Contact Information Space is provided on the back of your badge to list name and telephone numbers of your emergency contacts. Please complete this information before inserting your badge in your badge holder. *All important locations are located in the Boston Convention and Exhibition Center.
program 2 0 1 4 book ABOUT THE ANNUAL MEETING Participation Statement This Annual Meeting is sponsored by the American College of Rheumatology for educational purposes only. The material presented is not intended to represent the only or the best methods appropriate for the medical conditions being discussed, but rather is intended to present the opinions of the authors or presenters, which may be helpful to other healthcare professionals arriving at their own conclusions and consequent application. Attendees participating in this medical education program do so with full knowledge that they waive any claim they may have against the College for reliance on any information presented during these educational activities. The College does not guarantee, warrant or endorse any commercial products or services. The ACR s CME purpose is to provide comprehensive education to improve the knowledge and performance of physicians, scientists and other health professionals in order to improve the quality of care in those with or at risk for arthritis and rheumatic and musculoskeletal diseases. The Annual Meeting program s content was developed through a planning process that included a practice gap analysis that identified educational needs in knowledge, competence and/or performance. Planners took professional activities, practice setting, ABIM recertification requirements and physician attributes into account and have designed this activity to obtain desired outcomes in terms of improved physician competence and performance. Global Learning Objectives At the conclusion of the 2014 ACR/ARHP Annual Meeting, participants should be able to: Identify recent developments in the diagnosis and management of patients with rheumatic diseases; Outline new technologies for the treatment of rheumatologic problems; Describe potential challenges in the delivery of care to patients with rheumatic diseases and to specify possible solutions; Utilize new research data to improve the quality of care of patients with rheumatic diseases; and Summarize recent rheumatology research findings. Printing of this publication is supported by Amgen, Inc. This publication was printed by an FSC validated printer on eco-friendly paper.
TABLE OF CONTENTS POLICIES Copyright Materials Policy...11 Photographs and Video Recording Policy...11 Media...11 Embargo Policy...12 Abstract Reprint Policy...12 MEETING INFORMATION Cell Phones, PDAs & Other Electronic Devices...13 Children...13 Child Care...13 Nursing Mothers Room...13 Exhibit Hall...13 Meeting Room Capacity/Imortant First Safety Information...13 Photoograpy and Videotaping...13 Name Badges...13 No Smoking...13 MEETING NAVIGATION GUIDE Tracks and State CME Designations...14 Session Formats...14 Abstract Formats...14 Abstract Categories...14 MEETING SERVICES Annual Meeting App...17 Discovery Center...17 Membership Booth...18 Lost and Found...18 Newsroom...18 Attendee Lounge...18 Concierge Center...18 Registration...18 Shuttle Bus...20 Speaker Ready Room...20 Wi-Fi Way and Recharge Access...20 Rheumatology Research Foundation Donors Lounge...20 SPECIAL OFFERS SessionSelect...19 What Would Make the Meeting Better?...20 Medical Bag...20 POSTER SESSIONS Poster Session Presenter Instructions...21 Poster Presenter No-shows...21 Guided Poster Tours...21 ACR/ARHP Annual Meeting Program Pre-Meeting Program Friday, November 14, 2014 Pre-Meeting Courses ACR Musculoskeletal Ultrasound Course for Rheumatologists Day One of Two...22 ACR Advanced Rheumatology Coding Course: Developing Experts in Rheumatology Coding and ICD-10-CM...23 ACR Basic Research Conference: Emerging Perspectives on the Microbiome in the Rheumatic Diseases Day One of Two...23 ACR Clinical Research Conference: Patient-Centered Outcomes in Rheumatology Day One of Two...24 ACR/ABIM Maintenance of Certification Learning Session 2014 Update in Rheumatology...25 Saturday, November 15, 2014 Pre-Meeting Courses ACR Musculoskeletal Ultrasound Course for Rheumatologists Day Two of Two...25 ACR Clinical Research Conference: Patient-Centered Outcomes in Rheumatology Day Two of Two...26 ACR Practice Management Pre-meeting Course...27 ACR Review Course...28 ACR Basic Research Conference: Emerging Perspectives on the Microbiome in the Rheumatic Diseases Day Two of Two...29 ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions...30 AAMC Medical Education Research Certificate (MERC) Workshop...31 Scientific Sessions ACR/ARHP Opening Lecture and Awards Opening Lecture: P4 Medicine Is Transforming Health Care: A Longitudinal, Framingham-like Study of 100,000 Well Patients Over 20-25 Years...31 ACR/ARHP Opening Reception...31 Sunday, November 16, 2014 ACR Sessions Age Before Beauty: Colchicine, Aspirin, Methotrexate and Their Mechanisms of Action...31 Pediatric Rheumatology Town Hall...32 Year in Review...32 ACR/ARHP Networking Event ACR/ARHP First-time Attendee Orientation...32 ACR Meet the Professor Sessions Basic Immunology for Clinical Rheumatologists (001)...32 Crystal: Diagnosis and Management of Gout (002)...32 Cutaneous Vasculitis (003)...33 Fibromyalgia 2014: Update on Management (004)...33 Macrophage Activation Syndrome (005)...33 Pain: Evaluation and Treatment of Back Pain (006)...33 Psoriatic Arthritis (007)...33 Reactive Arthritis: An Update (008)...33 Rheumatoid Arthritis: Challenging Cases (009)...33 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (010)...33 ACR Workshops Joint Injection Techniques (201)...33 Nail Calicoscopy (202)...34 Tai Chi in Rheumatic Disease (203)...34 2 2014 Program Book
TABLE OF CONTENTS ACR Sessions CARE: Maintenance of Certification Session One of Three Vasculitits...34 Current Understanding of Malignancies in Connective Tissue Diseases...34 Ethics and Rheumatology...34 Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...34 Osteoporosis: Current Concepts for the Clinician...35 Practice Issues: Health Care Bounty Hunters: A Closer Look at RACs, Audits and Medical Documentation...35 The Microbiome in Health and Disease...35 When Pills Are Not Enough: Multidisciplinary Approaches to Pediaric Pain and Hyperrmobility...35 ACR Poster Session A and Poster Tours Abstracts (#1-814)...36 ACR Sessions ACR Immunology Update: New Immunology of the Spondyloarthropathies...36 Advocacy: Meet the Expert...36 Sarcoidosis in 2014...36 Social Media Boot Camp: Twitter Basics...37 ARHP Sessions ARHP Keynote Address: Happiness From the Inside Out...37 Exhbits and Innovation Theater See page 238 for the complete Innovation Theater Listing. ACR Workshops Beyond Musculoskeletal Ultrasound for Rheumatologists (204)...37 Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (205)...37 Histopathology of Rheumatic Lung Disease (206)....................38 Synovial Fluid Analysis and Crystal Identification (207)...38 ACR Sessions Bone Biology...38 New ACR Recommendations for the Management of Rheumatoid Arthritis...38 ARHP Sessions Affordable Care Act...38 Immunology Boot Camp I: The Basics of Targeted Therapies...38 What Can Brain Imaging Tell Us About Pharmacologic and Non-Pharmacologic Treatment of Chronic Pain?...38 ACR Plenary Session I: Discovery 2014 Abstracts (#815-819)...39 ARHP Networking Event ARHP Networking Forum...42 ACR Meet the Professor Sessions Ankylosing Spondylitis: 2014 Update (011)...43 Ankylosing Spondylitis: Disease Modification (012)...43 Dermatological Manifestations of Rheumatic Diseases (013)...43 Hereditary Angioedema Update (014)...43 Pediatric Systemic Lupus Erythematosus (015)...43 Rheumatoid Arthritis: Biological Agents (016)...43 Systemic Lupus Erythematosus: Novel Treatments (017)...43 Vaccinations for Patients on Biologic Therapies (018)...43 Vasculitis: Update (019)...44 What is Not Central Nervous Angiitis: Making the Right Diagnosis (020)...44 ACR Sessions ACR Knowledge Bowl: Preliminary Round...42 Avoiding Electronic Health Record Errors and Their (Sometimes) Critical Consequences...44 Axial Spondyloarthritis Guidelines...44 Gout Management in 2014...44 How the Gut Primes the Immune System...44 Practice Issues: The Road to I10...44 Rheumatology Research Foundation Memorial Lectureship to Honor Dr. Stephen E. Malawista, MD: Innate Immunity at the Core of Rheumatic Disease...45 The Butterfly Effect: Lupus Rashes and Their Mimics...45 ACR Workshops Advanced Musculoskeletal Ultrasound (208)...45 Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (209)...45 ACR Sessions Autoimmunity in Immunodeficiency...45 Educator: Medical Education: The Year in Review...45 New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 The Great Debate: Belimumab for the Treatment of Systemic Lupus Erythematosus...46 ACR Concurrent Abstract Sessions Epidemiology and Public Health I: Drug and Vaccine Safety (#820-825)...46 Metabolic and Crystal Arthropathies I: Clinical Aspects (#826-831)...47 Miscellaneous Rheumatic and Inflammatory Diseases (#832-837)...47 Rheumatoid Arthritis Clinical Aspects I: Cardiovascular Disease Risk (#838-843)...48 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis Malignancy and Infection (#844-849)...48 Spondylarthropathies and Psoriatic Arthritis I Novel Treatments Axial Spondyloarthritis (#850-855)...49 Systemic Lupus Erythematosus Animal Models (#856-861)...50 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Cardiovascular Disease and Pregancy (#862-867)...50 Systemic Lupus Erythematosus Human Etiology and Pathogenesis I: Pathways of Inflammation/Injury (#868-873)...51 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics I: Systemic Sclerosis, Advances in Therapy (#874-879)...51 Vasculitis I (#880-885)...52 ARHP Sessions Google Minefield: Empowering Patients to Evaluate Online Resources...53 2014 Program Book 3
TABLE OF CONTENTS Practical Practice Management Session One: Improve Quality and Efficiency...53 Sports Medicine for the Rheumatology Provider...53 Young Adults with Rheumatic Disease: The Patient Perspective...54 ARHP Concurrent Abstract Session Exemplary Abstracts (#886-891)...54 ACR Workshops Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (210)...55 Muscle Involvement in Rheumatic Diseases (211)...55 Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (212)...55 Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (213)...55 ACR Sessions Therapeutic Targeting of the Innate Immune System...55 Thieves Market: Show Me Your Best Cases...55 ACR Concurrent Abstract Sessions Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes I: Research Perspectives (#892-897)...56 Health Services Research: Risk Assessment and Outcomes of Rheumatic Disease (#898-903)...56 Imaging of Rheumatic Diseases: Ultrasound (#904-909)...57 Muscle Biology,Myositis and Myopathies (#910-915)...58 Osteoporosis and Metabolic Bone Disease Clinical Aspects and Pathogenesis: Clinical Osteoporosis: Treatment and Safety (#916-921)...58 Pain: Basic and Clinical Aspects I (#922-927)...59 Pediatric Rheumatology Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis (#928-933)...60 Rheumatoid Arthritis Animal Models I (#934-939)...61 Rheumatoid Arthritis Clinical Aspects II: Remission and De-escalation of Therapy (#940-945)...61 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis Early in Development (#946-951)...62 Spondylarthropathies and Psoriatic Arthritis II Novel Treatments Psoriatic Arthritis (#952-957)...63 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Lupus Nephritis (#958-963)...63 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics I (#964-969)...65 ACR Meet the Professor Sessions Crystal: Diagnosis and Management of Gout (021)...66 Infections with Biologics (022)...66 Inflammatory Eye Disease/Uveitis (023)...66 Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (024)...66 Polymyalgia Rheumatica (025)...66 Pulmonary Hypertension in the Rheumatic Diseases (026)...66 Rheumatoid Arthritis: Biological Agents (027)...66 Rheumatology Practice 101: Starting Out in Practice for the Graduating Fellow (028)...67 Systemic Lupus Erythematosus: Novel Treatments (029)...67 Vitamin D and Bone Health (030)...67 ACR/ARHP Combined Abstract Session ACR/ARHP Combined Abstract Session: Epidemiology and Public Health (#970-975)...67 ARHP Sessions Say What? : Implications of Adolescent Development and Behavior in Communicating With Health Care Providers..........68 Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Multidisciplinary Management of Scleroderma...68 Practical Practice Management Session Two: Navigate HIPAA and Prevent Audits...68 ARHP Concurrent Abstract Session Osteoarthritis (#976-981)...68 Industry-Supported Post-Meeting Symposia...69 Monday, November 17, 2014 ACR Sessions Educator: Cultivating the Competent Medical Educator: A Growing Concern...69 Meniscus Biology in Osteoarthritis...69 Rheumatology Research Foundation Paul Klemperer, MD Memorial Lectureship: Gene-Environment Interactions as a Basis for Unravelling Adaptive Immunity and Preparing for Tolerizing Therapies in Rheumatoid Arthritis...69 ARHP Sessions Stats Boot Camp: The Effect Size: What Is It and How Can You Use It?...70 Update on Findings from Large Registries: Emphasis on Health Disparities in Rheumatioid Arthritis...70 What Are Biosimilars?...70 ACR Meet the Professor Sessions Ankylosing Spondylitis: 2014 Update (031)...70 Basic Immunology for Clinical Rheumatologists (032)...70 Controversies in Sjögren s Syndrome (033)...70 Dermatological Manifestations of Rheumatic Diseases (034)...70 Osteoarthritis: Update 2014 (035)...71 Pregnancy and Rheumatic Diseases (036)...71 Reactive Arthritis: An Update (037)...71 Rheumatoid Arthritis: Challenging Cases (038)...71 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (039)...71 Vasculitis: Update (040)...71 ACR/ARHP Workshops Advanced Musculoskeletal Ultrasound (214)...71 Complementary and Alternative Therapies in Rheumatic Disease (215)...71 Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (216)...72 The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Disease-Specific Measurements (217)...72 4 2014 Program Book
TABLE OF CONTENTS ACR Sessions CARE: Maintenance of Certification Session Two of Three...72 Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of Disease-modifying Antirheumatic Drugs (DMARDs) and Biologics in the Perioperative Period...72 Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...72 Practical Use of Registries...73 Practice Issues: Practice Success in an Environment of Transition...73 Strategies for Academic Success: The Roadmap From Mentee to Mentor...73 Systems Biology of Lupus Nephritis...73 The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 ACR/ARHP Poster Session B, Thieves Market Posters and Poster Tours Abstracts (#982 1793)...74 ACR Sessions Functional Genomics of Rheumatoid Arthritis: From Genes to Function to Therapy...75 Legislative Update: Chat with Congress...75 Prosthetic Device Infections, Or Infection as a Threat to the Bionic Man...75 Social Media Boot Camp: Blogging for Beginners...75 ARHP Session ARHP Distinguished Lectuer: Maintaining Health and Well-Being Despite Living with a Rheumatic Disease...75 Exhbits and Innovation Theater See page 238 for the complete Innovation Theater Listing. ACR Workshops Histopathology of Vasculitis (218)...76 Knee Braces, Foot Orthoses, and Shoe Gear for Managing Knee Osteoarthritis (219)...76 Musculoskeletal Ultrasound (220)...76 Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (221)...76 ACR Sessions ACR Immunology Update: Innate Lymphoid Cells...76 ACR Knowledge Bowl: Final Round...76 ARHP Sessions Evidence of the Benefits and Risks of Cannabis and Cannabinoids for Treating Chronic Pain...77 Immunology Boot Camp II: The Basics of Autoimmunity and Immunodeficiency...77 Stats Boot Camp: Statistical Analysis of Ordinal Data...77 ACR Plenary Session II: Discovery 2014 Abstracts (#1794-1799)...77 ARHP Networking Event ARHP Networking at Noon...81 ACR Meet the Professor Sessions Adult Inflammatory Myopathy (041)...81 Pediatric Rheumatology for Adult Rheumatologists (042)...81 Psoriatic Arthritis (043)...81 Rheumatoid Arthritis: Biological Agents (044)...82 Rheumatoid Arthritis: Challenging Cases (045)...82 Scleroderma Mimics (046)...82 Still s Disease and Autoinflammatory Syndromes (047)...82 Systemic Lupus Erythematosus: Central Nervous System (048)...82 Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (049)...82 Vasculitis Mimics (050)...82 ACR Sessions Classification Criteria for Gout...82 Classification Criteria for Myositis...83 Neonatal Lupus: From Bench to Bedside...83 Rheumatology On the Street...83 Telomeres, Telomerase and the Aging Immune System...83 ACR Workshops Joint Injection Techniques (222)...83 Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (223)...83 Synovial Fluid Analysis and Crystal Identification (224)...83 ACR Sessions Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk...84 Forefronts in Lupus Nephritis...84 Insight into Lung Fibrosis...84 ACR Concurrent Abstract Sessions Epidemiology and Public Health II: Osteoarthritis, Sedentary Behavior and more (#1800-1805)...84 Health Services Research: Improving Clinical Practice (#1806-1811)...85 Innate Immunity and Rheumatic Disease (#1812-1817)...85 Osteoarthritis Clinical Aspects I: Imaging in Osteoarthritis (#1818-1823)...86 Pediatric Rheumatology Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus (#1824-1829)...86 Quality Measures and Quality of Care (#1830-1835)...87 Rheumatoid Arthritis Clinical Aspects III: Malignancies, Vaccinations, Pregnancy and Surgery (#1836-1841)...88 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy III: Innovative Therapeutic Strategies in Rheumatoid Arthritis (#1842-1847)...89 Spondylarthropathies and Psoriatic Arthritis III Clinical Aspects Psoriatic Arthritis (#1848-1853)...90 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Complications of Systemic Lupus Erythematosus (#1854-1859)...90 Vasculitis II (#1860-1865)...91 ACR/ARHP Combined Abstract Session ACR/ARHP Combined Abstract Session: Pediatric Rheumatology (#1866-1871)...92 ARHP Sessions Alternative Medicine: Presenting the Evidence for Rheumatic Conditions...92 Biomarkers in Rheumatic Care...93 2014 Program Book 5
TABLE OF CONTENTS 6 Stats Boot Camp: A Call to Aims for Researchers! An Interactive Session to Obtain Feedback on Your Specific Aims Section...93 Thriving with Rheumatic Disease: Cultivating Resilience...93 ACR/ARHP Workshops Dermatopathology of Rheumatic Diseases (225)...93 Joint Injections (Knee, Ankle, Shoulder and Wrist) (226)...93 MDHAQ/RAPID3 and RHEUMDOC: Quantitative, Standard, Scientific Summaries of Patient History and Physical Exam, toward Better Clinical Decisions and Outcomes (227)...94 Musculoskeletal Ultrasonography: Basic (228)...94 ACR Session Clinicopathologic Conference...94 ACR Sessions Career Opportunities in Rheumatology: Making a Choice...94 Curbside Consults Ask the Experts...94 Fibrotic Complications of Scleroderma...95 The Role of Bone in the Pathogenesis of Osteoarthritis...95 Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management...95 ACR Concurrent Abstract Sessions Epidemiology and Public Health III: Gout and Systemic Lupus Erythematosus (#1872-1877)...95 Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes II: Clinical Perspectives (#1878-1883)...96 Genetics, Genomics and Proteomics I: Epigenetic Mechanisms in Autoimmunity (#1884-1889)...96 Imaging of Rheumatic Diseases: X-Ray, MRI and CT (#1890-1895)...97 Pediatric Rheumatology Pathogenesis and Genetics (#1896-1901)...98 Rheumatoid Arthritis Clinical Aspects IV: Promising Biomarkers (#1902-1907)...99 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy IV: Safety of Biologics and Small Molecules in Rheumatoid Arthritis Cardiovascular and Other Systems (#1908-1913)...99 Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology: From Genes to Cytokines (#1914-1919)...100 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Biomarkers in Systemic Lupus Erythematosus (#1920-1925)...100 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis (#1926-1931)...101 ACR Meet the Professor Sessions Antiphospholipid Syndrome (051)...102 Behçet s Syndrome (052)...102 Immunodeficiency Syndromes (053)...102 Infections with Biologics (054)...103 Myopathy: Issues in Diagnosis and Treatment (055)...103 Pulmonary Manifestations of Rheumatic Disease (056)...103 Raynaud s and Digital Ischemia (057)...103 Safety of Drugs Used to Treat Rheumatoid Arthritis (058)...103 Systemic Lupus Erythematosus: Lupus Nephritis (059)...103 Vasculitis Factors That Influence Disease Patterns (060)...103 2014 Program Book ARHP Sessions Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation...103 From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases...104 Role of Nutrition in Rheumatic Diseases...104 The Emerging Demand for Medicinal Cannabis by Young Adults and Beyond...104 ARHP Concurrent Abstract Session Health Disparities/Social Determinants of Health (#1932-1937)...104 Study Groups ACR Musculoskeletal Ultrasound Study Group...105 Antiphospholipid Syndrome Task Force Study Group...105 Capillaroscopy in Rheumatic Diseases Study Group...105 Childhood Vasculitis Study Group................................106 Clinical Anatomy Study Group...106 Crystal Study Group...106 Degos Disease Study Group...106 Hypermobility Study Group...106 Interstitial Lung Disease Group...106 Macrophage Activation Syndrome (MAS) Study Group...107 Myositis Study Group...107 Osteoarthritis Study Group...107 Pediatric Rheumatologists Interested in Medial Education Study Group...107 The Why and How of Disease Criteria Study Group...107 Veterans Affairs Rheumatology Study Group...107 Tuesday, November 18, 2014 ACR Sessions Glycosylation and Glycan Binding Proteins in Immune Function...108 Hepatitis C in 2014...108 Patient Access to Biologics Across the Globe...108 ARHP Sessions Clinical Features of Central Nervous System Lupus and Diagnosis of Cognitive Deficits and Psychiatric Disorders...108 Muscle and Adipose Tissue in Rheumatic Diseases: Location is Everything...108 ACR Meet the Professor Sessions Antiphospholipid Syndrome (061)...109 Controversies in Sjögren s Syndrome (062)...109 Footwear in Orthoarthritis (063)...109 Osteoporosis: Novel Treatments (064)...109 Pediatrics: Periodic Fevers in Children (065)...109 Rheumatoid Arthritis: Outcome Measures in Clinical Practice (066)...109 Safety of Drugs Used to Treat Rheumatoid Arthritis (067)...109 Systemic Lupus Erythematosus: Central Nervous System (068)...109 Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (069)...109 Vasculitis Factors That Influence Disease Patterns (070)...110 ACR/ARHP Workshops Advanced Musculoskeletal Ultrasound: Image Optimization and Pathology Recognition (229)...110 Basic Statistical Concepts for the Medical Researcher (230)...110
TABLE OF CONTENTS Joint Injections (Knee, Ankle, Shoulder and Wrist) (231)...110 Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (232)...110 ACR Sessions Bioenergetics and Energy Regulation...110 CARE: Maintenance of Certification Session Three of Three...110 Educator: Direct Observation of Clinical Skills: Educationally Indicated, Therapeutically Required...111 Macrophages Gone Wild...111 Myositis Mimics: Clinical and Molecular Diagnosis...111 Rheumatology Research Foundation: Special Session...111 Risk and Risk Management of Cardiovascular Disease in Patients with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases...111 ACR/ARHP Poster Session C, Late-Breaking and Thieves Market Posters and Poster Tours... 112 Abstracts (#1938 2780)...112 ACR Sessions ACR-EULAR R Guidelines...113 Metainflammation...113 Rheumatology Research Foundation Oscar S. Gluck Memorial Lectureship: Emerging Therapies in Bone Diseases: Cellular Basis and Challenges...113 ARHP Sessions Mycobacterium Infections in Immunocompromised Patients...113 RheumChat...113 Stats Boot Camp: The Prevalence Ratio as an Alternative to the Odds Ratio for Cross-Sectional Studies...114 Exhbits and Innovation Theater See page 238 for the complete Innovation Theater Listing ACR Workshops Musculoskeletal Ultrasound (233)...114 Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (234)...114 X-Ray Challenges in Rheumatic Diseases (235)...114 ACR Sessions Mesenchymal Stem Cells: Biology and Use in Rheumatic Diseases.....114 Protecting Bone Health in Pediatric Rheumatic Diseases...114 ARHP Sessions Immunology Boot Camp III: Applying Principles of Immunology to Treatment Decisions...115 Pathways to Resilience: Biopsychosocial Mechanisms for the Generation of Positive Affect in Chronic Pain...115 Providing Evidence for Mid-Level Providers in Rheumatology Practice...115 ACR Plenary Session III: Discovery 2014 Abstracts (#2781-2786)...115 ACR Meet the Professor Sessions Antiphospholipid Syndrome (071)...119 Challenging Cases in Osteoporosis Management (072)...119 Crystal: Diagnosis and Management of Gout (073)...119 Non-surgical Treatments for Osteoarthritis (074)...119 Osteoarthritis: Update 2014 (075)...119 Psoriatic Arthritis (076)...119 Spondylarthropathy: An Update (077)...119 Systemic Lupus Erythematosus: Lupus Nephritis (078)...119 Temporal Arteritis (079)...119 Vaccinations for Patients on Biologic Therapies (080)...120 ACR Sessions Clinical Issues Associated with the Use of Methotrexate...120 Hench Lectureship: Why Steroids Work in Some Inflammatory Diseases But Not in Others...120 New Regulatory T Cells...120 Uncovering the Role of Connective Tissues in Chronic Low Back Pain: From Bedside to Bench to Bedside...120 ARHP Sessions Etiology and Management of Peripheral Neuropathy in Patients with Rheumatic Disease...120 Pharmacotherapy: What s New in Rheumatology...120 Study Groups ACR-EULAR Study Group: Toward A New Understanding of Myositis Through International Collaboration...121 Autoantibodies in Diagnosis and Follow-Up of Rheumatic Diseases Study Group...121 Behçet s Disease Study Group...121 Biosimilars in Theumatology: Update Study Group...121 Closing the Gap Psoriasis to Psoriatic Arthritis Study Group...121 Global Musculoskeletal Health Initiatives Study Group...121 High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Imaging in Arthritis Study Group...122 Juvenile Arthritis Workgroup (JAW) Study Group...122 Latin American Study Group...122 Neuroendocrine Immunology...122 Pediatric Rheumatology Imaging Study Group...122 Polymyalgia Rheumatica Study Group...122 Sjögren s Syndrome Study Group...123 ACR/ARHP Workshops Dermatopathology of Rheumatic Diseases (236)...123 Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (237)...123 Musculoskeletal Ultrasonography: Basic (238)...123 The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Disease-specific Measurements (239)...123 ACR Session ACR Business Meeting...124 ACR Sessions Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session...124 Novel Regulatory Cell Subsets...124 Psoriatic Arthritis: Skin, Entheses and Joints...124 ACR Concurrent Abstract Sessions ACR Late-Breaking Abstract Session...124 2014 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship (#2787-2791)...125 Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis (#2792-2797)...125 2014 Program Book 7
TABLE OF CONTENTS Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I (#2798-2803)...126 Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease (#2804-2809)...126 Rheumatoid Arthritis Clinical Aspects V: Mortality and Other Outcomes (#2810-2815)...127 Rheumatoid Arthritis Human Etiology and Pathogenesis I: Mechanisms of Joint Damage 2013 Lee C. Howley, Sr. Prize (#2816-2820)...127 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy V: Novel Therapies in Rheumatoid Arthritis Late in Development (#2821-2826)..............................128 Spondylarthropathies and Psoriatic Arthritis IV Clinical Aspects Axial Spondyloarthritis (#2827-2832)...129 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Novel Therapies for Systemic Lupus Erythematosus (#2833-2838)...129 Systemic Lupus Erythematosus Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis (#2839-2844)...130 T cell Biology and Targets in Autoimmune Disease (#2845-2850)...131 Vasculitis III (#2851-2856)...131 ACR/ARHP Combined Abstract Session ACR/ARHP Combined Abstract Session: Rehabilitation (#2857-2862)...133 ARHP Sessions Brief Action Planning (BAP): A Motivational Interviewing (MI) Technique to Enhance Patient Self-Management and Improve Outcomes...133 Osteoporosis: Emerging Treatments Both Pharmacological and Non-Pharmacological...134 The Psychosocial Impact and Treatment Options for Patients with Neuropsychiatric Lupus and Their Caregivers...134 Treatment Considerations in Chronic Pain...134 ACR Workshops Getting Electronic Health Records Right (240)...134 Systemic Sclerosis: How to Perform Skin Scores (241)...135 Ultrasound Injection Guidance (242)...135 ACR Sessions Autophagy in Rheumatic Diseases...135 Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management...135 Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond...135 ACR Concurrent Abstract Sessions Antiphospholipid Syndrome (#2863-2868)...135 B cell Biology and Targets in Autoimmune Disease (#2869-2874)...137 Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II (#2875-2880)...137 Education (#2881-2886)...138 Epidemiology and Public Health IV: Rheumatoid Arthritis Pathogenesis (#2887-2892)...138 Osteoarthritis Clinical Aspects II: Osteoarthritis Risk Factors and Therapies (#2893-2898)...139 Pediatric Rheumatology Clinical and Therapeutic Aspects: Miscellaneous Pediatric Rheumatic Diseases (#2899-2904)...140 Rheumatoid Arthritis Animal Models II (#2905-2910)...140 Rheumatoid Arthritis Clinical Aspects VI: Impact of Treatment and Other Interventions (#2911-2916)...141 Rheumatoid Arthritis Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes (#2917-2922)...142 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy VI: Biomarkers and Predictors of Rheumatoid Arthritis Disease Response and Outcomes (#2923-2928)...142 Sjögren s Syndrome I: Clinical Perspectives (#2929-2934)...143 Spondylarthropathies and Psoriatic Arthritis V Clinical Aspects and Treatment (#2935-2940)...144 ACR Meet the Professor Sessions Adult Inflammatory Myopathy (081)...144 Behçet s Syndrome (082)...145 Calcium Crystal Arthritis (083)...145 Juvenile Dermatomyositis (084)...145 Myopathy: Issues in Diagnosis and Treatment (085)...145 Pregnancy and Rheumatic Diseases (086)...145 Pulmonary Manifestations of Rheumatic Disease (087)...145 Raynaud s and Digital Ischemia (088)...145 Rheumatoid Arthritis: Challenging Cases (089)...145 Temporal Arteritis (090)...145 ARHP Sessions Multidisciplinary Management of the Juvenile Idiopathic Arthritis Patient...146 Patient-Reported Outcomes Data for Comparative Effectiveness Research in Arthritis Care...146 State-of-the-Art Interventional Recommendations for Chronic Low Back Pain...146 Successful Aging in Rheumatic Disease...146 ARHP Concurrent Abstract Session Epidemiology/Public Health (#2941-2946)...147 Industry-Supported Post-Meeting Symposia... 147 Wednesday, November 19, 2014 ACR Sessions Co-Stimulation Pathways: Therapeutic Opportunities for the Rheumatic Diseases...147 Rheumatology Roundup: Highlights from the 2014 Annual Meeting...147 ARHP Sessions Physical and Occupational Therapy for Juvenile Dermatomyositis: Treatment Planning and Case Presentations...148 Rheumatic Manifestations of Malignancy...148 ACR Sessions Complement in Rheumatic Disease...148 Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside...148 Primary Angiitis of the Central Nervous System and Its Mimics...148 8 2014 Program Book
TABLE OF CONTENTS ACR Concurrent Abstract Sessions Biology and Pathology of Bone and Joint II: Cartilage Biology and Synovial Activation (#2947-2952)...149 Genetics, Genomics and Proteomics II: Genetics of Autoimmunity (#2953-2958)...149 Metabolic and Crystal Arthropathies II: Mechanisms of Disease (#2959-2964)...150 Pain: Basic and Clinical Aspects II/Orthopedics, Low Back Pain and Rehabilitation (#2965-2970)...151 Rheumatoid Arthritis Clinical Aspects VII: New Aspects of Monitoring Disease (#2971-2976)...152 Sjögren s Syndrome II: Insights into Pathophysiology (#2977-2982)...152 Spondylarthropathies and Psoriatic Arthritis VI Imaging and Biomarkers (#2983-2988)...153 Systemic Lupus Erythematosus Clinical Aspects and Treatment: CNS and Other Clinical Aspects (#2989-2994)...154 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics III: Updates in Predictors and Outcomes in Systemic Sclerosis (#2995-3000)...155 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics II (#3001-3006)...156 ARHP Sessions Exercise Adherence in Arthritis: The Role of Technology...156 Nothing About Us Without Us: Engaging Patients in Rheumatology Research...157 ARHP Concurrent Abstract Sessions Clinical Practice/Patient Care (#3007-3012)...157 Innovations in Rheumatologic Care (#3013-3018)...157 ACR Sessions Inflammation and Atherothrombosis...158 Advances in Molecular Profiling and Relevance to Autoimmune Disease...158 Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment...159 ARHP Sessions Work and Worker Health: Easy Accommodations Keep People With Arthritis Employed...159 Industry-Supported Post-Meeting Symposia...159 ACR Poster Session A Antiphospholipid Syndrome (#1-18)...160 Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling (#19-39)...160 Epidemiology and Public Health: Osteoporosis, Non-Inflammatory Arthritis and More (#40-73)...161 Genetics, Genomics and Proteomics I (#74-93)...161 Health Services Research (#94-118)...163 Imaging of Rheumatic Diseases: Ultrasound (#119-154)...163 Metabolic and Crystal Arthropathies: Clinical Aspects (#155-185)...165 Orthopedics, Low Back Pain and Rehabilitation (#186-199)...165 Osteoarthritis Clinical Aspects: Imaging and Biomechanics (#200-222)...166 Osteoporosis and Metabolic Bone Disease Clinical Aspects and Pathogenesis: Osteoporosis: Pathogenesis, Epidemiology and Diagnosis (#223-240)...167 Pain: Basic and Clinical Aspects (#241-268)...167 Pediatric Rheumatology Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis (#269-304)...168 Pediatric Rheumatology Pathogenesis and Genetics (#305-321)...169 Rheumatoid Arthritis Animal Models (#322-347)...170 Rheumatoid Arthritis Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity (#348-432)...170 Rheumatoid Arthritis Human Etiology and Pathogenesis (#433-456)...173 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis (#457-519)...174 Sjögren s Syndrome: Pathophysiology (#520-535)...176 Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment I (#536-602)...177 Spondylarthropathies and Psoriatic Arthritis Pathogenesis, Etiology (#603-633)...179 Systemic Lupus Erythematosus Animal Models (#634-664)...180 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Treatment and Management Studies (#665-719)...181 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics: Systemic Sclerosis Measures and Outcomes (#720-743)...182 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics (#744-774)...183 Vasculitis (#775-814)...184 ACR/ARHP Poster Session B B cell Biology and Targets in Autoimmune Disease: Rheumatoid Arthritis and Related Diseases (#982-1000)...185 Biology and Pathology of Bone and Joint: Cartilage, Synovium and Osteoarthritis (#1001-1026)...186 Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis (#1027-1050)...187 Epidemiology and Public Health (ACR): Rheumatoid Arthritis and Systemic Lupus Erythematosus Outcomes (#1051-1082)...187 Epidemiology and Public Health (ARHP): Epidemiology and Public Health (#1083-1092)...188 Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Clinical Focus (#1093-1120)...189 Genetics, Genomics and Proteomics II (#1121-1140)...189 Health Services Research (ACR) (#1141-1165)...190 Health Services Research (ARHP): Health Services Research (#1166-1168)...191 Imaging of Rheumatic Diseases: Magnetic Resonance Imaging (MRI) (#1169-1193)...191 Innate Immunity and Rheumatic Disease: Signaling Mechanisms (#1194-1213)...192 Metabolic and Crystal Arthropathies: Mechanisms of Disease (#1214-1224)...192 Miscellaneous Rheumatic and Inflammatory Diseases (#1225-1254)...193 2014 Program Book 9
TABLE OF CONTENTS 10 Muscle Biology, Myositis and Myopathies: Myositis Autoantibodies and Disease Phenotype (#1255-1273)...194 Osteoarthritis Clinical Aspects: Epidemiology and Pathogenesis (#1274-1293)...194 Pediatric Rheumatology Clinical and Therapeutic Aspects (ARHP): Pediatrics (#1294-1329)...195 Pediatric Rheumatology Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis (ACR) (#1330-1331)...196 Psychology/Social Sciences (ARHP) (#1332-1339)...196 Quality Measures and Quality of Care (#1340-1361)...196 Rheumatoid Arthritis Clinical Aspects (ACR): Comorbidities, Treatment Outcomes and Mortality (#1362-1443)...197 Rheumatoid Arthritis Clinical Aspects (ARHP): Clinical Practice/Patient Care (#1444-1453)...200 Rheumatoid Arthritis Human Etiology and Pathogenesis (#1454-1477)...200 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis (#1478-1541)...201 Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment II (#1542-1603)...203 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies (#1604-1626)...205 Systemic Lupus Erythematosus Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies (#1627-1673)...206 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics: Systemic Sclerosis, Diagnostic and Therapeutic Aspects (#1674-1703)...207 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics (#1704-1732)...208 T cell Biology in Rheumatoid Arthritis and Other Arthritis (#1733-1753)...209 Vasculitis (#1754-1793)...209 ACR/ARHP Poster Session C B cell Biology and Targets in Autoimmune Disease: Systemic Lupus Erythematosus and Related Diseases (#1938-1956)...211 Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis (#1957-1980)...211 Education (ACR) (#1981-2005)...212 Education (ARHP): Education/Community Programs (#2006-2013)...213 Epidemiology and Public Health (ACR): Rheumatoid Arthritis Pathogenesis and Treatment (#2014-2044)...214 Epidemiology and Public Health (ARHP) (#2045-2054)...214 Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Research Focus (#2056-2083)...214 Genetics, Genomics and Proteomics (#2084-2102)...215 Health Services Research (#2103-2125)...216 Imaging of Rheumatic Diseases: Various Imaging Techniques (#2126-2150)...217 Infections, Infection-related Biomarkers and Impact of Biologic Therapies (#2151-2163)...217 Innate Immunity and Rheumatic Disease: Mediators, Cells and Receptors (#2164-2185)...218 Miscellaneous Rheumatic and Inflammatory Diseases (#2186-2209)...218 2014 Program Book Muscle Biology, Myositis and Myopathies: Immunological Aspects of Inflammatory Myopathy (#2210-2229)...219 Osteoarthritis Clinical Aspects: Therapeutics (#2230-2252)...220 Osteoporosis and Metabolic Bone Disease Clinical Aspects and Pathogenesis: Osteoporosis: Treatment, Safety, and Long Term Outcomes (#2253-2268)...221 Pediatric Rheumatology Clinical and Therapeutic Aspects: Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and Miscellaneous Pediatric Rheumatic Diseases (#2269-2304)...221 Quality Measures and Quality of Care (#2305-2324)...222 Rehabilitation Sciences (ARHP) (#2325-2334)...223 Research Methodology (ARHP) (#2335-2338)...223 Rheumatoid Arthritis Animal Models (#2339-2364)...223 Rheumatoid Arthritis Clinical Aspects (ACR): Impact of Various Interventions and Therapeutic Approaches (#2365-2429)...224 Rheumatoid Arthritis Clinical Aspects (ARHP): Clinical Practice/Patent Care (#2430-2444)...226 Rheumatoid Arthritis Human Etiology and Pathogenesis (#2445-2466)...227 Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis (#2467-2530)...227 Sjögren s Syndrome: Clinical Science (#2531-2552)...230 Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment III (#2553-2618)...230 Systemic Lupus Erythematosus Clinical Aspects and Treatment: Epidemiology, Women s Health, Cardiovascular and CNS (#2619-2672)...232 Systemic Lupus Erythematosus Human Etiology and Pathogenesis: T and B Cell Signaling and Genetic Variants (#2673-2696)...234 Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics: Determinants of Disease, Classification and Response (#2697-2721)...235 T cell Biology in Lupus, Vasculitis, Myositis and Other Autoimmunity (#2722-2743)...235 Vasculitis (#2744-2780)...236 INNOVATION THEATER LISTING...238 INDUSTRY-SUPPORTED POST MEETING SYMPOSIA...239 CERTIFICATES OF CME CREDIT OR PARTICIPATION Accredidation Statements...246 Evaluations, CME Credit and Cerfiticates...246 When Claiming CME Credit...246 Conflict of Interest and Disclosure...246 RECOGNITIONS ACR/ARHP Annual Meeting Leadership...248 Exhibitors...252 Supporter Acknowledgements...256 INDICIES ACR/ARHP Annual Meeting Planning Committee Disclosures...258 ACR/ARHP Abstract Category Chair and Reviwer Disclosures...260 Invited Speaker Moderator Index...268 ACR/ARHP Abstract Author Index...288 ACR/ARHP Abstract Moderator Disclosure Index...346
The most comprehensive online collection of rheumatology-related images. Serving as a centralized resource for clinicians, researchers and health care professionals, the Rheumatology Image Bank provides invaluable assistance in self-study or the education of others. Start your visual exploration of rheumatology today at http://images.rheumatology.org! Stop by the ACR s Discovery Center, located in Exhibit Hall A (Booth #731), or the Concierge Center, located in the North Lobby, and speak with staff to learn more about the Rheumatology Image Bank and all it can offer you. The ACR would like to thank the following company for their generous support of the Rheumatology Image Bank: general information COPYRIGHT MATERIALS POLICY The Annual Meeting is a private event. Programs presented at the meeting are for the education of attendees and purchasers of recorded presentations as authorized by the American College of Rheumatology. Information displayed or presented at all sessions during the Annual Meeting is the property of the ACR or the presenter. Information may not be recorded, photographed, copied, photocopied, transferred to electronic format, reproduced or distributed without the written permission of the ACR and the presenter. Any use of the program content, which includes but is not limited to oral presentations, audiovisual materials used by speakers and program handouts, without the written consent of the ACR is prohibited. This policy applies before, during and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it. Use of American College of Rheumatology s Name The names, insignias, logos and acronyms of the ACR, the ARHP and the Rheumatology Research Foundation are proprietary marks. Use of the names in any fashion, by any entity, for any purpose, is prohibited without the written permission of the College. PHOTOGRAPHS AND VIDEO RECORDING POLICY As a courtesy to our presenters, ACR policy does not permit photographs or recordings during educational sessions, including poster sessions. The only exception to this is for registered media, who should review their registration materials for more information. MEDIA Credentialed media attend the Annual Meeting to cover stories for consumer, trade and other media outlets, and are easily identified by their black press ribbons. Media has access to all general sessions and limited access (at the discretion of speakers) to Meet the Professor and Workshop sessions. Media may use hand-held audio recorders and still cameras; moving video recording is also permitted with the permission of the presenter(s). The exception to this policy is that no photos or video are allowed in the Exhibit Hall. Press who would like general photos of the Exhibit Hall can obtain these after the meeting from the ACR. Attendees who have questions about the ACR s media policies should contact the ACR Public Relations department at pr@rheumatology.org. 2014 Program Book 11
general information EMBARGO POLICY Accepted abstracts are made available to the public online in advance of the meeting and are published in a special supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until 4:30 pm Eastern Time on Saturday, November 15, 2014. Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. ABSTRACT REPRINT POLICY Copyright law covers all Annual Meeting abstracts published by the American College of Rheumatology. All rights reserved. No abstracts may be reproduced in any form or by any means, except as permitted under section 107 and 108 of the United States Copyright Act, without the prior permission of the publisher. For the purposes of this statement, the term ACR abstracts refers to all Annual Meeting abstracts as published in Arthritis & Rheumatology and posted online, including the abstracts accepted for presentation during ARHP sessions and the latebreaking category. For the purposes of this statement, the term ACR posters refers to the accepted abstracts as presented during the Annual Meeting. All ACR posters are the property of the ACR or the presenting author and cannot be reproduced or distributed without written permission from the ACR and the presenting author. For the purposes of this statement, the term reproduce includes all forms of reproduction including, but not limited to, print, electronic and photographed formats. For the purposes of this statement, the term presenting author refers to the author who is designated as the individual who will present the work during the ACR Annual Meeting, as identified through the abstract submission process. Approval Process Excerpts of ACR abstracts or ACR abstracts in their entirety may not be reproduced without the prior written permission of the publisher. Permission requests and other permission inquiries should be addressed to: Permissions Department c/o John Wiley & Sons, Inc. 111 River Street Hoboken, NJ 07030 Fax: (201) 748-6008 www.wiley.com/go/permissions aa! Commercial entities seeking permission to reprint must obtain all materials from the author and/or publisher John Wiley & Sons, Inc. ACR cannot provide any materials. Reproducing ACR Abstracts and ACR Poster Presentations for Dissemination During the Annual Meeting Following approval (see approval process), an exhibiting organization may: Disseminate copies of individual ACR abstracts from its exhibit space. Booklets of abstracts (e.g., two or more) may not be produced. Disseminate information summaries (title/date/time/ poster number) of ACR abstracts from its exhibit space. Summaries may not reference company or product names. Requests for approval must be submitted in writing to abstractreprints@rheumatology.org. Presenting authors may disseminate individual copies of their ACR poster during their assigned poster presentation time. Dissemination must be limited to the area directly in front of their assigned poster space and may not interfere with other poster presentations. Reproducing ACR Abstracts and ACR Poster Presentations for Dissemination After the Annual Meeting Following approval (see approval process above), the ACR permits ACR abstracts to be reprinted and disseminated following the Annual Meeting. Booklets of abstracts (e.g., two or more) must include the following statement on the front of the booklet: Abstracts reprinted from the ACR/ARHP Annual Meeting held November 14-19, 2014. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by (insert name of supporting company). Booklets cannot contain corporate or product logos or any advertisements. No exceptions. 12 2014 Program Book
general information ACR Posters Following approval from the ACR and the presenting author, copies of ACR poster presentation images may be reproduced. IMPORTANT: The ACR does not retain and cannot provide poster presentation images. Requests to reproduce individual ACR posters or booklets of posters (e.g., two or more) must be submitted via e-mail to abstractprints@rheumatology.org. Poster reproduction requests must include the following: Abstract ID Number Abstract title Presenting author s name A copy of presenting author s written approval (Please Note: An e-mail approval from the presenting author is acceptable). The following statement must be listed under each poster reprint: Poster reprinted from the ACR/ARHP Annual Meeting held November 14-19, 2014. The American College of Rheumatology does not guarantee, warrant, or endorse any commercial products or services. Reprinted by (insert name of supporting company). Use of the ACR Scientific Program Content Information displayed or presented at all sessions during the Annual Meeting is the property of the ACR or the presenter. Information may not be recorded, photographed, copied, photocopied, transferred to electronic format, reproduced or distributed without the written permission of the ACR and the presenter. Any use of the program content, which includes but is not limited to oral presentations, audiovisual materials used by speakers and program handouts, without the written consent of the ACR is prohibited. This policy applies before, during and after the meeting. The ACR will enforce its intellectual property rights and penalize those who infringe upon it. MEETING INFORMATION Cell Phones, PDAs & Other Electronic Devices As a courtesy to meeting attendees, electronic devices must be operated in silent/vibrate mode within educational sessions; devices that beep, ring, etc. are prohibited. Cell phone conversations are not permitted in meeting rooms. Children For safety reasons, strollers are not permitted in the exhibit hall and all children must be accompanied by an adult. Only registered attendees will be permitted into meeting rooms. Child Care KiddieCorp is providing child care services for our attendees during meeting hours. If you did not reserve space in advance, you can inquire about space availability by calling (617) 954-3451. Nursing Mothers Room During scientific session hours, a staffed Nursing Mothers room will be available in Room 162-A. This room will have a private seating area, a refrigerator and a bulletin board for information exchange, advice and suggestions. Exhibit Hall Located in Hall A, you will find the latest technology and services demonstrated or on display in the exhibit hall. See page 252 for more information. Exhibit Hall hours: Sunday, November 16... 10:00 AM 5:00 Monday, November 17... 10:00 AM 5:00 Tuesday, November 18... 10:00 AM 2:30 Meeting Room Capacity/Important Fire Safety Information Attendance at scientific sessions is on a first-come, first-served basis. Rooms which have reached the maximum capacity may be closed according to local fire and safety regulations. Standing in the aisle or against the walls is not permitted. If overcrowding occurs, staff/security personnel will close the session. Sessions closed due to overcrowding may be redirected to an overflow room or made available on SessionSelect within 24 hours following the session. See page 19 for more information on SessionSelect. Photography and Videotaping Photographers will be present at the meeting. Registration and attendance at, or participation in, ACR meetings and other activities constitutes an agreement by the registrant for the ACR s use and distribution (both now and in the future) of the registrant or attendee s image or voice in photographs, videotapes, electronic reproductions and audio tapes of such events and activities. Visual reproduction of sessions is prohibited without prior written permission of the ACR. The ACR reserves the rights to audio and video reproduction at the 2014 ACR/ARHP Annual Meeting. See copyrighted materials policy for more information on page 11. Name Badges For security reasons, your badge will be required for admittance to all sessions, exhibits, social events and shuttle buses. Please wear your badge so it can be easily seen at all times. Lost badges should be reported to the registration staff immediately. No Smoking All meeting facilities at the convention center, hotel meeting rooms and other venues have been designated as non-smoking areas. 2014 Program Book 13
general information MEETING NAVIGATION GUIDE Use the following track icons to help you identify the most relevant content based on your specialty. PRIMARY TRACKS Basic Science Business/Administration Clinical Practice Clinical Science Exhibits and Industry-Supported Sessions provide attendees with an opportunity to learn about the latest technological advances in the treatment of rheumatic diseases within the exhibit hall via various exhibitions and non-cme sessions in the Innovation Theater, as well as evening and post-meeting symposia. Meet the Professor Sessions provide an opportunity for interaction and consultation with highly respected professionals who have expertise in a particular area. A separate registration is required. Networking Events provide unique opportunities to socialize and network with peers in smaller group settings. 14 Educators Ed Pd PrM FIT Pediatrics Ed Pd PrM FIT Sd PrM FIT Fellows-In-Training 2014 Program Book SECONDARY TRACKS Practice Management STATE CME DESIGNATIONS Pain Management The ACR designates certain sessions for pain management credit as required by the Medical Board of California (AB487). This designation is identified by the icon shown and will be placed next to the session title. Patient Safety The ACR designates certain sessions that will satisfy patient safety/risk management requirements of the Medical Board of Pennsylvania. This designation is identified by the icon shown and will be placed next to the session title. SESSION FORMATS ACR Sessions provide an update on the most recent developments in the field of rheumatology and provide instruction to improve patient care. Developments from other specialties and practical patient management skills will be emphasized. ARHP Sessions offer educational programs of interest to various health professionals. Concurrent sessions include invited speakers; peer-reviewed programs and lectures; and research and special interest abstract sessions. ACR and ARHP Concurrent Abstract Sessions provide a platform for the presentation of the most up-to-date basic science and clinical research data in the field of rheumatology. Sessions are grouped by topic or theme and include short oral presentations of high scoring accepted abstracts. Poster Sessions include accepted abstracts not selected for oral presentation. Poster sessions are arranged by topic/category. Presenters are required to accompany their posters during designated poster presentation times. Pre-Meeting Courses offer attendees, with a specific interest, a unique learning opportunity. A separate registration is required. Study Groups bring together attendees with a common interest in one disease, a group of related disorders or a specialized field of study for discussion and dissemination of information. Workshops foster Hands-On learning, and provide an opportunity for interaction and consultation with highly respected professionals who have expertise in a particular area. A separate registration is required. ABSTRACT FORMATS Late-Breaking Session features truly late-breaking research. Oral Presentations are the main forum for didactic presentation of original research related to rheumatic diseases. Plenary Sessions highlight abstracts of significant novelty and importance. There will be three theme-based sessions offered. Poster Presentations feature poster displays of abstracts, while facilitating one-on-one interaction between the presenter and the audience. Poster Tours are small groups guided by experts in a particular field. Each tour will highlight selected posters of novel or recent developments within an abstract category. There is no additional cost to participate, although a separate registration is required. ABSTRACT CATEGORIES ACR Basic Science 1. B-cell Biology and Targets in Autoimmune Disease: B-lymphocyte differentiation, B-cell subsets, plasma cells, autoantigens, autoreactive B-cells and tissue injury. 2. Biology and Pathology of Bone and Joint: joint biology and biochemistry, cartilage and chondrocyte biology, basic studies of osteoarthritis, bone structure and function, bone mineral and matrix, osteoblasts and osteoclasts.
general information 3. Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis: cytokines, chemokines and their receptors; downstream signaling effects and biologic pathways; cell-cell recognition and adhesion molecules, cell matrix interactions, matrix characteristics and properties, lymphoid organogenesis. 4. Genetics, Genomics and Proteomics: techniques, strategies and observations related to disease susceptibility and expression; bioinformatics and systems biology. 5. Innate Immunity and Rheumatic Disease: dendritic cells, antigen presentation, auto-inflammatory pathogenesis, pattern recognition receptors and their ligands, NK cells, complement and Fc receptors. 6. Pain Basic Aspects: studies on pain mechanisms, animal models of pain and pain physiology. 7. Pediatric Rheumatology Pathogenesis and Genetics: pathological, genetic and other laboratory-based aspects of pediatric rheumatology conditions. 8. Rheumatoid Arthritis Animal Models: animal models of inflammatory synovitis, mechanisms and treatment. 9. Rheumatoid Arthritis Human Etiology and Pathogenesis: genetics, susceptibility loci, etiology and pathogenesis. 10. Spondylarthropathies Psoriatic Arthritis Pathogenesis, Etiology: etiology and pathogenesis, including genetics, reactive arthritis and animal models. 11. Systemic Lupus Erythematosus Animal Models: animal models, mechanisms and treatment. 12. Systemic Lupus Erythematosus Human Etiology and Pathogenesis: genetics, susceptibility loci, etiology and pathogenesis. 13. Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics: cellular and molecular mechanisms, biomarkers. 14. T-cell Biology and Targets in Autoimmune Disease: T-lymphocyte antigens and subpopulations, cognate interactions, T-lymphocyte activation and proliferation. CLINICAL 15. Antiphospholipid Syndrome: pathophysiology, presentation and management. 16. Education: research on curriculum design and implementation; educational research projects; and outcomes research on physician and trainee education including associated health training. 17. Epidemiology and Public Health: descriptive and/or analytical studies of populations. 18. Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: regional pain syndromes, local diseases of muscle, ligament and tendon, fibromyalgia. 19. Health Services Research: delivery of care affecting patients with rheumatic disease; health systems and health care economic and ultization analysis. 20. Imaging of Rheumatic Diseases: radiography, nuclear medicine, magnetic resonance imaging (MRI), ultrasound and computed tomography (CT). 21. Infection-related Rheumatic Disease: musculoskeletal manifestations of infectious disease, infectious arthritis and pathogenesis. 22. Metabolic and Crystal Arthropathies: crystal-induced arthritis, metabolic conditions including endocrine abnormalities. 23. Miscellaneous Rheumatic and Inflammatory Diseases: rheumatic manifestations and therapy of less common and even rare illnesses not included in other categories (e.g., RS3PE, reticulohistiocytosis, SAPHO). 24. Muscle Biology, Myositis and Myopathies: muscle biology, inflammatory and non-inflammatory muscle disease. 25. Orthopedics, Low Back Pain and Rehabilitation: orthopedic conditions and interventions, physical medicine techniques and outcomes, sports medicine. 26. Osteoarthritis Clinical Aspects: patient-oriented studies of osteoarthritis, including treatment, diagnosis and outcomes. 27. Osteoporosis and Metabolic Bone Disease Clinical Aspects and Pathogenesis: patient-oriented studies of bone structure and integrity and its change in various disease states. 28. Pain Clinical Aspects: studies on pain evaluation, pain management and pain-related functional imaging. NEW! 29. Pediatric Rheumatology Clinical and Therapeutic Aspects: clinical aspects and treatment of inflammatory and non-inflammatory pediatric conditions. 30. Quality Measures and Quality of Care: development and use of tools to measure or quantify healthcare processes, outcomes, patient perceptions, organizational structures and/or systems relating to healthcare goals including safety, effectiveness, patient centricity, equity and timeliness. NEW! 31. Rheumatoid Arthritis Clinical Aspects: clinical aspects of rheumatoid arthritis. Should not contain any treatment studies. 32. Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy: treatment of human rheumatoid arthritis including DMARDs, NSAIDs, glucocorticoids, new potential small molecules, biologics and gene therapy approaches. Human use only. 33. Sjögren s Syndrome: pathophysiology, presentation and treatment. 2014 Program Book 15
Stop by the Discovery Center to learn what s new at the College! We re located in the center of the Exhibit Hall (Booth #731). L E A R N C O N N E C T E N G A G E S E E Get details about our 2015 educational activities Find answers to your coding and billing questions Talk with ACR staff about The Lupus Initiative, CME activities, registries, MOC tools, and more Get Social by meeting with a social media mentor Speak with key representatives from the ACR and ARHP journals Hear about the Foundation s programs and initiatives Learn about the latest advocacy efforts and how you can get involved Enroll in the ACR Rheumatology Musculoskeletal Ultrasound Certification Program Demo popular online tools and resources View and order the latest Rodnan Commemorative Gout Print Collect complimentary product brochures, publications and patient education materials Discovery Center Hours: Sunday, November 16... 10:00 am 5:00 pm Monday, November 17... 10:00 am 5:00 pm Tuesday, November 18... 10:00 am 2:30 pm
general information 34. Spondylarthropathies and Psoriatic Arthritis Clinical Aspects and Treatment: small molecule and biologic therapies of spondyloarthropathies, reactive arthritis and psoriatic arthritis. 35. Systemic Lupus Erythematosus Clinical Aspects and Treatment: diagnosis, clinical manifestations, outcomes, and treatment, including new small molecules, biologics and gene therapy. Human lupus only. 36. Systemic Sclerosis, Fibrosing Syndromes, and Raynaud s Clinical Aspects and Therapeutics: clinical aspects of these syndromes and of treatments. 37. Vasculitis: genetics, etiology, pathogenesis, polygmatic rheumatica, presentation and management. ARHP 38. Clinical Practice/Patient Care: care of patients, practice management, medication monitoring/adherence and complementary and alternative strategies. 39. Education/Community Programs: patient education, professional education, community-based programs and public health programs. 40. Epidemiology and Public Health: descriptive and analytical studies of health status and health outcomes of populations and patient groups. 41. Health Services Research: health care systems and delivery, economic evaluations, quality improvements and analysis. 42. Pediatrics: pediatric practice and patient care. 43. Psychology/Social Sciences: social, emotional and behavioral factors affecting patients, families and providers. 44. Rehabilitation Sciences: physical therapy, occupational therapy, exercise programs, splinting/orthotics and other rehabilitation services. 45. Research Methodology: quantitative and qualitative studies, new assessment tools and methodology, new analytical techniques and research study management. MEETING SERVICES Annual Meeting App Everything You Need, in One Place Search the program, retrieve syllabi, view abstracts and access recorded sessions on SessionSelect. See page 19 for more information on SessionSelect. NEW! Discovery Center The Spot for All Things ACR, ARHP and the Foundation! Discovery Center Hours: Sunday, November 16... 10 : 0 0 AM 5:00 Monday, November 17... 10 : 0 0 AM 5:00 Tuesday, November 18... 10 : 0 0 AM 2:30 Located in the center of Exhibit Hall A, Booth #731, the Discovery Center is designed to highlight all of the College s exceptional programs and services. ACR s professional staff is on hand to demonstrate online tools and resources, introduce new initiatives of the College that are under way, provide information and answer any questions you may have. The Discovery Center has it all in one place! See page 16 for more information. Look for these specific areas in the Discovery Center: Advocacy Get the most up-to-date information on the legislative and regulatory issues affecting your profession. We have talking points on all ACR legislative priorities and tips on how to get more involved with the ACR s advocacy efforts. You can also receive information on RheumPAC the ACR s political action committee. Education Learn about ACR/ARHP educational offerings and upcoming meetings in 2015 and beyond. You can also demo online products, tools and training programs like SessionSelect, Advanced and Fundamentals of Rheumatology Courses and the popular Rheumatology Image Bank. Rheumatology Research Foundation Learn about the latest activities the Foundation is doing to ensure the future of rheumatology. View and order the latest poster in the Rodnan Commemorative Gout Print poster series, and hear about Foundation programs and initiatives. Practice Management & Coding Visit with ACR certified coders and practice management experts for any coding, billing, insurance or practice management questions. We have all the resources you need for an efficient rheumatology practice. You can also pick up the latest copy of the ACR s monthly RheumWATCH. Take advantage of the new Annual Meeting App! Publications The editorial office staff of the Arthritis & Rheumatology and Arthritis Care & Research journals will be available to answer questions concerning online article submission and article review processes for the journals. 2014 Program Book 17
general information Simple Tasks Learn how the ACR s Simple Tasks campaign is educating lawmakers and referring physicians and others who influence rheumatology on the severity of inflammatory rheumatic diseases and the importance of rheumatologists and rheumatology health professionals in the treatment of those diseases. You can also learn how you can get involved in the Campaign in Action initiative. Quality & Informatics Learn how enrollment in the Rheumatology Clinical Registry can benefit you by providing Hands-On measurement tools and reports that enable you to comparatively assess the quality and outcome of rheumatologic care you provide. Plan on attending interactive demonstrations of this tool offered throughout the meeting. Certification Need help navigating Maintenance of Certification? We have answers to help steer your route to success with the American Board of Internal Medicine s Maintenance of Certification program. An ABIM representative will be on site to help answer your questions. Musculoskeletal Ultrasound Certification Interested in certifying in ultrasound? The ACR is providing a voluntary pathway for physicians, physician assistants and nurse practitioners who perform ultrasound as part of their practice in rheumatology to demonstrate competence to patients, peers and payers through its first certification program. Lost and Found Found items should be returned to the ACR Office, Room 260. If you are looking for a lost item, go to the ACR Office or call (617) 954-3940. Newsroom Located in Room 252, use of the Newsroom is limited to media representatives with press passes. Attendee Lounge Located in the Ballroom Lobby, attendees are welcome to relax and enjoy seating while networking with colleagues, checking e-mail and recharging their laptops or smartphones. Concierge Center Need directions to your next session or interested in discovering all things ACR? Stop by the Concierge Center located in the center of the North Lobby (Level 1). Staff is on hand to assist you and answer general questions about the Annual Meeting, ACR/ ARHP events, programs, resources and services of the College and we re happy to give directions to your next session, too. Concierge Center Hours: Friday, November 14... 6:3 0 AM 6:00 Saturday, November 15... 6:3 0 AM 6:30 Sunday, November 16... 6:3 0 AM 6:00 Monday, November 17... 6:3 0 AM 6:00 Tuesday, November 18... 6:3 0 AM 6:00 Wednesday, November 19... 7: 0 0 AM 1:00 Career Connection Employers and candidates are encouraged to take advantage of the online Career Connection to post position openings, search nationwide rheumatology career opportunities and much more. Career Fair On Friday, November 14 from 6:00 8:00 pm, potential employers and candidates can meet in the Grand Ballroom C-D-E at the Westin Boston Waterfront and enjoy complimentary hors d oeuvres and beverages while discussing career opportunities. During this time, employers who have registered for the Career Fair can distribute handouts, flyers or business cards to potential candidates. aa A Take-Away Gift Just for You! Come by the Discovery Center and take home a meeting souvenir get your picture taken with one of the landmarks of Boston and discover where the 2015 ACR/ARHP Annual Meeting will be held! Membership Booth Located in Registration (Exhibit Level), this is the place to go if you want to become a member, pay dues, reinstate your membership, learn more about member benefits and awards or volunteer to serve on a committee. Registration Registration counters are located in East Registration (Exhibit Level). Registration Hours: Friday, November 14... 6:3 0 AM 6:00 Saturday, November 15... 6:3 0 AM 6:30 Sunday, November 16... 6:3 0 AM 6:00 Monday, November 17... 7: 0 0 AM 6:00 Tuesday, November 18...7:00 AM 6:00 Wednesday, November 19... 7: 0 0 AM 1:00 18 2014 Program Book
Get On-Demand Annual Meeting Education with SessionSelect! ATTENDEE BONUS! Your Annual Meeting registration fee gives you FREE access to the online content of the 2014 Annual Meeting in SessionSelect for one year! Starting on Monday (November 17), you can view fully-synchronized presentations online, complete with speaker slides and audio, within 24 hours from the completion of the live session just as if you were actually attending each session. Take advantage of the most convenient way to experience education from the Annual Meeting at your own pace. With SessionSelect you can: Stay up to date on the most relevant information and research pertaining to rheumatic diseases Apply session information to your practice to enhance your knowledge, competence and performance Watch and learn 24/7 View content on your mobile device or download MP3 files for listening to audio on-the-go To learn more about SessionSelect or to view a demo, be sure to stop by the ACR s Discovery Center, located in Exhibit Hall A (Booth #731), or the Concierge Center, located in the North Lobby, or go to www.acrannualmeeting.org/sessionselect. www.rheumatology.org/sessionselect Recordings of individual sessions are subject to change. Ticketed sessions and pre-meeting courses are not included in complimentary access. CME credit is not available for viewing 2014 sessions online.
general information Shuttle Bus Shuttle service will be provided to and from the Boston Convention and Exhibition Center and ACR hotels that are designated as non-walking hotels. On Friday, Saturday and Wednesday, service operates continuously. On Sunday through Tuesday, service operates from 6:30-10:30 am and 2:30-6:30 pm. Full shuttle service information will be posted in ACR hotel lobbies and at the shuttle bus entrances of the convention center. This service is complimentary for attendees and registered guests who booked their rooms through ACR Housing. Attendees who have booked their rooms on their own in contracted or noncontracted ACR hotels may purchase an ACR shuttle bus pass at the ACR registration counter for $50. Speaker Ready Room Located in Room 206, check-in is expected of all speakers and oral abstract presenters (excluding Meet the Professor and Workshop speakers, as well as poster presenters). Plan to check in at least 3 hours prior to your presentation time. In the Speaker Ready Room, you can review your presentation and approve the file to be uploaded to the central server. Professional audiovisual technicians will be available to assist you. Computers in the Speaker Ready Room will be configured with hardware and software exactly like the ones in the meeting rooms and will allow you to preview your presentation, identify problems and make corrections as necessary before your presentation. Speaker Ready Room Hours: Friday, November 14... 6:3 0 AM 6:00 Saturday, November 15... 6:3 0 AM 6:30 Sunday, November 16... 6:3 0 AM 6:00 Monday, November 17... 6:3 0 AM 8:00 Tuesday, November 18... 6:3 0 AM 6:00 Wednesday, November 19... 7: 0 0 AM 12:30 Wi-Fi Way and Recharge Access Complimentary Wi-Fi access is available in all rooms of the convention center. Recharge areas will be available in Wi-Fi Way (Exhibit Hall A), the Attendee Lounge (Ballroom Lobby) and the Technology Center (North Lobby). Rheumatology Research Foundation Donors Lounge Experience the perks of supporting the Rheumatology Research Foundation while at the 2014 ACR/ARHP Annual Meeting in Boston! Attendees with access are invited to enjoy a hot breakfast every morning and gourmet coffee service throughout the day. Located in the Boardroom, the Donors Lounge is a great place to check your e-mail between sessions or catch up on work at our private computer stations. Donors are also invited to relax, watch television and network with their colleagues. Eligible donors will be able to get into the lounge with the 2014 Donors Lounge Access Pass. Passes will be distributed on site to individuals who have donated a total of $500 or more during fiscal year 2014 (July 1, 2013 through June 30, 2014). Donors Lounge Hours: Saturday, November 15... Noon 5:00 Sunday, November 16... 7: 0 0 AM 6:00 Monday, November 17... 7: 0 0 AM 6:00 Tuesday, November 18... 7: 0 0 AM 6:00 Wednesday, November 19... 7: 0 0 AM 12:30 SPECIAL OFFERS AT THE ANNUAL MEETING SessionSelect no need to miss a session! Within 24 hours of virtually every live session at the Annual Meeting, video recordings of the presentations, including oral abstracts, will be available through SessionSelect. As an attendee benefit, you get FREE online access for one year to hundreds of hours of Annual Meeting content over $500 of added value. See page 19 for more information. Please Note: Recordings of individual sessions are subject to change. Ticketed sessions and pre-meeting courses are not included in complimentary access. CME credit is not available for viewing 2014 sessions through SessionSelect. What Would Make This Meeting Better? You ve got ideas to share, and we ve made it easy for you to share them. Tweet your idea using the #ACR2014 hashtag. Submit your session proposal or topic idea for the 2015 meeting at ACRannualmeeting.org. Medical Bag Don t forget to pick up a Medical Bag prior to visiting the exhibits. Each bag contains special offers and invitations from our exhibitors and will be distributed from the exhibition entrance while supplies last. 20 2014 Program Book
general information POSTER SESSIONS Poster presentations facilitate one-on-one interaction between the presenters and attendees. Posters are grouped by topic and will remain displayed in the poster hall (Exhibit Hall B) from 9:00 am - 4:00 pm, Sunday, November 16 - Tuesday, November 18. Poster presenters will be available at their poster from 9:00-11:00 am. One poster session will be held each day; however, there is no poster session on Wednesday. Poster presentations will be unopposed during the 10:00-11:00 am hour. The number on the poster boards refers to the abstract presentation number, and this number will change for each poster session. Late-breaking abstract posters will be available for viewing Sunday, November 16 - Tuesday, November 18. Late-breaking abstract presenting authors will be available at their posters on Tuesday, November 18 from 9:00 am - 11:00 pm Thieves Market posters will be presented on Monday, November 17 and Tuesday, November 18. NEW THIS YEAR! aa Two new ACR clinical science abstract categories have been introduced: Pain: Clinical Aspects and Quality Measures and Quality of Care.! The abstract supplement will no longer be offered in the flash drive version. All attendees will be able to easily access the abstract supplement publication online. Posters must be mounted by 8:30 am of the designated poster session and dismantled after 4:00 pm as outlined in the abstract acceptance notification. Posters not dismantled by 5:00 pm each day will be recycled. Poster storage will not be available in the poster hall. In order to ensure a positive experience for both attendees and poster presenters, it is important to make sure that all posters are properly mounted and presenters are present from 9:00-11:00 am for poster presentations to answer questions from attendees. Poster presenter ribbons will be available in the Speaker Ready Room (Room 206). Poster Presenter No-shows Please Note: The ACR will be monitoring posters during the presentation hours in an effort to make certain the College is meeting the educational needs and expectations of attendees. Poster Sessions - Sunday, November 16 through Tuesday, November 18 from 9:00 am - 4:00 pm Set Up:... 7:00 8:30 AM Presentation:..................... 9:00 11:00 AM Poster Tours:... 9:00 9:45 AM 10:15 11:00 AM Posters to remain up until 4:00 pm Poster pick up:... 4:00 6:30 ACR Removal:... 6:30 * * The ACR will remove and promptly recycle all posters not picked up by 6:30 pm each day. Guided Poster Tours Guided poster tours, led by experts in the field, will guide small groups of attendees during the poster presentation times to highlight novel or recent developments. Selected posters from various abstract categories will be included in the tours. Although there is no fee to participate, pre-registration is required and each tour is limited to 20 registered scientific attendees. If you would like to participate and have not registered, you can check tour availability and request a ticket at registration, located in East Registration on the Exhibit Level. If you registered in advance of the meeting, your ticket is located on the back of your name badge. Once you have your ticket, it is important that you collect your headset from the Poster Tour Kiosk and meet your group 10 minutes before your tour departs from the entrance of the poster hall, located in Exhibit Hall B. Poster tour reservations will be released to stand-by attendees five minutes before the tour. 2014 Program Book 21
FRIDAY november 14, 2014 Great Meetings Come from Great Ideas! Call for Proposals: Submit your session idea or study group topic for the 2015 ACR/ARHP Annual Meeting at ACRannualmeeting.org TODAY! We are looking for proposals that: Reflect clinical innovation and cutting edge research. Convey best practices. Present evidence-based medicine. Stimulate discussion and challenge mind-sets. Tell us about learning models that: Address challenges in your area of practice. Create opportunities to share information across geographical demographics. Encourage collaboration between subspecialities Promote partnership among physicians and health professionals. Relevant topics may include: Technological advances impacting practice. World-wide trends in patient care. Outcomes assessment and holistic treatment. Deadline for submissions is Friday, November 21, 2014 acr/arhp scientific sessions FRIDAY, NOVEMBER 14, 2014 PRE-MEETING COURSES ACR MUSCULOSKELETAL ULTRASOUND COURSE FOR RHEUMATOLOGISTS DAY ONE OF TWO 7:45 am 5:30 pm 109 A Admission to the ACR Musculoskeletal Ultrasound Course for Rheumatologists requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. demonstrate proper ultrasound exam technique and procedure guidance, applying standardized protocols identify and describe normal sonographic anatomy and fundamental pathology for rheumatology indications explain the requirements for documentation related to musculoskeletal ultrasound Moderator: Eugene Y. Kissin, MD Faculty: Catherine J. Bakewell, MD; Jurgen Craig-Muller, MD; Paul J. DeMarco, MD; Amy M. Evangelisto, MD; Janak R. Goyal, MD; Jay B. Higgs, MD; Gurjit S. Kaeley, MBBS, MRCP; Eugene Y. Kissin, MD; Minna J. Kohler, MD; Gary A. Kunkel, MD; Clara Lin, MD; Daniel G. Malone, MD; Bethany A. Marston, MD; Midori Jane Nishio, MD; Anthony M. Reginato, PhD, MD; Johannes Roth, MD; Jonathan Samuels, MD; Darren Tabechian, MD; Ralf G. Thiele, MD, RhMSUS; Karina Marianne Torralba, MD, MMED; Alicia Weeks, MD 7:00 7:45 am Continental Breakfast 7:45 am Introduction Eugene Y. Kissin, MD 8:00 am Principles of Musculoskeletal Ultrasound for Rheumatologists Jay B. Higgs, MD 22 2014 Program Book
scientific sessions 8:30 am Introduction to Typical Sonographic Findings and Tissue Characteristics in Rheumatology Clara Lin, MD 9:15 9:30 am Morning Break 9:30 11:30 am Hand and Wrist 4:30 5:30 pm Pediatrics 4:30 pm Lecture: Pediatric Anatomy in Musculoskeletal Ultrasound Johannes Roth, MD 5:00 pm Hands-On Scanning: The Upper Extremity in Pediatrics Bethany A. Marston, MD and Johannes Roth, MD FRIDAY november 14, 2014 9:30 am Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Eugene Y. Kissin, MD 10:00 am Live Demonstration: Hand and Wrist Eugene Y. Kissin, MD 10:15 am Hands-On Scanning: The Hand and Wrist All Faculty 11:30 am 12:30 pm Boxed Lunch 12:30 2:15 pm The Elbow 12:30 pm Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Amy M. Evangelisto, MD 1:00 pm Live Demonstration: Scanning of the Elbow Amy M. Evangelisto, MD 1:15 pm Hands-On Scanning: The Elbow All Faculty 2:15 2:30 pm Afternoon Break 2:30 4:30 pm The Shoulder 2:30 pm Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Gurjit S. Kaeley, MBBS, MRCP 3:00 pm Live Demonstration: Scanning of the Shoulder Gurjit S. Kaeley, MBBS, MRCP 3:15 pm Hands-On Scanning: The Shoulder All Faculty ACR ADVANCED RHEUMATOLOGY CODING COURSE: DEVELOPING EXPERTS IN RHEUMATOLOGY CODING AND ICD-10-CM 9:00 am 5:00 pm 257 A Admission to the ACR Certified Rheumatology Coder Course requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. This course is not eligible for CME credit. 8:00 9:00 am Continental Breakfast Speakers: Antanya Chung, CPC, CPC-I, CRHC, CCS-P and Melesia Tillman, CPC, CPC-I, CRHC, CHA exhibit proficiency in adjudicating claims for accurate medical coding for diagnoses, procedures and services in physicianbased settings demonstrate knowledge of medical coding rules and regulations including compliance and reimbursement evaluate, revise and focus physician educational efforts and queries to meet documentation requirements for medical necessity and ICD-10-CM identify the impact ICD-10-CM will have on organizations and workflow implement strategies that will improve clinical documentation and facilitate a smooth transition to ICD-10-CM recognize how ICD-10-CM documentation requirements will affect principal diagnosis selection, additional diagnosis reporting and diagnosis sequencing ACR BASIC RESEARCH CONFERENCE: EMERGING PERSPECTIVES ON THE MICROBIOME IN THE RHEUMATIC DISEASES DAY ONE OF TWO 1:00 6:10 pm 210 B Admission to the Basic Research Conference requires a separate registration. describe underlying principles and evidence demonstrating how the microbiome may affect immune development and thresholds of immune responsiveness 2014 Program Book 23
scientific sessions FRIDAY november 14, 2014 24 examine the technologic and bioinformatics tools that are used to provide quantitative data that enable correlations with host phenotypes and alterations (or dysbioses) within the microbiome describe disease states that may be affected by microbial dysbioses 1:00 1:45 pm Keynote Lecture: Microbiome and Host Immune Defenses Speaker: Dan Littmann, MD, PhD 1:45 4:00 pm Session I: Overview of General Principles Moderator: Heidi H. Kong, MD, MHSc 1:45 pm Culture Independent Surveys of Microbiomes Rob Knight, PhD 2:15 pm Surveys of Human Populations and Families Jack Gilbert, PhD 2:45 pm Analysis and Models of Microbiomes Eric A. Franzosa, PhD 3:15 pm Multi-Omics Janet Jansson, PhD 3:45 pm Afternoon Break 4:00 6:10 pm Session II: The Microbiome and Regional Immunity Moderator: Susan A. Boackle, MD 4:00 pm Microbial Molding of Mucosal Immunity Hiroshi Kiyono, DDS, PhD 4:30 pm Microbiome and Lung Susan Lynch, PhD 5:00 pm Microbial Regulation of Responses in the Skin Heidi H. Kong, MD, MHSc 5:30 pm Immunity at the Barriers Yasmine Belkaid, PhD 6:00 pm Questions and Answers 6:10 7:00 pm Networking Reception Reception combined with ACR Clinical Research Conference participants. 2014 Program Book ACR CLINICAL RESEARCH CONFERENCE: PATIENT-CENTERED OUTCOMES IN RHEUMATOLOGY DAY ONE OF TWO 1:00 6:00 pm 205 B Admission to the ACR Clinical Research Conference requires a separate registration. define the role of patient-centered outcomes from the perspectives of clinical researchers, patients, caregivers and other stakeholders define the contribution of patient-centered outcomes in a learning health care system describe the case for patient-reported outcomes in clinical care and identify strategies to overcome barriers to use identify and select key variables to consider in selection of patient-reported outcomes measures incorporate patient-reported outcomes results into shared decision making in their respective clinical settings 1:00 4:00 pm Session I: Methodology and Development Moderators: Esi Morgan DeWitt, MD, MSCE 1:00 pm Patient-Centered Outcome Research: Why Methods Matter Sherine E. Gabriel, MD, MSc 1:15 pm Modern Methods in Patient-Reported Outcomes Measure Development Karon Cook, PhD 2:00 pm Advances in Comparative Effectiveness Research Methods in Rheumatoid Arthritis Jeffrey R. Curtis, MD, MPH, MS 2:30 pm Patient-Centered Outcomes Research Institute (PCORI) and Patients as Partners in Research Joe V. Selby, MD, MPH 3:00 pm Nothing About Me Without Me : Including the Patient in Outcomes Research Leslie Kelly-Hall 3:30 pm Questions and Answers 3:45 pm Afternoon Break 4:00 6:00 pm Session II: Translating Patient-Centered Outcomes to the Real World Setting Moderator: Sherine E. Gabriel, MD, MSc
scientific sessions 4:00 pm The Role of Patient-Centered Outcomes in a Learning Health System L. Charles Bailey, MD, PhD 4:30 pm How New Treatments Show They Are Working Laure Gossec, MD, PhD 5:00 pm Learning Health System and Patient-Centered Outcomes in Pediatric Rheumatology Esi M. Morgan DeWitt, MD, MSCE 5:30 pm Questions and Answers 5:45 pm Wrap-Up Sherine E. Gabriel, MD, MSc and Esi Morgan DeWitt, MD, MSCE 6:00 7:00 pm Networking Reception Reception combined with ACR Basic Research Conference participants. ACR/ABIM MAINTENANCE OF CERTIFICATION LEARNING SESSION 2014 UPDATE IN RHEUMATOLOGY 1:00 6:00 pm 258 B Admission to the ACR/ABIM Maintenance of Certification Learning Session requires a separate registration. Learn in an interactive environment as clinical experts lead you through 30 case-based questions from ABIM s 2014 Update in Rheumatology Module. After the session, submit your answers online to the ABIM to receive 10 medical knowledge points for the Maintenance of Certification program. assess strengths and weaknesses in rheumatology medical base knowledge state major developments in rheumatology over the past ten years satisfy a self-evaluation requirement for the American Board of Internal Medicine Maintenance of Certification program 2:40 3:00 pm Afternoon Break 3:00 4:30 pm Session II: Questions from 2014 Update Speaker: Seetha U. Monrad, MD 4:30 6:00 pm Session III: Questions from 2014 Update Speaker: Erika H. Noss, MD, PhDSATURDAY, NOVEMBER 15, 2014 SATURDAY, NOVEMBER 17, 2014 PRE-MEETING COURSES ACR MUSCULOSKELETAL ULTRASOUND COURSE FOR RHEUMATOLOGISTS DAY TWO OF TWO 7:15 am 5:50 pm 109 A Admission to the ACR Musculoskeletal Ultrasound Course for Rheumatologists requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. Moderator: Eugene Y. Kissin, MD Faculty: Catherine J. Bakewell, MD; Jurgen Craig-Muller, MD; Paul J. DeMarco, MD; Amy M. Evangelisto, MD; Janak R. Goyal, MD; Jay B. Higgs, MD; Gurjit S. Kaeley, MBBS, MRCP; Eugene Y. Kissin, MD; Minna J. Kohler, MD; Gary A. Kunkel, MD; Clara Lin, MD; Daniel G. Malone, MD; Bethany A. Marston, MD; Midori Jane Nishio, MD; Anthony M. Reginato, PhD, MD; Johannes Roth, MD; Jonathan Samuels, MD; Darren Tabechian, MD; Ralf G. Thiele, MD, RhMSUS; Karina Marianne Torralba, MD, MMED; Alicia Weeks, MD demonstrate proper ultrasound exam technique and procedure guidance, applying standardized protocols identify and describe normal sonographic anatomy and fundamental pathology for rheumatology indications explain the requirements for documentation related to musculoskeletal ultrasound SATURDAY november 15, 2014 1:00 pm Introduction Carol A. Langford, MD, MHS 1:10 2:40 pm Session I: Questions from 2014 Update Speaker: Carol A. Langford, MD, MHS 6:45 7:15 am Continental Breakfast 7:15 am Opening Remarks Eugene Y. Kissin, MD 7:30 9:15 am The Hip 7:30 am Lecture: Standard Scans, Sonographic Anatomy and Basic 2014 Program Book 25
scientific sessions Sonographic Pathology Midori Jane Nishio, MD of Procedures Janak R. Goyal, MD SATURDAY november 15, 2014 8:00 am Live Demonstration: Scanning of the Hip Midori Jane Nishio, MD 8:15 am Hands-On Scanning: The Hip All Faculty 9:15 9:30 am Morning Break 9:30 11:30 am The Knee 9:30 am Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Gary A. Kunkel, MD 10:00 am Live Demonstration: Scanning of the Knee Gary A. Kunkel, MD 10:15 am Hands-On Scanning: The Knee All Faculty 11:30 am 12:30 pm Boxed Lunch 12:30 pm 2:30 pm Foot and Ankle 12:30 pm Lecture: Standard Scans, Sonographic Anatomy and Basic Sonographic Pathology Ralf G. Thiele, MD, RhMSUS 1:00 pm Live Demonstration: Scanning of Foot and Ankle Ralf G. Thiele, MD, RhMSUS 1:15 pm Hands-On Scanning: Foot and Ankle All Faculty 2:30 pm ACR Musculoskeletal Ultrasound Course for Rheumatologists Billing, Coding and Report Generation Paul J. DeMarco, MD 3:00 pm 3:15 pm Afternoon Break 3:15 pm 5:00 pm Ultrasound Needle Guidance 3:15 pm Lecture: Evidence Base and Technique of Ultrasound Guidance 3:45 pm Panel Discussion Implementing Musculoskeletal Ultrasound in the Practice of Rheumatology Catherine Bakewell, MD; Paul J. DeMarco, MD; Eugene Y. Kissin, MD; and Ralf G. Thiele, MD, RhMSUS 4:15 pm Hands-On Scanning: Ultrasound Guidance of Procedures All Faculty 5:00 5:50 pm Pediatrics 5:00 pm Lecture: The Lower Extremity in Pediatrics Johannes Roth, MD 5:20 pm Hands-On Scanning: Pediatrics Bethany A. Marston, MD and Johannes Roth, MD ACR CLINICAL RESEARCH CONFERENCE: PATIENT-CENTERED OUTCOMES IN RHEUMATOLOGY DAY TWO OF TWO 7:45 am 4:30 pm 205 B Admission to the ACR Clinical Research Conference requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. define the role of patient-centered outcomes from the perspectives of clinical researchers, patients, caregivers and other stakeholders define the contribution of patient-centered outcomes in a learning health care system describe the case for patient-reported outcomes in clinical care and identify strategies to overcome barriers to use identify and select key variables to consider in selection of patient reported outcomes measures incorporate patient-reported outcomes results into shared decision making in their respective clinical settings 7:00 7:45 am Continental Breakfast 7:45 8:00 am Introduction Speakers: Sherine E. Gabriel, MD, MSc and Esi Morgan DeWitt, MD, MSCE 8:00 9:30 am Session III: Research Perspective Moderator: Kenneth G. Saag, MD, MSc 26 2014 Program Book
scientific sessions 8:00 am Patient-Centered Outcomes Research in ANCA-Associated Vasculitis Peter A. Merkel, MD, MPH 2:00 4:30 pm Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials Moderator: Dinesh Khanna, MD 8:30 am Patient-Centered Outcomes Research in Pediatrics Angelo Ravelli, MD 9:00 am Patient-Centered Outcomes Research in Scleroderma Dinesh Khanna, MD, MSc 9:30 am 1:00 pm Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs) Moderator: Nora G. Singer, MD 2:00 pm The Patient-Reported Outcomes Measurement Information System in Rheumatology James P. Witter, MD, PhD 2:30 2:50 pm Afternoon Break 2:50 pm Incorporating Patient-Centered Outcomes (PCOs) in Product Development: Industry Perspective Arijit X. Ganguli, MBA, PhD SATURDAY november 15, 2014 9:30 am Use of Patient-Reported Outcomes in Rheumatology Clinical Practice Clifton O. Bingham III, MD 10:00 am Passive Patient-Reported Outcomes: Biosensors and Social Media to Track Patient Outcomes Brennan Spiegel, MD, MSHS 10:30 10:45 am Morning Break 10:45 am Shared Decision Making: Incorporating Patient-Centered Outcomes Liana Fraenkel, MD, MPH 11:15 am Family Communication The Next Frontier for Improving Patient Satisfaction Richard Siegrist, Jr., MBA, MS, CPA 11:45 am Big Data and the Point of Care Kenneth D. Mandl, MD, MPH 12:15 1:00 pm Boxed Lunch 1:00 2:00 pm Session V: Patient Perspective Moderator: Sherine E. Gabriel, MD, MSc 1:00 pm Importance of Patient-Centered Outcomes From the Patient s Viewpoint Kelly Young, BA 1:30 pm Parent Engagement in Care and Research Judy K. Crosby, JD 3:20 pm Abstract Presentations 3:50 pm Questions and Answers 4:00 pm Wrap-Up Sherine E. Gabriel, MD, MSc and Esi Morgan DeWitt, MD, MSCE ACR PRACTICE MANAGEMENT PRE-MEETING COURSE 8:00 am 4:00 pm 257 A Admission to the ACR Practice Management Pre-meeting Course requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. Moderator: Nilsa Cruz 7:00 8:00 am Continental Breakfast 8:00 9:00 am Customer Service That Rocks: Boost Patient Satisfaction Speaker: Brandi Young, DNP identify steps to achieve outstanding patient satisfaction results and discover reliable methods for dealing with demanding patients outline breaking through ordinary communication and outdated work habits and improve overall customer service from check-in to check-out discuss specific techniques to implement for over-the-phone or in-person communications to calm upset patients 9:00 9:30 am Morning Break 2014 Program Book 27
scientific sessions SATURDAY november 15, 2014 9:30 10:30 am Improve Time-of-Service Collections From the Front End Speaker: Mark Painter discuss why it is important to move from a back-end collections strategy to a front-end strategy identify all that should be collected at the time of service and the difference it will make in collections (e.g., co-insurance, co-pay, self-pay) define the practice collection process and what it means to the practice bottom line identify tactics, tools and technologies to optimize collections from self-pay patients and reduce days in accounts receivable 10:30 11:30 am Managing Denials in a Complex Reimbursement Environment Speaker: Mark Painter identify how to set up a tracking mechanism to collect data on denials improve front and back office processes to prevent future denials determine root causes, patterns and process breakdowns responsible for denials, and explaining how establishing corrective steps may reduce the volume of denied claims and write-offs 11:30 am 12:30 pm Boxed Lunch 12:30 1:30 pm Ins and Outs of an Effective Compliance Plan Speaker: Anita Henderson Sumpter, MBA, MHA, CPC, CMOM discuss how to structure an effective anti-corruption compliance program. identify the vital elements of an effective compliance program discuss the role of a compliance office in fighting fraud and implementing a compliance program 1:30 2:00 pm Afternoon Break 2:00 3:00 pm Increase Team Performance and Productivity Speaker: Mark Painter discuss how to reduce staff conflict and build a team with a common purpose and shared vision identify the elements of building a high-performance team discuss the key principles of team dynamics, such as balance, conflict management and team alignment to provide practical insight into productivity and team success 3:00 4:00 pm Take Your Appeals to the Next Level Speaker: Jessica Farrell, PharmD identify how to customize appeal letters for Level II appeals so no higher level appeals are rejected identify the steps to appeal for all carriers, which forms to use and proven strategies for successful appeals discuss how to craft effective appeals letters and get your claims paid ACR REVIEW COURSE 8:00 am 4:00 pm Exhibit Hall C Admission to the ACR Review Course requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. Moderators: Simon M. Helfgott, MD and Kristine M. Lohr, MD, MS 6:30 8:00 am Continental Breakfast 8:00 8:45 am Pregnancy Management and Outcome in Systemic Lupus Erythematosus Speaker: Lisa R. Sammaritano, MD review the key clinical issues related to pregnancy in the lupus patient discuss some of the more common clinical challenges facing the rheumatologist and obstetrician formulate some recommendations regarding the management of pregnancy and the role of the rheumatologist 8:45 9:30 am The Diagnosis and Management of Macrophage Activation Syndrome Speaker: Alexei A. Grom, MD identify the clinical features of macrophage activation syndrome review the steps required to establish the diagnosis, using lab and clinical criteria discuss treatment options for macrophage activation syndrome 9:30 10:15 am Interstitial Lung Disease in Rheumatic Disease: A Focused Review Speaker: Aryeh Fischer, MD evaluate patterns of interstitial lung disease (ILD) and the clinical landscape of ILD disease in rheumatic diseases 28 2014 Program Book
scientific sessions review the evaluation of rheumatic patients with ILD and the evaluation for occult rheumatic diseases in those presenting with presumed idiopathic ILD outline the management of ILD in patients with rheumatic disease 10:15 10:45 am Morning Break 10:45 11:30 am Genomics for the Clinician Speaker: Soumya Raychaudhuri, MD, PhD review how genomics affects the clinician s understanding of specific rheumatic diseases such as rheumatoid arthritis discuss the future role of genomics and how it may fit into the rheumatology practice of tomorrow 11:30 am 12:15 pm Management of Salivary Gland Involvement in Sjögren s Syndrome Speaker: Alan N. Baer, MD describe salivary gland anatomy and methods to assess function and structure recognize symptoms and signs of salivary gland disease and MALT lymphoma in Sjögren s syndrome recommend management of salivary hypofunction and MALT lymphoma in Sjögren s syndrome 12:15 1:15 pm Boxed Lunch 1:15 2:00 pm Management of Pseudogout: Insights for Clinicians Speaker: Geraldine M. McCarthy, MD describe the clinical features of calcium pyrophosphate dihydrate (CPPD) crystal-associated arthropathy formulate a diagnostic approach to CPPD arthropathy and screening for predisposing metabolic disease manage CPPD arthropathy 2:00 2:45 pm Assessing Disease and Managing Large Vessel Vasculitis Speaker: Kenneth J. Warrington, MD recognize the presentations of Takayasu arteritis and giant cell arteritis describe vascular involvement in large vessel vasculitis recommend short- and long-term management of large vessel vasculitis 2:45 3:15 pm Afternoon Break 3:15 4:00 pm Rheumatoid Arthritis Therapy After Diagnosis of Malignancy Speaker: Iain B. McInnes, PhD discuss interactions of medications used to treat rheumatoid arthritis and malignancy discuss the risks and benefits of rheumatoid arthritis treatment in the setting of malignancy modify rheumatoid arthritis treatment in the setting of malignancy ACR BASIC RESEARCH CONFERENCE: EMERGING PERSPECTIVES ON THE MICROBIOME IN THE RHEUMATIC DISEASES DAY TWO OF TWO 8:00 am 4:30 pm 210 B Admission to the ACR Basic Research Conference requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. describe underlying principles and evidence demonstrating how the microbiome can affect immune development and thresholds of immune responsiveness examine the technologic and bioinformatics tools that are used to provide quantitative data that enable correlations with host phenotypes and alterations (or dysbioses) within the microbiome describe disease states that may be affected by microbial dysbioses 7:00 8:00 am Continental Breakfast 8:00 10:30 am Session III: Mechanisms of Immune Activation and Regulation Moderator: Kevin D. Deane, MD, PhD 8:00 am Mechanisms of Immune Activation and Regulation Andrew Gewirtz, PhD 8:30 am Microbiome and Gut T Cell Signaling June L. Round, PhD 9:00 am Microbiota and Tumor Immunity Romina Goldszmid, PhD 9:30 am The Microbiome as a Potential Risk Factor for Psoriatic Arthritis Anne Barton, PhD SATURDAY november 15, 2014 2014 Program Book 29
scientific sessions SATURDAY november 15, 2014 10:00 am Questions and Answers 10:10 10:30 am Morning Break 10:30 am 1:30 pm Session IV: Microbiome and Rheumatic Disease Moderator: Gregg J. Silverman, MD 10:30 am Microbiome and Psoriatic Arthritis James T. Rosenbaum, MD 11:00 am Microbiome and Rheumatoid Arthritis Jose U. Scher, MD 11:30 am Microbiome and Inflammatory Bowel Disease Jonathan Braun, MD, PhD Noon GALT Mediated Regulation of Immunologic Tolerance and Systemic Lupus Erythematosus Jo Spencer, PhD 12:30 pm Questions and Answers ARHP CLINICAL FOCUS COURSE: DIAGNOSTIC IMAGING USE IN DIFFERENTIAL DIAGNOSIS FOR COMMON RHEUMATIC AND MUSCULOSKELETAL CONDITIONS 8:00 am 4:30 pm 254 A Admission to the ARHP Clinical Focus Course requires a separate registration. Registration includes complimentary Continental Breakfast and a boxed lunch. Moderator: Karen Huisinga, MN, ARNP review the concepts of common, patient-specific rheumatic differential diagnosis develop basic knowledge of diagnostic imaging focusing on plain film, MRI and ultrasound define the role, utilization and limitations of diagnostic imaging in plain film, MRI and ultrasound in the clinical setting identify the appropriate imaging modality to apply in the clinical setting 7:00 8:00 am Continental Breakfast 8:00 am Introduction Karen Huisinga, MN, ARNP 30 12:45 1:30 pm Boxed Lunch 1:30 4:30 pm Session V: Prospects for Manipulating Disease Through the Microbiome Moderator: Jose U. Scher, MD 1:30 pm Consequences for Disease and Health of Shifting the Microbiome: Antibiotics, Probiotics and Nutriceuticals David A. Mills, MS, PHD 2:00 pm Treatment of Inflammatory Bowel Disease With Nematodes Joel Weinstock, MD 2:30 pm Manipulating the Urogenital Microbiome of Women Gregor Reid, PhD, MBA 3:00 3:15 pm Afternoon Break 3:15 pm Fecal Transplants Michael J. Sadowsky, PhD 3:45 pm Abstract Presentations 4:20 pm Wrap-Up Heidi H. Kong, MD, MHSc and Rob Knight, PhD 2014 Program Book 8:15 9:00 am Diagnostic Imaging: A Tool for Differential Diagnosis Michael D. Ross, PT, DHSc, OCS 9:00 11:00 am Plain Film 9:00 am Outlining the Value of Plain Film Michael D. Ross, PT, DHSc, OCS 9:45 10:00 am Morning Break 10:00 am Plain Film Case Presentation Michael D. Ross, PT, DHSc, OCS 10:45 am Plain Film Questions and Answer 11:00 am 1:30 pm Ultrasound 11:00 am Outline the Value of Ultrasound Patrick Astourian, MPAS, PA-C 11:45 am 12:30 pm Boxed Lunch 12:30 pm Ultrasound Case Presentations Patrick Astourian, MPAS, PA-C
scientific sessions 1:15 pm Ultrasound Case Questions and Answer 1:30 3:30 pm Magnetic Resonance Imaging (MRI) 1:30 pm Outlining the Value of MRI Stacy Smith, MD SCIENTIFIC SESSIONS ACR/ARHP OPENING LECTURE AND AWARDS 4:30 6:15 pm Exhibit Hall C Moderators: Joseph Flood, MD, ACR President and Karen L. Smarr, PhD, ARHP President 2:15 2:30 pm Afternoon Break 2:30 3:15 pm MRI Case Presentations Stacy Smith, MD 3:15 3:30 pm MRI Case Questions and Answer 3:30 4:30 pm Audience Response Interactive Session 4:15 pm Wrap-Up AAMC MEDICAL EDUCATION RESEARCH CERTIFICATE (MERC) WORKSHOP 9:00 am 4:00 pm 204 A This workshop is not eligible for CME credit. 9:00 am Noon Formulating Research Questions and Designing Studies Speaker: Karen Richardson-Nassif, PhD write a FINER (feasible, interesting, novel, ethical, relevant) educational research question specify an educational research area of interest evaluate whether they need Institutional Review Board approval for their study select the correct design for their research question 4:30 pm ACR Presidential Address 5:00 pm Recognition of 2014 ACR Masters Recognition of 2014 ACR Awards of Distinction Recipients Recognition of 2014 ARHP Merit Awards Recipients Recognition of 2014 ACR Distinguished Fellows Awards Recipients Recognition of 2014 Rheumatology Research Foundation Corporate Roundtable Donors 5:30 6:15 pm Opening Lecture: P4 Medicine Is Transforming Health Care: A Longitudinal, Framingham-like Study of 100,000 Well Patients Over 20-25 Years Speaker: Leroy Hood, MD, PhD review systems medicine and how its technologies and strategies are changing medicine describe how P4 medicine differs from evidence-based medicine explain the power of a longitudinal, Framingham-like 100,000 person wellness study for optimizing wellness for each individual and for studying wellness to disease transitions at the earliest stage ACR/ARHP OPENING RECEPTION 6:15 9:00 pm Ballroom East and West SUNDAY november 16, 2014 Noon 1:00 pm Boxed Lunch SUNDAY, NOVEMBER 16, 2014 1:00 4:00 pm Measuring Educational Outcomes With Reliability and Validity Speaker: Karen Richardson-Nassif, PhD identify three types of reliability (inter-rater, test-retest and internal consistency) match types of reliability with appropriate statistical measures describe the relationship between reliability and validity describe multiple forms of evidence for validity select an approach to reliability and validity assessment for a particular study ACR SESSIONS 7:30 8:30 am 253 B Age Before Beauty: Colchicine, Aspirin, Methotrexate and Their Mechanisms of Action Moderator: Wael N. Jarjour, MD Speaker: Bruce N. Cronstein, MD 2014 Program Book 31
scientific sessions SUNDAY november 16, 2014 review methotrexate-putative mechanisms of action in rheumatoid arthritis and gene expression data in methotrexate-naïve patients before and after treatment review hydroxychloroquine mechanisms of action including discussion of effects on autophagy and TLR signaling in rheumatoid arthritis and lupus review rituximab-recognized mechanisms of action and immune phenotypic changes in rheumatoid arthritis 104 B Pediatric Rheumatology Town Hall Moderator: Anna Huttenlocher, MD delineate the American Board of Pediatrics Maintenance of Certification program clarify the ACGME milestones for pediatrics identify current work initiated for pediatric rheumatology by the ACR 7:30 am Update on the Modifications to the American Board of Pediatrics Maintenance of Certification Program C. Egla Rabinovich, MD, MPH 7:50 am Update on Accreditation Council for Graduate Medical Education Pediatric Milestones Marilynn G. Punaro, MD NETWORKING EVENT 7:30 8:30 am 102 A ACR/ARHP First-time Attendee Orientation First-time annual meeting attendees are invited to an orientation to learn the ins and outs of the annual meeting. Dr. Audrey Uknis, ACR Immediate Past President and Dr. Jan Richardson, ARHP Immediate Past President, will assist you in planning how to get the most out of your first annual meeting. This session is not eligible for CME credit. Coffee and tea will be provided. Moderators: Audrey B. Uknis, MD and Jan K. Richardson, PT, PhD, OCS ACR MEET THE PROFESSOR SESSIONS 7:45 9:15 am Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. 8:10 am American College of Rheumatology Update and Pediatric Awards Polly J. Ferguson, MD Exhibit Hall C Year in Review Moderator: Chester V. Oddis, MD discuss selected recent publications on the pathophysiological basis of rheumatic diseases by literature review of important publications describe selected treatment modalities for rheumatic diseases from the recent published literature evaluate how these new advances may impact the practice of rheumatology 7:30 am Clinical Perspective S. Louis Bridges Jr., MD, PhD 8:00 am Basic Science Perspective Cornelia M. Weyand, MD, PhD Westin Paine (Lobby) *Basic Immunology for Clinical Rheumatologists (001) Speaker: John Atkinson, MD describe how the immune system functions in normal individuals identify abnormalities of immune regulation that lead to autoimmunity Westin Otis (Lobby) Crystal: Diagnosis and Management of Gout (002) Speaker: Theodore R. Fields, MD recall the various published guidelines for diagnosis of gout, including the most recent and appreciate the input that, when appropriate, can be added with ultrasound and Dual Energy CT scanning appreciate the challenges in gout patient education and medication adherence recall the 2012 ACR guidelines for gout management and appreciate those issues that still remain controversial or unresolved discuss the types of agents in the pipeline for future gout therapy and potential future approaches to gout management 32 2014 Program Book
scientific sessions Westin Hancock (Lobby) Cutaneous Vasculitis (003) Speaker: Ruth Ann Vleugels, MD, MPH use the cutaneous exam to help distinguish between small and medium-sized vasculitides observe the histopathological features of cutaneous vasculitis, which lead directly to clinical disease observable on the skin identify vasculitis mimickers with cutaneous involvement define the role of dermatologists in the diagnosis, work-up and management of cutaneous vasculitides Westin Revere (Lobby) Fibromyalgia 2014: Update on Management (004) Speaker: Daniel J. Clauw, MD identify newly proposed biological mechanisms for fibromyalgia and centralized pain discuss the role of central nervous system dysfunction in the pathogenesis of fibromyalgia describe the drug and non-drug treatments that are effective in fibromyalgia Westin Stone (Lobby) *Macrophage Activation Syndrome (005) Speaker: Alexei A. Grom, MD recognize the signs and symptoms of macrophage activation syndrome (MAS) in rheumatology recognize markedly distinct nature of the systemic form of juvenile idiopathic arthritis and the fact that MAS most frequently occurs in patients with this disease discuss current treatment approaches in MAS Westin Webster (Lobby) Pain: Evaluation and Treatment of Back Pain (006) Speaker: Rajiv Dixit, MD describe the clinically relevant anatomy of the lumbar spine clinically evaluate a patient with acute or chronic back pain or a patient with an associated nerve root compression syndrome formulate a rational and cost effective management plan with a clear understanding of surgical indications Westin Alcott (Mezzanine) Reactive Arthritis: An Update (008) Speaker: John D. Reveille, MD identify various causes of reactive arthritis discuss mechanisms of disease pathogenesis describe current treatment options for reactive arthritis Westin Douglas (Mezzanine) *Rheumatoid Arthritis: Challenging Cases (009) Speaker: Daniel Furst, MD, MPH discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients Westin Faneuil (Mezzanine) *Systemic Lupus Erythematosus: Difficult-to-Treat Systemic Lupus Erythematosus (010) Speaker: Maria Dall Era, MD review established data from the medical literature in order to improve clinical practice related to the treatment of systemic lupus erythematosus examine management strategies for refractory cutaneous manifestations of systemic lupus erythematosus discuss management of progressive or relapsing lupus nephritis discuss management of severe cytopenias ACR WORKSHO 7:45 9:45 am Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. SUNDAY november 16, 2014 Westin Adams (Mezzanine) *Psoriatic Arthritis (007) Speaker: Dafna D. Gladman, MD discuss advances in diagnosis and classification of psoriatic arthritis determine if patients with psoriatic arthritis should be treated aggressively determine treatment options for patients with psoriatic arthritis 152 *Joint Injection Techniques (201) Speaker: Atul A. Deodhar, MD and Kenneth S. O Rourke, MD discuss indications and contraindications for joint aspirations and injections identify and avoid common mistakes in joint injection procedures perform common joint and soft tissue injections on upper and lower extremities 2014 Program Book 33
scientific sessions SUNDAY november 16, 2014 161 *Nailfold Capillaroscopy (202) Speaker: Maurizio Cutolo, MD 154 distinguish between normal nailfold capillary array and early/advanced microvascular changes that allows the early differential diagnosis between primary and secondary Raynaud s phenomenon by using nailfold videocapillaroscopy (NVC) identify the early scleroderma pattern, the predictive/ prognostic value of NVC for the SSc clinical complications (by models/indexes) as linked to the NVC patterns quantify the microvascular lesions distinguish between the difference of combined predictive value of the NVC patterns and nuclear antibodies, the links with peripheral blood changes, as well as the effects of systemic sclerosis therapeutic treatments on NVC patterns Tai Chi in Rheumatic Disease (203) Speaker: Mary L. Jurisson, MD describe the practice of tai chi and qigong and advise patients of its evidence-based benefits and risks practice 1 or 2 qigong exercises independently describe some of the simplified curricula ACR SESSIONS 8:30 10:00 am 52 A CARE: Maintenance of Certification Session One of Three Vasculitis All annual meeting scientific attendees will receive access to the CARE: MOC module on their ACR profiles. Successful completion of the 30 case-based question online module with a score of 70% or higher will enable submission to the ABIM to receive ten (10) medical knowledge points for the Maintenance of Certification program. Ten (10) vasculitis questions will be covered at this session. Attendance at the session(s) is not required to participate in the online module. Moderator: Carol A. Langford, MD, MHS Speaker: Carol A. Langford, MD, MHS assess strengths and weaknesses in rheumatology medical knowledge review the diagnosis, management and treatment of rheumatic diseases that are part of the ABIM s rheumatology MOC examination blueprint satisfy a self-evaluation of medical knowledge requirement for the ABIM MOC program Ballroom East Current Understanding of Malignancies in Connective Tissue Diseases Moderator: Dinesh Khanna, MD review the mechanisms of cancer-associated autoimmune diseases discuss data related to associations of scleroderma and idiopathic inflammatory myopathies with malignancy and relationships with autoantibodies 8:30 am Idiopathic Inflammatory Myopathies Whom Should We Screen for Malignancy? Frederick W. Miller, MD, PhD 9:00 am Scleroderma Whom Should We Screen for Malignancy? Ami A. Shah, MD, MHS 9:30 am Cancers and Autoimmune Disease What Is the Link? Antony Rosen, MD 254 A Ethics and Rheumatology Ed Pd Ed PrM Eth Pd FIT PrM FIT Moderators: Robert H. Shmerling, MD and Jane Kang, MD develop knowledge and skills to address ethical conflicts that arise in rheumatologic practice and research recognize how social and cultural perspectives affect the approach to ethical decision making identify key ethical issues concerning social media for health professionals in general and rheumatologists in particular 8:30 am Ethical Challenges in Rheumatologic Research Arthur L. Caplan, PhD 9:00 am Ethics Concerns of the ACR Membership C. Ronald MacKenzie, MD 9:30 am Ethical Challenges Posed By Social Media Elizabeth A. Kitsis, MD, MBE 257 A Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts Ed Pd PrM FIT Moderators: Joan M. Bathon, MD, Editor, Arthritis & Rheumatology and Marian T. Hannan, DSc, MPH, Editor, Arthritis Care & Research peer-review scientific manuscripts within a field of interest assess one s own work prior to submission in terms of clarity of message and importance of the findings 34 2014 Program Book
scientific sessions describe the requirements and scientific preferences of the journals of the ACR 8:30 am Outline and Key Points of Conducting a Review Joan M. Bathon, MD and Marian T. Hannan, DSc, MPH 8:50 am Panel Presentation: Reviewing Clinical Science Articles Karen H. Costenbader, MD, MPH explain how to effectively respond to allegations of overpayments identify ways to improve workflow to handle the everincreasing number of multi-payer audits identify automated tools for tracking the status of individual claims appraise the types of audits to expect and key areas that each audit program may target (i.e., medical necessity, documentation, etc.) 9:00 am Panel Presentation: Reviewing Translational Articles Richard J. Bucala, MD, PhD 9:10 am Panel Presentation: Reviewing Genetics/Genome-Wide Association Study Articles S. Louis Bridges Jr., MD, PhD 9:20 am Panel Presentation: Reviewing From a Biostatistics Perspective Michael P. LaValley, PhD 9:30 am Questions and Answers Exhibit Hall C Osteoporosis: Current Concepts for the Clinician Moderator: Margaret R. Wilkes, MD discuss etiologies, diagnosis and management of low bone density in premenopausal women describe secondary causes of low bone density in men and treatment strategies for male osteoporosis review current data for best practice regarding utilization of bone turnover markers and duration of antiresorptive therapy in the treatment of osteoporosis 8:30 am Osteoporosis in Young Women Elizabeth J. Shane, MD 9:00 am Osteoporosis in Men Benjamin Z. Leder, MD 9:30 am Antiresorptive Therapies and Utilization of Bone Turnover Markers in the Management of Osteoporosis Karen E. Hansen, MD, MS 160 B Practice Issues: Health Care Bounty Hunters: A Closer Look at RACs, Audits and Medical Documentation Moderator: Douglas White, MD, PhD Speaker: Anita Henderson Sumpter, MBA, MHA, CPC, CMOM discuss the scope and purpose of the RAC, ZIPC and CERT contractors and audits trends for each program 258 B The Microbiome in Health and Disease Moderator: Robert A. Colbert, MD, PhD review the skin microbiome system and its role in dermatologic and systemic diseases evaluate the interactions between the microbiome and host gender in disease predisposition examine the role of the microbiome in inflammatory arthritides 8:30 am The Skin Microbiome Elizabeth A. Grice, PhD 9:00 am Gender, Microbiome and Autoimmunity Jayne Danska, PhD 9:30 am The Microbiome in Inflammatory Arthritides Jose U. Scher, MD 104 B When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility Ed Pd PrM FIT Moderators: Laura E. Schanberg, MD and Kenneth N. Schikler, MD describe novel insights in juvenile fibromyalgia diagnosis and prognosis effectively diagnose hypermobility syndromes and discuss prognosis recognize the value and the role of medications in the management of non-inflammatory musculoskeletal pains in children and adolescents 8:30 am Juvenile Fibromyalgia: Diagnosis, Severity and Prognosis Susmita Kashikar-Zuck, PhD 9:00 am The Spectrum of Pediatric Hypermobility A Geneticist s Viewpoint Brad Tinkle, MD, PhD 2014 Program Book 35 SUNDAY november 16, 2014
scientific sessions 9:30 am Integrated Management of Non-Inflammatory Musculoskeletal Pain in Children Kenneth Goldschneider, MD ACR POSTER SESSION A AND POSTER TOURS 8:30 am 4:00 pm Poster presenters will be available from 9:00 11:00 am (abstracts # 1 814). Poster tours will be held 9:00 9:45 am and 10:15 11:00 am. Morning snacks will be available from 9:00 10:30 am. Metabolic and Crystal Arthropathies Poster Tour (308) Tour Guide: N. Lawrence Edwards, MD Past President s Picks Poster Tour (309) Tour Guide: David G. Borenstein, MD Rheumatoid Arthritis: Clinical Aspects Poster Tour (310) Tour Guide: Jennifer Barton, MD Systemic Lupus Erythematosus: Clinical Aspects Poster Tour (311) Tour Guide: Megan E. B. Clowse, MD, MPH Vasculitis Poster Tour (312) Tour Guide: Robert F. Spiera, MD SUNDAY november 16, 2014 Poster Hall (Exhibit Hall B) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 15 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until five minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Exhibit Level: East Registration). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first-served basis five minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 15 minutes of the end of the tour. 9:00 9:45 am Fellows Only: How to Navigate the Poster Hall (301) Tour Guide: Calvin R. Brown, Jr, MD Pain: Basic and Clinical Aspects (302) Tour Guide: Anne-Marie Malfait, MD, PhD Past President s Picks Poster Tour (303) Tour Guide: Mary K. Crow, MD Past President s Picks Poster Tour (304) Tour Guide: Michael Weinblatt, MD Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy Poster Tour (305) Tour Guide: Iain B. McInnes, PhD Systemic Lupus Erythematosus: Clinical Aspects Poster Tour (306) Tour Guide: Diane L. Kamen, MD, MS 10:15 11:00 am Antiphospholipid Syndrome Poster Tour (307) Tour Guide: Pier Luigi Meroni, MD ACR SESSIONS 9:00 10:00 am 210 B ACR Immunology Update: New Immunology of the Spondyloarthropathies Moderator: Gregg J. Silverman, MD Speaker: Christopher T. Ritchlin, MD, MPH review the demographics and common clinical presentations for these conditions appraise insights gained from genetic surveys and evolving insights into cellular and molecular pathogenesis discuss recent advances in clinical trials with new therapeutic agents 102 A Advocacy: Meet the Expert A Senator s Perspective on Advocacy Best Practices Moderator: William F. Harvey, MD, MSc Speaker: The Honorable Tim Hutchinson (U.S. House 1993-1997; U.S. Sen. 1997-2003) review how rheumatologists can interact with elected officials locally review how rheumatologists can interact with elected officials nationally appraise effective and ineffective ways of approaching elected officials Ballroom West Sarcoidosis in 2014 Moderator: Elana J. Bernstein, MD, MSc discuss the diagnosis and management of cardiac sarcoidosis discuss the diagnosis and management of neurosarcoidosis 9:00 am Cardiac Sarcoidosis Daniel Culver, DO 36 2014 Program Book
scientific sessions 9:30 am Neurosarcoidosis Nadera J. Sweiss, MD 153 B Social Media Boot Camp: Twitter Basics Moderator: Paul Sufka, MD create an Twitter account recognize proper and improper usage of tweeting in professional environments identify whom to follow, e.g., rheumatologists and other interesting people in medicine identify and define a hashtag demonstrate how to tweet demonstrate how to retweet or favorite noteworthy information 9:00 am Introduction Paul Sufka, MD 9:05 am Why Tweet? Ronan Kavanagh, MD, MRCP (Booths #139 and #1401) Innovation Theater A and B Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. Innovation Theater A presentations will be held from 10:30 11:15 am, 12:30 1:15 pm and 2:30 3:15 pm. Innovation Theater B presentations will be held from 11:30 am 12:15 pm, 1:30 2:15 pm and 3:30 4:15 pm. For a complete listing of Innovation Theater presentations, see page 238. ACR WORKSHO 10:30 am 12:30 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. SUNDAY november 16, 2014 9:30 am How to Tweet Christopher E. Collins, MD 9:55 am Question and Answer ARHP SESSION 9:00 10:00 am 107 B ARHP Keynote Address: Happiness from the Inside Out Moderator: Afton L. Hassett, PsyD Speaker: Cynthia Coney, MEd, CAPP identify the three stages patients may traverse after a diagnosis of chronic illness list at least three personal strengths that resilient people exhibit apply resiliency skills into personal and professional lives EXHIBITS 10:00 am 5:00 pm Exhibit Hall A Join your colleagues in the Exhibit Hall for morning and afternoon refreshments from 10:00 11:00 am and 2:00 3:00 pm. 159 *Beyond Musculoskeletal Ultrasound for Rheumatologists (204) Speaker: Minna J. Kohler, MD identify non-musculoskeletal uses of ultrasound in rheumatology patients. recognize some common ultrasound abnormalities in patients with rheumatic diseases. recognize the importance of proper ultrasound transducer selection and system settings to obtain adequate ultrasound images. apply introductory ultrasound scanning techniques for nonmusculoskeletal scanning. apply introductory ultrasound scanning techniques to assess for vasculitis 152 *Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (205) Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD demonstrate clinical anatomy of the lower extremities in performing the physical examination apply knowledge of clinical anatomy to better understanding and diagnosis of the common regional pain syndromes administer the physical examination of the lower extremities on healthy volunteers 2014 Program Book 37
scientific sessions SUNDAY november 16, 2014 154 161 Histopathology of Rheumatic Lung Disease (206) Speakers: Allen Burke, MD and Fabio Tavora, MD, PhD appraise the basic patterns of lung injury as seen microscopically compare pathologic findings in rheumatologic lung diseases with their idiopathic counterparts distinguish histologic features of drug induced lung injury from rheumatologic injury Synovial Fluid Analysis and Crystal Identification (207) Speakers: Brian F. Mandell, MD, PhD; Gilda M. Clayburne, MLT and Lan Chen, MD, PhD prepare synovial fluid samples for microscopic examination identify various components of synovial fluid identify crystals in synovial fluid ACR SESSIONS 11:00 am Noon 210 B Bone Biology Moderators: George C. Tsokos, MD and Steven R. Goldring, MD Speaker: Laurie H. Glimcher, MD review how the skeleton remodels itself continuously through bone formation and resorption establish familiarity with the signaling pathways that operate in osteoblasts recognize the need for new therapeutics to treat low bone mass 11:20 am Presentation of the New ACR Rheumatoid Arthritis Guidelines Jasvinder A. Singh, MD, MPH 11:50 am Questions and Answers Kenneth G. Saag, MD, MSc ARHP SESSIONS 11:00 am Noon 257 A Affordable Care Act Moderator: Daniel F. Battafarano, DO Speaker: Angela K. Golden, DNP describe the changes that the Affordable Care Act will have on health care explain how reimbursement will be affected by the Affordable Care Act summarize the changes of the Affordable Care Act that will impact rheumatology directly 52 A Immunology Boot Camp I: The Basics of Targeted Therapies Moderators: Deborah McCloskey, RN, BSN and Brandi Young, DNP, FNP-C Speaker: Troy R. Torgerson, MD, PhD describe the basic building blocks of the immune system summarize the components of innate immunity, including sensing self and foreign explain the body s immediate response to an antigen Ballroom East New ACR Recommendations for the Management of Rheumatoid Arthritis Moderators: S. Louis Bridges Jr., MD, PhD and Raveendhara R. Bannuru, MD describe the recommended treatment approach for patients with rheumatoid arthritis outline the ACR s recommendations for use of non-biologic and biologic disease-modifying agents in the treatment of rheumatoid arthritis explain the ACR s recommendations for use of corticosteroids in the treatment of rheumatoid arthritis 11:00 am Overview of Guideline Development, Including Methods and Literature Review Timothy E. McAlindon, MD, MPH, MRCP 254 A What Can Brain Imaging Tell Us About Pharmacologic and Non-Pharmacologic Treatment of Chronic Pain? Moderator: Daniel J. Clauw, MD explain some of the basic principles of brain neurochemistry and brain connectivity and how these are altered in chronic pain describe how brain neurotransmitters and connectivity patterns may be altered by pharmacologic and nonpharmacologic treatment recognize how neuroimaging outcomes can be used to guide clinical decision making 11:00 am Pharmacologic Neuroimaging in Chronic Pain Richard E. Harris, PhD 38 2014 Program Book
scientific sessions 11:30 am Neuroplastic Response to Non-Pharmacologic Treatment in Chronic Pain Vitaly Napadow, PhD ACR PLENARY SESSION I DISCOVERY 2014 11:00 am 12:30 pm Conclusion: We identify ch2b as an antigenic target of the ACPA immune response and our findings suggest that intra-articular histone citrullination can link innate immunity via NETosis and adaptive immunity via generation of citrullinated histone immune complexes. The generation of citrullinated histone antigens during low grade articular inflammation provides a potential mechanism for the conversion from asymptomatic ACPA seropositivity to clinical RA. Exhibit Hall C ACR Plenary Session I: Discovery 2014 Moderators: Joseph Flood, MD and Chester V. Oddis, MD 11:00 am Rheumatology Research Foundation Corporate Roundtable Awards 11:15 am 815. Netosis Induced Histone Citrullination Facilitates Onset and Propagation of Rheumatoid Arthritis Dong Hyun Sohn and Jeremy Sokolove, VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are characteristic of rheumatoid arthritis however, their presence years before onset of clinical RA is perplexing. Although multiple putative citrullinated antigens have been identified, including citrullinated products of NETosis, no studies have demonstrated the capacity of these antigens to initiate inflammatory arthritis. We sought to identify citrullinated products of NETosis targeted by the RA immune response and with the capacity to drive inflammatory arthritis. Methods: We performed proteomic analysis of human NETs to identify all citrullinated proteins including those targeted as part of the RA immune response. Using a combination of ELISA and IHC we compared RA and OA serum, synovial fluid and synovial tissue for levels of histone 2B (H2B), anti-h2b antibodies, as well as H2B-containing immune complexes. Using macrophage activation assays we assessed the effect of histone citrullination on immunostimulatory capacity and evaluated the stimulatory capacity of native and citrullinated H2B-containing immune complexes. Finally, we immunized mice with citrullinated H2B (ch2b) with and without the induction of low grade collagen induced arthritis to assess the potential for anti-ch2b antibodies to mediate arthritis in vivo. Results: Proteomic interrogation of NET-derived proteins, RA serum, synovium and synovial fluid identified robust targeting of NET-derived citrullinated histones by the ACPA immune response. Over 90% of RA patients have anti-ch2b antibodies and over half have measurable levels of synovial fluid H2B immune complexes. We observe that histone citrullination increases innate immunostimulatory capacity and that immune complexes containing citrullinated histones both activate macrophage cytokine production and propagate NETosis. Finally, we demonstrate that autoimmunity to ch2b is arthritogenic, both by primary immunization as well as immune serum transfer, but only in the setting of underlying low grade articular inflammation. Disclosures: D. H. Sohn, None; J. Sokolove, None. 11:30 am 816. TRNT1 Missense Mutations Define a New Periodic Fever Syndrome Angeliki Giannelou, National Institute for Arthritis and Musculoskeletal and Skin Diseases,Bethesda, MD Background/Purpose: Two thirds of the 1700 patients seen at our NIH clinic for autoinflammatory diseases do not have a genetic diagnosis. Whole exome sequencing permits analysis of most of the protein coding regions of the human genome. Methods: With the use of whole exome sequencing and candidate gene screening, we identified five children from four unrelated families, who had unexplained autoinflammatory disease and shared mutations in one common gene. One family from Saudi Arabia was consanguineous with two affected daughters. The second family of mixed Czech and British background had one affected boy. The third and fourth families were of mixed European ancestry from the United States and each family had one affected daughter. We performed additional experiments in patients samples including flow cytometry, immunophenotyping, cytokine profiling, mitochondria related function and ribosomal assembly assays. Protein function was studied with morpholino knockdowns in zebrafish embryos. Results: All patients carried missense recessive mutations in one common gene, the TRNT1 (trna Nucleotidyl Transferase, SUNDAY november 16, 2014 2014 Program Book 39
scientific sessions SUNDAY november 16, 2014 CCA-Adding, 1), on chromosome 3. The two affected Saudi Arabian sisters were homozygous for a p.h215r missense mutation, while the other three children were compound heterozygous for a missense mutation, p. I223T or p. R99W and one shared mutation p.d163v. The p.h215r mutation was not found in any public database neither in 1061 Arab control DNA samples. From the three Caucasian mutations, the p.r99w was novel whereas the p. I223T and p.d163v were found at a very low allele frequency (<0.001) at the NHLBI exomedatabase. All mutations affect highly conserved amino acid residues and are predicted to be damaging to the protein function. All children had recurrent episodes of high fevers with negative sepsis work up that occurred in association with microcytic anemia and a spectrum of multisystem features. Neurologic involvement ranged from mild developmental delay to nystagmus, hypotonia, optic nerve atrophy and sensorineural hearing loss. Other variables manifestations include dysmorphic features, musculoskeletal and gastrointestinal symptoms, B cell immunodeficiency and hypogammaglobulinemia. Studies performed so far, point towards a maturation defect of the B cell lineage in the bone marrow, as a possible cause of the observed immunodeficiency. Preliminary data from cytokine analysis in two patients have shown elevated levels of the proinflammatory cytokines interleukin 6 and type 1interferon, suggesting possible therapeutic targets. Knockdown of the zebrafish TRNT1 homologue caused hydrocephaly, defects in tail development, anemia and a reduction in the number of hair cells present in the lateral line, that has function resembling human inner ear. Conclusion: The CCA-adding TRNT1 enzyme catalyzes the addition of the CCA terminus to the 3 prime end of all trnas precursors, a step that is essential for trna aminoacylation and protein synthesis. The discovery that missense mutations in this essential and ubiquitously expressed gene cause a newly defined periodic fever syndrome, will allow further understanding of mechanisms underlying inflammation. Disclosures: A. Giannelou, None. matched by age, gender and calendar year. Cox regression was used to calculate hazard ratios (HR) to determine baseline risk factors for increased mortality in the BeSt population. Results: During 10 years, 72 of 508 patients died at a mean age of 75 years. No difference in survival was observed between the treatment strategies (p=0.805) (figure), with 16/126, 15/121, 21/133 and 20/128 deaths in arm 1 to 4, respectively. Based on the general Dutch population, 62 deaths were expected and 72 deaths occurred, resulting in an overall SMR of 1.16 (95% confidence interval, CI 0.92 1.46). Comparing the general population to each of the treatment strategies resulted in a SMR (95% CI) of 1.00 (0.61 1.64), 1.02 (0.61 1.69), 1.30 (0.85 1.99) and 1.32 (0.85 2.04) in arm 1 to 4, respectively. In the BeSt population, baseline age (HR 1.13, 95% CI 1.10-1.16), male gender (HR 1.78, 95% CI 1.06-2.99), smoking at baseline (HR 5.19, 95% CI 3.08-8.75) and health assessment questionnaire at baseline (HR 1.89, 95% CI 1.29-2.76) were associated with an increased risk of mortality. Randomization arm was not associated with an increased risk of mortality (arm 1 as reference category; arm 2 HR 0.99, 95% CI 0.49 2.00; arm 3 HR 1.27, 95% CI 0.66 2.44; arm 4 HR 1.25, 95% CI 0.65 2.41). Conclusion: After 10 years of continued tight controlled treatment in patients with rheumatoid arthritis in the BeSt study, the survival rate was comparable to the general Dutch population, without differences between the treatment strategies. Higher age, male gender, smoking and worse functional ability were associated with an increased risk of mortality within our study population. These results suggest that treatment targeted at DAS 2.4 prevents increased mortality previously associated with RA and that the medication used in these strategies does not increase mortality. 40 11:45 am 817. Mortality in a Large Cohort of Patients with Early Rheumatoid Arthritis That Were Treated-to-Target for 10 Years I.M. Markusse, Leiden University Medical Center, Leiden, Netherlands Background/Purpose: Recent studies showed diverging results about mortality trends in patients with rheumatoid arthritis (RA). Our aim was to determine survival after 10 years of treatto-target therapy in patients with early RA, to compare these survival rates with the general population and to define risk factors for mortality during the 10 years duration of the BeSt study. Methods: The BeSt study enrolled 508 Dutch patients with recent-onset active RA (1987 criteria) who were randomized to: sequential monotherapy, step-up therapy, initial combination including either prednisone or infliximab. During 10 years, all patients were treated-to-target, aiming at a disease activity score (DAS) 2.4. Kaplan-Meier curves and the log-rank test were used to compare survival rates in the four treatment strategies. Standardized mortality ratios (SMR) were calculated to compare the BeSt population to the general Dutch population, 2014 Program Book Disclosures: I. M. Markusse, None. Noon 818. Incident Rheumatoid Arthritis and Risk of Mortality Among Women Followed Prospectively from 1976 to 2010 in the Nurses Health Study Jeffrey A. Sparks, Brigham and Women s Hospital, Harvard Medical School, Boston, MA Background/Purpose: RA has been associated with increased mortality compared to general population estimates. Previous studies were limited due to the inability to directly compare RA patients to controls, short follow-up and lack of detailed data on clinical, lifestyle and serologic factors. We evaluated mortality among women followed prospectively prior to RA diagnosis, directly comparing to women without RA. Methods: We conducted a study of RA and mortality among 121,700 women followed from 1976 to 2010 in the Nurses Health Study (NHS). Incident RA was validated by medical record
scientific sessions review according to the 1987 ACR RA criteria and classified by serostatus. Women who reported RA or other connective tissue diseases before the start of NHS were excluded. Women were followed from cohort entry to death or end of follow-up and were censored for loss to follow-up. Deaths were validated by the National Death Index; death certificate and medical record review determined cause of death. Cox regression models estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for all-cause, cardiovascular disease (CVD), cancer and respiratory mortality for women with RA compared to women without RA. We obtained HRs for mortality by RA duration and serologic RA phenotype. Models were adjusted for age, demographics and other mortality factors, including physical activity, smoking, obesity, comorbidities and family history of cancer, CVD and diabetes. Results: We validated 960 incident RA cases and identified 25,699 deaths in 34 years of NHS follow-up. Of the 261 deaths among women with RA, 75 (29%) were from cancer, 58 (22%) were from CVD and 43 (16%) were from respiratory causes. Compared to women without RA, women with RA had increased all-cause mortality that remained significant after adjusting for age and other mortality factors (HR 2.07, 95% CI 1.83-2.35, Table). Mortality was significantly increased for seropositive (HR 2.33, 95% CI 2.00-2.71) and seronegative RA (HR 1.60, 95% CI 1.30-1.98) compared to non-ra women. Each five years of RA duration conferred a 32% (95% CI 27-36%) increased mortality compared to non-ra. Women with RA had significantly increased risk for mortality from CVD (HR 1.87, 95% CI 1.44-2.43), cancer (HR 1.35, 95% CI 1.07-1.69) and respiratory (HR 4.50, 95% CI 3.28-6.17) causes compared to women without RA. Respiratory mortality for women with seropositive RA was sixfold higher than non-ra women (HR 6.23, 95% CI 4.38-8.85). Conclusion: In 34 years of prospective follow-up, women diagnosed with RA had a two-fold increased risk of death from any cause compared to women without RA. Respiratory mortality was six-fold higher in seropositive RA and women with RA were significantly more likely to die from CVD and cancer than women without RA. Respiratory mortality appears to be an important but understudied cause of death in RA. These findings provide evidence of high RA mortality burden that is unexplained by traditional mortality predictors. Table. Hazard ratios for all-cause and cause-specific mortality in RA serologic phenotypes among women in the Nurses Health Study, 1976-2010 (n = 119,264). All-cause mortality Ageadjusted HR Multivariable HR (95% CI)* (95% CI) CVD-specific mortality Multivariable HR (95% CI)* Cancerspecific mortality Multivariable HR (95% CI)* Respiratoryspecific mortality Multivariable HR (95% CI)* All RA No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA 1.42 (1.26-1.61) 2.07 (1.83-2.35) 1.87 (1.44-2.43) 1.35 (1.07-1.69) 4.50 (3.28-6.17) No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA duration 1.16 (1.13- (per 5 years) 1.20) 1.32 (1.27-1.36) 1.24 (1.15-1.33) 1.22 (1.14-1.30) 1.55 (1.42-1.69) Seropositive RA No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA 1.54 (1.33-1.79) 2.33 (2.00-2.71) 1.80 (1.27-2.55) 1.25 (0.92-1.70) 6.23 (4.38-8.85) No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA duration 1.20 (1.15- (per 5 years) 1.25) 1.38 (1.33-1.44) 1.26 (1.15-1.39) 1.23 (1.13-1.34) 1.69 (1.53-1.85) Seronegative RA No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA 1.15 (0.93-1.41) 1.60 (1.30-1.98) 1.84 (1.23-2.73) 1.40 (0.99-1.98) 1.97 (0.97-3.98) No RA 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) 1.00 (ref) RA duration 1.08 (1.02- (per 5 years) 1.15) 1.20 (1.14-1.28) 1.19 (1.06-2.73) 1.18 (1.06-1.31) 1.23 (1.00-1.51) * Adjusted for age, questionnaire period, US region, race/ethnicity, education, husband s education, body mass index (<18.5, 18.5-24.9, 25-29.9, 30), cigarette smoking pack-years (never, 0-10, 10.1-20, >20), post-menopausal hormone use, physical activity, healthy eating index, cancer, cardiovascular disease, diabetes mellitus, family history of diabetes, family history of cancer, family history of myocardial infarction <60 years of age and aspirin use through follow-up. Modifiable factors were adjusted up to RA diagnosis (cigarette smoking pack-years, physical activity and body mass index). Among women with RA, there were a total of 43 respiratory deaths that were due to pneumonia (11), emphysema (8), chronic interstitial lung disease (5), asthma (1) and other respiratory diseases (18). Disclosures: J. A. Sparks, None. 12:15 pm 819. Secukinumab, a Monoclonal Antibody to Interleukin- 17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a 52-Week Phase 3 Randomized Placebo-Controlled Trial with Intravenous Loading and Subcutaneous Maintenance Dosing Dominique L. Baeten, Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands Background/Purpose: A phase 2, proof-of-concept study indicated that secukinumab, an anti IL-17A monoclonal antibody, suppressed signs and symptoms of active ankylosing spondylitis (AS) by Week (Wk) 6. We present Wk 16 and Wk 52 efficacy and safety data from MEASURE 1 (NCT01358175), a phase 3 study assessing secukinumab vs. placebo (PBO) in patients (pts) with AS. Methods: Pts with active AS fulfilling modified New York Criteria and BASDAI 4, despite current or previous therapy with NSAIDs, DMARDs and/or anti-tnf agents, were randomized to receive: i.v. secukinumab 10 mg/kg (Wk 0, 2, 4) followed by s.c. secukinumab 75 mg every 4 wks (10 IV 75 SC), s.c. secukinumab 150 mg every 4 wks (10 IV 150 SC), or PBO on same i.v. and s.c. schedules. Endpoints included ASAS20 at Wk 16 (primary), ASAS40, hscrp, ASAS 5/6, BASDAI, SF-36 PCS, ASQoL and ASAS partial remission. Statistical analyses followed a pre-defined hierarchical hypothesis testing strategy to adjust for multiplicity. PBO pts were re-randomized to secukinumab 75 mg or 150 mg s.c. based on ASAS20 response at Wk 16, with nonresponders switched at Wk 16 and responders at Wk 24. Results: Baseline characteristics of the 371 randomized pts were similar between study arms: mean age 40.1-43.1 years, mean disease duration 6.5-8.3 years, mean BASDAI 6.05-6.51, ~27% inadequate response to anti-tnf agents (TNF-IR). The study met its primary efficacy endpoint with a significantly higher ASAS20 response at Wk 16 in the 10 IV 75 SC (59.7%) and 10 IV 150 SC (60.8%) groups vs. PBO (28.7%; P < 0.01 for each dose); ASAS20 response rates in TNF-naïve pts were 60.0%, 66.3% and 32.6% and in the TNF-IR pts were 58.8%, 45.5% and 18.2%, in 2014 Program Book 41 SUNDAY november 16, 2014
SUNDAY november 16, 2014 scientific sessions the 10 IV 75 SC, 10 IV 150 SC and PBO groups, respectively (P< 0.01 vs. PBO). Significant improvements with both doses of secukinumab vs. PBO were observed for all pre-specified secondary endpoints at Wk 16 (Table), with responses sustained through Wk 52. Onset of action of secukinumab was rapid, with significant improvements in ASAS20, ASAS40, hscrp, ASAS5/6 and BASDAI seen at Wk 1. Through to Wk 16, drug exposure levels were similar in the secukinumab groups due to the i.v. loading doses. Secukinumab was generally well tolerated. At Wk 16, 66.9% of pts in the 10 IV 75 SC group and 69.6% in the 10 IV 150 SC group experienced an AE, vs. 55.7% on PBO; SAE rates were 1.6%, 2.4% and 4.1%, respectively. Through Wk 52 visit of the last pt (average exposure [range]: 451.7 [8 757] days), AE/SAE rates were 76.5%/10.1% and 85.1%/9.4% for pts receiving secukinumab 75 or 150 mg s.c., respectively, at any point in the study. Table. Summary of 16-week efficacy results Week 16 Data Secukinumab 10 mg/kg i.v. 75 mg s.c. (N = 124) Secukinumab 10 mg/kg i.v. 150 mg s.c. (N = 125) Placebo (N = 122) ASAS20 response 59.7%* 60.8%* 28.7% ASAS40 response 33.1%* 41.6%* 13.1% hscrp, post-baseline to baseline ratio (LSM±SE) 0.45 ± 1.092* 0.40 ± 1.090* 0.97 ± 1.095 ASAS5/6 45.2%* 48.8%* 13.1% BASDAI, mean change from baseline score (LSM±SE) -2.34 ± 0.175* -2.32 ± 0.172* -0.59 ± 0.180 SF-36 PCS, mean change from baseline score (LSM±SE) 5.64 ± 0.595* 5.57 ± 0.586* 0.96 ± 0.612 ASQoL, mean change from baseline -3.61 ± 0.424* score (LSM±SE) -3.58 ± 0.420* -1.04 ± 0.437 ASAS partial remission 16.1%* 15.2%* 3.3% *P<0.01 vs. placebo Prespecified hierarchical statistical testing strategy used to account for multiplicity. Missing data for categorical variables were imputed as nonresponse ASAS, Assessment of SpondyloArthritis International Society Criteria; ASQoL, Ankylosing Spondylitis Quality of Life; BASDAI, Bath Ankylosing Spondylitis Disease Activity Index; hscrp, high-sensitivity C-reactive protein; LSM, least square mean; SE, standard error; NS, not significant; SF-36 PCS, short form 36 physical component summary Conclusion: The selective IL-17A inhibitor secukinumab provided rapid and significant improvement of signs and symptoms in pts with active AS, regardless of prior anti-tnf exposure. Improvements were observed from Wk 1 and sustained through 52 wks. Secukinumab was well tolerated through 52 wks with no unexpected safety findings. Disclosures: D. L. Baeten, Research grants from Boehringer Ingelheim, Janssen, MSD, Novartis, Pfizer, 2, 9, Consulting fees from AbbVie, Boehringer Ingelheim, BMS, Eli Lilly, Jannsen, MSD, Novartis, Pfizer, Roche, UCB, 5. ARHP NETWORKING EVENT 12:30 2:15 pm Commonwealth Ballroom Networking Forum All ARHP attendees are invited to this kick-off forum for the annual meeting. A box lunch will be provided for the first 250 people. You will have an opportunity to meet and network with other health professionals. Discipline tables will be arranged to help facilitate connections. This session is not eligible for CME credit. ACR SESSION 12:45 2:15 pm Ballroom West ACR Knowledge Bowl: Preliminary Round Moderator: Rebecca L. Manno, MD, MHS identify key images that are important to recognize in clinical practice describe factual information related to various rheumatic diseases identify historical facts relevant to the field of rheumatology Competing Teams: Bourbon Street Bunions Nirupa J. Patel, MD; Kenneth Van Dyke, DO and Joseph Martinez, MD Complement ary Medicine! Sobia Hassan, BM BS, MRCP; Maria Antonelli, MD and Santosh Bhusal, MD Combat Rheumatology Ramon Arroyo, MD; Joshua Scott, DO, MS, BS and Ian Ward, MD Drugs ANCAnna Help Your GPA Soumya Chatterjee, MD, MS; Piyush Poddar, MD and David Theis, DO, BA Healing Hinges Kenneth J. Warrington, MD; Megan L. Krause, MD and Abha G. Singh, MBBS Motor City Road Runners Alireza Meysami, MD; Reshma Khan, MD and Reshma Marri, BS, MD Rheumatology Research Unit Rosa Daniela Grembiale, MD; Francesco Ursini, PhD, MD and Saverio Naty, MD Rheumawiz Rohini Samant, MBBS, MD; Piyush Joshi, MBBS, MD and Yathish GC, MBBS, MD Sweet Bones Alabama Laura B. Hughes, MD, MSPH; Xena Whittier, MD, MS, BA and Jenny Lin, MD Team Galveston Vijaya Murthy, MD; Rajani Rudrangi, MD and Niharika Ganti, MD Team Ireland John J. Carey, CCD, MS; Richard Conway, BAO, BCh, MB, MRCPI and Orla Ni Mhuircheartaigh, BAO, BCh, MB, MRCPI The Bauer Rumble Robert P. Friday, MD, PhD; Sara Schoenfeld, MD and Zachary Wallace, MD 42 2014 Program Book
scientific sessions The Brooklyn Rheuminators Deana M. Lazaro, MD; Nina Ramessar, MBBS and Jigar Shah, MD The Hawkeyes Namrata Singh, MBBS; Bharat Kumar, MD and Vijay Aluri, MD Triple Therapy: Triple Threat Ted R. Mikuls, MD, MSPH; Manpreet Sethi, MBBS; and Priyanka Vashisht, MD Westin Revere (Lobby) Hereditary Angioedema Update (014) Speaker: Peter Deane, MD discuss the pathophysiology of hereditary angioedema discuss the proper approach to the patient with angioedema discuss current treatment options The Honey Badgers Andrew Östör, MD; Andra Negoescu, MD; and Elena Nikiphorou, MRCP, MD (Res), PGCME ACR MEET THE PROFESSOR SESSIONS 12:45 2:15 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. Westin Paine (Lobby) *Ankylosing Spondylitis: 2014 Update (011) Speaker: Lianne S. Gensler, MD discuss the spectrum of axial spondyloarthritis, including ankylosing spondylitis discuss the early diagnosis of ankylosing spondylitis and axial spondyloarthritis describe clinical and radiographic outcome measures used in clinical trials and practice summarize axial spondyloarthritis treatment options and evaluate the impact of treatment on outcomes Westin Otis (Lobby) *Ankylosing Spondylitis: Disease Modification (012) Speaker: Joachim Sieper, MD outline what is known about the pathophysiology of disease modification in spondyloarthritis review outcomes relevant to the concept of disease modification in spondyloarthritis and assess their relevance to clinical practice review therapeutic issues relevant to the concept of disease modification discuss assessment of disease modification clinical trial Westin Hancock (Lobby) *Dermatological Manifestations of Rheumatic Diseases (013) Speaker: Ruth Ann Vleugels, MD, MPH identify cutaneous findings associated with underlying rheumatic disease construct a differential diagnosis for these conditions design a strategy for management of skin disease seen in patients with rheumatic diseases Westin Stone (Lobby) *Pediatric Systemic Lupus Erythematosus (015) Speaker: Kelly A. Rouster-Stevens, MD, MS discuss the epidemiology of pediatric systemic lupus erythematosus describe the differences in organ involvement between pediatric and adult systemic lupus erythematosus discuss the management and treatment of pediatric systemic lupus erythematosus review consensus treatment plans for the induction of proliferative lupus nephritis in pediatric patients discuss novel biomarkers that in the future may be beneficial in managing pediatric systemic lupus erythematosus Westin Webster (Lobby) *Rheumatoid Arthritis: Biological Agents (016) Speaker: Edward C. Keystone, MD describe recent trends in the use of biologics to improve outcomes and utility describe strategies to reduce costs of biologics discuss emerging biologics, including biosimilars and their advantage for the therapeutic algorithm Westin Adams (Mezzanine) *Systemic Lupus Erythematosus: Novel Treatments (017) Speaker: Susan Manzi, MD, MPH describe the history of therapeutic agents and the rationale for further drug development in lupus review new data to support standard therapies for management of lupus discuss the newest therapies approved for lupus and those currently under investigation Westin Alcott (Mezzanine) *Vaccinations for Patients on Biologic Therapies (018) Speaker: Jeffrey R. Curtis, MD, MPH, MS recognize the importance of appropriate vaccinations in patients with autoimmune disease identify the different types of immunizations especially those which are live viruses describe the effect of different classes of immunomodulatory medications on vaccine efficacy and safety 2014 Program Book 43 SUNDAY november 16, 2014
scientific sessions SUNDAY november 16, 2014 Westin Douglas (Mezzanine) *Vasculitis: Update (019) Speaker: Raashid A. Luqmani, DM describe the current definitions of vasculitis according to affected vessel size discuss the role of simple clinical evaluation alongside the various available laboratory and imaging tests, including antineutrophil cytoplasm antibodies identify current and novel therapeutic modalities Westin Faneuil (Mezzanine) *What Is Not Central Nervous Angiitis: Making the Right Diagnosis (020) Speaker: Leonard H. Calabrese, DO list and elaborate on the diagnostic criteria for primary angiitis of the central nervous system discuss the test operating characteristic of commonly employed neurodiagnostics, i.e., magnetic resonance, angiography, cerebrospinal fluid analysis, etc. list and appraise diagnostic heuristics for the recognition and diagnosis of primary angiitis of the central nervous system and the separation of mimics that can confound the diagnosis ACR SESSIONS 1:00 2:00 pm 254 A Avoiding Electronic Health Record Errors and Their (Sometimes) Critical Consequences Moderator: Salahuddin Kazi, MD Speaker: Steven K. Magid, MD recognize common errors in electronic health record systems and how to prevent these issues evaluate legal and social implications of unintended consequences in electronic health records review approaches to mitigate electronic health record related errors using a strategic set of solutions 157 B Axial Spondyloarthritis Guidelines Moderators: John D. Reveille, MD and Atul A. Deodhar, MD describe the ACR-SAA-SPARTAN recommendations for management of patients with axial spondyloarthritis/ ankylosing spondylitis review the process and methods used in the development of the new ACR-SAA-SPARTAN guidelines 1:00 pm Overview of Guidelines Development, Including Methods and Literature Review Liron Caplan, MD, PhD 1:25 pm Presentation of the Draft ACR-SAA-SPARTAN Axial Spondyloarthritis/Ankylosing Spondylitis Guidelines Michael M. Ward, MD 1:50 pm Questions and Answers Exhibit Hall C Gout Management Edin 2014 Pd PrM FIT Moderators: Jasvinder A. Singh, MD, MPH and Alan N. Baer, MD describe the effective management of gout in the setting of chronic kidney disease discuss the current best treatment for tophaceous gout and emerging therapies 1:00 pm Effective Management of Gout in the Setting of Renal Disease Lisa K. Stamp, PhD 1:30 pm Tophaceous Gout: Past, Present and the Future of Therapeutics Tuhina Neogi, MD, PhD 102 A How the Gut Primes the Immune System Moderator: Wael N. Jarjour, MD Speaker: Hilde Cheroutre, PhD examine the collaboration of the intestinal host-microbial interface and the innate and adaptive immune system in the detection and regulation of microbial populations and maintaining homeostasis examine the effects of disruption of the intestinal-host microbial interface and its contribution to chronic inflammatory disease 151 A Practice Issues: The Road to I10 Moderator: Douglas White, MD, PhD describe the challenges in the physician practice and the workflow for staff and patients identify any productivity loss due to coding backlogs discuss delays in turnaround time due to training assess performance in the new environment discuss any reimbursement disruptions and the flow of denials and/or adjustments for claims billed with ICD-9 codes for the earlier part of the year 1:00 pm The Advocacy Movement William F. Harvey, MD, MSc 44 2014 Program Book
scientific sessions 1:20 pm Physician s Perspective of ICD-10 Jonathan Kay, MD 1:40 pm Process and Strategy From the Coder s Viewpoint Evan Gwilliam, DC, MBA, BS, CPC, NCICS, CCPC, CCCPC, CPC-I MCS-P 104 B Rheumatology Research Foundation Memorial Lectureship to Honor Dr. Stephen E. Malawista, MD: Innate Immunity at the Core of Rheumatic Disease Eth Moderator: Linda Bockenstedt, MD Speaker: Robert Terkeltaub, MD evaluate novel translational vision and action in the science and practice of rheumatology, by reviewing lucid examples of Dr. Malawista s seminal works and their evolving fate recognize the power of clinical observation and creative thinking in fleshing out etiopathogenesis, epidemiology and treatment of rheumatic diseases, exemplified by Lyme disease and gout appraise phagocyte innate immune responses to exogenous infectious and endogenous particulate danger signals and how nuances in macrophage differentiation and function orchestrate inflammatory responses and can be therapeutically corralled in rheumatic disease Ballroom East The Butterfly Effect: Lupus Rashes and Their Mimics Moderators: Elana J. Bernstein, MD, MSc and Meenakshi Jolly, MD, MS Speaker: Bonnie T. Mackool, MD, MSPH identify mimics of lupus rashes distinguish between lupus rashes and their mimics discuss the management of lupus rashes, including the treatment of rashes refractory to initial therapy 159 *Advanced Musculoskeletal Ultrasound (208) Speaker: Jay B. Higgs, MD 152 demonstrate improvement in their techniques for performing selected musculoskeletal ultrasound examinations use practical knowledge of ultrasound technology to improve image quality Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (209) Speakers: Robert A. Kalish, MD and Pablo Villasenor Ovies, MD demonstrate clinical anatomy of the lower extremities in performing the physical examination apply knowledge of clinical anatomy to better understanding and diagnosis of the common regional pain syndromes perform the physical examination of the lower extremities on healthy volunteers ACR SESSIONS 2:30 4:00 pm 52 A Autoimmunity in Immunodeficiency Moderators: Nora G. Singer, MD and Jose Carlos Crispin Acuna, MD describe the presence of autoimmune manifestations in patients with primary immunodeficiency discuss the molecular basis for the development of autoimmunity in primary immunodeficiency consider therapeutic approaches for autoimmune manifestations in patients with primary immunodeficiency 2:30 pm Autoimmunity and Autoimmune Diseases in Primary Immunodeficiencies Erin Janssen, MD, PhD SUNDAY november 16, 2014 ACR WORKSHO 1:15 3:15 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. 3:15 pm The Abnormal Regulation of B-Cell Tolerance in Patients with Autoimmune Disease and Primary Immunodeficiencies Eric Meffre Sr., PhD 102 A Educator: Medical Education: The Year in Review Ed Pd PrM FIT Moderators: Deana M. Lazaro, MD and Michael J. Battistone, MD Speaker: Andrew R. Hoellein, MD recognize the major research reports and scholarship in the field of medical education over the past year 2014 Program Book 45
scientific sessions SUNDAY november 16, 2014 translate results of educational research to their own educational programs formulate ideas for educational research at their own institution 205 B New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines Ed Pd PrM FIT Moderators: Jasvinder A. Singh, MD, MPH and Timothy E. McAlindon, MD, MPH, MRCP summarize the evidence regarding weight loss in the management of osteoarthritis assess the role of arthroscopic debridement in treatment of osteoarthritis discuss how to reconcile differences between recent osteoarthritis treatment guidelines from the ACR, AAOS and other leading organizations 2:30 pm Weight Loss in the Management of Osteoarthritis: Lessons From Randomized Trials Stephen P. Messier, PhD 3:00 pm Arthroscopic Debridement and Meniscal Tear Surgery in Osteoarthritis Patients: Who Needs It and When and When Not to Do It Jeffrey N. Katz, MD, MSc 3:30 pm Recommendations for Management of Osteoarthritis: Can We Reconcile Differences? Marc C. Hochberg, MD, MPH, MACP Exhibit Hall C The Great Debate: Belimumab for the Treatment of Systemic Lupus Erythematosus Moderator: Elana J. Bernstein, MD, MSc identify predictors of response to belimumab discuss the efficacy of belimumab in the treatment of systemic lupus erythematosus evaluate the limitations of belimumab in the treatment of systemic lupus erythematosus describe the safety issues with belimumab discuss the outcomes and limitations of the BLISS-52 and BLISS-76 trials 2:30 pm Pro Perspective Bevra H. Hahn, MD 3:05 pm Pro Rebuttal David A. Isenberg, MD 3:13 pm Con Perspective David A. Isenberg, MD 3:48 pm Con Rebuttal Bevra H. Hahn, MD 3:56 pm Pro Final Bevra H. Hahn, MD 3:58 pm Con Final David A. Isenberg, MD ACR CONCURRENT ABSTRACT SESSIONS 2:30 4:00 pm 253 B Epidemiology and Public Health I: Drug and Vaccine Safety Moderators: Kaleb Michaud, PhD and Cynthia S. Crowson, MS 2:30 pm 820. Herpes Zoster Infection Risk in Auto-Immune and Inflammatory Diseases: Implications for Vaccination Huifeng Yun 1, Shuo Yang 2, Lang Chen 2, Fenglong Xie 2, K. L. Winthrop 3, John Baddley 2, Kenneth G. Saag 4, Jasvinder Singh 2 and Jeffrey R. Curtis 2, 1 University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2 University of Alabama at Birmingham, Birmingham, AL, 3 Oregon Health and Science University, Portland, OR, 4 The University of Alabama at Birmingham, Birmingham, AL 2:45 pm 821. Pregnancy Outcome in Women Treated with Adalimumab for the Treatment of Rheumatoid Arthritis: An Update Christina D Chambers 1, Diana L Johnson 2, Yunjun Luo 2, Ronghui Xu 1 and Kenneth L Jones 2, 1 University of California San Diego Department of Family and Preventive Medicine, La Jolla, CA, 2 University of California San Diego Department of Pediatrics, La Jolla, CA Pharmaceuticals, 2, Sandoz, 2, Sanofi-Aventis Pharmaceutical, 2, Teva Pharmaceuticals, 2, UCB, 2. 3:00 pm 822. Meloxicam and Risk of Myocardial Infarction: A Population-Based Cohort Study Deepan Dalal 1, Maureen Dubreuil 2, Yuqing Zhang 2, Christine Peloquin 2, Tuhina Neogi 2, Hyon Choi 2 and David T. Felson 2, 1 Boston Medical Center, Boston, MA, 2 Boston University School of Medicine, Boston, MA 3:15 pm 823. Risk of Active Tuberculosis in Patients with Arthritis Receiving TNF-α Inhibitors: A Look Beyond the Baseline Tuberculosis Screening Protocol Alina Soare, Carina Mihai, Ana Maria Gherghe, Rucsandra Dobrota, Raida Oneata, Simona Pintilie, Mihaela Milicescu, 46 2014 Program Book
scientific sessions Ioan Ancuta, Andrei Martin, Mariana Sasu, Claudia Ciofu, Liviu Macovei, Victor Stoica and Mihai Bojinca, Carol Davila University of Medicine and Pharmacy & Cantacuzino Hospital, Bucharest, Romania 3:30 pm 824. Impact of Oral Glucocorticoid Therapy on Mortality in Patients with Rheumatoid Arthritis and Diabetic Mellitus Mohammad Movahedi and William G Dixon, Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom 3:45 pm 825. Serious Infections on TNF Inhibitors: Have the Risks Changed over Calendar Time and How High Are They? Elizabeth V. Arkema, Karolinska Institutet, Stockholm, Sweden Disclosures: E. V. Arkema, None. 104 B Metabolic and Crystal Arthropathies I: Clinical Aspects Moderators: N. Lawrence Edwards, MD and Janitzia Vazquez- Mellado, MD PhD 2:30 pm 826. Comparison of Classification Criteria for Gout Using Monosodium Urate Crystal Identification By a Certified Examiner As the Gold-Standard in a Large Multi-National Study William Taylor 1, Nicola Dalbeth 2, Jaap Fransen 3, Tuhina Neogi 4, H. Ralph Schumacher Jr. 5 and Tim Jansen 6, 1 University of Otago Wellington, Wellington, New Zealand, 2 University of Auckland, Auckland, New Zealand, 3 Radboud University, Nijmegen, Netherlands, 4 Boston University School of Medicine, Boston, MA, 5 University of Pennsylvania VA Medical Center, Philadelphia, PA, 6 Radboud University Medical Center, Nijmegen, Netherlands 2:45 pm 827. Gout and the Risk of Alzheimer s Disease: A Population- Based Cohort Study Na Lu 1, Yuqing Zhang 1, Alberto Ascherio 2, Miguel Hernan 2, Tuhina Neogi 1, Maureen Dubreuil 3 and Hyon Choi 4, 1 Boston University School of Medicine, Boston, MA, 2 Harvard School of Public Health, Boston, MA, 3 Boston University Medical Center, Boston, MA, 4 Harvard Medical School, Boston, MA 3:00 pm 828. Extent of Urate Deposition in Asymptomatic Hyperuricemia and Symptomatic Gout: A Dual Energy Computed Tomography Study Nicola Dalbeth 1, Meaghan House 1, Opetaia Aati 1, Paul Tan 1, Christopher Franklin 1, Anne Horne 1, Gregory Gamble 1, Lisa K. Stamp 2, Anthony Doyle 1 and Fiona M. McQueen 1, 1 University of Auckland, Auckland, New Zealand, 2 University of Otago, Christchurch, New Zealand 3:15 pm 829. Asymptomatic Deposit of Monosodium Urate Crystals Associates to a More Severe Coronary Calcification in Hyperuricemic Patients with Acute Coronary Syndrome Mariano Andrés 1, María Amparo Quintanilla 1, Francisca Sivera 1, Paloma Vela 2 and Juan Miguel Ruiz-Nodar 3, 1 Hospital General Universitario de Elda, Alicante, Spain, 2 Universidad Miguel Hernández, Alicante, Spain, 3 Hospital General Universitario de Alicante, Alicante, Spain 3:30 pm 830. Profound Hypouricemia Induced in Human Subjects By Novel Bifunctional Inhibitors of Xanthine Oxidase and URAT1 Raymond P. Warrell Jr. 1, Anna Klukovits 2, Keith Barnes 3, Chitkala Satyanarayana 4, Chris Cheeseman 5 and John Piwinski 1, 1 Relburn- Metabolomics, Inc., Westfield, NJ, 2 SOLVO Biotechnology, Budapest, Hungary, 3 AMRI, Albany, NY, 4 AMRI, Singapore, Singapore, 5 University of Alberta, Alberta, AB 3:45 pm 831. Bisphosphonates and Risk of Acute Pseudogout: A Case- Control Study in the Clinical Practice Research Datalink (CPRD) Edward Roddy, Sara Muller, Zoe Paskins, Samantha Hider, Milisa Blagojevic-Bucknall and Christian Mallen, Keele University, Keele, United Kingdom 160 B Miscellaneous Rheumatic and Inflammatory Diseases Moderators: Mehrdad Maz, MD and Isabelle Koné-Paut, MD 2:30 pm 832. NOD2-Associated Autoinflammatory Disease: The Largest Cohort Study Qingping Yao, Min Shen, Christine McDonald, Felicitas Lacbawan and Bo Shen, Cleveland Clinic, Cleveland, OH 2:45 pm 833. Canakinumab Use in Patients with Cryopyrin-Associated Periodic Syndrome: Interim Safety and Efficacy Results from Beta-Confident Registry Hal M. Hoffman 1, Jasmin B. Kuemmerle-Deschner 2, Philip N. Hawkins 3, T. van der Poll 4, Ulrich A. Walker 5, Ken Abrams 6 and Hugh H. Tilson 7, 1 University of California at San Diego, La Jolla, CA, 2 University Hospital Tuebingen, Tuebingen, Germany, 3 University College London Medical School, London, United Kingdom, 4 University of Amsterdam, Amsterdam, Netherlands, 5 Department of Rheumatology, University Hospital Basel, Basel, Switzerland, Basel, Switzerland, 6 Novartis Pharmaceutical Corporation, East Hanover, NJ, 7 University of North Carolina, Chapel Hill, NC 3:00 pm 834. Interleukin-18 (IL-18) As a Biomarker for Diagnosis and Evaluation of Disease Activity in Patients with Adult Onset Still s Disease and Systemic Onset Juvenile Idiopathic Arthritis Holger Kudela 1, Susanne Drynda 2, Anke Lux 3, Gerd Horneff 4 and Joern Kekow 2, 1 Univ of Magdeburg, Clinic for Rheumatology, Vogelsang-Gommern, Germany, 2 Univ of Magdeburg, Clinic of Rheumatology, Vogelsang-Gommern, Germany, 3 Univ of Magdeburg, Institute for Biometry and Medical Informatics, Magdeburg, Germany, 4 Asklepios Clinic Sankt Augustin, Sankt Augustin, Germany SUNDAY november 16, 2014 2014 Program Book 47
scientific sessions SUNDAY november 16, 2014 3:15 pm 835. Relapsing Polychondritis Can Be Characterized By 3 Different Clinical Phenotypes: Analysis of a Series of 142 Patients Jeremie Dion 1, Nathalie Costedoat-Chalumeau 1, Damien Sène 2, Judith Cohen-Bittan 3, Gaëlle Leroux 3, Charlotte Dion 4, Camille Francès 5 and Jean-Charles Piette 3, 1 National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, Paris, France, 2 Hopital Lariboisière, service de Médecine Interne, Paris, France, 3 CHU Pitié-Salpêtrière, Paris, France, 4 Ecole des hautes études en sciences sociales, Paris, France, 5 Hôpital Tenon, Paris Cedex 20, France 3:30 pm 836. Categorical Change in 6MWD in Patients with Connective Tissue Disease Associated Pulmonary Arterial Hypertension Receiving Ambrisentan over 3-Years Aryeh Fischer 1, Virginia D. Steen 2, Steven Nathan 3, Hunter Gillies 4, James Tislow 4 and Chris Blair 4, 1 National Jewish Health, Denver, CO, 2 Georgetown University Medical Center, Washington, DC, 3 Inova Medical Group, Falls Church, VA, 4 Gilead Sciences, Inc., Foster City, CA 3:45 pm 837. Progressive Multifocal Leukoencephalopathy Associated with Biologic Therapy in Rheumatic Diseases: Strengthening Association with Rituximab Eamonn Molloy 1 and Leonard H. Calabrese 2, 1 St Vincent University Hospital, Dublin, Ireland, 2 Cleveland Clinic Foundation, Cleveland, OH Ballroom East Rheumatoid Arthritis Clinical Aspects I: Cardiovascular Disease Risk Moderators: Grant H. Louie, MD, MHS and Jon Giles, MD, MPH 2:30 pm 838. The Impact of Rheumatoid Arthritis Disease Activity on Cardiovascular Disease Risk: What Is the Role of the Flare? Elena Myasoedova 1, Arun K. Chandran 1, Birkan İlhan 2, Brittny T. Major 1, C. John Michet 1, Eric L. Matteson 1 and Cynthia S. Crowson 1, 1 Mayo Clinic, Rochester, MN, 2 Marmara University School of Medicine, Istanbul, Turkey 2:45 pm 839. Cardiovascular Risk with NSAIDs in Rheumatoid Arthritis: An Analysis Using Routinely Collected Data Fowzia Ibrahim 1, Antigoni Grigoriou 2, Khaldoun Chaabo 2, David L. Scott 2, Sophia Steer 2 and James Galloway 2, 1 King s College London, Department of Rheumatology, London, United Kingdom, 2 King s College Hospital, Department of Rheumatology, London, London, United Kingdom 3:00 pm 840. Vascular Calcifications on Hand and Wrist Radiographs Are Associated with Cardiovascular Risk Factors, Antigen- Specific Anti-Citrullinated Protein Antibodies and Mortality in Rheumatoid Arthritis E. Blair Solow 1, Fang Yu 2, Geoffrey M. Thiele 3, Jeremy Sokolove 4, William H. Robinson 5, Zachary M. Pruhs 3, Kaleb Michaud 3, Alan R. Erickson 3, Harlan Sayles 3, Gail S. Kerr 6, Angelo L. Gaffo 7, Liron Caplan 8, Lisa A. Davis 8, Grant W. Cannon 9, Andreas M. Reimold 10, Joshua Baker 11, Pascale Schwab 12, Daniel Anderson 3 and Ted R. Mikuls 3, 1 UT Southwestern Medical Center, Dallas, TX, 2 University of Nebraska Medical Center, Omaha, NE, 3 Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 4 VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 5 VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 6 Washington DC VAMC, Georgetown and Howard University, Washington, DC, 7 Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL, 8 Denver VAMC and Univ of Colorado School of Medicine, Aurora, CO, 9 Salt Lake City VA and University of Utah, Salt Lake City, UT, 10 Dallas VA and University of Texas Southwestern, Dallas, TX, 11 University of Pennsylvania and Philadelphia VAMC, Philadelphia, PA, 12 Oregon Health & Science University, Portland, OR 3:15 pm 841. Lipid Control and Cardiovascular Risk for Patients with Rheumatoid Arthritis Compared with Matched Non- Rheumatoid Arthritis Patients J An 1, E Alemao 2, K Reynolds 3, H Kawabata 2, D H Solomon 4, K P Liao 4 and T C Cheetham 3, 1 Western University of Health Sciences, Pomona, CA, 2 Bristol-Myers Squibb, Princeton, NJ, 3 Kaiser Permanente Southern California, Pasadena, CA, 4 Brigham and Women s Hospital, Boston, MA 3:30 pm 842. Is Rheumatoid Arthritis a Coronary Heart Disease Risk Equivalent, Similar to Diabetes? Jie Zhang 1, Shuo Yang 2, Lang Chen 2, Fenglong Xie 2, Huifeng Yun 3, Paul M. Muntner 2, Emily Levitan 2, Monica Safford 2, Kenneth G. Saag 4, Jasvinder Singh 2 and Jeffrey R. Curtis 2, 1 Univ. of Alabama at Birmingham, Birmingham, AL, 2 University of Alabama at Birmingham, Birmingham, AL, 3 University of Alabama at Birmingham School of Public Health, Birmingham, AL, 4 The University of Alabama at Birmingham, Birmingham, AL 3:45 pm 843. Exercise Is Associated with Protective Cardiovascular Risk Profile Including Increased HDL Particle Number in Patients with Rheumatoid Arthritis Kevin Byram, Annette Oeser, MacRae F. Linton, Sergio Fazio, C Michael Stein and Michelle Ormseth, Vanderbilt University, Nashville, TN Ballroom West Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis Malignancy and Infection Moderators: Stephen A. Paget, MD and Peter C. Taylor, MD, PhD 2:30 pm 844. Frequency of Significant Infection in Patients with RA Following Initiation of Rituximab with up to 5 Years of Followup in a US Observational Study 48 2014 Program Book
scientific sessions Kenneth G. Saag 1, Kevin L. Winthrop 2, D E Furst 3, Kimberly Alexander 4, Angelika Jahreis 5, Carol Chung 6 and Kurt Oelke 7, 1 The University of Alabama at Birmingham, Birmingham, AL, 2 Oregon Health & Science University, Portland, OR, 3 University of California at Los Angeles, Los Angeles, CA, 4 Genentech, Inc., South San Francisco, CA, 5 Genentech, South San Francisco, CA, 6 Genentech, Inc, South San Francisco, CA, 7 Rheumatic Disease Center, Glendale, WI 2:45 pm 845. The Risk of Cancer with Tumor Necrosis Factor Inhibitors in Patients Concomitantly Exposed to Non-Biological Immunosuppressants Differs According to the Indication Layla Saliba 1, Guillaume Moulis 2, Malak Aboutaam 3, Grégory Pugnet 2, Vanessa Rousseau 1, Leila Chebane 1, Nadine Petitpain 4, Bernadette Baldin 5, Jean-Louis Montastruc 1 and Haleh Bagheri 1, 1 Toulouse University Hospital, Clinical Pharmacology Department, University of Toulouse, Toulouse, France, 2 Toulouse University Hospital, Department of Internal Medicine, University of Toulouse, INSERM UMR 1027, Toulouse, France, 3 Reims University Hospital, Pharmacovigilance Regional Center, Reims, France, 4 Nancy University Hospital, Pharmacovigilance Regional Center, Nancy, France, 5 Nice University Hospital, Pharmacovigilance Regional Center, Nice, France 3:00 pm 846. Rheumatoid Arthritis, Anti-Tumor Necrosis Factor Therapy and Risk of Squamous Cell and Basal Cell Skin Cancer- a Nationwide Population Based Prospective Cohort Study from Sweden Pauline Raaschou 1, Julia F Simard 2, Charlotte Asker-Hagelberg 3, Johan Askling 4 and the ARTIS Study group 5, 1 Karolinska Institutet, Stockholm, Sweden, 2 Stanford School of Medicine, Stanford, CA, 3 Swedish Medical Products Agency, SE-751 03 Uppsala, Sweden, 4 Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 5 Karolinska Institutet och Svensk Reumatologisk förening, Solna, Sweden 3:15 pm 847. Safety of TNF Inhibitor Therapy in Patients Who Have Had a Prior Malignancy Seung-Hyeon Bae, Doo-Ho Lim, Soo Min Ahn, Seokchan Hong, Yong-Gil Kim, Chang-Keun Lee and Bin Yoo, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea 3:30 pm 848. Malignant Progression of Precancerous Lesions of the Uterine Cervix Following DMARD Therapy in Female Arthritis Patients René Cordtz 1, Lene Mellemkjær 2, Bente Glintborg 1, Merete Lund Hetland 3 and Lene Dreyer 1, 1 Copenhagen University Hospital Gentofte, Hellerup, Denmark, 2 The Danish Cancer Society, Copenhagen, Denmark, 3 Copenhagen University Hospital Glostrup. On behalf of all departments of Rheumatology in Denmark., Glostrup, Denmark 3:45 pm 849. Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: Safety and Efficacy in Open-Label, Long-Term Extension up to 6 Years J. Wollenhaupt 1, J. Silverfield 2, E.B. Lee 3, S.P. Wood 4, K. Terry 4, H. Nakamura 5, K. Kwok 6, A. Anisfeld 6, C. Nduaka 4, R. Riese 4 and L. Wang 4, 1 Schoen-Klinik Hamburg-Eilbek Teaching Hospital of the University of Hamburg, Hamburg, Germany, 2 Healthpoint Medical Group, Tampa, FL, 3 Seoul National University, Seoul, South Korea, 4 Pfizer Inc, Groton, CT, 5 Pfizer Inc, Tokyo, Japan, 6 Pfizer Inc, New York, NY 210 B Spondyloarthropathies and Psoriatic Arthritis I Novel Treatments for Axial Spondyloarthritis Moderators: Atul A. Deodhar, MD and Lianne S. Gensler, MD 2:30 pm 850. Targeting Synovial Mast Cells in Spondyloarthritis: A Proof-of-Concept Study with the Tyrosine Kinase Inhibitor Nilotinib Jacqueline E. Paramarta 1, Maureen C. Turina 1, Tanja F. Heijda 1, Iris C. Blijdorp 2, Troy Noordenbos 1, Nataliya Yeremenko 1 and Dominique L. Baeten 2, 1 Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 2 Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands 2:45 pm 851. A Tailored Approach to Reduce Dose of Anti-TNF Drugs Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Propensity Score-Matched Cohort Study Jakub Zavada 1, Michal Uher 2, Katarina Sisol 3, Sarka Forejtova 3, Katerina Jarosova 3, Herman F. Mann 4, Jiri Vencovsky 5 and Karel Pavelka 6, 1 Charles University, Prague, Czech Republic, 2 Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic, 3 Institute of Rheumatology, Prague, Czech Republic, 4 Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Prague, Czech Republic, 5 Institute of Rheumatology and Clinic of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 6 Institute of Rheumatology, Praha, Czech Republic 3:00 pm 852. Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis Joachim Sieper 1, Martin Rudwaleit 2, Désirée M. van der Heijde 3, Walter P. Maksymowych 4, Maxime Dougados 5, Philip Mease 6, Jürgen Braun 7, Atul A. Deodhar 8, Bengt Hoepken 9, Tommi Nurminen 9 and Robert B. M. Landewé 10, 1 Charité Universitätsmedizin Berlin, Berlin, Germany, 2 Endokrinologikum, Berlin, Germany, 3 Leiden University Medical Center, Leiden, Netherlands, 4 University of Alberta, Edmonton, AB, 5 Université Paris René Descartes and Hôpital Cochin, Paris, France, 6 Swedish Medical Center and University of Washington, Seattle, WA, 7 Ruhr-University Bochum, Herne, Germany, 8 Oregon Health and Sciences University, Portland, OR, 9 UCB Pharma, Monheim, Germany, 10 Amsterdam Rheumatology Center, Amsterdam, Netherlands SUNDAY november 16, 2014 2014 Program Book 49
scientific sessions SUNDAY november 16, 2014 3:15 pm 853. Cancer Incidence in TNF Inhibitor Treated Patients with Axial Spondyloarthritis and Psoriatic Arthritis a Study from the ARTIS and Danbio Registers Johan Askling 1, Lene Dreyer 2, Merete Lund Hetland 3, Lennart Jacobsson 4, Lars-Erik Kristensen 5, Bente Glintborg 6,. ARTIS and DANBIO study groups 7 and Karin Hellgren 1, 1 Karolinska Institutet, Stockholm, Sweden, 2 Gentofte University Hospital, Hellreup, Denmark, 3 Glostrup University Hospital, Glostrup, Denmark, 4 Sahlgrenska Academy, Gothenburg, Sweden, 5 Lund University, Lund, Sweden, 6 Gentofte University Hospital, Gentofte, Denmark, 7 Karolinska Institutet, Stockholm, Sweden 3:30 pm 854. Golimumab Versus Pamidronate for the Treatment of Axial Spondyloarthropathy (SpA): A 48-Week Randomized Controlled Trial Chi Chiu Mok, Angela Li, Kar Li Chan and Ling Yin Ho, Tuen Mun Hospital, Hong Kong, Hong Kong 3:45 pm 855. Active and Structural Lesions on MRI of the Sacroiliac Joints Predict Major Clinical Responses in Patients with Non- Radiographic Axial Spondyloarthritis Treated with Etanercept WP Maksymowych 1, S Wichuk 1, H Jones 2, A Szumski 2, L Marshall 2, J Bukowski 2 and RG Lambert 1, 1 University of Alberta, Edmonton, AB, 2 Pfizer Inc., Collegeville, PA 153 B Systemic Lupus Erythematosus Animal Models Moderators: Keith B. Elkon, MD and Ram P. Singh, PhD 2:30 pm 856. A Pathogenic Role for the Gut Microbiota in Murine Antiphospholipid Syndrome and Lupus Silvio M. Vieira, Andrew Yu, Michael Hiltesperger, Odelya E. Pagovich, Eleni Tiniakou, William Ruff, John Sterpka and Martin Kriegel, Yale School of Medicine, New Haven, CT 2:45 pm 857. Amelioration of Systemic Lupus Erythematosus (SLE) in NZM 2328 Mice By Selectively Blocking Engagement of Two BAFF Receptors Chaim O. Jacob, Ning Yu and William Stohl, University of Southern California Keck School of Medicine, Los Angeles, CA 3:00 pm 858. ABT-199, a Potent and Selective BCL-2 Inhibitor, Prevents Lupus Nephritis in the Spontaneous NZB/W F1 Mouse Model By Depleting Selective Lymphocyte Populations While Sparing Platelets Li Chun Wang 1, Stuart Perper 1, Annette Schwartz 1, Christian Goess 1, Liz O connor 1, Dawna Hartman 1, Candace Graff 1, Andrew Souers 2, Joel Leverson 2, Steven Elmore 2 and Lisa Olson 1, 1 AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 2 AbbVie Inc, North Chicago, IL 3:15 pm 859. TGF-β3-Producing CD4 + CD25 - LAG3 + Regulatory T Cells Control B Cell Responses Tomohisa Okamura 1, Kaoru Morita 1, Mariko Inoue 1, Toshihiko Komai 1, Yukiko Iwasaki 1, Shuji Sumitomo 1, Shinichiro Nakachi 1, Hirofumi Shoda 2, Keishi Fujio 2 and Kazuhiko Yamamoto 1, 1 Graduate School of Medicine, the University of Tokyo, Tokyo, Japan, 2 The University of Tokyo, Tokyo, Japan 3:30 pm 860. Inhibition of G Protein βγ Signaling Inhibits Nephritis in Lupus Prone Mice Teresa Owen, Javier Rangel-Moreno, Jesi To, Bruce Goldman, Alan Smrcka and Jennifer H. Anolik, University of Rochester, Rochester, NY 3:45 pm 861. Ultraviolet B Generates Type 1 Interferon and Induces Autoantibody-Mediated Disease in a Mouse Model of Cutaneous Lupus Clayton Sontheimer and Keith B. Elkon, University of Washington, Seattle, WA 258 B Systemic Lupus Erythematosus Clinical Aspects and Treatment: Cardiovascular Disease and Pregnancy Moderators: Wendy Marder, MD and Eliza Chakravarty, MD, MS 2:30 pm 862. Risk Factors for Changes in Subclinical Atherosclerosis As Measured By Carotid Intima Media Thickness (IMT) and Plaque over 5 Years in Women with Systemic Lupus Erythematosus (SLE) Apinya Lertratanakul 1, Peggy W. Wu 1, Alan Dyer 1, William Pearce 1, Emma Barinas-Mitchell 2, Trina Thompson 2 and Rosalind Ramsey- Goldman 3, 1 Northwestern University, Chicago, IL, 2 University of Pittsburgh, Pittsburgh, PA, 3 Northwestern University and Feinberg School of Medicine, Chicago, IL 2:45 pm 863. Metabolic Syndrome in Young Premenopausal Female Lupus Patients Is Mainly Influenced By Therapies Luciana Muniz 1, Rosa M.R. Pereira 1, Thiago Silva 1, Eloisa Bonfá 2 and Eduardo Ferreira Borba 1, 1 University of São Paulo, São Paulo, Brazil, 2 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 3:00 pm 864. Association of Coronary Artery Calcification with Brown and White Pericardial Adipose Tissue in SLE Kelly J. Shields, Lupus Center of Excellence / Allegheny Health Network, Pittsburgh, PA 3:15 pm 865. Cardiovascular Events Prior to or Early after Diagnosis of SLE Murray B. Urowitz 1, Dafna D. Gladman 1, Nicole Anderson 1, Dominique Ibanez 1 and Systemic Lupus International Collaborating Clinics (SLICC) 2, 1 University of Toronto, Toronto Western Hospital, Toronto, ON, 2 University of Toronto, Toronto Western Hospital (Coordinating Center), Toronto, ON 50 2014 Program Book
scientific sessions 3:30 pm 866. Heart Rate Variability: An Inflammatory Biomarker in Systemic Lupus Erythematosus Aikaterini Thanou 1, Stavros Stavrakis 2, John Dyer 2, Stan Kamp 1, Melissa E. Munroe 1, David Albert 3, Judith A. James 1 and Joan T. Merrill 1, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 3 AliveCor, Inc., San Francisco, CA 3:45 pm 867. Specific SLE Disease Manifestations in the Six Months Prior to Conception Predict Similar Manifestations during Pregnancy Sara K. Tedeschi, Hongshu Guan, Alexander Fine, Bonnie L. Bermas and Karen H. Costenbader, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 107 B Systemic Lupus Erythematosus Human Etiology and Pathogenesis I: Pathways of Inflammation/Injury Moderators: Robert M. Clancy, PhD and Susan Boackle, MD 2:30 pm 868. Protein Phosphatase 5 (PP5) Regulates Methylation Sensitive Gene Expression in CD4+ T Cells Dipak R. Patel, Gabriela Gorelik and Bruce C. Richardson, University of Michigan, Ann Arbor, MI 2:45 pm 869. UBE2L3 genotype Influences Plasma Cell Proliferation in Systemic Lupus Erythematosus By Regulation of NF-κB By the Linear Ubiquitination Assembly Complex Myles J. Lewis 1, Simon Vyse 1, Adrian M. Shields 2, Sebastian Boeltz 2, Patrick Gordon 2, Timothy D. Spector 2, Paul J. Lehner 3, Henning Walczak 4 and Timothy J. Vyse 2, 1 Queen Mary University of London, London, United Kingdom, 2 King s College London, London, United Kingdom, 3 University of Cambridge, Cambridge, United Kingdom, 4 University College London, London, United Kingdom 3:00 pm 870. IRF1 Influences on Histone H4 Acetylation in Systemic Lupus Erythematosus Yiu Tak Leung 1, Lihua Shi 2, Kelly Maurer 2, Li Song 2, Zhe Zhang 3, Michelle Petri 4 and Kathleen E. Sullivan 2, 1 University of Pennsylvania, Philadelphia, PA, 2 The Children s Hospital of Philadelphia, Philadelphia, PA, 3 Bioinformatics, Children s Hospital of Philadelphia, Philadelphia, PA, 4 Johns Hopkins University School of Medicine, Baltimore, MD 3:15 pm 871. Antimalarials Regulate TLR7/8 Mediated Macrophage Activation Via Epigenetic Modification at the TNFα Promoter Androo J. Markham 1, Mark Halushka 2, Cristiana Guiducci 3, Robert M. Clancy 1 and Jill P. Buyon 1, 1 New York University School of Medicine, New York, NY, 2 John Hopkins Pathology, Baltimore, MD, 3 Dynavax Technologies, Berkeley, CA 3:30 pm 872. Interferon-α and Angiogenic Dysregulation in Pregnant Lupus Patients Destined for Preeclampsia Danieli Andrade 1, Mimi Kim 2, Luz P. Blanco 3, S. Ananth Karumanchi 4, Gloria Koo 1, Patricia M. Redecha 1, Kyriakos A. Kirou 1, Angela M. Alvarez 5, Melissa J. Mulla 5, Mary K. Crow 1, Vikki Abrahams 5, Mariana J. Kaplan 3 and Jane E. Salmon 1, 1 Hospital for Special Surgery, New York, NY, 2 Albert Einstein College of Medicine, Bronx, NY, 3 National Institutes of Health, Bethesda, MD, 4 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 5 Yale School of Medicine, New Haven, CT 3:45 pm 873. The Second Messenger, Cyclic GMP-AMP Dinucleotide (cgamp) and the Enzyme, Cyclic GMP-AMP Synthase (cgas), Are Expressed in Systemic Lupus Erythematosus Jie An, Joshua Woodward, Reynold Karr, Thomas H. Teal and Keith B. Elkon, University of Washington, Seattle, WA 157 B Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics I: Systemic Sclerosis, Advances in Therapy Moderators: Sindhu R. Johnson, MD, PhD and Christopher P. Denton, MD, PhD 2:30 pm 874. Safety and Efficacy of Subcutaneous Tocilizumab in Adults with Systemic Sclerosis: Week 24 Data from a Phase 2/3 Trial Dinesh Khanna 1, Christopher P. Denton 2, Jacob M. van Laar 3, Angelika Jahreis 4, Sabrina Cheng 4, Helen Spotswood 5, Jeffrey Siegel 4 and Daniel E. Furst on behalf of FaSScinate Clinical Trial in Patients With SS 6, 1 University of Michigan Health System, Ann Arbor, MI, 2 University College London Medical School, London, United Kingdom, 3 University Medical Center Utrecht, Utrecht, Netherlands, 4 Genentech, South San Francisco, CA, 5 Roche Products Ltd., Welwyn Garden City, United Kingdom, 6 University of California, Los Angeles, CA 2:45 pm 875. Treatment-Related Outcomes in Connective Tissue Disease-Associated Pulmonary Arterial Hypertension: A Pooled Analysis of 12 Randomized Controlled Trials Rennie L. Rhee 1, Nicole B. Gabler 1, Amy Praestgaard 1, Peter A. Merkel 2 and Steven M. Kawut 1, 1 University of Pennsylvania, Philadelphia, PA, 2 Vasculitis Center, University of Pennsylvania, Philadelphia, PA 3:00 pm 876. SAR100842, an Antagonist of Lysophosphatidic Acid Receptor 1, As a Potential Treatment for Patients with Systemic Sclerosis: Results from a Phase 2a Study Dinesh Khanna 1, Christopher P. Denton 2, Alexandre Jagerschmidt 3, Martine Jasson 4, Oliver Distler 5 and Yannick Allanore 6, 1 University of Michigan Scleroderma Program, Ann Arbor, MI, 2 UCL Medical School Royal Free Campus, London, United Kingdom, 3 Sanofi-Aventis, Chilly-Mazarin, France, 4 Sanofi-Aventis, Paris, France, 5 Zurich University Hospital, Zurich, SUNDAY november 16, 2014 2014 Program Book 51
scientific sessions SUNDAY november 16, 2014 Switzerland, 6 Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France 3:15 pm 877. Sildenafil Attenuates the Fibrotic Phenotype in Scleroderma Skin Fibroblasts Tomoaki Higuchi 1, Yasushi Kawaguchi 1, Kae Takagi 1, Akiko Tochimoto 1, Yuko Ota 1, Yasuhiro Katsumata 1, Takahisa Gono 1, Masanori Hanaoka 1, Yuko Okamoto 1, Hidenaga Kawasumi 1 and Hisashi Yamanaka 2, 1 Tokyo Women s Medical University, Tokyo, Japan, 2 Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 3:30 pm 878. Luminex and Autoantigen Microarray Analysis of Sera from Patients with Diffuse Cutaneous Systemic Sclerosis Reveals Changes Associated with Imatinib Mesylate Treatment D. James Haddon 1, Hannah Wand 1, Paul J. Utz 1, Robert F. Spiera 2, Jessica K. Gordon 2 and Lorinda Chung 3, 1 Stanford University School of Medicine, Stanford, CA, 2 Hospital for Special Surgery, New York, NY, 3 Stanford University School of Medicine, Palo Alto, CA 3:45 pm 879. Efficacy of Autologous Hematopoietic Stem Cell Transplantation in Rapidly Progressive Systemic Sclerosis: Prolonged Remission of Disease Activity in a Long-Term Follow up Eleonora Zaccara 1, Domenico Sambataro 2, Wanda Maglione 1, Gianluca Sambataro 1, Francesco Onida 3, Claudio Annaloro 3, Giorgia Saporiti 3, Elena Tagliaferri 3, Agostino Cortelezzi 3, Rosaria Giordano 3, Claudio Vitali 4 and Nicoletta Del Papa 2, 1 Osp. G. Pini, Milano, Italy, 2 Istituto G.Pini, Milan, Italy, 3 Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico-University of Milan, Milano, Italy, 4 Istituto San Giuseppe, Lecco, Italy 156 B Vasculitis I Moderators: Maria C. Cid, MD. PhD and Kenneth J. Warrington, MD 2:30 pm 880. An Immunochip Study Confirms a Strong Contribution of HLA Class I and II Genes in the Susceptibility to Giant Cell Arteritis Francisco David Carmona 1, Sarah Mackie 2, Jose Ezequiel Martin 1, John Taylor 2, Augusto Vaglio 3, Lara Bossini-Castillo 1, Santos Castañeda 4, Maria C. Cid 5, José Hernández-Rodríguez 5, Roser Solans 6, Ricardo Blanco 7, Lorenzo Beretta 8, Claudio Lunardi 9, Marco A. Cimmino 10, Cisca Wijmenga 11, Torsten Witte 12, Julia Holle 13, Frank Moosig 13, Verena Schönau 14, Andre Franke 15, Øyvind Palm 16, Andreas P. Diamantopoulos 17, Benedicte A. Lie 18, Simon Carette 19, David Cuthbertson 20, Gary S. Hoffman 21, Nader A. Khalidi 22, Curry L. Koening 23, Carol A. Langford 24, Carol McAlear 25, Larry Moreland 26, Paul A. Monach 27, Christian Pagnoux 19, Philip Seo 28, Antoine G. Sreih 29, Kenneth J. Warrington 30, Steven R. Ytterberg 30, Colin T. Pease 31, Andrew Gough 32, Michael Green 33, Lesley Hordon 34, Stephen Jarrett 35, Richard Watts 36, Sarah Levy 37, Yusuf Patel 38, Sanjeet Kamath 39, Bhaskar Dasgupta 40, Paul IW. de Bakker 41, Bobby P.C. Koeleman 41, Jennifer H. Barrett 2, Carlo Salvarani 42, Peter A. Merkel 25, Miguel A. Gonzalez-Gay 7, Ann W. Morgan 2 and Javier Martin 1, 1 Instituto de Parasitología y Biomedicina López-Neyra, IPBLN-CSIC, Armilla (Granada), Spain, 2 University of Leeds, Leeds, United Kingdom, 3 University Hospital of Parma, Parma, Italy, 4 Hospital Universitario de La Princesa, IISP, Madrid, Spain, 5 Hospital Clínic University of Barcelona, Institut d Investigacions Biomèdiques August Pi i Sunyer (IDIBA), Barcelona, Spain, 6 Hospital Vall d Hebron, Autonomous University of Barcelona, Barcelona, Spain, 7 Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain, 8 Referral Center for Systemic Autoimmune Diseases, Fondazione IRCCS Ca Granda Ospedale Maggiore Policlinico di Milano, Milan, Italy, 9 Università degli Studi di Verona, Verona, Italy, 10 University of Genova, Genova, Italy, 11 University Medical Hospital Groningen, University of Groningen, Groningen, Netherlands, 12 Hannover Medical School, Hannover, Germany, 13 Vasculitis Clinic, Klinikum Bad Bramstedt & University Hospital of Schleswig Holstein, Bad Bramstedt, Germany, 14 Universitätsklinikum Erlangen, Erlangen, Germany, 15 Christian-Albrechts-University of Kiel, Kiel, Germany, 16 Oslo University Hospital and University of Oslo, Oslo, Norway, 17 Hospital of Southern Norway Trust, Kristiansand, Norway, 18 University of Oslo and Oslo University Hospital, Oslo, Norway, 19 University of Toronto, Toronto, ON, 20 University of South Florida, Tampa, FL, 21 Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 22 St. Joseph s Hospital, McMaster University, Hamilton, ON, 23 University of Utah, Salt Lake City, UT, 24 Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 25 Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 26 Vasculitis Center, of University of Pittsburgh Medical Center, Pittsburgh, PA, 27 Vasculitis Center, Boston University School of Medicine, Boston, MA, 28 Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 29 The University of Pennsylvania, Philadelphia, PA, 30 Mayo Clinic, Rochester, MN, 31 Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, 32 Harrogate and District Foundation Trust, Harrogate, United Kingdom, 33 York Teaching Hospital NHS Foundation Trust, York, United Kingdom, 34 Mid Yorkshire Hospitals NHS Trust, Dewsbury, United Kingdom, 35 Mid Yorkshire Hospitals NHS Trust, Wakefield, United Kingdom, 36 Ipswich Hospital NHS Trust, Ipswich, United Kingdom, 37 Croydon Health Service NHS Trust, Croydon, United Kingdom, 38 Hull and East Yorkshire NHS Trust, Hull East Yorkshire, United Kingdom, 39 Staffordshire and Stoke-on-Trent Partnership NHS Trust, Staffordshire, United Kingdom, 40 Southend University Hospital, Essex, United Kingdom, 41 University Medical Center Utrecht, Utrecht, Netherlands, 42 Azienda Ospedaliera ASMN, Istituto di Ricovero e Cura a Carattere Scientifico, Reggio Emilia, Italy 2:45 pm 881. DNA Methylation Analysis of the Temporal Artery Microenvironment Reveals a Robust T Cell Signature and Suggests a Role for TNF-α in Giant Cell Arteritis Patrick S. Coit, Lindsey B. De Lott, Bin Nan, Victor M. Elner and Amr H. Sawalha, University of Michigan, Ann Arbor, MI 52 2014 Program Book
3:00 pm 882. A Signature of micrornas Overexpressed in Inflamed Temporal Arteries of Patients with Giant Cell Arteritis Stefania Croci, Alessandro Zerbini, Luigi Boiardi, Francesco Muratore, Alessandra Bisagni, Giulia Pazzola, Luca Cimino, Antonio Moramarco, Davide Nicoli, Enrico Farnetti, Bruno Casali, Alberto Cavazza, Maria Parmeggiani and Carlo Salvarani, Arcispedale S Maria Nuova, Reggio Emilia, Italy 3:15 pm 883. Accuracy of High Resolution MRI of Scalp Arteries for the Diagnosis of Giant Cell Arteritis: Results of a Prospective Study Maxime Rhéaume 1, Ryan Rebello 2, Christian Pagnoux 3, Simon Carette 3, Marie Clements-Baker 4, Violette Cohen-Hallaleh 2, David Doucette-Preville 2, B. Stanley Jackson 5, Sam Salama 6, George Ioannidis 7 and Nader A. Khalidi 8, 1 Division of Rheumatology, St. Joseph s Hospital, McMaster University, Hamilton, ON, 2 Department of Radiology, St. Joseph s Hospital, McMaster University, Hamilton, ON, 3 University of Toronto, Toronto, ON, 4 Queens University, Kingston, ON, 5 Department of Surgery, St. Joseph s Hospital, McMaster University, Hamilton, ON, 6 Department of Pathology, St. Joseph s Hospital, McMaster University, Hamilton, ON, 7 St Joseph s Healthcare Hamilton, Hamilton, ON, 8 St. Joseph s Hospital, McMaster University, Hamilton, ON 3:30 pm 884. Interleukin 6 Does Not Upregulate Pro Inflammatory Cytokine Expression in an Ex-Vivo Model of Giant Cell Arteritis Lorraine O Neill 1, Jennifer McCormick 2, Wei Gao 2, Conor Murphy 3, Geraldine M. McCarthy 4, Douglas J. Veale 1, Ursula Fearon 2 and Eamonn S. Molloy 1, 1 St. Vincent s University Hospital, Dublin 4, Ireland, 2 Translational Rheumatology Research Group, Dublin, Ireland, 3 Royal Victoria Eye and Ear Hospital, Dublin, Ireland, 4 Mater Misericordiae University Hospital, Dublin 7, Ireland 3:45 pm 885. A 2-Week Single-Blind, Randomized, 3-Arm Proof of Concept Study of the Effects of Secukinumab (anti-il17 mab), Canakinumab (anti-il-1 b mab), or Corticosteroids on Initial Disease Activity Scores in Patients with R, Followed By an Open-Label Extension to Assess Safety and Effect Duration Eric L. Matteson 1, Bhaskar Dasgupta 2, Wolfgang A. Schmidt 3, Carlo Salvarani 4, Nagui Gendi 5, Mauro Galeazzi 6, Sylvie Stitah 7, Yue Li 7, Marie-Anne Valentin 7, Bolan Linghu 8 and Stephen J. Oliver 7, 1 Mayo Clinic, Rochester, MN, 2 Southend University Hospital, Essex, United Kingdom, 3 Immanuel Krankenhaus, Berlin, Germany, 4 Arcispedale-Santa-Maria-Nuova, Reggio Emilia, Italy, 5 Basildon & Thurroch University Hospitals NHS Trust, Basildon, Essex, United Kingdom, 6 Università di Siena, Siena, Italy, 7 Novartis Pharma AG, Basel, Switzerland, 8 Novartis Pharma AG, Cambridge, MA ARHP SESSIONS 2:30 4:00 pm scientific sessions 255 Google Minefield: Empowering Patients to Evaluate Online Resources Ed Pd PrM Ed FIT Pd PrM FIT identify quality resources for patients regarding arthritis education describe process of online search for arthritis education resources evaluate health literacy of online content to selectively identify content that meets the needs of specific patients/ consumers 2:30 pm Online Patient Resources for Arthritis and Strategies to Locate Quality Information and Usability Maura D. Iversen, BSc, DPT, SD, MPH 3:15 pm Empowering Patients to Navigate the Google Minefield Laura E. Ray, MA, MLS 256 Practical Practice Management Session One: Improve Quality and Efficiency Moderators: Lee Anderson, BSN and Brandi Young, DNP recognize the links between quality improvement initiatives and payment reform apply techniques in quality measurement to drive practice improvement in rheumatology utilize tools created by the ACR, including the Rheumatology Clinical Registry (RCR) and the Rheumatology Informatics System for Effectiveness (RISE) Registry, to successfully report quality measures for their practices 2:30 pm Payment Reform: What s Coming? Robert Warren, MD, PhD, MPH 3:00 pm Quality Improvement in Rheumatology Jinoos Yazdany, MD, MPH 151 A Sports Medicine for the Rheumatology Provider Moderator: Judy Foxworth, PhD, PT identify mechanisms of injury of common sports medicine injuries of both the shoulder and knee of the older athlete discuss medical/surgical management of common sports medicine injuries of the knee and shoulder with special consideration of athletes with osteoarthritis present evidence of best practices for rehabilitation for older athletes with common shoulder and knee injuries with rheumatic disease 2014 Program Book 53 SUNDAY november 16, 2014
scientific sessions SUNDAY november 16, 2014 2:30 pm Most Common Sports Medicine Injuries of the Older Athlete Karl Fields, MD 3:15 pm Special Considerations for Sports Participation for Those with Rheumatic Disease James J. Irrgang, ATC, PhD, PT 254 A Young Adults with Rheumatic Disease: The Patient Perspective Ed Pd PrM FIT Moderator: Sandra Mintz, BSN enhance their knowledge of the multifaceted experiences of living with a rheumatic disease discuss the importance of patient advocacy and how to help develop it at any age employ tips towards engaging patients and providing them opportunities to develop their toolset for living with a rheumatic disease 2:30 pm Patient Perspective Jennifer R. Horonjeff, MS 3:15 pm Young Adults with Rheumatic Disease: The Patient Perspective Kiana Johnson, PhD ARHP CONCURRENT ABSTRACT SESSION 2:30 4:00 pm Gil 10, Mariana Salcedo 11 and Gustavo Citera 1, 1 Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, 2 Hospital San Roque de Gonnet, La Plata, La Plata, Argentina, 3 Hospital Britanico, Buenos Aires, Argentina, 4 British Hospital, Buenos Aires, Argentina, 5 Hospital Gral. de agudos Dr. E. Tornú, Buenos Aires, Argentina, 6 Hospital General de Agudos Dr. E. Tornú, Buenos Aires, Argentina, 7 Instituto de Investigaciones Medicas Alfredo Lanari, Buenos Aires, Argentina, 8 Insituto de Investigaciones Medicas de la UBA, Capital Federal, Argentina, 9 Hospital Señor del Milagro, Salta, Argentina, 10 Hospital Municipal de agudos Dr. Leonidas Lucero, Bahía Blanca, Argentina, 11 Consultorio Privado, San Nicolás, Argentina 3:00 pm 888. Annual Medical Care Expenditures Among US Adults with Gout, 2005 2011 Miriam G. Cisternas 1, Louise Murphy 2, David J. Pasta 3, Edward H. Yelin 4 and Charles Helmick 2, 1 MGC Data Services, Carlsbad, CA, 2 Centers for Disease Control and Prevention, Atlanta, GA, 3 DMA Corporation, Palo Alto, CA, 4 University of California, San Francisco, San Francisco, CA 3:15 pm 889. Exercise, Manual Therapy and Use of Booster Sessions in Physical Therapy for Knee OA: A Multi-Center Randomized Clinical Trial G Kelley Fitzgerald 1, Julie Fritz 2, John Childs 3, Gerard P. Brennan 4, Douglas P. Landsittel 5, Brett Neilson 6, Alexandra Gil 1 and J. Haxby Abbott 7, 1 University of Pittsburgh, Pittsburgh, PA, 2 University of Utah, Salt Lake City, UT, 3 US Army-Baylor University, Schertz, TX, 4 Intermountain Healthcare, Murray, UT, 5 University of Pittsburgh, Center for Health Care Research Data Center, Pittsburgh, PA, 6 Henry M. Jackson Foundation, Bethesda, MD, 7 University of Otago, Dunedin, New Zealand 257 A Exemplary Abstracts Moderators: Scott Hasson, Pt, PhD and Robert M. McLean, MD 2:30 pm 886. Measuring Rheumatoid Arthritis Remission: Which Index of Disease Activity Best Predicts Work Status? Nancy A. Baker 1, Heather Eng 2, Juan (June) Feng 2, Jason Lyons 2, Yong Gil Hwang 1, Kimberly P. Liang 1 and Larry W. Moreland 1, 1 University of Pittsburgh, Pittsburgh, PA, 2 University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA 2:45 pm 887. The Impact of Inadequate Health Literacy on Disease Activity in Patients with Rheumatoid Arthritis Maria Celeste Orozco 1, Maria Florencia Marengo 1, Christian A. Waimann 1, Ana Inés Marcos 2, Amelia Granel 2, Sofia Velez 3, Federico Zazzetti 3, Juan C. Barreira 4, Paula Kohan 5, Oscar L. Rillo 6, María Victoria Collado 7, Graciela Gómez 8, Ricardo V. Juárez 9, Veronica Lencina 9, Andrea D Orazio 10, Gustavo Rodriguez 3:30 pm 890. Test of the NIH Patient-Reported Outcomes Measurement Information System (PROMIS) 29-Item Profile in a Large Cohort of Rheumatic Disease Patients Patricia P. Katz 1, Sofia Pedro 2 and Kaleb Michaud 3, 1 University of California, San Francisco, San Francisco, CA, 2 National Data Bank, Wichita, KS, 3 University of Nebraska Medical Center and National Data Bank, Omaha, NE 3:45 pm 891. Randomized Clinical Trial of Group Vs. Individual Physical Therapy for Knee Osteoarthritis Kelli D. Allen 1, Dennis Bongiorni 2, Hayden B. Bosworth 3, Cynthia Coffman 3, Santanu Datta 3, David Edelman 3, Jennifer H. Lindquist 2, Eugene Oddone 3 and Helen Hoenig 3, 1 Durham VA Medical Center and University of North Carolina at Chapel Hill, Durham, NC, 2 Durham VA Medical Center, Durham, NC, 3 Durham VA Medical Center and Duke University Medical Center, Durham, NC 54 2014 Program Book
scientific sessions ACR WORKSHO 4:00 6:00 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. demonstrate the mechanism leading to mechanical neck and lumbar pain and the approach at the bedside to discerning the mechanisms and its treatment demonstrate how to more easily determine joint swelling particularly in the metacarpophalangeal joint, proximal interphalangeal joint and wrists ACR SESSIONS 4:30 6:00 pm 52 A Therapeutic Targeting of the Innate Immune System 159 161 Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (210) Speaker: Walter P. Maksymowych, MD recognize typical active and structural lesions of spondyloarthritis recognize complicated/subtle lesions of spondyloarthritis recognize lesions that may mimic spondyloarthritis recognize pitfalls in the interpretation of MRI in spondyloarthritis Muscle Involvement in Rheumatic Diseases (211) Speaker: Sakir Humayun Gultekin, MD identify the histologic abnormalities of steroid myopathy, polymyositis, dermatomyositis and inclusion body myositis examine the major differential diagnostic possibilities in possible myositis cases interpret the findings in the muscle biopsy pathology report 154 *Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (212) Speaker: Stuart L. Silverman, MD use bone mineral density and clinical risk factors in determination of absolute risk of fracture discuss the concept of intervention threshold assess limitations of the Fracture Risk Assessment Algorithm in clinical practice Moderator: Betsy Barnes, PhD describe mechanisms and molecules involved in activation of the innate immune system identify new potential therapeutic targets to maintain immune tolerance recognize the multifunctional role of high mobility group box 1 (HMBG1) in inflammation 4:30 pm High Mobility Group Box 1 as Chemokine and Cytokine Helena E. Harris 5:00 pm Dendric Cells in Tolerance and Immune Activation Michel C. Nussenzweig, MD, PhD 5:30 pm Activation of the Immune System by Intracellular Nucleic Acids Tracy McGaha, PhD Ballroom East Thieves Market: Show Me Your Best Cases Moderators: Rula Hajj-Ali, MD; N. Lawrence Edwards, MD and Rebecca L. Manno, MD, MHS compare their diagnostic and management approaches of selected clinical problems with those of other rheumatologists and the presenters recognize unusual presentations of common diseases identify and recognize essential mimics of the rheumatic diseases 4:30 pm Image Competition Presentation Erika H. Noss, MD SUNDAY november 16, 2014 152 Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (213) Speaker: Edward C. Keystone, MD describe the concept of referred pain and its presentation with neck and lumbar disorders 4:50 pm Case Presentation 1: A Rapid Decline Kevin Wei, MD PhD 5:00 pm Case Presentation 2: An Uncommon Cause of a Common Presentation David McCormick, MB, BaO, BCh, MRCP 2014 Program Book 55
scientific sessions SUNDAY november 16, 2014 5:10 pm Case Presentation 3: Groundhog Day P. W. James Russell, MB, BChir 5:20 pm Case Presentation 4: It is Not a Simple Headache Catherine E. Najem, MD 5:30 pm Case Presentation 5: Lesions in the Spine A Diagnostic Dilemma Mehwish Khan, MBBS, MD 5:40 pm Case Presentation 6: The Nose Knows Sarah Goglin, MD ACR CONCURRENT ABSTRACT SESSIONS 4:30 6:00 pm 104 B Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes I: Research Perspectives Moderators: Laurence A. Bradley, PhD and Leslie J. Crofford, MD 4:30 pm 892. Symptom Increase in Fibromyalgia Is Not Consistent with the Central Sensitization or Central Hyperresponsiveness Hypothesis Frederick Wolfe 1, Brian T. Walitt 2, Johannes Rasker 3, Robert S. Katz 4 and Winfried Häuser 5, 1 National Data Bank for Rheumatic Diseases, Wichita, KS, 2 Washington Hospital Center, Washington, DC, 3 University Twente, Enschede, Netherlands, 4 Rush Medical College, Chicago, IL, 5 Klinikum Saarbrücken, Saarbrücken, Germany 4:45 pm 893. Polysymptomatic Distress Categories for Clinical and Research Use Frederick Wolfe 1, Brian T. Walitt 2, Johannes Rasker 3, Robert S. Katz 4 and Winfried Häuser 5, 1 National Data Bank for Rheumatic Diseases, Wichita, KS, 2 Washington Hospital Center, Washington, DC, 3 University Twente, Enschede, Netherlands, 4 Rush Medical College, Chicago, IL, 5 Klinikum Saarbrücken, Saarbrücken, Germany 5:00 pm 894. Small Fiber Neuropathy in Women with Fibromyalgia. a Clinical-Pathological Correlation Using Confocal Corneal Biomicroscopy Manuel Ramírez-Fernández 1, Laura-Aline Martinez-Martinez 2, Angelica Vargas-Guerrero 2, Manuel Martínez-Lavín 2, Everardo Hernandez Quintela 1 and Jorge Velazco-Caspia 1, 1 Asociación para Evitar la Ceguera en México, Mexico City, Mexico, 2 Instituto Nacional de Cardiologia, Mexico City, Mexico 5:15 pm 895. The Fibromyalgia Syndrome and Widespread Pain Frequency in Active Duty U.S. Service Members with Posttraumatic Stress Disorder Bernard Hildebrand Jr. 1, Jay B. Higgs 1, Douglas Williamson 2, Edna Foa 3, Patricia Resick 4, Jim Mintz 2, Antoinette Brundige 2, Kevin Kelly 5, Adam Borah 5, Stacey Young-McCaughan 2, Brett Litz 6, Elizabeth Hembree 3 and Alan Peterson 2, 1 San Antonio Military Medical Center, JBSA Fort Sam Houston, TX, 2 The University of Texas Health Science Center at San Antonio, San Antonio, TX, 3 University of Pennsylvania, Philadelphia, PA, 4 Duke University, Durham, NC, 5 Carl R. Darnall Army Medical Center, Fort Hood, TX, 6 VA Boston Healthcare System, Boston, MA 5:30 pm 896. Development of Fibromyalgia and Polysymptomatic Distress Definitions in the National Health Interview Survey Brian Walitt 1, Richard Nahin 2, Robert S. Katz 3, Martin J. Bergman 4 and Frederick Wolfe 5, 1 MedStar Health, Washington, DC, 2 National Institutes of Health, Bethesda, MD, 3 Rush Medical College, Chicago, IL, 4 Taylor Hospital, Ridley Park, PA, 5 National Data Bank for Rheumatic Diseases, Wichita, KS 5:45 pm 897. Resting State Functional Connectivity Differs Between Chronic Fatigue Syndrome Patients and Healthy Controls Jason Craggs 1, Charles Gay 1, Andrew O Shea 1, Ricky Madhavan 1, Donald Price 1, Michael Robinson 1 and Roland Staud 2, 1 University of Florida, Gainesville, FL, 2 Univ of Florida Med Ctr/JHMHC, Gainesville, FL 151 A Health Services Research: Risk Assessment and Outcomes of Rheumatic Disease Moderators: Edward H. Yelin, PhD and Katherine Liao, MD, MPH 4:30 pm 898. Traditional Cardiovascular Risk-Factor Management in Patients with Rheumatoid Arthritis Compared with Matched Non-Rheumatoid Arthritis Patients in a US Managed Care Setting J An 1, K Reynolds 2, E Alemao 3, H Kawabata 3, D H Solomon 4, K P Liao 4 and T C Cheetham 2, 1 Western University of Health Sciences, Pomona, CA, 2 Kaiser Permanente Southern California, Pasadena, CA, 3 Bristol-Myers Squibb, Princeton, NJ, 4 Brigham and Women s Hospital, Boston, MA 4:45 pm 899. Insurance Status and U.S. Region Associated with Placement of Permanent Vascular Access in Dialysis Patients with End-Stage Renal Disease Secondary to Lupus Nephritis Laura Plantinga 1, Cristina M. Drenkard 1, Rachel Patzer 1, William McClellan 1, Stephen Pastan 1 and S. Sam Lim 2, 1 Emory University, Atlanta, GA, 2 Emory University School of Medicine, Division of Rheumatology, Atlanta, GA 56 2014 Program Book
scientific sessions 5:00 pm 900. Race and Sex Specific Incidence Rates and Predictors of Total Knee Arthroplasty: Data from the Osteoarthritis Initiative, 7 Years Follow up Jamie E. Collins, Bhushan Deshpande, Jeffrey N. Katz and Elena Losina, Brigham and Women s Hospital, Boston, MA 5:15 pm 901. Rate of Serum Uric Acid (SUA) Assessment in Gout Patients Treated with Urate-Lowering Therapy: Treating to Target? Robert Morlock 1, David M. Kern 2, Ozgur Tunceli 2, Siting Zhou 2, Laura Horne 3, Sulabha Ramachandran 3 and Hyon Choi 4, 1 Ardea Biosciences, San Diego, CA, 2 HealthCore, Inc., Wilmington, DE, 3 AstraZeneca, Wilmington, DE, 4 Harvard Medical School, Boston, MA 5:30 pm 902. Co-Management for Children with JIA: A Survey of Primary Care Providers Regarding Current Practices and Willingness to Provide Services Amanda Mroczek, Gary Freed and Meredith Riebschleger, University of Michigan, Ann Arbor, MI 5:45 pm 903. Poor Adherence to Medications for Systemic Lupus Erythematosus Predicts Higher Health Care Utilization in U.S. Medicaid Beneficiaries Jinoos Yazdany 1, Candace H. Feldman 2, Hongshu Guan 3 and Karen H. Costenbader 3, 1 University of California, San Francisco, San Francisco, CA, 2 Brigham and Women s Hospital, Boston, MA, 3 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 210 B Imaging of Rheumatic Diseases: Ultrasound Moderators: Jay B. Higgs, MD and Wolfgang A. Schmidt, MD 904. Ultrasound Synovitis Reflects Synovial Inflammation at a Histopathological Level Nora Ng, Stephen Kelly, Frances Humby, Maria DiCicco, Vidalba Rocher, Rebecca Hands, Michele Bombardieri and Costantino Pitzalis, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom 4:45 pm 905. First Step in the Development of an Ultrasound Joint Inflammation Score for Rheumatoid Arthritis: A Data Driven Approach Anna-Birgitte Aga 1, Hilde Berner Hammer 1, Inge C. Olsen 1, Till Uhlig 1, Tore K. Kvien 1, Désirée van der Heijde 2, Elisabeth Lie 1, Espen A. Haavardsholm 1 and the Arctic study Group 1, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 Leiden University Medical Center, Leiden, Netherlands 5:00 pm 906. How Long Does Sonographic Joint Activity Continue in Clinically Remittive Joints of Patients with Rheumatoid Arthritis? Miriam Gärtner, Farideh Alasthi, Gabriela Supp, Peter Mandl, Josef Smolen and Daniel Aletaha, Medical University of Vienna, Vienna, Austria 5:15 pm 907. Ultrasonographic Tenosynovitis Score Is Responsive to Biologic Treatment in Patients with Rheumatoid Arthritis Hilde B. Hammer and Tore K. Kvien, Diakonhjemmet Hospital, Oslo, Norway 5:30 pm 908. Ultrasound-Detected Tenosynovitis Independently Associates with Flare in Patients with Rheumatoid Arthritis in Clinical Remission Emanuela Bellis 1, Greta Carrara 2, Carlo Alberto Scirè 2, Alessandra Bortoluzzi 3, Alberto Batticciotto 4, Antonella Adinolfi 5, Giovanni Cagnotto 6, Marta Caprioli 7, Marco Canzoni 8, Francesco Cavatorta 9, Fulvia Ceccarelli 10, Orazio De Lucia 11, Valentina Di Sabatino 12, Antonella Draghessi 13, Georgios Filippou 12, Ilaria Farina 3, Maria Cristina Focherini 14, Paola Frallonardo 15, Alessandra Gabba 16, Angelica Gattamelata 10, Marwin Gutierrez 13, Luca Idolazzi 17, Filippo Luccioli 18, Pierluigi Macchioni 19, Marco Massarotti 20, Claudio Mastaglio 21, Luana Menza 21, Giulia Mirabelli 18, Maurizio Muratore 22, Simone Parisi 23, Valentina Picerno 12, Matteo Piga 24, Roberta Ramonda 25, Bernd Raffeiner 15, Daniela Rossi 26, Paola Rossini 27, Garifallia Sakellariou 28, Crescenzio Scioscia 29, Carlo Venditti 30, Annamaria Iagnocco 10 and Marco Matucci-Cerinic 31, 1 Ospedale Mauriziano, Turin, Italy, 2 Italian Society for Rheumatology, Milan, Italy, 3 A.O.U. S.Anna di Cona, Ferrara, Italy, 4 L.Sacco University Hospital, Milan, Italy, 5 Policlinico le Scotte, Siena, Italy, 6 IRCCS Policlinico San Matteo, Pavia, Italy, 7 Istituto di Cura Città di Pavia, Pavia, Italy, 8 A.O. Sant Andrea, Rome, Italy, 9 A.O.U.P. Santa Chiara, Trento, Italy, 10 Sapienza University of Rome, Rome, Italy, 11 Orthopedic Institute Gaetano Pini, Milano, Italy, 12 University of Siena, Siena, Italy, 13 Università Politecnica delle Marche, Jesi, Italy, 14 Ospedale Infermi, Rimini, Italy, 15 University of Padova, Padova, Italy, 16 A.O.U. di Cagliari, Cagliari, Italy, 17 Ospedale Civile Maggiore, Verona, Italy, 18 University of Perugia, Perugia, Italy, 19 Arcispedale S Maria Nuova, IRCCS, Reggio Emilia, Italy, 20 Istituto Clinico Humanitas, Rozzano, Italy, 21 Moriggia-Pelascini, Gravedona, Italy, 22 Department of Rheumatology, Hospital Galateo, San Cesario di Lecce, Italy, 23 A.O. Città della Salute e della Scienza di Torino, Turin, Italy, 24 Unit and Chair of Rheumatology, University Hospital of Cagliari, Cagliari, Italy, 25 University of Padua, Padova, Italy, 26 University of Turin, Turin, Italy, 27 P.O. Destra Secchia, Pieve di Coriano, Italy, 28 Rheumatology and Translational Immunology Research Laboratories (LaRIT), Division of Rheumatology, IRCCS Policlinico S. Matteo Foundation/University of Pavia, Pavia, Italy, 29 University of Bari, Bari, Italy, 30 A.O. Rummo, Benevento, Italy, 31 University of Florence, Florence, Italy SUNDAY november 16, 2014 2014 Program Book 57
scientific sessions SUNDAY november 16, 2014 5:45 pm 909. A Diagnostic Protocol for Giant Cell Arteritis (GCA) Using Ultrasound Assessment Jennifer Piper 1, Ana Sofia Serafim 1, Cristina Ponte 1, Surjeet Singh 2, Bhaskar Dasgupta 3, Wolfgang A. Schmidt 4, Eugene McNally 5, Andreas P. Diamantopoulos 6, Andrew Hutchings 7 and Raashid Luqmani 8, 1 University of Oxford, Oxford, United Kingdom, 2 Sciences, Oxford, England, 3 Southend University Hospital, Essex, United Kingdom, 4 Immanuel Krankenhaus, Berlin, Germany, 5 Oxford University, Oxford, United Kingdom, 6 Hospital of Southern Norway Trust, Kristiansand, Norway, 7 London School of Hygiene and Tropical Medicine, London, United Kingdom, 8 Oxford NIHR Musculoskeletal Biomedical Research Unit, Oxford, United Kingdom 160 B Muscle Biology, Myositis and Myopathies Moderator: Megan Curran, MD 4:30 pm 910. The Selective Sphingosine-1-Phosphate Receptor 1/5 Modulator Siponimod (BAF312) Shows Beneficial Effects in Patients with Active, Treatment Refractory Polymyositis and Dermatomyositis: A Phase IIa Proof-of-Concept, Double-Blind, Randomized Trial Katalin Danko 1, Jiri Vencovsky 2, Ingrid E. Lundberg 3, Anthony A Amato 4, Chester V. Oddis 5, Maria Molnar 6, Antonette Mallari Moher 7, Laurence Colin 8, Florian Muellershausen 9, David Lee 9 and Peter Gergely 9, 1 University of Debrecen, Hungary, Debrecen, Hungary, 2 Charles University, Prague, Czech Republic, 3 Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 4 Brigham and Women s Hospital and Harvard Medical School, Boston, MA, 5 University of Pittsburgh, Pittsburgh, PA, 6 Institute of Genomic Medicine and Rare Disorders, Semmelweis University, Budapest, Hungary, 7 Novartis Institutes for Biomedical Research (former employee), Basel, Switzerland, 8 Novartis Pharma, Basel, Switzerland, 9 Novartis Institutes for Biomedical Research, Basel, Switzerland 4:45 pm 911. Bioluminescent Imaging of Histidyl-Transfer RNA Synthetase-Induced Myositis Reveals Early-Phase Involvement of NF-Kb-Mediated Inflammation Nicholas A. Young 1, Lai-Chu Wu 1, Michael Bruss 1, Wael N. Jarjour 1 and Dana P. Ascherman 2, 1 The Ohio State University Wexner Medical Center, Columbus, OH, 2 Miami VAMC, Miami, FL 5:00 pm 912. A Consensus Hybrid Definition Using a Conjoint Analysis Is the Proposed As Response Criteria for Minimal and Moderate Improvement for Adult Polymyositis and Dermatomyositis Clinical Trials Rohit Aggarwal 1, Lisa G. Rider 2, Nicolino Ruperto 3, Nastaran Bayat 2, Brian Erman 4, Brian M. Feldman 5, Adam M. Huber 6, Chester V. Oddis 1, Ingrid E. Lundberg 7, Anthony A. Amato, MD 8, Robert G. Cooper, MD, FRCP 9, Hector Chinoy 10, Maryam Dastmalchi 11, David Fiorentino 12, David Isenberg 13, James D. Katz 14, Andrew L. Mammen 15, Marianne de Visser 16, Steven R. Ytterberg 17, Katalin Danko 18, Luca Villa 19, Mariangela Rinaldi 19, Howard Rockette 1, Peter A. Lachenbruch 20, Frederick W. Miller 2 and Jiri Vencovsky, MD, DSc 21, 1 University of Pittsburgh, Pittsburgh, PA, 2 Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 3 Istituto Giannina Gaslini, Genoa, Italy, 4 Social and Scientific Systems, Inc., Durham, NC, 5 The Hospital for Sick Children, Toronto, ON, 6 IWK Health Centre, Halifax, NS, 7 Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 8 Brigham and Women s Hospital and Harvard Medical School, Boston, MA, 9 University of Liverpool, Liverpool, United Kingdom, 10 Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 11 Karolinska University Hospital in Solna, Karolinska Institutet, Stockholm, Sweden, 12 Stanford University, Redwood City, CA, 13 Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 14 NIH, Bethesda, MD, 15 Johns Hopkins University, Baltimore, MD, 16 Academic Medical Centre, Amsterdam, Netherlands, 17 Mayo Clinic, Rochester, MN, 18 University of Debrecen, Hungary, Debrecen, Hungary, 19 IRCCS Istituto G. Gaslini, Genova, Italy, 20 NIEHS, NIH, Bethesda, MD, 21 Charles University, Prague, Czech Republic 5:15 pm 913. Long Term Outcomes of Patients with Moderate Creatine Kinase (CK) Elevation Seen in a Rheumatology Clinic Lyudmila Kirillova 1, Abraham Tacang 1, Andrea Berger 2, Thomas M. Harrington 1 and Androniki Bili 1, 1 Geisinger Health System, Danville, PA, 2 Center for Health Research, Geisinger Health System, Danville, PA 5:30 pm 914. A Predictive Model of Disease Outcome in Rituximab- Treated Myositis Patients Using Clinical Features, Autoantibodies and Serum Biomarkers Jeannette Olazagasti 1, Cynthia S. Crowson 1, Molly S. Hein 1, Consuelo Lopez de Padilla 1, Rohit Aggarwal 2, Chester V. Oddis 2 and Ann M. Reed 1, 1 Mayo Clinic, Rochester, MN, 2 University of Pittsburgh, Pittsburgh, PA 5:45 pm 915. Increased Risk of Myocardial Infarction in Dermatomyositis and Polymyositis: A General Population- Based Cohort Study Kateryna Vostretsova 1, Erin Carruthers 2, Eric C. Sayre 2, John Esdaile 2 and J Antonio Avina-Zubieta 3, 1 University of British Columbia, Vancouver, BC, 2 Arthritis Research Centre of Canada, Richmond, BC, 3 University of British Columbia, Department of Experimental Medicine, Vancouver, BC 153 B Osteoporosis and Metabolic Bone Disease Clinical Aspects and Pathogenesis: Clinical Osteoporosis: Treatment and Safety Moderators: Simpson Bobo Tanner, MD and Chad Deal, MD 58 2014 Program Book
scientific sessions 4:30 pm 916. Effects of 2 Years of Treatment with Romosozumab Followed By 1 Year of Denosumab or Placebo in Postmenopausal Women with Low Bone Mineral Density MR McClung 1, A Chines 2, JP Brown 3, A Diez-Perez 4, H Resch 5, J Caminis 6, MA Bolognese 7, S Goemaere 8, HG Bone 9, JR Zanchetta 10, J Maddox 2, O Rosen 2, S Bray 11 and A Grauer 2, 1 Oregon Osteoporosis Center, Portland, OR, 2 Amgen Inc., Thousand Oaks, CA, 3 Laval University and CHU de Québec Research Centre, Quebec City, QC, 4 Autonomous University of Spain, Barcelona, Spain, 5 St. Vincent Hospital, Vienna, Austria, 6 UCB, Raleigh, NC, 7 Bethesda Health Research Center, Bethesda, MD, 8 Ghent University Hospital, Ghent, Belgium, 9 Michigan Bone and Mineral Clinic, Detroit, MI, 10 Instituto de Investigaciones Metabólicas, Buenos Aires, Argentina, 11 Amgen Ltd., Cambridge, United Kingdom 4:45 pm 917. Evaluation of Invasive Oral Procedures and Events in Women with Postmenopausal Osteoporosis Treated with Denosumab: Results from the Pivotal Phase 3 Fracture Study Extension Nelson B. Watts 1, John T. Grbic 2, Michael McClung 3, Socrates Papapoulos 4, David Kendler 5, Christence S. Teglbjaerg 6, Lawrence O Connor 7, Rachel B. Wagman 7, Eric Ng 7, Nadia S. Daizadeh 7 and Pei-Ran Ho 7, 1 Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH, 2 Columbia University, New York, NY, 3 Oregon Osteoporosis Center, Portland, OR, 4 Leiden University Medical Center, Leiden, Netherlands, 5 University of British Columbia, Vancouver, BC, 6 Center for Clinical and Basic Research, Ballerup, Denmark, 7 Amgen Inc., Thousand Oaks, CA 5:00 pm 918. Findings from Denosumab (Prolia ) Postmarketing Safety Surveillance for Serious Infections W Golden 1, DB Crittenden 1, M Uhart 1, RB Wagman 1, C Stehman-Breen 1, S Papapoulos 2 and NB Watts 3, 1 Amgen Inc., Thousand Oaks, CA, 2 Leiden University Medical Center, Leiden, Netherlands, 3 Mercy Health Osteoporosis and Bone Health Services, Cincinnati, OH 5:15 pm 919. Glucocorticoid Exposure and Fracture Risk in a Large Cohort of Commercially-Insured Rheumatoid Arthritis Patients Under Age 65 Akhila Balasubramanian 1, Sally Wade 2, Robert A Adler 3, Celia Fang (Lin) 4, Michael Maricic 5, Cynthia O Malley 1, Kenneth G. Saag 6 and Jeffrey R. Curtis 6, 1 Amgen, Inc., Thousand Oaks, CA, 2 Wade Outcomes Research and Consulting, Salt Lake City, UT, 3 Hunter Holmes McGuire VA Medical Center, Richmond, VA, 4 Amgen, Thousand Oaks, CA, 5 Catalina Pointe Rheumatology, Tucson, AZ, 6 The University of Alabama at Birmingham, Birmingham, AL 5:30 pm 920. Randomized Controlled Trial to Assess the Safety and Efficacy of Odanacatib in the Treatment of Men with Osteoporosis Eric Orwoll 1, Silvano Adami 2, Neil Binkley 3, Roland Chapurlat 4, Bente Langdahl 5, Steven Doleckyj 6, Hilde Giezek 7, Boyd Scott 8 and Arthur Santora 8, 1 Oregon Health and Science University, Portland, OR, 2 Rheumatology Department, University of Verona, Verona, Italy, 3 University of Wisconsin, Madison, WI, 4 Hopital Edouard Herriot, Lyon, France, 5 Aarhus University Hospital, Aarhus, Denmark, 6 Merck & Co., Inc., Whitehouse Station, NJ, 7 MSD Belgium, Brussels, Belgium, 8 Merck Sharp & Dohme Corp., Whitehouse Station, NJ 5:45 pm 921. Comparison of Infection Rates in Patients Receiving Denosumab, Denosumab and Biologics and Biologics Alone in a Suburban Rheumatology Clinic Sajina Prabhakaran 1 and Charles Pritchard 2, 1 Drexel University College of Medicine, Philadelphia, PA, 2 Drexel University College of Medicine, Willow Grove, PA 156 B Pain: Basic and Clinical Aspects I Moderators: Yvonne C. Lee, MD and Martin K. Lotz, MD and Camilla Svensson, PhD 4:30 pm 922. A Potential Role for TLR4 Activation in Osteoarthritis Associated Pain Rachel E. Miller 1, Shingo Ishihara 1, Phuong Tran 1, Richard J. Miller 2 and Anne-Marie Malfait 1, 1 Rush University Medical Center, Chicago, IL, 2 Northwestern University, Chicago, IL 4:45 pm 923. Phenotypes of Osteoarthritis-Related Knee Pain and Their Transitions over Time: The Osteoarthritis Initiative Na Lu 1, Tuhina Neogi 1, K. Douglas Gross 1, Jingbo Niu 1, Hyon Choi 2 and Yuqing Zhang 1, 1 Boston University School of Medicine, Boston, MA, 2 Harvard Medical School, Boston, MA 5:00 pm 924. Characteristics of Pain Flares in Knee Osteoarthritis Susan L. Murphy 1, Angela K. Lyden 1, Arnold Gammaitoni 2, David A. Williams 3, Daniel J. Clauw 1, J. Ryan Scott 1 and Kristine Phillips 1, 1 University of Michigan, Ann Arbor, MI, 2 Zogenix, Inc, San Diego, CA, 3 Univ of MI Hlth System-Lobby M, Ann Arbor, MI 5:15 pm 925. Cortical Reorganization after Duloxetine Treatment- Related Pain Decrease in Knee Osteoarthritis Pascal Tetreault, Marwan Baliki, Etienne Vachon-Presseau, Renita Evonne Yeasted, Thomas J. Schnitzer and A. Vania Apkarian, Northwestern University, Chicago, IL SUNDAY november 16, 2014 2014 Program Book 59
scientific sessions SUNDAY november 16, 2014 5:30 pm 926. Does a Family History of Total Knee Replacement for Knee Osteoarthritis Influence Knee Pain and Structural Progression? a Prospective Longitudinal Cohort Study Feng Pan 1, Hussain Khan 1, Changhai Ding 1, Tania Winzenberg 1, Johanne Martel-Pelletier 2, Jean-Pierre Pelletier 2, Flavia Cicuttini 3 and Graeme Jones 1, 1 Menzies Research Institute Tasmania, University of Tasmania, Hobart,7000, Australia, 2 Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Notre-Dame Hospital, Montreal, QC, 3 School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia 5:45 pm 927. Urate Crystal Induced Inflammation and Joint Pain Are Reduced in Transient Receptor Potential Ankyrin 1 (TRPA1) Deficient Mice a New Potential Role for TRPA1 in Gout Lauri J Moilanen, Mari Hämäläinen, Lauri Lehtimäki, Riina Nieminen and Eeva Moilanen, The Immunopharmacology Research Group, University of Tampere School of Medicine and Tampere University Hospital, Tampere, Finland 253 B Pediatric Rheumatology Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis Moderators: Murray H. Passo, MD and Andrew S. Zeft, MD, MSCE Ed Pd PrM FIT 4:30 pm 928. A Multinational Study of the Epidemiology, Treatment and Outcome of Childhood Arthriti: Preliminary Data from 6,940 Patients Alessandro Consolaro 1, Amita Aggarwal 2, Troels Herlin 3, Olga Vougiouka 4, Rubén Burgos-Vargas 5, Ilonka Orban 6, Nahid Shafaie 7, Maria Trachana 8, Lidia Rutkowska-Sak 9, Ingrida Rumba-Rozenfelde 10, Dimitrina Mihaylova 11, Alberto Martini 1 and Angelo Ravelli 12, 1 Istituto Giannina Gaslini, Genova, Italy, 2 Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, 3 Aarhus University Hospital, Aarhus, Denmark, 4 P. A. Kyriakou Children s Hospital of Athens University, Athens, Greece, 5 Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, 6 National Institute of Rheumatology and Physiotherapy, Budapest, Hungary, 7 Tehran University of Medical Sciences, Tehran, Iran, 8 Aristotle University, Thessaloniki, Greece, 9 Institute of Rheumatology, Warsaw, Poland, 10 University of Latvia, Riga, Latvia, 11 University Children Hospital, Sofia, Bulgaria, 12 Istituto Giannina Gaslini and University of Genova, Genova, Italy dupont Hospital for Children, Thomas Jefferson University, Wilmington, DE, 4 Rutgers Biomedical and Health Sciences, Newark, NJ 5:00 pm 930. An Exploratory Analysis of Predictors of Response from 12-Weeks of Canakinumab Therapy in Patients with Active Systemic Juvenile Idiopathic Arthritis Hermine I. Brunner 1, Nicola Ruperto 2, Isabelle Koné-Paut 2, Bo Magnusson 2, Seza Ozen 2, Flavio Sztajnbok 2, Jordi Anton 2, Judith Barash 2, Reinhard Berner 2, Fabrizia Corona 2, Karine Lheritier 3, Corine Gaillez 3, Alberto Martini 2 and Daniel Lovell 1, 1 PRCSG, Cincinnati, OH, 2 PRINTO-Istituto Gaslini, Genova, Italy, 3 Novartis Pharma AG, Basel, Switzerland 5:15 pm 931. Response to Canakinumab Treatment Is Maintained in Systemic Juvenile Idiopathic Arthritis Patients N.M. Wulffraat 1, N. Ruperto 2, H.I. Brunner 3, S. Oliveira 2, Y. Uziel 2, K. Nistala 2, R. Cimaz 2, M. Ferrandiz 2, B. Flato 2, M.L. Gamir 2, I. Koné-Paut 2, C. Gaillez 4, K. Lheritier 4, K. Abrams 5, A. Martini 2 and D.J. Lovell 3, 1 UMC Utrecht, Utrecht, Netherlands, 2 PRINTO- Istituto Gaslini, Genova, Italy, 3 PRCSG, Cincinnati, OH, 4 Novartis Pharma AG, Basel, Switzerland, 5 Novartis Pharmaceuticals Corporation, East Hanover, NJ 5:30 pm 932. MRP8/14 Serum Level As Predictor of Response to Starting and Stopping Anti-TNF Treatment in Non-Systemic Juvenile Idiopathic Arthritis Janneke Anink 1, Marieke H. Otten 1, Lisette W.A. van Suijlekom- Smit 1, Marion A.J. Van Rossum 2, Koert M. Dolman 3, Esther P.A. Hoppenreijs 4, Rebecca ten Cate 5, Simona Ursu 6, Lucy R Wedderburn 7, Gerd Horneff 8, Thomas Vogl 9, Dirk Föll 10, Johannes Roth 9 and Dirk Holzinger 11, 1 Erasmus MC Sophia Children s Hospital, Rotterdam, Netherlands, 2 Emma Kinderziekenhuis Academic Medical Center, Amsterdam, Netherlands, 3 St. Lucas Andreas Hospital and Reade Institute, Amsterdam, Netherlands, 4 Radboud University Medical Center, Nijmegen, Netherlands, 5 Leiden University Medical Center, Leiden, Netherlands, 6 Arthritis Research UK Centre for Adolescent Rheumatology at University College London, Great Ormond Street Hospital and UCLH, University College London, London, United Kingdom, 7 Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 8 Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 9 Institute of Immunology University of Muenster, Muenster, Germany, 10 University Children s Hospital Muenster, Muenster, Germany, 11 University Hospital Muenster, Muenster, Germany 4:45 pm 929. Antibiotic Exposure and the Development of Juvenile Idiopathic Arthritis: A Population-Based Case-Control Study Daniel B. Horton 1, Frank I. Scott IV 2, Kevin Haynes 1, Mary E. Putt 1, Carlos D. Rose 3, James D. Lewis 1 and Brian L. Strom 4, 1 Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 2 Division of Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, 3 Division of Rheumatology, Nemours A.I. 5:45 pm 933. A Multi-Center, Double-Blind, Randomized-Withdrawal Trial of Subcutaneous Golimumab in Pediatric Patients with Active Polyarticular Course Juvenile Idiopathic Arthritis Despite Methotrexate Therapy: Week 48 Results Hermine I. Brunner 1, Nicolino Ruperto 2, N Tzaribachev 3, Gerd Horneff 4, Carine Wouters 5, Violeta Vladislava Panaviene 2, Vyacheslav Chasnyk 6, Carlos Abud-Mendoza 7, Ruben Cuttica 8, Andreas Reiff 9, M Maldonado-Velázquez 1, Nadina Rubio-Pérez 10, 60 2014 Program Book
scientific sessions Rik Joos 11, V Keltsev 12, Evgeny Nasonov 13, Daniel Kingsbury 14, M Bandeira 15, Earl Silverman 16, F Weller-Heinemann 10, A van Royen-Kerkhof 17, Alan M. Mendelsohn 18, Lilianne Kim 18, Daniel Lovell 19 and A Martini 20, 1 PRCSG, Cincinnati, OH, 2 Istituto Giannina Gaslini, Genoa, Italy, 3 PRINTO & PRCSG, Bramstedt, Germany, 4 Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, 5 University Hosp Gasthuisberg, Leuven, Belgium, 6 Novartis Pharma, Saint-Petersburg, Russia, 7 Hospital Central & Facultad de Medicina, Universidad Autónoma de San Luis Potosí, San Luis Potosí, Mexico, 8 Hospital de Ninos Pedro de Elizalde, Capital Federal, Argentina, 9 Children s Hospital of Los Angeles, Los Angeles, CA, 10 PRINTO, Genoa, Italy, 11 UZ Gent, Gent, Belgium, 12 Paediatric Rheumatology International Trials Organisation IRCCS [PRINTO], Genoa, Italy, 13 State Institute of Rheumatology of RAMS, Moscow, Russia, 14 Randall Children s Hospital at Legacy Emanuel, Portland, OR, 15 Hospital Infantil Pequeno Príncipe, Curitiba, Brazil, 16 Hosp for Sick Children, Toronto, ON, 17 Department of Pediatric Immunology & Rheumatology, Wilhelmina Children s Hospital, University Medical Center Utrecht, Utrecht, Netherlands, 18 Janssen Research & Development, LLC., Spring House, PA, 19 Division of Rheumatology, Cincinnati Children s Hospital Medical Center, Department of Pediatrics, University of Cincinnati, Cincinnati, OH, 20 Istituto Gaslini-PRINTO, Genova, Italy 107 B Rheumatoid Arthritis Animal Models I Moderators: Peter A. Nigrovic, MD and Ewa Cairns, PhD 4:30 pm 934. Amelioration of Inflammatory Arthritis By Anti-TNF Therapy Is Associated with Restoration of Lymphatic Contraction Echoe M. Bouta 1, Igor Kuzin 2, Karen de Mesy-Bentley 1, Ronald Wood 3, Homaira Rahimi 4, Rui-Cheng Ji 5, Christopher T. Ritchlin 3, Andrea Bottaro 2, Lianping Xing 1 and Edward M. Schwarz 1, 1 University of Rochester, Rochester, NY, 2 Cooper Medical School, Camden, NJ, 3 University of Rochester Medical Center, Rochester, NY, 4 University of Rochester/Golisano Children s Hospital, Rochester, NY, 5 Oita University, Oita, Japan 4:45 pm 935. Targeting Glycolysis in Rheumatoid Arthritis Monica Guma 1, Alessia Lodi 2, Ajit Divakaruni 1, Anne Murphy 1, Stefano Tiziani 2 and Gary S. Firestein 3, 1 University of California, San Diego, La Jolla, CA, 2 University of Texas at Austin, Austin, TX, 3 University of California at San Diego School of Medicine, La Jolla, CA 5:00 pm 936. Active Invasion of Periodontal Bacteria into Synovial Joint Exacerbates Collagen-Induced Arthritis in Disease-Prone B10 Riii Mice Sasanka Chukkapalli 1, Mercedes Rivera-Kweh 1, Irina Velsko 1, Indraneel Bhattacharyya 1, S. John Calise 2, Edward Chan 1, Minoru Satoh 3 and Lakshmyya Kesavalu 1, 1 College of Dentistry, University of Florida, Gainesville, FL, 2 University of Florida, Gainesville, FL, 3 Univ. Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan 5:15 pm 937. A Unique Role for IL-18 Receptor-α in Monocyte Migration in RA and K/BxN Serum Transfer Arthritis W. Alexander Stinson 1, Phillip L. Campbell 1, Jeffrey Ruth 1, Gautam Edhayan 1, Ray A. Ohara 1, Nicholas Lepore 1, Alisa E. Koch 2, David A. Fox 1 and M. Asif Amin 1, 1 Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 2 Department of Veteran s Affairs and University of Michigan, Ann Arbor, MI 5:30 pm 938. C1q Is Mandatory for Disease Development in Experimental Arthritis and Expression of Its Receptors Correlates with Disease Activity in Patients Matthieu Ribon 1, Julie Mussard 1, Roxane Herve 1, Marina Botto 2, Marie-Christophe Boissier 3 and Patrice Decker 1, 1 INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité and Rheumatology Department, Avicenne Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Bobigny, France, 2 Imperial College, London, United Kingdom, 3 INSERM UMR 1125, Li2P, University Paris 13, Sorbonne Paris Cité, Bobigny, France 5:45 pm 939. Prenatal Methyl-Rich Diet Decreases Inflammation in Collagen Induced Arthritis Sanjay Garg 1, Dipak R. Patel 2 and Raymond Yung 2, 1 University of Michigan, Ann Arbor, MI, Ann Arbor, MI, 2 University of Michigan, Ann Arbor, MI Exhibit Hall C Rheumatoid Arthritis Clinical Aspects II: Remission and De-Escalation of Therapy Moderators: Clifton O. Bingham III, MD and Kimme Hyrich, MD, PhD 4:30 pm 940. Study of Reduction of Therapy in Patients with Rheumatoid Arthritis in Ongoing Remission Judith Haschka 1, Jürgen Rech 1, Matthias Englbrecht 1, Stephanie Finzel 1, Michaela Reiser 1, Axel J. Hueber 1, Arnd Kleyer 1, Hans- Peter Tony 2, Martin Fleck 3, Karin Manger 4, Wolfgang Ochs 5, Jörg Wendler 6, Hanns-Martin Lorenz 7, Hubert Nüßlein 8, Rieke Alten 9, Winfried Demary 10 and Georg Schett 1, 1 University of Erlangen- Nuremberg, Erlangen, Germany, 2 University Hospital Würzburg, Würzburg, Germany, 3 Asklepios Medical Center Bad Abbach, Bad Abbach, Germany, 4 Rheumatology Practice Bamberg, Bamberg, Germany, 5 Rheumatology Practice Bayreuth, Bayreuth, Germany, 6 Rheumatology Practice Erlangen, Erlangen, Germany, 7 University of Heidelberg, Heidelberg, Germany, 8 Rheumatology Practice Nuremberg, Nuremberg, Germany, 9 Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, 10 Rheumatolgy Practice Hildesheim, Hildesheim, Germany 4:45 pm 941. Biologic De-Escalation in Rheumatoid Arthritis: Cost Savings and Clinical Success Tarun S. Sharma 1, Lyudmila Kirillova 2, Andrea Berger 3 and Eric D. Newman 2, 1 Geisinger Medical Center, Danville, PA, 2 Geisinger Health System, Danville, PA, 3 Center for Health Research, Geisinger Health System, Danville, PA 2014 Program Book 61 SUNDAY november 16, 2014
scientific sessions SUNDAY november 16, 2014 5:00 pm 942. ACR/EULAR Remission in RA patients in Clinical Practice Does Substitution of Patient Global with Pain Score Change Remission Rates? Data from the Danish Danbio Registry Merete Lund Hetland, The Danish Rheumatologic Database (DANBIO), Glostrup Hospital., Copenhagen, Denmark 5:15 pm 943. Improvements in the Proportion of Patients Achieving DAS, CDAI and SDAI Remission By Omitting the Patient Global Assessment (PtGA): an Analysis from a Prospective, Observational Registry Philip Baer 1, WG Bensen 2, Carter Thorne 3, Boulos Haraoui 4, Denis Choquette 5, Regan Arendse 6, John Kelsall 7, Maqbool Sheriff 8, John S. Sampalis 9, Emmanouil Rampakakis 9, Francois Nantel 10, May Shawi 10, Allen J Lehman 10, Susan Otawa 10 and Edward Keystone 11, 1 Private Practice, Scarborough, ON, 2 St Joseph s Hospital and McMaster University, Hamilton, ON, 3 Southlake Regional Health Centre, Newmarket, ON, 4 University of Montreal Hospital Centre, Montreal, QC, 5 Institut de rhumatologie de Montréal (IRM), Montréal, QC, 6 University of Saskatchewan, Saskatoon, SK, 7 The Mary Pack Arthritis Centre, Vancouver, BC, 8 Nanaimo Regional General Hospital, Nanaimo, BC, 9 JSS Medical Research, Montreal, QC, 10 Janssen Inc., Toronto, ON, 11 Mount Sinai Hospital, University of Toronto, Toronto, ON 5:30 pm 944. Predict the Chance of Remission for Your RA Patient in Real Life Till Uhlig 1, Vibeke Norvang 1, Elisabeth Lie 1, Erik Rødevand 2, Knut Mikkelsen 3, Åse S. Lexberg 4, Synøve Kalstad 5 and Tore K. Kvien 1, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 St. Olavs Hospital, Trondheim, Norway, 3 Revmatismesykehuset, Lillehammer, Norway, 4 Vestre Viken Hospital, Drammen, Norway, 5 University Hospital of Northern Norway, Tromsø, Norway 5:45 pm 945. Disease Remission Reduces Risk of Heart Failure in Rheumatoid Arthritis Patients Independent of Treatment Strategy Thomas Schau 1, Michael Gottwald 2, Christian Butter 1 and Michael Zaenker 2, 1 Cardiology Dept., Immanuel Klinikum Bernau Heart Center Brandenburg, Bernau, Germany, 2 Immanuel Klinikum Bernau, Rheumatology Center Northern Brandenburg, Bernau, Germany Ballroom West Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis Early in Development Moderators: Vivian P. Bykerk, MD and Iain B. McInnes, PhD 4:30 pm 946. Phase 1 Study of Immunotherapy Using Autoantigen- Loaded Dendritic Cells in Patients with Anti-Citrullinated Peptide Antigen Positive Rheumatoid Arthritis Young Bin Joo 1, Jun-Eui Park 2, Chan-Bum Choi 3, Jeongim Choi 1, Jin-ah Jang 2, Minkyu Heo 2, Hak-yeop Kim 2, Hye-Soon Lee 1, Yong- Soo Bae 4 and Sang-Cheol Bae 5, 1 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2 JW CreaGene Research Institute, JWCreaGene Inc., Seongnam-si, South Korea, 3 Hanyang University Hospital for Rheumatic Diseases, Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 4 Sungkyunkwan University, Suwon, South Korea, 5 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea 4:45 pm 947. Efficacy and Safety of NNC0114 0006, an Anti-IL-21 Monoclonal Antibody, in Patients with Active Rheumatoid Arthritis Juan D. Cañete 1, Piotr Leszczynski 2, Rikke Riisbro 3 and Klaus S. Frederiksen 3, 1 Hospital Clínic of Barcelona, Barcelona, Spain, 2 Department of Rheumatology and Rehabilitation, Poznan Medical University, Poznan, Poland, 3 Novo Nordisk A/S, Søborg, Denmark 5:00 pm 948. A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Who Have Had an Inadequate Response to Methotrexate Alan J. Kivitz 1, Anna Zubrzycka-Sienkiewicz 2, Sergio R. Gutierrez- Ureña 3, Jeffrey Poiley 4, Rita Kristy 5, Kathyjo Shay 5 and Jay P. Garg 5, 1 Altoona Center for Clinical Research, Duncansville, PA, 2 ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, 3 Hospital Civil de Guadalajara FAA, CUCS UdG, Guadalajara, Mexico, 4 Arthritis Associates, Orlando, FL, 5 Astellas Pharma Global Development, Northbrook, IL 5:15 pm 949. Safety and Efficacy of CF101 in Rheumatoid Arthritis Patients: A Phase II Study Rumen M. Stoilov 1, Rodina N. Licheva 2, Mariyana K. Mihaylova 3, Tatiana Reitblat 4, Emil A. Dimitrov 1, Krasimira M. Shimbova 1, Girish Bhatia 5, Amit Pispati 6, Alexandra Gurman- Balbir 7, B R Bagaria 5, Boytcho A. Oparanov 2, Sari Fishman 8, Zivit Harpaz 8, Motti Farbstein 8, Shira Cohen 8, Michael H. Silverman 8 and Pnina Fishman 8, 1 Multiprofile Hospital for Active Treatment Sv. Ivan Rilski EAD, Clinic of Rheumatology, Sofia, Bulgaria, 2 Diagnostic Consulting Center, Rheumatology office, Sofia, Bulgaria, 3 3Diagnostic Consulting Center, Rheumatology office, Sofia, Bulgaria, 4 Barzilai Medical Center,, Ashkelon, Israel, 5 Malpani Multispeciality Hospital, Mumbai, India, 6 Bhatia Hospital Medical Research Society, Mumbai, India, 7 Rambam Medical Center, Haifa, Israel, 8 CanFite Biopharma Ltd, Petah Tikva, Israel 5:30 pm 950. Multiple Mechanisms of Tolerance Characterize the Immune Response to Autologous Modified Dendritic Cells Exposed to Citrullinated Peptides in Patients with Rheumatoid Arthritis Soi-Cheng Law 1, Hendrik Nel 2, Ahmed Mehdi 2, Kim-Anh Le Cao 2 and Ranjeny Thomas 1, 1 Univ of Queensland, Brisbane, Australia, 2 University of Queensland, Brisbane, Australia 62 2014 Program Book
scientific sessions 5:45 pm 951. Safety, Tolerability and Functional Activity of ABT-122, a Dual TNF- and IL-17A Targeted DVD-Ig, Following Single-Dose Administration in Healthy Subjects Heikki Mansikka 1, Melanie Ruzek 2, Margaret Hugunin 2, Alexander Ivanov 2, Alyssa Brito 2, Anca Clabbers 2, Carolyn Cuff 2, Chung-Ming Hsieh 2, Martin Okun 1, Renee Heuser 1, David Carter 1, Barbara Hendrickson 1, Dipak Pisal 1, Sandra Goss 1, Jia Liu 1, Charles Locke 1, Nasser Khan 1 and Robert Padley 1, 1 AbbVie, Inc, North Chicago, IL, 2 AbbVie, Inc, Worcester, MA 258 B Spondyloarthropathies and Psoriatic Arthritis II Novel Treatments for Psoriatic Arthritis Moderators: Philip Mease, MD and Eric Ruderman, MD 4:30 pm 952. A Phase IIb, Randomized, Double-Blind, Placebo- Controlled, Dose-Ranging, Multicenter Study to Evaluate the Efficacy and Safety of Clazakizumab, an Anti-IL-6 Monoclonal Antibody, in Adults with Active Psoriatic Arthritis Philip Mease 1, A B Gottlieb 2, A Berman 3, E Drescher 4, J Xing 5, S Banerjee 5 and R Wong 5, 1 Swedish Medical Center and University of Washington, Seattle, WA, 2 Tufts Medical Center and Tufts University School of Medicine, Boston, MA, 3 Centro Médico Privado de Reumatología, Tucuman, Argentina, 4 Csolnoky Ferenc Hospital, Veszprém, Hungary, 5 Bristol-Myers Squibb, Princeton, NJ 4:45 pm 953. Secukinumab, a Human Anti Interleukin-17A Monoclonal Antibody, Improves Active Psoriatic Arthritis and Inhibits Radiographic Progression: Efficacy and Safety Data from a Phase 3 Randomized, Multicenter, Double-Blind, Placebo- Controlled Study Philip Mease 1, Iain B. McInnes 2, Bruce Kirkham 3, Arthur Kavanaugh 4, Proton Rahman 5, Désirée van der Heijde 6, Robert Landewé 7, Peter Nash 8, Luminita Pricop 9, Jiacheng Yuan 9, Hanno Richards 10 and Shephard Mpofu 10, 1 Swedish Medical Center and University of Washington, Seattle, WA, 2 University of Glasgow, Glasgow, United Kingdom, 3 Guy s and St Thomas NHS Foundation Trust, London, United Kingdom, 4 UCSD School of Medicine, La Jolla, CA, 5 Memorial University of Newfoundland, St. John s, NF, 6 Leiden University Medical Center, Leiden, Netherlands, 7 Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 8 University of Queensland, Brisbane, Australia, 9 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 10 Novartis Pharma AG, Basel, Switzerland 5:00 pm 954. Secukinumab, a Monoclonal Antibody to Interleukin- 17A, Provides Significant and Sustained Inhibition of Joint Structural Damage in Active Psoriatic Arthritis Regardless of Prior TNF Inhibitors or Concomitant Methotrexate: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study Désirée van der Heijde 1, Robert B. M. Landewé 2, Philip Mease 3, Iain B. McInnes 4, Philip G. Conaghan 5, Luminita Pricop 6, Gregory Ligozio 6, Hanno Richards 7 and Shephard Mpofu 7, 1 Leiden University Medical Center, Leiden, Netherlands, 2 Division of Clinical Immunology and Rheumatology, Academic Medical Center / University of Amsterdam & Atrium Medical Center, Amsterdam, Netherlands, 3 Swedish Medical Center, Seattle, WA, 4 University of Glasgow, Glasgow, United Kingdom, 5 NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 6 Novartis Pharmaceuticals Corporation, East Hanover, NJ, 7 Novartis Pharma AG, Basel, Switzerland 5:15 pm 955. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pharmacodynamic Results of a Phase 3, Randomized, Controlled Trial Peter Schafer 1, Peng Chen 2, Lorraine Fang 2, Andrew Wang 2 and Rajesh Chopra 1, 1 Celgene Corporation, Summit, NJ, 2 Celgene Corporation, Warren, NJ 5:30 pm 956. Real-World Validation of the Minimal Disease Activity Index in Psoriatic Arthritis: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada Proton Rahman 1, Saeed Shaikh 2, Michael Starr 3, William Bensen 4, Denis Choquette 5, Wojciech Olszynski 6, Maqbool Sheriff 7, Michel Zummer 8, Emmanouil Rampakakis 9, John S. Sampalis 9, Allen J Lehman 10, Susan Otawa 10, Francois Nantel 10, Vincent Letourneau 10 and May Shawi 10, 1 Memorial University of Newfoundland, St. John s, NF, 2 McMaster University, Hamilton, ON, 3 Montreal General Hospital, Montreal, QC, 4 Division of Rheumatology, McMaster University, Hamilton, ON, 5 Notre Dame Hospital, Montreal, QC, 6 University of Saskatchewan, Saskatoon, SK, 7 Nanaimo Regional General Hospital, Nanaimo, BC, 8 Université de Montréal, Montreal, QC, 9 JSS Medical Research, Montreal, QC, 10 Janssen Inc., Toronto, ON 10:15 am 957. Long-Term Evaluation of NT-Probnp Levels in Ankylosing Spondylitis Patients Under TNF Blockers: A Marker of Persistent Disease Activity? Debora Russo 1, Carla G.S. Saad 2, Ana C.M. Ribeiro 1, Cláudia Goldeinstein-Schainberg 2, Percival D Sampaio-Barros 2, Celio R. Gonçalves 2, Eloisa Bonfá 1 and Julio C. B. Moraes 2, 1 University of Sao Paulo, Sao Paulo, Brazil, 2 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 205 B Systemic Lupus Erythematosus Clinical Aspects and Treatment: Lupus Nephritis Moderators: Maria Dall Era, MD and Cynthia Aranow, MD 4:30 pm 958. The 10-Year Followup of a Trial Comparing Azathioprine and Mycophenolate Mofetil for Longterm Immunosuppression of Lupus Nephritis Farah Tamirou 1, David D Cruz 2, Shirish Sangle 3, Philippe Remy 4, Carlos Vasconcelos 5, Christoph Fiehn 6, Maria del Mar Ayala Gutierrez 7, Inge-Margrethe Gilboe 8, Maria Tektonidou 9, Daniel Blockmans 10, Isabelle Ravelingien 11, Véronique le Guern 12, SUNDAY november 16, 2014 2014 Program Book 63
scientific sessions SUNDAY november 16, 2014 Geneviève Depresseux 1, Loïc Guillevin 13, Ricard Cervera 14 and Frédéric A. Houssiau 15, 1 Institut de Recherche Expérimentale et Clinique, Université catholique de Louvain, Bruxelles, Belgium, 2 Louis Coote Lupus Unit, St Thomas Hospital, London, United Kingdom, 3 St Thomas Hospital, London, United Kingdom, 4 Hôpital Henri Mondor, Créteil, France, 5 Hospital Geral Santo Antonio, Porto, Portugal, 6 ACURA Centre for Rheumatic Diseases, Baden-Baden, Germany, 7 Hospital Regional Universitario Carlos Haya, Malaga, Spain, Malaga, Spain, 8 Oslo University Hospital Rikshospitalet, Oslo, Norway, 9 First Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 10 UZ Leuven, Leuven, Belgium, 11 Onze-Lieve- Vrouwzienkenhuis, Aalst, Belgium, 12 Hôpital Cochin, Paris, France, 13 Hôpital Cochin, University Paris V Descartes, Paris, France, 14 Hospital Clínic of Barcelona, Barcelona, Spain, 15 Université catholique de Louvain, Brussels, Belgium 4:45 pm 959. Discoid Lupus Onset and Decrease Risk of Renal Disease in Patients with Systemic Lupus Erythematosus: Data from a Large Latin American Cohort Guillermo J. Pons-Estel 1, Gaobin Bao 2, Bernado Pons-Estel 3, Daniel Wojdyla 4, Veronica Saurit 5, Alejandro J. Alvarellos 6, Francisco Caeiro 7, Emilia I. Sato 8, Enrique R. Soriano 9, Lilian Tereza Costallat 10, Oscar Neira 11, Antonio A. Iglesias- Gamarra 12, Gil Reyes Llerena 13, Mario Cardiel 14, Eduardo M. Acevedo-Vásquez 15, Rosa Chacon 16 and Cristina M. Drenkard 2, 1 Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, 2 Emory University, Atlanta, GA, 3 Hospital Provincial de Rosario, Rosario, Argentina, 4 Universidad Nacional de Rosario, Argentina, Rosario, Argentina, 5 Hospital Privado de Córdoba, Córdoba, Argentina, 6 Hospital Privado Córdoba, Córdoba, Argentina, 7 Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, 8 Escola Paulista de Medicina Universidade Federal de São Paulo, Sao Paulo, Brazil, 9 Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Instituto Universitario Hospital Italiano de Buenos Aires and Fundacion Catoggio, Buenos Aires, Argentina, 10 Unicamp, Campinas, Brazil, 11 Univ of Chile Hosp Salvador, Santiago, Chile, 12 Professor- Universidad Nacional de Colombia, Bogota, Colombia, 13 Centro de Investigaciones Médico Quirúrgicas (CIMEQ), La Habana, Cuba, 14 Secretaría de Salud de Michoacán, Morelia, Mexico, 15 Hospital Nacional Guillermo Almenara Irigoyen, Lima, Peru, 16 Hospital Universitario, Centro Nacional de Enfermedades Reumáticas and Hospital de Clínicas Caracas, Caracas, Venezuela 5:00 pm 960. Allogeneic Mesenchymal Stem Cell Transplantation for Lupus Nephritis Patients Refractory to Conventional Therapy Dandan Wang, Huayong Zhang, Xuebing Feng and Lingyun Sun, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China 5:15 pm 961. Outcome of Lupus Nephritis and Impact on Health Related Quality of Life: Results from an International, Prospective, Inception Cohort Study John G. Hanly for the Systemic Lupus International Collaborating Clinics 1, Aidan O Keeffe 2, Li Su 3, Murray B. Urowitz 4, Juanita Romero-Diaz 5, Caroline Gordon 6, Sang-Cheol Bae 7, Sasha R Bernatsky 8, Ann E. Clarke 9, Daniel J. Wallace 10, Joan T. Merrill 11, David A. Isenberg 12, Anisur Rahman 13, Ellen M. Ginzler 14, Paul Fortin 15, Dafna D. Gladman 4, Jorge Sanchez-Guerrero 16, Michelle A. Petri 17, Ian Bruce 18, Mary Anne Dooley 19, Rosalind Ramsey- Goldman 20, Cynthia Aranow 21, Graciela S. Alarcon 22, Barri Fessler 22, Kristjan Steinsson 23, Ola Nived 24, Gunnar Sturfelt 24, Susan Manzi 25, Munther A. Khamashta 26, Ronald F. van Vollenhoven 27, Asad Zoma 28, Manuel Ramos-Casals 29, Guillermo Ruiz-Irastorza 30, S. Sam Lim 31, Thomas Stoll 32, Murat Inanc 33, Kenneth C. Kalunian 34, Diane L. Kamen 35, Peter Maddison 36, Christine A. Peschken 37, Søren Jacobsen 38, Anca Askanase 39, Jill P. Buyon 40, Chris Theriault 41, Kara Thompson 41 and Vernon Farewell 3, 1 Dalhousie University and Capital Health, Nova Scotia, Canada, Halifax, NS, 2 MRC Biostatistics Unit, Institute of Public Heath, Cambridge, United Kingdom, 3 MRC Biostatistics Unit, Institute of Public Health, University Forvie Site, Cambridge, United Kingdom, 4 University of Toronto, Toronto Western Hospital, Toronto, ON, 5 Instituto Nacional de Ciencias Médicas y Nutricion, Mexico City, Mexico, 6 Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 7 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 8 Division of Rheumatology and Clinical Epidemiology, McGill University, Montreal, Quebec, QC, 9 Division of Rheumatology, University of Calgary, Alberta, Calgary, AB, 10 Cedars-Sinai/David Geffen School of Medicine at UCLA, Los Angeles, CA, 11 Department of Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 12 Centre for Rheumatology, Department of Medicine, University College London, London, United Kingdom, 13 University College London, London, United Kingdom, 14 SUNY-Downstate Medical Center, Brooklyn, NY, 15 Division of Rheumatology, Centre Hospitalier Universitaire de Quebec et Universite Laval, Quebec, QC, 16 Centre for Prognosis Studies in the Rheumatic Diseases, Toronto Western Hospital and University of Toronto, Toronto, ON, 17 Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 18 Arthritis Research UK Epidemiology Unit, Institution of Inflammation and Repair, University of Manchester, NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 19 Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, 20 Northwestern University and Feinberg School of Medicine, Chicago, IL, 21 Feinstein Institute for Medical Research, Manhasset, NY, 22 Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 23 Center for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland, 24 Department of Rheumatology, University Hospital Lund, Lund, Sweden, 25 Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 26 Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, 27 Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 28 Lanarkshire Centre for Rheumatology, Hairmyres Hospital, East Kilbride, 64 2014 Program Book
scientific sessions United Kingdom, 29 Josep Font Autoimmune Diseases Laboratory, IDIBA, Department of Autoimmune Diseases, Hospital Clinic, Barcelona, Spain, 30 Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Spain, 31 Emory University School of Medicine, Division of Rheumatology, Atlanta, GA, 32 Kantonsspital Geissbergstr, Schaffhausen, Switzerland, 33 Division of Rheumatology, Department of Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, 34 UCSD School of Medicine, La Jolla, CA, 35 Medical University of South Carolina, Charleston, SC, 36 Ysbyty Gwynedd Bangor, North Wales, United Kingdom, 37 University of Manitoba, Winnipeg, MB, 38 Department of Rheumatology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark, 39 Columbia University Medical Center, New York, NY, 40 New York University School of Medicine, New York, NY, 41 Department of Medicine, Queen Elizabeth II Health Sciences Centre and Dalhousie University, Halifax, NS 5:30 pm 962. A Systematic Review and Network Meta-Analysis of the Risk of Serious Infections with Immunosuppressives for Lupus Nephritis Jasvinder Singh 1, Alomgir Hossain 2, Ahmed Kotb 2 and George Wells 3, 1 University of Alabama at Birmingham, Birmingham, AL, 2 University of Ottawa, Ottawa, ON, 3 University of Ottawa Heart Institute, Ottawa, ON 5:45 pm 963. Reduction in Proteinuria and Normalization of C4 Complement Levels Predict Response to Treatment of Lupus Nephritis with Low-Dose Pulse Cyclophosphamide and Abatacept Sarah Goglin 1, David Wofsy 1, Miriam G. Cisternas 2 and Maria Dall Era 1, 1 University of California, San Francisco, San Francisco, CA, 2 MGC Data Services, Carlsbad, CA 157 B Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics I Moderators: Jessica K. Gordon, MD, MSc and Robert Lafyatis, MD 4:30 pm 964. Skin Collagen Synthesis Rates Distinguish Between Early and Late Diffuse Scleroderma Patients Claire Emson 1, Martin Decaris 1, Michelle Gatmaitan 1, Flora Luo 1, Dan Holochwost 1, Simplicia FloraCruz 1, Thomas Angel 1, Kelvin Li 1, Marc Hellerstein 1, Fredrick M. Wigley 2, Scott Turner 1 and Francesco Boin 2, 1 KineMed Inc., Emeryville, CA, 2 Johns Hopkins University School of Medicine, Baltimore, MD 4:45 pm 965. Blockade of TLR4 Signaling By TAK242 Ameliorates Experimental Organ Fibrosis Swati Bhattacharyya 1, Wenxia Wang 1, Zenshiro Tamaki 1, Yasuhiro Tsukimi 2, Masashi Yamasaki 2 and John Varga 3, 1 Northwestern University, Feinberg School of Medicine, Chicago, IL, 2 Takeda Pharmaceutical Company Limited, Kanagawa, Japan, 3 Northwestern University Feinberg School of Medicine, Chicago, IL 5:00 pm 966. Adiponectin Is an Endogenous Anti-Fibrotic and Target in Systemic Sclerosis: Novel Link Between Fibrosis and Metabolism Feng Fang 1, Roberta G. Marangoni 1, Xingchun Zhou 2, Wen Hong 2, Boping Ye 2, Asano Yoshihide 3, Shinichi Sato 3, Yuri Masui 3, Chengning Zhang 1, Katja Lakota 1, Jun Wei 1, Monique E. Hinchcliff 1, Philipp Scherer 4, Laszlo Otvos 5 and John Varga 6, 1 Northwestern University, Feinberg School of Medicine, Chicago, IL, 2 China Pharmaceutical University, Nanjing, China, 3 University of Tokyo, Tokyo, Japan, 4 University of Texas Southwestern Medical Center, Dallas, TX, 5 Temple University, Philadelphia, PA, 6 Northwestern University Feinberg School of Medicine, Chicago, IL 5:15 pm 967. Mir-145 Protects Against Skin Fibrosis in Vivo by targeting TGF-β Signaling Serena Vettori 1, Christian Beyer 2, Matthias Brock 1, Naoki Iwamoto 1, Britta Maurer 1, Michelle Trenkmann 1, Astrid Jüngel 1, Renate E. Gay 1, Maurizio Calcagni 3, Gabriele Valentini 4, Steffen Gay 1, Joerg H. W. Distler 2 and Oliver Distler 1, 1 Zurich University Hospital, Zurich, Switzerland, 2 Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen- Nuremberg, Erlangen, Germany, 3 Division of Plastic Surgery and Hand Surgery, University Hospital Zurich, Zurich, Switzerland, 4 Second University of Naples, Napoli, Italy 5:30 pm 968. Priming of WNT Signalling during Fibrosis Is Mediated By TGF-β Induced Axin-2 Downregulation Justin Gillespie 1, Emma C. Derrett-Smith 2, Michael McDermott 1, Paul Emery 3, Christopher P Denton 2 and Francesco Del Galdo 3, 1 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 2 UCL Medical School Royal Free Campus, London, United Kingdom, 3 Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom 5:45 pm 969. Caspase-8 Prevents Lung Fibrosis in a Murine SSc-like Disease Model By Preventing Macrophage Differentiation Alexander Misharin 1, Carla M. Cuda 2, Luisa Morales-Nebreda 3, Gokhan Mutlu 1, GR Scott Budinger 3 and Harris R. Perlman 2, 1 Northwestern University, Chicago, IL, 2 Northwestern University Feinberg School of Medicine, Chicago, IL, 3 Northwestern University, Feinberg School of Medicine, Chicago, IL SUNDAY november 16, 2014 2014 Program Book 65
scientific sessions SUNDAY november 16, 2014 ACR MEET THE PROFESSOR SESSIONS 4:30 6:00 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. Westin Paine (Lobby) Crystal: Diagnosis and Management of Gout (021) Speaker: Saima Chohan, MD review diagnostic criteria for gout assess treatment options for hyperuricemia, acute and chronic gout assess the current ACR recommendations for the treatment of acute and chronic manifestations of gout Westin Otis (Lobby) *Infections with Biologics (022) Speaker: Kathryn H. Dao, MD discuss the risk of infection related to inflammation and disease discuss the risk factors for infection recognize the magnitude of risk imposed by steroids and biologics determine the approach to risk reduction Westin Hancock (Lobby) *Inflammatory Eye Disease/Uveitis (023) Speaker: Sergio Schwartzman, MD review the clinical manifestations of inflammatory eye disease encountered by rheumatologists discuss diagnostic pearls for the evaluation of someone with inflammatory eye disease discuss the treatment paradigms used for the inflammatory eye diseases Westin Revere (Lobby) Pediatrics: Difficult-to-Treat Juvenile Idiopathic Arthritis (024) Ed Pd PrM FIT Speaker: Thomas J. A. Lehman, MD discuss the differences in the treatment of the difficult situations for the different subtypes of juvenile idiopathic arthritis recognize some of the complications of the disease and appropriate management explain the difficulties posed by non-adherence and inadequate decision making Westin Stone (Lobby) Polymyalgia Rheumatica (025) Speaker: Antoine G. Sreih, MD distinguish the clinical subtleties of polymyalgia rheumatica and outline an evaluative process that can help differentiate it from other inflammatory conditions and identify manifestations of giant cell arteritis discuss the new EULAR/ACR classification criteria and the scoring algorithm for polymyalgia rheumatica review the therapeutic strategies used for the treatment of polymyalgia rheumatica, including the range of glucocorticoid regimens, other disease modifying therapies, steroid-sparing approaches and new investigative drugs Westin Webster (Lobby) Pulmonary Hypertension in the Rheumatic Diseases (026) Speaker: James R. Seibold, MD describe the World Health Organization classification of pulmonary hypertension and how to recognize the frequent overlap of these syndromes in the clinical setting of connective tissue disease discuss the utility, sensitivity and specificity of non-invasive screening tests and algorithms for determining which patients are appropriate for right heart catheterization explain the benefits, risks, costs and effects on outcome of the available therapies for pulmonary arterial hypertension Westin Adams (Mezzanine) *Rheumatoid Arthritis: Biological Agents (027) Speaker: Josef Smolen, MD describe similarities and differences between approved biological agents in terms of efficacy and safety discuss issues around biosimilars assess the place of biologicals in the therapeutic cascade according to the updated EULAR management recommendations appraise the potential of induction therapy with biologics followed by withdrawal of the biologic as a potential future treatment approach Westin Alcott (Mezzanine) *Rheumatology Practice 101: Starting Out in Practice for the Graduating Fellow Ed Pd (028) PrM FIT Speakers: Alexandru F. Kimel, MD prepare for their first job search 66 2014 Program Book
scientific sessions assess expectation when starting out (perceptions versus reality) adapt to new practice styles and build a referral base identify ways to ensure long term success and personal life balance Westin Douglas (Mezzanine) *Systemic Lupus Erythematosus: Novel Treatments (029) Speaker: Liz Lightstone, MD, PhD review immunosuppressive therapy of lupus nephritis classes II-V, including novel biologics discuss the management of lupus nephritis in pregnancy discuss novel approaches to improving adherence to therapy in lupus nephritis describe the use of reno-protective and anti-proteinuria therapies in lupus nephritis outline the future research agenda for clinical trials in lupus nephritis Westin Faneuil (Mezzanine) Vitamin D and Bone Health (030) Speaker: Nancy E. Lane, MD state current Food and Nutrition Board recommendations for vitamin D intake in older men and women recall evidence-based medicine conclusions regarding vitamin D and osteoporotic fracture identify the range of serum 25(OH)D levels believed optimal for bone health Dan Caspi 7 and Ori Elkayam 8, 1 Tel Aviv medical center, Tel Aviv, Israel, 2 Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 3 Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel, 4 Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel-Aviv, Israel, 5 Tel Aviv Sourasky Medical Ctr, Tel-Aviv University, Tel Aviv, Israel, 6 Department of rheumatology. Tel Aviv Medical Center, Tel Aviv, Israel, 7 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 8 Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel 5:00 pm 972. Racial, Gender and Geographic Differences in Systemic Lupus Erythematous and Lupus Nephritis Mortality Rates in the Unites States, 1968-2010 Eric Y Yen 1, Magda Shaheen 2, Jennifer MP Woo 1, Deborah K. McCurdy 1 and Ram Raj Singh 3, 1 UCLA Division of Pediatric Rheumatology, Los Angeles, CA, 2 Charles R. Drew University of Medicine and Science, Los Angeles, CA, 3 UCLA Division of Rheumatology, Los Angeles, CA 5:15 pm 973. Relation of Pelvic Drop during Walking to Risk of Incident Medial Knee Osteoarthritis: The Multicenter Osteoarthritis Study K. Douglas Gross 1, Emily K. Quinn 2, Michael C. Nevitt 3, James C. Torner 4, Cora E. Lewis 5 and David T. Felson 1, 1 Boston University School of Medicine, Boston, MA, 2 Boston University, Boston, MA, 3 UCSF (University of California, San Francisco), San Francisco, CA, 4 University of Iowa, Iowa City, Iowa City, IA, 5 The University of Alabama at Birmingham, Birmingham, AL SUNDAY november 16, 2014 ACR/ARHP COMBINED ABSTRACT SESSION 4:30 6:00 pm 109 A ACR/ARHP Combined Abstract Session: Epidemiology and Public Health Moderator: Elizabeth G. Salt, PhD 4:30 pm 970. Risk of Developing Antiphospholipid Syndrome Following Infection: A Systematic Review and Meta-Analysis of Observational Studies Noha Abdel-Wahab 1, Maria A. Lopez-Olivo 1, Saurabh Talathi 2 and Maria E. Suarez-Almazor 1, 1 The University of Texas, MD Anderson Cancer Center, Houston, TX, 2 The University of Texas Health Science Center at Houston, School of Public Health, Houston, TX 4:45 pm 971. The Long-Term Efficacy of an Anti-Pneumococcal Polysaccharide Vaccine (PV23, Pneumovax) Among Autoimmune Inflammatory Rheumatic Patients Adi Broyde 1, Uri Arad 2, Noa Madar-Balakinski 2, Daphna Paran 3, Ilana Kaufman 4, Ira Litinsky 5, David Levartovsky 6, Irena Wigler 2, 5:30 pm 974. Obesity Paradox in Osteoarthritis Progression What Effects Are We Measuring? Qiong Louie-Gao 1, Hyon K Choi 1, David T. Felson 2, Tuhina Neogi 1, Uyen Sa D.T. Nguyen 1, Na Lu 1 and Yuqing Zhang 1, 1 Boston University School of Medicine, Boston, MA, 2 University of Manchester, Manchester, United Kingdom 5:45 pm 975. Chronic Pain Predicts Reduced Physical Activity in a Large Population Cohort Study Kathryn Remmes Martin, Marcus Beasley, Gary J. Macfarlane and Daniel Whibley, University of Aberdeen, Aberdeen, United Kingdom 2014 Program Book 67
scientific sessions SUNDAY november 16, 2014 ARHP SESSIONS 4:30 6:00 pm 255 Say What? : Implications of Adolescent Development and Behavior in Communicating with Health Care Providers Ed Pd PrM FIT Moderator: Thuy T. Beam, BSN, RN Speakers: Kiana Johnson, PhD and Courtney Wells, MPH, MSW evaluate the cultural competency skills of professionals working with adolescents with rheumatic diseases recognize the developmental needs of adolescents with rheumatic diseases use knowledge of adolescent development and behavior to learn how to talk with adolescents develop comfort in speaking with adolescent patients 254 A Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations Eth Moderator: Catherine L. Backman, PhD define mobile health/ehealth and evaluate its utilization in the care of people with arthritis examine mobile health applications and identify functionality options to enhance consumer and health care provider utilization outline potential and actual ethical situations that may arise in the era of ehealth 4:30 pm Take Two Apps and Call Me in the Morning: An Overview of Mobile Health Applications to Improve Quality of Care Elizabeth A. Breeden, PharmD 5:00 pm State of the Science: A Conversation on Digital Resources to Support Self-Management Linda C. Li, PhD, PT and Maura D. Iversen, BSc, DPT, SD, MPH 5:30 pm The e-patient: Engaged, Empowered, Equipped, Enabled and Ethical? Anne F. Townsend, MA, PhD 102 A Multidisciplinary Management of Scleroderma Moderator: Deborah McCloskey, RN, BSN explain the medical management for the skin, vascular and organ involvement in scleroderma 256 describe the rehabilitation interventions used by occupational and physical therapists to manage functional disability in scleroderma discuss the management of psychosocial issues that can occur in scleroderma 4:30 pm Targeted Therapy for Systemic Sclerosis Virginia D. Steen, MD 5:00 pm Rehabilitation Techniques to Improve Function in Scleroderma Janet L. Poole, OTR, PhD 5:30 pm Managing Psychosocial Challenges in Scleroderma Vanessa L. Malcarne, PhD Practical Practice Management Session Two: Navigate HIPAA and Prevent Audits Moderator: Karen Huisinga, MN, ARNP review the latest national HIPAA requirements evaluate current pre-audit preventive measures and strategies for responding to audits develop an up-to-date small practice compliance plan 4:30 pm HIPAA in 2014: Don t Forget Research, Quality Measures and Electronic Medical Records Bruce Toppin, JD 5:15 pm Audits, Affordable Care Act, ICD-10 I m at the End of the Rope Karen Zupko, BS ARHP CONCURRENT ABSTRACT SESSION 4:30 6:00 pm 257 A Osteoarthritis Moderators: Sara R. Piva, PhD, PT and Jan K. Richardson, PT, PhD 4:30 pm 976. Measurement Properties of the Health Assessment Questionnaire Disability Index (HAQ-DI) in Patients with Generalized Osteoarthritis (GOA) Nienke Cuperus 1, Elien A.M. Mahler 1, Thea Vliet Vlieland 2, Thomas Hoogeboom 3 and Cornelia H.M. van den Ende 1, 1 Sint Maartenskliniek, Nijmegen, Netherlands, 2 Leiden University Medical Center, Leiden, Netherlands, 3 CAPHRI school for public health and primary care, CCTR centre for Care Technology Research, Maastricht University, Maastricht, Netherlands 68 2014 Program Book
4:45 pm 977. Randomized Clinical Trial of a Patient and Provider Intervention for Managing Osteoarthritis in Veterans Kelli D. Allen 1, Hayden B. Bosworth 2, Amy Jeffreys 1, Cynthia Coffman 2, Santanu Datta 2, Jennifer McDuffie 3, Eugene Oddone 2, Jennifer Strauss 3 and William S. Yancy Jr. 3, 1 Durham VA Medical Center, Durham, NC, 2 Durham VA Medical Center and Duke University Medical Center, Durham, NC, 3 Duke University Medical Center, Durham, NC 5:00 pm 978. Socioeconomic Status Measures Are Associated with Increasing Pain, Stiffness and Physical Function Among Individuals with Knee and Hip Osteoarthritis Rebecca Cleveland 1, Jordan B. Renner 2, Joanne M. Jordan 3 and Leigh F. Callahan 4, 1 University of North Carolina at Chapel Hill, Chapel Hill, NC, 2 University of North Carolina Department of Radiology, Chapel Hill, NC, 3 University of North Carolina Dept of Epidemiology, Chapel Hill, NC, 4 University of North Carolina, Chapel Hill, NC 5:15 pm 979. Genome-Wide Association Study for Severe Radiographic Knee Osteoarthritis Youfang Liu 1, Michelle Yau 2, Laura Yerges-Armstrong 3, Braxton Mitchell 3, Rebecca D. Jackson 4, Marc C. Hochberg 3, Shad Smith 1, William Maixner 1, Luda Diatchenko 5 and Joanne M. Jordan 6, 1 University of North Carolina, Chapel Hill, NC, 2 University of Maryland, Baltimore,, MD, 3 University of Maryland School of Medicine, Baltimore, MD, 4 The Ohio State University, Columbus, OH, 5 McGill University, Montreal, QC, 6 University of North Carolina Dept of Epidemiology, Chapel Hill, NC 5:30 pm 980. Annual Medical Care Expenditures Among US Adults with Osteoarthritis, 2008 2011 Miriam G. Cisternas 1, Louise Murphy 2, David J. Pasta 3, Daniel H. Solomon 4 and Charles G. Helmick 2, 1 MGC Data Services, Carlsbad, CA, 2 Centers for Disease Control and Prevention, Atlanta, GA, 3 DMA Corporation, Palo Alto, CA, 4 Brigham and Women s Hospital, Boston, MA 5:45 pm 981. The Effect of Compression Gloves in Hand Osteoarthritis: A Pre-Post-Test Trial Alison Hammond 1, Yeliz Prior 1, Vivienne Jones 1, Mary Dooley 2, Yvonne Hough 3 and Angela Jacklin 4, 1 University of Salford, Greater Manchester, United Kingdom, 2 Southport & Formby District Hospital, Southport, United Kingdom, 3 St Helens Hospital, St Helens, United Kingdom, 4 Stepping Hill Hospital, Stockport, United Kingdom scientific sessions INDUSTRY-SUPPORTED SYMPOSIA 6:30 9:30 pm These symposia are both CME-accredited and non-cme company-directed programs. For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. All non-cme programs are wholly sponsored and supported by commercial entities. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 239 for more information. ACR SESSIONS 7:30 8:30 am MONDAY, NOVEMBER 17, 2014 102 A Educator: Cultivating the Competent Medical Educator: A Growing Concern Moderator: Kenneth S. O Rourke, MD Speaker: Kelley M. Skeff, MD, PhD Ed Pd PrM FIT discuss the major aspects of effective teaching in medical school and clinical environments describe proposed competencies for medical educators based on this framework describe personal goals for improving teaching effectiveness 104 B Meniscus Biology in Osteoarthritis Moderator: Richard F. Loeser, MD Speaker: Robert Brophy, MD review the normal function of the meniscus in stabilizing the joint appraise how meniscal injury contributes to osteoarthritis pathogenesis describe the pro-inflammatory mediators produced by the meniscus that could promote osteoarthritis Ballroom East Rheumatology Research Foundation Paul Klemperer, MD Memorial Lectureship: Gene-Environment Interactions as a Basis for Unravelling Adaptive Immunity and Preparing for Tolerizing Therapies in Rheumatoid Arthritis Moderator: David R. Karp, MD, PhD Speaker: Lars Klareskog, MD, PhD critically evaluate studies on genetic and environmental/life style risk factors for RA and other rheumatic diseases appraise the power of such studies for identifying subsets of disease with different etiologies, molecular pathologies, disease course and response to therapy MONDAY november 17, 2014 2014 Program Book 69
scientific sessions MONDAY november 17, 2014 recognize the effects of genes and environment/life style in clinical practice to advise patients and their relatives in avoiding and ameliorating disease critically evaluate the potentials of tolerizing therapies as future options for prevention and treatment of rheumatoid arthritis ARHP SESSIONS 7:30 8:30 am 151 A Stats Boot Camp: The Effect Size: What Is It and How Can You Use It? Moderator: Uyen Sa D.T. Nguyen, DSc, MPH Speaker: Nancy A. Baker, MPH, OTR, OTR/L distinguish between effect size and statistical significance define common effect sizes calculate and interpret common effect sizes discuss practical uses of effect sizes 255 Update on Findings from Large Registries: Emphasis on Health Disparities in Rheumatoid Arthritis Moderator: Scott Hasson, PT, PhD Speaker: Jeffrey D. Greenberg, MD, MPH discuss the incidence and prevalence of rheumatoid arthritis in ethnic populations describe disease severity and clinical course of disease among different ethnic groups discuss who are the medically underserved in this patient population 153 B What Are Biosimilars? Moderator: Susan Chrostowski, MS, ANP-C, RN summarize the basic concept of biosimilar drugs discuss the development, clinical trial and approval process for biosimilar drugs evaluate how the availability of biosimilars may affect their rheumatology practice and patient care approaches 7:30 am What Are Biosimilars? Lee S. Simon, MD ACR MEET THE PROFESSOR SESSIONS 7:45 9:15 am Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. Westin Paine (Lobby) *Ankylosing Spondylitis: 2014 Update (031) Speaker: Lianne S. Gensler, MD discuss the spectrum of axial spondyloarthritis, including ankylosing spondylitis discuss the early diagnosis of ankylosing spondylitis and axial spondyloarthritis describe clinical and radiographic outcome measures used in clinical trials and practice summarize axial spondyloarthritis treatment options and understand the impact of treatment on outcomes Westin Otis (Lobby) *Basic Immunology for Clinical Rheumatologists (032) Speaker: John Atkinson, MD describe how the immune system functions in normal individuals identify abnormalities of immune regulation that lead to autoimmunity Westin Hancock (Lobby) Controversies in Sjögren s Syndrome (033) Speaker: Frederick Vinino, MD identify the best approach to establish a diagnosis of Sjögren s syndrome differentiate among various causes of salivary and/or lacrimal gland swelling discuss current treatment algorithms for dry eyes, dry mouth and systemic manifestations identify risk factors and markers for lymphoma in Sjögren s syndrome patients 8:00 am Where Are We Now with Biosimilars? Vibeke Strand, MD Westin Revere (Lobby) Dermatological Manifestations of Rheumatic Diseases (034) Speaker: Ruth Ann Vleugels, MD, MPH identify cutaneous findings associated with underlying rheumatic disease 70 2014 Program Book
scientific sessions construct a differential diagnosis for these conditions design a strategy for management of skin disease seen in patients with rheumatic diseases Westin Stone (Lobby) Osteoarthritis: Update 2014 (035) Speaker: Joanne M. Jordan, MD, MPH describe the pathogenesis of osteoarthritis including factors that lead to its development and the underlying biology responsible for the progression of osteoarthritis discuss advances in the management of osteoarthritis that include non-pharmacologic interventions evaluate the potential benefits of new disease- or structuremodifying treatments for osteoarthritis Westin Webster (Lobby) *Pregnancy and Rheumatic Diseases (036) Speaker: Eliza Chakravarty, MD, MS describe risk factors for adverse maternal and fetal outcomes in systemic autoimmune diseases. describe key elements of preclinical risk assessment and counseling for women who desire a future pregnancy discuss the impact of active maternal autoimmune disease upon pregnancy outcomes discuss the risk-to-benefit analysis of common anti rheumatic and immunosuppressive medications during pregnancy Westin Adams (Mezzanine) Reactive Arthritis: An Update (037) Speaker: John D. Reveille, MD identify various causes of reactive arthritis discuss mechanisms of disease pathogenesis describe current treatment options for reactive arthritis Westin Alcott (Mezzanine) Rheumatoid Arthritis: Challenging Cases (038) Speaker: Daniel Furst, MD, MPH discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients Westin Douglas (Mezzanine) *Systemic Lupus Erythematosus: Difficult-to-Treat Systemic Lupus Erythematosus (039) Speaker: Maria Dall Era, MD review established data from the medical literature in order to improve clinical practice related to the treatment of systemic lupus erythematosus including: examine management strategies for refractory cutaneous manifestations of systemic lupus erythematosus discuss management of progressive or relapsing lupus nephritis discuss management of severe cytopenias Westin Faneuil (Mezzanine) *Vasculitis: Update (040) Speaker: Raashid A. Luqmani, DM describe the current definitions of vasculitis according to affected vessel size discuss the role of simple clinical evaluation alongside the various available laboratory and imaging tests, including antineutrophil cytoplasm antibodies identify current and novel therapeutic modalities ACR/ARHP WORKSHO 7:45 9:45 am Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. 159 *Advanced Musculoskeletal Ultrasound (214) Speaker: Jay B. Higgs, MD 161 demonstrate improvement in their techniques for performing selected musculoskeletal ultrasound examinations use practical knowledge of ultrasound technology to improve image quality Complementary and Alternative Therapies in Rheumatic Disease (215) Speaker: Donald M. Marcus, MD describe the differences between the regulation of dietary supplements and conventional medications and to inform patients about current evidence concerning their efficacy and safety inform patients about the efficacy of acupuncture and chiropractic manipulation for relief of musculoskeletal pain and osteoarthritis 2014 Program Book 71 MONDAY november 17, 2014
scientific sessions MONDAY november 17, 2014 154 152 Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (216) Speaker: Stuart L. Silverman, MD use bone mineral density and clinical risk factors in determination of absolute risk of fracture discuss the concept of intervention threshold address limitations of the Fracture Risk Assessment Algorithm in clinical practice The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Disease-Specific Measurements (217) Speaker: Arthur M. Mandelin II, MD, PhD Facilitators: Barbara A. Slusher, PA-C, MSW and Kori A. Dewing, DNP, ARNP define the importance of using disease activity measurement tools in daily practice, the barriers which hinder routine widespread use and how these barriers can be overcome in nearly any practice setting learn and practice several of the most common and wellrecognized disease activity measurement tools used in rheumatology care, including the Disease Activity Score for 28 Joints (DAS-28) and Clinical Disease Activity Index (CDAI) for rheumatoid arthritis; the Psoriatic Arthritis Response Criteria (PsARC) for psoriatic arthritis; measurements of spine and hip flexibility as well as the Ankylosing Spondylitis Disease Activity Score (AS-DAS) for spondyloarthropathies; and the modified Rodnan skin score for systemic sclerosis ACR SESSIONS 8:30 10:00 am 52 A CARE: Maintenance of Certification Session Two of Three Seronegative Spondyloarthropathies and Infectious Diseases All annual meeting scientific attendees will receive access to the CARE: MOC module on their ACR profiles. Successful completion of the 30 case-based question online module with a score of 70% or higher will enable submission to the ABIM to receive ten (10) medical knowledge points for the Maintenance of Certification program. Ten (10) seronegative spondyloarthropathies and infectious diseases questions will be covered at this session. Attendance at the session(s) is not required to participate in the online module. Moderator: Carol A. Langford, MD, MHS Speaker: Atul A. Deodhar, MD, MRCP assess strengths and weaknesses in rheumatology medical knowledge review the diagnosis, management and treatment of rheumatic diseases that are part of the ABIM s rheumatology MOC examination blueprint satisfy a self-evaluation of medical knowledge requirement for the ABIM MOC program Exhibit Hall C Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics and Management of Disease-Modifying Antirheumatic Drugs (DMARDs) and Biologics in the Perioperative Ed Period Pd PrM FIT Moderators: Jasvinder A. Singh, MD, MPH and James R. O Dell, MD review the findings of comparative effectiveness of biologics and oral small molecules from registries and direct comparator trials for treatment discuss the comparative harms of biologics and oral small molecules from registries and direct comparator trials for treatment with biologics summarize how to manage biologics and traditional diseasemodifying antirheumatic drugs in the perioperative period 8:30 am Comparative Efficacy and Effectiveness of Biologics: Head-to- Head Trials vs. Registry Studies Arthur Kavanaugh, MD 9:00 am Comparative Harms of Biologics: How to Best Learn from the Data? William G. Dixon, MRCP, PhD 9:30 am Perioperative Management of Biologics and Traditional Disease-Modifying Antirheumatic Drugs Susan M. Goodman, MD 107 B Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art Ed Pd PrM FIT Moderators: Kelly A. Rouster-Stevens, MD, MS and Angela Robinson, MD, MPH review the latest information on the pathogenesis of juvenile dermatomyositis review the different clinical phenotypes of juvenile dermatomyositis review cutting-edge developments in treatments and outcome measures for juvenile dermatomyositis 8:30 am Pathogenesis of Juvenile Dermatomyositis Ann M. Reed, MD 72 2014 Program Book
scientific sessions 9:00 am The Clinical and Autoantibody Phenotypes of Juvenile Myositis Lisa G. Rider, MD 9:30 am Outcome Assessment and Advances in Therapies Adam M. Huber, MD, MSc 204 A Practical Use of Registries Moderator: Melissa Francisco describe the importance of data collection and synthesis in evidence-based care evaluate the importance of their role as a participant in the Rheumatology Informatics System for Effectiveness registry develop strategies for participating in the registry and accessing collective data as a part of improving patient care 8:30 pm Rheumatology Informatics System for Effectiveness and Its Applications Salahuddin Kazi, MD 156 B Strategies for Academic Success: The Roadmap From Mentee to Mentor Ed Pd PrM FIT Moderators: Flavia V. Castelino, MD and Darcy S. Majka, MD identify the necessary measures for a productive menteementor relationship develop time management and organizational skills for academic success develop a strategy to transition from a mentored relationship to independence 8:30 am Your Role as a Mentee S. Louis Bridges Jr., MD, PhD 8:50 am Effective Time Management Leena Sharma, MD 9:20 am Transitioning to Independence Liana Fraenkel, MD, MPH 8:45 pm The Value of Participating Registries Jeffrey R. Curtis, MD, MPH, MS 9:00 am RISE Demonstration Tim Parr 109 A Practice Issues: Practice Success in an Environment of Transition Moderator: Suzanne Moore, MD review the next steps for Physician Quality Reporting System (PQRS), Electronic Prescribing (erx) and Electronic Health Record (EHR) Incentive Programs discover how to avoid penalties review ways to avoid Health Insurance Portability and Accountability Act (HIPAA) violations 9:40 am Panel Discussion 253 B Systems Biology of Lupus Nephritis Moderators: Shu Man Fu, MD, PhD and Vasileios C. Kyttaris, MD review how a systems analysis of mouse and human renal gene expression analysis can lead to the identification of major pathogenic cell populations and pathways evaluate how a single cell characterization of local renal immune responses can lead to identification of disease amplification mechanisms describe how to identify and test novel disease biomarkers 8:30 am Stage Specific Systems Analysis of Lupus Nephritis: From Mice to Men Anne Davidson, MBBS MONDAY november 17, 2014 8:30 am Physician Quality Reporting System (PQRS) Reporting Made Easy Robert Warren, MD, PhD, MPH 9:00 am Health Insurance Portability and Accountability Act (HIPAA) A Guide to Compliance Evan Gwilliam, DC, MBA, BS, CPC, NCICS, CCPC, CCCPC, CPC-I MCS-P 9:00 am Systems Analysis of the Immunoglobulin Gene Repertoire in Nephritic Kidneys Suggests Local Antigenic Drive Marcus R. Clark, MD 9:30 am Proteomic Analysis of Lupus Urines Leads to the Identification of Potential Renal Biomarkers Chandra Mohan, MD, PhD 9:30 am The Fundamentals of Value-Based Modifier Evan Gwilliam, DC, MBA, BS, CPC, NCICS, CCPC, CCCPC, CPC-I MCS-P 2014 Program Book 73
scientific sessions MONDAY november 17, 2014 Ballroom West The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be? Moderators: Dinesh Khanna, MD and N. Lawrence Edwards, MD describe the development and content of the recent ACR Gout Guidelines examine the components of the guidelines that have generated concern and controversy examine the historic success of guideline implementation and which factors influence this success 8:30 am An Overview of the 2012 ACR Gout Management Guidelines John D. FitzGerald, MD, PhD 9:00 am Strengths, Weakness and Controversies of the Gout Guidelines Kenneth G. Saag, MD, MSc 9:30 am The Trouble With Guidelines Implementation and What We Can Do About It Robert T. Keenan, MD, MPH ACR/ARHP POSTER SESSION B, THIEVES MARKET POSTERS AND POSTER TOURS 8:30 am 4:00 pm Poster presenters will be available from 9:00 11:00 am (abstracts # 982 1793). Poster tours will be held 9:00 9:45 am and 10:15 11:00 am. Morning snacks will be available from 9:00 10:30 am. Poster Hall (Exhibit Hall B) Thieves Market Posters TM 1. Friday Evening Consult...Vasculitis? Manpreet Sethi, MBBS TM 2. Numbness Matters Nandita Gatla, MD TM 3. Scary Salmonella Yathish GC, MBBS, MD TM 4. When Oral and Genital Ulcers Are Not Behçet s... Kim M. Wu, MD TM 5. 47-Year-Old Woman With Fever and Anasarca Kensuke Nakanishi, MD TM 6. A Case of An Orbital Mass Namrata Singh, MBBS TM 7. Arthritis Mutilans in a Teenage Girl from Panama Vidya Raman, MD Poster Hall (Exhibit Hall B) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 15 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until five minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Exhibit Level: East Registration). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first-served basis five minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 15 minutes of the end of the tour. 9:00 9:45 am Epidemiology and Health Services Research Poster Tour (313) Tour Guide: Cheryl Barnabe, MD, MSc Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes Poster Tour (314) Tour Guide: Daniel J. Claw, MD Imaging of Rheumatic Diseases Poster Tour (315) Tour Guide: Wolfgang A. Schmidt, MD Pediatric Rheumatology: Clinical Aspects Poster Tour (316) Tour Guide: Bryce A. Binstadt, MD, PhD Rheumatoid Arthritis: Clinical Aspects Poster Tour (317) Tour Guide: Merete Lund Hetland, DMSc, MD, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics Poster Tour (318) Tour Guide: Robert Lafyatis, MD 10:15 11:00 am Pediatric Rheumatology: Clinical Aspects Poster Tour (319) Tour Guide: Lisa F. Imundo, MD Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy Poster Tour (320) Tour Guide: Vivian P. Bykerk, MD Rheumatoid Arthritis: Clinical Aspects Poster Tour (321) Tour Guide: Grant H. Louie, MD, MHS Spondyloarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour (322) Tour Guide: Robert D. Inman, MD Systemic Lupus Erythematosus: Clinical Aspects Poster Tour (323) Tour Guide: Eliza Chakravarty, MD Vasculitis Poster Tour (324) Tour Guide: Kenneth J. Warrington, MD 74 2014 Program Book
scientific sessions ACR SESSIONS 9:00 10:00 am 104 B Functional Genomics of Rheumatoid Arthritis: From Genes to Function to Therapy Moderator: Lindsey A. Criswell, MD, MPH Speaker: Ranjeny Thomas, MBBS, MD review the molecular mechanisms whereby HLA-DRB1 contributes to the pathogenesis of rheumatoid arthritis appraise subtle differences in the structure of HLA-DR molecules permitting the binding of specific autoantigens describe the rationale for contemporary approaches to peptide specific immunotherapy for the treatment of rheumatoid arthritis 102 A Legislative Update: Chat with Congress Moderator: David Goddard, MD describe the latest developments in federal health policy discuss legislative initiatives currently before Congress appraise how legislative outcomes could affect the rheumatology community 9:00 am Congressional Update Speaker to be Determined 9:30 am Legislative Update William F. Harvey, MD, MSc 153 B Social Media Boot Camp: Blogging for Beginners Moderator: Ronan Kavanagh, MD, MRCP describe a blog and its relevance in professional social engagement identify the challenges and opportunities of communicating through blogs in a public environment evaluate appropriate content for blogging define self-hosting vs. writing for an established platform create a basic blog in WordPress produce strategies for basic blog promotion and building readership 9:00 am Introduction Ronan Kavanagh, MD, MRCP 9:05 am Why Blog: An Overview Philip Gardiner, MD 9:30 am How to Blog Paul Sufka, MD 9:55 am Question and Answer ARHP SESSION 9:00 10:00 am 254 A ARHP Distinguished Lecturer: Maintaining Health and Well-Being Despite Living with a Rheumatic Disease MONDAY november 17, 2014 Ballroom East Prosthetic Device Infections, or Infection as a Threat to the Bionic Man Moderator: Kenneth S. O Rourke, MD Speaker: James E. Peacock Jr., MD define the utilization of prosthetic devices in musculoskeletal diseases and the risk of infection associated with those devices describe the pathogenesis of prosthetic device infection, including the bacterial elaboration of extracellular glycocalyx (biofilm) and how it impacts the choice and duration of antibiotic therapy discuss the management strategies for infected joint prostheses, including the impact of immunosuppressive medications on the development and outcome of treatment Moderator: Afton L. Hassett, PsyD Speaker: Monique A. Gignac, PhD describe factors beyond health symptoms and treatment that are important in understanding the behaviors and perceptions of patients with rheumatic diseases in living with and managing their disease help patients find ways to maintain social participation in diverse roles and activities in terms of physical health and well-being develop strategies in combination with patients to promote the maintenance of social participation and further promote health and well-being 2014 Program Book 75
scientific sessions MONDAY november 17, 2014 EXHIBITS 10:00 am 5:00 pm Exhibit Hall A Join your colleagues in the Exhibit Hall for morning and afternoon refreshments from 10:00 11:00 am and 2:00 3:00 pm. (Booths #139 and #1401) Innovation Theater A and B Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. Innovation Theater A presentations will be held from 10:30 11:15 am, 12:30 1:15 pm and 2:30 3:15 pm. Innovation Theater B presentations will be held from 11:30 am 12:15 pm, 1:30 2:15 pm and 3:30 4:15 pm. For a complete listing of Innovation Theater presentations, see page 238. ACR WORKSHO 10:30 am 12:30 pm 154 Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. Histopathology of Vasculitis (218) Speakers: Allen Burke, MD and Fabio Tavora, MD, PhD describe histological features of normal blood vessels distinguish pathologic reactions to vascular injury identify histological features of major vasculitis syndromes 152 *Knee Braces, Foot Orthoses and Shoe Gear for Managing Knee Osteoarthritis (219) Speakers: Howard J. Hillstrom, PhD and Kelly D. Krohn, MD review the biomechanical rationale for the use of knee braces and foot orthoses for knee osteoarthritis discuss the clinical data to support these modalities apply these modalities to their patients 159 *Musculoskeletal Ultrasound (220) Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD 161 demonstrate how to properly position the ultrasound transducer to visualize targeted musculoskeletal structures based on an understanding of the local bony landmarks differentiate tissue types on their ultrasound properties recognize the ultrasound appearance of some of the basic musculoskeletal pathologies Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (221) Speaker: Anthony Chang, MD identify the pathologic changes that occur in lupus nephritis discuss the pathologic basis for the classification of lupus nephritis and how it relates to clinical management describe the histological changes in the kidneys of patients with vasculitis ACR SESSIONS 11:00 am Noon 52 A ACR Immunology Update: Innate Lymphoid Cells Moderator: Leonard H. Sigal, MD Speaker: Hergen Spits, MD, PhD provide an overview of human innate lymphoid cells subsets discuss development and plasticity of innate lymphoid cells subsets discuss the possible roles of innate lymphoid cells in human diseases Ballroom West ACR Knowledge Bowl: Final Round Moderator: Rebecca L. Manno, MD, MHS identify key images that are important to recognize in clinical practice describe factual information related to various rheumatic diseases identify historical facts relevant to the field of rheumatology Competing Teams: Portlandumabs Defending 2013 ACR Knowledge Bowl Champions Cailin H. Sibley, MD; Navid Mehraban, MD and Daniela Ghetie, MD Winners from the 2014 ACR Knowledge Bowl: Preliminary Round View the full list of competing 2014 Knowledge Bowl Teams on page 41. 76 2014 Program Book
scientific sessions ARHP SESSIONS 11:00 am Noon ACR PLENARY SESSION II DISCOVERY 2014 11:00 am 12:30 pm 259 A Evidence of the Benefits and Risks of Cannabis and Cannabinoids for Treating Chronic Pain Moderator: Kenneth N. Schikler, MD Speaker: Daniel J. Clauw, MD summarize the research-based evidence for the benefits to medicinal marijuana and cannabinoids for treating chronic pain review the research-based evidence for the risks to medicinal marijuana and cannabinoids enhance patient and provider education by using contemporary scientific knowledge to clarify the appropriate position of this class of drugs in the overall treatment algorithms for chronic pain 257 A Immunology Boot Camp II: The Basics of Autoimmunity and Immunodeficiency Moderator: Benjamin J Smith, PA-C Speaker: Troy R. Torgerson, MD, PhD describe mechanisms of tolerance review the cellular changes responsible for autoimmunity describe the relevance of genetic predisposition for rheumatic diseases recognize when the immune system fails to recognize threats and mount an appropriate response 254 A Stats Boot Camp: Statistical Analysis of Ordinal Data Moderator: Michael P. LaValley, PhD identify the ubiquity of ordinal data and contrast it with continuous data review contingency table analysis of ordinal data describe common statistical models for ordinal outcome data interpret and report results generated by ordinal data methods 11:00 am Ordinal Data: Overview and Contingency Table Analysis Todd A. Schwartz, DrPH 11:30 am Statistical Modeling of Ordinal Data Rebecca J. Cleveland, PhD Exhibit Hall C ACR Plenary Session II: Discovery 2014 Moderators: Eric L. Matteson, MD, MPH and Mary E. Cronin, MD 11:00 am 1794. The Sting Pathway Regulates Bone Remodeling in a Model of Autoimmune Disease Rebecca Baum, University of Massachusetts Medical School, Worcester, MA Background/Purpose: Cytosolic DNA sensors detect viral and bacterial DNA, inducing inflammatory cytokines and type I IFNs via the adaptor stimulator of interferon genes (STING) to clear infection. The STING pathway also responds to endogenous DNA from dying cells and contributes to autoimmune disease. We have identified a potentially important role for cytosolic DNA sensor pathways in bone by studying a mouse that develops inflammatory polyarthritis and articular erosions in the setting of DNA accrual. In this model, DNA accumulates in macrophages due to deletion of the lysosomal endonuclease DNaseII and is detected by cytosolic sensors that signal through STING. Type I IFNs in DNaseII-/- mice lead to anemia-related embryonic lethality; thus co-deletion of the type I IFN receptor is required (DNaseII/IFN-IR double deficient, (DKO) mouse). We investigated the impact of DNA and of the STING pathway in bone in this model of autoimmune disease. Methods: STING-/- mice were intercrossed with DKO mice to generate STING/DNaseII/IFN-IR triple knock out (TKO) mice. uct was performed on TKO, DKO and control femurs from 6-16 month-old mice. Mesenchymal colony forming unit (CFU) assays were used to determine the number of osteoblast precursor cells in bone. uct was performed on femurs from 6 month-old STING-/- and littermate controls. Finally, RNA from wild type (WT) osteoblasts was analyzed for the expression of cytosolic DNA sensors. To determine the potential for osteoblasts to respond directly to DNA, MC3T3 osteoblast-lineage cells were transfected with poly(da:dt) and RNA was analyzed by qpcr. Results: Inflammatory cytokines in the DKO model would be expected to induce bone loss in the axial skeleton, as well as articular erosions. Paradoxically, we found that bone accumulates in long bones, with significant replacement of the marrow cavity by 16 months. CFU assays demonstrate increased osteoblast precursor numbers and osteoid is also significantly increased in DKO compared to controls (13,881 vs. 424 µm2, p=0.02). Surprisingly, ectopic bone forms in DKO spleens, a site of DNA accrual in macrophages. We thus sought to define the contribution of cytosolic DNA sensor pathways to bone accrual. STING deficiency almost completely abrogates both arthritis and bone accrual in the spleen and long bones of DKO mice (BV/TV: Het = 0.44%, DKO = 11.47%, TKO = 1.99%, p<0.02 compared to DKO). STING also contributes to bone homeostasis, independent of DNaseII deficiency, as revealed by uct performed on femurs from STING-/- and littermate controls (BV/TV: STING-/- = 1.39%, WT = 0.62%, p=0.011). Furthermore, cytosolic DNA sensors are MONDAY november 17, 2014 2014 Program Book 77
scientific sessions MONDAY november 17, 2014 expressed in osteoblasts and expression of several sensors is increased in osteoblasts upon transfection with a DNA ligand. Conclusion: The STING pathway plays a role in bone remodeling in situations of DNA accrual as well as in bone homeostasis. Cytosolic DNA sensors are expressed in differentiating osteoblasts and expression is upregulated by DNA. These findings have relevance to SLE and other autoimmune diseases in which DNA plays a pathogenic role. Discovery of new pathways linking bone and the immune system may identify new targets for the treatment of bone loss in inflammatory autoimmune diseases. Disclosures: R. Baum, None. 11:15 am 1795. Denosumab Restores Cortical Bone Loss at the Distal Radius Associated with Aging and Reduces Wrist Fracture Risk: Analyses from the Cross-Over Group in the Extension of the Denosumab Pivotal Fracture Trial JP Bilezikian, College of Physicians and Surgeons, Columbia University, New York, NY and JP Brown, CHU de Québec Research Centre and Laval University, Quebec City, QC Background/Purpose: Cortical bone loss is a major determinant of increased fracture risk. Denosumab (DMAb) has been shown to increase BMD at sites of cortical bone, including the radius, a skeletal site not responsive to most osteoporosis treatments. Here, we evaluated changes over time in radius BMD and wrist fracture incidence during 3 years of placebo (Pbo) and up to 5 subsequent years of DMAb therapy in FREEDOM and its Extension (EXT). Methods: We evaluated 2207 women who received Pbo during FREEDOM (3 years) and enrolled in the EXT to receive DMAb 60 mg Q6M (cross-over group); all women received daily calcium and vitamin D. A subset of these women (n=115) participated in a distal radius DXA substudy and were evaluated at baseline and during FREEDOM and EXT. Analysis of mean percentage changes in BMD over time from FREEDOM and EXT baselines consisted of a repeated measure model. Wrist fracture rates (per 100 subject-years), rate ratios and 95% CI were computed. Results: At FREEDOM baseline, the mean (SD) 1/3 radius T-score was 2.53 (1.18). During FREEDOM, daily calcium and vitamin D alone was associated with a progressive and significant loss of BMD at the 1/3 radius ( 1.2%); however, during EXT, DMAb halted and reversed bone loss (Figure). With 5 years of DMAb treatment, a significant gain in BMD (1.5% at EXT Year 5) was observed, compared with EXT baseline. The wrist fracture rate during the Pbo period in FREEDOM was 1.02 (0.80 1.29) per 100 subject-years. During the first 3 years of EXT, BMD recovered to the original baseline levels in response to DMAb and the wrist fracture rate remained comparable to the FREEDOM Pbo rate (Table); with 2 additional years of DMAb treatment, BMD increased further and the wrist fracture rate declined to levels significantly lower than the FREEDOM Pbo rate (rate ratio=0.57, 95% CI=0.34 0.95; p=0.03). Conclusion: In untreated women with postmenopausal osteoporosis, cortical bone density at the radius declined significantly. DMAb treatment for 3 years fully reversed this bone loss and 2 additional years of treatment resulted in further BMD gains that translated to significantly lower wrist fracture rates, highlighting the clinical importance of reversing cortical bone loss. Disclosures: J. Bilezikian, NIH, Amgen Inc., N, 2, Columbia University, 3, Merck, Amgen Inc., N, Lilly, Johnson&Johnson, 5, Elsevier Press, 7; J. Brown, Actavis, Amgen Inc., Eli Lilly, Merck, Novartis, 2, Amgen Inc., Eli Lilly, 5, Amgen Inc., Eli Lilly, 8. 11:30 am 1796. Autotaxin Is Highly Expressed in Systemic Sclerosis (SSc) Skin, Mediates Dermal Fibrosis Via IL-6 and Is a Target for SSc Therapy Flavia V. Castelino, Massachusetts General Hospital, Boston, MA Background/Purpose: Autotaxin (ATX) is an enzyme present in biological fluids that is responsible for the production of the lipid mediator, lysophosphatidic acid (LPA). We previously implicated LPA and its receptor, LPA1 in SSc pathogenesis.1 Here we studied the role of ATX in SSc dermal fibrosis using the bleomycin (BLM) mouse model and skin biopsy samples from SSc patients and healthy controls. We evaluated the role of IL-6, a cytokine implicated in SSc, in mediating ATX-induced fibrosis. Additionally, we investigated the therapeutic potential of targeting ATX, by using a novel ATX inhibitor, PAT-048 in this model. Methods: BLM or saline (PBS) was administered subcutaneously to C57Bl/6 mice daily for 3, 7, 14 and 28 days. 6mm dermal punch biopsies were obtained and ATX levels were measured by qpcr and ELISA. ATX inhibition with PAT-048 (20mg/kg oral gavage daily) was assessed in the model. PAT-048 was administered concurrently with BLM or PBS for 28 days, or initiated at 7 or 14 days after BLM. Dermal thickness was measured using H&E-stained sections. Collagen was visualized by Masson s trichrome stain and quantified by hydroxyproline measurement. Skin IL-6 expression was evaluated by immunohistochemistry (IHC). The effect of LPA-induced ATX expression was tested on human dermal fibroblasts transfected with IL-6 sirna. Additionally, healthy and SSc dermal fibroblasts were stimulated with LPA and IL-6 in vitro and IL-6 and ATX induction were evaluated by ELISA, respectively. Skin ATX expression was measured in SSc patients and healthy controls by qpcr and IL-6 expression by IHC. Results: ATX expression at both the mrna and protein level was increased at Day 3 after BLM injection (3-fold increase, p=0.05) suggesting a role for ATX early in fibrosis. Treatment with PAT-048 attenuated BLM-induced dermal fibrosis in all treatment groups (50% reduction, Day 28, p=0.01) and reduced IL-6 expression in the dermis. In vitro studies of human dermal fibroblasts showed that LPA-induced ATX expression was 78 2014 Program Book
scientific sessions attenuated with sirna knock-down of IL-6 (65% reduction, p<0.05). SSc fibroblasts demonstrated increased LPA-induced IL-6 expression and increased IL-6-induced ATX expression, compared to healthy fibroblasts. Furthermore, ATX expression was increased in SSc skin (n=7) compared to healthy controls (n=5; 3-fold increase, p=0.006) and IL-6 expression by IHC was increased in SSc skin compared to healthy controls (n=3 per group). Conclusion: We demonstrate that ATX has an important role in SSc fibrosis. Pharmacologic inhibition of ATX with a novel inhibitor, PAT-048, attenuated dermal fibrosis and IL-6 expression. Knock-down of IL-6 in fibroblasts in vitro abrogated LPA-induced ATX expression, suggesting an autocrine loop for ATX/LPA/IL-6 signaling. Both ATX and IL-6 are increased in SSc skin compared to healthy controls and LPA-induced IL-6 and IL-6- induced ATX expression are increased in SSc fibroblasts, further supporting an ATX/LPA/IL-6 autocrine loop in SSc. Targeting ATX may thus be an effective new therapeutic strategy for SSc fibrosis. Reference: Castelino FV et al. Amelioration of dermal fibrosis by genetic deletion or pharmacologic antagonism of LPA1 in a mouse model of scleroderma. Arth Rheum, 2011; 63(5):1405-15. Disclosures: F. V. Castelino, None. 11:45 am 1797. One-Year Survival of Adults with Systemic Sclerosis Following Lung Transplantation: A Nationwide Cohort Study Elana J. Bernstein, Columbia University College of Physicians & Surgeons, New York, NY Background/Purpose: Lung transplantation is a potentially life-saving treatment for patients with systemic sclerosis (SSc) who have developed end-stage lung disease due to interstitial lung disease and/or pulmonary hypertension. However, many transplant programs are hesitant to offer lung transplantation (LTx) to those with SSc due to concerns about extra-pulmonary involvement that might affect short- and long-term survival. However, survival data for lung transplantation in SSc are sparse. The primary aim of this study was to determine whether adults with SSc have higher 1-year mortality rates after LTx compared to those with interstitial lung disease (ILD) or pulmonary arterial hypertension (PAH) not due to SSc. We hypothesized that adults with SSc would have higher 1-year mortality rates after LTx than those with ILD or PAH not due to SSc. Methods: We performed a retrospective cohort study of adults who underwent double or single LTx in the United States between May 4, 2005 (the date of implementation of the lung allocation score) and September 14, 2012. Data were provided by the United Network for Organ Sharing, a non-profit organization that records data on all solid organ transplants performed in the US. Subjects were included if they were at least 18 years of age at the time of LTx; had a diagnosis of SSc, ILD, or PAH; and were transplanted at a center that has performed at least 1 LTx for SSc. Subjects were excluded if they had received a heart-lung transplant; if they received a LTx from a living donor; or if they had missing data on survival time. We modeled diagnosis (SSc) as the independent binary variable of interest in stratified Cox regression models where survival time was the dependent variable, adjusting for recipient, donor and procedural factors (Table 1). We used multiple imputation to account for missing covariate data. Results: A total of 3763 adults were transplanted during the study period and met inclusion criteria: 229 with SSc, 201 with PAH and 3333 with ILD (Table 1). The 1-year unadjusted mortality rate following LTx per 100 person-years was 21.4 among adults with SSc, 19.0 among adults with PAH and 17.8 among adults with ILD. A diagnosis of SSc was associated with a multivariable-adjusted 48% relative increase in the 1-year mortality rate compared to a diagnosis of ILD (HR 1.48, 95% CI 1.01-2.17). However, a diagnosis of SSc was not associated with a relative increase in the 1-year mortality rate compared to a diagnosis of PAH (HR 0.85, 95% CI 0.50-1.44). Conclusion: Adults with SSc had a 48% increased risk of death at 1 year following LTx compared to adults with ILD, but no increase in risk of death at 1 year compared to adults with PAH. Rather than denying SSc patients LTx because of their SSc diagnosis, variables need to be identified that will enable risk stratification of these patients prior to LTx, with particular attention to modifiable risk factors. MONDAY november 17, 2014 2014 Program Book 79
scientific sessions MONDAY november 17, 2014 Table 1: Recipient Characteristics and Covariates Recipient Characteristics SSc N = 229 PH N = 201 ILD N = 3333 Age, years 53 (44-59) 46 (34-57) 62 (56-66) Female sex 135 (58.95%) 126 (62.69%) 941 (28.23%) Race/Ethnicity White 162 (70.74%) 161 (80.10%) 2782 (83.47%) Black 38 (16.59%) 17 (8.46%) 199 (5.97%) Hispanic 25 (10.92%) 17 (8.46%) 261 (7.83%) Asian 3 (1.313%) 5 (2.49%) 67 (2.01%) Other 1 (0.44%) 1 (0.50%) 24 (0.72%) LAS score 44.31 (38.03-52.48) 36.90 (33.93-46.00) 45.36 (39.42-58.10) Height, cm 168.97 (10.29) 169.59 (9.62) 172.28 (9.56) Body mass index (kg/m 2 ) 25.10 (4.21) 24.93 (4.36) 27.16 (3.99) Steroid use 117 (52.00%) N = 225 Pulmonary artery systolic pressure, mmhg Forced vital capacity, %predicted 48 (37-66) N = 223 44 (34-60) N = 225 45 (23.20%) N = 194 83 (68-98) N = 194 73 (60-87) N = 197 1741 (53.75%) N = 3239 39 (32-48) N = 3206 45 (36-57.5) N = 3300 Creatinine, mg/dl 0.8 (0.7-1.0) 1.0 (0.8-1.2) 0.9 (0.7-1.0) N = 3322 Extracorporeal membrane 11 (4.80%) 5 (2.49%) 50 (1.50%) oxygenation Mechanical ventilation 23 (10.04%) 6 (2.99%) 232 (6.96%) Oxygen requirement, L/ min 5 (3-6) N = 228 4 (2-6) N = 200 4 (3-6) N = 3310 Covariates adjusted for in Cox regression models Recipient factors Age; Sex; Race/Ethnicity; LAS score; Height; BMI; Steroid use; Pulmonary artery systolic pressure; Forced vital capacity; Creatinine; Extracorporeal membrane oxygenation; Mechanical ventilation Donor factors Age; Sex; Height; Body mass index; PaO 2 on FiO 2 of 1.0; Pulmonary infection; 20 Pack-years smoking; Heavy alcohol use; Cause of death Procedural factors Ischemic time; Single vs. bilateral transplant; Transplant center; Distance from donor hospital to transplant center; Recipient-donor sex mismatch; CMV mismatch (D+/R-); 3 HLA mismatches * Data presented as mean (SD), median (IQR) and frequency (percentage) ** LAS = lung allocation score; PaO 2 = arterial oxygen tension; FiO 2 = fraction of inspired oxygen; CMV = cytomegalovirus; D+ = donor positive; R- = recipient negative; HLA = human leukocyte antigen Disclosures: E. J. Bernstein, None. Noon 1798. Interaction Between Innate Immunity and Anti-Ro52 Antibodies is Critical for the Induction of Sjögren s Syndromelike Disease in Mice Paulina Kaplonek and Umesh Deshmukh, Oklahoma Medical Research Foundation, Oklahoma City, OK Background/Purpose: Autoantibodies reactive with Ro52 are present in almost 70% of Sjögren s syndrome (SS) patients. This study was undertaken to investigate the role of Ro52 induced immune responses in the pathogenesis of SS in an experimental mouse model system. Methods: New Zealand Mixed (NZM) 2758 mice were immunized with mouse Ro52, adsorbed on to alum adjuvant. Control mice were injected either with Maltose binding protein (MBP) or only with alum. Mice were monitored for anti-ro52 antibody production, sialoadenitis, serum cytokine levels and pilocarpine induced salivation. Antibody binding to salivary gland cells was analyzed in vivo and in vitro by immunofluorescence. Sera from immunized mice were passively transferred into untreated or alum injected NZM2758 mice. Internalization of antibodies by live cells was investigated by using the salivary gland cell line SCA9-15. Clinical data from the Oklahoma pss patient cohort that met the AECG classification criteria for SS was analyzed for anti-ro reactivity, minor labial salivary gland biopsy focus scores and xerostomia. Results: By day 30 post-immunization, Ro52 immunized mice generated immunoprecipitating anti-ro52 antibodies and they had the maximum drop in saliva production. The glandular dysfunction in these mice was significantly associated with the level of anti-ro52 antibody. Both Ro52 immunized and control mice showed evidence for very mild sialoadenitis. However, only Ro52 immunized mice had antibody deposition in their salivary glands. Passive transfer of Ro52 immune sera induced salivary gland dysfunction in the recipient mice, only if the recipients were pre primed with alum. The levels of IL-1α and CXCL1 were significantly upregulated in alum injected mice, indicative of the inflammasome pathway activation. In vitro, antibodies from Ro52 immune sera were internalized by SCA9-15 cells and the antibodies recognized cytoplasmic Ro52. The antibody internalization was inhibited by Cytochalasin D treatment, indicating it to be an active uptake process. Amongst the 298 pss patients in Oklahoma cohort, 28 patients (9.3%) were anti- Ro positive and had a focus score of 0; and 37 anti-ro positive patients (12%) had a focus score of >0 but <1. Several of these patients have dry mouth and dry eyes Conclusion: Our data show for the first time that antibodies induced by Ro52 are capable of inducing salivary gland dysfunction and this phenomenon is dependent on the activation of innate immunity. The mouse model presented in this study mimics a subset (22%) of pss patients in our cohort, who are biopsy negative (or have low focus scores) and are anti- Ro antibody positive. In this group of patients, in the absence of sialoadenitis, it is possible that salivary gland dysfunction is caused by autoantibodies. Our data also suggests that antibody deposition within the salivary glands might be an important step for the induction of glandular dysfunction. Overall this study suggests that down modulation of autoantibody responses should constitute a major therapeutic strategy for the treatment of SS. Disclosures: P. Kaplonek, None; U. Deshmukh, None. 12:15 pm 1799. Elevated Indoleamine-2,3-Dioxygenase (IDO) Activity and Kynurinene-3-Monooxygenase (KMO) Expression in Interferon Positive Primary Sjogrens Syndrome Patients Is Associated with Increased CD25hiFoxP3+ regulatory Tcells: A Skew Towards Neurotoxicity or an Attempt to Rescue? Naomi I Maria, Erasmus Medical Center, Immunology, Rotterdam, Netherlands Background/Purpose: A role for indoleamine-2,3-dioxygenase (IDO) in suppression of effector T-cell function and promotion of regulatory T-cell (Treg) differentiation has been described. IDO the rate-limiting enzyme in tryptophan (TRP) catabolism is driven in part by type I and type II IFNs. Systemic overactivation of IFN-signaling is evident in Primary Sjögrens syndrome (pss) and could shift the delicate regulatory balance towards a more auto-reactive state in these patients. Interestingly 80 2014 Program Book
scientific sessions aberrant systemic TRP catabolism, resulting in a shift from neuroprotective towards neurotoxic downstream metabolites, has been associated with mood disturbances as well as neurophsychiatric consequences and possibly contributes to symptoms of fatigue and depression in pss. Here we investigate the role of IDO and downstream TRP catabolism in pss and hypothesize an increase in Tregs, in concordance with increased IDO-activity in IFNpositive pss patients. Methods: In a Cohort of 20 Healthy controls (HC), 18 IFNnegative and 21 IFNpositive pss patients, diagnosed according to the 2002 American-European criteria, CD4+CD45RO+ T helper (Th) memory cell populations defined by chemokine receptor expression: CD25hiFoxP3+ Tregs, CCR6+CCR4+CXCR3-CCR10- Th17, CCR6+CCR4+CXCR3 CCR10+ Th22, CCR6-CXCR3+CCR4- Th1 and CCR6-CXCR3 CCR4+ Th2- cells were analyzed by flow cytometry in peripheral blood mononuclear cells (PBMCs). Analysis of TRP and Kynurenine (KYN) were performed simultaneously in serum using HPLC. CD14+ monocyte mrna-expression of IDO1and downstream enzymes was assessed using real-time quantitative PCR, to investigate the direction of downstream TRP catabolism in pss. Results: Activity of IDO (p=0.0054) as determined by measuring levels of the KYN/TRP-ratio in sera and CD25hiFoxP3+ Tregs (p=0.039) were significantly increased in IFNpositive pss patients. In addition, CD25hiFoxP3+ Tregs significantly correlated with the KYN/TRP-ratio (p=0.002;r=0.509) as well as the IFNscore (p=0.011;r=0.375). Peripheral monocytes showed an upregulation of IDOexpression (p<0.0001) in IFNpositive pss, also highly correlating with the IFNscore (p<0.0001;r=0.816). Interestingly the neuroprotective downstream enzymes KAT1 (p=0.0003), KAT3 (p=0.016) and KAT4 (p=0.04) were downregulated, whereas the neurotoxic enzymes KMO (p=0.0057) and KYNU (p=0.0001) which convert KYN into the neutoxic metabolite Quinolinic acid were upregulated in these patients, suggesting a skew towards neurotoxicity. Conclusion: Here we find enhanced IDO activity in coherence with increased CD25hiFoxP3+ Tregs and evidence for a shift towards production of more neurotoxic metabolites previously associated with sickness behavior in IFNpositive pss. This imbalance towards neurodegenerative effects might contribute to increased fatigue and depressive symptoms in these patients. However, whether this shift in Tregs reflects an immune rescuemechanism or increases tolerance to self remains unknown. Intervening in these IFN and IDO-induced imbalances offers new possibilities for therapeutic interventions. Disclosures: N. I. Maria, None. ARHP NETWORKING EVENT Noon 2:00 pm Commonwealth Ballroom ARHP Networking at Noon Sit down with your colleagues over a complimentary lunch and participate in open discussion on various research, practice and clinical topics. Each roundtable discussion will be facilitated by a rheumatology expert. All ARHP attendees are welcome to participate in this event. This session is not eligible for CME credit. ACR MEET THE PROFESSOR SESSIONS 12:45 2:15 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. Westin Paine (Lobby) *Adult Inflammatory Myopathy (041) Speaker: Robert L. Wortmann, MD review the clinical manifestations of inflammatory myopathies including important extra-muscle manifestations discuss diagnostic pearls for the evaluation of someone suspected of having an inflammatory myopathy discuss the treatment paradigm for inflammatory myopathies Westin Otis (Lobby) Pediatric Rheumatology for Adult Rheumatologists (042) Speaker: Daniel Lovell, MD, MPH identify how the evaluation of children with rheumatic diseases may be different from that of adults identify the evaluation and treatment of arthralgia in children diagnose the various forms of arthritis that are unique to children describe current treatment of chronic arthritis in children Westin Hancock (Lobby) *Psoriatic Arthritis (043) Speaker: Dafna D. Gladman, MD discuss advances in diagnosis and classification of psoriatic arthritis appraise if patients with psoriatic arthritis should be treated aggressively choose treatment options for patients with psoriatic arthritis MONDAY november 17, 2014 2014 Program Book 81
scientific sessions MONDAY november 17, 2014 Westin Revere (Lobby) *Rheumatoid Arthritis: Biological Agents (044) Speaker: Edward C. Keystone, MD describe recent trends in the use of biologics to improve outcomes and utility describe strategies to reduce costs of biologics discuss emerging biologics, including biosimilars and their advantage for the therapeutic algorithm Westin Stone (Lobby) *Rheumatoid Arthritis: Challenging Cases (045) Speaker: Stephen A. Paget, MD discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients Westin Webster (Lobby) Scleroderma Mimics (046) Speaker: Faye N. Hant, DO, MSCR present an overview of scleroderma-like conditions review the clinical phenotypes and classification of scleroderma create a differential diagnosis for conditions that may mimic features of scleroderma discuss features of specific scleroderma mimics and strategies to distinguish them explain potential diagnostic and initial management/ treatment of these conditions Westin Adams (Mezzanine) *Still s Disease and Autoinflammatory Syndromes (047) Speaker: John J. Cush, MD describe the clinical features of Still s disease and other febrile syndromes describe the immunogenetic mechanisms and treatment for adult Still s disease and related syndromes Westin Alcott (Mezzanine) *Systemic Lupus Erythematosus: Central Nervous System (048) Speaker: Cynthia Aranow, MD identify neuropsychiatric manifestations attributable to systemic lupus erythematosus recognize the utility of diverse autoantibodies in the diagnosis of neuropsychiatric syndromes of systemic lupus erythematosus patients formulate a treatment plan in patients with neuropsychiatric lupus Westin Faneuil (Mezzanine) *Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (049) Speaker: Robyn T. Domsic, MD, MPH use clinical and serologic classification systems of systemic sclerosis to identify the natural history of clinical subsets explain the concept of disease staging in both diffuse and limited cutaneous systemic sclerosis use knowledge of clinical/serologic classification and disease staging to develop screening and management plans Webster (Mezzanine) Vasculitis Mimics (050) Speaker: Peter A. Merkel, MD, MPH discuss the broad categories and specific entities that constitute clinical mimics of vasculitis distinguish the subtleties of mimics of vasculitis including common clinical situations of mimics in a patient with a known diagnosis of vasculitis develop a methodology for clinically evaluating patients with possible vasculitis with particular attention to differentiating mimics from true vasculitis ACR SESSIONS 1:00 2:00 pm 205 B Classification Criteria for Gout Moderators: Jasvinder A. Singh, MD, MPH and Nicola Dalbeth, MBChB, MD recognize the limitations of existing classification criteria and why new criteria are needed review the latest evidence related to various imaging modalities and clinical parameters for classification of gout identify the key elements of the new proposed preliminary gout classification criteria 1:00 pm Gout Classification Criteria: Where Have We Been and Where Do We Need to Go? Tim L. Jansen, MD, PhD 1:10 pm Key Clinical Considerations in Developing New Gout Classification Criteria William Taylor, PhD, MBChB 1:35 pm The Proposed New Preliminary Gout Classification Criteria Tuhina Neogi, MD, PhD 82 2014 Program Book
scientific sessions 107 B Classification Criteria for Myositis Moderators: Chester V. Oddis, MD and Lisa G Rider, MD discuss the history of and differences between criteria used in myositis describe the new classification criteria for myositis appraise how to use the new classification criteria in clinical settings and research 1:00 pm History of Classification Criteria for Idiopathic Inflammatory Myopathies Frederick W. Miller, MD, PhD 1:25 pm New Classification Criteria for Idiopathic Inflammatory Myopathies Ingrid E. Lundberg, MD, PhD discuss how cellular senescence impacts cell function and the immune system determine how current research on families with telomere syndromes informs biology of normal aging process and how it impacts the immune system ACR WORKSHO 1:15 3:15 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. 1:50 pm Panel Discussion Ballroom East Neonatal Lupus: From Bench to Bedside Moderators: Elana J. Bernstein, MD, MSc and Rennie N. G. Howard, MD Speaker: Jill P. Buyon, MD identify pregnant women at risk for having babies affected by neonatal lupus and describe the clinical manifestations of neonatal lupus discuss the pathogenesis of heart block in neonatal lupus and describe the diagnostic evaluation of heart block due to neonatal lupus discuss the treatment of congenital heart block Ballroom West Rheumatology on the Street Moderator: Kristine M. Lohr, MD, MS Speaker: Jonathan D. Graf, MD summarize medical complications associated with certain types of illicit drug use describe the rheumatic manifestations of cocaine use review an update of the clinical manifestations and autoantibody profiles associated with levamisole toxicity 52 A Telomeres, Telomerase and the Aging Immune System Moderator: Leonard H. Sigal, MD Speaker: Jonathan Alder, PhD describe current concepts of telomeres and telomerase biology 152 *Joint Injection Techniques (222) Speakers: Atul A. Deodhar, MD and Kenneth S. O Rourke, MD 159 161 discuss indications and contraindications for joint aspirations and injections identify and avoid common mistakes in joint injection procedures practice common joint and soft tissue injections on upper and lower extremities Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (223) Speaker: Walter P. Maksymowych, MD recognize typical active and structural lesions of spondyloarthritis recognize complicated/subtle lesions of spondyloarthritis recognize lesions that may mimic spondyloarthritis recognize pitfalls in the interpretation of magnetic resonance imaging in spondyloarthritis Synovial Fluid Analysis and Crystal Identification (224) Speakers: Brian F. Mandell, MD, PhD; Lan Chen, MD, PhD; and Gilda M. Clayburne, MLT prepare synovial fluid samples for microscopic examination identify various components of synovial fluid identify crystals in synovial fluid MONDAY november 17, 2014 2014 Program Book 83
scientific sessions ACR SESSIONS 2:30 4:00 pm 205 B Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk Moderators: Shreyasee Amin, MD CM, MPH and Alan N. Baer, MD describe the central and peripheral nervous system manifestations of Sjögren s syndrome recognize the different presenting manifestations of lymphoma, including of mucosa-associated lymphoid tissue (MALT) lymphoma, in patients with Sjögren s syndrome outline the approach for evaluating patients with Sjögren s syndrome who have neurologic manifestations or symptoms of lymphoma 2:30 pm Neurological Complications of Sjögren s Syndrome: Central Nervous System Manifestations Julius Birnbaum, MD, MHS 52 A Insight into Lung Fibrosis Moderators: John Varga, MD and Flavia V. Castelino, M.D. review classification and biology of lung fibrosis recognize immune dysregulation in lung fibrosis review cell-based approaches to lung regeneration 2:30 pm Insight into Lung Fibrosis Timothy Blackwell, MD 3:00 pm Immune Networks of Lung Fibrosis Thomas Wynn, PhD 3:30 pm Lung Regeneration and Cell-Based Therapies Darrell Kotton, MD ACR CONCURRENT ABSTRACT SESSIONS 2:30 4:00 pm MONDAY november 17, 2014 84 3:00 pm Neurological Complications of Sjögren s Syndrome: Peripheral Nervous System Manifestations Julius Birnbaum, MD, MHS 3:30 pm Lymphoma and Sjögren s: What the Clinician Should Know Elke Theander, MD, PhD Ballroom East Forefronts in Lupus Nephritis Moderator: George Stojan, MD recognize the pitfalls of current lupus nephritis treatment guidelines discuss the emerging role of Rituxan challenge the dogma of the need for steroid use in lupus nephritis 2:30 pm Clinical Pearls and Pitfalls in Diagnosis and Management of Lupus Nephritis Michelle Petri, MD, MPH 2:45 pm Guidelines for Lupus Nephritis More Recommendations than Data? Derek M. Fine, MD 3:00 pm The Parable of the Lost Sheep The Rituximab Redemption Liz Lightstone, MD, PhD 2014 Program Book 253 B Epidemiology and Public Health II: Osteoarthritis, Sedentary Behavior and More Moderators: Jeffrey N. Katz, MD, MSc and Catherine Hill, MD, MBBS 2:30 pm 1800. Objectively Measured Sedentary Behavior Is a Distinct Risk Factor from Low Moderate-to-Vigorous Activity in Predicting Subsequent Frailty: Evidence from Osteoarthritis Initiative Jing Song 1, Lee A. Lindquist 1, Rowland W. Chang 1, Pamela A. Semanik 2, Linda S. Ehrlich-Jones 3, Jungwha Lee 1, Min-Woong Sohn 1 and Dorothy D. Dunlop 1, 1 Northwestern University Feinberg School of Medicine, Chicago, IL, 2 Rush University Medical Center, Chicago, IL, 3 Rehabilitation Institute of Chicago, Chicago, IL 2:45 pm 1801. The Association of Knee Shape with Sex: The Osteoarthritis Initiative Barton L. Wise 1, Lisa Kritikos 1, Felix Liu 2, Neeta Parimi 2, John A. Lynch 2, Yuqing Zhang 3 and Nancy E. Lane 1, 1 Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA, 2 University of California at San Francisco, San Francisco, CA, 3 Boston University School of Medicine, Boston, MA 3:00 pm 1802. Are Outcomes after Total Knee Arthroplasty Worsening over Time? a Time-Trends Study of Activity Limitation and Pain Outcomes Jasvinder A Singh 1 and David Lewallen 2, 1 University of Alabama and VA Medical Center, Birmingham, AL, 2 Mayo Clinic college of medicine, Rochester, MN
scientific sessions 3:15 pm 1803. Knee Osteoarthritis and All-Cause Mortality: The Wuchuan Osteoarthritis Study Qiang Liu 1, Xu Tang Sr. 2, Jingbo Niu 3, Xu Wu 2, Yan Ke 4, Jian Huang 5, Rujun Li 4, Hu Li 4, Xin Zhi 4, Kai Wang 4, Zhengming Cao 1 and Jianhao Lin 2, 1 Arthritis Institute, People s Hospital, Peking University, Beijing, China, 2 Peking University Health Science Center, Beijing, China, 3 Boston University, Boston, MA, 4 Peking University People s Hospital, Beijing, China, 5 The Second Affiliated Hospital of Inner Mongolia Medical University, Hohhot, China 3:30 pm 1804. Increased Mortality in Ankylosing Spondylitis Results from a National Population Based Study Sofia Exarchou 1, Elisabeth Lie 2, Johan Askling 3, Helena Forsbladd Elia 4, Carl Turesson 1, Lars Erik Kristensen 5 and Lennart T. Jacobsson 2, 1 Section of Rheumatology, Department of Clinical Sciences, Malmö, Lund University, Malmö, Sweden, 2 Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 3 Clinical Epidemiology Unit, Rheumatology Unit, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden, 4 Department of Rheumatology and Inflammation Research, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 5 Lund University, Malmö, Sweden 3:45 pm 1805. Prevalence and Associating Factors with Atypical Femoral Fractures: An Asian Single Center Based Case-Control Study Dam Kim 1, Yoon-Kyoung Sung 1, Soo-Kyung Cho 1, Minkyung Han 1 and Yee-Suk Kim 2, 1 Clinical Research Center for Rheumatoid Arthritis (CRCRA), Seoul, South Korea, 2 Hanyang University Hospital, Seoul, South Korea 160 B Health Services Research: Improving Clinical Practice Moderators: Una Makris, MD and Elena Losina, PhD 2:30 1806. WITHDRAWN 2:45 pm 1807. Problems with Fee for Service Payments for Academic Rheumatology Practices: A Need for Payment Reform: Allen P. Anandarajah 1 and Christopher T. Ritchlin 2, 1 Univ of Rochester Medical Ctr, Rochester, NY, 2 University of Rochester Medical Center, Rochester, NY 3:00 pm 1808. Role of HLA-B*5801 Genetic Testing and a Safety Programme When Initiating Allopurinol Therapy for Chronic Gout Management: A Cost-Effectiveness Analysis Di Dong 1, Wei Chuen Tan-Koi 2, Gim Gee Teng 3, Eric Finkelstein 4 and Cynthia Sung 4, 1 Duke-NUS Graduate Medical School, Singapore, Singapore, 2 Saw Swee Hock School of Public Health, National University of Singapore, Singapore, Singapore, 3 Division of Rheumatology, University Medicine Cluster, National University Health System, Singapore, Singapore, 4 Duke-NUS Graduate Medical School, Singapore, Singapore, Singapore 3:15 pm 1809. Is Team Care Better? a Comparison of Rheumatoid Arthritis Disease Activity Among Patients Cared for in Practices with Nurse Practitioners and Physicians Assistants Versus Rheumatologist Only DH Solomon 1, Liana Fraenkel 2, Bing Lu 1, Erika Brown 1, Peter Hsun Tsao 3, Elena Losina 1, Jeffrey N. Katz 1 and Asaf Bitton 1, 1 Brigham and Women s Hospital, Boston, MA, 2 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 3 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 3:30 pm 1810. Improper Use of Antinuclear Antibody (ANA) Test Can Result in Misdiagnosis, Increased Patient Anxiety and Wasted Health Care Resources Sahar Eivaz Mohammadi 1, Imam H Shaik 1, Parag Chevli 1, Fernando Gonzalez-Ibarra 1, Sohini Sarkar 1, Saurav Acharya 1, Prerna Dogra 1, Hesam Hekmatjou 2, Maushmi Savjani 2, Waheed Abdul 2 and Valentin Marian 1, 1 Jersey City Medical Center- Barnabas Health, Jersey City, NJ, 2 St. George s University SOM, St. George s, Grenada 3:45 pm 1811. The Burden of Depression on Healthcare Utilization in a Population-Based Cohort of Patients with Systemic Lupus Erythematosus Alfredo Aguirre 1, Gaobin Bao 1, S. Sam Lim 2 and Cristina Drenkard 1, 1 Emory University, Atlanta, GA, 2 Emory University School of Medicine, Division of Rheumatology, Atlanta, GA 156 B Innate Immunity and Rheumatic Disease Moderators: Philip L. Cohen, MD and Edward M. Behrens, MD 2:30 pm 1812. Investigation of the Sting/Interferon Pathway Activation in a Novel Vasculopathy and Pulmonary Syndrome Yin Liu 1, Adriana Almeida de Jesus 2, Bernadette Marrero 1, Dan Yang 3, Gina A. Montealegre Sanchez 2, Steve Brooks 1, Zuoming Deng 2, Amy Paller 4, Manfred Boehm 3 and Raphaela Goldbach- Mansky 2, 1 NIAMS/NIH, Bethesda, MD, 2 National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 3 National Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, 4 Northwestern University Feinberg School of Medicine, Chicago, IL 2:45 pm 1813. DNA Sensors Regulate Inflammation in a Model of Autoimmune Arthritis Rebecca Baum 1, Shruti Sharma 1, Sudesh Pawaria 1, Susan Carpenter 2, Katherine A. Fitzgerald 1, Ann Marshak-Rothstein 1 MONDAY november 17, 2014 2014 Program Book 85
scientific sessions and Ellen M. Gravallese 3, 1 University of Massachusetts Medical School, Worcester, MA, 2 University of California, San Francisco, San Francisco, CA, 3 UMass Memorial Medical Center, Worcester, MA Boston, MA, 2 Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, 3 Tufts Medical Center, Boston, MA, 4 Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI MONDAY november 17, 2014 3:00 pm 1814. RNA-Containing Immune Complexes Shift Human Neutrophils from Phagocytosing Cells to Efficient Releasers of Oxidized DNA in a Process Requiring Crosstalk Between Tolllike Receptors and Fc Gamma Receptor IIa Christian Lood 1, Xizhang Sun 1, Lena Tanaka 1, Andrew Oberst 2, Jeffrey Ledbetter 3 and Keith B. Elkon 1, 1 University of Washington, Seattle, WA, 2 Department of Immunology, University of Washington, Seattle, WA, 3 Division of Rheumatology, University of Washington, Seattle, WA 3:15 pm 1815. STAT3-Mediated Regulation of Mitochondrial Membrane Potential Is Critical for NLRP3 Inflammasome Activation Jehad H. Edwan 1, Raphaela Goldbach-Mansky 2 and Robert A. Colbert 3, 1 NIAMS NIH, Bethesda, MD, 2 NIH Building 10 Room 6D47B, Bethesda, MD, 3 NIAMS/NIH, Bethesda, MD 3:30 pm 1816. Toll-like Receptor 4-Induced Interleukin-1 Defines the Intestinal Microbiome and Mucosal Immune Response in Arthritis-Prone IL-1 Receptor Antagonist Deficient Mice Tom Ederveen 1, Rebecca Rogier 1, Jos Boekhorst 1, Harm Wopereis 2, Johan Garssen 2, Sacha van Hijum 1, Fons A.J. van de Loo 1, Marije I. Koenders 1, Wim B. van den Berg 1 and Shahla Abdollahi-Roodsaz 1, 1 Radboud university medical center, Nijmegen, Netherlands, 2 Danone Research, Wageningen, Netherlands 3:45 pm 1817. Connecting Two Pathways through Ca 2+ Signaling: NLRP3 Inflammasome Activation Induced By a Hypermorphic PLCG2 Mutation Jae Jin Chae 1, Yong Hwan Park 1, Chung Park 2, Il-Young Hwang 2, Patrycja Hoffmann 1, John Kehrl 2, Ivona Aksentijevich 1 and Daniel L. Kastner 1, 1 National Human Genome Research Institute, Bethesda, MD, 2 National Institute of Allergy and Infectious Diseases, Bethesda, MD 104 B Osteoarthritis Clinical Aspects I: Imaging in Osteoarthritis Moderators: Grace H. Lo, MD, MSc and Leena Sharma, MD 2:45 pm 1819. WITHDRAWN 3:00 pm 1820. Discordance of Hip Pain with Radiographic Hip Osteoarthritis: The Osteoarthritis Initiative Chan Kim 1, Michael C. Nevitt 2, Pia M. Jungmann 3, Irina Tolstykh 4, Nancy E. Lane 5, Thomas M. Link 4 and David T. Felson 6, 1 Boston University, Boston, MA, 2 UCSF (University of California, San Francisco), San Francisco, CA, 3 Technische Universitaet Muenchen, Munich, Germany, 4 University of California, San Francisco, San Francisco, CA, 5 Center for Musculoskeletal Health, UC Davis School of Medicine, Sacramento, CA, 6 University of Manchester, Manchester, United Kingdom 3:15 pm 1821. The Co-Occurrence Patterns of MRI Lesions and Incident Knee Osteoarthritis: The MOST Study Jingbo Niu 1, David T. Felson 2, Tuhina Neogi 2, Michael C. Nevitt 3, Cora E. Lewis 4, James Torner 5, Ali Guermazi 2, Frank Roemer 6 and Yuqing Zhang 2, 1 Boston University, Boston, MA, 2 Boston University School of Medicine, Boston, MA, 3 UCSF (University of California, San Francisco), San Francisco, CA, 4 University of Alabama, Birmingham, Birmingham, AL, 5 University of Iowa, Iowa City, IA, 6 Klinikum Augsburg, Augsburg, Germany 3:30 pm 1822. Increasing Synovitis and Bone Marrow Lesions Are Associated with Incident Joint Tenderness in Hand Osteoarthritis Ida K. Haugen 1, Barbara Slatkowsky-Christensen 1, Pernille Boyesen 1, Sølve Sesseng 1, Désirée van der Heijde 1 and Tore K. Kvien 2, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 PsAID taskforce, EULAR, Zurich, Switzerland 3:45 pm 1823. Inflammation Is Associated with Erosive Progression in Patients with Hand Osteoarthritis: A Prospective Ultrasonography Study Marion C. Kortekaas 1, Wing Yee Kwok 2, Monique Reijnierse 2, Theo Stijnen 2 and Margreet Kloppenburg 2, 1 Flevoziekenhuis, Almere-Stad, Netherlands, 2 Leiden University Medical Center, Leiden, Netherlands. 2:30 pm 1818. Subchondral Bone Mineral Density Improves Prediction of Knee Osteoarthritis Progression Compared with Clinical Factors Alone: Data from the Osteoarthritis Initiative Michael P. Lavalley 1, Grace H. Lo 2, Lori Lyn Price 3, Jeffrey Driban 3, Charles Eaton 4 and Timothy E. McAlindon 3, 1 Boston University, 157 B Pediatric Rheumatology Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus Ed Pd PrM FIT Moderators: Mical Cidon, MD and Lisa F. Imundo, MD 86 2014 Program Book
scientific sessions 2:30 pm 1824. A Randomized Double-Blind Placebo-Controlled Trial of Vitamin D Supplementation in Juvenile-Onset Systemic Lupus Erythematosus: Improvement in Disease Activity and Fatigue Scores Glauce Lima, Juliane Paupitz, Liliam Takayama, Eloisa Bonfa and Rosa M R Pereira, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 2:45 pm 1825. Cognitive Performance Scores for the Pediatric Automated Neuropsychological Assessment Metrics in Childhood-Onset Systemic Lupus Erythematosus Patricia Vega-Fernandez 1, Shana Vanderburgh 2, Deborah M. Levy 3, Frank A. Zelko 4, Eyal Muscal 5, Natasha M. Ruth 6, Adam M. Huber 7, Marisa S. Klein-Gitelman 8, Kasha Wiley 9, Wenjie Zheng 9, Lori B. Tucker 10, Tresa Roebuck-Spencer 11, Jun Ying 2 and Hermine Brunner 12, 1 Cincinnati Children s Hospital, Cincinnati, OH, 2 University of Cincinnati, Cincinnati, OH, 3 The Hospital for Sick Children and University of Toronto, Toronto, ON, 4 Northwestern University Feinberg School of Medicine, Chicago, IL, 5 Texas Children s Hospital, Houston, TX, 6 Medical University of South Carolina, Charleston, SC, 7 IWK Health Centre, Halifax, NS, 8 Ann & Robert H. Lurie Children s Hospital of Chicago, Chicago, IL, 9 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 10 BC Children s Hospital and University of British Columbia, Vancouver, BC, 11 University of Oklahoma, Norman, OK, 12 PRCSG, Cincinnati Children s Hospital Medical Center, Cincinnati, OH 3:00 pm 1826. A Renal Activity Index May Predict Histological Activity in Lupus Nephritis in Children Khalid Abulaban 1, Michael Bennett 1, Marisa Klein-Gitelman 2, Stacy P. Ardoin 3, Kelly A. Rouster-Stevens 4, Lori B. Tucker 5, Kasha Wiley 6, Shannen Nelson 7, Karen Onel 8, Nora G. Singer 9, Kathleen M. O Neil 10, Elizabeth Brooks 11, B Anne Eberhard 12, Lawrence K. Jung 13, Lisa F. Imundo 14, Tracey Wright 15, David Witte 16, Jun Ying 17, Prasad Devarajan 1 and Hermine I. Brunner 7, 1 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 2 Anne & Robert H Lurie Children s Hospital of Chicago, Chicago, IL, 3 Ohio State University College of Medicine, Columbus, OH, 4 Emory University School of Medicine, Atlanta, GA, 5 BC Children s Hospital and University of British Columbia, Vancouver, BC, 6 Cincinnati Children s Hospital Medical Center, c, OH, 7 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 8 University of Chicago Hospitals, Chicago, IL, 9 Division of Rheumatology, MetroHealth Medical Center, Case Western Reserve University, Cleveland, OH, 10 Riley Hospital for Children, Indianapolis, IN, 11 Univ Hospitals of Cleveland, Cleveland, OH, 12 Cohen Children s Medical Center, Lake Success, NY, 13 Children s National Medical Center, Washington, DC, 14 Columbia University Medical Center, New York, NY, 15 UT Southwestern Medical Center, Dallas, TX, 16 Cincinnati Children s Hospital, Cincinnati, OH, 17 University of Cincinnati, Cincinnati, OH 3:15 pm 1827. Anti-Ro and Anti-La Antibodies in the General Pregnant Population Evelyn V. Rozenblyum 1, Sharon Sukhdeo 1, Edgar Jaeggi 2, Lisa Hornberger 3, Philip Wyatt 4, Carl A. Laskin 5 and Earl D. Silverman 6, 1 University of Toronto, Toronto, ON, 2 The Hospital for Sick Children, University of Toronto, Toronto, ON, 3 Stollery Children s Hospital, Edmonton, ON, 4 North York General Hospital, Toronto, ON, 5 University of Toronto and LifeQuest Centre for Reproductive Medicine, Toronto, ON, 6 The Hospital for Sick Children, Toronto, ON 3:30 pm 1828. Adverse Pregnancy Outcomes in Adolescents and Young Women with Systemic Lupus Erythematosus: A National Estimate Nicole Ling, Isabel E. Allen, Erica F. Lawson and Emily von Scheven, University of California, San Francisco, San Francisco, CA 3:45 pm 1829. Role of Fluorinated Steroids in Preventing the Progression of Anti-SSA/Ro Associated Isolated Congenital Heart Block to Disease Beyond the Conduction System Ummara Shah 1, Amit Saxena 1, Sara Sahl 1, Deborah Friedman 2, Jill P. Buyon 1 and Peter M. Izmirly 1, 1 New York University School of Medicine, New York, NY, 2 New York Medical College, Valhalla, NY 153 B Quality Measures and Quality of Care Moderators: Eric D. Newman, MD and Jinoos Yazdany, MD MPH 2:30 pm 1830. A Novel Population Care Model in Rheumatoid Arthritis Significant Improvement in Quality and Reduction in Cost of Care Eric D. Newman 1, William T. Ayoub 2, David M. Pugliese 3, Chelsea Cedeno 1, Jason Brown 1, Thomas M. Harrington 1, Thomas P. Olenginski 1, Androniki Bili 1, Alfred E. Denio 1, Lisa L. Schroeder 1, Dennis Torretti 1, Tarun Sharma 1, Lyudmila Kirillova 1, Susan Mathew 1, Jonida Cote 1, Brian Oppermann 2, Cynthia Sullivan 2, Shantanu Bishwal 4, Brian DelVecchio 3 and Howard Aylward 2, 1 Geisinger Health System, Danville, PA, 2 Geisinger Health System, State College, PA, 3 Geisinger Health System, Wilkes-Barre, PA, 4 Geisinger Health System, Wilkes Barre, PA 2:45 pm 1831. Monitoring Patients with Rheumatoid Arthritis in Routine Care Experiences from a Treat-to-Target Strategy Using the Danbio Registry Merete Lund Hetland 1, Dorte Vendelbo Jensen 2 and Niels Steen Krogh 3, 1 DANBIO, Glostrup Hospital, Glostrup, Denmark, 2 DANBIO, Glostrup, Denmark, 3 ZiteLab ApS, Copenhagen, Denmark MONDAY november 17, 2014 2014 Program Book 87
scientific sessions MONDAY november 17, 2014 3:00 pm 1832. National Quality Forum Measure Achievement and Costs in Rheumatoid Arthritis Patients in a Large Managed Care Population Roxanne Meyer 1, Susan C. Bolge 2, Joseph Tkacz 3, Brenna Brady 3 and Charles Ruetsch 4, 1 Janssen Scientific Affairs, Horsham, PA, 2 Janssen Scientific Affairs, LLC, Horsham, PA, 3 Health Analytics, LLC, Columbia, MD, 4 Health Analytics LLC, Columbia, MD 3:15 pm 1833. Quality of Primary Care Management of Patients with and without Rheumatoid Arthritis (RA) Jessica Widdifield 1, Claire Bombardier 2, Jacqueline Young 1, Noah Ivers 2, R. Liisa Jaakkimainen 3, Sasha Bernatsky 4, J. Michael Paterson 1, J. Carter Thorne 5, Pooneh S.Akhavan 6, Debra Butt 1, Vandana Ahluwalia 7 and Karen Tu 1, 1 Institute for Clinical Evaluative Sciences, Toronto, ON, 2 University of Toronto, Toronto, ON, 3 Sunnybrook Health Sciences Centre, Toronto, ON, 4 McGill University Health Centre, Montreal, QC, 5 Southlake Regional Health Centre, Newmarket, Newmarket, ON, 6 Mount Sinai Hospital, Toronto, ON, 7 William Osler Health Center, Brampton, ON 3:30 pm 1834. Uptake of the American College of Rheumatology s (ACR) Rheumatology Clinical Registry (RCR): Quality Measure Summary Data Natalie Fisk 1, Melissa Francisco 1, Jinoos Yazdany 2 and Salahuddin Kazi 3, 1 American College of Rheumatology, Atlanta, GA, 2 University of California, San Francisco, San Francisco, CA, 3 UT Southwestern Medical Center, Dallas, TX 3:45 pm 1835. Anti-Osteoporosis Medication Use after Hip or Vertebral Fracture Robert A. Overman 1 and Chad L. Deal 2, 1 University of North Carolina, Chapel Hill, NC, 2 Cleveland Clinic, Cleveland, OH 210 B Rheumatoid Arthritis Clinical Aspects III: Malignancies, Vaccinations, Pregnancy and Surgery Moderators: Lin Brown, MD and Jennifer Barton, MD 2:30 pm 1836. Safety of Zoster Vaccination Administration in Rheumatic Patients on Current Biologic Therapy Stephen Lindsey 1, Brandi Oufnac 2 and Holly Walker 2, 1 Ochsner Clinic Baton Rouge, Baton Rouge, LA, 2 Ochsner Health Systems, Baton Rouge, LA 2:45 pm 1837. First Results of a European Registries Collaborative Project to Compare the Spectrum of Lymphomas Between Different Exposure Groups in Rheumatoid Arthritis Louise Mercer 1, Xavier Mariette 2, William Dixon 1, Eva Baecklund 3, Karin Hellgren 4, Lene Dreyer 5, Merete Lund Hetland 6, Lene Mellemkjær 7, Kimme Hyrich 8, Anja Strangfeld 9, Angela Zink 10, Helena Canhao 11, Fernando Martins 12, Victoria Hernández 13, Florence Tubach 14, Jacques-Eric Gottenberg 15, Jacques Morel 16, Jakub Zavada 17, Piet van Riel 18, Axel Finckh 19, Florenzo Iannone 20, Johan Askling 4 and Joachim Listing 9, 1 The University of Manchester, Manchester, United Kingdom, 2 Université Paris-Sud, Le Kremlin Bicêtre, France, 3 Uppsala University, Uppsala, Sweden, 4 Karolinska Institutet, Stockholm, Sweden, 5 Copenhagen University Hospital at Gentofte, Gentofte, Denmark, 6 DANBIO, Glostrup Hospital, Glostrup, Denmark, 7 The Danish Cancer Society, Copenhagen, Denmark, 8 Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 9 German Rheumatism Research Center, Berlin, Germany, 10 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 11 Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, 12 Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal, 13 BIOBADASER Registry, Madrid, Spain, 14 Universite Paris Diderot, Paris, France, 15 Department of rheumatology CHU, Strasbourg, France, 16 Universite Montpellier, Montpellier, France, 17 Charles University, Prague, Czech Republic, 18 Radboud University Medical Centre, Nijmegen, Netherlands, 19 University of Geneva, Geneva, Switzerland, 20 Reumatologia Universita e Policlinico di Bari, Bari, Italy 3:00 pm 1838. No Increased Risk of Developing a First Invasive Melanoma in Rheumatoid Arthritis Patients Treated with Biologics: Results of a Collaborative Project of 11 European Biologics Registers Louise Mercer 1, Johan Askling 2, Pauline Raaschou 2, William Dixon 1, Lene Dreyer 3, Merete Lund Hetland 4, Lene Mellemkjær 5, Anja Strangfeld 6, Angela Zink 7, Florenzo Iannone 8, Axel Finckh 9, Jakub Zavada 10, Helena Canhao 11, Fernando Martins 12, Xavier Mariette 13, Jacques Morel 14, Jacques-Eric Gottenberg 15, Adele Green 1, Victoria Hernández 16, Florence Tubach 17, Piet van Riel 18, Kimme Hyrich 19 and Joachim Listing 6, 1 The University of Manchester, Manchester, United Kingdom, 2 Karolinska Institutet, Stockholm, Sweden, 3 Copenhagen University Hospital at Gentofte, Gentofte, Denmark, 4 DANBIO, Glostrup Hospital, Glostrup, Denmark, 5 The Danish Cancer Society, Copenhagen, Denmark, 6 German Rheumatism Research Center, Berlin, Germany, 7 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 8 Reumatologia Universita e Policlinico di Bari, Bari, Italy, 9 University of Geneva, Geneva, Switzerland, 10 Charles University, Prague, Czech Republic, 11 Instituto de Medicina Molecular, Universidade de Lisboa, Lisbon, Portugal, 12 Instituto de Medicina, Universidade de Lisboa, Lisbon, Portugal, 13 Université Paris-Sud, Le Kremlin Bicêtre, France, 14 Universite Montpellier, Montpellier, France, 15 Department of rheumatology CHU, Strasbourg, France, 16 BIOBADASER Registry, Madrid, Spain, 17 Universite Paris Diderot, Paris, France, 18 Radboud University Medical Centre, Nijmegen, Netherlands, 19 Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom 88 2014 Program Book
scientific sessions 3:15 pm 1839. Risk of Recurrent Non-Melanoma Skin Cancer with Methotrexate and Anti-TNF Use in Rheumatoid Arthritis Frank I Scott 1, Ronac Mamtani 1, Colleen Brensinger 1, Kevin Haynes 2, Zelma ChiesaFuxench 1, Huifeng Yun 3, Jie Zhang 4, Lang Chen 5, Fenglong Xie 5, David Margolis 1, James D. Lewis 2 and Jeffrey R. Curtis 6, 1 University of Pennsylvania, Philadelphia, PA, 2 Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 3 University of Alabama at Birmingham School of Public Health, Birmingham, AL, 4 Univ. of Alabama at Birmingham, Birmingham, AL, 5 University of Alabama at Birmingham, Birmingham, AL, 6 The University of Alabama at Birmingham, Birmingham, AL 3:30 pm 1840. Pregnancy Outcomes Following Exposure to Abatacept during Pregnancy M Kumar 1, L Ray 1, S Vemuri 2 and T Simon 1, 1 Bristol-Myers Squibb, Hopewell, NJ, 2 Bristol-Myers Squibb, Plainsboro, NJ Johannes W.J. Bijlsma 4, Bart van den Bemt 1 and Alfons A. den Broeder 1, 1 Sint Maartenskliniek, Nijmegen, Netherlands, 2 Rheumatology Centre Sint Maartenskliniek and Radboud university medical center, Ubbergen (Nijmegen), Netherlands, 3 Unit for clinical therapy research (ClinTrid), Karolinska Institute, Stockholm, Sweden, 4 University Medical Center Utrecht, Utrecht, Netherlands 3:00 pm 1844. Identification of a Patient Phenotype Which Impacts Response to Therapy in Rheumatoid Arthritis Clinical Trials: Certolizumab Pegol Phase 4 Trial Data Jeffrey R. Curtis 1, Melvin Churchill 2, Alan Kivitz 3, Laura Gauer 4, Christopher Herrem 4, David Carter 5, Jeffrey Melin 4 and Yusuf Yazici 6, 1 The University of Alabama at Birmingham, Birmingham, AL, 2 Arthritis Center of Nebraska, Lincoln, NE, 3 Altoona Arthritis & Osteoporosis Center, Duncansville, PA, 4 UCB Pharma, Smyrna, GA, 5 UCB Pharma, Brussels, Belgium, 6 New York University Hospital for Joint Diseases, New York, NY 3:45 pm 1841. Eventual Joint Failure and Surgery Rates in Rheumatoid Arthritis Remain High in Patients with Moderate Disease Activity in the First 5 Years of Disease Elena Nikiphorou 1, Lewis Carpenter 1, Sam Norton 2, Josh Dixey 3, Patrick Kiely 4, David Walsh 5 and Adam Young 6, 1 University of Hertfordshire, Hatfield, United Kingdom, 2 King s College London, London, United Kingdom, 3 New Cross Hospital, Wolverhampton, United Kingdom, 4 St. Georges Healthcare NHS Trust, London, United Kingdom, 5 University of Nottingham, Nottingham, United Kingdom, 6 ERAS, St Albans City Hospital, St Albans, United Kingdom Exhibit Hall C Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy III: Innovative Therapeutic Strategies in Rheumatoid Arthritis Moderators: Maarten Boers, MD, MSc, PhD and Mark C. Genovese, MD 2:30 pm 1842. High Rates of Failure after Biological DMARD Discontinuation While in Remission in a Japanese Multi-Center Registry Kazuki Yoshida 1, Mitsumasa Kishimoto 2, Helga Radner 1, Kazuo Matsui 3, Masato Okada 2, Yukihiko Saeki 4, Daniel H. Solomon 1 and Shigeto Tohma 5, 1 Brigham and Women s Hospital, Boston, MA, 2 St. Luke s International Hospital, Tokyo, Japan, 3 Kameda Medical Center, Kamogawa, Japan, 4 Osaka-Minami Medical Center, Osaka, Japan, 5 Sagamihara Hospital, National Hospital Organization, Sagamihara, Japan 2:45 pm 1843. Randomised Controlled Non-Inferiority Study of Dose Reduction and Withdrawal of Adalimumab and Etanercept in Rheumatoid Arthritis Noortje van Herwaarden 1, Aatke van der Maas 1, Michiel Minten 1, Frank H.J. van den Hoogen 2, Ronald F. van Vollenhoven 3, 3:15 pm 1845. Tocilizumab Combination Therapy or Monotherapy or Methotrexate Monotherapy in Methotrexate-Naive Patients with Early Rheumatoid Arthritis: 2-Year Clinical and Radiographic Results from a Randomized, Placebo-Controlled Trial Gerd Burmester 1, William Rigby 2, Ronald F. van Vollenhoven 3, Jonathan Kay 4, Andrea Rubbert-Roth 5, Ricardo Blanco 6, Ariella Kelman 7, Sophie Dimonaco 8 and Nina Mitchell 8, 1 Charité- Universitätsmedizin Berlin, Free University and Humboldt University of Berlin, Berlin, Germany, 2 Geisel School of Medicine at Dartmouth, Lebanon, NH, 3 Karolinska Institute, Stockholm, Sweden, 4 UMass Memorial Medical Center, Worcester, MA, 5 University of Cologne, Cologne, Germany, 6 Hospital Marques de Valdecilla, Santander, Spain, 7 Genentech, South San Francisco, CA, 8 Roche Products Ltd., Welwyn Garden City, United Kingdom 3:30 pm 1846. The Association Between Hydroxychloroquine Treatment and Cardiovascular Morbidity Among Rheumatoid Arthritis Patients Michael Shapiro 1 and Yair Levy 2, 1 Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 2 Meir Medical Center, Kfar Saba, Israel 3:45 pm 1847. Effect of Disease Duration on Clinical Outcomes in Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate Josef S. Smolen 1, David Collier 2, Annette Szumski 3, Heather Jones 3 and Lisa Marshall 3, 1 PsAID taskforce, EULAR, Zurich, Switzerland, 2 Amgen, Inc., Thousand Oaks, CA, 3 Pfizer Inc., Collegeville, PA 2014 Program Book 89 MONDAY november 17, 2014
scientific sessions MONDAY november 17, 2014 90 258 B Spondyloarthropathies and Psoriatic Arthritis III Clinical Aspects of Psoriatic Arthritis Moderators: Arthur Kavanaugh, MD and Enrique R. Soriano, MD, MSc 2:30 pm 1848. Risk of Cancer in Patients with Severe Psoriatic Arthritis Requiring Tumour-Necrosis Factor Alpha Inhibition Karen M. Fagerli 1, Louise K. Mercer 2, Kath D. Watson 2, Jonathon Packham 3, Deborah Symmons 4, Kimme L. Hyrich 5 and. On behalf of the BSRBR 6, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 3 Institute of Science and Technology in Medicine, Keele, United Kingdom, 4 Arthritis Research UK Centre for Epidemiology, The University of Manchester, Manchester, United Kingdom, 5 Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 6 British Society for Rheumatology, London, United Kingdom 2:45 pm 1849. Risk of Malignancy Among Medicare Psoriasis/Psoriatic Arthritis Patients Huifeng Yun 1, Kevin L. Winthrop 2, Lang Chen 3, Wilson Smith 3, Benjamin Chan 4, Fenglong Xie 3, Allison Taylor 3 and Jeffrey R. Curtis 3, 1 University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2 Oregon Health & Science University, Portland, OR, 3 University of Alabama at Birmingham, Birmingham, AL, 4 Oregon Health and Science University, Portland, OR 3:00 pm 1850. The Incidence and Risk Factors for Psa in Patients with Psoriasis a Prospective Cohort Study Lihi Eder 1, Amir Haddad 1, Hua Shen 2, Cheryl Rosen 1, Vinod Chandran 1, Richard J. Cook 2 and Dafna D. Gladman 3, 1 University of Toronto, Toronto Western Hospital, Toronto, ON, 2 University of Waterloo, Waterloo, ON, 3 Toronto Western Research Institute, Toronto Western Hospital, Toronto, ON 3:15 pm 1851. Serious Infection Events in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience Robert Kalb 1, David Fiorentino 2, Mark Lebwohl 3, Craig Leonardi 4, John Toole 5, Kavitha Goyal 6, Steve Calabro 6, Wayne Langholff 7 and Steve Fakharzadeh 8, 1 SUNY at Buffalo, School of Medicine and Biological Sciences, Buffalo, NY, 2 Stanford University, Redwood City, CA, 3 Mount Sinai Medical Center, New York, NY, 4 Central Dermatology, St. Louis, MO, 5 University of Manitoba, Dermadvances Research, Winnipeg, MB, 6 Janssen Services, LLC, Horsham, PA, 7 Janssen Research and Development, LLC, Spring House, PA, 8 Janssen Services, LLC, Spring House, PA 2014 Program Book 3:30 pm 1852. Increased Cardiovascular Risk in Patients Recently Diagnosed with Psoriatic Arthritis: A Population-Based, Cohort Study Katelynn Wilton 1, Floranne C. Ernste 1, Cynthia S. Crowson 2, Eric L. Matteson 2, Hilal Maradit Kremers 2 and Marta Sánchez- Menéndez 3, 1 Mayo Clinic Rochester, Rochester, MN, 2 Mayo Clinic, Rochester, MN, 3 Centro Medico de Asturias, Oviedo, Spain 3:45 pm 1853. Persistence and Predictors of Biologic TNFi Therapy Among Biologic naïve Psoriatic Arthritis Patients in a US Registry Philip Mease 1, David Collier 2, Chitra Karki 3, Guo Li 4, Bojena Bitman 5 and Jeffrey D. Greenberg 6, 1 Swedish Medical Center, Seattle, WA, 2 Amgen, Inc., Thousand Oaks, CA, 3 Corrona, LLC., Southborough, MA, 4 Axio Research LLC, Seattle, WA, 5 Amgen, Inc., San Francisco, CA, 6 New York University School of Medicine, New York, NY Ballroom West Systemic Lupus Erythematosus Clinical Aspects and Treatment: Complications of Systemic Lupus Erythematosus Moderators: S. Sam Lim, MD, MPH and Iris Navarro-Millan, MD 2:30 pm 1854. Systemic Lupus Erythematosus Patients Have Increased Risk of Short Term Adverse Events after Total Hip Arthroplasty Jordan Roberts 1, Lisa A. Mandl 2, Edwin Su 2, David J. Mayman 2, Mark P. Figgie 2, Arielle Fein 2, Yuo-Yu Lee 2, Ummara Shah 3 and Susan M. Goodman 2, 1 Weill Cornell Medical College, New York, NY, 2 Hospital for Special Surgery, New York, NY, 3 New York University School of Medicine, NYC, NY 2:45 pm 1855. Not Keeping up with the Times: High Mortality and Early Death Due to Disease in North American Natives with Systemic Lupus Erythematosus (SLE) Ripneet Puar 1, Carol A. Hitchon 1, David B. Robinson 1, Hani El-Gabalawy 1, Navjot Dhindsa 1 and Christine A. Peschken 2, 1 University of Manitoba, Winnipeg, MB, 2 University of Manitoba, Canada, Winnipeg, MB 3:00 pm 1856. National Hospitalization Trends in Lupus Reveal Rising Rates of Herpes Zoster and Declines in Pneumocystis Infections Sara G. Murray, Gabriela Schmajuk, Laura Trupin, Lianne S. Gensler and Jinoos Yazdany, University of California, San Francisco, San Francisco, CA 3:15 pm 1857. Determinants of Annual Healthcare Utilization and Overall Cost of Care in Individuals with Systemic Lupus Erythematosus in a Large Insurance Claims Database: Glucocorticoid Use Shih-Yin Chen 1, Chan-Bum Choi 2, Qian Li 3, Wei-Shi Yeh 1, Yuan- Chi Lee 4, Amy H Kao 1 and Matthew H. Liang 5, 1 Biogen Idec,
scientific sessions Cambridge, MA, 2 VA Healthcare System, Boston, MA, 3 Evidera, Lexington, MA, 4 Formerly of Evidera, Lexington, MA, 5 Harvard Medical School, Boston, MA 3:30 pm 1858. Standardized Mortality Ratios for Cause-Specific Deaths in Lupus Patients Followed Prospectively at a Single Centre Lupus Clinic Barry J. Sheane, Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON 3:45 pm 1859. Age-Specific Predictors of Mortality in SLE Dominique Ibanez, Dafna D. Gladman and Murray B. Urowitz, University of Toronto, Toronto Western Hospital, Toronto, ON 107 B Vasculitis II Moderators: Robert F. Spiera, MD and Sebastian H. Unizony, MD 2:30 pm 1860. Serum Calprotectin and Disease Relapse in ANCA- Associated Vasculitis Juliana B Draibe 1, Ruth J. Pepper 1, Peter A. Merkel 2, Alan D. Salama 1 and for The RAVE-ITN Investigators 3, 1 University College London, London, United Kingdom, 2 Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 3 Immune Tolerance Network, San Francisco, CA 2:45 pm 1861. The Role of Macrophage Migration Inhibitory Factor (MIF) and MIF Gene Polymorphisms in the Pathogenesis of Granulomatosis with Polyangiitis Antoine G. Sreih 1, Rana Ezzeddine 2, Juan Fan 3, Lin Leng 3, Simon Carette 4, David Cuthbertson 5, Gary S. Hoffman 6, Nader A. Khalidi 7, Carol A. Langford 8, Carol McAlear 9, Paul Monach 10, Philip Seo 11, Ulrich Specks 12, Steven R. Ytterberg 12, Peter A. Merkel 13 and Richard Bucala 14, 1 The University of Pennsylvania, Philadelphia, PA, 2 Bristol-Myers Squibb, Wallingford, CT, 3 Yale University, New Haven, CT, 4 University of Toronto, Toronto, ON, 5 University of South Florida, Tampa, FL, 6 Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 7 St. Joseph s Hospital, McMaster University, Hamilton, ON, 8 Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 9 Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 10 Boston University, Boston, MA, 11 Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 12 Mayo Clinic, Rochester, MN, 13 Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 14 Yale University School of Med, New Haven, CT 3:00 pm 1862. The Association of Low-Density Granulocytes with Disease Activity and Response to Treatment in ANCA- Associated Vasculitis Peter C. Grayson 1, Carmelo Carmona-Rivera 1, Lijing Xu 2, Noha Lim 2, Adam Asare 2, Deborah J. Phippard 2, Mariana J. Kaplan 1, Peter A. Merkel 3 and Paul A. Monach 4, 1 National Institutes of Health, Bethesda, MD, 2 Immune Tolerance Network, Bethesda, MD, 3 Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 4 Vasculitis Center, Boston University School of Medicine, Boston, MA 3:15 pm 1863. CCX168, an Orally Administered C5aR Inhibitor for Treatment of Patients with Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Pirow Bekker 1, David Jayne 2, Annette Bruchfeld 3, Matthias Schaier 4, Kazimierz Ciechanowski 5, Lorraine Harper 6, Michel Jadoul 7, Mårten Segelmark 8, Daina Selga 9, Istvan Szombati 10, Michael Venning 11, Christian Hugo 12, Paul L. van Daele 13, Ondrej Viklicky 14, Antonia Potarca 15 and Thomas J. Schall 15, 1 Chemocentryx, Inc., Mountain View, CA, 2 Addenbrookes Hospital University of Cambridge, Cambridge, United Kingdom, 3 Karolinska Institute, Stockholm, Sweden, 4 University of Heidelberg, Heidelberg, Germany, 5 Pomeranian Medical University, Szczecin, Poland, 6 University of Birmingham, Birmingham, United Kingdom, 7 Cliniques Saint-Luc, Brussels, Belgium, 8 Linkoping University, Linkoping, Sweden, 9 Lund University, Lund, Sweden, 10 Budaclinic, Budapest, Hungary, 11 Manchester University, Manchester, United Kingdom, 12 Dresden University, Dresden, Germany, 13 Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 14 Instit of Clin and Exp Med, Prague, Czech Republic, 15 ChemoCentryx, Inc., Mountain View, CA 3:30 pm 1864. Granulomatosis with Polyangiitis or Microscopic Polyangiitis: Long-Term Outcomes of Comparing Azathioprine Vs Methotrexate for Remission-Maintenance in 126 Patients Xavier Puéchal 1, Christian Pagnoux 2, Elodie Perrodeau 3, Mohamed Hamidou 4, Jean-Jacques Boffa 5, Xavier Kyndt 6, François Lifermann 7, Thomas Papo 8, Dominique Merrien 9, Amar Smail 10, Philippe Delaval 11, Catherine Hanrotel-Saliou 12, Bernard Imbert 13, Chahéra Khouatra 14, Marc Lambert 15, Charles Leské 16, Kim Heang Ly 17, Edouard Pertuiset 18, Pascal Roblot 19, Marc Ruivard 20, Jean-François Subra 21, Jean-Francois Viallard 22, Benjamin Terrier 1, Pascal Cohen 1, Luc Mouthon 1, Philippe Ravaud 3 and Loïc Guillevin for the French Vasculitis Study Group 1, 1 National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, Paris, France, 2 University of Toronto, Toronto, ON, 3 Epidemiology, Université Paris-Descartes, Paris, Paris, France, 4 CHU Hôtel Dieu, Nantes, Nantes, France, 5 Hôpital Tenon, Paris, Paris, France, 6 CH, Valenciennes, Valenciennes, France, 7 CH Côte d Argent, Dax, Dax, France, 8 Bichat Hospital, Paris, Paris, France, 9 CH Compiègne-Noyon, Compiègne, France, 10 CHU Amiens Nord, Amiens, France, 11 CHU Rennes Sud, Rennes, France, 12 CHU Cavale Blanche, Brest, Brest, France, 13 CHU, Grenoble, Grenoble, France, 14 CHU Louis Pradel, Lyon, Lyon, France, 15 Internal Medicine University Lille Hospital, Lille, Lille, France, 16 CH, Cholet, Cholet, France, 17 CHU Dupuytren, Limoges, Limoges, France, 18 René Dubos Hospital, Pontoise, France, 19 CHU, Poitiers, Poitiers, 2014 Program Book 91 MONDAY november 17, 2014
scientific sessions France, 20 CHU Estaing, Clermont Ferrand, Clermont Ferrand, France, 21 CHU, Angers, Angers, France, 22 Hôpital Haut-Lévêque, Bordeaux, CHU Bordeaux, France 3:45 pm 1865. Increased Risk of Myocardial Infarction and Cerebrovascular Accidents after Diagnosis of Granulomatosis with Polyangiitis: A General Population-Based Cohort Study Neda Amiri 1, Natasha Dehghan 1, Eric C. Sayre 2, Kamran Shojania 1 and J. Antonio Avina-Zubieta 2, 1 University of British Columbia, Vancouver, BC, 2 Arthritis Research Centre of Canada, Richmond, BC ACR/ARHP COMBINED ABSTRACT SESSION 2:30 4:00 pm 3:15 pm 1869. Child Pain, Function and Psychological Outcomes in an Intensive Interdisciplinary Pediatric Pain Rehabilitation Program Cara Hoffart, Rawni Anderson, Amy Chapman, Brandi Dorton, Danielle Feltrop, Misty Wilson and Dustin Wallace, Children s Mercy Hospital, Kansas City, MO 3:30 pm 1870. Children and Parent Satisfaction in the Pediatric Rheumatology Clinic: Patient Orientated Quality Service Measures Jenny Tekano 1, Lori B. Tucker 2 and Audrea Chen 3, 1 BC Children s Hospital, Vancouver, BC, 2 BC Children s Hospital and University of British Columbia, Vancouver, BC, 3 research student, Vancouver, BC MONDAY november 17, 2014 102 A ACR/ARHP Combined Abstract Session: Pediatric Rheumatology Ed Pd PrM FIT Moderators: Marisa S. Klein-Gitelman, MD, MPH and Bryce A. Binstadt, MD, PhD 2:30 pm 1866. Birth Outcomes in Women with a History of Juvenile Idiopathic Arthritis Debbie Ehrmann Feldman 1, Evelyne Vinet 2, Sasha Bernatsky 3, Ciaran Duffy 4, Elizabeth Hazel 5, Marie-Pierre Sylvestre 1, Garbis Meshefedjian 6 and Anick Bérard 1, 1 Université de Montréal, Montréal, QC, 2 McGill University Health Center, Montreal, QC, 3 McGill University, Montreal, QC, 4 Children s Hospital of Eastern Ontario, Ottawa, ON, 5 McGill University Health Center, Montreal, QC, 6 Public Health Department of Montreal, Montreal, QC 2:45 pm 1867. Mandibular Movement in Healthy Individuals from 4-17 Years of Age Peter Stoustrup 1, Kasper Dahl Kristensen 2, Annelise Küseler 3, Thomas Klit Pedersen 4 and Troels Herlin 4, 1 University of Aarhus, Aarhus C, Denmark, 2 Specialist Oral Health Center for Western Norway, Rogaland Stavanger, Norway, 3 Aarhus University, Aarhus, Denmark, 4 Aarhus University Hospital, Aarhus, Denmark 3:00 pm 1868. Can DAS 28 at 3 Months after the 1 st Biologic Therapy Predict Subsequent Sustainable Clinical Remission in Polyarticular Juvenile Idiopathic Arthritis Patients? Tomohiro Kubota 1, Syuji Takei 2, Tsuyoshi Yamatou 3, Tomokazu Nagakura 4, Hiroyuki Imanaka 3, Yukiko Nonaka 3, Tomoko Takezaki 3, Harumi Akaike 3 and Mio Matsuura 5, 1 Kagoshima University Hospital, Kagoshima City, Japan, 2 Kagoshima University, Kagoshima, Japan, 3 Kagoshima University Hospital, Kagoshima, Japan, 4 House of Meguminoseibo, Usuki, Japan, 5 Kagoshima University, Kagoshima-Shi, Japan 3:45 pm 1871. Puberty and Disease Activity in JIA Philomine A. van Pelt 1, Aike.a. Kruize 2, Anita C.S. Hokken- Koelega 3, Radboud JEM Dolhain 4, Johannes WJ Bijlsma 5 and Nico M. Wulffraat 5, 1 Erasmus MC, Rotterdam, Netherlands, 2 University Medical Center Utrecht, Utrecht, Netherlands, 3 Erasmus Medical Center- Sophia Children s Hospital, Rotterdam, Netherlands, 4 Erasmus MC University Medical Center Rotterdam, Rotterdam, Netherlands, 5 University Medical Centre Utrecht, Utrecht, Netherlands ARHP SESSIONS 2:30 4:00 pm 257 A Alternative Medicine: Presenting the Evidence for Rheumatic Conditions Moderators: Deborah McCloskey, RN, BSN and Lisa Shelton, BSc, BSN, RN evaluate the mounting evidence to support the use of acupuncture for a variety of chronic pain conditions in rheumatology describe the regulatory differences between dietary supplements, medical foods and drug products discuss safety and efficacy data on dietary supplements and medical foods utilized for rheumatic conditions 2:30 pm Efficacy of Acupuncture for Treatment of Chronic Pain Richard E. Harris, PhD 3:15 pm Dietary Supplements in Rheumatology James Torr, PharmD 92 2014 Program Book
scientific sessions 254 A Biomarkers in Rheumatic Care Moderators: Jennifer L. Trizuto, MPT and Chokkalingam Siva, MD recognize what biomarkers are explain how biomarkers can be useful tools with diagnostic and prognostic utility identify the obstacles in the validation of candidate biomarkers 2:30 pm Biomarkers in Rheumatic Care Richard D. Brasington, MD 3:00 pm Biomarkers in the Assessment of Lupus Disease Activity Chaim Putterman, MD express the importance of positive affect experiences in promoting resilience recognize how resilience can promote successful adaptation to the stresses of chronic illness 2:30 pm Temperament and Affect Balance Style: Maximizing Strengths to Promote Resilience Kim Sibille, PhD 3:00 pm Identifying Modifiable Biopsychosocial Pathways of Resilience to Chronic Illness Alex Zautra, PhD 3:30 pm Valued Life Activities and Psychological Well-Being Patricia P. Katz, PhD 256 3:30 pm Biomarkers in the Assessment of Vasculitis Peter A. Merkel, MD, MPH Stats Boot Camp: A Call to Aims for Researchers! An Interactive Session to Obtain Feedback on Your Specific Aims Section Moderator: Robert R. McLean, DSc, MPH recognize the importance of the Specific Aims section of a research proposal describe the essential elements of a compelling Specific Aims section develop Specific Aims that effectively sell a research idea and form a partnership with reviewers enhance Specific Aims in current development based on direct feedback given by experienced investigators during breakout group review sessions 2:30 pm How to Develop a Convincing Specific Aims Section Kelli D. Allen, PhD 3:05 pm Common Pitfalls of Specific Aims and How to Avoid Them Linda C. Li, PhD, PT 3:40 pm Review of Attendees In Progress Specific Aims in Small Breakout Groups Led by Speakers Kelli D. Allen, PhD; Linda C. Li, PhD, PT 255 Thriving with Rheumatic Disease: Cultivating Resilience Moderator: Hazel L. Breland, PhD, OTR/L explain the importance of preserving valued life activities to maintain psychological well-being ACR/ARHP WORKSHO 4:00 6:00 pm 161 Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. Dermatopathology of Rheumatic Diseases (225) Speaker: Daniel Miller, MD identify what information can be gained from a skin biopsy in patients with rheumatic diseases describe the importance of dermatopathology in clinical decision making in patients with rheumatic diseases apply the knowledge gained to clinical practice 152 *Joint Injections (Knee, Ankle, Shoulder and Wrist) (226) Speakers: Jemima Albayda, MD and Pari Basharat, MD describe indications for lower extremity joint injection and aspiration identify anatomic landmarks for injection of the knee and ankle using joint prosthetics apply principles of joint aspiration and injection using ankle and knee joint prosthetics MONDAY november 17, 2014 2014 Program Book 93
scientific sessions MONDAY november 17, 2014 154 MDHAQ/RAPID3 and RHEUMDOC: Quantitative, Standard, Scientific Summaries of Patient History and Physical Exam, Toward Better Clinical Decisions and Outcomes (227) Speaker: Theodore Pincus, MD summarize the rationale for the use of MDHAQ/RAPID3 and RHEUMDOC to help establish an agenda or road map for the encounter proficiency in scoring RAPID3 and interpretation using RHEUMDOC in using different levels of scores for clinical decisions recognize how to use other components of MDHAQ beyond RAPID3, including RADAI self-report joint count (rheumatoid arthritis disease activity index), review of systems and recent medical history and RHEUMDOC help improve doctor-patient communication and save time for the doctor. 159 *Musculoskeletal Ultrasonography: Basic (228) Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, MBBS, MRCP explain basic concepts of ultrasound physics assess how to perform a proper ultrasound examination identify various tissues in an ultrasound image ACR SESSION 4:30 5:30 pm Md Pd PrM FIT Ballroom East Clinicopathologic Conference: A 17-Year-Old Young Woman with Chronic Ankle and Back Pain Moderators: Simon M. Helfgott, MD and Derrick J. Todd, MD, PhD assess chronic ankle and back pain in adolescent patients determine the differences between inflammatory and noninflammatory joint pain synthesize clinical, radiologic and pathologic data in formulating a diagnosis 4:30 pm Case Presentation Derrick J. Todd, MD, PhD 4:45 pm Radiologic Findings Barbara N. Weissman, MD 5:05 pm Histologic Findings Margaret Seton, MD Ed Pd PrM FIT 5:15 am Guest Speaker Ronald Laxer, MD ACR SESSIONS 4:30 6:00 pm 204 A Career Opportunities in Rheumatology: Making a Choice Moderators: Marcy B. Bolster, MD and Kristine M. Lohr, MD, MS discuss examples of different career paths available to rheumatologists explain the pros and cons of the various career paths in rheumatology 4:30 pm Basic Research Ellen M. Gravallese, MD 4:47 pm Clinical Research Jane E. Salmon, MD 5:04 pm Clinician Educator Kenneth S. O Rourke, MD 5:21 pm Private Practice David G. Borenstein, MD 5:38 pm Industry Primal P. Kaur, MD 5:55 pm Questions and Answers Ballroom West Curbside Consults Ask the Experts Moderators: Rula Hajj-Ali, MD, Rebecca L. Manno, MD, MHS and N. Lawrence Edwards, MD compare the personal management approaches of selected clinical problems with those of the presenters develop an approach to evaluating and managing patients with a new diagnosis of granulomatosis with polyangiitis devise an approach to evaluating and managing patients with cryoglobulinemic vasculitis describe therapeutic options for common but difficult complications of the antiphospholipid syndrome 94 2014 Program Book
scientific sessions 4:30 pm A New Diagnosis of Granulomatosis with Polyangiitis: How Do I Treat This Patient? Carol A. Langford, MD 5:00 pm The Role of Wnt Signaling in Bone and Cartilage in Osteoarthritis Rik Lories, PhD, MD 5:00 pm Cryoglobulinemic Vasculitis...Help! Patrice Cacoub, MD 5:30 pm Antiphospholipid Syndrome: How Do I Approach This Patient? Robert Roubey, MD 160 B Fibrotic Complications of Scleroderma Moderators: Dinesh Khanna, MD and Virginia D. Steen, MD review the management of early skin involvement in systemic scleroderma discuss the management of lung fibrosis in systemic scleroderma explain the management of heart involvement in systemic scleroderma 4:30 pm Skin Fibrosis in Systemic Sclerosis Current Management Strategies Oliver Distler, MD 5:00 pm Management of Interstitial Lung Disease Whom to Treat Philip J. Clements, MD, MPH 5:30 pm Primary Cardiac Involvement in Systemic Sclerosis Management Strategies Yannick Allanore, MD, PhD 5:30 pm Transforming Growth Factor Beta (TGF-ß), Bone Marrow Mesenchymal Stem Cells and Osteoarthritis Xu Cao, Phd 205 B Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management Moderators: Kerry Stone, MD and Rodney Tehrani, MD Ed Pd PrM FIT develop a rational treatment approach to fibromyalgia develop a rational approach to the diagnosis and treatment of low back pain describe the etiologies and diagnosis of amplified musculoskeletal pain syndrome develop a multidisciplinary approach for the treatment of amplified musculoskeletal pain syndrome 4:30 pm Fibromyalgia Don L. Goldenberg, MD 5:00 pm Low Back Pain Rajiv Dixit, MD 5:30 pm Amplified Musculoskeletal Pain Syndrome David D. Sherry, MD ACR CONCURRENT ABSTRACT SESSIONS 4:30 6:00 pm MONDAY november 17, 2014 102 A The Role of Bone in the Pathogenesis of Osteoarthritis Moderator: Richard F. Loeser, MD describe the relationship between bone marrow lesions and pain and disease progression in osteoarthritis define the biological and mechanical factors that regulate bone remodeling in osteoarthritis appraise how transforming growth factor beta in bone activates mesenchymal stem cells that contribute to osteoarthritis pathogenesis 4:30 pm The Relationship of Bone Marrow Lesions to Pain and Progression in Osteoarthritis David T. Felson, MD, MPH 253 B Epidemiology and Public Health III: Gout and Systemic Lupus Erythematosus Moderators: Evelyne Vinet, MD and Dorothy D. Dunlop, PhD 4:30 pm 1872. Gout in Older Adult Mara McAdams-DeMarco 1, Anna Kottgen 2, Bridget Burke 3, Andrew Law 4, Josef Coresh 1 and Alan N. Baer 5, 1 Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, 2 University Hospital Freiburg, Freiburg, Germany, 3 Johns Hopkins University, Baltimore, MD, 4 Johns Hopkins, Baltimore, MD, 5 Johns Hopkins University School of Medicine, Baltimore, MD 4:45 pm 1873. Food Sources of Protein and Risk of Incident Gout in the Singapore Chinese Health Study Gim Gee Teng 1, An Pan 2, Jian-Min Yuan 3 and Woon-Puay Koh 4, 1 Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 2 Saw Swee Hock School 2014 Program Book 95
scientific sessions MONDAY november 17, 2014 96 of Public Health, National University of Singapore, Singapore, Singapore, 3 Division of Cancer Control and Population Sciences, University of Pittsburgh Cancer Institute and Department of Epidemiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, PA, 4 Duke-NUS Graduate Medical School Singapore, Singapore, Singapore 5:00 pm 1874. Obesity Paradox in Recurrent Gout a Metrological Clarification and Remedy Uyen Sa D.T. Nguyen 1, Qiong Louie-Gao 1, Yuqing Zhang 1, David T. Felson 1, Michael P. Lavalley 2 and Hyon Choi 3, 1 Boston University School of Medicine, Boston, MA, 2 Boston University, Boston, MA, 3 Harvard Medical School, Boston, MA 5:15 pm 1875. Can Allopurinol Survival Impact Reverse Depending on Patients Characteristics? a Propensity-Score-Based Subgroup Analysis Na Lu 1, Hyon Choi 2, Maureen Dubreuil 3, Qiong Louie-Gao 1 and Yuqing Zhang 1, 1 Boston University School of Medicine, Boston, MA, 2 Harvard Medical School, Boston, MA, 3 Boston University Medical Center, Boston, MA 5:30 pm 1876. Influence of Alcohol Consumption on the Risk of SLE Among Women in the Nurses Health Studies Medha Barbhaiya, Bing Lu, Shun-Chiao Chang, Jeffrey A. Sparks, Elizabeth W. Karlson and Karen H. Costenbader, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 5:45 pm 1877. Pregnancy Outcomes in SLE: Before and after Elizabeth V. Arkema 1, Kristin Palmsten 2, Christopher Sjöwall 3, Elisabet Svenungsson 4, Jane E. Salmon 5 and Julia F Simard 6, 1 Karolinska Institutet, Stockholm, Sweden, 2 University of California, San Diego, La Jolla, CA, 3 Linköping University, Linköping, Sweden, 4 Rheumatology Unit, Karolinska Institutet, Stockholm, Sweden, 5 Hospital for Special Surgery, New York, NY, 6 Stanford School of Medicine, Stanford, CA 104 B Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes II: Clinical Perspectives Moderators: Muhammad Yunus, MD and Lisa Suter, MD 4:30 pm 1878. A Combination of Celecoxib and Famciclovir Is Efficacious in the Treatment of Fibromyalgia: Results of a Phase IIa Randomized, Double-Blind, Placebo-Controlled Study William Pridgen 1, Carol Duffy 2, Judith Gendreau 3 and R Michael Gendreau 3, 1 Innovative Med Concepts, Tuscaloosa, AL, 2 University of Alabama, Tuscaloosa, AL, 3 Gendreau Consulting, LLC, Poway, CA 2014 Program Book 4:45 pm 1879. The Efficacy of Pregabalin for Treating Fibromyalgia Patients with Moderate or Severe Baseline Widespread Pain Andrew Clair and Birol Emir, Pfizer Inc, New York, NY 5:00 pm 1880. Moderate Alcohol Consumption Is Associated with Lower Risk (and severity) of Chronic Widespread Pain: Results from a Population-Based Study Gary J. Macfarlane and Marcus Beasley, University of Aberdeen, Aberdeen, United Kingdom 5:15 pm 1881. Patients Who Fail Biologics Are More Likely to Have Concomitant Fibromyalgia Robert S. Katz 1 and Jessica L. Polyak 2, 1 Rush Medical College, Chicago, IL, 2 Rheumatology Associates, Chicago, IL 5:30 pm 1882. Examination of Patients Newly Diagnosed with Fibromyalgia: Use of Guideline-Recommended Therapies and Opioids in Clinical Practice Sonali N. Shah 1, Rachel Halpern 2, Joseph C. Cappelleri 3, Elizabeth T. Masters 4, Andrew G. Clair 1, Cori Blauer-Peterson 2 and Damon Van Voorhis 5, 1 Pfizer, Inc., New York, NY, 2 Optum, Eden Prairie, MN, 3 Pfizer, Inc., Groton, CT, 4 Pfizer Inc, New York, NY, 5 Optum Life Sciences, Eden Prairie, MN 5:45 1883. WITHDRAWN 156 B Genetics, Genomics and Proteomics I: Epigenetic Mechanisms in Autoimmunity Moderators: Patrick Gaffney, MD and Amr Sawalha, MD 4:30 pm 1884. Differential DNA Methylation Associated with Rheumatoid Arthritis in Disease Discordant Monozygotic Twins Amy Webster 1, Flore Zufferey 2, Darren Plant 3, Anne Barton 4, Frances Williams 2 and Jane Worthington 5, 1 Arthritis Research UK Centre for Genetics and Genomics, The University of Manchester, Manchester, United Kingdom, 2 Dept Twin Research and Genetic Epidemiology, Kings College London, London, United Kingdom, 3 NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, 4 Arthritis Research UK Centre for Genetics and Genomics, University of Manchester, Manchester, United Kingdom, 5 The University of Manchester, Manchester, United Kingdom 4:45 pm 1885. Integrative Omics Profiling Reveals Dysregulated Novel Pathways Mediated By micrornas and DNA Methylation in Osteoarthritis Kathleen M. Fisch 1, Ryuichiro Akagi 2, Oscar Alvarez-Garcia 1, Takeshi Teramura 1, Yuta Muramatsu 1, Masahiko Saito 3, Stuart
scientific sessions Duffy 1, Shawn Grogan 1, Takahisa Sasho 4, Darryl D Lima 1, Andrew I. Su 1 and Martin K. Lotz 1, 1 The Scripps Research Institute, La Jolla, CA, 2 The Scripps Research Institute, San Diego, CA, 3 Toho University Sakura Medical Center, Sakura, Japan, 4 Chiba University School of Medicine, Chiba, Japan Indianapolis, IN, 5 Daiich Sankyo Co. Ltd, Tokyo, Japan, 6 Daiichi Sankyo Co. Ltd, Tokyo, Japan, 7 University of California, San Francisco, CCBR-Synarc, Newark, Tiburon, CA, 8 Leiden University Medical Center, Leiden, Netherlands, 9 Keio University School of Medicine, Tokyo, Japan 5:00 pm 1886. A Novel Monocyte-Specific Transcript Underlies the Chromosome 21q22 Intergenic Genetic Association in Ankylosing Spondylitis Katelin Haynes, Tony Kenna, Evgeny Glazov, Matthew A. Brown and Gethin Thomas, University of Queensland Diamantina Institute, Brisbane, Australia 5:15 pm 1887. Genome-Wide DNA Methylation Analysis of Twin Pairs Discordant for Systemic Sclerosis Reveals Distinct Signatures in Blood and Dermal Fibroblasts Paula S. Ramos 1, Rick Jordan 2, James Lyons-Weiler 2, Thomas A. Medsger Jr. 2 and Carol A. Feghali-Bostwick 1, 1 Medical University of South Carolina, Charleston, SC, 2 University of Pittsburgh, Pittsburgh, PA 5:30 pm 1888. PU.1, Mitf and Their Novel Co-Partner, Eomes, Set up a Transcription Factor Network That Is Critical for Osteoclast Differentiation Heather Carey 1, Sankha Ghosh 1, Eason Hildreth III 1, Jennifer Cabrera 1, Dias Kurmashev 1, Wael N. Jarjour 2, Ramiro Toribio 1, Sudarshana Sharma 1 and Michael Ostrowski 1, 1 The Ohio State University, Columbus, OH, 2 The Ohio State University Wexner Medical Center, Columbus, OH 5:45 pm 1889. Rheumatoid Arthritis (RA)-Associated Risk Allele LBH Alters the Function of a Differentially Methylated LBH Enhancer Deepa Hammaker 1, Gary S. Firestein 2, Wei Wang 3, John W. Whitaker 4 and Anna-Karin Ekwall 5, 1 University of California San Diego, La Jolla, CA, 2 University of California at San Diego School of Medicine, La Jolla, CA, 3 UCSD, La Jolla, CA, 4 UCSD, San Diego, CA, 5 UC San Diego, La Jolla, CA 52 A Imaging of Rheumatic Diseases: X-Ray, MRI and CT Moderators: Charles Peterfy, MD, PhD and Orrin M. Troum, MD 4:30 pm 1890. Consistent Inhibition of Bone Destruction By Denosumab in Important Subgroups of Japanese Patients with Rheumatoid Arthritis Naoki Ishiguro 1, Yoshiya Tanaka 2, Hisashi Yamanaka 3, Toshiyuki Yoneda 4, Takeshi Ohira 5, Naoki Okubo 6, Harry K. Genant 7, Desiree van der Heijde 8 and Tsutomu Takeuchi 9, 1 Nagoya University Graduate School of Medicine, Nagoya, Japan, 2 University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, 3 Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan, 4 Indiana University School of Medicine, 4:45 pm 1891. Early MRI Endpoints Provide a Valid Measure of Structural Damage While Reducing Study Duration and Participant Numbers in Rheumatoid Arthritis Clinical Trials Joshua Baker 1, Philip G. Conaghan 2, Paul Emery 3, Daniel Baker 4 and Mikkel Østergaard 5, 1 Philadelphia VA Medical Center, Philadelphia, PA, 2 University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, 3 NIHR-Leeds Musculoskeletal Biomedical Research Unit and Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, 4 Janseen R&D, Spring House, PA, 5 Copenhagen Center for Arthritis Research, Copenhagen University Hospital at Glostrup, Glostrup, Denmark 5:00 pm 1892. In Vivo Visualization of Cortical Microchannels in Metacarpal Bones in Patients with Cutaneous Psoriasis By High Resolution Peripheral Computed tomography - Detecting Cortical Pathologies before the Clinical Onset of Psoriatic Arthritis David Simon, Francesca Faustini, Arnd Kleyer, Judith Haschka, David Werner, Axel J. Hueber, Michael Sticherling, Georg Schett and Juergen Rech, University of Erlangen-Nuremberg, Erlangen, Germany 5:15 pm 1893. Substantial Structural Lesions on MRI in the Sacroiliac Joints of Patients with Non-Radiographic Axial Spondyloarthritis Even in the Absence of MRI Inflammation WP Maksymowych 1, S Wichuk 1, H Jones 2, A Szumski 2, L Marshall 2, J Bukowski 2 and RG Lambert 1, 1 University of Alberta, Edmonton, AB, 2 Pfizer Inc., Collegeville, PA 5:30 pm 1894. Is It Worth to Include MRI of the Spine in the ASAS Classification Criteria for Axial Spondyloarthritis Manouk de Hooge 1, Jean-Baptiste Pialat 2, Antoine Feydy 3, Monique Reijnierse 1, Pascal Claudepierre 4, Alain Saraux 5, Maxime Dougados 3 and Désirée van der Heijde 1, 1 Leiden University Medical Center, Leiden, Netherlands, 2 Hôpital Edouard Herriot, Lyon, France, 3 Descartes University, Cochin Hospital, Paris, France, 4 Henri Mondor Teaching Hospital, Creteil, France, 5 CHU de la Cavale Blanche, Brest Cedex, France 5:45 pm 1895. Sacroiliitis at Diagnosis in Children with Juvenile Spondyloarthritis Pamela Weiss 1, Rui Xiao 2 and Nancy Chauvin 1, 1 Children s Hospital of Philadelphia, Philadelphia, PA, 2 University of Pennsylvania, Philadelphia, PA 2014 Program Book 97 MONDAY november 17, 2014
scientific sessions MONDAY november 17, 2014 98 157 B Pediatric Rheumatology Pathogenesis and Genetics Ed Pd PrM FIT Moderators: Karyl Barron, MD, PhD and Nora G. Singer, MD 4:30 pm 1896. Validation of a Novel IFN-Regulated Gene Score As Biomarker in Chronic Atypical Neutrophilic Dermatosis with Lipodystrophy and Elevated Temperature (CANDLE) Patients on Baricitinib, a Janus Kinase 1 /2 Inhibitor, a Proof of Concept Hanna Kim 1, Steve Brooks 2, Yin Liu 1, Adriana Almeida de Jesus 1, Gina A. Montealegre Sanchez 1, Dawn C. Chapelle 1, Nicole Plass 1, Yan Huang 1 and Raphaela Goldbach-Mansky 1, 1 National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 2 NIAMS/NIH, Bethesda, MD 4:45 pm 1897. Circulating T-Helper Cell- Associated Cytokines and Chemokines in Localized Scleroderma Kathryn S. Torok 1, Katherine Kurzinski 2, Christina Kelsey 3, Kelsey Magee 4, Jonathan Yabes 4, Abbe N. Vallejo 4, Thomas A. Medsger Jr. 4 and Carol A. Feghali-Bostwick 5, 1 Children s Hospital of Pittsburgh of UC, Pittsburgh, PA, 2 Univ of Pittsburgh Med Ctr, Pittsburgh, PA, 3 University of Pittsburgh/UC, Pittsburgh, PA, 4 University of Pittsburgh, Pittsburgh, PA, 5 Medical University of South Carolina, Charleston, SC 5:00 pm 1898. Identification of autoinflammatory interferonopathies? a New Class of Autoinflammatory Conditions? Adriana Almeida de Jesus 1, Zuoming Deng 1, Stephen Brooks 2, Yin Liu 1, Hanna Kim 1, Gina A. Montealegre Sanchez 1, Dawn C. Chapelle 1, Yan Huang 1, Philip Hashkes 3, Gulnara Nasrullayeva 4, Maria Teresa Terreri 5, Bita Arabshahi 6, Marilynn G. Punaro 7, Lakshmi N. Moorthy 8, Adam Reinhardt 9, Clovis A. Silva 10, Emilia I. Sato 11, Vibke Lilleby 12, Thomas Fleisher 13 and Raphaela Goldbach- Mansky 1, 1 National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, MD, 2 NIAMS/NIH, Bethesda, MD, 3 Shaare Zedek Medical Center, Jerusalem, Israel, 4 Azerbaijan Medical University, Baku, Azerbaijan, 5 University of Federal De Sao Paulo, Sao Paulo, Brazil, 6 Inova Fairfax Hospital for Children, Fairfax, VA, 7 University of Texas Southwestern Medical Center, Dallas, TX, 8 Robert Wood Johnson Medical School-Rutgers University, New Brunswick, NJ, 9 Children s Specialty Physicians, Omaha, NE, 10 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 11 Escola Paulista de Medicina Universidade Federal de São Paulo, Sao Paulo, Brazil, 12 Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, 13 National Institutes of Health, Bethesda, MD 5:15 pm 1899. Blockade of Interleukin-33 Signaling Prevents Death in a Mouse Model of Familial Hemophagocytic Lymphohistiocytosis Julia Rood 1, Portia Kreiger 2, Erietta Stelekati 1, E. John Wherry 1 and Edward M. Behrens 3, 1 Perelman School of Medicine at the 2014 Program Book University of Pennsylvania, Philadelphia, PA, 2 Alfred I. dupont Hospital for Children, Wilmington, DE, 3 The Children s Hospital of Philadelphia, Philadelphia, PA 5:30 pm 1900. HLA-DRB1*1101, Regulatory Variants of the MHC and a Regulatory Region Near an Intergenic Long Noncoding RNA on Chromosome 1 Are Risk Factors for Systemic Juvenile Idiopathic Arthritis Michael J. Ombrello 1, Elaine F. Remmers 2, Ioanna Tachmazidou 3, Alexei Grom 4, Dirk Föll 5, Alberto Martini 6, Marco Gattorno 7, Seza Ozen 8, Sampath Prahalad 9, Andrew S. Zeft 10, John F. Bohnsack 11, Norman T. Ilowite 12, Jane L. Park 13, Elizabeth D. Mellins 13, Ricardo A. G. Russo 14, Claudio A. Len 15, Sheila K. Feitosa de Oliveira 16, Rae SM Yeung 17, Lucy R. Wedderburn 18, Jordi Anton 19, Tobias Schwarz 20, Buhm Han 21, Richard H. Duerr 22, Jean-Paul Achkar 10, M. Ilyas Kamboh 22, Kenneth M. Kaufman 23, Leah C. Kottyan 4, Dalila Pinto 24, Stephen Scherer 17, Marta E. Alarcón-Riquelme 25, Elisa Docampo Martinez 26, Xavier Estivill 27, Ahmet Gul 28, Colleen Satorius 29, Paul I.W. de Bakker 30, Soumya Raychaudhuri 21, Carl D. Langefeld 31, Susan D. Thompson 4, Eleftheria Zeggini 3, Wendy Thomson 32, Daniel L. Kastner 29, Patricia Woo 33 and International Childhood Arthritis Genetics (INCHARGE) Consortium, 1 National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 3 The Wellcome Trust Sanger Institute, Cambridge, United Kingdom, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 University Children s Hospital Muenster, Muenster, Germany, 6 University of Genova, Genova, Italy, 7 Instituto Giannina Gaslini, Genoa, Italy, 8 Deptartment. of Pediatric Rheumatology, Hacettepe University, Ankara, Turkey, 9 Emory University School of Medicine, Atlanta, GA, 10 Cleveland Clinic, Cleveland, OH, 11 University of Utah, Salt Lake City, UT, 12 Albert Einstein College of Medicine, Bronx, NY, 13 Stanford University Medical Center, Stanford, CA, 14 Hospital de Pediatria Garrahan, Buenos Aires, Argentina, 15 Universidade Federal de São Paulo/Escola Paulista de Medicina, São Paulo, Brazil, 16 Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, 17 The Hospital for Sick Children, Toronto, ON, 18 University College London (UCL) Institute of Child Health, London, United Kingdom, 19 Pediatric Rheumatology Unit. Hospital Sant Joan de Déu. Universitat de Barcelona, Barcelona, Spain, 20 University of Wuerzburg, Wuerzburg, Germany, 21 Broad Institute of MIT and Harvard, Cambridge, MA, 22 University of Pittsburgh, Pittsburgh, PA, 23 Cincinnati Children s Hospital Medical Center and the University of Cincinnati, Cincinnati, OH, 24 Icahn School of Medicine at Mount Sinai, New York, NY, 25 Arthritis and Clinical Immunology Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 26 GIGA-Université de Liège, LIege, Belgium, 27 Center for Genomic Regulation, Barcelona, Spain, 28 Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 29 National Human Genome Research Institute, Bethesda, MD, 30 University Medical Center Utrecht, Utrecht, Netherlands, 31 Center for Public Health Genomics and Department of Biostatistical Sciences, Wake Forest School of Medicine, Winston-Salem, NC, 32 Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 33 University College London, London, United Kingdom
scientific sessions 5:45 pm 1901. Interferon-γ (IFNγ) in Macrophage Activation Syndrome (MAS) Associated with Systemic Juvenile Idiopathic Arthritis (sjia). High Levels in Patients and a Role in a Murine MAS Model Claudia Bracaglia 1, Ivan Caiello 1, Kathy De Graaf 2, Giovanni D Ario 2, Florence Guilhot 2, Walter Ferlin 2, Lidia Meli 1, Giusi Prencipe 1, Sergio Davì 3, Grant Schulert 4, Angelo Ravelli 5, Alexei Grom 4, Cristina De Min 2 and Fabrizio De Benedetti Sr. 1, 1 Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 2 Novimmmune S.A., Plan-Les-Ouates, Geneva, Switzerland, 3 Istituto Giannina Gaslini, Genova, Italy, 4 Cincinnati Children s Hospital Medical Center, Cincinnati, OH, 5 Istituto Giannina Gaslini and University of Genova, Genova, Italy 258 B Rheumatoid Arthritis Clinical Aspects IV: Promising Biomarkers Moderators: S. Louis Bridges Jr., MD, PhD and Kristen Demoruelle, MD 4:30 pm 1902. Utility of Glyca, a Novel Inflammatory Marker, for Assessment of Rheumatoid Arthritis Disease Activity Michelle Ormseth 1, Cecilia P. Chung 1, Joseph F. Solus 1, Annette M. Oeser 1, Margery A. Connelly 2, Jim Otvos 2 and C Michael Stein 1, 1 Vanderbilt University, Nashville, TN, 2 LipoScience, Inc., Raleigh, NC 4:45 pm 1903. Change in 14-3-3η Expression in Early RA Patients Treated with DMARDs Corresponds with Change in DAS28 and Good EULAR Responses Dirkjan van Schaardenburg 1, Mairead Murphy 2, Yuan Gui 2, Samina Turk 1, Walter P. Maksymowych 3 and Anthony Marotta 2, 1 Reade, Amsterdam, Netherlands, 2 Augurex Life Sciences Corp., North Vancouver, BC, 3 University of Alberta, Edmonton, AB 5:00 pm 1904. Rheumatoid Factor Isotype Testing to Identify Individuals in the Preclinical Period of Rheumatoid Arthritis M. Kristen Demoruelle 1, Anthony Kahr 1, Mark C. Parish 1, Marie L. Feser 1, Ryan W. Gan 2, Jason R. Kolfenbach 1, William R. Gilliland 3, Jess D. Edison 3, Michael H. Weisman 4, James R. O Dell 5, Ted R. Mikuls 6, Richard M. Keating 7, Peter K. Gregersen 8, Jane H. Buckner 9, Jill M. Norris 2, V. Michael Holers 1 and Kevin D. Deane 1, 1 University of Colorado School of Medicine, Aurora, CO, 2 Colorado School of Public Health, Aurora, CO, 3 Walter Reed National Military Medical Center, Bethesda, MD, 4 Cedars-Sinai Medical Center, Los Angeles, CA, 5 Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 6 Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 7 Scripps Clinic, La Jolla, CA, 8 Feinstein Institute for Medical Research, Manhasset, NY, 9 Benaroya Research Institute at Virginia Mason, Seattle, WA 5:15 pm 1905. Within-Day Variation and Influence of Physical Exercise on Circulating Galectin-3 in Patients with Rheumatoid Arthritis and Healthy Individuals Saida Farah Issa 1, Anne Friesgaard Christensen 2, Tine Lottenburger 2, Kirsten Junker 3, Hanne M. Lindegaard 1, Kim Hoerslev-Petersen 4 and Peter Junker 1, 1 Department of Rheumatology, Odense University Hospital, Odense, Denmark, 2 Department of Rheumatology, Vejle Hospital, Vejle, Denmark, 3 Institute of Molecular Medicine, Cardiovascular & Renal Research, University of Southern Denmark, Odense, Denmark, 4 Research Unit at King Christian X Hospital for Rheumatic Diseases, Graasten, Graasten, Denmark 5:30 pm 1906. IL-6 Blockade Reduces Circulating N-Terminal Pro-Brain Natriuretic Peptide Levels in Patients with Active Rheumatoid Arthritis Atsuma Nishiwaki 1, Hitomi Kobayashi 1, Yasuyuki Kobayashi 2, Isamu Yokoe 1, Noboru Kitamura 1, Hidetake Shiraiwa 1, Takamasa Nozaki 1, Hirotake Inomata 1, Natsumi Ikumi 1, Kaita Sugiyama 1, Yousuke Nagasawa 1 and Masami Takei 3, 1 Nihon University School of Medicine, Tokyo, Japan, 2 St.Marianna University School of Medicine, Kawasaki, Japan, 3 Nihon University School of Medicine, Itabashi Tokyo, Japan 5:45 pm 1907. Clinical Evaluation of Anti-Aminoacyl trna Synthase Antibodies in Rheumatoid Arthritis Patients Masakazu Matsushita, Ken Yamaji, Naoto Tamura and Yoshinari Takasaki, Juntendo University School of Medicine, Tokyo, Japan Exhibit Hall C Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy IV: Safety of Biologics and Small Molecules in Rheumatoid Arthritis Cardiovascular and Other Systems Moderators: Gerd Burmester, MD and Alan K. Matsumoto, MD 4:30 pm 1908. Pregnancy Outcomes in the Tofacitinib RA Safety Database through April 2014 A. Marren 1, Y. Chen 1, D. Frazier 2 and J. Geier 3, 1 Pfizer Inc, Collegeville, PA, 2 Pfizer Inc, Groton, CT, 3 Pfizer Inc, New York, NY 4:45 pm 1909. Incidence of Congestive Heart Failure in Subjects with Rheumatoid Arthritis Receiving Anti-Tumour Necrosis Factor Drugs: Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Alper van Sijl 1, Mamas Mamas 2, Mark Lunt 3,. BSRBR Control Centre Consortium 4, Kath Watson 5, Deborah P. Symmons 4 and Kimme L. Hyrich 6, 1 Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, University of Manchester, Manchester, United Kingdom, 2 Manchester Heart Centre, Manchester Royal Infirmary, Oxford Road, Manchester, UK; MONDAY november 17, 2014 2014 Program Book 99
scientific sessions MONDAY november 17, 2014 Institute of Cardiovascular Sciences, University of Manchester, Manchester, United Kingdom, 3 University of Manchester, Manchester, United Kingdom, 4 Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester, United Kingdom, 5 Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester, United Kingdom, 6 Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom 5:00 pm 1910. Risk of Hypersensitivity Among Medicare Patients with Rheumatoid Arthritis Who Were Taking Biologics Huifeng Yun 1, Fenglong Xie 2, Lang Chen 2, James Lewis 3 and Jeffrey R. Curtis 2, 1 University of Alabama at Birmingham School of Public Health, Birmingham, AL, 2 University of Alabama at Birmingham, Birmingham, AL, 3 University of Pennsylvania, Philadelphia, PA 5:15 pm 1911. Disease Modifying Anti-Rheumatic Drug Use and the Risk of Incident Hyperlipidemia in Patients with Early Rheumatoid Arthritis: A Retrospective Cohort Study Rishi Desai, Wesley Eddings, Katherine Liao, DH Solomon and Seoyoung C. Kim, Brigham and Women s Hospital, Boston, MA 5:30 pm 1912. Tocilizumab Therapy for Rheumatoid Arthritis Patients with Chronic Renal Insufficiency Shunsuke Mori, NHO Kumamoto Saishunsou National Hospital, Kumamoto, Japan 5:45 pm 1913. Rosuvastatin Induced Carotid Plaque Regression in Patients with Inflammatory Joint Diseases Silvia Rollefstad 1, Eirik Ikdahl 1, Jonny Hisdal 2, Inge C. Olsen 1, Ingar Holme 3, Hilde Berner Hammer 1, Knut T. Smerud 4, G Kitas 5, Terje R. Pedersen 6, Tore K. Kvien 7 and Anne Grete Semb 1, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 Uslo University Hospital-Aker, Oslo, Norway, 3 Oslo University Hospital, Oslo, Norway, 4 Smerud Medical Research International AS, Oslo, Norway, 5 The Dudley Group of Hospitals NHS Foundation Trust, Dudley, United Kingdom, 6 University of Oslo, Oslo, Norway, 7 PsAID taskforce, EULAR, Zurich, Switzerland 153 B Spondyloarthropathies and Psoriatic Arthritis Pathogenesis, Etiology: From Genes to Cytokines Moderators: Christopher T. Ritchlin, MD, MPH and Robert D. Inman, MD 4:30 pm 1914. IL-17A Deficiency Promotes Periosteal Bone Formation in a Model of Inflammatory Arthritis Anita T. Shaw 1, Yukiko Maeda 1, Catherine Manning 1 and Ellen M. Gravallese 2, 1 University of Massachusetts Medical School, Worcester, MA, 2 UMass Memorial Medical Center, Worcester, MA 4:45 pm 1915. IL-17 Gene Transfer induces Myeloid Precursor Cells That Initiate Epidermal Hyperplasia Independently of IL-23R + /CD4 + and γδ T Cells Erika Suzuki, Ritu Sarin, Emanual Maverakis and Iannis E. Adamopoulos, University of California at Davis, Sacramento, CA 5:00 pm 1916. Stromal Overexpression of Transmembrane TNF Induces Spa-like Arthritis and Spondylitis in Mice Leonie M. van Duivenvoorde 1, Melissa N. van Tok 1 and Dominique L. Baeten 2, 1 Department of Clinical Immunology and Rheumatology and Department of Experimental Immunology, Academic Medical Centre/University of Amsterdam, Amsterdam, Netherlands, 2 Academic Medical Center / University of Amsterdam, Amsterdam, Netherlands 5:15 pm 1917. IL-23 Expression and Activation of Autophagy in Synovium and PBMCs of HLA-B27 Positive Patients with Ankylosing Spondylitis Barbara Neerinckx, Shea Carter and Rik Lories, KU Leuven, Leuven, Belgium 5:30 pm 1918. IL23 Overexpression Demonstrates Gut-Joint Inflammation Link and Increased Expression of Spondyloarthopathy Associated Genes In Vivo Donald Souza II, Boehringer Ingelheim Pharmaceuticals Inc., Ridgefield, CT 5:45 pm 1919. HLA-B27 Expression Shapes the Intestinal Microbiota Mark Asquith 1, Phoebe Lin 1, Tejpal Gill 2, Justine Debelius 3, Patrick Stauffer 1, Sean Davin 1, Gail Ackermann 3, Robert A. Colbert 2, Rob Knight 3 and James Rosenbaum 4, 1 Oregon Health and Science University, Portland, OR, 2 NIAMS/NIH, Bethesda, MD, 3 University of Colorado Boulder, Boulder, CO, 4 Legacy Hospital, Portland, OR 210 B Systemic Lupus Erythematosus Clinical Aspects and Treatment: Biomarkers in Systemic Lupus Erythematosus Moderators: Diane L. Kamen, MD, MS and Anca D. Askanase, MD 4:30 pm 1920. Predicting SLE Disease Activity in the Next Year Based on Measures of Four Gene Transcripts and Two Proteins Laurence S Magder 1, Eric Zollars 2, Jadwiga Bienkowska 3, Chris Stebbins 4, Carrie Wager 4, Linda Burkly 4, Nicolas Wisniacki 5, Ann Ranger 4 and Michelle Petri 2, 1 University of Maryland School of Medicine, Baltimore, MD, 2 Johns Hopkins University School of Medicine, Baltimore, MD, 3 Biogen Idec Inc., Cambridge, MA, 4 Biogen Idec, Cambridge, MA, 5 Formerly with Biogen Idec, Cambridge, MA 100 2014 Program Book
scientific sessions 4:45 pm 1921. The Deposition of Complement C4d Split Product on Platelets and Erythrocytes Correlate with Disease Activity and Improvement in Systemic Lupus Erythematosus Joan T. Merrill 1, Aikaterini Thanou 1, Stan Kamp 1, John Conklin 2, Derren Barken 2 and Thierry Dervieux 2, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 Exagen Diagnostics, Inc., Vista, CA 5:00 pm 1922. Hydroxychloroquine Use Is Associated with Decreased Soluble TNF Receptor Levels in SLE Patient Samples Rufei Lu 1, Adam Przebinda 1, Melissa E. Munroe 2, Joel M. Guthridge 2, Joan T. Merrill 2 and Judith A. James 2, 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2 Oklahoma Medical Research Foundation, Oklahoma City, OK 5:15 pm 1923. Vitamin D Restores Lupus Myeloid Angiogenic Cell Function Via Down-Regulation of IP-10/CXCL-10 John A. Reynolds 1, David W. Ray 2, Yvonne Alexander 3 and Ian N. Bruce 4, 1 Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, United Kingdom, Manchester, United Kingdom, 2 Institute of Human Development, The University of Manchester, Manchester, United Kingdom, 3 Manchester Metropolitan University, Manchester, United Kingdom, 4 Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Institute of Inflammation and repair, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom 5:30 pm 1924. Cell Bound Complement Activation Products Have Higher Sensitivity Than Serum C3 and C4 Levels in Systemic Lupus Erythematosus Rosalind Ramsey-Goldman 1, Richard Furie 2, Chaim Putterman 3, Anka Askanase 4, Jill P. Buyon 5, Kenneth Kalunian 6, W. Winn Chatham 7, E Massarotti 8, Kyriakos A. Kirou 9, A. Weinstein 10, Puja Chitkara 11, Susan Manzi 12, Joe Ahearn 13, Leilani Wolover 14, John Conklin 14, Tyler O Malley 14, Claudia Ibarra 14, Derren Barken 14 and Thierry Dervieux 14, 1 Northwestern University, Chicago, IL, 2 North Shore-LIJ Health System, Great Neck, NY, 3 Albert Einstein College of Medicine, Bronx, NY, 4 Colombia University, New York, NY, 5 New York University School of Medicine, New York, NY, 6 UCSD School of Medicine, La Jolla, CA, 7 University of Alabama at Birmingham, Birmingham, AL, 8 Brigham and Women s Hospital, Boston, MA, 9 Hospital for Special Surgery, New York, NY, 10 Washington Hospital Center, Washington, DC, 11 Sharp Memorial Hospital, San Diego, CA, 12 Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 13 West Penn Allegheny Health System, Pittsburgh, PA, 14 Exagen Diagnostics, Inc., Vista, CA 5:45 pm 1925. Determinants of Blood Hydroxychloroquine Concentration Variations in Systemic Lupus Erythematosus Patients Moez Jallouli 1, Lionel Galicier 2, Olivier Aumaître 3, Camille Francès 4, Véronique Le-Guern 5, F. Lioté 6, Amar Smail 7, Nicolas Limal 8, L. Perard 9, H. Desmurs-Clavel 10, Du Boutin 11, B. Asli 12, Jean Emmanuel Kahn 13, Jacques Pourrat 14, Laurent Sailler 15, F. Ackermann 13, T. Papo 16, Karim Sacre 17, O. Fain 18, J. Stirnemann 18, Patrice Cacoub 1, Gaëlle Leroux 1, Judith Cohen-Bittan 1, Js Hulot 19, Zahir Amoura 20, Jean-Charles Piette 1 and Nathalie Costedoat- Chalumeau 5, 1 CHU Pitié-Salpêtrière, Paris, France, 2 Hopital St Louis, AP-HP, Paris, France, 3 Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont Ferrand, Clermont Ferrand, France, 4 Hôpital Tenon, Paris Cedex 20, France, 5 Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP HP, Université Paris Descartes, Paris, France, 6 Hôpital Lariboisière, Université Paris-Diderot, Sorbonne Paris- Cité, Paris, France, 7 CHU Amiens Nord, Amiens, France, 8 Hôpital Henri Mondor, APHP, Creteil, France, 9 Hospices Civils de Lyon, groupement Hospitalier Edouard Herriot, Lyon, France, 10 Hospice civils de Lyon, Lyon, France, 11 Assistance Publique-Hôpitaux de Paris, Hopital Pitié-Salpétrière, Paris, France, 12 Hopital Saint Louis, Université Paris Diderot, Sorbonne Paris Cité, Paris, France, 13 Hopital Foch, Suresnes, France, 14 CHU Toulouse, Hopital Rangueil, University of Paul Sabatier, Toulouse, France, 15 CHU Toulouse, Hopital Purpan, University of Paul Sabatier, Toulouse, France, 16 Hopital Bichat Claude Bernard, University of Paris Diderot, Sorbonne Paris cité, Paris, France, 17 University Paris-7, INSERM U699, APHP, Bichat Hospital, Paris, France, 18 Hopital Jean Verdier, University Paris Nord, Sorbonne Paris Cité, Paris, France, 19 CHU Pitié-Salpêtrière, UC, University Paris 6, Paris, France, 20 Pitié-Salpêtrière Hospital (AP-HP), Paris, France 107 B Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis Moderator: Robyn T. Domsic, MD, MPH and Laura K. Hummers, MD 4:30 pm 1926. Nailfold Videocapillaroscopy Patterns Associated with Calcinosis and Acro-Osteolysis in Systemic Sclerosis Jerome Avouac 1, Laetitia Morardet 2, Maya Sammour 3, Andre Kahan 2, Antoine Feydy 3 and Yannick Allanore 1, 1 Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, 2 Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, 3 Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France MONDAY november 17, 2014 2014 Program Book 101
scientific sessions MONDAY november 17, 2014 102 4:45 pm 1927. A Retrospective Look at the Recurrence of Digital Ulcers in Patients with Scleroderma after Discontinuation of Oral Treprostinil Ami A. Shah 1, Elena Schiopu 2, Soumya Chatterjee 3, Mary Ellen Csuka 4, Tracy Frech 5, Avram Goldberg 6, Robert F. Spiera 7, Stanford L. Peng 8 and Virginia D. Steen 9, 1 Johns Hopkins University School of Medicine, Baltimore, MD, 2 University of Michigan, Ann Arbor, MI, 3 Cleveland Clinic, Cleveland, OH, 4 Medical College of Wisconsin, Milwaukee, WI, 5 University of Utah, Salt Lake City, UT, 6 North Shore-LIJ Health System, Great Neck, NY, 7 Hospital for Special Surgery, New York, NY, 8 Benaroya Research Institute/Virginia Mason, Seattle, WA, 9 Georgetown University Medical Center, Washington, DC 5:00 pm 1928. A Multicenter, Prospective Cohort Study Using Nailfold Videocapillaroscopy and Other Clinical Characteristics to Determine the Risk of Developing New Digital Ulcers in Patients with Systemic Sclerosis Vanessa Smith 1, Maurizio Cutolo 2, Ariane Herrick 3, Oliver Distler 4, Mike Becker 5, Emma Beltran 6, Patrick Carpentier 7, Clodoveo Ferri 8, Murat Inanc 9, Panayiotis Vlachoyiannopoulos 10, Harbajan Chadha-Boreham 11, Emmanuelle Cottreel 11, Thomas Pfister 11, Daniel Rosenberg 11 and Juan Torres, on behalf of the CAP study investigators 12, 1 Ghent University Hospital, Ghent, Belgium, 2 Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, 3 Centre for Musculoskeletal Research, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, 4 Zurich University Hospital, Zurich, Switzerland, 5 Charité University Hospital, Berlin, Germany, 6 Hospital La Fe, Valencia, Spain, 7 La Tronche Hospital, Grenoble, France, 8 University of Modena & Reggio E, Moderna, Italy, 9 Division of Rheumatology, Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey, 10 School of Medicine, National University of Athens, Athens, Greece, 11 Actelion Pharmaceuticals Ltd, Allschwil, Switzerland, 12 Syntax for Science SL, Basel, Switzerland 5:15 pm 1929. Echocardiographic Phenomics for Novel Classification of Cardiac Involvement in Systemic Sclerosis Monique Hinchcliff, Vistasp Daruwalla, Lauren Beussink-Nelson, Sofia Podlusky, Mary A. Carns, John Varga and Sanjiv J. Shah, Northwestern University Feinberg School of Medicine, Chicago, IL 5:30 pm 1930. The Value of Repeated Nailfold Capillaroscopy in Raynaud s Phenomenon in Daily Practice: A Follow-up Study in the Netherlands B. de Boer 1, J. Meijs 1, J. van Aken 2, T.W.J. Huizinga 1, A.a. Schouffoer 3 and J.K. de Vries-Bouwstra 1, 1 Leiden University Medical Center, Leiden, Netherlands, 2 Spaarne Ziekenhuis, Hoofddorp, Netherlands, 3 Haga Hospital, The Hague, Netherlands 2014 Program Book 5:45 pm 1931. Mycophenolate Mofetil (MMF) Use in Scleroderma Patients with Pulmonary Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort Lesley Ann Saketkoo 1, Matthew R. Lammi 2, Aryeh Fischer 3, Jerry A. Molitor 4 and Virginia D. Steen 5, 1 Louisiana State University Health Sciences Center, New Orleans, LA, 2 Louisiana State University Health Sciences Center, Pulmonary and Critical Medicine, New Orleans, LA, 3 National Jewish Health, Denver, CO, 4 University of Minnesota, Minneapolis, MN, 5 Georgetown University Medical Center, Washington, DC ACR MEET THE PROFESSOR SESSIONS 4:30 6:00 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. Westin Paine (Lobby) Antiphospholipid Syndrome (051) Speaker: Doruk Erkan, MD review the spectrum of antiphospholipid syndrome explain the diagnostic utility of antiphospholipid antibody tests discuss the management of persistently antiphospholipid antibody-positive patients with different antiphospholipid antibody-related clinical manifestation Westin Otis (Lobby) *Behçet s Syndrome (052) Speaker: Yusuf Yazici, MD discuss the epidemiology, disease mechanisms and the differential diagnosis of Behçet s syndrome describe current approaches to the management of patients with Behçet s syndrome Westin Hancock (Lobby) Immunodeficiency Syndromes (053) Speaker: Troy R. Torgerson, MD, PhD review the immunology and clinical manifestations of the major immune deficiency syndromes that both adult and pediatric rheumatologists might encounter discuss the diagnostic evaluation for someone suspected of having an immune deficiency syndrome illustrate therapeutic options with cases
scientific sessions Westin Revere (Lobby) *Infections with Biologics (054) Speaker: Kathryn H. Dao, MD discuss the risk of infection related to inflammation and disease discuss the risk factors for infection recognize the magnitude of risk imposed by steroids and biologics determine the approach to risk reduction Westin Stone (Lobby) *Myopathy: Issues in Diagnosis and Treatment (055) Speaker: Rohit Aggarwal, MD, MS differentiate myositis mimics from idiopathic inflammatory myopathies describe the importance of myositis antibodies and muscle magnetic resonance imaging in diagnosis and prognosis review myositis diagnosis in difficult cases including review of clinical features, muscle biopsy and electromyography review management of refractory myopathy including management of extra-muscular manifestations especially interstitial lung disease Westin Alcott (Mezzanine) *Safety of Drugs Used to Treat Rheumatoid Arthritis (058) Speaker: Lee S. Simon, MD examine the drug safety literature with greater expertise prescribe DMARDs with a broader and deeper knowledge of potential toxicities discuss DMARD toxicities with their patients with greater comfort manage potential DMARD toxicities with greater skill Westin Douglas (Mezzanine) *Systemic Lupus Erythematosus: Lupus Nephritis (059) Speaker: Brad H. Rovin, MD review immunosuppressive therapy of lupus nephritis Classes II-V, including novel biologics discuss the use of renoprotective and anti-proteinuria therapies in lupus nephritis discuss diagnosis and treatment of renal thrombotic microangiopathy and podocytopathies outline the future research agenda for clinical trials in lupus nephritis Westin Webster (Lobby) *Pulmonary Manifestations of Rheumatic Disease (056) Speaker: Aryeh Fischer, MD identify emerging concepts regarding the pathophysiology of inflammation and fibrosis in autoimmune lung disease recognize the appropriate use of diagnostic tests in the evaluation of patients with rheumatic disorders and autoimmune lung disease discuss the limits of traditional therapeutic options and possible emerging therapies in managing autoimmune lung disease Westin Adams (Mezzanine) Raynaud s and Digital Ischemia (057) Speaker: Fredrick M. Wigley, MD discuss the current understanding of the pathogenesis of Raynaud s phenomenon classify type of Raynaud s phenomenon and differentiate it from mimickers describe the appropriate investigations for Raynaud s phenomenon and be aware of those patients at risk for the development of an autoimmune rheumatic disease discuss current options and evidence for treatment of Raynaud s phenomenon, threatened digital ischemia and digital ulcers Westin Faneuil (Mezzanine) Vasculitis Factors That Influence Disease Patterns (060) Speaker: Gary S. Hoffman, MD review advances in diagnosis and staging of vasculitis and updates on prognostic information of interest to clinicians and patients review advances in therapeutic intervention (including biologics) in the treatment of the systemic vasculitides such as granulomatosis with polyangiitis, cryoglobulinemic vasculitis and giant cell arteritis assess how to incorporate recent research data and practices into providing clinical care in the community for patients with vasculitis ARHP SESSIONS 4:30 6:00 pm 254 A Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation Moderator: Judy Foxworth, PhD, PT differentiate total knee arthroplasty prosthesis types and surgical techniques evaluate predictors of success following total knee arthroplasty implement best practices in a rehabilitation program for total knee arthroplasty MONDAY november 17, 2014 2014 Program Book 103
scientific sessions 4:30 pm Innovations in Total Knee Arthroplasty Jason Lang, MD 5:00 pm Predictors for Best Outcome After Total Knee Arthroplasty Chad M. Brummett, MD 5:00 pm Diet and Nutritional Supplements in Rheumatoid Arthritis Susanna Proudman, MBBS, PhD 5:30 pm Diet in Gout Hyon Choi, MD, PhD MONDAY november 17, 2014 256 5:30 pm Best Practice Rehabilitation Following Total Knee Arthroplasty Sara R. Piva, PhD, PT From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases Moderator: Jasvinder A. Singh, MD, MPH recognize the relative importance of immune mechanisms in the onset of atherosclerosis among patients with inflammatory rheumatic diseases review the generalizability of such mechanisms to people without inflammatory rheumatic diseases evaluate the role of oxidative stress in non-autoimmune diseases and autoimmune diseases on the incidence of atherosclerosis 4:30 pm Immunological Underpinnings of Atherosclerosis Cornelia M. Weyand, MD, PhD 5:00 pm Atherosclerotic Cardiovascular Diseases and Oxidative Stress: The Case of Crystalline Arthritis Eswar Krishnan, MD 255 The Emerging Demand for Medicinal Cannabis by Young Adults and Beyond Ed Pd PrM FIT Moderator: Lori B. Tucker, MD summarize the research-based evidence for the benefits and risks to medicinal cannabis on young adults evaluate environmental and psychosocial factors that may drive a request for physician-approved medicinal cannabis by young adults discuss the medicolegal implications for rheumatologists and for patients in this era of increasing demand for medicinal cannabis 4:30 pm A Prescription for Herbal Cannabis: Primum Non Nocere Mary-Ann Fitzcharles, MBChB, MD 5:15 pm Medicolegal Considerations for Herbal Cannabis Use in Rheumatology Practice Peter A. Ste-Marie, BA, LLB ARHP CONCURRENT ABSTRACT SESSION 4:30 6:00 pm 104 5:30 pm Innate Immunity and Atherosclerosis in Inflammatory Rheumatic Diseases Mariana J. Kaplan, MD 257 A Role of Nutrition in Rheumatic Diseases Moderators: Susan J. Bartlett, PhD and Carole V. Dodge, OT, CHT summarize current scientific evidence underlying the role of nutrition in rheumatic diseases discuss the role of diet and nutritional supplements in managing rheumatoid arthritis care recognize how the intake of various foods and drinks may affect patients with gout 4:30 pm Role of Nutrition in Rheumatic Diseases- An Overview Shivani Sahni, PhD 2014 Program Book 109 Health Disparities/Social Determinants of Health Ed Pd PrM FIT Moderators: Jillian A. Rose, LCSW and Leigh F. Callahan, PhD 4:30 pm 1932. Increasing Access to Inflammatory Arthritis Education in Rural and Remote Communities Using Telemedicine Carol Kennedy 1, Kelly Warmington 2, Carol Flewelling 1, Rachel Shupak 1, Angelo Papachristos 3, Caroline Jones 4, Dorcas Beaton 5, Sydney Brooks 6 and Denise Linton 1, 1 St. Michael s Hospital, Toronto, ON, 2 The Hospital for Sick Children, Toronto, ON, 3 St Michael s Hospital, Toronto, ON, 4 St. Michael s Hospital, Aurora, ON, 5 Mobility Program Clinical Research Unit, Li Ka Shing Knowledge Institute, St. Michaels Hospital, Toronto, ON, 6 The Arthritis Society, Ontario Division, Toronto, ON 4:45 pm 1933. Getting a Grip on Arthritis Online: Web-Based Continuing Education Supports the Dissemination of Arthritis Clinical Practice Guidelines Among Rural/Remote Primary Care Providers Sydney Lineker 1, Mary Bell 2, Lisa Fleet 3, Elizabeth M. Badley 4, Vernon Curran 3, Marlene Del Pino 5, Fran Kirby 3, Anne Lyddiatt 6,
scientific sessions Lynn Moore 1, Karla Simmons 3, Raquel Sweezie 1, Peter Tugwell 7 and Ed Ziesmann 1, 1 The Arthritis Society, Toronto, ON, 2 Sunnybrook Health Sciences Ctr, Toronto, ON, 3 Memorial University, St. John s, NF, 4 Division of Health Care and Outcomes Research, Toronto Western Research Institute; Dalla Lana School of Public Health, University of Toronto, Toronto, ON, 5 Health Canada, Regina, SK, 6 Patient Partners in Arthritis, Toronto, ON, 7 Institute of Population Hlth, Ottawa, ON 5:00 pm 1934. Examining Why Minority Women Are Risk Averse : A Qualitative Study Sonal Bhalla 1, Kristin Mattocks 2 and Liana Fraenkel 3, 1 Yale- New Haven Hospital, New Haven, CT, 2 VA Central Western Massachusetts Healthcare System, University of Massachusetts Medical School, Leeds, MA, 3 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT 5:15 pm 1935. Racial Disparities in Attitude Towards Treatment in Young Women Raluca Cozmuta 1, Sonal Bhalla 2 and Liana Fraenkel 3, 1 Yale University School of Medicine, New Haven, CT, 2 Yale University, New Haven, CT, 3 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT 5:30 pm 1936. Ageism, Fear and Competing Co-Morbidities Why Older Patients May Not Seek Care for Restricting Back Pain: A Qualitative Study Una Makris 1, Robin Higashi 2, Emily Marks 2, Liana Fraenkel 3, Joanna Sale 4 and CM Reid 5, 1 Dallas VA Medical Ctr, Dallas, TX, 2 UT Southwestern Medical Center, Dallas, TX, 3 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 4 University of Toronto, St. Michael s Hospital, Toronto, ON, 5 Weill Cornell Medical College, New York City, NY 5:45 pm 1937. Model Examining Factors Related to Physicians Ratings of Disease Activity in Patients with RA Julia R. Ayeroff 1, Sarah R. Ormseth 2, David Hardy 3, Michael R. Irwin 2, Michael H. Weisman 4 and Perry M. Nicassio 2, 1 University of Southern California, Los Angeles, CA, 2 University of California, Los Angeles, Los Angeles, CA, 3 Loyola Marymount University, Los Angeles, CA, 4 Cedars-Sinai Medical Center, Los Angeles, CA ACR STUDY GROU 6:30 7:45 pm Study Groups are non-cme activities open to all attendees. 109 A ACR Musculoskeletal Ultrasound Study Group 6:30 pm The American End of the Tendon and Enthesis Ralf G. Thiele, MD 6:45 pm The European End of the Tendon and Enthesis George A. W. Bruyn, MD, PhD 7:00 pm Sonographic Evaluation of the Enthesis and Enthesopathy Maria-Antonietta d Agostino, MD, PhD 7:15 pm Ultrasound Assessment of Dactylitis Gurjit S. Kaeley, MBBS, MRCP 7:30 pm Closing Statements 157 B Antiphospholipid Syndrome Task Force Study Group 6:30 pm Introduction Past, Present and Future of Antiphospholipid Syndrome Task Forces Doruk Erkan, MD 6:35 pm 2013 Antiphospholipid Syndrome Laboratory Diagnostics and Trends Task Force Report Maria Laura Bertolaccini, MD, PhD 6:50 pm 2013 Antiphospholipid Syndrome Clinical Diagnostics Task Force Report Roger A. Levy, MD 7:05 pm 2013 Antiphospholipid Syndrome Obstetric Diagnostics and Treatment Task Force Report Ware D. Branch, MD 7:20 pm 2016 Antiphospholipid Syndrome Diagnostic and Classification Criteria Task Force Update MG Tektonidou, MD 7:30 pm 2013/2016 Antiphospholipid Syndrome Treatment Trends Task Force Report/Update Danieli Andrade, MD 256 Capillaroscopy in Rheumatic Diseases Study Group 6:30 pm Evaluation Tools for Microcirculation Analysis: Morphology Versus Flow Ariane L. Herrick, MD 6:50 pm Capillaroscopy in Systemic Sclerosis: Clinical Applications Vanessa Smith, MD, PhD MONDAY november 17, 2014 2014 Program Book 105
scientific sessions 7:05 pm Capillaroscopy in Systemic Sclerosis: Basic Science Maurizio Cutolo, MD 7:25 pm Practical Issues in Videocapillaroscopy Including Scoring Systems and Links with Other Diagnostic Tools Alberto Sulli, MD 255 Childhood Vasculitis Study Group 6:30 pm Childhood Vasculitis in North American and Europe Marinka Twilt, MD 6:55 pm Childhood Vasculitis in South Africa Christiaan Scott, MD 7:10 pm Potential Role of Uricosuric Agents in the Contemporary Management of Gout Peter A. Simkin, MD 107 B Degos Disease Study Group 6:30 pm The Pathology of Degos Cynthia Magro, MD 6:55 pm Parvovirus Infection: Effects on Endothelium Stanley J. Naides, MD 7:20 pm Formation of Degos Registry J. Patrick Whelan, MD, PhD MONDAY november 17, 2014 7:20 pm Childhood Vasculitis in India Sathish Kumar 259 A Clinical Anatomy Study Group 6:30 pm Clinical Anatomy: An Unmet Need in Rheumatology Training Robert A. Kalish, MD 6:45 pm The Clinical Anatomy Program at Los Angeles County Christine Evelyn, MD 7:00 pm Ultrasonography as a Teaching Tool of Musculoskeletal Anatomy Karina D. Torralba, MD, MAppSc 7:15 pm Development and Experience of the Mexican Group for the Study of Clinical Anatomy (GMAC) Pablo Villasenor Ovies, MD 7:30 pm A Clinical Scholar s Perspective Richard S. Panush, MD 102 A Crystal Study Group 6:30 pm Introduction Naomi Schlesinger, MD 6:35 pm Forms of Monosodium Urate Crystal (MSUC) Deposits in Tissue Eliseo Pascual, MD, PhD 104 B Hypermobility Study Group 6:30 pm Joint Hypermobility Syndrome and the Impact on Day to Day Functioning in Children Amanda Kirby, MBBS, MRCGP, PhD 6:55 pm Joint Hypermobility and Autonomic Hyperactivity: Relevance to Neurodevelopmental Disorders Jessica Eccles, MB, BCh, MA, MSc, MRCPsych 7:20 pm Dysautonomia and Fatigue in Hypermobility Nelly Ninis, MRCP, MD 7:45 pm Physical Therapy Management of Adolescents with Postural Orthostatic Tachycardia Syndrome and Ehlers Danlos Syndrome Hypermobility Type Jane Simmonds, MCSP, MMACP 160 B Intestinal Lung Disease Study Group 6:30 pm Emerging and Adjunctive Therapies for Intestinal Lung Disease Due to Connective Tissue Disease: Lessons from Idiopathic Pulmonary Fibrosis Trials Aryeh Fischer, MD 7:00 pm Appropriate Utilization of Imaging in Intestinal Lung Disease Associated with Connective Tissue Disease Rachna Madan, MD 106 2014 Program Book
scientific sessions 156 B Macrophage Activation Syndrome Study Group 6:30 pm The Genetics of Macrophage Activation Syndrome/ Haemophagocytic Lymphohistiocytosis in Adults Lisa Filipovich, MD 6:55 pm The Propensity to Develop Macrophage Activation Syndrome in the Setting of Systemic Lupus Erythematosus W. Winn Chatham, MD 7:20 pm Macrophage Activation Syndrome Along the Spectrum of Juvenile Idiopathic Arthritis and Adult-Onset Still s-disease Peter A. Nigrovic, MD 7:05 pm Incorporating Active Learning Techniques into Your Teaching Presentations Kristen Hayward, MD, MS 7:40 pm Wrap-Up Kristen Hayward, MD, MS 254 A The Why and How of Disease Criteria Study Group 6:30 pm Is an n of 1 Trail of Low Dose Prednisone and Methotrexate More Definitive and Cost-Effective than an Extensive and Expensive Evaluation to Meet Criteria? Theodore Pincus, MD 153 B Myositis Study Group 6:30 pm Introduction Ignacio Garcia-De La Torre, MD 6:35 pm Update on the Pathogenesis of Inclusion Body Myositis Steven A. Greenberg, MD 7:10 pm Novel Therapeuptic Approaches for Inclusion Body Myositis Thomas E. Lloyd, MD, PhD 257 A Osteoarthritis Study Group 6:30 pm Introduction Carla R. Scanzello, MD, PhD 6:35 pm In-Vitro Models of Cartilage Injury and Post-Traumatic Osteoarthritis George Dodge, PhD 7:10 pm Anterior Cruciate Ligament Injury and Osteoarthritis: Biomarkers and Therapeutic Approaches Richard Frobell, PT, PhD 6:55 pm Criteria for Systemic Vasculitis: Diagnosis vs. Classification or One and the Same? Hasan Yazici, MD 7:20 pm Criteria for Defining Rheumatoid Arthritis: Is New Always Better? Yusuf Yazici, MD 204 A Veterans Affairs Rheumatology Study Group 6:30 pm Utilization of Computerized Patient Record System Templates to Capture Patient Outcomes During Clinical Practice Mathilde Pioro, MD 6:55 pm Opportunities for Participation in Veterans Affairs (VA) Rheumatology Research Through Involvement in VA Disease Specific Registries Elizabeth Chang, MD 7:20 pm Rheumatology Field Advisory Update: How to Use Available Productivity Measures to Optimizing Veterans Affairs Practice Grant W. Cannon, MD MONDAY november 17, 2014 151 A Pediatric Rheumatologists Interested in Medial Education Study Group 6:30 pm Development of a Peer Review Process for Educational Materials Submitted to Ouch My Leg! Megan L. Curran, MD 2014 Program Book 107
scientific sessions TUESDAY november 18, 2014 ACR SESSIONS 7:30 8:30 am TUESDAY, NOVEMBER 18, 2014 205 B Glycosylation and Glycan Binding Proteins in Immune Function Moderator: Leonard H. Sigal, MD Speaker: Sean Ryan, PhD identify roles for protein glycosylation in immune function identify roles for glycan binding molecules in immune function describe the importance of glycans and their binding partners in health and disease Ballroom West Hepatitis C in 2014 Moderator: Elana J. Bernstein, MD, MSc Speaker: Raymond T. Chung, MD describe the natural history of hepatitis C infection describe the extrahepatic manifestations of hepatitis C infection discuss which patients are appropriate for therapy and how to predict response to therapy describe available treatment regimens and novel/investigative treatment regimens for hepatitis C infection 151 A Patient Access to Biologics Across the Globe Moderators: Joseph Flood, MD and Maurizio Cutolo, MD discuss the access to biologics for patients in various regions of the world locate the areas where patients access differs significantly identify potential solutions to overcome identified barriers to providing biologics 7:30 am Intro and Overview of International League of Associations for Rheumatology (ILAR) Joseph Flood, MD; Maurizio Cutolo, MD Ed Pd PrM FIT 8:00 am Patient Access to Biologics in African League of Associations for Rheumatology (AFLAR) Regions Olufemi Adelowo, MD 8:10 am Patient Access to Biologics in Asian Pacific League of Association for Rheumatology (APLAR) Regions Kevin Pile, MD 8:20 am Question and Answers ARHP SESSIONS 7:30 8:30 am 254 A Clinical Features of Central Nervous System Lupus and Diagnosis of Cognitive Deficits and Psychiatric Disorders Moderator: Shawn Rose, MD, PhD Speaker: Michelle Petri, MD, MPH review the mechanisms contributing to involvement of the central nervous system summarize the diagnostic criteria and screening tools used to identify the presence of psychiatric and cognitive deficits and whether they are due to active central nervous system systemic lupus erythematosus or other factors recognize the range of cognitive changes and psychiatric disorders found in systemic lupus erythematosus patients 257 A Muscle and Adipose Tissue in Rheumatic Diseases: Location Is Everything Moderator: Kelli D. Allen, PhD Speaker: Jon T. Giles, MD, MPH differentiate between abnormal body composition phenotypes (sarcopenia, overfat and sarcopenic obesity) summarize the relationships between muscle and adipose tissue in rheumatoid arthritis evaluate the implications of fat and muscle distribution on disease-associated outcomes in rheumatic diseases 7:40 am Patient Access to Biologics in Pan American League of Associations for Rheumatology (PANLAR) Regions Carlos Pineda, MD, MSc 7:50 am Patient Access to Biologics in The European League Against Rheumatism (EULAR) Regions Maurizio Cutolo, MD ACR MEET THE PROFESSOR SESSIONS 7:45 9:15 am Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. 108 2014 Program Book
scientific sessions Westin Paine (Lobby) Antiphospholipid Syndrome (061) Speaker: Alana B. Levine, MD review classification criteria for antiphospholipid syndrome review non-criteria manifestations of antiphospholipid syndrome discuss the management of obstetric antiphospholipid syndrome, catastrophic antiphospholipid syndrome and difficult cases posed by the audience review of current international research efforts in antiphospholipid syndrome Westin Otis (Lobby) Controversies in Sjögren s Syndrome (062) Speaker: Frederick Vinino, MD identify the best approach to establish a diagnosis of Sjögren s syndrome differentiate among various causes of salivary and/or lacrimal gland swelling discuss current treatment algorithms for dry eyes, dry mouth and systemic manifestations identify risk factors and markers for lymphoma in Sjögren s syndrome patients relate the pathogenesis of these syndromes to knowledge of the various gene functions discuss the treatment rationale based on the pathogenesis and to expand on practical issues in the management of these patients Westin Webster (Lobby) *Rheumatoid Arthritis: Outcome Measures in Clinical Practice (066) Speaker: J. Timothy Harrington, MD discuss outcome measures used in rheumatoid arthritis integrate outcome measures into an office-based practice Westin Adams (Mezzanine) Safety of Drugs Used to Treat Rheumatoid Arthritis (067) Speaker: Lee S. Simon, MD examine the drug safety literature with greater expertise prescribe DMARDs with a broader and deeper knowledge of potential toxicities discuss DMARD toxicities with their patients with greater comfort manage potential DMARD toxicities with greater skill Westin Hancock (Lobby) Footwear in Orthoarthritis (063) Speaker: Najia Shakoor, MD, MS establish the biomechanical pathophysiology of osteoarthritis discuss the impact of footwear choice on biomechanics of the lower extremity discuss the impact of footwear choice on clinical conditions at the knees and feet Westin Revere (Lobby) Osteoporosis: Novel Treatments (064) Speaker: Linda Russell, MD review the basic biology of bone as it relates to treatment examine the potential benefits and risks of antiresorptive therapies discuss the potential benefits and risks of anabolic therapies review the current knowledge and understanding of how to pick the best therapy for each patient and for how long to treat each patient with osteoporosis Westin Stone (Lobby) Pediatrics: Periodic Fevers in Children (065) Speaker: Daniel L. Kastner, MD, PhD Ed Pd PrM FIT describe the differential diagnosis and expanding spectrum of these syndromes Westin Alcott (Mezzanine) Systemic Lupus Erythematosus: Central Nervous System (068) Speaker: Meggan Mackey, MD, MS identify neuropsychiatric manifestations attributable to systemic lupus erythematosus recognize the utility of diverse autoantibodies in the diagnosis of neuropsychiatric syndromes of systemic lupus erythematosus patients formulate a treatment plan in patients with neuropsychiatric lupus Westin Douglas (Mezzanine) Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (069) Speaker: Robyn T. Domsic, MD, MPH use clinical and serologic classification systems of systemic sclerosis to identify the natural history of clinical subsets explain the concept of disease staging in both diffuse and limited cutaneous systemic sclerosis use knowledge of clinical/serologic classification and disease staging to develop screening and management plans TUESDAY november 18, 2014 2014 Program Book 109
scientific sessions Westin Faneuil (Mezzanine) Vasculitis: Factors that Influence Disease Patterns (070) Speaker: Gary S. Hoffman, MD identify anatomic landmarks for injection of the knee and ankle using joint prosthetics apply principles of joint aspiration and injection using ankle and knee joint prosthetics TUESDAY november 18, 2014 review advances in diagnosis and staging of vasculitis and updates on prognostic information of interest to clinicians and patients review advances in therapeutic intervention (including biologics) in the treatment of the systemic vasculitides such as granulomatosis with polyangiitis, cryoglobulinemic vasculitis and giant cell arteritis assess how to incorporate recent research data and practices into providing clinical care in the community for patients with vasculitis ACR/ARHP WORKSHO 7:45 9:45 am Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. 159 *Advanced Musculoskeletal Ultrasound: Image Optimization and Pathology Recognition (229) Speaker: Jay B. Higgs, MD use practical knowledge of ultrasound technology to improve image quality recognize common pathology patterns in musculoskeletal ultrasound 154 Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (232) Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard, DMSc, MD, PhD recognize the most common types of magnetic resonance images (as T1- and T2-weighted, fat-saturated, STIR and contrast-enhanced) and the appearance of the most common joint pathologies on these discuss the rationale and evidence for using magnetic resonance imaging in clinical practice identify the advantages and disadvantages of dedicated extremity magnetic resonance imaging ACR SESSIONS 8:30 10:00 am 253 B Bioenergetics and Energy Regulation Moderator: Antonio La Cava, MD, PhD describe the relationship between metabolism and apoptosis recognize the interactions between metabolism and activation of both the innate and adaptive immune response recognize the beneficial effects of reactive oxygen species 8:30 am Homeostatic Mechanisms of the Mitochondria Richard Siegel, MD, PhD 9:15 am Homeostatic Mechanisms of the Mitochondria Navdeep S. Chandel, PhD 161 Basic Statistical Concepts for the Medical Researcher (230) Speakers: Dorothy D. Dunlop, PhD and Jungwha Lee, PhD, MPH identify factors influencing sample size and power interpret confidence intervals, odds ratio and relative risk identify factors that confound study results 152 *Joint Injections (Knee, Ankle, Shoulder and Wrist) (231) Speakers: Jemima Albayda, MD and Pari Basharat, MD describe indications for lower extremity joint injection and aspiration 52 A CARE: Maintenance of Certification Session Three of Three Rheumatoid Arthritis All annual meeting scientific attendees will receive access to the CARE: MOC module on their ACR profiles. Successful completion of the 30 case-based question online module with a score of 70% or higher will enable submission to the ABIM to receive ten (10) medical knowledge points for the Maintenance of Certification program. Ten (10) rheumatoid arthritis questions will be covered at this session. Attendance at the session(s) is not required to participate in the online module. Moderator: Carol A. Langford, MD, MHS Speaker: Jonathan Kay, MD 110 2014 Program Book
scientific sessions assess strengths and weaknesses in rheumatology medical knowledge review the diagnosis, management and treatment of rheumatic diseases that are part of the ABIM s rheumatology MOC examination blueprint satisfy a self-evaluation of medical knowledge requirement for the ABIM MOC program 102 A Educator: Direct Observation of Clinical Skills: Educationally Indicated, Therapeutically Required Ed Pd PrM FIT Moderator: Kenneth S. O Rourke, MD Speaker: William Iobst, MD discuss the importance of direct observation for assessment of clinical skills summarize the status of evaluation skills describe strategies for direct observation and rater training methods 104 B Macrophages Gone Wild Ed Pd PrM FIT Moderators: Randy Q. Cron, MD, PhD and Karyl Barron, MD review the pathophysiology of macrophage activation syndrome recognize new classification criteria for macrophage activation syndrome discuss macrophage activation syndrome outside of the context of systemic juvenile idiopathic arthritis 8:30 am Inside the World of a Killer: Understanding the Pathogenesis of Macrophage Activation Syndrome Edward M. Behrens, MD 9:00 am Diagnosis of Macrophage Activation Syndrome in the Age of Biologics Angelo Ravelli, MD 9:30 am Macrophage Activation Syndrome Independent of Systemic Juvenile Idiopathic Arthritis Rayfel Schneider, MBBCh Ballroom East Myositis Mimics: Clinical and Molecular Diagnosis Moderator: Alan N. Baer, MD review muscle diseases which may mimic adult-onset polymyositis describe diagnostic features of a myopathy suggestive of a muscular dystrophy or metabolic myopathy create an approach to the diagnosis of unusual forms of myopathy that may mimic polymyositis 8:30 am Differential Diagnosis of Polymyositis Andrew L. Mammen, MD, PhD 9:15 am Molecular Diagnosis of Adult-Onset Muscular Dystrophy and Metabolic Myopathies Anthony A. Amato, MD 153 B Rheumatology Research Foundation Special Session: Disease Targeted Research Moderator: Anne Davidson, MBBS review functional differences among large numbers of fibroblast-like synoviocytes and determine if the differences are genetically determined describe how to use the blood level of high density lipoprotein as a powerful determinant for predicting risk for cardiovascular disease in patients with rheumatoid arthritis describe the role of innate immune receptors in osteoclast development and how they relate to bone loss during inflammation 8:30 am Synovial Fibroblast Phenotypes After Activation Bv TNF/lL-17 Michael B. Brenner, MD 9:00 am Dysfunctional High-Density Lipoprotein, Rheumatoid Arthritis and Cardiovascular Disease Subramaniam Pennathur, MD 9:30 am Regulation of Osteoclasts During Inflammation Julia F. Charles, MD, PhD Exhibit Hall C Risk and Risk Management of Cardiovascular Disease in Patients with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases define the clinical aspects and epidemiology of cardiovascular disease in systemic rheumatic diseases, particularly rheumatoid arthritis interpret mechanisms of cardiovascular disease in patients with rheumatoid arthritis generate pragmatic guidance for the evaluation and management of cardiovascular disease in patients with rheumatoid arthritis TUESDAY november 18, 2014 2014 Program Book 111
scientific sessions TUESDAY november 18, 2014 8:30 am Epidemiology of Cardiovascular Disease in Rheumatoid Arthritis and Other Rheumatic Diseases Sherine E. Gabriel, MD, MSc 9:00 am Cardio-Rheumatology: Approach to the Patient Anne Grete Semb, MD, PhD 9:30 am Which Tests Should Be Done and When? Sharon Mulvagh, MD ACR/ARHP POSTER SESSION C, Late- Breaking and THIEVES MARKET POSTERS AND POSTER TOURS 8:30 am 4:00 pm Poster presenters will be available from 9:00 11:00 am (abstracts # 1938 2780). Poster tours will be held 9:00 9:45 am and 10:15 11:00 am. Morning snacks will be available from 9:00 10:30 am. Poster Hall (Exhibit Hall B) Thieves Market Posters TM 8. Acute Onset of Headaches, Dysarthria, Vision Changes in a 17 y/o Male Angela Bryan, MD TM 9. Discharged but Not Better for Long Aixa Toledo-Garcia, MD TM 10. Masquerader of Adult Still s Michael Thomas Avery, DO TM 11. Refractory Knee Joint Swelling in a Patient With Systemic Lupus Erythematosus Minyoung Her, MD TM 12. The Thin Young Man -- Ed Oberle Edward J. Oberle, MD TM 13. Whispers of Disease Rikitha Menezes, MD Poster Hall (Exhibit Hall B) Guided Poster Tours Guided poster tours allow scientific attendees to ask questions and gain insights from some of the best-known rheumatology leaders. Tours are complimentary; however, registration is required and is limited to scientific attendees. If you preregistered for a tour, you should have received a ticket with your meeting materials. Once you have your ticket, check in at the tour desk 15 minutes prior to the start of your tour to receive your headset. Your reservation will be held only until five minutes prior to the start of the tour. After this time, your reservation is not guaranteed and may be released to standby attendees. If you did not pre-register, tickets may be available in the registration area (Exhibit Level: East Registration). Alternatively, you may go directly to the poster tour desk and wait for a standby ticket. Standby tickets will be assigned on a first-come, first-served basis five minutes prior to the start of each tour. Each tour participant will receive a wireless headset which will be registered against the participants registration ID. Participants will be charged $50 if the headset is not returned within 15 minutes of the end of the tour. 9:00 9:45 am Osteoarthritis Clinical Aspects Poster Tour (325) Tour Guide: Grace H. Lo, MD, MSc Quality Measures and Quality of Care Poster Tour (326) Tour Guide: Gabriela Schmajuk, MD, MS Rheumatoid Arthritis: Clinical Aspects Poster Tour (327) Tour Guide: Inmaculada Del Rincon, MD, MSc Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy Poster Tour (328) Tour Guide: Joseph A. Markenson, MD Spondyloarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour (329) Tour Guide: Philip Mease, MD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics (330) Tour Guide: Laura K. Hummers, MD, ScM 10:15 11:00 am Epidemiology and Health Services Research Poster Tour (331) Tour Guide: Kaleb Michaud, PhD Health Services Research Poster Tour (332) Tour Guide: Salahuddin Kazi, MD, PhD Rheumatoid Arthritis: Human Etiology and Pathogenesis Poster Tour (333) Tour Guide: David S. Pisetsky, MD, PhD Rheumatoid Arthritis Treatment Small Molecules, Biologics and Gene Therapy Poster Tour (334) Tour Guide: Jonathan Kay, MD Rheumatology 360 Poster Tour (335) Tour Guide: Eric L. Matteson, MD Spondyolarthropathies and Psoriatic Arthritis: Clinical Aspects and Treatment Poster Tour (336) Tour Guide: John D. Reveille, MD 112 2014 Program Book
scientific sessions ACR SESSIONS 9:00 10:00 am ARHP SESSIONS 9:00 10:00 am 107 B ACR-EULAR Polymyalgia Rheumatica Guidelines Moderators: Steven E. Carsons, MD and Andy Abril, MD review the approach to polymyalgia, the relevant investigations, differential diagnosis and overlap with other conditions, classification criteria review Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology and available evidence for polymyalgia rheumatica therapies, prognostic factors, values and preferences of patients and professionals on polymyalgia rheumatica review ACR-EULAR polymyalgia rheumatica treatment guidelines including glucocorticoids, disease modifiers, biologic agents and future research agenda and clinical trials 9:00 am Polymyalgia: What Does It Mean? Bhaskar Dasgupta, MD 204 A Mycobacterium Infections in Immunocompromised Patients Moderator: Susan Richmond, MS, PA-C recognize the risk of non-tuberculosis mycobacterium infection in immunosuppressed patients evaluate tuberculosis risk factors in immunosuppressed patients and recognize the need to maintain vigilance for tuberculosis during treatment with immunosuppressants review available screening tests, including the Tuberculin Skin Test, Quantiferon-Gold and TB-spot 9:00 am Evaluating Tuberculosis Risk in Immunocompromised Patients Lisa Shelton, BSc, BSN, RN 9:15 am Mycobacterium Infections in Immunocompromised Patients Kevin L. Winthrop, MD, MPH 9:20 am Polymyalgia Rheumatica: Grading the Evidence Christian Dejaco, MD, PhD 9:40 am Polymyalgia Rheumatica: Treatment Guidelines and Next Steps Eric L. Matteson, MD, MPH 156 B Metainflammation Speaker: Gökhan S. Hotamisligil, PhD, MD review metabolic aspects of inflammation discuss metabolic pathways 210 B Rheumatology Research Foundation Oscar S. Gluck Memorial Lectureship: Emerging Therapies in Bone Diseases: Cellular Basis and Challenges Moderator: Michael Maricic, MD Speaker: Roland Baron, DDS, MD review the mechanisms regulating bone homeostasis and the process of bone remodeling evaluate the effects of anti-resorptive and osteo-anabolic drugs and the differences between them review the mode of action and anticipated effects of molecules currently in development for the treatment of osteoporosis 157 B RheumChat Moderator: Afton L. Hassett, PsyD describe the newest science and the oldest debates in the field of pain research describe a potential means by which autoimmune disorders may be cured discuss the intersection of research and clinical care in the context of history, health policy and technology 9:00 am Pain! Sean Mackey, MD, PhD 9:12 am Jumping Across the Knowledge Gap: The Roles of Significance and Innovation in Rheumatology Research Marian T. Hannan, DSc, MPH 9:24 am It s Time that We Started to Talk About Cure in Severe Autoimmune Disease Troy R. Torgerson, MD, PhD 9:36 am Did We Care More When We Knew Less? Andrew A. Guccione, DPT, PhD TUESDAY november 18, 2014 2014 Program Book 113
scientific sessions TUESDAY november 18, 2014 259 A Stats Boot Camp: The Prevalence Ratio as an Alternative to the Odds Ratio for Cross-Sectional Studies Moderator: Alyssa B. Dufour, PhD review when to use the prevalence ratio and when to use the odds ratio recognize with the regression models that can generate the prevalence odds ratio explain the methodological issues that may arise when estimating prevalence ratios analyze data using the prevalence ratio with popular statistical packages 9:00 am Regression Models for Prevalence Ratios Kamil E. Barbour, PhD 9:30 am Examples of the Prevalence Ratio vs. the Odds Ratio in Rheumatology Research Yvonne M. Golightly, PT, MS, PhD EXHIBITS 10:00 am 2:30 pm Exhibit Hall A Join your colleagues in the Exhibit Hall for morning refreshments from 10:00 11:00 am. (Booths #139 and #1401) Innovation Theater A and B Non-CME accredited presentations have been planned and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. Innovation Theater A presentations will be held from 10:30 11:15 am and 12:30 1:15 pm. Innovation Theater B presentations will be held from 11:30 am 12:15 pm and 1:30 2:15 pm. For a complete listing of Innovation Theater presentations, see page 238. ACR WORKSHO 10:30 am 12:30 pm Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. 159 161 154 Musculoskeletal Ultrasound (233) Speakers: Eugene Y. Kissin, MD and Amy M. Evangelisto, MD demonstrate how to properly position the ultrasound transducer to visualize targeted musculoskeletal structures based on an understanding of the local bony landmarks differentiate tissue types based on their ultrasound properties recognize the ultrasound appearance of some of the basic musculoskeletal pathologies Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (234) Speaker: Anthony Chang, MD identify the pathologic changes that occur in lupus nephritis discuss the pathologic basis for the classification of lupus nephritis and how it relates to clinical management describe the histological changes in the kidneys of patients with vasculitis X-Ray Challenges in Rheumatic Diseases (235) Speaker: Donald J. Flemming, MD describe the potential causes and exacerbating factors of the disease discuss the appropriate use of laboratory testing and imaging modalities design an efficacious, safe and cost-effective therapeutic strategy ACR SESSIONS 11:00 am Noon 253 B Mesenchymal Stem Cells: Biology and Use in Rheumatic Diseases Moderator: Dana P. Ascherman, MD Speaker: Paolo Bianco, MD review the biology of MSCs and differences from hematopoietic stem cells (HSCs) appraise anti-inflammatory versus remodeling properties associated with MSCs define limitations in pre-clinical models, barriers in clinical application 104 B Protecting Bone Health in Pediatric Rheumatic Diseases Ed Pd PrM FIT Moderators: Stacy P. Ardoin, MD, MS and Kelly A. Rouster- Stevens, MD, MS Speaker: Jon M. Burnham, MD, MSCE 114 2014 Program Book
scientific sessions evaluate threats to bone health in children with rheumatic diseases review effects of rheumatic diseases and their therapies on bone density, structure, strength and fracture risk describe best practices for bone health monitoring and preventive measures, such as calcium and vitamin D supplementation and bisphosphonate use ARHP SESSIONS 11:00 am Noon explain the characteristics of rheumatology practices with and without mid-level providers in the scope of the treat-to-target concept discuss the research that has been done in regards to midlevel providers in rheumatology practice describe the role of a mid-level provider in rheumatology care 11:00 am Study Comparing Practices with and without Midlevel Providers Daniel H. Solomon, MD, MPH 257 A Immunology Boot Camp III: Applying Principles of Immunology to Treatment Decisions Eth Moderator: Barbara A. Slusher, PA-C, MSW Speaker: Troy R. Torgerson, MD, PhD 255 256 compare several biologic treatment options for active rheumatoid arthritis differentiate existing treatment options for systemic lupus erythematosus when hydroxychloroquine is not enough discuss how psoriasis and psoriatic arthritis differ from rheumatoid arthritis when anti-tnfs fail to control active inflammation examine treatment considerations for refractory myopathies Pathways to Resilience: Biopsychosocial Mechanisms for the Generation of Positive Affect in Chronic Pain Moderator: Donah Z. Crawford, BS, MA discuss the state of the science on positive emotions and pain determine the mechanistic links between dopaminergic neurotransmission, reward-related behaviors and coping with chronic pain introduce the role of social relations in pain adaptation and a promising new intervention in social intelligence that may build social resourcefulness among patients with chronic pain 11:00 am Mechanisms of Positive Emotion and Reward in Chronic Pain Patrick Finan, PhD 11:30 am The Importance of Social Relations in Positive Emotion and Resilience to Chronic Pain Alex Zautra, PhD Providing Evidence for Mid-Level Providers in Rheumatology Practice Moderator: Kori A. Dewing, DNP, ARNP 11:15 am The Role of Mid-level Providers in Rheumatology Care Benjamin J. Smith, PA-C ACR PLENARY SESSION III DISCOVERY 2014 11:00 am 12:30 pm Exhibit Hall C ACR Plenary Session III: Discovery 2014 Moderators: John Varga, MD and Mary K. Crow, MD 11:00 am 2781. Cost-Effectiveness of Adding Etanercept Vs. Sulfasalazine and Hydroxychloroquine to Methotrexate Therapy: A Randomized Noninferiority Trial Nick Bansback, University of British Columbia, Vancouver, BC Background/Purpose: To estimate the incremental costeffectiveness of etanercept plus methotrexate versus a triple regimen of disease-modifying anti rheumatic drugs (methotrexate, sulfasalazine and hydroxychloroquine) over 24 weeks and 48 weeks in patients with active rheumatoid arthritis despite methotrexate therapy (RACAT). Methods: In this double blind, noninferiority trial 353 patients were randomized to etanercept plus methotrexate or a triple regimen. After 24 weeks of treatment patients not achieving a DAS28 improvement of 1.2 were switched in a blinded fashion to the other therapy. Quality Adjusted Life Years (QALYs) were estimated using US societal values from the EQ-5D instrument which was measured every 24 weeks. Costs of drugs, hospitalizations, procedures, tests, visits and lost productivity were prospectively tracked and monetized from a societal perspective in 2014 US dollars. Incremental costeffectiveness ratios were calculated using standard procedures assuming an intent-to-treat analysis, with missing data analyzed using multiple imputation and uncertainty assessed using bootstrapping. Results: Both strategies showed significant improvements in EQ-5D, with etanercept providing marginally more accumulated QALYs (0.358 vs 0.354 over 24 weeks and 0.742 vs 0.726 over 48 weeks for etanercept and triple regimen strategies respectively). The etanercept strategy accumulated substantially higher drug costs even considering the switches between treatments at 24 weeks ($11,286 vs $369 cumulative costs from 0 to 24 weeks and $19,625 vs $3,721 cumulative costs from 0 to 48 weeks for 2014 Program Book 115 TUESDAY november 18, 2014
scientific sessions etanercept and triple regimen respectively). The differences in other health care and productivity costs across strategies were negligible. The resultant incremental cost-effectiveness ratios for etanercept vs. triple regimen were $2.7 million/qaly (95%CI 0.87 to ) gained over 24 weeks and $0.95 million/qaly (95%CI 0.41 to ) over 48 weeks. Conclusion: This economic evaluation based on a prospective tracking of resource use and QALY measurement in a blinded, randomized trial demonstrates that the additional costs associated with using etanercept prior to a triple regimen does not provide good value for money at generally acceptable willingness to pay thresholds. A limitation of the study is its short time frame. However, even when considering the long-term perspective, since the incremental benefits are so small, even under the most optimistic scenarios imaginable, etanercept has only a small probability of being cost-effective compared to triple therapy. Given the opportunity cost associated with all health care spending, adapting a triple regimen prior to etanercept would free up scarce health dollars for use on alternative health care interventions that provide greater health benefits. 5 ACPAs were reverted to the germ line sequences and the corresponding antibodies were also expressed for the above tests. Results: The relative frequencies of circulating plasmablasts were significantly higher in RA patients than in healthy donors ( p = 0.0015). About 19.5% of circulating plasmablast-derived recombinant antibodies from CCP-positive RA patients, but none from the CCP-negative RA patient or healthy donors, specifically recognized citrullinated RA autoantigens ( p = 0.0001). The immunoglobulin genes encoding these ACPAs were highly mutated with increased replacement/silent mutation ratios, suggesting that the generation of ACPAs involved active antigen selection. Interestingly, 63% of these ACPAs cross-reacted with the outer membrane antigens and/or citrullinated enolase from P. gingivalis. Germ-line reversions of some ACPAs completely eliminated their reactivity to citrullinated RA autoantigens but retained their reactivity to P. gingivalis antigens. Conclusion: These results suggest that circulating plasmablasts in RA patients produce ACPAs and this process may be, in part, initiated by the anti-p. gingivalis immune responses. Disclosures: S. Li, None. TUESDAY november 18, 2014 Disclosures: N. Bansback, None. 11:15 am 2782. Autoantibodies from Single Circulating Plasmablasts React with Citrullinated Antigens and Porphyromonas Gingivalis in Rheumatoid Arthritis Song Li, University of Nebraska Medical Center, Omaha, NE Background/Purpose: Anti-citrullinated protein antibodies (ACPAs) are highly specific for rheumatoid arthritis (RA) and also believed to play a pathogenic role in RA. Porphyromonas gingivalis (P. gingivalis), a Gram negative oral pathogen associated with periodontitis, has long been speculated as a trigger for the anti-citrulline autoimmune responses in RA patients. However, the detail relation between ACPA and P. gingivalis is still unclear. Methods: In this study, we made 195 recombinant monoclonal antibodies from anti-cyclic citrullinated peptide (CCP)-positive RA patients (N=6), 23 recombinant monoclonal antibodies from CCP-negative RA patients (N=1) and 110 recombinant monoclonal antibodies from healthy controls (N=4) using a single cell-based antibody cloning approach. All the 7 RA patients satisfied the 2010 ACR classification criteria. Monoclonal ACPAs were determined by commercial anti-ccp test and fine specificity with 3 synthesized citrullinated peptides. Cross-reactivity of ACPA to P. gingivalis was tested by ELISA against P. gingivalis outer membrane protein and citrullinated peptide from P. gingivalis enolase. Immunoglobulin genes of 11:30 am 2783. Effect of Synovitis, Effusion and Bone Marrow Lesions on Development of Sensitization in Knee OA: The Multicenter Osteoarthritis Study Tuhina Neogi, Boston University School of Medicine, Boston, MA Background/Purpose: Alterations in the peripheral and central nervous systems including sensitization are thought to play an important role in the pain experience in knee OA. While sensitization could occur due to an underlying predisposition, it is hypothesized that joint inflammation and/or tissue injury in OA could provide sufficient peripheral nociceptive input to cause sensitization. We previously reported that radiographic knee OA severity or duration do not appear to be related to sensitization. However, whether specific MRI lesions related to inflammation (e.g., synovitis, effusion), or mechanical load or remodeling related to noninflammatory tissue injury (e.g., bone marrow lesions (BMLs)) are risk factors for development of sensitization is not yet known. Methods: The Multicenter Osteoarthritis (MOST) Study is a NIHfunded longitudinal cohort of persons with or at risk of knee OA. Subjects had x-rays and MRIs (1.0 T) of each knee obtained at each study visit and a standardized somatosensory evaluation of mechanical temporal summation and pressure pain thresholds (PPT) at the patella at 60- and 84-months. Temporal summation was defined by increased pain during repeated mechanical stimulation (1 Hz x 30-sec) with a 60g monofilament. PPT was assessed with an algometer (1 cm2 tip, 0.5 Kg/sec) as the point at which the subject felt the pressure change to slight pain. Lower PPT indicates more sensitivity. Synovitis, effusion and BMLs on MRIs were scored using WORMS (one knee per person); these lesions were considered to be present if their score was 1 in any subregion. In sensitivity analyses, we assessed the sum of BML scores across all knee subregions as a measure of BML burden. We assessed the relation of presence of synovitis, effusion and BMLs at 60-mo to incident temporal 116 2014 Program Book
scientific sessions summation in the same knee at 84-mo among those who did not have temporal summation at 60-mo and to change in PPT in the same knee between 60- and 84-mo in the whole sample using logistic and linear regression, respectively, adjusted for relevant potential confounders, including OA severity. Results: There were 1111 subjects (mean age 66.9, mean BMI 29.7, 62% female) in the whole sample. 22.6% developed incident temporal summation at the 84-mo visit and the range in change of PPT between the 60- and 84-mo visits was -7.35 to 7.15 kg/cm2. Presence of synovitis was associated with a significant decrease in PPT (i.e., more sensitized) over 24 mo, while effusion was significantly associated with incident temporal summation (Table). BML presence or burden were not associated with temporal summation or PPT. Conclusion: Inflammation, as evidenced by synovitis or effusion, may drive the occurrence of sensitization in knee OA. In contrast, BMLs do not appear to contribute to sensitization in knee OA. Early targeting of inflammation in knee OA may be a reasonable strategy to test for its ability to prevent occurrence of sensitization, thereby reducing pain severity in knee OA. MRI Lesion at 60-mo Presence of synovitis Presence of effusion Presence of BMLs Sum of BMLs ( BML burden ) (per unit increase) Incident Temporal Summation at 84-mo (N=716) Prevalence of MRI Lesion 62% 67% 79% Range: 0-19 Adjusted* OR (95% CI) 1.12 (0.75, 1.66), p=0.6 1.54 (1.01, 2.36), p=0.04 0.92 (0.56, 1.49), p=0.7 1.00 (0.92, 1.07), p=0.9 Change in PPT (60- to 84-mo) (N=1111) Prevalence of MRI Lesion 60% 66% 79% Range: 0-19 Adjusted* Beta (95% CI) -0.30 (-0.52, -0.08), p=0.01-0.04 (-0.28, 0.19), p=0.7 0.03 (-0.25, 0.31), p=0.8-0.01 (-0.05, 0.04), p=0.8 * Analyses adjusted for age, sex, BMI, clinic site, race, catastrophizing, depressive symptoms, widespread pain, KL grade Disclosures: T. Neogi, None. 11:45 am 2784. Contribution at the Spinal Level of Innate and Adaptive Immunity to the Development of Persistent Post-Inflammatory Mechanical Allodynia in Arthritic Mice Sarah Woller, UCSD, La Jolla, CA Background/Purpose: Individuals with arthritis frequently develop persistent pain despite adequate treatment of synovitis. There is a need to better understand the mechanisms underlying pain occurring with arthritis. Recently, it has been shown that Toll-like receptor 4 (TLR4) mediates the transition from acute to chronic pain in a murine model of arthritis. Rather than developing persistent pain, animals deficient in TLR4 showed an attenuation of the late phase of pain. This receptor is unique in signaling through both MyD88-dependent and independent pathways. In order to further understand the role of TLR signaling, we examined the development of arthritis and persistent pain in mice deficient in these adaptor proteins. Methods: Adult arthritic K/BxN mice were bled and the sera pooled. 100μl of the pooled sera was injected into recipient mice on Days 0 and 2. Clinical arthritis scores and mechanical reactivity, using the up-down method of von Frey testing, were assessed over a period of 28 days in male C57Bl/6, Tlr4-/-, Triflps2, Myd88-/-, Tnf-/- and Ifnar1-/- mice. Spinal cords were collected from WT and Tlr4-/- arthritic mice and changes in gene expression were measured using nanostring ncounter analysis. Behavioral data were analyzed using repeated measures ANOVAs and Duncan New Multiple Range post-hoc analyses when appropriate. Results: As shown previously, WT mice develop a persistent increase in mechanical reactivity that outlasts the period of inflammation; the 50% withdrawal thresholds dropped from 1.66 at baseline to 0.74 on day 28. In addition, Tlr4- /- mice develop an initial increase in reactivity, which resolves concurrent with inflammation (WT AUC 13.2 and TLR4 AUC 9.7, p<.05). MyD88 and TRIF play distinct roles in the development of pain: mice lacking MyD88 do not develop swelling or allodynia (AUC 2.6, p<0.01), while those deficient in TRIF develop a prolonged allodynia (AUC 12.2), similar to WT animals and outlasting the period of inflammation. NanoString ncounter analysis of 516 immune genes in the spinal cords of WT and Tlr4-/- mice harvested on Day 10 of arthritis showed differences in expression levels of IL2, RANKL, IFNβ and TNF transcripts. Therefore, we also examined the development of pain resulting from arthritis in Rag1-/-, Ifnar1-/- and Tnf-/- mice. In the Tnf-/- mice there was an attenuated development of pain (AUC 8.0, p<.001), the Rag1 (10.0, p<.05) mice developed pain, which resolved with the resolution of inflammation similar to Tlr4-/- mice and Ifnar1-/- mice developed pain that was not different than the WT mice (AUC 12.2). Conclusion: These results suggest that pain can persist after resolution of inflammation. The innate and adaptive immune systems appear to have distinct roles in the development of the chronic pain state and this pain cannot be attributed solely to increased TNF or IFNβ transcription. Disclosures: S. Woller, None. Noon 2785. Joint Specific Positional Differences in Coding and Noncoding Transcriptome of Synovial Fibroblasts As a Determinant of the Susceptibility of Synovial Joints to Rheumatoid Arthritis Caroline Ospelt, Center of Experimental Rheumatology, University Hospital Zurich, Zurich, Switzerland Background/Purpose: The molecular mechanisms underlying the topographic differences in the susceptibility of synovial joints to develop rheumatoid arthritis (RA) are unknown. Positional embryonic expression of Hox genes along proximaldistal and anterior-posterior body axes is critical for proper limb development. Adult skin fibroblasts retain the positional embryonic Hox code and exhibit major anatomic differences in their transcriptome, defining their unique positional identities. Synovial fibroblasts (SF) in the joints of RA patients drive joint destruction and inflammation locally. We hypothesized that SF from different joints show a joint specific, positional gene expression pattern, which can predispose joints to develop certain types of arthritides, like RA or osteoarthritis (OA). Methods: SF were derived from knees, shoulders and metacarpophalangeal joints (MCPs) of RA and OA patients (n=9 each) undergoing joint replacement surgery. SF were obtained TUESDAY november 18, 2014 2014 Program Book 117
scientific sessions TUESDAY november 18, 2014 also from front paws, ankles and knees of wildtype (wt) and TNF transgenic (TNFtg) mice (n=7 each). Total RNA was extracted and RNA sequencing was performed with the Illumina HiSeq 2000 sequencing system followed by hierarchical clustering. Functional annotation clustering of mrnas was done using Database for Annotation, Visualization and Integrated Discovery (DAVID). Positionally expressed RNAs were validated by qpcr. Results: Unsupervised hierarchical cluster analysis showed clustering of SF according to anatomic joint localization rather than disease. The positional embryonic HOX code was retained in SF, clearly differentiating between different joints. Among the Hox cluster residing long noncoding RNAs, HOTTIP was expressed in distal, MCP-derived SF and HOTAIR in posterior, knee-derived SF. Several positionally expressed mrnas, e.g.hoxc8 and HOXD13, were differentially expressed in MCP-derived RA and OA SF. DAVID analysis showed positional enrichment of GOTERM limb development, anterior/posterior patterning, cartilage development, extracellular region part, cell adhesion, regulation of transcription. While some outliers where found when clustering was based on mrna expression, clustering of SF into knee, shoulder and MCPs was perfect when based on mir expression. For example, mir-24 was positionally expressed in shoulder, mir-34c in MCP and mir-137 in kneederived SF, irrespective of disease. The positional expression of these mirs was confirmed in wt and TNFtg mice. Interestingly, mir-204 and mir-146a were positionally expressed in MCPs of OA but not of RA patients. These mirs were indeed positional also in wt mice but their MCP specific expression in humans correlated to ankle specific expression in wt mice. In addition, their expression was significantly changed in ankles of TNFtg compared to wt mice. Conclusion: SF from joints of different anatomic sites exhibit particularly different mrna and mir expression patterns suggesting that functionally unique subsets of SF populate different joints. The existence of positionally imprinted risk signatures of SF may account for the susceptibility of certain synovial joints to develop RA in humans and mice and may have major implications for synovial disease pathways operating early in RA. Disclosures: C. Ospelt, IMI BTCure, EuroTEAM, IAR, CABMM start-up grant, 2. 12:15 pm 2786. Aortitis: Outcomes from a Cohort of 196 Patients Alison Clifford, Cleveland Clinic Foundation, Cleveland, OH Background/Purpose: Idiopathic aortitis is a rare diagnosis that may occur in the context of a primary systemic vasculitis, as part of a systemic autoimmune disease, or in isolation. In patients with focal isolated aortitis (FIA), surgery alone may be curative; however, new vascular lesions have been reported to develop in between 5-47% of cases. The risk of progression to systemic disease and optimal management strategy for FIA patients is uncertain. Methods: Patients with biopsy-proven aortitis, diagnosed following thoracic aortic surgery at the Cleveland Clinic between 1996 and 2012, were retrospectively reviewed. Patients were classified into clinical subgroups [Giant cell arteritis (GCA), Takayasu s arteritis (TAK), Focal Isolated Aortitis (FIA) or Other] at the time of surgery using pre-defined criteria. Symptoms, pathology, laboratory and imaging results were recorded at surgery and over time using a standardized database. Patients with FIA at surgery were followed for progression to systemic disease and outcomes of clinical subgroups were compared. Results: Of 7,551 patients who underwent thoracic aortic surgery between 1996-2012, 196 patients with biopsy-proven aortitis were identified for review. Median age at surgery was 69 years (range 15-88) and 67% were female. At the time of surgery, 129 (65.8%) patients met criteria for FIA, 42 (21.4%) for GCA, 14 (7.1%) for TAK and 11 (5.6%) for Other. A minimum of 6 months of clinical follow-up was available for 73 FIA patients. During follow-up (median 45 months, range 6-201 months), 14/73 (19.2%) FIA patients developed symptoms of systemic disease, 17/40 (42.5%) developed elevated inflammatory markers, 29/65 (44.6%) developed new vascular lesions on imaging, 30/73 (41.1%) required a second vascular surgery, 7(9.6%) dissected and 9 died (12.3%.) Ultimately 23 of 73 (31.5%) with FIA progressed to have features of a systemic disease: 21 GCA, 1 TAK and 1 Other. When compared to patients with known systemic disease at surgery, patients with FIA were less likely to develop symptoms (p=0.01) but no different with respect to development of elevated inflammatory markers (p=0.19), new vascular lesions by imaging (p=0.92), need for further vascular surgery (p=0.84), dissection (p=0.40) or death (p=0.76) over time. Only 12 patients with FIA at surgery received immunosuppressive therapy post-operatively. Over time, 0/11 treated FIA patients with follow-up imaging developed aneurysms, but 2 (18.2%) developed new stenoses. Among the 54 untreated FIA patients with imaging available, 27 (50%) developed new lesions (23 aneurysms and 5 stenoses.) Additional tissue obtained after subsequent surgery in 2 untreated FIA patients revealed persistent inflammation in the distal aorta. Conclusion: Over time, nearly one third of patients classified as FIA at the time of surgery progressed to have features of a systemic autoimmune disease. Patients with FIA are less likely to develop overt symptoms, but equally likely to develop elevated inflammatory markers or new vascular lesions on imaging when compared to GCA, TAK and Others. These patients require regular clinical follow-up and serial imaging to assess for progression. Disclosures: A. Clifford, None. ACR MEET THE PROFESSOR SESSIONS 12:45 2:15 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. 118 2014 Program Book * Sessions denoted with an asterisk were sold out as of August 30.
scientific sessions Westin Paine (Lobby) Antiphospholipid Syndrome (071) Speaker: Doruk Erkan, MD review the spectrum of antiphospholipid syndrome explain the diagnostic utility of antiphospholipid antibody tests discuss the management of persistently antiphospholipid antibody-positive patients with different antiphospholipid antibody-related clinical manifestation Westin Otis (Lobby) *Challenging Cases in Osteoporosis Management (072) Speaker: Kenneth G. Saag, MD, MSc recognize bisphosphonate drug holidays discuss timing of use of various anti-osteoporosis therapies in postmenopausal osteoporosis recognize current treatment approaches to steroid-induced osteoporosis identify other forms of metabolic bone disease that present to rheumatologists as low bone mass Westin Stone (Lobby) Osteoarthritis: Update 2014 (075) Speaker: Joanne M. Jordan, MD, MPH describe the pathogenesis of osteoarthritis including factors that lead to its development and the underlying biology responsible for the progression of osteoarthritis discuss advances in the management of osteoarthritis that include non-pharmacologic interventions evaluate the potential benefits of new disease- or structuremodifying treatments for osteoarthritis Westin Webster (Lobby) *Psoriatic Arthritis (076) Speaker: Philip Mease, MD discuss advances in understanding of the pathogenesis of psoriatic arthritis and implications for diagnosis and treatment learn the value of and how to accomplish a treat-to-target approach to psoriatic arthritis in daily practice appraise the data on current and emerging treatments for psoriatic arthritis, including ustekinumab, apremilast, IL-17 inhibitors and other emerging agents Westin Hancock (Lobby) Crystal: Diagnosis and Management of Gout (073) Speaker: John S. Sundy, MD, PhD discuss the pathogenesis and pathophysiology of acute and chronic gout, including the distinctive treatment modalities affecting patient outcomes appreciate the renal mechanisms underlying the hyperuricemia of most gout patients and therapeutic rationales applied to urate-lowering therapies critically assess current ACR recommendations for the treatment of acute and chronic manifestations of gout Westin Revere (Lobby) Non-Surgical Treatments for Osteoarthritis (074) Speaker: David T. Felson, MD, MPH explain how to measure the relative efficacy of treatments using effect sizes illustrate knowledge of data supporting efficacy of exercise, bracing, glucosamine, intra-articular steroids and hyaluronic acid in osteoarthritis identify pros and cons of treatments modifying knee biomechanics for knee osteoarthritis including braces, orthotics, the All Phases of Step-cycle system and others assess emerging treatments for osteoarthritis such as nerve growth factor inhibitors and where they may fit in the therapeutic armamentarium Westin Adams (Mezzanine) Spondyloarthropathy: An Update (077) Speaker: Robert D. Inman, MD identify the challenge in the early diagnosis of spondyloarthritis discuss mechanisms of disease pathogenesis describe current treatment options for spondyloarthritis Westin Alcott (Mezzanine) *Systemic Lupus Erythematosus: Lupus Nephritis (078) Speaker: Brad H. Rovin, MD review immunosuppressive therapy of lupus nephritis Classes II-V, including novel biologics discuss the use of renoprotective and anti-proteinuria therapies in lupus nephritis discuss diagnosis and treatment of renal thrombotic microangiopathy and podocytopathies outline the future research agenda for clinical trials in lupus nephritis Westin Douglas (Mezzanine) Temporal Arteritis (079) Speaker: Robert F. Spiera, MD discuss current concepts in the diagnosis of temporal arteritis including use of imaging modalities identify evolving concepts of the treatment of temporal arteritis including the appropriate use of glucocorticoids and the efficacy of steroid sparing agents TUESDAY november 18, 2014 2014 Program Book 119
scientific sessions describe the relationship between temporal arteritis and polymyalgia rheumatica outline current concepts of the pathogenesis of temporal arteritis Westin Faneuil (Mezzanine) Vaccinations for Patients on Biologic Therapies (080) Speaker: Kevin L. Winthrop, MD, MPH recognize the importance of appropriate vaccinations in patients with autoimmune disease identify the different types of immunizations especially those which are live viruses describe the effect of different classes of immunomodulatory medications on vaccine efficacy and safety ACR SESSIONS 1:00 2:00 pm Ballroom East Clinical Issues Associated with the Use of Methotrexate Moderator: Mary E. Cronin, MD review the pharmacology of methotrexate discuss rational prescription of methotrexate as a solo agent or in combination therapy identify side effects and their prevention and/or treatment 1:00 pm Clinical Issues Associated with the Use of Methotrexate Joel M. Kremer, MD 253 B New Regulatory T Cells Moderators: George C. Tsokos, MD and Amit Golding, MD, PhD Speaker: Harvey Cantor, MD describe the two major T cell subsets that mediate regulatory activity summarize evidence for the contribution of Treg to selftolerance summarize evidence that defective Treg activity may contribute to autoimmune disease 210 B Uncovering the Role of Connective Tissues in Chronic Low Back Pain: From Bedside to Bench to Bedside Moderators: Tuhina Neogi, MD, PhD and Kerry Stone, MD Speaker: Helene Langevin, MD identify the different types of specialized and general connective tissues that may be of relevance for musculoskeletal pain describe the alterations in connective tissue functioning found in chronic low back pain and recognize the potential roles of inflammatory and fibrotic pathways in alterations of these connective tissues develop scientific rationale for why certain physical therapy and exercise approaches may be beneficial for chronic low back pain ARHP SESSIONS 1:00 2:00 pm TUESDAY november 18, 2014 1:30 pm Clinical Issues Associated with the Use of Methotrexate Michael E. Weinblatt, MD Exhibit Hall C Hench Lectureship: Why Steroids Work in Some Inflammatory Diseases but Not in Others Moderator: John M. Davis III, MD, MS Speaker: Peter Barnes, DM, DSc review how inflammatory genes are activated through histone acetylation appraise how corticosteroid suppress inflammation by engaging histone deacetylase-2 describe how oxidative stress induces corticosteroid resistance by inactivating HDAC2 review how this steroid resistance mechanism may be reversed, leading to new therapeutic approaches 255 Etiology and Management of Peripheral Neuropathy in Patients with Rheumatic Disease Moderator: Jennifer L. Trizuto, MPT Speaker: Charles E. Argoff, MD describe the various causes for neuropathy evaluate the treatment options available for treatment of neuropathy discuss neuropathic signs and symptoms in the context of various rheumatic diseases 257 A Pharmacotherapy: What s New in Rheumatology Moderator: Joan C. McTigue, PA-C, MS Speaker: Susan Bruce, PharmD critique the evidence of triple therapy vs. early aggressive biologic therapies for arthritis in light of treat-to-target guidelines 120 2014 Program Book
scientific sessions explain the mechanism of action of the new kinase inhibitors and recognize where the new oral agent tofacitinib fits in the current armamentarium of therapies examine existing and emerging treatment options for systemic lupus erythematosus ACR STUDY GROU 1:00 2:00 pm Study Groups are non-cme activities open to all attendees. 109 A ACR-EULAR Study Group: Toward a New Understanding of Myositis Through International Collaboration 1:00 pm Development of Transatlantic Registry Studies in Myositis Ingrid E. Lundberg, MD, PhD 1:30 pm New Insights into the Biology of Myositis Ann M. Reed, MD 107 B Autoantibodies in Diagnosis and Follow-Up of Rheumatic Diseases Study Group 1:15 pm Oral Health in Behçet s Disease Pathogenesis Haner Direskeneli, MD 1:30 pm Epidemiology of Behçet s Disease Alfred Mahr, MD, PhD 1:45 pm Biologics in the Treatment of Behçet s Disease: Which and When? Ina Kotter, MD, PhD 157 B Biosimilars in Rheumatology: Update Study Group 1:00 pm Introduction Morton A. Scheinberg, MD, PhD 1:10 pm Biosimilars in Asia: Where We Are Arvind Chopra, DNB, MBBS, MD 1:35 pm Biocopies and Biosimilars: Concerns and Risks Jonathan Kay, MD 1:00 pm IgG4-related Disease: Historical Background and Clinical Spectrum Hiroki Takahashi, MD 1:30 pm IgG4-related Disease: Pathophysiology and Diagnostic Challenges John H. Stone, MD, MPH 160 B Behçet s Disease Study Group assess epigenetic mechanisms and recent advances that implicate dynamic epigenetic changes during the course of Behçet s disease discuss recent data related to oral health and its effect on prognosis discuss epidemiology, genetic susceptibility factors and potential non-genetic risk determinants review the existing data of biological treatment options and management recommendations for Behçet s disease patients with severe ocular manifestations or treatment resistant symptoms 1:00 pm Epigenetics in Behçet s Disease Amr H. Sawalha, MD 151 A Closing the Gap Psoriasis to Psoriatic Arthritis Study Group 1:00 pm Review the Current Evidence of Predictors of Psoriasis Patients to Develop Psoriatic Arthritis Joseph F. Merola, MD and Vinod Chandran, MBBS, MD, DM, PhD 1:24 pm Identify Strategies to Detect Psoriatic Arthritis Earlier in Its Disease Course (Clinical Presentation, Biomarkers, or Imaging) Christopher T. Ritchlin, MD, MPH 1:36 pm Optimization of Screening Methods for Psoriatic Arthritis M. Elaine Husni, MD, MPH and Abrar A. Qureshi, MD, MPH 254 A Global Musculoskeletal Health Initiatives Study Group 1:00 pm Need for Standardized Surveillance Tools for Prevalence and Impact - Variations between International Surveys Lyn March, MBBS, MSc, PhD 1:12 pm Healthcare Quality Indicators to Enable Equity of Care Ingemar F. Petersson, MD, PhD TUESDAY november 18, 2014 2014 Program Book 121
scientific sessions TUESDAY november 18, 2014 1:24 pm Indicators of Equity of Care Francis Guillemin, MD, PhD 1:36 pm Measuring Musculoskeletal Disability in Developing Countries Damian Hoy, BPhysio, PhD 1:48 pm Round Table Discussion to Agree Core Questions for Health Interview and Examination Surveys Anthony D. Woolf, MBBS 259 A High-Resolution Peripheral Quantitative Computed Tomography (HR-pQCT) Imaging in Arthritis Study Group 1:00 pm Radiology Perspective on the Role of Magnetic Resonance Imaging and High-Resolution Peripheral Quantitative Computed Tomography in Trials and Clinical Practice Charles G. Peterfy, MD, PhD 1:12 pm Multimodality Comparison: High-Resolution Peripheral Quantitative Computed Tomography With Magnetic Resonance Imaging and Ultrasound Xiaojuan Li, PhD 1:24 pm High-Resolution Peripheral Quantitative Computed Tomography in the Study of Psoriatic Arthritis Stephanie Boutroy, PhD 1:36 pm Reliability of High-Resolution Peripheral Quantitative Computed Tomography and Use for Longitudinal Studies Erosion Assessment Stephanie Finzel, MD 1:48 pm Reliability of High-Resolution Peripheral Quantitative Computed Tomography and Use for Longitudinal Studies Joint Space Assessment Andrew J. Burghardt, BS 156 B Juvenile Arthritis Workgroup (JAW) Study Group 1:40 pm Study Design for Treating Temporomandibular Joint Arthritis in Children with Juvenile Idiopathic Arthritis Carol A. Wallace, MD 153 B Latin American Study Group 1:00 pm Education in Rheumatology Carlo Vinicio-Caballero, MD 1:30 pm Red de Excelencia en Artritis Latinoamerica Loreto Massardo, MD 204 A Neuroendocrine Immunology Study Group 256 1:00 pm Neuroendocrine Modulation of Pain Leslie J. Crofford, MD 1:20 pm Stress and Pain John McBeth, PhD 1:40 pm Autonomic Mediators of Inflammation and Pain Gary S. Firestein, MD Pediatric Rheumatology Imaging Study Group 1:00 pm The Enthesis in Children, Normal Anatomy and Pathologic Findings Johannes Roth, MD 1:20 pm Frequency of Spinal Involvement in Children with Juvenile Idiopathic Arthritis Xenofon Baraliakos, MD 1:40 pm Magnetic Resonance Imaging vs High-resolution Peripheral Quantitative Computed Tomography for Erosions in Children with Juvenile Idiopathic Arthritis Stephanie Finzel, MD 1:00 pm Treatment of Temporomandibular Joint Arthritis in Juvenile Idiopathic Arthritis: What We Know and What We Don t Randy Q. Cron, MD, PhD 1:20 pm A Scoring System for Evaluation of Temporomandibular Joint Arthritis in Children with Juvenile Idiopathic Arthritis Yoginder Vaid, MD 104 B Polymyalgia Rheumatica Study Group 1:00 pm Update on Polymyalgia Rheumatica Guidelines Bhaskar Dasgupta, MD 122 2014 Program Book
scientific sessions 1:20 pm Prospective Study of Overlap in Inflammatory Diseases of the Elderly Eric L. Matteson, MD, MPH 1:40 pm Glucocorticoid Receptors in Polymyalgia Rheumatica Christian Dejaco, MD, PhD 102 A Sjögren s Syndrome Study Group 1:00 pm Sjögren s Cohort in India Debashish Danda, DM 154 Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (237) Speakers: Philip G. Conaghan, MD, PhD and Mikkel Ostergaard, DMSc, MD, PhD recognize the most common types of magnetic resonance images (as T1- and T2-weighted, fat-saturated, STIR and contrast-enhanced) and the appearance of the most common joint pathologies on these discuss the rationale and evidence for using magnetic resonance imaging in clinical practice identify the advantages and disadvantages of dedicated extremity magnetic resonance imaging 1:15 pm Sjögren s Cohorts in South America Juan-Manuel Anaya, MD PhD 159 Musculoskeletal Ultrasonography: Basic (238) Speakers: Janak R. Goyal, MD and Gurjit S. Kaeley, MBBS, MRCP 1:30 pm The United Kingdom Sjögren s Initiative Wan-Fai Ng, MA, PhD, CCT 1:45 pm Oklahoma Sjögren s Cohort Kathy Silvis, PhD ACR/ARHP WORKSHO 1:15 3:15 pm 161 Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. Dermatopathology of Rheumatic Diseases (236) Speaker: Daniel Miller, MD identify what information can be gained from a skin biopsy in patients with rheumatic diseases describe the importance of dermatopathology in clinical decision making in patients with rheumatic diseases apply the knowledge gained to clinical practice 152 explain basic concepts of ultrasound physics define how to perform a proper ultrasound examination identify various tissues in an ultrasound image The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Disease-Specific Measurements (239) Speaker: Arthur M. Mandelin II, MD, PhD Facilitators: Barbara A. Slusher, PA-C, MSW and Kori A. Dewing, DNP, ARNP define the importance of using disease-activity measurement tools in daily practice, the barriers which hinder routine widespread use and how these barriers can be overcome in nearly any practice setting review the practice of several of the most common and well-recognized disease activity measurement tools used in rheumatology care, including the Disease Activity Score for 28 Joints (DAS-28) and Clinical Disease Activity Index (CDAI) for rheumatoid arthritis; the Psoriatic Arthritis Response Criteria (PsARC) for psoriatic arthritis; measurements of spine and hip flexibility as well as the Ankylosing Spondylitis Disease Activity Score (AS-DAS) for spondyloarthropathies; and the modified Rodnan skin score for systemic sclerosis TUESDAY november 18, 2014 2014 Program Book 123
ACR SESSION 2:00 2:30 pm scientific sessions Ballroom West ACR Business Meeting This session is not eligible for CME credit. Moderator: Joseph Flood, MD participate in a meeting with ACR leadership recognize ACR initiatives summarize what the ACR is doing to address various practice issues and other issues 2013-2014 College Year in Review Election of ACR Secretary Election of ACR Board of Directors Members Installation of 78 th ACR President ACR SESSIONS 2:30 4:00 pm 52 A Novel Regulatory Cell Subsets Moderator: Jennifer H. Anolik, MD, PhD review the mechanisms by which immune cell subsets regulate inflammatory responses recognize the role that mesenchymal stem cells play in downmodulating immune responses recognize the role that antigen-presenting cell subsets play in regulating immune responses 2:30 pm Regulatory Roles of Mesenchymal Stem Cells Arnold I. Caplan, PhD 3:00 pm Regulatory B Cells Claudia Mauri, PhD 3:30 pm Regulatory Macrophages James Hutchinson, MBBChir, PhD TUESDAY november 18, 2014 255 Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session Ed Pd PrM FIT Moderators: Sharon L. Kolasinski, MD and Deana M. Lazaro, MD discuss novel approaches to curriculum development for medical students and residents in the musculoskeletal and rheumatic diseases discuss new approaches to teaching in the rheumatic and musculoskeletal diseases determine the unique and important roles of the clinician scholar educator in medical education and training 2:30 pm Development of Curricula in Metabolic Bone Disease Juliet Aizer, MD, MPH 2:50 pm Web-Based Learning Portfolios in Pediatric Rheumatology Michal Jennifer Cidon, MD 3:10 pm Development of Rheumatology Objective Structured Clinical Examination (ROSCE) Stations With Follow-up Modules Lisa G. Criscione-Schreiber, MD 3:30 pm A Dynamic, Competency Based Learning Modules Rodney Tehrani, MD 3:50 pm Question and Answer 210 B Psoriatic Arthritis: Skin, Entheses and Joints Moderators: Rennie N. G. Howard, MD and Rebecca L. Manno, MD, MHS describe the clinical manifestations of the variants of psoriasis and discuss current treatment options for psoriasis describe the concept of the synovio-entheseal complex and its role in psoriatic arthritis describe theories of the pathogenesis of psoriatic arthritis, discuss the clinical manifestations and diagnosis of psoriatic arthritis and develop a rational approach to the treatment of psoriatic arthritis 2:30 pm Psoriatic Kenneth B. Gordon, MD 3:00 pm The Synovio-Entheseal Complex Dennis McGonagle, PhD 3:30 pm Psoriatic Arthritis Christopher T. Ritchlin, MD, MPH ACR CONCURRENT ABSTRACT SESSIONS 2:30 4:00 pm Exhibit Hall C ACR Late-Breaking Abstract Session Moderator: Chester V. Oddis, MD 124 2014 Program Book
scientific sessions Ballroom East 2014 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship Moderators: Daniel J. Wallace, MD and Maureen A. McMahon, MD 2:30 pm Introductory Talk Daniel J. Wallace, MD 2:45 pm 2787. Identification of Urinary Biomarkers for Lupus Nephritis Carolina Landolt-Martincorena, MD Carolina Landolt-Marticorena 1, Stephenie Prokopec 2, Heather Reich 3, James Scholey 4, Carmen Avila-Casado 3, Paul R. Fortin 5, Paul Boutros 2 and Joan wither 6, 1 Toronto Western Hospital, Toronto, ON, 2 Ontario Institute for Cancer Research, Toronto, ON, 3 University Health Network, Toronto, ON, 4 The Toronto Western Hospital, Toronto, ON, 5 Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, 6 University of Toronto, Toronto, ON 3:00 pm 2788. Preliminary Population- Based Incidence and Prevalence Estimates of SLE: The California Lupus Surveillance Project Maria Dall Era 1, Kurt Snipes 2, Miriam Cisternas 3, C. Gordon 4 and Charles G. Helmick 5, 1 University of California, San Francisco, San Francisco, CA, 2 California Department of Public Health, Sacramento, CA, 3 MGC Data Services, San Diego, CA, 4 Medical School, Birmingham, United Kingdom, 5 Centers for Disease Control and Prevention, Atlanta, GA 3:15 pm 2789. Medical Marijuana Related Outcomes in Patients with Systemic Lupus Erythematosus Basmah Jalil 1, Wilmer Sibbitt Jr 2, Romy Cabacangun 3, Clifford Qualls 3, Arthur Bankhurst 4 and Roderick Fields 5, 1 University of New Mexico, Albuquerque, NM, 2 University of New Mexico HSC, Albuquerque, NM, 3 UNM, Albuquerque, NM, 4 University of NM Med Ctr, Albuquerque, NM, 5 University of New Mexico School of Medicine, Albuquerque, NM 3:30 pm 2790. CMR with Quantitative T2 Mapping in Patients with Active SLE Stacy P. Ardoin 1, Wael Jarjour 2, Subha V. Raman 2, Amanda Kibler 2 and Tam Tran 2, 1 Ohio State University College of Medicine, Columbus, OH, 2 Ohio State University, Columbus, OH 3:45 pm 2791. Lung Cancer in SLE Sasha Bernatsky 1, Rosalind Ramsey-Goldman 2, Michelle Petri 3, Murray B. Urowitz 4, Dafna D. Gladman 4, Edward H. Yelin 5, Christine Peschken 6, John G. Hanly 7, James E. Hansen 8, Jean-Francois Boivin 1, Lawrence Joseph 1, Patrice Chrétien Raymer 9, Mruganka Kale 10, Ann E. Clarke 11 and Systemic Lupus International Collaborating Clinics (SLICC) 12, 1 McGill University, Montreal, QC, 2 Northwestern University, Chicago, IL, 3 Johns Hopkins University School of Medicine, Baltimore, MD, 4 University of Toronto, Toronto Western Hospital, Toronto, ON, 5 University of California, San Francisco, San Francisco, CA, 6 University of Manitoba, Winnipeg, MB, 7 Dalhousie University and Capital Health, Halifax, NS, 8 Yale University, New Haven, CT, 9 McGill University Health Centre, Montreal, QC, 10 RI McGill Univ Health Ctr, Montreal, QC, 11 University of Calgary, Calgary, AB, 12 Systemic Lupus International Collaborating Clinics (SLICC), ON 102 A Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis Moderators: Ellen M. Gravallese, MD and Julia F. Charles, MD, PhD 2:30 pm 2792. Methotrexate Prevents Inflammatory Osteolysis By Activation of the Adenosine a 2A Receptor (A2AR) Aranzazu Mediero 1, Tuere Wilder 1 and Bruce N. Cronstein 2, 1 NYU School of Medicine, New York, NY, 2 NYU School of Medicine, Division of Rheumatology, New York, NY 2:45 pm 2793. BMP2 Requires TGF-Beta to Induce Osteophytes during Experimental Osteoarthritis Esmeralda Blaney Davidson 1, Arjen Blom 2, Arjan van Caam 1, Elly Vitters 2, Miranda Bennink 1, Wim van den Berg 2, Fons van de Loo 1 and Peter van der Kraan 2, 1 Radboud university medical center, Nijmegen, Netherlands, 2 Radboud University Medical Center, Nijmegen, Netherlands 3:00 pm 2794. Deletion of the Inhibitory Receptor Motif, ITIM, on DC- STAMP Alters Osteoclast Differentiation and Function Yahui Grace Chiu 1, Edward M. Schwarz 1, Dongge Li 1, Yuexin Xu 1, Minsoo Kim 1 and Christopher T. Ritchlin 2, 1 University of Rochester, Rochester, NY, 2 University of Rochester Medical Center, Rochester, NY 3:15 pm 2795. Blockade of IL-6R Signaling by Sarilumab Suppressed Circulating Markers of Bone Resorption and Synovial Damage in Rheumatoid Arthritis Patients from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study Anita Boyapati 1, Jérôme Msihid 2, Emmanuelle Cousin 2, Ling Cai 3, Janet van Adelsberg 1, Jennifer D Hamilton 1, Neil Graham 1, Tanya Momtahen 4 and Stefano Fiore 4, 1 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 2 Sanofi R&D, France, Chilly-Mazarin, France, 3 Sanofi R&D, China, Beijing, China, 4 Sanofi, Bridgewater, NJ 3:30 pm 2796. A Novel Mouse Model of Osteochondromagenesis By Deleting NFATc1 in Mesenchymal Progenitors and Postnatal Chondrocytes Xian-Peng Ge, Susan Y. Ritter, Julia F. Charles, Kelly Tsang and Antonios O. Aliprantis, Brigham and Women s Hospital, Harvard Medical School, Boston, MA TUESDAY november 18, 2014 2014 Program Book 125
scientific sessions TUESDAY november 18, 2014 3:45 pm 2797. Anti-Citrullinated Proteins Antibodies Promotes Osteoclastogenesis and Bone Destruction in Rheumatoid Arthritis Akilan Krishnamurthy 1, Vijay Joshua 1, Heidi Wähämaa 1, Catia Cerqueira 1, Lars Klareskog 2, Vivianne Malmström 3, Jimmy Ytterberg 1 and Anca I Catrina 1, 1 Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 2 Karolinska Institute, Stockholm, Sweden, 3 Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden 107 B Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I Moderator: Shiva Shahrara, PhD 2:30 pm 2798. C5orf30 a Novel Regulator of Inflammation and Tissue Damage in Rheumatoid Arthritis Munitta Muthana 1, Sarah Hawtree 1, Holly Davies 1, Hannah Roberts 1, Sachin Khetan 1, Mohammed Akil 2, Fiona Wright 1, Barbara Ciani 1, Ursula Fearon 3, DJ Veale 4 and Anthony G. Wilson 5, 1 University of Sheffield, Sheffield, United Kingdom, 2 Rheumatology Department, Sheffield South Yorkshire, United Kingdom, 3 Translational Rheumatology Research Group, Dublin, Ireland, 4 St. Vincent s University Hospital, Dublin, Ireland, 5 University College Dublin, Dublin, Ireland 2:45 pm 2799. The Differential Impact of Obesity on the Pathogenesis of RA or Preclinical Models Is Contingent on the Disease Status Zhenlong Chen 1, Seung-jae Kim 1, Abdul Essani 1, Michael V. Volin 2, Suncica Volkov 1, William Swedler 1, Shiva Arami 1, Giamila Fantuzzi 1, Nadera J. Sweiss 1 and Shiva Shahrara 1, 1 University of Illinois at Chicago, Chicago, IL, 2 Chicago College of Osteopathic Medicine Midwestern University, Downers Grove, IL 3:00 pm 2800. Tofacitinib Regulates Synovial Angiogenesis in Psoriatic Arthritis through Induction of Negative Feedback Inhibitors Wei Gao, Jennifer McCormick, Carl Orr, Mary Connolly, Ursula Fearon and Douglas J. Veale, Translational Rheumatology Research Group, Dublin, Ireland Horst 2 and Sander W. Tas 1, 1 Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 2 Arthrogen BV, Amsterdam, Netherlands 3:45 pm 2803. Methotrexate Impacts the Effects of Tofacitinib, but Not Tocilizumab, on Clinically Relevant Biomarkers in Human Primary Cell Based BioMAP Disease Models: Can We Utilize in Vitro Models to Predict Clinical Outcomes? Alison O Mahony 1, Ellen L. Berg 1, Xitong Li 1, Markus R. John 2, Kandeepan Ganeshalingam 2 and Ernest H. Choy 3, 1 BioSeek, South San Francisco, CA, 2 F. Hoffmann-La Roche, Basel, Switzerland, 3 Cardiff University, Cardiff, United Kingdom 151 A Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease Moderators: Andy Abril, MD and John D. Carter, MD 2:30 pm 2804. Rituximab in IgG4-Related Disease: A Large Single-Center Experience Zachary Wallace, Mollie Carruthers and John H. Stone, Massachusetts General Hospital, Boston, MA 2:45 pm 2805. IgG4-Related Disease: Baseline Features in 100 Patients with Biopsy-Proven Disease Zachary Wallace 1, Vikram Deshpande 1, Hamid Mattoo 2, Vinay Mahajan 2, Mollie Carruthers 1, Maria Kulikova 1, Shiv Pillai 1 and John H. Stone 1, 1 Massachusetts General Hospital, Boston, MA, 2 Massachusetts General Hospital, Harvard Medical School, Boston, MA 3:00 pm 2806. Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjögren s Syndrome and Healthy Controls Shintaro Hirata, Shingo Nakayamada, Satoshi Kubo, Maiko Yoshikawa, Naoki Yunoue, Kazuhisa Nakano, Kunihiro Yamaoka, Kazuyoshi Saito and Yoshiya Tanaka, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan 3:15 pm 2801. IL-38: A New Factor in Rheumatoid Arthritis Shinjiro Kaieda 1, Katsuya Kanezaki 2, Naomi Yoshida 1, Yukiko Kunitake 1, Hiroaki Ida 1 and Tomoaki Hoshino 1, 1 Kurume University School of Medicine, Kurume, Japan, 2 Nagata orthopedic hospital, Omuta, Japan 3:30 pm 2802. Non-Canonical NF-Kappab Signaling Promotes Angiogenesis in a Novel 3D Spheroid Model of Rheumatoid Arthritis Synovial Inflammation Chrissta X. Maracle 1, Boy Helder 1, Ae-Ri Noort 1, Corine van der 3:15 pm 2807. Comparison of Outcomes in Septic Arthritis Caused By MRSA and MSSA Deepa Panikkath 1, Sian Yik Lim 2, Swetha Gadwala 3, Ragesh Panikkath 3 and Kenneth Nugent 2, 1 Texas Tech University of Health Sciences, Lubbock, LUBBOCK, TX, 2 Texas Tech University Health Sciences Center, Lubbock, TX, 3 Texas Tech University of Health Sciences, Lubbock, TX 3:30 2808. WITHDRAWN 126 2014 Program Book
scientific sessions 3:45 2809. Human Papilloma Virus and Chlamydia Trachomatis Infections in Rheumatoid Arthritis Under Anti-TNF Therapy Mariana G Waisberg 1, Ana C.M. Ribeiro 2, Wellington M. Candido 1, Poliana B. Medeiros 1, Cezar N. Matsuzaki 1, Mariana C. Beldi 1, Maricy Tacla 1, Helio H. Caiaffa-Filho 1, Eloisa Bonfá 1 and Clovis A Silva 3, 1 Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2 University of Sao Paulo, Sao Paulo, Brazil, 3 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil 258 B Rheumatoid Arthritis Clinical Aspects V: Mortality and Other Outcomes Moderators: Jennifer Barton, MD and Aryeh Fischer, MD Pharma, Inc., Deerfield, IL, 5 Axio Research LLC, Seattle, WA 3:30 pm 2814. Time-to-Remission, Time-to-Relapse and Disease Severity at the Time of Relapse in RA- Results from the Ontario Best Practices Research Initiative (OBRI) Bindee Kuriya 1, Xiuying Li 2, Binu Jacob 2, Pooneh Akhavan 3, Jessica Widdifield 1, Mark Tatangelo 1, Janet E. Pope 4, Edward Keystone 5 and Claire Bombardier 6, 1 University of Toronto, Toronto, ON, 2 University Health Network, Toronto General Research Institute, Toronto, ON, 3 Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, 4 Western University, London, ON, 5 Mount Sinai Hospital, University of Toronto, Toronto, ON, 6 Institute for Work & Health, Toronto, ON 2:30 pm 2810. Reduced Mortality Risk in Rheumatoid Arthritis: Findings from Two UK Inception Cohorts Sam Norton 1, Elena Nikiphorou 2, Lewis Carpenter 2, David Walsh 3, Patrick Kiely 4, Josh Dixey 5 and Adam Young 6, 1 King s College London, London, United Kingdom, 2 University of Hertfordshire, Hatfield, United Kingdom, 3 University of Nottingham, Nottingham, United Kingdom, 4 St. Georges Healthcare NHS Trust, London, United Kingdom, 5 New Cross Hospital, Wolverhampton, United Kingdom, 6 ERAS, St Albans City Hospital, St Albans, United Kingdom 2:45 pm 2811. Improvements in Rheumatoid Arthritis Related Fatigue Are Driven By Reductions in Pain, Not Disease Activity Results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis Katie L Druce, Gareth T Jones, Gary J. Macfarlane and Neil Basu, University of Aberdeen, Aberdeen, United Kingdom 3:00 pm 2812. Is Rheumatoid Arthritis the Same Disease in Women and Men?- Joint Damage in Patients with EARLY Rheumatoid Arthritis at 10 YEARS after Diagnosis Juha Asikainen 1, Kalevi Kaarela 2, Heidi Mäkinen 3, Hannu Kautiainen 4, Pekka Hannonen 5, Tuomas Rannio 6 and Tuulikki Sokka 7, 1 Jyvaskyla Central Hospital, Jyväskylä, Finland, 2 Jyväskylä Central Hospital, Jyväskylä, Finland, 3 Tampere University Hospital, Tampere, Finland, 4 Medcare Oy, Äänekoski, Finland, 5 Jyväskylä Central Hospital, Jyvaskyla, Finland, 6 Kuopio University Hospital, Kuopio, Finland, 7 Jyvaskyla Central Hospital, Jyvaskyla, Finland 3:15 pm 2813. Correlation of Morning Stiffness with Measures of Higher Disease Activity in a Large US Registry Population of Rheumatoid Arthritis Patients Vibeke Strand 1, Robert J. Holt 2, Katherine C. Saunders 3, Jeffery D. Kent 4, Ping Xu 5, Amy Y. Grahn 4, Marc Mason 3 and Carol J. Etzel 3, 1 Stanford University, Palo Alto, CA, 2 University of Illinois Chicago, Chicago, IL, 3 Corrona, LLC., Southborough, MA, 4 Horizon 3:45 pm 2815. Better Functional Ability with Less Biologicals 2 years after Induction with Combination DMARD Therapy versus methotrexate Monotherapy T. Martijn Kuijper 1, J.J. Luime 1, P.H.P. de Jong 1, A. H. Gerards 2, D. van Zeben 3, I. Tchetverikov 4, P.B.J. de Sonnaville 5, M. van Krugten 6, B. Grillet 7, J.M.W. Hazes 8 and A.E.a.M. Weel 9, 1 Erasmus University Medical Center, Rotterdam, Netherlands, 2 Vlietland Hospital, Schiedam, Netherlands, 3 Sint Franciscus Gasthuis, Rotterdam, Netherlands, 4 Albert Schweitzer Hospital, Dordrecht, Netherlands, 5 Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, 6 Admiraal de Ruyter Hospital, Vlissingen, Netherlands, 7 ZorgSaam Hospital, Terneuzen, Netherlands, 8 Erasmus MC, Rotterdam, Netherlands, 9 MD, PhD, Rotterdam, Netherlands 104 B Rheumatoid Arthritis Human Etiology and Pathogenesis I: Mechanisms of Joint Damage Includes 2013 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk Moderator: Miriam A. Shelef, MD, PhD and Bruce N. Cronstein, MD 2:30 pm 2013 Lee C. Howley, Sr. Prize for Arthritis Research Introductory Talk Bruce N. Cronstein, MD 2:45 pm 2816. Distinctive DNA Methylome Signatures in Early Rheumatoid Arthritis (RA) Synoviocytes Compared with Longstanding (RA) and Other Inflammatory Arthritides Rizi Ai 1, John W. Whitaker 2, David L. Boyle 3, Paul Peter Tak 4, Danielle M. Gerlag 5, Wei Wang 6 and Gary S. Firestein 3, 1 UC San Diego, La Jolla, CA, 2 UCSD, San Diego, CA, 3 University of California at San Diego School of Medicine, La Jolla, CA, 4 Academic Medical Center / University of Amsterdam, Department of Clinical Immunology and Rheumatology & GlaxoSmithKline, Amsterdam, Netherlands, 5 Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands, 6 UCSD, La Jolla, CA TUESDAY november 18, 2014 2014 Program Book 127
scientific sessions TUESDAY november 18, 2014 128 3:00 pm 2817. Histone Deacetylase One Contributes to the Auto- Aggressive Phenotype of Rheumatoid Arthritis Sarah Hawtree 1, Munitta Muthana 1, J. Mark Wilkinson 1, Anthony G. Wilson 1 and Mohammed Akil 2, 1 University of Sheffield, Sheffield, United Kingdom, 2 Rheumatology Department, Sheffield South Yorkshire, United Kingdom 3:15 pm 2818. SH2 Domain-Containing Phosphatase 2 Promotes Aggressiveness of Rheumatoid Fibroblast-like Synoviocytes Stephanie M. Stanford 1, German R. Aleman Muench 1, Cristiano Sacchetti 1, Lifan Zeng 2, David L. Boyle 3, Gen-Sheng Feng 4, Zhong-Yin Zhang 2, Maripat Corr 3, Gary S. Firestein 3 and Nunzio Bottini 1, 1 La Jolla Institute for Allergy and Immunology, La Jolla, CA, 2 Indiana University School of Medicine, Indianapolis, IN, 3 University of California at San Diego School of Medicine, La Jolla, CA, 4 University of California at San Diego Division of Biological Sciences, La Jolla, CA 3:30 pm 2819. The YAP Pathway Regulates Fibroblast-like Synoviocyte Invasion Beatrix Bartok, University of California, San Diego, La Jolla, CA 3:45 pm 2820. Dual Role for B Cells in Promoting Bone Erosion in Rheumatoid Arthritis Via Effects on Osteoclast and Osteoblast Differentiation Nida Meednu, Hengwei Zhang, Teresa Owen, Lianping Xing and Jennifer H. Anolik, University of Rochester, Rochester, NY 253 B Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy V: Novel Therapies in Rheumatoid Arthritis Late in Development Moderators: Jonathan Kay, MD and Joseph A. Markenson, MD 2:30 pm 2821. Efficacy and Safety/Tolerability of Mavrilimumab, a Human GM-CSFRá Monoclonal Antibody in Patients with Rheumatoid Arthritis Gerd Burmester 1, Iain B. McInnes 2, Joel M. Kremer 3, Pedro Miranda 4, Mariusz Korkosz 5, Jiri Vencovsky 6, Andrea Rubbert- Roth 7, Eduardo Mysler 8, Sara Sandbach 9, Matthew A. Sleeman 9, Alex Godwood 9, David Close 9 and Michael Weinblatt 10, 1 Charité University Medicine Berlin, Berlin, Germany, 2 University of Glasgow, Glasgow, United Kingdom, 3 Albany Medical College and the Center for Rheumatology, Albany, NY, 4 Centro de Estudios Reumatologicos, Santiago, Chile, 5 Malopolskie Centrum Medyczne, Krakow, Poland, 6 Charles University Institute of Rheumatology, Praha, Czech Republic, 7 University of Cologne, Koln, Germany, 8 OMI, Buenos Aires, Argentina, 9 MedImmune Ltd, Cambridge, United Kingdom, 10 Brigham & Women s Hospital, Harvard Medical School, Boston, MA 2014 Program Book 2:45 pm 2822. Safety and Efficacy of Baricitinib through 128 Weeks in an Open-Label, Long-Term Extension Study in Patients with Rheumatoid Arthritis Edward C. Keystone 1, Peter C. Taylor 2, Mark C Genovese 3, Douglas E. Schlichting 4, Inmaculada De La Torre 5, Scott D. Beattie 4 and Terence Rooney 4, 1 Mount Sinai Hospital, Toronto, ON, 2 University of Oxford, Oxford, United Kingdom, 3 Stanford University Medical Center, Palo Alto, CA, 4 Eli Lilly and Company, Indianapolis, IN, 5 Eli Lilly and Company, Alcobendas, Spain 3:00 pm 2823. Comparable Efficacy with Sarilumab Plus Methotrexate in Biologic-Experienced and Biologic-Naïve Patients with Moderate-to-Severe Rheumatoid Arthritis from a Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study Roy Fleischmann 1, Dennis L. Decktor 2, Chunpeng Fan 3, Hubert Van Hoogstraten 3 and Mark C Genovese 4, 1 Metroplax Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, 2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3 Sanofi, Bridgewater, NJ, 4 Stanford University Medical Center, Palo Alto, CA 3:15 pm 2824. A Profile of the Efficacy of Sarilumab Plus Methotrexate in Rheumatoid Arthritis Patients: Results of a 52-Week, Phase 3, Randomized, Double-Blind, Placebo-Controlled, International Study Arthur Kavanaugh 1, Dennis L. Decktor 2, Chunpeng Fan 3, Janet van Adelsberg 2, Renata Martincova 4 and Mark C. Genovese 5, 1 University of California San Diego, La Jolla, CA, 2 Regeneron Pharmaceuticals, Inc., Tarrytown, NY, 3 Sanofi, Bridgewater, NJ, 4 Sanofi Czech Republic, Prague, Czech Republic, 5 Stanford University Medical Center, Palo Alto, CA 3:30 pm 2825. A Randomized, Double-Blind, Phase 3 Equivalence Trial Comparing the Etanercept Biosimilar, HD203, with Etanercept (Enbrel ), in Combination with Methotrexate (MTX) in Patients with Rheumatoid Arthritis (RA) Sang-Cheol Bae 1, Jinseok Kim 2, Jung-Yoon Choe 3, Won Park 4, So-Ra Lee 5, Yongho Ahn 6 and Yunjeong Seo 5, 1 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 2 Jeju National University, Jeju, Korea, South Korea, 3 Catholic University of Daegu School of Medicine, Daegu, South Korea, 4 Inha University Hospital, Incheon, South Korea, 5 Hanwha Chemical, Seoul, South Korea, 6 Hanwha Chemical, Daejeon, South Korea 3:45 pm 2826. A Phase 2b, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Finding, Multi-Center Study to Evaluate the Safety and Efficacy of ASP015K in Moderate to Severe Rheumatoid Arthritis Subjects Not on Concomitant Methotrexate Mark C. Genovese 1, Maria Greenwald 2, Christine Codding 3, Mario H. Cardiel 4, Anna Zubrzycka-Sienkiewicz 5, Alan J. Kivitz 6,
scientific sessions Steve Wisseh 7, Kathyjo Shay 8 and Jay P. Garg 8, 1 Stanford University Medical Center, Palo Alto, CA, 2 Desert Medical Advances, PALM DESERT, CA, 3 Health Research of Oklahoma, Oklahoma City, OK, 4 Centro de Investigacion Clinica de Morelia, Morelia, Mexico, 5 ARS Rheumatica sp. Zo.o, Reumatika, Warszawa, Poland, 6 Altoona Center for Clinical Research, Duncansville, PA, 7 Biocis, Chicago, IL, 8 Astellas Pharma Global Development, Northbrook, IL Ballroom West Spondyloarthropathies and Psoriatic Arthritis IV Clinical Aspects Axial Spondyloarthritis Moderators: John D. Reveille, MD and Nigil Haroon, MD, PhD, DM 2:30 pm 2827. Cervical Spine Fracture and Mortality in Ankylosing Spondylitis Katherine D. Wysham, Sara G. Murray, Nancy K. Hills, Edward H. Yelin and Lianne S. Gensler, University of California, San Francisco, San Francisco, CA 2:45 pm 2828. A Physically Demanding Job May Amplify the Effect of Disease Activity on the Development of Syndesmophytes in Patients with Ankylosing Spondylitis Sofia Ramiro 1, A.M. van Tubergen 2, Robert Landewé 3, Annelies Boonen 2, Carmen Stolwijk 2, Maxime Dougados 4, Filip Van den Bosch 5 and Desiree van der Heijde 6, 1 Amsterdam Rheumatology Center/University of Amsterdam, Amsterdam, Netherlands, 2 Maastricht University Medical Center, Maastricht, Netherlands, 3 Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, 4 Université Paris René Descartes and Hôpital Cochin, Paris, France, 5 Ghent University Hospital, Ghent, Belgium, 6 Leiden University Medical Center, Leiden, Netherlands 3:00 pm 2829. Spondyloarthritis Is Associated with Increased Cardiovascular and Cerebrovascular Mortality Nigil Haroon 1, Nisha Nigil Haroon 2, Ping Li 3, Michael Paterson 3 and Robert D. Inman 4, 1 Toronto Western Research Institute, Toronto, ON, 2 University of Toronto, Toronto, ON, 3 Institute of Clinical Evaluative Sciences, Toronto, ON, 4 University of Toronto and Toronto Western Hospital, Toronto, ON 3:15 pm 2830. Progression to and Type of Orthopaedic Surgery in Juvenile Vs. Adult-Onset Ankylosing Spondylitis Deepak R. Jadon 1, Gavin Shaddick 2, Amelia Jobling 2, Athimalaipet V Ramanan 3 and Raj Sengupta 1, 1 Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, 2 University of Bath, Bath, United Kingdom, 3 University of Bristol Hospital Trust, Bristol, United Kingdom 3:30 pm 2831. Development of New Radiographic Vertebral Fractures in Patients with Ankylosing Spondylitis during 4 Years of TNF-α Blocking Therapy: Results from the Glas Cohort Fiona Maas 1, Anneke Spoorenberg 1, Elisabeth Brouwer 2, Reinhard Bos 3, Rizwana N. Chaudhry 1, Freke Wink 3, Hendrika Bootsma 4, Eveline van der Veer 1 and Suzanne Arends 4, 1 University Medical Center Groningen, Groningen, Netherlands, 2 University of Groningen, University Medical Center Groningen, Groningen, Netherlands, 3 Medical Center Leeuwarden, Leeuwarden, Netherlands, 4 University Medical Center Groningen, University of Groningen, Groningen, Netherlands 3:45 pm 2832. The Effect of Co-Medication with Conventional Synthetic Disease Modifying Anti-Rheumatic Drugs on TNF Inhibitor Drug Survival in Patients with Ankylosing Spondylitis: Results from a Nationwide Prospective Study Elisabeth Lie 1, Lars Erik Kristensen 2, Helena Forsblad-d Elia 3, Johan Askling 4 and Lennart T. Jacobsson 3, 1 Diakonhjemmet Hospital, Oslo, Norway, 2 Lund University, Malmö, Sweden, 3 Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden, 4 Karolinska Institutet, Stockholm, Sweden 205 B Systemic Lupus Erythematosus Clinical Aspects and Treatment: Novel Therapies for Systemic Lupus Erythematosus Moderators: Megan E. B. Clowse, MD, MPH and Kenneth C. Kalunian, MD 2:30 pm 2833. SM101, a Novel Recombinant, Soluble, Human FcγIIB Receptor, in the Treatment of Systemic Lupus Erythematosus: Results of a Double-Blind, Placebo-Controlled Multicenter Study Sascha Tillmanns 1, Claudia Kolligs 1, David P. D Cruz 2, Andrea Doria 3, Eric Hachulla 4, Reinhard E. Voll 5, Michael Tansey 1 and Klaus Schollmeier 1, 1 SuppreMol GmbH, Martinsried, Germany, 2 Louise Coote Lupus Unit, Guy s and St Thomas Hospital, London, United Kingdom, 3 University of Padova, Padova, Italy, 4 Lille University, Lille, France, 5 University Hospital Freiburg, Freiburg, Germany 2:45 pm 2834. Correlation of Laboratory and Clinical Parameters with British Isles Lupus Assessment Group Response in an Open- Label Extension Study of Epratuzumab in Systemic Lupus Erythematosus Richard A. Furie 1, Michelle A. Petri 2, Caroline Gordon 3, Vibeke Strand 4, Catrinel Galateanu 5, Sabine Bongardt 6, Willem Koetse 7 and Daniel J. Wallace 8, 1 North Shore Long Island Jewish Health System, Great Neck, NY, 2 Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 3 Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 4 Biopharmaceutical TUESDAY november 18, 2014 2014 Program Book 129
scientific sessions TUESDAY november 18, 2014 Consultant, Portola Valley, CA, 5 UCB Pharma, Brussels, Belgium, 6 UCB Pharma, Monheim, Germany, 7 UCB Pharma, Raleigh, NC, 8 Cedars-Sinai Medical Center, Los Angeles, CA 3:00 pm 2835. A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Proof-of-Concept Study to Evaluate the Efficacy and Safety of Sirukumab in Patients with Active Lupus Nephritis Cynthia Aranow 1, R. van Vollenhoven 2, Brad H. Rovin 3, Carrie Wagner 4, Bei Zhou 4, Robert Gordon 4 and Benjamin Hsu 4, 1 The Feinstein Institute, Manhasset, NY, 2 The Karolinska Institute, Stockholm, Sweden, 3 Ohio State University Medical Center, Columbus, OH, 4 Janssen Research & Development, LLC., Spring House, PA 3:15 pm 2836. Effects of Blisibimod, an Inhibitor of B Cell Activating Factor, on Patient Reported Outcomes and Disease Activity in Patients with Systemic Lupus Erythematosus Michelle Petri 1, Renee S. Martin 2, Colin Hislop 2, Morton A. Scheinberg 3 and Richard Furie 4, 1 Johns Hopkins University School of Medicine, Baltimore, MD, 2 Anthera Pharmaceuticals Inc, Hayward, CA, 3 Rheumatology Hospital Abreu Sodre Pesquisa Clínica, São Paulo, Brazil, 4 North Shore Long Island Jewish Health System, Great Neck, NY 3:30 pm 2837. Induction of Clinical Remission By Low-Dose Interleukin-2 in Refractory SLE Jens Y. Humrich 1, Caroline von Spee-Mayer 1, Elise Siegert 1, Angelika Rose 1, Tobias Alexander 1, Falk Hiepe 1, Andreas Radbruch 2, Gerd Burmester 3 and Gabriela Riemekasten 1, 1 Charité University Hospital, Berlin, Germany, 2 German Rheumatism Research Centre Berlin (DRFZ), an institute of the Leibniz Association, Berlin, Germany, 3 Charité University Medicine, Dept. Medicine/Rheumatology and Clinical Immunology, Berlin, Germany 3:45 pm 2838. Exploratory Analysis of Pharmacokinetic Effects of Atacicept in Patients with Moderate to Severe Systemic Lupus Erythematosus David Wofsy 1, Caroline Gordon 2, Yong Li 3, Stephen D. Wax 4 and David Isenberg 5, 1 Division of Rheumatology, University of California, San Francisco, CA, 2 Rheumatology Research Group, School of Immunity and Infection, College of Medical and Dental Sciences, University of Birmingham, Birmingham, United Kingdom, 3 R&D Global BioStatistics, EMD Serono, Billerica, MA, 4 Global Clinical Development Center Immunology, EMD Serono Inc, Rockland, MA, 5 Centre for Rheumatology Research, University College Hospital London, London, United Kingdom 156 B Systemic Lupus Erythematosus Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis Moderators: Gary S. Gilkeson, MD and Susan A. Boackle, MD 2:30 pm 2839. BCL-2 As a Potential Therapeutic Target in Human Lupus Tubulointerstitial Inflammation Kichul Ko 1, Denisse Yanez 1, Natalya Kaverina 1, Vladimir M. Liarski 1, Yahui Peng 2, Li Lan 1, Stuart Perper 3, Annette Schwartz 3, Liz O connor 3, Andrew Souers 4, Steven Elmore 4, Lisa Olson 3, Maryellen L. Giger 1, Li Chun Wang 3 and Marcus R. Clark 1, 1 University of Chicago, Chicago, IL, 2 Beijing Jiaotong University, Beijing, China, 3 AbbVie Inc, AbbVie Bioresearch Center, Worcester, MA, 4 AbbVie Inc, North Chicago, IL 2:45 pm 2840. Targeting the RhoA-Rock Pathway to Reverse T Cell Dysfunction in SLE Cristina T. Rozo, Laura Leuenberger, Kyriakos A. Kirou, Margaret Robotham, Sanjay Gupta, Reena Khianey, Alessandra B. Pernis and Jane E. Salmon, Hospital for Special Surgery, New York, NY 3:00 pm 2841. Identifying Novel Lupus Severity Risk Variants through Identification of Alleles with High Ethnic Variability Worldwide Belinda A. Waltman 1, Kimberly E. Taylor 1, Julio Molineros 2, Sarah French 1, Joanne Nitiham 1, Jennifer Kelly 2, Adam Adler 2, Judith A. James 2, Swapan Nath 2, Marta Alarcon-Riquelme 2 and Lindsey A. Criswell 1, 1 University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, 2 Oklahoma Medical Research Foundation, Oklahoma City, OK 3:15 pm 2842. An Anti CD123 Monoclonal Antibody (CSL362) Depletes Plasmacytoid Dendritic Cells and Inhibits CpG Upregulated IFNα Production and IFNα-Inducible Gene Expression in Peripheral Blood Mononuclear Cells from Patients with Systemic Lupus Erythematosus Shereen Oon 1, Nicholas Wilson 1 and Ian Wicks 2, 1 The University of Melbourne, Melbourne, Australia, 2 The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia 3:30 pm 2843. SLE Patients Carrying a Disease-Associated PTPN22 R620W Variant Show Reduced Interferon-Inducing Capacity Yaya Wang, David Ewart, Ami Yamamoto, Emily C. Baechler, Parastoo Fazeli and Erik J. Peterson, University of Minnesota, Minneapolis, MN 130 2014 Program Book
scientific sessions 3:45 pm 2844. Intracellular Complement C3 Is Exposed on the Cell Surface upon Apoptosis Induction and Participates in the Clearance of Apoptotic Cells By Phagocytes Lucrezia Colonna 1, Christian Lood 1, YuFeng Peng 1, Xizhang Sun 1, Lena Tanaka 1, Sandip Panicker 2 and Keith B. Elkon 1, 1 University of Washington, Seattle, WA, 2 True North Therapeutics, South San Francisco, CA 109 A T Cell Biology and Targets in Autoimmune Disease Moderators: Insoo Kang, MD and Andras Perl, MD, PhD 2:30 pm 2845. Altered Plasticity of Inflammatory CD4 T Cells Contributing to Th17 Shift in Rheumatoid Arthritis Jan Leipe, Fausto Pirronello, Simon Hermann, Matthias Witt, Hendrik Schulze-Koops and Alla Skapenko, University of Munich, Munich, Germany 2:45 pm 2846. CaMK4 Inhibition Ameliorates the Development of Th17 Driven Inflammatory Diseases By Preventing Recruitment of IL- 17 Producing Cells to Target Organs Tomohiro Koga 1, Kotaro Otomo 2, Masayuki Mizui 2, Nobuya Yoshida 2, José C. Crispin 2, Atsushi Kawakami 1 and George C. Tsokos 3, 1 Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences, Nagasaki, Japan, 2 Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3 Beth Israel Deaconess Medical Center/Harvard Medical School, Boston, MA 3:00 pm 2847. Survivin Co-Ordinates Formation of Follicular T-Cells in Rheumatoid Arthritis Maria Bokarewa 1, Karin Andersson 2, Malin Erlandsson 2, Mattias Svensson 2, Nicola Cavallini 3 and Mikael Brisslert 2, 1 University of Goteborg, Goteborg, Sweden, 2 University of Gothenburg, Gothenburg, Sweden, 3 University of Göteborg, Göteborg, Sweden 3:15 pm 2848. T-Cell Signaling Defects Can be Corrected By Manipulating TCR Signal Fine-Tuning Molecules That Are Altered Due to Increased Ubiquitination in Systemic Autoimmune Disease Julia Pinkhasov and Ram Raj Singh, UCLA, Los Angeles, CA 3:30 pm 2849. Involvement of CD8 + T Cells in the Pathogenesis of Giant Cell Arteritis and Polymyalgia Rheumatica Maxime Samson 1, Sylvain Audia 1, Malika Trad 2, Marion Ciudad 2, Hervé Devilliers 3, Alexandrine Gautheron 2, Valérie Quipourt 4, Francois Maurier 5, Nadine Meaux Ruault 6, Patrick Manckoundia 4, Paul Ornetti 7, Jean-Francis Maillefert 8, Jean-François Besancenot 3, Christophe Ferrand 9, Philippe Saas 9, Laurent Martin 10, Nona Janikashvili 2 and Bernard Bonnotte 1, 1 INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Internal Medicine and Clinical Immunology, Dijon, France, 2 INSERM UMR 1098, Besançon, Dijon, France, 3 Department of internal medicine and systemic diseases, Dijon, France, 4 Department of Geriatric Internal Medicine, Dijon, France, 5 Department of Internal Medicine, Metz, France, 6 Department of Internal Medicine, Besançon, France, 7 Department of Rheumatology, Dijon, France, 8 University Hospital Dijon, Dijon, France, 9 INSERM UMR1098, Besançon, France, 10 INSERM UMR 1098, Besançon ; University of Burgundy, Faculty of Medicine, IFR100 ; Department of Pathology, Dijon, France 3:45 pm 2850. MiR-125a Is Critical Regulator for Controlling Autoimmunity in Multiple Autoimmune Diseases through Stabilizing Treg Mediated Immune Homeostasis Wan Pan 1, Shu Zhu 1, Dai Dai 1, John Harley 2 and Nan Shen 1, 1 Institute of Health Sciences, Shanghai Institutes for Biological Sciences (SIBS), Chinese Academy of Sciences (CAS) & Shanghai Jiao Tong University School of Medicine (SJTUSM), Shanghai, China, 2 The Center for Autoimmune Genomics and Etiology (CAGE), Cincinnati Children s Hospital Medical Center, Cincinnati, Ohio, United States of America, Cincinnati, OH 157 B Vasculitis III Moderators: Tanaz A. Kermani, MD and Alfred Mahr, MD, PhD 2:30 pm 2851. The Relationship of ARMS2 Genotype with Idiopathic Inflammatory Vasculitis Christopher Mecoli 1, Fan Wang 2, Christopher Pappas 3, Peter C. Grayson 4, David Cuthbertson 5, Simon Carette 6, Christian Pagnoux 6, Gary S. Hoffman 7, Nader A. Khalidi 8, Curry L. Koening 9, Carol A. Langford 10, Carol McAlear 11, Paul A. Monach 12, Larry W. Moreland 13, Philip Seo 14, Ulrich Specks 15, Steven R. Ytterberg 15, Rui Feng 1, Gregory Hageman 3 and Peter A. Merkel 11, 1 University of Pennsylvania, Philadelphia, PA, 2 University of Pennsylvania, Philadelphia, OK, 3 University of Utah School of Medicine, Salt Lake City, UT, 4 National Institutes of Health, Bethesda, MD, 5 University of South Florida, Tampa, FL, 6 University of Toronto, Toronto, ON, 7 Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, 8 St. Joseph s Hospital, McMaster University, Hamilton, ON, 9 University of Utah, Salt Lake City, UT, 10 Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, 11 Vasculitis Center, University of Pennsylvania, Philadelphia, PA, 12 Vasculitis Center, Boston University School of Medicine, Boston, MA, 13 University of Pittsburgh, Pittsburgh, PA, 14 Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, 15 Mayo Clinic, Rochester, MN 2:45 pm 2852. Evaluation of KIR3DL1/KIR3DS1 Association with Behçet s Disease in Turkish Individuals Burak Erer 1, Elaine F. Remmers 1, Masaki Takeuchi 1, Colleen Satorius 1, Duran Ustek 2, Ilknur Tugal-tutkun 3, Emire Seyahi 4, Yilmaz Ozyazgan 5, Ahmet Gul 3, Daniel L. Kastner 6 and Michael J. TUESDAY november 18, 2014 2014 Program Book 131
scientific sessions TUESDAY november 18, 2014 Ombrello 7, 1 National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, 2 Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey, 3 Istanbul Faculty of Medicine, Istanbul University, Istanbul, Turkey, 4 Cerrahpasa Medical Faculty, University of Istanbul, Istanbul, Turkey, 5 Cerrahpasa Medical Faculty, Istanbul University, Istanbul, Turkey, 6 National Human Genome Research Institute, Bethesda, MD, 7 National Institute of Arthritis Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD 3:00 pm 2853. Comparative Study of Infliximab Versus Adalimumab in Patients with Refractory Uveitis Due to Behçet s Disease. Multicenter Study of 125 Cases Leyre Riancho-Zarrabeitia 1, Vanesa Calvo-Río 1, Ricardo Blanco 1, Paz Rodríguez-Cundín 1, Emma Beltrán 2, Juan Sánchez Bursón Sr. 3, Marina Mesquida 4, Alfredo Adan 4, M. Victoria Hernández 5, Marisa Hernandez Grafella 6, Elia Valls Pascual 7, Lucía Martinez- Costa 8, Agusti Sellas-Fernandez 9, Miguel Cordero-Coma 10, Manuel Díaz-Llopis 11, Roberto Gallego 11, Jose Luis García Serrano 12, Norberto Ortego-Centeno 13, Jose M Herreras 14, Alejandro Fonollosa 15, Angel M. Garcia-Aparicio 16, Olga Maiz Alonso 17, Ana Blanco 18, Ignacio Torre Salaberri 19, Cruz Fernández- Espartero 20, Vega Jovani 21, Diana Peiteado 22, Esperanza Pato 23, Juan Cruz 24, Carlos Férnandez Cid 25, Elena Aurrecoechea 26, Miriam García-Arias 27, Miguel Angel Caracuel-Ruiz 28, Carlos Alberto Montilla Morales 29, Antonio Atanes-Sandoval 30, Félix Francisco 31, Santos Insua 32, Senen González-Suárez 33, Maria Amalia Sanchez Andrade 34, Fernando Gamero 35, Luis Francisco Linares Ferrando 36, Fredeswinda Romero 37, A. Javier García- González 38, Raquel Almodóvar González 39, Enrique Minguez 40, Carmen Carrasco Cubero 41, Alejandro Olive 42, Julio Vázquez 43, Oscar Ruiz Moreno 44, Fernando Jiménez-Zorzo 44, Javier Manero 44, Santiago MuÑoz Fernandez 45, Javier Rueda-Gotor 1, Trinitario Pina 1, Montserrat Santos-Gómez 1 and Miguel A. González-Gay 1, 1 Hospital Universitario Marqués de Valdecilla. IDIVAL. Santander. Spain, Santander, Spain, 2 Hospital General Universitario de Valencia. Spain, Valencia, Spain, 3 Rheumatology. Hospital de Valme., Sevilla, Spain, 4 Hospital Clinic. Barcelona. Spain, Barcelona, Spain, 5 Hospital Clinic, Barcelona, Barcelona, Spain, 6 Ophthalmology. Hospital General universitario de Valencia, Spain, 24 Rheumatology. Hospital de Pontevedra, Pontevedra, Spain, 25 Ophthalmology. Hospital de Pontevedra, Pontevedra, Spain, 26 Hospital Sierrallana. Torrelavega, Torrelavega, Spain, 27 Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, 28 H. Reina Sofia, Cordoba, Spain, 29 Hospital Clínico Universitario de Salamanca, Salamanca, Spain, 30 Rheumatology Division. C. Hospitalario Universitario A Coruña, A Coruña, Spain, 31 Hospital Doctor Negrín. Las Palmas de Gran Canaria. Spain, Las Palmas de Gran Canaria, Spain, 32 Rheumatology. Hospital Universitario Santiago de Compostela, A Coruña, Spain, 33 Rheumatology. Hospital Cabueñes, Gijón, Spain, 34 Hosp. Lucus Augusti, Lugo, Spain, 35 Rheumatology. Hospital San Pedro Alcantara, Cáceres, Spain, 36 Hospital Virgen de la Arrixaca. Murcia. Spain, Murcia, Spain, 37 Jiménez Díaz Foundation University Hospital, Madrid, Spain, 38 Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain, 39 Hospital Universitario Fundación Alcorcón, Madrid, Spain, 40 Ophthalmology. Hospital Clínico de Zaragoza, Zaragoza, Spain, 41 Hospital de Merida, Mérida, Spain, 42 Germans Trias Pujol Hospital, Barcelona, Spain, 43 Rheumatology. Hospital de Ferrol, A Coruña, Spain, 44 Ophthalmology and Rheumatology. Hospital Miguel Servet Zaragoza, Spain, Zaragoza, Spain, 45 Sección de Reumatología, Hospital Universitario Infanta Sofía, San Sebastián de los Reyes, Madrid, Spain 3:15 2854. Effect of Apremilast on Quality of Life and Physical Function in Patients with Behçet s Syndrome Gulen Hatemi 1, Melike Melikoglu 1, Recep Tunc 2, Cengiz Korkmaz 3, Banu Turgut Ozturk 4, Cem Mat 5, Peter A. Merkel 6, Kenneth Calamia 7, Lilia Pineda 8, Ziqi Liu 8, Randall M. Stevens 8, Hasan Yazici 1 and Yusuf Yazici 9, 1 Istanbul University, Cerrahpasa Medical Faculty, Rheumatology, Istanbul, Turkey, 2 Necmettin Erbakan University, Meram Medical Faculty, Division of Rheumatology, Konya, Turkey, 3 EskiÅŸehir Osmangazi University, EskiÅŸehir, Turkey, 4 Selçuk University, Konya, Turkey, 5 Istanbul University, Cerrahpasa Medical Faculty, Dermatology, Istanbul, Turkey, 6 Vasculitis Center, Division of Rheumatology, University of Pennsylvania, Philadelphia, PA, 7 Mayo Clinic Health System in Waycross, Waycross, GA, 8 Celgene Corporation, Warren, NJ, 9 New York University School of Medicine, New York, NY Valencia, Spain, 7 Rheumatology. Hospital Peset, Valencia, Spain, 8 Ophthalmology. Hospital Peset, Valencia, Spain, 9 H. Vall d Hebron, Barcelona, Spain, 10 Hospital de León. Spain, León, Spain, 11 Hospital Universitario La Fe. Valencia. Spain, Valencia, Spain, 12 Ophthalmology. Hospital San Cecilio, Granada, Spain, 13 Systemic Autoimmune Diseases Unit, Hospital Clínico San Cecilio, Granada, Spain, 14 Ophthalmology. Hospital Universitario, IOBA, Valladolid, Spain, 15 Hospital de Cruces. Bilbao. Spain, Bilbao, Spain, 16 Virgen de la Salud Hospital, Toledo, Spain, 17 Hospital Universitario de Donostia. San Sebastián. Spain, San Sebastián, Spain, 18 Ophthalmology. Hospital Donosti, San Sebastián, Spain, 19 Hospital Universitario de Basurto. Bilbao. Spain, Bilbao, Spain, 20 Hospital Universitario de Móstoles. Madrid. Spain, Madrid, Spain, 21 Rheumatology. Hospital General de Alicante, Alicante, Spain, 22 Hospital La Paz IdiPaz, Madrid, Spain, 23 Rheumatology. Hospital Clínico San Carlos, Madrid, 3:30 pm 2855. Efficacy and Safety of Rituximab Retreatment Regimen at Clinical Relapse in Severe Cryoglobulinemic Vasculitis Luca Quartuccio 1, Francesca Zuliani 2, Patrizia Scaini 3, Marco Lenzi 4, Antonio Tavoni 5, Marco Sebastiani 6, Teresa Urraro 7, Francesco Saccardo 8, Costanza Sbreglia 9, Pietro Pioltelli 10, Paolo Fraticelli 11, Davide Filippini 12, Salvatore Scarpato 13, Oreste Perrella 9, Armando Gabrielli 14, Dario Roccatello 15, Anna Linda Zignego 7, Clodoveo Ferri 16, Stefano Bombardieri 17, Maurizio Pietrogrande 18, Massimo Galli 19, Giuseppe Monti 8 and Salvatore De Vita 1, 1 DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, 2 Rheumatology Clinic, University Hospital of Udine, Udine, Italy, 3 Nephrology, Spedali Civili di Brescia, Brescia, Italy, 4 University of Bologna, Bologna, Italy, 5 Rheumatology Clinic, University of Pisa, Pisa, Italy, 132 2014 Program Book
scientific sessions 6 Rheumatology Clinic, University of Modena and Reggio Emilia, Modena, Italy, 7 Center for Systemic Manifestations of Hepatitis Viruses (MASVE), Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, 8 Internal Medicine Unit, Saronno Hospital, Azienda Ospedaliera di Busto Arsizio, Saronno (VA), Italy, 9 Rheumatology Unit, AO Cotugno, Naples, Italy, 10 Hematology, S.Gerardo Hospital, Monza, Italy, 11 Istituto di Clinica Medica, Università Politecnica delle Marche, Ancona, Italy, 12 Rheumatology Unit, Ospedale Niguarda Ca Granda, Milan, Italy, 13 Rheumatology Unit, M. Scarlato Hospital, Scafati, Salerno, Italy, 14 Università Politecnica delle Marche, Ancona, Italy, 15 UNIVERSITY OF TURIN (ITALY), TURIN, Italy, 16 Univ Modena Reggio Emilia, Modena, Italy, 17 Rheumatology Unit, University of Pisa, Pisa, Italy, 18 Internal Medicine Unit, Policlinico San Marco, Bergamo, Italy, 19 Istituto di Malattie Infettive e Tropicali, Università di Milano c/o Ospedale L. Sacco, Milano, Italy 3:45 pm 2856. Update on Long-Term Outcomes after Reversible Cerebral Vasoconstriction Syndrome (RCVS) Seby John 1, Aneesh Singhal 2, Leonard H. Calabrese 1, Ken Uchino 1, Tariq Hammad 1, Stewart Tepper 1, Mark Stillman 1 and Rula A Hajj- Ali 1, 1 Cleveland Clinic Foundation, Cleveland, OH, 2 Massachusetts General Hospital, Boston, MA ACR/ARHP COMBINED ABSTRACT SESSION 2:30 4:00 160 B ACR/ARHP Combined Abstract Session: Rehabilitation Moderators: Nancy A. Baker, MPH and Daniel K. White, PT, ScD, MSc 2:30 pm 2857. Restricting Back Pain Is Strongly Associated with Disability in Community-Living Older Persons over the Course of 13 Years Una Makris 1, Liana Fraenkel 2, Ling Han 3, Linda Leo-Summers 3 and Thomas M. Gill 4, 1 Dallas VA Medical Ctr, Dallas, TX, 2 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 3 Department of Medicine, New Haven, CT, 4 Yale University, New Haven, CT 2:45 pm 2858. Education Effects on Outcome Expectations for Exercise in Adults with Knee Osteoarthritis Tressa Gamache, Lori Lyn Price, Jeffrey B. Driban, William F. Harvey and Chenchen Wang, Tufts Medical Center, Boston, MA 3:00 pm 2859. Randomized Controlled Trial of Postoperative Care Navigation in Total Knee Arthroplasty Patients: Does One Size Fit All? Elena Losina, Jamie E. Collins, John Wright, Meghan E. Daigle, Laurel Donnell-Fink, Doris Strnad, Vladislav Lerner, Stanley Abrams and Jeffrey N. Katz, Brigham and Women s Hospital, Boston, MA 3:15 pm 2860. Randomised Comparison of the Effectiveness of a Non- Pharmacological Multidisciplinary Face-to-Face Group-Based Treatment Program Vs. a Telephone-Delivered Treatment Program on Daily Function in Patients with Generalized Osteoarthritis Nienke Cuperus 1, Thomas Hoogeboom 2, Clarinda Kersten 1, Leonie Rietveld 1, Alfons den Broeder 1, Thea Vliet Vlieland 3 and Cornelia H.M. van den Ende 1, 1 Sint Maartenskliniek, Nijmegen, Netherlands, 2 CAPHRI school for public health and primary care, CCTR centre for Care Technology Research, Maastricht University, Maastricht, Netherlands, 3 Leiden University Medical Center, Leiden, Netherlands 3:30 pm 2861. Changes in Knee Kinematics from a 6-Week Hip and Trunk Strengthening Program for Persons with Patellofemoral Osteoarthritis Lisa Hoglund 1, Laura Pontiggia 1, John Kelly IV 2, Mark Arnott 1, Olumide Babalola 1, Andrew Gushen 1 and James Carey 2, 1 University of the Sciences, Philadelphia, PA, 2 University of Pennsylvania, Philadelphia, PA 3:45 pm 2862. Satisfaction Following Total Knee Replacement: Journey or Destination? Jeffrey N. Katz 1, Yan Dong 1, Jamie E. Collins 1, John Wright 1, David Dalury 2, Kirk Kindsfater 3 and Elena Losina 1, 1 Brigham and Women s Hospital, Boston, MA, 2 Townson Orthopedics, Maryland, Baltimore, MD, 3 Orthopedic Center for the Rockies, Ft. Collins, CO ARHP SESSIONS 2:30 4:00 pm 204 A Brief Action Planning (BAP): A Motivational Interviewing (MI) Technique to Enhance Patient Self- Management and Improve Outcomes Moderator: Christine A. Stamatos, DNP, ANP-C TUESDAY november 18, 2014 Ed Pd PrM FIT explain how clinicians can efficiently, effectively engage their patients for enhanced self-management of chronic illness and improved outcomes describe the eight core competencies of Brief Action Planning (BAP) and the four elements of the Spirit of Motivational Interviewing (MI) 2014 Program Book 133
scientific sessions apply the principles and practices of BAP and MI in routine clinical work for enhanced patient self-management and improved outcomes 2:30 pm Brief Action Planning: Eight Core Competencies and the Spirit of Motivational Interviewing Steven Cole, MD 3:15 pm How to Apply Brief Action Planning in Your Routine Clinical Practice Joseph Weiner, MD, PhD 256 Osteoporosis: Emerging Treatments Both Pharmacological and Non-Pharmacological Moderator: Karen Huisinga, MN, ARNP integrate new pharmacological treatment regiments for osteoporosis evaluate current evidence supporting new treatment paradigms for osteoporosis formulate rehabilitation recommendations for the treatment of osteoporosis for those with rheumatic diseases 3:15 pm Coping for Caregivers: Strength-Based Coping Strategies for Family, Friends and Partners of Patients Living with Neuropsychiatric Lupus Liz Morasso, LCSW 153 B Treatment Considerations in Chronic Pain Moderator: Afton L. Hassett, PsyD describe the pathophysiologic mechanisms that occur when acute pain becomes chronic pain discuss the latest research in treatment options for chronic pain describe at least one new technique that may revolutionize our management of persistent pain 2:30 pm Recent Advances in the Diagnosis and Management of Chronic Pain Daniel J. Clauw, MD 3:15 pm Treatment Considerations in Chronic Pain Sean Mackey, MD, PhD TUESDAY november 18, 2014 2:30 pm Emerging Medicines for the Treatment of Osteoporosis Barry Gruber, MD 3:15 pm Rehabilitation Techniques for the Treatment of Osteoporosis Jennifer L. Trizuto, MPT 257 A The Psychosocial Impact and Treatment Options for Patients with Neuropsychiatric Lupus and Their Caregivers Moderator: Shawn Rose, MD, PhD identify the psychosocial quality of life indicators that are frequently impacted by nervous system involvement in lupus patients and to follow-through with a referral to a mental health professional, where appropriate summarize the pharmacological and non-pharmacological approaches currently in place to treat nervous system lupus recognize the psychological impact and lifestyle adjustments experienced by family members, friends and partners of patients with neuropsychiatric symptoms apply strength-based strategies to assist the caregivers of patients with neuropsychiatric symptoms ACR WORKSHO 4:00 6:00 pm 154 Admission to Workshops requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. Getting Electronic Health Records Right (240) Speaker: Salahuddin Kazi, MD describe the basic structure and capability of an electronic health record explain the principles and design of rheumatology-specific templates and order sets identify the key elements in current clinical processes and workflow to help optimize the utilization of an electronic health record 2:30 pm Neuropsychiatric Lupus: Health-Related Quality of Life and Treatment Options John G. Hanly, MD 134 2014 Program Book
scientific sessions 152 Systemic Sclerosis: How to Perform Skin Scores (241) Speaker: Daniel Furst, MD, MPH review the usefulness and reasons to do a modified Rodman skin score explain how to do a modified Rodman skin score demonstrate modified Rodman skin score under the supervision of experts 159 *Ultrasound Injection Guidance (242) Speaker: Gurjit S. Kaeley, MBBS, MRCP summarize the evidence for improved outcomes with ultrasound guidance of joint injections describe methods to optimize needle visualization review best practices for maintaining aseptic technique and probe positioning explain the anatomic approach for sonographically guided injection of major joints ACR SESSIONS 4:30 6:00 pm 160 B Autophagy in Rheumatic Diseases Moderator: Wael N. Jarjour, MD review the concept autophagy examine the role of autophagy in autoimmune diseases consider whether autophagy pathways are potential therapeutic targets 4:30 pm Autophagy-Inflammation-Cell Death Axis Jenny Ting, PhD 5:00 pm Autophagy and Autoimmune Diseases Cornelia M. Weyand, MD, PhD 5:30 pm Autophagy Pathways as Therapeutic Targets Andras Perl, MD, PhD 210 B Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management Moderators: Shreyasee Amin, MD CM, MPH and David T. Felson, MD, MPH discuss the potential role for different nutrients in osteoarthritis management describe the current evidence for specific vitamins in managing osteoarthritis recommend specific exercise prescriptions for knee and hip osteoarthritis may can be implemented in clinical practice 4:30 pm What Should I Eat to Help My Osteoarthritis? Shivani Sahni, PhD 5:00 pm Is There Evidence that Vitamins Can Help Osteoarthritis? Timothy E. McAlindon, MD, MPH, MRCP 5:30 pm Exercise for Osteoarthritis Management: Science in Action! Ewa M. Roos, PT, PhD 52 A Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond Ed Pd PrM FIT Moderators: Michael H. Weisman, MD and Arthur Kavanaugh, MD identify important safety issues in the drug treatment of rheumatic diseases integrate knowledge of new safety issues into their treatment strategies review how to more fully advise patients about the safety issues related to treatments for rheumatic diseases recognize evolutions at the FDA that will affect drug safety monitoring and reporting 4:30 pm Rheumatological Drugs in Pregnancy: Update on Fetal Safety Gideon Koren, MD 4:50 pm Update and Safety Issues of Recently Approved Agents for Rheumatic Diseases Nikolay P. Nikolov, MD 5:15 pm The Year in Review Update on Safety Issues at the FDA for the Last 12 Months Janet W. Maynard, MD, MHS ACR CONCURRENT ABSTRACT SESSIONS 4:30 6:00 pm 104 B Antiphospholipid Syndrome Moderators: Roger A. Levy, MD and Joyce Rauch, PhD 2014 Program Book 135 TUESDAY november 18, 2014
scientific sessions TUESDAY november 18, 2014 4:30 pm 2863. IgG Antiphospholipid Antibodies Enhance Stroke Damage: An in Vivo Ischemia/Reperfusion Study Charis Pericleous 1, Valerie Taylor 2, Lauren Bourke 3, Daniel Stuckey 2, Jed Wingrove 4, Mark Lythgoe 2, Silvia S. Pierangeli 5, Anisur Rahman 4, Ian Giles 1 and Yiannis Ioannou 6, 1 Centre for Rheumatology, University College London, London, United Kingdom, 2 Centre for Advanced Biomedical Imaging (CABI), University College London, London, United Kingdom, 3 Centre for Rheumatology Research, University College London, London, United Kingdom, 4 University College London, London, United Kingdom, 5 University of Texas Medical Branch, Galveston, TX, 6 Centre for Rheumatology Research, University College Hospital London, London, United Kingdom 4:45 pm 2864. Markers of Thrombotic Events in Autoimmune Diseases: Comparison of Antiphospholipid Score (apl-s) and Global Anti- Phospholipid Syndrome Score (GAS) Kenji Oku, Olga Amengual, Ryo Hisada, Kazumasa Oomura, Ikuma Nakagawa, Toshiyuki Watanabe, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Hokkaido University Graduate School of Medicine, Sapporo, Japan 5:00 pm 2865. The Cellular Effects of ANTI-Factor Xa Antibodies Isolated from Patients with Antiphospholipid Syndrome ARE Inhibited By Factorxa Inhibitors, Hydroxychloroquine and Fluvastatin Bahar Artim-Esen 1, Natalia Smoktunowicz 2, Vera M. Ripoll 3, Charis Pericleous 3, Rachel Chambers 2, Ian Mackie 4, David Isenberg 5, Anisur Rahman 6, Yiannis Ioannou 5 and Ian Giles 3, 1 Rheumatology Division, Department of Internal Medicine, Istanbul Faculty of Medicine,Istanbul University, Istanbul, Turkey, 2 Respiratory Research Unit, University College London, London, United Kingdom, 3 Centre for Rheumatology, University College London, London, United Kingdom, 4 Haemostasis Research Unit, University College London, London, United Kingdom, 5 Centre for Rheumatology Research, University College Hospital London, London, United Kingdom, 6 University College London, London, United Kingdom 3 Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d interface, Nancy, F-54000, France, Nancy, France, 4 CHU Nancy, Vandoeuvre, France, 5 Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, 6 INOVA Diagnostics, San Diego, CA, 7 Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, 8 University of Lorraine, Nancy, France, 9 Department of Nephrology and Internal Medicine, Hôpital Edouard Herriot, Lyon, France, Lyon, France, 10 Bensançon University Hospital, Besançon, France, 11 Nouvel Hospital Civil, Strasbourg Cedex, France, 12 Lille University Hospital, Lille, France, 13 Hopital Du Bocage, Service de Médecine Interne et Immunologie Clinique, Dijon, France, 14 Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, 15 INSERM, Centre d Investigation Clinique Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, 16 Nancy University Hospital and INSERM U961, Vandoeuvre-Les-Nancy, France 5:30 pm 2867. Antiphospholipid Antibodies Promote the Release of Neutrophil Extracellular Traps: a New Mechanism of Thrombosis in the Antiphospholipid Syndrome Srilakshmi Yalavarthi 1, Levi F. Mazza 1, Alexandra E. Morris 1, Carlos Núñez-Álvarez 2, Diego Hernández 2, Paula L. Bockenstedt 1, Antonio R. Cabral 2 and Jason S. Knight 1, 1 University of Michigan, Ann Arbor, MI, 2 Instituto Nacional de Ciencias Medicas y Nutricion, Mexico City, Mexico 5:45 pm 2868. Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (A ACTION) Clinical Database and Repository Initial Analysis Doruk Erkan 1, Danieli Andrade 2, Maria Tektonidou 3, Amaia Ugarte 4, Alessandra Banzato 5, Angela Tincani 6, Pier-Luigi Meroni 7, Ricard Cervera 8, Paul R. Fortin 9, Roger A. Levy 10 and On Behalf of A Action 11, 1 Hospital for Special Surgery, New York, NY, 2 University of São Paulo, São Paulo, Brazil, 3 First Department 5:15 pm 2866. External Validation of the Global Anti-Phospholipid Syndrome Score in Comparison to IgG Antibodies Directed Against Domain I of ß 2 -Glycoprotein I. a Prospective Multicentre Cohort Study Stephane Zuily 1, Bas De Laat 2, Veronique Regnault 3, Pierre Kaminsky 4, Hilde Kelchtermans 5, Zakera Shums 6, Roger Albesa 6, Gary L Norman 6, Philip de Groot 7, Anne-Christine Rat 8, Jacques Ninet 9, Nadine Magy-Bertrand 10, Jean-Louis Pasquali 11, Marc Lambert 12, Bernard Lorcerie 13, Thomas Lecompte 14, Francis Guillemin 15 and Denis Wahl 16, 1 CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, 2 Biochemistry, CARIM, Maastricht University, Maastricht, Netherlands, of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, 4 Hospital Universitario Cruces, Bizkaia, Spain, 5 Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, 6 Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, 7 University of Milan, Milano, Italy, 8 Hospital Clinic, Barcelona, Spain, 9 Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, 10 Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, 11 A ACTION, New York, NY 136 2014 Program Book
scientific sessions 109 A B Cell Biology and Targets in Autoimmune Disease Moderators: Jennifer H. Anolik, MD, PhD and Shaun Jackson, MD PhD 4:30 pm 2869. TLR7 Influences Autoreactive B Cell Selection in the Germinal Center Weiqing Huang 1, Megan Woods 1, Alexis Boneparth 2, Ramalingam Bethunaickan 1, Ranjit Sahu 1 and Anne Davidson 1, 1 Feinstein Institute for Medical Research, Manhasset, NY, 2 Rutgers-Robert Wood Johnson Medical School, New Brunswick, NJ 4:45 pm 2870. B Cell-Intrinsic Deletion of the Type 1 Interferon Receptor Does Not Impact the Development of Murine Lupus Shaun W. Jackson, Nicole Scharping, Socheath Khim and David Rawlings, Seattle Children s Research Institute, Seattle, WA 5:00 pm 2871. Break of Anergy in Human Autoreactive B Cells By T Helper Signals Restores B Cell Receptor Signaling Capacity and Is Dependent on Upregulation of CD45 Phosphatase Activity-a Possible Novel Mechanism of Breech of B Cell Tolerance in Rheumatic Diseases Peter Szodoray 1, Stephanie M. Stanford 2, Nunzio Bottini 2 and Britt Nakken 1, 1 Institute of immunology, Rikshospitalet, Oslo University Hospital, Oslo, Norway, 2 La Jolla Institute for Allergy and Immunology, La Jolla, CA 5:15 pm 2872. B-Cell Autoepitope and Tetramer Analysis Reveals Expansion of Apoptotic Autoantigen La and snrnp Reactive B Cells in BXD2 Mice Jennie Hamilton 1, Jun Li 1, Qi Wu 1, PingAr Yang 1, Bao Luo 1, Hao Li 1, Troy Randall 1, John Edwin Bradley 1, Justin J. Taylor 2, John D. Mountz 3 and Hui-Chen Hsu 1, 1 University of Alabama at Birmingham, Birmingham, AL, 2 Fred Hutchinson Cancer Research Center, Seattle, WA, 3 Birmingham VA Medical Center, Birmingham, AL 5:30 pm 2873. Epratuzumab Induces Broad Inhibition of B Cell Receptor Proximal Signaling but Has Opposing Effects on Distal Signaling in B Cell Subsets: A Profile of Effects on Functional Immune Signaling By Single Cell Network Profiling Alison Maloney 1, Drew Hotson 2, Stephen Rapecki 1, Gianluca Fossati 1, Simon Lumb 1, David Rosen 2, Santosh Putta 2, Nikil Wale 2, David Spellmeyer 2, Alessandra Cesano 2, Rachael Hawtin 2 and Anthony Shock 1, 1 UCB Pharma, Slough, United Kingdom, 2 Nodality Inc., South San Francisco, CA 5:45 pm 2874. Pro-Inflammatory FcRL4+ Memory B Cells in Joints of RA Patients: Immunoglobulin Gene Characteristics and Antigen Specificity Khaled Amara 1, Lorraine Yeo 2, Natalie Sippl 1, Philip Titcombe 1, Andrew Filer 3, Karim Raza 3, Dagmar Scheel-Toellner 2 and Vivianne Malmström 4, 1 Rheumatology Unit, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, SE-17176 Solna, Stockholm, Sweden., Stockholm, Sweden, 2 Rheumatology Research Group, Centre for Translational Inflammation Research, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, UK, Birmingham, United Kingdom, 3 Rheumatology Research Group, MRC Centre for Immune Regulation, School of Immunity and Infection, University of Birmingham, Birmingham, United Kingdom, 4 Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden 107 B Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis II Moderators: George D. Kalliolias, MD, PhD and Dana E. Orange, MD, MS 4:30 pm 2875. Macrophage Expression of Hypoxia-Inducible Factor-2 Alpha Promotes Rheumatoid Arthritis Progression Munitta Muthana 1, William Jacob Hardy 1, Sarah Hawtree 1, Fiona Wright 1, Ursula Fearon 2, DJ Veale 3, Mauro Perretti 4 and Anthony G. Wilson 5, 1 University of Sheffield, Sheffield, United Kingdom, 2 Translational Rheumatology Research Group, Dublin, Ireland, 3 St. Vincent s University Hospital, Dublin, Ireland, 4 Barts and the London School of Medicine, London, United Kingdom, 5 University College Dublin, Dublin, Ireland 4:45 pm 2876. Interleukin-10 Receptor Blockade during Lcmv Infection Results in Macrophage Activation Syndrome-like Disease in Mice Lehn K. Weaver 1 and Edward M. Behrens 2, 1 Children s Hospital of Philadelphia, Philadelphia, PA, 2 Childrens Hospital of Philadelphia, Philadelphia, PA 5:00 pm 2877. Novel Function of Tocilizumab As a Modulator of Interleukin-27-Mediated Anti-Inflammatory Responses Misato Hashizume 1, Jun Kikuchi 2, Keiko Yoshimoto 2 and Tsutomu Takeuchi 2, 1 Chugai Pharmaceutical Co., Ltd., Gotemba, Japan, 2 Keio University School of Medicine, Tokyo, Japan 5:15 pm 2878. G Protein Signaling Modulator 3 (GM3) Deficiency Is Protective in Inflammatory Arthritis Models and Altered GM3 Gene Products Correlate with Single Nucleotide Polymorphisms in Humans Teresa K. Tarrant 1, D. Stephen Serafin 1, Elizabeth Sugg 1, Roman Timoshchenko 1, Matthew J. Billard 1, David P. Siderovski 2 and Kristy Richards 3, 1 Thurston Arthritis Research Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, 2 West Virginia University School of Medicine, Morgantown, WV, 3 Dept. of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC 5:30 pm 2879. Epigallocatechin-3-Gallate (EGCG) Suppresses IL-1β- 2014 Program Book 137 TUESDAY november 18, 2014
scientific sessions Induced IL-6 and IL-8 Synthesis By Selectively Inhibiting TAK1 Activation in Human Rheumatoid Arthritis Synovial Fibroblasts Anil Singh 1, Sharayah Riegsecker 2, Sadiq Umar 1 and Salahuddin Ahmed 1, 1 Washington State University, Spokane, WA, 2 University of Toledo, Toledo, OH 5:45 pm 2880. Elevated Levels of Soluble Inflammatory Mediators and Lupus-Specific Connective Tissue Disease Questionnaire Scores Discern Unaffected First Degree Relatives of Lupus Patients from Unaffected Individuals Not Related to Lupus Patients Melissa E. Munroe 1, Kendra A. Young 2, Jennifer Fessler 1, Dustin Fife 1, Diane L. Kamen 3, Joel M. Guthridge 1, Timothy B. Niewold 4, Michael H. Weisman 5, Mariko L. Ishimori 5, Daniel J. Wallace 5, David R. Karp 6, John B. Harley 7, Gary S. Gilkeson 3, Jill M. Norris 2 and Judith A. James 1, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 Colorado School of Public Health, Aurora, CO, 3 Medical University of South Carolina, Charleston, SC, 4 Mayo Clinic, Rochester, MN, 5 Cedars-Sinai Medical Center, Los Angeles, CA, 6 UT Southwestern Medical Center, Dallas, TX, 7 Cincinnati Children s Hospital Medical Center; US Department of Veterans Affairs Medical Center, Cincinnati, OH 5:15 pm 2884. Training the Rheumatologists of Tomorrow: The Canadian Experience Alfred Cividino 1, Volodko Bakowsky 2, Susan Barr 3, Louis Bessette 4, Nader Khalidi 5, Christian A. Pineau 6, Janet E. Pope 7, David Robinson 8, Kam Shojania 9, Elaine Yacyshyn 10, Lynne Lohfeld 1 and Diane Crawshaw 1, 1 McMaster University, Hamilton, ON, 2 Dalhousie University, Halifax, NS, 3 Heritage Medical Research Bldg, Calgary, AB, 4 Laval University, Québec, QC, 5 Division of Rheumatology, McMaster University, Hamilton, ON, 6 McGill University Health Center, Montreal, QC, 7 St Joseph Health Care, London, ON, 8 University of Manitoba, Winnipeg, MB, 9 University of British Columbia, Vancouver, BC, 10 University of Alberta, Edmonton, AB 5:30 pm 2885. Clinical Training Opportunities in Two Innovative Ambulatory Resources: The Primary Care Musculoskeletal Clinic and Center of Excellence Multidisciplinary Clinic Michael J. Battistone, Andrea M. Barker, Marissa Grotzke, Peter Beck, Jeffery Berdan, Phillip Lawrence and Grant W. Cannon, Salt Lake City VA and University of Utah, Salt Lake City, UT TUESDAY november 18, 2014 156 B Education Ed Pd PrM FIT Moderators: Kenneth S. O Rourke, MD and Deana M. Lazaro, MD 4:30 pm 2881. The Center of Excellence in Musculoskeletal Care and Education: A Sustainable Interprofessional, Multidisciplinary Programmatic Innovation Developed with the Department of Veterans Affairs Michael J. Battistone, Andrea M. Barker, Marissa Grotzke, Peter Beck, Jeffery Berdan, Caroline Milne, JoAnn Rolando and Grant W. Cannon, Salt Lake City VA and University of Utah, Salt Lake City, UT 4:45 pm 2882. Using Decision-Based Learning to Highlight Rheumatic Disease for Third-Year Medical Students Karen Law 1, J Richard Pittman 1 and Chad Miller 2, 1 Emory University School of Medicine, Atlanta, GA, 2 Tulane University Health Sciences Center School of Medicine, New Orleans, LA 5:00 pm 2883. Rheumatology-Specific Milestones for a Musculoskeletal Radiology Curriculum Michelle Newkirk 1, Liem Mansfield 1, Jay B. Higgs 2 and Daniel Battafarano 1, 1 San Antonio Military Medical Center, JBSA Ft Sam Houston, TX, 2 San Antonio Military Medical Center, JBSA Fort Sam Houston, TX 5:45 pm 2886. Assessing Rheumatology Fellows Teaching Skills Using the Objective Structured Teaching Exercise (OSTE) Eli M. Miloslavsky 1, Marcy B. Bolster 1, Kenneth S. O Rourke 2 and Lisa G. Criscione-Schreiber 3, 1 Massachusetts General Hospital, Boston, MA, 2 Wake Forest School of Medicine, Winston-Salem, NC, 3 Duke University Health System, Durham, NC 258 B Epidemiology and Public Health IV: Rheumatoid Arthritis Pathogenesis Moderators: Cheryl Barnabe, MD, MSc and Yvonne C. Lee, MD, MMSc 4:30 2887. Post-Menopausal Factors and the Risk of Seropositive and Seronegative Rheumatoid Arthritis Phenotypes: Results from the Nurses Health Study Camilla Bengtsson 1, Susan Malspeis 2, Jeffrey A. Sparks 2, Karen H. Costenbader 2 and Elizabeth W. Karlson 2, 1 Karolinska Institutet, Stockholm, Sweden, 2 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 4:45 pm 2888. Amount of Smoking, Duration of Smoking Cessation and Their Interaction with Silica Exposure in the Risk of Rheumatoid Arthritis: Results from the Swedish Epidemiological Investigation of Rheumatoid Arthritis Study Xia Jiang 1, Camilla Bengtsson 1, Henrik Källberg 1, Lars Klareskog 2 and Lars Alfredsson 3, 1 Karolinska Institutet, Stockholm, Sweden, 2 Karolinska University Hospital, Stockholm, Sweden, 3 The Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden 138 2014 Program Book
scientific sessions 5:00 pm 2889. The Association Between Changes in Inflammation and High Density Lipoprotein Cholesterol Efflux Capacity in Rheumatoid Arthritis K P Liao 1, Martin Playford 2, Michelle A. Frits 1, Christine K. Iannaccone 1, Jonathan S. Coblyn 1, Michael E. Weinblatt 1, Nancy A. Shadick 3 and Nehal N. Mehta 4, 1 Brigham and Women s Hospital, Boston, MA, 2 National Heart, Blood and Lung Institute, Bethesda, MD, 3 Brigham and Women s Hospital/ Harvard University, Cambridge, MA, 4 University of Pennsylvania, Philadelphia, PA 5:15 pm 2890. Does a Family History of RA Influence the Clinical Presentation and Treatment Response in RA? Thomas Frisell 1, Saedis Saevarsdottir 2 and Johan Askling 3, 1 Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Stockholm, Sweden, 2 Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 3 Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden 4:30 pm 2893. Genome-Wide Association Study of Osteoarthritis Progression: Results from the Osteoarthritis Initiative Michelle S. Yau 1, Laura M. Yerges-Armstrong 1, Youfang Liu 2, David J. Duggan 3, Joanne M. Jordan 2, Braxton D. Mitchell 1, Rebecca D. Jackson 4 and Marc C. Hochberg 1, 1 University of Maryland School of Medicine, Baltimore, MD, 2 University of North Carolina, Chapel Hill, NC, 3 Translational Genomics Research Institute, Phoenix, AZ, 4 The Ohio State University, Columbus, OH 4:45 pm 2894. Relationship of Dermal Advanced Glycation End Products and Hand OA Charles Eaton 1, Jeffrey Driban 2, Bing Lu 3, Mary Roberts 4 and Timothy E. McAlindon 2, 1 Center for Primary Care and Prevention, Memorial Hospital of Rhode Island, Providence, RI, 2 Tufts Medical Center, Boston, MA, 3 Brigham and Women s Hospital, Foxboro, MA, 4 Center for Primary Care and Prevention, Pawtucket, RI 5:30 pm 2891. Inflammatory Genes Are Associated with Autoantibodies in Rheumatoid Arthritis-Free Individuals Who Are at-risk for Future Disease Ryan W. Gan 1, Kendra A. Young 1, M. Kristen Demoruelle 2, Michael H. Weisman 3, Jane H. Buckner 4, P. K. Gregersen 5, Ted R. Mikuls 6, James R. O Dell 6, Richard M. Keating 7, Elizabeth W. Karlson 8, Kevin D. Deane 2, V. Michael Holers 2 and Jill M. Norris 1, 1 Colorado School of Public Health, Aurora, CO, 2 University of Colorado School of Medicine, Aurora, CO, 3 Cedars-Sinai Medical Center, Los Angeles, CA, 4 Benaroya Research Institute at Virginia Mason, Seattle, WA, 5 Feinstein Institute Medical Research and North Shore-Long Island Jewish Health System, Manhasset, NY, 6 Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 7 Scripps Clinic, La Jolla, CA, 8 Brigham and Women s Hospital, Harvard Medical School, Boston, MA 5:45 pm 2892. The Relative Risk of Incident NON-Ischemic Heart Failure in Prevalent Rheumatoid Arthritis Ängla Mantel 1, Marie Holmqvist 2, Johan Askling 3, Lars Lund 4 and Daniel Andersson 5, 1 Clinical Epidemiology Unit, Dept of Medicine, Karolinska Institutet, Solna, Sweden, 2 Unit of Clinical Epidemiology, Department of Medicine, Stockholm, Sweden, 3 Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 4 Unit of Cardiology section for Heart Failure. Department of Medicine, Stockholm, Sweden, 5 Unit of Cardiology Section for Heart Failure. Department of Medicine, Stockholm, Sweden 153 B Osteoarthritis Clinical Aspects II: Osteoarthritis Risk Factors and Therapies Moderators: Philip G. Conaghan, MD, PhD and Margreet Kloppenburg, MD, PhD 5:00 pm 2895. Habitual Running Any Time in Life Is Not Detrimental and May be Protective of Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative Grace H. Lo 1, Jeffrey B. Driban 2, Andrea Kriska 3, Kristi Storti 3, Timothy E. McAlindon 2, Richard Souza 4, Charles B. Eaton 5, Nancy J. Petersen 6 and Maria E. Suarez-Almazor 7, 1 Michael E. DeBakey VA Medical Center, Baylor College of Medicine, Houston, TX, 2 Tufts Medical Center, Boston, MA, 3 University of Pittsburgh, Pittsburgh, PA, 4 University of California, San Francisco, San Francisco, CA, 5 Memorial Hospital of Rhode Island, Pawtucket, RI, 6 Baylor College of Medicine, Houston, TX, 7 The University of Texas, MD Anderson Cancer Center, Houston, TX 5:15 pm 2896. A Multi-Center Double-Blind, Randomized, Controlled Trial (db-rct) to Evaluate the Effectiveness and Safety of Co- Administered Traumeel (Tr14) and Zeel (Ze14) Intra articular (IA) Injections Versus IA Placebo in Patients with Moderate-to- Severe Pain Associated with OA of the Knee Carlos Lozada 1, Eve del Rio 2, Donald Reitberg 3, Robert Smith 3, Charles Kahn 4 and Roland W. Moskowitz 5, 1 University of Miami Miller School of Medicine, Miami, FL, Miami, FL, 2 Rio Pharmaceutical Services, LLC, Bridgewater, Afghanistan, 3 Rio Pharmaceutical Services, LLC, Bridgewater, NJ, 4 South Florida Rheumatology, Hollywood, FL, 5 University Hospitals Case Medical Center, Cleveland, OH 5:30 pm 2897. Exercise Therapy and/or Manual Therapy for Hip or Knee Osteoarthritis: 2-Year Follow-up of a Randomized Controlled Trial J. Haxby Abbott 1, Cathy Chapple 1, Daniel Pinto 2, Alexis Wright 3 and Jean-Claude Theis 1, 1 University of Otago, Dunedin, New Zealand, 2 Northwestern University, Chicago, IL, 3 High Point University, High Point, NC TUESDAY november 18, 2014 2014 Program Book 139
scientific sessions TUESDAY november 18, 2014 5:45 pm 2898. New Insights into the Primary Care Osteoarthritis Consultation with Implications for Practice Zoe Paskins, Tom Sanders, Peter Croft and Andrew Hassell, Keele University, Keele, United Kingdom 205 B Pediatric Rheumatology Clinical and Therapeutic Aspects: Miscellaneous Pediatric Rheumatic Diseases Ed Pd PrM FIT Moderators: Andreas Reiff, MD and Lisa F. Imundo, MD 4:30 pm 2899. High Dose Aspirin for Treating Kawasaki Disease Outdated Myth or Effective Aid? Gil Amarilyo 1, Yael Koren 2, Dafna Brik Simon 1, Maskit Bar-Meir 3, Hilla Bahat 4, Mona Hanna Helou 5, Amir Mendelson 6, Yackov Berkun 7, Eli Eisenstein 7, Yonatan butbul Aviel 5, Galia Barkai 8, Yoav Bolkier 8, Shai Padeh 8, Philip J. Hashkes 3, Riva Brik 5, Liora Harel 1 and Yosef Uziel 6, 1 Schneider Children s Medical Center of Israel, Petach Tikvah, Israel, 2 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 3 Shaare-Zedek Medical Center, Jerusalem, Israel, 4 Assaf Harofeh Medical Center, Zerifin, Israel, 5 Rambam Medical Center, Haifa, Israel, 6 Meir Medical Center, Kfar Saba, Israel, 7 Hadassah Hebrew University Medical Center, Jerusalem, Israel, 8 Sheba Medical Center, Tel-Hashomer, Israel 4:45 pm 2900. Clinically Inactive Disease in Juvenile Dermatomyositis a Proposed Revision to the Pediatric Rheumatology International Trials Organisation Criteria Beverley Almeida 1, Raquel Campanilho-Marques 2, Katie Arnold 2, Lucy R. Wedderburn 3, Clarissa A Pilkington 1 and Kiran Nistala 4, 1 Great Ormond Street Hospital for Children NHS Trust, London, United Kingdom, 2 UCL Institute for Child Health, London, United Kingdom, 3 UCL, UCLH, GOSH NHS Trust, London, United Kingdom, 4 University College London, London, United Kingdom 5:00 pm 2901. Predictors of Relapse after Discontinuing Systemic Treatment in Childhood Autoimmune Chronic Uveitis Gabriele Simonini 1, Claudia Bracaglia 2, Marco Cattalini 3, Andrea Taddio 4, Alice Brambilla 1, Cinzia DeLibero 5, Denise Pires Marafon 6, Roberto Caputo 5 and Rolando Cimaz 1, 1 Anna Meyer Children s Hospital-University of Firenze, Florence, Italy, 2 Division of Rheumatology, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy, 3 Pediatric Immunology and Rheumatology Unit, Brescia, Italy, 4 Institute of Child Health, IRCCS Burlo Garofolo, University of Trieste, Trieste, Italy, 5 Anna Meyer Children s Hospital, Florence, Italy, 6 Ospedale Pediatrico Bambino Gesù, IRCCS, Roma, Italy 5:15 pm 2902. The Health Status of Patients with Juvenile Idiopathic Arthritis (JIA) Significantly Worsens after Transfer from Pediatric to Adult Care Kirsten Minden 1, Jens Klotsche 2, Martina Niewerth 2, Angela Zink 3 and Gerd Horneff 4, 1 Charité University Medicine, Berlin, Germany, 2 German Rheumatism Research Center, Berlin, Germany, 3 German Rheumatism Research Centre and Charité University Medicine, Berlin, Germany, 4 Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany 5:30 pm 2903. Early Outcomes in Pediatric Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV) Kimberly Morishita 1, Susanne Benseler 2, Rae S.M. Yeung 3, Thomas Mason II 4, Dawn Wahezi 5, Kenneth N. Schikler 6, Erica F. Lawson 7, Susan Nielsen 8, Sirirat Charuvanij 9, Paul Dancey 10, Susan Shenoi 11, Linda Wagner-Weiner 12, Angelyne Sarmiento 1, David A. Cabral 1 and For the PedVas Initiative 1, 1 BC Children s Hospital and University of British Columbia, Vancouver, BC, 2 Department of Pediatrics/University of Calgary, Calgary, AB, 3 The Hospital for Sick Children and University of Toronto, Toronto, ON, 4 Mayo Clinic, Rochester, MN, 5 Children s Hospital at Montefiore, Bronx, NY, 6 Univ of Louisville Schl of Med, Louisville, KY, 7 University of California, San Francisco, San Francisco, CA, 8 Rigshospitalet, Copenhagen, Denmark, 9 Siriraj Hospital, Bangkok, Thailand, 10 Janeway Children s Hospital, St. John s, NL, 11 Seattle Childrens Hospital, Seattle, WA, 12 University of Chicago Hospital, Chicago, IL 5:45 pm 2904. Clinical and Radiological Features of Down s Arthropathy Charlene Foley, Orla Killeen and Emma Jane MacDermott, The National Centre for Paediatric Rheumatology, Dublin, Ireland 151 A Rheumatoid Arthritis Animal Models II Moderators: Harris R. Perlman, PhD and Thomas Pap, MD 4:30 pm 2905. The IL-6/Th17 Axis Promotes Autoantibody-Associated Autoimmune Valvular Carditis in Mice Jennifer L. Auger, Brianna J. Engelson, Yaya Wang, Erik J. Peterson and Bryce A. Binstadt, University of Minnesota, Minneapolis, MN 4:45 pm 2906. Systemic Delivery of Short Hairpin RNA Targeting Calcium Release-Activated Calcium Channel 3 Down-Regulates Severity of Collagen-Induced Arthritis Shuang Liu 1, Takeshi Kiyoi 2, Shohei Watanabe 3 and Kazutaka Maeyama 1, 1 Informational Biomedicine, Ehime University Graduate School of Medicine, Toon-shi, Ehime, Japan, 2 Integrated Center for Sciences, Ehime University, Ehime, Japan, 3 Japan Community Health Care Organization Uwajima Hospital, Ehime, Japan 140 2014 Program Book
scientific sessions 5:00 pm 2907. Loss of microrna-146a Exacerbates Inflammatory Arthritis Victoria Saferding 1, Antonia Puchner 1, Eliana Goncalvesalves 1, Birgit Niederreiter 1, Silvia Hayer 1, Gernot Schabbauer 2, Marije Koenders 3, Josef S. Smolen 1, Kurt Redlich 1 and Stephan Blueml 1, 1 Medical University of Vienna, Vienna, Austria, 2 Medical University Vienna, Vienna, Austria, 3 Radboud University Nijmegen Medical Center, Nijmegen, Netherlands 5:15 pm 2908. Flip Deficiency in Dendritic Cells Promotes Spontaneous Arthritis Mediated By Reduced Treg and Increased Autoreactive CD4 + t Cells Qiquan Huang 1, Harris R. Perlman 1, Robert Birkett 1, Renee E. Doyle 1, Deyu Fang 1, G Kenneth.Haines 2, William H. Robinson 3, Syamal K. Datta 1, Hyewon Phee 1 and Richard M. Pope 4, 1 Northwestern University Feinberg School of Medicine, Chicago, IL, 2 Mount Sinai Hospital School of Medicine, New York, New York, NY, 3 VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 4 Northwestern University Feinberg school of Medicine, Chicago, IL 5:30 pm 2909. Tolerogenic Splenic IDO+ Dendritic Cells from the Mice Treated with Induced-Treg Cells Could Suppress Collagen- Induced Arthritis Jie Yang 1, Huahua Fan 2 and Hejian Zou 1, 1 Division of Rheumatology, Huashan Hospital, Fudan University, Shanghai 200040, China, Shanghai, China, 2 Blood Engineering Laboratory, Shanghai Blood Center, Shanghai 200051, China, Shanghai, China 5:45 pm 2910. Tofacitinib Facilitates the Expansion of Myeloid-Derived Suppressor Cells and Ameliorates Arthritis in SKG Mice Keisuke Nishimura, Jun Saegusa, Fumichika Matsuki, Kengo Akashi, Goichi Kageyama and Akio Morinobu, Kobe University Graduate School of Medicine, Kobe, Japan Ballroom East Rheumatoid Arthritis Clinical Aspects VI: Impact of Treatment and Other Interventions Moderators: Clifton O. Bingham, III, MD and Nancy A. Shadick, MD, MPH 4:30 pm 2911. Clinical Outcomes of Early RA after 7 Years Does T2T Approach Overcome Delay of Therapy? Tuulikki Sokka 1, Hannu Kautiainen 2, Tuomas Rannio 3, Juha Asikainen 1 and Pekka Hannonen 1, 1 Jyvaskyla Central Hospital, Jyväskylä, Finland, 2 Medcare Oy, Äänekoski, Finland, 3 Kuopio University Hospital, Kuopio, Finland 4:45 pm 2912. Impact of Failure to Adhere to Treat-to-Target of Rheumatoid Arthritis in Real World Practice: Data from the International Rheumatoid Arthritis Biomarker Program WP Maksymowych 1, M. Østergaard 2, O Elkayam 3, R Landewé 4, J Homik 5, C Thorne 6, M Backhaus 7, S Shaikh 8, G Boire 9, M Larche 10, B Combe 11, T Schaeverbeke 12, A Saraux 13, G Ferraccioli 14, M Dougados 15, C Barnabe 16, M Govoni 17, PP Tak 18, D. van Schaardenburg 19, D van der Heijde 20, R Dadashova 1, E Hutchings 1, J Paschke 1 and Oliver FitzGerald 21, 1 CaRE Arthritis, Edmonton, AB, 2 Copenhagen Center for Arthritis Research, Glostrup, Denmark, 3 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 4 Amsterdam Rheumatology Center, Amsterdam, Netherlands, 5 University of Alberta, Edmonton, AB, 6 Southlake Regional Health Centre, Newmarket, ON, 7 Charite University Hospital, Berlin, Germany, 8 Niagara Peninsula Arthritis Centre, Hamilton, ON, 9 CHUS-Sherbrooke University, Sherbrooke, QC, 10 St Joseph s Healthcare Hamilton, Hamilton, ON, 11 Hôpital Lapeyronie, Montpellier, France, 12 Bordeaux University Hospital, Bordeaux, France, 13 CHU Brest and EA 2216, UBO, Brest, France, 14 Catholic University of The Sacred Heart, Rome, Italy, 15 Hopital Cochin, Paris, France, 16 University of Calgary, Calgary, AB, 17 Universita di Ferrara, Ferrara, Italy, 18 Academic Medical Center, Amsterdam, Netherlands, 19 Jan van Breemen Research Institute, Amsterdam, Netherlands, 20 Leiden University Medical Center, Leiden, Netherlands, 21 St. Vincent s University Hospital, Dublin, Ireland 5:00 pm 2913. Does Corticosteroid Therapy at Disease Onset Influence Disease Progression of RA? Results from the Swiss Prospective Observational Cohort Ruediger Mueller 1, Nazim Reshiti 2, Toni Kaegi 1, Axel Finckh 3, Hendrik Schulze-Koops 4, Michael H. Schiff 5 and Johannes von Kempis 6, 1 Kantonsspital St. Gallen, St. Gallen, Switzerland, 2 Division of Rheumatology, St. Gallen, Switzerland, 3 Geneva University Hospital, Geneva, Switzerland, 4 University of Munich, Munich, Germany, 5 University of Colorado, Denver, CO, 6 St. Gallen Hospital, CH- 9007 St. Gallen, Switzerland 5:15 pm 2914. The Clinical and Radiographic Course of Early Undifferentiated Arthritis Under Treatment Is Not Dependent on the Amount of Erosions at Diagnosis. Results from the Swiss Prospective Observational Cohort Ruediger Mueller 1, Toni Kaegi 1, Sarah Haile 2 and Johannes von Kempis 3, 1 Kantonsspital St. Gallen, St. Gallen, Switzerland, 2 University of Zurich, Switzerland, Zurich, Switzerland, 3 St. Gallen Hospital, CH- 9007 St.Gallen, Switzerland 5:30 pm 2915. Effects of Methotrexate on Anti-TNF Treatment in Rheumatoid Arthritis: An in-depth Analysis of a Prospective Observational Study with Adalimumab Marc Schmalzing 1, Frank Behrens 2, Eva C. Scharbatke 1, Michaela Koehm 3, Bianca Wittig 4, Gerd Greger 5, Harald Burkhardt 2 and Hans-Peter Tony 1, 1 University of Würzburg, Würzburg, Germany, 2 Goethe-University Frankfurt, Frankfurt, Germany, 3 Fraunhofer TUESDAY november 18, 2014 2014 Program Book 141
scientific sessions TUESDAY november 18, 2014 Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, 4 Abbvie Deutschland GmbH & Co. KG, Wiesbaden, Germany, 5 AbbVie GmbH & Co KG, Wiesbaden, Germany 5:45 pm 2916. Effects of Exercise on Body Composition, Cardiovascular Fitness, Muscle Strength and Cognition in Patients with Rheumatoid Arthritis: A Randomised Controlled Trial of a Patient-Specific Exercise Programme Maha Azeez 1, Ciara Clancy 2, Tom O Dwyer 2, Fiona Wilson 2 and Gaye Cunnane 1, 1 St James s Hospital and Trinity College Dublin, Dublin, Ireland, 2 Trinity College Dublin, Dublin, Ireland 157 B Rheumatoid Arthritis Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes Moderators: Erik J. Peterson, MD and Jeremy Sokolove, MD 4:30 pm 2917. Inhibition of PAD4 Activity and the Formation of Neutrophil Extracellular Traps Via PTPN22, but Not Its Rheumatoid Arthritis-Prone W620 Variant I-Cheng Ho 1, Hui-Hsin Chang 1, Nishant Dwivedi 1, Hsiao-Wei Tsao 1 and Anthony Nicholas 2, 1 Brigham and Women s Hospital, Boston, MA, 2 University of Alabama at Birmingham, Birmingham, AL 4:45 pm 2918. Fine-Mapping Major Histocompatibility Complex Associations in ACPA-Positive Rheumatoid Arthritis Identified Shared HLA Amino Acid Polymorphisms in Asian and European Populations Yukinori Okada 1, Kwangwoo Kim 2, Buhm Han 3, Nisha E. Pillai 4, Rick T-H. Ong 4, Woei-Yuh Saw 4, Ma Luo 5, Lei Jiang 6, Jian Yin 6, So- Young Bang 7, Hye-Soon Lee 7, Matthew A. Brown 8, Sang-Cheol Bae 9, Huji Xu 10, Yik-Ying Teo 4, Paul IW. de Bakker 11 and Soumya Raychaudhuri 3, 1 Tokyo Medical and Dental University, Tokyo, Japan, 2 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 4 National University of Singapore, Singapore, Singapore, 5 University of Manitoba, Winnipeg, MB, 6 The Second Military Medical University, Shanghai, China, 7 Hanyang University Guri Hospital, Guri, South Korea, 8 University of Queensland Diamantina Institute, Brisbane, Australia, 9 Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 10 Shanghai Changzheng Hospital, Shanghai, China, 11 University Medical Center Utrecht, Utrecht, Netherlands 5:00 pm 2919. The Novel Rheumatoid Arthritis (RA) Risk Gene, LBH, Is Regulated By TGFß and PDGF and Modulates Cell Growth in Fibroblast-like Synoviocytes Anna-Karin Ekwall 1, Deepa Hammaker 2, John W. Whitaker 3, William Bugbee 4, Wei Wang 5 and Gary S. Firestein 6, 1 UC San Diego, La Jolla, CA, 2 University of California San Diego, La Jolla, CA, 3 UCSD, San Diego, CA, 4 Scripps Clinic, La Jolla, CA, 5 UCSD, La Jolla, CA, 6 University of California at San Diego School of Medicine, La Jolla, CA 5:15 2920. WITHDRAWN 5:30 2921. Contraceptive Factors Are Associated with Serum Antibodies to Citrullinated Protein Antigens in Women at Elevated Risk for Future Rheumatoid Arthritis Sonia Khatter 1, Mark C. Parish 1, Marie L. Feser 1, Jason R. Kolfenbach 1, Ryan W. Gan 2, Michael H. Weisman 3, James R. O Dell 4, Ted R. Mikuls 5, Richard M. Keating 6, Peter K. Gregersen 7, Jane H. Buckner 8, V. Michael Holers 1, Kevin D. Deane 1, Jill M. Norris 2 and M. Kristen Demoruelle 1, 1 University of Colorado School of Medicine, Aurora, CO, 2 Colorado School of Public Health, Aurora, CO, 3 Cedars-Sinai Medical Center, Los Angeles, CA, 4 Veteran Affairs Nebraska Western Iowa Health Care System and University of Nebraska Medical Center, Omaha, NE, 5 Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 6 Scripps Clinic, La Jolla, CA, 7 Feinstein Institute for Medical Research, Manhasset, NY, 8 Benaroya Research Institute at Virginia Mason, Seattle, WA 5:45 pm 2922. Association of Single Nucleotide Polymorphisms of PADI4 Gene with Susceptibility to Rheumatoid Arthritis-Related Lung Disease Seong-Wook Kang, Seung-Taek Song, Song Soo Kim, Ji Young Kim, So Young Lee, Su-Jin Yoo, In-Seol Yoo, Jinhyun Kim and Seung- Cheol Shim, Chungnam National University School of Medicine, Daejeon, South Korea 253 B Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy VI: Biomarkers and Predictors of Rheumatoid Arthritis Disease Response and Outcomes Moderators: Stanley B. Cohen, MD and Duncan Porter, MD 4:30 pm 2923. Protein Quantification Using Mass Spectrometry Methods to Predict Response to Abatacept and Methotrexate Combination Therapy in Rheumatoid Arthritis A Obry 1, P Cosette 1, T Lequerré 2, Maria-Antonietta d Agostino 3, C Gaillez 4, M Le Bars 5 and O Vittecoq 2, 1 UMR 6270 CNRS, PISSARO Proteomic Facility, IRIB, Normandy University, University of Rouen, Rouen, France, 2 Rouen University Hospital, Rouen, France, 3 AP-HP Ambroise Paré Hospital, Boulogne-Billancourt, France, 4 Formerly of Bristol-Myers Squibb, Rueil-Malmaison, France, 5 Bristol-Myers Squibb, Rueil-Malmaison, France 142 2014 Program Book
scientific sessions 4:45 pm 2924. Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis Meghna Jani 1, Hector Chinoy 1, Richard B. Warren 2, Christopher E.M Griffiths 2, Ann W. Morgan 3, Anthony G. Wilson 4, Kimme L. Hyrich 1, John Isaacs 5, Darren Plant 1 and Anne Barton 6, 1 Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, 2 Dermatology Centre, University of Manchester, Manchester, United Kingdom, 3 University of Leeds, Leeds, United Kingdom, 4 University College Dublin, Dublin, Ireland, 5 Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, 6 NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom 5:00 pm 2925. Serum MMP-3 Predicts a Subgroup with No Radiographic Progression in Rheumatoid Arthritis Patients with Low-Dose Methotrexate (MTX) Monotherapy Kazuko Shiozawa 1, Takashi Yamane 1, Miki Murata 1, Chihiro Tanaka 1, Noriaki Yo 1, Ryosuke Yoshihara 1, Yasushi Tanaka 1, Ken Tsumiyama 2 and Shunichi Shiozawa 2, 1 Kohnan Kakogawa Hospital, Kakogawa, Japan, 2 Kyushu University Beppu Hospital, Beppu, Japan 5:15 pm 2926. Calprotectin Serum Levels Reflect Residual Inflammatory Activity in Patients with Rheumatoid Arthritis and Psoriatic Arthritis on Clinical Remission or Low Disease Activity Undergoing TNF-Antagonists Therapy Jose Inciarte-Mundo 1, M. Victoria Hernández 1, Sonia Cabrera- Villalba 1, Julio Ramirez 1, Andrea Cuervo 1, Virginia Ruiz-Esquide 1, Azucena González Navarro 1, Jordi Yagüe 2, Juan D. Cañete 1 and Raimon Sanmarti 1, 1 Hospital Clínic of Barcelona, Barcelona, Spain, 2 Hospital Clinic Barcelona, Barcelona, Spain 5:30 pm 2927. Baseline Serum Interferon Beta/Alpha Ratio Predicts Response to Tumor Necrosis Factor Alpha Inhibition in Rheumatoid Arthritis Priyanka Vashisht 1, Jessica M. Dorschner 2, Mark A. Jensen 2, Beverly Chrabot 3, Theresa Wampler Muskardin 2, Marlena Kern 4, Tetrad Investigators 5, ABCoN Consortium 6, S. Louis Bridges Jr. 7, P.K. Gregersen 8 and Timothy B. Niewold 2, 1 University of Nebraska Medical Center, Omaha, NE, 2 Mayo Clinic, Rochester, MN, 3 University of Chicago, Chicago, IL, 4 Feinstein Institute for Medical Research, Manhasset, NY, 5 AL, 6 NY, 7 University of Alabama at Birmingham, Birmingham, AL, 8 The Feinstein Institute for Medical Research, Manhasset, NY 5:45 pm 2928. Serum IL-33 Level Is Increased in Rheumatoid Arthritis and Predicts Response to Rituximab in Combination with High Serum IgG Level and Autoantibody Positivity: An Open-Label, Prospective, Multicentre Biological Trial Jérémie Sellam 1, Houria Chavez 2, Stéphanie Rouanet 3, Nathalie Vernet 3, Bineta Ly 4, Sandrine Marion-Thore 5, Bernard Combe 6, Jean Sibilia 7, Jacques Tebib 8, Gilles Chiocchia 9, Maxime Dougados 10, Yassine Taoufik 2 and Xavier Mariette 11, 1 AP-HP, Saint- Antoine Hospital, Rheumatology Department and DHU i2b, Paris, France, 2 Hopital Bicetre, Université Paris Sud, AP-HP, Kremlin Bicetre, France, 3 Roche France, Boulogne-Billancourt, France, 4 Universite Paris-Sud, Kremlin Bicetre, France, 5 Université Versailles Saint-Quentin, Montigny le Bretonneux, France, 6 Hôpital Lapeyronie, Montpellier, France, 7 University Hospital of Strasbourg, Strasbourg, France, 8 University Hospital Lyon, Lyon, France, 9 Université Versailles-Saint Quentin, Montigny le Bretonneux, France, 10 INSERM (U1153): Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France., Paris, France, 11 Université Paris-Sud, Le Kremlin Bicêtre, France 102 A Sjögren s Syndrome I: Clinical Perspectives Moderators: Arthur A. M. Bookman, MD and Stefano Bombardieri, MD 4:30 pm 2929. Molecular Diagnostics for Patient Subsetting in Sjögren s Syndrome John C. Hall 1, Alan N. Baer 1, Mi Y. Lam 2, Lindsey A. Criswell 3, Antony Rosen 1 and Livia Casciola Rosen 1, 1 Johns Hopkins University School of Medicine, Baltimore, MD, 2 University of California San Francisco, San Francisco, CA, 3 University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA 4:45 pm 2930. Precisely Quantified Fibrosis in Labial Salivary Glands Predicts Sjögren s Syndrome Classification in a Multiple Regression Model Kerry M. Leehan 1, Michael Brown 2, Courtney Montgomery 2, Astrid Rasmussen 2, David M. Lewis 1, Lida Radfar 1, Donald U. Stone 1, Stephen Young 1, R. Hal Scofield 1, Kathy L. Sivils 2 and A. Darise Farris 2, 1 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2 Oklahoma Medical Research Foundation, Oklahoma City, OK 5:00 pm 2931. Longitudinal Examination with Salivary Gland Ultrasonography (SGUS) of Patients with Primary Sjögren s Syndrome: A Single Center Experience Chiara Baldini 1, Nicoletta Luciano 1, Francesca Sernissi 1, Daniela Martini 1, Francesco Ferro 1, Marta Mosca 2 and Stefano Bombardieri 2, 1 Rheumatology Unit, Pisa, Italy, 2 Rheumatology Unit, University of Pisa, Pisa, Italy 5:15 pm 2932. Increased Risk of Deep Vein Thrombosis and Pulmonary Embolism in Sjögren s Syndrome: A General Population-Based Cohort Study Marko Yurkovich 1, Hyon K Choi 2, Eric C. Sayre 3, Kamran Shojania 1 and J. Antonio Avina-Zubieta 3, 1 University of British Columbia, Vancouver, BC, 2 Boston University School of Medicine, Boston, MA, 3 Arthritis Research Centre of Canada, Richmond, BC 2014 Program Book 143 TUESDAY november 18, 2014
scientific sessions 5:30 pm 2933. Metabolic Syndrome, Adipocytokines and Inflammation in Sjögren s Syndrome Kristopherson Lustosa Augusto 1, Eloisa Bonfá 2, Rosa M. R. Pereira 1, Cleonice Bueno 1, Vilma S. T. Viana 3 and Sandra G. Pasoto 1, 1 Faculdade de Medicina da Universidade de São Paulo, Sao Paulo, Brazil, 2 University of Sao Paulo, Sao Paulo, Brazil, 3 Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil Descartes University, Paris, France, 4 University of Alberta, Alberta, AK, 5 Merck & Co., Inc., Whitehouse Station, NJ 5:30 pm 2939. Increased Diagnosis of Spondyloarthritis in Female Patients Started in the Early Biologic Era Nisha Nigil Haroon 1, Ping Li 2, Michael Paterson 2 and Nigil Haroon 3, 1 Department of Medicine, University of Toronto, Toronto, ON, 2 Institute of Clinical Evaluative Sciences, Toronto, ON, 3 Toronto Western Research Institute, Toronto, ON TUESDAY november 18, 2014 5:45 pm 2934. Abatacept reduces Circulating Effector Memory T-Helper Cells in Patients with Primary Sjögren s Syndrome Gwenny Verstappen 1, Wayel H. Abdulahad 2, Petra M. Meiners 1, Suzanne Arends 1, Silvia Beijer-Liefers 1, Arjan Vissink 1, Frans G.M. Kroese 1 and Hendrika Bootsma 1, 1 University Medical Center Groningen, University of Groningen, Groningen, Netherlands, 2 University Medical Center Groningen, Groningen, Netherlands Ballroom West Spondyloarthropathies and Psoriatic Arthritis V Clinical Aspects and Treatment Moderators: Filip Van den Bosch, MD, PhD and Robert B. M. Landewé, MD, PhD 4:30 pm 2935. Attainment of Minimal Disease Activity Using Methotrexate in Psoriatic Arthritis Barry J. Sheane, Arane Thavaneswaran, Dafna D. Gladman and Vinod Chandran, University of Toronto, Toronto Western Hospital, Toronto, ON 4:45 pm 2936. Is Ankylosing Spondylitis a Risk Factor for Cardiovascular Diseases and How Does These Risks Compare to Those in Rheumatoid Arthritis? Johan Askling 1, Lennart Jacobsson 2 and Jonas Eriksson 1, 1 Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, 2 Sahlrenska Academy, Gothenburg, Sweden 5:45 pm 2940. Do Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Respond Similarly Well to Nsaids? a Prospective Study Including Magnetic Resonance Imaging Xenofon Baraliakos 1, Uta Kiltz 1, Frank Heldmann 1, Heiner Appel 2, Friedrich Dybowski 3, Manfred Igelmann 4, Ludwig Kalthoff 5, Dietmar Krause 6, Hans-Jürgen Menne 7, Ertan Saracbasi 8, Elmar Schmitz-Bortz 9 and Jürgen Braun 1, 1 Rheumazentrum Ruhrgebiet, Herne, Germany, 2 Rheumatology and Nephrology Practice, Hamm, Germany, 3 Rheumatology Practice, Herne, Germany, 4 Rheumatology Practice, Bochum, Germany, 5 Rheumatology practice, Herne, Germany, 6 Rheumatology practice, Gladbeck, Germany, 7 Rheumatology practice, Dortmund, Germany, 8 Rheumatology practice, Oberhausen, Germany, 9 Rheumatology practice, Hattingen, Germany ACR MEET THE PROFESSOR SESSIONS 4:30 6:00 pm Admission to Meet the Professor sessions requires a separate registration and ticket. To verify which session you registered for, the registration code on your ticket needs to match the three-digit code in parentheses below. If you are interested in participating in one of these sessions or exchanging your ticket, visit the ACR registration desk to check space availability. View the session overview and learning objectives online in the Annual Meeting App. Access and download the app at www.acrannualmeeting.org. * Sessions denoted with an asterisk were sold out as of August 30. 144 5:00 pm 2937. Evaluation of Referral Models for Axial Spondyloarthritis in Primary Care in the Spondyloarthritis Caught Early Cohort Ozair Abawi, Rosaline van den Berg, Désirée van der Heijde and Floris van Gaalen, Leiden University Medical Center, Leiden, Netherlands 5:15 pm 2938. A Randomized, Double-Blind, Placebo-Controlled, 16- Week Study of Subcutaneous Golimumab in Patients with Active Nonradiographic Axial Spondyloarthritis J Sieper 1, D van der Heijde 2, M Dougados 3, W Maksymowych 4, J Boice 5, G Bergman 5, S Curtis 5, A Tzontcheva 5, S Huyck 5 and HH Weng 5, 1 University Clinic Benjamin Franklin, Berlin, Germany, 2 Leiden University Medical Center, Leiden, Netherlands, 3 Paris- 2014 Program Book Westin Paine (Lobby) Adult Inflammatory Myopathy (081) Speaker: Robert L. Wortmann, MD, MACR review the clinical manifestations of inflammatory myopathies including important extra-muscle manifestations discuss diagnostic pearls for the evaluation of someone suspected of having an inflammatory myopathy discuss the treatment paradigm for inflammatory myopathies
scientific sessions Westin Otis (Lobby) Behçet s Syndrome (082) Speaker: Yusuf Yazici, MD discuss the epidemiology, disease mechanisms and the differential diagnosis of Behçet s syndrome describe current approaches to the management of patients with Behçet s syndrome Westin Hancock (Lobby) Calcium Crystal Arthritis (083) Speaker: Ann K. Rosenthal, MD describe the common clinical pictures of calcium pyrophosphate disease and basic calcium phosphate arthritis as well as appreciate unusual presentations describe currently available and emerging diagnostic modalities to confirm suspected calcium crystal arthritis, including ultrasound and novel techniques for BCP crystal identification describe currently available therapies and understand the rationale behind some promising new therapies for these diseases Westin Revere (Lobby) Juvenile Dermatomyositis (084) Speaker: Susan Kim, MD, MMSc Ed Pd PrM FIT discuss what is known about the pathogenesis and epidemiology of juvenile dermatomyositis discuss the approach to the evaluation of a patient referred with possible juvenile dermatomyositis discuss different therapeutic approaches to the treatment of juvenile dermatomyositis, ranging from mild to severe Westin Stone (Lobby) Myopathy: Issues in Diagnosis and Treatment (085) Speaker: Rohit Aggarwal, MD, MS differentiate myositis mimics from idiopathic inflammatory myopathies describe the importance of myositis antibodies and muscle magnetic resonance imaging in diagnosis and prognosis review myositis diagnosis in difficult cases including review of clinical features, muscle biopsy and electromyography review management of refractory myopathy including management of extra-muscular manifestations especially interstitial lung disease Westin Webster (Lobby) Pregnancy and Rheumatic Diseases (086) Speaker: Eliza Chakravarty, MD, MS describe risk factors for adverse maternal and fetal outcomes in systemic autoimmune diseases. describe key elements of preclinical risk assessment and counseling for women who desire a future pregnancy discuss the impact of active maternal autoimmune disease upon pregnancy outcomes. discuss the risk-to-benefit analysis of common anti rheumatic and immunosuppressive medications during pregnancy Westin Adams (Mezzanine) Pulmonary Manifestations of Rheumatic Disease (087) Speaker: Aryeh Fischer, MD identify emerging concepts regarding the pathophysiology of inflammation and fibrosis in autoimmune lung disease recognize the appropriate use of diagnostic tests in the evaluation of patients with rheumatic disorders and autoimmune lung disease discuss the limits of traditional therapeutic options and possible emerging therapies in managing autoimmune lung disease Westin Alcott (Mezzanine) Raynaud s and Digital Ischemia (088) Speaker: Fredrick M. Wigley, MD discuss the current understanding of the pathogenesis of Raynaud s phenomenon classify type of Raynaud s phenomenon and differentiate it from mimics describe the appropriate investigations for Raynaud s phenomenon and be aware of those patients at risk for the development of an autoimmune rheumatic disease discuss current options and evidence for treatment of Raynaud s phenomenon, threatened digital ischemia and digital ulcers Westin Douglas (Mezzanine) Rheumatoid Arthritis: Challenging Cases (089) Speaker: Stephen A. Paget, MD discuss the management of patients with refractory rheumatoid arthritis identify novel treatment options for those failing conventional therapies create effective management plans for complicated rheumatoid arthritis patients Westin Faneuil (Mezzanine) Temporal Arteritis (090) Speaker: Robert F. Spiera, MD discuss current concepts in the diagnosis of temporal arteritis including use of imaging modalities identify evolving concepts of the treatment of temporal arteritis including the appropriate use of glucocorticoids and the efficacy of steroid-sparing agents TUESDAY november 18, 2014 2014 Program Book 145
scientific sessions describe the relationship between temporal arteritis and polymyalgia rheumatica outline current concepts of the pathogenesis of temporal arteritis 5:00 pm Patient Advocacy, Patient Reported Outcomes and Social Media Seth Ginsberg TUESDAY november 18, 2014 ARHP SESSIONS 4:30 6:00 pm 255 256 Multidisciplinary Management of the Juvenile Idiopathic Arthritis Patient Ed Pd PrM FIT Moderator: Michael Blakley, MD review how to perform the cursory history and physical exam that may lead to the diagnosis of juvenile idiopathic arthritis facilitate and initiate the multidisciplinary management of a child with juvenile idiopathic arthritis employ techniques to trouble shoot difficult juvenile idiopathic arthritis cases 4:30 pm Review of Seven Subtypes of Juvenile Idiopathic Arthritis Peter Chira, MD, MS 4:55 pm Nursing Management of the Juvenile Idiopathic Arthritis Patient Karla Jones, RN 5:20 pm Physical and Occupational Therapy Management of the Juvenile Idiopathic Arthritis Patient Speaker to be determined 5:45 pm Questions and Answers Patient-Reported Outcomes Data for Comparative Effectiveness Research in Arthritis Care Moderator: Jonathan Krant, MD, MPH review patient reported outcomes (PRO) review comparative effectiveness research (CER) recognize the differences between print and social media as regards messaging and data capture translate PRO and CER into policy regarding quality metrics and assessment of physician performance 4:30 pm Introduction of Speakers and Overview of Rheumatology Practice Management for Complex Diagnoses Jonathan Krant, MD, MPH 5:30 pm Comparative Effectiveness Research and Optimization of Patient Outcomes Jeffrey R. Curtis, MD, MPH, MS 257 A State-of-the-Art Interventional Recommendations for Chronic Low Back Pain Moderators: David G. Borenstein, MD and Kimberly F. Kimpton, PT evaluate the current evidence for the use of transcutaneous electrical nerve stimulation for chronic low back pain discuss the benefits of physical therapy for chronic low back pain review existing evidence for the efficacy of epidural steroid injections and other interventional procedures for chronic low back pain and spinal stenosis and delineate appropriate patient selection identify clinical characteristics of chronic low back pain and spinal stenosis that warrant referral for surgical evaluation, as well as treatment to include standard and minimally invasive surgical options 4:30 pm Physical Therapy for Chronic Low Back Pain Adam Goode, DPT, PT 5:00 pm Interventional Pain Management for Chronic Low Back Pain Chad M. Brummett, MD 5:30 pm Surgical Considerations for Lumbar Stenosis and Chronic Low Back Pain Barton L. Sachs, MD, MBA 204 A Successful Aging in Rheumatic Disease Moderator: Patricia P. Katz, PhD recognize the traits that contribute to successful aging recommend interventions that can help patients successfully age explain how rheumatic disease affects the aging process 4:30 pm Successful Aging: What Does the Research Say? Marian R. Stuart, PhD 5:15 pm Successful Aging in Rheumatic Disease Kim M. Huffman, MD, PhD 146 2014 Program Book
ARHP CONCURRENT ABSTRACT SESSION 2:30 4:00 pm 254 A Epidemiology/Public Health Moderators: Kelli D. Allen, PhD and Uyen Sa D.T. Nguyen, DSc, MPH 4:30 pm 2941. Physical Function Is Independently Associated with Mortality Among Individuals with Knee and/or Hip OA: The Johnston County Osteoarthritis Project Rebecca Cleveland 1, Todd Schwartz 1, Jordan B. Renner 2, Joanne M. Jordan 3 and Leigh F. Callahan 4, 1 University of North Carolina at Chapel Hill, Chapel Hill, NC, 2 University of North Carolina Department of Radiology, Chapel Hill, NC, 3 University of North Carolina Dept of Epidemiology, Chapel Hill, NC, 4 University of North Carolina, Chapel Hill, NC 4:45 pm 2942. A Longitudinal Population-Based Study 1994-2010 of Age, Period and Cohort Effects in the Prevalence of Arthritis: The Effect of Improving Socioeconomic Status and Increasing Obesity over Time Elizabeth M. Badley 1, Mayilee Canizares 2, Anthony V. Perruccio 2, Sheilah. Hogg-Johnson 2 and Monique A.M. Gignac 2, 1 Toronto Western Research Institute, Toronto, ON, 2 University of Toronto, Toronto, ON 5:00 pm 2943. Severity of Foot Pain Is Linked to the Prevalence of Depressive Symptoms: The Framingham Foot Study Arunima Awale 1, Alyssa B. Dufour 2, Patricia P. Katz 3, Virginia A. Casey 1 and Marian T. Hannan 4, 1 Hebrew SeniorLife, Boston, MA, 2 Hebrew SeniorLife, Harvard Medical School & Beth Israel Deaconess Medical Center, Boston, MA, 3 University of California, San Francisco, CA, 4 Institute for Aging Research, Hebrew SeniorLife, Dept. of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 5:15 pm 2944. Sedentary Time Is an Independent Risk Factor for Disability Onset Among Adults at Elevated Risk: Prospective Cohort Study Jungwha Lee 1, Jing Song 1, Barbara Ainsworth 2, Rowland W. Chang 1, Linda S. Ehrlich-Jones 3, Christine Pellegrini 1, Pamela Semanik 4, Dorothy D. Dunlop 1 and Leena Sharma 5, 1 Northwestern University Feinberg School of Medicine, Chicago, IL, 2 Arizona State University, Phoenix, AZ, 3 Rehabilitation Institute of Chicago, Chicago, IL, 4 Rush University, Chicago, IL, 5 Northwestern University, Chicago, IL 5:30 pm 2945. Foot Structure and Function Show Associations with Lower Extremity Physical Function Yvonne M. Golightly 1, Marian T. Hannan 2, Patricia P. Katz 3, Howard J. Hillstrom 4, Alyssa B. Dufour 5 and Joanne M. Jordan 1, 1 University of North Carolina Dept of Epidemiology, Chapel Hill, NC, 2 Institute for Aging Research, Hebrew SeniorLife, Dept. scientific sessions of Medicine Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, 3 University of California, San Francisco, San Francisco, CA, 4 Hospital Special Surgery (HSS), New York, NY, 5 Hebrew SeniorLife & Boston Univ, Boston, MA 5:45 pm 2946. The Association Between Accelerometer Monitored Sedentary Behavior and Observed Physical Function Loss Pamela Semanik 1, Rowland W. Chang 2, Jing Song 2, Jungwha Lee 2 and Dorothy D. Dunlop 2, 1 Rush University College of Nursing, Chicago, IL, 2 Northwestern University Feinberg School of Medicine, Chicago, IL INDUSTRY-SUPPORTED SYMPOSIA 6:30 9:30 pm These symposia are both CME-accredited and non-cme company-directed programs. For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. All non-cme programs are wholly sponsored and supported by commercial entities. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 239 for more information. ACR SESSIONS 7:30 8:30 am WEDNESDAY, NOVEMBER 19, 2014 52 A Co-Stimulation Pathways: Therapeutic Opportunities for the Rheumatic Diseases Moderators: Gregg J. Silverman, MD and Adam Mor, MD, PhD Speaker: Vassiliki A. Boussiotis, MD, PhD examine the roles of co-receptor-mediated inhibitory pathways for the immunosurveillance of cancer and the development of autoimmune diseases, including rheumatoid arthritis and lupus appraise the relative contributions of the CD28, CTLA4, PD-1, ICOS and VISTA systems to immunoregulation review emerging data from therapeutic trials for the potential utility of manipulating these signaling pathways Ballroom East Rheumatology Roundup: Highlights from the 2014 Annual Meeting Moderator: Chester V. Oddis, MD Speakers: John J. Cush, MD and Arthur Kavanaugh, MD list research highlights from the scientific presentations discuss the clinical impact of selected research reports presented at the ACR meeting evaluate the therapeutic potential of selected clinical trials presented at the meeting 2014 Program Book 147 WEDNESDAY november 19, 2014
ARHP SESSIONS 7:30 8:30 am 255 scientific sessions Physical and Occupational Therapy for Juvenile Dermatomyositis: Treatment Planning and Case Presentations Ed Pd PrM FIT Moderator: Sandra Mintz, BSN review the unique therapy needs of the juvenile dermatomyositis population at all stages of the disease process evaluate a patient with juvenile dermatomyositis formulate appropriate treatment plans for patients with juvenile dermatomyositis review the molecular and cellular pathways that link complement activation to systemic autoimmunity 9:00 am Effector Pathways Linking Complement Activation to Systemic Lupus Erythematosus Susan A. Boackle, MD 9:15 am Immune-Mediated Membranolytic Pathways: Key to Rheumatoid Arthritis Felipe Andrade, MD, PhD 9:30 am The Role of Complement in CD4+ T Cell Homeostasis and Effector Function Claudia Kemper, PhD WEDNESDAY november 19, 2014 148 256 7:30 am Juvenile Dermatomyositis Stages, Physical Therapy Evaluation and Treatment Jill R. Blitz, PT, DPT 8:00 am Occupational Therapy Evaluation and Treatment for Juvenile Dermatomyositis Talitha Cox, MA, OTR/L Rheumatic Manifestations of Malignancy Moderator: Kori A. Dewing, DNP, ARNP review how patients can have a rheumatic disease as the presenting feature of a hidden malignancy explain the clinical features of paraneoplastic rheumatic disorders describe the evaluation and management of paraneoplastic rheumatic disorders 7:30 am Rheumatic Disease as a Manifestation of Malignancy David I. Daikh, MD, PhD 8:00 am Vasculitis as a Manifestation of Malignancy John H. Stone, MD, MPH ACR SESSIONS 9:00 10:30 am 253 B Complement in Rheumatic Disease Moderators: Susan A. Boackle, MD and Leendert A. Trouw, PhD review current evidence that supports a key role for complement and its receptors in regulating T-cell function review the repertoire of complement-mediated effector responses in autoimmunity 2014 Program Book Ballroom East Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside Moderators: Shreyasee Amin, MD CM, MPH and Swamy Venuturupalli, MD describe major subsets of lupus patients defined by cytokine, autoantibody and genetic profiles recognize how this information may influence therapeutic strategies and responses describe emerging biomarkers that may help with disease monitoring and treatment decisions 9:00 am Defining Biological Subsets in Systemic Lupus Erythematosus: Progress Toward Personalized Therapy Timothy B. Niewold, MD 9:30 am Influence of Biomarkers, Race and Ethnicity on Disease Severity and Treatment Response in Systemic Lupus Erythematosus David A. Isenberg, MD 10:00 am Improving Return on Investment: Molecular Analysis of the Kidney Biopsy for Lupus Nephritis Brad H. Rovin, MD Ballroom West Primary Angiitis of the Central Nervous System and Its Mimics Moderators: Elana J. Bernstein, MD, MSc and Rula Hajj-Ali, MD formulate a diagnostic approach to primary angiitis of the central nervous system and describe best practices in the management of primary angiitis of the central nervous system discuss the pathophysiology, clinical manifestations, diagnosis and treatment of the reversible cerebrovascular
scientific sessions vasoconstriction syndromes describe non-atherosclerotic cerebral vasculopathies that can mimic primary angiitis of the central nervous systems 9:00 am Primary Angiitis of the Central Nervous System Leonard H. Calabrese, DO 9:30 am Reversible Cerebrovascular Vasoconstriction Syndromes Aneesh Singhal, MD 10:00 am Non-Atherosclerotic Central Nervous System Vasculopathies Cenk Ayata, MD ACR CONCURRENT ABSTRACT SESSIONS 9:00 10:30 am 160 B Biology and Pathology of Bone and Joint II: Cartilage Biology and Synovial Activation Moderators: Anne-Marie Malfait, MD, PhD and Antonios O. Aliprantis, MD, PhD 9:00 am 2947. Adenosine a 2A Receptor As a Potential New Therapeutic Target for the Prevention/Treatment of Osteoarthritis Carmen Corciulo 1, Aranzazu Mediero 1, Tuere Wilder 1 and Bruce N. Cronstein 2, 1 NYU School of Medicine, New York, NY, 2 NYU School of Medicine, Division of Rheumatology, New York, NY 9:15 am 2948. S100 Proteins Induce Canonical Wnt Signaling, Which Causes Increased Expression of MMPs in the Synovium Martijn H. van den Bosch 1, Arjen B. Blom 1, R. Pelle Hoek 1, Rik F. Schelbergen 1, Sylvia W. Suen 1, Anke E. van Erp 1, Wim B. van den Berg 1, Peter M. van der Kraan 1 and Peter L. van Lent 2, 1 Radboud university medical center, Nijmegen, Netherlands, 2 Experimental Rheumatology, Radboud University, Nijmegen, Netherlands 9:30 am 2949. Activation of AMP-Activated Protein Kinase (AMPK) By Berberine Limits Both Surgical Knee Instability-Induced and Aging-Related Osteoarthritis in Mice Ru Bryan 1, Xianling Zhao 2, Yun Wang 3, Han Sol Lee 2, Hyunje Kim 4, Alifah Akasdi 2 and Robert Terkeltaub 5, 1 VA Medical Center/ University of California San Diego, San Diego, CA, 2 VAMC, San Diego, CA, 3 VA Medical Ctr/UCSD, San Diego, CA, 4 Yeungnam University, Daegu, South Korea, 5 VA Medical Ctr/University of California San Diego, San Diego, CA 9:45 am 2950. Synovial Macrophages Promote TGF-β Activation after Intra-Articular Injections of Oxidized LDL in Naïve Murine Knee Joints, Preventing Production of Pro-Inflammatory Factors S100A8/9, Chemokines and Aggrecanase-Induced Neo- Epitopes Wouter de Munter, Peter M. van der Kraan, Wim B. van den Berg and Peter L. van Lent, Radboud university medical center, Nijmegen, Netherlands 10:00 am 2951. Syndecan-4 Regulates Chondrocyte Phenotype and Cartilage Homeostasis Via the WNT Signaling Pathway Charlotte Kimberley Clarke 1, Annelena Held 1, Richard Stange 2, Uwe Hansen 2, Lars Godmann 2, Jessica Bertrand 2, Thomas Pap 3, Giovanna Nalesso 4, Frank Echtermeyer 5, Francesco Dell Accio 6 and Joanna Sherwood 4, 1 Institute of Experimental Musculoskeletal Medicine (IEMM), Muenster, 48149, Germany, 2 University Hospital Münster, Münster, Germany, 3 University Hospital Muenster, Muenster, Germany, 4 Queen Mary University London, London, United Kingdom, 5 University Hospital Hannover, Hanover, Germany, 6 William Harvey Research Institute, Barts and the London Queen Mary s School of Medicine and Dentistry, Centre for Experimental Medicine and Rheumatology, London, United Kingdom 10:15 am 2952. S100A9 Inhibitor Paquinimod (ABR-215757) reduces Joint Destruction in Experimental Osteoarthritis and Blocks Activating Effects of S100A9 in OA Synovium Peter L. van Lent 1, Rik Schelbergen 1, Arjen B. Blom 1, Tomas Leanderson 2, Helena Eriksson 3 and Wim B. van den Berg 1, 1 Radboud university medical center, Nijmegen, Netherlands, 2 Lund University, Lund, Sweden, 3 Active Biotech AB, Lund, Sweden 153 B Genetics, Genomics and Proteomics II: Genetics of Autoimmunity Moderators: Lindsey A. Criswell, MD, MPH and Patrick Gaffney, MD 9:00 am 2953. International Immunochip Study in the Idiopathic Inflammatory Myopathies Identifies Novel Susceptibility Loci and Confirms HLA As Strongest Genetic Risk Factor Simon Rothwell 1, Robert G. Cooper 2, Ingrid E. Lundberg 3, Frederick W. Miller 4, Peter K. Gregersen 5, Jiri Vencovsky 6, Katalin Danko 7, Lucy R Wedderburn 8, Vidya Limaye 9, Albert Selva O Callaghan 10, Michael G. Hanna 11, Pedro Machado 11, Lauren M. Pachman 12, Ann M. Reed 13, Lisa G. Rider 4, Joanna Cobb 1, Hazel Platt 14, Øyvind Molberg 15, Olivier Benveniste 16, Pernille Mathiesen 17, Timothy Radstake 18, Andrea Doria 19, Jan De Bleecker 20, Boel De Paepe 20, Britta Maurer 21, William E. Ollier 14, WEDNESDAY november 19, 2014 2014 Program Book 149
scientific sessions WEDNESDAY november 19, 2014 Leonid Padyukov 3, Terrance P. O Hanlon 4, Annette Lee 22, Hector Chinoy 1 and Janine Lamb 14, 1 Centre for Genetics and Genomics, Arthritis Research UK, University of Manchester, Manchester, United Kingdom, 2 University of Liverpool, Liverpool, United Kingdom, 3 Rheumatology Unit, Karolinska University Hospital, Solna, Karolinska Institutet, Stockholm, Sweden, 4 Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 5 The Feinstein Institute for Medical Research, Manhasset, NY, 6 Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University in Prague, Prague, Czech Republic, 7 University of Debrecen, Debrecan, Hungary, 8 Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, 9 Royal Adelaide Hospital, Adelaide, Australia, 10 Vall d Hebron General Hospital, Barcelona, Spain, 11 MRC Centre for Neuromuscular Diseases, UCL Institute of Neurology, London, United Kingdom, 12 Ann & Robert H. Lurie Children s Hospital of Chicago Research Center, Chicago, IL, 13 Mayo Clinic, Rochester, MN, 14 Centre for Integrated Genomic Medical Research, University of Manchester, Manchester, United Kingdom, 15 Department of Rheumatology, Oslo University Hospital Rikshospitalet, Oslo, Norway, 16 Pitié-Salpêtrière Hospital, APHP, Paris, France, 17 Paediatric Department, Holbaek University Hospital, Holbaek, Denmark, 18 University Medical Center Utrecht, Utrecht, Netherlands, 19 University of Padova, Padova, Italy, 20 University of Ghent, Ghent, Belgium, 21 Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 22 Feinstein Institute Med Rsch, Manhasset, NY 9:15 am 2954. The Amino Acid Positions 11, 13 and 26 of HLA- DR Beta Chain 1 Explain the Majority of the Association Between Systemic Lupus Erythematosus and the Major Histocompatibility Complex Locus Kwangwoo Kim 1, So-Young Bang 2, Hye-Soon Lee 2, Yukinori Okada 3, Woei-Yuh Saw 4, Paul IW. de Bakker 5, Yik-Ying Teo 6, Soumya Raychaudhuri 7 and Sang-Cheol Bae 2, 1 Brigham and Women s Hospital, Harvard Medical School, Boston, MA, 2 Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, 3 Broad Institute, Cambridge, MA, 4 National University of Singapore, Singapore, Singapore, 5 University Medical Center Utrecht, Utrecht, Netherlands, 6 Genome Institute of Singapore, Agency for Science, Technology and Research, Singapore, Singapore, 7 Broad Institute of MIT and Harvard, Cambridge, MA 9:30 am 2955. The Impact of Northern European Ancestry and Susceptibility Loci on the Risk of Lupus Nephritis Sarah French 1, Kimberly E. Taylor 1, Sharon A. Chung 1, Joanne Nitiham 1, Michelle Petri 2, Peter K. Gregersen 3, Ward Ortmann 4, Annette T. Lee 3, Timothy W. Behrens 4, Susan Manzi 5, F. Yesim Demirci 6, M. Ilyas Kamboh 6, Robert R. Graham 4, Michael F. Seldin 7 and Lindsey A. Criswell 1, 1 University of California, San Francisco, Rosalind Russell / Ephraim P. Engleman Rheumatology Research Center, San Francisco, CA, 2 Johns Hopkins University School of Medicine, Baltimore, MD, 3 Feinstein Institute for Medical Research, Manhasset, NY, 4 Genentech, Inc., South San Francisco, CA, 5 Division of Rheumatology, University of Pittsburgh School of Medicine, Pittsburgh, PA, 6 University of Pittsburgh, Pittsburgh, PA, 7 University of California, Davis, Davis, CA 9:45 am 2956. Identification of Autoimmune Functional Variants Under Positive Selection in the Gullah African American Population of South Carolina Paula S. Ramos 1, Satria Sajuthi 2, Jasmin Divers 2, Yiqi Huang 3, Uma Nayak 3, Wei-Min Chen 3, Kelly J. Hunt 1, Diane L. Kamen 1, Gary S. Gilkeson 1, Jyotika K. Fernandes 1, Ida J. Spruill 1, W. Timothy Garvey 4, Michèle M. Sale 3 and Carl D. Langefeld 2, 1 Medical University of South Carolina, Charleston, SC, 2 Wake Forest School of Medicine, Winston-Salem, NC, 3 University of Virginia, Charlottesville, VA, 4 University of Alabama at Birmingham, Birmingham, AL 10:00 am 2957. The Rheumatoid Arthritis -Risk Locus CCR6 and Its SNP- Dependent Response to Estrogen: A Possible Genomic Link Between Sex Hormones and the IL-17 Inflammatory Pathway Ming-Fen Ho, Richard M. Weinshilboum, Liewei Wang and Tim Bongartz, Mayo Clinic, Rochester, MN 10:15 am 2958. Polygenic Analysis of Transport, Metabolism and Immune Related Genomic Compartments in Serum Urate and Gout Eli A. Stahl 1, Tony R. Merriman 2, Amanda Dobbyn 3, David B. Mount 4, Peter Kraft 5 and Hyon Choi 6, 1 Mt Sinai School of Medicine, New York City, NY, 2 University of Otago, Dunedin, New Zealand, 3 Icahn School of Medicine at Mount Sinai, New York, NY, 4 Brigham and Women s Hospital, Boston, MA, 5 Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, MA, 6 Harvard Medical School, Boston, MA 104 B Metabolic and Crystal Arthropathies II: Mechanisms of Disease Moderators: Nicola Dalbeth, MBChB, MD and Alexander So, MD 9:00 am 2959. Twenty-Eight Loci That Influence Serum Urate Levels: Analysis of Association with Gout Tony R. Merriman 1, Marilyn E. Merriman 1, Ruth Topless 1, Sara Altaf 1, Grant Montgomery 2, Christopher Franklin 3, Gregory T. Jones 1, Andre M. van Rij 1, Douglas HN White 4, Lisa K. Stamp 5, 150 2014 Program Book
scientific sessions Nicola Dalbeth 3 and Amanda Phipps-Green 1, 1 University of Otago, Dunedin, New Zealand, 2 Queensland Institute of Medical Research, Brisbane, Australia, 3 University of Auckland, Auckland, New Zealand, 4 Waikato Clinical School, Waikato Hospital, Hamilton, New Zealand, 5 University of Otago, Christchurch, New Zealand 9:15 am 2960. Urate Genetic Loci and the Risk of Incident Cases of Confirmed Gout in Two Prospective Cohort Studies Hyon K Choi 1, Gary Curhan 2, Ying Bao 3, Eli A. Stahl 4, Peter Kraft 5, Robert M. Plenge 3, Yuqing Zhang 1 and Tony R. Merriman 6, 1 Boston University School of Medicine, Boston, MA, 2 Harvard Medical School, Boston, MA, 3 Brigham and Women s Hospital, Boston, MA, 4 Mt Sinai School of Medicine, New York City, NY, 5 Program in Molecular and Genetic Epidemiology, Harvard School of Public Health, Boston, MA, 6 University of Otago, Dunedin, New Zealand 9:30 am 2961. Conditional Analysis of 30 Serum Urate Loci Identifies 25 Additional Independent Effects Eli Stahl 1, Hyon Choi 2, Murray Cadzow 3, Tanya Flynn 3, Ruth Topless 3 and Tony R. Merriman 3, 1 Mt Sinai School of Medicine, New York City, NY, 2 Harvard Medical School, Boston, MA, 3 University of Otago, Dunedin, New Zealand 9:45 am 2962. Association of the Toll-like Receptor 4 (TLR4) Gene with Gout Humaira Rasheed 1, Ruth Topless 1, Richard Day 2, Diluk Kannangara 3, Kenneth Williams 3, Linda Bradbury 4, Matthew Brown 5, Catherine Hill 6, Susan Lester 7, Maureen Rischmueller 8, Malcolm Smith 6, Mariano Andrés 9, Thomas Bardin 10, Michael Doherty 11, Matthijs Janssen 12, Tim Jansen 13, Leo Joosten 13, Fernando Perez-Ruiz 14, Timothy Radstake 15, Philip L. Riches 16, Ed Roddy 17, Anne-Kathrin Tausche 18, Lisa K. Stamp 19, Nicola Dalbeth 20, Frederic Lioté 21, Alex So 22, Cushla McKinney 1 and Tony R. Merriman 1, 1 University of Otago, Dunedin, New Zealand, 2 St. Vincent s Hospital, Sydney, Australia, 3 University of New South Wales, Sydney, Australia, 4 The University of Queensland, Brisbane, Australia, 5 University of Queensland Diamantina Institute, Brisbane, Australia, 6 Queen Elizabeth Hospital, Adelaide, Australia, 7 Queen Elizabeth Hospital, Woodville South, Australia, 8 The Queen Elizabeth Hospital, SA, Australia, 9 Hospital General Universitario de Alicante, Alicante, Spain, 10 Hôpital Lariboisière, Paris, France, 11 City Hospital, Nottingham, United Kingdom, 12 Rijnstate Hospital, Arnhem, Netherlands, 13 Radboud University Medical Center, Nijmegen, Netherlands, 14 Hospital De Cruces, Baracaldo, Spain, 15 University Medical Center Utrecht, Utrecht, Netherlands, 16 University of Edinburgh, Edinburgh, United Kingdom, 17 Keele University, Staffordshire, United Kingdom, 18 Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, 19 University of Otago, Christchurch, New Zealand, 20 University of Auckland, Auckland, New Zealand, 21 Université Paris Diderot, Paris, France, 22 CHUV, Lausanne, Switzerland 10:00 am 2963. The URAT1 Uric Acid Transporter Is Important in Uric Acid Homeostasis and Its Activity May be Altered in Gout Patients and in Drug-Induced Hyperuricemia Philip K. Tan, Sha Liu and Jeffrey N. Miner, Ardea Biosciences, Inc., San Diego, CA 10:15 am 2964. Association Analysis of Apolipoprotein B and Very Low- Density Lipoprotein with Hyperuricemia and Gout Humaira Rasheed 1, Angela Hsu 1, Nicola Dalbeth 2, Lisa K. Stamp 3, Sally McCormick 1 and Tony R. Merriman 1, 1 University of Otago, Dunedin, New Zealand, 2 University of Auckland, Auckland, New Zealand, 3 University of Otago, Christchurch, New Zealand 107 B Pain: Basic and Clinical Aspects II/Orthopedics, Low Back Pain and Rehabilitation Moderators: Yvonne C. Lee, MD, MMSc and M. Elaine Husni, MD, MPH 9:00 am 2965. Effects of Anti-NGF Strategies in Two Animal Models of Osteoarthritis (OA) Lilian Ngozi Nwosu 1, Paul Mapp 1, Karyn Bouhana 2, Steven Andrews 2, Victoria Chapman 1 and David Walsh 1, 1 Arthritis Research UK Pain Centre, University of Nottingham, Nottingham, United Kingdom, 2 Array BioPharma, Boulder, CO 9:15 am 2966. Genome-Wide Association Analysis of Pain Reduction in Rheumatoid Arthritis Patients Treated with TNF Inhibitors Marieke J.H. Coenen 1, Maša Umicevic-Mirkov 1, Sophine B. Krintel 2, Julia Johansen 3, Corinne Miceli-Richard 4, Henrik Kallberg 5, Hans Scheffer 1, Wietske Kievit 1, Mart A. van de Laar 6, Piet L.C.M. van Riel 1, X. Mariette 7, Saedis Saevarsdottir 8, Merete Lund Hetland 9, Sita Vermeulen 1 and Cornelis A. Albers 1, 1 Radboud university medical center, Nijmegen, Netherlands, 2 Copenhagen University Hospital at Glostrup, Glostrup, Denmark, 3 University of Copenhagen, Frederiksberg, Denmark, 4 Université Paris-Sud 11, Bicêtre Hospital,, Kremlin Bicêtre, France, 5 Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden, 6 University Twente & Medisch Spectrum Twente, Enschede, Netherlands, 7 Paris-Sud University, Paris, France, 8 Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, 9 DANBIO, Center for Rheumatology and Spine Diseases, Glostrup Univ Hospital, Glostrup, Denmark WEDNESDAY november 19, 2014 2014 Program Book 151
scientific sessions 9:30 am 2967. Patient Reported Pain By the Paindetect Questionnaire Reveals Multimodal Elements to Pain Perception in Rheumatoid Arthritis Saqa Ahmed 1, Tejal Magan 1, Mario Vargas 1, Abiola Harrison 1 and Nidhi Sofat 2, 1 St George s, University of London, London, United Kingdom, 2 St. George s University of London, London, United Kingdom 9:15 am 2972. Elevations of Certain Memory-Effector T Cell and Inflammatory Monocyte Subpopulations in Rheumatoid Arthritis Are Associated with the Presence of Subclinical Coronary Artery Atherosclerosis Robert Winchester 1, Jon T. Giles 1, Simona Nativ 2, Hui-Zhu Zhang 1, Kendall Downer 1 and Joan Bathon 1, 1 Columbia University, New York, NY, 2 Morristown Medical Center, Morristown, NJ WEDNESDAY november 19, 2014 9:45 am 2968. Improvement Following Total Knee Replacement (TKR) Surgery: Exploring Preoperative Symptoms and Change in Preoperative Symptoms Ernest R. Vina 1, Michael J. Hannon 2 and C. Kent Kwoh 3, 1 University of Pittsburgh and VA Healthcare System, Pittsburgh, PA, 2 University of Pittsburgh School of Medicine, Pittsburgh, PA, 3 University of Arizona, Tucson, AZ 10:00 am 2969. Mortality after Knee Replacement Surgery for Osteoarthritis in a Population-Based Propensity-Score Matched Cohort Devyani Misra 1, Tuhina Neogi 1, Na Lu 1, David T. Felson 1, Thomas Einhorn 1, Hyon Choi 2, Jessica Maxwell 3 and Yuqing Zhang 1, 1 Boston University School of Medicine, Boston, MA, 2 Harvard Medical School, Boston, MA, 3 Boston University, Boston, MA 10:15 am 2970. Psoriatic Arthritis is Associated with Heterotopic Ossification after Total Hip Arthroplasty Mario Cedillo 1, Arielle Fein 2, Susan M. Goodman 2, Rebecca Zhu 2, Mark P. Figgie 2, Michael Alexiades 2, Jayme C. Burket 2 and Lisa A. Mandl 2, 1 Weill Cornell Medical College, New York, NY, 2 Hospital for Special Surgery, New York, NY 258 B Rheumatoid Arthritis Clinical Aspects VII: New Aspects of Monitoring Disease Moderators: Merete Lund Hetland, DMSc, MD, PhD and Barbara Goldstein, MD, MMSc 9:00 am 2971. Patient s Self-Monitoring Via Smartphone: The Compass Study Correlation Between Patient Self-Assessment of Rheumatoid Arthritis Disease Activity Via Smartphone Technology and Physicians Validated Scores Ruediger Mueller 1, Ulrich Walker 2, Diego Kyburz 3, Robert Theiler 4, Adrian Forster 5, Fabiana Ganz 6 and Patrick Dufner 6, 1 Kantonspital St. Gallen, St. Gallen, Switzerland, 2 Department of Rheumatology, Basel University, Basel, Switzerland, 3 University Hospital, Basel, Switzerland, 4 Triemli spital, Zurich, Switzerland, 5 Spital Thurgau AG, Diessenhofen, Switzerland, 6 Abbvie AG, Baar, Switzerland 9:30 am 2973. The Multi-Biomarker Disease Activity Score As a Predictor of Radiographic Progression in a Registry of Patients with Rheumatoid Arthritis Eric H. Sasso 1, George Wu 1, CC Hwang 1, Michael E. Weinblatt 2, Nancy A. Shadick 2, Claire Alexander 1 and Oscar Segurado 1, 1 Crescendo Bioscience Inc., South San Francisco, CA, 2 Brigham and Women s Hospital, Boston, MA 9:45 am 2974. Multi-Biomarker Disease Activity Score Is Associated with Power Doppler Ultrasound in Patients with Rheumatoid Arthritis in Low Disease Activity State Margaret H. Ma 1, Toby Garrood 2, Wanying Li 3, Nadine A. Defranoux 3, Gabrielle H. Kingsley 4, Andrew P. Cope 5 and David L. Scott 6, 1 King s College Hospital, London, United Kingdom, 2 Guy s and St. Thomas Foundation Hospital NHS Trust, London, United Kingdom, 3 Crescendo Bioscience Inc., South San Francisco, CA, 4 Kings College London, London, United Kingdom, 5 King s College London, London, United Kingdom, 6 King s College London, Department of Rheumatology, London, United Kingdom 10:00 am 2975. Residual Large Joint Synovitis By Power Doppler Ultrasonography Is Associated with Higher Disease Activity and Significant Impact of Disease in Multi-Ethnic Asian Patients with Established Rheumatoid Arthritis Yu Xiao Guo 1, Manjari Lahiri 2 and Peter Cheung 2, 1 Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore, 2 Division of Rheumatology, National University Hospital, Singapore, Singapore 10:15 am 2976. Lung Ultrasound Screening for Interstitial Lung Disease in Rheumatoid Arthritis. Comparison with Usual Detection Algorithms in Clinical Practice Marco Antivalle, Michel Chevallard, Michele Battellino, MariaChiara Ditto, Valentina Varisco, Federica Rigamonti, Alessandra Mutti, Fabiola Atzeni, Alberto Batticciotto and Piercarlo Sarzi-Puttini, L. Sacco University Hospital, Milano, Italy 152 2014 Program Book
scientific sessions 157 B Sjögren s Syndrome II: Insights Into Pathophysiology Moderators: Alan N. Baer, MD and Kathy L. Sivils, PhD 9:00 am 2977. Distinct Serum Protein Signature and Novel Biomarkers of primary Sjögren s Syndrome Revealed by comprehensive High-Throughput Proteomic Analysis Ayumi Nishikawa 1, Katsuya Suzuki 1, Yoshiaki Kassai 2, Yuumi Gotou 3, Takahiro Miyazaki 2, Maiko Takiguchi 4, Masaru Takeshita 1, Atsuko Murota 1, Rimpei Morita 5, Akihiko Yoshimura 5 and Tsutomu Takeuchi 1, 1 Keio University School of Medicine, Tokyo, Japan, 2 Takeda Pharmaceutical Company Limited, Kanagawa, Japan, 3 Takeda Pharmaceutical Company Limited, Tokyo, Tokyo, Japan, 4 Takeda Pharmaceutical Company Limited, Tokyo, Japan, 5 Department of Microbiology and Immunology, Keio University School of Medicine, Tokyo, Japan 9:15 am 2978. Characterization of the Sjögren s Syndrome Intergenic Non-Coding RNA 1 (SSINCR1) John A. Ice 1, He Li 1, Indra Adrianto 1, Mikhail G. Dozmorov 1, Astrid Rasmussen 1, Graham B. Wiley 1, Jennifer A. Kelly 1, Kimberly S. Hefner 2, Donald U. Stone 3, Raj Gopalakrishnan 4, David M. Lewis 3, Stephen Young 3, Michael D. Rohrer 4, Juan-Manuel Anaya 5, Swamy Venuturupalli 6, Barbara M. Segal 7, Nelson L. Rhodus 4, Lida Radfar 3, Michael H. Weisman 8, Judith A. James 1, Courtney G. Montgomery 1, R. Hal Scofield 9, Patrick M. Gaffney 1, Linda F. Thompson 1, A. Darise Farris 10, Susan Kovats 1, Jonathan D. Wren 1, Kathy L. Sivils 3 and Christopher J. Lessard 1, 1 Oklahoma Medical Research Foundation, Oklahoma City, OK, 2 Hefner Eye Care and Optical Center, Oklahoma City, OK, 3 University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4 University of Minnesota, Minneapolis, MN, 5 Center for Autoimmune Diseases Research (CREA), Universidad del Rosario., Bogota, Colombia, 6 Cedars-Sinai Medical Center, West Hollywood, CA, 7 Hennepin County Medical Center, Minneapolis, MN, 8 Cedars-Sinai Medical Center, Los Angeles, CA, 9 US Department of Veterans Affairs Medical Center, Oklahoma City, OK, 10 Oklahoma Medical Research Foun, Oklahoma City, OK 9:30 am 2979. Nucleic Acid Sensing Receptors TLR7, RIG-I and MDA5 Collaborate in Driving the Systemic IFN Signature and Amplify the Pathogenic Loop: Potential New Targets for Therapy in Primary Sjögren s Syndrome Naomi I Maria 1, Cornelia G. van Helden-Meeuwsen 1, Eline C. Steenwijk 1, Arne S. IJpma 2, Wouter Beumer 1, Zana Brkic 1, Virgil A. Dalm 1, Paul L. van Daele 1, P. Martin van Hagen 1, Peter J. van der Spek 2, Hemmo A. Drexhage 1 and Marjan A. Versnel 1, 1 Erasmus Medical Center, Immunology, Rotterdam, Netherlands, 2 Erasmus Medical Center, Bioinformatics, Rotterdam, Netherlands 9:45 am 2980. Genome-Wide DNA Methylation Analysis of CD19+ B Cells in Primary Sjögren s Syndrome Gunnel Nordmark 1, Juliana Imgenberg-Kreuz 2, Jonas Carlsson Almlöf 2, Jessica Nordlund 2, Roald Omdal 3, Katrine B. Norheim 3, Maija-Leena Eloranta 4, Lars Rönnblom 4 and Johanna K. Sandling 2, 1 Rheumatology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2 Molecular Medicine and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 3 Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway, 4 Department of Medical Sciences, SciLife Lab, Rheumatology, Uppsala University, Uppsala, Sweden, Uppsala, Sweden 10:00 am 2981. Prognostic Value of the Complex P2X7 Receptor- Inflammasome in Patients with Primary Sjögren s Syndrome at Lymphoma Risk Chiara Baldini 1, Eleonora Santini 2, Chiara Rossi 2, Francesca Sernissi 1, Daniela Martini 1, Alessia Gallo 3, Valentina Donati 2, Nicoletta Luciano 1, Francesco Ferro 1, Illias Alevizos 3, Anna Solini 2 and Stefano Bombardieri 2, 1 Rheumatology Unit, Pisa, Italy, 2 Rheumatology Unit, University of Pisa, Pisa, Italy, 3 NIDCR, Bethesda, MD 10:15 am 2982. Identification of Whole Blood Gene Expression Signature in Primary Sjögren s Syndrome Associated Lymphoma Shereen Al-Ali 1, Simon Cockell 2, Andrew Skelton 3, Katherine James 2, Jessica Tarn 2, David Young 3, Bridget Griffiths 4, Simon Bowman 5, James Locke 2 and Wan-Fai Ng 2, 1 University of Basrah, Basrah, Iraq, 2 Newcastle University, Newcastle upon Tyne, United Kingdom, 3 Newcastle University, Newcastle Upon Tyne, United Kingdom, 4 Freeman Hospital, Newcastle Upon Tyne, United Kingdom, 5 University Hospital Birmingham, Birmingham, United Kingdom 205 B Spondyloarthropathies and Psoriatic Arthritis VI Imaging and Biomarkers Moderators: Robert Inman, MD and Juergen Braun, MD 9:00 am 2983. Infliximab Added to Naproxen Does Not Increase Frequency of New Fatty Lesions on MRI of the Sacroiliac Joints and of the Spine As Compared to Naproxen Alone in Early Axial Spondyloarthritis Denis Poddubnyy and Joachim Sieper, Charité Universitätsmedizin Berlin, Berlin, Germany WEDNESDAY november 19, 2014 2014 Program Book 153
scientific sessions WEDNESDAY november 19, 2014 9:15 am 2984. Degenerative Changes of the Spine on MRI in Patients with Inflammatory Back Pain F. de Bruin 1, Marc Olivier Treyvaud 2, Antoine Feydy 2, Maxime Dougados 3, Laure Gossec 4, J.L Bloem 1, Désirée van der Heijde 1 and Monique Reijnierse 1, 1 Leiden University Medical Center, Leiden, Netherlands, 2 Paris Descartes University, Radiology B department, Cochin Hospital, Paris, France, 3 Descartes University, Cochin Hospital, Paris, France, 4 UC Paris 06 University, GRC 08, Paris France and Pitié Salpétrière Hospital Paris France, Paris, France 9:30 am 2985. Autoantibodies to 14-3-3η Are Novel Biomarkers Associated with Inflammation and Radiographic Progression in Ankylosing Spondylitis WP Maksymowych 1, Stephanie Wichuk 1, RG Lambert 1, Mairead Murphy 2 and Anthony Marotta 2, 1 University of Alberta, Edmonton, AB, 2 Augurex Life Sciences Corp., North Vancouver, BC 9:45 am 2986. Fat Metaplasia on MRI of the Sacroiliac Joints Is a Lead Indicator of Radiographic Progression in the Spine of Patients with Ankylosing Spondylitis WP Maksymowych 1, S Wichuk 1, P Chiowchanwisawakit 2, RG Lambert 1 and Sj Pedersen 3, 1 University of Alberta, Edmonton, AB, 2 Mahidol University, Bangkok, Thailand, 3 Copenhagen Center for Arthritis Research, Copenhagen, Denmark 10:00 am 2987. Value of Color Doppler Ultrasound Assessment of Sacroiliac Joints in Patients with Inflammatory Chronic Low Back Pain Maximiliano Bravo 1, Leandro Ferreyra Garrott 1, David A. Navarta 1, Emmanuel Bertiller 1, Ricardo Garcia-Monaco 2, Santiago Ruta 1, Javier Rosa 3 and Enrique Soriano 1, 1 Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, 2 Radiology and Imagenology Department, Hospital italiano de Buenos Aires, Buenos Aires, Argentina, 3 Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina 10:15 am 2988. Calgranulin Levels Are Elevated in Spondyloarthritis and Reflect the Presence of Acute Microscopic Gut Inflammation Heleen Cypers 1, Gaëlle Varkas 1, Liesbet Van Praet 1, Johannes Roth 2, Thomas Vogl 2, Claude Cuvelier 3, Dirk Föll 4, Miha Lavric 4, Filip van Den Bosch 1 and Dirk Elewaut 1, 1 Department of Rheumatology Ghent University Hospital, Ghent, Belgium, 2 Institute of Immunology University of Muenster, Muenster, Germany, 3 Department of Pathology Ghent University Hospital, Ghent, Belgium, 4 University Children s Hospital Muenster, Muenster, Germany 52 A Systemic Lupus Erythematosus Clinical Aspects and Treatment: Central Nervous System and Other Clinical Aspects Moderators: Dafna D. Gladman, MD and Stacy P. Ardoin, MD, MS 9:00 am 2989. Lupus Impact Tracker Is Responsive to Changes in Disease Activity in Lupus David Giangreco 1, Hervé Devilliers 2, Narender Annapureddy 1, Joel A. Block 1 and Meenakshi Jolly 1, 1 Rush University Medical Center, Chicago, IL, 2 Department of internal medicine and systemic diseases, Dijon, France 9:15 am 2990. Risk Factors for Posterior Reversible Encephalopathy Syndrome in Systemic Lupus Erythematosus Patients: A Single Center Study Javier Merayo-Chalico 1, Elia Apodaca 2, Ana Barrera-Vargas 1, Jorge Alcocer-Varela 1 and Diana Gómez-Martín 1, 1 Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 2 Instituto Nacional de Ciencias Médicas y Nutrición, Mexico City, Mexico 9:30 am 2991. Anti-Ribosomal P Antibody Is a Key Autoantibody Associated with Complications of NP-SLE with High-Levels of CSF IL-8 Hidenaga Kawasumi 1, Takahisa Gono 1, Yasushi Kawaguchi 1, Yasuhiro Katsumata 1, Hisae Ichida 1, Akiko Tochimoto 1, Masanori Hanaoka 1, Yuko Okamoto 1, Sayuri Kataoka 1 and Hisashi Yamanaka 2, 1 Tokyo Women s Medical University, Tokyo, Japan, 2 Institute of Rheumatology, Tokyo Women s Medical University, Tokyo, Japan 9:45 am 2992. Usefulness of Diagnostic Biomarker for Neuropsychiatric Systemic Lupus Erythematosus By Anti-Microtubule Associated Protein 2 Antibody in Cerebrospinal Fluid Yusuke Yamada, Department of Internal Medicine and Rheumatology, Juntendo University Faculty of Medicine, Tokyo, Japan 10:00 am 2993. MRI in Neuropsychiatric Lupus: Correlations with the 1999 ACR Case Definitions Minyoung Her 1, Dongyook Kim 1, Na young Park 1, Seong-Kyu Kim 2, Lee Sung Won 3 and Lee sang Yeob 3, 1 Inje University, Pusan 154 2014 Program Book
scientific sessions Paik Hospital, Busan, South Korea, Busan, South Korea, 2 Catholic University of Daegu, Daegu, South Korea, Daegu, South Korea, 3 Dong-A university, Busan, South Korea, Pusan, South Korea 10:15 am 2994. WITHDRAWN 151 A Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Clinical Aspects and Therapeutics III: Updates in Predictors and Outcomes in Systemic Sclerosis Moderators: Laura K. Hummers, MD, ScM and Sindu R. Johnson, MD, PhD 9:00 am 2995. Surrogate Measures of Extent of Interstitial Lung Disease As Measured By Quantitative Radiographic Analysis in Patients with Systemic Sclerosis Elizabeth Volkmann 1, Donald Tashkin 2, Chi-hong Tseng 1, Kim Hyun 1, Jonathan Goldin 1, Philip J. Clements 3, Daniel E. Furst 1, Dinesh Khanna 4, Eric Kleerup 1, Michael Roth 1 and Robert Elashoff 5, 1 University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, 2 University of California at Los Angeles, Los Angeles, CA, 3 University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 4 University of Michigan Health System, Ann Arbor, MI, 5 University of California, Los Angeles, Los Angeles, CA 9:15 am 2996. Intestinal Pseudo-Obstruction in Patients with Systemic Sclerosis: An Analysis of the Nationwide Inpatient Sample Antonia Valenzuela 1, Shufeng Li 1, Laren Becker 1, Nielsen Fernandez-Becker 1, Dinesh Khanna 2, Linda Nguyen 1 and Lorinda Chung 1, 1 Stanford University School of Medicine, Palo Alto, CA, 2 University of Michigan Health System, Ann Arbor, MI 9:30 am 2997. Development and External Validation of a Five-Year Mortality Risk Stratification Tool for Early Diffuse Systemic Sclerosis Patients Robyn T. Domsic 1, Svetlana I. Nihtyanova 2, Mary Lucas 1, Stephen R. Wisniewski 3, Michael J. Fine 4, C. Kent Kwoh 5, Christopher P. Denton 6 and Thomas A. Medsger Jr. 1, 1 University of Pittsburgh, Pittsburgh, PA, 2 Royal Free and University College Medical School, London, United Kingdom, 3 University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, 4 University of Pittsburgh and Center for Health Equity Research and Promotion, VA Pittsburgh Healthcare, Pittsburgh, PA, 5 The University of Arizona Arthritis Center, Tucson, AZ, 6 Centre for Rheumatology, Royal Free and University College Medical School, London, United Kingdom 9:45 am 2998. Screening for Interstitial Lung Disease in Systemic Sclerosis: Performance of High-Resolution Computed Tomography with Limited Number of Slices a Prospective Study Thomas Frauenfelder 1, Anna Winklehner 1, Thi Dan Linh Nguyen 1, Rucsandra Dobrota 2, Stephan Baumüller 1, Britta Maurer 3 and Oliver Distler 3, 1 Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Zurich, Switzerland, 2 Department of Internal Medicine and Rheumatology, Dr.I.Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, 3 Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland 10:00 am 2999. Development of a Composite Index for Clinical Trials in Early Diffuse Cutaneous Systemic sclerosis the Combined Response Index in Systemic Sclerosis Dinesh Khanna 1, Veronica Berrocal 2, Edward Giannini 3, Maureen Mayes 4, Peter A. Merkel 5, Jeffrey Siegel 6, James R. Seibold 7, Murray Baron 8, Philip J. Clements 9, Yannick Allanore 10, Virginia D. Steen 11, Christopher P. Denton 12, Oliver Distler 13, Sindhu R. Johnson 14, Marco Matucci-Cerinic 15, Lazlo Czirjak 16, Janet E. Pope 17, Susanna Proudman 18, Weng Kee Wong 19, Athol U. Wells 20 and Daniel E. Furst 9, 1 University of Michigan Scleroderma Program, Ann Arbor, MI, 2 University of Michigan, Ann Arbor, MI, 3 Childrens Hosp Med Ctr, Cincinnati, OH, 4 University of TX Health Science Center -Houston, Houston, TX, 5 Boston University School of Medicine, Boston, MA, 6 Genentech, South San Francisco, CA, 7 Scleroderma Research Consultants LLC, Avon, CT, 8 Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC, 9 University of California, Los Angeles, Department of Medicine, Los Angeles, CA, 10 Department of Rheumatology, University Paris Descartes and Cochin Hospital, Paris, France, 11 Georgetown University Medical Center, Washington, DC, 12 UCL Medical School Royal Free Campus, London, United Kingdom, 13 University Hospital Zurich, Zurich, Switzerland, 14 Division of Rheumatology, Toronto Western Hospital, University Health Network Pulmonary Hypertension Programme, Toronto General Hospital, Mount Sinai Hospital and University of Toronto, Toronto, ON, 15 University of Florence, Florence, Italy, 16 University of Pécs, Pécs, Hungary, 17 Western University, London, ON, 18 Royal Adelaide Hospital, Adelaide, Australia, 19 UCLA Fielding School of Public Health, Los Angeles, CA, 20 Department of Radiology, London, United Kingdom 10:15 am 3000. Comparison of Systemic Sclerosis Subsets As Predictors of Mortality and Morbidity Hebah Alhajeri 1, Marie Hudson 1, Canadian Scleroderma Research Group CSRG 1 and Murray Baron 2, 1 McGill University, Montreal, QC, 2 Lady David Institute for Medical Research and Jewish General Hospital, Montreal, QC WEDNESDAY november 19, 2014 2014 Program Book 155
scientific sessions 156 B Systemic Sclerosis, Fibrosing Syndromes and Raynaud s Pathogenesis, Animal Models and Genetics II Moderators: Sandeep K. Agarwal, MD, PhD and Romy Christmann, MD, PhD 9:00 am 3001. Targeting IL-6 By Both Passive or Active Immunization Strategies Prevents Inflammation-Driven Skin Fibrosis Jerome Avouac 1, Lucille Desallais 2, Maxime Fréchet 3, Muriel Elhai 3, Jean François Zagury 2 and Yannick Allanore 1, 1 Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, 2 Chaire de Bioinformatique, Laboratoire Génomique, Bioinformatique et Applications, EA 4627, Conservatoire National des Arts et Métiers, Paris, France, 3 INSERM U1016, Cochin Institute, Paris, France 9:15 am 3002. Anti-Fibrotic Effects of a Newly Discovered HGF Receptor Carboxy-Terminal Fragment in Systemic Sclerosis Yuichiro Shirai 1, Ilia Atanelishvili 2, Tanjina Akter 1, Richard Silver 3 and Galina Bogatkevich 1, 1 Medical University of South Carolina, Charleston, SC, 2 Medical University of South Carolina, Charleston,USA, Charleston, SC, 3 Medical University of South Carolina, Charleston, SC 9:30 am 3003. Am80 Ameliorates Bleomycin-Induced Dermal Fibrosis By Suppressing the Pro-Fibrotic Phenotype of Fibroblasts, Endothelial Cells and Immune Cells Tetsuo Toyama 1, Yoshihide Asano 1, Takehiro Takahashi 1, Ryosuke Saigusa 1, Yohei Ichimura 1, Takashi Taniguchi 1, Shinji Noda 1, Kaname Akamata 1, Shinichi Sato 1, Takafumi Kadono 1 and Koichi Shudo 2, 1 University of Tokyo Graduate School of Medicine, Tokyo, Japan, 2 Reseach Foundation ITSUU Laboratory, Tokyo, Japan 10:15 am 3006. Activation of the Thromboxane A2 Receptor By 8-Isoprostane Inhibits the Pro-Angiogenic Effect of Vascular Endothelial Growth Factor in Scleroderma Pei-Suen Tsou 1, George Zakhem 2, Beatrix Balogh 2, M. Asif Amin 3, Phillip Campbell 3, Gautam Edhayan 3, Ray A. Ohara 3, Elena Schiopu 3, Dinesh Khanna 1, Alisa E. Koch 4 and David A. Fox 3, 1 University of Michigan Scleroderma Program, Ann Arbor, MI, 2 University of Michigan Medical School, Ann Arbor, MI, 3 Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, 4 Department of Veteran s Affairs and University of Michigan, Ann Arbor, MI ARHP SESSIONS 9:00 10:30 am 256 Exercise Adherence in Arthritis: The Role of Technology Moderator: Jennifer M. Hootman, PhD identify established barriers to/risk factors of poor exercise adherence discuss the prevalence of aerobic and strength exercise in arthritis review the measurement of activity adherence and challenges and opportunities in the field describe the innovative use of technology to promote adherence and the evidence to support it 9:00 am Barriers to Exercise Adherence: Challenges and Opportunities to Foster Adherence Julie J. Keysor, PhD, PT WEDNESDAY november 19, 2014 9:45 am 3004. Autoantibody-Mediated Raynaud s Phenomenon: Animal Model and Human Disease Dana P. Ascherman 1, Yunjuan Zang 2, Laisel Martinez 1, Judith Pignac-Kobinger 2, Irina Fernandez 2 and Eric L. Greidinger 2, 1 Miami VAMC, Miami, FL, 2 University of Miami, Miami, FL 10:00 am 3005. Essential Role for Alternately Spliced Tenascin C and TLR4 Signaling in Persistent Organ Fibrosis Swati Bhattacharyya 1, Wenxia Wang 1, Luisa Morales-Nebreda 1, Katja Lakota 1, Robert Lafyatis 2, Monique E. Hinchcliff 1, GR Scott Budinger 1, Zenshiro Tamaki 1 and John Varga 3, 1 Northwestern University, Feinberg School of Medicine, Chicago, IL, 2 Boston University School of Medicine, Boston, MA, 3 Northwestern University Feinberg School of Medicine, Chicago, IL 9:30 am Exercise Adherence in Arthritis: Can We Improve It with Technology? Kristin Baker, PhD 10:00 am Environmental Barriers to Physical Activity in Arthritis Molly Vaughn, PhD 156 2014 Program Book
scientific sessions 255 Nothing About Us without Us: Engaging Patients in Rheumatology Research Moderator: Janet L. Poole, OTR, PhD evaluate and apply best practices for engaging patients in the research process, from the investigator perspective, including specific examples of successes and challenges describe the patient experience as a member of the research team review the funding agency perspective regarding expectations and best practices for patient engagement on the research team 9:00 am Patient Engagement from the Researcher Perspective Monique A. Gignac, PhD 9:25 am The Patient Experience: A Research Team Member Amye L. Leong, MBA 9:50 am Funding Agency Perspective on Patient Engagement Suzanne Schrandt, JD 10:15 am Panel Discussion ARHP CONCURRENT ABSTRACT SESSIONS 9:00 10:30 AM 257 A Clinical Practice/Patient Care Moderator: Marian T. Hannan, DSc, MPH 9:00 am 3007. Can Knee Pain be Prevented through Diet and Exercise Among Those at High Risk? Daniel White 1, Tuhina Neogi 2, W. Jack Rejeski 3, Michael Walkup 3, Cora E. Lewis 4, Michael Nevitt 5, Capri Foy 3 and David T. Felson 2, 1 Boston Univ School of Med, Boston, MA, 2 Boston University School of Medicine, Boston, MA, 3 Wake Forest University, Winston-Salem, NC, 4 The University of Alabama at Birmingham, Birmingham, AL, 5 UCSF, San Francisco, CA 9:15 am 3008. High Prevalence of Subclinical Ultrasonographic Enthesopathy and Synovitis in Patients with Inflammatory Bowel Disease without Clinical Signs or Symptoms of Spondyloarthritis Esther Vicente 1, Silvia Pérez-Esteban 2, María Chaparro 1, Francisco Rodríguez-Salvanés 1, Lorena Vega 1, Santos Castañeda 1 and Javier P Gisbert 3, 1 Hospital Universitario de La Princesa, IISP, Madrid, Spain, 2 Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, 3 Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain 9:30 AM 3009. Stem Cell Augmentation for Cardiovascular Risk in Rheumatoid Arthritis Nidhi Garg 1, Ashit Syngle 2 and Pawan Krishan 1, 1 Punjabi University Patiala, India, Patiala, India, 2 Healing Touch City Clinic, Fortis Multispeciality Hospital, Chandigarh, India 9:45 am 3010. The Development and Evaluation of a Self-Monitoring and Patient-Initiated Follow-up Service for People with Rheumatoid or Psoriatic Arthritis on Methotrexate Hayley McBain 1, Michael Shipley 2, Abigail Olaleye 2, Samantha Moore 3, Shashi Hirani 4 and Stanton Newman 4, 1 East London Foundation Trust, London, United Kingdom, 2 University College Hospital London, London, United Kingdom, 3 University College London, London, United Kingdom, 4 City University London, London, United Kingdom 10:00 am 3011. Ambulatory Gait Analysis in Clinical Practice: Single or Dual Task Conditions? Bernard Auvinet 1, Claude Touzard 2 and Vincent Goëb 3, 1 Polyclinic, LAVAL, France, 2 Hospital of Laval, LAVAL, France, 3 Amiens University Hospital, Amiens, France 10:15 am 3012. Needs Assessment Survey Evaluation of Sexual Dysfunction Among Patients at a Tertiary Rheumatology Clinic Sharon Nesher Peleg 1, Ori Elkayam 2, Bruria Yahini 1 and Jacob N. Ablin 1, 1 Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 2 Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel 259 A Innovations in Rheumatologic Care Moderators: Carol M. Greco, PhD and Elizabeth M. Badley, PhD Ed Pd PrM FIT 9:00 am 3013. The Reserve Capacity Model in Patients with Rheumatoid Arthritis: Understanding the Relationship of Socioeconomic Status, Psychosocial Resources, Mood and Pain Desiree Azizoddin 1, Taylor Draper 1, Sarah Ormseth 1, Perry M. Nicassio 1, Michael R. Irwin 1, Michael Weisman 2 and Hilary Wilson 1, 1 University of California, Los Angeles, Los Angeles, CA, 2 Cedars-Sinai Medical Center, Los Angeles, CA WEDNESDAY november 19, 2014 2014 Program Book 157
scientific sessions WEDNESDAY november 19, 2014 9:15 am 3014. Does the Order or Amount of Risk-Benefit Information Presented Influence patients Perceived Value of a Proposed New Medication? Liana Fraenkel 1, Richard Street 2, Harjinder Chowdhary 3, Sarah Swift 3 and Ellen Peters 4, 1 Yale University School of Medicine, Veterans Affairs Connecticut Healthcare Systems, New Haven, CT, 2 Texas A&M University, College Station, TX, 3 Yale University, New Haven, CT, 4 Ohio State University, Columbus, OH 9:30 am 3015. Evaluation of the effuc Educational Needs Assessment Tool (ENAT) Focused Patient Education on Health Outcomes in Patients with Rheumatoid Arthritis a Randomised Controlled Trial Adewale O. Adebajo 1, Dawn Johnson 2, Hardware Bernadette 3, Claire Hale 4 and Mwidimi Ndosi 4, 1 University of Sheffield, Sheffield, United Kingdom, 2 Barnsley Hospital NHS Foundation Trust, Barnsley, United Kingdom, 3 Barnsley Hospital NHS Foundation Trust, Baarnsley, United Kingdom, 4 University of Leeds, Leeds, United Kingdom 9:45 am 3016. Measuring the Impact of an Early RA Support and Education Program Using a Program Evaluation with Patient Identified Outcomes Adena Batterman 1, Kathryn Klingenstein 1, Roberta Horton 1, Linda Leff 1, Theodore R. Fields 2 and Vivian P. Bykerk 1, 1 Hospital for Special Surgery, New York, NY, 2 Hospital for Special Surgery Weill Cornell Medical College, New York, NY 10:00 am 3017. Program Evaluation of the Joint Clinic : An Innovative Clinical Service for Patients with Hip or Knee Osteoarthritis J. Haxby Abbott 1, Helen Harcombe 1, Chris Crane 2, Liam Hutton 2, Kirsten Stout 2, Cathy Chapple 1 and David Gwynne-Jones 1, 1 University of Otago, Dunedin, New Zealand, 2 Southern District Health Board, Dunedin, New Zealand 10:15 am 3018. Testing of a Newly Developed Computerized Animated Activity Questionnaire for Assessing Activity Limitations in Patients with Hip and Knee Osteoarthritis. Wilfred FH Peter 1, Mick Loos 1, Henrica de Vet 1, Maarten Boers 1, Jaap Harlaar 1, Leo D. Roorda 2, Rudolf Poolman 3, Vanessa Scholtes 3, Jan Bogaard 1, Hilda Buitelaar 1, Martijn P.M. Steultjens 4, Ewa M. Roos 5, Anne-Christine Rat 6, Francis Guillemin 7, Maria Grazia Benedetti 8, Antonio Escobar Martinez 9, Nina Østerås 10 and Caroline Terwee 1, 1 VU University Medical Center, Amsterdam, Netherlands, 2 Amsterdam Rehabilitation Research Center Reade, Amsterdam, the Netherlands, Amsterdam, Netherlands, 3 Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, 4 Glasgow Caledonian University, Glasgow, Scotland, 5 University of Southern Denmark, Odense, Denmark, 6 University of Lorraine, Nancy, France, 7 INSERM, Centre d Investigation Clinique Epidémiologie Clinique (CIC-EC) CIE6, Nancy, France, 8 Istituto Ortopedico Rizzoli, Bologna, Italy, 9 Basurto University Hospital, Bilbao, Spain, 10 Diakonhjemmet Hospital, Oslo, Norway ACR SESSION 11:00 am Noon Exhibit Hall C Inflammation and Atherothrombosis Moderators: Swamy Venuturupalli, MD and Anne Bass, MD Speaker: Paul M. Ridker, MD, MPH discuss the immune mechanisms responsible for atherothrombosis explain the use of statins to prevent venous thromboembolic events review the recent AHA/ACC guidelines for statin ACR SESSIONS 11:00 am 12:30 pm 52 A Advances in Molecular Profiling and Relevance to Autoimmune Disease Moderator: Dana P. Ascherman, MD review the role of proteomics-based profiling in rheumatic disease with respect to biomarker development, delineation of pathogenesis describe metabolomics and its relationship to human autoimmune/rheumatic disease acknowledge differences between metabolomics and proteomics demonstrate the utility versus limitations of molecular profiling 11:00 am Proteomics Composite Signaling Molecule Profiles William H. Robinson, MD, PhD 11:30 am Proteomics 2 Assessment of Post-Translationally Modified Target Molecules Paul Eggleton, PhD 158 2014 Program Book
scientific sessions Noon Metabolomics Relevance to Autoimmune Disease Stephen Young, BSc, PhD Ballroom East Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment Moderators: Alan N. Baer, MD and Grant H. Louie, MD, MHS 11:00 am Accommodations Work: Evidence for People with Arthritis Linda C. Batiste, JD 11:30 am Overview of Arthritis-Attributable Work Limitation in U.S. Adults Kristina A. Theis, MPH describe the concept of non-radiographic axial spondyloarthritis explain the natural history of non-radiographic axial spondyloarthritis discuss differential treatment response in non-radiographic axial spondyloarthritis and ankylosing spondylitis 11:00 am Non-Radiographic Axial Spondyloarthritis: A Primer Michael M. Ward, MD 11:30 am Does Non-Radiographic Axial Spondyloarthritis Represent Pre- Radiographic Axial Spondyloarthritis? Maxime Dougados, MD, PhD Noon The Meaning and Importance of Work Nancy A. Baker, MPH, OTR, OTR/L INDUSTRY-SUPPORTED POST MEETING SYMPOSIA 1:00 4:00 pm For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Please visit the organization s exhibit booth, the industry-supported symposia booth or see page 239 for more information. Noon Are Treatment Responses in Non-Radiographic Axial Spondyloarthritis Similar Axial Spondyloarthritis? Jürgen Braun, MD ARHP SESSION 11:00 am 12:30 pm 255 Work and Worker Health: Easy Accommodations Keep People with Arthritis Employed Moderator: Julie J. Keysor, PhD, PT describe the prevalence and impact of arthritis-attributable work limitations in U.S. adults discuss justification for the importance of working for people with arthritis health and well-being share information with participants on the Job Accommodation Network and how this resource can be used to facilitate workers remaining in the workforce explain necessary steps for disclosing and/or requesting legally protected accommodations WEDNESDAY november 19, 2014 2014 Program Book 159
ACR POSTER INDICES SUNDAY, NOVEMBER 16, 2014 Poster Hall (Exhibit Hall B) Antiphospholipid Syndrome 1. Lymphocyte Proliferation to a Cross-Reactive Gut Commensal Candidate in Antiphospholipid Syndrome 2. Thrombocytopenia in Primary Antiphospholipid Syndrome Is Related to Arterial Thrombosis 3. Is There an Association Between Persistently High Positive Antiphospholipid Antibody Profile and Organ Damage Accrual in Lupus Patients? 4. Detection of Anti-Beta2glycoprotein I Domain 1 Antibodies By an Automated Chemiluminescence Assay in a Cohort of 400 Clinically Characterized Consecutive Routine Samples 5. Antiphospholipid-Associated Nephropathy Is a Risk for Developing Arterial Thromboses in Patients with Systemic Lupus Erythematosus 6. Performance Evaluation and Clinical Associations of the Aphl ELISA Compared to Criteria Antiphospholipid Immunoassays in Lupus Patients 7. Beneficial Effects of in Vivo Ubiquinol Supplementation on Athero-Thrombosis Prevention in Antiphospholipid Syndrome Patients 8. Safety and Efficacy of New Oral Direct Inhibitors of Thrombin and Factor Xa in Antiphospholipid Syndrome 9. A Risk-Stratified Perioperative Management Strategy for Antiphospholipid Antibody Positive Patients Undergoing Kidney Transplantation 10. Antiphospholipid Antibodies and Neuropsychiatric Events in Pediatric Patients 11. Sustained Moderate Intensity Levels of Oral Anticoagulant Therapy and the Rate of Recurrent Thrombosis in Patients with Primary Antiphospholipid Syndrome 12. Non-Criteria Antiphospholipid Antibodies in Obstetrical seronegative Anti-Phospholipid syndrome 13. Eculizumab in Antiphospholipid Antibody Syndrome 14. Rivaroxaban Use in Patients with Antiphospholipid Syndrome Patients and Previous Poor Anticoagulation Control with Vitamin K Antagonists 15. Performance of an Automated Chemiluminescence Assay for Anti-Cardiolipin and Anti-Beta2glycoprotein I Antibodies Detection in a Cohort of 400 Clinically Characterized Consecutive Routine Samples 16. Differential Assay Reactivity of IgA Anti-B2glycoprotein I Antibodies: Implications for Clinical Interpretation of Antiphospholipid Antibody Testing 17. Antiphospholipid Syndrome Following Infection: A Systematic Review of Case Reports 18. The Effect of Clinically Significant Antiphospholipid Antibody Positivity on Organ Damage in Systemic Lupus Erythematosus Biology and Pathology of Bone and Joint: Osteoclasts, Osteoblasts and Bone Remodeling 19. Adenosine Receptors Stimulate Bone Regeneration 20. High Systemic LDL Cholesterol Levels during Experimental Osteoarthritis Lead to Increased Synovial Activation and Ectopic Bone Formation at End-Stage Osteoarthritis, While Excessive Levels Accelerate Development of Joint Pathology Already at Early-Stage O 21. Mendelian Randomization Analysis to Examine for Causal Relationships Between Serum Urate Levels and Bone Mineral Density 22. Adenosine a2a Receptor (A2AR) Stimulation Inhibits Osteoclast Differentiation and Promotes Osteoblast Formation By Regulation of Axon Guidance Proteins 23. Activation of EPAC1/2 Is Essential for Osteoclast Formation By Modulating NFkB Nuclear Translocation and Actin Cytoskeleton Rearrangements 24. Netrin1 Is Highly Expressed and Required in Inflammatory Infiltrates in Wear Particle-Induced Osteolysis 25. DC-STAMP Modulates Osteoblast Differentiation and Regulates Bone Repair 26. Functional Osteoclasts Differentiate Spontaneously from the Rheumatoid Joint 27. CD115+ Osteoclast Precursors Arise before Clinical Onset of Arthritis and Are Regulated By Proinflammatory Cytokines 28. Evidence for Receptor Activator of NF-Kb (RANK)- Independent Bone Erosion in the Cherubism Mouse Model of Inflammatory Arthritis 29. Impaired Bone Healing in Patients Suffering from Rheumatoid Arthritis - Anti-Inflammatory Therapy As Confounder 30. Inhibiting Autocrine Interleukin-6 (IL-6) Trans-Signalling in Human CD14+VE Monocultures Reduces Osteoclast Differentiation 160 2014 Program Book
ACR POSTER INDICES 31. Interaction of FGF-8 and TNF-a in the Regulation of BMP- Induced Osteoblast Differentiation 32. Regulation of Senescence and Inflammatory Mediators By N- and C-Terminal Parathyroid Hormone-Related Protein in Osteoarthritic Human Osteoblasts 33. Stimulation of the Adenosine a2a receptor (A2AR) Regulates the Expression of Netrin1 and Their Receptors (Unc5b, DCC) and Inhibits Osteoclast Differentiation and Inflammatory Bone Destruction 34. Pro-Nerve Growth Factor (ProNGF) Stimulates Bone Growth By Stimulating Osteoblasts and Inhibiting Osteoclast Differentiation, an Explanation for Anti-NGF- Mediated Osteonecrosis; Prongf Is a Novel Therapeutic Target for Treatment of Osteonecrosis and Charc 35. Hydrogen Sulfide Inhibits Human Osteoclast Differentiation in Vitro By Triggering Sustained Antioxidant Response and Inhibiting the RANKL/OPG Ratio 36. The Use of Three-Dimensionally Printed β-tricalcium Phosphate/Hydroxyapatite to Further Understand the Regulation of Adenosine Receptors in Osteoclast Formation and Promotion in Bone Regeneration 37. Regulation of Osteoclast and T Cell Differentiation By DC- STAMP and TRAF3 38. Angiopoietin-like 4 Is over-expressed in Rheumatoid Arthritis: A Potential Role in Pathological Bone Resorption 39. Human CD14+ Monocytes Stimulated with a Combination of TNFα and IL-6 Differentiate into Osteoclast-like Cells with Bone-Resorption Activity Epidemiology and Public Health: Osteoporosis, Non-Inflammatory Arthritis and More 40. Prevalence of Spondyloarthritis (ASAS Criteria) in First- Degree Relatives of Patients with Ankylosing Spondylitis 41. The Impact of Ankylosing Spondylitis on Work Impairment: Data from the Scotland Registry for Ankylosing Spondylitis 42. The Prevalence of Ankylosing Spondylitis in Sweden a Nationwide Register Study 43. Deaths Associated with Ankylosing Spondylitis in France from 1969 to 2009 44. Physical Function, Hyperuricemia and Gout in Older Adults 45. Body Mass Index Across the Lifespan and Lifetime Incidence of Gout in Men 46. Xanthine Oxidase Inhibitors and Risk of Type 2 Diabetes in Patients with Gout 47. The Risk of Aplastic Anemia and Pancytopenia with Colchicine: A Retrospective Study of Integrated Health System Database 48. Osteoporotic Women at High Risk for Fractures Despite Two Years of Oral Bisphosphonate Therapy: Analysis Using the Canadian Multicentre Osteoporosis Study 49. Long-Term Oral Bisphosphonate Use for Osteoporosis Among Older Women US and Canadian Perspective 50. Incidence and Risk Factors for Osteoporotic Vertebral Fracture in Low-Income Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study 51. High Incidence of Non-Vertebral Osteoporotic Fracture and Hip Fracture in Brazilian Low-Income Community- Dwelling Elderly: A Population-Based Prospective Cohort Analysis from the São Paulo Ageing & Health (SPAH) Study 52. Visceral Fat Measured By Dual-Energy X-Ray Absorptiometry Is Associated with Increased Risk of Non-Spine Fractures in Nonobese Elderly Women: a Population-Based Prospective Cohort Analysis from the São Paulo Ageing & Health (SPAH) Study 53. Spine-Hip Diagnostic Discordance in the United Arab Emirates 54. Concordance with the National Osteoporosis Foundation Treatment Guidelines After DXA Result Notification 55. Validation of the Diagnosis of Avascular Necrosis of Bone in Administrative Data 56. High Prevalence of Cervical Malignant and Premalignant Lesions Among Women with Rheumatoid and Psoriatic Arthritis 57. Risk of Hospitalized Infection in a Psoriasis/Psoriatic Arthritis Cohort 58. What Does the Patient Global Assessment Mean for Patients with Psoriatic Arthritis? A Post-Hoc Analysis of 223 Patients with Psoriatic Arthritis 59. Assessing Dietary Habits in a Large Cohort of Rheumatoid Arthritis and Psoriatic Arthritis Patients: Results of the Spanish Imid Consortium 60. Epidemiology of Polymyalgia Rheumatica in Korea 61. Advocating for Pediatric Rheumatology Care in the Mid-Canadian Provinces: Large Geographic Area, Large Pediatric Population, Low Number of Pediatric Rheumatologists and Allied Health Workers Identified As Unique Challenges 2014 Program Book 161
ACR POSTER INDICES 62. Severe Spine Osteoarthritis in Older Men Is Associated with the Risk of Incident Fragility Fracture 63. Spine Osteoarthritis Is Associated with All Cause Mortality in Older Men 64. Effect of Family Support on Short-and Intermediate Term Pain and Function Outcomes after Knee or Hip Replacement 65. Impact of Dropout and Total Knee Replacement on Joint Space Narrowing Estimation: Data from Osteoarthritis Initiaive 66. Association of Knee Osteoarthritis and Limitations in Physical Function in a Rural Chinese Population: The Wuchuan OA Study 67. Effects of Exercise on Depressive Symptoms in Adults with Arthritis: A Systematic Review with Meta-Analysis 68. Physical Inactivity to Activity Associated with Less Decline in Physical Function 69. Assessment of Exercise Status in Routine Care Using Patient Reported Outcomes: Initiating Exercise Is Associated with Better Outcomes Than No Exercise 70. The Odds of Work Disability, Unemployment and Depending on Living Allowances Are More Influenced By the Number of Morbidities Than By the Presence of a Musculoskeletal Disease 71. Prevalence of Pain Reporting in Different Ethnic Groups in the UK: Results from a Large Biobank 72. The Association Between Doctor-Diagnosed Arthritis and Falls and Fall Injuries Among Middle-Aged and Older Adults 73. Frequency and Risk Factors for Recurrent Falls in Community-Dwelling Elderly: A Population-Based Prospective Cohort Study in Brazil. the São Paulo Ageing & Health (SPAH) Study Genetics, Genomics and Proteomics I 74. Influence of the Polymorphism IL1ß (-511 A/C) and IL6 (- 174 G/C) on the Activity, Radiographic Damage and Clinical Forms of Patients with Psoriatic Arthritis (A) 75. Robust Identification of Anti-TNF Non-Responders in RA from Blood 76. Identification of Synovial Genes and Pathways Associated with Disease Progression in a Cohort of Early Symptomatic Osteoarthritis Patients Using a Transcriptomic Approach 77. Epigenome Profiling Reveals Robust Hypomethylation of Interferon Signature Genes in Lupus Neutrophils 78. a HPLC-SRM-MS Based Method for the Detection and Quantification of Methotrexate Used at Doses in Clinical Practice for Patients with Rheumatological Disease in Urine 79. PECAM-1 GENE Polymorphisms and Soluble PECAM-1 LEVEL in Rheumatoid Arthritis and Systemic LUPUS Erythematosus Patients Is There a Link with Clinical Atherosclerotic Events? 80. Cellular Responses of IL6 Inhibition (Tocilizumab) in Rheumatoid Arthritis Using High-Accuracy Tandem Mass Spectrometry 81. Elevated Peripheral Blood Leukocyte Inflammatory Gene Expression in Radiographic Progressors with Symptomatic Knee Osteoarthritis: NYU and OAI Cohorts 82. HLA-DPB1*04:01 Confers Risk for PR3-ANCA Positive ANCA-Associated Vasculitis (AAV), but Protects Against MPO-ANCA Positive AAV, in a Japanese Population 83. Whole Exome Sequencing Analysis Performed on a Patient with Fibroblastic Rheumatism 84. Amerindian Ancestry Influences Polyautoimmunity 85. Protective Association of HLA-DRB1*13:02 Against MPO- ANCA Positive ANCA-Associated Vasculitis in a Japanese Population 86. Association of Leukocyte Immunoglobulin-like Receptor A3 (LILRA3) with Systemic Sclerosis 87. Association of TRIM21 (RO52) Polymorphisms with Systemic Lupus Erythematosus in a Japanese Population 88. Microbiomes of Inflammatory and Non-Inflammatory Thoracic Aortic Aneurysms 89. Global mirna Expression Profiling in Peripheral Blood and Synovial Fluid Mononuclear Cells of Patients with Enthesitis Related Arthritis 90. Genetic Variants in IL-6, IL-10, C5-TRAF1 and FCRL3 and Progression of Joint Damage in Rheumatoid Arthritis; A Study on Six Cohorts 91. Quantitative Proteomics Using Dimethyl Isotope Labeling for Comparison of Fresh Frozen Versus Formalin-Fixed, Paraffin-Embedded Tissue for Lupus Nephritis 92. Long Noncoding RNA Nron Regulates the Activity of NFAT5 through Ubiquitin-Independent Proteasome Pathway in Rheumatoid Arthritis 162 2014 Program Book
ACR POSTER INDICES 93. Protein Profiling of Secretome Human Cartilage to Identify Potential EARLY Specific Biomarkers in Osteoarthritis Health Services Research 94. Possible Effects of Medicare-Only Insurance Coverage on the Use of Biologics in Patients with RA 95. Comparison of Patient Characteristics, Healthcare Costs, and Biologic Persistence Between Patients with Rheumatoid Arthritis Initiating First- or Second-Line Subcutaneous Abatacept, Adalimumab, or Etanercept 96. Comparison of Cardiovascular Risk Factor Management in Patients with RA and Matched Non-RA Patients 97. Identification of Tuberculosis in Rheumatoid Arthritis Patients Initiating Therapy with Biologic or Non-Biologic Disease-Modifying Anti-Rheumatic Drugs Using Health Insurance Claims Data 98. Costs of Musculoskeletal Diseases in the United States, 1996-2011: Population Growth, Population Aging, Health Care Utilization, or Prices? 99. Impact of Comorbidities on Health Resource Utilization in Patients with Spa 100. Evaluation of Real World Experience with Non-Biologic DMARD in the Treatment of RA: Data from an Electronic Health Record Database 101. Country of Residence and Its Wealth Determine Disease Activity Levels in RA: Results from Multi-National Study Across 17 Countries (COMORA) 102. Real-World Utilization, Patient Characteristics and Persistency of Certolizumab Pegol Vs Other Anti-TNFs for the Treatment of Rheumatoid Arthritis in the United Kingdom 103. Rheumatology e-consult Services: a Rheumatology Workforce Management Model 104. Reasons for Leaving an Academic Career in Research Among Rheumatologists in the United States 105. Resource Use and Health Related Quality of Life Burden of Gout Exacerbated By Common Comorbidities: Results from the 2012-2013 National Health and Wellness Survey 106. Patient Reported Outcomes Following Upper Extremity Arthroplasties in RA -a Report from the Swedish National Register of Rheuma Surgery (RAKIR) 107. Use of Internet in Adolescents and Young Adults with JIA 108. Patient Reported Outcomes Following Total Knee Arthroplasty in Rheumatoid Arthritis and Osteoarthritis 109. Knee Arthroscopy in an International Training Centre: An Audit of Safety and Impact on Work Days 110. Use of Smartphones in Collecting Patient Reported Outcomes: Can Passively-Collected Behavior Determine Rheumatic Disease Activity? Early Results from a Nation- Wide Pilot Study 111. Low Rates of Bone Mineral Density Testing in Medicare Beneficiaries with Breast Cancer Starting Aromatase Inhibitor Therapy 112. Relationship Between Rheumatology Physician Supply and Travel Distances to Rheumatologists for Medicare Beneficiaries in the United States 113. Dermatologic Rheumatism: Our Experience with a Multidisciplinary Dermatology/Rheumatology Clinic 114. Treat-to-Target (T2T) and Measuring Outcomes in RA Care: a 2014 Longitudinal Survey of US Rheumatologists 115. Biologic Dmards Modify the Association Between Patient Expectations and Outcomes of Total Knee Replacement in Rheumatoid Arthritis Patients 116. Is Socioeconomic Status at Diagnosis Associated with Long-Term Direct Medical Costs in Systemic Sclerosis? a General Population-Based Cohort Study 117. Predictors of Gout Flares in a US Managed Care Setting 118. Difficult to Treat Gouty Arthritis Associated with Poor Health Related Quality of Life and High Resource Utilization: Post- Hoc Analysis Imaging of Rheumatic Diseases: Ultrasound 119. Sonographic Evaluation of the Fifth Metatarsophalangeal Joint Erosion in Rheumatoid Arthritis 120. Can We Use Ultrasound to Identify Rheumatoid Arthritis Patients in Remission Who Cannot Taper Their Medication? 121. Predictors of Persistence of Power Doppler Ultrasound Synovitis in Rheumatoid Arthritis Patients in Clinical Remission 122. The Use of Ultrasound to Detect Residual Joint Inflammation in Patients with Rheumatoid Arthritis in Clinical Disease Remission 123. Combination with Joint Power Doppler Signals with Anti- Citrullinated Peptide Antibody Predicts Joint Destruction in Rheumatoid Arthritis 2014 Program Book 163
ACR POSTER INDICES 124. Ultrasound Power Doppler Findings in the Wrists and Hands Joints of Anti-CCP Antibody Positive Individuals with Non-Specific Musculoskeletal Symptoms and the Development of Inflammatory Arthritis 125. PD Signal Detected By Ultrasonography Relates to Joint Destruction in Rheumatoid Arthritis Under Biologics Therapy in Real World 126. Asymptomatic Versus Symptomatic Ankle Joints in Rheumatoid Arthritis: A High Resolution B-Mode and Power Doppler Ultrasound Study 127. Metacarpophalangeal Cartilage Loss in Rheumatoid Arthritis. a Simple and Fast Ultrasonographic Assessment Comparing Patients and Healthy Controls 128. A Rapid 4- Joint Ultrasonographic Score to Daily Monitoring Disease Activity in Patients with Rheumatoid Arthritis: Validity and Sensitivity to Change 129. Seven Joints Ultrasound Scoring System May be Useful and Effective in Assessing Disease Activity in Patients with Rheumatoid Arthritis in the State of Remission in Daily Clinical Practice 130. Inter-Rater Reliability of the US-7 Score in a Population of Volunteers: Is a Post-Hoc Analysis of Still Images Comparable to the Dynamic Analysis? Results from the German Rheuma-Truck Cohort 131. Detection of Synovitis and Erosions with an Automated Ultrasound System: Data from a Prospective Cohort with Early and Established RA 132. Do Ultrasound (PDUS) and DAS28 Measure Different Aspects of Disease Activity? Analyses from the First Prospective International Phase IIIb Study of PDUS Response in Abatacept-Treated Patients with Rheumatoid Arthritis (RA) 133. On-Demand Ultrasonography Assessment in the Most Affected Joint Is Efficient for Management of RA Patients in Daily Practice 134. Histopathological Correlation of Ultrasound-Defined Active Synovitis in Patients with Rheumatoid Arthritis in Clinical Remission. Preliminary Results 135. Comparison of the Ultrasonography Images and Synovial Pathology of the Joints in Patients with Rheumatoid Arthritis Treated with Biological Agents 136. Serum Calprotectin (S100A8/9) Is an Independent Predictor of Ultrasound Synovitis in Patients with Rheumatoid Arthritis 138. Can Ultrasonography of Peripheral Entheses Play a Role in the Diagnosis and Understanding of Diffuse Idiopathic Skeletal Hyperostosis (DISH)? 139. Ultrasound Enthesitis in Primary Care Psoriasis Patients with Musculoskeletal Complaints 140. Are Entheses Ultrasound Findings Similar in Axial Spa Patients and in Athletes? 141. Prevalence of Subclinical Enthesopathy in Asymptomatic First Degree Relatives of Patients with Spondyloarthritis 142. Prevalence of Subclinical Entheseal Involvement in Patients with Paediatric Inflammatory Bowel Disease: An Ultrasonographic Study 143. Detailed Anatomical Distribution of Synovial Inflammation Revealed By Ultrasound in Patients with Blau Syndrome 144. Sonographic Differentiation of Heel Pain: Focal Degenerative Versus Systemic Inflammatory Enthesitis 145. A Cut-Off Value Analysis By Ultrasound for the Diagnosis of Giant Cell Arteritis (GCA) 146. Ultrasonographic Evaluation of Joint and Tendon Involvement in Patients with Early Systemic Lupus Erythematosus (SLE) in Comparison with Early Rheumatoid Arthritis (RA) 147. US Lung Examination in SSc Patients: A Comparison of Two Different Scoring Systems 148. Value of Ultrasonography Parotid Glands in Patients with Suspected Primary Sjögren s Syndrome 149. Automated Digital Analysis of Major Salivary Gland Ultrasound Images 150. Ultrasonographic Evaluation of Major Salivary Glands in Primary Sjögren s Syndrome: Comparison of Two Scoring Systems and Diagnostic Value of Sonoelastography 151. Sonographic Measurements Can be Misleading for Diagnosing Carpal Tunel Syndrome in Patients with Rheumatoid Arthritis 152. Subclinical Synovial Inflammation in Gout 153. Musculoskeletal Ultrasound of Finger and Foot Joints in a Population of Volunteers: Is Osteoarthritis an Underestimated Problem? Results from the German Rheuma-Truck Cohort 154. Cimt in Individuals with Rheumatoid Arthritis Compared to Individuals with Type2 Diabetes 137. Evaluation of Metalloproteinase-3 As a Soluble Biomarker of Synovitis Using Weighted Joint Counts Assessed Clinically and on Ultrasound Imaging 164 2014 Program Book
ACR POSTER INDICES Metabolic and Crystal Arthropathies: Clinical Aspects 155. Cost-Effectiveness Analysis of HLA-B5801 Genotyping in the Treatment of Gout Patients with Chronic Renal Insufficiency in Korea 156. Colchicine and the Risk of Acute Cardiovascular (CV) Events Among Gout Patients: The New York Department of Veterans Affairs Retrospective Cohort Study 157. Can We Diagnose Acute Gout without Joint Aspiration? Results of a Prospective Study of 112 Patients Presenting with Acute Arthritis 158. Performance of Joint Ultrasonography in the Diagnosis of Suspected Acute Crystal Arthritis : Results of a Prospective Study of 112 Patients 159. Canakinumab in Frequently Flaring Gouty Arthritis Patients, Contraindicated, Intolerant or Unresponsive to non-steriodal Anti-Inflammatory drugs and/or Colchicine: Safety and Efficacy Results from Long Term Follow-up 160. All Men with Gout Should be Screened for Erectile Dysfunction 161. Ultrasonographic Measurement of Renal and Carotid Artery Resistive Indices and Diastolic Function of the Heart in Gout Patients 162. Development of Preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises 163. Is the Rate of Skin Reactions to Febuxostat Increased in Patients with a History of Skin Intolerance to Allopurinol? a Retrospective, Hospital-Based Study Involving 101 Patients Consecutively Treated with Allopurinol and Febuxostat 164. Gouty Patients with History of Adverse Reaction to Allopurinol Are Not at Higher Risk of Reaction to Febuxostat 165. Prevalence of Gout in the Adult Population of France in 2013 166. Risk Factors for Gout Attack Recurrence during Urate- Lowering Allopurinol Treatment 167. Target Serum Urate: Do Patients Know Their Goal? 168. Positive Association Between Tomato Consumption and Serum Urate: Investigating an Anecdotal Trigger of Gout Flares 169. Is Gout a Coronary Heart Disease Risk Equivalent, Similar to Diabetes? 170. Increased Risk of Skin Reactions with Gout Medications: An Analysis of VA Databases 171. High-Protein Diet (Atkins Diet) and Uric Acid Response 172. Sleep Apnea and Risk of Incident Gout: A Population- Based Body-Mass Index Matched Cohort Study 173. Self-Management Education for Patients with Gout: A Review of Existing Resources 174. Long Term Safety and Efficacy of Canakinumab Liquid Formulation in Acute Gouty Arthritis Patients: Results from a 36 Week Extension Study 175. Efficacy and Safety of Canakinumab in Acute Gouty Arthritis Patients with Chronic Kidney Disease Stage Greater Than or Equal to 3: A Post-Hoc Analysis of 12- Week Data 176. Comparative Cardiovascular (CV) Risk and Outcomes Among Patients with Gout, Osteoarthritis (OA), or Both 177. Increase in Thyroid Stimulating Hormone (TSH) Levels in Patients with Gout Treated with Inhibitors of Xanthine- Oxido-Reductase 178. The Effect of Initiating Pharmacologic Insulin on Serum Uric Acid Levels in Patients with Diabetes 179. Effect of Allopurinol on All-Cause Mortality in Adults with Incident Gout: Propensity Score Matched Landmark Analysis 180. Analytical Comparison Between Point of Care Uric Acid Testing Meters 181. Adherence to Treatment Recommendations of Gout: A Patient Survey in China 182. Effect of Urate-Lowering Therapy on Radiographic Changes in Gout Patients 183. Musculoskeletal Ultrasound Reveals Calcific Deposition Arthropathy in Seronegative Inflammatory Arthritis Patients 184. Ultrasound Versus X-Rays Versus Synovial Fluid Analysis for the Diagnosis of Calcium Pyrophosphate Dihydrate Deposition Disease: Is It CPPD? Ask US! 185. Distribution of Haemochromatosis Arthropathy. High Ankle and Mid Foot Prevalence; A Diagnostic Clue? Orthopedics, Low Back Pain and Rehabilitation 186. The Association Between Low Back Pain and Radiographic Features: A Systematic Review with Meta-Analysis 187. Revision Arthroplasty in Rheumatoid and Osteoarthritis: Does Methotrexate Decrease Radiographic Lucency in RA Patients? 2014 Program Book 165
ACR POSTER INDICES 166 188. Time Trends in Total Ankle Arthroplasty in the U.S.: A Study of the Nationwide Inpatient Sample 189. Sex Differences in Characteristics, Utilization and Outcomes of Patient Undergoing Total Elbow Arthroplasty: A Study of the U.S. Nationwide Inpatient Sample 190. Hospital Volume Predicts Outcomes and Complications after Total Shoulder Arthroplasty 191. Utilization and Outcomes Following Total Shoulder Arthroplasty in Elderly and Non-Elderly Patients 192. Title: Use of Non-Traditional Modalities for Pain Management after Knee or Hip Joint Replacement 193. Pre-Operative Pain and Function: Profiles of Patients Selected for Total Knee Replacement Among Surgeons in the United States 194. Differences in Total Knee Replacement Outcomes Based on Age 195. Dependence on Walking Aids and Patient-Reported Outcomes after Total Knee Arthroplasty 196. Dependence on Walking Aids Is Associated with Pain and Mobility Limitation after Total Hip Arthroplasty 197. Differences in Total Hip Replacement Outcomes Based on Age 198. Implant Survival and Patient-Reported Outcomes after Total Hip Arthroplasty in Young Patients with JIA 199. Increasing Complexity of Patients Undergoing Primary Total Hip Arthroplasty in the U.S Osteoarthritis - Clinical Aspects: Imaging and Biomechanics 200. Leg Length Inequality and Hip Osteoarthritis 201. Measures of Hip Morphology Are Related to Development of Incident Radiographic Hip Osteoarthritis over 6 to 13 Year Follow-up: The Johnston County Osteoarthritis Project 202. Is Schuss View Alone Enough for the Diagnosis of Femorotibial Osteoarthritis? the Khoala Cohort Study 203. Predictors of Radiographic Progression of Interphalangeal Finger Joints in Erosive Osteoarthritis: A Prospective Study 204. Ultrasonographic Predictors for Clinical and Radiological Progression in Knee Osteoarthritis after 2 Years Follow up 205. Natural History and Clinical Significance of Meniscal Tears over 8 Years in a Largely Non-Osteoarthritic Cohort 2014 Program Book 206. Risk Factors for Increased Extrusion of the Meniscus Body in Subjects Free of Radiographic Knee Osteoarthritis: 6-Year MRI Data from the Osteoarthritis Initiative 207. Changes in Knee Compartment Distriubtion of Cartilage Loss and Bone Marrow Lesions over 7 Years: The MOST Study 208. Correlates of Knee Bone Marrow Lesions in Younger Adults 209. Physical Performance and Obesity Measures Are Associated with Tibial Cartilage Volume and Explains the Sex Difference in Cartilage Volume 210. Preliminary Assessment of Predictive Validity of Cartilage Thickness MRI Biomarkers in Knee OA - the Fnih OA Biomarkers Consortium 211. Association Between Baseline External Knee Adduction and Flexion Moments during Gait and Medial Tibiofemoral Cartilage Thickness Loss over Two Years in Persons with Knee Osteoarthritis (OA) 212. Relation of Shoe Stability to Risk of Knee Cartilage Damage: The Multicenter Osteoarthritis Study 213. Foot Center of Pressure in Knee Osteoarthritis (OA) and Its Association with Knee Load Reduction with Barefoot Walking 214. Knee Instability and Advanced Function Decline in Persons with Knee Osteoarthritis 215. External Hip Adduction Moment and Progression of Medial Tibiofemoral Cartilage Damage and Bone Marrow Lesions in Persons with Knee Osteoarthritis 216. Hip Adiposity, Not Local Knee Adiposity, Is Associated with Knee Pain Independent of Radiographic Osteoarthritis Severity 217. The Relationship of Quadriceps and Hamstrings Intramuscular Fat and Lean Muscle with Power in Women with Knee Osteoarthritis 218. Surface Area and Fatty Infiltration of Vastus Medialis Measured By Magnetic Resonance Imaging Are Risk Factors for the Progression of Knee Osteoarthritis and Discriminate Two Osteoarthritis Phenotypes 219. DXA Body Composition, Sarcopenia and Knee and Hip Osteoarthritis: Results from the Khoala Cohort 220. Lower Extremity Presarcopenia Is Associated with the Severity of Knee Pain 221. An Analysis of Age-Related Loss of Skeletal Muscle Mass and Its Significance on Osteoarthritis in a Korean Population
ACR POSTER INDICES 222. OA Phenotypes Rather Than Disease Stage Drive Structural Progression Identification of Structural Progressors from 2 Phase III Randomized Clinical studies with Symptomatic Knee OA Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Osteoporosis: Pathogenesis, Epidemiology and Diagnosis 223. Risk Factors for Clinical Vertebral Fractures in Japanese Men and Women with Rheumatoid Arthritis: Results from a Large Prospective Observational Cohort Study 224. Is the Protective Effect of Obesity Against Hip Fracture Due to Changes of Proximal Femur Shape? 225. Association Between Lean Mass and Hip Bone Mineral Density 226. Improved Prediction of Hip Fracture Using the Health Assessment Questionnaire-Disability Index and FRAX in Japanese Patients with Rheumatoid Arthritis: A Prospective Observational Study 227. Increasing Fat-Mass May Reverse Bone Loss As Detected By DXA Scan 228. Is Adult Hypophosphatasia a Cardiovascular Risk Factor? 229. Correlates of Heel Bone Mass in Young Adults: The Role of Cholesterol over 20 Years from Childhood to Early Adulthood 230. Risk Factors That Predict Poor Bone Health in Those Aged over 75 Years - a Cross Sectional Study 231. Factors Predicting Fracture in the over-75s: An Observational Case-Control Study 232. Significance of Serum Srankl and Osteoprotegerin Concentration in Patients with Rheumatoid Arthritis 233. Significance of Serum Marker Levels of Wnt/ß-Catenin Signaling Pathway in Patients with Systemic Autoimmune Diseases Under Glucocorticoid Therapy; A Prospective Study 234. The Decrease in Prescription of Anti-Osteoporotic Drugs Has No Impact on Hip Fracture Incidence 235. Lower P1NP Serum Levels: a Predictive Marker of Bone Loss after One-Year Follow-up in premenopausal SLE Patients 236. Risk Factors for Prevalent and Progressive Bone Deficits Among Adult Men and Women with Cystic Fibrosis 237. Analysis of Vitamin D Receptor Gene Polymorphisms and Bone Mineral Density in a Population of Women with Rheumatoid Arthritis in Use of Steroid 238. RANKL and OPG Gene Polymorphisms: Association with Vertebral Fractures and Bone Mineral Density in Premenopausal Systemic Lupus Erythematosus 239. Does Adjusting BMI for Lean Mass Deficits Affect Calculated Fracture Risk Using FRAX in Rheumatoid Arthritis? 240. An Observational Study on the Influence of Glucocorticoid Exposure on Bone Pain: Basic and Clinical Aspects 241. Reduced Estimated Glomerular Filtration Rate Was Improved after Cessation of NSAID and Switching to Tramadol Hydrochloride/Acetaminophen Tablets (UltracetTM) in Patients with Chronic Musculoskeletal Pain 242. WOMAC Pain Score Reflects Preceding Daily Pain Ratings in Knee Osteoarthritis Interventional Randomized Clinical Trials 243. Safety of Solumatrix Diclofenac in Adults with Osteoarthritis: Results of a 12-Month, Phase 3 Study 244. Onset, Magnitude, and Durability of Pain Relief in Patients with Knee OA Receiving a Fixed-Dose Combination Tablet of Enteric-Coated (EC) Naproxen Plus Immediate-Release (IR) Esomeprazole Magnesium Versus Celecoxib and Placebo: Pooled Results from Two Ran 245. WITHDRAWN 246. Neuropathic PAIN in Patients with Ankylosing Spondylitis 247. Cognitive Task Related Hypoperfusion of Frontal Gyrus in Patients with Chronic Fatigue 248. Is the Basdai Score Driven By Pain in Ankylosing Spondylitis Patients Treated with Anti-TNF? 249. A Phase 3 Open-Label Trial of Low-Dose Solumatrix Diclofenac in Patients with Osteoarthritis Pain: Impact of Long-Term Administration on Patient-Reported Outcomes 250. Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment 251. Chronic Fatigue Is Associated with Hypoperfusion of Parahippocampal Gyrus 252. Preliminary Validation of the Michigan Body Map 253. Evaluating Neuropathic Complaints By DN4 and Lanss Scales after Local Corticosteroid Therapy in Carpal Tunnel Syndrome 2014 Program Book 167
ACR POSTER INDICES 168 254. The Effect of Milnacipran on Pain in Rheumatoid Arthritis Patients with Widespread Pain: a Randomized Blinded Crossover Trial 255. Pain As Predictor of Organ Involvement in Fabry Disease 256. Characteristics of Pain in Fabry Disease 257. Quality of Life Assessment of Adults Patients with X-Linked Hypophosphoremia 258. Pain Characteristics Among Patients with Rheumatoid Arthritis in the Context of Patient-Physician Discordance in Disease Activity Assessments 259. Development of Pediatric Item Banks to Measure Pain Behavior in the Patient Reported Outcomes Measurement Information System 260. Validation of the Dutch-Flemish Promis Physical Functioning Item Bank in Patients with Chronic Pain 261. Validation of the Dutch-Flemish Promis Pain Behavior and Pain Interference Item Banks in Patients with Chronic Pain 262. Longitudinal Assessment of Promis Pediatric Item Banks in Children with Chronic Musculoskeletal Pain 263. Nutraceutical Products and Pain or Non-Pain Medications Use in Patients with Knee Osteoarthritis 264. Efficacy and Safety of Cannabinoid Treatments in the Rheumatic Diseases: A Systematic Review of Randomized Controlled Trials 265. Prevalence of Medicinal Marijuana Use Among 1000 Rheumatology Patients Attending a Community-Based Rheumatology Clinic: A Prospective Cross-Sectional Study 266. An Examination of the Interaction of Opioid Use, Pain, and Depression 267. Selective and Peripheral-Specific Trk Inhibitor Shows Potent Analgesic Effect Comparable to Morphine in Rat Osteoarthritis Model without CNS Toxicity 268. The Effect of Treatment with Resiniferatoxin and Capsaicin on Dynamic Weight Bearing Measures and Evoked Pain Responses in a Chronic Inflammatory Arthritis Murine Model Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis 269. Discontinuation of Concomitant Medication for Enthesitis- Related Arthritis during 52 Weeks of Treatment with Adalimumab 270. Disease Burden Is Comparable in Children with Enthesitis- Related Arthritis and Polyarticular Juvenile Idiopathic Arthritis 2014 Program Book 271. Predicting Treatment Response to Etanercept in Juvenile Idiopathic Arthritis: Results from the British Society for Paediatric and Adolescent Rheumatology Etanercept Cohort Study (BSPAR-ETN) 272. Factors Associated with Choice of First Biologic Among Children with Juvenile Idiopathic Arthritis: A Combined Analysis from 2 UK Paediatric Biologic Registers 273. Long-Term Safety and Effectiveness of Adalimumab in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis 274. Treatment Prescribing Patterns in a Cohort of Patients with Juvenile Idiopathic Arthritis (JIA). Data from the Childhood Arthritis Prospective Study 275. Environmental Risk Factors and Development of Juvenile Idiopathic Arthritis 276. Growth during Tocilizumab Therapy for Polyarticular- Course Juvenile Idiopathic Arthritis: 2-Year Data from a Phase 3 Clinical Trial 277. Nearly 20% of Children ARE NOT Correctly Classified According to Current ILAR Classification in a Printo Dataset of More THAN 12,000 Juvenile Idiopathic Arthritis Patients 278. Is It Worth Allowing the Presence of Morning Stiffness in the Definition of Inactive Disease in Juvenile Idiopathic Arthritis? 279. Focus on Patient Reported Outcomes in Juvenile Idiopathic Arthritis: There Is Room to Improve Care 280. Biologic Treatment of Adult Patients with Juvenile Idiopathic Arthritis Followed in the National Registry 281. Retrospective Review of Immobilization Vs. Immediate Resumption of Activity in Patients with Oligoarticular Juvenile Idiopathic Arthritis and Corticosteroid Knee Injections 282. Pharmacovigilance in Juvenile Idiopathic Arthritis Patients (PHARMACHILD) Treated with Biologic Agents and/or Methotrexate. Consolidated Baseline Characteristics from Pharmachild and Other National Registries 283. Agreement Between Enthesitis Evaluation By Manual Palpation and Dolorimetry in Juvenile Spondyloarthritis 284. Single Hub and Access Point for Paediatric Rheumatology in Europe (SHARE) Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Idiopathic Arthritis 285. Drug Safety in Treatment of Juvenile Idiopathic Arthritis (JIA): Biologic Therapy Compared with MTX
ACR POSTER INDICES 286. Using the 2011 ACR Recommendations for the Treatment of Juvenile Idiopathic Arthritis (JIA) to Evaluate a Single Centre Treatment Pathway: A Feasibility Study 287. Role of Joint Status in Decreased Accelerometer-Assessed Daily Physical Activity in Juvenile Idiopathic Arthritis 288. Establishing Clinical Meaning and Defining Important Differences in Patient Reported Outcome Measures of Physical Function, Fatigue and Pain Interference in Juvenile Idiopathic Arthritis 289. Patient-Reported Outcomes in Children with Moderately to Severely Active Polyarticular or Polyarticular-Course Juvenile Idiopathic Arthritis Who Are Prescribed and Treated with Adalimumab 290. Patterns of Active Joint Involvement in JIA 291. Development of a Serious Game Designed for Children with Juvenile Idiopathic Arthritis 292. Flares in Children with JIA: Results from the Reacch-out Cohort 293. Long Term Functional Outcome and Quality of Life of Patients with Refractory Juvenile Idiopathic Arthritis Treated with Etanercept: Results of the Dutch Arthritis and Biologicals in Children Register 294. Long-Term Pharmacokinetics of Body Surface Area- Adjusted Doses of Golimumab Following Repeated Subcutaneous Administrations in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis 295. Intra-Articular Corticosteroid Injections in Juvenile Idiopathic Arthritis: Results from a UK Prospective Collaborative Study 296. Countermeasures Against Methotrexate Intolerance in Juvenile Idiopathic Arthritis Instituted By Parents Show No Effect 297. S100 Proteins in Oligoarticular Juvenile Idiopathic Arthritis 298. Long-Term Impact of Juvenile Idiopathic Arthritis in the Greek adults Psychosocial Life 299. A Controlled Trial of Intra-Articular Corticosteroids with or without Methotrexate in Oligoarticular Juvenile Idiopathic Arthritis 300. Patient-Reported Joint Count in Juvenile Idiopathic Arthritis: The Reliability of a Mannequin Format 301. Pregnancies in Females with Juvenile Idiopathic Arthritis (JIA) Who Were Exposed to Biologics and/or Methotrexate Results from a Biologic Register 302. Qualitative Assessment of Important Long-Term Outcomes in Juvenile Idiopathic Arthritis 303. Predicting Chronic Pain in Children with Juvenile Idiopathic Arthritis: Results from the Childhood Arthritis Prospective Study 304. Juvenile Rheumatoid Arthritis and Future Risk for Cardiovascular Disease; A Multicenter Population-Based Study Pediatric Rheumatology - Pathogenesis and Genetics 305. Understanding the Molecular Pathogenesis of and Response to Canakinumab Treatment in TNF Receptor- Associated Periodic Syndrome By Gene Expression Profiling of Whole Blood from Patients 306. Association of Kawasaki Disease with Tropospheric Winds in Central Chile: Is Wind-Borne Desert Dust a Risk Factor? 307. Sibling Exposure and Risk of Juvenile Idiopathic Arthritis 308. Tenascin-C, a TLR4 Ligand Levels in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis: Cross- Sectional and Longitudinal Study 309. Clinical Significance of Cytokine Profile with Interleukin-18 and -6 in Systemic Juvenile Idiopathic Arthritis 310. Differential Expression of microrna in Monocytes from Children with Systemic Juvenile Idiopathic Arthritis: Implications for Polarized Phenotype 311. Inhibition of Natural Killer (NK) Cell Cytotoxicity By Interleukin-6 (IL-6): Implications for the Pathogenesis of Macrophage Activation Syndrome 312. Mutations in the MTHFR Gene Are Not Associated with Methotrexate Intolerance in Patients with Juvenile Idiopathic Arthritis 313. Elevated Cardiovascular Disease Burden and Inflammatory Biomarker Levels in Adults with Juvenile Idiopathic Arthritis 314. Next Generation Sequencing Reveals Restriction of the Treg Cell Repertoire and an Abundance of Shared Synovial Treg Clonotypes in JIA 315. NLRC4-Related Macrophage Activation Syndrome (NLRC4- MAS): A Novel Primary Autoinflammatory Syndrome Caused By Activating Mutations in NLRC4 316. Cytokines in Systemic Juvenile Idiopathic Arthritis and Macrophage Activation Syndrome: Tipping the Balance Between Interleukin-18 and Interferon-Gamma 317. Myeloid Related Proteins 8 and 14 (MRP 8/14) - Potential Biomarkers of Disease Activity of Arthritis in Children with Trisomy 21 2014 Program Book 169
ACR POSTER INDICES 318. HLA-B27 Subtypes in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis 319. Systemic Juvenile Idiopathic Arthritis and Exposure to Fine Particulate Air Pollution 320. Autoantibodies in Juvenile Systemic Sclerosis 321. Mutations of Familial Hemophagocytic Lymphohistiocytosis (FHL) Related Genes and Abnormalities of Cytotoxicity function tests in Patients with Macrophage Activation Syndrome (MAS) Occurring in Systemic Juvenile Idiopathic Arthritis (sjia) Rheumatoid Arthritis - Animal Models 322. Superior Therapeutic Efficacy of a Novel Oral Small Molecule Retinoic Acid Receptor-Related Orphan Receptor Gamma T [Rorgt] Inverse Agonist Inv-17: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis 323. Anti-Inflammatory Marine Compound, Lyy-B2, Ameliorates Rheumatoid Arthritis through Inhibition of Osteoclast Differentiation 324. Regulation of TNF-α-Mediated Activation of Rheumatoid Synovial Fibroblasts By Transcription Factor Snail 325. Tadalafil Decreases Joint Inflammation in TNF-Tg Mice By Restoring Passive Lymphatic Transport 326. IL-1 Receptor Antagonis (IL-1Ra)-Fc Ameliorate Autoimmune Arthritis By Regulation of the Th17 Cells/ Treg Balance and Arthrogenic Cytokine Activation 327. AMPK Activation in Inflammatory Arthritis 328. Etanercept, Abatacept and Anakinra Treatment Ameliorates Inflammation and Pain in a Novel Mono- Arthritic Multi-Flare Model of Streptococcal Cell Wall Induced Arthritis: Further Characterization in a Rodent Model of Collagen Induced Arthritis 329. A Novel, Small Molecule Cyclin-Dependent Kinase 4/6 Inhibitor As the New Option for Treatment of Rheumatoid Arthritis 330. Prolactin Reduces Bone Erosion in Adjuvant-Induced Arthritis 331. WITHDRAWN 332. Improvement of the Stability of RNA Aptamers Against Interleukin-17A 333. Deletion of the Prolactin Receptor Aggravates the Course of Antigen-Induced Arthritis 334. Inflammatory Arthritis in K/BxN Mice Is Associated with Abnormal HDL Function 335. Interleukin-33 Suppresses Experimental Arthritis through Promoting Foxp3+ Regulatory T-Cells and Type-2 Immune Responses in Mice 336. The Additive Inflammatory in Vivo and in Vitro Effects of Thymic Stromal Lymphopoietin (TSLP) and IL-7 in Arthritis Underscore the Therapeutic Rationale for blockade of Their Common Receptor Subunit 337. Effect of Etanercept on Endothelial Dysfunction in Rat Adjuvant-Induced Arthritis 338. Bombina Variegate peptide8/prokineticin 2: A Novel Arthritis-Inducible Chemokine 339. Toll-like Receptor Dependent Autoantigens and Vesicles from P.Gingivalis in Animal Models of RA to Modulate Collagen and Collagen Antibody Induced Arthritis 340. Role of Beta-Catenin Signaling to Control Dendritic Cell Function in Collagen-Induced Arthritis 341. Death Receptor 3 Causes Vascular Dysfunction in a Murine Model of Rheumatoid Arthritis 342. Vascular Permeability As an Imaging Biomarker for Chronic Inflammatory Arthritis: A Dynamic Contrast Enhanced Magnetic Resonance Imaging Study 343. The Caspase 8/RIPK3 Signaling Axis Has Opposing Roles in Myeloid and Dendritic Cells during Progression of a Murine Model of Acute Inflammatory Arthritis 344. Reduced Macrophages in the Synovium Contribute to the Effective Treatment of Spontanneous Arthritis Observeded in Human TNF-Transgenic Mice 345. A Low Salt Diet Ameliorates Clinical Manifestations in Collagen-Induced Arthritis 346. Treatment of Collagen Induced Artritis with Human Embrionic Stem Cell-Derived Multipotent Mesenchymal Stromal Cells (hesc-msc) 347. Salt Aggravates Arthritis By Th17 Polarization Rheumatoid Arthritis - Clinical Aspects: Novel Biomarkers and Other Measurements of Disease Activity 348. Smoking Status Is Associated with Inflammatory Cytokine Profile and Disease Activity: Decreased Inflammation and Disease Improvement with Smoking Cessation? 349. Galectin-3 in the Systemic Circulation Is Increased in Newly Diagnosed Rheumatoid Arthritis and Is Associated with Anti-CCP and Bone Marrow Edema 170 2014 Program Book
ACR POSTER INDICES 350. Rho-Associated Protein Kinase (ROCK) Activity Is Elevated in Rheumatoid Arthritis (RA) Patients and May be Responsive to RA Therapies 351. Doctor, Will My Fatigue be Better If I m in Remission? an Exploratory Analysis of 1284 Rheumatoid Arthritis (RA) Patients Indicates Fatigue Is the Only Aspect of Patient- Perceived Impact to Remain Significant in ACR/EULAR Boolean Remission 352. Remaining Pain in Spite of Suppressed Inflammation in Early Rheumatoid Arthritis Long-Term Strongly Increased Risk for Widespread Pain and Fatigue 353. Sensitivity of Unique Multidimensional Health Assessment Questionnaire Items Compared to Items on Both the HAQ and MDHAQ in Patients with RA and SLE 354. Increased Vascular Wall Inflammation in Patients with Active Rheumatoid Arthritis As Measured By an 18F-FDG- PET/CT Scan 355. Increased Left Ventricular Mass Index and Decreased Ejection Fraction Are Associated with Disease Activity in Rheumatoid Arthritis Patients without Cardiac Symptoms; Comparison Between Non-Biologic and Biologic Dmards Treatment Groups, Using a Cardiac Mag 356. The Rheumatoid Arthritis Impact of Disease Score Is Associated with Disease Activity By Clinical, Laboratory and Ultrasonographic Measures: Validation in an inception Cohort of DMARD naïve Patients with Rheumatoid Arthritis 357. Development and Validation of a Diagnostic Bead- Based Multiplex Autoantibody Assay:Screening for Autoantibodies to Detect Seronegative Rheumatoid Arthritis 358. Parity and Severity of ACPA-Positive/Negative Rheumatoid Arthritis. Results from the Swedish EIRA Study 359. 14-3-3η Cit:Arg Antibody Ratios: Are We Overlooking the Prognostic Utility of Citrullinated Antibodies By Only Looking at Titers? 360. 88% of Recent Onset Polyarthritis Patients Are Positive for 14-3-3η Markers and 14-3-3η Auto-Antibodies Inform a Favourable Prognosis 361. Citrullinated 14-3-3η Antibodies Are Specific for Early and Established RA and Are Complementary to ACPA 362. 14-3-3η Early RA Biomarkers: Does Seronegative RA Exist? 363. Increased Prevalence of Plasma Anti-Nuclear, Anti-SSA, and Connective Tissue Disease Associated Antibodies in African American Patients with Rheumatoid Arthritis 364. In Early Rheumatoid Arthritis, the Multi-Biomarker Disease Activity Score at Different Time-Points Is Predictive of Subsequent Radiographic Progression 365. Differential Relative Contribution of Individual Components on DAS28 over Time: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada 366. Soluble 4-1BB Is a Marker of Joint Involvement and Disease Activity in Rheumatoid Arthritis 367. In Early Rheumatoid Arthritis Patients with Non- Response to Methotrexate Monotherapy the Change in Multi-Biomarker Disease Activity Score Is Differentially Associated with Subsequent Response to Non-Biological Versus Biological Therapy 368. Serum C1M Level Predicts Disease Progression and Early Treatment Efficacy in Rheumatoid Arthritis 369. Validation of Snapshot, a Rheumatoid Arthritis Assessment Tool, Against CDAI, DAS28 (ESR), and DAS28 (CRP) in Canadian Patients with Rheumatoid Arthritis 370. Double Positivity of RA Serologies More Prevalent Yet Associated with Clinical Response in Ethnic Minority Patients with Rheumatoid Arthritis 371. The Impact of Missing Anti-Citrullinated Protein Antibody (ACPA) on Outcomes in Early Rheumatoid Arthritis: From the Canadian Early Arthritis Cohort 372. Diagnostic Accuracy and Associated Costs of Rheumatoid Factor Testing in Primary Care: A Population-Based Cohort Study in Spain 373. Biomarkers of Cardiac Dysfunction and Inflammation in Plasma Predict Occult Coronary Plaque Burden and Composition in Rheumatoid Arthritis 374. IL-33 and Soluble ST2 Levels As Novel Predictors for Remission and Progression of Carotid Plaque in Early Rheumatoid Arthritis: A Prospective Study 375. Evaluation of RAPID3 with Minimal Joint Count and ACR/ EULAR Provisional Remission Definitions As Predictors of Future Good Radiographic + Functional Outcome in a Double-Blind, Phase 3, Randomized Controlled Trial of Tocilizumab 376. Using the Multi-Biomarker Disease Activity Score As a Complementary Inclusion Criterion for Clinical Trials in Rheumatoid Arthritis May Enhance Recruitment 377. Fatigue Fluctuates Substantially over Time in Rheumatoid Arthritis Patients Despite Stable Disease Activity during Treatment with Biological Agents 378. The Use of Week 12 CDAI, RAPID3 and DAS28(CRP) Responses to Predict Optimal Response to Methotrexate 2014 Program Book 171
ACR POSTER INDICES 379. What Level of Disease Activity at 6 Months Predicts Achieving or Sustaining Remission at 12 Months? 380. In Palindromic Rheumatism, Older Age, Shorter Interval Between Attacks and Positive Anti-CCP Antibodies May Predict Progression to RA 381. Distribution and Clinical Significance of Anti-Heterogenic Nuclear Ribonucleoprotein A2 Antibody in Connective Tissue Diseases 382. What Is More Predictive of Achieving Remission at 12 Months: The Percentage of Baseline Improvement or the Actual Disease State Achieved at 6 Months? 383. How Low Is Low Disease Activity? an Analysis from a Prospective, Observational Registry 384. Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient Activity Score (PAS) and Routine Assessment of Patient Index Data (RAPID) 385. Validation of a Prognostic Model to Predict Structural Damage Assessed By X-Ray in Patients with RA Using MRI Data from a Clinical Trial 386. Association of Pharmacogenetic Markers with Treatment Response in Patients with Rheumatoid Arthritis 387. Levels of IgG Autoantibodies to Oxidation-Associated MDA Neo-Determinants Are a Biomarker for Systemic Inflammation and Disease Activity in SLE and RA 388. Soluble TREM-1 Is a Biomarker of Anti-CCP-Positive, DMARD-Naive Early Rheumatoid Arthritis 389. High 11B-HSD1 Activity Is Associated with Progression to Rheumatoid Arthritis in Patients with a New Onset of Inflammatory Arthritis 390. Prevalence and Correlates of Patient-Physician Discordance in Early Rheumatoid Arthritis 391. Self-Assessment Tool of Rheumatoid Arthritis Disease Activity: Handgrip Strength Measured By a Smartphone Connected to a Dynamometer 392. Neuroendocrine Hormone and Metabolic Peptide Levels in the Earliest Phases of Rheumatoid Arthritis Do Free Fatty Acids Play a Role? 393. Influence of Body Mass Index on Disease Activity and Radiographic Joint Damage in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis 394. Very Low or High Body Mass Index Negatively Affects patients Ability to Achieve Sustained Remission in Early RA in a Multicenter Canadian Cohort 395. Could Osteoprotegerin and TNF-Related Apoptosis- Inducing Ligand Assessments Help Us to Manage Early Rheumatoid Arthritis? Results from the Espoir Cohort 396. Disease Activity Scoring: Comparing Patient and Physician Global Assessment of Disease Activity in Rheumatoid Arthritis 397. Th9 Lymphocytes in Rheumatoid Arthritis 398. Anti-Rheumatic Therapy Decreases Syndecan-1 Shedding in Rheumatoid Arthritis (RA) 399. Lipid Concentrations and Particle Sizes in Drug Naive Patients with Rheumatoid Arthritis 400. Clinical Utility of 14-3-3η in the Evaluation of Inflammatory Arthritis 401. Association of Anti-Thyroid Autoantibodies with Fibromyalgia in Rheumatoid Arthritis 402. Can GP88 (Progranulin) be Used As a Biomarker for the Diagnosis and Therapy Evaluation of Rheumatoid Arthritis? 403. Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity to Response to Therapy in Early Rheumatoid Arthritis 404. The Relationship Between Disease Activity and Levels of HMGB1 in Patients with Rheumatoid Arthritis 405. 14-3-3η: A Mechanistic Biomarker That Supports the Concept of Uncoupling of Inflammation and Joint Damage 406. The Utility of HLA-DR Genotypification As a Complementary Tool to Discriminate Undifferentiated and Rheumatoid Arthritis Patients in Early Arthritis 407. Serum 14-3-3η Protein Supplements Traditional Rheumatoid Arthritis Biomarkers 408. 14-3-3η Auto-Antibody Positivity Informs Better Clinical Outcomes in RA 409. Soluble CD163 Is a Marker of Disease Activity in Early Rheumatoid Arthritis and Reflects TNFα Levels 410. Vascular Endothelial Function Changes during Treatment in Patients with Rheumatoid Arthritis 411. ABCB1 and ABCG2 Drug-Efflux Transporters Function and Its Association with Disease Activity in a Cohort of Patients with Rheumatoid Arthritis 412. Determinants of Radiological Progression in Rheumatoid Arthritis: Relationship with Serum Levels of OPG, RANKL and DKK-1 172 2014 Program Book
ACR POSTER INDICES 413. Association of Antinuclear Antibodies with Lung Disease, Malignancy and Joint Replacement in Rheumatoid Arthritis 414. Relationship Between Range of Motion of Joints in Upper Limbs and Physical Function in Patients with Long- Standing Rheumatoid Arthritis: Multicenter Prospective Cohort Study for Evaluation of Joint Surgery on Physical Function 415. a Dual-Center, Double Blind Randomized Study for a New Scientific Approach in Assessment of Tender Joints in Inflammatory Arthritis Using the Smart Joint Assessor Glove Device (Smart JAG Device) 416. Using Patient Reported Outcome Measures to Classify Disease Activity States in Rheumatoid Arthritis: A Comparison of Patient-Derived Versions of Clinical Disease Activity Index (CDAI), Simplified Disease Activity Index (SDAI) and Disease Activity Score 28 417. Normal Scores of 0 (floor effects) Are Seen in 33-83% of Patients with Rheumatoid Arthritis (RA) on 8 HAQ Activities Which Also Are Found on the MDHAQ, but in Fewer Than 32% of Patients on 2 Unique MDHAQ Complex Activities Walk 2 Miles or 3 Kilometers, 418. Prevalence of Morning Stiffness in a US Registry Population of Rheumatoid Arthritis Patients 419. Comparative Dynamics of Rheumatoid Arthritis Disease Activity and Disease Severity Measures Using Rarbis, Ciras and DAS28 in a Population Based Cohort of Patients with RA 420. Less Is More: The Shorter Physical Function Measure Promis-PF10a Outperforms HAQ in an Ethnically Diverse, Urban Rheumatoid Arthritis Clinic Population 421. Prediction of Remission By Patients and Physicians: Does the Doctor Know Best? 422. Correlation of RAPID3, DAS28 and CDAI in Disease Activity and Effects of Education Level and Co-Morbid Diseases on This Assesment in RA 423. Circulating Anti-Citrullinated Peptide Antibodies and Cytokines As Biomarkers of Response to Disease- Modifying Antirheumatic Drugs Therapy in Early Rheumatoid Arthritis 424. The Comparison Between Physical and Ultrasound Joint Examination for the Hand Joints in Patients with Rheumatoid Arthritis 425. Beyond Disease Activity: Patient Global Scores Also Reflect Treatment Expectations and Emotional Reactions to Living with Rheumatoid Arthritis 426. Exploring the DAS: What Is the Level of Agreement in the Classification of Remission and Low Disease Activity (LDA) Among the Various Versions of the Disease Activity Score (DAS) and Their Correlation? an Analysis from a Prospective, Observational Registr 427. Multimedia Patient Education Tool for Patients with Rheumatoid Arthritis 428. Patient-Physician Discordance of Disease Activity Assessments Predicts Inadequate Treatment Response in Early Rheumatoid Arthritis 429. Investigation of MRI Bone Changes in Early-Stage RA Patients Achieved in Sustained Clinical Good Response: Sub-Analysis from Nagasaki University Early Arthritis Cohort 430. Minimally Important Difference in the European Quality of Life-Five Dimensions in Patients with Rheumatoid Arthritis 431. Joint Dermal Temperature Specifically Identifies the Individual RA Patient Most Likely to Develop Radiographic Change on Sharp Score; An Exam in Less Than a Minute Can Predict Who Specifically Needs Biologic Therapy 432. Rheumatoid Arthritis-Associated Interstitial Lung Disease: Risk Factors for Disease Progression Rheumatoid Arthritis - Human Etiology and Pathogenesis 433. Bronchiectasis: A Model for Chronic Bacterial Infection Inducing Autoimmunity in Rheumatoid Arthritis 434. Characterization of Lung Inflammation in the Lungs of Early Rheumatoid Arthritis 435. Smoking Functions As a Negative Regulator of IGF-1 Levels and Adipokine Network in Patients with Rheumatoid Arthritis 436. Increasing Cartilage Turnover in Smokers Developing Rheumatoid Arthritis Is Associated with High Disease Activity in Early Disease 437. Anti-Citrullinated Heat Shock Protein 90 Antibodies Identified in Bronchoalveolar Lavage Fluid Are a Marker of Lung-Specific Immune Responses 438. Distinct Profiles of Proinflammatory Macrophages in Rheumatoid Arthritis and Coronary Artery Disease 439. The Anti-IL-6 Antibody Sirukumab Inhibits Vascular Inflammation in a Human Surrogate Model of Atherosclerosis 2014 Program Book 173
ACR POSTER INDICES 440. Comparison of C-Reactive Protein (CRP) and Erythrocyte Sedimentation Rate (ESR) with Estimated Glomerular Filtration Rate (egfr) in Patients with Rheumatoid Arthritis (RA) 441. Arthritis Associated Autoantibodies in Non-Rheumatoid Arthritis Patients with Mucosal Inflammation 442. Anti-Carbamylated Protein Antibody Levels Are Elevated in Seropositive Rheumatoid Arthritis and Correlate with Anti-Sa/Citrullinated Vimentin Antibody Levels 443. Sputum Anti-Citrullinated Protein Antibodies in Patients with Long Standing Rheumatoid Arthritis 444. Evidence for Citrullination of the Nuclear Transciption Factor Inhibitor of DNA Binding 1 (Id1) in Rheumatoid Arthritis 445. Differing Specificities of Anticitrullinated Peptide/Protein Antibodies in Palindromic Rheumatism and Rheumatoid Arthritis: A Case-Control Study 446. Immunoglobulin a Antibodies to Cyclic Citrullinated Protein Predominate in Individuals at-risk for Future Rheumatoid Arthritis 447. Rheumatoid Factor Isotypes in Relation to Antibodies Against Citrullinated Peptides in Individuals before Onset of Rheumatoid Arthritis 448. Citrulline-Specific Autoimmunity Resides in Quiescent Circulating Memory B Cells in Rheumatoid Arthritis 449. Citrullinated-Vimentin-Specific Regulatory T-Cell Responses Associate with ACPA Positive Individuals with Non-Specific Musculoskeletal Symptoms 450. The Mucosal Anti-Citrullinated Protein Antibody Response in Pre-Clinical Rheumatoid Arthritis 451. The Association of Fine Specificities of Anti-Citrullinated Protein Antibodies (ACPA) with disease Severity in African-Americans with RA 452. The Use of Multiplex Bead Array to Follow the Effect of Rituximab on IgG and IgA Serum Autoantibody Responses to Citrullinated Epitopes in Patients with Rheumatoid Arthritis 453. In a Periodontal Disease Cohort without RA, Indeterminate or Low-Positive Anti-CCP-2 Antibodies Are Associated with Multiple Distinct ACPA 454. The Specificity of Anti-Carbamylated Protein Antibodies for Rheumatoid Arthritis in a Setting of Early Arthritis 455. Clinical and Tissue Specificity of Antibodies Against Carbamylated Proteins in Patients with Rheumatoid Arthritis 456. AAA-Atpase p97 Regulates Autophagy-Associated Cell Death in Arthritis Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Safety of Biologics and Small Molecules in Rheumatoid Arthritis 457. First Confirmation Data of Long Term Safety for Tocilizumab in Real-World Setting; 3 Year Follow-up Postmarketing Surveillance of 5573 Patients with Rheumatoid Arthritis in Japan 458. Meta-Analysis of Serious Infections with Tofacitinib and Biological Treatment in Rheumatoid Arthritis Clinical Trials 459. Evaluation of the Effect of Tofacitinib on Measured Glomerular Filtration Rate in Patients with Active Rheumatoid Arthritis 460. Analysis of Non-Melanoma Skin Cancer Across the Tofacitinib Rheumatoid Arthritis Clinical Program 461. Comprehensive Summary of the Efficacy and Safety of Tofacitinib 5mg Twice Daily in Patients with Rheumatoid Arthritis and an Inadequate Response to Disease- Modifying Antirheumatic Drugs 462. Infections and Gastrointestinal Side Effects in a Comparison of Rheumatoid Arthritis Therapies 463. Golimumab 5-Year Safety: an Analysis of Pooled Data from the Long Term Extensions of Randomized, Double- Blind, Placebo-Controlled Studies in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis 464. Analysis of Pooled Data from Two Randomized Controlled Trials and Their Open-Label Extensions: Long-Term Safety in Rheumatoid Arthritis before and after Certolizumab Pegol Dose Increase/Decrease 465. 18-Month Worldwide Post-Marketing Surveillance Experience of Tofacitinib 466. Should Anti-Tnfa treatment of RA be Stopped before Orthopedic Surgery? 467. Evaluation of the Rabbit Risk Score for Serious Infections in a UK Anti-TNF Treatment Cohort 468. Identification of Baseline Risk Factors for Adverse Events in Certolizumab Pegol Treated Rheumatoid Arthritis Patients 469. Safety of Rituximab in Patients with Chronic Inflammatory Arthritis. Seven-Year Follow-up Observational Study 470. Safety Profile of Biologic Agents for Rheumatoid Arhtisitis Treatment after the Complication with Methotrexate- Related Lymphoproliferative Disorder 174 2014 Program Book
ACR POSTER INDICES 471. Improving of Safety in Treatment with Biologics during First Seven-Years Experiences; Long-Term Results from Observational Cohort Study of Clinical Practice Using Multicenter Registry in Japan 472. Abatacept Can be Used Safely for RA Patients with Interstitial Lung Disease 473. Complications of Varicella Zona Virus Infections Are More Frequent in Patients Treated with Biologic Drugs When Combined with Steroids 474. Assessment of 12-Month Efficacy and Safety of 168 Certolizumabpegol Rheumatoid Arthritis Treated Patients from a Multicenter Retrospective National Study in Spain 475. Risk Analysis of a First Adverse Event and Recurrent Infections during Biological Therapy in Chronic Inflammatory Arthritis 476. Medium-Term Safety of TNF-Alpha Inhibitors in Rheumatoid Arthritis: A Meta-Analysis of Randomized Controlled Trials 477. Leflunomide Use Is Not Associated with an Increased Risk of Lung Disease in Rheumatoid Arthritis: A Meta-Analysis of Randomised Controlled Trials 478. Adverse Events and Infections in Patients with Rheumatoid Arthritis Treated with Conventional Drugs or Biologic Agents: A Real World Study 479. Long Term Safety of Intravenous Golimumab and Comparison with Subcutaneous Golimumab in Rheumatoid Arthritis: Results through 2 Years 480. Serious Infection Risk By Treatments and Types in Patients with RA 481. Efficacy and Safety of Etanercept in Rheumatoid Arthritis Patients over 75 Years Old 482. Incidence of Opportunistic Infections in Rheumatoid Arthritis Treated with Biological Agents 483. Risk of HBV Reactivation in Rheumatoid Arthritis Patients Undergoing Treatment with Newer Biological Dmards, Tocilizumab and Abatacept: A Single-Center Real Life Experience 484. Reactivation of Hepatitis B Virus in Patients with Rheumatoid Arthritis after Anti-TNF Therapy 485. Incidence of Clinical and Serological Lupus-like Disease during Anti-Tnfα-Treatment a Two-Year Prospective Study in an Interdisciplinary Patient Cohort 486. Tofacitinib Improves Arterial Stiffness Despite up- Regulating Serum Cholesterol with Chronic Cardiovascular Disease in Methotrexate-Resistant Active Rheumatoid Arthritis Patients. a Cohort Study 487. Assessment of Lipid Changes in Patients with Early Rheumatoid Arthritis Treated with Tofacitinib or Methotrexate over 24 Months 488. Increases in Serum Cholesterol with Baricitinib Treatment Are Associated with Favorable Changes in Apolipoprotein Content and with Improvement in DAS28-CRP in Patients with Rheumatoid Arthritis 489. Rosuvastatin Improves Arterial Stiffness in Patients with Inflammatory Joint Diseases 490. A Randomised Controlled Trial Evaluating the Effect of Humira upon Endothelial Function in ACPA Positive Rheumatoid Arthritis an Interim Analysis 491. Do Patients with Congestive Heart Failure Treated with Biologics for RA Have a Lower Risk of Fatal Outcome of Serious Infections? 492. Patient-Reported Outcomes from a Canadian Study of Patients Taking Methotrexate and Etanercept 493. Efficacy and Safety of Tofacitinib Following Inadequate Response to Nonbiologic DMARD or Biologic DMARD 494. Estimation of Cost per Effectively Treated Patients with Biologic Disease Modifying Anti-Rheumatic Drugs in US Veterans with Rheumatoid Arthritis 495. Discontinuation of Biologics in Patients with Rheumatoid Arthritis after Achieving Low-Activity Disease Status 496. Efficacy and Safety of Induction Therapy for Rheumatoid Arthritis with Simultaneous Administration of Methotrexate and Low-Dose Tacrolimus: A Retrospective Study 497. Efficacy and Safety Study of a Sequential Therapy of Tocilizumab and, If Initially Inadequately Responded to Tocilizumab, Followed By Rituximab in Patients with Rheumatoid Arthritis and Inadequate Response to Traditional Disease Modifying Anti-Rheumatic Drugs 498. Patient Experience with Initiation of SQ and Oral MTX 499. Biologic Discontinuation in Rheumatoid Arthritis: Experience from a Canadian Clinic 500. Prediction of Successful Dose Reduction or Discontinuation of Adalimumab or Etanercept Using Serum Drug Levels and Antidrug Antibody Measurement 501. Bio-naïve Patients with Rheumatoid Arthritis Benefit More from Abatacept Treatment Compared to Those Who Are Inadequate Responders to Other Biologics Results from the National Swedish Rheumatology Quality Register 2014 Program Book 175
ACR POSTER INDICES 176 502. Tocilizumab Use in Patients with Rheumatoid Arthritis Having Failed One Previous Anti-TNF Agent: Comparison with Adalimumab, Etanercept and Infliximab 503. Does a Higher Dose of Folic Acid Reduce Adverse Effects of Methotrexate in Rheumatoid Arthritis? a Randomized Controlled Trial 504. Abatacept after Rituximab in Rheumatoid Arthritis. a Pan-European Collaboration of RA Registries 505. A Structured Approach for Comparative Benefit- Risk Assessment of Rituximab for the Treatment of Rheumatoid Arthritis 506. Trial of Six Weeks Interval of Tocilizumab Infusion in Patients with Rheumatoid Arthritis 507. Efficacy and Safety of Adalimumab Therapy in Japanese Patients with Rheumatoid Arthritis 508. Relationship Between NK Cell Count and Important Safety Events in Rheumatoid Arthritis Patients Treated with Tofacitinib 509. Etanercept Have Better Drug Survival Than Monoclonal Antibodies in Rheumatoid Arthritis: Results of Single Center Hur-BIO Registry 510. Similar Short Term Survival on Drug for Patients with Rheumatoid Arthritis Treated with Subcutaneous and Intravenous Abatacept - Results from the National Swedish Rheumatology Quality Register 511. First and Second Line Continuation Rates of Non Anti-TNF-α Biological DMARD for the Treatment of Rheumatoid Arthritis 512. Effect and Safety of Concomitant Methotrexate and Tacrolimus on Clinical Response of Abatacept in Rheumatoid Arthritis Patients with Prior Use of Biological Dmards 513. Analysis of Shoulder Joint Destruction in Rheumatoid Arthritis Patients Treated with Biologics 514. Methotrexate Reduces the Frequency of Prediabetes in Patients with Rheumatoid Arthritis or Psoriatic Arthritis 515. Dosing of Intravenous Tocilizumab in a Real-World Setting Analyses from a US RA Registry 516. The Safety and Treatment Efficacy of Abatacept in Rheumatoid Arthritis Patients with Pulmonary Complications: From the Tsurumai Biologics Communication Registry (TBCR) Multicenter Study 517. Real-World Use of Tocilizumab in Rheumatoid Arthritis Patients in Canada: Interim Results 2014 Program Book 518. Risk of Infection Associated with Subsequent Biologic Use Following Rituximab Results from a National RA Patient Registry 519. Patterns of Tocilizumab Use and Safety in Patients with Rheumatoid Arthritis: Interim Results from a Multinational Observational Study Sjögren s Syndrome: Pathophysiology 520. Genetic Variant and High Levels of CCL11 in Serum Are Associated with the Occurrence of Lymphoma and Disease Activity in Primary Sjögren s Syndrome Patients (pss) 521. CXCL13 Serum Levels Is Associated with Lymphoma, High B Cells Markers and Diseases activity in Primary Sjögren s Syndrome Patients 522. Whole Blood microrna Signature for Primary Sjögren s Syndrome-Related Lymphoma 523. Serum CXCL4 Is Increased in Patients with Primary Sjögren s Syndrome and Is Associated with Features of Microvascular Impairment 524. Distinct Patterns of DNA Methylation in Labial Salivary Gland Tissue Based on Sjögren s Syndrome Disease Status 525. The Genetic Basis of Sjögren s Syndrome (SS) Clinical Manifestations from Genome-Wide Association Analysis of Subphenotype Extremes in an International Cohort 526. A Descriptive and Comparative Study of the Transcriptome from Salivary Exosomes of Sjögren s Syndrome Patients Using RNA-Seq 527. Salivary Expression of S100A7/Psoriasin and Oral Damage in Primary Sjögren s Syndrome and Overlapping Disorders 528. Calcium-Calcineurin-NFAT Signaling Pathway Regulates AQP5 Expression in Primary Salivary Gland Acinar Cells 529. IP3R3 Deficit Underlies the Loss of Fluid Secretion in Salivary Glands from Sjögren s Syndrome Patients 530. Downregulation of Microrna-183 in Sjögren s Syndrome Minor Salivary Glands. Implications in Control of Ezrin Expression and Salivary Gland Function 531. Expression of Indoleamine 2,3 Dioxygenase-1 and -2 in Focal Sialoadenitis of Patients with Sjögren s Syndrome 532. Adipose Tissue Is Prominent in Salivary Glands of Sjögren s Syndrome Patients and Appears to Influence the Autoimmune Microenvironment in These Organs 533. Predictive Significance of CCL21 and CXCL13 Levels in the Minor Salivary Glands of Patients with Sjögren s Syndrome
ACR POSTER INDICES 534. Serum Biomarkers of Inflammation and Fibrosis in Advancing Diagnosis, Prognosis and Treatment of Anti-Ro Associated Congenital Heart Block 535. WITHDRAWN Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment I 536. Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Signs and Symptoms of Active Ankylosing Spondylitis: Results of a Phase 3, Randomized, Placebo-Controlled Trial with Subcutaneous Loading and Maintenance Dosing 537. Secukinumab, a Human Anti Interleukin-17A Monoclonal Antibody, Significantly Reduces Psoriasis Burden in Patients with Psoriatic Arthritis: Results from a Phase 3 Randomized Controlled Trial 538. Secukinumab, a Monoclonal Antibody to Interleukin-17A, Significantly Improves Physical Function and Quality of Life in Subjects with Active Ankylosing Spondylitis: Results of a Phase 3 Randomized, Placebo-Controlled Trial with Intravenous Loading and Subc 539. Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylitis and Peripheral Joint Involvement: Results from a Phase 3, Multicenter, Double- Blind, Placebo-Controlled Study 540. Two Years Sacroiliac Radiographic Progression Rate and Influence of Baseline Markers of Inflammation in Recent Onset Spondyloarthritis 541. Collagen II Neo-Epitopes in Spondyloarthritis. 542. Predictors for Cardiovascular Events in Patients with Psoriatic Arthritis a Cohort Study 543. Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Axial Spondyloarthritis Patients Treated with Certolizumab Pegol 544. Observed Incidence Rates of Uveitis over 96 Weeks of Certolizumab Pegol Treatment in Patients with Axial Spondyloarthritis 545. Long-Term Safety and Efficacy of Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis with and without Prior Tumor Necrosis Factor Inhibitor Exposure 546. Psoriatic Arthritis Mutilans: Characteristics and Radiographic Progression 547. Comparison of Clinical and Imaging Characteristics of Axial Psoriatic Arthritis and Axial Spondyloarthritis 548. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in Measures of Disease Activity in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials 549. Reliability and Construct Validity of the Psoriasis Symptom Inventory in Subjects with Psoriatic Arthritis 550. Secukinumab, an Anti Interleukin-17A Monoclonal Antibody, Improves Physical Function, Quality of Life and Work Productivity in Patients with Active Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial 551. Predictors Associated with Rheumatologist Referral Time in Patients with Ankylosing Spondylitis 552. Sustained Improvement in Physical Function, Health- Related Quality of Life, and Work Productivity with Adalimumab Treatment in Non-Radiographic Axial Spondyloarthritis 553. Comparison of Baseline Extra-Articular Manifestations, Comorbidities, and Long-Term Safety in Patients Treated with Adalimumab for Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis 554. Myocardial Infarction Risk with Diclofenac Use in Spondyloarthropathy Versus Non-Inflammatory Low Back Pain 555. Urinary Excretion of Type II Collagen C-Telopeptide and Glucosyl-Galactosyl-Pyridinoline As Prognostic Biomarkers in Early Spondyloarthritis 556. Defining Flare in Spondyloarthritis : Thresholds of Disease Activity Variations 557. Translation and Cross-Cultural Adaptation of the ASAS Health Index and the environmental Item Set into 15 Languages 558. Therapeutic Response in Adalimumab-Treated Patients with Non-Radiographic Axial Spondyloarthritis Is Similar Regardless of Body Mass Index 559. Ultra Sonographic Evaluation of the Anterior Chest Wall in Spondyloarthritis. a Prospective Study 560. High Sensitivity of the ASAS Classification Criteria in Patients with HLA-B27 Positive Undifferentiated Spondyloarthritis with Onset of Disease after Age 45 561. A Psychometric Analysis of Outcome Measures in Trials of Peripheral Spondyloarthritis 562. Clinical Response and Remission in Patients with Non- Radiographic Axial Spondyloarthritis after Three Years of Adalimumab Therapy 2014 Program Book 177
ACR POSTER INDICES 178 563. Evaluation of Clinical Parameters and Quality of Life in Smokers with Ankylosing Spondylitis: Results from the Scotland Registry for Ankylosing Spondylitis 564. Cardiovascular Events in Ankylosing Spondylitis. an Updated Meta-Analysis 565. Effect of Certolizumab Pegol over 96 Weeks of Treatment on Inflammation of Spine and Sacroiliac Joints Measured By Magnetic Resonance Imaging in Patients with Axial Spondyloarthritis 566. Structural Progression of the Spine Measured By X-Ray in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol over 96 Weeks, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis 567. Use of Monotherapy Anti-Tnf Agents in Ankylosing Spondylitis Patients from the rhumadata Registry: 8-Year Comparative Effectiveness of Adalimumab, Etanercept and Infliximab 568. Secondary Amyloidosis Complicating Spondyloarthritis: Still Present after All These Years 569. Better Outcomes in Ankylosing Spondylitis: The Synergistic Association Between Exercise and Tumor Necrosis Factor Inhibitors 570. Sleep Disturbances in Korean Patients with Ankylosing Spondylitis Are Associated with Increased Disease Activity 571. Unraveling the Familial Tendency for Ankylosing Spondylitis in Korea 572. Objective Evaluation of Physical Functioning after TNFi Therapy in Ankylosing Spondylitis Patients; A Selection of Three Feasible Performance-Based Tests 573. Three-Year Course and Prediction of Physical Functioning in Ankylosing Spondylitis Patients Treated with TNF- Inhibitors 574. Do Extra-Articular Manifestations Influence Outcome in Ankylosing Spondylitis? a 12 Year Follow-up Study 575. Disease Activity Strongly Influences Work Productivity and Physical Health Related Quality of Life in Early Axial Spondyloarthritis: Data from the SPACE-Cohort 576. Dikkopf-1 (Dkk-1) Serum Levels in Axial Spondyloarthritis (axspa) Are Related to Disease Duration 577. A Substantial Decrease in Work Productivity and Physical Health-Related Quality of Life in Chronic Back Pain of Recent Onset: Data from the SPACE-Cohort 578. Female Patients but Not Male Patients with Ankylosing Spondylitis Are at Increased Risk of Developing Ischemic Heart Disease: A Population-Based Cohort Study 2014 Program Book 579. Patients with Ankylosing Spondylitis Do Not Adapt to Their Disease: Evidence from the then Test in Patients Treated with TNF-Inhibitors 580. MRI Is Often Negative in Clinically Suspected Non- Radiographic Axial Spondyloarthritis 581. Evaluation of the Nonsteroidal Anti-Inflammatory Drug- Sparing Effect of Etanercept in Axial Spondyloarthritis: Results of a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial 582. Non-Steroidal Anti-Inflammatory Drugs in Axial Spondyloarthritis: A Cochrane Review 583. What Is the Correlation of Individual HAQ and Basdai Questions with Disease Activity Measures in Ankylosing Spondylitis? Implications for Instrument Reduction 584. Flare in Spondyloarthritis: Proposal of a Meaningful Change in Symptomatic Outcome Measures in Axial Spondyloarthritis 585. Optimism Levels Are Moderate and Similar in Patients with Axial Spondyloarthritis and Chronic Low Back Pain, and Are Related to Mental Quality of Life but Not Physical Quality of Life. a Cross Sectional Study of 277 Patients 586. Helplessness in Coping Is Associated with Worse Patient Reported Outcomes Among Patients with Ankylosing Spondylitis: A Longitudinal Multi-Country Cohort Study 587. Clinical Characteristics of Nonradiographic Axial Spondyloarthritis in Korea: A Comparison with Ankylosing Spondylitis 588. Blacks with As Have Greater Disease Severity Than Whites 589. Patients with Nr-Axspa Show a Statistically Higher Disease Burden in Clinical Practice Compared with Patients with Radiographic Axial Spa 590. Factors Associated with a Poor Functional Prognosis in Early Inflammatory Back Pain: Results from the DESIR Cohort 591. The Fat Spondyloarthritis Spine Score (FASSS) Independently Predicts Radiographic Progression in Patients with Ankylosing Spondylitis 592. Clinical and Psychological Correlates of Sleep Difficulties in Patients with Spondyloarthropathies Compared to Patients with Rheumatoid Arthritis 593. The Clinimetric Outcomes of Two Bath Ankylosing Spondyltis Metrology Indices in Treatment with TNF-á Blockers 594. Do Bone Marrow Edema Lesions in the Sacroiliac Joint Change into Fatty Lesions over a 1-Year Period in Patients with Axial Spondyloarthritis or Possible Spondyloarthritis
ACR POSTER INDICES 595. Radiographic Sacroiliitis Progression in an Early Axial Spondyloarthritis Cohort 596. Clinical Value of ASDAS Index in Spanish Patients with Ankylosing Spondylitis 597. Inflammatory Burden in Recent-Onset Axial Spondyloarthritis 598. Anti-Drug Antibodies As a Predictor for the Discontinuation of Anti-TNF Agents in Patients with Spondyloarthrtis 599. Is There Any Gender Specific Difference in the Cut Off Values of Ankylosing Spondylitis Disease Activity Score (ASDAS) in Patients with Axial Spondyloarthritis? 600. Differing Patterns of Axial Spondyloarthritis in Females and Males 601. Combined Hip Abduction Angle Measured By Using Iphone Compass Application; A Novel Measurement Tool to Asses Hip Mobility 602. A Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-Week) Improvements in Physical Function Spondylarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology 603. Periostin May Have a Role in Ankylosing Spondylitis and It Is Associated with Wnt Signalling Pathway Regulators 604. Characterisation of Mucosal-Associated Invariant T (MAIT) Cells in Ankylosing Spondylitis Patients 605. Decreased Frequencies of Circulating Follicular Helper T Cell Counterparts and Plasmablasts in Ankylosing Spondylitis Patients Naïve for TNF Blockers 606. The Immunological Basis of the Sex-Bias in Ankylosing Spondylitis: Th17 Expansion Is Restricted to Male Patients and Correlates with Sex-Related Alteration in Vitamin D Metabolism 607. The HLA-B27 Peptidome in Vivo in Transgenic Rats 608. Identification of Novel Autoantibodies in Patients with Ankylosing Spondylitis Using Human Protein Microarray 609. Induced Pluripotent Stem Cells (ics) As a Tool for Unraveling the Role of Different Cell Types in the Disease Process of Spondyloarthritis Pathogenesis 610. Functional Implications of the Endoplasmic Reticulum Aminopeptidase 2 (ERAP2) Association with Ankylosing Spondylitis and Crohn s Disease: Impact on the Unfolded Protein Response 611. Autophagy and Unfolded Protein Response: A Fine Balance That Can Influence the Pathogenesis of Ankylosing Spondylitis and Inflammatory Bowel Disease 612. Association of Platelet Endothelial Cell Adhesion Molecule-1 and beta1 Integrin Gene Polymorphisms with Uveitis Development in Ankylosing Spondylitis 613. The Amount of Free Heavy Chain and β2-microglobulin in the Cytoplasm of B*2705 Ankylosing Spondylitis Patients Compared to B*2705 and B*2709 Healthy Subjects Does Not Support the UPR Theory. Influence of ERAP1 Polymorphisms 614. The Association of P1A with Inflammasome Activation in Ankylosing Spondylitis 615. Analysis of the Gut Transcriptome in HLA-B27 Transgenic Rats By RNA-Seq Reveals Prominent Interferon and IL-23/ IL-17 Axis Signatures 616. In Situ Analysis of Mechanisms of New Bone Formation in Zygapophyseal Joints from Patients with Ankylosing Spondylitis 617. Shared HLA Class I and II Alleles in Susceptibility to Ankylosing Spondylitis Among Three Ethnic Groups 618. A Gender Bias in Gut Microbiota of SKG Mice Colonized with a Limited Bacterial Consortium Associated with Severity of Spondyloarthritis and Ileitis Triggered By Beta- Glucan 619. Effect of ERAP1 Knockdown on Conformation of HLA-B27 and Other HLA Class I Molecules in Human Monocytic Cells 620. Innate Immune Stimulation Triggers Altered IL-1a/b Gene Expression and Experimental Spondyloarthritis in HLA-B27/huβ2m Transgenic Rats 621. ERAP1 Knockdown Affects HLA-B27 Misfolding and Endoplasmic Reticulum Stress in HLA-B27 Transgenic Rat Macrophages 622. Gut Microbiota Variations Correlate with Disease Activity in Spondyloarthritis (SpA) and Rheumatoid Arthritis (RA) 623. Epigenetic Studies in Maternally Versus Paternally Transmitted Psoriatic Disease 624. Genome-Wide Methylome Investigation Reveals New Candidate Genes Associated with Arthritis Mutilans 625. Fine-Mapping Major Histocompatibility Complex Associations Identified Contribution of Multiple Class I and II HLA Genes on Risk of Psoriasis and Its Clinical Subtypes 2014 Program Book 179
ACR POSTER INDICES 180 626. The Impact of the Interaction Between Human Leukocyte Antigen Alleles and Obesity on Psoriatic Arthritis Risk 627. HLA Markers for Disease Severity Are Associated with a Higher Burden of Atherosclerosis in Patients with Psoriatic Disease 628. The Predictive Value of Cardiovascular and Metabolic Biomarkers for Progression of Atherosclerosis in Psoriatic Disease 629. Biomarkers of Chondrocyte Activity Are Increased in Psoriasis Arthritis and Spondyloarthritis 630. Biomarkers of Bone Remodeling Are Elevated in Psoriatic Arthritis 631. Joint and Bone Related Pathways Discriminate Psoriatic Arthritis Lesional Skin from Psoriasis vulgaris Lesional Skin 632. IL-23 Mediates Psoriasis-like Inflammation in the SKG Mouse Model of Spondyloarthropathy 633. Immunological and Clinical Relationships of Synovial IL- 17+ T Cells in Psoriatic Arthritis Systemic Lupus Erythematosus - Animal Models 634. Characterization of CD4+ T Cell Response and Effects of Regulatory T Cells in Pristane Induced Lupus (PIL) 635. Mir-663 Impairs the Effects of Bone Marrow-Derived Mesenchymal Stem Cells on MRL/Lpr Mice 636. Liposomal-Glucocorticoids: A Novel Approach to the Therapy of SLE 637. Decreased Inflammatory Dendritic Cells in Lupus-Prone Estrogen Receptor Alpha Knockout (ERαKO) Mice Correlate with Increased Survival 638. Commensal Microbiota Influence Systemic Autoimmune Responses 639. Lack of Response Gene to Complement-32 Impairs Th17 Differentiation and Attenuates Lupus-like Chronic Graft Versus Host Disease 640. A Peptide Mimic Inhibits the Cross Reaction of Anti-DNA Antibodies with Glomerular Antigens 641. Peptidylarginine Deiminase Inhibition Mitigates NET Formation and Protects Against Kidney, Skin, and Vascular Disease in Lupus-Prone MRL/Lpr Mice 642. Treatment with a Glycolipid Ameliorates Lupus Dermatitis and Expands Skin ãä T Cells That Promote the Migration of Langerhans Dendritic Cells 643. The Effect of TNF Inhibition on the Autoreactive B Cell Repertoire in SLE Prone Mice 2014 Program Book 644. HM-0523, a Novel Syk Inhibitor Blocks Glomerulonephritis and Extends Life Spans in Lupus Prone MRL/Lpr Mice 645. The Combination of Metformin and 2-Deoxy-D-Glucose Normalizes CD4 T Cell Metabolism and Functions, and Reverse Disease in Murine Models of Lupus 646. ONO-4059 - a Highly Potent and Dual Oral Inhibitor of Bruton s Tyrosine Kinase (Btk) and Tec Kinase: Improves Anti-Nuclear Antibodies mediated SLE in Mice 647. Helminthes Derivative for Treating Lupus and Colitis in Mice Models 648. Influenza A (H1N1) Virus Infection Triggers Severe Pulmonary Inflammation in Lupus-Prone Mice Following Viral Clearance 649. Enhance Translatability Using Multi-Modality Disease Evaluation Approach in Lupus Model 650. Decreased Severity of Pristane Induced Lupus in mir155 Deficient Mice 651. Inhibiting Tweak (TNF-like weak inducer of apoptosis) Signaling Improves Blood Brain Barrier Integrity and Protects from Neuronal Damage in Murine Neuropsychiatric Lupus 652. Identification of Eat-2 As a Lupus Susceptibility Gene in New Zealand Black (NZB) Mice That Regulates Dendritic Cell Function 653. Dermal Injury Promotes Nephritis Flare in Lupus-Prone NZM2328 Mice 654. Type I Interferon Induces the Depletion and Dysfunction of Endothelial Progenitor Cells in Gld. ApoE-/- C57BL/6 Mice 655. Hydroxycholorquine Is Cardioprotective in an In Vivo Rat Model of Myocardial Ischaemic Reperfusion Injury 656. Breach of B Cell Tolerance in New Zealand Black Chromosome 1 Congenic Mice 657. Distinct Contributions of C1q and C3 in Preventing Immunogenicity of Apoptotic Cells in Lupus 658. 17β Estradiol Regulates VCAM-1 Expression during Glomerulonephritis 659. Breakdown of Tolerance at the Tissue Level in Systemic Autoimmunity: Role of Tissue-Resident Dendritic Cells 660. Microthrombotic Renal Vascular Lesions Are Associated to Increased Renal Inflammatory Infiltration in a Mouse Model of Lupus Nephritis
ACR POSTER INDICES 661. Dysfunction of Glycosphingolipid Metabolism in Lupus Nephritis 662. Interferon Regulatory Factor-5 Promotes Disease in the MRL/Lpr Mouse Model of Lupus 663. STAT3 Inhibition Delays the Onset of Lupus Nephritis in MRL/Lpr Mice 664. The Pathogenesis of Neuropsychiatric Systemic Lupus Erythematosus Is Dependent on Brain Intrinsic Factors Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Treatment and Management Studies 665. Safety and Efficiency of Low-Dose Interleukin-2 Treatment in Systemic Lupus Erythematosus 666. Approach to Discriminate Treatment Impact in Both Moderate and Severe SLE 667. 24-Month Outcomes Associated with Belimumab in Patients with Systemic Lupus Erythematosus in Clinical Practice Settings 668. Evolution of Patients with Systemic Lupus Erythematous Treated with Belimumab in Clinical Practice Settings 669. Predicted Chronic Exposure and Dose Selection for Belimumab Administered Subcutaneously to SLE Patients 670. Decreased Disease Activity and Corticosteroid Usage and No Renal Flares during Belimumab Treatment in Patients with Systemic Lupus Erythematosus 671. Belimumab Reduces the Frequency of Flares in Patients with Refractory SLE: DATA from Clinical Practice Setting 672. Favorable Response to Belimumab in Pediatric-Onset Systemic Lupus Erythematosus 673. A Comparison of Rheumatoid Arthritis and Systemic Lupus Erythematosus Trial Design: Ways to Improve Positive Trials in Systemic Lupus Erythematosus 674. A Novel Strategy to Identify and Evaluate Approved Drugs and Treatments for Repositioning As Therapies for Systemic Lupus Erythematosus (SLE) 675. Use of Rituximab in Systemic Lupus Erythematosus: A Single Center Experience 676. Response to Rituximab in Patients with Refractory Systemic Lupus Erythematosus (SLE): Results from a National Multicentre Register 677. Pharmacokinetics, Safety, and Biological Activity of Intravenously or Subcutaneously Administered Tabalumab in Subjects with Rheumatoid Arthritis or Systemic Lupus Erythematosus 678. The Effectiveness of Tacrolimus for Minor Flares of the Patients with Systemic Lupus Erythematosus 679. Hydroxychloroquine Dosing and Disease Activity in a Large Multi-Racial Lupus Cohort 680. Influence of Antimalarial doesn t Modify the Outcome of Cytopenias in Systemic Lupus Erythematosus 681. Hydroxychloroquine Use Is Associated Independently with Improved Quality of Life in Systemic Lupus Erythematosus 682. Impact of Patient s Priorities on the Management of Systemic Lupus Erythematosus 683. Impact of Lupus on Work Productivity in Patients and Caregivers: Findings from a Cross-Sectional Online Survey in the United States 684. Effects of Current Therapies for Lupus on Disease Activity and Renal Flares 685. Successful Withdrawal and Discontinuation of Immunosuppressants in Lupus Patients: Outcomes and Predictors 686. Clinicians Approaches to the Management of Background Therapy in SLE Patients in Clinical Remission: Results of an International Survey 687. Effect of Corticosteroid Use By Dose on the Risk of Developing Organ Damage over Time in Systemic Lupus Erythematosus the Hopkins Lupus Cohort 688. Corticosteroids in Early Treatment Pathways in SLE 689. Prednisone, Disease Activity and Hypertension Independently Predict Cataracts in Systemic Lupus Erythematosus (SLE) 690. Lupus Patients Requiring First Corticosteroid Intervention Late in Disease Course - a Phenotypic Description 691. Prevalence of Subclinical Echocardiographic Abnormalities in Patients with Systemic Lupus Erythematosus (SLE) 692. Circulating Anti-Ro/SSA Antibodies Are Associated with the Presence of Severe Mitral Regurgitation in Systemic Lupus Erythematosus 693. Acute Myocarditis in Patients with Systemic Lupus Erythematosus: Experience from Affiliated Hospitals of Catholic University of Korea 694. Lupus Myocarditis: Clinical, Echocardiographic and Magnetic Resonance Characteristics 695. Osteonecrosis in Patients with Systemic Lupus Erythematosus: Risk Factors and Clinical Outcome 2014 Program Book 181
ACR POSTER INDICES 696. Clinical Characteristics and Outcome of Intestinal Pseudo-Obstruction in Patients with Systemic Lupus Erythematosus 697. Venous and Arterial Thrombosis in SLE: Differences in Natural History 698. Grip Strength Identifies Increased Physical Disability in Women with Systemic Lupus Erythematosus 699. Osteonecrosis in Systemic Lupus Erythematosus: Prevalence, Patterns and Outcomes 700. Decreased Lung Diffusion Capacity in Asymptomatic Patients with Systemic Lupus Erythematosus Does Not Predict Future Lung Disease 701. How Important Is Physical Activity for Patients with Systemic Lupus Erythematodes? -Results of Lula-Study 702. Protein Losing Enteropathy in Systemic Lupus Erythematosus 703. Autoimmune Hepatitis in Systemic Lupus Erythematosus 704. Utility and Associated Risk of Pulmonary Embolism CT Scans in the Michigan Lupus Cohort 705. Lupus Chest Pain in the Emergency Department: a Common Diagnostic Dilemma 706. Humoral Immunodeficiency in Patients Presenting with Clinical Features of Systemic Lupus Erythematosus 707. Characteristics of Lupus Patients with Interstitial Lung Disease and Relationship with Jo-1 Antibody 708. Determining Risk Factors That Increase Hospitalizations in Patients with Systemic Lupus Erythematosis 709. Impact of Sleep Disorders in Quality of Life, Pain and Disease Activity Using Actigraphy and Pittsburgh Sleep Quality Index (QI)in Female with Systemic Lupus Ertyhematosus (SLE). 710. Splenectomy in Systemic LUPUS Erythematosus and AUTOIMMUNE Hematological Diseases. a Comparative Analysis 711. Is the Disease-Specific Lupusqol Sensitive to Changes of Disease Activity in SLE Patients after Treatment of a Flare? 712. Mapping the Disease-Specific Lupusqol to the SF-6D 713. Lupuspro Is Responsive to Changes in Disease Activity over Time 714. The Validity of Patient and Physician Global Disease Activity Assessments of Systemic Lupus Erythematosus: Results from the Lupus Activity Scoring Tool (LAST) As Compared to the Selena Sledai (SS) Modification Multicentre Study 715. The REAL Life with Lupus Study: Developing a Patient Reported Outcome Measure for Use in Clinical Trials and Clinical Care 716. Simple Disease Assessment for People with Lupus Erythematosus 717. Comparison of Responsiveness of Lupus Impact Tracker with Lupus Quality of Life to Selena Responder Index 718. Safety of Gardasil Vaccine in Systemic Lupus Erythematosu, Trial Update 719. Target Modulation of a Type I Interferon (IFN) Gene Signature with Sifalimumab or Anifrolumab in Systemic Lupus Erythematosus (SLE) Patients in Two Open Label Phase 2 Japanese Trials Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics: Systemic Sclerosis Measures and Outcomes 720. Measures of Disease Status in Systemic Sclerosis: Systematic Review 721. Muscle Disease in Systemic Sclerosis Is Associated with an Increased Risk for Cardiac Involvement 722. Prediction of Improvement in Skin Fibrosis in Diffuse Cutaneous Systemic Sclerosis 723. Early Mortality in Australian, Canadian and Spanish Scleroderma Patients: Rationale for Establishing a Multi- National Inception Cohort of Patients with Systemic Sclerosis 724. Moderate Decline in Forced Vital Capacity is Associated with a Poor Outcome in Systemic Sclerosis Patients 725. Reduced Diffusing Capacity of Carbon Monoxide Is Independently Associated with Worse Subclinical Left Ventricular Function on Speckle-Tracking Echocardiography in Systemic Sclerosis 726. Risk of Ischemic Stroke in Patients with Systemic Sclerosis: A Systematic Review and Meta-Analysis 727. International Classification of Functioning, Disability, and Health (ICF) Core Sets for Connective Tissue Disease Interstitial Lung Disease (CTD-ILD) and Idiopathic Pulmonary Fibrosis (IPF) a Necessary Map to Health Care Provision in the Era of ICD-11 182 2014 Program Book
ACR POSTER INDICES 728. Prediction and Impact of Attacks of Raynaud s Phenomenon, As Judged By Patient perception 729. A Dilated Esophagus Is an Independent Risk Factor for Interstitial Lung Disease in SSc 730. Prediction of Cardiac and Vascular Events in Systemic Sclerosis: Input from Endothelin-1 Type a Receptor Antibodies 731. Performance of the Old ACR and the New ACR-EULAR Systemic Sclerosis Classification Criteria in Patients with Limited Cutaneous Disease: Effect on the Ascertainment of Severe Pulmonary Arterial Hypertension 732. Predictors of Inpatient Mortality in Patients with Systemic Sclerosis: A Case Control Study 733. Impact of Geographic Variation on the Risk of Digital Ulcers Development in Systemic Sclerosis: A Brazilian Multicenter Registry 734. Lower Socioeconomic Status, Male Gender and Diffuse Scleroderma Are Associated with Worse Survival in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Cohort 735. Sarcopenia in Systemic Sclerosis: Prevalence and Association with Functional Parameters and Quality of Life 736. Serum Galectin-3 Levels in Early Diffuse Systemic Sclerosis and the Relationship to Skin Score and Skin Score Change 737. Reliability of Nailfold Capillary Density Measurement As a Possible Outcome Measure for Systemic Sclerosis-Related Microangiopathy 738. Troponin T as a Diagnostic and Prognostic Biomarker of Primary Cardiac Involvement in Systemic Sclerosis 739. Lack of Association Between Esophageal Symptoms and Abnormal Findings in High-Resolution Manometry in a Mexican Mestizo Cohort with Systemic Sclerosis (SSc) 740. Right Ventricular Diastolic Impairment Is Common in Systemic Sclerosis and Is a Marker of Several Organ-Target Damage of the Disease 741. Abnormal Right Ventricular Longitudinal Strain Detected in Systemic Sclerosis Patients Prior to Abnormalities in Conventional Measures of Right Ventricular Size and Function 742. Precision of Ultrasound Skin Thickness Measurements: Influence of Examiner and Ultrasound Transducer 743. Outcome of Patients with Systemic Sclerosis Admitted to the Intensive Care Unit Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics 744. Integrin Inhibitor Modulates Pulmonary Fibrosis in the Reactive Oxygen Species Murine Model of Systemic Sclerosis 745. Genetic Susceptibility Loci of Idiopathic Interstitial Pneumonitis Do Not Represent Risk for Systemic Sclerosis 746. Elevated Pentraxin 3 in Patients with Systemic Sclerosis: Associations with Vascular Manifestations and Defective Vasculogenesis 747. Systemic Sclerosis Patients with Antitopoisomerase Antibodies Showed Significant Association with CCR6 Polymorphisms 748. Increased Expression of Chemerin in Endothelial Cells Due to Fli1 Deficiency May Contribute to the Development of Digital Ulcers in Systemic Sclerosis 749. Progranulin Overproduction Due to Fli1 Deficiency Contributes to the Resistance of Dermal Fibroblasts to Tumor Necrosis Factor a in Systemic Sclerosis 750. Molecular Characterization of Systemic Sclerosis Esophageal Pathology Identifies Inflammatory and Proliferative Signatures with Few Fibrotic Markers 751. Dissecting the Heterogeneity of Skin Gene Expression Patterns in Systemic Sclerosis 752. Potential Roles of Toll-like Receptor 4 in the Murine Models of Systemic Sclerosis 753. Identification of IL12RB1 As a Novel Systemic Sclerosis Susceptibility Locus 754. The Global mirna Whole Blood Profile in Systemic Sclerosis and Its Correlation with Serum Cytokine Levels 755. Increased Degradation of BMPR2 in a TGFβ Dependent Transgenic Mouse Model of Scleroderma with Susceptibility to Pulmonary Arterial Hypertension 756. Nucleosome, a Basic Repeating Unit of Chromatin, in Patients with Systemic Sclerosis: Possible Association with Immunological Abnormalities Via Abnormal Activation of T and B Cells 757. Distinctive Patterns of Telomere Shortening and Apoptosis in Limited and Diffuse cutaneous Systemic Sclerosis 758. Assessment of mrna Gene Expression Based on Forearm Skin Score in Systemic Sclerosis Patients 759. The Anti-Fibrotic Effect of Endostatin-Derived Peptide Is Mediated By Urokinase 2014 Program Book 183
ACR POSTER INDICES 760. Use of Multiplex Cytokine Analysis of Dermal Blister Fluid to Assess Local Inflammatory and Immune Activity in Systemic Sclerosis 761. Specific Autoantibody Profiles and Disease Subgroups Correlate with Circulating Micro-RNA in Systemic Sclerosis 762. IQGAP1 Enhances Contractility of Scleroderma Lung Fibroblasts and Promotes Bleomycin-Induced Pulmonary Fibrosis 763. Caveolin-1 and Peroxisome Proliferator-Activated Receptor Gamma Co-Regulate the Differentiation of Monocytes to Adipocytes and Myofibroblasts in Vivo and in Vitro 764. ERG and FLI1 in Systemic Sclerosis-Associated Pulmonary Complications 765. Gene-Gene Interaction of IRF5 and BLK Polymorphisms in US and Spanish Cohorts of Systemic Sclerosis (SSc) 766. Endothelial Fli1 Deficiency Delays Wound Healing Due to Impaired Anastomosis of Newly Formed Vessels a Possible Mechanism of Refractory Skin Ulcers in Systemic Sclerosis 767. The Impact of Plasmacytoid Dendiritc Cells (pdcs) on Fibrosis in bleomycin induced Murine Model of Systemic Sclerosis (SSc) 768. Transforming Growth Factor Beta Induces anti Angio and Vasculo-Genesis Phenotype in Dermal Fibroblasts through Secretion of Pigment Epithelium Derived Factor 769. Anti-Fibrotic Effects of an Investigational Drug: Bis- Oxetanyl Sulfoxide 770. Detection of Proteins in Lung Tissues of Patients with Systemic Sclerosis Using Tissue Microarrays 771. Development of a Bifluorescent Lineage Tracker Reporter Mouse Strain to Analyze the Phenotypic Conversion of Endothelial Cells into Myofibroblasts in Vivo. Application to Study the Synergistic Effects of Endothelin-1 on TGF-β1- Induced Endothelial-to-Mesen 772. RNA-Seq and Mir-Seq Analysis of SSc Skin Across Intrinsic Gene Expression Subsets Shows Differential Expression of Non-Coding RNAs Regulating SSc Gene Expression 773. Functional Autoantibodies from Patients with Systemic Sclerosis Reactive to Angiotensin II Type 1 and Endothelin-1 Type a Receptor Induce Inflammatory Lymphocyte Infiltration into Lungs of Mice 774. Endothelin-1 Synergistically Increases TGF-β-Induced Hif1α Expression Under Normoxic Conditions during Endothelial-to-Mesenchymal Transition in Murine Endothelial Cells. a Novel Mechanism for the Fibrogenic Effects of Endothelin Vasculitis 775. HLA-DRB1 Alleles in Susceptibility to Giant Cell Arteritis: Literature Review and Meta-Analysis 776. A Candidate Gene Approach Identifies IL33 as a Novel Genetic Risk Factor for GCA 777. Influence of the IL17A Locus in Giant Cell Arteritis Susceptibility 778. PTPN22 rs2476601 and Susceptibility to Biopsy Proven Giant Cell Arteritis (GCA) in an Australian Sample 779. Toll-like Receptor 2 Agonism Induces Inflammation, Angiogenesis and Cell Migration in Giant Cell Arteritis 780. Novel Roles for Zyxin in the Pathogenesis of Giant Cell Arteritis 781. Rho Kinase (ROCK) Activity in Aortitis: Comparison of Giant Cell Arteritis (GCA), Takayasu Arteritis (TA) and Isolated Aortitis (IA) 782. Temporal Artery Microbiome in Giant Cell Arteritis 783. Increased Migration and Proliferation Potential Characterize Vascular Smooth Muscle Cells from Patients with Giant Cell Arteritis 784. Novel Inhibitory Effects of Mast Cells in Aortitis Involves Aortic Expression of Suppressor of Cytokine Signaling-1 785. Incidence, Prevalence and Survival of Biopsy-Proven Giant Cell Arteritis in Northern Italy 786. The Incidence and Mortality Rates of Giant Cell Arteritis in Southern Norway Are Lower Than Previous Reported 787. Cardiovascular Risk Factors and Incident Giant Cell Arteritis 788. Fast-Track Diagnostic Procedure for Giant Cell Arteritis 789. Association Between Histological Features and Clinical Features of Patients with Biopsy Positive Giant Cell Arteritis 790. Correlations Between Histopathological Findings and Clinical Manifestations in a Large Monocentric Cohort of Patients with Biopsy-Proven Giant Cell Arteritis 791. Comparison of Clinical Manifestations in Different Histological Subsets of Biopsy-Proven Giant Cell Arteritis 792. Is Temporal Artery Biopsy the Gold Standard for the Diagnosis of Giant Cell Arteritis? 793. Preliminary Analysis of Histological Findings in Diagnosis of Giant Cell Arteritis Biopsy Positive Patients 184 2014 Program Book
ACR POSTER INDICES 794. Color Doppler Ultrasonography Findings in Giant Cell Arteritis and Their Relationship with Clinical Manifestations 795. High Interobserver Agreement on Ultrasonographic Findings in Patients with Large Vessel Vasculitis 796. Early Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis 797. PET/CT for the Diagnosis of Giant Cell Arteritis: A Prospective Study 798. Frequency and Predictive Variables of Relapses in Patients with Biopsy-Proven Giant Cell Arteritis 799. Peripheral Arterial Disease in Patients with Giant Cell Arteritis: A Systematic Review and Meta-Analysis 800. Hospitalization Rates and Utilization Among Patients with Giant Cell Arteritis: A Population-Based Study from 1987 to 2012 801. Venothromboembolism in Large Vessel Vasculitis 802. Inpatient Complications in Patients with Giant Cell Arteritis: Increased Risk of Thromboembolism, Delirium and Adrenal Insufficiency 803. Corticosteroid-Related Adverse Events in Patients with Giant Cell Arteritis: A Claims-Based Analysis 804. Vasculitis and Inflammatory Bowel Diseases: A Study of 32 Patients with Both Conditions and Systematic Review of the Literature 805. Takayasu Arteritis and Ulcerative Colitis High Concurrence Ratio and Genetic Overlap 806. Association of a Single Nucleotide Polymorphism (SNP) in IL-12B Region with Clinical Features and Peripheral T Cell Profiles of Patients with Takayasu Arteritis 807. Serum Cytokine Profiles in Takayasu s Arteritis: A Search for a Biomarker 808. Biomarkers of Disease Activity in Vasculitis 809. Risk Factors for Severe Ischemic Complications in Takayasu Arteritis: A French Multicenter Retrospective Cohort of 182 Patients 810. Damage Assessment in Takyasu Arteritis Using Takayasu Arteritis Damage Score (TADS) 811. Biologics in Takayasu Arteritis: Preliminary Data from the French Registry 812. Prognosis of Clinically Inactive Takayasu s Arteritis 813. Long-Term Outcomes of Takayasu s Arteritis Patients with Renal Artery Involvement 814. Tocilizumab in Giant Cell Arteritis: Multicenter Open-Label Study of 22 Patients MONDAY, NOVEMBER 17, 2014 Poster Hall (Exhibit Hall B) B cell Biology and Targets in Autoimmune Disease: Rheumatoid Arthritis and Related Diseases 982. Identification of Potential SERUM Autoantibody Biomarkers in Rheumatic Diseases Using a New Generation of Protein Arrays 983. Identification of Annexin A2 As an Autoantigen in Rheumatoid Arthritis and in Lyme Arthritis 984. Apolipoprotein B Is a Target of T and B Cell Responses in a Subgroup of Patients with Lyme Disease 985. Labial Salivary Gland Antibody-Secreting Cell Specificity and Characteristics in Sjögren s Patients 986. Integrated Comprehensive Analysis of Immune Cell Subsets and Serum Protein Profile Identifies the Role of Pre-Germinal Center B Cells in Sjögren s Syndrome Pathogenesis 987. Novel Auto-Antigen in Aortic Aneurysms of Large Vessel Vasculitis 988. Serum CXCL13 As a Biomarker of Disease Activity and Severity in Rheumatoid Arthritis: Comparison with Acute Phase Reactants and the Autoantibody Profile 989. Fcgamma Receptor IIb Facilitates Rapid Internalisation of Rituximab (type 1 anti-cd20 antibody) in B Cells from Patients with RA and SLE and Contributes to Less Efficient B Cell Lysis Than Type 2 Anti-CD20 Antibodies, in Vitro 990. WITHDRAWN 991. The Alternative CD20 Transcript Variant Is Not a Factor for Resistance to Rituximab in Patients with Rheumatoid Arthritis 992. Differential Antigen-Presenting B-Cell Phenotype from Synovial Microenvironment of Rheumatoid Arthritis and Psoriatic Arthritis Patients 993. Anti-Citrullinated Proteins Antibodies Promote Synovial Fibroblast Migration in Rheumatoid Arthritis 2014 Program Book 185
ACR POSTER INDICES 186 994. IL-7 Modulates B Cell Immunoglobulin Isotype Production and Increases B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Synovial Fibroblasts from Osteoarthritis (OA) and Rheumatoid Arthritis (RA) Patients 995. Rheumatoid Arthritis Patients Have Alterations in Inherently Autoreactive 9G4+ B-Cell Subpopulations in Peripheral Blood 996. Memory B Cell Subtype Modulation in Patients with Rheumatoid Arthritis 997. Explore Translational Pharmacokinetics/ Pharmacodynamics Response/Efficacy Relationship of a Novel Bruton s Tyrosine Kinase Inhibitor in Rat Collagen- Induced Arthritis Model 998. β2 Adrenoceptor Signal Is Augmented in B Cells in the Course of Arthritis to Increase IL-10 999. Microrna-155 As an Epigenetic Regulator of B-Cell Activation in Rheumatoid Arthritis: In Vivo and in Vitro Evidences 1000. Pathogenic Role of CXC Chemokine receptor 3-Positive B Cells in Bone Destruction of Rheumatoid Arthritis Biology and Pathology of Bone and Joint: Cartilage, Synovium and Osteoarthritis 1001. Fibroblast-like Synoviocytes Inhibit Wnt Signaling Pathway By Secreting Dockcop-1 1002. Global Transcriptome Analysis in Osteoarthritic Cartilage Reveals Significant Differential Gene Expression and Associations with Histologic Disease Progression 1003. Proteomic Analysis of Connexin 43 Reveals Novel Interactors Related to Osteoarthritis 1004. Elevated Levels of BMP2 Compensate for Loss of TGF-Beta in Articular Cartilage during Experimental Osteoarthritis 1005. Histone Lysine Demethylase KDM6A Mediates Joint Destruction in Osteoarthritic Knees By Epigenetic Disturbance of SOX9 Promoter and Histone H3K27 1006. Interleukin-4 As Promising, Anti-Inflammatory Transgene for Gene Therapeutic Application in Joint Diseases 1007. Markedly Increased Mesenchymal Stem Cell Activity in MRI Bone Marrow Lesions Compared with Non-Involved Bone in Osteoarthritic Hips 1008. Autophagy Activation Protects from Mitochondrial Dysfunction in Human Chondrocytes 1009. Regeneration of Articular Cartilage in Situ with Bone Marrow-Derived Mesenchymal Stem Cells 2014 Program Book 1010. Catecholaminergic-to-Cholinergic Transition of Sympathetic Nerve Fibers in Arthritis and in a Co-Culture System of Sympathetic Ganglia in Vitro 1011. Fibroblast Growth Factor-2 and Its Receptor Antagonists in Osteoarthritis 1012. Role of High Glucose Environment on Chondrocyte Activation and Characterization of Diabetic Osteoarthritic Cartilage: Toward Pathophysiological Delineation of Diabetes Mellitus-Related Osteoarthritis 1013. Mitochondrial Function Is Impaired in Human Knee Osteoarthritic (OA) Chondrocytes and Improved By Pharmacologic AMPK Activation Via SIRT1 and PGC-1α 1014. Harpagide, a Low Molecular Weight Natural Product, Suppresses IL-1â-Induced IL-6 Expression By Blocking the Activation of p38 MAPK and Transcription Factors CEBPâ and AP-1 in Primary Human Osteoarthritis Chondrocytes 1015. Mir-9/MCPIP1 Axis Mediated Regulation of IL-6 Expression in Osteoarthritis Chondrocytes 1016. Reduced Expression of Circadian Rhythm Genes in Human Osteoarthritis Cartilage: NR1D1 Suppression Alters Chondrocyte Response to IL-1β Stimulation 1017. BMP9-Induced psmad1/5/8 Signaling and Chondrocyte Hypertrophy Are Effectively Inhibited By TGFβ1 1018. Monolayer Culture Induced the Expression of Zyxin- Related Protein 1 (ZRP-1), αvβ3 integrin Complex and Leptin in Human Articular Chondrocytes 1019. Targeting the Bone-Driven Metabolic OA Phenotype By a Novel Dual Amylin Calcitonin Receptor Agonist, KBP-056 1020. Changes in Peripheral Blood Immune Cell Composition in Osteoarthritis 1021. Transthyretin and Amyloid in Cartilage Aging and Osteoarthritis 1022. Fibroblast-like Synovial Cells and Monocytes Team up in the Organization and the Dynamic Modelling of the Synovial Tissue 1023. Chronic PTHrP Treatment Promotes Hypertrophic Differentiation and Inflammatory Gene Expression in Chondrocytes 1024. Racial Differences in Biochemical Knee Cartilage Composition Between African American and Caucasian American Women with MR-Based T2 Relaxation Time Measurements Data from the Osteoarthritis Initiative 1025. Leptin Production By Osteoarthritis Synovial Fibroblasts: Stimulation By Glucocorticoids and Mineralocorticoids through the Glucocorticoid Receptor and GILZ (Glucocorticoid-Induced Leucine Zipper) Protein
ACR POSTER INDICES 1026. Monosodium Urate Monohydrate Crystals Induces the Expression of Ihh and MMP-13 in ATDC5 Cells: Implications in Osteoarthritis (OA) Development. Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis 1027. Hematopoietic Cell Kinase (HCK) As a Novel Regulator of Fibroblast-like Synoviocyte Function in RA 1028. ADAM-10 Plays Monocyte Migration and Adhesion in Rheumatoid Arthritis Synovial Fibroblasts 1029. Anandamide and Related Eicosanoids Decrease the Production of Pro-Inflammatory Cytokines in Synovial Fibroblasts By a COX-2 Dependent Mechanism: Involvement of Calcium and TRP Channels 1030. ABT-122, a Novel Dual Variable Domain (DVD)-IgTM, Targeting TNF and IL-17, Inhibits Peripheral Blood Mononuclear Cell Production of GM-CSF and Decreases Lymphocyte Expression of CXCR4 in Healthy Subjects 1031. Induction of Pro-Apoptotic Noxa Expression By Ursolic Acid Sensitizes Rheumatoid Arthritis Synovial Fibroblasts to Apoptosis: A Role of Mir-181a 1032. Neutralization of IL-17 Ameliorated Kidney Pathology Associated with Immune-Complex Mediated Autoimmune Glomerulonephritis 1033. Stat3 Promotes IL-10 Expression in SLE T Cells through Trans-activation and Chromatin Remodeling 1034. Therapeutic Potential of Targeting Sialic Acid Modified Receptors in Osteoarthritis 1035. TNF-á Modulates the Expression of Circadian Clock Genes Via Calcium Signaling in Rheumatoid Synovial Cells 1036. Synergism Between GM-CSF and IL-17 Causes Enhanced Joint Pathology Via the Production of IL-6 and IL-23 1037. Anti-MDA5 Antibody Associated Myositis Compared to DM Patient: A Distinct Muscular Pattern Associated with a shared IFN Signature 1038. Macrophage-Fibroblast Crosstalk Pathways Amplify RA Joint Pathology 1039. Interleukin-20 Is Triggered By TLR Ligands and Associates with Rheumatoid Arthritis Disease Activity 1040. Dysregulated Serum Interleukin 16 Concentration Associated with Clinical Disease Activity in Patients with Rheumatoid Arthritis Is Efficiently Corrected By Immunological Intervention 1041. Imaging the Role of Chemoattractants in Inflammatory Arthritis 1042. IL-1β and TNF-α Promote Monocyte Viability through the Induction of GM-CSF Expression By Rheumatoid Arthritis Synovial Fibroblasts 1043. Identification of Putative Biomarkers and Molecular Mechanisms Associated with Adverse Tissue Reactions to Metal-on-Metal and Modular Neck Hip Implants 1044. Novel Compound Cytokine Release Inhibitory Drug 3 (CRID3) Inhibits the NLRP3 Inflammasome in Rheumatoid Arthritis 1045. Tertiary Lymphoid Organ Developmental Program: Diversgent Paradigm of Lymphoid Organogenesis 1046. Modulatory Effect of Adiponectin on Apoptosis and Proliferation of Synovial Fibroblasts from Rheumatoid Arthritis Patients 1047. Type I and II Interferon Signatures in Sjögren s Syndrome: Contributions in Distinct Clinical Phenotypes and Sjögren s Related Lymphomagenesis 1048. Oncostatin M Suppresses Activation of IL-17/Th17 Via Suppressor of Cytokine signaling3 (SOCS3) Regulation in CD4+ T Cells 1049. Bioactive TGF-β Is Present on Bovine Milk-Derived Exosomes: Consequences for Patients? 1050. A Role for Purinergic Receptor Signalling in Basic Calcium Phosphate Crystal-Induced Inflammation Epidemiology and Public Health: Rheumatoid Arthritis and Systemic Lupus Erythematosus Outcomes 1051. Rates of Renal Remission with Immunosuppressives in Lupus Nephritis: A Systematic Review and Network Meta- Analysis 1052. Time Trends in Comorbidities Among Patients with Rheumatoid Arthritis Compared to the General Population 1053. Co-Morbidity Is Associated with Disease Severity in Early Rheumatoid Arthritis 1054. Rheumatoid Factor, Not ACPA, Is Associated with Disease Activity in Rheumatoid Arthritis 1055. Identifying Flare in Rheumatoid Arthritis (RA): Performance of the Flare-Assessment in RA (FLARE) Questionnaire in a US Population 1056. Factors Associated with Impairment on Quality of Life in Early or Established RA Patients 1057. Work-Related Behavior and Experiences in Patients with Rheumatoid Arthritis 2014 Program Book 187
ACR POSTER INDICES 1058. Levels of Fatigue Are Dependent on Country of Residence in Rheumatoid Arthritis: An Analysis Among 3920 Patients from 17 Countries 1059. Patients with RA from Wealthier Countries Perform Better on Clinical Disease Activity Measures, but Tend to Show Worse Person Reported Outcomes 1060. Musculoskeletal Surgeries and Procedures in Patients with RA: Results from a UK Retrospective Study 1061. How Does Rheumatoid Arthritis Disease Activity Affect Development of Upper Cervical Lesions? a Retrospective Study of Cervical Spine X-Rays Combined with a Cohort Study in Rheumatoid Arthritis Patients 1062. Impact of Obesity on 1 Year Outcomes: Results from the Meteor Foundation International Rheumatoid Arthritis Cohort 1063. Management of Hyperlipidemia Among Patients with Rheumatoid Arthritis in the Primary Care Setting 1064. Unique Profile of Cardiovascular Risk Factors in Rheumatoid Arthritis High-Risk Populations with Insufficient Risk Control 1065. Characteristics of Rheumatoid Arthritis Patients with and without Cardiovascular Diseases - Data from the Ontario Best Practice Research Initiative (OBRI) 1066. Factors Associated with Recording of Rheumatoid Arthritis on Death Certificate 1067. Mortality Trends in Rheumatoid Arthritis during the Biologic Era, 1998 to 2011 1068. Smoking-Related Mortality in Rheumatoid Arthritis: A Retrospective Cohort Study Using Electronic Medical Records 1069. Impact of Rheumatoid Arthritis on the Mortality of Patients Who Develop Cancer: A Population-Based Study 1070. Mortality Risk in Patients with Rheumatoid Arthritis Who Develop Non Hodgkin s Lymphoma 1071. What Is the Impact of Chronic Systemic Inflammation Such As Rheumatoid Arthritis on Mortality Following Cancer? 1072. Sex Ratio of Offspring Born to Women with Lupus and Rheumatoid Arthritis 1073. Prescription Medication Trends in Medicaid-Enrolled Pregnant Women with Rheumatoid Arthritis, Psoriasis, and Systemic Lupus Erythematosus 1074. A Meta-Analysis of the Risk of Venous Thromboembolism in Inflammatory Rheumatic Diseases 1075. Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with Systemic Lupus Erythematosus on Immunosuppressive Drugs 1076. U.S. Geographic Trends in the Distribution and Treatment Practices of Juvenile Systemic Lupus Erythematosus: An Analysis of the Childhood Arthritis and Rheumatology Research Alliance Registry 1077. A Real-World Characterization of US Patients with Moderate-to-Severe Systemic Lupus Erythematosus 1078. Work-Related Behavior and Experiences in Patients with Systemic Lupus Erythematosus 1079. Prevalence of Cardiac Arrhythmias in Systemic Lupus Erythematosus 1080. Stroke Risks Among U.S. Medicaid Recipients with Systemic Lupus Erythematosus, 2000-2006: Racial and Ethnic Variation 1081. Prediction of Mortality Risk Related to Cerebrovascular Accidents in Patients with Systemic Lupus Erythematosus (SLE) vs Anti-Phospho-Lipid-Antibody (apl) syndrome 1082. Risk of Intra Cranial Hemorrhage among Patients with Anti-Phospho-Lipid-Antibody (apl) syndrome vs Systemic Lupus Erythematosus (SLE) in Stroke Population: A Nationwide Analysis Epidemiology and Public Health (ARHP) 1083. The Relation of Step Length to MRI Features of Osteoarthritis in the Patellofemoral Joint: The MOST Study 1084. Obesity Is a Risk Factor for Depression in Systemic Lupus Erythematosus (SLE) 1085. Trajectories and Predictors of Physical Activity over Two Years in Rheumatoid Arthritis 1086. The Effect of Foot Pain on Mobility Disability in Older Adults: The Framingham Foot Study 1087. The Prevalence of Knee Arthritis and Associated Self- Reported Limitation of Activity in Chinese Populations 1088. Socioeconomic Disparities in Health Outcomes Among Individuals with, or at Risk for, Osteoarthritis from the United States: Data from the Osteoarthritis Initiative 1089. Trajectories of Disability over Time Among Patients with Systemic Sclerosis 1090. Association of Objectively Measured Physical Activity and Metabolic Syndrome Among Adults with Osteoarthritis in the United States 188 2014 Program Book
ACR POSTER INDICES 1091. Skeletal Muscle Fat and Its Association with Physical Function and Physical Activity in Adults with Rheumatoid Arthritis 1092. Does Arthritis Status Predict Starting or Stopping Work over a 2-Year Period? Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Clinical Focus 1093. Female Sexual Function in Fibromyalgia 1094. Work Productivity and Healthcare Utilization in Patients with Fibromyalgia and Comorbid Depression Taking Antidepressant Medication 1095. Treatment of Fibromyalgia with Neurostimulation: A Randomized, Double-Blinded, Sham-Controlled Trial 1096. Fibromyalgia Patients Who Have More Symptoms at Their Initial Office Visit Tend to Have a Worse Clinical Course 1097. Can We Help Identify Learning Disabilities in Fibromyalgia Patients? 1098. Clinical Efficacy of the High-Concentration Capsaicin Patch for the Treatment of Carpal Tunnel Syndrome 1099. Which Stresses Bother Fibromyalgia Patients Most? 1100. System Review: The Most Common Symptoms of Fibromyalgia Patients Other Than Pain, Fatigue, Insomnia, and Cognitive Dysfunction 1101. Numbness and Tingling: Neurological Symptoms in Fibromyalgia 1102. Anxiety in Fibromyalgia Patients 1103. Analgesic and Anti-Hyperalgesic Effects of Deep Dry Needling Therapy in Fibromyalgia Patients 1104. Utility of the 2010 ACR Diagnostic Criteria for Fibromyalgia for Pediatric Patients with Juvenile Fibromyalgia 1105. The Effectiveness of Mirror Therapy in Patients with Adhesive Capsulitis 1106. Most Patients Diagnosed with Fibromyalgia By Physicians Do Not Have Fibromyalgia: The 2012 National Health Interview Survey Fibromyalgia Study 1107. A Strong Association Between Memory Loss and Word Finding Difficulties in Fibromyalgia 1108. Understanding Baseline Clinical Characteristics May be of Use in Considering the Response to Pregabalin in FM Patients with Comorbid Depression 1109. Impact of Age on Symptom Severity and Disease Management at Fibromyalgia Diagnosis 1110. The Comparative Efficacy of Kinesio Taping and Local Injection Therapy in Patients with Subacromial Impingement Syndrome 1111. The Effect of High Intensity Laser Therapy in the Management of Myofascial Pain Syndrome of the Trapezius: A Double Blind, Placebo-Controlled Study 1112. Cognitive Symptoms in Fibromyalgia Patients Compared with Rheumatoid Arthritis Patients 1113. Mayor Trocanter Painful Syndrome. Treatment with Hyaluronic Acid Versus Triamcinolone Acetonide Injections. a Comparative Study 1114. Clinical Effectiveness of Exercise and Corticosteroid Injection for Subacromial Impingement Syndrome: A Randomised Controlled Trial 1115. The Effects of Mulligan s Mobilization with Movement Techniques in Patients with Lateral Epicondylitis 1116. Mindfulness Is Associated with Sleep Quality Among Patients with Fibromyalgia 1117. Fibromyalgia Patients Taking Opioids Have Low Self- Efficacy and High Pain Catastrophizing but No Reduction in Pain or Improvement in Activity 1118. Olecranon Bursitis Is Often Hemorrhagic and Responds to Steroid Injections 1119. Comparison High Intensity Laser Therapy and Wrist Splint in the Treatment of Lateral Epicondylitis 1120. The Relationship Between Tender Points and Disease Severity in Patients with Fibromyalgia Genetics, Genomics and Proteomics II 1121. The mtdna Haplogroups Influence the DNA Methylome of Articular Chondrocytes 1122. Transmitocondrial Cybrids: A Tool to Study the Role of mtdna Haplogroups in OA Pathogenesis 1123. Impact of Genes Modulating Serum Low-Density Lipoprotein Cholesterol Levels on Progression of Joint Destruction in Japanese Patients with Rheumatoid Arthritis 1124. Genome-Wide Profiling of DNA from Cartilage Reveals Regions Differently Methylated in Osteoarthritis Patients 1125. The Mitochondrial Genome Influences the Risk of Incident Knee OA. DATA from the Osteoarthritis Initiative 2014 Program Book 189
ACR POSTER INDICES 1126. Quantitative Proteomics (itraq) Reveals Putative Biomarkers in Pre-Radiological Osteoarthritis 1127. Mass Spectrometry Imaging Revealed Potential Lipid Chondrogenic Biomarkers for Cell-Based Therapy in Cartilage 1128. Regulation of PIWIL4 By Histone Modifications in Rheumatoid Arthritis 1129. FCGR2A Polymorphism and Response to Anti-TNF Treatment in Rheumatoid Arthritis 1130. IRF8 Gene Contributes to Disease Susceptibility and Interacts with NF-KB By Modulating Interferon Signature in Patients with Systemic Sclerosis 1131. Identification of Genetic Variants Associated with Response to Adalimumab Plus Methotrexate in Patients with Early Rheumatoid Arthritis 1132. A Novel Epigenetic Mark, Histone H1 Fucosylation, Orchestrates Macrophage Differentiation and Plasticity By Remodeling the Enhancer Landscape in Rheumatoid Arthritis 1133. Genetic Variants Influencing Joint Damage in Mexican Americans and European Americans with Rheumatoid Arthritis 1134. Role of NOD2 Pathway in Sarcoidosis Cases with Characteristics of Blau Syndrome 1135. Genes Involved in Cartilage Synthesis and Risk to Knee Osteoarthritis 1136. Transcriptional Heterogeneity of the SLC2A9 Gene Encoding the GLUT9 Urate Transporter 1137. Multiway Transcriptomic Analysis of Monocyte-Derived Dendritic Cells Discriminates Effects of Disease and of HLA-B27 in Spondyloarthritis 1138. Vasoactive Intestinal Peptide (VIP) Genetic Variants Determine VIP Serum Levels and Could be Used As a Prognosis Biomarker 1139. TACR1 rs3771863 Single Nucleotide Polymorphism Is a Genetic Risk Factor for Sicca Syndrome in Fibromyalgia Patients 1140. Association of Polymorphisms on OPG, RANK and RANKL with ACPA Presence and Erosions: Results of a Meta- Analysis on 1570 Rheumatoid Arthritis Patients from 3 French Cohorts Health Services Research (ACR) 1141. Comparisons of Quality of Life, Resource Use and Physical Functioning in RA Patients Classified As High, Moderate or Low Risk for Rapid Radiographic Progression 1142. Healthcare Costs Associated with Serious Infections Among Biologic-Naïve Rheumatoid Arthritis Patients Initiating First-Line Biologic Treatment 1143. Preferences of Biologic Treatment Characteristics Among Rheumatoid Arthritis Patients Who Are Current Biologic Therapy Users 1144. Economic Implications for Policies Regarding Triple Therapy Use in Patients with Rheumatoid Arthritis 1145. Evaluation of Biologic Treatment Patterns, Clinical Outcomes, and Healthcare Resource Utilization Post- Tumor Necrosis Factor Inhibitor Discontinuation in Rheumatoid Arthritis 1146. Cost-Effectiveness of Adalimumab for Rheumatoid Arthritis in Germany 1147. Economic Implications of Flares Among Patients with Early Rheumatoid Arthritis (RA) 1148. Evaluation of a Methodological Approach to Determine Timing of Rheumatoid Arthritis Disease Onset Using Administrative Claims Data 1149. Novel Adherence Measures for Infusible Therapeutic Agents in Rheumatoid Arthritis 1150. Marked Differences in Euro-Qol-5-Dimensions Preference Sets Based on Hypothetical or Experience Based Valuation 1151. Barriers and Facilitators of a Career in Research Among Rheumatologists in the United States 1152. Euroqol-5-Dimensions Utility Gain in Rheumatoid Arthritis, Treated with Abatacept, Rituximab, Tocilizumab or Tumor Necrosis Factor Inhibitors 1153. Area of Residence and Socio-Economic Factors Significantly Affect Access to Biological Therapy for Rheumatoid Arthritis Patients in Romania 1154. Increasing Discrepancies Between Physician Assessment of Disease Activity and Patient Global Health in Germany Between 2000 and 2012 1155. Economic Impact of Frequent Gout Flares in a Managed Care Setting 1156. Satisfaction with Rural Rheumatology Telehealth Service 1157. Delay in Diagnosis from Onset of Symptoms By More Than One Year in 31% of Patients with Different Rheumatic Diseases in Australia 190 2014 Program Book
ACR POSTER INDICES 1158. A Patient Survey Study of Zoledronic Acid Utilization and Factors Associated with Persistence 1159. Long-Term Quality of Life, Productivity Impairment, Disease Severity and Health Care Costs in Relation to Functional Impairment in Ankylosing Spondylitis Patients in the Czech Republic 1160. Annual Real-Practice Costs of Biologics for 200 Cases with Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Treated By Tight Control and Treat to Target Strategy Permitting Dose Reduction 1161. The Price of a Positive Test: Is It Worth the Cost? 1162. Patterns of Use of Long-Term (> 5 Years) Oral Bisphophonate Prescription Among Primary Care Providers and Rheumatologists for the Treatment of Osteopenia and Osteoporosis in a Veteran Population 1163. Predictors of Cholesterol and Lifestyle Discussions in Rheumatoid Arthritis Visits: Impact of Perceived RA Control and Comparison with Other Prevention Topics 1164. Inequity: Level of Education Is Associated with Access to Biologic Dmards Even in a Country with Highly Developed Social Welfare (Norway) 1165. Evaluation of Symptom Control Among Treated Gout Patients in the United States, United Kingdom, and Germany Health Services Research (ARHP) 1166. 5 Year Budget Impact Analysis of Biosimilar Infliximab for the Treatment of Rheumatoid Arthritis in UK, Italy, France and Germany 1167. A Description and Comparison of Treatments for Low Back Pain in the United States 1168. Usng an Advanced Clinician Practitioner in Arthritis Care Trained Physiotherapist and a Standardized Electronic Medical Record Triage Assessment Tool to Detect Inflammatory Arthritis and Initiate Dmards Earlier in a Community Rheumatology Office Setting Imaging of Rheumatic Diseases: Magnetic Resonance Imaging (MRI) 1169. Hippocampal Atrophy Is Associated with Anti-NR2 Antibodies in Patients with Systemic Lupus Erythematosus and Primary Sjögren s Syndrome 1170. Neurological Complications during Anti-TNF Therapy: A Prospective Imaging and Electrophysiological Study 1171. Diffusion weighted Magnetic Resonance Imaging (MRI) of Wrist and Hands in Patients with Rheumatoid arthritis reproducibility and Correlation with Conventional MRI 1172. Assessing the Validity and Reliability of a Novel MRI Semi- Automated Algorithm for Quantifying Bone Loss in the Hand 1173. Magnetic Resonance Imaging of Inflammatory Severity and Cartilage Damage of Finger Joints in Rheumatoid Arthritis 1174. Evaluating MRI-Detected Tenosynovitis of the Hand and Wrist in Early Arthritis 1175. Association of Hand MRI Findings with the Level of Plasma Cytokines in Patients with Newly Diagnosed Rheumatoid Arthritis 1176. Feasibility and Clinical Implication of Radiocarpal Cartilage T1ρ MR Imaging in Rheumatoid Arthritis 1177. Evaluation of a Simplified Version of the Rheumatoid Arthritis Magnetic Resonance Imaging Score (RAMRIS) Comprising 5 Joints (RAMRIS5) 1178. Novel Quantification of MRI Provides a More Sensitive Outcome Measure Than Ramris 1179. Efficacy of Tocilizumab in Patients with Rheumatoid Arthritis: Sequential Evaluation Using Whole-Body Magnetic Resonance Imaging 1180. Dynamic Magnetic Resonance Imaging in the Assessment of the Response to Certolizumab Pegol in Rheumatoid Arthritis Patients: Results from a Phase IIIb Randomized Study 1181. Effects of Tofacitinib on Bone Marrow Edema, Synovitis, and Erosive Damage in Methotrexate-Naïve Patients with Early Active Rheumatoid Arthritis (Duration 2 Years): Results of an Exploratory Phase 2 MRI Study 1182. Do Patients with Active RA Also Have Inflamed Atherosclerotic Plaques on PET-MRI? 1183. Validation of the Omeract Psoriatic Arthritis Magnetic Resonance Imaging Score for the Hand and Foot in a Randomized Placebo-Controlled Trial 1184. Subclinical Inflammation in Psoriatic Patients with No History of Psoriatic Arthritis: An Assessment By Magnetic Resonance Imaging 1185. Feature of Fatty Deposition in Sacroiliac Joints in Ankylosing Spondylitis Patients Seen By MRI 1186. Prevalence of MRI Spinal Lesions Typical for Axial Spondyloarthritis in Patients with Inflammatory Back Pain 1187. Scoring of Spinal Lesions Compatible with Axial Spondyloarthritis on MRI in Clinical Practice By Local Radiologist or Rheumatologist in Desir; Comparison with Central Reading 2014 Program Book 191
ACR POSTER INDICES 1188. Reproducibility of Magnetic Resonance Imaging Diffusion Weighted Imaging in Axial Spondyloarthritis Patients and Healthy Subjects 1189. Conventional Magnetic Resonance Imaging (MR) and Hybrid 18F-Fluoride Positron Emission Tomography MRI (18F-F- PET/MRI) of the Spine and the Sacroiliac Joints a Detailed Description of Pathologic Signals in Patients with Active Ankylosing Spondylitis 1190. Osteoarthritis-like Changes Are Present in the Tibia and Femur 1 Year Following ACL Reconstruction 1191. The Kimriss Bone Marrow Lesion Score in Patients with Osteoarthritis of the Knee Correlates with WOMAC Pain Status Using Target-Lesion Based Scoring Methodology; Data from the Osteoarthritis Initiative 1192. Erosions Detected By Magnet Resonance Imaging in Patients with Juvenile Idiopathic Arthritis (JIA) Are True Erosions As Visualized By Computed Tomography 1193. Diagnostic value of Contrast-Enhanced MR-Angiography in diagnosing large Vessel Vasculitis Innate Immunity and Rheumatic Disease: Signaling Mechanisms 1194. Cofilin-1 Is a ROS Sensor in Regulating the NLRP3 Inflammasome 1195. Activation of the nlrp3 Inflammasome By an Endogenous TLR2 Ligand in Rheumatoid Arthritis 1196. Inflammation Develops in a Toll-like Receptor 9-Independent Manner in Experimental Arthritis and Rheumatoid Arthritis 1197. Febuxostat Inhibits Monosodium Urate Crystal-Induced IL- 1beta Secretion and Cell Death Via ROS- and Intracellular ATP-Dependent Pathways 1198. Prolactin Is Locally Produced in the Synovium of Patients with Inflammatory Arthritic Diseases and Promotes Macrophage Activation 1199. Alarmins S100A8/S100A9 Aggravate Osteophyte Formation in Experimental Osteoarthritis and Predict Osteophyte Progression in EARLY Human Osteoarthritis in the Dutch Check Cohort 1200. Plasma Levels of Pattern Recognition Molecules of the Lectin Pathway Are Altered in SLE Patients 1201. Hypoxia Modulates Peptidyl Arginine Deiminase 4 Activity and Neutrophil Extracellular Trap Formation 1202. Type I Interferon Promotes Inflammatory Cytokine Production By Inhibiting Mir-146a Maturation in SLE 1203. NK/NKT Cells from Early and Definite Systemic Sclerosis Patients Show Different Immunological Responses after IL-2 Stimulation 1204. Oral Administration of Nano-Emulsion Curcumin in Mice Suppresses Inflammatory-Induced NFkB Signaling and Macrophage Migration 1205. Expression of Lectin-like Transcript 1, the Ligand for CD161, in Rheumatoid Arthritis 1206. Low Dose Colchicine Anti-Inflammatory Effects Are Transduced By AMP-Activated Protein Kinase (AMPK) 1207. Novel Role of Liver X Receptor Alpha (LXRα) in the Attenuation of TLR Signalling: Implications in Congenital Heart Block 1208. Cholesterol Loading Induces Neutrophil Extracellular Traps, and Atorvastatin Attenuates This Effect 1209. Anti-Scavenger Receptor Autoantibodies Disrupted Marginal Zone Macrophage Integrity Via Bruton s Tyrosine Kinase 1210. The Role of the Transcription Factor camp Responsive Element Binding Protein 1 in Lipopolysaccharide-Induced Tolerance 1211. Gene Expression Profile in Muscle Tissue before and after Immunosuppressive Treatment in Patients with Myositis 1212. Behcets Disease in Females Due to Mutation in NEMO, the NF-Kb Essential Modulator 1213. Absence of Hormone Responsive Estrogen Receptor Alpha Reduces the Activation of Plasmacytoid Dendritic Cells in Lupus Prone Mice Metabolic and Crystal Arthropathies: Mechanisms of Disease 1214. Oxidative Stress from Use of Allopurinol - Is There a Reason for Patients with Gout to Take Vitamin C? 1215. Circulating Mediators of Bone Remodeling in Patients with Tophaceous Gout 1216. The Relationship Between Serum Homocysteine, Uric Acid and Renal Function in Chronic Gouty Patients: 2 Year Follow-up Results 1217. The Random Urine Uric Acid to Creatinine Ratio As a Predictor of 24-Hour Urine Uric Acid Excretion in Gout Patients 1218. The Reduction of Serum Uric Acid Level Might Prevent Atherosclerosis in Mice 192 2014 Program Book
ACR POSTER INDICES 1219. Lack of Gene-Diuretic Interactions on Risk of Incident Gout: The Nurses Health Study and Health Professionals Follow-up Study 1220. Higher Inflammatory Response in Elderly Patients during Gout Attack 1221. Serum Uric Acid As an Independent Risk Factor on Progression of Chronic Kidney Disease in Gout Patients with Uric Acid Lowering Agent 1222. Suppressive Effect of Butyrate on Monosodium Urate (MSU) Crystal-Induced IL-1beta Production Is Mediated Via Inhibition of Class I Histone Deacetylases 1223. Enhancement of Proinflammatory Cytokine Production By Uric Acid in Human Cells Via Down Regulation of IL-1Ra 1224. Pegloticase for Tophus Debulking: Comparison of Dual Energy Computerized Tomography (DECT), Musculoskeletal Ultrasound (MSK-US) and Topographic Caliper Measurement for Assessing Debulking Rate Miscellaneous Rheumatic and Inflammatory Diseases 1225. Clinical Presentation and Cytokine Production Abnormalities in a Cohort of Patients Carrying NLRP12 GENE Variants 1226. Studying Patients with Autoinflammatory Diseases: The Past, Present, and a Perspective for the Future 1227. Cryopyrinopathy with a Myeloid-Specific NLRP3 Mutation 1228. Involvement of the IFN-Õ Pathway in a Patient with Candle Syndrome Carrying a Novel Variant of MB8 Gene 1229. Is NOD2-Associated Autoinflammatory Disease Remotely Related to Familial Mediterranean Fever or Continuum of It? 1230. Efficacy of Interleukin-1 Targeting Drugs in Familial Mediterranean Fever Patients 1231. Evidence Based Recommendations for Genetic Diagnosis of Familial Mediterranean Fever 1232. Canakinumab Therapy in Patients with Familial Mediterranean Fever 1233. Tocilizumab (TCZ) in the Treatment of AA Amyloidosis in Patients with Familial Mediterranean Fever 1234. Periodic Fever Syndromes in an Academic Medical Center 1235. Recovery of Renal Function after Corticosteroid Therapy for IgG4-Related Kidney Disease 1236. IgG4 Immunostaining Is Common but Not Specific in Orbitbal Inflammatory Diseases 1237. Retroperitoneal Fibrosis and IgG4 Disease: Response to Immunosuppressive Therapy - a Single Centre Retrospective Study 1238. Proportion of Peripheral Plasmacytoid Dendritic Cells and Plasmablasts Reflects Disease Activity in IgG4-related Disease 1239. Is Lymphocytic Sialadenitis IgG4-Related? 1240. Efficacy of Anakinra in Refractory Adult-Onset Still s Disease: Multicenter Study of 41 Patients 1241. Efficacy of Tocilizumab Therapy in Korean Patients with Adults Onset Still s Disease: Multicenter Retrospective Study of 20 Cases 1242. Switching Biologic Agents in Refractory Adult-Onset Still s Disease: Efficacy and Safety in a Cohort of 20 Patients at a Single Referral Center 1243. Macrophage Activation Syndrome Complicating Adult Onset Still s Disease - Single Center Experience and Literature Review 1244. The Prevalence of Malignancy in Adult-Onset Still s Disease 1245. Long Term Outcome of Infliximab in Severe and Refractory Systemic Sarcoidosis: Report of 16 Cases 1246. Assessment of Protective Factors of Bone Mineral Density in a New Orleans Sarcoidosis Population 1247. The Prevalence of Sacroiliitis and Spondyloarthritis in Patients with Sarcoidosis 1248. Serologic and Clinical Overlap Between Sarcoidosis and the Rheumatic Autoimmume Diseases 1249. Efficacy of Tocilizumab in Patients with Uveitis Refractory to Other Biologic Drugs: A Multicenter Study on 31 Cases 1250. Golimumab As an Alternative Therapy in Patients with Uveitis Refractory to Other Anti-TNFα Drugs. Multicenter Study of 29 Cases 1251. Efficacy of Certolizumab in Patients with Refractory Uveitis to Other Biologic Therapy. Study of 7 Cases 1252. Intravenous Methylprednisolone Pulse Therapy in Severe Inflammatory Eye Disease. a Multicenter Study 1253. Anakinra a Promising New Therapy for Idiopathic Recurrent Pericarditis 2014 Program Book 193
ACR POSTER INDICES 194 1254. Anakinra for the Management of Resistant Idiopathic Recurrent Pericarditis in Adults Muscle Biology, Myositis and Myopathies: Myositis Autoantibodies and Disease Phenotype 1255. Pathogenic Role of Tyrosyl Transfer RNA Synthetase in Anti-Synthetase Syndrome 1256. Clinical and Temporal Characterization of Anti-Jo-1 Positive Anti-Synthetase Syndrome: Preliminary Results of an International Multicentre Study 1257. A New Multianalyte Assay for Detection of Dermatomyositis-Specific Autoantibodies Undetectable By Commercially Available Immunoassays 1258. Enzyme-Linked Immunosorbent Assays for Detection of Anti-Transcriptional Intermediary Factor-1 Gamma and Anti-Mi-2 Autoantibodies in Dermatomyositis: Utility and Crossreactivity 1259. A Multi-Center Study for Validation of a New Assay for Anti-Melanoma Differentiation-Associated Gene 5 (MDA5) Autoantibody 1260. The Early Use of Cyclosporine Is Beneficial for Long-Term Prognosis in Patients of Polymyositis/Dermatomyositis- Associated Interstitial Lung Disease with Anti- Synthetase Antibodies 1261. Pulmonary Arterial Hypertension in Patients with Anti- -Scl Antibody 1262. Mechanisms of Muscular Necrosis in Auto-Immune Myopathies Associated with Anti-Signal Recognition Particle and Anti-3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase Antibodies: Pathogenic Role of Auto- Antibodies 1263. Evidence for the Involvement of NK Cells in Antisynthetase Syndrome 1264. Analysis of Clinical Manifestations and Myositis-Specific Autoantibodies Associated with Severity of Physical Dysfunction after Treatment for Polymyositis and Dermatomyositis 1265. Diabetes and Atorvastatin Are Potential Risk Factors for Statin-Associated Myopathy with Autoantibodies Against 3-Hydroxy-3-Methylglutaryl-Coenzyme a Reductase 1266. Anti-MDA5 Is Associated with Rapidly-Progressive Interstitial Lung Disease and Poor Survival in U.S. Patients with Amyopathic and Myopathic Dermatomyositis 1267. Are Anti-SRP Auto-Antibodies Specific for Myositis? 2014 Program Book 1268. Study of Autoantibodies in a cohort of Mexican patients with idiopathic inflammatory myopathies 1269. Epidemiology and Characteristics of Antisynthetase Syndrome in the African Descent Population of Martinique 1270. Distinctive Muscle Histopathological Features of Anti- Synthetase Syndrome 1271. Myocarditis in Antisynthetase Syndrome 1272. Myositis-Specific and Myositis Associated Autoantibodies in Indian Patients with Inflammatory Myositis 1273. Assessment of the Effect of Rituximab in the Treatment of Interstitial Lung Disease associated with the Antisynthetase Syndrome Osteoarthritis - Clinical Aspects: Epidemiology and Pathogenesis 1274. Patients with Osteoarthritis Do NOT Have Increased Risk of Cardiovascular Disease in Ullensaker Community in Norway 1275. Association Between Cardiometabolic Disorders and Hand Osteoarthritis Severity: A Cross-Sectional and Longitudinal Study 1276. Hyperglycemia and Risk of Osteoarthritis 1277. Retinal Arteriolar Narrowing and Incidence of Knee Replacement for Osteoarthritis: A Prospective Cohort Study 1278. Association of Low Birth Weight and Preterm Birth with the Incidence of Knee and Hip Arthroplasty for Osteoarthritis 1279. Pre-Operative Musculoskeletal Comorbidities Limit Improvement in Functional Outcomes and Hip Pain in Total Hip Arthroplasty Patients 1280. Relationship of Buckling and Knee Injury to Pain Exacerbation in Knee Osteoarthritis: A Web-Based Case- Crossover Stud 1281. Knee Pain and a Prior Injury Are Associated with Increased Risk of a New Knee Injury: Data from the Osteoarthritis Initiative 1282. Systemic Pain Modulation Is Related to Body Perception in People with Knee Osteoarthritis 1283. WITHDRAWN 1284. Sensitivity to Change of Patient Preference Outcome Measures for Pain in Trials of Patients with Knee Osteoarthritis
ACR POSTER INDICES 1285. Prevalence of Risk Factors for Gastrointestinal Side Effects of Drugs for the Treatment of Pain in Rheumatic Diseases and the Provision of Gastroprotective Treatment Results of a Large Non-Intervention Study 1286. The Natural Course of Physical Function in People with Symptomatic Knee Osteoarthritis: Data from the Osteoarthritis Initiative 1287. Patient Perspective of the Main Health Concerns and Needs of Living with Hand Osteoarthritis 1288. Older Adults with Osteoarthritis Do Not Have an Increased Risk of Cognitive Impairment 1289. Classification of Osteoarthritis Phenotypes By Metabolomics Analysis 1290. Knee Osteoarthritis Progression Is Predictable By Genetic Polymorphisms. Results from a Multicenter Association Study 1291. Relationships Between Inflammation, Disease Severity and Synovial Fluid Calcium Crystals Detected By Scanning Electronic Microscopy in Early Osteoarthritis 1292. Synovitis Characteristics and Associated Intra- Articular Pathology in a Cohort of Patients Undergoing Meniscectomy for Meniscal Tear 1293. Identification of an Inflammation-Driven Phenotype of Osteoarthritis By Quantification of Synovial Inflammation Ex Vivo and in Serum from Patients Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis 1294. Gender Differences in the Lupus Nephritis Biomarkers in Children 1295. Childhood-Onset Systemic Lupus Erythematosus: Short- Term Treatment Response Rates in Proliferative Lupus Nephritis 1296. Pulse- Pediatric Update on Lupus in South Africa: Epidemiology and Management 1297. Safety and Efficacy of Rituximab in Pediatric Lupus and Other Rheumatic Diseases 1298. Macrophage Activation Macrophage Activation Syndrome: A Severe and Frequent Manifestation of Acute Pancreatitis in Childhood-Onset Compared to Adult Systemic Lupus Erythematosus Patients 1299. A Cross-Sectional Study of Mental Health Symptoms and Mental Health Care in Pediatric SLE/MCTD Patients and Their Peers 1300. Subclinical Right Ventricle Systolic Dysfunction By Two- Dimensional Speckle-Tracking Echocardiography in Childhood-Onset Systemic Lupus Erythematosus Patients 1301. Trabecular Bone Impairment Assessed By HR-pQCT in Juvenile-Onset Systemic Lupus Erythematous with Vertebral Fractures 1302. The Psychological Impact on Health-Related Quality of Life in Childhood-Onset Lupus 1303. Accuracy of Laboratory Measures and Clinical Renal Activity Indices for Reflecting Biopsy-Proven Lupus Nephritis (LN) Activity 1304. Development of an Index to Non-Invasively Quantify Lupus Nephritis Chronicity in Children 1305. Adiposity and Adipokines Are Associated with Insulin Resistance in Pediatric Systemic Lupus Erythematosus 1306. Outcome of Lupus Nephritis in Children Less Than 12 Years Old from North-India 1307. Monitoring of Mid-Interval Plasma Levels of Mycophenolic Acid in Pediatric Lupus Nephritis Patients 1308. Antinucleosome Antibodies As Potential Diagnostic and Prognostic Biomarkers in Childhood Onset Systemic Lupus Erythematosus 1309. Does Anti-C1q Antibody Have Diagnostic and Prognostic Roles in Childhood Onset Systemic Lupus Erythematosus? 1310. Predicting Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus Patients at Diagnosis 1311. Lupus Nephritis in Mexican Children 1312. Features, Treatment and Outcome of Macrophage Activation Syndrome in Pediatric Systemic Lupus Erythematosus 1313. Comorbidity Patterns in Children with Juvenile Idiopathic Arthritis and Systemic Lupus Erythematosus: The Childhood Arthritis and Rheumatology Research Alliance Registry 1314. Comparison of the Utility and Validity of Three Scoring Tools to Detect Skin Disease in Patients with Juvenile Dermatomyositis 1315. Cross-Sectional Evaluation of Hydroxychloroquine (HCQ) Therapy in Children with Juvenile Dermatomyositis (JDM) Enrolled in the Childhood Arthritis and Rheumatology Research Alliance (CARRA) Registry 2014 Program Book 195
ACR POSTER INDICES 196 1316. A Hybrid Conjoint Analysis Model Is Proposed As the Definition of Minimal, Moderate and Major Clinical Improvement in Juvenile Dermatomyositis Clinical Trials 1317. Anti-p155/140 Autoantibodies and Selected Features at Illness Onset Are Associated with a Chronic Course of Illness in the Juvenile Idiopathic Inflammatory Myopathies 1318. Illness Onset Features and Misdiagnosis in Juvenile Idiopathic Inflammatory Myopathies (JIIM) Differ Among Clinical and Autoantibody (Ab) Subgroups 1319. Safety of Rituximab in Treating Pediatric Rheumatic disease 1320. Analysis of Risk Factors for Thrombosis in Pediatric Patients with Systemic Lupus Erythematosus 1321. A Pilot Study to Evaluate the Feasibility of Conducting Juvenile Localized Scleroderma Comparative Effectiveness Treatment Studies 1322. Cardiopulmonary Involvement in Juvenile Systemic Sclerosis: Development of Recommendations for Screening and Investigation 1323. Gastrointestinal Involvement in Juvenile Systemic Sclerosis: Development of Recommendations for Screening and Investigation 1324. Predictors of Disease Relapse in Juvenile Localized Scleroderma 1325. Single Hub and Access Point for Pediatric Rheumatology in Europe (SHARE): Evidence Based Recommendations for Diagnosis and Treatment of Juvenile Localized Scleroderma and Juvenile Systemic Sclerosis 1326. Transition of Care and Long-Term Outcomes of Juvenile Systemic Sclerosis during Adulthood: Results from a French Single-Center Case-Control Study 1327. Decreased CD3-CD16CD56+ Natural Killer Cell Counts Are Associated with Disease Activity in Children with Orbital Myositis 1328. Modulation of Natural IgM-Autoantibodies to Oxidative Stress-Related Neo-Epitopes on Apoptotic Cells in Newborns of Mothers with Anti-Ro Autoimmunity 1329. Comparison of Clinical and Serological Features of Childhood Sjögren Syndrome Based on the Presence or Absence of Parotitis 2014 Program Book Pediatrics (ARHP) 1330. The Efficacy of a Multidisciplinary Intervention Strategy for the Treatment of Benign Joint Hypermobility Syndrome (BJHS) in Childhood: A Randomized, Single Center Parallel Group Trial 1331. Factors Associated with Pain in Children with Hypermobility - a Pilot Study Psychology/Social Sciences (ARHP) 1332. From Social Support to Information Sharing, How Are Persons with Rheumatoid Arthritis Using Disease-Specific Facebook Communities? a Content Analysis 1333. Bridging the Social Support Needs Gap for African American Women with Systemic Lupus Erythematosus through the Chronic Disease Self-Management Program 1334. Social Support and Suicidal Ideation in Systemic Lupus Erythematosus: Georgians Organized Against Lupus Cohort 1335. Early Birds Versus Night Owls: Morning/Evening Preference and Its Association with Sleep Problems, Fatigue, and Emotional Well-Being Among RA Patients 1336. Associations of Physical and Mental Factors with Outcome Expectations for Exercise in a Clinical Trial 1337. Mindfulness Is Associated with Symptom Severity and Pain Impact in Patients with Fibromyalgia 1338. Correlates of Body Image Dissatisfaction in Patients with Limited and Diffuse Systemic Sclerosis 1339. Is Psychological Status Related to Symptom Experience in Behçet s Syndrome? Quality Measures and Quality of Care 1340. Choosing Subserologies Wisely: An Opportunity for Rheumatologic Healthcare Resource Savings 1341. Choosing Not so Wisely: The Tale of Antinuclear Antibody Testing 1342. Improving Serologic Testing for Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus 1343. A Quality Improvement Initiative to Improve Pneumococcal Vaccination Rates in Immunosuppressed Patients 1344. Electronic Medical Record-Based Best Practice Alert Used By Clinical Staff Improved Pneumococcal Vaccination and Documentation Among Immunosuppressed Rheumatoid Arthritis Patients
ACR POSTER INDICES 1345. Improving Pneumococcal Immunization Rates for Patients on Immunosuppressant Medications at an Academic Rheumatology Clinic 1346. Leveraging Electronic Health Records to Improve Vaccination Rates for Patients with Rheumatoid Arthritis 1347. Understanding Vaccination Rates Among Patients with Rheumatoid Arthritis 1348. Improvement in Herpes Zoster Vaccination and Documentation for Rheumatoid Arthritis Patients Using Electronic Medical Record 1349. A Decision Support Tool to Improve Herpes Zoster Vaccination Rates Among Patients Starting Biologic Medications 1350. Practice What You Preach? Suboptimal Guideline Adherence By Rheumatologists in Patients with Rheumatoid Arthritis 1351. Assessment of ACR Endorsed Quality Indicators in Rheumatoid Arthritis Patients a Quality Improvement Initiative 1352. Rheumatoid Arthritis (RA) Disease Activity Assessment and Population Management Processes Used By Clinician Rheumatologists 1353. Integrating Collection of Rheumatoid Arthritis Disease Activity and Physical Function Scores into an Academic Rheumatology Practice to Improve Quality of Care 1354. Improving the Measurement of Disease Activity for Patients with Rheumatoid Arthritis: Validation of an Electronic Version of the Routine Assessment of Patient Index Data (RAPID 3) 1355. Population Management of Rheumatoid Arthritis (RA) in Rheumatology Practices: A Quality Improvement Project 1356. Collaboration Between a Third Party Payer and Community Rheumatologists to Create a Clinical Pathway for the Treatment of Rheumatoid Arthritis to Assure Proper Use of Biologics and Quality of Care 1357. Improving Compliance for Tuberculosis Screening for Patients on Biologics in Rheumatology Clinics 1358. A Systematic Analysis of the Safety of Prescribing Anti- Rheumatic Immunosuppressive and Biologic Drugs in Pregnant Women 1359. Care of Women with Rheumatological Conditions during Family Planning and Pregnancy 1360. Monitoring Methotrexate and Leflunomide Treatment for Liver Toxicity: the Kaiser Permanente Experience 1361. Rheumatologists Attitudes on Cardiovascular Risk and Lipid Screening in Patients with Rheumatoid Arthritis at an Academic Medical Center Rheumatoid Arthritis - Clinical Aspects: Comorbidities, Treatment Outcomes and Mortality 1362. Impact of Rapid Attainment of Stringent Measures of Efficacy in Rheumatoid Arthritis on Patient-Reported Outcomes 1363. Psychosocial Comorbidities Are Independently Associated with Subclinical Atherosclerosis in Rheumatoid Arthritis 1364. Accelerated Diastolic Dysfunction in Premenopausal Women with Rheumatoid Arthritis 1365. ARE Erosions a Disappearing Feature in Rheumatoid Arthritis (RA)?Joint Damage in Patients with EARLY RA at 10 YEARS after Diagnosis 1366. Outcomes of Interstitial Lung Disease Associated with Rheumatoid Arthritis in High Volume Referral Centers 1367. Cardiovascular Morbidity and Associated Risk Factors in Spanish Patients with Chronic Inflammatory Rheumatic Diseases Attending Rheumatology Clinics 1368. Are Tender Joints Better Than Synovitis to Predict Structural Damage in Rheumatoid Arthritis? 1369. Predictors of Deterioration in Subjective Cognition: Results from a Rheumatoid Arthritis (RA) Observational Cohort Study 1370. The Association of Body Mass Index (BMI) and Radiographic Progression of Joint Disease in Rheumatoid Arthritis (RA) 1371. Impact of Metabolic Syndrome (MetS) on Rheumatoid Arthritis Disease Activity 1372. Prevalence of Cardiovascular Disease in US Veterans with Rheumatoid Arthritis and Hepatitis C Infection 1373. Physical Function of Patients with RA Varies Importantly Across Countries, and These Differences Are Not Attributed to GDP: Results from Multi-National Study with 17 Countries 1374. A Comparison of the Risk for Cardiovascular Event in Patients with Rheumatoid Arthritis Treated with Biologic Disease Modifiers and Patients Treated with Methotrexate Only 1375. Educational Level and Not Ethnicity an Important Determinant of Disease Progression in Patients with Rheumatoid Arthritis 2014 Program Book 197
ACR POSTER INDICES 198 1376. Angiographic Pattern Among Rheumatoid Arthritis Patients Who Are Hospitalized Due to Acute Coronary Syndrome 1377. Anti-Citrullinated Peptide Antibody Titers and the Prevalence of Interstitial Lung Disease in Patients with and without Rheumatoid Arthritis 1378. The Impact of Rheumatoid Arthritis Activity and Medications on Pregnancy Outcomes 1379. Studies on Ageing and the Severity of Radiographic Joint Damage in Rheumatoid Arthritis 1380. Patient Global Impression of Change for Patient Reported Outcomes in Rheumatoid Arthritis: Impact of Comorbidities 1381. Subaxial Cervical Spine Involvement in Symptomatic Rheumatoid Arthritis Patients: Comparison with Cervical Spondylosis 1382. The Longitudinal Course of Fatigue in Rheumatoid Arthritis Results from the Norfolk Arthritis Register 1383. Disease Characteristics and RA Development in Undifferentiated Arthritis: A 2-Year Follow-up Study of 413 Patients with Arthritis of Less Than 16 Weeks Duration 1384. Fibromyalgia and Its Effect on Treatment Response in Early Rheumatoid Arthritis Patients 1385. What Discriminates Best Flares in Rheumatoid Arthritis (RA)? a Subanalysis of the Strass Treatment Tapering in RA Study 1386. Disease Flares during 10 Year Follow-up in Patients with Rheumatoid Arthritis Are Associated with Joint Damage Progression and Disability 1387. Radiographic Progression Differs Between Trajectory Clusters Defined By DAS28 Scores in Early Rheumatoid Arthritis 1388. Prevalence and Predictive Factors of Drug-Free and Sustained Remission in Patients with Early Arthritis 1389. Osteophytes Increase the Ambiguity of Clinical Evaluation of Joint Swelling in Rheumatoid Arthritis 1390. Heterogeneity in Cardiovascular Risk Factors, Event Rates and RA Disease Characteristics Among Patients with Rheumatoid Arthritis Across 10 Countries - Implications for CV Risk Assessment 1391. Weight Loss and Risk of Death in Rheumatoid Arthritis 1392. Predictors of Long-Term Changes in Body Mass Index in Rheumatoid Arthritis 2014 Program Book 1393. Periodontal Disease and Its Impact on Structural Joint Damage in a Rheumatoid Arthritis Peruvian Population 1394. Low Vitamin D Level Is Not Associated with Increased Risk of Cardiovascular Disease in Rheumatoid Arthritis Patients 1395. Disease Activity Is Associated with Insulin Resistance in Early Rheumatoid Arthritis 1396. Assessment of Pulmonary Function in Rheumatoid Arthritis Patients Attending Rheumatology Clinics in Nairobi,Kenya 1397. Impact of Corticosteroid Use on Remission Sustainability and Infection Rates Among Rheumatoid Arthritis Patients in Remission While on Infliximab: Treatment Implications Based on a Real-World Canadian Population 1398. Spontaneous Regression of Methotrexate (MTX)-Related Lymphoproliferative Disorder Correlates with Lymphocyte Restoration after MTX Withdrawal 1399. Proteinase K-like Serine Protease PCSK9 Influence on the Dyslipidemia and Endothelial Dysfunction Observed in Rheumatoid Arthritis Patients 1400. Risk of Venous Thromboembolic Events in Patients with Rheumatoid Arthritis: A Meta-Analysis of Observational Studies 1401. Higher-Order Neuropsychological Deficits Are Frequent and Occur Early in RA and SLE: The Impact of Basic Processing Abilities on Psychological Well-Being 1402. Parameters of Periodontitis Correlate with Anti- Citrullinated Protein Antibodies and P. Gingivalis Antibody Titers in Patients with Early or Chronic Rheumatoid Arthritis 1403. Psychosocial Impact of Rheumatoid Arthritis Patients on Their Family Members 1404. Presence and Significance of Anti-CCP Antibody in Patients with Interstitial Lung Disease with and without Clinically Apparent Rheumatoid Arthritis 1405. Five-Year Changes in Myocardial Structure and Function in Patients with Rheumatoid Arthritis 1406. Comorbidity in Rheumatoid Arthritis. It Is Feasible to Record Concomitant Medical Conditions and Multi- Morbidity in Observational Research Studies. Can This be Extended to Routine Clinical Settings? 1407. Low HAQ and Pain Predict Patient Perceived Remission in Rheumatoid Arthritis Patients Receiving MTX or Anti-TNF- Alpha Treatment 1408. Inflammatory Biomarkers, Sleep Quantity and Sleep Quality in Rheumatoid Arthritis
ACR POSTER INDICES 1409. Pregnancy Outcomes after Exposure to Certolizumab Pegol: Updated Results from Safety Surveillance 1410. Low Rates of Cardiovascular Risk Factor Modification Among High-Risk Rheumatoid Arthritis Patients: Barrier to Cardiovascular Prevention Strategies? 1411. Psychological Distress over Time in Early Rheumatoid Arthritis: Results from a Longitudinal Study in an Early Arthritis Cohort 1412. Sarcopenia and Its Impact on Disability in Rheumatoid Arthritis, a Pilot Study 1413. The Prevalence of Renal Impairment in Patients with Rheumatoid Arthritis 1414. Investigation of the Association Between Gastroesophageal Reflux Disease and Clinical Factors in Patients with Rheumatoid Arthritis 1415. Differential Gender Impact in the Quality of Life of Patients with Rheumatoid Arthritis. Comprehensive Study Including Clinical, Comorbidity and Psicho-Social Variables. 1416. Analysis of Cardiac Involvement in Patients with Amyloid a (AA) Amyloidosis Due to Rheumatoidarthritis 1417. Red Cell Distribution Width: A Measure for Cardiovascular Risk in Rheumatoid Arthritis Patients? 1418. Prevalence of Vitamin D Deficiency in Rheumatoid Arthritis 1419. Rituximab Use in Patients with Rheumatoid Arthritis- Associated Interstitial Lung Disease and Other Connective Tissue Disease-Associated Interstitial Lung Disease: A Single Center Experience 1420. Non-Use of Glucocorticoid and Osteoarthritis Absence As Predictors of Clinical Remission in AR 1421. Preclinical Interstitial Lung Disease in Early Rheumatoid Arthritis 1422. Demographic Differences in Health Related Information Technology Use Among Patients with Rheumatic Diseases 1423. Cardiovascular Risk Estimation in Rheumatoid Arthritis: What Is Missing in Traditional Risk Estimators? 1424. Bone Erosions in Patients with RA: Exploring the Impact of the Anatomy of Interest on the Relationship Between MRI and X-Ray Erosion Detection 1425. Screening Behavior and Prevalence of Hepatitis C Virus in Mexico 1426. Periodontal disease and Clinical Activity of Rheumatoid Arthritis Patients 1427. Low Prevalence of Sarcopenic Obesity in Rheumatoid Arthritis Patients with Moderate Clinical Activity 1428. Comparison of Application of the European Society Cardiology, Adult Treatment Panel III, and ACC/AHA Guidelines for Cardiovascular Disease Prevention in a French Cohort of Rheumatoid Arthritis 1429. Systemic Inflammation in Alzheimer s Disease: Relevance to Patients with Rheumatoid Arthritis 1430. IMPACT of Initiative to Control Cardiovascular Risk Factors in Collaboration with LOCAL Doctors in Patients with Rheumatoid Arthritis 1431. Influence of Radiographic Joint Damage in Mortality Risk in a Cohort of Rheumatoid Arthritis Patients: A 20 Years Survival Study 1432. Mortality Ratio of Rheumatoid Arthritis Under Biological Treatment 1433. Clinical Characterization of Subclinical Rheumatoid Arthritis-Associated Interstitial Lung Disease 1434. The Longitudinal Association Between Inflammation and Blood Pressure in Rheumatoid Arthritis 1435. Changes in the Types and Prognoses of Infections Complicated in RA Patients during the Last 15 Years, in Japan. 1436. Impact of Depression on Clinical and Social Outcomes in Patients with Rheumatoid Arthritis: Comparative Study in Germany and Brazil 1437. Cholesterol Efflux Capacity of HDL and Coronary Atherosclerosis in Rheumatoid Arthritis 1438. Association Between Chronic Inflammatory Conditions and Anti Cyclic Citrullinated Peptide Antibodies in Patients with Early Rheumatoid Arthritis 1439. Miscarriage in Rheumatoid Arthritis Association with Disease Characteristics and Medication Use 1440. Asymptomatic Carotid Plaques in RA Patients Are Associated with Increased HDL Function 1441. Accelerated Aging in DMARD and Treatment Naive Early Rheumatoid Arthritis Patients Measured By a Stem Cell Assay Is Associated with Increased LDL and Is Linked to Impaired Cardiopulmonary Function 1442. The 2013 ACC/AHA Cardiovascular Risk Prediction Model and Coronary Atherosclerosis in Patients with Rheumatoid Arthritis 2014 Program Book 199
ACR POSTER INDICES 1443. Increased Occurence of Carotid and Femoral Plaques, but Not Increased Arterial Stiffness of Hypertrophy, in Classical Risk Factor-Free Patients with Rheumatoid Arthritis Clinical Practice/Patient Care (ARHP) 1444. The Vocational Experiences of Young People with Juvenile Idiopathic Arthritis and the Role of the Multidisciplinary Team Supporting Positive Employment Outcomes 1445. Improving Osteoarthritis Outcomes Utilizing a Multidisciplinary Model of Care; Experience in a Diverse Multicultural Urban Teaching Hospital 1446. Utility of Ultrasound in the Nuffield Orthopaedic Centre Emergency Rheumatology Clinic: Survey of Clinical Effectiveness 1447. Implementing American College of Rheumatology (ACR) Quality Indicators for Rheumatoid Arthritis (RA) in the United Arab Emirates (UAE) 1448. A Questionnaire Assessment of Knowledge about Methotrexate of Patients with Rheumatoid Arthritis 1449. WITHDRAWN 1450. Spironolactone As a Novel DMARD in Rheumatoid Arthritis 1451. Use of Analgesics in Patients with Knee and/or Hip Osteoarthritis: Results from the Amsterdam Osteoarthritis Cohort 1452. Timing of Decisions to Adjust Disease Modifying Anti- Rheumatic Drug (DMARD) Therapy for Rheumatoid Arthritis (RA) Patients with Active Disease in a Usual Practice Setting 1453. Gastrointestinal Risk Factors and Treatment Patterns of Rheumatoid Arthritis Versus Osteoarthritis Patients in Korea Rheumatoid Arthritis - Human Etiology and Pathogenesis 1454. Quantitative and Qualitative Tracking of Expanded CD4+ T Cell Clones in Rheumatoid Arthritis Patients 1455. Ex Vivo-Expanded, but Not in Vitro-Induced, Human Regulatory T Cells Are Suitable for Cell Therapy in Rheumatological Autoimmune Diseases Thanks to Stable FOXP3 Demethylation 1456. Foxp3+ Regulatory T Cells in Peripheral Blood and Synovial Fluid of Patients with RA: A Comparative Phenotypic Analysis 1457. Stem Cell Growth Factor Expression in Rheumatoid Arthritis 1458. Functional Phenotype of Synovial Monocytes Modulating Inflammatory T-Cell Response in Rheumatoid Arthritis 1459. IL-22 Secreted By NKp44+NK Cells Promote the Proliferation of Synovium in Patients with Rheumatoid Arthritis By Activation of STAT3 1460. Midkine, a Growth Factor, May Play a Pathophysiological Role in Patients with Rheumatoid Arthritis 1461. Quantitave Analysis of Cadherin-11 and Beta-Catenin Signaling during Proliferation of Rheumatoid Arthritis- Derived Synovial Fibroblast Cells 1462. Cadherin-11 mrna Expression in the Peripheral Blood of Rheumatoid Arthritis Patients As a Marker of Active Polyarthritis 1463. Dickkopf-1 Perpetuated Synovial Fibroblast Activation and Synovial Angiogenesis in Rheumatoid Arthritis 1464. Numbers of Circulating CD4 Positive CD28null T Cells Are Increased in Patients with Rheumatoid Arthritis and Are Associated with Rheumatoid Factor Positivity but Not Subclinical Cardiovascular Disease 1465. Follicular Helper T Cells Control Autoimmunity through IL- 21/IL-21 Receptor Interaction in RA Patients 1466. Patients with Active Rheumatoid Arthritis Display an Expanded Population of GM-CSF Expressing Peripheral B Cells 1467. Do G-CSF and Neutrophils Contribute to the Pathophysiology of Rheumatoid Arthritis? 1468. Mechanism of Effectiveness of IL-6 Blockade for Reduction of SAA Production and Amyloid a Deposition in AA Amyloidosis Patients with RA 1469. Methotrexate Treatment Reduces Serum IL-6 Level By Decreasing a CD14brightCD16+ Intermediate Non-Classical Subset of Monocytes in RA Patients 1470. Malondialdehyde-Acetaldehyde Adducts (MAA) and Anti- Malondialdehyde-Acetaldehyde Antibody in Rheumatoid Arthritis 1471. TNFα Influences the Status of B and T Cells By Acting on BCR and TCR Pathways Via RasGRP1 and RasGRP3 Proteins 1472. Synovial Fluid from Rheumatoid Arthritis Patients Modulates the Immunophenotype and Viability of Monocytes 200 2014 Program Book
ACR POSTER INDICES 1473. Manocept-Cy3 Localizes CD206 + Macrophages in Synovial Tissue and Fluid from Rheumatoid Arthritis Patients Differentially Compared to Controls 1474. Anti-Peptidyl Arginine Deiminase 4 Antibodies in African- Americans with Rheumatoid Arthritis and Radiographic Scores 1475. Porphyromonas Gingivalis and Bone Turnover Biomarkers in Rheumatoid Arthritis 1476. a Dose Response Relationship Between Shared Epitope and ACPA Level: But Not All SE Alleles Are Created Equal 1477. Overweight and Obesity Are Associated with Reduced Risk of Rheumatoid Arthritis in Men, but Not in Women Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel Therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis 1478. Pharmacokinetics, Bioavailability and Safety of a Modified-Release Once-Daily Formulation of Tofacitinib in Healthy Volunteers 1479. Impact of Clinical Remission on Physical Function in Patients with Rheumatoid Arthritis Treated with ALX- 0061: Post-Hoc Analysis of Phase I/II Data 1480. Dose Selection of GLPG0634, a Selective JAK1 Inhibitor, for Rheumatoid Arthritis Phase 2B Studies: PK/PD and Exposure-DAS28 Modeling Approach 1481. Phase 1 and Phase 2 Data Confirm That GLPG0634, a Selective JAK1 Inhibitor, Has a Low Potential for Drug- Drug Interactions 1482. Response of Patient Reported Symptoms of Stiffness and Pain during the Day from Adding Low-Dose Delayed- Release (DR) Prednisone to Stable DMARD Therapy over 12 Weeks in Patients with Moderate Rheumatoid Arthritis (RA) 1483. Efficacy and Safety of Baricitinib in Japanese Rheumatoid Arthritis Patients during a 52 Week Extension Phase 1484. Discovery of ARN-4079 - a Potent, Orally Available Dual Target Inhibitor of Janus Kinase 3 (JAK3) and Interleukin-2 Inducible T-Cell Kinase (ITK) for Rheumatoid Arthritis 1485. Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study 1486. Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá 1487. A Phase 1 Dose-Ranging Repeated-Dose Trial of Parenteral Staphylococcal Protein A (PRTX-100) in Patients with Active Rheumatoid Arthritis on Methotrexate or Leflunamide Therapy 1488. Clinical Efficacy of Add-on Iguratimod Therapy in Patients with Active Rheumatoid Arthritis Despite of Methotrexate ~a Multicenter Registry Study~ 1489. Influences of Disease Activity at the Initiation of Iguratimod, a Small Molecule Antirheumatic Drug, on Efficacy of Iguratimod in Patients with Rheumatoid Arthritis a Multicenter Registry Study- 1490. Can Tumor Necrosis Factor Inhibitors Protect Rheumatoid Arthritis Patients from Osteoporosis? Impact of Tumor Necrosis Factor Inhibitors on Bone Mineral Density and Bone Remodeling Markers 1491. Discovery and Characterization of COVA322, a Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases 1492. Safety and Tolerability of NNC0114 0006, an Anti-IL-21 Monoclonal Antibody, at Multiple s.c. Dose Levels in Patients with Rheumatoid Arthritis 1493. A Phase 1 Study of FPA008, an Anti-Colony Stimulating Factor 1 Receptor (anti-csf1r) Antibody in Healthy Volunteers and Subjects with Rheumatoid Arthritis (RA): Preliminary Results 1494. Treatment of Rheumatoid Arthritis Patients with the JAK1-Selective Inhibitor GLPG0634 Reverses an Arthritis- Specific Blood Gene Signature to Healthy State 1495. Preclinical and Clinical Phase I Profile of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain- Associated Protein Kinase 70 Inhibitor, Developed for the Treatment of Rheumatoid Arthritis 1496. Exposure-Response Analysis for Mavrilimumab Phase2b Study in RA Patients with Informative Dropout 1497. Efficacy and Safety of Iguratimod for Rheumatoid Arthritis 1498. ALX-0061, an Anti-IL-6R Nanobody for use in Rheumatoid Arthritis, Demonstrates a Different in Vitro Profile As Compared to Tocilizumab 1499. Characterization of ABT-494, a Second Generation Jak1 Selective Inhibitor 1500. Preclinical and Clinical Characterization of MK-8457, a Selective Spleen Tyrosine Kinase and Zeta-Chain- Associated Protein Kinase 70 Inhibitor, in Normotensive and Hypertensive Cardiovascular Models 2014 Program Book 201
ACR POSTER INDICES 202 1501. Immunogenicity Assessment of PF-06438179, a Potential Biosimilar to Infliximab, in Healthy Volunteers 1502. A Phase I Trial Comparing PF-05280586 (A Potential Biosimilar) and Rituximab in Subjects with Active Rheumatoid Arthritis 1503. Demonstration of Functional Similarity Comparing Adalimumab to Biosimilar Candidate ABP 501 1504. Pharmacokinetic Equivalence of ABP 501 Relative to Adalimumab: Results from a Randomized, Single-Blind, Single-Dose, Parallel Group Study in Healthy Subjects 1505. The Biosimilar Landscape: A Systematic Review of Its Current Status 1506. Incidence of Adverse Events in Patients Treated with Intended Copies of Biologic Therapeutic Agents in Colombia and Mexico 1507. Patient Perspectives on the Introduction of Subsequent Entry Biologics in Canada 1508. Impact of Anti-Drug Antibody on Efficacy and Safety over Week 24 in Both CT-P10 and Innovator Rituximab Treatment Groups 1509. A Randomized, Double-Blind, Three-Arm, Parallel Group, Single-Dose Study to Compare the Pharmacokinetics, Safety, and Tolerability of Three Formulations of Infliximab (CT-P13, EU-sourced Infliximab and US-sourced Infliximab) in Healthy Volunteers 1510. Blockade of TLR5 Ligation Is a Novel Strategy for RA Therapy 1511. COVA322: A Clinical Stage Bispecific TNF/IL-17A Inhibitor for the Treatment of Inflammatory Diseases 1512. Therapeutic Efficacy of a Novel Oral Small Molecule Macrophage Migration Inhibitory Factor [MIF] Inhibitor: A Promising Safe & Efficacious Treatment for Rheumatoid Arthritis 1513. Selection of Vagus Nerve Stimulation Parameters for a First-in-Human Study in Rheumatoid Arthritis: A Unique Translational Medicine Challenge 1514. An Analysis of in-vitro Cytokine Inhibition Profiles of Tofacitinib and Other Janus Kinase Inhibitors at Clinically- Meaningful Concentrations 1515. The Impact on Anti-Citrullinated Protein Antibody Isotypes and Epitope Fine Specificity in Patients with Early RA Treated with Abatacept and Methotrexate 1516. TNF-Alpha Inhibitors Normalizes Melanocortin Receptor Subtype 2, 3 and 4 Expression in CD8+, CD14+ and CD19+ Leukocyte Subsets in Rheumatoid Arthritis 2014 Program Book 1517. Analysis of Gene Expression Fluctuation with Abatacept Highlights the Involvement of the Proteasome Pathway As a Mechanism of Action of Abatacept in Rheumatoid Arthritis 1518. Disentangling the Effects of Tocilizumab on Neutrophil Survival and Function 1519. Implementation of an Acid Dissociation Procedure for Immunogenicity Detection in Patients Treated with ANTI- TNF Drugs 1520. Gene Expression Analyses of Abatacept- and Adalimumab- Treated Patients from the Ample Trial 1521. Sustained Improvements in Magnetic Resonance Imaging Outcomes with Abatacept Following the Withdrawal of All Treatment in Patients with Early Rheumatoid Arthritis 1522. Impact of Sarilumab on Health Related Quality of Life (HRQoL), Fatigue, and Sleep in Rheumatoid Arthritis Patients at Week 24 - Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study 1523. Follow-up Data on the Rheumatoid Arthritis Comparison of Active Therapies Trial: Observational Cohort 1524. Rituximab Done! What s Next in RA? 1525. Cumulative Clinical Response in Rheumatoid Arthritis Patients with Rituximab Repeated Courses after Failure to Tumor Necrosis Factor Inhibitors in Routine Clinical Practice 1526. Sustained Clinical Efficacy after Multiple Courses of Rituximab in Rheumatoid Arthritis Patients with Inadequate Response to Tumor Necrosis Factor Inhibitors: 3-Year Data 1527. Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: An Indirect Comparison 1528. Efficacy and Safety of MK-8457, a Novel SYK Inhibitor for the Treatment of Rheumatoid Arthritis in Two Randomized, Controlled, Phase 2 Studies 1529. Evaluation of the Pharmacokinetics and Safety of the Interactions Between the Anti-Interleukin-6 Monoclonal Antibody Sirukumab and Cytochrome P450 Activities in Patients with Rheumatoid Arthritis 1530. Autologous Tolerogenic Dendritic Cells for Rheumatoid and Inflammatory Arthritis 1531. CUT-Off LEVEL of Adalimumab and Prevalence of Antibodies ANTI-Adalimumab in Patients with Ankylosing Spondylitis: Results from a LOCAL Registry 1532. Efficacy of the Subcutaneous Formulation of Abatacept/ Orencia in Rheumatoid Arthritis, a Single-Center Italian Experience
ACR POSTER INDICES 1533. Study of One Vial (400mg) per Body Infusion of Tocilizumab in Patients with Active Rheumatoid Arthritis 1534. Disease Severity and Treatment of Rheumatoid Arthritis: A Comparative Study Between Sudan and Sweden 1535. Use of Rituximab Compared to Anti-Tnf Agents As Second and Third Line Therapy in Patients with Rheumatoid Arthritis: A Report from the rhumadata Clinical Database and registry 1536. Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata Clinical Database and Registry 1537. Clinical Characteristics of RA Patients Newly Prescribed Tofacitinib Citrate (tofacitinib) in the United States after Food and Drug Administration Approval: Results from the Corrona US Rheumatoid Arthritis Registry 1538. Sustained Clinical Benefit with Multiple Courses of Rituximab in Second Line for All Rheumatoid Arthtritis Patients Irrespective to the Inhibitor of Tumour Necrosis Factor Previously Used 1539. Relation Between Number of Previous Anti TNF Agents and Clinical Response in Rheumatoid Arthritis Patients Treated with Rituximab 1540. Treatment Patterns of Biologics Used in Rheumatoid Arthritis and Ankylosing Spondylitis in the US Veterans Population 1541. Distinct Regulation of T Helper Cell Differentiation By Biologic DMARD Therapy in Rheumatoid Arthritis Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment II 1542. Predicting Successful Long-Term Treatment with Tumour Necrosis Factor-Alpha Inhibitors in Patients with Psoriatic Arthritis 1543. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvement in the Signs and Symptoms of Psoriatic Arthritis in DMARD- Naive Patients: Results from a Phase 3, Randomized, Controlled Trial 1544. Economic and Comorbidity Burden Among Moderate-to- Severe Psoriasis Patients Comorbid with Psoriatic Arthritis 1545. Better Performance of the Leeds and Sparcc Enthesitis Indices Compared to the Mases in Patients with Peripheral Spondyloarthritis during Treatment with Adalimumab 1546. Risk of Non Melanoma Skin Cancer Among Medicare Psoriasis/Psoriasis Arthritis Patients 1547. Endocrine Co-Morbidities in Patients with Psoriatic Arthritis: A Population-Based Study 1548. Treatment Effect of Ustekinumab on Fatigue in Patients with Psoriatic Arthritis: Results from a Phase 3 Clinical Trial 1549. The Swedish Early Psoriatic Arhtritis (SWEA) Registry 5-Yeear Follow-up: Slow Radiographic Progression with Highest Scores in Male Feet and in Patients with Baseline X-Ray Abnormalities 1550. Prevalence of Enthesitis and Dactylitis, Impact on Disease Severity and Evolution over 12 Months in Psa Patients Treated with Anti-TNF in a Real-World Setting 1551. Correlation of Individual HAQ Questions with Disease Activity Measures in Psoriatic Arthritis: Implications for Instrument Reduction 1552. Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Psoriatic Arthritis 1553. Disease Activity and Clinical Response Early in the Course of Treatment Predict Long-Term Outcomes in Psoriatic Arthritis Patients Treated with Certolizumab Pegol 1554. Early and Sustained Modified Psarc Response in Psoriatic Arthritis Patients Treated with Ustekinumab: Results from 2 Phase 3 Studies 1555. An Indirect Comparison and Cost per Responder Analysis of Adalimumab, Methotrexate (MTX) and Apremilast in the Treatment of MTX-naïve Psoriatic Arthritis (PsA) Patients 1556. Integrated Safety of Ustekinumab in Psoriatic Arthritis: 2 Year Follow-up from the Psoriatic Arthritis Clinical Development Program 1557. Clinical Response in Subjects with Psoriatic Arthritis Following One Year of Treatment with Brodalumab, an Anti-Interleukin-17 Receptor Antibody 1558. Evaluation of Extreme Enthesitis and/or Patient-Related Outcome Score As Potential Surrogates for Fibromyalgia and As Potential Confounding Factors of Anti-TNF Response 1559. Long Term Improvements in Physical Function Are Associated with Improvements in Dactylitis, Enthesitis, Tender and Swollen Joint Counts, and Psoriasis Skin Involvement: Results from a Phase 3 Study of Ustekinumab in Psoriatic Arthritis Patients 1560. Rheumatoid Factor Status Is a Predictor of Osteoporosis in Patients with Psoriatic Arthritis 2014 Program Book 203
ACR POSTER INDICES 1561. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, and the Impact of Baseline Weight and BMI on ACR20 and HAQ-DI Response: Pooled Results from 3 Phase 3, Randomized, Controlled Trials 1562. Psoriasis Longitudinal Assessment and Registry: Global Update upon Full Enrollment 1563. Malignancies in the Psoriasis Longitudinal Assessment and Registry Study: Cumulative Experience 1564. Long-Term (104-Week) Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial and Open-Label Extension 1565. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Improvement of Pain, Fatigue, and Disability in Patients with Psoriatic Arthritis: Results from 3 Phase 3, Randomized, Controlled Trials 1566. The Efficacy and Safety of Biological Disease Modifying Anti-Rheumatic Drugs and Apremilast in the Treatment of Psoriatic Arthritis: A Systematic Review and Meta-Analysis 1567. The Spectrum of Autoimmune Ophthalmic Manifestations in Psoriatic Disease 1568. Joint Damage Is Not Associated with Smoking Status in Patients with Psoriatic Arthritis 1569. Persistence of Biologic Therapy in Psoriatic Disease: Results from the Psoriasis Longitudinal Assessment and Registry 1570. Relationship Between Psoriatic Arthritis Severity, Duration, and Comorbidities 1571. Musculoskeletal Complaints and Psoriatic Arthritis in Primary Care Patients with Psoriasis 1572. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (52-Week) Improvements in Enthesitis and Dactylitis in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial 1573. Norwegian Psoriatic Arthritis Patients Are More Obese Than Rheumatoid Arthritis and Axial Spondyloarthropathy Patients 1574. University Students with Psoriatic Nail Changes Have a Greater Number of Tender Enthesial Points Than Those with Normal Nails 1575. The Association Between Obesity and Disease Phenotype in Psoriatic Arthritis 1576. Reversal of Damage in Psoriatic Arthritis 1577. Value and Prediction of Minimal Disease Activity in Patients with Psoriatic Arthritis 1578. Abatacept Improves Synovitis As Assessed By Magnetic Resonance Imaging (MRI) in Psoriatic Arthritis - Preliminary Analysis from a Single Centre, Placebo- Controlled, Crossover Study 1579. Change in Weight from Baseline with Apremilast, an Oral Phosphodiesterase 4 Inhibitor: Pooled Results from 3 Phase 3, Randomized, Controlled Trials 1580. Gender Differences in Disease Activity Accounting for Inflammatory Biomarkers in a Psoriatic Arthritis Routine Care Cohort 1581. Inflammatory Back Pain in Psoriasis and Psoriatic Arthritis Is Suggestive of Undiagnosed Spondyloarthropathies 1582. Cumulative Inflammatory Burden Is Independently Associated with Increased Arterial Stiffness in Patients with Psoriatic Arthritis 1583. Screening for Psa in Primary Care Psoriasis Patients with Musculoskeletal Complaints with PEST, PASE & Earp 1584. Evaluation of the Patient Acceptable Symptom State in Patients with Psoriatic Arthritis 1585. Presence of Swollen and Tender Joints in Patients Fulfilling Minimal Disease Activity Criteria 1586. Quantitative Proteomic Analysis of Synovial Fluid and Skin Identifies Putative Psoriatic Arthritis Biomarkers 1587. The Economic Impact of Psoriatic Arthritis in Toronto, Ontario 1588. Resistance Training in Patients with Psoriatic Arthritis Improves Function, Disease Activity and Quality of Life 1589. Risk of Opportunistic Infection and Herpes Zoster Infection in a Psoriasis/Psoriatic Arthritis Cohort 1590. Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvements in Patients with Psoriatic Arthritis: Results from a Phase 3, Randomized, Controlled Trial 1591. Exploring the Association of Serum Paraoxonase and Arylesterase Activities with Cardiovascular Risk in Psoriasis and Psoriatic Arthritis 1592. Ability of Clinical Variables to Predict Radiographic Damage in Psoriatic Arthritis 1593. Neutrophil-Lymphocyte Ratio As a Marker of Disease Activity in Psoriatic Arthritis 204 2014 Program Book
ACR POSTER INDICES 1594. Persistence of Low Disease Activity after Tumor Necrosis Factor Inhibitor Withdrawal in Patients with Psoriatic Arthritis 1595. Economic Evaluation of Sequencing Strategies in the Treatment of Psoriatic Arthritis in the United States 1596. Clinical Characteristics and Outcome of Golimumab Treatment Differs Between Bio-naïve and Patients Previously Exposed to Biologicals. Nationwide Results on Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) and Other Spondyl 1597. Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results of a Phase 3, Randomized, Controlled Trial 1598. Serum Fetuin-a, Intercellular Adhesion Molecule -1 and Interleukin -18 Levels in Ankylosing Spondylitis and Psoriatic Arthritis 1599. Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis Pregnancies: Disease Activity, Treatment, and Outcomes 1600. Is There a Role for Inflammasome Activation in PsA Pathogenesis and Its Comorbidities? 1601. Are There Gender Specific Differences in Patient Characteristics at Initiation of Biologic Treatment in Ankylosing Spondylitis and Psoriatic Arthritis? 1602. Th9 Cells in Inflammatory Cascades of Autoimmune Arthritis 1603. Effect of Methotrexate on the Immunogenicity of TNF Inhibitors in Spondyloarthritis Patients Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies 1604. IFN-γ (Th1), IL4 (Th2), and IL5 (Th2) Are Elevated in Pre- Clinical SLE and Predict Transition to Classified Disease Prior to Appearance of Autoantibodies or Clinical Criteria 1605. Elevated Regulatory Mediators and Interferon Gamma Associated Responses, but Not Interferon Alpha, BLyS or IP-10, Accompany High-Titer Anti-Ro Autoantibodies in Asymptomatic Mothers of Children with Neonatal Lupus 1606. Profiling a Broad Range of Autoantibodies in Healthy and Systemic Lupus Erythematosis Revealed Autoantibody Patterns Associated with Autoantibody Transition and Disease Activity 1607. B Cell and Neutrophil-Related Transcripts Predict and Characterize a Lupus Flare 1608. Erythrocyte C4d and Antibodies to Anti-C1q Are Associated with Proteinuria in Lupus Nephritis 1609. Dissection of the Type I Interferon Response in Systemic Lupus Erythematosus : Serum IFNα Is Elevated in Lupus Nephritis and Correlates with IFN Score; IFNβ Is Elevated in Mucocutaneous Disease 1610. New Autoantigens Associated with Lupus Nephritis 1611. Modular Transcriptional Neutrophil Signature As Predictive of Nephritis and of Its Severity in SLE Patients 1612. Deficient Repair of DNA Double-Strand Breaks and Increased Apoptosis in Patients with Lupus Nephritis 1613. Circulating micrornas As Candidate Biomarkers of Diagnosis in Systemic Lupus Erythematosus 1614. Functional Analysis of Interferon Responsiveness in PBMC from SLE Donors Identifies Subgroups with Higher and Lower Disease Activity 1615. MiR-127-3p As a Novel Regulator of Type I Interferon Signaling Pathway in SLE 1616. Functional Profiling of PBMC from SLE Patients Versus Healthy Controls Identifies Subgroups with Disease- Associated Dysfunctional Signaling 1617. Single Cell Interferon Signatures in Lupus Patient Monocytes Reveal a Differential Impact of Interferon Signaling Between Monocyte Subtypes 1618. Suppression of IFN-α Production from Systemic Lupus Erythematosus Immune Complexes Via C1 Complex Enzymatic Properties 1619. Interferon Dysregulation in an Academic SLE Cohort Is Associated with Distinct Signaling Differences in Blood Neutrophils Versus PBMCs 1620. Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE) 1621. A Shift Towards Trans-Signalling Explains Relatively Low CRP Despite an Active Interleukin-6 (IL-6)/IL-6-Receptor (IL-6R) System in SLE 1622. Th1 and Th2 Cytokines Are Associated with Cerebral Atrophy in Systemic Lupus Erythematosus 1623. Increased CD95 (Fas) Expression on Naive B Cells Is Associated with a Switch to Double Negative and Plasma Cells in the Peripheral Blood, and Correlates with Disease Activity in Systemic Lupus Erythematosus 1624. The Role of B Lymphocyte Stimulator in Monocyte Subpopulation Differentiation in SLE 2014 Program Book 205
ACR POSTER INDICES 206 1625. Interferon Stimulates Transglutaminase Activity on Human Monocytes and Their Microparticles 1626. Autoantibodies Against High Mobility Group Box 1 (HMGB1) in Patients with SLE Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarker, Translational and Nephritis Studies 1627. The Global Antiphospholipid Syndrome Score (GAS) Differentiates Between Transient Ischemic Attack and Stroke in Patients with Antiphospholipid Antibodies 1628. Upregulation of Myxovirus Resistance Protein 1 in Patients with Neuropsychiatric Systemic Lupus Erythematosus 1629. Added Value of the Determination of Anti-Ribosomal and Anti-Ku Antibodies for Diagnosis of Systemic Lupus Erythematosus 1630. A Novel NMR Biomarker of Inflammation (GlycA) Is Elevated in Systemic Lupus Erythematosus 1631. Cell Bound Complement Activation Products and Their Relationship to Disease Activity and Quality of Life Measures in Systemic Lupus Erythematosus 1632. Is Liopxin A4 a Biomarker for Systemic Lupus Erythematosus? 1633. Galectin-3-Binding Protein Is Associated with Disease Activity, but Not with Atherosclerosis in SLE Patients 1634. Thrombophilia Associated with DFS70 Antibodies 1635. Association Between Carrying at Least One Apolipoprotein1 Variant Allele and Hypertension in Lupus Patients with Normal Renal Function 1636. Disease Phenotype Is Associated with TH1, TH2 and TH17 Cytokines in Childhood-Onset Systemic Lupus Erythematosus 1637. LACK of Association of ANTI CCP and Arthritis in SLE 1638. Anti-Dense Fine Speckled 70 Antibodies: Long-Term Followup Study of Clinical Associations in a US Laboratory Patient Population 1639. Serum Anti-Müllerian Hormone Levels in SLE Patients. the Disease Severity and Cyclophosphamide Reduce the Ovarian Reserve 1640. Cyclophosphamide Diminishes Plasmablasts and Transitional B Cells and Suppresses Autocrine Production of B Cell Activating Factor of Tumor Necrosis Factor Family (BAFF) in These Cells in Patients with Systemic Lupus Erythematosus 2014 Program Book 1641. Baseline Factors That Predict High BLyS Levels in Patients with Systemic Lupus Erythematosus (SLE) and High Disease Activit 1642. A Prospective Study of Vitamin D Effects on T Cells Phenotype in Patients with Systemic Lupus Erythematosus Treated with Different Regimens of Supplementation for Two Years 1643. Role of Inflammasome Activation in Systemic Lupus Erthematosus: Are Innate Immune Cells Activated? 1644. Mycophenolic Acid and Ribavirin Induces Cytoplasmic Autoimmunogenic Rods and Rings Structures in Vivo 1645. Interferon Gene Signature Expression and Serological Differences in Japanese and Non-Japanese SLE Patients 1646. Molecular, Cellular and Histopathologic Assessment of Baseline Characteristics of Sixteen Subjects with Discoid Lupus Erythematosus Prior to Treatment with AMG 811 (anti-ifnγ) 1647. Relationship Between Apom/S1P Levels and Atherosclerosis in Women with Systemic Lupus Erythematosus 1648. Urinary T Cells and Macrophages Strongly Reflect the Disease Activity, Kidney Function, and the Histopathologic Classification in Patients with Lupus Nephritis 1649. High Specificity of Skin Immunoglobulin Deposits for diagnosing SLE in Patients with Lupus Nephritis 1650. Prevalence and Prognostic Implications of IgG4 in Membranous Lupus Nephritis 1651. Association of Glomerular Macrophage Phenotypes and Urine Soluble CD163 with Disease Activity in Human Lupus Nephritis 1652. Biomarkers of Lupus Nephritis and Ethnic Disparities in Systemic Lupus Erythematosus 1653. Serum Cystatin C As a Biomarker for Clinical Practice in Patients with Lupus Nephritis 1654. Thrombotic Microangiopathy and Poor Renal Outcome in Lupus Patients Is Not Associated with Antiphospholipid Syndrome and/or Other Lupus Conventional Features 1655. Lupus Nephritis: Clinicopathological Correlation in 126 Biopsies 1656. Rate of Histological Transformation to Higher Grade Nephritis in Class II Mesangial Proliferative Lupus Glomerulonephritis 1657. Does Advanced Age Influence the Type of Renal Injury and the Prognosis of Lupus Nephritis?
ACR POSTER INDICES 1658. Renal Thrombotic Microangiopathy in Systemic Lupus Erythematosus: Novel Risk Factors and Clinical Outcomes 1659. The Clinical Relevance of a Repeat Biopsy in Lupus Nephritis (LN) Flares 1660. A Systematic Review and Network Meta-Analysis of Cyclophosphamide and Mycophenolate Mofetil in Lupus Nephritis 1661. Are Repeat Renal Biopsies Important in Managing Lupus Nephritis Flares? 1662. Lupus Nephritis Patients Who Stopped Maintenance Immunosuppressive Therapy without Relapse 1663. Influence of Ethnicity on Efficacy of Current Immunosuppressive Protocols in Proliferative Lupus Nephritis 1664. Novel Risk Factors for Systemic Lupus Erythematosus (SLE) Flares in Patients with End-Stage Renal Disease: Is SLE in Patients with End-Stage Renal Disease a sleeping beauty? 1665. Efficacy Versus Safety of Prednisone in Lupus Nephritis Since 1988 1666. The Relevance of Urinary Podocyte Number and Urinary Podocalyxin Level with Response to Treatment and 1 Year Renal Prognosis in Systemic Lupus Erythematosus 1667. Probability of 3 and 6 Month Complete Response in Lupus Nephritis 1668. Identifying Patient Perceptions of Medication Decision Making Barriers in Minorities with Lupus Nephritis 1669. Validation of a Machine Learning Lupus Nephritis Decision Support Tool to Predict Complete Response to Therapy 1670. Characterization of Patients with Lupus Nephritis Included in a Large Cohort from the Spanish Society of Rheumatology Registry of Patients with Systemic Lupus Erythematosus 1671. Renal Relapses Are Common in Lupus Nephritis 1672. Facilitating the Medication Decision-Making process What Do Patients with Lupus Nephritis Say? 1673. Disease Specific Quality of Life in Patients with Lupus Nephritis Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics: Systemic Sclerosis, Diagnostic and Therapeutic Aspects 1674. Long-Term Efficacy of Rituximab in Systemic Sclerosis 1675. Regional Implantation of Adipose Tissue-Derived Cells Induces a Prompt Healing of Long-Lasting Indolent Digital Ulcers in Patients with Systemic Sclerosis 1676. Physical Therapy for Systemic Sclerosis: Systematic Review and Meta-Analysis 1677. Association of Gastrointestinal Symptoms with Immunosuppressant Use in the Prospective Registry of Early Systemic Sclerosis Cohort 1678. Initial Therapy with an Endothelin Receptor Antagonist Is Associated with Worse Outcomes in Patients with Systemic Sclerosis and Pulmonary Arterial Hypertension: Observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Sclero 1679. A Double Blind Randomized Control Trial of Oral Tadalafil in Interstitial Lung Disease of Scleroderma 1680. An Indirect Comparisons Analysis of Medications Used for Treatment of Raynaud s Phenomenon 1681. Heart Transplantation in 6 Patients with Systemic Sclerosis and a Primary Cardiac Involvement 1682. Mycophenolate Mofetil Versus Azathioprine in Scleroderma-Associated Interstitial Lung Disease: Results from the Australian Scleroderma Cohort Study 1683. Botulinum Toxin-a for the Treatment of Severe Raynaud Phenomenon 1684. Treatment of Scleroderma Associated Lung Disease with Mycophenolate Mofetil: A Community-Based Study 1685. Effects of Mycophenolate Mofetil on Pulmonary Lung Function in Interstitial Lung Disease of Systemic Sclerosis 1686. DUAL Energy Computed Tomography for the Evaluation of Calcinosis in Systemic Sclerosis 1687. Key Role of Cardiac Biomarkers in the Assessment of Systemic Sclerosis: Contribution of High Sensitivity Cardiac Troponin 1688. Early Detection of Left Ventricular Morphological, Functional Abnormalities and Myocardial Characteristics in Systemic Sclerosis without Cardiac Symptoms Using Cardiac Magnetic Resonance Imaging: A Preliminary Report 1689. Microhaemorrages and Giant Capillaries in Nailfold Videocapillariscopies Are Able to Accurately Predict Disease Activity Level in Systemic Sclerosis 1690. Improvement of Digital Ulcerative Disease in Patients with Systemic Sclerosis Is Associated with Better Functional Prognosis 2014 Program Book 207
ACR POSTER INDICES 1691. Systemic Sclerosis Patients with Pulmonary Hypertension Have a Lower Change in End Tidal Carbon Dioxide Following Three Minutes of Step Exercise Than Systemic Sclerosis Patients without Pulmonary Hypertension: A Cross-Sectional Study 1692. The Additive Value of Nailfold Videocapillaroscopy Patterns to Disease-Specific Autoantibodies in Discrimination of Patients with Systemic Sclerosis at Risk for Severe Organ Involvement 1693. Progressive Disease in Systemic Sclerosis after One Year of Follow-up; Results of a Standardized Multidisciplinary Health Care Program 1694. A Feasibility Study of Subjective and Objective Assessment of Sublingual Abnormalities in Systemic Sclerosis 1695. Validation of Vesmeter As a Diagnostic Tool of Scleroderma 1696. Left Atrial Area Measurement Is Useful for Evaluating Left Ventricular Diastolic Dysfunction Coexisting with Pulmonary Arterial Hypertension Associated with Systemic Sclerosis 1697. High Frequency Skin Ultrasound Detects Subclinical Diffuse Dermal Involvement in Patients with Limited Cutaneous Systemic Sclerosis 1698. Peripheral Blood Eosinophil Counts Increase in Patients with Systemic Sclerosis and Associated with Its Disease Severity 1699. Endothelial and Platelet Microparticles As Potential Novel Biomarkers of Peripheral Microvascular Dysfunction in Systemic Sclerosis and Primary Raynaud s Phenomenon 1700. Laser Speckle Contrast Analysis in the Follow-up of Digital Ulcers in Systemic Sclerosis Patients 1701. Short-Term Effects of Iloprost on Micro-Vessels Hemodynamics in Systemic Sclerosis Patients Evaluated By Laser Doppler Flowmetry 1702. Antiphospholipid Antibodies in Systemic Sclerosis: Prevalence and Clinical Significance? 1703. An Association of Anti-/Scl Antibody Reactivity with Risk of Malignancy in Scleroderma Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics 1704. CXCL4 Promotes Fibrosis By Increasing Expression of Extracellular Matrix Modifying Factors and By Facilitating Epithelial/Endothelial Mesenchymal Transition 1705. The Lectin Pathway of Complement a Potential Role in the Pathogenesis and Disease Manifestations of Systemic Sclerosis 1706. Prevention of SU5416-Induced Pulmonary Hypertension in a TGFβ Dependent Genetic Mouse Model of Scleroderma Using the Endothelin Receptor Antagonist Macitentan 1707. High Oxidative Stress in Fibrotic and Non-Fibrotic Skin of Patients with Systemic Sclerosis 1708. The Pathogenic Role of Immune Complexes Containing Scleroderma-Specific Autoantibodies in the Inductor Phase of the Disease 1709. WITHDRAWN 1710. Endothelin-1 Is a Downstream Mediator of Profibrotic Effects by Transforming Growth Factor-β1 in Systemic Sclerosis Skin Fibroblasts 1711. The Relationship Between Vascular Biomarkers and Disease Characteristics in Systemic Sclerosis: Elevated MCP-1 Is Associated with Predominantly Fibrotic Manifestations 1712. Monocytic Angiotensin and Endothelin Receptor Imbalance Determines Secretion of the Profibrotic Chemokine Ligand CCL18 1713. Increased Number of CD206+cells in Peripheral Blood and Skin of Systemic Sclerosis Patients 1714. IL-6 Trans-Signalling Activates M2 Macrophage Polarisation and Mediates Fibrotic Response in Scleroderma 1715. Serum Levels of CD163/Tweak Predict Risk of Digital Ulcers in Patients with Systemic Sclerosis 1716. MHC Class I and Class II Genes Influence Systemic Sclerosis Susceptibility, Clinical Presentation and Autoantibody Profile in a Mexican Admixed Population 1717. Endothelial to Mesenchymal Transition Contributes to the Development of Pulmonary Vasculopathy in Systemic Sclerosis PAH 1718. B Cell Subsets Homeostasis and Functional Properties Are Altered in a Murine Model of Systemic Sclerosis 1719. Periostin May Promote Productin of Extracellular Matrix By Modulating TGF-β Signaling in Human Skin Fibroblasts 1720. GATA6 Deficiency Activates UPR Pathways in Endothelial Cells during the Development of Pulmonary Arterial Hypertension 1721. Investigating the SCF/c-Kit Pathway in Scleroderma Fibrosis 208 2014 Program Book
ACR POSTER INDICES 1722. TLR4 and TLR7 Are Required for Gadolinium Based Contrast Agent Induction of Dermal and Pulmonary Fibrosis in an Adenine-Induced Model of Chronic Renal Failure 1723. Identification of the Microbiome As a Potential Trigger of Systemic Sclerosis By Metagenomic RNA-Sequencing of Skin Biopsies 1724. Loss of IRF5 Ameliorates Tissue Fibrosis in a Murine Model of Systemic Sclerosis 1725. The SYK Inhibitor Fostamatinib Limits Tissue Damage and Fibrosis in a Bleomycin-Induced Scleroderma MOUSE MODEL 1726. Therapeutic Efficacy of Mesenchymal Stem Cells in Diffuse Murine Hypochlorite-Induced Systemic Sclerosis 1727. Poly(ADP-ribose) Polymerase-1 (PARP-1) Suppresses the Profibrotic Effects of Transforming Growth Factor â in Systemic Sclerosis 1728. Bromodomain Inhibitor JQ1 Modulates Collagen Processing and Ameliorates Bleomycin Induced Dermal Fibrosis in Mice 1729. Adenosine A2A Receptor (A2AR) Promotes Collagen Type 3 Expression Via β-catenin Activation 1730. Identification of Novel Scleroderma associated Antigens and Development of an Autoantibody Assay Panel Enabling Their Subsequent Validation 1731. Translocation of IGFBP-5 to the Nucleus and Its Interaction with Nucleolin Do Not Dictate Its Fibrotic Effects 1732. Attenuation of Sclerodermatous Graft Versus Host Disease (sclgvhd) in IL4RA Receptor-Deficient Mice T cell Biology in Rheumatoid Arthritis and Other Arthritis 1733. Immunomodulatory Effects of Dietary Non-Digestible Oligosaccharides in T Cell-Mediated Autoimmune Arthritis 1734. IL-22 Plays a Significant Role in the Initiation and Augmentation of Th17-Dependent Experimental Arthritis 1735. T cell Tolerance Induction By the Glycosylated Type II Collagen Peptide-Based Vaccination in Murine Arthritis 1736. Immune Related Adverse Events Associated with Anti- CTLA-4 Antibodies: Systematic Review and Meta-Analysis 1737. Altered Phenotype and Function of Senescent Regulatory T Cells in Rheumatoid Arthritis 1738. Prominent Role of CCR6+ T Helper Cells in the Pathogenesis of ACPA+ Patients with Early RA 1739. Immunomodulatory Properties of CD271+ and CD271- Synovial Mesenchymal Cells 1740. Predicting the Evolution of Inflammatory Arthritis in ACPA-Positive Individuals: Can T-Cell Subsets Model Help? 1741. Anti-TNFα Treatment Increases IL-17A+ and IL-22+ T Cells in Spondyloarthritis Regardless of Concomittant Gut Inflammation 1742. Depletion of Reactive Oxygen Species Biases T Cells to Proinflammatory Cytokine Production in Rheumatoid Arthritis 1743. Antigen-Specificity Regulates Peripheral Homeostasis of Regulatory T Cells 1744. CD4+ T Cell Subpopulations in Blood and Synovial Fluid Defined By Differential Expression of Integrins 1745. Memory Stem T Cells Are Selectively Enriched in Patients with Rheumatoid Arthritis, Contract upon Anti-TNF Treatment, and May Provide a Long-Term Reservoir of Arthritogenic Lymphocytes 1746. Involvement of IL-17-Producing MAIT Cells in the Pathogenesis of Rheumatoid Arthritis 1747. WITHDRAWN 1748. CCR6+CD4+ Cells Are Counterparts of Follicular T-Cells Supporting Autoantibody Production in Rheumatoid Arthritis 1749. Molecular Mechanisms Underlying 1,25(OH)2D3- Mediated Suppression of Th17 Cell Activity 1750. The Effect of a Pro-Inflammatory Milieu on Tregalizumab (BT-061)-Induced Regulatory T-Cell Activity 1751. CD4 Aptamer-RORγt shrna Chimera Inhibits IL-17 Synthesis By Human CD4+ T cells 1752. CD30 As a Target of Aptamers and Delivery Portal for Aptamer-shRNA to Block Th17 Cells 1753. Human T-Cells Express RANKL in Response to Combination of ZAP-70, Calcineurin and Voltage-Gated K+-Channel Signaling Following Co-Ligation of the Adhesion Molecule CD2 and the T-Cell Receptor Complex Vasculitis 1754. Peripheral CD5+ b-cells in ANCA-Associated Vasculitis 1755. Proteomic Analysis of ANCA Vasculitis Serum Reveals Broad Neutrophil Activation, Angiogenesis, and Selective Inflammatory Pathway Activation 2014 Program Book 209
ACR POSTER INDICES 210 1756. Molecular Diagnosis Reveals a Surprising Prevalence of Limited Gpa Among Patients with Orbital Inflammatory Diseases 1757. An Analysis of the Incidence and Characteristics of ANCA Positive Vasculitis before and after the Christchurch Earthquake 1758. Environmental Risk Factors for Granulomatous Polyangiitis (GPA): Southern Hemisphere Similar to Northern Hemisphere 1759. Analysis of Employment, Work Disability and Quality of Life of Patients with ANCA-Associated Vasculitis 1760. United Kingdom & Ireland Vasculitis Registry Cross- Sectional Data on the First 1085 Patients 1761. Standardisation of Disease Assesment in Systemic Vasculitis: Use of a Novel Web-Based Software Training Application 1762. The Muscle Biopsy Is a Useful and Noninvasive Procedure in Diagnosing Systemic Vasculitis Affecting Small-to- Medium-Sized Vessels: A Prospective Evaluation 1763. Tobacco Differentially Affects the Clinical-Biological Phenotype of ANCA-Associated Vasculitides at Diagnosis 1764. Clinical and Other Differences Observed Between Cocaine Induced and Non-Cocaine Induced Anti-Neutrophil Cytoplasmic Antibody Positive Vasculitis 1765. Comparison of Clinical Characteristics of Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis By the Serotype Specificity to Myeloperoxidase and Proteinase-3 1766. Comparison of Clinicopathologically- and Serologically- Based Classification Systems for ANCA-Associated Vasculitis 1767. Granulomatosis with Polyangiitis (Wegener s) According to Geographic Origin and Ethnicity: Clinical-Biological Presentation and Outcome 1768. Cardiac Involvement in Granulomatosis with Polyangiitis: A Magnetic Resonance Imaging Study of 31 Consecutive Patients 1769. Abdominal Visceral Adipose Tissue Measured By DXA As a Novel Surrogate Marker of Cardiovascular Risk in Primary Necrotizing Vasculitides 1770. Increased Risk of Chronic Obstructive Pulmonary Disease in Granulomatosis with Polyangiitis: A General Population-Based Study 1771. Arterial Thrombotic Events in Systemic Vasculitis 1772. Venous Thromboembolic Events in Eosinophilic Granulomatosis with Polyangiitis (EGPA) 2014 Program Book 1773. Otolaryngologic Lesions Are Not Rare and Closely Related with Pachymeningitis and Cranial Neuropathy in MPO- ANCA Associated Vasculitis 1774. Granulomatosis with Polyangiitis (Wegener s): Endoscopic Management of Tracheobronchial Stenosis - Results from a Multicenter Experience in 47 Patients 1775. Predicting Relapse in Patients with Granulomatosis with Polyangiitis - the Potential Use of Monitoring in Vitro ANCA Production 1776. Factors Predictive of ANCA-Associated Vasculitis Relapse in Patients Given Rituximab-Maintenance Therapy 1777. Staphylococcus Aureus Nasal Carriage and Relapses, Bvas, ANCA-Positivity and Cotrimoxazole Use in ANCA- Associated Vasculitis 1778. Rituximab Versus Azathioprine for ANCA-Associated Vasculitis Maintenance Therapy: Impact in Health-Related Quality of Life 1779. Plasmapheresis Therapy in ANCA-Associated Vasculitides: A Single-Center Retrospective Analysis of Renal Outcome and Mortality 1780. Outcomes of Triple Therapy (Plasma Exchange, Cyclophosphamide and Systemic Corticosteroid) for Anti-Neutrophil Cytoplasm Antibody (ANCA)-Associated Vasculitis 1781. Long-Term Outcomes Among Patients with Renal Disease Secondary to ANCA-Associated Vasculitis: Temporal Trends over 25 Years 1782. Long-Term Follow-up of Non-HBV Polyarteritis Nodosa and Microscopic Polyangiitis with Poor-Prognosis Factors 1783. The Importance of Histopathological Classification of ANCA-Associated Glomerulonephritis in Renal Function and Renal Survival 1784. Prognostic Factors for Interstitial Lung Disease with Microscopic Polyangiitis 1785. Survival of Microscopic Polyangiitis (MPA) Patients with and without Pulmonary Fibrosis (PF) 1786. Vasculitis As Underlying Cause of Death in the United States: 1999 2010 1787. HLA-DRB1*01 Is Associated with Henoch- Schönlein Purpura in the Spanish Population 1788. Association of HLA-B*41 with Henoch-Schönlein Purpura in Spanish Individuals Irrespective of the HLA-DRB1 Status 1789. Are EULAR/Printo/PRES Classification Criteria Appropriate for Classification of IgA Vasculitis in Adults?
ACR POSTER INDICES 1790. Follow up of an Unselected IgA Vasculitis (Henoch- Schönlein Purpura) Population at Single Rheumatology Center 1791. Applicability of the 2006 European League Against Rheumatism (EULAR) Criteria for the Classification of Henoch-Schönlein Purpura. an Analysis Based on 766 Patients with Cutaneous Vasculitis 1792. Clinical-Biological and Pathological Spectrum and Outcome of IgA Vasculitis in Adults: A French Study 1793. Efficacy and Safety of IFN-Alpha in Induction and Maintenance of Remission in Patients with Eosinophilic Granulomatosis with Polyangiitis (EGPA). Single Center Observational Study TUESDAY, NOVEMBER 18, 2014 Poster Hall (Exhibit Hall B) B cell Biology and Targets in Autoimmune Disease: Systemic Lupus Erythematosus and Related Diseases 1938. Effects of Mesenchymal Stem Cells on Human B Cell Proliferation 1939. Development of Cell Based Enzyme Linked Immunosorbent Assay for the Quantification of Anti M type phospholipase a receptor Antibodies and Its Clinical Usefulness in Patients with Membranous Nephropathy 1940. A Novel Murine Model of B Cell-Mediated Glomerular Injury Is Mediated By Cytokines 1941. Neuropsychiatric Lupus Is Substantially Unaffected By B-Cell Deficiency 1942. Regulation of the Responses of Human B Cell Subsets to Innate Immune Signals By Epratuzumab, a Humanized Monoclonal Antibody Targeting CD22 1943. In Vivo Effects of Epratuzumab, a Monoclonal Antibody Targeting Human CD22, on B Cell Function in Human CD22 Knock-in (Huki) Mice 1944. Targeting CD22 with Epratuzumab Impacts Cytokine Production By B Cells 1945. Pharmacodynamic Effects of the CD22-Targeted Monoclonal Antibody Epratuzumab on B Cells in Patients with Systemic Lupus Erythematosus 1946. CD22 Is Required for Formation of Memory B Cell Precursors within Germinal Centers 1947. Prolactin Promotes Survival of Immature B Cells from MRL/Lpr Mice 1948. A Dual Role for IFN-γ in Development of Peripheral B Cells in Lupus-Prone MRL/Lpr Mice 1949. Defective PTEN Regulation and Function Contributes to B Cell Hyper-Responsiveness in Systemic Lupus Erythematosus 1950. Circulating CD19+CD38+CD43+ B Cell Subset in SLE Patients Have More Cell Cycle Related Genes Than Healthy Controls 1951. A Novel CD27(-) Spleen Tyrosine Kinase (Syk) Bright Memory B-Cell Subset Is Expanded in SLE 1952. Elucidation of Molecular Mechanisms of Breg Induction in Autoimmune Diseases 1953. Circulating Plasmablasts from Patients with Systemic Lupus Erythematosus Produce Autoantibodies Reactive to Epstein-Barr Virus 1954. Successfull Long-Term Depletion of Memory Plasma Cells Requires a Combined Depletion of Plasma Cells and Their Precurors in NZB/W Mice 1955. Disparity in Internalisation of Monoclonal Antibodies Targeting B Cell Antigens and Regulation By Fc Gamma Receptor IIb: Implications for Targeted Therapy in SLE 1956. Increased IL-6 Production By Effector B Cells in Giant Cell Arteritis and Polymyalgia Rheumatica Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis 1957. Dysregulation of CC Chemokines at Microvascular Endothelial Cells of Blood and Lymphatic Vessels Under Inflammatory Conditions 1958. Pyrrolopyrimidine Derivatives That Inhibit Binding of BAFF to Its Receptor, BR3, Are Drug Candidates for Primary Sjögren s Syndrome 1959. Interaction of PDE4 and β-arrestin Reverses Anti- Inflammatory Effects of Catecholamine-Producing Cells in Chronic Arthritis Via Adrenoceptor Switching from Gαs to GαI Signalling 1960. NF-κB-Inducing Kinase (NIK) Is Expressed in Synovial Endothelial Cells in Early Arthritis Patients and Correlates with Local Disease Activity and Systemic Markers of Inflammation 1961. Chemokine-like Receptor 1 (CMKLR1) is Expressed on Synoviocytes and Proinflammatory Monocytes in Arthritis and is Predominantly Regulated By β arrestin 2 and G Protein Coupled Receptor Kinase (GRK) 6 1962. Inflammatory Properties of Inhibitor of DNA Binding 1 As a Unique Fibroblast Derived Nuclear Protein 2014 Program Book 211
ACR POSTER INDICES 212 1963. Hierarchical Role of PI3K/Akt/mTOR Signaling Cascade on: Tissue Inflammation, Organization and Angiogenesis in Autoimmune Arthritis 1964. Changes in Soluble CD18 Reflect Latency in the Immune System and Predict Radiographic Progression in Early Rheumatoid Arthritis 1965. Characterization of the Thyroid Hormone System in Rheumatoid Arthritis 1966. CTLA4-Ig (abatacept) Modulate in Vitro the ICAM1 and VEGFR-2 Expression in Human Endothelial Cells 1967. Transforming Growth Factor Beta Is a Major Regulator of Micro-RNA Synthesis in Rheumatoid Arthritis Synovial Fibroblasts 1968. Highly activated IL-23/Th17 axis and JAK2/STAT3 signal pathway in PBMC of active AS patients involve in pathogenesis of AS 1969. Neurotrophin Receptor p75 (CD271) Defines a Distinct Synovial Fibroblast Subset in Rheumatoid and Osteoarthritic Synovial Tissues with Enhanced Proinflammatory Potential 1970. TH17 Inflammatory Responses Occur in a Subset of Patients with Erythema Migrans or Lyme Arthritis, but Are Not Predominant Responses in Joints 1971. The Role of the Proinflammatory Mediator High-Mobility Group Box Protein 1 (HMGB1) in Anti-Collagen-Antibody- Induced Arthritis Is Dependent on Vascular Endothelial Growth Factor (VEGF) 1972. Analysis of Anakinra in Primary Human Cell Systems Reveals an in Vitro Signature for Skin-Related Side Effects 1973. Ectopic Lymphoid Neogenesis Is Strongly Associated with Activation of the IL-23/IL-17 Pathway in Rheumatoid Synovitis 1974. Sex Steroids, Interleukin-1, and Interleukin-10 Inhibit interferon gamma (IFN-γ) Induced B Cell Activating Factor of the Tumor Necrosis Factor Family (BAFF) in Human Synovial Fibroblasts 1975. Profiling 14-3-3η in Human Primary Cell Based BioMAP Disease Models Reveals a Unique Pro-Inflammatory Phenotypic Signature Consistent with RA-Inflammation Biology 1976. Elevation and Functional Activity of Interferon Omega in Human Systemic Lupus Erythematosus 1977. The Proangiogenic Function of the Epigenetic Regulator EZH2 in Synovial Tissue Is Mediated By Fibroblasts in Rheumatoid Arthritis 2014 Program Book 1978. Role of Monocytes Subsets in the Pathology of Rheumatoid Arthritis: Involvement in Endothelial Dysfunction and Proinflammatory Profile 1979. Pseudostarvation By AMPK Activator Therapy Is Associated with Reduced Disease Activity and Downregulation of Pro-Inflammatory Responses in Rheumatoid Arthritis (RA) 1980. Thrombospondin-1 Is Elevetad in the Plasma of Patients with Antiphospholipid Syndrome and Is Correlated with Soluble Fas Ligand and Free Active TGF-B levels Education (ACR) 1981. A Qualitative Analysis of Methotrexate Injection Videos on Youtube 1982. Final Year Medical Students Prefer E-Reading Content to Interactive Case-Based Quizzes in a Pediatric Rheumatology E-Learning Module 1983. Improving Resident Confidence with the Musculoskeletal Exam through a Rheumatology-Dedicated Musculoskeletal Workshop 1984. Implementation and Performance of an Objective Structured Clinical Examination (OSCE) in a National Certification Process of Trainees in Rheumatology. Two Years of Experience 1985. Rheumatology Learning Management System 1986. Ambulatory Rheumatology Curriculum: Effect of Multimodal Curriculum Enhancement 1987. Simulation in Continuing Education: Improving Evidence- Based Decisions for Rheumatoid Arthritis Management 1988. Process Outcomes and Community-Wide Efficacy of the Amigo Inter-Institutional Mentoring Initiative within Pediatric Rheumatology 1989. Application of an Experiential Learning Framework for Clinician Scholar Educator Training in a Rheumatology Fellowship 1990. Pilot Musculoskeletal Workshop for Internal Medicine Residents 1991. Integration of Nailfold Capillary Microscopy and Dermoscopy into the Rheumatology Fellows Curriculum 1992. Resident s Guide to Rheumatology Mobile Application: An International Needs Assessment 1993. Does Psychological Safety Impact Learning Environments Among Rheumatology Fellows: Findings from Veterans Affairs Learners Perception Survey
ACR POSTER INDICES 1994. Incorporation of Musculoskeletal Ultrasound Curriculum and 6-Month Assessment of Knowledge Retention into the 2nd Year of Medical Student Training 1995. Design and Implementation of a Clinical Teaching Tool for Approach to Children with Suspected New Rheumatologic Diagnosis 1996. Improvement in Basic Bone Health Knowledge Among VA Primary Care Practitioners during a Focused Musculoskeletal Mini-Residency 1997. Structured Integrative Rheumatology Modules (SIRM) 1998. pgals Training Increases Kenyan Pediatric Residents Confidence in Performing a Musculoskeletal Exam 1999. Internal Medicine Resident Confidence in Rheumatologic and Musculoskeletal Diseases: A Needs Assessment Survey 2000. The Effect of a Rheumatology Ambulatory Rotation for Medical Residents on Documentation of Musculoskeletal Complaints 2001. The Musculoskeletal Mini-Residency Collaborative Network: A National Department of Veterans Affairs Interdisciplinary and Interprofessional Educational Innovation for Primary Care Providers 2002. Implementation of a Collaborative Rheumatology and Physiatry Musculoskeletal Ultrasound Training Program 2003. Pilot Study of a Web-Based Module on Gout 2004. Osteoporosis Screening and Fracture Risk Assessment Tool Usage Among House Staff 2005. Multimedia Patient Education Tool for Patients with Osteoporosis Education (ARHP): Education/Community Programs 2006. Multiple Joint Osteoarthritis: Patient Preferences for a Generic Exercise and Self-Management Programme 2007. Using Photovoice Techniques to Empower Lupus Patients and Create Public Awareness: A Program Evaluation 2008. Personalized Risk Education for Rheumatoid Arthritis Improves Self-Perceived Risk Accuracy and Risk Factor Knowledge in First-Degree Relatives 2009. Development of Multimedia Patient Education Tools (MM-PtET) for Osteoarthritis (OA), Osteoporosis (OP) and Rheumatoid Arthritis Patients (RA) 2010. Reaching out to Physical Therapists: Results of a Survey on Physical Therapists Preferences for Learning about Evidence-Based Community Programs 2011. What Do State Legislators Think about Arthritis? Results of Focus Groups with State Legislators 2012. Moving Social Media Beyond Health Education and into Patient Engagement 2013. Quality Appraisal of Educational Websites on Osteoporosis and Bone Health Epidemiology and Public Health (ACR): Rheumatoid Arthritis Pathogenesis and Treatment 2014. Performance of Self-Reported Measures for Periodontitis in Rheumatoid Arthritis and Osteoarthritis 2015. Fine Particulate Air Pollution and Systemic Autoimmune Rheumatic Disease in Two Canadian Provinces 2016. Occupation and Risk of Developing Rheumatoid Arthritis 2017. Fish Consumption and Risk of Rheumatoid Arthritis Among Women in Large Prospective Cohorts 2018. Do Mediterranean or Vegetarian Diets Influence Risk of Rheumatoid Arthritis? 2019. Antibodies to Citrullinated Clusterin, Filaggrin, Vimentin, and Fibrinogen Are Associated with Blood Pressure in First-Degree Relatives of Rheumatoid Arthritis Patients: The Studies of the Etiology of Rheumatoid Arthritis 2020. Circulating Carotenoids and Subsequent Risk of Rheumatoid Arthritis 2021. The Association Between Rheumatoid Factor and Cardiovascular Disease in Healthy Adults 2022. First Nations Persons Have an Increased Risk of Developing Rheumatoid Arthritis with an Early Onset Age but Are Seen Less Frequently By Rheumatologists: A Population Based Study 2023. Prevalence of Inflammatory Arthritis Conditions in the First Nations Population of Alberta 2024. Prevalence of Rheumatoid Arthritis in French West Indies, an African Ancestry Population. the Eppra Study 2025. Factors Associated with Time to Diagnosis from Symptom Onset in Early Rheumatoid Arthritis Patients 2026. Treatment Delays and Worse Outcomes Associated with Lower Socioeconomic Status in Rheumatoid Arthritis 2027. Higher Educational Level Correlates with Retarded Onset and Less Severe Disease in Rheumatoid Arthritis Patients 2014 Program Book 213
ACR POSTER INDICES 2028. Effect of Age at Rheumatoid Arthritis Onset on Clinical, Radiographic, and Functional Outcomes: The Espoir Cohort 2029. Treatment Patterns of Multimorbid Rheumatoid Arthritis Patients: Results from an International Cross-Sectional Study 2030. Predicting Failure of Conventional Disease Modifying Antirheumatic Drugs in Treatment Naive Early Rheumatoid Arthritis Patients: A Single Centre Inception Prognostic Factor Cohort Study 2031. Early Adherence to Methotrexate in Rheumatoid Arthritis (RA) Is High: a Prospective Longitudinal Study of New Users 2032. Psychological Factors Predict Adherence to Methotrexate (MTX) in Rheumatoid Arthritis (RA); Findings from a Systematic Review of Rates, Predictors and Associations with Patient Outcomes 2033. Patient Factors Associated with Oral Glucocorticoid Prescribing Patterns in UK Primary Care for Patients with Rheumatoid Arthritis 2034. A Treat-to-Target Strategy Preserves Work Capacity in Early Rheumatoid Arthritis (RA) 2035. Joint Distribution and Outcome in 350 Patients with Monoarthritis of Less Than 16 Weeks Duration: Data from a Multicenter Longitudinal Observational Study in Eastern Norway 2036. Biologic Disease-Modifying Antirheumatic Drugs and Risk of High-Grade Cervical Dysplasia and Cervical Cancer in Women with RA 2037. Incidence and Prevalence of Myasthenia Gravis in Rheumatoid Arthritis Patients with and without Treatment Compared with the General Population 2038. Respiratory Cause Mortality Was Significantly Predicted By Incident Rheumatoid Arthritis (RA) and Higher Pre-RA Levels (0.50+ SD) of Soluble Interleukin-2 Receptor Alpha (sil-2rá): Results of a 21-Year Community-Based Cohort Survival Analysis 2039. Among Persons Assayed with Lower Serum Interleukin-1 Beta (IL-1β) Levels, Serum Androstenedione (Δ4A) and Testosterone (T) Were Significantly Lower in a Community-Based Cohort of Rheumatoid Arthritis Multi- Years before Clinical Onset (Pre-RA) Than in Non- 2040. Opportunistic Infections in Patients Treated with Biologic Drug Therapy 2041. Performance of a Two-Step Latent Tuberculosis Screening Algorithm in Patients with Rheumatoid Arthritis, Psoriatic Arthritis or Ankylosing Spondylitis Prior to Treatment with Tumor Necrosis Alpha Inhibitors: Prospective Observational Data from the Biorx.S 2042. Tuberculin Conversion in Patients with Autoimmune Arthropathies Receiving Biologic Therapy 2043. How Correct Are the Assumptions Made for Tuberculosis Screening Algorythms before TNF-Alpha Antagonists? 2044. Systematic Review of the Effect of Anti-Rheumatic Therapies upon Vaccine Immunogenicity Epidemiology and Public Health (ARHP) 2045. Interaction Effects Between Genes and Blood Lead Level on a Composite Score of Multiple Joint Symptoms: The Johnston County Osteoarthritis Project 2046. Perceived Discrimination in Individuals with Radiographic Knee and Hip Osteoarthritis 2047. No Association of Serum Uric Acid with Hip Fracture Risk in Older Men and Women from the Framingham Original Cohort 2048. Disability in Discretionary Valued Life Activities and Self- Efficacy Explain a Significant Portion of RA Patients Global Assessments 2049. Fatigue Is a Risk Factor for Subsequent Functional Decline in SLE 2050. Knee Arthritis Is Positively Associated with Physical Impairment: Conclusion Based on Physical Examinations from a Cross-Sectional Study of 17708 Chinese Residents 2051. Modification of Effects of Household Income and Homeownership By Block Group Poverty on Health Outcomes in a Cohort of African Americans with Rheumatoid Arthritis 2052. Foot and Ankle Characteristics Associated with Falls in Adults with Rheumatoid Arthritis 2053. Mortality Decreases in Patients with Rheumatoid Arthritis: a 15-Year Prospective Cohort Study 2054. Physical and Mental Functioning in Patients with Established Rheumatoid Arthritis over an 11-Year Followup Period: The Role of Specific Comorbidities Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes: Research Focus 2055. Are There Immunological Abnormalities in Fibromyalgia Patients: Flow Cytometry Analysis 214 2014 Program Book
ACR POSTER INDICES 2056. Fibromyalgia Symptoms Beyond the Pain and Its Impact on the Patient 2057. Electrophysiological Evaluation of Autonomic Nervous System and Cutaneous Silent Period in Patients with Fibromyalgia Syndrome 2058. The Impact of Environmental Stress on Pain in Fibromyalgia Patients 2059. Muscle Tension Is Increased in Fibromyalgia 2060. Do Fibromyalgia Patients Have a Distinct Sleep Signature? 2061. Unexpectedly High Prevalence of Immunoglobulin Deficiency in Fibromyalgia 2062. WITHDRAWN 2063. Analysis of the Fibromyalgia Rapid Screening Tool Spanish Version to Detect Fibromyalgia in Primary Health Care Centers 2064. Assessment of the Spanish Version of the American College Rheumatology Preliminary Diagnostic Criteria for Fibromyalgia 2065. A Cross-Sectional Analysis of Psychological Symptoms, Sleep Quality, and Functional Balance in Fibromyalgia 2066. Ultra Orthodox Religious Orientation Associated with Reduced Rates of Pain, Anxiety and Fatigue in a Population Based Study 2067. Understanding the Factors Influencing Time to Diagnosis in Fibromyalgia 2068. Joint Hypermobility Syndrome and Postural Orthostatic Tachycardia Syndrome (HyPOTS) 2069. Investigation of the Effects of Physical Exercise on the Control Mechanisms of Cutaneous Circulation in Patients with Fibromyalgia Syndrome 2070. Elevated Serum Leptin Concentrations in a Subset of Fibromyalgia Patients with High Inflammatory Markers 2071. Chronic Widespread Pain Versus Multi-Site Pain: Does the Distribution Matter? 2072. Ultrasound Assessment of Both Hands in Fibromyalgia Patients: What Could We Detect? 2073. Is Susceptibility to Fibromyalgia a Trait? 2074. Hypervigilance and FMS 2075. The Lumbar Spine in Fibromyalgia 2076. Predictive Modeling of a Fibromyalgia Diagnosis: Increasing the Accuracy Using Real World Data 2077. A New Tender Point on the Plantar Arch in Primary Juvenile Fibromyalgia: A Potential Point to be Considered 2078. A Proposed Simple 3-Variable Index for Identification of Fibromyalgia, Analogous to Classification Criteria for RA and SLE 2079. The Association Between Straight Neck and Fibromyalgia 2080. Carryover Effects in Crossover Design Studies in Fibromyalgia and Other Pain Conditions 2081. Ehlers-Danlos Hypermobile (EDS-HT) Patients and Postural Instability : Another Clue to Explain Pain and Fatigue? 2082. Presence of Acrocyanosis in Patients with Joint Hypermobility 2083. Evaporative Dry-Eye Disease and Aqueous Deficient Dry- Eye Disease Associated with Fibromyalgia Genetics, Genomics and Proteomics 2084. Are Genetic Markers Associated with Myocardial Infarction in Patients with Early Rheumatoid Arthritis? 2085. Association of Circulating Mirnas with Spinal Involvement in Patients with Axial Spondyloarthritis 2086. Replication of PTPRC As Genetic Biomarker of Response to TNF Inhibitors in Patients with Rheumatoid Arthritis 2087. Defective Regulation of L1 Endogenous Retroelements in Primary Sjögren s Syndrome and Systemic Lupus Erythematosus: Role of Methylating Enzymes 2088. Association of TNFAIP3 Gene Polymorphisms with the Risk for RA and Prediction of Therapy Outcome of TNFα- Blocker Treatment 2089. The APOL1 Gene Is Not Associated with Lupus Nephritis in Individuals with Enriched Amerindian Ancestry 2090. Contribution of MTHFR Gene Polymorphisms in Sjögren s Syndrome Related Lymphomagenesis 2091. Plasma Microparticle Protein Features Distinctively Classify Systemic Lupus Erythematosus and Systemic Sclerosis and Their Clinical Phenotype 2092. Proteomic Phenotyping of Rheumatoid Arthritis Disease Activity 2093. Improvement of Rituximab Response Prediction in Rheumatoid Arthritis Via Correction for Prednisone- Related Suppression of Type I Interferon Response Gene Expression 2014 Program Book 215
ACR POSTER INDICES 2094. Deep Sequencing Reveals Differential RNA Expression during Malignant Transformation in Major Salivary Glands in a Mouse Model of Sjögren s Syndrome 2095. Two Novel Serum Urate Levels Associated Genetic Loci Identified By GWAS in European Were Confirmed in Chinese Han Population 2096. Assessment of RA Heterogeneity in Two Independent Cohorts of Patients 2097. Identification of Diagnostic and Activity Metabolomic Urine Biomarkers in Six Immune-Mediated Inflammatory Diseases 2098. Genetic Variants of the NLRP3 Inflammasome Are Associated with Stroke in Patients with Rheumatoid Arthritis 2099. Serum C-X-C Motif Chemokine 10 (CXCL10) Is Elevated in Psoriasis Patients Prior to Psoriatic Arthritis Onset 2100. Activation of NFkβ Pathways in Sjögren s Syndrome Related Lymphomagenesis-Role of the His159Tyr Mutation of the BAFF-R Receptor 2101. Epigenetic Study of Advanced Ankylosis in Patients with Ankylosing Spondylitis 2102. A Tissue-Specific Lincrna in the TRAF1-C5 Risk Locus As a Putative Cis-Regulator, Bridging Genetics and Disease Health Services Research 2103. Benefits of Early Onset of DAS28 (CRP) <2.6 on Physical Functioning, Quality of Life and Resource Use Among RA Patients in a Clinical Practice Setting 2104. Effectiveness of a Workplace Integrated Care Intervention on Work Productivity in Workers with Rheumatoid Arthritis 2105. Nonsurgical Treatment Patterns in Patients with Chronic Spinal Cord Injury 2106. Surgical Compared with Nonsurgical Management of Fractures in Men with Chronic Spinal Cord Injury 2107. Characterization of Social Stigma in Rheumatic Diseases and Correlation with Quality of Life and Medication Adherence 2108. Anxiety in Caregivers of Patients with Chronic Rheumatic Conditions 2110. WITHDRAWN 2111. Overcoming Barriers to Acute Patient Access: Is There a Need for Urgent Care Clinics in Rheumatology Practices? 2112. Patterns of Medication Use Before, During, and After Pregnancy Among Women with Systematic Lupus Erythematosus: A Population-Based Study 2113. The Number of Morbidities Drives the Health Care Expenditures and Presence of a Musculoskeletal Condition Is Additionally Accountable for Higher Costs 2114. Comorbidity Characteristics of Patients Starting First- Line Acute Gout Agents - Colchicine, NSAID, and Corticosteroids 2115. Inflammatory Arthritis Treatment Outcomes at a First Nations Reserve Rheumatology Specialty Clinic 2116. Hospitalization Rates and Utilization Among Rheumatoid Arthritis Patients: A Population-Based Study from 1987 to 2012 2117. Association Between Depression and High Utilization of Emergency Department in Patients with Systemic Lupus Erythematosus from the Southeastern United States: The Goal Cohort 2118. Lower Socioeconomic Status at Disease Onset Is Associated with Higher Health Care Costs in Patients with Systemic Lupus Erythematosus: A General Population- Based Cohort Study 2119. Off Work Days Decreased RATE in Muskuloeskeletal Disease Patients: Usefulness of the EARLY Intervention Program 2120. Societal Preferences for Rheumatoid Arthritis Treatments. Evidence from a Discrete Choice Experiment 2121. Real-World Cost Comparison of Urate Lowering Therapies in Patients with Gout and Moderate to Severe Chronic Kidney Disease 2122. Variation in the Prescribing Practices of Biologic Dmards 2123. Significant State-Level Variation in Source of Biologic Drug Coverage Among Beneficiaries with Rheumatoid Arthritis 2124. Characteristics of Medicare Beneficiaries Travelling Long Distances to Visit a Rheumatologist 2125. Burden of Illness in Refractory Gouty Arthritis: A One-Year Prospective Multinational, Observational Study 2109. Are Patient Ratings of Providers and Health Plans Associated with Technical Quality of Care in SLE? 216 2014 Program Book
ACR POSTER INDICES Imaging of Rheumatic Diseases: Various Imaging Techniques 2126. The Utility of Digital Activity Fluorescence Optical Imaging in Quantifying Hand and Wrist Inflammation in Rheumatic Diseases 2127. Subclinical Arthritis Is Detected By Macrophage Targeting and Positron Emission Tomography (PET) in Early RA Patients in Clinical Remission 2128. Effectiveness of 18f-Fluoro-Dexoxyglucose Positron Emission Tomography for the Diagnosis of Polymyalgialike Illness 2129. Sensitivity and Specificity of the Green Nail Sign in Fluorescence Optical Imaging in Psoriatic Arthritis 2130. Bone Microstructure in Patients with Cutaneous Psoriasis and No History of Psoriatic Arthritis Shows Bone Anabolic Changes at a Greater Extent Than in Healthy Controls 2131. The Impact of Patient-Reported Flares on Radiographic Progression in Rheumatoid Arthritis Patients with Low- Disease Activity: Secondary Analyses from a Randomized Trial 2132. What Is Associated with X- Ray Progression at 5 Years in Rheumatoid Arthritis (RA) Patients in Low Disease Activity? 2133. Efficacy of Tocilizumab Therapy in Patients with Rheumatoid Arthritis Based on FDG-PET/CT 2134. Baseline Scintigraphic Detection of TNFá As a Predictor of Therapy Response after Treatment with Certolizumab Pegol in Rheumatoid Arthritis and Spondyloarthritis Patients 2135. Patients with Moderate Disease Activity in the First 5 Years of Rheumatoid Arthritis Still Progress Radiographically Despite Conventional Disease Modifying Therapy 2136. Rheumatoid Arthritis Erosion Detection and Measurement in Longitudinal Datasets Using High-Resolution Peripheral Quantitative Computed Tomography 2137. Linear Extrapolation of Missing Radiographic Progression Scores Does Not Spuriously overestimate overall Radiographic Progression in Rheumatoid Arthritis 2138. Radiological Outcomes after Two Years of Remission Steered Treatment in Early Arthritis Patients 2139. Predictors of Radiologic Disease Progression during the Rheumatoid Arthritis Comparison of Active Therapies Trial 2140. Agreement Among FDG-PET/CT, Ultrasound and Physical Examination in Patients with Inflammatory Arthritis. 2141. Sensitivity to Change of Joint Space Width Measurements in Hand Osteoarthritis in a Two Year Follow-up Study 2142. Sensitivity and Precision of Automated Osteophyte Volumetric Measurement in Knee Osteoarthritis over Four Years 2143. Cortical Breaks and Bone Erosions in the Hand Joints: A Cadaver Study Comparing Conventional Radiography with High-Resolution and Micro-Computed Tomography 2144. Cuantification of Hand Bone Mineral Density By Radiogrammetry and Dual X-Ray Absorptiometry in Early Arthritis Patients 2145. Diagnostic Performance and Disease Activity Assessment By FDG-PET in Large-Vessel Vasculitis: A Systematic Literature Review and Meta-Analysis 2146. Optimal Hand Position for Reliable Volumetric Joint Space Width Measurements Using High-Resolution Peripheral Quantitative Computed Tomography 2147. Automatically Extracted Quantitative Biomarkers for Assessing Connective Tissue Disease Using Nailfold Capillaroscopy 2148. Dual Energy CT Scanning: Variable Sensitivity for Gout in Non-Tophaceous and Tophaceous Disease and in Individual Erosions 2149. Relationship Between the Magnitude of Bone Formation in the Anterior Vertebral Corners, As Assessed through 18F-Fluoride Uptake, and Lumbar Spine Bone Mineral Density in Patients with Ankylosing Spondylitis 2150. The Craniocervical Junction in Ankylosing Spondylitis: A Computed Tomography Based Study Infections, Infection-related Biomarkers and Impact of Biologic Therapies 2151. Abatacept Related Infections: No Association with Gammaglobulin Reduction 2152. Frequency of Postoperative Deep Infection in Patients with Rheumatoid Arthritis 2153. Clinical Characteristics and Outcomes in Synovial Fluid Culture Negative Septic Arthritis 2154. Risk for Developing Adult T-Cell Leukemia in Patients with Human T Lymphotropic Virus Type-I Carrier Receiving Immunosuppressive Therapy 2155. Chikungunya Fever in Patients Under Biologics 2156. Persistent Arthralgia Following Chikungunya Fever 2014 Program Book 217
ACR POSTER INDICES 218 2157. Tuberculosis Reactivation Risk in Patients Treated with Tumor Necrosis Factor Alpha Inhibitors: A Turkish Experience with Higher Mortality and Different Background Diseases 2158. Severe Neutropenia in Patients with Rheumatic Diseases at a Tertiary Care Hospital in South Korea 2159. Human T-Lymphotropic Virus Type 1 Biomarkers in Patients with Rheumatoid Arthritis 2160. WITHDRAWN 2161. Interest of Systematic Lyme Serology in Context of Recent Onset Arthritis 2162. Immunological Abnormalities in Adult Patients with Parvovirus B19 Infection : A study of 23 Cases 2163. Genetic Variants of TNFAIP3 in Patients with HCV Related Lymphoma Are Associated with the Presence of Rheumatoid Factor (RF) Innate Immunity and Rheumatic Disease: Mediators, Cells and Receptors 2164. Self-Phospholipids Regulate Inflammation Via Activation of CD1d-Restricted T-cells and Induction of antiinflammatory Myeloid-Derived Suppressor Cells (MDSC) 2165. Myeloid-Derived Suppressor Cells in Rheumatoid Arthritis: Friend or Foe? 2166. Bim Suppresses the Development of Glomerulonephritis By Inhibiting M2 Polarization 2167. Snapin Is Critical for Cathepsin D Activation and the Normal Lysosomal Function 2168. Extramedullary Myelopoiesis Drives Persistent Toll-like Receptor-Mediated Inflammation 2169. Targeting ITGAM+ Cells Successfully Treats a Model of Anti-RNP-Associated Pulmonary Hypertension 2170. Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor Are Optimal for Regulatory T Cell Induction-a Comparative Study 2171. Polymorphisms in the FCN1 Gene Coding for M-Ficolin Are Associated with Disease Activity, Radiographic Damage and Are the Strongest Predictors of DAS28 Remission in 180 DMARD naïve Early Rheumatoid Arthritis Patients 2172. PTPN22 Promotes TLR-Induced Amelioration of Arthritis 2173. Role of Natural Killer Cells and Gamma Delta T Cells in Enthesitis Related Arthritis Category of Juvenile Idiopathic Arthritis 2014 Program Book 2174. MicroRNA-146a in Salivary Gland Epithelial Cells Inhibits Co-Stimulatory Molecule CD80 Expression and Increases Autoreactive T Cell Activation in Sjögren s Syndrome 2175. Macrophages from the Synovium of Active Rheumatoid Arthritis Exhibit an Activin a- Dependent Pro- Inflammatory Profile 2176. Macrophages-Mediated Response to Uric Acid Crystals Is Modulated By Their Functional Polarization 2177. Class a Scavenger Receptor SR-a Exacerbated Synovial Fibroblasts-Mediated Inflammation in Rheumatoid Arthritis 2178. Extensive Natural Killer Cell Receptor Phenotyping on NK and T Cells Discloses Differences in RA and Psa, Potentially Mirroring Diverse Immunoregulatory Functions 2179. The Monocyte-Phagocyte System in Gout: Enhanced Inflammasome Activity and Expansion of CD14++CD16+ Monocytes in Patients with Gout 2180. Macrophage Depletion Ameliorates Nephritis Induced By Pathogenic Antibodies 2181. Investigating Myeloid and Plasmacytoid Dendritic Cell Activation within the Synovium and Peripheral Blood of Rheumatoid Arthritis Patients 2182. Investigating the Roles of Factor H-Related Proteins in Systemic Lupus Erythematosus (SLE) and Other Autoimmune Diseases 2183. Release of Enzymatically Active Peptidyl Arginine Deiminases (PADs) By Neutrophils Allows Generation of Citrullinated Extracellular Autoantigens in the Synovial Fluid of Patients with Rheumatoid Arthritis 2184. Selective Consumption of C2 Component in HCV Patients 2185. Alterations in B Cell Complement Processing Related to a Lupus-Associated Variant in Complement Receptor 2 Miscellaneous Rheumatic and Inflammatory Diseases 2186. Clinical and Immunologic Correlates in Cocaine Users with Serum Anti-Neutrophil Cytoplasmic Antibodies 2187. Revisiting RS3PE after Twenty Five Years: A Systematic Review of 250 Cases 2188. Incidence and Mortality of Relapsing Polychondritis in the United Kingdom: A Population-Based Cohort Study 2189. Multicentric Reticulohistiocytosis- Case Series from a Tertiary Care Center 2190. Features of Interstitial Lung Disease Associated with Connective Tissue Disease in a Spanish Southwest Cohort
ACR POSTER INDICES 2191. Intravenous Sodium Thiosulfate for Treatment of Refractory Calcinosis in Rheumatic Disease 2192. Successful Therapy with Intravenous Sodium Thiosulfate for Adult Dermatomyositis Associated Calcinosis 2193. Prevalence of Raynaud s Phenomenon and Nailfold Capillaroscopic Abnormalities in Fabry s Disease: A Cross- Sectional Study 2194. Blue Digit Syndrome: The Rheumatologist s Perspective 2195. Eculizumab Treatment of Malignant Atrophic Papulosis (Köhlmeier-Degos Disease): World Experience to Date 2196. Treprostinil Use in Malignant Atrophic Papulosis (Köhlmeier-Degos Disease): Review of Worldwide Experience to Date 2197. Malignant Atrophic Papulosis (MAP) Complicating Connective Tissue Diseases (CTDs) 2198. The Aromatase Inhibitor Induced Musculoskeletal Syndrome: Is There a Potential Role of Osteoporosis Therapy and Menopause Timing? 2199. Intravenous Immunoglobulin Therapy for Secondary Hemophagocytic Lymphohistiocytosis : A Retrospective Study of 46 Patients 2200. Elevated Serum Ferritin Levels in Adult Inpatients As a Predictor of in-hospital Mortality and Association with Macrophage Activation Syndrome 2201. Haematological Complications in Rheumatic Diseases: Not Only Lymphomas 2202. Pilot Study of Tocilizumab in Patients with Erdheim- Chester Disease 2203. Adalimumab Therapy Improves Insulin Sensitivity in Non- Diabetic Psoriatic Patients: A 6-Month Prospective Study 2204. New Onset Vitiligo Under Biological Agents: A Case Series 2205. Management of Asymptomatic Coccidioidomycosis in Patients with Rheumatic Disease 2206. The Incidence of Zoster in Patients with Cutaneous Lupus Erythematosus and Dermatomyositis Is Increased Compared to the Average U.S. Population 2207. Decreased Bone Mineral Density in Patients with Ehler- Danlos Syndrome 2208. Ovarian Reserve Alterations in Premenopausal Women with Rheumatoid Arthritis, Behcet s Disease and Spondyloarthritis Impact on Anti-Muellerian Hormone Levels 2209. Novel Biomarkers of Extracellular Matrix Remodeling in Inflammatory Bowel Disease: Different Patterns of Gut Injury in UC and CD Muscle Biology, Myositis and Myopathies: Immunological Aspects of Inflammatory Myopathy 2210. Redefining Dermatomyositis: Description of New Diagnostic Criteria That Differentiate Pure Dermatomyositis from Overlap Myositis with Dermatomyositis Features 2211. Epidemiologic and Clinical Features of Patients with Adult and Juvenile Dermatomyositis, Polymyositis and Inclusion Body Myositis from Myovision, a National Myositis Patient Registry 2212. Serum Adipokines in Dermatomyositis: Correlation with Risk Factors Associated to Cardiovascular Diseases and Metabolic Syndrome 2213. Gene Expression Profiling of T Helper Subsets in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with Juvenile and Adult Dermatomyositis 2214. Power Doppler Ultrasonography for Detection of Abnormal Fascial Vascularity: A Potential Early Diagnostic Tool in Fasciitis of Dermatomyositis 2215. Clinical Characteristics and Prognosis of Malignancies Associated with Active Myositis 2216. Muscle Type I Interferon Gene Expression May Predict Therapeutic Responses to Rituximab in Myositis Patients 2217. Ultrasonography Analysis of Carotid Parameters in Patients with Idiopathic Inflammatory Myopaties: Correlation with Demographic Profile and Disease Activity 2218. Endoplasmic Reticulum (ER) Stress-Induced Mitochondrial Dysfunction and Atrophy Can be Prevented By Pharmacological Upregulation of Heat Shock Protein 70 (HSP) in Cultured Murine Myotubes 2219. Contribution of Tripartite Motif Proteins Modulating Membrane Repair to the Pathogenesis of Autoimmune- Mediated Myositis 2220. Overexpression of Ankyrin Repeat Domain Containing Protein 1 Gene (ANKRD1) in Polymyositis Muscle Biopsies Is Correlated to Hypoxia 2221. Reduction of Ovarian Reserve in Adult Patients with Dermatomyositis 2222. Predictors of Myositis Treatments Received and Associated Treatment Responses in Myovision, a National Myositis Patient Registry 2014 Program Book 219
ACR POSTER INDICES 2223. High Prevalence of Hepatitis C Virus Infection in a Japanese Inclusion Body Myositis Cohort 2224. Increased Immune Complex Levels in Children with Juvenile Dermatomyositis Are Not Associated with Levels of Von Willebrand Factor Antigen, C4, Duration of Illness, Disease Activity Score, or the Absolute NK Count 2225. Does Previous Corticosteroid Treatment Affect the Inflammatory Infiltrate Found in Polymyositis Muscle Biopsies? 2226. Systemic Treatment for Clinically Amyopathic Dermatomyositis 2227. Physical Impairment in Patients with Idiopathic Inflammatory Myopathies Is Predicted By the American College of Rheumatology Functional Status Measure 2228. Has MRI an Added Value over Serum Creatine Kinase Measurement in Myositis? 2229. How Often Are Clinically Amyopathic Dermatomyositis Patients Truly Amyopathic? Osteoarthritis - Clinical Aspects: Therapeutics 2230. Treatment of Symptomatic Knee Osteoarthritis with Oral Salmon Calcitonin: Results from Two Phase 3 Randomized Clinical Trials 2231. Combined Chondroitin Sulfate and Glucosamine Is Comparable to Celecoxib for Painful Knee Osteoarthritis. Results from a Multicenter, Randomized, Double-Blind, PHASE IV NON-Inferiority TRIAL 2232. Cost-Effectiveness of Glucosamine, Chondroitin Sulfate, Their Combination, Celecoxib,Non-Selective Non-Steroidal Anti-Inflammatory Drugs, and Placebo in Treating Knee Osteoarthritis 2233. A PHASE 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy Study of Apremilast (CC-10004) in Subjects with Erosive Hand Osteoarthritis 2234. Safety and Efficacy of Liposome Intra-Articular Injection in Moderate Knee Osteoarthritis. a Prospective Randomized Double-Blinded Study 2235. Cost-Effectiveness of Long-Term Opioid Use in the Treatment of Knee Osteoarthritis in Older Patients with Multiple Comorbidities 2236. Plant Derived Products Are Effective for Treatment of OA Pain and Safer Than Other Active Therapies 2237. Interleukin-1 Dual-Variable Domain Immunoglobulin Reduces Multiple Inflammatory Markers in Knee Osteoarthritis Patients 2238. Exploratory Six Month Phase IIa Study of a Potential Disease Modifying Drug in Patients with OA of the Knee 2239. Efficacy of Ketoprofen Lysine Salt in Reducing Inflammation and Pain in Primary Osteoarthritis of the Hand: Preliminary Results of a Retrospective and Prospective Clinical Trial 2240. An Exploratory 4-Week Study of a P2X3 Antagonist AF-219 in the Treatment of Patients with Osteoarthritis (OA) of the Knee 2241. Intermittent Analgesic Use and Risk of Pain Exacerbation in Knee Osteoarthritis: A Web Based Case-Crossover Study 2242. Effects of Intraarticular (IA) Corticosteroid Injections on Bone Markers and Endogenous Cortisol in Patients with Knee Osteoarthritis (OA): A Randomized, Double-Blind, Placebo Controlled Trial 2243. Comparison Between Two Diclofenac Diethylamine Gel Formulations, 1.16% Vs 2.32%: Is It Only Increasing the Strength of the Active Ingredient Enough? 2244. Multimedia Patient Education Tool for Patients with Osteoarthritis 2245. Characteristics of Conventional Footwear and Their Association with Reductions in Knee Loading with a Flexible Footwear Intervention 2246. Reduction of Knee Osteoarthritis Symptoms in a Cohort of Bariatric Surgery Patients 2247. Bariatric Surgery Improves Quality of Life in Patients with Osteoarthritis and Obesity Compared to Non-Surgical Weight Loss 2248. Clinical Outcomes, Neuropathic Pain and Patient Satisfaction over a 15 Year Period Following Primary Tka: A Repeat-Cross-Sectional Analysis 2249. Criteria for Clinically Important Worsening in Knee and Hip Osteoarthritis 2250. The Effects of Treatment on Disease Symptoms and Progression of Structural Changes in Knee Osteoarthritis Participants from the Osteoarthritis Initiative Progression Cohort 2251. Kneeling Disability Associated with the Treatment of Osteoarthritis: Analysis of a Copcord Study in Mexico 2252. Autoimmune Thyroid Disease Is Associated with a Higher Frequency of Spinal Degenerative Disc Disease 220 2014 Program Book
ACR POSTER INDICES Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Osteoporosis: Treatment, Safety, and Long Term Outcomes 2253. Effect of Teriparatide in Patients with Osteoporosis with Prior Vertebral Fracture 2254. Changes in Subject Characteristics in the Denosumab Pivotal Fracture Trial and Its Extension for up to 8 Years 2255. Vertebral Cortical Bone Mass and Structure Significantly Improved with Romosozumab Compared with Teriparatide: HR-QCT Analyses of Postmenopausal Women with Low BMD from a Phase 2 Study 2256. Effects of Pre-Dosage Alendronate Treatment on Bone Metabolic Indices and Bone Mineral Density in Patients Treated with Glucocorticoids: A Prospective Study 2257. How Does Non-Compliance to Prolia (DENOSUMAB) Impact the Change in Bone Mineral Density (BMD) in Osteoporotic Patients? 2258. WITHDRAWN 2259. Changes in serum Soluble RANKL and Osteoprotegerin Levels after Teriparatide Administration in Rheumatic Disease Patients with Glucocorticoid-Induced Osteoporosis 2260. Effects of Daily Teriparatide on the Spine and Femoral Strength Assessed By Finite Element Analysis of Clinical Computed Tomography in Rheumatoid Arthritis Patients 2261. A Meta-Anlaysis of Bisphosphonate and Parathyroid Hormone (PTH) Use in Osteoporosis 2262. Raloxifene for Osteoporosis in Postmenopausal Women with Rheumatic Diseases 2263. Continued Zoledronic Acid Use in a Large Healthcare System 2264. Denosumab for Long-Term Glucocorticoid Users Who Have Inadequate Response to the Bisphosphonates: A 12-Month Randomized Control Trial 2265. Comparative Effects of Raloxifene and Bisphosphonate on Bone Mineral Density and Osteoporotic Fracture Outcomes in Rheumatoid Arthritis Patients 2266. Risk Factors for Treatment Failure in Osteoporotic Patients with Rheumatoid Arthritis 2267. Percentage of Women Achieving Non-Osteoporotic BMD T-Scores at the Spine and Hip over 8 Years of Denosumab Treatment 2268. Odanacatib Anti-Fracture Efficacy and Safety in Postmenopausal Women with Osteoporosis: Results from the Phase III Long-Term Odanacatib Fracture Trial Pediatric Rheumatology - Clinical and Therapeutic Aspects: Systemic Juvenile Idiopathic Arthritis, Spondyloarthropathy and Miscellaneous Pediatric Rheumatic Diseases 2269. Efficacy and Safety of High Dose Infliximab in the Treatment of Uveitis in Pediatric Patients 2270. Changes in Cerebral Blood Flow Velocity in Patients with Familial Mediterranean Fever 2271. Symptom and Treatment Characteristics of Juvenile Primary Fibromyalgia Syndrome: Are Males and Females Created Equal? 2272. Assessment of Transition Readiness in Adolescents and Young Adults with Rheumatic and Other Chronic Health Conditions 2273. Does a Standardized Multidisciplinary Approach Improve Outcomes for Children with NMDA Receptor Antibody Encephalitis? : A Preliminary Assessment of a Single Center Experience 2274. TNF Inhibitors Provide Long-Term Clinical Benefits in 6 Patients with Early-Onset Sarcoidosis 2275. Immunization Status and Barriers in Childhood Rheumatic Diseases 2276. Consensus Statement on the Transition Process from Pediatric Care to Adult Care in Patients with Chronic Inflammatory Rheumatic Diseases with Childhood-Onset 2277. Inpatient Pediatric Rheumatic Diseases: Characteristics, Cost and Trends 2278. Orbital Pseudotumor As the Presenting Symptom of Pediatric ANCA-Associated Vasculitis 2279. Evidence Based Recommendations for Diagnosis and Management of Tumor Necrosis Factor Receptor-1 Associated Periodic Syndrome (TRA) 2280. Evidence Based Recommendations for the Management of Cryopyrin Associated Periodic Syndromes (CA) 2281. Dissecting the Heterogeneity of Macrophage Activation Syndrome 2282. Evidence Based Recommendatinos for Diagnosis and Management of Mevalonate Kinase Deficiency (MKD) 2283. Steroid-Sparing Effect of Anakinra (Kineret ) in the Treatment of Patients with Severe Cryopyrin-Associated Periodic Syndrome 2014 Program Book 221
ACR POSTER INDICES 2284. Joint Involvement in Pediatric Crohn s Disease Is Related to Higher Disease Activity and Worse Quality of Life 2285. Safety and Efficacy of Rilonacept in Patients with Deficiency of Interleukin-1 Receptor Antagonist (DIRA) 2286. Food Allergy and Celiac Disease in Children with Juvenile Idiopathic Arthritis 2287. Cartilage Thickness and Bone Health in Children with Juvenile Idiopathic Arthritis 2288. The Research in Arthritis in Canadian Children Emphasizing Outcomes (ReACCh Out) Cohort: Independent Risk Factors and Medication Use in New Onset Uveitis in Juvenile Idiopathic Arthritis 2289. Accuracy of the Use of Administrative Diagnostic Codes to Identify Pediatric in-patient Musculoskeletal Conditions in an African Tertiary Hospital 2290. Race and Other Risk Markers of Uveitis in a Prospective Cohort of Children with Juvenile Idiopathic Arthritis 2291. Canakinumab in Biologic-naïve Versus Previously Biologic- Exposed Systemic Juvenile Idiopathic Arthritis Patients: Efficacy Results from a 12 Week Pooled Post Hoc Analysis 2292. Demographic, Clinical and Treatment Characteristics of the Childhood Arthritis and Rheumatology Research Alliance Registry Systemic JIA Cohort 2293. Preliminary Results from the Childhood Arthritis and Rheumatology Research Alliance Systemic JIA Consensus Treatment Plans Pilot Study 2294. The Presentation and Initial Treatment of Systemic Juvenile Idiopathic Arthritis According to Observational Data from the United States and the United Kingdom 2295. A Pharmacometric Based Analysis of the Occurrence of Selected Safety Events of Special Interest and Canakinumab Exposure in Systemic Juvenile Idiopathic Arthritis Patients 2296. Tocilizumab Therapy in Children with Systemic Juvenile Idiopathic Arthritis. DATA from Russian Register of Sjia 2297. Efficacy of Canakinumab in Patients with Systemic Juvenile Idiopathic Arthritis (SJIA) using JADAS Criteria - an Analysis of 12-Week Pooled Data 2298. Canakinumab Treatment Shows Maintained Efficacy in Systemic Juvenile Idiopathic Arthritis (SJIA) Patients at Individual Patient Level: An Analysis of 12 Week Pooled Data 2299. M-Ficolin and Masp-2 As Inflammatory Markers in Oligoarticular and Systemic Juvenile Idiopathic Arthritis 2300. Biologic Treatment in Systemic Juvenile Idiopathic Arthritis: Single Center Experience 2301. The New Proposal Classification Criteria for Juvenile Spondyloarthropaties 2302. Classification of Juvenile Spondyloarthropathies According to ASAS Criteria 2303. Clinical Observation on Ankylosing Spondylitis Patients with Different Phenotypes 2304. Positive HLA-B27 in Juvenile Spondyloarthritis Is Associated to Early Sacroiliitis and Progression to Ankylosing Spondylitis Quality Measures and Quality of Care 2305. Improving Screening for Hyperlipidemia in Patients with Rheumatoid Arthritis at an Academic Rheumatology Practice 2306. Quality of Care for Cardiovascular Prevention in RA: Compliance with Diabetes Screening Guidelines 2307. Cardiovascular Disease Prevention in Rheumatic disease: Assessing Screening in a Primary Care Setting 2308. Quality of Care for Cardiovascular Disease Prevention in RA: Compliance Lipid Screening Guidelines 2309. A Novel Approach to Assess Wait-Times to Rheumatologists 2310. Improving Access to Health Care in Rheumatology Practices through Initiation of an Outpatient Urgent Care Clinic, a Paradigm Shift 2311. Tele-Rheumatology: Despite Improved Access Could There be a Potential Delay in Care without a Skilled Presenter? 2312. Use of Physician Extenders to Improve Quality and Efficiency of Clinical Visits 2313. Best Practices for Best Practice Alerts: Evaluation of a Best Practice Alert to Detect Chronic Glucocorticoid Use 2314. Dexa Testing in Long-Term Steroid Use 2315. Glucocorticoid Induced Osteoporosis Screening and Treatment in a Cohort of Male Patients with Underlying Rheumatologic Diagnosis in a Tertiary Care Setting 2316. Adherence to Denosumab in a Large Healthcare System 2317. Towards Reliable Implementation and Optimal Use of Medication Decision Aid Cards for Shared Decision Making in Juvenile Idiopathic Arthritis 222 2014 Program Book
ACR POSTER INDICES 2318. Increasing Rates of Remission in Juvenile Idiopathic Arthritis through a Quality Improvement Learning Network the Pediatric Rheumatology Care and Outcomes Improvement Network 2319. Standardizing and Documenting Patient Education and Disease Indices in Childhood-Onset Systemic Lupus Erythematosus 2320. Initial Benchmarking of the Quality of Medical Care of Childhood-Onset Systemic Lupus Erythematosus 2321. Quality Improvement in the Identification of Crystals from Synovial Fluid: Hospital Laboratory Versus Rheumatology Department Evaluation 2322. Aim for Better Gout Control: A Retrospective Analysis of Preventable Hospital Admissions for Gout 2323. WITHDRAWN 2324. Only 30% Rheumatologists Collect Basdai in Patients with Axial Spa in Daily Practice: The Potential Role of a Consensual Meeting to Improve It Rehabilitation Sciences (ARHP) 2325. A Systematic Review of the Educational Approach of Occupational Therapy for Rheumatoid Arthritis 2326. Investigation of Parameters Used to Test Quadriceps Muscle Power Using Isokinetic Dynamometer in Arthritis 2327. Delivering ESCAPE-Pain (Enabling Self-Management and Coping of Arthritic Pain through Exercise ) - an Online Guide for Healthcare Professionals 2328. The Physical and Psychosocial Effects of Exercise on Chronic Hip and Knee Pain: A Cochrane Review with Meta- Analysis 2329. Course and Outcome of Rehabilitation Care in Different Rheumatological Diagnosis Groups. a Descriptive Study Using the STAR-Etic Registry 2330. Construct Validity of the Adult Myopathy Assessment Tool in Individuals with Inclusion Body Myositis 2331. People s Views, Beliefs and Experiences of Exercise for Chronic Hip and Knee Pain: Cochrane Review with Qualitative Synthesis 2332. Use of Wrist Hand Orthoses during Hand Function Skills and Functional Tasks By Adults with and without Rheumatoid Arthritis 2333. The Natural Use of Activity Pacing in Daily Life Does Not Result in Lower Symptoms in Osteoarthritis 2334. Understanding the Experiences of Rural Community- Dwelling Older Adults in Using a New DVD-Delivered Otago Exercise Programme Research Methodology (ARHP) 2335. Reliability and Validity of the Arthritis Helplessness Index in Systemic Sclerosis 2336. Evaluating the Use of Video-Stimulated Recall to Research the Osteoarthritis Consultation in Primary Care: Reaching Parts Other Methods don t Reach 2337. The Cost and Effectiveness of Various Recruitment Strategies in a Mind Body Clinical Trial Among Older Adults with Knee Osteoarthritis 2338. Cost-Effectiveness and Yield of Different Recruitment Strategies Utilized in an Exercise Trial of Fibromyalgia Patients Rheumatoid Arthritis - Animal Models 2339. Detecting Inflammation in Vivo Using Activatable Fluorescence Contrast Agents in Inflammatory Arthritis 2340. Human Osteoclasts Are Mobilized in Erosive Arthritis of Epstein-Barr Virus-Infected Humanized NOD/Shi-Scid/IL- 2Rγnull Mice 2341. The Combination Therapy of Cell Cycle Regulation Therapy Combined and TNF Blockade Ameliorated the Established Arthritis 2342. Redox Regulation of a New Autoimmune Mouse Model, Glucose-6-Phosphate Isomerase Peptide Induced Arthritis in Mice 2343. Therapeutic Effects of Mesenchymal Stem Cells, Anti- Tumor Necrosis Factor and Anti-CD20 Treatment on Collagen Induced Arthritis 2344. Amelioration of Collagen-Induced Arthritis By Water- Soluble Fullerene C60(OH)36 Nanoparticles through the Inhibition of Angiogenesis 2345. Anti-IL-6 Receptor Antibody Prevents Deterioration in Bone Structure in a Mouse Model of Collagen-Induced Arthritis 2346. Specific Overexpression of FPR2 (FPRL-1) on Th1 Cells in GPI-Induced Arthritis and Patients with Rheumatoid Arthritis 2347. Therapeutic Effect of a Novel Histone Deacetylase 6 Inhibitor, CKD-L, on Collagen Induced Arthritis and Peripheral Blood Mononuclear Cells from Patients with Rheumatoid Arthritis 2014 Program Book 223
ACR POSTER INDICES 224 2348. Activatory Fc Gamma Receptor IV Plays a Crucial Role in Pathogenesis of Experimental Immune Complex Mediated Chronic Arthritis 2349. Early Sympathectomy Inhibits Egress of Lymphocytes in Control and Arthritic Animals and Ameliorates Arthritic Disease 2350. A Humanized Monoclonal Antibody Raised Against a Heat Shock Protein Epitope Suppresses Autoimmune Inflammatory Diseases By Skewing the Immune System Selectively Towards an Anti-Inflammatory Response 2351. Ligand of Glucocorticoid-Induced Tumor Necrosis Factor Receptor Enhances Th17 Cells Response in Collagen- Induced Arthritis Via P38 MAPK and STAT3 Pathway 2352. RORγt Expressing Foxp3+ Regulatory T Cells Regulates the Development of Autoimmune Arthritis in Mice 2353. The Nitric Oxide Receptor Soluble Guanylyl Cyclase Is Found in Lymphatic Vessels of Arthritic Mice and Inhibition Alters Lymphatic Pulse 2354. Efficacy of a Novel Orally Bioavailable JAK1 Selective Compound in a Preclinical Rat Collagen-Induced Arthritis Model 2355. Apremilast, a Novel Phosphodiesterase 4 Inhibitor, and Methotrexate Independently Prevent Inflammation in Vivo and in Vitro 2356. Toluenesulfonylamido-Chalcone, 4-(p-toluenesulfonylamido)-4-Hydroxychalcone (TSAHC) Suppresses Inflammatory Response and Joint Destruction in an Experimental Arthritic Mice and Fibroblast-like Synoviocytes 2357. Vascular Adhesion Molecule-1 Overexpression in Collagen-Induced Arthritis: Modeling Vascular Dysfunction in Rheumatoid Arthritis 2358. The Role of Dendritic Cells during Inflammatory Arthritis 2359. CGEN-15001, a Novel Immunomodulatory Fusion Protein of the B7 Family Induces Immune Tolerance and Shows Efficacy in Mouse Models of Rheumatoid Arthritis and Psoriasis 2360. Glucocorticoids and Vascular Function in Arthritis: Benefic or Deleterious Effects? Study in Rat 2361. the Role of CD146 in the Therapeutic Potential of Mesenchymal Stem Cells in Favor of CD146+ Cells for Experimental Arthritis 2362. Enhanced Efficacy of Dexamethose with Synovial Fibroblast Targeted Micelles in a Collagen-Induced Arthritis Mouse Model 2014 Program Book 2363. Leucine-Rich Alpha-2 Glycoprotein Is a Potential Disease Activity Marker Under IL-6 Suppression in Autoimmune Arthritis 2364. PET-CT Imaging of Joints: A Quantitative Tool for Developing Novel Anti-Inflammatory Drugs Rheumatoid Arthritis - Clinical Aspects: Impact of Various Interventions and Therapeutic Approaches 2365. Comparison of the Effects of a Pharmaceutical Industry Decision Guide and Decision Aids on Patient Choice to Intensify Rheumatoid Arthritis Therapy with Etanercept 2366. Effectiveness, Tolerability, and Safety of Subcutaneous Methotrexate in Early Rheumatoid Arthritis: Clinical Data from the St. Gallen Cohort 2367. Physician Awareness of Suboptimal Patient Adherence to MTX: Results from a Large U.S. Rheumatoid Arthritis Registry 2368. Impact of Physicians Adherence to Treat-to-Target Strategy on Outcomes in Early Rheumatoid Arthritis 2369. Management of Perioperative Tumor Necrosis -á Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis 2370. Management of Perioperative Tumor Necrosis Factor α Inhibitors in Rheumatoid Arthritis Undergoing Arthroplasty: A Systematic Review and Meta-Analysis 2371. Efficacy of First Line Biological Monotherapy in RA: Data from the Czech Registry Attra 2372. Fatigue and Related Factors in Patients with Rheumatoid Arthritis Treated with Tocilizumab in Daily Clinical Setting 2373. Compliance in the Rheumatoid Arthritis Comparison of Active Therapies Trial: Triple Vs Etanercept 2374. Use of Hydroxychloroquine Associated with Improved Lipid Profile in Rheumatoid Arthritis Patients 2375. Should Physician Reduce patients Glucocorticoids to Offset the Risk of Serious Infection Event Among RA Patients Who Switched from Non-Biologic Dmards and Glucocorticoid to Biologics? 2376. Safety of Rapid Rituximab Infusion in Rheumatoid Arthritis in a Single Community Practice 2377. A Pilot Randomized Controlled Trial of a Tailored Smoking Cessation Intervention for Rheumatoid Arthritis Patients 2378. Ethnic Minorities with Rheumatoid Arthritis Achieve a Meaningful Clinical Response at 12 Months Despite Infrequent Use of Biologic Therapies
ACR POSTER INDICES 2379. Minimal Radiographic Progression in RA Patients Receiving Routine Care in the Espoir Early Arthritis Cohort: Similar Prognosis According to 6 Different Remission Criteria 2380. Durability of First Biologic Is Not Influenced By Initial/ Early DAS28 2381. Adherence to a Treat-to-Target (T2T) Strategy in Early Rheumatoid Arthritis. Is It Feasible in Daily Clinical Practice? 2382. Adherence to Dmards in the First Six Months of Treatment in Early Arthritis Patients; Comparing Three Adherence Measures 2383. The 12-Years Retention Rate of the First-Line TNF-Inhibitor in the Treatment of Rheumatoid Arthritis: Real-Life Data from a Local Registry 2384. Factors Associated with Methotrexate Treatment Duration, Including Subcutaneous Use, in Patients with Rheumatoid Arthritis: Observations from the VA Database 2385. Reasons for Non-Vaccination in Rheumatoid Arthritis and Spondyloarthritis Patients 2386. Patients Interpretations of Rheumatoid Arthritis Model Disease States in a Safety-Net Rheumatology Clinic 2387. Relation Between Disease Activity Indices and Their Individual Components and Radiographic Progression in Rheumatoid Arthritis: A Systematic Literature Review 2388. DMARD Use after an Initial Acute MI Is Associated with Reduced Risk of a Recurrent Event and Mortality 2389. MRI Osteitis at Baseline Predicts the Development of Rapid Radiographic Progression at 1 Year Toward Patients with Early-Stage Rheumatoid Arthritis 2390. Determinants and Impact of Early Initiation of Disease- Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis 2391. Sustained Rheumatoid Arthritis Remission and Low Disease Activity: Analysis of 13 Years of Follow up in Clinical Practice 2392. Anti-Carbamylated Antibodies (anti-carpa) Are Associated with Long Term Disability and Increased Disease Activity in Patients with Early Inflammatory Arthritis: Results from the Norfolk Arthritis Register (NOAR) 2393. Similar Improvements in Physical Function, Quality of Life and Work Productivity Among Rheumatoid Arthritis Patients Treated with 2 Different Doses of Methotrexate in Combination with Adalimumab 2394. Sustained Remission Improves Physical Function in RA Patients Treated with Tumor Necrosis Factor Inhibitor 2395. Understanding Patient Preferences Associated with the Use of Therapies for Rheumatoid Arthritis: Results of a Conjoint Analysis 2396. Treat to Target in Routine Clinical Practice 2397. Improvement of Fatigue in Patients with Rheumatoid Arthritis Treated with Biologics: Relationship with Sleep Disorders, Depression and Clinical Efficacy. a Prospective, Multicenter Study 2398. Continued Participation in a 10-Year Tight Control Treatto-Target Study in Rheumatoid Arthritis: Why Keep Patients Doing Their BeSt? 2399. Non-Adherence to Disease-Modifying Anti-Rheumatic Drugs in Patients with Rheumatoid Arthritis: An Italian Survey 2400. Comparing a Tapering Strategy to the Standard Dosing Regimen of TNF Inhibitors in Patients with Rheumatoid Arthritis in Remission or with Low Disease Activity 2401. Interrupted and Delayed Care in First Nation Patients with Rheumatoid Arthritis: The Best Target for Therapy? 2402. Evaluation of Perceived Self-Efficacy, Learned Helplessness and Functional Capacity in Patients with Rheumatoid Arthritis 2403. From Early Arthritis Clinic to Remission Clinic: Short-Term Outcome and Ultrasonographic-Synovitis Dynamics in Rheumatoid Arthritis Patients in DMARD-Induced SDAI- Remission during Drug-Free Follow-up 2404. RA Patients with Inadequate Response to Oral MTX Maintain Satisfactory Disease Control and Durable Long- Term Response When Switched to SC MTX Monotherapy 2405. Quality of Patient- Clinician Communication in a Diverse Cohort of Adults with Rheumatoid Arthritis 2406. Primary Non-Adherence, Associated Clinical Outcomes and Healthcare Resource Utilization Among Rheumatoid Arthritis Patients Prescribed Injectable Biologics 2407. Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes 2408. Frequency of Rheumatoid Arthritis Flares in Clinical Practice: Analysis of a Monocentric Cohort of Patients in Stable Remission or Low Disease Activity 2409. Omega-3 Fatty Acids and Mediterranean Diet As Complimentary Therapies for Rheumatoid Arthritis 2410. Working Status and Improvements in Work Productivity over Time in an Early Rheumatoid Arthritis (ERA) Cohort 2014 Program Book 225
ACR POSTER INDICES 2411. Assessing Treatment Durability of Infliximab in the Management of Psoriatic Arthritis and Rheumatoid Arthritis Patients in a Canadian Setting 2412. Regime of Use of Rituximab in Patients with Rheumatoid Arthritis in Daily Clinical Practice 2413. Similar Response Rates to Anti-Tumor Necrosis Factor and Non- Anti-Tumor Necrosis Factor Biologic Therapies in Ethnic Minority Patients at 6 Months 2414. Etanercept in Mono Therapy or in Combination with MTX: Results from a Sub Analysis of a German Non- Interventional Study 2415. Characteristics of Rheumatoid Arthritis Patients Not Receiving Early Initiation of Disease Modifying Therapy 2416. Do Patterns of Joint Swelling or Tenderness in Rheumatoid Arthritis Patients Impact Disease Activity Outcomes and Pain? Implications for Clinical Practice 2417. Is Remission Really Achievable in EARLY Rheumatoid Arthritis? 2418. Treatment Pattern and Direct Cost of Biologics for Rheumatoid Arthritis Patients: A Real-World Analysis of Nationwide Japanese Claims Data 2419. Efficacy of Biologic Medications in Active Rheumatoid Arthritis: A Systematic Review 2420. Quality Assessment of Controlled Trials Evaluating Chinese Herbal Medicine in Patients with Rheumatoid Arthritis: a Systematic Review 2421. Patient Treatment Goals in Rheumatoid Arthritis: Results of Focus Groups Among Rheumatologists, English and Spanish-Speaking Patients 2422. A Tailored Approach to Reduce Dose of TNF Inhibitors Is Equally Effective, but Substantially Less Costly Than Standard Dosing in Patients with Rheumatoid Arthritis over One and Two Years: A Prospective Cohort Study 2423. Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration 2424. Comparison of Medication Use in Rheumatoid Arthritis Patients Between University and Private Settings Results from Ontario Best Practice Research Initiative 2425. Rheumatoid Arthritis Stable Follow up Visits 3 Month Versus 6 Month Intervals 2426. Comparison of Patient Self-Reported and Physician Reported Rheumatoid Arthritis Medication Use - Results from the Ontario Best Practices Research Initiative 2427. Attainment of Low Disease Activity Is Predictive of Maintenance of Disease Control upon Adalimumab Discontinuation for Two Years Following Combination Therapy in Japanese Patients with Early Rheumatoid Arthritis 2428. Comparative Study of Rheumatoid Arthritis Disease Activity Indices in Two Populations of Meteor Database 2429. Seasonal Changes May Influence Activity of Rheumatoid Arthritis Clinical Practice/Patent Care (ARHP) 2430. Serological and Clinical Characteristics of a Large Collection of Incomplete Lupus Erythematosus Patients 2431. Tai Chi and Yoga Are Effective for Improving Physical Function in Adults with Rheumatoid Arthritis- a Meta- Analysis 2432. Nutritional Assessment in Patients with Systemic Lupus Erythematosus and Systemic Sclerosis 2433. Efficacy of Ketoprofen Vs Ibuprofen and Diclofenac for Treating Pain in Patients with Rheumatoid Arthritis: A Systematic Review and Meta-Analysis 2434. Gait Instability in the Elderly: A New Dedicated out- Patients Consultation 2435. It s like the Worst Toothache You ve Ever Had How Persons with Rheumatoid Arthritis Describe and Manage Pain in Daily Life 2436. Analytical and Clinical Evaluation of an Immunoassay for Estimating Immunogenicity of Infliximab and Etanercept in Indian Population 2437. Why Doesn t Participation in Activity Increase Following Hip or Knee Replacement? 2438. A Multi-Centre Survey of Tolerability Problems for Patients on Regular Methotrexate 2439. Knee Joint Pathology in Patients with Rheumatoid Arthritis and Osteoarthritis Using a Validated Ultrasound Scoring System: A Cross Sectional Study 2440. Factors Influencing Health Related Quality of Life (HR- QOL) for Korean Patients with Rheumatoid Arthritis 2441. Prevalence and Determinants of Treatment Adherence Among Patients with Rheumatoid Arthritis 2442. Aligning Ethics with Digital Health Technologies and Shared Decision-Making: Interview Accounts of Patients and Clinicians 226 2014 Program Book
ACR POSTER INDICES 2443. A New Meta-Analysis on Safety of Ketoprofen Vs Ibuprofen and Diclofenac: Risk and Benefit of Nsaids Beyond Efficacy Meta-Analysis 2444. Pharmacist-Developed Letters May Enhance Success in Obtaining Insurer Approval for Off-Label Use of Biologics Rheumatoid Arthritis - Human Etiology and Pathogenesis 2445. A Distinct Profile of Circulating Microparticles Is Associated with Disease Features in Rheumatoid Arthritis Patients and Impairs Endothelial Functionality in Vitro 2446. DNA Methylation Profiles That Distinguish Rheumatoid Arthritis from Osteoarthritis in Fibroblast-like Synoviocytes Can be Detected in Immune Cells from Peripheral Blood 2447. The Role of TET3-Mediated DNA Demethylation By Pro- Inflammatory Cytokines in Rheumatoid Arthritis 2448. DNA Methylation Analysis of Lymph Node Stromal Cells of Rheumatoid Arthritis Patients 2449. Microrna-346 Regulation of Follicular Helper T Cells Is Involved in the Pathogenesis of rheumatoid Arthritis Disease 2450. Downregulation of Mirna-196a and Its Downstream HOXC8 Target Gene in Rheumatoid Arthritis Synovial Fibroblasts 2451. Mir-155 Expression Correlates with Clinical Disease Activity and Has Effector Function in Rheumatoid Arthritis 2452. Protective Effect of the IL33 rs3939286 Gene Polymorphism in the Development of Subclinical Atherosclerosis in Patients with Rheumatoid Arthritis 2453. High-Density Genotyping of Risk Loci in African Americans with RA 2454. Genetic Influences on Rheumatoid Arthritis in African- Americans 2455. IL-6 Proximal Promoter SNP rs18000795 Genotype Strongly Correlates with Synovial Fibroblast IL-6 Expression 2456. Associations of Toll-like Receptor (TLR)-4 Single Nucleotide Polymorphisms and Rheumatoid Arthritis Disease Progression 2457. Anti-Major Histocompatibility Complex Class I-Related Chain a (MICA) Antibodies in Rheumatoid Arthritis Patients with Interstitial Lung Disease 2458. Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome Alteration in Peripheral Blood By RA Treatments 2459. Osteoprotegerin CGA Haplotype Protection Against Cerebrovascular Complications in Anti-CCP Negative Patients with Rheumatoid Arthritis 2460. Phospho-STAT1/3 and Gene Expression Measurement in Circulating CD4+ T Cells As Diagnostic Tools in Early Autoantibody-Negative Rheumatoid Arthritis 2461. Osteprotegerin Concentrations Are Independently Related to Established Cardiovascular Disease in Rheumatoid Arthritis 2462. Centrosomal Protein 70kDa Is Down-Regulated By Decoy Receptor 3 in Specifically Rheumatoid Synovial Fibroblasts 2463. Stromal Cell Markers Are Differentially Expressed in the Synovial Tissue of Patients with Early Arthritis 2464. Anti-Arthritic Effect of Tubastatin A, a Novel Histone Deacetylases-6 Inhibitor, Is Mediated By Stabilization of IkB Via Suppression of Ubiquitin-Proteasome Pathway 2465. Cyclic Phosphatidic Acid (cpa) Suppresses MMP-3, a Disintegrin and Metalloproteinase with Thrombospondin Motifs(ADAMTS)-4, -5 and Stimulates HAS2 Expression in Inflammatory Rheumatoid Synovial Fibroblasts Induced with IL-1β and/or TNF-α 2466. Increased Risk of Rheumatoid Arthritis (RA) Among Shared Epitope-Negative (SE-) Mothers with Shared Epitope-Positive (SE+) Children Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Therapeutic Strategies, Biomarkers and Predictors of Outcomes in Rheumatoid Arthritis 2467. Effectiveness and Safety of Tocilizumab in Biologics Naïve RA Patients - Interim Analysis of S for Investigating Success in Achieving Clinical and Functional Remission and Sustaining Efficacy with Tocilizumab in Biologics-Naïve RA Patients Study 2468. Stringent Criteria for Low Disease Activity and Remission after 12 Months of Treatment, and after Treatment Withdrawal, with Abatacept Monotherapy, Abatacept with Methotrexate or Methotrexate Alone in Early Rheumatoid Arthritis 2469. The Efficacy and Safety of Tocilizumab Subcutaneous Q2W and Following Escalation from Q2W to QW Therapy in Combination with Traditional Dmards in Patients with Moderate to Severe Rheumatoid Arthritis at 96 Weeks 2470. Treatment Strategy for Maximizating the Effect of Adalimumab in Japanese Patients with Rheumatoid Arthritis : Retrospective Analyses of Data Collected from the Patient Treated with Adalimumab in Routine Clinical Practice in Hamamatsu Area 2014 Program Book 227
ACR POSTER INDICES 2471. Effect of Teriparatide in Patients with Osteoporosis and Rheumatoid Arthritis 2472. The First, Multicenter, Double-Blind, Randomized, Parallel-Group Study of Certolizumab Pegol in Early Rheumatoid Arthritis Demonstrates Inhibition of Joint Damage Progression 2473. Post-Marketing Surveillance of Efficacy and Safety of Tacrolimus Add-on Therapy in Japanese Rheumatoid Arthritis Patients Who Failed to Show an Adequate Response to Biological Dmards : Interim Analysis 2474. Efficacy and Tolerability of Subcutaneous Methotrexate for Inflammatory Arthritis: A Retrospective Observational Cohort Study 2475. Multiple Approaches for Implementation of Long-Term Efficacy: Interpretation of Certolizumab Pegol Data in Rheumatoid Arthritis Case Study 2476. WITHDRAWN 2477. Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis 2478. Analysis of the Clinical Sustained Response after Retreatment with a Lower Dose of Rituximab in Patients with Chronic Inflammatory Arthropathies 2479. Utility of Adjustment of Administration Interval in Tocilizumab in Rheumatoid Arthritis 2480. Is there a Difference in the Effectiveness in the Treatment of Rheumatoid Arthritis with Rituximab when Using a Dose of 1 or 2 Grams per Cycle? a Systematic Review 2481. Which Factors Influence the Prescription of Tocilizumab Alone or in Combination with DMARDs in Rheumatoid Arthritis Patients in a Real Life Setting?: An Interim Analysis of Safety and Efficacy at 6 Months 2482. Use of Biologic Therapy As Monotherapy in Patients with Rheumatoid Arthritis 2483. Treatment Adjustment Strategy after Achieving Remission or Low Disease Activity in Rheumatoid Arthritis : A Systematic Review and Meta-Analysis 2484. Adding an Initial Six-Month Course of Infliximab to an Active Combination Treatment Is Cost Saving in Working- Aged Early Rheumatoid Arthritis Patients 2485. Predictors of Drug-Free Remission Following Treatment with Abatacept (in Combination with Methotrexate or as Monotherapy) in Early Rheumatoid Arthritis 2486. Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis 2487. Effects of Tofacitinib on Health Care Resource Utilization and Work Productivity in US Patients with Rheumatoid Arthritis 2488. Relationship Between Different Clinical Measurements and Patient-Reported Outcomes 2489. Analysis of Early Neutropenia, Clinical Response, and Serious Infection Events in Patients Receiving Tofacitinib for Rheumatoid Arthritis 2490. Assessment of Structural Benefits of SC Abatacept Using MRI in Patients with RA Who Have Failed 1 or 2 TNFs and Correlated with Clinical Outcomes As Measured By DAS28(ESR) 2491. Prognostic Factors for IV Abatacept Retention in Patients Who Have Received at Least One Prior Biologic Agent: 2-Year Results from a Prospective, International, Real- World Study 2492. Does Body Mass Index Impact Long-Term Retention with Abatacept in Patients with RA Who Have Received at Least One Prior Biologic Agent? 2-Year Results from a Real-World, International, Prospective Study 2493. Prediction of Remission and Low Disease Activity in DMARD-Refractory Patients with RA Treated with Golimumab 2494. Persistence on Single Disease Modifying Anti-Rheumatic Drug Therapy in US Veterans with Rheumatoid Arthritis Is Extremely Rare 2495. Impact of Golimumab on Physical Function and Employability of Patients with Rheumatoid Arthritis: 5-Year Data from 3 Phase III Clinical Trials 2496. Predictors of ACR/EULAR Boolean and SDAI Remission in Patients with Established Rheumatoid Arthritis Treated with Anti-TNF: An Analysis from the Prospective, Observational, Biological Treatment Registry Across Canada 2497. Correlation Between Time to Switch and Clinical Response Amplitude to Rituximab in Second Line Treatment in Rheumatoid Arthritis Patients with Treatment Failure to Tumor Necrosis Factor Inhibitors: 3-Year Data from Repeat Observational Study 2498. Characteristics of Responding Versus Non-Responding Moderate Rheumatoid Arthritis Patients Treated with Etanercept Plus Methotrexate 228 2014 Program Book
ACR POSTER INDICES 2499. Early Response Indicator early Predicts Clinical Response to Certolizumab in Rheumatoid Arthritis Patients 2500. Genetic Variation in the TLR5 Locus Is Associated with Anti-TNF Response Among Rheumatoid Arthritis Patients 2501. Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis 2502. Ten Year Follow-up Results of Four Dynamic Treat to Target Strategies in Patients with ACPA Negative Rheumatoid Arthritis 2503. Early Response to Full-Dose Etanercept-Plus-Methotrexate Induction Therapy Predicts Sustained Remission with Reduced-Dose Combination Therapy in Early Rheumatoid Arthritis Patients 2504. Impact of Concomitant Methotrexate on the Enhanced Clinical Efficacy of Abatacept after 24 Weeks in Rheumatoid Arthritis Patients 2505. Long-Term Treatment with Tocilizumab (TCZ) Strongly Suppresses Joint Destruction in Biologic-naïve Patients with Rheumatoid Arthritis (RA) Regardless of Inflammation Status 2506. Decrease in the Number of Peripheral Leukocytes and Neutrophils and Increase of the Percentage of Eosinophils at 4 Week Predict the DAS28-ESR Remission at 24 Weeks after Administration of Tocilizumab 2507. Is There an Autoinflammatory Component in Rheumatoid Arthritis Associated with Better Response to Anakinra (Kineret )? 2508. Tocilizumab Serum Trough Levels and Its Relationship with Disease Activity and Drug Dosage in Rheumatoid Arthritis Patients 2509. ADAM-10 As a Tocilizumab Treatment Predictive Factor in Rheumatoid Arthritis 2510. Good Response to Methotrexate (MTX) and/or MTX Plus Adallimumab (ADA): 3 Yrs Study Results in Patients with Rheumatoid Arthritis (RA) 2511. Predictors of Discontinuation of Biologic DMARD Therapy Due to Remission in Patients with Rheumatoid Arthritis in a National Registry 2512. Golimumab Therapy Retention Rates in Patients with Rheumatoid Arthritis and Seronegative Spondyloarthritis: Data from the Italian Lorhen Registry 2513. The Monitoring of Infliximab Levels at Early Stages Can Predict the Development of Anti-Infliximab Antibodies in a Cohort of Rheumatoid Arthritis Patients Treated with Infliximab 2514. Biological Treatment for Rheumatoid Arthritis (RA): A Fifteen Years Multicentric Overview 2515. Serum Survivin in Early Rheumatoid Arthritis 2516. Reasons and Risk Factor for Discontinuation of Biologic Agents in Rheumatoid Arthritis Patients 2517. Long-Term Clinical, Structural, and Functional Consequences of Not Adopting Treatment in MTX Suboptimal Responders 2518. What Is the Level of Agreement Between Disease Activity Indices and Response Criteria Among Rheumatoid Arthritis Patients Treated with TNF Inhibitors? 2519. Are Patients with Rheumatoid Arthritis Initiating a TNF Biologic Comparable to Patients Initiating a Non TNF? 2520. Patient, Genetic and Disease Factors Influence the Response to the Disease Modifying Anti-Rheumatic Drug Leflunomide 2521. Analysis on Predictors for Long-Term Clinical Efficacies of Golimumab in Patients with Rheumatoid Arthritis 2522. Effect of Infliximab Dose Increase in Rheumatoid Arthritis at Different Trough Concentrations 2523. Are Biologic Agents Effective on the Treatment of Secondary Amyloidosis: A Multicenter Report on Turkish Rheumatoid Arthritis and Ankylosing Spondylitis Patients 2524. Smoking and Response to Rituximab in Anti-CCP Positive and Negative Rheumatoid Arthritis Results from an International European Collaboration 2525. Infliximab Versus Conventional Combination Treatment and Work Loss in Early RA over 7 Years: A Randomized Trial 2526. Efficacy of Biological Therapies in Rheumatoid Arthritis: Graphical Modeling of DAS28 Components Evolution over Time 2527. The Effect of Biological Agents on Work in Patients with Chronic Inflammatory Arthritides: A Meta-Analysis of Randomized Controlled Trials and Controlled Cohorts 2528. Efficacy Meta-Analysis of Randomized Controlled Trials (RCTs) of Biologics in Methotrexate-Naive Patients with Early Rheumatoid Arthritis 2529. Efficacy of Infliximab, Adalimumab, and Tocilizumab Can be Improved Under the Baseline ADAMTS5 Selection 2530. PRE.MARK-TNF Test Based on Iga-Specific Autoantigens Predicts Therapy Response in Rheumatoid Arthritis Patients Treated with TNFα Inhibitors 2014 Program Book 229
ACR POSTER INDICES Sjögren s Syndrome: Clinical Science 2531. Risk of Venous Thromboembolism in Patients with Sjögren s Syndrome: A Systematic Review and Meta- Analysis 2532. Characteristics of Primary Sjögren Syndrome in the Black Population of Martinique 2533. Utility of the American-European Consensus Group and American College of Rheumatology Classification Criteria for Sjögren s Syndrome in Patients with Systemic Autoimmune Diseases in the Clinical Setting 2534. Ocular Surface Temperature in Early Sjögren s Syndrome and Established Disease 2535. Performance of the Ocular Staining Score (OSS) Vs. the Van Bijsterveld Score in the Assessment of Sjögren s Syndrome-Related Keratoconjunctivitis Sicca 2536. The Sjögren s Syndrome Responder Index, a Data-Driven Combined Endpoint, Could Detect Biologics Efficacy 2537. Diagnostic Accuracies of Sialography and Salivary Ultrasonography in Sjögren s Syndrome Patients: A Meta- Analysis 2538. Ultrasound-Guided Core Needle Biopsy of the Major Salivary Glands Is a Safe and Useful Diagnostic Tool in the Evaluation of Suspected or Established Sjögren s Syndrome 2539. Antibodies to Human Interferon-Inducible Protein-16 Are Present in Primary Sjögren s Syndrome and Systemic Lupus, but Are Rare in Dermatomyositis 2540. Sjö, an Advanced Diagnostic Panel for Detection of Sjögren s Syndrome Autoantibodies 2541. Autoantibodies in Pediatric Sjögren s Patients 2542. La Positive, Ro60 Negative Subset of Primary Sjögren s Syndrome Is a Reality 2543. Anti-Ro/SSA Positive Incomplete Sjögren s Syndrome 2544. How Does a Younger Age at the Onset of Sjögren s Syndrome (pss) Influence the Clinical Presentation and the Clinical Course of the Disease? 2545. Risk of Cervical Root and Incisal Caries in Patients with Sjögren s Syndrome 2546. Metabolic Disorders Causing Fatigue in Sjögren s Syndrome 2547. The Impact of Primary Sjögren s Syndrome on Female Sexual Function 2548. Primary Sjögren s Syndrome Is Associated with Significant Cognitive Dysfunction 2549. Renal Involvement in Primary Sjögren s Syndrome: A Multicenter French Study of 95 Biopsy Proven Cases 2550. Impaired Speckle Tracking As a Marker of Subclinical Left Ventricular Dysfunction in Patients Affected By Primary Sjögren s Syndrome 2551. Presence of Germinal Centers at Baseline Is Associated with Clinical Response of Glandular Essdai Domain after Abatacept Treatment in Primary Sjögren s Syndrome 2552. Effectiveness and Safety of Low-Dose Cyclosporine a in Patients with Primary Sjögren s Syndrome (pss) with Articular Involvement Results of a Pilot Study Spondylarthropathies and Psoriatic Arthritis - Clinical Aspects and Treatment III 2553. Compromised Volumetric Bone Density, Bone Microarchitecture and Bone Strength in Patients with Ankylosing Spondylitis: High-Resolution Peripheral Quantitative Computerized Tomography (HRpQCT) Based Study 2554. Do TNF Alpha Inhibitors Have an NSAID Sparing Effect in Real Life in Early Axial Spa? Results from the DESIR Cohort 2555. The Effect of Co-Medication with Conventional Synthetic (cs)dmards on Achieving Low Disease Activity While Persisting on Adalimumab Therapy in Patients with Ankylosing Spondylitis/ Axial Spondylarthritis (AS) Analysis from the Czech Biologics Registry At 2556. Is the Degree of NSAID Treatment in Early Axial Spondyloarthritis a Reflection of the physician s Diagnosic Confidence? Results from the DESIR Cohort 2557. Are We over-treating with Nsaids Our Early Axial Spa Patients? Results from the DESIR Cohort 2558. Etanercept Increases Bone Mineral Density in Ankylosing Spondylitis, but Does Not Prevent Vertebral Fractures 2559. Vitamin D insufficiency and Deficiency in Two European Cohorts of Patients with Inflammatory Rheumatic Disorders 2560. Sustained Improvements in Workplace and Household Productivity and Social Participation with Certolizumab Pegol over 96 Weeks in Patients with Axial Spondyloarthritis, Including Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis 2561. Low Cardio-Respiratory Fitness Is Associated with Increased Arterial Stiffness in Patients with Ankylosing Spondylitis 230 2014 Program Book
ACR POSTER INDICES 2562. The Comparative One-Year Drug Survival Rate of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid arthritis and ankylosing spondylitis; results from Turkbio Registry 2563. The Distribution of Inflammatory Lesions in the Anterior and Posterior Structures of the Spine in Patients with Active Ankylosing Spondylitis and the Effect of TNF-α- Blockade 2564. Ileocolonoscopic Findings in the Korean Patients with Ankylosing Spondylitis 2565. The Effect of DMARD Co-Therapy on the Clinical Efficacy of Anti-TNF Medications in Patients with Axial Spondyloarthritis 2566. Spinal Mobility in the Cervical and the Lumbar Spine Correlates with Magnetic Resonance Imaging Findings in Patients with Ankylosing Spondylitis 2567. Vascular Endothelial Growth Factor and C-Reactive Protein Serum Levels Lack Predictive Value for Radiographic and Magnetic Resonance Imaging Outcomes in Patients with Active Ankylosing Spondylitis Treated with the Tumor Necrosis Factor-Inhibitor Golimumab 2568. Routine Assessment of Patient Index Data (RAPID3) Provides Similar Information Compared to Ankylosing Spondylitis Specific Indices: Analyses of the DESIR French Cohort 2569. Profiles of Switches in Patient with Ankylosing Spondylitis: Comparing Adalimumab, Etanercept, Infliximab, Golimumab and Certolizumab 2570. Validation of Modified Disease Activity and Functional Status Questionnaires in Spondyloarthritis 2571. Disease Activity and Risk of Cardiovascular Disease in Patients with Ankylosing Spondylitis with High and Low Body Mass Index 2572. Recognition of Spondyloarthritis By General Practitioners in Daily Practice and the Effect of Education on This; A Study with Standardized Patients 2573. Preferences of Patients with Spondyloarthritis for the Items of the ASAS Health Index : A Best Worst Scaling 2574. Do Patients with Axial Spondyloarthritis (AxSpA) Perform Enough Physical Activity? a Cross-Sectional Study of 207 Patients 2575. Validation of the RAPID-3 Questionnaire in a Cohort of Patients with Axial Spondyloarthritis 2576. Diffusing Weight Magnetic Resonance Imaging May Suggest the Treatment Strategy in Ankylosing Spondylitis 2577. The Ankylosing Spondylitis Disease Activity Score More Closely Reflects MRI Parameters of Sacroiliitis Than the Bath Ankylosing Spondylitis Disease Activity Index in Patients with Non-Radiographic Axial Spondyloarthritis 2578. Disease Activity Is the Major Determinant of Quality of Life and Physical Function in Patients with Early Axial Spondyloarthritis. Results from the Esperanza Cohort. 2579. How Should We Calculate the ASDAS If the Conventional C-Reactive Protein Is below the Limit of Detection? an Analysis in the DESIR Cohort 2580. A Comparison of Baseline Characteristics and Real-Life Effectiveness of Anti-TNF Therapy in Non-Radiographic Axial Spondyloarthritis Versus Ankylosing Spondylitis a Single Center Cohort Study 2581. Clinically Active Non-Radiographic Axial Spondyloarthritis Patients Who Initially Have a Negative MRI and Normal CRP May Develop a Positive MRI or Elevated CRP at a Later Timepoint 2582. Serum Levels of Bone Morphogenetic Protein-7 and Sclerostin Are Elevated in Ankylosing Spondylitis, but Not Linked with Structural Damage 2583. Unexpected High Prevalence of Cardiac Disease in Patients with Ankylosing Spondylitis 2584. Smoking Is Not Associated with Response to TNF Blockers in Patients with Axial Spondyloarthritis 2585. Association of Smoking with Acute Phase Reactants and Molecules Involved in Bone Formation in Patients with Ankylosing Spondylitis 2586. Which Characteristics of Inflammatory Back Pain (CBP) Forecast the Presence of Sacroiliitis on Magnetic Resonance Imaging (MRI)? Results from the Esperanza Cohort 2587. Predictors of Treatment Response to Tumor Necrosis Factor-Alpha Blockers in Spondyloarthritis: Systematic Review and Meta-Analysis 2588. Which Characteristics of Inflammatory Back Pain (CBP) Forecast the Presence of HLA-B27? Results from the Esperanza Cohort 2589. EULAR Recommendations for the Use of Imaging in Spondyloarthritis in Clinical Practice 2590. Comparison of Radiographic Damage Score in Ankylosing Spondylitis According to Tumor Necrosis Factor Inhibitor: Observation Study of Korean Spondyloarthropathy Registry (OSKAR) Data 2591. Effects of Self-Management Model on the Disease-Related Knowledge, Joint Function and Quality of Life in Patients with Ankylosing Spondylitis 2014 Program Book 231
ACR POSTER INDICES 2592. Assessment of Spondyloarthritis International Society Endorsed Recommendations for Early Referral of Patients Suspected for Axial Spondyloarthritis 2593. Patients with Non-Radiographic Axial Spondyloarthritis and Ankylosing Spondylitis Demonstrate the Same Clinical Disease Course over Two Years: Results from the Gespic Cohort 2594. Differences in Localization and Activity of the Entheseal Involvement Between Non-Radiographic and Radiographic Axial Spondyloarthritis By the Ultrasound Assessment 2595. Using Iphone Compass Application for the Assessment of Cervical Rotation in Patients with Ankylosing Spondylitis 2596. Similarities and Differences Between Axial and Peripheral Predominant Forms in patients with Early Spondyloarthritis (SpA): Results from the Esperanza Cohort. 2597. Impact of Repeating Imaging of the Sacro-Iliac Joints over One Year on the Classification According the ASAS Axial Spa Criteria of Patients 2598. Disease Characteristics Associated with the Presence of Dactylitis in Patients with EARLY Spondyloarthritis: Results from Esperenza Cohort 2599. Do Patients Diagnosed As Axial Spondyloarthritis (AxSpA) Who Have Primary Inefficacy to Anti-TNF Really Have AxSpA? a Five-Year Follow-up Study of 27 Patients with Primary Inefficacy to Anti-TNF 2600. Gender-Attributable Differences in Outcome of Ankylosing Spondylitis: Long-Term Results from the Outcome in Ankylosing Spondylitis International Study 2601. Serum Biomarkers Associated with Changes in ASDAS and MRI Following Treatment of Ankylosing Spondylitis with Golimumab 2602. Prevalence of Subclinical Atherosclerosis in Patients with Spondyloarthritis without Clinically Evident Cardiovascular Disease Using Carotid Intima-Media Thickness 2603. Short-Term Non-Steroidal Anti-Inflammatory Drug (NSAID) Use Induces Subclinical-Kidney-Injury in Spondyloarthritis Patients: Urinary Biomarker Study 2604. Ankylosing Spondylitis and Non- Radiographic Axial Spondyloarthritis : the Same Syndrome or Different Diseases? Analysis from Esperanza Cohort 2605. Profiling Ankylosing Spondylitis Patients Likely to Respond to NSAID Treatment 2606. How to Classify Spondyloarthritis after a Two Year Follow up? Results from the French Recent onset spondyloarthritis Cohort 2607. Fatigue in Ankylosing Spondylitis: A Multivariable Analysis Implicates Inflammation As the Key Determinant of Disability 2608. Do You Assess Gastro-Intestinal Auto-Antibodies and Symptoms in Patients with Spondyloarthritis? 2609. Treating Axial-Spa to Target: Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) Inactive Disease in a Cohort of Patients Treated with Anti-TNFα Agents 2610. The Role of IL-20 in the Pathogenesis of Ankylosing Spondylitis with Peripheral Joint Involvement 2611. Short Term Efficacy of Tumor Necrosis Factor Inhibitors in Patients with non radiographic Axial Spondylarthritis and ankylosing Spondylitis; Results from Turkbio Registry 2612. Different Performance of the Major Disease Activity Measures ASDAS and Basdai in Patients with Axial Spondyloarthritis Treated with Non-Steroidal Anti- Inflammatory Agents Results from a Prospective Study 2613. Positive Spine MRI for Inflammation Predicts Radiographic Progression in Patients with Ankylosing Spondylitis 2614. Reliability of Electronic Patient Self-Assessment of Swollen and Tender Joints in Psoriatic Arthritis: A Comparison Study with B-Mode Ultrasonography, Physician and Nurse Assessments 2615. Preliminary Assessment of a Multi-Biomarker Disease Activity Test for Axial Spondyloarthritis 2616. Comparison of Characteristics of Ankylosing Spondylitis in Association with Familial Mediterranean Fever with Those of Typical Ankylosing Spondylitis 2617. No Evidence of Accelerated Atheromatosis, Increased Arterial Stiffness or Hypertrophy in Ankylosing Spondylitis: A Systematic Case-Control Study 2618. Impact of Ustekinumab on Active Inflammation and Post-Inflammatory Structural Changes As Detected By Magnetic Resonance Imaging in Patients with Active Ankylosing Spondylitis: Results of a 28-Week, Prospective, Open-Label, Proof-of-Concept Study Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Epidemiology, Women s Health, Cardiovascular and CNS 2619. Low Socioeconomic Status (SES) As Measured By Education Is (not) Associated with Worse Outcome in SLE: Data from the 1000 Canadian Faces of Lupus 2620. Mortality and Survival in Systemic Lupus Erythematosus Patients: Trends in a Spanish Cohort from 1985 to 2013 2621. Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus 232 2014 Program Book
ACR POSTER INDICES 2622. Systemic LUPUS Erythematosus in Spanish Males 2623. Treatment Patterns and Resource Utilization of Systemic Lupus Erythematosus Patients Newly Initiating Standard of Care: United States Commercial and Medicare Supplemental Claims Analysis 2624. Impact of Provider Specialty on the Diagnosis and Management of Systemic Lupus Erythematosus in the American Indian/Alaska Native Population 2625. Work Productivity in Systemic Lupus Erythematosus: Relationship with Clinical Features 2626. Relationship of Socio-Demographic and Disease Factors with Loss-to-Follow-up and Appointment Noncompliance in Indigent Patients with Systemic Lupus Erythematosus 2627. Comparison of Disease Characteristics and Organ Damage in Patients with Juvenile and Adult-Onset Systemic Lupus Erythematosus in Large Cohort from Turkey 2628. Risk of Cancer Is Not Increased in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study 2629. Childhood-Onset and Adult-Onset Systemic Lupus Erythematosus: Distinctions in an Underserved Ethnic Minority Cohort 2630. An Evaluation of Quality of Life of Patients with Systemic Lupus Erythematosus Attending Rheumatology Clinic in Kenyatta National Hospital, Nairobi, Kenya 2631. Overall Cause and Cause-Specific Mortality in a Multinational Inception Cohort of SLE 2632. The Cornerstone to Reasonable Allocation of Health Resource: Valuation of Health Utility in Systemic Lupus Erythematosus 2633. Factors Associated with Damage Accrual and Survival in Chinese Patients with Systemic Lupus Erythematosus (SLE): A Prospective Cohort Analysis of 747 Patients 2634. A Signal of Improvement in Lupus Disease Activity at 3 Months Predicts Further Valid Improvement at 6 Months 2635. Noncalcified Plaque Progression in Systemic Lupus Erythematosus 2636. Vitamin D Improves Endothelial Function in Patients with Clinically Stable Systemic Lupus Erythematosus (SLE) 2637. Assessment of Plaque Thickness and Area in Patients with SLE As Measures of Atherosclerosis - Associations with Disease Activity 2638. The Protective Effects of Statins for Thrombosis in Patients with Systemic Lupus Erythematosus Positive for Antiphospholipid Antibodies 2639. Coronary-Artery Atherosclerosis in Males with Systemic Lupus Erythematosus 2640. Prevalence and Predictors of ECG Cardiovascular Abnormalities in Lupus Patients 2641. Cardiac Magnetic Resonance Imaging in Systemic Lupus Erythematosus 2642. Risk of Cardiovascular Events in Patients with Cutaneous Lupus Erythematosus: A Population-Based Study 2643. Angiogenic and Antiangiogenic Factors in Patients with Systemic Lupus Erythematosus 2644. Carotid Intima-Media Thickness and Plaque in Mexican Mestizos with Systemic Lupus Erythematosus: A Case- Control Study 2645. Long-Term Efficacy and Safety of Pulse Cyclophosphamide for Neuropsychiatric Systemic Lupus Erythematosus: A Two-Centre Experience 2646. Mood Disorders in Systemic Lupus Erythematousus (SLE): Results from an International, Inception Cohort Study 2647. Predictors of Incident Seizure in Systemic Lupus Erythematosus 2648. Prednisone Is a Risk Factor for Incident Depression in Systemic Lupus Erythematosus 2649. Point of Care Neurocognitive Testing for Neuropsychiatric Systemic Lupus Erythematosis (NLE) 2650. Cognitive Impairment in SLE and Non-Criterion Anti- Phospholipid Antibodies 2651. Predictors of Therapeutic Outcomes in Patients with Neuropsychiatric Systemic Lupus Erythematosus 2652. Headache in Patients with Systemic Lupus Erythematosus Is Associated with Reduced Cerebral Grey Matter Volume, but not with Measures of Glial Activation, Anti-NR2-, or Anti-P Antibodies 2653. Clinical Features in Patients with Anti-Triosephosphate Isomerase Antibody-Positive Neuropsychiatric Systemic Lupus Erythematosus 2654. Cognitive Function in Systemic Lupus Erythematosus Patients with Past History of Neuropsychiatric Manifestations : A Longitudinal Study 2655. Cerebral Small Vessel Disease in Systemic Lupus Erythematosus: Histopathological Study 2656. The Burden of Neuropsychiatric Symptoms in Systemic Lupus Erythematosus: Physician s and Patient s Perspectives 2014 Program Book 233
ACR POSTER INDICES 234 2657. Brain Gray and White Matter Volume Losses and Their Associations with Glucocorticoid Use in Patients with Newly Diagnosed Systemic Lupus Erythematosus (SLE) a Prospective MR Study 2658. Cognitive Symptoms and Associated Disease and Non- Disease Related Factors in Patients with Systemic Lupus Erythematosus : A Longitudinal Study 2659. Neurofilament H Is Associated with White Matter Lesions in Childhood-Onset Systemic Lupus Erythematosus 2660. Metabolic Syndrome Features Can Influenciate Cognitive Functions and Brain Lesions in Childhood-Onset Systemic Lupus Erythematosus 2661. Serum Neuronal Biomarkers and Brain Atrophy in Childhood-Onset Systemic Lupus Erythematosus 2662. Attribution Protocol and Clinical Significance of Neuropsychiatric Manifestations in Childhood-Onset Systemic Lupus Erythematosus 2663. Sense of Smell, Anti-Ribosomal P Antibodies and Neuropsychiatric Manifestations in Systemic Lupus Erythematosus 2664. Increased Risk of Hematological Malignancies in Children Born to Women with SLE 2665. Risk of Hydrocephalus and/or Macrocephaly in Children Born to Mothers with SLE 2666. Causes of Stillbirths in Women with SLE 2667. First-Trimester Disease Activity Does Not Predict Pre- Eclampsia in SLE Pregnancy 2668. Maternal Clinical Characteristics of SLE and Pregnancy: Hopkins Lupus Pregnancy Cohort 2669. Systemic Lupus Erythematosus and Lactation: Factors Affecting Infant Feeding Choices in Women with SLE 2670. Premature Delivery in Patients with Systemic Lupus Erythematosus 2671. Impact of Glucocorticoid Dose on Maternal and Fetal Outcomes in Lupus Pregnancies 2672. Characteristics of the Reproductive System in Systemic Lupus Erythematosus: A Cross-Sectional Survey with Pair- Matched Controls Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: T and B Cell Signaling and Genetic Variants 2673. High-Throughput Sequencing of 219 Candidate Genes for Identification of SLE-Associated Risk Variants 2014 Program Book 2674. The Effect and Mechanisms of Icaritin on Regulating Foxp3/IL17a Expression in CD4+ T Cells from SLE 2675. The Selective Loss of SLAMF4+ CD8+ T Cells Contributes to the Decreased Cytotoxic Capacity Observed in Systemic Lupus Erythematosus 2676. The E3 Ligase Casitas B Lineage Lymphoma b (Cbl-b) Modulates Peripheral Regulatory T Cell Function Via p27kip1 in Patients with Systemic Lupus Erythematosus 2677. Decreased Levels of SRSF1 (Serin/Arginine-Rich Splicing Factor1) Induced Lower Levels of RasGRP1 in T Cells from Patients with Systemic Lupus Erythematosus 2678. UC-MSCs Inhibit T Cell Autophagy and Apoptosis in Patients with Systemic Lupus Erythematosus through Mitochondrial Transfer 2679. Mucosal-Associated Invariant T Cell Deficiency in Systemic Lupus Erythematosus 2680. DNA Hydroxymethylation Changes in CD4+T Cells from Patients with Systemic Lupus Erythematosus 2681. Activated SLE-T Cells Enhance the Interferon-Alpha Production By Plasmacytoid Dendritic Cells Stimulated By RNA-IC 2682. Serine Arginine-Rich Splicing Factor 1 (SRSF1) Regulates Transcriptional Activation of the T Cell Receptor CD3 Zeta Chain in Human T Cells 2683. The Discovery of Novel Splicing Variants of Neurogranin and Their Role in the Pathogenesis of Systemic Lupus Erythematosus 2684. Association of Adam33 Polymorphisms with Systemic Lupus Erythematosus 2685. Ten-Eleven Translocation 2 Protein Down-Regulates DNA Methylation of Interleukin-17A Promoter and Induces Its Expression in CD4+t Cells of Patients with Systemic Lupus Erythematosus 2686. Gene Array Analysis Reveals Unique Estrogen Signature in Peripheral Blood Mononuclear Cells of Patients with Systemic Lupus Erythematosus 2687. Estrogen-Mediated STAT1 Activation By Estrogen Receptor a Induces TLR8 Expression: A Novel Pathogenic Mechanism in Systemic Lupus Erythematosus 2688. Comparison of Systemic Lupus Erythematosus and Healthy Anti-Nuclear Antibody Positive African-Americans Reveals Distinct Differences in T Cell and Progenitor Populations 2689. The CUL4CRBN E3 Ubiquitin Ligase Modulator CC-220 Induces Degradation of the Transcription Factors Ikaros and Aiolos: Immunomodulation in Healthy Volunteers and Relevance to Systemic Lupus Erythematosus
ACR POSTER INDICES 2690. Autoregulatory Function of IL-10 Producing Pre-Naïve B Cells Is Defective in Systemic Lupus Erythematosus 2691. A Novel CD123-CD11c- Dendritic Cell Subset Increased in Relation to Disease Activity in Patients with Systemic Lupus Erythematosus 2692. Up-Regulated Expression of CXCR4 on Circulating B Cells in Patients with Systemic Lupus Erythematosus 2693. Hyporesponsiveness to TLR9 in Term of Cytokines Production By B Cells in SLE-Patients 2694. B Lymphocyte Stimulator (BLyS) Promotes Dysregulated Monocyte Function in Systemic Lupus Erythematosus(SLE) 2695. Alterations in B Cell Subsets and BAFF Levels in Autoimmune Rheumatic Diseases Treated with B Cell Depletion Therapy: Rituximab 2696. Relationship Between Soluble scd23 and B Cell Activation Factor in Patients with Systemic Lupus Erythematosus before and after Rituximab Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics: Determinants of Disease, Classification and Response 2697. Gender Disparities in Lung Transplantation in Patients with Systemic Sclerosis-Related Interstitial Lung Disease and Pulmonary Hypertension 2698. Survival in Systemic Sclerosis-Pulmonary Arterial Hypertension By Serum Autoantibody Status 2699. Optimizing Scleroderma Centers of Excellence: Perspectives from Patients and Scleroderma (SSc) Experts 2700. Clinical Phenotype of Systemic Sclerosis Patients with Anti-RNA Polymerase III Antibodies: A New French Cohort, Systematic Review and Meta-Analysis 2701. Relevance of the 6-Minute Walking Test in Assessing the Severity and Outcome of Pulmonary Arterial Hypertension Associated with Systemic Sclerosis, without Extensive Interstitial Lung Disease 2702. Key Roles for Mir-155 and Mir-21 in Progressive Lung Fibrosis Associated with Systemic Sclerosis (SSc-ILD) 2703. Elevated Serum Levels of Endostatin in Mixed Connective Tissue Disease - Association with Pulmonary Fibrosis and Digital Ulcers 2704. Fatigue in Systemic Sclerosis 2705. Reduction of Cerebral and Corpus Callosum Volume in Systemic Sclerosis. a Volumetric Magnetic Resonance Imaging Study 2707. Systemic Sclerosis Related Calcinosis: Patients Provide What Specialists Want to Learn 2708. Post-Occlusive Reactive Hyperemia (PORH) Test Mirrors Vascular Changes in Systemic Sclerosis (SSc):a Laser Speckle Contrast (LASCA) Study 2709. Could a Fibroblast-Free Environment Protect the Microcirculation in Systemic Sclerosis? Evidence from Retinal Vascular Imaging Research 2710. The New ACR-EULAR 2013 Systemic Sclerosis Classification Criteria Show Good Performance in a Capillaroscopy Clinic 2711. Joint and Tendon Involvement Predict Severe Disease Progression in Systemic Sclerosis: A Prospective Study 2712. Nailfold Videocapillaroscopy in Healthy Children and Adolescents: Description of Patterns of Normality 2713. The Relationship of Patient Reported Skin Symptoms to the Scleroderma HAQ, the Modified Rodnan Skin Score and Skin Pathology. 2714. Application of the 2013 ACR/EULAR Classification Criteria for Systemic Sclerosis in Korean Patients with Raynaud Phenomenon 2715. Reliability and Validity of the Duruöz Hand Index in an Argentinian Population with Scleroderma 2716. Development of a Renal Crisis Prevention Card As an Educational Tool Aimed at Improving Outcomes in High- Risk Patients with Systemic Sclerosis 2717. Comparison of PROMIS survey Between Scleroderma Patients in an Academic Center and Patient-Based Scleroderma Foundations 2718. The UCLA Gastrointestinal Tract Questionnaire (GIT)2.0 and GI Visual Analogue Scale(GI-VAS) Reflect Different Aspects of GI Involvement in Systemic Sclerosis 2719. Performance of the New ACR Criteria in Systemic Sclerosis: A Multicenter Study 2720. Prevalence and Features of Metabolic Syndrome in Systemic Sclerosis 2721. Patients Perspective of Skin Involvement in Systemic Sclerosis T cell Biology in Lupus, Vasculitis, Myositis and Other Autoimmunity 2722. Rapamycin Corrects GATA-3 Deficiency in Lupus Treg 2723. Programmed Death 1 Inhibits T-Cell Adhesion By Regulating Rap1 2706. Ulnar and Radial Stenosis in Systemic Sclerosis 2014 Program Book 235
ACR POSTER INDICES 2724. Deficiency of Ro52/TRIM21 in Different Subsets of Peripheral Blood Mononuclear Cells from Patients with Inflammatory Myopathies 2725. Enhanced Expression of CCL25 to Facilitate Increased Numbers of CCR9-Expressing Tfh-like Cells in Salivary Glands of Primary Sjögren s Syndrome Patients 2726. CD28null T Cells from Polymyositis Patients Are Cytotoxic to Autologous Muscle Cells in Vitro Via Perforin- Dependent Mechanisms 2727. T Cells Trigger Interstitial Pneumonia in Polymyositis 2728. Reduction of MAIT Cell Frequency Associated with Reduced Cell Proliferation and Enhanced Cell Death in Systemic Lupus Erythematosus 2729. To Live or Let Die... the Battle Between PD-1 and OX40 on SLE T Cells 2730. FcγRIIIa Ligation in Human Peripheral CD4+ T-Cells Generate TH17 like Population 2731. Th1 and Th17 Cytokines Drive Takayasu Arteritis Inflammation 2732. Massive Ex Vivo Expansion of Functionally Stable Behcet s Patient-Derived Regulatory T Cell Clones 2733. Decreased CXCR3+CCR4-CCR6+ CD4+ Effector Memory T Cells in Patients with Granulomatosis with Polyangiitis 2734. B55β Regulates T Cell Survival through the Modulation of AKT during Cytokine Deprivation 2735. Association of a-kinase Anchoring Protein-79 (AKAP79) to PKC Mediates Inhibition of IL2 Transcription and Erk Activation in T Cells 2736. Female Specific Increase in T Cell Glycosylation in Lupus 2737. Microrna-155 Suppresses IL-21 Signaling and Production in Systemic Lupus Erythematosus 2738. Shk-186, a Kv1.3 channel inhibitor That Targets Effector Memory T Cells: Safety and Tolerability in Humans and Its Evaluation in a Model of Rapidly Progressive Glomerulonephritis 2739. SHP-1 Regulates the Activation Threshold of inkt Cells 2740. Microbiota Modulate Intraepithelial Lymphocyte Presence and Function 2741. The Role of Fli1 in Lupus T Cell Function and Nephritis 2742. Polymorphisms in the Slam Family of Molecules Play a Role in the Development and Function of Invariant Natural Killer T Cells in New Zealand Black Mice Vasculitis 2744. Mi-RNA Profile of Active Vascular BEHÇET S Patients 2745. Plasma of Patients with Active Behçet s Disease (BD) Increases Neutrophil Extracellular Trap Formation, Oxidative Metabolism and NADPH-Oxidase Expression in Normal and BD Neutrophils, and Carries Several Neutrophil Stimulating Factors 2746. The Importance of the Serum Visfatin Levels in Behcet s Disease Patients 2747. Identification of Potential Serum Biomarkers for Behcet Disease By High Resolution Quantitative Proteomic Analysis 2748. Microparticles May Play a Role in Causing Thrombosis in Behçet s Syndrome and Act As a Biomarker for Risk Management 2749. The Clinical Course of Acute Deep Vein Thrombosis of the Legs in Behçet s Syndrome 2750. Effects of Anticoagulant Treatment on the Incidence of New Vascular Events in Patients with Behcet s Disease with Vascular Involvement 2751. 18F-FDG PET/CT in Vascular Disease Due to Behçet s Syndrome 2752. Budd-Chiari Syndrome Due to Behçet s Syndrome: Some Patients Present without Liver Related Symptoms and Have a Better Outcome 2753. Reduced Heart Rate Variability in Patients with Behcet s Disease 2754. Predictors of Quality of Life in Behçet s Syndrome 2755. Disease Activity and Quality of Life in BEHÇET S Disease: The Role of Patients Reportedoutcomes 2756. Treatment of Mucocutaneous Manifestations in Behçet s Disease with Anakinra: A Pilot Open-Label Study 2757. Efficacy and Safety of ANTI-TNF ALPHA in BEHÇET Disease: A International Multicenter Registry of 122 Patients 2758. Predictive Factors for the Response to Infliximab Therapy in Patients with Behçet s Disease 2759. Anti-TNF Treatment for Refractory Vascular Involvement of Behçet s Syndrome 2760. Interferon Alfa-Associated Depression in Patients with Behçet s Syndrome 2761. Increased Risk of Parenchymal Neurological Involvement in Behcet s Syndrome Patients with Panuveitis 236 2743. CD27 Is a Key Regulator of T Cell Responses 2014 Program Book
ACR POSTER INDICES 2762. Atrophy of Hippocampal Region in Chronic Progressive Neuro-Behçet s Disease 2763. Long-Term Outcome of Chronic Progressive Neurological Manifestations in Behcet s Disease 2764. S100B Astrocyte Protein May Serve As a Prognostic Factor in Reversible Cerebral Vasoconstrictive Syndromes 2765. Putative Blood Biomarkers of Reversible Cerebral Vasoconstriction Syndrome 2766. Mycophenolate Mofetil in the Treatment of Primary Central Nervous System Vasculitis 2767. Core Outcome Domains and Potential Measurement Instruments in polymyalgia Rheumatica (R) Using Omeract Filter 2.0 2768. Patient Reported Outcomes and Acute Phase Reactants in Polymyalgia Rheumatica in Patients Treated with Prednisone Versus Modified-Release Prednisone 2769. Validation of New 2012 EULAR/ACR Classification Criteria for Polymyalgia Rheumatica: Comparison with the Previous Criteria in a Prospective Multi-Center Study 2770. Polymyalgia Rheumatica Relapse and Silence Large Vessel Vasculitis. Is There Any Association? 2771. PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica 2772. The Use of Imaging in the Diagnosis of Polymyalgia Rheumatica: Systematic Literature Review and Meta- Analysis 2773. Whole-Body MRI Reveals Characteristic Extracapsular Pattern of Inflammation in Polymyalgia Rheumatica 2774. Why Leg Ulcers Do Not Heal? a Prospective Study Showing High Proportion of Small Vessel Vasculitis 2775. Cutaneous Vasculitis Associated with Severe Bacterial Infections. Study of 27 Patients from a Series of 766 Cutaneous Vasculitis 2776. Drug-Associated Cutaneous Vasculitis: Study of 239 Patients from a Single Referral Center 2777. Clinical-Biological Spectrum and Therapeutic Management of Hypocomplementemic Urticarial Vasculitis: Data from a French Nationwide Study on 57 Patients 2778. Non-Systemic Vasculitic Neuropathy: Presentation, Therapeutic Management and Outcome 2779. Systemic Inflammatory and Autoimmune Manifestations Associated with Myelodysplastic Syndrome: A French Multicenter Retrospective Study 2780. Effectiveness of a Sequential Treatment with Intravenous Prostaglandins Followed By Bosentan in Patients with Buerger Disease and Severe Ischemic Lesions: A Case Series 2014 Program Book 237
INNOVATION THEATER These non-cme accredited presentations have been planned and will be implemented with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. Innovation Theater A Each of the following Innovation Theater presentations will be held in Exhibit Hall A (Booth #139). 10:30-11:15 am Sunday, NOVEMBER 16, 2014 Transforming Infusion Therapy in the U.S. Healthcare System Presented by Janssen Biotech, Inc. 12:30-1:15 pm First in a New Class of JAK Inhibitors for the Treatment of Moderate to Severe Rheumatoid Arthritis Presented by Pfizer, Inc. 2:30-3:15 pm Otezla (apremilast) for the Treatment of Adults With Active Psoriatic Arthritis Presented by Celgene Corporation Innovation Theater B Each of the following Innovation Theater presentations will be held in Exhibit Hall A (Booth #1401). Sunday, NOVEMBER 16, 2014 11:30 am - 12:15 pm The Role of IL-6 in Rheumatoid Arthritis: What Have We Learned So far? Presented by Regeneron Pharmaceuticals 1:30-2:15 pm When Is the Right Time for ORENCIA (abatacept)? Presented by Bristol-Myers Squibb 3:30-4:15 pm 2014 Update: Examining the Treatment Paradigm in RA Presented by Medac Pharma, Inc. Monday, NOVEMBER 17, 2014 10:30-11:15 am Rituxan (rituximab) for the Treatment of Granulomatosis With Polyangiitis (GPA) and Microscopic Polyangiitis (MPA) with Updated Data for GPA/MPA Presented by Genentech, a Member of the Roche Group 12:30-1:15 pm Serious Infections in Moderately to Severely Active Rheumatoid Arthritis: Hepatitis B Reactivation Presented by Amgen, Inc. 2:30-3:15 pm The Uric Acid Journey: From Purine to Crystal Presented by AstraZeneca Monday, NOVEMBER 17, 2014 11:30 am - 12:15 pm Vectra DA: A Better Measure for Predicting Radiographic Progression in Rheumatoid Arthritis? Presented by Crescendo Bioscience, Inc. 1:30-2:15 pm Rheumatologists Perspectives on the Diagnosis and Treatment of CA and SJIA Presented by Novartis Pharmaceuticals 3:30-4:15 pm The New Era of Biologic Therapy in Rheumatology Presented by Celltrion Healthcare Co., LTD. Tuesday, NOVEMBER 18, 2014 10:30-11:15 am Understanding the Role of the IL-17 Receptor and Cytokines in Psoriatic Arthritis Presented by Amgen, Inc. 12:15-1:00 pm Demystifying Biosimilars in Rheumatology Presented by Pfizer, Inc. Tuesday, NOVEMBER 18, 2014 11:30-12:15 am Serum 14-3-3η: Novel Mechanistic Biomarker Enables a More Accurate and Earlier Diagnosis of RA Presented by Quest Diagnostics 1:30-2:15 pm Advancing the Science of Analgensia With SoluMatrix NSAIDs SoluMatrix is a trademark of iceutica Pty Ltd and is licensed to Iroko. Presented by Iroko Pharmaceuticals, LLC 238 2014 Program Book
INDUSTRY-SUPPORTED SYMPOSIA Sunday, NOVEMBER 16, 2014 6:30 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. Practical Considerations for Treating Patients With XELJANZ (tofacitinib citrate) Developed and offered by Pfizer, Inc. Seaport Hotel, Plaza Ballroom Learning Objectives Upon completion of this activity, participants should be able to: Provide practical guidance regarding the use of XELJANZ in clinical practice through a series of case-based presentations and panel discussion among rheumatologists 6:30 pm 6:35 pm Introduction and Welcome Andrew Koenig, DO, FACR, Immunology Lead, US Medical Affairs, Pfizer, Inc. 6:35 pm 7:35 pm Case Presentations Case Study 1 MTX-IR Patient, XELJANZ Monotherapy Alvin Wells, MD, PhD, Rheumatology & Immunotherapy Center, Oak Creek, WI Case Study 2 MTX-IR Patient, XELJANZ Combination Therapy R. Elaine Lambert, MD, Stanford University School of Medicine, Stanford, CA 7:35 pm 7:40 pm Summary and Wrap Up Andrew Koenig, DO, FACR, Immunology Lead, US Medical Affairs, Pfizer, Inc. 6:30 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. The IL-17 Receptor and Cytokine Axis: New Insights Into the Pathogenesis of Psoriatic Arthritis Developed and offered by Amgen, Inc. Renaissance Boston Waterfront, Pacific Grand Ballroom Learning Objectives Upon completion of this activity, participants should be able to: Understand the impact of psoriatic arthritis, including a review of the disease and related comorbidities Examine the unmet medical need for patients who may not meet the therapeutic goals with current treatment options Discuss new research highlighting the role of the IL-17 pathway in the pathogenesis of psoriatic arthritis 6:30 7:00 pm Registration and Dinner 7:00 7:10 pm Chairman s Welcome Iain B. McInnes, PhD, FRCP, FRSE, Institute of Infection, Immunity, and Inflammation, University of Glasgow Biomedical Research Centre, Glasgow, Scotland 7:10 7:30 pm The Systemic Impact of Psoriatic Arthritis Alice B. Gottlieb, MD, PhD, Tufts Medical Center Boston, Massachusetts 7:30 7:50 pm The Current Unmet Medical Need Among Psoriatic Arthritis Patients Arthur F. Kavanaugh, MD, University of California, San Diego School of Medicine, San Diego, California 7:50 8:15 pm The Importance of the IL-17 Receptor and Cytokine Pathway in the Pathogenesis of Psoriatic Arthritis Christopher T. Ritchlin, MD, MPH, University of Rochester Medical Center Rochester, New York 8:15 8:30 pm Question and Answer All Faculty 6:30 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. Otezla (apremilast): Redefining Management of Psoriatic Arthritis Developed and offered by Celgene Corporation Westin Waterfront, Harbor Ballroom 1 3 Learning Objectives Upon completion of this activity, participants should be able to: Understand the pathophysiology and mechanism of the disease of psoriatic arthritis Review the efficacy and safety for a new oral treatment option for adults with active psoriatic arthritis Understand the patient types appropriate for treatment with Otezla (apremilast) 6:30 7:00 pm Registration and Dinner 7:00 7:05 pm Introduction and Program Objectives Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA 7:05 7:15 pm Unmet Needs in Psoriatic Arthritis Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA 2014 Program Book 239
INDUSTRY-SUPPORTED SYMPOSIA 240 7:15 8:00 pm Overview of Otezla Martin Bergman, MD, Arthritis and Rheumatology, Ridley Park, PA 8:00 8:10 pm Case Study Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA 8:10 8:30 pm Question and Answer Session Martin Bergman, MD, Arthritis and Rheumatology, Ridley Park, PA Philip Mease, MD, Seattle Rheumatology Associates, Seattle, WA 6:30 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. The Future of Spondyloarthritis: Understanding a Challenging Group of Diseases Developed and offered by AbbVie, Inc. Westin Waterfront, Grand Ballroom A E Needs Assessment Statement There have been numerous advances in the field of psoriatic arthritis including updated criteria, characterization of the burden of disease, new treatment options and more. This will provide the US rheumatologist with a consolidated update on the latest evidence in these areas. Learning Objectives Upon completion of this activity, participants should be able to: Evaluate Treat to Target in the Management of Spondyloarthritis Assess the True Prevalence of Spondyloarthritis Address the Complexity of Managing Psoriatic Arthritis-Treating the skin vs treating the Joints 6:30 7:15 pm Registration and Dinner 7:15 7:20 pm Welcome and Introductions John J. Cush, MD, Baylor University Medical Center, Dallas, TX 7:20 7:40 pm Topic 1: In PsA: What Takes Priority, the Skin or the Joints? Eric M. Ruderman, MD, Feinberg School of Medicine, Chicago, IL Ken Gordon, MD, Feinberg School of Medicine, Chicago, IL 7:40 7:55 pm Panel Discussion All Faculty 7:55 8:05 pm Topic 2: Targeting Spondyloarthritis Sergio Schwartzman, MD, Weill Medical College of Cornell University, New York, NY 8:05 8:20 pm Panel Discussion All Faculty 2014 Program Book 8:20 8:30 pm Topic 3: The Prevalence of Spondyloarthritis Atul A. Deodhar, MD, MRCP, FACP, FACR, Oregon Health & Science University, Portland, OR 8:30 8:45 pm Panel Discussion All Faculty 8:45 8:50 pm Postprogram Evaluation 8:50 9:15 pm Dessert Reception Tuesday, NOVEMBER 18, 2014 6:30 pm Non-CME Symposium The event listed below is a non-cme program wholly sponsored and supported by the commercial entities listed. By holding the program, the commercial entity has represented that the program has been developed and will be implemented in accordance with the requirements of the FDA and applicable standards of the PhRMA Code on Interactions with Healthcare Professionals. The commercial entity is to observe all guidelines established by federal and state regulatory agencies regarding non-cme educational or promotional presentations throughout the duration of the program. The content and views expressed during the program are those of the commercial entities and presenters. The ACR by making this venue available does not guarantee, warrant or endorse the content of the program nor the products discussed and reviewed during the program. Chronic Rheumatologic Disorders in the Age of Treat-to-Target (T2T) Strategies: Why? How? Developed and offered by Eli Lilly & Company Westin Waterfront, Harbor Ballroom 1 3 Needs Assessment Statement The T2T approach has gained recognition as an indispensable strategy for the prevention of several ubiquitous, prevalent diseases associated with very significant morbidity and mortality: diabetes, arterial hypertension and coronary heart disease. While heterogeneity of therapeutic aims and patient expectations characterize daily practice in the treatment of chronic rheumatologic disorders, a growing body of evidence supports the benefits of treating these disorders strategically. This strategic approach entails treating according to defined outcome targets by adopting therapeutic changes within distinct timeframes, and ideally following therapeutic algorithms. Learning Objectives Discuss the rationale for the T2T approach: Evidence from other chronic diseases Assess the clinical issues and barriers in the practical implementation of T2T in RA Examine the emerging T2T paradigm in SLE and critically assess similarities and differences between the RA and SLE algorithms Explore the pros and cons of personalized T2T in RA and SLE 6:30 7:00 pm Registration and Dinner 7:00 7:10 pm Welcome and Introductions Susan Manzi, MD, MPH, Lupus Center of Excellence, Pittsburgh, PA 7:10 7:30 pm Treat-to-Target: What It Is and Why It Is a Good Idea Joanne M. Foody, MD, Brigham and Women s Hospital, Boston, MA
INDUSTRY-SUPPORTED SYMPOSIA 7:30 7:50 pm Treat-to-Target for RA: Outcomes-based Treatment Approach Edward C. Keystone, MD, FRCP(C), University of Toronto, Canada 7:50 8:10 pm Treat-to-Target for SLE: The Emerging Paradigm Professor Ronald van Vollenhoven, Sweden 8:10 8:30 pm Treat-to-Target for RA/SLE: Charting the Road Ahead All faculty 8:30 8:40 pm Question and Answer All faculty 8:40 8:45 pm Concluding Remarks Susan Manzi, MD, MPH, Lupus Center of Excellence, Pittsburgh, PA 6:30 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. The Master Clinician s Approach: Diagnosis and Management of Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Supported by an educational grant from UCB, Inc. Sponsored by Cleveland Clinic Westin Waterfront, Grand Ballroom A & B Physician (ACCME) Accreditation Statement The Cleveland Clinic Foundation Center for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement The Cleveland Clinic Foundation Center for Continuing Education designates this live activity for a maximum of 2 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Participants claiming CME credit from this activity may submit the credit hours to the American Osteopathic Association for Category 2 credit. Needs Assessment Statement In the United States, rheumatic diseases are one of the most prevalent chronic conditions, diagnosed in more than 1% of adults (1.3 million).1 Research into the pathogenesis, diagnosis, and management of rheumatic diseases, specifically rheumatoid arthritis (RA), psoriatic arthritis (PsA), and ankylosing spondyloarthritis (AS), has produced important findings in terms of therapeutic outcomes. Given the health care impact of these diseases, education that highlights clinical standards for screening, diagnosis, and management, engages clinicians, and improves the disease identification and treatment has the potential to improve outcomes in this patient population. Learning Objectives Describe the impact of revised guidelines for early recognition and treatment on outcomes in patients with RA, PsA, and AS Recognize psoriatic skin involvement, describe skin scoring systems, and define best practices for dermatology-rheumatology collaborations Summarize the expanding spectrum of AS, including inflammatory back pain and nonradiographic axial spondyloarthropathy Identify the extra-articular variants of AS, especially occult IBD and ocular effects Institute recent evidence-based recommendations on the therapeutic role of biologics, especially emerging data on TNF inhibitors and their use in early and aggressive therapy Critically appraise emerging data on the potential impact of therapies on patient outcomes, and list the patient characteristics that best predict response to therapy 6:30 7:30 pm Registration and Dinner 7:30 7:40 pm Welcome Leonard Calabrese, DO, Cleveland Clinic, Ohio 7:40 8:00 pm Rheumatoid Arthritis New Guidelines for Diagnosis and Management: How Early and Aggressive Should Management Be? Paul Emery, MD, University of Leeds, Leeds, United Kingdom 8:00 pm 8:20 pm Psoriatic Arthritis in the Clinic: Treating to Target and Working with Dermatologists for Patient Centered Care Philip Mease, MD, University of Washington School of Medicine, Seattle, Washington 8:20 8:40 pm Spondyloarthropathy in Practice: From Inflammatory Back Pain to Ankylosing Spondylitis Michael Weisman, MD, Cedars-Sinai Medical Center, Los Angeles, CA 8:40 9:30 pm Challenge the Master Clinicians: Interactive Case-based Panel in RA, PsA, and SpA Moderators: Leonard Calabrese, DO, and M. Elaine Husni, MD, MPH, Cleveland Clinic Faculty: Paul Emery, MD; Philip Mease, MD; and Michael Weisman, MD Virtual Consultants: Brian Feagan, MD; Douglas A. Jabs, MD, MBA; Abrar Qureshi, MD, MPH; and Michael Roizen, MD 6:30 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. So You Think You Know Gout: Fresh Perspectives on Hyperuricemia for Today s Complicated Patients Supported by an educational grant from AstraZeneca. Sponsored by Creative Educational Concepts Renaissance Boston Waterfront Pacific Grand Ballroom A H Physician (ACCME) Accreditation Statement In support of improving patient care, Creative Educational Concepts, Inc. (CECI) is accredited by the American Nurses Credentialing Center (ANCC), the Accreditation Council for Pharmacy Education (ACPE), and the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for the healthcare team. Credit Designation Statement CECI designates this live educational activity for a maximum of 2.0 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Needs Assessment Statement With such a long history, it is surprising that gout is often inappropriately managed. It is a more complex disease state than many believe, often presenting in patients with serious comorbidities with the possibility for multiple drug-drug interactions. Adding to these complications is the fact that gout is not a priority in training programs for the majority of healthcare professionals, including rheumatologists. Education outreach programs can bridge this knowledge gap, giving clinicians the knowledge to improve patient outcomes. Clinicians must understand the new insights into gout biology, new treatment options, complicating comorbidities, as well as new recommendation and guidelines, in order to resist the comfort of relying on long-standing therapies, thus bringing gout treatment from ancient history into the new millennium. 2014 Program Book 241
INDUSTRY-SUPPORTED SYMPOSIA 242 Learning Objectives Upon completion of this activity, participants should be able to: Review inadequacies in the traditional treatment of gout while examining how new understandings of the disease process have led to improvements in treatment, especially when dealing with resistance hyperuricemia. Analyze current and emerging pharmacologic treatment options for gout, answering questions about recent changes to traditional therapies and highlighting the potential role for newer agents. Consider the effect of comorbidities on the treatment of gout from the standpoint of drug selection, drug-drug interactions, and contraindications while assessing the impact of hyperuricemia in other disease states, and the necessity of screening gout patients. Discuss the challenges of treating gout patients with renal insufficiency, addressing pharmacologic choices, patient screening, and the role or uric acid in renal disease progression. 6:30 pm 7:00 pm Registration and Buffet Dinner 7:00 pm 7:10 pm Welcome and Introductions/Pre-test Brian F. Mandell, MD, PhD, FACR, MACP (Activity Chair) 7:10 pm 7:30 pm Case 1: I Want To Go Home! Brian F. Mandell, MD, PhD, FACR, MACP 7:30 pm- 8:05 pm Case 2: My Big Toe is Killing Me, but Won t Diabetes or a Heart Attack Really Kill Me? Robert T. Keenan, MD, MPH 8:05 pm- 8:45 pm Case 3: What Does the Gout Pain in My Hands Have To Do With My Kidneys? N. Lawrence Edwards, MD 8:45 pm- 9:00 pm Conversations with the Experts and Q&A/Post-test All Faculty; Moderated by Brian F. Mandell, MD, PhD, FACR, MACP 2014 Program Book Wednesday, November 19, 2014 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Rheums With Views Workshop: Challenging Conventional Wisdom on Psoriatic Arthritis Care Supported by an educational grant from Celgene Corporation Sponsored by Albert Einstein College of Medicine Westin Waterfront, Commonwealth Ballroom A C Physician (ACCME) Accreditation Statement Albert Einstein College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing education for physicians Credit Designation Statement Albert Einstein College of Medicine designates this educational activity for a maximum of 2.0 AMA PRA Category 1 Credits. Each course participant should only claim credits commensurate with the extent of their participation in the activity. Needs Assessment Statement Physicians are not necessarily screening for comorbidities that have related etiologies with psoriatic arthritis (PsA); therefore, patients are not being optimally treated and outcomes often remain poor. This assessment process is compromised by the fact that clinicians do not fully understand the etiologic interrelationship of inflammatory processes of comorbid conditions associated with PsA, nor the inflammatory cascade of events that drive PsA and its severity. Moreover, despite available guidelines to diagnose PsA, many patients are not diagnosed early in the course of the disease and many go undiagnosed. Moreover, the diagnosis of PsA often is missed, partly because patients may present with inflammatory spinal pain, tendonitis, enthesitis, or dactylitis rather than a true arthritis. If PsA is not identified early and managed appropriately, progressive joint damage with deformities and disability may result. Clinicians are also not knowledgeable of nor competent to administer all treatment options available for PsA. Learning Objectives Discuss the spectrum of PsA disease based on clinical presentation, patient reported outcomes and clinical assessment tools Recognize the need for early intervention and implementation of aggressive treatment strategies based on dominant PsA clinical features and classification domains Identify and treat the most common comorbid conditions associated with PsA to ensure optimal patient outcomes Outline the currently approved and emerging treatments for psoriasis and PsA in regards to mechanism of action, safety and efficacy Utilize biologic therapy when appropriate with the goals of minimizing disease progression and improving quality of life 1:00 1:30 pm Buffet Lunch 1:30 1:35 pm Welcome and Introductions Stanley Cohen, MD, Rheumatology Associates, Dallas, TX 1:35 1:50 pm Brief Overview of Psoriatic Arthritis Epidemiology, Including Relation to Plaque Psoriasis, Diagnosis and Classification Criteria Elaine Husni, MD, Cleveland Clinic, Cleveland, OH 1:50 2:05 pm Review of PsA Pathophysiology and Inflammatory Cascade Stanley Cohen, MD, Rheumatology Associates, Dallas, TX 2:05 3:05 pm Case Discussions Case 1: Newly Diagnosed Patient With PsA Case 2: Loss of Response With TNF inhibition Case 3: Worsening Disease With Comorbidities Stanley Cohen, MD, Rheumatology Associates, Dallas, TX Elaine Husni, MD, Cleveland Clinic, Cleveland, OH 3:05 3:15 pm Closing Remarks All Faculty 3:15 3:30 pm Audience Question and Answer All faculty 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Prevention and Management of Infections With Biologic Therapy: Do s, Don ts, and Maybe Supported by an educational grant from Oxford Immunotec Sponsored by CME Outfitters, LLC Westin Waterfront, Harbor Ballroom 1
INDUSTRY-SUPPORTED SYMPOSIA Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of CME Outfitters, LLC, and Jespersen & Associates, LLC. CME Outfitters, LLC is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement CME Outfitters, LLC designates this live activity for a maximum of 1.75 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity. Needs Assessment Statement A recent review of international recommendations on the management of latent tuberculosis infection determined that there is a general consensus that evaluation of the global risk of TB infection is a crucial point and that patients with LTBI must receive chemoprophylaxis prior to biologic therapy. 1 The study also concluded the critical point is implementing dissemination and awareness of the recommendations among rheumatologists to improve adherence in real life. 1 Rheumatologists and other healthcare professionals treating patients with rheumatic diseases undergoing biologic therapy need to be educated on the best screening methods for detecting LTBI in rheumatic patients and how to keep their patients safe from developing TB and other infections while receiving biologic therapy. 1. Iannone F, Cantini F, Lapadula G. J Rheumatol Suppl. 2014;91:41-46. Learning Objectives Describe the most important opportunistic infections in the setting of biologic and synthetic disease modifying antirheumatic drug (DMARD) therapy. Assess the utility of various screening and prevention algorithms for TB, HBV, and other infections in the setting of biologic therapy. Describe appropriate vaccination strategies and timing for patients using DMARD therapy. Discuss the appropriate clinical management in cases of patients who develop infections during therapy. 1:00 1:15 pm Registration and Lunch Buffet 1:15 1:45 pm Screening and Risk of Opportunistic Infections With Emphasis on HBV and TB Leonard Calabrese, DO, Cleveland Clinic, Cleveland, OH 1:45 2:15 pm Vaccination To Do or Not To Do, and When Kevin Winthrop, MD, Oregon Health & Science University, Portland, OR 2:15 2:45 pm Co-management of Infections and DMARD Therapies Clinical Conundrums Daniel Furst, MD, David Geffen School of Medicine at UCLA, Westwood, CA 2:45 3:00 pm Panel Discussion All Faculty 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. SPARTAN-GRAPPA-ASAS Educational Symposium on Axial Spondyloarthritis (SpA) and Psoriatic Arthritis (PsA) Supported by an educational grant from AbbVie, Inc. Sponsored by Ohio State University Westin Waterfront, Grand Ballroom C, D, E Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Oregon Health & Science University School of Medicine and NW Arthritis & Osteoporosis Institute. The OHSU School of Medicine is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement OHSU School of Medicine, Division of CME, designates this live activity for a maximum of 4.5 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity. Needs Assessment Statement There have been numerous new developments in our understanding of the pathogenesis and approach to management of spondyloarthritides within the last few years. The role of microbiome in the etiopathology of Spondyloarthritis continues to evolve. Basic mechanisms of osteoproliferation and pharmacotherapy to prevent them continue to evolve. New strategy trials on treat to target are being conducted in Spondyloarthritis. These topics need to be informed to attendees. Learning Objectives Discuss the classification criteria for axial spondyloarthritis (SpA) and psoriatic arthritis (PsA) Describe the new understanding in the pathogenesis of axial spondyloarthritis and psoriatic arthritis Develop an evidence based treatment plan for the management of axial spondyloarthritis and psoriatic arthritis 1:00 pm Registration and Lunch 1:00 1:05 pm Welcome and Introductions Philip Mease, MD, Swedish Medical Center/University of Washington 1:05 1:20 pm Pre-test (Quiz using audience response system) Speaker to be Determined 1:20 1:45 pm Role of Gut Microbiome in SpA Pathogenesis Dirk Elewaut, MD, University of Ghent, Belgium 1:45 2:10 pm Year-in-Review in Spondyloarthritis John Reveille, MD, University of Texas Health Science Center Atul Deodhar, MD, Oregon Health & Science University 2:10 2:35 pm Treat-to-target Concept for SpA Philip Helliwell, MD, University of Leeds, UK 2:35 3:00 pm Osteoporosis and Osteoproliferation in AxSpA: Pathology, Prevention and Treatment Lianne Gensler, University of San Francisco 3:00 3:15 pm Post-Test (Quiz using audience response system) Speaker to be Determined 3:15 4:00 pm Break-out Session Hands-On Assessment of Axial SpA and PsA: Axial SpA and PsA Physical Exam: Spine, Enthesitis, Skin & Nails Speakers to be Determined 2014 Program Book 243
INDUSTRY-SUPPORTED SYMPOSIA 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Multicenter Osteoarthritis Intervention Study With Sysadoa (MOVES): An International, Double-blind, Randomized Trial Comparing Combined Chondroitin Sulfate and Glucosamine Versus Celecoxib Supported by an educational grant from Bioiberica, S.A. Sponsored by Medical Education Resources Westin Waterfront, Burroughs Physician (ACCME) Accreditation Statement This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Medical Education Resources (MER) and Consensus Medical Communications. MER is accredited by the ACCME to provide continuing medical education for physicians. Credit Designation Statement MER designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credit(s). Physicians should only claim credit commensurate with the extent of their participation in the educational activity. Needs Assessment Statement Knee osteoarthritis (OA) is a major cause of pain and functional restriction in older adults. Effective treatment of OA must focus on addressing all aspects of pathophysiology, including identification, prevention and treatment of joint cartilage, synovial membrane and subchondral bone injuries. Current data suggest the use of combined chondroitin sulfate and glucosamine may provide disease-modifying benefits and an option that may prevent knee OA progression. Combined chondroitin sulfate and glucosamine may result in improved quality of life for patients with OA, as well as significantly reduced costs of this disease to society. This program will investigate the mechanism of action of combined chondroitin sulfate and glucosamine, as well as current data and outcomes from the MOVES [multicenter OA intervention study with symptomatic slow acting drugs for OA (SYSADOA)] clinical trial. Learning Objectives Evaluate the synergistic mechanism of action of combined chondroitin sulfate and glucosamine Appraise current clinical data and outcomes concerning combined chondroitin sulfate and glucosamine in osteoarthritis Assess safety considerations from relevant clinical trials Examine the relationship between meniscal extrusion, knee cartilage, and subchondral bone 1:20 1:25 pm Welcome and Introduction Marc C. Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MD, United States 1:25 1:40 pm Mechanisms of Action and Synergic Activity of Combined Chondroitin Sulfate and Glucosamine Patrick du Souich, MD, PhD, University of Montreal, Montreal, Quebec, Canada 1:40 1:55 pm MOVES Rationale, Protocol and Study Design Allen Sawitzke, MD, University of Utah School of Medicine, Salt Lake City, UT 1:55 2:10 pm Effects of Combined Chondroitin Sulfate and Glucosamine vs Celecoxib in Patients With Moderate-to-Severe Knee OA Pain Jean-Pierre Pelletier, MD, University of Montreal, Montreal, Quebec, Canada 2:10 2:25 pm Post-hoc Analyses and Safety Considerations From MOVES Trial Marc C. Hochberg, MD, MPH, University of Maryland School of Medicine, Baltimore, MD 2:25 2:40 pm Impact of Meniscal Extrusion on the Progression of Knee OA Structural Changes: Data From the Osteoarthritis Initiative Progression Cohort. Johanne Martel-Pelletier, PhD, University of Montreal, Montreal, Quebec, Canada 2:40 2:55 pm Question and Answer Session All Faculty 2:55 3:00 pm Concluding Remarks Marc C. Hochberg, MD, MP, University of Maryland School of Medicine, Baltimore, MD 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Psoriasis and Psoriatic Arthritis: Emerging Paradigms and Treatment Options Supported by an educational grant from Celgene Corporation Sponsored by North American Center for Continuing Medical Education, an HMP Communications Holding Company and National Psoriasis Foundation Westin Waterfront, Harbor Ballroom 2 Accreditation North American Center for Continuing Medical Education, LLC (NACCME) is accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team. Credit Designation Statement CME NACCME designates this live activity for a maximum of 2 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity CNE This continuing nursing education activity awards 2.0 contact hours. Provider approved by the California Board of Registered Nursing, Provider #13255 for 2.0 contact hours. Needs Assessment Statement While rheumatologists rarely treat psoriasis alone, understanding the inflammation cascade is important in determining a treatment plan that aggressively pursues remission goals. Collaboration among dermatologists and rheumatologists is critical to optimize management of psoriasis and psoriatic arthritis. Studies show patients are more likely to receive a systemic medication or biologic agent through a multidisciplinary collaborative care approach. This multidisciplinary care approach may facilitate the earlier diagnosis of joint disease and is shown to offer a more comprehensive treatment approach for patients with both psoriasis and psoriatic arthritis (PsA). Learning Objectives Implement routine assessment of disease status, progression and comorbid conditions using clinical and patient-reported measurement tools Utilize patient engagement and education to improve adherence and develop patient-centric care approaches 244 2014 Program Book
INDUSTRY-SUPPORTED SYMPOSIA Develop early intervention, treat-to-remission strategies based on an improved understanding of disease pathophysiology, epidemiology, inflammatory cascade, clinical features, and classification Implement processes to improve co-management and decisionmaking with other providers who care for patients with PsA, psoriasis and other immune mediated inflammatory diseases 1:00 1:30 pm Registration and Lunch 1:30 2:15 pm Implementing Routine Assessment of Disease Status, Progression and Comorbid Conditions Using Clinical and Patient-Reported Measurement Tools Utilizing Patient Engagement and Education to Improve Adherence and Develop Patient-Centric Care Approaches Speaker to be Determined 2:15 3:00 pm Developing Early Intervention, Treat-to-Remission Strategies base on Disease Pathophysiology, Epidemiology, Inflammatory Cascade, Clinical Features, and Classification Processes for Improved Co-Management and Decision-Making with Other Providers Who Care for Patients with PsA, Psoriasis and Other Immune-Mediated Inflammatory Diseases Speaker to be Determined 3:00 3:30 pm Question and Answer Session Luis R. Espinoza, MD, Louisiana State University School of Medicine, New Orleans, LA Joseph F. Merola, MD, MMSc, Brigham and Women s Hospital, Boston, MA 1:00 pm CME-Accredited Symposium For CME-accredited symposia, the sponsoring organization is responsible for planning and providing CME credit. Sequential Therapy for Established Rheumatoid Arthritis: New Targeted Therapies as Part of an Individualized Approach to Care Supported by an educational grant from Lilly USA, LLC Sponsored by Med Learning Group Westin Waterfront, Harbor Ballroom 3 Learning Objectives Review and interpret the ACR new classification criteria, and updated ACR and EULAR treatment guidelines and the new remission criteria for RA Evaluate different biologic DMARDs-based regimens and small molecule kinase inhibitors for their efficacy and safety in the contest of individual patient treatment plan across several lines of therapy Explain how frequent assessment of disease progression, response monitoring and treatment switching can optimize RA management 1:00 1:30 pm Registration and Buffet Lunch 1:30 1:40 pm Welcome and Introductions Jeffrey R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, Birmingham, AL Gregg J. Silverman, MD, NYU School of Medicine, New York, NY 1:40 2:05 pm Rheumatoid Arthritis: Overarching Concepts Treat to Target: Evidence Supporting the Principle Composite Measures of Disease Activity and Assessment New ACR/EULAR Classification Criteria: Review and Implementation in Clinical Ppractice New Definition of Remission Gregg J. Silverman, MD, NYU School of Medicine, New York, NY 2:05 2:30 pm Role of DMARDs-based Regimens in Established Disease Treatment Options After Inadequate Response to Methotrexate (MTX-IR) Superiority Trials and Head-to-Head for Comparing Biologic Agents, and the First Approved TKI 2012 ACR and 2013 EULAR Treatment Guidelines Case Study Jeffrey R. Curtis, MD, MS, MPH, University of Alabama at Birmingham, Birmingham, AL 2:30 2:45 pm Conclusions All Faculty 2:45 3:00 pm Questions and Answers All Faculty Physician (ACCME) Accreditation Statement Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement Med Learning Group designates this live activity for a maximum of 1.5 AMA Category 1 Credit(s) TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity. Needs Assessment Statement In 2010, the American College of Rheumatology (ACR) and the European League Against Rheumatism (EULAR) issued new clinical classification criteria for RA with the goal of codifying a strategy to identify patients with early RA and to get them into treatment before joint damage progresses (Aletaha 2010). Several factors were identified that best discriminate patients with a new presentation of undifferentiated inflammatory synovitis who are at high risk of developing persistent and/or erosive disease from those who are not at high risk. The resulting classification of definite RA is based on the (Aletaha 2010). In addition, indices used for monitoring disease activity in clinical trials (e. g. PAS, PASII and DAS28) have been validated and proposed for wider use in clinical practice. They characterize RA according to whether there is low disease activity, moderate disease activity, high disease activity or remission (Singh 2012). 2014 Program Book 245
CERTIFICATES OF CME CREDIT OR PARTICIPATION Accreditation Statement: The American College of Rheumatology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Designation Statement: The ACR designates this live educational activity for a maximum of 52.25 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. International Physicians: International physicians who register as part of a group and require AMA PRA Category 1 Credit(s) must provide the following information to your tour leader: full name, mailing address, telephone and fax numbers and e-mail address. The information will be used to verify your meeting attendance. The American Medical Association has an agreement of mutual recognition of continuing medical education credit with the European Union of Medical Specialties. International physicians interested in converting AMA PRA Category 1 Credit to EACCME credit should contact the UEMS. Health Professionals: Participants may claim hours to receive a Certificate of Participation for an activity designated for AMA PRA Category 1 Credit(s). For non-cme sessions, attendees may also request a certificate of participation. EVALUATIONS, CME CREDIT AND CERTIFICATES Your evaluation of the meeting is very important. The ACR/ ARHP Annual Meeting Planning Committee uses feedback from attendees to assist in the development of future educational activities; therefore, we encourage you to complete your session evaluations. Overall meeting and session evaluations can be completed online at www.acrannualmeeting.org. You will be able to e-mail and print your CME certificate or certificate of participation. At the on-site Technology Center located in Level 1: North Lobby, computers are available for you to complete overall meeting and session evaluations and claim your hours for a CME Certificate or Certificate of Participation. International physicians requiring a Certificate of Attendance, can find one enclosed in your meeting bag.please complete the session evaluations and CME application online at www.acrannualmeeting.org or at the on-site Technology Center located in Level 1: North Lobby. CLAIMING CME CREDIT You may claim your CME credit at the Technology Center, located on Level 1 in the North Lobby, during or at the end of the meeting for all sessions attended. You may also claim your credit online during and after the meeting at ACRannualmeegting.org. How Do I Claim Credit? It is an AMA requirement that you claim only the EXACT amount of time spent in each educational session. This accurately reflects the extent of your participation in the activity. You may attend sessions for LESS than their entirety and claim partial credit to the nearest quarter hour. Note that you may NOT claim credit hours for attending two full sessions at a given time in their entirety. Therefore, if you inaccurately record your credit hours and exceed the meeting maximum of AMA/PRA Category 1 Credits TM, you will need to correct your claim in order to receive your certificate. Example: You attend half of a 1-hour session and half of another in the same time slot. You must report that you spent.5 hours in the first session and.5 in the second session. If you attempt to claim full credit (1hr) for each of the two sessions, the claim system may over-calculate your CME credit and you may exceed the maximum number of credit hours allowed. In this case you would not be able to receive your certificate. How Do I Claim Credit for Poster Sessions? You may only be awarded CME credit for viewing posters during the 9:00-11:00 AM time slot. It is an AMA requirement that poster presenters must be available to engage learners. You must therefore claim ONLY the credit commensurate with the extent for your participation in the activity during this time slot. You may claim partial credit. 246 2014 Program Book
CERTIFICATES OF CME CREDIT OR PARTICIPATION CONFLICT OF INTEREST AND DISCLOSURE As an educational provider accredited by the Accreditation Council for Continuing Medical Education, the American College of Rheumatology must ensure balance, independence, objectivity and scientific rigor in all its educational activities. Therefore, all those in a position to control content (e.g., speakers and moderators) participating in an ACR-sponsored activity are required to disclose to the planning committee and audience any financial or other relationships including, but not limited to: None: Nothing to disclose 1. Stock, stock options or bond holdings in a for-profit corporation or self-directed pension plan 2. Research grants 3. Employment (full or part time) 4. Ownership or partnership 5. Consulting fees or other remuneration (payment) 6. Non-remunerative positions of influence such as officer, board member, trustee or public spokesperson 7. Receipt of royalties 8. Speakers bureau 9. Other Disclosures for invited speakers are listed in the indices by presenters last name. Abstract author disclosures are published online and in a supplement to the October issue of Arthritis & Rheumatology. Disclosures for the late-breaking abstracts are published online and in the December issue of Arthritis & Rheumatology. Any individual who refuses to disclose relevant financial relationships is ineligible to serve as a planning committee member, presenter or author of an ACR CME activity, and cannot have control of, or responsibility for, the development, management, presentation or evaluation of the CME activity. Disclosure Policy It is the policy of the American College of Rheumatology to ensure that its CME activities are independent and free of commercial bias. To ensure content objectivity and balance, and guarantee that the content presented is in the best interest of its learners and the public, the ACR requires that all individuals in a position to control content disclose all relevant financial relationships with any commercial interest if the relationship is financial and occurred within the past 12 months. This includes the relationships of spouse/partners. If there are relationships that create a conflict of interest, these must be resolved in accordance with the ACR s CME Resolution of Conflict policy prior to the participation of the individual in the development or presentation of CME content. Sunshine Act Compliance at the Annual Meeting The Sunshine Act Under the Physician Payment Sunshine Act (Section 6002 of the Patient Protection and Affordable Care Act), medical device, biologic and drug companies are required to track all payments and transfers of value (TOV) to U.S. physicians. Companies must report any payment or TOV with a minimum value of $10/ payment or cumulatively $100/year or more to the Department of Health & Human Services (HHS) which publicly discloses the information on their Web site. As defined by the Sunshine Act, TOV include, but are not limited to, gifts, food and beverages of a certain nature, entertainment, consulting fees and honoraria. At the Annual Meeting this means companies will be required to track certain items handed out at their exhibit booths at meetings and conventions. As an accredited provider honoraria are exempt from reporting. National Provider Identification Number The National Provider Identifier (NPI) number, a unique identification number assigned to you if you have received payments from the federal government for services you provided to a patient, will be used to record and track these transactions. The ACR requested that you voluntarily provide your NPI number during the registration process. If you do not know your NPI number a searchable registry is available at https://npiregistry. cms.hhs.gov/nppesregistry/npiregistryhome.do. This number will be transferred to exhibiting companies when your badge is scanned in the exhibit hall or at an industry supported session. 2014 Program Book 247
2014 ACR/ARHP ANNUAL MEETING LEADERSHIP Thank You! The ACR/ARHP Board of Directors extends its gratitude to the ACR/ARHP Annual Meeting Planning Subcommittee, ACR Abstract Oversight Committee, ACR Abstract Selection Committee, ARHP Abstract Review Panels and ARHP Clinical Focus Task Force members for their leadership and volunteering their services to plan the 2014 Annual Meeting. Their significant contributions and expertise make the Annual Meeting the premier event for specialists in the field of rheumatology. ACR/ARHP Annual Meeting Planning Subcommittee Chester V. Oddis, MD, Chair Richard F. Loeser, MD, Chair Elect Mary Cronin, MD, Clinical Sub-chair Jasvinder Singh, MD, MPH, MTP/Workshop/ Study Group Sub-chair John Varga, MD, Basic Science Sub-chair Mary K. Peggy Crow, MD, Abstract Selection Co-Chair (Basic Science) Eric Matteson, MD, Abstract Selection Co-Chair (Clinical) Afton Hassett, PsyD, ARHP Chair Hazel L. Breland, PhD, OTR/L, ARHP Chair Elect Robert R. McLean, DSc, MPH, ARHP Abstract Selection Chair Shreyasee Amin, MDCM, MP Stacy Ardoin, MD Dana Ascherman, MD Alan N. Baer, MD Thuy T. Beam, RN Elana Bernstein, MD Susan Boackle, MD, Committee on Research Representative Hermine Brunner, MD, MSc, MBA Dominic O. Co, MD, PhD Andrew P. Cope, MD, PhD Betty Diamond, MD N. Lawrence Edwards, MD Judy Fozworth, PhD, PT Mark F. Gourley, MD Rula Hajj-Ali, MD Marian T. Hannan, DSc, MPH, Committee on Journal Publications Representative Jonathan Hausmann, MD, Fellows Subcommittee Representative Simon Helfgott, MD Rennie Howard, MD Laurie Hughell, PA-C, MPH Wael Jarjour, MD Meenakshi Jolly, MD, MS Mariana J. Kaplan, MD Dinesh Khanna, MD, MSc Sharon Kolasinski, MD, Committee on Government Affairs Representative Kristine M. Lohr, MD, MS, Committee on Rheuamtology Training and Workforce Issues Representative Rebecca L. Manno, MD William McClatchey, MD, Committee on Registries and Health Information Technology Representative Sandra J. Mintz, RN, BSN, ARHP Executive Committee Representative Kenneth S. O Rourke, MD Egla Rabinovich, MD, MPH Leonard H. Sigal, MD Gregg J. Silverman, MD, Committee on Research Representative Nora Singer, MD, Committee on Research Representative Chokkalingam Chuck Siva, MD, MS Christine Stamatos, ANP-C George Stojan, MD Kerry Stone, MD Greg Taylor, MSW Rodney Tehrani, MD George C. Tsokos, MD Swamy R. Venuturupalli, MD Douglas W. White, MD, PhD, Committee on Rheumatologic Care Representative Margaret R. Wilkes, MD Ex Officio Members Joel A. Block, MD, Chair, Committee on Education Joseph Flood, MD, ACR President ACR Abstract Oversight Committee Steven R. Ytterberg, MD, Chair C. Ronald MacKenzie, MD Shreyasee Amin, MD Kathleen M. O Neil, MD Emily C. Somers, PhD, ARHP Representative ARHP Clinical Focus Task Force Karen Huisinga, MN, ARNP, Chair Aleksander Feoktistov, MD Scott M. Hasson, EdD, PT Michael J. Jennings, RT, CBDT Amanda F. Sells, PA-C ACR and ARHP Abstract Selection Committees (including category chairs, reviewers and ad hoc reviewers) Mary K. Peggy Crow, MD, Abstract Selection Co-Chair (Basic Science) Eric Matteson, MD, Abstract Selection Co-Chair (Clinical) Jennifer H. Anolik, MD, PhD Alan N. Baer, MD Dominique L. Baeten, MD, PhD Thomas Bardin, MD Cheryl Barnabe, MD Jennifer Barton, MD Michael J. Battistone, MD Thuy T. Beam, BSN, RN Clifton O. Bingham III, MD Bryce A. Binstadt, MD, PhD Arthur A. M. Bookman, MD Chad Boomershine, MD, PhD Hazel L. Breland, PhD Lin A. Brown, MD Hermine Brunner, MD Rachelle Buchbinder, PhD Lenore M. Buckley, MD Gerd Burmester, MD Jill P. Buyon, MD Vivian P. Bykerk, MD Megan E. B. Clowse, MD Philip L. Cohen, MD Philip G. Conaghan, MD, PhD Mary E. Cronin, MD Nicola Dalbeth, MD Maria Dall era, MD Kathryn H. Dao, MD Anne Davidson, MBBS John M. Davis III, MD, MS Atul A. Deodhar, MD N. Lawrence Edwards, MD Keith B. Elkon, MD Polly J. Ferguson, MD Aryeh Fischer, MD John FitzGerald, MD, PhD Oliver FitzGerald, MD Judy Foxworth, PhD Patrick M. Gaffney, MD Gary S. Gilkeson, MD Dafna D. Gladman, MD Mary B. Goldring, PhD Jessica K. Gordon, MD Paulette C. Hahn, MD William F. Harvey, MD Afton L. Hassett, PsyD Merete Lund Hetland, MD, PhD Jay B. Higgs, MD Laurie A. Hughell, PA-C Laura K. Hummers, MD M. Elaine Husni, MD Lisa F. Imundo, MD Robert D. Inman, MD Sindhu R. Johnson, MD, PhD George D. Kalliolias, MD, PhD Diane L. Kamen, MD Insoo Kang, MD Jeffrey N. Katz, MD Arthur Kavanaugh, MD Jonathan Kay, MD Salahuddin Kazi, MD 248 2014 Program Book
2014 ACR/ARHP ANNUAL MEETING LEADERSHIP Robert Lafyatis, MD Andrew J. Laster, MD Yvonne C. Lee, MD Roger A. Levy, MD S. Sam Lim, MD Grace H. Lo, MD Richard F. Loeser, MD Grant H. Louie, MD Anne-Marie Malfait, MD, PhD Joseph A. Markenson, MD Ann Marshak-Rothstein, PhD Mehrdad Maz, MD Iain B. McInnes, PhD Philip Mease, MD Kaleb Michaud, PhD Timothy B. Niewold, MD Peter A. Nigrovic, MD Nancy J. Olsen, MD Lauren M. Pachman, MD Stephen A. Paget, MD Harris R. Perlman, PhD Alessandra B. Pernis, MD David S. Pisetsky, MD, PhD Joyce Rauch, PhD Ann M. Reed, MD John D. Reveille, MD Carla R. Scanzello, MD, PhD Gabriela Schmajuk, MD Wolfgang A. Schmidt, MD Thomas J. Schnitzer, MD, PhD Shiva Shahrara, PhD Victoria K. Shanmugam, MBBS, MRCP Nora G. Singer, MD Ram P. Singh, PhD Chokkalingam Siva, MD Robert F. Spiera, MD Christine A. Stamatos, DNP Lisa Suter, MD Gregory Taylor, MSW Filip van Den Bosch, MD, PhD Kenneth J. Warrington, MD Jinoos Yazdany, MD Andrew Zeft, MD Angela Zink, PhD Andy Abril, MD Paul M. Adam, MSW Rohit Aggarwal, MD Daniel Aletaha, MD Yannick Allanore, MD, PhD Kelli D. Allen, PhD Cynthia Aranow, MD Dana P. Ascherman, MD Anca Askanase, MD Shervin Assassi, MD Catherine L. Backman, PhD Nancy A. Baker, ScD Kamil E. Barbour, PhD April Barnado, MD Franck Barrat, PhD Christie M. Bartels, MD Susan J. Bartlett, PhD Mara L Becker, MD Edward M. Behrens, MD Jessica Berman, MD Maria Laura Bertolaccini, MD, PhD Timothy Beukelman, MD Neal S. Birnbaum, MD Susan J. Blalock, PhD Susan A. Boackle, MD Maarten Boers, MD, PhD Francesco Boin, MD Stefano Bombardieri, MD Laurence A. Bradley, PhD Juergen Braun, MD S. Louis Bridges Jr., MD, PhD Mary Brothers, MSN Ewa Cairns, PhD Leigh F. Callahan, PhD Liron Caplan, MD, PhD Roberto Caricchio, MD John D. Carter, MD Flavia V. Castelino, MD Isabel Castrejón, MD, PhD Eliza Chakravarty, MD Vinod Chandran, MD, PhD Julia F. Charles, MD, PhD W. Winn Chatham, MD Di Chen, MD, PhD Hyon Choi, MD, PhD Mary E. Christenson, PhD Cecilia P. Chung, MD Maria C. Cid, MD. PhD Michal Cidon, MD Marcus R. Clark, MD Daniel O. Clegg, MD Dominic Co, MD, PhD Stanley B. Cohen, MD Maripat Corr, MD Mary-Beth Coty, PhD, RN Talitha Cox, OTR/L Joseph E. Craft, MD Lindsey A. Criswell, MD Bruce N. Cronstein, MD Mary K. Crow, MD Cynthia Crowson, MS J. R. Curtis, MD Aileen M. Davis, PhD Kurt L. de Vlam, MD Kevin D. Deane, MD, PhD Kristen Demoruelle, MD Christopher P. Denton, MD, PhD Kori A. Dewing, DNP, ARNP William G. Dixon, PhD Robyn T. Domsic, MD Robin K. Dore, MD Leonard L. Dragone, MD, PhD Alyssa B. Dufour, PhD Dorothy D. Dunlop, PhD Linda S. Ehrlich-Jones, PhD, RN Dirk Elewaut, MD, PhD Helen M. Emery, MD Doruk Erkan, MD Agustin Escalante, MD John M. Esdaile, MD, Luis R. Espinoza, MD Carol A. Feghali-Bostwick, PhD Candace H. Feldman, MD Theodore R. Fields, MD Nadine M. Fisher, EdD Roy Fleischmann, MD David A. Fox, MD Cem Gabay, MD, PhD Angelo L. Gaffo, MD Harry K. Genant, MD, PhD MC Genovese, MD Lianne S. Gensler, MD Piet Geusens, MD, PhD Allan Gibofsky, MD Jon T. Giles, MD John A. Goldman, MD Steven R. Goldring, MD Barbara L. Goldstein, MD Yvonne M. Golightly, PhD Adam P. Goode, DPT, PhD Susan M. Goodman, MD Carol M. Greco, PhD K. Douglas Gross, DPT, ScD Andrew A. Guccione, PhD Loic Guillevin, MD Nigil Haroon, MD, PhD Philip S. Helliwell, PhD Catherine L. Hill, MD K. Hobbs, MD Haochu Huang, PhD Marie Hudson, MD David Hunter, PhD Kimme Hyrich, MD, PhD Maura D. Iversen, DPT Binu Jacob, MSc, PhD Karla Jones, RN Roland Jonsson, DDS, PhD Gurjit S. Kaeley, MBBS, MRCP Kenneth Kalunian, MD Mariana J. Kaplan, MD Lisa M. Kastanek, RN Robert S. Katz, MD Robert T. Keenan, MD Tanaz A. Kermani, MD Susan Kim, MD Wan-Uk Kim, MD, PhD Kyriakos A. Kirou, MD Eugene Y. Kissin, MD Marisa S. Klein-Gitelman, MD Margreet Kloppenburg, MD, PhD Isabelle Koné-Paut, MD Dwight H. Kono, MD Bindee Kuriya, MD 2014 Program Book 249
2014 ACR/ARHP ANNUAL MEETING LEADERSHIP C. Kent Kwoh, MD Vasileios C. Kyttaris, MD Robert Landewé, MD, PhD Marissa N. Lassere, MD, PhD Terri M. Laufer, MD Michael P. Lavalley, PhD Edward S. Leib, MD Alana B. Levine, MD Gerald D. Levy, MD Linda C. Li, PhD Katherine P. Liao, MD Stamatis Nick Liossis, MD Rik J. Lories, MD, PhD Martin K. Lotz, MD Steven K. Magid, MD Alfred Mahr, MD, PhD Una E. Makris, MD Brian F. Mandell, MD, PhD Lisa A. Mandl, MD Wendy Marder, MD Richard Martin, MD Thomas Mason II, MD Alan K. Matsumoto, MD Eric L. Matteson, MD Robert R. McLean, DSc Maureen A. McMahon, MD Ted R. Mikuls, MD Shikha Mittoo, MD Chandra Mohan, MD, PhD Laurence Morel, PhD Kathy Moser Sivils, PhD Iris Navarro-Millan, MD Oscar Neira, MD Tuhina Neogi, MD, PhD Uyen Sa D.T. Nguyen, DSc Chester V. Oddis, MD James O Dell, MD Terry H. Oh, MD Catalina Orozco, MD Nicole M. Orzechowski, DO Thomas Osborn, MD Mikkel Ostergaard, MD, PhD Thomas Pap, MD Christopher T. Parker, DO Murray H. Passo, MD Andras Perl, MD, PhD Christine A. Peschken, MD Charles G. Peterfy, MD, PhD Erik J. Peterson, MD Kristine Phillips, MD, PhD Michael H. Pillinger, MD Janet L. Poole, PhD Duncan Porter, MD Sampath Prahalad, MD Chaim Putterman, MD Kate T. Queen, MD Andreas Radbruch, PhD Anisur Rahman, MD, PhD Soumya Raychaudhuri, MD, PhD Andreas Reiff, MD Christopher T. Ritchlin, MD Jillian A Rose, LMSW Shawn Rose, MD, PhD Ann K. Rosenthal, MD Robert Roubey, MD Kelly A. Rouster-Stevens, MD Eric Ruderman, MD Shivani Sahni, PhD Elizabeth G. Salt, PhD Amr H. Sawalha, MD Jose U. Scher, MD Elizabeth A. Schlenk, PhD, RN Kara M. Schmidt, MD Hendrik Schulze-Koops, MD, PhD Sergio Schwartzman, MD Nancy A. Shadick, MD Leena Sharma, MD Miriam A. Shelef, MD, PhD Lisa Shelton, RN Caroline H. Shiboski, PhD Gregg J. Silverman, MD Robert W. Simms, MD Karen L. Smarr, PhD Alexander So, MD Jeremy Sokolove, MD Jason Jungsik Song, MD Enrique Soriano, MD William St.Clair, MD Lisa K. Stamp, PhD Anne M. Stevens, MD, PhD Camilla Svensson, PhD Deborah P. Symmons, MD, PhD Zoltan Szekanecz, MD, PhD Clement E. Tagoe, MD, PhD S. Bobo Tanner, MD Laura L. Tarter, MD Janalee Taylor, CPNP Nora R. Taylor, MD Peter C. Taylor, MD, PhD Regina Taylor-Gjevre, MD Akaluck Thatayatikom, MD Ralf G. Thiele, MD Derrick J. Todd, MD, PhD Kathryn S. Torok, MD Sebastian Unizony, MD Paul J. Utz, MD, PhD Rafael R. Valle, MD John Varga, MD Peter van der Kraan, PhD Yvonne JL van Eijk-Hustings, RN Piet van Riel, MD, PhD Ronald van Vollenhoven, MD, PhD Barbara J Vilen, PhD Ernest R. Vina, MD Evelyne Vinet, MD David Walsh, PhD Michael H. Weisman, MD David A. Williams, PhD Barton L. Wise, MD Joan E. Wither, MD, PhD Edward H. Yelin, PhD John H Yost, DO Brandi Young, DNP Muhammad B. Yunus, MD JoAnn Zell, MD Carol M. Ziminski, MD 250 2014 Program Book
2014 Fellows Education Fund Through the Fellows Education Fund, the ACR is accelerating the education and training of the next generation of rheumatologists. The ACR Fellows Education Fund has a proven track record of successfully providing rheumatology fellows-in-training with outstanding educational opportunities to advance their knowledge and skills to treat an ever-changing patient population. The ACR thanks the following organizations for their support of the 2014 Fellows Education Fund: Bristol-Myers Squibb Janssen Biotech, Inc. The ACR thanks the following companies for providing educational grant support for the 2014 ACR Fellows-in-Training Scholarship Program: Celgene Corporation Takeda Pharmaceuticals International, Inc., US Region
EXHIBITORS 4S DAWN Clinical Software Office Software/Equipment Booth#: 1011 www.rheumatologysoftware. com A Trans-Atlantic Cardiovascular risk Calculator for Rheumatoid Arthritis (ATACC-RA) Booth#: 329 AbbVie Pharmaceuticals Booth#: 211, 919 www.abbvie.com Actelion Pharmaceuticals Pharmaceuticals, Therapeutic/ Patient Aid Products Booth#: 1218 Alexion Pharmaceuticals Booth#: 301 www.alxn.com AmbiMedInc Medical Device Booth#: 430 www.ambimedinc.com American Board of Internal Medicine Booth#: 3 www.abim.org American College of Physicians/ Annals of Internal Medicine Nonprofit Organization, Publisher Booth#: 11 www.acponline.org Amgen, Inc. Biotech Booth#: 943, 1111 www.amgen.com Antares Pharma Medical Device, Pharmaceuticals Booth#: 1159 www.antarespharma.com APLAR Nonprofit Organization Booth#: 6 www.aplar.org Apricus Biosciences Booth#: 304 www.apricusbio.com Arthritis Foundation Nonprofit Organization Booth#: 743 www.arthritis.org ARTHROS (Annual Rheumatology & Therapeutics Review for Organizations & Societies) Booth#: 400 www.arthros.org AstraZeneca Biotech, Pharmaceuticals Booth#: 1255 www.astrazeneca.com Autoimmune Diseases Association Booth#: 210 www.aarda.org Bayer Healthcare Pharmaceuticals Booth#: 1347 www.bayer.com Besse Medical Distributor, Pharmaceuticals Booth#: 428 www.besse.com Bioxydyn Contract Research Booth#: 1424 www.bioxydyn.com bmj/ard/rheumatology Booth#: 224 Bristol-Myers Squibb Pharmaceuticals Booth#: 1133 www.bms.com British Society for Rheumatology Nonprofit Organization Booth#: 1525 www.rheumatology.org.uk Celgene Corporation Pharmaceuticals Booth#: 655 www.celgene.com Celltrion Healthcare Co., LTD Pharmaceuticals, Therapeutic/ Patient Aid Products Booth#: 401 www.celltrionhealthcare.com CESAS Medical Nonprofit Organization Booth#: 1527 www.cytokinesignalling.com Chugai Pharmaceutical Co., Ltd Pharmaceuticals Booth#: 447 Cleveland Clinic Contract Research, Educational Materials for Patients, Registry Booth#: 325 Clinical and Experimental Rheumatology Publisher Booth#: 1039 www.clinexprheumatol.org ContextMedia:Health Digital Media, Educational Materials for Patients Booth#: 1138 www.contextmediahealth.com Corrona, LLC Biotech Booth#: 959 www.corrona.org Crealta Pharmaceuticals Booth#: 649 www.crealtapharma.com Crescendo Bioscience, Inc. Diagnostic Products Booth#: 643 www.crescendobio.com Diplomat Specialty Pharmacy Booth#: 1058 www.diplomat.is Edan Diagnostic Products, Medical Device Booth#: 221 www.edandiagnostics.com Elsevier Publisher Booth#: 1110 www.elsevierhealth.com EMD Serono, Inc. Pharmaceuticals Booth#: 510 www.emdserono.com Enovative Technologies Medical Device Booth#: 315 www.enovativetech.com Esaote North America Diagnostic Equipment/Products Booth#: 1447 www.esaoteusa.com ESCEO asbl Nonprofit Organization Booth#: 327 European Journal of Rheumatology Digital Media, Nonprofit Organization Booth#: 4 www.eurjrheumatol.org European League Against Rheumatism (EULAR) Nonprofit Organization Booth#: 226 www.eular.org Everidis Health Sciences Nutritional Products Booth#: 1529 www.everidis.com Exagen Diagnostics, Inc Diagnostic Products Booth#: 514 www.avisetest.com Federation of Clinical Immunology Socieites (FOCIS) Nonprofit Organization Booth#: 1557 www.focisnet.org Ferring Pharmaceuticals Inc. Medical Device Booth#: 1013 www.euflexxa.com/physician Fidia Pharma USA Inc. Biotech, Medical Device Booth#: 1457 www.fidiapharma.us Find-A-Code Booth#: 203 www.findacode.com Fresenius Kabi Booth#: 302 www.fresenius-kabi.ca 252 2014 Program Book
EXHIBITORS FUJIFILM SonoSite, Inc. Diagnostic Equipment/Products, Medical Device Booth#: 1301 www.sonosite.com GE Healthcare Diagnostic Equipment/Products, Medical Device Booth#: 846 Genentech, A Member of the Roche Group Pharmaceuticals Booth#: 421 www.gene.com Genzyme, a Sanofi company Biotech Booth#: 842 GlaxoSmithKline Pharmaceuticals Booth#: 1339, 1548 Hawaiian Moon Sunblock/Skincare Booth#: 311 Horizon Pharma, Inc. Pharmaceuticals Booth#: 229 www.horizonpharma.com Hospira Pharmaceuticals Booth#: 1421 www.hospira.com Image Analysis Medical Device, Pharmaceuticals Booth#: 1546 www.imageanalysis.org.uk Immco Diagnostics, A Trinity Biotech Company Booth#: 511 www.immco.com Inova Diagnostics, Inc. Diagnostic Products, Laboratory Equipment/Products Booth#: 1060 www.inovadx.com inpractice Resources LLC. Booth#: 410 www.inpractice.com International Foundation for Autoimmune Arthritis Booth#: 8 www.ifautoimmunearthritis.org Investigator Databank Booth#: 1014 www.investigatordatabank.org Iroko Pharmaceuticals, LLC Pharmaceuticals Booth#: 411 www.iroko.com Janssen Biotech, Inc. Pharmaceuticals Booth#: 1139 www.janssenbiotech.com Johns Hopkins Rheumatology Medical Conference, Nonprofit Organization Booth#: 911 www.hopkinsrheumatology.org Journal of Rheumatology, The Publisher Booth#: 333 www.jrheum.org La Lettre Du Rhumatologue - EDIMARK SANTE Publisher Booth#: 1547 www.edimark.fr LabCorp Booth#: 826 Letter to Editor Rheumatology Digital Media, Publisher Booth#: 220 www.lettertoeditor.org Lilly USA, LLC. Pharmaceuticals Booth#: 1310, 1554 www.lilly.com LipoScience Diagnostic Products, Medical Device Booth#: 1160 www.liposcience.com MBL International Biotech, Diagnostic Products Booth#: 1404 www.mblintl.com Mallinckrodt Autoimmune & Rare Diseases (formerly Questcor) Pharmaceuticals Booth#: 457, 1061 www.questcor.com McKesson Specialty Health Distributor, Pharmaceuticals Booth#: 610 www.rheumatology. mckessonspecialtyhealth.com MD Conference Express Booth#: 1521 www.mdconferencexpress.com Medac Pharma, Inc. Pharmaceuticals Booth#: 1319 www.medacpharma.com MediNatura Pharmaceuticals Booth#: 422 www.medinatura.com METEOR Nonprofit Organization Booth#: 9 www.meteorfoundation.com Metro Medical Distributor Booth#: 313 www.metromedical.com Mission Pharmacal Company Booth#: 1459 www.missionpharmacal.com Mitek Sports Medicine Booth#: 1015 www.depuysynthes.com Modernizing Medicine Office Software/Equipment Booth#: 726 www.modmed.com MotherToBaby Pregnancy Studies conducted by Organization of Teratology Information Specialists Nonprofit Organization Booth#: 2 www.pregnancystudies.org Multispecialty Physician Partners Booth#: 424 www.multispecailtyphysician. com mycme Digital Media, Educational Materials for Patients Booth#: 414 www.mycme.com, www. haymarketmedicaleducation. com National Data Bank for Rheumatic Diseases Nonprofit Organization Booth#: 321 www.ndb.org National Institute of Arthritis and Musculoskeletal and Skin Diseases Educational Materials for Patients, Government Agency Booth#: 319 www.niams.nih.gov National Jewish Health Booth#: 1519 www.njlabs.org National Library of Medicine Educational Materials for Patients, Government Agency Booth#: 1 www.nlm.gov National Scleroderma Core Centers Contract Research, Nonprofit Organization Booth#: 205 www.bu.edu/sscores Neovacs Biotech Booth#: 747 www.neovacs.fr Novartis Pharmaceuticals Corporation Pharmaceuticals Booth#: 1328, 1328A,1329, 1429 www.novartis.com NYU Langone Medical Center - NYU Hospital for Joint Diseases Nonprofit Organization Booth#: 418 www.nyulmc.org/cmc/ rheumatology 2014 Program Book 253
EXHIBITORS Ossur Americas Medical Device Booth#: 1114 www.ossur.com Otto Trading Inc Booth#: 1451 www.irestmassager.com Oxford Immunotec Diagnostic Products Booth#: 955 www.oxfordimmunotec.com Oxford University Press Publisher Booth#: 1012 www.oup.com PAIGE1 Booth#: 1402 PANLAR Nonprofit Organization Booth#: 228 www.panlar.org Patient Access Network Foundation Nonprofit Organization Booth#: 10 www.panfoundation.org PatientPoint Digital Media, Educational Materials for Patients Booth#: 639 www.patientpoint.com Pfizer, Inc. Pharmaceuticals Booth#: 611 www.pfizer.com QIAGEN Biotech, Diagnostic Products Booth#: 402 www.quantiferon.com Quest Diagnostics Diagnostic Products Booth#: 513 Quintiles Booth#: 212 www.quintiles.com R. J. Fasenmyer Center for Clinical Immunology Nonprofit Organization Booth#: 323 Raintree Systems, Inc. Booth#: 1551 www.raintreeinc.com RDL Reference Laboratory Diagnostic Products Booth#: 631 www.rdlinc.com Regeneron Pharmaceuticals, Inc. Pharmaceuticals Booth#: 1147 www.regeneron.com RheumaKnowledgy Digital Media, Publisher Booth#: 426 www.rheumaknowledgy.com Rheumatology News Publisher Booth#: 1325 www.rheumatologynews.com Rottapharm Ltd Nutritional Products, Pharmaceuticals Booth#: 1054 www.rottapharm.com Scandinavian Journal of Rheumatology Nonprofit Organization Booth#: 331 www.scandjrheumatol.dk Scleroderma Foundation Educational Materials for Patients, Nonprofit Organization Booth#: 232 www.scleroderma.org Scleroderma Research Foundation Booth#: 13 www.srfcure.org SI-BONE Medical Device Booth#: 738 www.si-bone.com Sjögren s Syndrome Foundation Nonprofit Organization Booth#: 432 Sobi, Inc Biotech, Pharmaceuticals Booth#: 1055 www.sobi.com Spondylitis Association of America Educational Materials for Patients, Nonprofit Organization Booth#: 218 www.stopas.org Springer Publisher Booth#: 1305 www.springer.com Takeda Pharmaceuticals U.S.A., Inc. Pharmaceuticals Booth#: 1200 www.tpna.com The Gout & Uric Acid Education Society Educational Materials for Patients, Nonprofit Organization Booth#: 230 www.gouteducation.org The Myositis Association Nonprofit Organization Booth#: 7 www.myositis.org The RAConnection Booth#: 1560 www.theraconnection.com TheraTest Laboratories, Inc. Diagnostic Equipment/Products, Diagnostic Products Booth#: 612 Tonix Pharmaceuticals Booth#: 1517 TSI Healthcare Office Software/Equipment Booth#: 614 www.tsihealthcare.com UCB, Inc. Pharmaceuticals Booth#: 439 www.ucb.com University of Alabama at Birmingham Booth#: 222 US Rheumatology Booth#: 201 Value-Based Care in Rheumatology Publisher Booth#: 627 www.valuebasedrheumatology. com Vasculitis Foundation Educational Materials for Patients, Nonprofit Organization Booth#: 5 www.vasculitisfoundation.org Wiley Publisher Booth#: 1010 www.wiley.com Wolters Kluwer Health Booth#: 727 www.lww.com Zimmer Booth#: 1400 www.zimmer.com 254 2014 Program Book
Corporate Roundtable The Rheumatology Research Foundation is making great strides in its mission to advance research and training to improve the health of people with rheumatic diseases. The Foundation is increasing its funding for research and training thanks in large part to the generosity of its Corporate Roundtable donors. Participation in the Corporate Roundtable is a direct investment in the Foundation s efforts to develop the next generation of rheumatology professionals who will provide high quality care for patients, as well as accelerate research that will lead to advances in treatments and, one day, cures. Donations from the Corporate Roundtable support the Foundation through Journey to Cure: The Campaign to Advance Patient Care and Accelerate Discoveries. The Foundation thanks the Corporate Roundtable donors for their exemplary support. Leadership ($7,500,000+) Principal ($2,500,000+) Partner ($1,000,000+) Follow us on social media: Corporate Roundtable members as of September 30, 2014
AcKNOWLEDGMENTS The ACR and the ARHP wish to thank the following organizations for providing support for the 2014 ACR/ARHP Annual Meeting AbbVie Networking Lounges Exhibit Hall Stair Clings Digital Media Tower Video Wall and Plasma Network North Lobby Banner Amgen, Inc. North Lobby Area Column Clings Scientific Program Book Session Tracker ARHP Morning Forum Bristol-Myers Squibb Company Hanging Aisle Signs Wi-Fi Way Celgene Corporation Exhibit Hall Floor Decals North Lobby Banner Genentech, a Member of the Roche Group Hotel Key Cards Pfizer, Inc. North Lobby Window Clings Shuttle Buses Regeneron Digital Media Tower 256 2014 Program Book
AcKNOWLEDGMENTS In addition to the support provided for the 2014 ACR/ARHP Annual Meeting, the ACR, the ARHP and the Foundation wish to thank the following organizations for providing support for activities and programs throughout the year. AbbVie Corporate Roundtable, Leadership Level Fellows Education Fund State-of-the-Art Clinical Symposium Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals Musculoskeletal Ultrasound Course for Rheumatologists with Interventional Cadaver Workshop Intermediate Membership Directory Annual Meeting Corporate Roundtable Symposium Annual Meeting Industry-Supported Post-Conference Symposium Amgen, Inc. Corporate Roundtable, Leadership Level Fellows Education Fund Amgen Fellowship Training Award Pediatric Visiting Professorship Award Pediatric Research Award ARHP Morning Forum Annual Meeting Corporate Roundtable Symposium AstraZeneca Corporate Roundtable, Principal Level Annual Meeting Corporate Roundtable Symposium Bioiberica, S.A. Annual Meeting Industry-Supported Post-Conference Symposium Bristol-Myers Squibb Company Corporate Roundtable, Partner Level Fellows Education Fund Winter Rheumatology Symposium Rheumatology Program Directors Conference Rheumatology Maintenance of Certification Course Pediatric Rheumatology Symposium Clinical Rheumatology for Health Professionals State-of-the-Art Clinical Symposium CARE 2014 ARHP Advanced Rheumatology Course Celgene Corporation Corporate Roundtable, Principal Level Rheumatology Program Directors Conference Rheumatology Maintenance of Certification Course Pediatric Rheumatology Symposium Clinical Rheumatology for Health Professionals State-of-the-Art Clinical Symposium CARE 2014 ARHP Advanced Rheumatology Course Annual Meeting FIT Scholarship Annual Meeting Corporate Roundtable Symposium Annual Meeting Industry-Supported Post-Conference Symposium Eli Lilly and Company Corporate Roundtable, Principal Level Winter Rheumatology Symposium Rheumatology Program Directors Conference Rheumatology Maintenance of Certification Course Pediatric Rheumatology Symposium Clinical Rheumatology for Health Professionals State-of-the-Art Clinical Symposium CARE 2014 ARHP Advanced Rheumatology Course Annual Meeting Corporate Roundtable Symposium Annual Meeting Industry-Supported Post-Conference Symposium GE Healthcare Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals Musculoskeletal Ultrasound Course for Rheumatologists with Interventional Cadaver Workshop - Intermediate Genentech, a Member of the Roche Group Corporate Roundtable, Principal Level Janssen Biotech, Inc. Corporate Roundtable, Partner Level Fellows Education Fund Scientist Development Award Oxford Immunotec Annual Meeting Industry-Supported Post-Conference Symposium Pfizer, Inc. Corporate Roundtable, Leadership Level State-of-the-Art Clinical Symposium Musculoskeletal Ultrasound Course for Rheumatologists Fundamentals Musculoskeletal Ultrasound Course for Rheumatologists with Interventional Cadaver Workshop Intermediate Image Bank Annual Meeting Corporate Roundtable Symposium Takeda Pharmaceuticals Annual Meeting FIT Scholarship UCB, Inc. Corporate Roundtable, Principal Level Annual Meeting Corporate Roundtable Symposium 2014 Program Book 257
Annual Meeting Planning Committee (AMPC) Disclosures The AMPC provides oversight and guidance on all educational activities related to the ACR/ARHP Annual Scientific Meeting. Because it is not always clear what content or topic will be discussed, committee members are asked to disclose all financial relationships. Recusal is the primary mechanism for resolution. However by the nature of committee work, the peer process also plays a role in ensuring balance. Amin, Shreyasee, MDCM, MP Disclosure: Tissue Gene, Inc., 5 Ardoin, Stacy, MD Disclosure: Johnson & Johnson, 5 Ascherman, Dana, MD Disclosure: Intermune, 2 Baer, Alan N., MD Disclosure: Nothing to disclose Beam, Thuy T., RN Disclosure: Nothing to disclose Bernstein, Elana, MD Disclosure: Nothing to disclose Block, Joel A., MD Disclosure: Ferring, Inc., 5; PLx Pharma, Inc., 9; Agios, Inc., 7; Daiichi-Sankyo, 7; Glaxo-SmithKline, 7; Elsevier, Inc. - other (Editor); Gilead, Inc., 1 Boackle, Susan, MD Disclosure: National institute of Health, 2; University of Colorado Denver, 3; National Institutes of Health, 5; American College of Rheumatology, Arthritis Foundation, 6 Breland, Hazel L., PhD, OTR/L Disclosure: Nothing to disclose Brunner, Hermine, MD, MSc, MBA Disclosure: Novartis, 5; Novartis, 8; Roche, 5; UCB, 5; Janssen, 5; Pfizer, 5; Medimmune, 5; Merck/Serono, 5; Celgene, 5; Abbvie, 5 Co, Dominic O., MD, PhD Disclosure: Orasure Technologies, 1 Cope, Andrew P., MD, PhD Disclosure: Roche, 5; Roche, 8; BMS, 5; Cellgene, 5 Cronin, Mary, MD Disclosure: Nothing to disclose Crow, Mary K. Peggy, MD Disclosure: Johnson & Johnson, 1; Pfizer, 1; Pregeneron, 1; Biogen Idec, 1; Amgen, 1; Merck, 1; Novo Nordisk, 2; Bristol Myers Squibb, 5; GlaxoSmithKline, 5; Takeda, 5; UCB, 5; EMD Merck Serono, 5; Roche Genentech, 5; Eisai, 5; Lilly, 5 Diamond, Betty, MD Disclosure: Nothing to disclose Edwards, N. Lawrence, MD Disclosure: Cymabay Pharmaceutical, 5; Novartis Pharmaceutical, 5; Quarteer Pharmaceutical, 5 Flood, Joseph, MD Disclosure: Nothing to disclose Foxworth, Judy, PhD, PT Disclosure: Nothing to disclose Gourley, Mark F., MD Disclosure: Nothing to disclose Hajj-Ali, Rula, MD Disclosure: Intuitive Surgical, 5; Endocave, 5; Ethicon, 5; Roche, 8; Up to date, 7 Hannan, Marian T., DSc, MPH Disclosure: Nothing to disclose Hassett, Afton, PsyD Disclosure: Bristol-Myers Squibb, 2; Pfizer, Inc., 2 Hausmann, Jonathan, MD Disclosure: Nothing to disclose Helfgott, Simon, MD Disclosure: Abbvie, 5; Genetech, 5; Best Doctors, 5; Up To Date, 7 Howard, Rennie, MD Disclosure: Nothing to disclose Hughell, Laurie, PA-C, MPH Disclosure: Nothing to disclose Jarjour, Wael, MD Disclosure: Naridea Biopharmaceutical, 2; Naridea Biopharmaceutical, 5 Jolly, Meenakshi, MD, MS Disclosure: GSK, 5; Medlmmune, 5; LupusPro, 7 Kaplan, Mariana J., MD Disclosure: Nothing to disclose Khanna, Dinesh, MD, MSc Disclosure: NIH/NAIMS, 2; Scleroderma Foundation, 2; Pulmonary Hypertension Association, 2; Astra Zeneca, 2; BMS, 2; Savient, 2; The University of Michigan, 3; Actelion, 5; Astra Zeneca, 5; Bayer, 5; BMS, 5; Celgene, 5; DIGNA, 5; InterMune, 5; Merck, 5; Roche, 5; Sanofi-Aventis, 5; Takeda, 5 Kolasinski, Sharon, MD Disclosure: Nothing to disclose Loeser, Richard F., MD Disclosure: Nothing to disclose Lohr, Kristine M., MD, MS Disclosure: MEDISYS, 1; Baxter, 1; Merck, 1; Pfizer, 1; St Jude Medical, 1; Walgreen s, 1; Colgate, 1; Palmolive, 1; Sanofi, 1; Takeda Clinical Trail, 2; Site PI, 2; American College of Rheumatology, 2; Rheumatology Research Foundaition 2 Manno, Rebecca L., MD Disclosure: Nothing to disclose 258 2014 Program Book See page 247 for the list of disclosure relationships.
Annual Meeting Planning Committee (AMPC) Disclosures Matteson, Eric, MD Disclosure: Mesoblast, 2; Pfizer, 2; UCB Pharma, 2; Novartis, 2; Johnson & Johnson, 2; Janssen, 2; Celgene, 2; Roche/ Genetech, 2; Ardea Biosciences In Practice, 2; Medscape, 7; Up to Date, 7 McClatchey, William, MD Disclosure: Nothing to disclose McLean, Robert R., DSc, MPH Disclosure: Nothing to disclose Mintz, Sandra J., RN, BSN Disclosure: Nothing to disclose Oddis, Chester V., MD Disclosure: Questcor, 2; Questcor, 5; atyr Pharma (advisory board), 5 O Rourke, Kenneth S., MD Disclosure: Genetech (multicenter clinical trials), 2; Human Genome Sciences (multicenter clinical trials), 2 Rabinovich, Egla, MD, MPH Disclosure: Janssen Research & Develop, 2; UCB Pharma, 2; Abbvie, 2; Hoffman- LaRoche, 2 Sigal, Leonard H., MD Disclosure: BMS, 1; Novo Nordisk, 1; I work for a Clinical Research Organization and have been involved in trials for many companies, yet in no case do I benefit from that relationship or success of the study Silverman, Gregg J., MD Disclosure: Nothing to disclose Singer, Nora, MD Disclosure: Nothing to disclose Singh, Jasvinder, MD, MPH Disclosure: Takeda research grants; Savien, 2; Taked, 5; Savient, 5; Allergan, 5; Novartis Regeneron, 5; Market Research Companies (<$500 one time interviews), 5 Siva, Chokkalingam Chuck, MD, MS Disclosure: Nothing to disclose Stamatos, Christine, ANP-C Disclosure: Nothing to disclose Stojan, George, MD Disclosure: Nothing to disclose Stone, Kerry, MD Disclosure: Merck & Company (Husband), 3 Taylor, Greg, MSW Disclosure: Nothing to disclose Rodney Tehrani, MD Disclosure: Nothing to disclose Tsokos, George C., MD Disclosure: GSK, 5; Biogen (DMC) Member), 5; Elsevier Consulting (editor), 5 Varga, John, MD Disclosure: JBT, 1; Baxter, 2; Takeda, 2; Actelion, 2; Roche, 2; Bioline, 5; Biogen, 5; Sprige, 7 Venuturupalli, Swamy R., MD Disclosure: Nothing to disclose White, Douglas W., MD, PhD Disclosure: Crescendo Bioscience, 5 Wilkes, Margaret R., MD Disclosure: Nothing to disclose 2014 Program Book 259
2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures ACR/ARHP Abstract CATEGORY Chairs A Anolik, Jennifer H., MD, PhD Disclosure: Karyopharm Therapeutics, Inc., 2; Medimmune, 2 B Baer, Alan N., MD Baeten, Dominique L., MD, PhD Bardin, Thomas, MD Disclosure: Manarini, Savient, Astra Zeneca, Novartis, Sobi, 5 Barnabe, Cheryl, MD, MSc Barton, Jennifer, MD Disclosure: Investigator-initiated research grant from Pfizer; ending 10/2014, 2 Battistone, Michael J., MD Beam, Thuy T., BSN, RN Bingham III, Clifton O., MD Disclosure: Abbvie, 9; BMS, Pfizer, Janssen, 2; Lilly, NovoNordisk, UCB, Janssen, BMS, Abbvie, Genentech/Roche, Pfizer, 5; OMERACT, 6; PCORI, NIH, 2; UpToDate, 7 Binstadt, Bryce A., MD, PhD Bookman, Arthur A. M., MD Disclosure: Journal of Rheumatology, 6 Boomershine, Chad, MD, PhD Disclosure: Pfizer Inc, 8; Takeda, 8 Breland, Hazel L., PhD, OTR/L Brown, Lin A., MD Brunner, Hermine, MD Buchbinder, Rachelle, MBBS, MSc, PhD Buckley, Lenore M., MD, MPH Burmester, Gerd, MD Disclosure: AbbVie, BMS, Medmune, MSD, Novartis, Pfizer, Roche, UCB, 5; AbbVie, BMS, MSD, Pfizer, Roche, UCB, 8; AbbVie, BMS, Pfizer, Roche, UCB, 2 Buyon, Jill P., MD Bykerk, Vivian P., MD Disclosure: Amgen, 9; Antares Pharma Inc, 9; Becton Dickinson, 9; Bristol-Myers Squibb, 9; Genentech/Roche Inc, 9; Medac Inc, 9; Merck Pharmaceuticals, 9; Novartis Pharmaceutical Corporation, 1; Pfizer Inc, 9; UCB Pharmaceuticals, 9 Clowse, Megan E. B., MD, MPH Disclosure: UCB, 9 Cohen, Philip L., MD Disclosure: Janssen Pharmaceutica Product, L.P., 2 Conaghan, Philip G., MD, PhD Disclosure: Abbvie, 8; Bioiberica, 8; Bristol- Myers Squibb, 5; Janssen Pharmaceutica Product, L.P., 5; Merck Pharmaceuticals, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 8; UCB, 8 Dalbeth, Nicola, MBChB, MD Disclosure: Ardea, 2; AstraZeneca, 5; Fonterra, 5; Menorini, 8; Takeda, 5 C D Dall era, Maria, MD Dao, Kathryn H., MD Disclosure: Merck Human Health, 5; Pfizer, Celgene, UCB, Novartis, 2 Davidson, Anne, MBBS Disclosure: Eisai, 5; Eli Lilly and Company, 5; GSK, 8 Davis III, John M., MD, MS Deodhar, Atul A., MD Disclosure: Abbvie, Novartis, Pfizer, UCB, 5; Amgen, Abbvie, Novartis, Pfizer, UCB, 2 E Edwards, N. Lawrence, MD Disclosure: Cymabay Pharma; AstraZeneca Pharma: Takeda Pharma; Questcor Pharma, 5 Elkon, Keith B., MD Ferguson, Polly J., MD Fischer, Aryeh, MD FitzGerald, John, MD, PhD FitzGerald, Oliver, MD Disclosure: Cellgene, UCB, Janssen, 8; Janssen, UCB, 5; Pfizer Inc, BMS, Abbott, MSD, 2 Foxworth, Judy, PhD, PT F G Gaffney, Patrick M., MD Gilkeson, Gary S., MD Disclosure: Alexion Pharmaceuticals, Inc., 7; Berg, 2; Dynavax, 2; GlaxoSmithKline, 2 Gladman, Dafna D., MD Disclosure: BMS, 2, 5 Goldring, Mary B., PhD Disclosure: Abbott Laboratories; Biogen-IDEC, 2; Endocyte, 5 Gordon, Jessica K., MD, MSc H Hahn, Paulette C., MD Harvey, William F., MD, MSc Disclosure: Vindico Medical Education, 5 Hassett, Afton L., PsyD Disclosure: Bristol-Myers Squibb, 2; Lexicon Pharmaceuticals, 5; Pfizer Inc, 2 260 2014 Program Book See page 247 for the list of disclosure relationships.
2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures Hetland, Merete Lund, DMSc, MD, PhD Higgs, Jay B., MD Hughell, Laurie A., PA-C, MPH Hummers, Laura K., MD, ScM Disclosure: Actelion Pharmaceuticals US, 2; Medimmune, 2; Novartis Pharmaceutical Corporation, 2; Roche Pharmaceuticals, 2 Husni, M. Elaine, MD, MPH Disclosure: Genzyme Corporation, 2 Imundo, Lisa F., MD Inman, Robert D., MD Disclosure: Abbvie, Amgen, Janssen, Pfizer, UCB, 5 Johnson, Sindhu R., MD, PhD Kalliolias, George D., MD, PhD Kamen, Diane L., MD, MS Kang, Insoo, MD Katz, Jeffrey N., MD, MSc I J K Kavanaugh, Arthur, MD Disclosure: Abbvie, 2; Amgen, 2; BMS, 2; Janssen Pharmaceutica Product, L.P., 2; UCB, 2 Kay, Jonathan, MD Disclosure: AbbVie Inc., 2, 5; Amgen, 5; Ardea Biosciences, Inc., 2; AstraZeneca, 5; Bristol- Myers Squibb, 5; Crescendo Bioscience, Inc., 5; Eli Lilly and Company, 2, 5; Epirus Biopharmaceuticals, Inc., 5; Genentech Inc., 5; Hospira, Inc., 5; Janssen Biotech, Inc., 5; PanGenetics, B.V., 5; Pfizer Inc, 5; Roche Laboratories, Inc., 2, 5 Kazi, Salahuddin, MD L Lafyatis, Robert, MD Disclosure: Biogen Idec, 5; BMS, 5; Bristol- Myers Squibb, 5; Celgene, 5; Genentech, 2; Human Genome Sciences, Inc., 2; Intermune, 5; Medimmune, 5; Precision Dermatology, 5; PRISM Pharma Co. Ltd., 5; Regeneron, 2; Shire, 2, 5; UCB, 2 Laster, Andrew J., MD Disclosure: Amgen; Genentech; Eli Lilly, 8; Genentech and Biogen IDEC Inc.; Eli Lilly, 5; ISCD, 6; MediMaps, 9 Lee, Yvonne C., MD, MMSc Disclosure: Cubist Pharmaceuticals, 1; Express Scripts Holding Co, 1; Forest Research Institute, 2; Merck and Co, 1; Perrigo Co, 1 Levy, Roger A., MD Lim, S. Sam, MD, MPH Disclosure: Accordant, 5; Bristol-Myers Squibb, 9; Eli Lilly and Company, 9; Exagen, 5; Genentech and Biogen IDEC Inc., 9; GSK, 2; MedImmune, 5, 9; Pfizer Inc, 9; Questcor, 5 Lo, Grace H., MD, MSc Disclosure: ACR, 9; NIH/NIAMS, 2 Louie, Grant H., MD, MHS Disclosure: AbbVie, 5 M Malfait, Anne-Marie, MD, PhD Disclosure: Ferring, 5 Markenson, Joseph A., MD Disclosure: Abbvie, 8; Amgen, 5; Anteres, 8; BMS, 8; Celgene, 8; Iroko, 8; Jansen, 8; Lilly, 5 Marshak-Rothstein, Ann, PhD Maz, Mehrdad, MD McInnes, Iain B., PhD Disclosure: Astra Zeneca, 2, 5; Janssen Pharmaceutica Product, L.P., 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 2, 5; UCB, 2 Mease, Philip J., MD Disclosure: AbbVie, 2, 5, 8; Amgen, 2, 5, 8; Bristol-Myers Squibb, 2, 5, 8; Celgene, 2, 5; Covagen, 5; Crescendo, 2, 5, 8; Genentech and Biogen IDEC Inc., 2, 5, 8; Janssen Pharmaceutica Product, L.P., 2, 5, 8; Lilly, 2, 5, 8; Merck Pharmaceuticals, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Pfizer Inc, 2, 5, 8; UCB, 2, 5, 8; Vertex, 2, 5 Michaud, Kaleb, PhD N Niewold, Timothy B., MD Nigrovic, Peter A., MD Disclosure: Alkermes, Inc., 5; Baxter, 2; Momenta, Inc., 5; Novartis Pharmaceutical Corporation, 5 O Olsen, Nancy J., MD Pachman, Lauren M., MD Paget, Stephen A., MD Disclosure: Crescendo Bioscience and Medscape, 5 Perlman, Harris R., PhD Pernis, Alessandra B., MD Pisetsky, David S., MD, PhD P R Rauch, Joyce, PhD Reed, Ann M., MD Reveille, John D., MD Disclosure: Abbvie, UCB, BMS, 5 2014 Program Book 261
2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures S Scanzello, Carla R., MD, PhD Schmajuk, Gabriela, MD, MS Schmidt, Wolfgang A., MD Disclosure: Abbvie, 2, 5, 8; Actelion Pharmaceuticals US, 2; Berlin Chemie, 5, 8; Esaote, 2; General Electric, 2; Medac, 8; Merck Pharmaceuticals, 2, 8; Mundipharma, 2, 8; Novartis Pharmaceutical Corporation, 2, 5; Pfizer Inc, 8; Roche Pharmaceuticals, 2, 5, 8; Savient, 2; Siemens, 2; UCB, 8 Schnitzer, Thomas J., MD, PhD Disclosure: Allergan, 5; Janssen Pharmaceutica Product, L.P., 5; Lilly, 2; McNeil Consumer & Specialty Pharmaceuticals, 5; Nuvo, 2 Shahrara, Shiva, PhD Shanmugam, Victoria K., MBBS, MRCP Disclosure: Multiple, 9 Singer, Nora G., MD Disclosure: abbvie, 5; Clinical site- contract wtih MetroHealth, 9; Merck Pharmaceuticals, 2 Singh, Ram P., PhD Siva, Chokkalingam, MD Spiera, Robert F., MD Disclosure: Actelion Pharmaceuticals US, 2; GlaxoSmithKline, 2; Intermmune, 2; Novartis Pharmaceutical Corporation, 2; Roche- Genetech, 2 Stamatos, Christine A., DNP, ANP-C Suter, Lisa, MD Taylor, Gregory, MSW T V van Den Bosch, Filip, MD, PhD W Warrington, Kenneth J., MD Yazdany, Jinoos, MD, MPH Y Z Zeft, Andrew, MD, MPH Disclosure: Merck Human Health, 1; Novartis Pharmaceutical Corporation, 5; OPKO, 1 Zink, Angela, PhD ACR/ARHP Abstract Reviewers A Abril, Andy, MD Adam, Paul M, MSW Aggarwal, Rohit, MD, MS Aletaha, Daniel, MD, MSc Allanore, Yannick, MD, PhD Disclosure: Actelion Pharmaceuticals US, 5; Pfizer Inc., 5; Roche Pharmaceuticals, 5; Sanofi-Aventis Pharmaceutical, 5 Allen, Kelli D., PhD Aranow, Cynthia, MD Ascherman, Dana P., MD Askanase, Anca, MD, MPH Disclosure: GSK. Centocor, 5 Assassi, Shervin, MD, MS B Backman, Catherine L., PhD Baker, Nancy A., MPH, OTR, OTR/L Barbour, Kamil E., PhD Barnado, April, MD Barrat, Franck, PhD Disclosure: Biogen Idec, 5 Bartels, Christie M., MD, MS Bartlett, Susan J., PhD Becker, Mara L, MD, MSCE Behrens, Edward M., MD Berman, Jessica, MD Bertolaccini, Maria Laura, MD, PhD Beukelman, Timothy, MD, MSCE Disclosure: Crescendo Bioscience, 5; Genentech and Biogen IDEC Inc., 5; McKesson Health Solutions, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 2; UCB, 5 Blalock, Susan J., PhD Boackle, Susan A., MD Boers, Maarten, MD, MSc, PhD Disclosure: BMS, 5; GSK, 5; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5 Boin, Francesco, MD 262 2014 Program Book See page 247 for the list of disclosure relationships.
2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures Bombardieri, Stefano, MD Bradley, Laurence A., PhD Disclosure: UpToDate Rheumatology, 7 Braun, Juergen, MD Bridges Jr., S. Louis, MD, PhD Brothers, Mary C., ARNP, CPNP Cairns, Ewa, PhD Callahan, Leigh F., PhD Caplan, Liron, MD, PhD Caricchio, Roberto, MD Carter, John D., MD Castelino, Flavia V., MD Castrejón, Isabel, MD, PhD Chakravarty, Eliza, MD, MS Chandran, Vinod, MBBS, MD, DM, PhD Disclosure: Abbvie, 2; Abbvie, Amgen, Celgene, Janssen, UCB, 5; Oxford University Press, 7 Charles, Julia F., MD, PhD Chatham, W. Winn, MD Chen, Di, MD, PhD Choi, Hyon K., MD, DrPH Christenson, Mary E., PhD, PT C Chung, Cecilia P., MD, MPH Cid, Maria C., MD. PhD Cidon, Michal, MD Clark, Marcus R., MD Clegg, Daniel O., MD Disclosure: Abbvie, 5 Co, Dominic, MD, PhD Disclosure: Orasure Technologies, 1 Cohen, Stanley B., MD Disclosure: Abbvie, 2; Amgen, 5; Amplimmune, 2; BMS, 5; Corrona, 6; Flexion, 2; Lilly, 2; Merck Human Health, 5; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2; Roche Pharmaceuticals, 2 Corr, Maripat, MD Coty, Mary-Beth, PhD, RN Cox, Talitha, MA, OTR/L Craft, Joseph E., MD Disclosure: AbbVie, Pfizer, Novo Nordisk, 5; L2 Diagnostics, 1; UV Therapeutics, 1 Criswell, Lindsey A., MD, MPH Disclosure: Medimmune, 5 Cronstein, Bruce N., MD Disclosure: AstraZeneca, 2; Bristol-Myers Squibb, 5; Canfite Pharma, 1; Celgene, 2; Eli Lilly & Co., 5; Gilead, 2; Numerous patents, 9; Takeda, 2 Crow, Mary K., MD Disclosure: Johnson & Johnson, 1 Crowson, Cynthia, MS Disclosure: Roche Pharmaceuticals, 2 Curtis, J. R., MD, MPH, MS Disclosure: Abbvie, 2, 5; Amgen, 2, 5; BMS, 2, 5; Celgene, 5; Corrona, 2, 5; Janssen Pharmaceutica Product, L.P., 2, 5; Merck Pharmaceuticals, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 2, 5; UCB, 2, 5 D Davis, Aileen M., PhD de Vlam, Kurt L., MD Disclosure: Abbott Laboratories, UCB, Janssen, MSD, Pfizer, 5; Pfizer, Janssen, 8 Deane, Kevin D., MD, PhD Demoruelle, Kristen, MD Denton, Christopher P., MD, PhD Disclosure: Actelion GSK, CSL Behring, Sanofi Aventis, Merck-Serono, Genentech-Roche, 5; Actelion Pharmaceuticals US, 2 Dewing, Kori A., DNP, ARNP Dixon, William G., MRCP, PhD Domsic, Robyn T., MD, MPH Disclosure: Actelion, 5 Dore, Robin K., MD Disclosure: Amgen, Eli Lilly, 2, 5, 8; UCB, 8 Dragone, Leonard L., MD, PhD Dufour, Alyssa B., PhD Dunlop, Dorothy D., PhD Ehrlich-Jones, Linda S., PhD, RN Elewaut, Dirk, MD, PhD Emery, Helen M., MD E Erkan, Doruk, MD Disclosure: Alexion Pharmaceuticals, Inc., 5; A ACTION Executive Committee Chair, 6; Eli Lilly and Company, 2; GlaxoSmithKline, 8; Lupus Clinical Trials Consortium, 2; New York Community Trust, 2 Escalante, Agustin, MD 2014 Program Book 263
2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures Espinoza, Luis R., MD Feghali-Bostwick, Carol A., PhD Feldman, Candace H., MD, MPH Disclosure: Pfizer Inc, 2 F Fields, Theodore R., MD Disclosure: AstraZenica Pharmaceutics, 5; Crealta Pharmaceuticals, 5; Pfizer Pharmaceuticals, 8; Takeda Pharmaceuticals, 5, 8 Fisher, Nadine M., EdD Fleischmann, Roy, MD Disclosure: AbbVie, Amgen, Pfizer, Janssen, UCB, BMS, Genentech, Roche, Lilly, Novartis, Vertex, Merck, Sanofi-Aventis, Regneron,, 2; AbbVie, Amgen, Pfizer, UCB, BMS, Lilly, Vertex, Sanofi-Aventis, Regeneron, 5 Fox, David A., MD Disclosure: Janssen Pharmaceutica Product, L.P., 2 Gabay, Cem, MD, PhD Disclosure: Abbott Immunology Pharmaceuticals, 5; Amgen, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 2, 5 G Gaffo, Angelo L., MD, MSPH Disclosure: Cymabay Inc, 5 Genant, Harry K., MD, PhD Disclosure: Amgen, Lilly, Merck, Pfizer, Janssen, Roche, Servier, Daiichi, Synarc, 5 Genovese, Mark C., MD Disclosure: Abbvie, 2, 5; Amgen, 2, 5; Lilly, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Pfizer Inc, 2, 5; Sanofi- Aventis Pharmaceutical, 2, 5; Vertex, 2, 5 Gensler, Lianne S., MD Disclosure: AbbVie, 5; OptumRx, 5; UCB, 5 Gibofsky, Allan, JD, MD Disclosure: Abbott Immunology Pharmaceuticals, 1, 5, 8; Amgen, 1, 5, 8; Antares Pharma, 5; Bristol-Myers Squibb, 1; Celgene, 5; FDA, 6; GlaxoSmithKline, 1; Horizon Pharma, 5; Iroko Pharma, 5; Johnson & Johnson, 1; Pfizer Inc, 1, 5, 8; UCB, 8 Giles, Jon T., MD, MPH Disclosure: Genentech and Biogen IDEC Inc., 5; Pfizer Inc, 2 Goldman, John A., MD Disclosure: Amgen, BMS, 1; Celgene, Pfizer, Amgen, 8 Goldring, Steven R., MD Goldstein, Barbara L., MD, MMSc Golightly, Yvonne M., PT, MS, PhD Goode, Adam P., DPT, PhD Goodman, Susan M., MD Greco, Carol M., PhD Guccione, Andrew A., PhD, DPT Guillevin, Loic, MD Disclosure: LECTURE FEES, 9 Haroon, Nigil, MD, PhD, DM Disclosure: Abbvie, Amgen, Pfizer, Celgene, UCB, Janssen, 5 Helliwell, Philip S., MA, PhD Disclosure: Janssen, Abbvie, BMS, Celgene, Amgen Eli Lilly, 5 H Hill, Catherine L., MBBS, MD Hobbs, Kathryn, MD Disclosure: Amgen., 5; UCB, 9 Huang, Haochu, PhD Hudson, Marie, MD, MPH Hunter, David J., MBBS, PhD Hyrich, Kimme, MD, PhD Disclosure: Pfizer Inc, 5 Iversen, Maura D., BSc, DPT, SD, MPH Jacob, Binu, MSc, PhD Jones, Karla, RN Jonsson, Roland, DDS, PhD Kaeley, Gurjit S., MBBS, MRCP Disclosure: Abbott Immunology Pharmaceuticals, 5; Esaote, 9; Sonosite, 9 Kalunian, Kenneth, MD Kaplan, Mariana J., MD Kastanek, Lisa M., RN, CCRC Katz, Robert S., MD Keenan, Robert T., MD, MPH Disclosure: AstraZeneca, 5; Takeda, 5 Kermani, Tanaz A., MD Kim, Susan S., MD Kim, Wan-Uk, MD, PhD Kirou, Kyriakos A., MD Kissin, Eugene Y., MD Disclosure: SonoSite inc, 9; USSONAR Secretary, 6 Klein-Gitelman, Marisa S., MD, MPH Disclosure: UCB, Abbott, BMS, Hoffman- LaRoche, 2 Kloppenburg, Margreet, MD, PhD Disclosure: Abbvie, 9; Arthritis and Rheumatology, 6; Dutch Arthritis Foundation, Pfizer, TI Pharma, 2; Leiden University Medical Center, 3; Pfizer Inc, 8 I J K 264 2014 Program Book See page 247 for the list of disclosure relationships.
2014 ACR/ARHP Abstract CATEGORY Chair and Reviewer Disclosures Koné-Paut, Isabelle, MD Disclosure: Novartis Pharmaceutical Corporation, Swedish orphan biovitrum, CHUGAI, PFIZER, 5 Kono, Dwight H., MD Kuriya, Bindee, MD, MS Kwoh, C. Kent, MD Disclosure: Abbott Immunology Pharmaceuticals, 2; Express Scripts, 5; Novartis Pharmaceutical Corporation, 9; Pfizer Inc, 9 Kyttaris, Vasileios C., MD Disclosure: Vertex Pharmaceuticals, 5 Landewé, Robert, MD, PhD Lassere, Marissa N., MD, PhD Laufer, Terri M., MD Lavalley, Michael P., PhD Leib, Edward S., MD Disclosure: Medi-Imaps, 5 Levine, Alana B., MD Levy, Gerald D., MBA, MD Li, Linda C., PhD, PT Liao, Katherine P., MD, MPH Liossis, Stamatis Nick, MD Lories, Rik J., MD, PhD Disclosure: Abbvie, 5; Boehringer Ingelheim, 2; Celgene, 2; Pfizer Inc, 5 Lotz, Martin K., MD L M Mahr, Alfred, MD, PhD Disclosure: Chemocentryx, 5; CSK Behring, 2; Laboratoires Français de Biotechnologies, 9; MSD, 9 Makris, Una E., MD Mandl, Lisa A., MD, MPH Marder, Wendy, MD Martin, Richard, MD Disclosure: Amgen, 9; Boehringer Ingelheim, 9; Eli Lilly and Company, 9; Resolve Therapeutics, 9 Matsumoto, Alan K., MD Disclosure: Abbott Immunology Pharmaceuticals, 2, 5; Amgen, 2, 5; Ardea Biosciences, 2; Astellas, 2; AstraZeneca, 5; Auxillium Pharmaceuticals, 2; Boehringer Ingelheim, 2; Bristol-Myers Squibb, 2; Celgene, 2, 5; Centocor, Inc., 2; Corrona, 2; Eli Lilly and Company, 2; Forest Laboratories, 2; Genentech and Biogen IDEC Inc., 2, 5; Hoffmann-La Roche, Inc., 2; Human Genome Sciences, Inc., 2; Janssen Pharmaceutica Product, L.P., 2; Novartis Pharmaceutical Corporation, 2; Paragon Scientific Corp, 2; Pfizer Inc, 2; Q Med AB, 2; Regeneron, 2; Sanofi-Aventis Pharmaceutical, 2; Seikagaku, 2; Takeda, 2; Xoma Corporation, 2 Matteson, Eric L., MD, MPH McLean, Robert R., DSc, MPH McMahon, Maureen A., MD Disclosure: GSK, 8; Questcor, 5 Mikuls, Ted R., MD, MSPH Disclosure: Roche/Genentech, 2 Mittoo, Shikha, MD, MHS Disclosure: Abbott Immunology Pharmaceuticals, 2; Abvie, 5; Celgene, 5; UCB, 5; UCB Pharmaceuticals, 2 Mohan, Chandra, MD, PhD Morel, Laurence, PhD Moser Sivils, Kathy, PhD N Navarro-Millan, Iris, MD Neogi, Tuhina, MD, PhD Nguyen, Uyen Sa D.T., DSc, MPH O O Dell, James R., MD Disclosure: Abbvie and Lilly, 5 Oh, Terry H., MD Orozco, Catalina, MD Orzechowski, Nicole M., DO Osborn, Thomas, MD Ostergaard, Mikkel, DMSc, MD, PhD Disclosure: Abbott/Abbvie, BMS, Boehringer- Ingelheim, Eli-Lilly, Centocor, GSK, Janssen, Merck, Mundipharma, Novo, Pfizer, Schering- Plough, Roche UCB, and Wyeth, 5; Abbott/ Abbvie, Centocor, Merck, Schering-Plough,, 2 Pap, Thomas, MD P Passo, Murray H., MD Disclosure: Pfizer Inc, 5 Perl, Andras, MD, PhD Disclosure: Pfizer Inc, 2 Peschken, Christine A., MD, MSc Peterfy, Charles G., MD, PhD Disclosure: Amgen, 8; Spire Sciences, Inc., 4 Peterson, Erik J., MD 2014 Program Book 265
Phillips, Kristine, MD, PhD Pillinger, Michael H., MD Disclosure: Takeda Inc, 9; Takeda Inc; Savient Inc, 2 Poole, Janet L., OTR, PhD Porter, Duncan, MD Disclosure: Medimmune, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 2, 5 Prahalad, Sampath, MD, MSc Putterman, Chaim, MD Q Queen, Kate T., MD R Radbruch, Andreas, PhD Rahman, Anisur, MD, PhD Ruderman, Eric, MD Disclosure: AbbVie, 5; Amgen, 5; Celgene, 5; Corrona, 5; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P., 5; Lilly, 5; Medac, 5; Pfizer Inc, 2, 9; UCB, 5; Vertex, 5 S Sahni, Shivani, PhD Disclosure: General Mills Bell Institute of Health and Nutrition, 2 Salt, Elizabeth G., PhD Disclosure: ACR Scientist development award, 2; I received honorarium for speaking for the Insion Nursing society, 9; I serve on Pfizer medical education grant Reew Group, 5; NIH co-investigator, 2; Smithkline Beecham, 1 Sawalha, Amr H., MD Scher, Jose U., MD Schlenk, Elizabeth A., PhD, RN Schmidt, Kara M., MD Schulze-Koops, Hendrik, MD, PhD Smarr, Karen L., PhD So, Alexander, MD Disclosure: Astra-Zeneca, 5; Menarini, 5 Sokolove, Jeremy, MD Song, Jason Jungsik, MD Soriano, Enrique, MD Disclosure: Abbvie, Bristol-Myers Squibb, Janssen, Roche, UCB, 2; Abbvie, UCB, Roche, 5; Bristol-Myers Squibb, Pfizer, Abbvie, UCB, Janssen, Roche, 8 St.Clair, William, MD Disclosure: Biogen Idec, 2; Bristol-Myers Squibb, 9; Merck Pharmaceuticals, 9 Stevens, Anne M., MD, PhD Svensson, Camilla, PhD Szekanecz, Zoltan, MD, PhD Raychaudhuri, Soumya, MD, PhD Reiff, Andreas, MD Ritchlin, Christopher T., MD, MPH Disclosure: Abbott Laboratories, 5; Eli Lilly and Company, 5; Janssen Pharmaceutica Product, L.P., 2, 5; Novartis Pharmaceutical Corporation, 5; Regeneron, 5 Rose, Jillian A, LMSW Rose, Shawn, MD, PhD Rosenthal, Ann K., MD Roubey, Robert, MD Rouster-Stevens, Kelly A., MD, MS Schwartzman, Sergio, MD Disclosure: Abbvie, 5, 8; Genentech and Biogen IDEC Inc., 5, 8; Janssen Pharmaceutica Product, L.P., 5, 8; Pfizer Inc, 1, 5, 8; UCB, 5, 8 Shadick, Nancy A., MD, MPH Disclosure: ABBVIE, 2; Amgen, 2; BMS, 9; Crescendo Biosciences, 2; Genentech and Biogen IDEC Inc., 2; UCB, 2 Sharma, Leena, MD Shelef, Miriam A., MD, PhD Shelton, Lisa, B.Sc., BSN, RN Shiboski, Caroline H., DDS, MPH, PhD Silverman, Gregg J., MD Disclosure: Genentech, Pfizer, Lilly, Onyx, 5 Simms, Robert W., MD Disclosure: Actelion Pharmaceuticals USte, 2; Gilead, 8; Medimmune, 2 Tagoe, Clement E., MD, PhD Tanner, S. Bobo, MD Disclosure: Anteres, AMGEN, UCB, 5; BMS, Pfizer, Anteres, 8; GSK, Genentech, Lilly, UCB, Astra Zeneca, Novartis, Pfizer, Merck, Centocor, 2 Tarter, Laura L., MD Taylor, Janalee, CNS, CPNP, MSN Taylor, Nora R., MD T Taylor, Peter C., MD, PhD Disclosure: I have received research grants from AstraZeneca and from UCB Pharma, 2; I have served as a consultant to NovoNordisk, AstraZeneca, Lilly, Merck, Pfizer, UCB, Celgene, FujiBiologics, 5 266 2014 Program Book See page 247 for the list of disclosure relationships.
Taylor-Gjevre, Regina, MD Thatayatikom, Akaluck, MD Thiele, Ralf G., MD Torok, Kathryn S., MD U Unizony, Sebastian, MD Utz, Paul J., MD V Valle, Rafael R., MD van der Kraan, Peter, PhD van Eijk-Hustings, Yvonne JL, MSc, RN van Riel, Piet, MD, PhD van Vollenhoven, Ronald, MD, PhD Disclosure: AbbVie, Biotest, BMS, GSK, Janssen, Lilly, Merck, Pfizer, Roche, UCB, Vertex, 5; AbbVie, BMS, GSK, Pfizer, Roche, UCB, 2 Vilen, Barbara J., PhD Vina, Ernest R., MD, MSc Vinet, Evelyne, MD W Walsh, David, PhD Disclosure: Pfizer Inc, 2 Weisman, Michael H., MD Disclosure: Abbvie, 5; Amgen, 2; Astellas Pharma Global Development, 5; Celgene, 5; Centocor, Inc., 2; Cephalon, 2; Crescendo Bioscience, 5; Dynavax, 2; Genentech and Biogen IDEC Inc., 2; GSK, 2; Lilly, 2, 5; Pfizer Inc, 2; Rigel Pharma, 2; Roche Pharmaceuticals, 2; Sanofi-Aventis Pharmaceutical, 2; Teva Pharmaceuticals, 2; UCB Pharma, 5 Williams, David A., PhD Disclosure: Pfizer Inc, 2 Wise, Barton L., MD Disclosure: Pfizer, Inc, 9 Wither, Joan E., MD, PhD Yelin, Edward H., PhD Yost, John H, DO Young, Brandi, DNP, FNP-C Disclosure: Abbott Immunology Pharmaceuticalsv, 8; Genentech and Biogen IDEC Inc., 8 Yunus, Muhammad B., MD Zell, JoAnn, MD Ziminski, Carol M., MD Y Z 2014 Program Book 267
Invited Speaker /Moderator Index 268 A Abril, Andy, MD ACR-EULAR Rheumatica Guidelines...113 Acuna, Jose Carlos Crispin, MD Autoimmunity in Immunodeficiency...45 Adelowo, Olufemi, MD Patient Access to Biologics Across the Globe..108 Aggarwal, Rohit, MD, MS Myopathy: Issues in Diagnosis and Treatment (055)...103 Disclosure: Questcor, 2, 5 Myopathy: Issues in Diagnosis and Treatment (085)...145 Disclosure: Questcor, 2, 5 Aizer, Juliet, MD, MPH Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session...124 Disclosure: Hospital for Special Surgery Rheumatology Academy of Medical Educators, 2; Rheumatology Research Foundation, 2 Albayda, Jemima, MD Joint Injections (Knee, Ankle, Shoulder and Wrist) (226)...93 Joint Injections (Knee, Ankle, Shoulder and Wrist) (231)...110 Alder, Jonathan, PhD Telomeres, Telomerase and the Aging Immune System...83 Allanore, Yannick, MD, PhD Fibrotic Complications of Scleroderma...95 Disclosure: Actelion Pharmaceuticals US, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 5; Sanofi- Aventis Pharmaceutical, 5 Allen, Kelli D., PhD Muscle and Adipose Tissue in Rheumatic Diseases: Location is Everything...108 Stats Boot Camp: A Call to Aims for Researchers! An Interactive Session to Obtain Feedback on Your Specific Aims Section...93 Aluri, Vijay, MD ACR Knowledge Bowl: Preliminary Round...42 ACR Knowledge Bowl: Final Round...74 Amato, Anthony A., MD Myositis Mimics: Clinical and Molecular Diagnosis...111 2014 Program Book Amin, Shreyasee, MD CM, MPH Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management...135 Disclosure: TissueGene, Inc, 9 Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk...84 Disclosure: TissueGene, Inc, 9 Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside...148 Disclosure: TissueGene, Inc, 9 Anderson, Lee, BSN Practical Practice Management Session One: Improve Quality and Efficiency...53 Andrade, Felipe, MD PhD Complement in Rheumatic Disease...148 Disclosure: Medimmune, 2; Padlock, 5 Anolik, Jennifer H., MD, PhD Novel Regulatory Cell Subsets...124 Antonelli, Maria, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Aranow, Cynthia, MD Systemic Lupus Erythematosus: Central Nervous System (048)...63 Ardoin, Stacy P., MD, MS Protecting Bone Health in Pediatric Rheumatic Diseases...114 Argoff, Charles E., MD Etiology and Management of Peripheral Neuropathy in Patients with Rheumatic Disease......................120 Arroyo, Ramon, MD ACR Knowledge Bowl: Final Round...76 Disclosure: Genentech and Biogen IDEC Inc., 8 ACR Knowledge Bowl: Preliminary Round...42 Disclosure: Genentech and Biogen IDEC Inc., 8 Ascherman, Dana P., MD Advances in Molecular Profiling and Relevance to Autoimmune Disease...158 Mesenchymal Stem Cells: Biology and Use in Rheumatic Diseases...114 Astourian, Patrick, MPAS, PA-C ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions Outline the Value of Ultrasound...30 ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions Ultrasound Case Presentations...30 Atkinson, John, MD Basic Immunology for Clinical Rheumatologists (001)...32 Disclosure: 9 R01 GM99111 (Atkinson, John P.) 2 P30 AR48335 (Yokoyama, Wayne) 5 T32 AR007279 (Atkinson, John P.) Edward N. and Della L. Thome Memorial Foundation (Atkinson, John P.) U54 HL112303 (Sadler, Evan) Alexion Pharmaceutic, 2; Compliment Corporation; Scientific Advisory Board, 2010 present., 1; Consulting/Employment Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc.; Consultant 2008 present Alnylam Pharmaceuticals, Consultant, 2010 present Biothera; Consultant Research Advisory Board 2012 Clinical Pharmacy Services, CDMI; Con, 5; Consulting/Employment Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc.; Consultant 2008 present Alnylam Pharmaceuticals, Consultant, 2010 present Biothera; Consultant Research Advisory Board 2012 Clinical Pharmacy Services, CDMI; Kyp, 3 Basic Immunology for Clinical Rheumatologists (032)...70 Disclosure: 9 R01 GM99111 (Atkinson, John P.) 2 P30 AR48335 (Yokoyama, Wayne) 5 T32 AR007279 (Atkinson, John P.) Edward N. and Della L. Thome Memorial Foundation (Atkinson, John P.) U54 HL112303 (Sadler, Evan) Alexion Pharmaceutic, 2; Compliment Corporation; Scientific Advisory Board, 2010 present., 1; Consulting/Employment Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc.; Consultant 2008 present Alnylam Pharmaceuticals, Consultant, 2010 present Biothera; Consultant Research Advisory Board 2012 Clinical Pharmacy Services, CDMI; Con, 5; Consulting/Employment Celldex Therapeutics, formerly Avant Immunotherapeutics, Inc.; Consultant 2008 present Alnylam Pharmaceuticals, Consultant, 2010 present Biothera; Consultant Research Advisory Board 2012 Clinical Pharmacy Services, CDMI; Kyp, 3 Avery, Michael Thomas, DO Thieves Market Posters - ACR/ARHP Poster Session C...112 Ayata, Cenk, MD Primary Angiitis of the Central Nervous System and Its Mimics...149 B Backman, Catherine L., PhD Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Baer, Alan N., MD ACR Review Course - Management of Salivary Gland Involvement in Sjögren s Syndrome...29 Disclosure: UptoDate, 7 Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk...84 Disclosure: UptoDate, 7 Gout Management in 2014...44 Disclosure: UptoDate, 7 See page 247 for the list of disclosure relationships.
Myositis Mimics: Clinical and Molecular Diagnosis...111 Disclosure: UptoDate, 7 Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment...159 Disclosure: UptoDate, 7 Bailey, L. Charles, MD, PhD ACR Clinical Research Conference - Session II: Translating Patient-Centered Outcomes to the Real World Setting...24 Baker, Kristin, PhD Exercise Adherence in Arthritis: The Role of Technology...156 Baker, Nancy A., MPH, OTR, OTR/L Stats Boot Camp: The Effect Size: What Is It and How Can You Use It?...70 Work and Worker Health: Easy Accommodations Keep People with Arthritis Employed.......159 Bannuru, Raveendhara R., MD New ACR Recommendations for the Management of Rheumatoid Arthritis...38 Barbour, Kamil E., PhD Stats Boot Camp: The Prevalence Ratio as an Alternative to the Odds Ratio for Cross- Sectional Studies...114 Barnes, Betsy, PhD Therapeutic Targeting of the Innate Immune System...55 Hench Lectureship: Why Steroids Work in Some Inflammatory Diseases But Not in Others...120 Baron, Roland, DDS, PhD Rheumatology Research Foundation Oscar S. Gluck Memorial Lectureship: Emerging Therapies in Bone Diseases: Cellular Basis and Challenges...113 Disclosure: Merck Pharmaceuticals, Chugai, 2; Merck, Amgen, Lilly, Radius Health, Bone Therapeutics, Ashi Kasei, Daiichi Sankyo, Pfizer, 5 Barron, Karyl, MD Macrophages Gone Wild...111 Bartlett, Susan J., PhD Role of Nutrition in Rheumatic Diseases...104 Barton, Anne, MD, PhD ACR Basic Research Conference - Session III: Mechanisms of Immune Activation and Regulation...29 Basharat, Pari, MD Joint Injections (Knee, Ankle, Shoulder and Wrist) (226)...93 Joint Injections (Knee, Ankle, Shoulder and Wrist) (231)...110 Bass, Anne, MD Inflammation and Atherothrombosis...158 Disclosure: Pfizer Inc, 9; Weill Cornell Medical College Clinical Translational Science Center, 2 Bathon, Joan M., MD Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...34 Batiste, Linda C., JD Work and Worker Health: Easy Accommodations Keep People with Arthritis Employed.......159 Battafarano, Daniel F., DO Affordable Care Act...38 Battistone, Michael J., MD Educator: Medical Education: The Year in Review...45 Beam, Thuy T., BSN, RN Say What? : Implications of Adolescent Development and Behavior in Communicating With Health Care Providers...68 Behrens, Edward M., MD Macrophages Gone Wild...111 Belkaid, Yasmine, PhD ACR Basic Research Conference - Session II: The Microbiome and Regional Immunity...24 Bernstein, Elana J., MD, MSc Hepatitis C in 2014...108 Neonatal Lupus: From Bench to Bedside...83 Primary Angiitis of the Central Nervous System and Its Mimics...148 Sarcoidosis in 2014...36 The Butterfly Effect: Lupus Rashes and Their Mimics...45 The Great Debate: Belimumab for the Treatment of Systemic Lupus Erythematosus...46 Bhusal, Santosh, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Bianco, Paolo, MD Mesenchymal Stem Cells: Biology and Use in Rheumatic Diseases...114 Bingham III, Clifton O., MD ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Disclosure: OMERACT, 6; PCORI, 2 Birnbaum, Julius, MD, MHS Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk...84 Blackwell, Timothy, MD Insight into Lung Fibrosis...84 Disclosure: Boerhringer Ingelheim, 5; Intermune, 9 Blakley, Michael, MD Multidisciplinary Management of the Juvenile Idiopathic Arthritis Patient...146 Blitz, Jill R., PT, DPT Physical and Occupational Therapy for Juvenile Dermatomyositis: Treatment Planning and Case Presentations...148 Boackle, Susan A., MD ACR Basic Research Conference - Session II: The Microbiome and Regional Immunity...24 Complement in Rheumatic Disease...148 Bockenstedt, Linda, MD Rheumatology Research Foundation Memorial Lectureship to Honor Dr. Stephen E. Malawista, MD: Innate Immunity at the Core of Rheumatic Disease...45 Disclosure: L2 Diagnostics, 2 Bolster, Marcy B., MD Career Opportunities in Rheumatology: Making a Choice...94 Borenstein, David G., MD Career Opportunities in Rheumatology: Making a Choice...94 Disclosure: Clinical Care Options, 9; Patient Access Network Foundation, 6; Sucampo, 5 State-of-the-Art Interventional Recommendations for Chronic Low Back Pain...146 Disclosure: Back In Control Inc, 1; Clinical Care Options, 9; Patient Access Network Foundation, 6; Sucampo, 5 Boussiotis, Vassiliki A., MD, PhD Co-stimulation Pathways: Therapeutic Opportunities for the Rheumatic Diseases..147 Invited Speaker /Moderator Index 2014 Program Book 269
Invited Speaker/Moderator Index Brasington, Richard D., MD Biomarkers in Rheumatic Care... Disclosure: Clinical Trials for GSK, 2; Pfizer Inc, 8 Braun, Jonathan, MD, PhD ACR Basic Research Conference - Session IV: Microbiome and Rheumatic Disease...30 Braun, Jürgen, MD Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment...159 Disclosure: Abbott Immunology Pharmaceuticals, 5; MSD, 5; Pfizer Inc, 5; UCB, 5 Breeden, Elizabeth A., PharmD Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Breland, Hazel L., PhD, OTR/L Thriving With Rheumatic Disease: Cultivating Resilience...93 Brenner, Michael B., MD Rheumatology Research Foundation: Disease Targeted Research Special Session...111 Disclosure: Adheron Therapeutics, 1, 5 Bridges Jr., S. Louis, MD, PhD Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...34 New ACR Recommendations for the Management of Rheumatoid Arthritis...38 Strategies for Academic Success: The Roadmap from Mentee to Mentor...73 Year in Review...32 Bucala, Richard J., MD, PhD Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...35 Burke, Allen, MD Histopathology of Rheumatic Lung Disease (206)...38 Histopathology of Vasculitis (218)...76 Burnham, Jon M., MD, MSCE Protecting Bone Health in Pediatric Rheumatic Diseases...114 Disclosure: National Institutes of Health, 2 Buyon, Jill P., MD Neonatal Lupus: From Bench to Bedside...83 C Cacoub, Patrice, MD Curbside Consults Ask the Experts...95 Disclosure: Astra Zeneca, Bayer, Boehringer Ingelheim, Gilead, Glaxo Smith Kline, Janssen, Merck Sharp Dohme, Roche, Servier, Vifor., 5 Calabrese, Leonard H., DO Primary Angiitis of the Central Nervous System and Its Mimics...149 What is Not Central Nervous Angiitis: Making the Right Diagnosis (020)...44 Cantor, Harvey, MD New Regulatory T Cells...120 Cao, Xu, PhD The Role of Bone in the Pathogenesis of Osteoarthritis...95 Castelino, Flavia V., MD Insight into Lung Fibrosis...84 Strategies for Academic Success: The Roadmap From Mentee to Mentor...73 Chakravarty, Eliza, MD, MS Pregnancy and Rheumatic Diseases (036)...71 Disclosure: UCB, 5 Pregnancy and Rheumatic Diseases (086)...145 Disclosure: UCB, 5 Chandel, Navdeep S., PhD Bioenergetics and Energy Regulation...110 Chang, Anthony, MD Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (221)...76 Disclosure: Amirsys Publishing, Inc, 7; Questcor Pharmaceuticals, Inc, 5; Roche Organ Transplantation Research Foundation, 2 Renal Histopathology in Systemic Lupus Erythematosus and Vasculitis (234)...114 Disclosure: Amirsys Publishing, Inc, 7; Questcor Pharmaceuticals, Inc, 5; Roche Organ Transplantation Research Foundation, 2 Charles, Julia F., MD, PhD Rheumatology Research Foundation Special Session...111 Chatterjee, Soumya, MD, MS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Chen, Lan, MD, PhD Synovial Fluid Analysis and Crystal Identification (207)...38 Synovial Fluid Analysis and Crystal Identification (224)...83 Brophy, Robert, MD Meniscus Biology in Osteoarthritis...69 Caplan, Arnold I., PhD Novel Regulatory Cell Subsets...124 Disclosure: Osiris, 7 Cheroutre, Hilde, PhD How the Gut Primes the Immune System...44 270 Bruce, Susan, PharmD Pharmacotherapy: What s New in Rheumatology...120 Brummett, Chad M., MD Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation...104 State-of-the-Art Interventional Recommendations for Chronic Low Back Pain...146 Bryan, Angela, MD Thieves Market Posters - ACR/ARHP Poster Session C...112 2014 Program Book Caplan, Arthur L., PhD Ethics and Rheumatology...34 Caplan, Liron, MD, PhD Axial Spondyloarthritis Guidelines...44 Carey, John J., CCD, MS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Carsons, Steven E., MD ACR-EULAR Rheumatica Guidelines...113 Chira, Peter, MD, MS Multidisciplinary Management of the Juvenile Idiopathic Arthritis Patient...146 Disclosure: BMS, UCB, NIH, 2 Chohan, Saima, MD Crystal: Diagnosis and Management of Gout (021)...66 Choi, Hyon K., MD, DrPH Role of Nutrition in Rheumatic Diseases...104 Disclosure: AstraZeneca, 5; Takeda, 5 Chrostowski, Susan, MS, ANP-C, RN What Are Biosimilars?...70 See page 247 for the list of disclosure relationships.
Chung, Antanya, CPC, CPC-I, CRHC, CCS-P ACR Advanced Rheumatology Coding Course: Developing Experts in Rheumatology Coding and ICD-10-CM...23 Chung, Raymond T., MD Hepatitis C in 2014...108 Disclosure: Gilead, Mass Biologic, Abbvie, 2 Cidon, Michal, MD Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session...124 Clark, Marcus R., MD Systems Biology of Lupus Nephritis...73 Disclosure: AbbVie, 2; Medimmune, 2 Clauw, Daniel J., MD Evidence of the Benefits and Risks of Cannabis and Cannabinoids for Treating Chronic Pain..77 Disclosure: Lilly, Pfizer, Forest, UCB, Astra Zeneca, Merck, J & J, Nuvo, Jazz, Abbott, Cerephex, Iroko, Tonix, Theravance, 5; Pfizer, Cypress Biosciences, Forest, Merck, Nuvo, Cerephex, 2 Fibromyalgia 2014: Update on Management (004)...33 Disclosure: Lilly, Pfizer, Forest, UCB, Astra Zeneca, Merck, J & J, Nuvo, Jazz, Abbott, Cerephex, Iroko, Tonix, Theravance, 5; Pfizer, Cypress Biosciences, Forest, Merck, Nuvo, Cerephex, 2 Treatment Considerations in Chronic Pain...134 Disclosure: Lilly, Pfizer, Forest, UCB, Astra Zeneca, Merck, J & J, Nuvo, Jazz, Abbott, Cerephex, Iroko, Tonix, Theravance, 5; Pfizer, Cypress Biosciences, Forest, Merck, Nuvo, Cerephex, 2; Pfizer, Lilly, Forest, Astellis, Therevance, Tonix, IMS, Wyeth, Nuvo, 5; Pfizer, Lilly, Forest, Wyeth, Cerephex, Nuvo, 2 What Can Brain Imaging Tell Us About Pharmacologic and Non-Pharmacologic Treatment of Chronic Pain?................38 Disclosure: Lilly, Pfizer, Forest, UCB, Astra Zeneca, Merck, J & J, Nuvo, Jazz, Abbott, Cerephex, Iroko, Tonix, Theravance, 5; Pfizer, Cypress Biosciences, Forest, Merck, Nuvo, Cerephex, 2 Clayburne, Gilda M., MLT Synovial Fluid Analysis and Crystal Identification (207)...38 Synovial Fluid Analysis and Crystal Identification (224)...83 Clements, Philip J., MD, MPH Fibrotic Complications of Scleroderma...95 Cleveland, Rebecca J., PhD Stats Boot Camp: Statistical Analysis of Ordinal Data...77 Clifford, Alison, MD ACR Plenary Session III: Discovery 2014...118 Colbert, Robert A., MD, PhD The Microbiome in Health and Disease...35 Cole, Steven, MD Brief Action Planning (BAP): A Motivational Interviewing (MI) Technique to Enhance Patient Self-Management and Improve Outcomes..134 Disclosure: Comprehensive Motivational Intervions, LLC, 4 Collins, Christopher E., MD Social Media Boot Camp: Twitter Basics...37 Conaghan, Philip G., MD, PhD Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (232)...110 Disclosure: Abbott Laboratories, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 8 Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (237)...123 Disclosure: Abbott Laboratories, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 8 Coney, Cynthia, MEd, CAPP ARHP Keynote Address: Happiness From the Inside Out...37 Conway, Richard, BAO, BCh, MB, MRCPI ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Cook, Karon, PhD ACR Clinical Research Conference - Session I: Methodology and Development............24 Costenbader, Karen H., MD, MPH Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...35 Cox, Talitha, MA, OTR/L Physical and Occupational Therapy for Juvenile Dermatomyositis: Treatment Planning and Case Presentations...148 Crawford, Donah Z., BS, MA Pathways to Resilience: Biopsychosocial Mechanisms for the Generation of Positive Affect in Chronic Pain...115 Disclosure: Abbvie, Pfizer, Lilly, Bioventus, Genentech, 9 Criscione-Schreiber, Lisa G., MD Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session...124 Cron, Randy Q., MD, PhD Macrophages Gone Wild...111 Disclosure: Novartis Pharmaceutical Corporation, 5; Swedish Orphan Biovitrum, 5 Cronin, Mary E., MD ACR Plenary Session II: Discovery 2014...77 Clinical Issues Associated with the Use of Methotrexate...120 Cronstein, Bruce N., MD Age Before Beauty: Colchicine, Aspirin, Methotrexate and Their Mechanisms of Action...31 Disclosure: ACR Board of Directors, Ex officio, 6; ACR Committee on Research, 6; Arthritis Foundation, 6; AstraZeneca, 2; Bristol- Myers Squibb, 5; Canfite Pharma, 1; Celgene Pharmaeuticals, 2; Eli Lilly and Company, 5; Gilead Pharmaceuticals, 2; Multiple Patents, 9; Rheumatology Research Foundation, 6 Crosby, Judy K., JD ACR Clinical Research Conference - Session V: Patient Perspective...27 Crow, Mary K., MD ACR Plenary Session III: Discovery 2014...115 Disclosure: Bristol-Myers Squibb, 5; Eisai, 5; GlaxoSmithKline, 5; Lilly, 5; Novo Nordisk, 2; Pfizer-CTI, 2; Takeda, 5 Cruz, Nilsa ACR Practice Management Pre-Meeting Course - Customer Service That Rocks: Boost Patient Satisfaction...27 ACR Practice Management Pre-Meeting Course - Improve Time-of-Service Collections From the Front-End...27 ACR Practice Management Pre-Meeting Course - Increase Team Performance and Productivity.. 27 ACR Practice Management Pre-Meeting Course - In s and Out s of an Effective Compliance Plan...27 ACR Practice Management Pre-Meeting Course - Managing Denials in a Complex Reimbursement Environment...27 ACR Practice Management Pre-Meeting Course - Take Your Appeals to the Next Level...27 Disclosure: UnitedHealthcare, 5 Culver, Daniel, DO Sarcoidosis in 2014...36 Curtis, Jeffrey R., MD, MPH, MS ACR Clinical Research Conference - Session I: Methodology and Development............24 Patient-Reported Outcomes Data for Comparative Effectiveness Research in Arthritis Care...146 Practical Use of Registries...73 Vaccinations for Patients on Biologic Therapies (018)...43 Invited Speaker/Moderator Index 2014 Program Book 271
Invited Speaker/Moderator Index Cush, John J., MD Rheumatology Roundup: Highlights from the 2014 Annual Meeting...147 Still s Disease and Autoinflammatory Syndromes (047)...82 Cutolo, Maurizio, MD Nailfold Capillaroscopy (202)...34 Patient Access to Biologics Across the Globe...108 D Daikh, David I., MD, PhD Rheumatic Manifestations of Malignancy...148 Dalbeth, Nicola, MBChB, MD Classification Criteria for Gout...82 Disclosure: AstraZeneca/Ardea, 2, 5; Takeda, 5; Teijin, 8 Dall era, Maria, MD Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (010)...33 Systemic Lupus Erythematosus: Difficult to Treat Systemic Lupus Erythematosus (039)...71 Danska, Jayne, PhD The Microbiome in Health and Disease...35 Dao, Kathryn H., MD Infections with Biologics (022)...66 Infections with Biologics (054)...103 Dasgupta, Bhaskar, MD ACR-EULAR Rheumatica Guidelines...113 Disclosure: Servier, 5 Davidson, Anne, MBBS Rheumatology Research Foundation Special Session: Disease Targeted Research...111 Systems Biology of Lupus Nephritis...73 Davis III, John M., MD, MS Hench Lectureship: Why Steroids Work in Some Inflammatory Diseases But Not in Others...120 Deane, Kevin D., MD, PhD ACR Basic Research Conference - Session III: Mechanisms of Immune Activation and Regulation...29 Deane, Peter, MD Hereditary Angioedema Update (014)...43 Dejaco, Christian, MD, PhD ACR-EULAR Rheumatica Guidelines...113 Disclosure: Pfizer, MSD, 2; Pfizer, MSD, Roche, UCB, BMS, AbbVie, 8 DeMarco, Paul J., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Billing, Coding and Report Generation...26 Disclosure: Abbott Immunology Pharmaceuticals, 8; Amgen, 8; Auxilium Pharmaceuticals, 2; UBM Medica US, 5 ACR Musculoskeletal Ultrasound Course for Rheumatologists - Ultrasound Needle Guidance...............................26 Disclosure: Abbott Immunology Pharmaceuticals, 8; Amgen, 8; Auxilium Pharmaceuticals, 2; UBM Medica US, 5 Deodhar, Atul A., MD Axial Spondyloarthritis Guidelines...44 Disclosure: Abbvie, Amgen, Janssen, Novartis, Pfizer, UCB, 5; Amgen, Abbvie, Novartis, Pfizer, UCB, 2 Joint Injection Techniques (201)...33 Joint Injection Techniques (222)...83 Deshmukh, Umesh, PhD ACR Plenary Session II: Discovery 2014...80 Dewing, Kori A., DNP, ARNP Providing Evidence for Mid-Level Providers in Rheumatology Practice...115 Rheumatic Manifestations of Malignancy...148 Distler, Oliver, MD Fibrotic Complications of Scleroderma...95 Disclosure: Actelion, Pfizer, Ergonex, BMS, Bayer, United BioSource Corporation, Roche/ Genentech, medac, Biovitrium, Boehringer Ingelheim Pharma, Novartis, 4D Science, Active Biotec, Sinoxa, Sanofi-Aventis, Serodapharm, GSK, Epipharm,, 5; Actelion, Pfizer, Ergonex, Sanofi-Aventis, 2 Dixit, Rajiv, MD Pain: Evaluation and Treatment of Back Pain (006)...33 Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management...95 Dixon, William G., MRCP, PhD Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of DMARDs and Biologics in the Perioperative Period...72 Dodge, Carole V., OT, CHT Role of Nutrition in Rheumatic Diseases...104 Domsic, Robyn T., MD, MPH Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (049)...82 Systemic Sclerosis: Disease Staging and Subsetting in Clinical Practice (069)...109 Dougados, Maxime, MD, PhD Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment...159 Disclosure: Pfizer Inc; Abbvie;Novartis,Sanofi,Li lly,ucb, 2, 5 Dufour, Alyssa B., PhD Stats Boot Camp: The Prevalence Ratio as an Alternative to the Odds Ratio for Cross-Sectional Studies...114 Dunlop, Dorothy D., PhD Basic Statistical Concepts for the Medical Researcher (230)...110 Disclosure: Pearson Publisher, 7 E Edwards, N. Lawrence, MD Curbside Consults Ask the Experts...94 Disclosure: Cymabay Pharma; AstraZeneca Pharma: Takeda Pharma; Questcor Pharma, 5; Cymabay Pharmaceuticals; AstraZeneca Pharmaceuticals; Takeda Pharmaceuticals: Questcor Pharmaceutical, 5 The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 Disclosure: Cymabay Pharma; AstraZeneca Pharma: Takeda Pharma; Questcor Pharma, 5; Cymabay Pharmaceuticals; AstraZeneca Pharmaceuticals; Takeda Pharmaceuticals: Questcor Pharmaceutical, 5 Thieves Market: Show Me Your Best Cases...55 Disclosure: Cymabay Pharma; AstraZeneca Pharma: Takeda Pharma; Questcor Pharma, 5; Cymabay Pharmaceuticals; AstraZeneca Pharmaceuticals; Takeda Pharmaceuticals: Questcor Pharmaceutical, 5 Eggleton, Paul, PhD Advances in Molecular Profiling and Relevance to Autoimmune Disease...158 Erkan, Doruk, MD Antiphospholipid Syndrome (051)...102 Disclosure: Alexion Pharmaceuticals, Inc., 2, 5; Eli Lilly and Company, 2; EMD Serono, 2; Lupus Clinical Trials Consortium, 2; New York Community Trust, 2 Antiphospholipid Syndrome (071)...119 Disclosure: Alexion Pharmaceuticals, Inc., 2, 5; Eli Lilly and Company, 2; EMD Serono, 2; Lupus Clinical Trials Consortium, 2; New York Community Trust, 2 Evangelisto, Amy M., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - The Elbow...22 Musculoskeletal Ultrasound (220)...76 Musculoskeletal Ultrasound (233)...114 272 2014 Program Book See page 247 for the list of disclosure relationships.
F Farrell, Jessica, PharmD ACR Practice Management Pre-Meeting Course - Take Your Appeals to the Next Level...28 Felson, David T., MD, MPH Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management...135 Non-surgical Treatments for Osteoarthritis (074)...119 Disclosure: Zimmer Knee Creations, 5 The Role of Bone in the Pathogenesis of Osteoarthritis...95 Disclosure: Zimmer Knee Creaions, 5 Ferguson, Polly J., MD Pediatric Rheumatology Town Hall...32 Fields, Karl, MD Sports Medicine for the Rheumatology Provider...54 Disclosure: Body Helix, 6 Fields, Theodore R., MD Crystal: Diagnosis and Management of Gout (002)...32 Disclosure: AstraZeneca Pharmaceuticals, 5; AstraZenica Pharmaceutics, 5; Crealta Pharmaceuticals, 5; Pfizer Pharmaceuticals, 8; Takeda Pharmaceuticals, 5, 8 Finan, Patrick, PhD Pathways to Resilience: Biopsychosocial Mechanisms for the Generation of Positive Affect in Chronic Pain...115 Fine, Derek M., MD Forefronts in Lupus Nephritis...84 Fischer, Aryeh, MD ACR Review Course - Interstitial Lung Disease in Rheumatic Disease: A Focused Review...106 Disclosure: Actelion Pharmaceuticals US, 5; Gilead Sciences, 5, 8; InterMune, 5 Pulmonary Manifestations of Rheumatic Disease (056)...103 Disclosure: Actelion Pharmaceuticals US, 5; Gilead Sciences, 5, 8; InterMune, 5 Pulmonary Manifestations of Rheumatic Disease (087)...145 Disclosure: Actelion Pharmaceuticals US, 5; Gilead Sciences, 5, 8; InterMune, 5 Fitzcharles, Mary-Ann, MBChB, MD The Emerging Demand for Medicinal Cannabis by Young Adults and Beyond...104 FitzGerald, John, MD, PhD The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 Disclosure: RAND, 5 Flemming, Donald J., MD X-Ray Challenges in Rheumatic Diseases (235)... 114 Disclosure: American Board of Radiology, 6; Elsevier, 7 Flood, Joseph, MD ACR Business Meeting...124 ACR Plenary Session I: Discovery 2014.......39 Patient Access to Biologics Across the Globe...108 Foxworth, Judy, PhD, PT Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation...103 Sports Medicine for the Rheumatology Provider...53 Fraenkel, Liana, MD, MPH ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Strategies for Academic Success: The Roadmap from Mentee to Mentor...73 Franzosa, Eric, PhD ACR Basic Research Conference - Session I: Overview of General Principles...24 Friday, Robert P., MD, PhD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Fu, Shu Man, MD, PhD Systems Biology of Lupus Nephritis...73 Furst, Daniel, MD, MPH Rheumatoid Arthritis: Challenging Cases (009)...33 Disclosure: Abbott Immunology Pharmaceuticals, 9; Actelion Pharmaceuticals US, 9; Amgen, 9; Bristol-Myers Squibb, 9; cytori, 5; Genentech and Biogen IDEC Inc., 9; gilead, 9; GlaxoSmithKline, 9; Janssen Pharmaceutica Product, L.P., 5; NIH, 9; Novartis Pharmaceutical Corporation, 9; Pfizer Inc, 9; Roche Pharmaceuticals, 9; UCB, 9 Rheumatoid Arthritis: Challenging Cases (038)...71 Disclosure: Abbott Immunology Pharmaceuticals, 9; Actelion Pharmaceuticals US, 9; Amgen, 9; Bristol-Myers Squibb, 9; cytori, 5; Genentech and Biogen IDEC Inc., 9; gilead, 9; GlaxoSmithKline, 9; Janssen Pharmaceutica Product, L.P., 5; NIH, 9; Novartis Pharmaceutical Corporation, 9; Pfizer Inc, 9; Roche Pharmaceuticals, 9; UCB, 9 Systemic Sclerosis: How to Perform Skin Scores (241)...135 Disclosure: Abbott Immunology Pharmaceuticals, 9; Actelion Pharmaceuticals US, 9; Amgen, 9; Bristol-Myers Squibb, 9; cytori, 5; Genentech and Biogen IDEC Inc., 9; gilead, 9; GlaxoSmithKline, 9; Janssen Pharmaceutica Product, L.P., 5; NIH, 9; Novartis Pharmaceutical Corporation, 9; Pfizer Inc, 9; Roche Pharmaceuticals, 9; UCB, 9 G Gabriel, Sherine E., MD, MSc ACR Clinical Research Conference - Session I: Methodology and Development............24 ACR Clinical Research Conference - Session II: Translating Patient-Centered Outcomes to the Real World Setting...25 ACR Clinical Research Conference - Session V: Patient Perspective...27 ACR Clinical Research Conference - Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials...27 Risk and Risk Management of Cardiovascular Disease in Patients with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases...111 Ganguli, Arijit X., MBA, PhD ACR Clinical Research Conference - Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials...27 Disclosure: AbbVie, Inc, 1, 3 Ganti, Niharika, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Gardiner, Philip, MD Social Media Boot Camp: Blogging for Beginners...75 Gatla, Nandita, MD Thieves Market Posters - ACR/ARHP Poster Session B...74 GC, Yathish, MBBS, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Thieves Market Posters - ACR/ARHP Poster Session B...74 Gensler, Lianne S., MD Ankylosing Spondylitis: 2014 Update (011)...43 Disclosure: AbbVie, 5; Celgene Corporation, 9; UCB, 5 Ankylosing Spondylitis: 2014 Update (031)...70 Disclosure: AbbVie, 5; Celgene Corporation, 9; UCB, 5 Gewirtz, Andrew, PhD ACR Basic Research Conference - Session III: Mechanisms of Immune Activation and Regulation...29 Invited Speaker/Moderator Index Ghetie, Daniela, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 2014 Program Book 273
Invited Speaker/Moderator Index Gignac, Monique A., PhD ARHP Distinguished Lecturer: Maintaining Health and Well-Being Despite Living With a Rheumatic Disease.......................75 Nothing About Us Without Us: Engaging Patients in Rheumatology Research...157 Gilbert, Jack, PhD ACR Basic Research Conference - Session I: Overview of General Principles...24 Giles, Jon T., MD, MPH Muscle and Adipose Tissue in Rheumatic Diseases: Location is Everything...108 Ginsberg, Seth Patient-Reported Outcomes Data for Comparative Effectiveness Research in Arthritis Care...146 Gladman, Dafna D., MD Psoriatic Arthritis (007)...33 Disclosure: Abbvie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, UCB, 5; Abbvie, Amgen, Celgene, Janssen, Novartis, Pfizer, UCB, 2; Abbvie, Amgen, Celgene, Janssen, Pfizer, UCB, 2 Psoriatic Arthritis (043)...81 Disclosure: Abbvie, Amgen, BMS, Celgene, Eli Lilly, Janssen, Novartis, Pfizer, UCB, 5; Abbvie, Amgen, Celgene, Janssen, Novartis, Pfizer, UCB, 2; Abbvie, Amgen, Celgene, Janssen, Pfizer, UCB, 2 Glimcher, Laurie H., MD Bone Biology...38 Disclosure: Bristol-Myers Squibb, 4, 5; Waters Corporation, 4, 5 Goddard, David, MD Legislative Update: Chat with Congress...75 Disclosure: Pizer Inc, Amgen, Eli Lilly, Takeda, Astra Zeneca, 8 Goglin, Sarah, MD Thieves Market: Show Me Your Best Cases..56 Golden, Angela K., DNP Affordable Care Act...38 Goldenberg, Don L., MD Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management...95 Disclosure: Pfizer Inc, 5 Golding, Amit, MD, PhD New Regulatory T Cells...120 Goldring, Steven R., MD Bone Biology...38 Goldschneider, Kenneth, MD When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility...36 Goldszmid, Romina, PhD ACR Basic Research Conference - Session III: Mechanisms of Immune Activation and Regulation...29 Golightly, Yvonne M., PT, MS, PhD Stats Boot Camp: The Prevalence Ratio as an Alternative to the Odds Ratio for Cross-Sectional Studies...114 Goode, Adam, DPT, PT State-of-the-Art Interventional Recommendations for Chronic Low Back Pain...146 Goodman, Susan M., MD Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of DMARDs and Biologics in the Perioperative Period...72 Gordon, Kenneth B., MD Psoriatic Arthritis: Skin, Entheses and Joints...124 Gossec, Laure, MD, PhD ACR Clinical Research Conference - Session II: Translating Patient-Centered Outcomes to the Real World Setting...25 Disclosure: AbbVie, Janssen, Novartis, Pfizer, Roche, UCB, 5 Goyal, Janak R., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Ultrasound Needle Guidance...............................25 Musculoskeletal Ultrasonography: Basic (228)...154 Musculoskeletal Ultrasonography: Basic (238)...123 Graf, Jonathan D., MD Rheumatology on the Street...83 Gravallese, Ellen M., MD Career Opportunities in Rheumatology: Making a Choice...94 Disclosure: AbbVie, 2; Eli Lilly and Company, 2 Greenberg, Jeffrey D., MD, MPH Update on Findings From Large Registries: Emphasis on Health Disparities in Rheumatic Arthritis...70 Grembiale, Rosa Daniela ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Grice, Elizabeth A., PhD The Microbiome in Health and Disease...35 Disclosure: Amway, 5; GoJo, 5; Janssen Research and Development, LLC, 2; Stiefel, 5 Grom, Alexei A., MD ACR Review Course - The Diagnosis and Management of Macrophage Activation Syndrome...28 Disclosure: Novartis Pharmaceutical Corporation, 5; Roche Pharmaceuticals, 5 Macrophage Activation Syndrome (005)...33 Disclosure: Novartis Pharmaceutical Corporation, 5; Roche Pharmaceuticals, 5 Gruber, Barry, MD Osteoporosis: Emerging Treatments Both Pharmacological and Non- Pharmacological...134 Disclosure: Amgen, 8; Genentech and Biogen IDEC Inc., 8; GlaxoSmithKline, 8; Janssen Pharmaceutica Product, L.P., 8; Questcor, 8 Guccione, Andrew A., PhD, DPT RheumCha...113t Gultekin, Sakir Humayun, MD Muscle Involvement in Rheumatic Diseases (211)...55 Gwilliam, Evan, DC, MBA, BS, CPC, NCICS, CCPC, CCCPC, CPC-I MCS-P Practice Issues: Practice Success in an Environment of Transition...73 Disclosure: Findacode, 3 Practice Issues: The Road to I10...45 Disclosure: Findacode, 3 H Hahn, Bevra H., MD The Great Debate: Belimumab for the Treatment of Systemic Lupus Erythematosus...46 Disclosure: Astellas, 5; Eisai, 5; Lilly, 5; Merck Human Health, 5 Hajj-Ali, Rula, MD Curbside Consults Ask the Experts...94 Primary Angiitis of the Central Nervous System and Its Mimics...148 Thieves Market: Show Me Your Best Cases... 55 Hanly, John G., MD The Psychosocial Impact and Treatment Options for Patients with Neuropsychiatric Lupus and Their Caregivers...134 274 2014 Program Book See page 247 for the list of disclosure relationships.
Hannan, Marian T., DSc, MPH Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...34 RheumCha...113t Hansen, Karen E., MD, MS Osteoporosis: Current Concepts for the Clinician...35 Hant, Faye N., DO, MSCR Scleroderma Mimics (046)...82 Harrington, J. Timothy, MD Rheumatoid Arthritis: Outcome Measures in Clinical Practice (066)...109 Disclosure: Joiner Associates LLC, Crescendo Bioscience, 5; Pfizer Inc, 5 Harris, Helena E., BSc, PhD Therapeutic Targeting of the Innate Immune System...55 Alternative Medicine: Presenting the Evidence for Rheumatic Conditions...92 What Can Brain Imaging Tell Us About Pharmacologic and Non-Pharmacologic Treatment of Chronic Pain?................38 Disclosure: Pfizer Inc, 2, 5 Harvey, William F., MD, MSc Advocacy: Meet the Expert - A Senator s Perspective on Advocacy Best Practices...36 Legislative Update: Chat with Congress...75 Practice Issues: The Road to I10...44 Hassan, Sobia, BM BS, MRCP ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Hassett, Afton L., PsyD ARHP Distinguished Lectuer: Maintaining Health and Well-Being Despite Living with a Rheumatic Disease...75 Disclosure: Bristol-Myers Squibb, 2; Lexicon Pharmaceuticals, 5 ARHP Keynote Address: Happiness From the Inside Out...37 Disclosure: Bristol-Myers Squibb, 2; Lexicon Pharmaceuticals, 5 RheumChat...113 Disclosure: Bristol-Myers Squibb, 2; Lexicon Pharmaceuticals, 5 Treatment Considerations in Chronic Pain...134 Disclosure: Bristol-Myers Squibb, 2; Lexicon Pharmaceuticals, 5 Hasson, Scott, Pt, PhD Update on Findings From Large Registries: Emphasis on Health Disparities in Rheumatic Arthritis...70 Helfgott, Simon M., MD ACR Review Course - Assessing Disease and Managing Large Vessel Vasculitis...29 Disclosure: Abbvie, 5 ACR Review Course - Genomics for the Clinician...29 Disclosure: Abbvie, 5 ACR Review Course - Interstitial Lung Disease in Rheumatic Disease: A Focused Review...28 Disclosure: Abbvie, 5 ACR Review Course - Management of Pseudogout: Insights for Clinicians...29 Disclosure: Abbvie, 5 ACR Review Course - Management of Salivary Gland Involvement in Sjögren s Syndrome...29 Disclosure: Abbvie, 5 ACR Review Course - Pregnancy Management and Outcome in Systemic Lupus Erythematosus...28 Disclosure: Abbvie, 5 ACR Review Course - Rheumatoid Arthritis Therapy After Diagnosis of Malignancy...29 Disclosure: Abbvie, 5 ACR Review Course - The Diagnosis and Management of Macrophage Activation Syndrome...28 Disclosure: Abbvie, 5 Clinicopathologic Conference: A 17-year-old Young Woman with Chronic Ankle and Back Pain...94 Disclosure: Abbvie, 5 Henderson Sumpter, Anita, MBA, MHA, CPC, CMOM ACR Practice Management Pre-Meeting Course - In s and Out s of an Effective Compliance Plan...28 Practice Issues: Health Care Bounty Hunters: A Closer Look at RACs, Audits and Medical Documentation...35 Her, Minyoung, MD Thieves Market Posters - ACR/ARHP Poster Session C...112 Higgs, Jay B., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Principles of Musculoskeletal Ultrasound for Rheumatologists...25 Advanced Musculoskeletal Ultrasound (208).. 45 Advanced Musculoskeletal Ultrasound (214).. 71 Advanced Musculoskeletal Ultrasound: Image Optimization and Pathology Recognition (229)...110 Hillstrom, Howard J., PhD Knee Braces, Foot Orthoses, and Shoe Gear for Managing Knee Osteoarthritis (219)...76 Hochberg, Marc C., MD, MPH New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 Disclosure: Bioiberica S.A., 5; Carbylan, 9; EMD Serono Inc., 5; Iroko Pharmaceuticals, 5; Moebius Medical Ltd., 5; Novartis Pharma AG, 5; Pfizer Inc, 5; Strategic Science and Technology, 5; Theralogix LLC, 1 Hoellein, Andrew R., MD Educator: Medical Education: The Year in Review...45 Hoffman, Gary S., MD Vasculitis - Factors That Influence Disease Patterns (060)...103 Disclosure: Roche Pharmaceuticals, 9 Vasculitis - Factors That Influence Disease Patterns (070)...110 Disclosure: Roche Pharmaceuticals, 9 Hood, Leroy, MD, PhD ACR/ARHP Opening Lecture and Awards...31 Hootman, Jennifer M., PhD Exercise Adherence in Arthritis: The Role of Technology...156 Horonjeff, Jennifer R., MS Young Adults with Rheumatic Disease: The Patient Perspective...54 Hotamisligil, Gökhan S., PhD, MD Metainflammation...113 Disclosure: Servier Pharmceuticals, UCB Pharmaceuticals, 2 Howard, Rennie N. G., MD Neonatal Lupus: From Bench to Bedside...83 Psoriatic Arthritis: Skin, Entheses and Joints.. 124 Huber, Adam M., MD MSc Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...73 Huffman, Kim M., MD, PhD Successful Aging in Rheumatic Disease...146 Hughes, Laura B., MD, MSPH ACR Knowledge Bowl: Final Round...76 Disclosure: Janssen Pharmaceutica Product, L.P., 5 ACR Knowledge Bowl: Preliminary Round...42 Disclosure: Janssen Pharmaceutica Product, L.P., 5 Huisinga, Karen, MN, ARNP ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - Introduction...30 Osteoporosis: Emerging Treatments Both Pharmacological and Non-Pharmacological...134 Disclosure: Pfizer Inc, 5 Practical Practice Management Session Two: Navigate HIPAA and Prevent Audits...68 Invited Speaker/Moderator Index Hutchinson, James, MBBChir, PhD Novel Regulatory Cell Subsets...124 2014 Program Book 275
Invited Speaker/Moderator Index 276 Hutchinson, Tim, The Honorable Advocacy: Meet the Expert - A Senator s Perspective on Advocacy Best Practices...36 Huttenlocher, Anna, MD Pediatric Rheumatology Town Hall...32 I Inman, Robert D., MD Spondylarthropathy: An Update (077)...119 Disclosure: Abbvie, Amgen, Janssen, Pfizer, UCB, 5; Amgen, Janssen, UCB, Abbvie, Pfizer, 5 Iobst, William, MD Educator: Direct Observation of Clinical Skills: Educationally Indicated, Therapeutically Required...111 Irrgang, James J., ATC, PhD, PT Sports Medicine for the Rheumatology Provider...54 Isenberg, David A., MD Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside...148 The Great Debate: Belimumab for the Treatment of Systemic Lupus Erythematosus... 46 Iversen, Maura D., BSc, DPT, SD, MPH Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Google Minefield: Empowering Patients to Evaluate Online Resources...58 J Jansen, Tim L., MD, PhD Classification Criteria for Gout...82 Disclosure: research grant for POET-US =additional study to nationwide TNFi stop study) from Abbvie, 2 Janssen, Erin, MD, PhD Autoimmunity in Immunodeficiency...45 Jansson, Janet, PhD ACR Basic Research Conference - Session I: Overview of General Principles...24 Jarjour, Wael N., MD Age Before Beauty: Colchicine, Aspirin, Methotrexate and Their Mechanisms of Action...31 Disclosure: Navidea Pharmaceutical, 5 Autophagy in Rheumatic Diseases...135 Disclosure: Navidea Pharmaceutical, 5 How the Gut Primes the Immune System...44 Disclosure: Navidea Pharmaceutical, 5 2014 Program Book Johnson, Kiana, PhD Young Adults with Rheumatic Disease: The Patient Perspective...54 Say What? : Implications of Adolescent Development and Behavior in Communicating With Health Care Providers...68 Jolly, Meenakshi, MD, MS The Butterfly Effect: Lupus Rashes and Their Mimics...45 Jones, Karla, RN Multidisciplinary Management of the Juvenile Idiopathic Arthritis Patient...146 Jordan, Joanne M., MD, MPH Osteoarthritis: Update 2014 (035)...71 Disclosure: Algynomics, 5; ClearView Healthcare Partners, 5; Flexion, 5; Samumed, 5; Trinity Partners, LLC, 5 Osteoarthritis: Update 2014 (075)...119 Disclosure: Algynomics, 5; ClearView Healthcare Partners, 5; Flexion, 5; Samumed, 5; Trinity Partners, LLC, 5 Joshi, Piyush, MBBS, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Jurisson, Mary L., MD Tai Chi in Rheumatic Disease (203)...161 K Kaeley, Gurjit S., MBBS, MRCP ACR Musculoskeletal Ultrasound Course for Rheumatologists - The Shoulder...23 Disclosure: AbbVie, 5; Esaote, 9 Musculoskeletal Ultrasonography: Basic (228).. 94 Disclosure: AbbVie, 5; Esaote, 9 Musculoskeletal Ultrasonography: Basic (238)...123 Disclosure: AbbVie, 5; Esaote, 9 Ultrasound Injection Guidance (242)...135 Disclosure: AbbVie, 5; Esaote, 9 Kalish, Robert A., MD Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (209)...45 Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (205)...37 Kang, Jane, MD Ethics and Rheumatology...34 Kaplan, Mariana J., MD From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases...104 Karp, David R., MD, PhD Rheumatology Research Foundation Paul Klemperer, MD Memorial Lectureship: Geneenvironment Interactions as a Basis for Unravelling Adaptive Immunity and Preparing for Tolerizing Therapies in Rheumatoid Arthritis...69 Kashikar-Zuck, Susmita, PhD When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility...35 Kastner, Daniel L., MD, PhD Pediatrics: Periodic Fevers in Children (065)..109 Katz, Jeffrey N., MD, MSc New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 Katz, Patricia P., PhD Successful Aging in Rheumatic Disease...146 Thriving With Rheumatic Disease: Cultivating Resilience...93 Kaur, Primal P., MD Career Opportunities in Rheumatology: Making a Choice...94 Disclosure: Amgen, 1, 3 Kavanagh, Ronan, MD, MRCP Social Media Boot Camp: Blogging for Beginners...75 Disclosure: Vidscrip / Clear.MD, 1; Viscrip / Clear. MD, 1 Social Media Boot Camp: Twitter Basics...37 Disclosure: Vidscrip / Clear.MD, 1; Viscrip / Clear. MD, 1 Kavanaugh, Arthur, MD Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of DMARDs and Biologics in the Perioperative Period...72 Disclosure: AbbVie, 2; Amgen, 2; Astellas, 2; BMS, 2; Janssen Pharmaceutica Product, L.P., 2; Pfizer Inc, 2; Roche Pharmaceuticals, 2; UCB, 2 Rheumatology Roundup: Highlights from the 2014 Annual Meeting...147 Disclosure: AbbVie, 2; Amgen, 2; Astellas, 2; BMS, 2; Janssen Pharmaceutica Product, L.P., 2; Pfizer Inc, 2; Roche Pharmaceuticals, 2; UCB, 2 Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond...135 Disclosure: Abbvie, 2; Amgen, 2; bms, 2; Janssen Pharmaceutica Product, L.P., 2; ucb, 2 Kay, Jonathan, MD Practice Issues: The Road to I10...44 Kazi, Salahuddin, MD Avoiding Electronic Health Record Errors and Their (Sometimes) Critical Consequences...44 Getting Electronic Health Records Right (240)...134 Practical Use of Registries...73 See page 247 for the list of disclosure relationships.
Keenan, Robert T., MD, MPH The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 Disclosure: AstraZeneca, 5; Crealta, 5; Takeda, 5 Kelly-Hall, Leslie ACR Clinical Research Conference - Session I: Methodology and Development............24 Disclosure: Healthwise, 3 Kemper, Claudia, PhD Complement in Rheumatic Disease...148 Keysor, Julie J., PhD, PT Exercise Adherence in Arthritis: The Role of Technology...156 Work and Worker Health: Easy Accommodations Keep People with Arthritis Employed.......159 Keystone, Edward C., MD Physical Examination Skills for Improved Detection of Synovitis and Cervical Thoracolumbar Disorders (213)...55 Rheumatoid Arthritis: Biological Agents (016)...43 Disclosure: Abbott Laboratories, 2, 5, 8; Amgen, 8; Amgen Canada, 2; AstraZeneca, 5, 8; Astrazeneca Pharmaceuticals LP, 2; Biotest, 5; Bristo-Myers Squibb, 2; Bristol-Myers Squibb, 5, 8; Eli Lilly and Company, 2, 5; F. Hoffman La-Roche Inc., 2, 8; F. Hoffman-La Roche Inc., 5; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P., 2, 5, 8; Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2, 5, 8; Sanofi-Aventis Pharmaceutical, 2; UCB, 8 Rheumatoid Arthritis: Biological Agents (044).. 82 Disclosure: Abbott Laboratories, 2, 5, 8; Amgen, 8; Amgen Canada, 2; AstraZeneca, 5, 8; Astrazeneca Pharmaceuticals LP, 2; Biotest, 5; Bristo-Myers Squibb, 2; Bristol-Myers Squibb, 5, 8; Eli Lilly and Company, 2, 5; F. Hoffman La-Roche Inc., 2, 8; F. Hoffman-La Roche Inc., 5; Genentech and Biogen IDEC Inc., 5; Janssen Pharmaceutica Product, L.P., 2, 5, 8; Merck Pharmaceuticals, 5; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2, 5, 8; Sanofi-Aventis Pharmaceutical, 2; UCB, 8 Khan, Mehwish, MBBS, MD Thieves Market: Show Me Your Best Cases...56 ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Khanna, Dinesh, MD, MSc ACR Clinical Research Conference - Session III: Research Perspective...27 ACR Clinical Research Conference - Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials...27 Disclosure: Actelion, Bayer, Biogen-idec, BMS, DIGNA, Genentech/ Roche, GSK, InterMune, Merck, Sanofi-Aventis, United Therapeutics, 5; NIH, PHA, Scleroderma Fdn, Astra Zeneca, 2 Current Understanding of Malignancies in Connective Tissue Diseases...34 Disclosure: Actelion, Bayer, Biogen-idec, BMS, DIGNA, Genentech/ Roche, GSK, InterMune, Merck, Sanofi-Aventis, United Therapeutics, 5; NIH, PHA, Scleroderma Fdn, Astra Zeneca, 2 Fibrotic Complications of Scleroderma...95 Disclosure: Actelion, Bayer, Biogen-idec, BMS, DIGNA, Genentech/ Roche, GSK, InterMune, Merck, Sanofi-Aventis, United Therapeutics, 5; NIH, PHA, Scleroderma Fdn, Astra Zeneca, 2 The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 Disclosure: Astra-Zeneca, Takeda, Savient, 5; NIH, Scleroderma Fdn, 2 Kim, Susan, MD, MMSc Juvenile Dermatomyositis (084)...145 Kimel, Alexandru F., MD Rheumatology Practice 101: Starting Out in Practice for the Graduating Fellow (028)...66 Kimpton, Kimberly F., PT State-of-the-Art Interventional Recommendations for Chronic Low Back Pain...146 Kissin, Eugene Y., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Hand and Wrist...23 Disclosure: SonoSite Inc, 9 ACR Musculoskeletal Ultrasound Course for Rheumatologists - Opening Remarks...25 Disclosure: SonoSite Inc, 9 ACR Musculoskeletal Ultrasound Course for Rheumatologists - Ultrasound Needle Guidance...............................26 Disclosure: SonoSite Inc, 9 ACR Musculoskeletal Ultrasound Course for Rheumatologists Introduction...22 Disclosure: SonoSite Inc, 9 Musculoskeletal Ultrasound (220)...76 Disclosure: SonoSite Inc, 9 Musculoskeletal Ultrasound (233)...114 Disclosure: SonoSite Inc, 9 Kitsis, Elizabeth A., MD, MBE Ethics and Rheumatology...34 Kiyono, Hiroshi, DDS, PhD ACR Basic Research Conference - Session II: The Microbiome and Regional Immunity...24 Klareskog, Lars, MD, PhD Rheumatology Research Foundation Paul Klemperer, MD Memorial Lectureship: Geneenvironment Interactions as a Basis for Unravelling Adaptive Immunity and Preparing for Tolerizing Therapies in Rheumatoid Arthritis...69 Knight, Rob, PhD ACR Basic Research Conference - Session I: Overview of General Principles...24 ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 Kohler, Minna J., MD Beyond Musculoskeletal Ultrasound for Rheumatologists (204)...37 Kolasinski, Sharon L., MD Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session...124 Kong, Heidi H., MD, MHSc ACR Basic Research Conference - Session I: Overview of General Principles...24 ACR Basic Research Conference - Session II: The Microbiome and Regional Immunity...24 ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 Koren, Gideon, MD Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond...135 Kotton, Darrell, MD Insight into Lung Fibrosis...84 Krant, Jonathan, MD, MPH Patient-Reported Outcomes Data for Comparative Effectiveness Research in Arthritis Care...146 Krause, Megan L., MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Kremer, Joel M., MD Clinical Issues Associated with the Use of Methotrexate...120 Krishnan, Eswar, MD From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases...104 Disclosure: Ardea, 2, 5; Takeda, 5; UCB, 2 Krohn, Kelly D., MD Knee Braces, Foot Orthoses, and Shoe Gear for Managing Knee Osteoarthritis (219)...76 Disclosure: Eli Lilly and Company, 3 Kumar, Bharat, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Kunkel, Gary A., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - The Knee...22 Invited Speaker/Moderator Index 2014 Program Book 277
Invited Speaker/Moderator Index 278 Kyttaris, Vasileios C., MD Systems Biology of Lupus Nephritis...73 Disclosure: Vertex Pharmaceuticals, 5 L La Cava, Antonio, MD, PhD Bioenergetics and Energy Regulation...110 Lane, Nancy E., MD Vitamin D and Bone Health (030)...67 Lang, Jason, MD Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation...104 Disclosure: Smith & Nephew, Inc., 5 Langevin, Helene, MD Uncovering the Role of Connective Tissues in Chronic Low Back Pain: From Bedside to Bench to Bedside...120 Langford, Carol A., MD ACR/ABIM MOC Learning Session - Session I: Questions from 2014 Update...25 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2 CARE: Maintenance of Certification Session One of Three...34 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2 CARE: Maintenance of Certification Session Three of Three...110 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2 CARE: Maintenance of Certification Session Two of Three...72 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2 Curbside Consults Ask the Experts...95 Disclosure: Bristol-Myers Squibb, 2; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2 Lavalley, Michael P., PhD Informative and Critical Peer Review for the ACR Journals: A Guide to Providing Excellent Peer Review of Manuscripts...35 Disclosure: Athritis Care & Research, 3 Stats Boot Camp: Statistical Analysis of Ordinal Data...77 Disclosure: Athritis Care & Research, 3 Laxer, Ronald, MD Clinicopathologic Conference: A 17-year-old Young Woman with Chronic Ankle and Back Pain...94 Lazaro, Deana M., MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session...124 Educator: Medical Education: The Year in Review...45 2014 Program Book Leder, Benjamin Z., MD Osteoporosis: Current Concepts for the Clinician...35 Disclosure: Amgen, 2; Lilly, 2; Merck Human Health, 5; Radius, 5 Lee, Jungwha, PhD, MPH Basic Statistical Concepts for the Medical Researcher (230)...110 Lehman, Thomas J. A., MD Pediatrics: Difficult to Treat Juvenile Idiopathic Arthritis (024)...66 Disclosure: Abbott Immunology Pharmaceuticals, 8; Genentech and Biogen IDEC Inc., 8; Novartis Pharmaceutical Corporation, 8 Leong, Amye L., MBA Nothing About Us Without Us: Engaging Patients in Rheumatology Research...157 Levine, Alana B., MD Antiphospholipid Syndrome (061)...109 Li, Linda C., PhD, PT Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Stats Boot Camp: A Call to Aims for Researchers! An Interactive Session to Obtain Feedback on Your Specific Aims Section...93 Lightstone, Liz, MD, PhD Forefronts in Lupus Nephritis...84 Disclosure: Anthera, EMD Serono, GSK, Medimmune, Merck, UCB, 5; Roche Pharmaceuticals, 2; UCB, GSK, 8 Systemic Lupus Erythematosus: Novel Treatments (029)...67 Disclosure: Anthera, EMD Serono, GSK, Medimmune, Merck, UCB, 5; Roche Pharmaceuticals, 2; UCB, GSK, 8 Lin, Clara, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Introduction to typical sonographic findings & Tissue Characteristics in Rheumatology...23 Lin, Jenny, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Littmann, Dan, MD, PhD ACR Basic Research Conference - Keynote Lecture: Microbiome and Host Immune Defenses...24 Loeser, Richard F., MD The Role of Bone in the Pathogenesis of Osteoarthritis...95 Lohr, Kristine M., MD, MS ACR Review Course - Assessing Disease and Managing Large Vessel Vasculitis...29 ACR Review Course - Genomics for the Clinician...29 ACR Review Course - Interstitial Lung Disease in Rheumatic Disease: A Focused Review...28 ACR Review Course - Management of Pseudogout: Insights for Clinicians...29 ACR Review Course - Management of Salivary Gland Involvement in Sjögren s Syndrome...29 ACR Review Course - Pregnancy Management and Outcome in Systemic Lupus Erythematosus...28 ACR Review Course - Rheumatoid Arthritis Therapy after Diagnosis of Malignancy...29 ACR Review Course - The Diagnosis and Management of Macrophage Activation Syndrome...28 Career Opportunities in Rheumatology: Making a Choice...94 Rheumatology on the Street...83 Lories, Rik, MD, PhD The Role of Bone in the Pathogenesis of Osteoarthritis...95 Louie, Grant H., MD, MHS Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment...159 Disclosure: AbbVie, 5 Lovell, Daniel, MD, MPH Pediatric Rheumatology for Adult Rheumatologists (042)...81 Disclosure: Bristol-Myers Squibb, 5; Celgene, 5; Forest Laboratories, 9; Genetech, 5, 8; Johnson & Johnson, 5; Novartis Pharmaceutical Corporation, 5; Roche Pharmaceuticals, 5 Lundberg, Ingrid E., MD, PhD Classification Criteria for Myositis...83 Luqmani, Raashid A., DM Vasculitis: Update (019)...44 Disclosure: GSK, 5 Vasculitis: Update (040)...71 Disclosure: GSK, 5 Lynch, Susan, PhD ACR Basic Research Conference - Session II: The Microbiome and Regional Immunity...24 Disclosure: Janssen Pharmaceuticals, 2 M MacKenzie, C. Ronald, MD Ethics and Rheumatology...34 See page 247 for the list of disclosure relationships.
Mackey, Meggan, MD, MS Systemic Lupus Erythematosus: Central Nervous System (068)...109 Mackey, Sean, MD, PhD RheumChat...113 Treatment Considerations in Chronic Pain...134 Mackool, Bonnie T., MD, MSPH The Butterfly Effect: Lupus Rashes and Their Mimics...45 Magid, Steven K., MD Avoiding Electronic Health Record Errors and Their (Sometimes) Critical Consequences...44 Majka, Darcy S., MD Strategies for Academic Success: The Roadmap from Mentee to Mentor...73 Maksymowych, Walter P., MD Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (210)...55 Magnetic Resonance Imaging in the Diagnosis and Management of Spondyloarthritis: A Clinician s Guide (223)...83 Malcarne, Vanessa L., PhD Multidisciplinary Management of Scleroderma...68 Mammen, Andrew L., MD, PhD Myositis Mimics: Clinical and Molecular Diagnosis...111 Mandelin II, Arthur M., MD, PhD The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Diseasespecific Measurements (217)...72 The Rheumatologic Musculoskeletal Screening Exam, with Emphasis on Objective Diseasespecific Measurements (239)...123 Mandell, Brian F., MD, PhD Synovial Fluid Analysis and Crystal Identification (207)...38 Synovial Fluid Analysis and Crystal Identification (224)...83 Mandl, Kenneth D., MD, MPH ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Manno, Rebecca L., MD, MHS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Curbside Consults Ask the Experts...94 Psoriatic Arthritis: Skin, Entheses and Joints...124 Thieves Market: Show Me Your Best Cases...55 Manzi, Susan, MD, MPH Systemic Lupus Erythematosus: Novel Treatments (017)...43 Disclosure: Eli Lilly and Company, 5; Exagen, 5, 7; GlaxoSmithKline, 2, 5 Marcus, Donald M., MD Complementary and Alternative Therapies in Rheumatic Disease (215)...71 Maricic, Michael J., MD Rheumatology Research Foundation Oscar S. Gluck Memorial Lectureship: Emerging Therapies in Bone Diseases: Cellular Basis and Challenges...113 Marri, Reshma, BS, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Marston, Bethany A., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Pediatrics...23 Martinez, Joseph, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Matteson, Eric L., MD, MPH ACR-EULAR Rheumatica Guidelines...113 Disclosure: Novartis Pharmaceutical Corporation, 2 Mauri, Claudia, PhD Novel Regulatory Cell Subsets...124 Maynard, Janet W., MD, MHS Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond...135 McAlindon, Timothy E., MD, MPH, MRCP Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management...135 Disclosure: ACR, 2; OARSI, 2; Sanofi-Aventis Pharmaceutical, 5 New ACR Recommendations for the Management of Rheumatoid Arthritis...38 Disclosure: ACR, 2; OARSI, 2; Sanofi-Aventis Pharmaceutical, 5 New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 McCarthy, Geraldine M., MD ACR Review Course - Management of Pseudogout: Insights for Clinicians...29 McCloskey, Deborah, RN, BSN Alternative Medicine: Presenting the Evidence for Rheumatic Conditions...92 Immunology Boot Camp I: The Basics of Targeted Therapies...38 Multidisciplinary Management of Scleroderma...68 McCormick, David, MB, BaO, BCh, MRCP Thieves Market: Show Me Your Best Cases..55 McGaha, Tracy, PhD Therapeutic Targeting of the Innate Immune System...55 McGonagle, Dennis, PhD Psoriatic Arthritis: Skin, Entheses and Joints...124 McInnes, Iain B., PhD ACR Review Course - Rheumatoid Arthritis Therapy After Diagnosis of Malignancy...29 Disclosure: Abbvie, 5; Astra Zeneca, 5; BMS, 5; Janssen Pharmaceutica Product, L.P., 5; Pfizer Inc, 2, 5; UCB, 2, 5 McLean, Robert R., DSc, MPH Stats Boot Camp: A Call to Aims for Researchers! An Interactive Session to Obtain Feedback on Your Specific Aims Section...93 McTigue, Joan C., PA-C, MS Pharmacotherapy: What s New in Rheumatology...120 Mease, Philip J., MD Psoriatic Arthritis (076)...119 Disclosure: AbbVie, 2, 5, 8; Amgen, 2, 5, 8; Bristol-Myers Squibb, 2, 5, 8; Celgene, 2, 5; covagen, 5; crescendo, 2, 5, 8; Genentech and Biogen IDEC Inc., 2, 5, 8; Janssen Pharmaceutica Product, L.P., 2, 5, 8; Lilly, 2, 5, 8; Merck Pharmaceuticals, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Pfizer Inc, 2, 5, 8; UCB, 2, 5 Meffre Sr., Eric, PhD Autoimmunity in Immunodeficiency...45 Mehraban, Navid, MD ACR Knowledge Bowl: Final Round Invited Speaker/Moderator Index 2014 Program Book 279
Invited Speaker/Moderator Index 280 Menezes, Rikitha, MD Thieves Market Posters - ACR/ARHP Poster Session C...112 Merkel, Peter A., MD, MPH ACR Clinical Research Conference - Session III: Research Perspective...26 Disclosure: Actelion Pharmaceuticals US, 2, 5; Bristol-Myers Squibb, 2; Chemocentryx, 5; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2; Sanofi-Aventis Pharmaceutical, 5 Biomarkers in Rheumatic Care...93 Disclosure: Actelion Pharmaceuticals US, 2, 5; Bristol-Myers Squibb, 2; Chemocentryx, 5; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2; Sanofi-Aventis Pharmaceutical, 5 Vasculitis Mimics (050)...82 Disclosure: Actelion Pharmaceuticals US, 2, 5; Bristol-Myers Squibb, 2; Chemocentryx, 5; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 2; Sanofi-Aventis Pharmaceutical, 5 Messier, Stephen P., PhD New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 Meysami, Alireza, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Mikuls, Ted R., MD, MSPH ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Miller, Daniel, MD Dermatopathology of Rheumatic Diseases (225)...93 Dermatopathology of Rheumatic Diseases (236)...123 Miller, Frederick W., MD, PhD Classification Criteria for Myositis...83 Current Understanding of Malignancies in Connective Tissue Diseases...34 Mills, David A., MS, PHD ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 Disclosure: Evolve Biosystems Inc., 4; Mars Inc., 5; Matatu Inc., 5; MicroTrek Inc., 4 Mintz, Sandra, BSN Physical and Occupational Therapy for Juvenile Dermatomyositis: Treatment Planning and Case Presentations...148 Young Adults with Rheumatic Disease: The Patient Perspective...54 2014 Program Book Mohan, Chandra, MD, PhD Systems Biology of Lupus Nephritis...73 Monrad, Seetha U., MD ACR/ABIM MOC Learning Session - Session II: Questions from 2014 Update...25 Moore, Suzanne, MD Practice Issues: Practice Success in an Environment of Transition...73 Mor, Adam, MD PhD Co-stimulation Pathways: Therapeutic Opportunities for the Rheumatic Diseases..147 Morasso, Liz, LCSW The Psychosocial Impact and Treatment Options for Patients with Neuropsychiatric Lupus and Their Caregivers...134 Morgan DeWitt, Esi M., MD, MSCE ACR Clinical Research Conference - Session I: Methodology and Development............24 ACR Clinical Research Conference - Session II: Translating Patient-Centered Outcomes to the Real World Setting...25 ACR Clinical Research Conference - Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials...27 Mulvagh, Sharon, MD Risk and Risk Management of Cardiovascular Disease in Patients with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases...112 Murthy, Vijaya, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 N Najem, Catherine E., MD Thieves Market: Show Me Your Best Cases... 56 Nakanishi, Kensuke, MD Thieves Market Posters - ACR/ARHP Poster Session B...74 Napadow, Vitaly, PhD What Can Brain Imaging Tell Us About Pharmacologic and Non-Pharmacologic Treatment of Chronic Pain?................39 Naty, Saverio, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Negoescu, Andra, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Neogi, Tuhina, MD, PhD Classification Criteria for Gout...82 Gout Management in 2014...44 Uncovering the Role of Connective Tissues in Chronic Low Back Pain: From Bedside to Bench to Bedside...120 Nguyen, Uyen Sa D.T., DSc, MPH Stats Boot Camp: The Effect Size: What Is It and How Can You Use It?...70 Ni Mhuircheartaigh, Orla, BAO, BCh, MB, MRCPI ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Niewold, Timothy B., MD Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside...148 Disclosure: Biogen Idec, EMD Serono, 5; Janssen Pharmaceutica Product, L.P., EMD Serono, 2 Nikiphorou, Elena, MRCP, MD(Res), PGCME ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Nikolov, Nikolay P., MD Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond...135 Nishio, Midori Jane, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - The Hip...26 Nussenzweig, Michel C., MD, PhD Therapeutic Targeting of the Innate Immune System...55 O O Dell, James R., MD Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of DMARDs and Biologics in the Perioperative Period...72 See page 247 for the list of disclosure relationships.
O Rourke, Kenneth S., MD Career Opportunities in Rheumatology: Making a Choice...94 Disclosure: American Board of Internal Medicine, 9; Genentech and Biogen IDEC Inc., 2; InPractice Rheumatology, 9 Educator: Cultivating the Competent Medical Educator: A Growing Concern...69 Educator: Direct Observation of Clinical Skills: Educationally Indicated, Therapeutically Required...111 Joint Injection Techniques (201)...33 Disclosure: American Board of Internal Medicine, 9; inpractice Rheumatology, 9 Joint Injection Techniques (222)...83 Disclosure: American Board of Internal Medicine, 9; inpractice Rheumatology, 9 Prosthetic Device Infections, Or Infection as a Threat to the Bionic Man...75 Oberle, Edward J., MD Thieves Market Posters - ACR/ARHP Poster Session C...112 Painter, Mark ACR Practice Management Pre-Meeting Course - Improve Time-of-Service Collections From the Front-End...27 Disclosure: Acatavis, 8; AMS, Inc, 8; Endo Pharmaceuticals Inc., 8; PRS Consulting,LLC, 4; PRS, I., 4; Relative Value Studies, Inc, 4 ACR Practice Management Pre-Meeting Course - Increase Team Performance and Productivity...28 Disclosure: Acatavis, 8; AMS, Inc, 8; Endo Pharmaceuticals Inc., 8; PRS Consulting,LLC, 4; PRS, I., 4; Relative Value Studies, Inc, 4 ACR Practice Management Pre-Meeting Course - Managing Denials in a Complex Reimbursement Environment...28 Disclosure: Acatavis, 8; AMS, Inc, 8; Endo Pharmaceuticals Inc., 8; PRS Consulting,LLC, 4; PRS, I., 4; Relative Value Studies, Inc, 4 Parr, Tim Practical Use of Registries...73 Disclosure: FiGMD, Inc., 3 Patel, Nirupa J., MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Poddar, Piyush, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Poole, Janet L., OTR, PhD Multidisciplinary Management of Scleroderma...68 Nothing About Us Without Us: Engaging Patients in Rheumatology Research...157 Proudman, Susanna, MBBS, PhD Role of Nutrition in Rheumatic Diseases...104 Punaro, Marilynn G., MD Pediatric Rheumatology Town Hall...32 Putterman, Chaim, MD Biomarkers in Rheumatic Care...93 Disclosure: Biogen Idec, 2; Exagen, 5; Immunarray, 5 Invited Speaker/Moderator Index Oddis, Chester V., MD Classification Criteria for Myositis...83 Disclosure: ATyr, 5; Questcor, 5 Rheumatology Roundup: Highlights from the 2014 Annual Meeting...147 Disclosure: ATyr, 5; Questcor, 5 Year in Review...32 Disclosure: ATyr, 5; Questcor, 5 Ostergaard, Mikkel, DMSc, MD, PhD Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (232...110 Disclosure: Abbott/Abbvie, BMS, Boehringer- Ingelheim, Eli-Lilly, Centocor, GSK, Janssen, Merck, Mundipharma, Novo, Pfizer, Schering- Plough, Roche UCB, and Wyeth, 5; Abbott/ Abbvie, Centocor, Merck, Schering-Plough, 2 Magnetic Resonance Imaging of Peripheral Joints in Rheumatology Practice (237)...123 Disclosure: Abbott/Abbvie, BMS, Boehringer- Ingelheim, Eli-Lilly, Centocor, GSK, Janssen, Merck, Mundipharma, Novo, Pfizer, Schering- Plough, Roche UCB, and Wyeth, 5; Abbott/ Abbvie, Centocor, Merck, Schering-Plough, 2 Östör, Andrew, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 P Paget, Stephen A., MD Rheumatoid Arthritis: Challenging Cases (045)...82 Disclosure: Crescendo bioscience, 5 Rheumatoid Arthritis: Challenging Cases (089)...145 Disclosure: Crescendo bioscience, 5 Peacock Jr., James E., MD Prosthetic Device Infections, Or Infection as a Threat to the Bionic Man...75 Disclosure: Pfizer Pharmaceuticals, 1 Pennathur, Subramaniam, MD Rheumatology Research Foundation: Disease Targeted Research Special Session...111 Perl, Andras, MD, PhD Autophagy in Rheumatic Diseases...135 Disclosure: Pfizer Inc, 2 Petri, Michelle, MD, MPH Clinical Features of Central Nervous System Lupus and Diagnosis of Cognitive Deficits and Psychiatric Disorders...108 Forefronts in Lupus Nephritis...84 Pile, Kevin, MD Patient Access to Biologics Across the Globe...108 Pincus, Theodore, MD MDHAQ/RAPID3 and RHEUMDOC: Quantitative, Standard, Scientific Summaries of Patient History and Physical Exam, Toward Better Clinical Decisions and Outcomes (227)...94 Disclosure: Abbvie, Celgene, 2; Pfizer, Abbvie, Merck, Health Report Services, 7 Pineda, Carlos, PhD Patient Access to Biologics Across the Globe...108 Piva, Sara R., PhD, PT Best Practices of Total Knee Arthroplasty From Surgery to Rehabilitation...104 R Rabinovich, C. Egla, MD, MPH Pediatric Rheumatology Town Hall...32 Raman, Vidya, MD Thieves Market Posters - ACR/ARHP Poster Session B...74 Ramessar, Nina, MBBS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Ravelli, Angelo, MD ACR Clinical Research Conference - Session III: Research Perspective...27 Macrophages Gone Wild...111 Ray, Laura E., MA, MLS Google Minefield: Empowering Patients to Evaluate Online Resources...53 Raychaudhuri, Soumya, MD, PhD ACR Review Course - Genomics for the Clinician...29 Reed, Ann M., MD Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...72 Reid, Gregor, MD, PhD ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 2014 Program Book 281
Invited Speaker/Moderator Index Reveille, John D., MD Axial Spondyloarthritis Guidelines...44 Disclosure: Abbvie, 5; Eli Lilly and Company, 5; UCB, 5 Reactive Arthritis: An Update (008)...33 Disclosure: Abbvie, 5; Eli Lilly and Company, 5; UCB, 5 Reactive Arthritis: An Update (037)...71 Disclosure: Abbvie, 5; Eli Lilly and Company, 5; UCB, 5 Richardson-Nassif, Karen, PhD AAMC Medical Education Research Certificate (MERC) Workshop: Formulating Research Questions and Designing Studies...31 AAMC Medical Education Research Certificate (MERC) Workshop: Measuring Educational Outcomes With Reliability and Validity...31 Richmond, Susan, MS, PA-C Mycobacterium Infections in Immunocompromised Patients...113 Rider, Lisa G., MD Classification Criteria for Myositis...83 Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...73 Ridker, Paul M., MD, MPH Inflammation and Atherothrombosis...158 Disclosure: AstraZeneca, Novartis, Pfizer, Amgen, 2; ISIS, Vascular Biogenics, BostonHeart, 5; Seimens, 7 Ritchlin, Christopher T., MD, MPH ACR Immunology Update: New Immunology of the Spondyloarthropathies...36 Disclosure: Amgen, 2; UCB, 2 Psoriatic Arthritis: Skin, Entheses and Joints...124 Disclosure: Amgen, 2; UCB, 2 Robinson, Angela, MD, MPH Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...72 Robinson, William H., MD, PhD Advances in Molecular Profiling and Relevance to Autoimmune Disease Disclosure: Atreca, Inc., 5 Roos, Ewa M., PT, PhD Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management...135 Rose, Jillian A., LCSW The Psychosocial Impact and Treatment Options for Patients with Neuropsychiatric Lupus and Their Caregivers...104 Rose, Shawn, MD, PhD Clinical Features of Central Nervous System Lupus and Diagnosis of Cognitive Deficits and Psychiatric Disorders...108 Rosen, Antony, MD Current Understanding of Malignancies in Connective Tissue Diseases...34 Rosenbaum, James T., MD ACR Basic Research Conference - Session IV: Microbiome and Rheumatic Disease...30 Rosenthal, Ann K., MD Calcium Crystal Arthritis (083)...145 Ross, Michael D., PT, DHSc, OCS ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - Diagnostic Imaging a Tool for Differential Diagnosis...30 ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - Outlining the Value of Plain Film...30 ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - Plain Film Case Presentation...30 Roth, Johannes, MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Pediatrics...23 Roubey, Robert, MD Curbside Consults Ask the Experts...95 Round, June L., PhD ACR Basic Research Conference - Session III: Mechanisms of Immune Activation and Regulation...29 Rouster-Stevens, Kelly A., MD, MS Juvenile Dermatomyositis: Clinical, Pathogenic and Therapeutic State of the Art...72 Pediatric Systemic Lupus Erythematosus (015)...43 Protecting Bone Health in Pediatric Rheumatic Diseases...114 Rovin, Brad H., MD Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside...148 Systemic Lupus Erythematosus: Lupus Nephritis (059)...103 Disclosure: aurina, 5; Centocor, Inc., 5; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 5; Lilly, 5; Medimmune, 5; Questcor, 2 Systemic Lupus Erythematosus: Lupus Nephritis (078)...119 Disclosure: aurina, 5; Centocor, Inc., 5; Genentech and Biogen IDEC Inc., 2; GlaxoSmithKline, 5; Lilly, 5; Medimmune, 5; Questcor, 2 Rudrangi, Rajani, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Russell, Linda, MD Osteoporosis: Novel Treatments (064)...109 Russell, P. W. James, MA (Cantab), MB BChir Thieves Market: Show Me Your Best Cases...56 Ryan, Sean, PhD Glycosylation and Glycan Binding Proteins in Immune Function...108 S Saag, Kenneth G., MD, MSc ACR Clinical Research Conference - Session III: Research Perspective...26 Disclosure: Abbott Immunology Pharmaceuticals, 5; AbbVie, 5; BMS, 5; Crescendo, 5; Iroko, 5; Lilly, 5; Merck Pharmaceuticals, 5; Roche Pharmaceuticals, 5 Challenging Cases in Osteoporosis Management (072)...119 Disclosure: Amgen, 2, 5; Lilly, 2, 5; Merck Pharmaceuticals, 2, 5 New ACR Recommendations for the Management of Rheumatoid Arthritis...38 Disclosure: Abbott Immunology Pharmaceuticals, 5; AbbVie, 5; BMS, 5; Crescendo, 5; Iroko, 5; Lilly, 5; Merck Pharmaceuticals, 5; Roche Pharmaceuticals, 5 The ACR Gout Management Guidelines: Have They Gotten Us to Where We Want to Be?...74 Disclosure: Ardea, 2; Takeda, 2 Sachs, Barton L., MD, MBA State-of-the-Art Interventional Recommendations for Chronic Low Back Pain...146 Disclosure: Globus Medical, 2, 7; United Health Care, 9 Sadowsky, Mike, PhD ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 Disclosure: CIPAC, LLC, 5 Sahni, Shivani, PhD Beyond Analgesics: State of the Evidence for Nutrition, Vitamins and Exercise Prescriptions in Osteoarthritis Management...135 Role of Nutrition in Rheumatic Diseases...104 282 2014 Program Book See page 247 for the list of disclosure relationships.
Salmon, Jane E., MD Career Opportunities in Rheumatology: Making a Choice...94 Samant, Rohini, MBBS, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Sammaritano, Lisa R., MD ACR Review Course - Pregnancy Management and Outcome in Systemic Lupus Erythematosus...28 Schanberg, Laura E., MD When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility...35 Disclosure: Arthritis Foundation, 2; Eli Lilly and Company, 5; NIAMS-NIH, 2; Novartis Pharmaceutical Corporation, 2; UCB, 5 Scher, Jose U., MD ACR Basic Research Conference - Session IV: Microbiome and Rheumatic Disease...30 ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 The Microbiome in Health and Disease...35 Schikler, Kenneth N., MD Evidence of the Benefits and Risks of Cannabis and Cannabinoids for Treating Chronic Pain...77 When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility...35 Schneider, Rayfel, MBBCh Macrophages Gone Wild...111 Schoenfeld, Sara, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Schrandt, Suzanne, JD Nothing About Us Without Us: Engaging Patients in Rheumatology Research...157 Schwartz, Todd A., DrPH Stats Boot Camp: Statistical Analysis of Ordinal Data...77 Schwartzman, Sergio, MD Inflammatory Eye Disease/Uveitis (023)...66 Disclosure: Abbott Immunology Pharmaceuticals, 5, 8; Amgen, 8; antares, 8; Genentech and Biogen IDEC Inc., 5, 8; Janssen Pharmaceutica Product, L.P., 5, 8; Paizer, 8; Pfizer Inc, 5; ucb, 5, 8 Scott, Joshua, DO, MS, BS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Seibold, James R., MD Pulmonary Hypertension in the Rheumatic Diseases (026)...66 Disclosure: Aries, 5; Bayer, 5; Boehringer Ingelheim, 5; EMD Serono, 5; Gilead, 5; InterMune, 5; Sigma Tau, 5; United Therapeutics, 5, 8 Selby, Joe V., MD, MPH ACR Clinical Research Conference - Session I: Methodology and Development............24 Semb, Anne Grete, MD, PhD Risk and Risk Management of Cardiovascular Disease in Patients with Rheumatoid Arthritis and Other Systemic Rheumatic Diseases...112 Sethi, Manpreet, MBBS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Thieves Market Posters - ACR/ARHP Poster Session B...74 Seton, Margaret, MD Clinicopathologic Conference: A 17-year-old Young Woman with Chronic Ankle and Back Pain...94 Shah, Ami A., MD, MHS Current Understanding of Malignancies in Connective Tissue Diseases...34 Shah, Jigar, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Shakoor, Najia, MD, MS Footwear in Orthoarthritis (063)...109 Disclosure: DJO and Dr. Comfort, 7 Shane, Elizabeth J., MD Osteoporosis: Current Concepts for the Clinician...35 Disclosure: Amgen, 2; Eli Lilly and Company, 2 Sharma, Leena, MD Strategies for Academic Success: The Roadmap from Mentee to Mentor...73 Shelton, Lisa, B.Sc., BSN, RN Alternative Medicine: Presenting the Evidence for Rheumatic Conditions...92 Mycobacterium Infections in Immunocompromised Patients...113 Sherry, David D., MD Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management... 95 Shmerling, Robert H., MD Ethics and Rheumatology...34 Sibille, Kim, PhD Thriving With Rheumatic Disease: Cultivating Resilience...93 Sibley, Cailin H., MD ACR Knowledge Bowl: Final Round...76 Siegrist, Richard, Jr., MBA, MS, CPA ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Sieper, Joachim, MD Ankylosing Spondylitis: Disease Modification (012)...43 Disclosure: Abbott Immunology Pharmaceuticals, Pfizer, Merck, 2 Sigal, Leonard H., MD ACR Immunology Update: Innate Lymphoid Cells...76 Glycosylation and Glycan Binding Proteins in Immune Function...108 Telomeres, Telomerase and the Aging Immune System...83 Silverman, Gregg J., MD ACR Basic Research Conference - Session IV: Microbiome and Rheumatic Disease...30 Disclosure: Genentech, Pfizer, Lilly, Onyx, 5 ACR Immunology Update: New Immunology of the Spondyloarthropathies...36 Co-stimulation Pathways: Therapeutic Opportunities for the Rheumatic Diseases...147 Silverman, Stuart, MD Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (212)...55 Disclosure: Pfizer, Amgen, Lilly, Roche, 5 Osteoporosis: Interpreting Dual Energy X-Ray Absorptiometry and Clinical Risk Factors: The New Fracture Risk Assessment Algorithm (216)...72 Disclosure: Pfizer, Amgen, Lilly, Roche, 5 Invited Speaker/Moderator Index Simon, Lee S., MD Safety of Drugs Used to Treat Rheumatoid Arthritis (058)...103 Disclosure: Affinergy, Astrazeneca, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, 2014 Program Book 283
Invited Speaker/Moderator Index Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Antares, Bayer, Rigel, Chelsea, Regeneron, Cypress, Savient, Nicox, Fi Safety of Drugs Used to Treat Rheumatoid Arthritis (067)...109 Disclosure: Affinergy, Astrazeneca, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Antares, Bayer, Rigel, Chelsea, Regeneron, Cypress, Savient, Nicox, Fi What Are Biosimilars?...70 Disclosure: Affinergy, Astrazeneca, Abraxxis, Alpha Rx, NuvoResearch, Roche, Pfizer, Novartis, PLx Pharma, Hisamatsu, Dr Reddys, Avanir, Cerimon, Leerink Swann, Alimera, Nomura, Luxor, Paraexel, Antares, Bayer, Rigel, Chelsea, Regeneron, Cypress, Savient, Nicox, Fi Singer, Nora G., MD ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Disclosure: Abbott Immunology Pharmaceuticals, 5; Abbott, Lilly, Roche/ Genentech, UCB, HGS, GSK, Celgene, 9; genetech/orche, 5; Merck Human Health, 2; Pfizer, 9 Autoimmunity in Immunodeficiency...45 Disclosure: Abbott Immunology Pharmaceuticals, 5; Abbott, Lilly, Roche/ Genentech, UCB, HGS, GSK, Celgene, 9; genetech/orche, 5; Merck Human Health, 2; Pfizer, 9 Singh, Abha G., MBBS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Singh, Jasvinder A., MD, MPH Classification Criteria for Gout...82 Disclosure: I am on the steering committee of the OMERACT, an organization that receives arms-length funding from 36 pharmaceutical companies, 9; Takeda, Savient, 2; Takeda, Savient, Regeneron, Allergan, 5 From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases...104 Disclosure: consultant fees from Savient, Takeda, Regeneron and Allergan, 5; Takeda, Savient, 2 Gout Management in 2014...44 Disclosure: consultant fees from Savient, Takeda, Regeneron and Allergan, 5; Takeda, Savient, 2 Hot Topics in Rheumatoid Arthritis: Comparative Effectiveness and Harms of Biologics, and Management of DMARDs and Biologics in the Perioperative Period...72 Disclosure: consultant fees from Savient, Takeda, Regeneron and Allergan, 5; Takeda, Savient, 2 New ACR Recommendations for the Management of Rheumatoid Arthritis...38 Disclosure: consultant fees from Savient, Takeda, Regeneron and Allergan, 5; Takeda, Savient, 2 New Frontiers in Osteoarthritis Treatment: The Role of Weight Loss, Surgery and Current Treatment Guidelines...46 Disclosure: consultant fees from Savient, Takeda, Regeneron and Allergan, 5; Takeda, Savient, 2 Singh, Namrata, MBBS ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...43 Thieves Market Posters - ACR/ARHP Poster Session B...74 Singhal, Aneesh, MD Primary Angiitis of the Central Nervous System and Its Mimics...149 Disclosure: Medicolegal Firms, 9 Siva, Chokkalingam, MD Biomarkers in Rheumatic Care...93 Skeff, Kelley M., MD, PhD Educator: Cultivating the Competent Medical Educator: A Growing Concern...69 Slusher, Barbara A., PA-C, MSW Immunology Boot Camp III: Applying Principles of Immunology to Treatment Decisions...115 Smith, Benjamin J, PA-C Immunology Boot Camp II: The Basics of Autoimmunity and Immunodeficiency...77 Providing Evidence for Mid-Level Providers in Rheumatology Practice...115 Smith, Stacy, MD ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - MRI Case Presentations...31 ARHP Clinical Focus Course: Diagnostic Imaging Use in Differential Diagnosis for Common Rheumatic and Musculoskeletal Conditions - Outlining the Value of MRI...31 Smolen, Josef, MD Rheumatoid Arthritis: Biological Agents (027)...66 Disclosure: Abbvie, Astra, BMS, Celgene, Glaxo, Janssen, Medimmune, MSD, Novartis-Sandoz, Pfizer, Samsung, UCB, 5; Abbvie, BMS, MSD, Pfizer, Roche, 2 Solomon, Daniel H., MD, MPH Providing Evidence for Mid-Level Providers in Rheumatology Practice...115 Spencer, Jo, PhD ACR Basic Research Conference - Session IV: Microbiome and Rheumatic Disease...30 Spiegel, Brennan, MD, MSHS, AGAF ACR Clinical Research Conference - Session IV: Clinical Care Perspective: Practical Tools for Using Patient-Reported Outcomes (PROs)...27 Disclosure: Amgen, 2; Ironwood, 2; Nestle Health Sciences, 2; Shire, 2; Takeda, 2 Spiera, Robert F., MD Temporal Arteritis (079)...119 Disclosure: Roche Genetch, 2; Roche-Genetech, 2 Temporal Arteritis (090)...145 Disclosure: Roche Genetch, 2; Rroche-Genetech, 2 Spits, Hergen, MD, PhD ACR Immunology Update: Innate Lymphoid Cells...76 Sreih, Antoine G., MD Polymyalgia Rheumatica (025)...66 Disclosure: Genentech and Biogen IDEC Inc., 5; Roche Pharmaceuticals, 5 Stamatos, Christine A., DNP, ANP-C Brief Action Planning (BAP): A Motivational Interviewing (MI) Technique to Enhance Patient Self-Management and Improve Outcomes...133 Stamp, Lisa K., PhD Gout Management in 2014...44 Disclosure: Abbvie, 9; Astra Zenec, 5; PHARMAC, 6 Ste-Marie, Peter A., BA, LLB The Emerging Demand for Medicinal Cannabis by Young Adults and Beyond...104 Steen, Virginia D., MD Fibrotic Complications of Scleroderma...95 Disclosure: Actelion Pharmaceuticals US, 8; Bayer, 5; CSL Berhing, 2; Gilead Science, 8; Intermune, 2; Roche Pharmaceuticals, 2; Sanofi- Aventis Pharmaceutical, 2; United Therapeutics, 5 Multidisciplinary Management of Scleroderma... 68 Disclosure: Actelion Pharmaceuticals US, 8; Bayer, 5; CSL Berhing, 2; Gilead Science, 8; Intermune, 2; Roche Pharmaceuticals, 2; Sanofi-Aventis Pharmaceutical, 2; United Therapeutics, 5 Stojan, George, MD Forefronts in Lupus Nephritis...84 Stone, John H., MD, MPH Rheumatic Manifestations of Malignancy...148 Stone, Kerry, MD Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management... 95 Uncovering the Role of Connective Tissues in Chronic Low Back Pain: From Bedside to Bench to Bedside...120 Strand, Vibeke, MD What Are Biosimilars?...70 Disclosure: Abbvie, 5; Amgen, 5; Anthera, 5; AstraZeneca/medimmune, 5; BiogenIdec, 5; BioMarin, 5; BMS, 5; Celltrion, 5; Genentech/ Roche, 5; GSK, 5; Hospira, 5; Incyte, 5; Janssen Pharmaceutica Product, L.P., 5; Lilly, 284 2014 Program Book See page 247 for the list of disclosure relationships.
5; MerckSerono, 5; Novartis Pharmaceutical Corporation, 5; Novo Nordisk, 5; Pfizer Inc, 5; Regeneron, 5; Royalty, 5; Sanofi - Genzyme, 5; Takeda, 5; UCB, 5; Vertex, 5 Stuart, Marian R., PhD Successful Aging in Rheumatic Disease...146 Sufka, Paul, MD Social Media Boot Camp: Blogging for Beginners...75 Social Media Boot Camp: Twitter Basics...37 Sundy, John S., MD, PhD Crystal: Diagnosis and Management of Gout (073)...119 Disclosure: Ardea/Astra Zeneca, 2, 5; General Electric, 1; Gilead Sciences, 3; Novartis Pharmaceutical Corporation, 5; PAR Pharma, 5; Pfizer Inc, 5; Pharmos, 2 Sweiss, Nadera J., MD Sarcoidosis in 2014...37 T Tavora, Fabio, MD, PhD Histopathology of Rheumatic Lung Disease (206)...38 Histopathology of Vasculitis (218)...76 Taylor, William, PhD, MBChB Classification Criteria for Gout...82 Disclosure: AstraZeneca, 5 Tehrani, Rodney, MD Educator: Innovative Educators, Novel Techniques: A Rheumatology Research Foundation Special Session...124 Disclosure: Rheumatology Research Foundation, 9 Treating Pain Doesn t Have to Be a Pain: Practical Approaches to Pain Management...95 Theis, Kristina A., MPH Work and Worker Health: Easy Accommodations Keep People with Arthritis Employed.......159 Thiele, Ralf G., MD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Foot and Ankle...26 Disclosure: Bioclinica, Virtual Scopics, Cresendo Biosience, 5; Amgen, Abbvie, 8; Sonosite, 9 ACR Musculoskeletal Ultrasound Course for Rheumatologists - Ultrasound Needle Guidance...............................26 Disclosure: Bioclinica, Virtual Scopics, Cresendo Biosience, 5; Amgen, Abbvie, 8; Sonosite, 9 Thomas, Ranjeny, MBBS, MD Functional Genomics of Rheumatoid Arthritis: From Genes to Function to Therapy...75 Disclosure: Johnson & Johnson, 9 Tillman, Melesia, CPC, CPC-I, CRHC, CHA ACR Advanced Rheumatology Coding Course: Developing Experts in Rheumatology Coding and ICD-10-CM...23 Ting, Jenny, PhD Autophagy in Rheumatic Diseases...135 Tinkle, Brad, MD, PhD When Pills Are Not Enough: Multidisciplinary Approaches to Pediatric Pain and Hypermobility...35 Disclosure: Various, 5 Todd, Derrick J., MD, PhD Clinicopathologic Conference: A 17-year-old Young Woman with Chronic Ankle and Back Pain...94 Toledo-Garcia, Aixa, MD Thieves Market Posters - ACR/ARHP Poster Session C...112 Toppin, Bruce, JD Practical Practice Management Session Two: Navigate HIPAA and Prevent Audits...68 RheumChat...113 Disclosure: atyr Pharmaceuticals, 5; Baxter Biosciences, 2, 5; CSL Behring, 2, 5; Questcor Pharmaceuticals, 5 Torr, James, PharmD Alternative Medicine: Presenting the Evidence for Rheumatic Conditions...92 Townsend, Anne F., MA, PhD Current Trends in Self-Management and Rheumatologic Care: mhealth, ehealth, Digital Technology and Emerging Ethical Considerations...68 Trizuto, Jennifer L., MPT Biomarkers in Rheumatic Care...93 Etiology and Management of Peripheral Neuropathy in Patients with Rheumatic Disease...120 Osteoporosis: Emerging Treatments Both Pharmacological and Non-Pharmacological...134 Trouw, Leendert A., PhD Complement in Rheumatic Disease...148 Tsokos, George C., MD Bone Biology...38 New Regulatory T Cells...120 Tucker, Lori B., MD The Emerging Demand for Medicinal Cannabis by Young Adults and Beyond...104 U Ursini, Francesco, MD, PhD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Invited Speaker/Moderator Index Terkeltaub, Robert, MD Rheumatology Research Foundation Memorial Lectureship to Honor Dr. Stephen E. Malawista, MD: Innate Immunity at the Core of Rheumatic Disease...45 Disclosure: Astar Zeneca, Takeda, Relburn, Abbvie, BioMarin, Quest, 5 Theander, Elke, MD, PhD Clinical Challenges in Sjögren s Syndrome: Neurological Complications and Lymphoma Risk...84 Theis, David, DO, BA ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Torgerson, Troy R., MD, PhD Immunodeficiency Syndromes (053)...102 Disclosure: atyr Pharmaceuticals, 5; Baxter Biosciences, 2, 5; CSL Behring, 2, 5; Questcor Pharmaceuticals, 5 Immunology Boot Camp I: The Basics of Targeted Therapies...38 Disclosure: atyr Pharmaceuticals, 5; Baxter Biosciences, 2, 5; CSL Behring, 2, 5; Questcor Pharmaceuticals, 5 Immunology Boot Camp II: The Basics of Autoimmunity and Immunodeficiency...77 Disclosure: atyr Pharmaceuticals, 5; Baxter Biosciences, 2, 5; CSL Behring, 2, 5; Questcor Pharmaceuticals, 5 Immunology Boot Camp III: Applying Principles of Immunology to Treatment Decisions...115 Disclosure: atyr Pharmaceuticals, 5; Baxter Biosciences, 2, 5; CSL Behring, 2, 5; Questcor Pharmaceuticals, 5 V Van Dyke, Kenneth, DO ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Varga, John, MD Insight into Lung Fibrosis...84 Vashisht, Priyanka, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 2014 Program Book 285
Invited Speaker/Moderator Index Vaughan, Molly, PhD Exercise Adherence in Arthritis: The Role of Technology...156 Venuturupalli, Swamy, MD Inflammation and Atherothrombosis...158 Moving Toward Personalized Medicine for Systemic Lupus Erythematosus Management: From Bench to Bedside...148 Villasenor Ovies, Pablo, MD Clinical Anatomy and Physical Exam: Essential Tools in Lower Extremity Regional Pain Syndromes (209)...45 Clinical Anatomy and Physical Exam: Essential Tools in Upper Extremity Regional Pain Syndromes (205)...37 Vinino, Frederick, MD Controversies in Sjögren s Syndrome (033)...70 Disclosure: Biogen-Idec, 5; Nicox, Inc., 5; Novartis, Inc., 9; Takeda, Inc., 5 Controversies in Sjögren s Syndrome (062)... 109 Disclosure: Biogen-Idec, 5; Nicox, Inc., 5; Novartis, Inc., 9; Takeda, Inc., 5 Vleugels, Ruth Ann, MD, MPH Cutaneous Vasculitis (003)...33 Dermatological Manifestations of Rheumatic Diseases (013)...43 Dermatological Manifestations of Rheumatic Diseases (034)...70 Ward, Michael M., MD Axial Spondyloarthritis Guidelines...44 Non-Radiographic Axial Spondyloarthritis: The Controversy of Diagnosis and Optimal Treatment...159 Warren, Robert, MD, PhD, MPH Practical Practice Management Session One: Improve Quality and Efficiency...53 Practice Issues: Practice Success in an Environment of Transition Warrington, Kenneth J., MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 ACR Review Course - Assessing Disease and Managing Large Vessel Vasculitis...29 Wei, Kevin, MD PhD Thieves Market: Show Me Your Best Cases...55 Weinblatt, Michael E., MD Clinical Issues Associated with the Use of Methotrexate...120 Disclosure: Antares, 5 Weiner, Joseph, MD, PhD Brief Action Planning (BAP): A Motivational Interviewing (MI) Technique to Enhance Patient Self-Management and Improve Outcomes...133 Weissman, Barbara, MD Clinicopathologic Conference: A 17-year-old Young Woman with Chronic Ankle and Back Pain...94 Wells, Alvin F., MD, PhD ACR Musculoskeletal Ultrasound Course for Rheumatologists - Ultrasound Needle Guidance...............................26 Wells, Courtney, MPH, MSW Say What? : Implications of Adolescent Development and Behavior in Communicating With Health Care Providers...68 Weyand, Cornelia M., MD, PhD Autophagy in Rheumatic Diseases From Inflammation to Atherosclerosis: The Case of Inflammatory Rheumatic Diseases...104 Year in Review White, Douglas, MD, PhD Practice Issues: Health Care Bounty Hunters: A Closer Look at RACs, Audits and Medical Documentation...35 Practice Issues: The Road to I10...44 Whittier, Xena, MD, MS, BA ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 W Wallace, Zachary, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Ward, Ian, MD ACR Knowledge Bowl: Final Round...76 ACR Knowledge Bowl: Preliminary Round...42 Weinstock, Joel, MD ACR Basic Research Conference - Session V: Prospects for Manipulating Disease Through the Microbiome...30 Disclosure: Coronado Biosciences, 5 Weisman, Michael H., MD Update on Safety Issues in the Treatment of Rheumatic Diseases From the FDA and Beyond...135 Disclosure: Abbvie, 5; Amgen, 2; Astellas Pharma Global Development, 5; Celgene, 5; Centocor, Inc., 2; Cephalon, 2; Crescendo Bioscience, 5; Dynavax, 2; Genentech and Biogen IDEC Inc., 2; GSK, 2; Lilly, 2, 5; Pfizer Inc, 2; Rigel Pharma, 2; Roche Pharmaceuticals, 2; Sanofi-Aventis Pharmaceutical, 2; Teva Pharmaceuticals, 2; UCB Pharma, 5 Wigley, Fredrick M., MD Raynaud s and Digital Ischemia (057)...103 Disclosure: CSL Behring, 2; Kinemed, 2; Medimmune, 2; Novartis Pharmaceutical Corporation, 5; Sanofi-Aventis Pharmaceutical, 2; United Therapeutics, 5 Raynaud s and Digital Ischemia (088)...145 Disclosure: CSL Behring, 2; Kinemed, 2; Medimmune, 2; Novartis Pharmaceutical Corporation, 5; Sanofi-Aventis Pharmaceutical, 2; United Therapeutics, 5 Wilkes, Margaret R., MD Osteoporosis: Current Concepts for the Clinician...35 286 2014 Program Book See page 247 for the list of disclosure relationships.
Winthrop, Kevin L., MD, MPH Mycobacterium Infections in Immunocompromised Patients...113 Disclosure: Abbvie, 5; Insmed, 2, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 5; UCB, 5 Vaccinations for Patients on Biologic Therapies (080)...120 Disclosure: Abbvie, 5; Insmed, 2, 5; Pfizer Inc, 2, 5; Roche Pharmaceuticals, 5; UCB, 5 Witter, James P., MD, PhD ACR Clinical Research Conference - Session VI: Patient-Reported Outcomes (PROs) Measures in Research and Clinical Trials...27 Wortmann, Robert L., MD, MACR Adult Inflammatory Myopathy (041)...81 Adult Inflammatory Myopathy (081)...144 Young, Kelly, BA ACR Clinical Research Conference - Session V: Patient Perspective...159 Young, Stephen, BSc, PhD Advances in Molecular Profiling and Relevance to Autoimmune Disease...158 Z Zautra, Alex, PhD Pathways to Resilience: Biopsychosocial Mechanisms for the Generation of Positive Affect in Chronic Pain...115 Thriving with Rheumatic Disease: Cultivating Resilience...93 Invited Speaker/Moderator Index Wu, Kim M., MD Thieves Market Posters - ACR/ARHP Poster Session B...74 Zupko, Karen, BS Practical Practice Management Session Two: Navigate HIPAA and Prevent Audits...68 Wynn, Thomas, PhD Insight into Lung Fibrosis...84 Y Yazdany, Jinoos, MD, MPH Practical Practice Management Session One: Improve Quality and Efficiency...53 Yazici, Yusuf, MD Behçet s Syndrome (052)...102 Disclosure: Celgen, BMS, Genentech, 2 Behçet s Syndrome (082)...145 Disclosure: Celgen, BMS, Genentech, 2 Young, Brandi, DNP, FNP-C ACR Practice Management Pre-Meeting Course - Customer Service That Rocks: Boost Patient Satisfaction...27 Disclosure: Abbott Immunology Pharmaceuticals, 8; Genentech and Biogen IDEC Inc., 8 Immunology Boot Camp I: The Basics of Targeted Therapies...38 Disclosure: Abbott Immunology Pharmaceuticalsv, 8; Genentech and Biogen IDEC Inc., 8 Practical Practice Management Session One: Improve Quality and Efficiency...53 Disclosure: Abbott Immunology Pharmaceuticalsv, 8; Genentech and Biogen IDEC Inc., 8 2014 Program Book 287
abstract author Index 288 A A Pilkington, C..1314, 1316, 1322, 1323, 2900 Aalokken, TM... 724, 2703 Aaron, L...256 Aati, O... 828, 1215 Abad, M...596 Abad, S...811 Abasolo, L... 482, 1431 Abawi, O...2937 Abbas, S...1409 Abbott, JH...889, 2897, 3017 Abbott, J... 711, 712 abd El Baky, N...1632 Abdala, M...1388, 1438, 2381 Abdel-Fattah, YH...2056 Abdel-Wahab, N... 17, 970, 2013 Abdelhaleem, M...1310 Abdi, D...1448 Abdollahi-Roodsaz, S.. 1733, 1734, 1816 Abdul, W...1810 Abdulahad, WH. 1775, 1956, 2733, 2738, 2934 Abdullah, A...1053 Abdullah, H... 610, 611 Abe, A...135 Abecasis, GR...625 Aberle, T...2430 Abignano, G...768 Abji, F...626, 627, 628, 630, 2099 Ablin, JN... 2066, 3012 Abou Zahr, Z...1070 Abou-Ghantous, J............622 Aboulhosn, J...740 Aboutaam, M...845 Abraham, D...1717, 1721, 1728 Abraham, DJ... 760, 1706 Abraham, TP...741 Abrahamowicz, M... 2306, 2308 Abrahams, V...872 Abram, F... 218, 2250 Abrams, K...2291 Abrams, K... 305, 931 Abrams, K...833 Abrams, RI...1990 Abrams, S...2859 Abramson, SB... 81, 2246 Abria, C... 1602, 1963 Absher, D...2454 Abud-Mendoza, C. 933, 1649, 1650 Abujam, B...1306 Abulaban, K...1294, 1303, 1304, 1826 Accortt, N...2037 Acevedo-Vásquez, EM...959 Acharya, S...1810 Achenbach, SJ......... 800, 2116 Achkar, JP...1900 2014 Program Book Acikel, C...2301 Ackermann, F...1925 Ackermann, G...1919 Acosta, A Sr....1113 Acosta Felquer, ML..........1585 Acosta-Hernandez, RI...2639 Adachi, J...2254 Adachi, JD...48, 217, 1172, 1424, 1566, 2257 Adam, P...384, 416, 2442 Adami, S...2267 Adami, S... 920, 2268 Adamidi, S...1466 Adamopoulos, IE...1915 Adan, A...1249, 1250, 1251, 2853 Adan, N... 330, 333 Addimanda, O... 2417, 2757 Adebajo, AO... 548, 602, 1543, 1561, 1564, 1572, 1579, 1590, 2438, 3015 Ades, L...2779 Adhikarakunnathu, S...1976 Adibnia, Y...1233 Adinolfi, A... 184, 908 Adler, A...2841 Adler, B...239 Adler, RA...919 Adler, S...1193 Adluri, RS...1484 Admiraglio, E...531 Admon, A...607 Adnan, E... 1610, 2170 Adriaans, A...2102 Adrianto, I... 1134, 2978 Adu, J...1117 Aegerter, P...2589 Aelion, JA...602, 1543, 1572 af Klint, E...2126 Affandi, AJ...1704 Affentranger, U...305 Aga, AB... 356, 905 Agard, C...1690 Agarwal, A...1319 Agarwal, SK...765 Agarwal, V...... 1272, 1679, 2603 Agca, R...354 Agewall, S...398 Aggarwal, A...89, 308, 318, 928, 1272, 2173 Aggarwal, R...318 Aggarwal, R. 912, 914, 1266, 1316, 1344, 1348, 1410 Agha, A...2334 Agnihotry, S...318 Agrawal, R...729 Aguado, P...2513 Aguero, S...2040 Aguiar, C...1 Aguiar, R...675 Aguilar-Salinas, CA...1371 Aguirre, A... 1811, 2117 Aguirre, MA... 1670, 2622 Aguirre Zamorano,... 7, 1978 Ahadieh, S...458 Ahearn, J...1924 Ahlstrand, I...2435 Ahluwalia, V. 517, 714, 1168, 1833, 2309, 2424 Ahmad, J...401 Ahmad, Y...711 Ahmadi, N...2127 Ahmed, S... 1031, 2879 Ahmed, S...2967 Ahmed Abdi, B... 760, 1721 Ahn, JK...2464 Ahn, SM. 614, 702, 703, 812, 847, 2564 Ahn, Y...2825 Ai, R...2816 Aigner, S...1750 Aihara, M...1719 Aikawa, NE...2304 Ailioaie, C...282 Aimer, P...................2377 Ainsworth, B...2944 Ainsworth, H...2089 Aire-MB, G... 1519, 1531 Airo, P... 1130, 1256 Aissopou, EK...2709 Aitken, D...205 Aiyer, A...1410 Aizaki, Y...39 Aizer, J...1989 Ajmone Marsan, N...1692 Ajmone Marsan, N...1693 Ak, F...2761 Akagi, M...241 Akagi, R... 1016, 1885 Akahoshi, M... 1000, 1952 Akaike, H... 1868, 2274 Akamata, K...748, 749, 752, 3003 Akar, S...603, 1230, 2157, 2616 Akasaki, Y...1021 Akasdi, A...2949 Akashi, K...2910 Akashi, K... 1000, 1952 Akdemir, G... 2138, 2502 Akdeniz Leblebicier, M...151 Akdogan, A...509, 1432, 2616 Akerkar, S...2436 Akhavan, P... 1065, 2814 Akikusa, J... 307, 2281 Akil, M...676, 711, 2798, 2817 Akilesh, S...1940 Akita, K...1950 Akiyama, M................1238 Akiyama, Y... 1435, 1765 Akiyama, Y...2529 Akiyama, Y...39 Akkoc, FN...1232 Akkoc, N...560 Akkoc, N.. 601, 1230, 1584, 2562, 2595, 2611, 2616 Akkurt, E...1119 Aksentijevich, I...816, 1227, 1817 Aksu, K... 2523, 2616 Aktay Ayaz, N...2281 Akter, T... 762, 3002 Akyuz, G... 151, 2057 Al, M... 96, 1141 Al adba, B...2300 Al Ghanim, N... 623, 2101 Al Maini, M...53 AL Osaimi, N... 384, 416 Al Sawah, S...683, 687, 2623 Al-Ali, S... 522, 2982 Al-Khalili, L...2726 Al-Suwairi, W...2281 Ala-Korpela, M...399 Alabiad, C...1756 Alade, R...1714 Alam, J....................2471 Álamo, M...2192 Alarcón, G...683 Alarcon, GS...6, 961, 1080, 1415, 2089, 2646 Alarcon Riquelme, ME...2089 Alarcon-Riquelme, M...2841 Alarcón-Riquelme, ME...1900 Alasthi, F...906 Alasti, F...1054 Alavi, A...2140 Alba, P...2625 Albani, S...1455 Albarrán Hernández, F...1683 Albers, CA...2966 Albert, D...1234 Albert, DA...2311 Albert, D...866 Albert, G.. 691, 1655, 1656, 1659, 2194, 2620 Albesa, R... 1629, 2866 Albrecht, K...1154 Alcañiz, C...2119 Alcaraz, MJ...32 Alcid, D...1341 Alcocer-Varela, J. 1658, 1664, 2676, 2724, 2990 Aldag, J...2038 Aldag, JC...2039 Alderaan, K... 689, 2667 Aldigeri, R...798 Aledrissy, M...1534 Alegre, C...2064 Alegre, JJ... 1670, 2622 Alegre de Miguel, C...2372
Alegre Sancho, JJ...1674 Alekseeva, E...277 Alemán-Sánchez, N...1650 Alemany, FX...2179 Alemao, E.96, 841, 898, 1060, 1141, 2103, 2486 Alemao, E... 385, 1362 Alemo Munters, L...1117 Alenius, GM...1549 Alessandro, R... 610, 611 Aletaha, D. 906, 1054, 1389, 1407, 2387 Alevizos, I... 526, 529, 530 Alevizos, I... 528, 2981 Alexander, C...2973 Alexander, K...844 Alexander, T... 2693, 2837 Alexander, Y...1182, 1464, 1699, 1923, 2636 Alexandersen, P... 222, 2230 Alexanderson, H...1211 Alexeeva, E... 282, 2296 Alexiades, M... 115, 2970 Alfaguter, I...2723 Alfaiate, T...1385 Alfaro-Lozano, JL...1393 Alfredsson, L.352, 358, 2016, 2018, 2888 Alhajeri, H...3000 Ali, Y...1999 Ali, Z...681 Alia, P...412 Alibaz-Oner, F... 807, 2750 Aliferis, CF...81 Aliprantis, AO...28, 1732, 2796 Alivernini, S...999 Alkatan, H... 1236, 1756 Allaart, CF.. 361, 817, 1386, 2138, 2398, 2502 Allaart, C...2428 Allanore, Y.473, 476, 722, 730, 740, 743, 747, 876, 1130, 1140, 1687, 1926, 2559, 2711, 2999, 3001 Allegra, M...278 Allegri, F...4, 15 Allen, IE...1828 Allen, J...737 Allen, KD... 891, 977 Allen, R...307 Allenbach, Y...1037, 1262, 1263, 1270 Allevi, E...2768 Allison, J.. 64, 192, 194, 197, 1279 Allison, P... 385, 1141 Alloush, J...2219 Ally, MM...423 Alm, G...2681 Almaghlouth, I... 600, 604 Almagor, O.211, 214, 215, 729, 750, 2698 Almayouf, S...2281 Almeida, B... 1314, 2900 Almeida, GJ...2326 Almeida de Jesus, A...315, 1812, 1896, 1898, 2285 Almodóvar González, R.2586, 2598, 2853 Almutairi, A................2339 Alonso, A...596 Alonso, A.59, 475, 2097, 2391, 2526 Alonso Blanco-Morales, E...2602 Alonso-Castro, S...2445 Alosco, S...1716 Aloush, V...2066 Alperi-López, M... 59, 2445 Alraqi, S...2614 Alsuwaidi, M...126 Altaf, S...2959 Altan, A... 117, 1155 Altavilla, D...744 Altawil, R...352 Altemus, J...782 Alten, R... 2491, 2492 Alten, R...159, 940, 1482 Altenburg, J...441 Altman, R... 243, 249 Alunno, A...2544 Alvarellos, A...1388 Alvarellos, AJ... 959, 2040 Alvarellos, T...406 Alvarenga Rezende, R...733 Alvarez, A...1388, 1438, 2381 Alvarez, A... 2040, 2625 Alvarez, AP...2672 Alvarez, AM...872 Álvarez, L............ 1791, 2775 Álvarez de Mon, M...1683 Alvarez-Garcia, O.1016, 1021, 1885 Alvarez-Vega, JL...40 Álvaro-Gracia, J...2412 Alves, CH...340 Alves, M...675 Alvey, C...1478 Amano, H...87 Amano, K...486 Amano, K...1497 Amano, K...486 Amara, K...2874 Amarilyo, G...2899 Amarnani, A...91 Amato, AA..................910 Amato, MD, AA...912 Amatruda, J. 370, 1375, 2378, 2413 Ambrose, N...2748 Ambrozic, A...514 Ambrus, J. 2094, 2540, 2541, 2546 Ambudkar, I... 528, 529 Amengual, O...2, 5, 1179, 1628, 2638, 2677, 2864 Amezcua-Guerra, LM... 692, 1984 Amici, S...2686 Amigo, E... 2452, 2459 Amin, MA...444, 937, 1962, 3006 Amin, S...1617 Aminoff, AR...297 Amiri, N... 1770, 1865 Amital, H...2493 Amital, H...2067 Amiya, E...805 Ammitzbøll, CG...2171 Amoruso, MC...1327 Amoura, Z. 811, 1263, 1634, 1792, 1925, 2778, 2779 Ampel, NM...2205 Amundsen, L................786 An, J... 841, 898 An, J...873 Anandarajah, AP...1807 Ananieva, LP...2711 Anavekar, N...1253 Anaya, JM... 84, 2978 Ancuta, C. 1525, 1526, 1538, 2497 Ancuta, I.. 823, 1153, 1525, 1526, 1538, 2497, 2524 Andersen, F...1441 Andersen, GN... 80, 1516 Andersen, J...2230 Andersen, M... 80, 1516 Andersen,...2500 Andersen, T...366, 1741, 2737 Andersen, V...2500 Anderson, AE... 1530, 2460 Anderson, D... 840, 1470 Anderson, E...1351 Anderson, JK...269, 270, 551, 553, 558, 562, 2581 Anderson, J...2031 Anderson, J...304 Anderson, JR...648 Anderson, K...304 Anderson, M...737 Anderson, N... 865, 2631 Anderson, R...1869 Anderson, R...423 Andersson, D...2892 Andersson, K...2847 Andersson, KM...1748 Andersson, M...536 Ando, K... 472, 1698 Andrade, D... 872, 2868 Andrade, JL...1300 Andrade, LEC...1644, 2184, 2745 Andrade Medeiros Freire, E...733 Andrade-Ortega, L... 1268, 1984 Andreassen, K...1019 Andreoli, L...4, 15, 671, 1642 Andrés, M... 99, 829, 2962 Andreu, JL... 668, 1670 Andrews, A...1467 Andrews, J...460 Andrews, JS...698 Andrews, S...2965 Aneja, R...53 Anema, J...2104 Angel, T...964 Angeles-Han, S... 104, 1151 Angeles-Han, ST...2290 Angelini, F...1971 Angerer, P... 1057, 1078 Aniel-Quiroga, MA...177 Anink, J... 293, 300, 932 Anis, AH... 1144, 2781 Anisfeld, A... 461, 849 Ankri, A... 8, 1634 Annaloro, C...879 Annan, A...1002 Annapureddy, N...353, 713, 717, 1990, 2111, 2207, 2315, 2989 Annunziata, K...105 Anolik, JH... 860, 2820 Anthanari, S...1358 Anthony, M...2037 Antivalle, M... 142, 2976 Antoch, G...1189 Antoch, PDG... 1173, 1177 Anton, A... 604, 606, 2553, 2605, 2607 Anton, J. 277, 282, 284, 930, 1231, 1325, 1900, 2279, 2282 Antonatou, K...1254 Antonelli, M...1417 Antoniol, MN...2672 Antonioli, A...2182 Anway, S...493 Aoyagi, K... 429, 2389 Aozasa, N...748 Aparicio, L...410 Apaz, M...2040 Apkarian, AV...925 Apodaca, E...2990 Apostolidis, S...1033 Apostolidis, SA...2734 Appel, H...616, 2612, 2940 Appenzeller, S...1169, 1622, 1636, 2320, 2659, 2660, 2661, 2662, 2663, 2705, 2720 Apras, S...2616 Apras Bilgen, S... 509, 1432 A Action, OBO...2868 Aqrawi, LA...532 Aquavella, J...2534 Aquino-Beaton, C...2107 Arabshahi, B...1898 Aractingi, S...2777 Arad, U...971 Aradi-Vegh, B... 1128, 2450 Arafat, A...2786 abstract author Index 2014 Program Book 289
abstract author Index Arami, S... 1510, 2799 Arana-Guajardo, A...739 Aranishi, T...1645 Aranow, C...684, 961, 2646, 2835 Arato, A...2284 Araújo, AC...675, 2409, 2656 Arbab, A...1962 Arbab, AS...444 Arbillaga, H...2619 Arce, CA...1984 Arce Gonzalez, N...695 Arce-Franco, MT...992 Arden, N...372 Arden, NK... 201, 2231 Ardern, R............. 623, 2101 Ardoin, S...2687 Ardoin, SP. 304, 1303, 1304, 1320, 1826, 2272, 2318, 2320, 2641, 2790 Ardouin, E...2397 Aref-Eshghi, E... 1124, 1289 Arena, V...1971 Arenas-Osuna, J...710 Arends, S...2547, 2831, 2934 Arendse, R...365, 382, 383, 943, 1550, 1551, 2416, 2496, 2518 Arendt-Nielsen, L... 1293, 2783 Arfi, S... 1269, 1767, 2024, 2155, 2532 Argyropoulou, M...1170 Arico, M Sr....321 Arida, AI... 1443, 2617 Arima, K...429, 1719, 2389, 2651 Aringer, M...1621 Arinobu, Y... 1000, 1952 Arinuma, Y...1696 Arismendi, M...1130 Ariza, Y...646 Ariza-Ariza, R... 40, 576 Arkachaisri, T...1308, 1309, 1618 Arkema, EV...825, 1072, 1877 Ärlestig, L... 2084, 2098 Armaka, M...2785 Armas-Gonzalez, E...992 Armengol, E.691, 1657, 1659, 2194, 2620, 2780 Armesto, S...2203, 2775, 2776 Armon, K...1330 Armstrong, A...439 Arnett, DK... 2453, 2454 Arnett, FC... 747, 765 Arnold, G...1646 Arnold, K... 1314, 2900 Arnott, M...2861 Arntz, OJ...1049 Arold, G...1479 Arron, S...1723 Arroyo-Villa, I...605 Arstila, L...399 Arthur, J...1669 Artieda, M.................1290 Artim-Esen, B... 2627, 2865 ARTIS and DANBIO study groups,. 853 Arturi, V... 1637, 2670 Arvikar, S...983 Arvikar, SL... 183, 1402 Arya, R...1133 Aryal, M...2187 Asai, N...471 Asai, S...471 Asako, K... 1218, 2762 Asami, Y...123 Asano, T...2653 Asano, Y. 748, 749, 752, 756, 766, 1724, 3003 Asare, A... 1754, 1862 Ascherio, A...827 Ascherman, DP...437, 911, 3004 Asfahani, L...2070 Ashcroft, M...1201 Ashkenazi, RI...1547 Asikainen, J...1365, 2812, 2911 Askanase, A..672, 715, 961, 1307, 2269, 2646 Askanase, A...1924 Askari, A...2068 Askari, A...1957 Asker-Hagelberg, C...846 Askling, J. 42, 825, 846, 853, 1071, 1072, 1376, 1804, 1837, 1838, 2018, 2832, 2890, 2892, 2936 Aslam, A...449 Aslanov, R... 56, 714, 1374 Asli, B...1925 Asmawidjaja, P...1749 Asmawidjaja,...340 Asquith, M... 615, 1919 Assassi, S. 588, 745, 747, 751, 753, 754, 765, 1677 Assimes, TL...438 Assirelli, E...1292 Astudillo, L...2777 Atagunduz, P... 1423, 2769 Atak Yucel, A...2548 Atanelishvili, I... 762, 3002 Atanes, A...1250 Atanes-Sandoval, A... 1249, 2853 Aten, A...2395 Aterido, A...1129 Athanasou, N...38 Atilla, N...2270 Atisha-Fregoso, Y.. 411, 694, 1779 Atkinson, ML...2008 Atsumi, T...2, 5, 456, 805, 1179, 1628, 2467, 2472, 2638, 2677, 2864 Attur, M... 81, 2246 Atzeni, F... 142, 2443 Atzeni, F.. 397, 2433, 2512, 2514, 2550, 2976 Aubin, A...2699 Auboire, L...2193 Auclair, M...1012 Audemard, A...1792 Audia, S...2849 Audisio, M...141 Audo, R...395 Auger, JL...2905 Augustin, M...1569 Augusto, KL...2933 Aulie, H...304 Aumaître, O...1776, 1778, 1925 Aurrecoechea, E.. 814, 1415, 2853 Auvinet, B... 2434, 3011 Avau, A...316 Avci, AB...2157 Avcin, T...1325 Avenano, C...1009 Avila, G...475, 1129, 2391, 2526 Avila, G...59 Avila-Casado, C... 2533, 2787 Avina, M...1400 Avina-Zubieta, JA..379, 915, 2306, 2308 Avina-Zubieta, JA...116, 382, 426, 1770, 1865, 2112, 2118, 2416, 2518, 2932 Avouac, J...476, 730, 740, 1130, 1687, 1926, 2711, 3001 Awale, A... 1086, 2943 Awosogba, JA...2122 Axelsen, M...2030 Axelsen, MB...1180 Axelsson, M...670 Ayala Gutierrez, MDM...958 Ayanoglu, G...649 Aydin, SZ... 119, 2769 Ayearst, R...606 Ayeroff, JR...1937 Ayers, D...194, 197, 1279 Ayers, DC...193 Aylward, H...1830 Ayoub, WT...1830 Ayral, X...2324 Ayvaz, S...1725 Azadi, P...1132 Azeez, M...2916 Azeni, F...563 Azizoddin, D...3013 Aznar, JJ...................2588 Aznar Sánchez, JJ... 597, 2190 Azukizawa, M...2152 B Babai, I...388 Babalola, O...2861 Babaoglu, H... 509, 1432 Babbe, H...2743 Bachiller Corral, J...1256 Backhaus, M...2912 Backhaus, M...130, 153, 2129 Backman, C... 2334, 2442 Bacon, H...1330 Baddley, J... 57, 820, 1589 Badea, T...639 Bader, RA...2362 Bader-Meunier, B... 316, 1326 Badley, EM... 1933, 2942 Badsha, H...1447 Bae, D...2347 Bae, EK...2464 Bae, SC.946, 961, 1056, 2025, 2158, 2646, 2825, 2918, 2954 Bae, SH.. 614, 703, 812, 847, 2564 Bae, SH...702 Bae, YS...946 Baechler, E...2213 Baechler, EC...2843 Baecklund, E...1837 Baek, IW...693 Baena, S...1139 Baer, AN.44, 525, 1872, 2148, 2538, 2539, 2929 Baer, P... 248, 365, 379, 382, 383, 426, 943, 2416, 2496, 2518 Baeriswyl, L...305 Baerlecken, NT...2771 Baerwald, CG...1436 Baeten, DL.536, 538, 561, 562, 620, 819, 850, 1916, 1973 Baffari, E...1472 Bagaria, BR...949 Bagavant, H...648, 1798, 2542 Bagchi, S...1207 Bagheri, H...845 Baglaenko, Y... 656, 2742 Bagnasco, M... 2239, 2443 Bagnato, G...744 Bagnato, G...744 Bagny, K...2204 Baguley, E...2396 Bahat, H...2899 Baik, YA...1457 Baildam, E...272, 274, 295, 303, 1322, 1323, 1325 Bailey, L... 2105, 2106 Baillet, A...632 Baillet, N...1269 Bailly, F...585 Bain, G...1796 Bajaj, P...1351 Bajocchi, G... 791, 1256 Bak, R...2737 Baker, AM...1578 Baker, D...1891 290 2014 Program Book
Baker, DW... 1346, 1347 Baker, J. 236, 732, 840, 1063, 1391, 1392, 1891, 2140, 2545 Baker, JF... 239, 1372 Baker, K...1493 Baker, M.365, 421, 583, 1551, 1601, 2496 Baker, N...97 Baker, NA...886 Bakker, A...2102 Bakker, P...594, 2589, 2597 Bakowsky, V...2884 Bakshi, R...252 Balanescu, A..58, 351, 1525, 1526, 1538, 1539, 2497 Balasubramanian, A...919 Balasubramanyam, A...216 Balblanc, JC...1385 Balci, MA...2719 Baldassari, AA... 1088, 2051 Baldin, B...845 Baldini, C.. 527, 1772, 2201, 2544, 2755, 2931, 2981 Baldini, M...1745 Baldissera, E... 1242, 1745 Baldwin, C... 813, 2112 Baldwin, N...2699 Bale, P...1330 Baliki, M...925 Balint, P...132 Balkarli, A. 2157, 2523, 2750, 2769 Ball, J...431 Ballanti, E...1472 Ballas, ZK...2189 Ballina, FJ...2482 Ballina, J...1129 Ballina-García, J...2445 Ballou, SP... 1417, 1997 Balogh, B...3006 Balsa, A.. 1603, 2400, 2459, 2513, 2522 Baltus, G...1495 Bananis, E...2488 Bananis, E...493 Bandeira, M...933 Bandyopadhyay, S...1520 Banerjee, S. 385, 952, 1141, 1362, 2103 Bang, D...1224 Bang, SY...1056, 2918, 2954 Bangs, A...1355 Bank, S...2500 Bankhurst, A... 1764, 2789 Baños, M...411 Bansal, P...1380 Bansback, N...1144, 2120, 2781 Banydeen, R...2024 Banzato, A...2868 Bao, G.959, 1334, 1811, 2117, 2626 Bao, Y...551, 586, 1147 Bao, Y... 1219, 2960 Bar-Meir, M...2899 Bar-On, Y...2067 Baracat, EC...2221 Baraf, HSB...1356 Baraliakos, X...536, 538, 579, 819, 1189, 2563, 2566, 2567, 2581, 2589, 2601, 2612, 2940 Baranda, L...1649 Barash, J...930 Baratham, A...2242 Barausse, G...1256 Barbarossa, S...2768 Barbarroja, N... 7, 1978 Barber, DF...660 Barber, X... 1519, 1531 Barber-Vallés, X...2423 Barbey, F...255 Barbhaiya, M...55, 1080, 1876 Barbo, A...427, 2005, 2009, 2244 Barbosa, J... 1172, 1424 Barbosa, R........... 2661, 2662 Barbour, KE...72 Barcellos, LF...524, 2446, 2466 Barchechath-Flaisler, F.......2527 Bardin, N...1611 Bardin, T. 159, 163, 164, 165, 2962 Barenholz, Y...636 Barham, B...1227 Barham, T...1333 Barile-Fabris, LA...1506 Barilla-LaBarca, ML...1994 Barinas-Mitchell, E...862 Barini, A...1639 Barini, A...1639 Barkai, G...2899 Barken, D. 1608, 1631, 1921, 1924 Barker, AM...2001, 2881, 2885 Barkmann, R...2255 Barnabe, C...2912 Barnabe, C.1387, 2015, 2023, 2115, 2136, 2146, 2410 Barnea, E...................607 Barnes, K...830 Barnetche, T. 393, 466, 1490, 1736, 2483 Barnett, K...259, 262, 288, 1104 Baron, M...720, 723, 745, 1089, 2707, 2999, 3000 Barone, F... 531, 1045 Barone, P...2281 Barr, S...2884 Barra, L...804 Barre, E... 132, 2485 Barreira, JC. 887, 2040, 2441, 2706 Barrera-Vargas, A.1658, 1664, 2676, 2724, 2990 Barrett, J...775 Barrett, JH...880 Barron, K.. 816, 1231, 2279, 2280, 2282 Barron, N...710 Barros, DL...1298 Barros Kahwage, C...733 Barrowman, N...2288 Barshack, I...647 Barsotti, S... 1256, 2217 Bartels, CM...1163 Barthe, Y...1275 Bartlett, SJ............. 394, 425 Bartok, B... 2339, 2819 Bartolome, N...1290 Bartoloni-Bocci, E... 1256, 2544 Barton, A... 78, 1884, 2392, 2460, 2924 Barton, D...................113 Barton, J.. 698, 1084, 2048, 2049, 2405, 2421 Barut, K... 2301, 2627 Bas, S...2769 Basharat, P...1265 Bashi, T...647 Bashir, M...1208 Baskaya, MC...1105 Bass, A... 1495, 1500 Bass, AR...1989 Bassani-Sternberg, M...607 Bassett, S...2052 Basu, N...1382, 1760, 2811 Bateman, B...1073 Bathon, J... 1363, 2972 Bathon, JM...1797 Batley, M...2404 Batman, B...1574 Battafarano, D...103, 1066, 1133, 2026, 2374, 2883 Battagliotti, C...2040 Battellino, M...2976 Batterman, A...3016 Batteux, F...1718 Batticciotto, A...142, 908, 2976 Battistone, M...1996 Battistone, MJ.. 2001, 2881, 2885 Batur, HZ...2548 Baum, R... 1794, 1813 Baumgarten, M...1288 Baumgartner, R...1528 Baumüller, S...2998 Bautista - Molano, W...557 Bautista-Caro, MB...605 Bautista-Molano, W...2608 Bava, C...278 Bay Laurberg, T...2030 Bayındır,...2523 Bay-jensen, AC. 222, 368, 541, 629, 1019, 1293, 2209, 2230 Bayan, N...386 Bayard, M...2307 Bayat, N...912, 1316, 2211, 2222 Bayer, M...2229 Baz, S...1993 Bazan Bardales, MC...425 Bazelier, M...578 Bazzichi, L...527, 2399, 2499 Beal, J...2489 Beall, D...2253 Beamer, M...1031 Bean, KM...1604 Bearden, A...1684 Beasley, M...71, 975, 1880, 2071 Beaton, D...1932 Beattie, K... 1172, 1424 Beattie, KA...217 Beattie, SD... 488, 2822 Beatty, M...2014 Beaudart, C...225 Beaulieu, A... 1557, 2493 Beaumont, J...2621 Bebris, L...529 Becciolini, A...2383 Beck, JP...2001 Beck, P... 2881, 2885 Becker, JCP...1502 Becker, L...2996 abstract author Index Becker, ML...1321 Becker, M...1928 Becker, MO...773 Bedaiwi, M... 2605, 2607 Bedenbaugh, AV...102 Beermann, H...1447 Behin, A...1262 Behrens, EM.279, 1899, 2168, 2876 Behrens, F... 1560, 2915 Behrens, TW...2955 Beiderwellen, K...1189 Beijer-Liefers, S...2934 Bejerano, C...2602 Bekker, P...1863 Belasco, J...631 Belchis, D...2538 Beldi, MC...2809 Belenguer, R... 2063, 2064 Belisle, L... 211, 214, 215 Belisle, P... 1771, 2015 Bell, E...2115 Bell, G...1530 Bell, M...1933 Bellance, R...1269 Bellini, B...2660 Bellis, E...908 Bello, JM...2608 Belmont, HM...1635 Beltrán, E. 1252, 1928, 2586, 2853 Beltrán-Catalán, E...1249 Ben-Ami Shor, D...647 Benaglio, F... 988, 2403 Benarous, L... 1759, 1763 Benavent, E...1657 2014 Program Book 291
abstract author Index 292 Bendele, A...1484 Bendele, P.................1484 Bendlin, KA...167 Benedek, G...1751 Benedetti, MG...3018 Bengtsson, AA...2091 Bengtsson, C...358, 2016, 2018, 2887, 2888 Benham, H...281 Benham, H... 618, 632 Benhamou, C...1795 Benissan-Messan, D...1470 Benjamin, K...683 Bennell, K... 1280, 2241 Bennet, B...649 Bennett, M.1294, 1303, 1304, 1826 Bennink, M...1004, 1036, 2793 Benoit, S... 1614, 1616 Benseler, S...61, 315, 2275, 2280, 2903 Benseler, SM...1310 Bensen, R... 369, 2257 Bensen, W...461 Bensen, W...421, 426, 943, 2491, 2492 Bensen, W...248, 383, 583, 956, 1507, 1550, 1566, 1601, 2411, 2424, 2496 Bensen, WG...369 Bensen, WG...1172, 1397, 1424, 2257 Bensen, W...369 Benson, J... 1976, 2743 Bentayou, D...291 Bentin, J...1368 Benveniste, O...1037, 1262, 1263, 1270, 1271, 2778, 2953 Benzaquen, N...1438 Bérard, A...1866 Berardi, G...738 Berdan, J... 2881, 2885 Berenbaum, F...581, 1012, 1275, 2028, 2231 Berendsen, A...2102 Beresford, MW... 272, 676 Bereswill, M... 273, 289 Beretta, L. 747, 753, 776, 777, 880, 1203, 1675 Berezne, A. 743, 1326, 1690, 1759, 1769, 2778 Berg, EL...1972, 1975, 2803 Berg, IJ... 2561, 2571 Bergamini, A...1472 Berger, A...913, 941, 1395 Berggren, O...2681 Berglin, E...90 Bergman, G...2938 Bergman, MJ. 375, 417, 896, 1106 Bergström, M...2435 Bergström, U... 436, 1477 Berke, Z...180 2014 Program Book Berks, M... 737, 2147 Berktold, J...2010 Berkun, Y...2899 Berland, Y...1611 Berman, A...952 Berman, A. 1388, 1438, 2077, 2381 Berman, H. 1388, 1438, 2077, 2381 Berman, J...1989 Berman, N.................2545 Bermas, BL...867 Bermudez, LM... 672, 2269 Bermudez-Santiago, LM...1307 Bernadette, H...3015 Bernal, JA...1240 Bernard, L...219 Bernard-Brunel, M...291 Bernard-Medina, A...1984 Bernardi, L...2408 Bernatsky, S...1771, 1833, 1866, 1998, 2015, 2023, 2289, 2309, 2619, 2664, 2665, 2666, 2791 Berner, R...930 Berner Hammer, H...132 Bernero, E...1697 Bernhard, J...2565 Bernstein, EJ... 1691, 1797 Berrocal, V... 2717, 2999 Bert, J...268 Berthelot, JM... 1385, 2536 Berthier, S...811 Berti, A...2202 Bertiller, E...1438 Bertiller, E... 2402, 2987 Bertolaccini, ML...1627 Bertoldi, I...184 Bertoli, AM... 141, 681, 716 Bertrand, A...1736 Bertrand, J...2951 Bertschinger, J... 1491, 1511 Bertsias, G... 1401, 2645 Berzi, A...397 Berzin, E...439 Besancenot, JF...2849 Bessette, L...118, 396, 502, 567, 1535, 1536, 2125, 2569, 2884 Bessis, N...335 Besson, C...2163 Betelli, M...2768 Bethel, M... 2105, 2106 Bethge, J...485 Bethunaickan, R...2869 Bettano, K...649 Bettendorf, B...1625 Bettio, S...671 Betts, K... 1147, 1555 Beukelman, T...302, 1297, 2293, 2294 Beumer, W...2979 Beussink-Nelson, L... 725, 1929 Bevers, K...204 Beyer, C... 967, 1322 Beyer, MK... 1169, 2652 Bhadra Brown, P... 1094, 1108 Bhalla, S... 1934, 1935 Bhalla, V...2205 Bhamra, K...1446 Bharat, A...498, 1422, 2367 Bharucha, KN...276 Bhatia, G...949 Bhatia, J...2246 Bhattacharyya, I...936 Bhattacharyya, S.. 750, 965, 3005 Bhavsar, SV...801 Bhuyan, Z...632 Biale, L....................2132 Bianchi, G...2399 Bianchini, E...2217 Bianchino, L...2399 Biancotto, A...315 Biard, L...1245 Biavasco, R...2202 Bica, B...2281 Bichile, T... 1265, 1665 Bielecki, M...1715 Bielfeld, P...2757 Bienkowska, J...1920 Bienvenu, B.....8, 255, 256, 1782, 1792, 2193 Biggioggero, M...2383 Biggs, C...1226 Bihlet, A... 222, 2230 Bijkerk, C...2138 Bijlsma, JWJ...204 Bijlsma, JWJ. 500, 1180, 1843, 2249 Bijlsma, JW...1871 Bijzet, J... 1205, 1626 Bilezikian, J...1795 Bilgin, E...2750 Bili, A...913, 1394, 1395, 1830 Billard, MJ... 1961, 2878 Billig, E...1391 Binda, E... 988, 2403 Bingham, CA...2318 Bingham, CO III...479, 608, 1537 Biniecka, M...1195 Binkley, N...920 Binstadt, BA...2905 BIOBADASER 2.0 study group, OBO. 2511 Biologics for Children with Rheumatic Diseases (BCRD) study, T...272 Biomdo, I...1396 Birbara, CA...548, 1561, 1579 Bird, P...461, 1178, 1183 Bird, P.602, 1543, 1565, 1572, 2419 Birkett, R...344, 2167, 2908 Birlik, M.. 1230, 1584, 2595, 2611 Birmingham, J..............2365 Birnbaum, J...2538 Birring, S...727 Bisagni, A...882 Biscetti, F...1971 Bischoff, S...1154 Bishwal, S...1830 Biswas, P...1032 Bitik, B... 2548, 2761 Bitman, B...1853 Biton, J...335 Bitterman, H...1547 Bitto, A...744 Bitton, A...1809 Björk, M...2435 Björnsson, J...787 Bjørneboe, O...2035 Blaauw, M...574 Black, RJ...2033 Blackman, B...439 Blackstone, E...2786 Blagojevic-Bucknall, M...831 Blair, C...836 Blaison, G...2757 Blakley, M... 1322, 1323 Blanchais, A...2324 Blanchard, F...1042 Blanchard-Delaunay, C. 1776, 1778 Blanco, A.. 1249, 1251, 1252, 2853 Blanco, F...59, 1129, 2097 Blanco, FJ...1290 Blanco, FJ... 1008, 2231 Blanco, FJ... 1003, 1034 Blanco, I...2649 Blanco, LP...872 Blanco, P...1609 Blanco, R.776, 777, 814, 880, 1240, 1249, 1250, 1251, 1252, 1787, 1788, 1791, 1845, 2203, 2452, 2459, 2461, 2775, 2776, 2853 Blanco Alonso, R...2622 Blanco Garcia, FJ...93, 982, 1121, 1122, 1125, 1126, 1127, 2602 Blanco-Favela, F...1947 Blaney Davidson, E...1004, 1017, 2793 Blangero, J...1133 Blank, M...647 Blauer-Peterson, C...1882 Blazer, A...1635 Blazevic, I... 681, 716 Bleck, E...357 Bledsoe, C...2386 Bleil, J...616 Blevins, D...1987 Bliddal, H... 1180, 2439 Bligh, M...797 Blijdorp, IC... 850, 1973 Blinn, J...322
Blits, M...2093 Blizzard, L... 205, 208, 209 Bloch, M...159 Block, J...353 Block, JA... 717, 1990 Block, JA.213, 713, 716, 2111, 2207, 2245, 2310, 2315, 2989 Blockmans, D...958 Bloem, JL... 1174, 2984 Blokland, SLM...2725 Blom, A...1004, 2348, 2793 Blom, AB...76, 1199, 2948, 2952 Blueml, S...2907 Bluett, J... 78, 2032 Blumen, H...401 Blüml, S... 27, 650, 2358 Boackle, SA...2185 Boas, R...156 Bobba, R... 1172, 1424 Bobba, S...2570 Boccassini, L...2550 Bockenstedt, PL...2867 Bodaghi, B...2757 Bodemer, C...1326 Boedigheimer, M...1646 Boehm, M...1812 Boekhorst, J...1816 Boellaard, R...354 Boeltz, S...869 Boers, M...132 Boers, M. 240, 260, 261, 361, 362, 2767, 3018 Boettner, F...1043 Boffa, JJ...1864 Bogaard, J...3018 Bogatkevich, G...3002 Bogatkevich, GS...762 Bohdanowicz, M...1587 Bohgaki, T. 2, 5, 1179, 1628, 2638, 2677, 2864 Bohnsack, J...273 Bohnsack, JF...1900 Bohórquez Heras, C...1683 Boiardi, L. 777, 785, 790, 791, 798, 882 Boice, J...2938 Boice, J...1495, 1500, 1528 Boin, F...964 Boire, G...2912 Boire, G.. 360, 361, 371, 394, 442, 1387, 2410 Boissier, MC. 335, 938, 1196, 2357 Boivin, JF...2791 Bojanowski, CM...1678 Bojinca, M. 823, 1525, 1526, 1538, 2497 Bojinca, V...1539 Bokarewa, M...435, 1748, 2515, 2847 Bolce, RJ... 364, 367 Bolce, RJ...376 Bolge, SC...1832 Bolkier, Y...2899 Bolland, M...21 Bolognese, M...916, 2254, 2255 Bolster, M...1349 Bolster, MB...1402, 2002, 2886 Bolt, I...2281 Bombardier, C...1065, 1833, 2309, 2380, 2424, 2426, 2814 Bombardieri, M...904 Bombardieri, S... 147, 527, 1772, 2201, 2217, 2432, 2499, 2544, 2656, 2708, 2755, 2855, 2931, 2981 Bond, G...683 Bond, H...1096, 2055, 2073 Bone, HG...2268 Bone, H... 916, 2254 Bonegio, R...662 Bonel, H...1193 Boneparth, A... 2271, 2869 Bonfa, AC...235 Bonfa, AC...238 Bonfa, E...235, 238, 863, 957, 1298, 1300, 1301, 1824, 2151, 2221, 2809, 2933 Bongardt, S... 1945, 2834 Bongartz, T...258, 390, 428, 2957 Bongiorni, D...891 Bonilla, E...2010 Bonilla, G... 1603, 2622 Bonilla, MG...2400, 2513, 2522 Bonilla, N...1137 Bonini, C...1745 Bonner, M...763 Bonnotte, B.......... 1778, 2849 Bonomi, F...2768 Bony, C...1726 Book, C...436 Boom, V...284 Boonacker, C...1317 Boonen, A...70, 101, 557, 578, 579, 586, 1058, 1059, 1164, 1373, 2113, 2573, 2828 Boot, C...2104 Booton, R...1286 Boots, AMH... 1205, 1956 Bootsma, H.2547, 2551, 2831, 2934 Borah, A...895 Borangiu, A...1539 Borba, EF...1298 Borba, EF...863 Borderie, D...1687 Borekci, S...2043 Borges, C...2702 Borghi, MO...1708 Borgia, RE... 1310, 1312 Borie, D...505 Borjas García, JA...1649 Borman, P... 246, 1110 Born, T...1503 Borofsky, MA...2469 Boros, C...1325 Borrego, ME...2232 Borrell, H.. 695, 1381, 1655, 1657, 1659, 2194, 2620, 2780 Bortoluzzi, A...908 Borzutzky, A...306 Bos, R...2831 Bosello, SL...738 Boshuizen, HC... 2053, 2054 Bossini-Castillo, L... 753, 880 Bosworth, HB... 891, 977 Botsios, C... 1160, 2408 Bottaro, A... 325, 934 Bottini, N... 2818, 2871 Botto, M...938 Boudaoud, S...2163 Bouée, S...165 Bouhana, K...2965 Boulenger, J...1411 Boulman, N...2150 Bouman, C...500 Boumier, P...2324 Boumpas, D...2645 Bourgeois, P...2132 Bourhis, F... 96, 1060 Bourji, KI...1707 Bourke, L... 655, 2863 Bournia, VK... 478, 2709 Bourré-Tessier, J...681, 716, 2210 Bourret, J... 1145, 2406 Bourrienne, MC...12 Bouta, EM...325, 934, 2353 Boutet, MA...1042 Boutin, D...1925 Boutros, P...2787 Boutroy, S...2136 Boveda, MD...455 Bovis, F...277, 282, 2281 Bowcock, AM...625 Bowes, MA...1178 Bowman, J...632 Bowman, S... 522, 2982 Boyapati, A...2795 Boyce, B...25, 37 Boyd, SK...2146 Boyer, O...1471 Boyesen, P...1822 Boyle, B...2272 Boyle, DL...1027, 2816, 2818 Bozcan, S...2754 Bozsaki, G...2284 Brabosa, R...1636 Bracaglia, C. 311, 321, 1225, 1228, 1901, 2901 Bracciolini, G................299 Bradburn, M...796 Bradbury, L... 778, 2962 Braddock, M...180 Bradley, JD...1181 Bradley, JE...2872 Bradley, LA...2783 Brady, B... 1149, 1832 Brady, TJ... 2010, 2011 Braesch, C...773 Brambilla, A...2901 Bramwit, M...1686 Branco, JC...2428 Brand, A...2015 Brandl*, C...1943 Brasier, A...6 Bratus, A...2785 Braun, J...557, 819, 2560, 2573 Braun, J...579 Braun, J... 58, 463, 536, 538, 565, 566, 852, 1189, 2563, 2566, 2567, 2593, 2601, 2612, 2940 Braun, N... 776, 777 Braun, T...2779 Bravi, E...1256 Bravo, B...1249 Bravo, M... 2072, 2987 Bray, S...916 Breban, M... 622, 1137 Breban, MA...2554 Breda, L... 299, 2281 Breda, S...2609 Bremander, A...106 Bremander, ABI...2329 Brennan, C...2764 Brennan, D...1591 Brennan, GP...889 Brenner, D...750 Brenner, M...2455 Brenner, MB...1744 Brensinger, C...1839 Brenton-Rule, A...2052 Brescia, AC...2278 Bretton, E...1487 Breuillard, P...2324 Brezin, A...783 Brick, M... 2010, 2011 Bridges, SL Jr..363, 451, 1132, 1474, 2051, 2453, 2454, 2927 Brik, R...2899 Brik Simon, D...2899 Brink, M...447 Brinkman, WB...2317 Brinkmann, GH... 1383, 2035 Brinks, DR...1177 Brinks, R...357, 701, 1057, 1078 Brion, R...1042 Briot, K...234, 257, 1769 Brisse, E...316 Brisslert, M...2847 abstract author Index 2014 Program Book 293
abstract author Index Brithmer, L...2024 Brito, A...951 Brito, M...2482 Brizzolara, R... 1713, 1966 Brkic, Z... 1799, 2979 Brock, M...967 Brocq, O...1385 Broder, MS...803 Brodmerkel, C...2092 Brodsky, J...2004 Broen, J...757 Broeren, MGA...1049 Brogan, P. 1231, 2279, 2280, 2282 Brohawn, P...719 Bromley, L...2738 Brooks, E...1826 Brooks, EB...1303 Brooks, L...772 Brooks, S... 315, 1898 Brooks, S...615, 1812, 1896 Brooks, S...1932 Brophy, M.. 462, 2139, 2373, 2781 Broussard, C...783 Brouwer, E...2767 Brouwer, E...1379 Brouwer, E. 441, 1205, 1956, 2831 Brouwer, J...1439 Brouwers-Haspels, I...340 Brown, B...2033 Brown, EE... 2089, 2454 Brown, E...1809 Brown, JP... 174, 175 Brown, JP...2267 Brown, J...1830 Brown, J... 916, 1795 Brown, J...1761 Brown, L...1345 Brown, LA...113 Brown, M... 632, 2962 Brown, MA...569, 617, 778, 1886, 2918 Brown, M... 2535, 2930 Brown, P...2460 Brown, RD Jr....2766 Brown, R...1503 Brown, T... 1346, 1347 Browne, L...2246 Broyde, A...971 Brubaker, J...2354 Bruce, I...686, 711, 961, 2646 Bruce, IN... 676, 712, 1182, 1464, 1923, 2636 Bruchfeld, A...1863 Bruet, A...1782 Bruijnen, STG...580 Brummett, C...266 Brummett, CM...252 Brun, JG...149 Brundidge, AD...283 Brundige, A...895 Bruni, C...1703 Brunier, L............ 2024, 2155 Brunier-Agot, L... 1269, 2532 Brunner, HI...2297 Brunner, HI...2291 Brunner, HI... 931, 2298 Brunner, H...273, 1294, 1825 Brunner, HH...2295 Brunner, HI...83, 276, 930, 933, 1302, 1303, 1304, 1826, 1988, 2211, 2222, 2320 Bruss, M...911, 1204, 2687 Bruyere, O...225 Bryan, R........ 1013, 1206, 2949 Brys, R...1494 Brzosko, M... 1598, 1715 BSPAR Etanercept Cohort Study, OBOT... 271, 272 BSRBR Control Centre Consortium, 467, 1909 Bucala, R...1861 Buchbender, DC. 1173, 1177, 1189 Buchbinder, R...582 Buchdaul, AL...2779 Buckeridge, D...1771 Buckinx, F...225 Buckley, C.. 389, 1045, 2183, 2463 Buckley, LM...10 Buckner, JH. 446, 453, 1904, 2891, 2921 Buckner, TR...16 Budde, P...1730 Budinger, GS... 969, 3005 Budoff, M...373 Bueno, C...2933 Bugatti, S... 988, 2403 Bugbee, W...2919 Buitelaar, H...3018 Bukhari, M.224, 227, 230, 231, 240 Bukowski, J...855, 1893, 2577 Bukowski, J...459 Bukowski, J...2503 Bulbin, D...1340 Bundy, N...1983 Buoncompagni, A...299 Burbridge, C...1094 Burd, C...2687 Burghardt, AJ... 1176, 2136 Burgos-Vargas, R...2477 Burgos-Vargas, R... 269, 557, 928 Burke, B............... 44, 1872 Burket, JC... 187, 2970 Burkhardt, H... 1560, 2915 Burkly, L... 651, 1920 Burmester, G...29, 339, 357, 378, 493, 497, 735, 773, 1485, 1486, 1515, 1518, 1521, 1845, 2468, 2485, 2486, 2491, 2492, 2530, 2552, 2693, 2821, 2837 Burnell, J...711 Burns, S... 2105, 2106 Burr, DB...1794 Burrell, S...797 Burrill, R...2699 Burska, A...137, 1020, 1740 Burtey, S...1611 Burtner, P...2332 Busch, M...2466 Busch, VJJF...2249 Busfield, S...1467 Bush, H...2227 Bushmakin, AG...2487 Busman, E...2707 Bussey, M...1343 Bussey, MR...1244, 1327, 1377 Busso, N...1197 Bussone, G...1326 Bustabad, S...992 Bustabad-Reyes, S...2276 Bustos Rivera Bahena, C...1426 butbul Aviel, Y...2899 Butera, P...2240 Butt, D... 1833, 2309 Butter, C...945 Butterwick, M...1395 Buttgereit, F. 29, 1006, 1482, 1518 Buttner, P...1156 Button, P...519 Buxbaum, J...1021 Buyon, JP...534, 672, 684, 871, 961, 1207, 1328, 1605, 1608, 1631, 1635, 1829, 1924, 2646 Buysman, E... 117, 1155 Byford, A...649 Bykerk, VP...187, 350, 361, 371, 394, 464, 1387, 1515, 1521, 2369, 2370, 2410, 2468, 2485, 2486, 3016 Byram, K...843 Byrjalsen, I...222, 368, 2230 Byrne, R...1022 Büsch, K...589 Bytautas, J...2437 Bzarova, T...2296 Bäcklund, J...1735 Bäuml, M...1974 Börsbo, B...2435 Bøyesen, P...1183 C Caamano, J...1045 Cabacangun, R...2789 Cabane, J..................1774 Cabral, AR...11, 1654, 2867 Cabral, DA... 276, 2903 Cabral, F...1273 Cabrera, J...1888 Cabrera, S... 469, 2478 Cabrera-Villalba, S. 134, 445, 2508, 2926 Cacoub, P. 8, 809, 811, 1245, 1792, 1925, 2163, 2731, 2757 Cadelis, G...1269 Cadet, C...1275 Cadet, M...2307 Cadzow, M... 21, 168, 2961 Caeiro, F.. 959, 1388, 1438, 2040, 2381 Cagatay, Y...2523, 2750, 2769 Caglar, E...2752 Cagnoni, M...2708 Cagnotto, G...908 Cai, A...2743 Cai, CH....................1501 Cai, L...2795 Cai, Y...644 Cai, Z...1483 Caiaffa-Filho, HH...2809 Caiello, I...311, 1228, 1901 Caini, S...2432 Cakir, N... 2523, 2719 Cakmak, A...1115 Calabrese, LH...837, 2764, 2765, 2856 Calabro, S. 1562, 1563, 1569, 1851 Calamia, K...2854 Calamia, V... 93, 982, 1127 Calandra, S...278 Calcagni, M...967 Calderillo, ML...2533 Caldwell, T...1009 Calero, I...74 Calero Munoz, S...372 Calise, SJ...936 Callaghan, MJ...1284 Callahan, LF.978, 1088, 2046, 2051, 2941 Callejas, JL...747 Callhoff, J..................2618 Callon, KE...1215 Calvet, J...1670 Calvo, I...1249 Calvo, K...816 Calvo-Alen, J.668, 814, 1415, 1670, 2622 calvo-gutierrez, J...1978 Calvo-Penedes, MI...2276 Calvo-Río, V.814, 1249, 1250, 1251, 1252, 1787, 1788, 1791, 2775, 2776, 2853 Cam, O...1230 Camacho, C...437 Camacho, M...2276 Cambon-Thomsen, A...1140 Cambridge, G. 452, 989, 995, 1955, 2696 294 2014 Program Book
Camellino, D...2771 Cameron, V...2377 Caminal-Montero, L...777 Caminis, J...916 Camp, H...1499 Campanilho-Marques, R.1314, 2900 Campbel, M...1020 Campbell, D...2534 Campbell, G...2255 Campbell, P...3006 Campbell, PL...444, 937, 1962 Campbell, S...1339 Campbell, TM...1007 Campochiaro, C... 1242, 2202 Campos, J...1045 Campos, LMA... 1298, 1300 Can, G...603 Can, G...1725 Can, M... 2157, 2769 Cañal Villanueva, J... 1250, 1252 Canavan, M...2181 Candido, WM...2809 Cañellas, J...568 Canestrari, G...738 Canestri, S...403, 999, 1639 Cañete, JD...58, 59, 134, 445, 469, 947, 992, 1129, 1739, 1969, 1973, 2097, 2478, 2508, 2926 Canhao, H. 504, 1524, 1837, 1838, 2428, 2524 Canioni, D...2163 Canizares, M...2942 Canna, S...315 Cannavale, T...1700 Cannella, A...1953 Cannon, GW..348, 494, 840, 1372, 1391, 1392, 1540, 1993, 1996, 2001, 2494, 2881, 2885 Cano, C...1519, 1531, 2423 Cantagrel, AG...466, 1140, 2028, 2483 Cantarini, L.1231, 2279, 2280, 2282 Canzoni, M...908 Cao, J...1202 Cao, X...1949 Cao, Y...1204 Cao, ZM...1087 Cao, Z...66, 1803, 2050 Caorsi, R...305 Caparbo, V.50, 51, 52, 73, 235, 238, 1301 Capdevila, O.695, 1655, 1659, 2620 Capeau, J..................1012 Capelozzi, VL...2702 Caplan, L.. 840, 1372, 1391, 1392, 2386, 2570 Caporali, R...483, 519, 988, 1256, 2403, 2512, 2514, 2609 Cappelleri, J...2395 Cappelleri, JC...1882 Capri, J...91 Caprioli, M...908 Capuccio, A...2040 Caputo, R...2901 Caracuel-Ruiz, MA...2853 Caramaschi, P... 1130, 2711 Carames, B...1008 Carandang, K...2325 Carbillon, L...12 Carbone, L... 2105, 2106 Carbonella, A...403 Cardenas-de La Garza, A...2644 Cardiel, M...959 Cardiel, MH...2826 Cardoso, A...122 Carette, S. 801, 804, 808, 880, 883, 1861, 2851 Carey, H...1888 Carey, J...2861 Carey, JJ...477 Carey, V...1754 Caricchio, R...658 Cariou, A...743 Carita, P...1522 Carle, A... 259, 262, 288 Carlesso, L...2437 Carletto, A...2399 Carli, L...147, 2432, 2656 Carlsen, AL...761 Carlsson Almlöf, J...2980 Carmona, FD...880 Carmona, L...99, 723, 731, 2710 Carmona-Fernandes, D...1629 Carmona-Rivera, C...1862 Carns, MA... 725, 1929 Caro, X...2061 Carpenter, L...1841, 2135, 2810 Carpenter, S...1813 Carpentier, P... 1690, 1928 Carpintero-Fernández, P...1003, 1034 CARRA Registry Investigators, T... 1076, 2271, 2292 Carranco, T...74 Carrara, G...908 Carrasco, R...274, 295, 303, 2294 Carrasco, S...2304 Carrasco Cubero, C.... 2190, 2853 Carrat, F...1275 Carreira, P...723, 747, 753, 1240, 2097, 2459, 2622 Carreira, PE.. 680, 731, 2710, 2711 Carretero, R...1978 Carrier, N... 360, 442 Carriero, A...2758 Carrillo, I...2706 Carrillo Vazquez, S...1506 Carrillo-Palacios, RA...2644 Carrino, JA...2148 Carro-Esteban, SR...2445 Carroll, K...1625 Carron, P...2134 Carron, PL...1778 Carruthers, E... 384, 416, 915 Carruthers, M...1349, 2804, 2805 Carter, A...2327 Carter, D... 951, 1844 Carter, D...2327 Carter, JD...440 Carter, R...1953 Carter, S...1917 Cartwright, A...433 Carubbi, F...2544 Caruso, A...2417 Carvalho, AF...592 Carvalho, C...2702 Casado, G... 519, 2040 Casali, B....................882 Casals, JL...596 Casanueva, B...1103, 2063, 2064 Casas, I...2622 Casciola Rosen, L...2929 Casciola-Rosen, L... 1265, 2539 Casella, CB...235 Casellas, J...2407 Casey, VA...2943 Caspi, D... 443, 700, 971 Castañeda, S...776, 777, 880, 1240, 1367, 1787, 1788, 2412, 2452, 2459, 3008 Castañeda-Sanz, S. 814, 1256, 2144 Castelino, FV...104, 1151, 1796 Castellani, RJ...2655 Castelli, C...2527 Castellvi, I.. 753, 1670, 1674, 2622 Castellvi Barranco, I...747 Castiblanco, J...84 Castillo, D...1674 Castillo, JR...2231 Castillo, R...1319 Castillo-Gallego, C. 595, 605, 2596 Castonguay, M...797 Castrejón, I...69, 353, 417, 1157, 2111, 2310, 2379, 2568 Castro, MC...2596 Catalán Pellet, A... 406, 1438 Catanoso, MG...798 Catanoso, M... 785, 2417 Catay, E...2402 Catelani, MB...2326 Cathebras, P...2779 Catoggio, C...2672 Catoggio, LJ...1783 Catrina, AI...434, 993, 2797 Catrina, SB...993 Cats, H...76 Cattalini, M...2901 Cauli, A...613 Cavagna, L...1256 Cavalli, G... 1242, 2202 Cavallini, N... 1748, 2847 Cavatorta, F...908 Cavazza, A. 785, 790, 791, 798, 882 Cavazzana, I... 1256, 1532 Cavill, C...546 Cavillion, E...2040 Cawston, H... 96, 1060 Cawston, H...1595 Cayetti, LA... 406, 2575 Cazenave, T...127, 128, 141, 410 Cazzato, M...2499 Ceccarelli, F...908 Ceccato, F...1438 Ceccatto, F...406, 1388, 2381 Cecchetti, S...1418 Cedeno, C...1830 Cedillo, M...2970 Cefle, A... 2157, 2750 Celik, S......................69 Celis, R... 134, 1973 Cella, D... 260, 261 Cellucci, T...1992 Cenac, S... 1246, 2707 Cendes, F...1622, 2659, 2661 Centeville, M...2320 Cerda, O... 1388, 1438 Cerda, OL...2042 Cerf-Payrastre, I...2162 Ceroti, M...2432 Cerqueira, C...2797 Cervera, R... 958, 2868 Cervinski, M...1234 Cesana, L...1708 Cesano, A...1614, 1616, 2873 Cesta, A...2426 Cetica, V...321 Cetin, A...2069 Cetin, P... 601, 1230, 1584, 2562, 2595, 2611, 2616 Cetinkaya, F...2749 Cha, HS.. 60, 182, 587, 598, 1056, 1221, 1241, 2464 Cha, S...2174 Chaabo, K...839 Chacon, R...959 Chadha-Boreham, H...1928 Chae, JJ... 1194, 1817 Chaer, FGG...237 Chafey, P...783 Chaganti, RK...420 Chagnaud, C...140 Chaichian, Y...432 Chaitow, J...1325 Chakravarthy, K...328, 997, 2354 Chakravarti, R... 88, 987 Chakravarty, E...1359 abstract author Index 2014 Program Book 295
abstract author Index 296 Chalan, P...1205 Chales, G... 163, 1368 Chales, GH...165 Challacombe, S...525 Challener, GJ...442 Chalmers, S...2180 Chalmeta, I...2119 Chalom, E...273 Chambers, CD...821 Chambers, R...2865 Chambers, R...759 Chamizo Carmona, E... 597, 2190 Chan, B...57, 1546, 1589, 1849 Chan, E...936 Chan, EKL...1644 Chan, KL...854 Chance, K...1505 Chandra, D...2390 Chandran, AK...419, 838, 1366 Chandran, V...542, 623, 624, 625, 626, 627, 628, 630, 1568, 1575, 1576, 1586, 1587, 1592, 1593, 1850, 2099, 2935 Chandy, KG...2738 Chang, AH... 211, 214, 215 Chang, BH...462 Chang, CCH...1452 Chang, DM...2361 Chang, EJ...614 Chang, E...803 Chang, H...772 Chang, HH...2917 Chang, JT...751 Chang, L...719 Chang, NH... 656, 2742 Chang, RW...68, 729, 750, 1800, 2698, 2944, 2946 Chang, S... 263, 1336 Chang, SC...818, 1876, 2017 Chang, SH...2690 Chang, SK...2455 Chang, S... 1527, 2501 Chang, WI...571 Chang, Y...342 Chanroux, L...2407 Chaparro, M...3008 Chaparro, R...406 Chaparro del Moral, R. 1388, 1438, 2381 Chapelle, DC...315, 1896, 1898 Chapelle Neal, DC...2285 Chapelon, C...1245 Chaplais, E...1137 Chapman, A...1869 Chapman, PT...173, 1214, 1757, 1758 Chapman, V...2965 Chapnick, J...105 Chappell, C...1946 Chapple, C... 2897, 3017 2014 Program Book Chapple, I...2183 Chapurlat, R... 62, 63, 920 Charby, G...2204 Charles, JF... 28, 2796 Charles, J...745 Charles, P...1767 Charles-Schoeman, C.334, 487, 493 Charlier, E... 1018, 1025 Charlton, J...2188 Charpentier, J...743 Chartier, M... 2491, 2492 Chartier, S...2210 Chartrand, S...1419 Charuel, JL...1634 Charuvanij, S...2903 Chary-Valckenaere, I...1368 Chary-Valkenaere, I...219 Chase, M...2211 Chasnyk, V...933 Chastek, BJ...1158 Chatelais, M...1042 Chatelus, E... 1681, 1707 Chatfield, S...1467 Chatham, WW...706, 1668, 1672, 1924, 1953, 2200 Chatterjee, S... 1261, 1927 Chatzidionysiou, K... 1524, 2524 Chaudhari, A...2364 Chaudhry, A...1760 Chaudhry, N...1118 Chaudhry, RN...2831 Chauhan, AK... 2224, 2730 Chaussabel, D...1611 Chauvin, N...1895 Chavda, R...1244 Chavez, H...2928 Chavez-Rueda, K...1947 Chávez-Sánchez, L...1947 Ché, H... 257, 2324 Cheah, P...152 Chebane, L...845 Checchi Gibilaro, J...2000 Checchio, T...458 Cheeseman, C...............830 Cheetham, TC... 841, 898 Chehab, G...701 Chen, A...1870 Chen, C...2730 Chen, CI...1522 Chen, CH...323 Chen, D...1529 Chen, H...1495 Chen, H...1949 Chen, JS...1280 Chen, J....................2678 Chen, L.. 57, 498, 820, 842, 1148, 1422, 1546, 1589, 1839, 1849, 1910, 2367, 2375, 2388 Chen, M...1465 Chen, N...552 Chen, P... 955, 1968 Chen, SY... 324, 2344 Chen, SY... 1857, 2621 Chen, S... 558, 2581 Chen, V...2065 Chen, WV...745 Chen, WM...2956 Chen, WH...259 Chen, W... 116, 2118 Chen, X...1459 Chen, Y...460, 465, 1908 Chen, YW...1211 Chen, YH...2344 Chen, YS...1005 Chen, YF...1503 Chen, Y Jr....2747 Chen, Y...1467 Chen, Z... 1510, 2799 Cheng, D...815 Cheng, LI...1158 Cheng, Q...1954 Cheng, S...874 CHENG, Y Jr....2747 Cheon, YH...220, 2262, 2356 Cherkas, Y... 2092, 2096 Chernitskiy, V... 420, 1353 Chernoff, D... 364, 367 Chervinsky, L...138 Cheung, A...2553 Cheung, P... 1368, 2975 Cheungpasitporn, W...726, 799, 2531 Chevalier, P...1165 Chevalier, X...2234 Chevallard, M...2976 Chevli, P...1810 Chevreau, M...1428 Chew, DW...1410 Chhana, A...1215 Chiba, A... 1746, 2728 Chiba, N...87 Chiche, JD...743 Chiche, L.. 809, 1611, 2536, 2549, 2731 Chicoine, A...1744 Chieng, A... 274, 295, 303 ChiesaFuxench, Z...1839 Chighizola, CB...1708 Childhood Arthritis Prospective Study (CA), OBO...274 Childs, J...889 Chimenti, MS...1472 Chinchilla, SP...177 Chines, A...916 Chino, K...1497 Chinoy, H...912, 2924, 2953 Chioccha, G...991 Chiocchia, G...622, 1137, 2928 Chiowchanwisawakit, P.2613, 2986 Chiowchanwisawakit, P.. 557, 591 Chistyakova, E..............2296 Chitkara, P...1924 Chitu, V...2180 Chiu, CS...2354 Chiu, YG... 25, 37, 2794 Chiu, Y...2229 Chiuzzi, E...1093 Chmiel, JS... 211, 214, 215 Cho, CS... 693, 1364 Cho, ML... 326, 1048 Cho, SK...1056, 1805, 2025, 2158 Cho, YN...2679 Chodick, G...2067 Chodosh, J...2543 Choe, HR...571 Choe, JY. 1056, 1508, 2025, 2078, 2825 Choi, B...1694 Choi, CB...946, 1056, 1857, 2025 Choi, D... 1236, 1756 Choi, H.. 171, 172, 822, 827, 901, 923, 1874, 1875, 2958, 2961, 2969 Choi, HK... 117, 974, 1136, 1155, 1219, 1400, 2114, 2932, 2960 Choi, IYK... 450, 2463 Choi, J...946 Choi, S...1400 Choi, ST...1216, 1217, 1241 Choi, SC...645 Choi, YI...2347 Choi, YJ...2262 Choi, YH...386 chollet Martin, S...12 Chong, C...2247 Chopra, R... 955, 2689 Choquette, D...365, 379, 382, 383, 396, 426, 499, 502, 567, 943, 956, 1535, 1536, 1550, 1551, 1601, 2569 Chorus, AM... 70, 2113 Chou, YK...1009, 1751, 1752 Choudat, D...1759 Chow, A.379, 421, 583, 1550, 1551, 1601, 2411 Chow, V...1504 Chowalloor, P...152 Chowdhary, H...3014 Chowdhary, V...1617, 2628, 2642 Choy, EH... 30, 2803 Chrabot, B...2927 Chrétien Raymer, P...2791 Christensen, A...2707 Christensen, AF.349, 541, 629, 1905 Christensen, B...1274 Christensen, R... 2030, 2131 Christiansen, C...222, 368, 2230 Christiansen, S...1783 Christiansen, T...1293
Christianson, TJH...2766 Christmann, R... 2702, 2721 Christodoulou, E...704 Christoffersen, C...1647 Christoph, E...198 Christopher-Stine, L...1265 Christopoulos, PF...1462 Christos, P... 2369, 2370 Chrobak, I...1720 Chrysidis, S...2770 Chu, CQ...1009, 1751, 1752 Chu, D...1567 Chua, RM...1354 Chuang, PC...1005 Chugh, S...1079 Chukkapalli, S...936 Chung, C... 505, 844 Chung, CP. 1117, 1442, 1630, 1902, 1986 Chung, J...1646 Chung, L.721, 734, 878, 2698, 2996 Chung, M... 263, 2065 Chung, SW...1403 Chung, SE...741 Chung, SA...2955 Chung, WT...1056 Churchill, M...1844 Cialic, R...1748 Ciambotti, B...321 Ciani, B...2798 Ciccia, F... 610, 611 Ciceri, F...1745 Cicmil, M...328, 649, 2354 Cicutinni, F... 205, 208, 209 Cicuttini, F...218, 926, 1277, 1278 Cid, MC... 776, 777, 880 Ciechanowski, K...1863 Cieri, N...1745 Cieza, A...2573 Cieza-Borrela, C...74 Cifaldi, L...311 Cigolotti, A...1292 Cillero-Pastor, B...1127 Cimaz, R...931 Cimaz, R... 1316, 2901 Cimino, L... 798, 882 Cimmino, MA...776, 880, 1966 Cimmino, MA... 1700, 2771 Cinar, M...................2750 Cinar, S...1711 Cioffi, E... 147, 2201 Ciofu, C...823 Cipriani, P...768 Cisternas, M... 1092, 2788 Cisternas, MG...98, 888, 963, 980 Citera, G...127, 128, 141, 406, 410, 887, 1285, 1388, 1438, 2040, 2042, 2381, 2402, 2441, 2575, 2706 Ciudad, M...2849 Ciurea, A... 1128, 2565 Ciurea, P.. 1525, 1526, 1538, 2497 Cividino, A. 1172, 1424, 1566, 2884 Civino, A...299 Clabbers, A...951 Clair, A... 1094, 1108, 1879, 2076, 2080 Clair, AG...1882 Clancy, C...2916 Clancy, M...200 Clancy, R...1635 Clancy, RM...387, 534, 871, 1207, 1328, 1605 Clancy, Z...1595 Clapp, C... 330, 333 Clark, E...1946 Clark, EA...1942 Clark, JD... 1614, 1616 Clark, K...653 Clark, KEN...760 Clark, MR...2839 Clarke, A...2619 Clarke, AE...681, 716, 961, 1673, 2015, 2646, 2664, 2665, 2666, 2791 Clarke, CK...2951 Clary, G...783 Claudepierre, P...540, 1186, 1187, 1894 Clausen, BE...340 Clauw, DJ... 254, 924 Clavel, G... 1196, 2357 Clayton, E...2003 Cleary, L...2227 Clegg, D...1570 Clegg, DO...2232 Cleland, LG...2520 Clements, PJ...1338, 2335, 2697, 2995, 2999 Clements-Baker, M...883 Cleophas, M... 1222, 1223 Clerson, P...163, 164, 165, 1690, 2701 Cleveland, R...978, 2051, 2941 Cleveland, RJ... 1088, 2046 Clifford, A... 88, 797, 2786 Clifford*, A...782 Close, D...1485, 1486, 1496, 2821 Clowse, MEB...679, 1359, 1378, 1409, 1599, 2669 Cluzel, P... 809, 2731 Co, C...2211 Co, DO... 2229, 2319 Coates, LC...1577 Cobankara, V...2157, 2523, 2750, 2769 Cobb, I...1997 Cobb, J...2953 Coblyn, JS. 1335, 1369, 1370, 1408, 2122, 2889 Cobraiville, G...1018 Coburn, B...2014 Coburn, BW... 167, 250 Coca, A...2534 Coca, M...2534 Cockell, S... 522, 2982 Codding, C...2826 Codner, D...624 Codreanu, C...1153, 1525, 1526, 1538, 2497 Coelho Horimoto, AM...733 Coenen, MJH...2966 Coeytaux, R.................186 Coffman, C... 891, 977 Coggeshall, M...985 Cohen, AD...1547 Cohen, F...2778 Cohen, H...2252 Cohen, JD...291 Cohen, M...265 Cohen, P.. 811, 1759, 1763, 1767, 1769, 1776, 1778, 1782, 1864 Cohen, S...465 Cohen, SB...1528 Cohen, S...949 Cohen-Aubart, F...1263 Cohen-Bittan, J... 835, 1925 Cohen-Hallaleh, V...883 Cohn, D...2268 Coindreau, J...1558 Coit, P...77 Coit,...881 Coladonato, L...1701 Colaone, F...1609 Colbert, RA...283, 607, 609, 615, 619, 621, 1815, 1919 Cole, M... 524, 2446 Coles, M...1045 Colgan, SP...2740 Colin, E...1749 Colin, L...910 Coll, J...1267 Coll, RC...1044 Collaborative Group, AR...1390 Collaborative Group, CP...1367 Collado, A...1139 Collado, MV... 887, 2441 Collado, S...439 Collantes- Estevez, E...40 Collantes-Estevez, E.. 7, 596, 1978, 2588, 2596 Collier, D...1847, 1853, 2498 Collier, D...1349 Collier, DS... 1402, 2425 Collins, CE...667 Collins, E...1938 Collins, FL...30 Collins, JE.65, 210, 900, 2235, 2859, 2862 Collins, K...1465 Collins, M...490 Collinson, N...803 Colmegna, I...... 425, 1998, 2289 Colombo, C...2550 Colombres, F...1388, 1438, 2381 Colonna, L...2844 Colunga-Pedraza, IJ...2644 Comarmond, C...811 Comarmond, C... 809, 2731 Combe, B. 395, 2477, 2485, 2486, 2493, 2912 Combe, BG...1515, 1521, 2468 Combe, B...121, 393, 581, 590, 1384, 1411, 1490, 2379, 2385, 2397, 2587, 2928 Comte, D...2675 Conaghan, PG... 124, 954, 1007, 1020, 1178, 1181, 1183, 1521, 1891, 2231, 2589 Conde-Jaldón, M... 1787, 1788 Condino-Neto, A...2745 Conigliaro, P...1472 Coniglio, ML...321 Conklin, J.. 1608, 1631, 1921, 1924 Conlon, D...1030 Conn, DL...2051 Connelly, MA... 1630, 1902 Connelly, M...2271 Connolly, K... 2699, 2717 Connolly, M...1044, 1195, 2800 Connolly, SE...1515 Connolly, S...1520 Conrad, K...1730 Conroy, A... 1614, 1616 Cons Molina, F...1508 Consolaro, A... 2297, 2298 Consolaro, A...277, 278, 282, 299, 928, 2281 Consortium, A...2927 Constantin, A...466, 1140, 2028, 2483 Constantin, T...284, 1322, 1323, 1325 Contini, P... 1713, 1966 Contreras-Yañez, I... 411, 1371 Conway, R...477 Cook, J...180 Cook, K...259, 260, 261, 288 Cook, RJ...542, 1576, 1592, 1850 Cooney, M.................1578 Cooper, A...1150 Cooper, C...372 Cooper, H...1333 Cooper, M...389 Cooper, MA...1044 Cooper, P...2183 Cooper, RG... 2218, 2953 Cooper, MD, FRCP, RG...912 Cope, AP...2974 abstract author Index 2014 Program Book 297
abstract author Index 298 Cope, F...1473 Corbí, L...2175 Corciulo, C...2947 Cordel, N...1269 Cordero, M...1252 Cordero-Coma, M...2853 Cordier, JF...2701 Cordingley, L...303, 2031, 2032 Cordtz, R... 377, 848 Coresh, J... 44, 1872 Cormier, C...2559 Cormier, H...2024 Cornec, D...2161, 2536, 2606 Cornish, J...1215 Corominas, H...2372 Corominas, H... 59, 474, 1129 Corona, F...930 Coronell, C...668 Corr, EM...1050 Corr, M...2818 Corr, M...2784 Corrales, A. 228, 2452, 2459, 2461 Correa, MDLA...2042 Correia, C...1377 Correig, X...2097 Corteguera, M...40 Cortelezzi, A...879 Cortes, J...668 Cortés-Pereira, E. 1121, 1122, 1125 Cortis, E...1225 Cosatti, MA...2625 Cosette, P...2923 Cosman, F...2267 Cossette, P...442 Cossio Jimenez, PJ...597 Cossu, M... 1203, 2178 Costa, JA...2428 Costallat, L... 1622, 2663 Costallat, LT...959 Costantino, F...1137 Costanza, D...2239 Coste, J...202 Costedoat-Chalumeau, N.. 8, 835, 1245, 1759, 1925, 2549, 2779 Costello, CE... 983, 984 Costenbader, KH. 55, 818, 867, 903, 1080, 1876, 2017, 2020, 2887 Costi, AC... 1637, 2670 Cote, J...1394, 1395, 1830 Cotrim, AP... 526, 529 Cottreel, E...1928 Couderc, M Sr.... 1413, 1448 Coudert, M...2481 Coughlan, RJ...477 Coulson, E...313 Coupal, L.396, 499, 502, 567, 1535, 1536, 2569 Courties, A... 1012, 1275 Cousin, E...2795 2014 Program Book Couto, S...................2424 Covelli, M...1701 Cowan, P...2010 Cowburn, D.................640 Cox, E...1480 Cox, V...1594 Cozic, C...473 Cozmuta, R...1935 Cozzi, F...1707 Crabol, Y...1777 Crackower, M...1495 Cragg, M... 989, 1955 Craggs, J... 247, 251, 897 Cram, P...54 Crane, C...3017 Craven, A...794 Crawshaw, D...2884 Créange, A...2778 Creese, A...2183 Cremer, I...1263 Crespo, G...1388 Crespo, G...2715 Crespo, ME. 406, 1388, 1438, 2381 Cretu, D...1586 Criado, G... 346, 660, 1739, 1969, 2175, 2735 Criales-Vera, S...2639 Crichlow, G...1512 Crins, M............... 260, 261 Crisan, T... 1222, 1223 Criscione-Schreiber, LG...3, 1983, 2886 Crispin, JC...1033, 2734, 2846 Cristanacce, P...1182 Criswell, LA...520, 524, 525, 2446, 2466, 2841, 2929, 2955 Crittenden, D...176 Crittenden, DB... 156, 1224 Crittenden, D...918 Crittenden, S...313 Croca, S...2637 Croci, S...882 Crofford, LJ... 1117, 2227 Croft, P... 2336, 2898 Croitoru, S...2150 Croker, B...645 Cron, RQ... 1297, 2281 Cronin, ME...1625 Cronstein, BN...19, 22, 23, 24, 33, 34, 36, 156, 187, 1729, 2355, 2792, 2947 Cross, M... 208, 209 Crow, C...1332 Crow, MK. 872, 1047, 1607, 2087, 2090 Crowe, S...648 Crowley, JT...984 Crowson, CS...258, 304, 390, 419, 428, 800, 838, 914, 1052, 1055, 1366, 1405, 1852, 2116, 2213, 2628, 2642 Cruickshank, S... 364, 367 Crump, G..................1355 Cruz, G...2466 Cruz, J...2853 Cruz Lagunas, A...1716 Cruz-Domínguez, P...710 Cryer, B... 243, 249 Cseh, A...2284 CSRG, CSRG................3000 Csuka, ME...1927 Cuadrado, MJ...7 Cubino, N...74 Cuchacovich, R... 1600, 1643 Cucho-Venegas, JM...1393 Cucnik, S...1789 Cuda, CM... 343, 969 Cudrici, C...639 Cuende Quintana, E...1683 Cuervo, A...134, 445, 469, 2478, 2926 Cuff, C... 951, 1030 Cui, J...1335, 1369, 1370, 1408 Cui, K...1065 Culpo, R...1325 Cumming, J... 2328, 2331 Cummings, S...2267 Cunnane, G... 1624, 2916 Cunningham, CC...1050 Cunningham, J...1358 Cunningham, MA... 637, 1213 Cunningham, N...1302 Cunnington, J...2396 Cuomo, G... 1130, 2711 Cuperus, N... 976, 2860 Cure, S...1595 Curhan, G...171, 1219, 2960 Curran, JE...1133 Curran, M...2092 Curran, V...1933 Curtis, JR... 460, 465 Curtis, JR...49, 57, 114, 169, 378, 468, 498, 515, 820, 842, 919, 1148, 1387, 1422, 1474, 1546, 1589, 1839, 1844, 1849, 1910, 2367, 2375, 2388 Curtis, S...2938 Curtis, S...1528 Cush, JJ... 114, 1409 Cusi, D...1130 Cuthbertson, D. 801, 804, 808, 880, 1861, 2851 Cutolo, M... 548, 737, 1561, 1565, 1697, 1700, 1713, 1928, 1966, 1991 Cuttica, M...725 Cuttica, R...933 Cuttica, RJ...1316 Cuvelier, C...2988 Cypers, H..................2988 Czerwinski, E...............2267 Czirják, L... 519, 2711 Czirjak, L...2999 Czyz, C... 1236, 1756 D D Elkhalifa, A...1534 d Agostino, MA...132, 1368, 1517, 2589, 2923 D Angelo, S... 560, 2758 D Ario, G...1901 D Artois, J...1479 d Ascanio, A...2217, 2432, 2708, 2755 D Cruz, D...958 D Cruz, DP. 676, 1237, 2188, 2695, 2833 D Lima, D...1885 D Orazio, A... 887, 2441 da Rocha, G...1436 Da Ros, M...321 da Silva, MA...1298 Dadashova, R...2912 Dadhania, D...9 Dadoun, S.. 585, 2527, 2574, 2599 Daele, PLV...1799, 1863, 2979 Dagfinrud, H... 575, 577 Dagfinrud, H... 2561, 2571 Dagna, L... 1242, 2202 Daha, N...2102 Dahlqvist, J...2673 Dai, D...2850 Dai, G...644 Dai, X...644 Daien, C.............. 393, 1490 Daien, CI...395 Daigle, ME...2859 Dailey, D...1117 Dailey, R... 1236, 1756 Daizadeh, NS...2267 Daizadeh, NS...917 Daizadeh, N... 1795, 2254 Dakin, P...2254 Dal Pra, F...406, 1438, 2381 Dalakas, M...2330 Dalal, D...822 Dalbeth, N. 21, 162, 168, 826, 828, 1215, 2052, 2959, 2962, 2964 Dalkilic, E...2157 Dall Ara, F...1642 Dall era, M.3, 667, 963, 1668, 1672, 2788 Dalm, VA... 1799, 2979 Dalprà, S...299 Dalury, D...2862 Daly, RP...683 Daly, RP... 715, 2012 Daly, T...987
Damian, LO...2645 Damm, T...2255 Damman, W...2141 Dampier, C... 259, 262 Dancey, P...2903 Danda, D... 810, 2542 Dandinoglu, T...253 Daniels, T...525 Danielsen, M...2625 Danila, MI.. 451, 1474, 2453, 2454 Dankers, W...1749 Danko, K...910, 912, 2953 Danoff, SK...1265 Danré, A...1385 Dantas, AT...733 Danve, A...547 Daoud, J...1447 Dare, J...273 Darghosian, L...1117 Daridon, C...1944, 1951, 2693 Darne, B...256 Darnige, L...8 Darrah, E...1474 Darrieutort-Laffite, C...1042 Daruwalla, V... 725, 1929 Das, L... 1308, 1309 Dasgupta, B...775, 793, 796, 880, 885, 909, 2493, 2772 DaSilva, CA...2268 Dastmalchi, M... 912, 1211 Datta, P...1114 Datta, S... 891, 977 Datta, SK...2908 Datta Mitra, A... 1602, 1963 Dauchet, L...2700 Daugas, E...1778 Daures, JP... 1411, 2161 Dave, A...1366 Dave, AJ...2122 Davelaar, N... 1738, 1749 Davenport, T...2330 Davi, F...2163 Davì, S...299, 1901, 2281 Davidson, A... 643, 2869 Davidson, J... 274, 295, 303 Davidson, K...1363 Davidson, M...1986 Davidsone, Z...2281 Davies, H...2798 Davies, O. 543, 544, 565, 566, 1553 Davies, R... 271, 272, 274 Davies, S...1437 Davin, S...1919 Davis, A...2437 Davis, HM... 294, 1529 Davis, JM III...258, 390, 428, 1052, 1405 Davis, LA...840, 1372, 2386, 2570 Davis, M...1743, 2628, 2642 Davis, M...2456 Davis, TE...2286 Davis, WE...1465 Davison, MJ...217 Dawood, H...2150 Day, R...2962 Dayanand, S...1680 de Almeida, MA...1133 de Alvarellos, T...141 De Avila, J...2608 De Avila, MD...1649 de Bakker, PIW...1900 de Bakker, PI. 625, 880, 2918, 2954 De Bandt, M... 2024, 2155 De Benedetti, F Sr...276, 299, 311, 321, 1225, 1228, 1901 de Bie, R... 70, 2113 De Bleecker, J...2953 de Boer, B... 1692, 1930 de Bruin, F...2984 De Bruin, ML...578 de Bruin, SE...2141 de Brum-Fernandes, AJ.. 360, 442 De Bruyn, S...1479 De Ceulaer, K...6 De Cunto, C...2281 De Cuyper, D...1409 De Dios, JR...1240 De Fusco, C...321 de Graaf, D...75 De Graaf, K...1901 de Gregório, LH...2267 de Groot, P...2866 de Hair, MJH... 1960, 2463 de Hair, MJH...392 de Hooge, M... 575, 577 de Hooge, M...594, 1186, 1187, 1894, 2597 De Inocencio, J... 2276, 2281 de Jager, J...2419 de Jesus, NR...2643 de Jong, J... 2136, 2143 de Jong, PHP... 1738, 2815 de Jong, TD...2093 de la Barrera, MI...1093 de la Morena Barrio, I...1674 De La Sota, M...2040 De La Torre, I...2822 de la Vega, MC...1093 De Laat, B...2866 de Lama, E... 1381, 1655 de Lautour, H...162 de Leeuw, K...1626 de Longueville, M....... 464, 468 de los Riscos, M...1240 De Lott, LB...881 De Luca, G...738 De Lucia, O...908 De Menis, E...1160 de Mesy-Bentley, K...934 de Miguel, E..595, 605, 777, 2578, 2586, 2596, 2598, 2604 de Min, C... 1228, 1901 De Moreuil, C...2757 de Munter, W...20, 1199, 2950 De Nard, F... 483, 2609 De Paepe, B...2953 de Seny, D... 1018, 1025 De Smet, K...1498 De Smit, E...778 de Smit, MJ...441 De Somer, L...316 de Sonnaville, PBJ... 2398, 2815 de Souza, AWS...2745 de Souza, FHC...2221 de Souza, MC...2720 de Souza Muller, C...733 De Sozya, A...433 De Swert, K...1479 De Toro, J...2602 De Vera, M... 1400, 2112 de Vera-Gonzalez, AM...1399 de Vet, H...260, 261, 3018 de Villiers, T...2268 de Visser, M...912 De Vita, S... 2544, 2855 de Vlam, K...................58 De Vos, F...2134 de Vries, A..................260 de Vries, D...1529 de Vries, F...578 de Vries, M...1049 de Vries-Bouwstra, JK. 1692, 1930 De Vries-Bouwstra, JK.. 753, 1693 de Wazières, B...2779 de Wit, M... 58, 351 Deal, CL...1835, 2263, 2316 Deamude, M.......... 369, 1507 Dean, LE... 41, 563 Dean, M...1705 Deane, KD. 446, 1904, 2019, 2891, 2921 DeBandt, M... 1269, 2532 Debelius, J...1919 DeBerardine, M...156 Decaris, M...964 Decaux, O...1776, 1778, 2779 Dechaisemartin, L...12 Dechartres, A...1774 Decker, P...335, 938, 1196 Decktor, DL... 2823, 2824 Dedeoglu, F. 314, 319, 1226, 1321 Deehan, R...75 Deering, D...1095 Defrance, T...1609 Defranoux, NA... 1486, 2974 Dehghan, N... 804, 1865 Dehlinger, V...1269, 2024, 2155, 2532 Deibjerg, L.................1441 Dejaco, C...1737 Dejonckheere, F... 1527, 2501 Dekker, J. 260, 261, 572, 573, 1451, 2053, 2054 del Blanco, J...1240 Del Galdo, F... 768, 968 Del Papa, N.. 531, 879, 1675, 1689 Del Pino, M...1933 Del Pino-Montes, J...74 Del Rey, MJ... 1739, 1969 del Rincon, I...1066, 2026, 2374 del Rio, AP... 2705, 2720 del Rio, E...2896 del Río-Martínez, P...2596 Delaval, P...1864 Delayen, A...163 Deleuran, B...26, 366, 409, 1200, 1741, 1964, 2729, 2737 Delgado, C.................2482 Delgado, M...2040 Delgado-Frias, E...1399 DeLibero, C...2901 Deligny, C. 1269, 1271, 1767, 2024, 2155, 2532 Dell Accio, F................2951 Dell Acqua, D...397 Della Rossa, A... 2432, 2708 Dellaripa, P...1273 Dellaripa, PF...1366 Delle Sedie, A...147 Dellyes, A...2584 Delorme, P...2250 DelVecchio, B...1830 Demary, W...940 Demattei, C...540 Demirci, FY...2955 Demirkaya, E...............2281 Demirovic, D...1441 Demirtas, S...1725 Demmelmaier, I...1085 Demmer, RT...453 Demoruelle, MK.. 446, 1904, 2891, 2921 Demougeot, C... 337, 2360 den Boer, E...2382 den Broeder, A... 1350, 2860 den Broeder, AA...204, 500, 1843, 2249 den Uyl, D...2127 Denayer, T...1498 Deng, H...2747 Deng, W...644 Deng, Z...315, 1812, 1898 Denio, AE... 1340, 1830 abstract author Index Denis, G...2779 2014 Program Book 299
abstract author Index 300 Denisova, R...2296 Deniz, G...1711 Denton, C...753, 1717, 1721 Denton, CP.. 755, 968, 1703, 1706 Denton, CP...760, 768, 874, 876, 1714, 2711, 2997, 2999 Denys, A...2357 Deodhar, AA...536, 538, 543, 544, 545, 547, 551, 819, 852, 1557, 2601 Depresseux, G...958 Deprez, X...511 DeQuattro, K...2629 Derambure, C...1517 Derambure, C...1471 Dereli, E...1115 Derfalvi, B...2284 Derk, CT...732 Dernis Labous, E.. 473, 1385, 1413, 2324 Deroux, A...1792, 2757, 2777 Derrett-Smith, EC...755, 768, 968, 1703, 1706 Dertkigil, S...2705 Dervieux, T.1608, 1631, 1921, 1924 Desai, K...2238 Desai, R...1073, 1434, 1911 Desai, SP...2122 Desallais, L...3001 Desbois, AC...2731 Deschamps, M...991 Deshayes, S...2193 Deshmukh, S...............2354 Deshmukh, U...985, 1798, 2542 Deshpande, B...900 Deshpande, GA...2021 Deshpande, V...2805 Desjardin, C...1137 Desjardins, O...499 Desmurs-Clavel, H...1925 Desmurs-Clavel, H...1776 Dessein, PH...2461 Dessole, G... 613, 2559 Detert, J...357 Devanarayan, V...1131 Devarajan, P...1294, 1303, 1304, 1826 Devauchelle, V...521, 1368, 2161, 2606 Devauchelle-Pensec, V...2536 Devenport, J...375 Devilliers, H...713, 717, 811, 1263, 1782, 2849, 2989 DeVito, A...1353 Dewey, CM...1986 Dey, P...1798 Dhar, JP...718 Dhar, R...718 Dhillon, N...2641 Dhillon, N...699 2014 Program Book Dhindsa, N... 1855, 2401 Dhir, V...503 Dhote, R...1774 Di, Y...665 Di Bello, S...560 Di Bernardo, A...531 Di Ceglie, I...2348 Di Lascio, N...2217 Di Luca, G...1675 Di Mario, C... 403, 999 Di Sabatino, V... 184, 908 Diamandis, E...1586 Diamantopoulos, A...1527 Diamantopoulos, AP.776, 786, 793, 795, 796, 880, 909, 1573, 2770 Dianongco, ML...2108 Diatchenko, L...979 Diaz, C... 2391, 2526 Diaz, C...475 Diaz, D...156 Diaz, J...281 Diaz, MP...2040 Diaz Alvarez, A...74 Díaz-Cordovés, G...1249 Diaz-Gonzalez, F.. 992, 1367, 1399 Díaz-Llopis, M... 1252, 2853 Diaz-Martin, A...992 Diaz-Torne, C...2179 Dibatake, A...1698 Diboll, J...1530 DiCarlo, EF...187 DiCarlo, JC...1521 DiCicco, M...904 Dickinson, A...1530 Dickson, K... 2328, 2331 Diderichsen, P...1480 Diego, S...2706 Diekman, LA...588 Dieude, P...520, 521, 747, 1130, 1140 Dieval, C...1271 Diez Alvarez, E...668, 814, 1670, 2622 Diez Lizuain, ML...1415 Diez-Perez, A...916 Dijkmans, BAC...2558 Dijkmans, BAC... 351, 572 Dijkstra, M... 293, 300 Dikranian, A... 487, 2489 Dileepan, K...784 Dilillo, D...142 Dimattia, M...315 Dimitraki, G...1401 Dimitrov, EA...949 Dimon, M...1723 Dimonaco, S...1845 Dimopoulou, D...298 Dinarello, C...1222 Dinc, A...2082 Dincer, F...1120 Dinçer,...253 Ding, C...205, 208, 209, 229, 926 Ding, J...1038 Ding, L...1766 Dinis, V...2151 Dinsdale, G... 737, 2147 Dion, C...835 Dion, J...835 Diot, E... 1130, 1690 Direskeneli, H.119, 807, 1423, 2157, 2750, 2769 Dirven, L...817, 1386, 2398, 2502 Dissanayake, T...1981 Distler, JHW...967 Distler, JH... 747, 753 Distler, O...727, 876, 967, 1928, 2998, 2999 Distler on behalf of the EUSTAR investigators and co-authors, O... 722 Ditto, M...2976 Divakaruni, A...935 Divekar, A...767 Divers, J...2956 Dixey, J...1841, 2135, 2810 Dixit, S...714, 1397, 2496 Dixon, W... 1837, 1838 Dixon, WG... 824, 2033 do Rosário e Souza, EJ...733 Dobbyn, A...2958 Dobrota, R...722, 823, 2998 Docampo Martinez, E...1900 Docherty, P...745 Dodeja, A...2013 Doerffel, Y...1518 Doerner, J... 651, 664 Dogra, P...1810 Doheny, K...525 Doherty, M...165, 179, 2962 Doi, T...1958 Doleckyj, S...920 Dolev, Y...2234 Dolezal, T...1159 Dolezalova, P...277, 284, 1325 Dolhain, RJ...107, 1439, 1871 Doll, H...683 Dolman, KM...932 Dolman, P... 1236, 1756 Dolstra, H...2178 Domènech, E...2097 Domiciano, DS...52 Domiciano, DS... 50, 51, 73 Domingues, V...9 Dominguez-Luis, MJ...992 Dominguez-Quintana, M...2639 Domont, F...2731 Domsic, RT. 736, 1677, 1678, 1694, 2997 Donath, E...1680 Donati, V...2981 Donato, A...2187 Dong, D...1808 Dong, LL...2683 Dong, Y... 55, 2862 Dong, Y...525 Donica, M...1002 Donlin, LT...1038 Donmez, S... 79, 2523 Donnell-Fink, L...2859 Donnelly, S... 1624, 2694 Donohue, JM...1452 Donovan, E...638 Dooley, M...981 Dooley, MA...684, 961, 2646 Doornbos-van der Meer, B...441 Dorais, M... 218, 2250 Doran, M...1624 Dore, R...2471 Dorfleutner, A...2167 Doria, A...671, 2408, 2833, 2953 Doria Medina, R...435 Dorman, CW...268 Dorr, A...1577 Dorris, ML... 607, 620 Dorschner, JM........ 1617, 2927 Dorton, B...1869 dos Santos, FC...2643 Doucette, S...688 Doucette-Preville, D...883 Dougados, M...1558, 2912, 2938 Dougados, M...101, 351, 536, 538, 540, 574, 581, 584, 590, 819, 852, 1058, 1059, 1186, 1187, 1368, 1373, 1413, 1418, 1428, 1894, 2029, 2161, 2324, 2379, 2554, 2556, 2557, 2568, 2599, 2600, 2606, 2828, 2928, 2984 Douillard, C... 255, 256 Dowell, S...370, 1375, 2378, 2413 Downer, K...2972 Dowty, ME...1514 Doyle, A... 828, 1215 Doyle, RE...2908 Doyle, T... 437, 1273 Dozmorov, MG...2978 Draghessi, A...908 Draibe, JB...1860 Drake, R....................661 Draper, T...3013 Draves, K...1946 Dregan, A...2188 Drenkard, C...1811, 2117, 2626 Drenkard, CM.899, 959, 1333, 1334 Drennan, M...638 Drescher, E...952 Drews-Botsch, C...2290 Drexhage, HA... 1799, 2979 Dreyer, L...848, 853, 1837, 1838
Driban, J...1336, 1818, 2894 Driban, JB. 216, 1281, 1337, 2065, 2337, 2858, 2895 Drier, A...1245 Driest, KD...1320 Drokman, I...443 Drosos, AA... 592, 1170 Drossaert, CHC...107 Drouin, EE...983, 984, 1970 Drubin, D... 75, 1619 Druce, KL... 1382, 2811 Drynda, S... 834, 2088 du Souich, P...2231 Duan, J...2227 Duan, L...2718 Duarte, V..................2715 Dubanchet, A...581 Dubinsky, D...2040 Dubost, JJ...520, 521, 1448, 2536 Dubovy, S...1756 Dubreuil, F...2024 Dubreuil, M...144, 172, 554, 822, 827, 1875 Dubucquoi, S... 1718, 2700 Duchesne, J................1764 Ducreux, J... 1609, 1623 Dudek, A...1180 Dudley, L...1345 Duerr, RH...1900 Dueymes, M...1269 Duffy, C...1878 Duffy, C...1866 Duffy, CM...2288 Duffy, S...1885 Dufner, P...2971 Dufour, AB. 1085, 1086, 2943, 2945 Dufrenot, D...2024 Duggan, DJ...2893 Duggirala, R...1133 Dumancas, G...1134 Dumortier, T...2295 Dumusc, A... 157, 158 Duncan, JA...315 Dundar, U...1111 Dunham, JS...2545 Dunkel, J...102 Dunlop, DD.. 68, 1800, 2944, 2946 Dunlop-Thomas, CM.. 1333, 1334 Dunne, A...1050 Dunogué, B...1759, 1763, 1767, 1769, 2199 Duny, Y...1490 Dupin, N...2777 Dupont, S...1494 Durán Santa Cruz, J...1384 Durandin-Truffinet, M...2324 Durden, E...2623 Durez, P...................2493 Durukan, E...1574 Duruoz, MT...557 Duryea, J...2142 Duryee, M...1620 Duryee, MJ...1470, 1475, 2782 Dusad, A... 108, 1475 Dussol, B... 255, 1611 Dutasta, F...8 Dutoit-Lefèvre, V...1718 Duval Modeste, AB...1690 Duymaz, J...79 Dvorkina, O...3 Dwivedi, N...2917 Dwyer, T... 208, 209, 229 Dybowski, F... 2612, 2940 Dyer, A...862 Dyer, J...866 Dzangue Tchoupou, G...1517 Dzhambazov, B...1735 Dälken, B...1750 Dörner, T... 497, 996, 1944, 1951, 2693 E E. Harper, P... 1124, 1289 Earley, K...2535 Eastman,...2615 Easton, V...1330 Eathakkattu Antony, BS.. 208, 209, 229 Eaton, C...1090, 1281, 1818, 2894 Eaton, CB... 216, 2895 Ebbo, M...2777 Ebeling, P...1795 Eberhard, BA...1303, 1304, 1826 Echtermeyer, F...2951 Eckman, J...649 Eckstein, F...210, 211, 1280 Edberg, JC...1209 Eddings, W...1911 Edelman, D...891 Eder, L.. 542, 626, 627, 628, 1575, 1850 Eder, V...2145 Ederveen, T... 1733, 1816 Edhayan, G.. 444, 937, 1962, 3006 Edison, JD...1904 Edmonds, S...54 Edwan, JH...619, 816, 1815 Edward, D... 1236, 1756 Edwards, C.. 548, 676, 1566, 1579 Edwards, CJ. 372, 602, 1543, 1561, 1565, 1572 Edwards, L...663 Edwards, RR...254 Edworthy, SM...2015 Eeg, I...1274 Effat, D...1632 Eggebeen, AT...2365 Eggleton, P...433 Egsgaard, LL...1293 Egsmose, EL...377 Eguchi, K... 2389, 2472 Egurbide, MV...747 Ehrenstein, BP...126 Ehrlich-Jones, LS... 1800, 2944 Ehrmann Feldman, D...1866 Eichenfield, A...1307 Eichenfield, AH... 672, 2269 Eijkel, G...1127 Eimon, A...2625 Einarsson, HB...26 Einarsson, JT...2394 Einhorn, T...2969 Eisen, D...1705 Eisenstein, E...2899 Eivaz Mohammadi, S...1810 Ejbjerg, BJ...1171 Ejstrup, L... 541, 629 Ekberg, S...1071 Ekpenyong, A...1990 Ekwall, AK... 1889, 2919 El-Gabalawy, H..1476, 1855, 2115, 2401 El-Gabalawy, HS...2022 El-Hallak, M...2277 El-Sawy, NA...2056 El-Zorkany, B...461 El-Zorkany, B...557 Elagib, E...1534 Elalouf, O...700 Elashoff, D...91 Elashoff, R...2995 Elassaiss-Schaap, J...1495 Elbagir, S...1534 Elberg Godskesen, L...2209 Elder, JT...625 Elefante, E... 2201, 2755 Elewaut, D.. 203, 638, 2134, 2988 Elford, K...1682 Elfving, P...399 Elhai, M...3001 Elias, B...2022 Elías-López, D...1371 Elkayam, O...2912 Elkayam, O...443, 700, 971, 3012 Elkon, KB.657, 861, 873, 1814, 2844 Ellegaard, K...2439 Ellinghaus, E...625 Ellingsen, T. 349, 1441, 2030, 2171 Ellis, J...307 Ellis, M... 1495, 1500 Ellsworth, J...61 Elmesmari, A...2451 Elmore, S... 858, 2839 Elner, VM...881 Eloranta, ML...2673, 2681, 2980 Elshafie, A...1534 Elting, L...111, 1069, 1070 Elwood, F...2354 Embi, PJ... 708, 1422 Emery, P.. 385, 1362, 1515, 1521, 2468, 2485, 2486 Emery, P... 124, 137, 380, 449, 536, 538, 768, 819, 968, 1020, 1178, 1740, 1891, 2495, 2503, 2773 Emil, NS...1764 Emir, B...1094, 1879, 2076, 2080 Emond, PD... 1172, 1424 Emoto, K...1483 Emson, C...964 Encinas, L...2381 Encinas, L...2040 Enciso, S...2281 Enck, R...2365 Endo, N...1651 Enecik, ME...2746 Eng, C... 88, 782 Eng, H...404, 886, 1410 Eng, SWM...290 Engelke, K...2136 Engelson, BJ...2905 England, BR...1067 Englbrecht, M.351, 940, 1184, 2130 Engler, A...1967 Englund, M...206 Enriquez Merayo, E...680 Epailly, E...1681 Epis, OM...2399 Eraña, F...1093 Erausquin, C...2622 Erb, N...676 Erba, G...2768 Ercalik, C...1105 Erden, A... 509, 1432 Erer, B...2157 Erer, B...2852 Erfani, T... 1280, 2241 Erguven, M...2291 Erhard-Ramírez, A...1425 Erickson, A...2139 Erickson, AR...840 Eriksson, A... 642, 659 Eriksson, H...2952 Eriksson, J... 42, 2936 Eriksson, JK...2525 Erkan, D... 1, 3, 9, 18, 2868 Erken, E...2750 Erlandsson, M...435, 1748, 2515, 2847 Erman, B... 912, 1316 Ermini, I...2432 Ernestam, S...2525 Ernst, M...1389 Ernste, FC... 1617, 1852 abstract author Index 2014 Program Book 301
abstract author Index 302 Erny, F...2527 Erondu, N... 549, 1557 Erra, A... 59, 1129 Ertenli, I.. 509, 1432, 2157, 2562, 2611 Eryilmaz, E...640 Esbrit, P...32 Escalante, A...1066, 1133, 2026, 2374 Escobar Martinez, A...3018 Escolano, E...2144 Escorpizo, R...727 Escribano, P...731 Escudero-Contreras, A...1978 Esdaile, J... 915, 2023 Esdaile, JM...1770, 2306, 2308 Esen, E...2069 Eskehave, T...1293 Esmaili, N...490 Espesen, J...2439 Espinosa, G...747 Espinosa, R...1253 Espinosa Cuervo, G...1676 Espinosa-Morales, R...1984 Espinoza, F Sr....391 Espinoza, LR.370, 1375, 1600, 1643, 2378, 2413 Espiritu, B...1985 Esquivel-Valerio, J... 1425, 1427 Essani, A... 1510, 2799 Essenmacher, L...718 Essers, I.. 557, 574, 578, 579, 2600 Esteban, MM...1252 Estis, J...373 Estivill, X...1900 Estrach, C...1053 Estrada, P.. 695, 1655, 1656, 1659 Estrada-Capetillo, L...2175 Estublier, C...62, 63 Etchepare, F...1368 Etcheto, A... 58, 257, 2324 Etomi, O...1721 Etzel, CJ...418, 1594, 2813 Eudaly, JG... 637, 1213 Eudy, A...2668 Euller Ziegler, L...202 Eun, JS...593 Evans-Young, G...2421 Evensen, E........... 1614, 1616 Ewart, D... 2172, 2843 Exarchou, S... 42, 1804 Exeni, IE...2040 Eymard, B...1262 Ezaki, Y...267 Ezzeddine, R...1861 2014 Program Book F Fabre, S... 585, 2574 Fabreguet, I... 157, 158 Facchini, A... 35, 1292 Fagerli, KM... 1542, 1848 Fahrleitner-Pammer, A...1795 Fain, O...1925 Fain, O.8, 12, 811, 2145, 2757, 2779 Faiq, A... 2211, 2222 Fairley, J...218 Fakharzadeh, S..1562, 1563, 1569, 1851 Falgarone, G...2779 Falk, R...1781 Falkmer, T...2435 Fall, N...310 Fallarino, F...316 Faltus, R...328, 649, 2354 Faltys, M...1513 Fan, C...48 Fan, C...1522 Fan, C... 2823, 2824 Fan, H...2909 Fan, J...1861 Fan, Q...2227 Fan, R...1953 Fanelli, P...1500 Fang, D...2908 Fang, F...966 Fang, H...6 Fang, L...955 Fang, MA..................2107 Fang, W...181 Fang (Lin), C...919 Fangxiang, M...381 Fanouriakis, A... 1401, 2645 Fantana, J...1621 Fantuzzi, G...2799 Faraawi, R.. 421, 583, 1397, 2376, 2411, 2496 Farbstein, M...949 Fardellone, P................202 Faré, R...134, 1739, 1969 Farewell, V... 961, 2646 Farias, F...2673 Farina, I...908 Farkasch, A...2075 Farnetti, E...882 Farook, VS...1133 Farraro, R...1694 Farrell, J... 259, 262 Farrell, JF. 2195, 2196, 2197, 2444, 2716 Farris, AD.. 985, 2543, 2930, 2978 Fassina, A...1292 Fasth, AER...2726 Fauchais, AL...520, 521, 2549 Faugier, E...1311 Faustini, F. 1184, 1892, 2130, 2233 Faustino, A...2428 Fautrel, B. 58, 202, 351, 585, 1055, 1385, 1413, 2028, 2132, 2379, 2483, 2527, 2574, 2599 Favalli, EG...2383, 2512, 2514 Faveeuw, C...1718 Favero, M...1292 Fayet, F...1448 Fazeli, P...2843 Fazio, S... 843, 1437 Fearon, U... 779, 884, 1044, 1195, 1977, 1979, 2181, 2798, 2800, 2875 Feaver, R...439 Feced, C...2119 Fechtenbaum, J...2324 Fedele, AL...403 Federici, C...783 Feghali-Bostwick, C.759, 769, 1720, 1731 Feghali-Bostwick, CA...757, 770, 1887, 1897 Fein, A...187, 1854, 2970 Feinberg, B...1356 Feist, E... 1518, 2552 Feitosa de Oliveira, SK. 1316, 1900 Feldhamer, I...1547 Feldman, B.1231, 1310, 1321, 2279, 2280, 2282 Feldman, BM... 912, 1316 Feldman, CH... 903, 1075 Feldman, S... 1075, 2036 Feldman, SR...1544 Feldon, M MD...83 Felea, I....................2645 Feller, L...400 Felson, DT...200, 207, 212, 822, 973, 974, 1083, 1276, 1284, 1286, 1384, 1820, 1821, 1874, 2721, 2969, 3007 Feltrop, D...1869 Femia, A...2226 Fenaux, P...2779 Feng, CW...323 Feng, GS...2818 Feng, J... 549, 1557 Feng, J... 886, 1410 Feng, R... 2206, 2851 Feng, X...1968 Feng, X...1968 Feng, X. 635, 654, 960, 2343, 2678 Ferdowsi, N...720 Ferguson, PJ... 1321, 1988 Ferlin, W...1901 Fernandes, JK...2956 Fernandes, PT...2660 Fernandez, I... 2169, 3004 Fernandez, JL...1121 Fernández, M...474 Fernández Berrizbeitia, O...2622 Férnandez Cid, C...2853 Fernández Dapica, MP...2598 Fernández de Castro, M...2622 Fernandez Gutierrez, B.. 59, 1129, 2459 Fernandez Moreno, M. 1121, 1122, 1125 fernandez Nacul, S...148 Fernandez Nebro, A.59, 1129, 1670, 2097, 2622 Fernández- Espartero, C.1250, 2853 Fernandez-Becker, N...2996 Fernández-Carballido, C.2578, 2604 Fernández-Costa, C. 93, 982, 1127 Fernández-Gutiérrez, B.. 90, 1139, 1431 Fernández-Gutiérrez, B...1138 Fernandez-Llaca, H..........2776 Fernandez-Lopez, C. 93, 982, 1121, 1122, 1125, 1126, 2602 Fernandez-Nebro, A...596 Fernández-Puente, P.93, 982, 1003, 1126, 1127 Fernández-Tajes, J.982, 1121, 1122, 1125 Ferraccioli, G...............2912 Ferraccioli, G..403, 738, 999, 1639, 1971 Ferrand, C... 991, 2849 Ferrándiz, C...2097 Ferrandiz, M...931 Ferrara, N...560 Ferrari, C...2217 Ferrari, G...1697 Ferrari, M...142 Ferrari, S...2254 Ferrari, S...2267 Ferrarini, M...2202 Ferraz, ML...1644 Ferraz-Amaro, I....... 1399, 2461 Ferreira, A... 118, 2125 Ferreira, WG...1622 Ferreiro-Iglesias, A...2086 Ferreti Silveira, L...2659 Ferreyra Garrott, L...2987 Ferreyra-Garrot, L...1585 Ferri, C.............. 1928, 2855 Ferrigno, C...2245 Ferrigno, C...213 Ferro, F...1772, 2201, 2931, 2981 Fert Bober, J...815 Ferucci, E...2624 Ferucci, ED...1476 Feser, ML... 1904, 2921 Fessler, B...961 Fessler, BJ... 745, 2646 Fessler, J...2880 Fessler, J...1737 Fetisova, A...2296 Fève, B...1012 Feydy, A... 540, 1186, 1187, 1894, 1926, 2984
Ficjan, AC...1737 Fiehn, C...958 Fields, R............. 1764, 2789 Fields, TR..................3016 Fife, D... 1604, 2880 Figgie, MP...115, 187, 198, 1854, 2970 Figueiredo, CP... 51, 52, 73 Filer, A...389, 2183, 2463, 2874 Filipescu, I...2645 Filippi, N...121 Filippini, D...2855 Filippou, G... 184, 908 Filippucci, E... 127, 2589 Filková, M...1128, 2085, 2450 Fillatreau, S...2693 Filocamo, G...299 Fina-Aviles, F...372 Finckh, A.. 504, 1837, 1838, 2565, 2913 Fine, A... 867, 1408 Fine, MJ...................2997 Finkelstein, E...1808 Finklestein, J...236 Finlay, K... 1172, 1424 Finzel, S...940, 1192, 2130, 2136 Fiore, S...2795 Fiorentino, D.721, 912, 1563, 1851, 2539 Fireman, E... 443, 700 Firestein, GS.935, 1027, 1889, 2339, 2816, 2818, 2919 Fisch, KM... 1016, 1885 Fischer, A...836, 1419, 1931 Fischer, K...1598 Fischer, N... 296, 312 Fischer-Betz, R... 357, 701 Fisher, K............. 1983, 2641 Fisher, MC...2425 Fisher, M... 322, 1512 Fisher, N... 1996, 2001 Fisher, P....................439 Fishman, E...2148 Fishman, P...949 Fishman, S...949 Fisk, N...1834 Fiter, J...1240 Fitilev, S...1492 Fitzcharles, MA...264, 265, 1109 Fitzgerald, GK...889 Fitzgerald, KA... 1794, 1813 FitzGerald, O...1578, 2614, 2912 Flageul, B...2777 Flanagan, R...2246 Flato, B...931 Flato, B...304 Flecher, E...1681 Fleck, M... 126, 940 Fleet, L...1933 Fleischer, S...1951 Fleischer, SJ... 1944, 2693 Fleischer, V... 1944, 2693 Fleischmann, R. 463, 465, 493, 545, 1520, 1553, 2488, 2495, 2823 Fleisher, T...1898 Fletcher, T...1478 Flewelling, C...1932 Flex, A...1971 Fligelstone, K...727, 2699, 2707, 2716 Flint, J...1358 Flipo, RM.163, 164, 165, 511, 1411, 2481 FloraCruz, S...964 Florence, N...1481 Florentinus, S...2517 Flores, A...1311 Flores, D...1984 Flores, NM...105 Flores-Alvarado, D... 1420, 1425 Flores-Fernández, R...1947 Flores-Suarez, LF...1785 Florestano, MC...2192 Flynn, JA...608 Flynn, T... 21, 168, 2961 Foa, E...895 Focherini, MC...908 Foeldvari, I...273, 282, 285, 1322, 1323, 1325 Foerster, M...1793 Fogel, O... 520, 521 Fogg, LF...213 Fojtikova, M...2085, 2555, 2594 Foley, C... 317, 2904 Foltz, V...2132 Fong, SL...2107 Fongen, C...2561 Fonollosa, A... 1252, 2853 Fonseca, C...753 Fonseca, E...2097 Fonseca, JE... 995, 2428 Fontsere, O...1431 Foody, JM...1080 Forbess, LJ...1079 Ford, A...2240 Ford, J...294 Forejtova, S. 136, 851, 2371, 2422, 2555, 2580, 2594 Forejtová,...2085 Forestier, A...1718 Forgues, M...1269 Forrester-Barker, W...793 Forsberg, S...106 Forsblad, H...1596 Forsblad-d Elia, H.. 42, 1804, 2832 Forslind, K... 364, 367, 376 Forster, A...2971 Fort, J...244 Fortin, I...365, 396, 421, 502, 567, 682, 1535, 1536, 1550, 1551, 1601, 2416, 2569 Fortin, P... 961, 2646 Fortin, PR. 682, 2015, 2619, 2787, 2868 Fossati, G... 1222, 2873 Foster, HE...313 Foster, H...274, 284, 295, 1998 Foster, HE...272, 303, 1444 Foster, J... 47, 49, 170 Foster, JM...297 Foster, J... 1236, 1756 Foster, N...1114 Foster, S...683 Foster, SA... 687, 2623 Fourcaudot, MJ...1133 Fourret, P...2731 Fowler, J... 230, 231 Fowler, R...95 Fox, C.....................2047 Fox, DA...444, 937, 1962, 3006 Fox, RS...1089, 1338, 2335 Foxworth, J...1684 Foy, C...3007 Fradin, J...2538 Fraenkel, L.1422, 1809, 1934, 1935, 1936, 2857, 3014 Fragkiadaki, K... 1443, 1462 Fragkioudaki, S...2090 Fragoso-Loyo, H... 411, 694 Fraison, JB...2757 Frallonardo, P... 908, 1291 Frampton, C...1757, 1758, 2377 França, CMP...1300 Francès, C... 835, 1925 Franceschini, F... 1256, 1532 Franchini, S...1242 Francisco, F...1250, 1252, 2853 Francisco, M...1834 Francois, H...2549 Frane, J...276 Franek, E...1795 Frank Bertoncelj, M... 92, 2785 Franke, A... 625, 880 Franklin, C... 828, 2959 Franklin, J...655 Franklin, PD.64, 192, 193, 194, 197, 1279 Fransen, J...826 Fraser, N...2227 Frassi, M...671 Fraticelli, P... 1675, 2855 Frauenfelder, T...2998 Frazier, D...1908 Frech, T...745, 1927, 2699, 2707 Frech, TM... 1677, 1694 Fréchet, M...3001 Fredberg, U...2030 Frederiksen, KS...947 Frediani, B...184 Freed, G...902 Freeston, JE... 1178, 2773 Freilich, B...2649 Freire, M... 1670, 2622 French, J...458 French, S... 2841, 2955 French Vasculitis Study Group (FVSG), T...1782 Frenkel, J.. 1231, 2279, 2280, 2282 Fréret, M...1471 Freshwater, T... 1495, 1500 Fresko, I...2043 Frey-Law, L...2783 Freyhult, E.................2084 Friday, SC...1962 Fridkin, M...647 Friedman, A...378, 1555, 1577 Friedman, D...1829 Frielinghausen, J...131 Frisell, T...2890 Frits, M... 1141, 2103 Frits, MA...1335, 1408, 2889 Fritschy, D...2248 Frittoli, R...2705 Fritz, J...889 Fritzler, M...1268, 1476, 2115 Fritzler, MJ...320, 745, 2210 Frizelle, S...268 Frobell, R...206 Froeschlin, J...2208 Frugoni, F...314 Fryburg, D...75 Fu, B...2493 Fu, B... 303, 2392 Fu, Q...2668 Fuegener, S...29 Fuentes, M...982 Fuhlbrigge, RC... 314, 1321 Fuhrer, O...2024 Fujii, H...1950 Fujii, T...806 Fujiki, Y...1784 Fujimoto, M...86, 1258, 1259 Fujimoto, M...2363 Fujio, K... 859, 1454 Fujio, N...232, 233, 1460, 2259 Fujisawa, Y...1258 Fujisawa, Y...146 Fujita, Y...1950 Fujiwara, S...2340 Fukuba, E...2773 Fukuda, K...2462 Fukui, N...2457 Fukui, S...429, 2389, 2651 Fukui, T...2, 5, 1179, 2638 Fukuma, Y...2418 abstract author Index 2014 Program Book 303
abstract author Index Fukushima, Y...2727 Fuld, M...2148 Fulla, Y...2559 Fulladosa, X...1655, 1656, 1659 Fuller, H...1301 Funahashi, K. 471, 512, 2504, 2516 Funchain*, P... 88, 782 Funkenbusch, SC...268 Furet, JP...622 Furey, A... 1124, 1289 Furie, R. 13, 672, 1608, 1631, 1924, 2836 Furie, RA... 684, 2834 Furst, DE.. 844, 1515, 1521, 2468, 2485, 2486, 2718 Furst, DE. 740, 745, 751, 767, 1338, 1678, 2335, 2697, 2995, 2999 Furst on behalf of FaSScinate Clinical Trial in Patients With SS, DE...874 Furukawa, H.. 82, 85, 86, 87, 2457 Furuya, H...2509 Furuya, K...2214 Furuya, T... 223, 226 Fusaro, E...1256, 2512, 2514 Föll, D...932, 1900, 2988 Förger, F...1409 Førre, T...398 G G. van Helden-Meeuwsen, C. 1799, 2979 Gabay, C...1524, 2524, 2565 Gabba, A...908 Gaber, T.......... 29, 1006, 1518 Gabler, NB...875 Gabriel, SE...258, 390, 428, 1052, 1055, 1405 Gabrielli, A... 1675, 2855 Gaches, F... 255, 256 Gadina, M... 609, 816 Gadwala, S...2807 Gaffen, SL...1032 Gaffney,...2978 Gaffo, AL...840 Gago-Fuentes, R... 1003, 1034 Gaillez, C...132, 1517, 2291, 2923 Gaillez, C...931, 2297, 2298 Gaillez, C...930 Galan, P...1418 Galarza-Delgado, D...1427 Galarza-Delgado, DA...2644 Galateanu, C...1077, 1945, 2834 Galaverna, S...2550 Galeazzi, M...132, 2491, 2492 Galeazzi, M... 184, 885 Galeotti, C. 1231, 2279, 2280, 2282 Galicier, L...1925 Galien, R...1494 304 2014 Program Book Galimberti, S...2201 Galindez-Agirregoikoa, E...1240, 1787, 1788 Galindo, M...346, 660, 2735 Galindo Izquierdo, M... 680, 1670 Galindo-Feria, AS...2724 Galindo-Izquierdo, M...2622 Gallagher, L...1979 Gallagher, P. 109, 1578, 2312, 2614 Gallardo, MDLA...2402 Gallardo-Perez, E...1122 Gallego, R... 1252, 2853 Gallego Flores, A... 597, 2190 Galli, M...2855 Gallizzi, R..................2281 Gallo, A...526, 530, 2981 Gallo, J......................45 Gallo, MC...278 Galloway, J... 839, 2044 Galo, J...2112 Galvani, S...1647 Gamache, T................2858 Gamba, MJ...1093 Gambari, L...35 Gamble, G... 828, 1215 Gamboa, J...1993 Gamboa-Cardenas, RV...1393 Gamero, F...2853 Gamir, ML...931 Gamir Gamir, ML...2276 Gammaitoni, A...924 Gamonet, C.................991 Gan, RW.. 446, 1904, 2019, 2891, 2921 Gancheva, R...161 Gandhi, K...2519 Gandjbakhch, F... 1183, 2132 Ganeshalingam, K...2803 Gangidi, S...2261 Ganguli, A...1555 Ganguly, R...1548 Ganser, G... 282, 285 Gansky, S...98 Gantes, M... 1670, 2622 Ganz, F...2971 Gao, N...696 Gao, W... 884, 2800 Gao, Y... 2654, 2658 Garchon, HJ... 622, 1137 García, A...306 Garcia, D...2111 Garcia, F...2608 Garcia, MV...2402 García, M. 406, 1388, 1438, 2040, 2381 García, MA... 1637, 2670 Garcia, S...1198 García, V...2097 García de la Peña, P... 1670, 2622 Garcia de Yebenes, MJ.. 731, 2710 García de Yebenes, MJ...2622 Garcia Kutzbach, A...2493 Garcia Montero, A...59 García Serrano, JL...1252 García Serrano, JL...2853 García Yébenes, MJ...1367 Garcia-Aparicio, AM...668, 1250, 2853 García-Arias, M...2853 García-Bermúdez, M.. 2452, 2459 Garcia-Carazo, S...2522 García-Carrasco, M...1531 Garcia-De La Torre, I...1268 Garcia-Fructuoso, F...2064 García-González, AJ...2853 García-Hernández, FJ...747 García-Herrero, C...660 Garcia-Martos, A...762 Garcia-Melchor, E... 2176, 2179 Garcia-Monaco, R... 2072, 2987 Garcia-Pompermayer, M...1420 Garcia-Rodriguez, F...1311 García-Trejo, P...1654 García-Unzueta, MT...228 Garcia-Vadillo, A...2412 Garcia-Valladares, I...370, 1268, 1375, 2378, 2413 Garcia-Vicuña, R. 1138, 2144, 2412 Garcia-Villanueva, MJ...777 Gardin, C...2779 Gardner, D...439 Gardner, M...1204 Garen, T... 724, 2703 Garesse, R...1122 Garg, JP... 948, 2826 Garg, N...547 Garg, N...3009 Garg, S...939 Garg, V...289, 1147, 2232, 2393 Garnery, B...2024 Garofalo, F...299 Garrido, M...2731 Garrood, T...2974 Garssen, J... 1733, 1816 Garvey, WT...2956 Garvin, K...108 Garyfallos, A...298 Garyfallos, G...298 Garza-Elizondo, M.739, 1420, 1427, 2251 Garza-Elizondo, MA...2644 Gasparini, S...2720 Gaspersic, N...514 Gates, DF...250 Gathany, TA................2495 Gatmaitan, M...964 Gattamelata, A...908 Gatterova, J................2594 Gattinara, M...299 Gatto, M...671 Gattorno, M...305 Gattorno, M.299, 1231, 1900, 2279, 2280, 2282 Gaubitz, M...2414 Gaud-Listrat, V...2324 Gaudin, P... 1428, 1517 Gaudin, P...351, 1368, 1385 Gaudric, J... 809, 2731 Gauer, L...1844 Gaujoux Viala, C...2527 Gaujoux-Viala, C... 1384, 1413 Gauna, A...2174 Gauna, M...2381 Gaur, N...1128 Gaur, P... 308, 2173 Gautheron, A...2849 Gaweco, A... 322, 1512 Gay, C...897 Gay, R... 92, 2450 Gay, RE.456, 967, 1128, 1210, 1967, 2448, 2785 Gay, S...92, 456, 967, 1128, 1210, 1967, 1977, 2085, 2448, 2450, 2785 Gaydukova, I...557 Gayed, M...1358 Gaylis, NB...2490 Gazeau, P...2606 Gazitt, T...815 Ge, C...1735 Ge, XP...2796 Geborek, P...364, 367, 376, 2394, 2525 Gebretsadik, T...1437 Gedalia, A...276 Geffray, L...8 Géher, P...557 Geier, J...458, 460, 1908 Geier, J...1537 Geiger, J...795 Geijer, M...1549 Gelber, AC...45 Gelfand, J...2140 Gelpi, M...2202 Genant, HK...1890 Gendi, N...885 Gendreau, J... 1095, 1878 Gendreau, RM... 1095, 1878 Genest, G...2666 Geng, L... 635, 654 Genovese, MC...488, 1522, 1557, 2495, 2822, 2823 Genovese, MC...549, 2824, 2826 Genre, F...1103, 2063, 2064 Genre, F. 1787, 1788, 2203, 2452, 2459, 2461 Gensler, LS...420, 569, 588, 617, 1856, 2827
Gent, YYJ...2127 Genta, M...94 Genty, M...2397 Geny, B...1707 George, A...2619 George, C...401 George, D...2187 George, E...2438 George, J...1499 George, LM...1796 georgin Lavialle, S...2779 Geraldes, R...794 Gerards, AH... 120, 2815 Gerber, N...498 Gerber, R...100, 1145, 2406, 2487 Gerenli, O...2744 Gergely, P...910 Gergiannaki, I...1401 Geri, G...1776 Gerin, M...2199 Gerlag, DM...450 Gerlag, DM. 392, 1198, 1960, 2816 Gerlag, DM... 2448, 2463 Gerli, R...2544 Gerloni, V...276, 299, 1225 Germanò, G... 790, 791 Gerou, S...2585 Gerschman, T... 61, 2275 Gerstein, M... 1310, 1312 Gervais, F... 997, 1495 Gessl, I... 634, 650 Getu, L............... 387, 1328 Geusens, P...2143 Gherardi, R...1037 Gherghe, AM... 823, 2387 Ghia, C....................2436 Ghillani-Dalbin, P...1634 Ghimbovschi, S...2216 Ghimire, S...2187 Gholizadeh, S...1089, 1338, 2335 Ghomrawi, H...115 Ghosh, S...1888 Giacomelli, C.......... 527, 2499 Giacomelli, R...768 Giancane, G...1231 Giangreco, D...353, 713, 2989 Giannelou, A...816 Giannini, C...2766 Giannini, E...2999 Giannini, EH... 2211, 2222 Gianturco, L...2550 Gibbon, M...2288 Gibney, SM...1799 Gibofsky, A... 243, 249 Gibson, KA... 417, 1157 Gibson, S...2438 Giesecke, C...1951 Giezek, H...920 Gigante, MR... 403, 1639 Giger, ML..................2839 Gignac, MAM...2942 Giguere, G...2668 Gil, A...889 Gil Latorre, F...1674 Gilbane, A... 1717, 1728 Gilbane, AJ... 755, 1706 Gilbert, A...68 Gilbert, M...10 Gilboe, IM...958 Gilchrist, DG...2451 Gilchrist, N...1795 Giles, BM...2185 Giles, I...1201, 1358, 2863, 2865 Giles, J... 1363, 1395 Giles, JT...2972 Giles, K...1132 Gilhar, A...2359 Gilio, M... 560, 2758 Gilkeson, GS.637, 1213, 1938, 1948, 2880, 2956 Gill, E...1178 Gill, T... 615, 1919 Gill, TM...2857 Gillespie, C...522 Gillespie, J... 768, 968 Gillet, P...1018 Gillies, H...836 Gilliland, WR...1904 Gillispie, L...415 Gillooly, AR...2682 Gilman, S...................715 Gilson, B...1782 Gilson, M...1413 Giltiay, NV...1942 Ginsberg, S... 498, 1422 Ginzler, EM...322, 684, 961, 1512, 2646 Giordano, R...879 Giraldo, CL... 2042, 2706 Girard, C...1774 Girard, JP...................335 Giraud, B...2324 Giraud, M...1130 Giri, S...2187 Gisbert, JP...3008 Gisbert, JP...2097 Gisi, K...2270 Gissel, C...1146 Gladman, DD...542, 545, 548, 623, 624, 625, 626, 627, 628, 630, 685, 690, 699, 865, 961, 1552, 1561, 1564, 1565, 1568, 1575, 1576, 1577, 1579, 1586, 1587, 1590, 1592, 1593, 1850, 1858, 1859, 2099, 2631, 2634, 2640, 2646, 2791, 2935 Glass, J...490 Glaysher, B...1045 Glazov, E...1886 Glerup, H...1741 Glintborg, B... 848, 853 Gloetzner, M...2088 Glushko, T...1998 Glüer, C...2255 Gnann, H...1560 Gobbi, C...2040 Gobeaux, C...1687 Gobert, P... 1776, 1778 Gochuico, B...437 Godeau, B...811 Godfrin-Valnet, M... 556, 559 Godmann, L...2951 Godmer, P. 1767, 1776, 1778, 2777 Godoy, A...370, 1375, 2378, 2413 Godwood, A...1485, 1486, 1496, 2821 Goeb, V.520, 521, 2434, 2536, 3011 Goekoop-Ruiterman, YP...1386 Goel, N...1505 Goel, R...810 Goemaere, S... 916, 2255 Goeminne, C...1681 Goesling, J............. 252, 266 Goess, C...858 Goettl, KH...2414 Goffin, L...2291 Goglin, S...963 Gogus, F...351 Gohr, C...1625 Goker, B.... 681, 716, 1673, 2548, 2761 Goksu, H...1110 Gokun, Y...1167 Gold, D...1755 Gold, DT...1158 Goldbach-Mansky, R...315, 1812, 1815, 1896, 1898, 2285 Goldbach-Mansky, RT...2756 Goldberg, A...1927 Goldberg, B... 2211, 2222 Goldberg, G...1467 Goldberg, GS...1034 Goldeinstein-Schainberg, C...957, 2304 Golden, W...918 Goldfien, R...1360 Goldin, J...2995 Golding, A... 104, 1151 Goldman, B...860 Goldring, MB...1292 Goldring, SR...24, 1043, 1292 Goldschneider, K... 259, 262 Goldsmith, CH... 384, 416 Goldsmith, DP...1226 Goldsmith, JV...2337 Goldstein, M...2010 Goldstein, N...463 Golembesky, A...1409 Golightly, YM... 1086, 2945 Golinski, ML...1471 Goltzman, D...48 Gomara, MJ...445 Gomariz, RP...1138 Gombert, B...2779 Gomes Ferraz, ML...2184 Gomez, A...1007 Gomez, E...2671 Gómez, G... 1093, 2040 Gómez, G...887, 2040, 2441 Gomez Arango, C...1240 Gomez Vaquero, C.695, 1381, 1430, 1657, 2194, 2780 Gómez-Centeno, A...2482 Gómez-Gerique, J...228 Gomez-Gomez, A...482 Gómez-Martín, D.1658, 1664, 2676, 2724, 2990 Gomez-Puerta, JA... 1080, 2511 Gomez-Reino, J..............458 Gomez-Reino, J... 548, 1579, 2086 Gomez-Reino, JJ...2511 Gomez-Reino, JJ..455, 1561, 1564, 1590, 2524 Gómez-Vaquero, C... 412, 2459 Gon, Y...145 Gonçalves, CR... 957, 2304 Goncalves-Alves, E... 27, 2358 Goncalvesalves, E...2907 Gondaira, F...1666 Gondouin, B...1611 Góngora-Rivera, F...2644 Gono, T... 877, 1255, 1264, 1640, 1710, 1939, 2991 Gonuguntla, S...53 Gonzalez, A... 455, 2086 Gonzalez, CM...59 Gonzalez, E... 6, 1357 Gonzalez, EB...2650 González, JA...474 Gonzalez, P...148 Gonzalez, R...74 González Escribano, F. 1787, 1788 Gonzalez Fernandez, C...596 González Navarro, A...2926 González Ortega, S...2144 González-Alvaro, I. 59, 1129, 1138, 2144, 2175, 2412, 2459, 2480 Gonzalez-Bello, Y...1268 González-Gay, M.1103, 1787, 1788, 2063, 2064, 2203, 2461 González-Gay, MA.747, 1240, 1249, 1252, 1256, 2452, 2459 González-Gay, MA...776, 777, 814, 880, 1250, 1251, 1367, 1399, 1791, 2775, 2776, 2853 Gonzalez-Ibarra, F...1810 abstract author Index González-Juanatey, C.. 1367, 2452, 2459, 2461 2014 Program Book 305
abstract author Index 306 González-López, MA.. 1791, 2203, 2775 Gonzalez-Navarro, A...2508 Gonzalez-Navarro, EA...2179 Gonzalez-Puig, L...2119 Gonzalez-Reyes, JA.............7 Gonzalez-Rivero, AF...1399 González-Rodríguez, C...576 González-Suárez, S...2853 Gonzalez-Vela, C.. 814, 1791, 2775, 2776 Gonzalez-Vela, MDC...2203 González-Zúñiga, A...710 Gonzalo-Gil, E... 346, 660 Gooberman-Hill, R...2006 Good, R... 1717, 1728 Goode, AP...186 Gooderham, M...1569 Goodman, A...1 Goodman, SM. 115, 187, 198, 350, 394, 1854, 2369, 2370, 2970 Goodpaster, B...1091 Goodsitt, M.................704 Goodson, N... 1053, 1062 Gopalakrishnan, R... 2543, 2978 Gordon, C...2788 Gordon, C...676, 711, 961, 1358, 2624, 2646, 2834, 2838 Gordon, C... 1172, 1424 Gordon, D...669 Gordon, JK. 734, 878, 1677, 1691, 1991, 2699, 2707 Gordon, M...2253 Gordon, P...869 Gordon, R...2835 Gorelik, G... 868, 2736 Gorla, R... 2512, 2514 Gorlova, O..................753 Gorlova, OY...745 Goronzy, JJ... 438, 1742 Gorter, S... 293, 2572 Goss, S.....................951 Gossec, L...58, 351, 557, 584, 585, 1058, 1059, 1385, 1413, 1428, 2132, 2554, 2556, 2557, 2574, 2599, 2984 Goto, H...457 Gotou, Y...2977 Gottenberg, J. 504, 520, 521, 1681, 2536 Gottenberg, JE.. 1707, 1837, 1838 Gottlieb, AB...952 Gottlieb, AB. 537, 539, 1548, 1554, 1556, 1559 Gottlieb, BS... 2317, 2318 Gottwald, M...945 Gough, A... 775, 880 Goulet, JR...2210 Goulet, L...1796 Gouni, S...315 Goupille,...1411 2014 Program Book Gourh, P...765 Gourlay, ML... 2263, 2316 Gouya, H...1768 Govoni, M...2477, 2493, 2912 Govoni, M...1256 Govoni, M Sr....2662 Goyal, J...122 Goyal, K...1562, 1563, 1569, 1851 Grabulovski, D... 1491, 1511 Gracey, E... 604, 606 Grader-Beck, T...2538 Grady-Benson, J...194 Graeber, A... 1029, 1965 Graessel, S...1010 Graf, J...2273 Graf, N...722 Graff, C... 858, 1499 Graft, J...1176 Graham, N... 1522, 2795 Graham, RR...2955 Graham, TB...2293 Grahn, AY.. 244, 418, 1482, 2415, 2813 Grainge, MJ...179 Grammatikos, AP...1033 Grammer, A...674 Gran, JT...724 Graña, G...2276 Graña, J...2482 Granados, J...1716 Granados Afonso de Faria, A..2184 Granel, A...887, 2040, 2042, 2441 Granger, B. 2132, 2554, 2556, 2557 Graninger, WB...1737 Grant, E...1755 Grant, R... 2328, 2331 Grasland, A...2204 Grassi, F...35 Gratacós, J... 59, 2097 Gratacos-Masmitja, J...595 Grateau, G. 1231, 2279, 2280, 2282 Grau, E...2119 Grauer, A...916 Gravallese, EM.. 1794, 1813, 1914 Gravani, F...1047 Graves, S... 1277, 1278 Gray, D...1761 Grayson, PC. 794, 801, 1862, 2756, 2851 Grazio, S...557 Grbic, JT...917 Greco, R...1745 Green, A...1838 Green, B...606 Green, K...286 Green, M... 775, 880 Green, RC...2008 Green, R... 1124, 1289 Greenberg, JD...156, 387, 448, 515, 518, 1148, 1537, 1853, 2367, 2375, 2415 Greenberg-Dotan, S...1547 Greenfield, M...2004 Greenspan, JS...525 Greenwald, M......... 431, 2826 Greenwald, MW...1557 Greer, J...1680 Greger, G...2915 Gregersen, PK...2891 Gregersen, PK...90, 1379, 2927 Gregersen, PK... 446, 625, 1904, 2019, 2453, 2454, 2921, 2953, 2955 Greidinger, EL... 2169, 3004 Greiner, J...2083 Greisen, S... 26, 409, 2729 Greloni, G...1783 Gremese, E.. 403, 999, 1639, 1971 Gressin, V...1690 Greth, W...719 Greve, OJ... 1169, 2652 Grewal, HK...1246 Greysen, H...2431 Griffin, M...2637 Griffin, N... 2317, 2318 Griffin, R...3 Griffin, T...2281 Griffing, WL...1685 Griffith, J... 1555, 2393 Griffiths, B...522, 676, 2982 Griffiths, CEM...2924 Griffiths, G...2014 Griffiths, H...2419 Grigg, JB...2738 Grignano, E...2779 Grigoriou, A...839 Grillet, B...2815 Grillo, E...2433 Grimaldi, A...2239 Grimaldi, D...743 Grimm, C...339 Grisius, M...529 Grodzicky, T...2210 Grogan, S...1885 Groh, M...783 Grom, A...2291 Grom, A...310, 319, 1900, 1901 Grom, AA...315 Grootenboer, S...12 Gross, AJ... 420, 1353 Gross, D...2007 Gross, KD...212, 923, 973, 1083, 2245 Grossman, JM...679 Grossniklaus, H...1236 Grosso, G...2768 Grosso, V...483, 2512, 2514, 2609 Grotle, M...2329 Grotzke, M...1996, 2881, 2885 Grotzke, MP...2001 Grouard-Vogel, G...1609 Gruben, D.. 100, 1145, 2406, 2487 Gruber-Baldini, A...1288 Grundahl, K...2543 Grunke, M...131 Grünke, M...2233 Grönwall, C...387, 448, 1328 Grøvle, L...1383 Gu, J...557, 1185, 2303, 2591 Gu, NY...2232 Guan, H...867, 903, 1080 Guay, H...2743 Gudjonsson, J...751 Gudman, NS...629 Gudmann, NS...541 Gudnason, V...787 Guellec, D...2161 Guenther, J... 773, 1712 Guenther, L...1562 Guerau, M.................2686 Guerette, B...378, 1577, 2517 Guerin, M...2204 Guermazi, A...200, 207, 210, 215, 1083, 1821, 2142 Guerra, SG...753 Guerra Vázquez, JL...596 Guerrier, T...1718 Guest, C...415 Guggino, G... 610, 611 Guh, D...1144 Gui, Y...360, 405, 1903, 1975 Guiducci, C...871 Guilhot, F...1901 Guillard, G...1178 Guillaume Czitrom, S...473 Guillemin, F.202, 1055, 2379, 2866, 3018 Guillén, MI...32 Guillevin, L...783, 811, 958, 1326, 1768, 1777, 1778, 1782, 2199, 2549, 2701 Guillevin for the French Vasculitis Study Group, L..1759, 1763, 1767, 1769, 1774, 1776, 1792, 1864, 2777, 2778 Guillot, X... 43, 559 Guillou, C...1471 Guilpain, P...1726 Guimarães, I...733 Gujar, B...1288 Gul, A... 1900, 2852 Gulati, G...2650 Gulati, N...631 Gulgielmi, B...2202 Gulinello, M... 651, 1941 Gull, E...106 Gulliford, MC...2188
Guma, M... 327, 935, 2176, 2179, 2339 Gumbiner, B...1502 Gunn, J...2474 Gunnarsson, I...670 Gunnarsson, R...2703 Guo, C...2165 Guo, J... 1495, 1500 Guo, J...665 Guo, R...1377 Guo, X...1619 Guo, YX...2975 Gupta, A...1306 Gupta, K...987 Gupta, N...503 Gupta, S... 350, 2840 Gupta, S...1756 Gupta, V...2169 Gurkan, H...79 Gurman- Balbir, A...949 Gushen, A...2861 Guthridge, JM...1604, 1922, 2430, 2688, 2880 Gutierrez, M... 127, 908 Gutierrez, MA...642 Gutierrez-Rubio, AK... 2108, 2156 Gutierrez-Ureña, SR...948 Guzman, J... 292, 2288 Gúzman, R...1506 Guzman, R...1646 Gvozdenovic, E...2428 Gwynne-Jones, D...3017 Gyftopoulos, S...1224 Gül, A...2157 Gülfe, A... 1150, 1152 Györi, N...2126 Gärtner, M...906 Götz, G...1146 Gøransson, LG... 1169, 2652 H Ha, CM... 444, 1962 Ha, N...2347 Ha, YJ... 1403, 2714 Haacke, EA...2551 Haake, R...1180 Haas, JP...285 Haas, JP... 296, 312 Haavardsholm, EA... 356, 905 Habers, GEA...1317 Hachiya, Y...86 Hachulla, E...255, 256, 520, 521, 1130, 1690, 2536, 2700, 2701, 2711, 2757, 2833 Hacioglu, A...1232, 1233, 2043 Hack, CE...336 Hackman, J...2001 Haddad, A...624, 1576, 1850 Haddon, DJ...878 Hade, EM...708 Hadji, P...2254 Hadziyannis, E...1466 Haga, N...414 Hagan, J....................754 Hagberg, N...2681 Hageman, G...2851 Hagemann, A...2552 Hahn, BH...684 Hahne, M...1518 Haibel, H...2593 Haidar, R...2081 Haider, S...1389 Haile, S... 2366, 2914 Haimovich, Y...607 Haines, GK III...343 Haji, Y... 2021, 2727 Hajj-Ali, R...2764 Hajj-Ali, RA... 2765, 2856 Hakky, M...2142 Hakl, M...1098 Halder, R...2164 Hale, C...3015 Hall, A...1114 Hall, JC...2929 Hall, S... 1564, 1590 Hallac, M...2751 Hallén, B...2283 Halliday, A...208 Halpern, M...586 Halpern, R...1882 Halushka, M... 871, 1207 Haluskas, B...154 Halvorsen, B...1440 Hama, M... 123, 125, 133 Hamalainen, M...1011 Hamann, D...450 Hamann, J...2463 Hambardzumyan, K. 364, 367, 376 Hambleton, J...1493 Hamblin, M...1404 Hamidou, M.811, 1778, 1782, 1864, 2779 Hamilton, BJ...442 Hamilton, B...1475 Hamilton, J...2872 Hamilton, JD...2795 Hamilton, S... 623, 2101 Hammad, T... 2765, 2856 Hammaker, D...1027, 1889, 2919 Hammenfors, DS...149 Hammer, A...1641 Hammer, HB...907 Hammer, HB...905, 1274, 1913 Hammer, RE...607 Hammond, A...981 Hammond, A...2404 Hammond, C...459 Hamuryudan, V. 1233, 2043, 2749, 2752, 2759 Han, BK...413 Han, B...625, 1900, 2918 Han, C... 1548, 2495 Han, KH... 817, 2502 Han, L...2857 Han, M... 1056, 1805 Han, R... 764, 1720 Han, SW...534 Han, X...1615 Hanafusa, T...1784 Hanaoka, B...2227 Hanaoka, H...2692 Hanaoka, M.877, 1255, 1264, 1640, 1710, 1939, 2991 Hands, R...904 Hanley, D...2255 Hanly, JG...688, 797, 2791 Hanly for the Systemic Lupus International Collaborating Clinics, JG... 961, 2646 Hanna, MG...2953 Hanna Helou, M...2899 Hannagan, K...462, 1523, 2139 Hannan, J...2182 Hannan, MT...1086, 2047, 2943, 2945 Hannon, MJ...2968 Hannonen, P...1365, 2812, 2911 Hanova, P... 129, 136 Hanrahan, LM...715 Hanrotel-Saliou, C...1864 Hansen, I...349 Hansen, JE...2791 Hansen, R...677 Hansen, U...2951 Hanson, E...1212 Hanson, H...1444 Hansson, M.................447 Hant, FN...1677 Hao, Y...723 Happe, J...1793 Haqqi, T... 1014, 1015 Haque, S...712 Hara, M...1666 Harada, ND...2107 Haraoui, B.371, 379, 383, 386, 394, 396, 421, 464, 468, 492, 502, 517, 519, 567, 943, 1387, 1397, 1535, 1536, 2410, 2496, 2569 Harbers, JB...2138 Harboe, E... 1169, 2652 Harcombe, H...3017 Hardie, DL...2463 Hardy, D...1937 Hardy, R...389 Hardy, WJ...2875 Harel, L...2899 Hargreaves, B...2460 Hargrove, J...1095 Harigae, H...1950 Harigai, M... 82, 85, 2467 Harkin, A...1799 Harlaar, J...3018 Harle, JR...1611 Harley, J...2850 Harley, JB...83, 1604, 2454, 2880 Harlow, L...437 Harmon, D...706 Harnett, J...100, 1145, 2406 Harniman, E...1445 Haro, I...445 Haroldsen, C...1392 Haroon, M... 1578, 2614 Haroon, N...600, 610, 611, 2605, 2607, 2829, 2939 Harpaz, Z...949 Harper, J...2176 Harper, L...1863 Harrington, C... 1236, 1756 Harrington, JT... 1352, 1355 Harrington, TM...913, 1395, 1830, 2322 Harris, EN...6 Harris, G... 1236, 1756 Harris, J...2543 Harris, J...2320 Harris, JG...2319 Harris, T...1288 Harris-Love, M...2330 Harrison, A...2967 Harrison, A...778 Harrison, DG...438 Harrison, DJ... 494, 1540 Harrison, H...1340 Harrison, M... 712, 2120 Harrold, L...193, 194, 197, 1279 Harrold, LR...518 Harry, R...1530 Harsha Strong, E...1346 Hart, D....................1699 Hart, L... 1172, 1424 Hart, R...1444 Hartgring, SAY...336 Hartman, C...108 Hartman, D...858 Hartmann, N...305 Hartog, A..................1733 Hartono, C...9 Hartung, W...126 Haruta, K...332 Harvey, AK...30 Harvey, BP.................1753 Harvey, J...1703 Harvey, P...2640 Harvey, WF. 200, 1336, 1337, 2065, 2337, 2338, 2858 abstract author Index 2014 Program Book 307
abstract author Index 308 Hasan Al Faruque, M...342 Haschka, J.. 940, 1184, 1892, 2130 Hase, N...329 Hasebe, N...82, 85 Haseeb, A... 1014, 1015 Hasegawa, H... 1610, 2170 Hasegawa, M...86 Hashiguchi, A...2692 Hashimoto, H... 82, 85, 87 Hashimoto, J...414 Hashimoto, N...1035 Hashimoto, T...1035 Hashiramoto, A...1035 Hashizume, M... 2345, 2877 Hashkes, P...1898 Hashkes, PJ...2899 Haskard, DO...2748 Hasler-Nguyen, N...2243 Hasni, S...681 Hassan, S... 1417, 1997 Hassebroek, A...2037 Hassell, A... 2336, 2898 Hassett, AL... 252, 266 Hassuna, D...2000 Hasturk, H...1402 Hasunuma, T. 232, 233, 1460, 2259 Hatemi, G. 1232, 2043, 2157, 2704, 2754, 2759, 2854 Hatron, PY...1778, 2536, 2700 Hatta, K...486 Hattori, H...1255 Hattori, Y...507 Hauari, H... 2328, 2331 Hauge, E...2524 Hauge, EM...26, 1524, 1964 Hauge, EM...2136 Haugeberg, G... 786, 1573 Haugen, AJ... 1383, 2035 Haugen, IK... 1274, 1822 Hausmann, JS...1226 Hauspie, C...1718 Hawkes, W...1288 Hawkins, PN...833 Hawtin, R...1614, 1616, 2873 Hawtree, S...2798, 2817, 2875 Hay, E...1114 Hayashi, E... 1746, 2728 Hayashi, M...380 Hayashi, N... 146, 424 Hayashi, S...2462 Hayashi, YK...2223 Haye Salinas, M. 1388, 1438, 2040, 2381 Hayem, G... 1767, 2536 Hayer, S... 27, 2907 Hayes, KW... 211, 214, 215 Hayes, S...1253 Haynes, K...1886 2014 Program Book Haynes, K... 929, 1839 Hayward, K...1995 Hazan, L...1487 Hazel, E...1866 Hazen, MM... 314, 2318 Hazen, S...1591 Hazes, JMW. 120, 139, 1571, 1583, 2382, 2815 Hazes, JMW...300 Hazes, JM... 1439, 1738 Haznedaroglu, S... 2548, 2761 Hazra, A.............. 508, 1478 Hazra, N...2188 He, D...617 He, J.......................644 He, J.................. 150, 665 He, Q...2471 He, T... 494, 1540 He, W...1949 He, X...2683 He, Y...629 Head, AJ...2365 Hearth-Holmes, M... 1620, 1953 Heath, J...240 Heathcote, G...797 Hecht, I...2359 Hecker, R...1064 Hedemann-Andersen, A...1441 Hedges, W...227 Hedrich, C...1033 Heegaard, N...1633 Heegaard, NHH.. 761, 2091, 2500 Heeren, RM...1127 Heeringa, P...1626, 1775, 2733 Hefelfinger, J... 2010, 2011 Heffernan, EJ...1578 Hefner, K...1798 Hefner, KS...2535, 2543, 2978 Heggeness, M... 2105, 2106 Heiberg, T... 58, 351 Heijda, TF...850 Heilmeier, U... 1024, 1176 Heimans, L...2138 Hein, MS... 914, 2213 Heine, G... 1944, 2693 Hejduk, K.. 280, 2371, 2555, 2580 Hekmatjou, H...1810 Helal, A...2056 Held, A...2951 Helder, B...2802 Heldmann, F...579, 2612, 2940 Hellerstein, M...964 Hellgren, K... 853, 1837 Helling, CA...2625 Helliwell,...58 Helliwell, T...2767 Helmick, C...888 Helmick, CG.. 72, 980, 2624, 2788 Helsen, MM...1036, 1733, 1734 Hembree, E...895 Hemmelgarn, B...2023 Hempfing, A...616 Hempstead, B...34 Henaux, S...2483 Henderson, LA...314 Hendrickson, B...951 Hendrickson, RC...2454 Hendrikx, T...493 Henes, JC...2208 Henes, M...2208 Hennon, T...2281 Henriksen, K...1019 Henriksen, M...2439 Henriksson, K...589 Henrotin, Y...2231 Henry, M...266 Hensor, E...137, 380, 1178 Hensor, EMA... 124, 1740 Hensvold, AH... 434, 993 Hentgen, V.1231, 2279, 2280, 2282 Hentzen, KS...167 Heo, M...946 Her, M...2993 Herbelin, A...335 Heredia, S.. 691, 695, 1657, 1659, 2194, 2620, 2780 Heretiu, L...2696 Herlin, T.277, 287, 928, 1867, 2287, 2299 Herlitz, L...2180 Herlyn, K...236 Hermann, KG...2618 Hermann, KGA..2563, 2566, 2567, 2601 Hermann, S...2845 Hermida-Gómez, T...1122 Hermine, O...2163 Hernan, M...827 Hernández, A...2586 Hernández, D...2867 Hernandez, JL...2064 Hernandez, J...2063 Hernandez, JL...2461 Hernández, JL...814, 1791, 2775, 2776 Hernández, MV...445, 469, 504, 1240, 1250, 2478, 2508, 2511, 2853, 2926 Hernández, MV... 134, 1249 Hernández, M... 1249, 1252 Hernandez, V...992 Hernández, V... 1837, 1838 Hernández Beiraín, J.. 1670, 2622 Hernandez Gañan, J... 412, 1381 Hernandez Grafella, M...2853 Hernandez Quintela, E...894 Hernández Vásquez, R...1506 Hernández-Cáceres, A...2251 Hernández-Cruz, B... 1670, 2622 Hernandez-diaz, S...1073 Hernández-González, R...1947 Hernández-Hernández, C...2533 Hernandez-Hernandez, V...1399 Hernandez-Molina, G...11, 1654, 2533 Hernández-Rodríguez,...40 Hernández-Rodríguez, J.. 776, 777, 880 Hernández-Sanz, A... 596, 2604 Herrem, C...1844 Herrera, F...2412 Herrera, S...1674 Herrera Van Oostdam, D...1650 Herrera-Garcia, A...992 Herreras, JM...2853 Herrero, M...1290 Herrero-Beites, AM...177 Herrick, A...728, 737, 753, 1928, 2147 Herrick, AL...747 Herrinton, L...1360 Herson, S............ 1037, 1262 Herve, R...938 Herve, R...335 Hervier, B. 1037, 1245, 1263, 1270, 1271 Heschel, B...1621 Heslinga, SC...2583 Heslop,...2438 Hesselstrand, R..... 737, 753, 761 Hetland, ML...349, 366, 409, 504, 848, 942, 1171, 1524, 1831, 1837, 1838, 2171, 2500, 2524, 2966 Heuck, C...2287 Heusch, P...1189 Heuser, R...951 Hewitt, A...778 Heyl, D...2011 Heymann, D...1042 Hickman, K...697 Hicks, A...997 Hidaka, M...82, 87 Hidaka, T...2159 Hidalgo-Calleja, C...74 Hider, S...831 Hié, M...811 Hiepe, F...1954, 2693, 2837 Hifinger, M... 1058, 1059 Higashi, R...1936 Higgins, GC... 1321, 2272 Higgs, BW...719 Higgs, JB... 895, 2883 Higuchi, T. 877, 1255, 1640, 1710, 1939 Higuchi, T...2458 Higuera, V...692 Hildebrand, B Jr....895 Hildreth, E III...1888
Hiligsmann, M...2573 Hilkens, C...1530 Hill, C... 1682, 2962 Hill, CL...778, 789, 2772 Hill, D.....................2668 Hillen, MR... 336, 2725 Hilliard, P...266 Hills, NK...2827 Hillstrom, HJ... 212, 2945 Hiltesperger, M...856 Hinchcliff, M..725, 745, 750, 1677, 1929, 2698 Hinchcliff, ME...729, 966, 3005 Hindman, H...2534 Hines, D...................1165 Hinojosa-Azaola, A...1779 Hinsch Gylvin, L...519 Hirabara, S...516, 1488, 1489 Hirai, K...2214 Hirai, Y...2389 Hiraki, LT... 1310, 1312 Hiramatsu, K...2427 Hiramoto, S...332 Hirani, S...................3010 Hirano, I...750 Hirano, Y...471, 512, 516, 1488, 1489, 2504, 2516 Hirao, K...457 Hirata, A... 146, 424 Hirata, S...2806 Hirayama, Y...1666 Hirohata, S. 87, 1696, 2652, 2762, 2763 Hirokawa, T...1958 Hiromura, K...1666 Hiron, M...1471 Hirosaki, Y... 1000, 1952 Hirose, T...508 Hirota, Y...267 Hirsh, JM...2386 Hisada, R... 2, 2638, 2864 Hisdal, J...489, 1913, 2571 Hishitani, Y...1695 Hislop, C...2836 Hissem, T...743 Hitchon, C. 394, 1387, 1998, 2289, 2410 Hitchon, CA.371, 1855, 2022, 2401, 2619 Hjeltnes, G...398 Hjuler, ST...1019 Hla, T...1647 Hmamouchi, I...101, 1058, 1059, 1373, 2029 Ho, IC.....................2917 Ho, LY...854, 2264, 2633 Ho, M...2137 Ho, MF...2957 Ho, PR...917 Ho, P...2254 Ho, RC...2657 Ho, V...1563 Hočevar, A...788, 1789, 1790 Hoagland, K...1500 Hoang, S...439 Hobeldin, I...53 Hocevar, A...514 Hochberg, M...............1142 Hochberg, M.......... 249, 2231 Hochberg, MC. 81, 243, 979, 1288, 2893 Hochfeld, M...1565 Hockings, P...1182 Hodge, M... 1614, 1616 Hodgin, J...1940 Hodgin, JB... 641, 653 Hodgson, RJ... 1007, 2773 Hodkinson, B...423 Hoeck, HC...1293 Hoek, RP...2948 Hoekstra, OS...2127 Hoenig, H...891 Hoepken, B... 545, 852 Hoerslev-Petersen, K.349, 366, 409, 1905, 2329 Hofer, M...2291 Hofer, M.. 1231, 2279, 2280, 2282 Hoff, P... 29, 1518 Hoffart, C... 1869, 2271 Hoffman, E...2216 Hoffman, GS...782, 801, 804, 808, 880, 987, 1754, 1766, 1861, 2786, 2851 Hoffman, HM...833 Hoffman, S...763 Hoffman, V...97 Hoffman*, GS...88 Hoffmann, P... 1227, 1817 Hoffmann-Vold, AM... 724, 2703 Hoffmeyer, P...2248 Hogan, SL...1781 Hogg-Johnson, S...2942 Hoglund, L...2861 Hoh, SF... 1308, 1309 Hojnik, M...1577 Hokken-Koelega, ACS...1871 Holers, VM. 446, 1904, 2019, 2182, 2891, 2921 Holgado, S... 568, 1267 Holingue, C...2446 Holinka, J...1022 Hollan, I...398 Holle, J...880 Holliday, K...303 Hollidt, J...2530 Hollins, A...1620 Holm, C...2737 Holmdahl, R... 1735, 2342 Holme, I... 489, 1913 Holmes, AM.755, 1706, 1717, 1728 Holmqvist, M... 1376, 2892 Holochwost, D...964 Holt, R... 244, 1482 Holt, RJ...418, 2415, 2813 Holt, S...295 Holzinger, D...932 Homey, B...2725 Homik, J...2912 Hong, EC...2464 Hong, F...1131 Hong, J...721 Hong, J...1166 Hong, J...342 Hong, MJ...2262 Hong, SD...1321 Hong, S.. 614, 702, 703, 812, 847, 2564 Hong, SJ... 1056, 2025 Hong, S... 619, 621 Hong, W...966 Hong, W...381 Hong, YH...221 Hood, DB....................16 Hoogeboom, T... 976, 2860 Hook, P...144 Hootman, J...67, 72 Hope, H... 2031, 2032 Hopkins, A...2520 Hoppenreijs, EPA... 293, 932 Horai, Y...429, 2159, 2389, 2651 Horcada, ML... 1670, 2622 Hordon, L... 775, 880 Hordyk, J...2257 Horie, K...329 Horikoshi, H... 496, 2128 Horita, T...2, 5, 805, 1179, 1628, 2638, 2677, 2864 Horiuchi, H...145 Horlyck, A...2287 Horn, EM...1691 Horn, HC...2131 Hornberger, L...1827 Horne, A...2281 Horne, A... 828, 1215 Horne, L... 901, 1143 Horneff, G...269, 273, 282, 284, 285, 289, 301, 834, 932, 933, 2281, 2902 Horowitz, D...13 Horslev-Petersen, K...2171 Horst, G... 1626, 1956 Horton, DB...929 Horton, R...3016 Hose, M...2001 Hoshi, D...430 Hoshino, T...2801 Hoshioka, A................2541 Hosono, Y...1260 Hosoya, T...2341 Hospach, T...282 Hossain, A...962, 1051, 1660 Hossain, MS...2726 Hota, K...332 Hotson, D...1614, 1616, 2873 Hou, Y...696 Hou, Z...665 Houard, X...1012 Hough, Y...981 Houghton, D...1236 Hourseau, M...1239 House, M...828 Houshyar, H... 1495, 1500 Houssiau, FA...958, 1609, 1623 Houvenagel, E...511 Howard, D... 1624, 2694 Howard, R...1331 Howell, K...737 Hoyer, BF...1954 Hoyos-Bachiloglu, R...306 Hrachovec, J...1995 Hrdy, MM...167 Hrycaj, P...1181 Hrycaj, P...1508 Hsia, EC...463, 479, 2495 Hsieh, CM...951 Hsu, A...2964 Hsu, B.463, 2563, 2566, 2567, 2601, 2835 Hsu, HC...1132, 1209, 2872 Hsu, V...1686 Hu, C. 548, 602, 1543, 1561, 1572, 1579, 1590 Hu, D...1748 Hu, F...1463, 2165, 2177 Hu, L...677 Hu, Y...2020 Hu, Z...1185 Hu, Z...2094 Hua, C...2385 Hua, M...2095 Hua, SY...1501 Huang, A...2310 Huang, B...288 Huang, C...2665 Huang, CC... 750, 2224 Huang, C...1976 Huang, C...2747 Huang, J... 1803, 2169 Huang, L...1953 Huang, QQ... 344, 2167 Huang, Q...2908 Huang, SY...323 Huang, WT... 187, 1691 Huang, W... 643, 2869 Huang, X... 2647, 2648 Huang, Y...315, 1896, 1898, 2285 abstract author Index 2014 Program Book 309
abstract author Index 310 Huang, Y...2956 Huber, A...1318 Huber, AM. 912, 1316, 1317, 1825 Huber, LH...1161 Hudry, C...585, 2324, 2574 Hudson, M...720, 723, 745, 1089, 2015, 2619, 3000 Hueber, AJ. 940, 1184, 1892, 2130, 2233 Hufnagl, P... 1037, 1262 Huggins, JL...83, 1302, 2320 Hughes, G...180 Hughes, GC...2186 Hughes, L...2327 Hughes, M...728 Hughes, R...2767 Hughes-Austin, JM...2019 Hugle, B... 296, 312 Hugo, C...1863 Hugunin, M...951 Hui-Yuen, J... 672, 2269 Hui-Yuen, JS...1307 Huisman, J...107 Huitema, MG...1205 Huizinga, TWJ...1515, 1521, 2468, 2485, 2486 Huizinga, TWJ...1174, 1692, 2138 Huizinga, TWJ..90, 594, 817, 1386, 1693, 1930, 2398, 2502, 2597 Huizinga, T... 1062, 2102 Huizinga, TWJ...454 Hulejova, H... 136, 1039 Hulot, J...1925 Hulscher, M...1350 Human, A...1295 Humbert, M...2701 Humbría, A...814 Humby, F... 102, 904 Hummel, A...1792 Hummers, LK... 741, 745 Humphrey, MB...1002 Humphreys, JH...2392 Humrich, JY...2837 Hunder, GG...2766 Hung, HC...323 Hunt, B...14 Hunt, KJ...2956 Hunt, L...124, 380, 449, 1740 Hunter, AG...1158 Hunter, DJ.. 210, 1280, 2235, 2241 Hunter, J... 41, 563 Hunzelmann, N.... 747, 753, 1730 Huppertz, H...285 Huppler, A...1032 Hur, JW...571 Hurley, BL...16 Hurley, MV...2327 Hurley,... 2328, 2331 Hurnakova, J... 129, 136 2014 Program Book Hurrel, A...1358 Huscher, D...1154 Husic, R...1737 Husmark, T... 589, 1549 Husni, ME...1429, 1591, 2247 Hussain, SM... 1277, 1278 Huston, J III...2766 Huston, KK...1684 Hutchings, A.. 793, 796, 909, 2772 Hutchings, E...2912 Hutchinson, D...433 Hutchinson, K...1638 Huttenlocher, A...1988 Hutton, L...3017 Huybrechts, K...1073 Huyck, S...2477, 2493, 2938 Huynh, DH...1594 Hvid, M.. 26, 366, 409, 1741, 1964 Hwang, C... 376, 2973 Hwang, IY...1817 Hwang, J.. 60, 182, 587, 598, 2464 Hwang, M...617 Hwang, YG... 404, 886 Hübbe, C...692 Hyland, D...1499 Hyphantis, T...592 Hyrich, K... 303, 467, 1837, 1838, 2031, 2032 Hyrich, KL. 271, 272, 274, 282, 295, 1542, 1848, 1909, 2294, 2924 Hyun, K...2995 Hähnlein, J...2448 Hämäläinen, M...927 Häuser, W... 892, 893 Höller, E...1737 Hørslev-Petersen, K... 1964, 2131 I Iaccarino, L...671 Iacobellis, C...1292 Iacono, D...523 Iadonato, SP...2738 Iagnocco, A...132 Iagnocco, A...908 Iannaccone, C... 1141, 2103 Iannaccone, CK..1335, 1369, 1370, 1408, 2889 Iannone, F. 504, 1701, 1837, 1838, 2228 Iannuzzi, MC...1134 Ibanez, D.685, 690, 699, 865, 1858, 1859, 2631, 2634, 2640 Ibanez Barcelo, M... 1670, 2622 Ibañez Ruán, J...1670 Ibarra, C...1924 Ibarra, MF... 1321, 2293 Ibrahim, F...839 Ibrahim, N...53 Ibrahim, S...1392 Ice, JA...2978 Ichida, H... 1264, 2991 Ichimura, Y...748, 749, 752, 756, 1724, 3003 Ichinose, K...429, 2389, 2651 Iczkovitz, S...688 Ida, H...2801 Idier, I...2481 Idler, K...1131 Idolazzi, L...908 Idrees, J...2786 Iervolino, S...138 Igel, A...1093 Igelmann, M... 2612, 2940 Iglarz, M...1706 Iglesias, G...2482 Iglesias-Gamarra, AA...959 Igoe, A...2543 Ihata, A...123 Iikuni, N...687 Iizuka, M...2352 Ijdo, JW...2189 IJpma, AS...2979 Ikari, K...223, 1061, 1123 Ikdahl, E... 489, 1913 Ikeda, K...143 Ikeuchi, H...1666 Ikic, A...1681 Iking-Konert, C...497 Ikle, D...1766 Ikuma, D...1666 Ikumi, N...355, 1688, 1906, 2340 Ilar, A...2016 İlhan, B... 419, 838 Ilikci, R...2610 Iliopoulos, A...2617 Ilizaliturri-Guerra, O...1427 Illei, G...719 Illei, GG... 529, 530 Ilowite, N...1313 Ilowite, NT... 1900, 2293 Imadome, K...2340 Imamura, M...424 Imanaka, H... 1868, 2274 Imasogie, O... 243, 249 Imbert, B... 1864, 2193 Imboden, JB...1176 Imgenberg-Kreuz, J...2980 Imran, M... 1404, 2242 Imundo, LF. 672, 1303, 1304, 1307, 1826, 2269 Imura, Y... 806, 1260 Inagaki, K...1028 Inagaki, K...31 Inanc, M.. 961, 1711, 1928, 2627, 2646 Inanc, N...119, 1423, 2769 Ince, A...370, 1375, 2378, 2413 Ince, O...1247 Inciarte-Mundo, J...134, 445, 469, 2478, 2508, 2926 Ingham, M...1149 Ingham, MP...2110 Ingleshwar, A...427, 2005, 2009, 2244 Ingolia, GM...446 Initiative, FTP...2903 Inmaculada, DR...1133 Inman, RD...600, 604, 606, 2553, 2601, 2605, 2607, 2829 Innala, L...2084 Inomata, H. 355, 1688, 1906, 2340 Inoue, A...2346 Inoue, E.. 223, 226, 430, 495, 1061 Inoue, M...859 Inoue, N...309 Inoue, Y...746 Inoue, Y...143 Insalaco, A.. 299, 321, 1225, 1228 Insua, S...2853 Investigation Group, M...2231 Investigators, C...363, 451, 2453 Investigators, P...1678 Investigators, RO...292 Investigators, R...2288 Investigators, T...363 Investigators, T...2927 Ioan-Fascinay, A...435 Ioannidis, C...1033 Ioannidis, G. 883, 1172, 1424, 2257 Ioannou, Y...274, 295, 655, 2863, 2865 Ionescu, R.1153, 1525, 1526, 1538, 1539, 2497 Ioseliani, M...2281 Irace, R...523 Irazoque-Palazuelos, F...1181 Irazoque-Palazuelos, F...1506 Irigoyen, P...2269 Irrera, N....................744 Irwin, MR... 1937, 3013 Isaacs, J...459 Isaacs, J...2924 Isaacs, JD... 1530, 2460 Isayeva, K...2296 Isenberg, D. 675, 912, 2637, 2838, 2865 Isenberg, DA..676, 961, 989, 1955, 2646, 2696 Isgro, J... 672, 2269 Ishack, S...36 Ishida, K...2473 Ishida, O...223, 226, 1061 Ishida, T...1784 Ishigaki, K...1454 Ishigatsubo, Y...125, 133, 2763 Ishiguro, N...380, 414, 471, 512, 516, 1488, 1489, 1890, 2427, 2467, 2472, 2504, 2516
Ishihara, M...1132 Ishihara, S...922 Ishii, K...1414 Ishii, S...1028 Ishii, T... 1645, 1950 Ishii, Y...2521 Ishikawa, H... 135, 414 Ishikawa, S...309 Ishimori, ML.705, 1079, 1287, 2880 Ishioka, E...1958 Ishiwata, H...1958 Ishizaki, J... 1610, 2170 Ismael, R...733 Isobe, M...805 Isojima, S...2509 Isozaki, T...1028, 1962, 2509 Issa, SF... 349, 1905 Issac, RJA..................1484 Itadani, S...267 Itert, L... 2211, 2222 Ito, H...2214 Ito, H...338 Ito, H... 146, 424 Ito, H...2152 Ito, K...1255 Ito, S... 87, 481, 1416 Ito, T...1235 Itoh, K... 496, 2128 Itou, T...1958 Ivanov, A...951 Ivanova, M...161 Ivashkiv, LB...1038 Ivers, N... 1833, 2309 Iversen, LV...2091 Iversen, MD...2008 Ivorra, J... 412, 2119 Ivorra-Cortes, J... 90, 1431 Iwai, H...2341 Iwaki, K...1255 Iwamoto, N.. 429, 967, 2389, 2651 Iwamoto, Y...1021 Iwanaga, M...2159 Iwasaki, Y...859 Iwata, M... 1688, 2340 Ix, JH...2019 Izmirly,. 534, 679, 1605, 1635, 1829 Izquierdo, E...2175 Izuhara, K...1719 Izumi, K...2479 J Jaakkimainen, RL... 1833, 2309 Jabbarzadeh-Tabrizi, S. 1000, 1952 Jachiet, M...2777 Jacklin, A...981 Jackson, BS...883 Jackson, MJ...2218 Jackson, RD... 979, 2893 Jackson, R...117, 1155, 2114 Jackson, SW...2870 Jackson, S...1114 Jacob, B.. 1065, 2380, 2424, 2426, 2814 Jacob, CO...857 Jacobs, J...1498 Jacobsen, S...961, 2091, 2646 Jacobsson, L. 436, 853, 1477, 1596, 2936 Jacobsson, LT...42, 1804, 2832 Jacobsson, LTH...1180 Jacobsson, LT...589 Jadon, DR... 546, 2830 Jadoul, M...1863 Jaeger, VK... 1524, 2699 Jaeggi, E...1827 Jafri, K...1063 Jagerschmidt, A...876 Jahan-Tigh, R...751 Jahreis, A.............. 844, 874 Jaimes-Piñón, GT...1650 Jain, R...2111, 2310, 2315 Jain, S...1940 Jain, S...1253 Jakez-Ocampo, J... 411, 694 Jakstadt, M...29 Jalil, B...2789 Jalilian, B...1964 Jallouli, M...1925 Jalota, L...2187 Jamal, S...394, 517, 2410 Jamalyaria, F...588 James, J...1182 James, J... 1605, 2430 James, JA...648, 707, 866, 985, 1002, 1604, 1922, 2688, 2841, 2880, 2978 James, K... 522, 2982 James, S...1376 Janech, M...1669 Jang, JA...946 Jang, SI... 526, 528, 529 Jani, M....................2924 Janigro, D...2764 Janikashvili, N...2849 Janot, A...1246 Janow, GL...2292 Jansen, A... 2211, 2222 Jansen, G...2093 Jansen, T.. 826, 1222, 1223, 2178, 2962 Janssen, E...314 Janssen, KMJ...441 Janssen, M...2962 Jara, LJ...710 Jara, LJ... 1984, 2671 Jaremko, J...1191 Jarjour, W...2790 Jarjour, WN. 708, 911, 1204, 1473, 1888, 2219, 2686, 2687 Jarosova, K.. 280, 851, 2371, 2422 Jaroszynska, A... 248, 2518 Jarraya, M...2142 Jarrett, S... 775, 880 Jarvis, J...2094 Jarvis, JN...780 Jasek, M...2540 Jasiek, M...2549 Jasson, M...876 Jatwani, K...1357 Jatwani, S...1357 Jaussaud, R...255, 2081, 2193 Javaid, MK...372 Jayakumar, K...2135 Jayne, D...676, 813, 1760, 1863 Jean, YH...323 Jean Baptiste, G... 1269, 2532 Jean-Baptiste, G... 2024, 2155 Jeanmaire, C...219 Jefferies, C... 1624, 2694 Jeffreys, A...977 Jeffries, MA...1002 Jego, P...1690 Jeka, S...1508 Jenei-Lanzl, Z...1959 Jeng, M...2281 Jenkins, K...2227 Jenkins, K...2290 Jenkins, M...2137 Jenkinson, CP...1133 Jennings, F...1588 Jensen, DV...1831 Jensen, MA... 1617, 2927 Jensen, MP...2333 Jensen, MD...2209 Jensen, P...2641 Jensen, S...2621 Jensenius, JC...1200, 2171, 2299 Jeon, HJ...220 Jeon, JY...1613 Jeon, MG..................2356 Jeong, H...60, 1221, 2464 Jeong, HJ...570 Jeong, H... 182, 587, 598 Jerabek, S...1043 Jerman, E...1330 Jernberg, T...1376 Jessome, M... 1172, 1424 Jeyaratnam, J...2282 Ji, RC...934 Jiang, K... 780, 2094 Jiang, L...2918 Jiang, X...2888 Jiang, Y... 1151, 2140 Jibaja-Weiss, M..427, 2005, 2009, 2244 Jibatake, A... 472, 2506 Jimenez, SA...771, 774, 1722 Jiménez Gómez, Y... 7, 1978 Jimenez Lopez-Guarch, C...731 Jiménez-Moleón, I...1240 Jiménez-Zorzo, F............2853 Jin, D...1496 Jin, HM...2679 Jin, JO...2174 Jin, X...2236 Jin, Y...2582 Jin, Z...1617 Jinzaki, M...1175 Jobling, A...2830 Joe, G...2330 Jog, N...658 Joh, K...2214 Johansen, J...2966 Johansson, A...............1071 Johansson, K...2018 Johansson, M...589 John, A... 505, 515, 518 John, ML... 580, 2583 John, MR...2803 John, S...2764, 2765, 2856 Johnson, A...2211, 2222, 2320 Johnson, D...3015 Johnson, DL...821 Johnson, D...1352 Johnson, H...1163 Johnson, J...1077 Johnson, KJ...808 Johnson, M...1723 Johnson, N... 61, 2275 Johnson, SR...2999 Johnston, D... 88, 987 Johnston, M...173 Johnston, S... 95, 1142 Johnstone, DA...1986 Jolly, M.. 353, 681, 713, 716, 717, 1673, 2310, 2989 Jonas, BL...2051 Jones, A...1227 Jones, CA...2023 Jones, C... 1445, 1932 Jones, E...1007 Jones, GT... 1382, 2811 Jones, GT... 41, 71, 563 Jones, G. 205, 208, 209, 229, 778, 926, 2236 Jones, GT...2959 Jones, H.... 855, 1558, 1893, 2577 Jones, H........ 1581, 1847, 2498 Jones, J...2198 Jones, JD...442 Jones, JT...1302 Jones, K...2272 Jones, KB...2317 abstract author Index 2014 Program Book 311
abstract author Index 312 Jones, KL...821 Jones, K...1332 Jones, N...383, 421, 745, 1601 Jones, PBB...168 Jones, SA...30 Jones, T...487 Jones, V...981 Jonsson, MV...149 Jonsson, R... 149, 532 Jonuleit, H...1750 Joo, K...2265 Joo, KB...2590 Joo, S...385, 1141, 1362, 2103 Joo, SH...166 Joo, YB...946 Joos, R...933 Joosten, L...1222, 1223, 2962 Jordan, A...1444 Jordan, J...1976 Jordan, J...81 Jordan, JM...201, 978, 979, 1088, 2045, 2046, 2235, 2893, 2941, 2945 Jordan, LA...30 Jordan, N..................2649 Jordan, R...1887 Jordana, M...1430 Jorgensen, C...276, 391, 1726 Jorgenson, B...2146 Jorquera, H...306 Joseph, GB...1024 Joseph, G... 810, 1522 Joseph, L...1771, 2015, 2791 Joseph, R...2033 Joseph, RM...1068 Joshi, AD... 551, 552, 586 Joshi-Barr, S...2339 Joshua, V...434, 993, 2797 Josse, R...2553 Jou, IM...324 Jouneau, S...1774 Joung, J...2096 Jourde-Chiche, N... 1611, 1792 Jousse-Joulin, S. 1368, 2161, 2536, 2606 Jovaisas, A.. 248, 383, 1397, 2411, 2416 Jovani, V...2853 Joven, BE...723 Joven, BE... 731, 2710 Jover, JA...482, 1139, 1431 Joyal, E...2756 Joyal, F...2210 Ju, JH... 326, 347, 484 Ju, Y...2353 Juan, M... 2176, 2179 Juanola, X.40, 596, 691, 1655, 2578, 2620 Juárez, RV.. 406, 887, 1388, 2381, 2441 2014 Program Book Juarez, V...1438 Juarranz, Y...1138 Juba, B...1514 Judge, A...794 Judo, M...649 Juengel, A... 1128, 2450 Julia, A...1129 Julia, T... 59, 2097 Juliao, H...2608 Julie, D...1481 Jullien, D...2204 Jun, JB...1056, 2025, 2158 June, R...1348 June, RR...363 Jung, B.....................750 Jung, HJ...2679 Jung, J...1613 Jung, KH...2265 Jung, LK...1303, 1304, 1826 Jung, SM... 326, 347, 484 Jung, YO... 1048, 1056 Jungmann,...1820 Junker, K... 349, 1905 Junker, P. 349, 366, 409, 541, 629, 1905, 1964, 2171 Jurado, T...2400, 2513, 2522 Jurcic, V...1789 Jurik, AG...2589 Jurriaans, E... 1172, 1424 Jussif, J...1514 Just, S...2439 Juverdeanu, R...475 Jüngel, A... 967, 2085 Jørgensen, H...1441 K Kaarela, K... 1365, 2812 Kaburaki, M. 232, 233, 1460, 2259 Kachaochana, A...2224 Kado, R...704 Kadono, T... 749, 3003 Kadono, Y... 1454, 2260 Kaegi, T... 2913, 2914 Kaeley, GS...122, 378, 2393 Kafaja, S...767, 1338, 2335, 2718 Kageyama, G... 1456, 2910 Kahan, A... 476, 740, 1687, 1768, 1926, 2559 Kahlenberg, JM...104, 653, 1151 Kahn, C...2896 Kahn, JE... 1925, 2779 Kahn, JE...809, 811, 1774, 2778 Kahr, A...1904 Kaieda, S...2801 Kaine, J...461 Kaine, J...1487 Kaipiainen-Seppanen, O...399 Kairalla, RA...2702 Kaiser, K...................2621 Kaji, H...2256 Kajiyama, H... 241, 1666 Kalabic, J. 122, 269, 270, 273, 289, 2393 Kalani, A...2257 Kalb, R...1851 Kale, M...2791 Kalia, SS...2008 Kalil, A...480 Kalinowski, M...2438 Kallankara, S...2396 Kallberg, H...2966 Kallenberg, C... 1754, 1766 Kallinich, T...2291 Kallinich, T. 1231, 2279, 2280, 2282 Kalstad, S...944 Kalthoff, L... 2612, 2940 Kaltsonoudis, E...1170 Kalunian, K...1608, 1631, 1924 Kalunian, KC...684, 961, 2646 Kaly, L...2150 Kalyoncu, U...58, 509, 1432, 2523, 2562, 2611, 2750 Kamali, S... 1711, 2627 Kamath, S...880 Kambe, N...143 Kamboh, MI... 1900, 2955 Kamboj, MK...2272 Kameda, H... 146, 424 Kamen, DL....672, 679, 961, 2646, 2880, 2956 Kamenicky,, P...257 Kaminsky, P... 255, 2866 Kamishima, T...1179 Kamiyama, R... 125, 133 Kamogawa, Y...1950 Kamp, S...866, 1605, 1921 Kan, H... 667, 2117 Kanamono, T...380 Kanayama, Y..471, 512, 516, 1488, 1489, 2504, 2516 Kanazawa, N...143 Kanazawa, T...486 Kandel, L...2234 Kane, D...1979 Kaneko, A.. 471, 516, 1488, 1489, 2516 Kaneko, H...1939 Kaneko, K...232, 233, 1460, 2259 Kaneko, S...2352 Kaneko, T...513 Kaneko, Y.. 470, 1175, 1398, 2479 Kaneshiro, K...1035 Kaneshita, S...2021 Kanezaki, K...2801 Kang, A...618 Kang, EH... 1403, 2215 Kang, JH...2679 Kang, JY... 347, 484 Kang, SW...612, 1458, 2684, 2922 Kang, YM... 342, 593 Kangas, A...399 Kannan, L...2675 Kannangara, D...2962 Kantarci, A...1402 Kantarci, F...2752 Kao, AH... 1857, 2621 Kapetanovic, MC...2394 Kaplan, MJ...77, 641, 872, 1862 Kaplanski, G...1611 Kaplonek, P...1798 Kapovic, AM...2281 Kapp, L...2313 Kapsimali, V...1462 Kapsogeorgou, EK...1047 Kapur, S... 426, 2411 Karaaslan, Y...422, 2746, 2761 Karaca, G...1119 Karaca, N...603 Karaca, T...1725 Karadag, O. 509, 1432, 2562, 2611, 2750 Karadag, YS...2761 Karademas, E...1401 Karadeniz, A...2750 Karadeniz, M...253 Karageorgas, T...2645 Karagoz, A...246 Karampetsou, M...2675 Karasawa, H...1688 Karasawa, R...780 Karasik, A...2424 Karatsourakis, TP...478 Karis, E...1224 Kariv, I...2354 Karki, C...515, 518, 1853 Karlson, EW.818, 1876, 2008, 2017, 2020, 2036, 2887, 2891 Karlsson, A...2126 Karlsson, JA...2525 Karlsson, JA... 1150, 1152 Karlsson, N...1485 Karmacharya, P...2187 Karonitsch, T...1022 Karouzakis, E.... 1967, 2448, 2785 Karp, DR... 2430, 2880 Karpouzas, GA...373 Karpus, ON...2463 Karr, R...873 Karras, A...1776, 1778, 2549 Karreman, MC...139, 1571, 1583 Karsdal, M...2209 Karsdal, MA... 629, 1293 Karsdal, MA. 222, 368, 1019, 2230, 2237 Karumanchi, SA...872
Karyekar, CS...1515, 1521, 2468, 2485, 2486 Kasama, T... 1028, 2509 Kasapcopur, O.. 1325, 2301, 2627 Kasapoglu Gunal, E...119 Kashikar-Zuck, S...259, 262, 1104, 1302 Kashner, TM...1993 Kashyap, S...2247 Kasifoglu, T... 2616, 2750 Kaso, A...2068 Kassai, Y...986, 1040, 1238, 2977 Kastbom, A...2098 Kastner, DL. 816, 1194, 1227, 1817, 1900, 2852 Kataoka, S... 1264, 2991 Katayama, M...87 Kato, H...2722 Kato, M...456 Katsahian, S...2145 Katsiari, C...1462 Katsicas, MM...2302 Katsumata, S...267 Katsumata, Y...877, 1255, 1264, 1640, 1710, 1939, 2991 Katsuyama, E...678 Katsuyama, T... 31, 678 Katz, A...2022 Katz, JD...912 Katz, JN. 55, 210, 900, 1809, 2036, 2235, 2859, 2862 Katz, PP...420, 698, 890, 1084, 1086, 2048, 2049, 2405, 2421, 2943, 2945 Katz, RS...892, 893, 896, 1096, 1097, 1099, 1100, 1101, 1102, 1106, 1107, 1112, 1662, 1881, 2055, 2058, 2059, 2060, 2073, 2074, 2075 Katz, SJ...1981 Katzavian, G...2350 Kaufman, I... 443, 700, 971 Kaufman, KM... 83, 1900 Kaufman, P...2198 Kaufmann, J...497 Kaur, A... 1380, 2390 Kaur, J...503 Kaur, M...460 Kaur, P...503 Kaur, PP...1504 Kautiainen, H...399, 1365, 2368, 2484, 2812, 2911 Kavanaugh, A..463, 464, 537, 539, 548, 550, 953, 1131, 1537, 1548, 1552, 1554, 1556, 1559, 1561, 1564, 1565, 1573, 1577, 1579, 1590, 1594, 2517, 2560, 2824 Kaverina, N...2839 Kavian, N...1718 Kawabata, H...841, 898, 2103 Kawabata, K...646 Kawabata, T...508 Kawabata, T...678 Kawabe, A...2447 Kawaguchi, H...2346 Kawaguchi, Y.805, 877, 1255, 1264, 1640, 1710, 1939, 2991 Kawahata, K...2341 Kawai, S...232, 233, 1460, 2259 Kawai, VK...1442 Kawakami, A...429, 1258, 1259, 2159, 2389, 2651, 2846 Kawamoto, M...1255, 1640, 1939 Kawana, K...2427 Kawano, M...1235 Kawano, S...1456 Kawasaki, A... 82, 85, 86, 87 Kawasaki, Y...1035 Kawashiri, SY... 429, 2651 Kawashiri, S...2389 Kawasumi, H...877, 1255, 1264, 1640, 1710, 1939, 2991 Kawazoe, M. 232, 233, 1460, 2259 Kawut, SM... 875, 2701 Kay, J... 463, 1845 Kay, S...1633 Kaygisiz, F...246 Kaymakcalan, Z...1753 Kayo, T.....................332 Kayser, C...733, 1130, 2712 Kazerooni, E...704 Kazi, S...1834 Kazim, M... 1236, 1756 Kazmi, S...530 Ke, Y... 66, 1803 Kearns, GM... 1624, 2694 Kearsley-Fleet, L... 271, 272 Keating, RM.446, 1904, 2891, 2921 Kecebas, HD...2043 Kedor, C...2552 Kee, SJ...2679 Keen, HI...152 Keen, KJ...727 Keenan, RT... 176, 1224 Kehrl, J...1817 Keir, PJ...217 Keith, MP...1604 Kekow, J... 834, 2088 Kelchtermans, H...2866 Keller, KK...1964 Kelley, GA...67 Kelley, KS...67 Kellner, H... 497, 2233 Kelly, A...732 Kelly, C...433 Kelly, J...2841 Kelly, JA...2978 Kelly, J IV...2861 Kelly, K...895 Kelly, S...1142 Kelly, S... 102, 904 Kelman, A...1845 Kelsall, J.... 383, 943, 1397, 1551, 1601, 2411, 2416, 2496 Kelsey, C... 1324, 1897 Kelsey, S...1340 Keltsev, V...933 Kemiche, F...2162 Kenar, G... 601, 2595 Kendler, D...917 Keniston, A...2386 Kenna, T...1886 Kennedy, A...2717 Kennedy, C...1932 Kennedy, C...2290 Kennedy, WP...1645 Kenneth.Haines, G...2908 Kent, J...244 Kent, JD...418, 2415, 2813 Keppeke, GD Sr....1644 Kerdel, F...1569 Keren, A...2359 Keren, R...1299 Kern, DM... 901, 1143 Kern, M...2927 Kerr, A...1167 Kerr, G...2494 Kerr, GS.348, 370, 840, 1372, 1375, 2378, 2413 Kerr, J.....................1500 Kerr, S...2442 Kersten, C...2860 Kerstens, PJSM...817, 1386, 2398, 2502 Kesavalu, L...936 Keser, G...2157 Keser, M...1584 Keshavamurthy, C...2390 Keskin, G...2746 Keskin, G... 2082, 2610 Keskin, H...2769 Keskin, Y...2760 Kessabi, S... 118, 2125 Keszei, A.70, 101, 1058, 1059, 1164, 1373, 2113 Kettle, A...1214 Keystone, E...361, 375, 379, 386, 421, 426, 943, 1523, 2139, 2373, 2410, 2426, 2814 Keystone, EC... 371, 382, 383, 394, 462, 463, 479, 488, 492, 1387, 2475, 2495, 2518, 2781, 2822 Khadka, P...2261 khaleghparast Athari, S...335 Khalidi, N...2884 Khalidi, NA.745, 801, 804, 808, 880, 883, 1861, 2851 Khalilova, I...1214 Khalique, S...2707 Khamashta, M... 1358, 1359 Khamashta, MA. 7, 676, 961, 1627, 2646 Khan, E...2748 Khan, H...926 Khan, HI...205 Khan, K... 760, 1714 Khan, M...415 Khan, MA...557 Khan, NA... 1380, 2390 Khan, N...951 Khan, O...1465 Khan, S...2022 Khan, T...53 Khandekar, P...2320 Khandelwal, S... 1990, 2207 Khanna, D...740, 745, 751, 874, 876, 1338, 1677, 1962, 2335, 2717, 2995, 2996, 2999, 3006 Khanna, S...2698 Khatter, S..................2921 Khau VAN Kien, A...1690 Khawaja, AA...1201 Khemis, A...2204 Khetan, S...2798 Khianey, R...350, 1989, 2840 Khifer, C...783 Khim, S...2870 Khodadadi, L...1954 Khoja, SS... 1091, 2326 Khouatra, C...1776, 1778, 1864 Khoury, M...2706 Khoury, V...2140 Khraishi, M.56, 517, 583, 714, 1374, 1550, 1551, 1581, 2496 Khraishi, MM...2416 Khraishi, S... 56, 714 Khubchandani, R...2320 Khurram, M...1171 Kiani, A...1652, 1669, 2635 Kibler, A...2790 Kida, D...516 Kiel, DP... 2047, 2268 Kiely, P...185, 1841, 2810 Kiener, HP...1022 Kievit, W...2966 Kikkawa, D... 1236, 1756 Kikly, K...632 Kikuchi, H...1218, 2762, 2763 Kikuchi, J...2877 Kilgallen, B...1945 Kilic, E...599 Kilic, G...599 Kilic, L...2157, 2523, 2611 Kilickap, S... 509, 1432 Kill, A... 773, 1712 Killeen, O... 317, 2904 Kiltz, U.. 58, 557, 2573, 2612, 2940 Kim, A...104, 1151, 1940 Kim, BS...1613 Kim, C... 200, 1820 Kim, D...1056, 1805, 2025 abstract author Index 2014 Program Book 313
abstract author Index 314 Kim, D...2993 Kim, GT... 2149, 2753 Kim, G...156 Kim, HY...946 Kim, HR...2690 Kim, H...315, 1896, 1898 Kim, HY... 347, 484 Kim, HW...571 Kim, HJ...1453 Kim, HA... 1241, 1613 Kim, HO... 220, 2356 Kim, H... 60, 182, 587, 598, 1221, 2464 Kim, H... 221, 2949 Kim, IJ...2690 Kim, IY... 60, 598 Kim, I... 182, 587 Kim, J...2538 Kim, JY...2922 Kim, JM... 570, 2158 Kim, J...1364 Kim, JJ...1241 Kim, J...612, 1458, 2684, 2922 Kim, J...587, 1056, 1221, 2825 Kim, J...1166 Kim, KJ... 693, 1364 Kim, K... 2918, 2954 Kim, L... 479, 933 Kim, M.....................872 Kim, M.....................221 Kim, M....................2794 Kim, N... 254, 1041 Kim, RB...386 Kim, R...997 Kim, S...1495 Kim, SH... 570, 2158 Kim, SK...1056, 2078, 2993 Kim, SC.46, 1073, 1075, 1434, 1911, 2036 Kim, SJ... 1510, 2799 Kim, SS...2922 Kim, S...314 Kim, TH... 571, 1056, 2025, 2158, 2590 Kim, TJ... 1056, 2590 Kim, TJ...557 Kim, WU...347, 693, 1364 Kim, YS...1805 Kim, YG.. 571, 614, 702, 703, 812, 847, 2564 Kim, Y...765 Kim, YS...570 Kimberly, R... 1953, 2089 Kimberly, RP...2454 Kimberly on behalf of PROFILE investigators, RP...1209 Kimmel, JN...156 Kimura, F... 496, 2128 Kimura, T...329 2014 Program Book Kimura, Y... 1218, 2762 Kimura, Y. 1313, 2292, 2293, 2294 Kimura-Hayama, E...2639 Kimyon, G. 2611, 2744, 2750, 2769 Kindsfater, K...2862 King, JK...659 Kingetsu, I...2214 Kingsbury, D...933 Kingsbury, DJ... 273, 289 Kingsley, GH...2974 Kinjo, M...................2154 Kir Karatas, O...1105 Kiraz, S...509, 1432, 2562, 2611 Kirby, F...1933 Kirby, S...2377 Kirchner, HL...1395 Kirillova, L...913, 941, 1395, 1830 Kirino, Y...123, 125, 133, 805 Kirkham, B...537, 550, 633, 953 Kirou, KA.. 872, 1118, 1607, 1924, 2087, 2840 Kirsh, S...2001 Kirwan, J...351 Kirwan, JR...2767 Kis-Toth, K...2675 Kisacik, B. 2157, 2523, 2562, 2611, 2616, 2744, 2750 Kise, T...1762 Kishimoto, D... 123, 125, 133 Kishimoto, M...1842, 2021, 2727 Kislat, A...2725 Kissin, EY...144 Kisten, Y...2126 Kita, J...2389 Kita, Y...1461 Kitagaichi, M...1746 Kitagori, K...806 Kitamura, N. 355, 1688, 1906, 2340 Kitas, G...1913 Kitas, GD... 1443, 2617 Kitt, M...2240 Kittelson, A...1282 Kivitz, A... 174, 175 Kivitz, AJ...459 Kivitz, A... 249, 602, 1487, 1543, 1572, 1844, 2240, 2469 Kivitz, AJ...243, 948, 2826 Kiyoi, T...2906 Kjeldsen, J...2209 Kjelgaard-Petersen, CF...1293 Klag, M...45 Klappenbach, J...2354 Klareskog, L...352, 358, 434, 447, 993, 2016, 2797, 2888 Klarich, K...1253 Klassen, L...1953 Klassen, LW... 1470, 2782 Klatt, S...2349 Klatzman, D...2731 Klearman, M...803 Kleerup, E...2995 Klein, K... 456, 1210 Klein, M... 129, 136 Klein-Gitelman, M...1303, 1304, 1826, 1988 Klein-Gitelman, MS...320, 1825, 2293, 2320 Kleinert, S...1064 Kleyer, A...940, 1184, 1892, 2130 Klimes, J...1159 Klinge, LG...2209 Klingenstein, K...3016 Klink, T...1193 Klopocki, A...1798 Kloppenburg, M...2141 Kloppenburg, M...1823 Klopsch, T...491 Klotsche, J... 301, 2902 Kloubert, I...701 Klukovits, A...830 Klumb, EM...2643 Kneepkens, EL... 573, 2400 Knemeyer, I...997 Knevel, R...90 Knight, A...1299 Knight, JS............. 641, 2867 Knight, R...1919 Knowles, H...38 Ko, DJ...166 Ko, HJ... 347, 484 Ko, JY...1005 Ko, K...2839 Kobak, S...1247 Kobayashi, A...430 Kobayashi, D... 481, 1416 Kobayashi, H...2653 Kobayashi, H...355, 1688, 1906 Kobayashi, S...82, 85 Kobayashi, T...1197 Kobayashi, Y...355, 1688, 1906 Kocak, A...1574 Kocer, EB...2548 Koch, AE... 937, 3006 Koch, T... 1057, 1078 Kochar, G...662 Kochi, Y... 805, 1454 Kocijan, R...1184, 2130, 2136 Kodama, S... 481, 1416 Kodera, Y...780 Koduri, G...2772 Koehm, M... 1560, 2915 Koeleman, BPC... 747, 753, 880 Koelsch, KA...985, 2542, 2543 Koenders, M...2907 Koenders, MI...1036, 1733, 1734, 1816 Koenig, A...100, 1145, 2395, 2406 Koenig, AS...1537 Koenig, CJ...2421 Koenig, M...2210 Koenig, M...1750 Koening, CL... 804, 808 Koening, CL...801, 880, 2851 Koessler, RE...2167 Koetse, W... 1945, 2834 Koga, T...429, 2389, 2651, 2846 Koh, EM. 60, 182, 587, 598, 1221, 2464 Koh, E... 1056, 2025 Koh, JH... 347, 484 Koh, M...1424 Koh, MX...1172 Koh, WP...1873 Kohan, P... 887, 2441 Kohler, MJ... 183, 2002 Kohsaka, H...329, 1645, 2341 Koide, H...2677 Koike, T...2472 Kojima, M...414 Kojima, T. 380, 414, 471, 512, 516, 1488, 1489, 2504, 2516 Kolarov, Z...161 Kolatat, K...1043 Kolfenbach, JR...446, 1904, 2921 Kollias, G...2785 Kolligs, C...2833 Kolling, C.92, 456, 1210, 1967, 2785 Kolomeyer, A...1567 Kolset, SO...398 Kolta, S...1769 Komai, T...859 Komarc, M... 129, 136 Komarla, A... 1361, 2305 Komiya, A...2457 Komori, H...486 Komuro, I...805 Kon, V...1437 Kondo, T...1497 Kondo, Y...1175 Kondo, Y... 87, 2352 Koné-Paut, I...931 Kone-Paut, I. 473, 930, 1231, 2279, 2280, 2282 Kong, W...2582 Konings, TC...2583 Konitsiotis, S...1170 Kono, H...87, 1218, 2762 Kono, M...2, 5, 456, 1179, 1628, 2638, 2677 Kononoff, A...399 Konsta, M...2617 Konstantonis, G... 1443, 2617 Konthur, Z...2530 Koo, G...872 Koopman, FA... 392, 1513 Koopman-Keemink, Y...293 Koppiker, N...581
Kordbarlag, C...2027 Koren, E....................636 Koren, Y...................2899 Korendowych, E...546 Korenstein, D...1999 Korkmaz, C...2854 Korkopoulou, P...1462 Korkosz, M... 1486, 2821 Korn, B... 1236, 1756 Korotkova, M...1211 Korrer, S... 117, 1155 Kortekaas, MC...1823 Korver, W... 1614, 1616 Koscielny, V... 667, 668 Kosek, J...2689 Koskas, F... 809, 2731 Kosloski, M...2237 Kossi, S...2599 Kostine, M... 1736, 2397 Kostis, J...160 Kotani, K...1645 Kotani, T...1784 Kotb, A...962, 1051, 1660 Kotsis, K...592 Kottaiyan, R...2534 Kottgen, A... 44, 1872 Kottyan, LC...1900 Kougkas, N...1401 Koumakis, E... 747, 1130 Koumitsu, N...1719 Koutsianas, C... 1254, 1466 Koutsilieris, M...1462 Kovats, S...2978 Kowal, K...1715 Kowal-Bielecka, O...722 Kowal-Bielecka, OM...1715 Kowalczyk, M...2699 Koyama, Y...2458 Koyanagi, T...267 Kozaci, LD...603 Kozakowski, N...650 Kozera, L...137 Koziell, A...1940 Kozlowski, J...997 Kozma, C...2110 Kozyrev, S...2673 Krabben, A...1174 Kraft, P...1219, 2958, 2960 Krag, A...2209 Kragstrup, T...26 Kragstrup, TW..............1964 Krams, T...2028 Krasnokutsky, S...176 Krasnokutsky Samuels, S.. 81, 156 Krasnokutsky-Samuels, S...1224 Krasowska, D...1715 Kratz, A...2333 Kraus, S...1184, 2130, 2136 Kraus, VB... 81, 210 Krause, A... 1154, 2414 Krause, D... 2612, 2940 Krause, M...1366 Krege, JH...2253 Kreiger, P...1899 Kreis, S... 585, 2574 Kremer, H...1681 Kremer, J...459 Kremer, JM...488, 515, 518, 1484, 1485, 1486, 1537, 2367, 2375, 2415, 2444, 2821 Kretzschmar, M...1024 Kreuter, A... 747, 753 Krieckaert, CLM...2400 Kriegel, M...1, 856 Krintel, SB...2966 Krishan, P... 1450, 3009 Krishnamurthy, A...2797 Krishnaswami, S...458, 508, 2489 Kriska, A...2895 Kristensen, KD...1867 Kristensen, LE...42, 1804, 2832 Kristensen, LE... 853, 1152 Kristy, R...948 Kritikos, L...1801 Kroegel, C...1793 Kroese, FGM...2547, 2551, 2934 Kroesen, BJ...1205 Kroft, LJM...1692 Kroft, L....................1693 Krogh, NS...1831 Krohn, KD... 2253, 2471 Kronenberg, M...2739 Kroon, F....................582 Kroop, S...................1986 Krueger, GG... 625, 1569 Krueger, JG...631 Krug, HE...268 Kruger, J...2494 Kruize, AA... 107, 2725 Kruize, AA...1871 Kruse Rasmussen, T...2729 Krüger, K...1064 Ktistaki, G...1401 Kubach, J...1750 Kubo, S...1541, 2691, 2806 Kubota, T...143, 1868, 2274 Kuchroo, VK...1748 Kucuksen, S...1119 Kudela, H...834 Kudrin, A...1166 Kueider, A...2003 Kuemmerle-Deschner, JB...1231 Kuemmerle-Deschner, J.2279, 2280, 2282 Kuemmerle-Deschner, JB...833 Kuester, RM...273 Kuettel, D...2131 Kuhn, KA...2740 Kuhn, M...2076 Kuhn, S...994 Kuijper, TM... 120, 2815 Kujime, R... 146, 424 Kulcsar, Z...2198, 2261, 2311 Kulikova, M...2805 Kullenberg, T...2283 Kumagai, S...1456 Kumanogoh, A...1695 Kumar, M...1840 Kumar, P...2268 Kumar, S...1133 Kume, K...486 Kumke, T...2475 Kumm, J...206 Kunadian, V...313 Kundurdjiev, A...161 Kundurzhiev, T...161 Kung, A...2268 Kunishita, Y... 123, 125, 133 Kunitake, Y...2801 Kuo, CF...179 Kupper, H...122, 273, 289, 1131, 2393 Kurano, T..................2148 Kurashima, Y...2346 Kurei, S...1258 Kuriakose, K...2390 Kurien, B...985 Kurien, BT... 2542, 2543 Kurisu, R...986 Kurita, T.. 2, 5, 1179, 1628, 2638, 2677 Kuriya, B.. 1065, 2410, 2426, 2814 Kurmashev, D...1888 Kuroki, A...2427 Kuroki, Y...2256 Kurosaka, D... 338, 2214 Kurosaka, M...2462 Kurosawa, H...1666 Kurowska-Stolarska, M...2451 Kurozumi, A...2447 Kurreeman, F...2102 Kurth, W...1018 Kurthen, R...497 Kurzinski, K... 1324, 1897 Kusaoi, M...87 Kushner, J...1478 Kusunoki, N. 232, 233, 1460, 2259 Kuusalo, L...2368 Kuwaba, N...486 Kuwajima, A... 1258, 1259 Kuwana, M. 746, 805, 1175, 1257, 1258, 1259, 1266, 2692 Kuwana, M...2763 Kuzin, I... 325, 934 Kvaløy, JT... 1169, 2652 Kvien, T...489 Kvien, TK...58, 101, 356, 905, 907, 944, 1164, 1274, 1373, 1383, 1440, 1822, 1913, 2035, 2524, 2561, 2571 Kvien, TK...351 Kwan, L...1097, 1662, 2073 Kwoh, CK... 2968, 2997 Kwok, K...2488 Kwok, K.. 460, 487, 493, 849, 2489 Kwok, SK... 326, 347, 484 Kwok, WY...1823 Kwon, HM...166 Kwon, SH...593 Kwon, SR...2265 Kwon, T...1508 Kyburz, D...2971 Küçükşahin, O...2523 Kühl, A...773 Kyndt, X...1864 Küseler, A...1867 Kyttaris, VC... 663, 1033 Källberg, H... 358, 2888 Kästner, P...497 L L Abbate, S...1772 La Batide Alanore, S...2324 La Cruz, L...2276 La Rocca Vieira, R...2246 Laasonen, L...399 Labalette, M...1718 Laborde, HA...2706 Laborde-Casterot, H...1759 Labrador, E...2119 Lacaille, D...384, 416, 2306, 2308 Lacaille, DV...1144 Lacalle, M...1791 Lacbawan, F...832 Lachenbruch, PA... 912, 1316 Lachmann, H................305 Lachmann, H....1231, 2279, 2280, 2282 Lackner, A...1737 LaCount, S...2272 Ladenburg, A...715 Lafaille, J...2732 Lafeber, FPJG...336 Lafeber, F...1199 Lafeber, FPJG...76 Laffan, MA...2748 Lafforgue, P... 140, 2584 Laforet, P...1262 LaFranco-Scheuch, L...649 Lafyatis, R...757, 758, 772, 1723, 1732, 1796, 2702, 2713, 2721, 3005 Lage-Hansen, PR...2770 Lages, A...1703 abstract author Index Lahdenne, P...284 2014 Program Book 315
abstract author Index 316 Lahey, LJ...348, 452, 815, 1476 Lahiri, M...2975 Lahouti H., A...1265 Lai, JS...2621 Lai, S... 247, 251 Laifenfeld, D...75 Laiguillon, MC...1012 Lakota, K... 966, 3005 Lakshman, U...1156 Laliberté, MC...499 Lallas, G...1462 Lally, L...781 Lam, MY... 525, 2929 Lamana, A...1138 Lamas, JR...1139 Lamaury, I...1269 Lamb, J...2953 Lamba, M... 508, 1478 Lambert, B...2134 Lambert, C...165 Lambert, D...2081 Lambert, M.811, 1864, 2700, 2757, 2866 Lambert, R. 855, 1191, 1893, 2577, 2613, 2985, 2986 Lambert, RG...591 Lamberth, S... 2092, 2096 Lammi, MR. 727, 1246, 1678, 1931, 2699 LaMoreaux, B...1983 Lampa, J...352 Lampropoulos, CE...478 Lan, L...2839 Lanata, L...2239, 2433, 2443 Lancioni, E...410 Land, J...1775 Landen, J... 1094, 1108 Landewé, R... 575, 2912 Landewé, R...361, 561, 574, 582, 953, 1164, 2137, 2579, 2592, 2600, 2828 Landewé, RBM. 544, 565, 566, 852, 954, 2387, 2475, 2586, 2588 Landi, M...406, 1388, 1438 Landis, JR...1781 Landolt-Marticorena, C...2787 Landry, T...264 Landsittel, DP...363, 889, 1410 Landstein, D...2350 Lane, NE.. 1024, 1276, 1801, 1820 Lanfranchi, H...525 Lanfranchi, MA...140 Lang, A... 29, 1006 Lang, D...341 Langdahl, B... 920, 2268 Lange, U...1146 Langefeld, CD...1900, 2454, 2956 Langella, P..................622 Langer, HE... 2129, 2507 Langfeld, CD...2089 2014 Program Book Langford, CA...801, 804, 808, 880, 1754, 1766, 1861, 2851 Langholff, W...1562, 1563, 1569, 1851 Langley, R...1563 Lanni, S...282 Lansdown, DA...1190 Lanyon, P...676, 711, 793, 1760 Lapa, AT. 1622, 2659, 2660, 2661, 2662, 2663, 2705 Lapadula, G...1701, 2228, 2399 Lapane, K...1090 Lapey, A....................236 Lappan, C...103 Lara, ME...2706 Lara, P...1311 Larche, M...2912 Larche, M... 1172, 1424 Lard, LR...2138 Larmann, J...1478 Larroche, C...520, 521, 2199 Larroude, M...2040 Larsen, T...1168 Larsson, PT...1549 Laska, MJ...1200 Laskin, CA...1827 Laskow, B...662 Laslett, L...2236 Lattanzi, B... 299, 2281 Latus, J...777 Lau, A... 1172, 1424 Lau, AN...369, 1507, 1566, 2257 Lau, EY....................2654 Laudes, M...485 Laufer, VA...2454 Lauffenburger, JC... 2263, 2316 Launay, D. 1718, 2700, 2701, 2779 Laurant-Noel, V...2081 Laurent, F...1777 Lauridsen, UB...349 Laurie, C...525 Laustsen, JK...2729 Lauvsnes, MB... 1169, 2652 Lauwerys, BR... 1609, 1623 Lavalley, MP...1286, 1818, 1874 Laven, JS...1439 Lavery, G...389 Lavery, J...................1487 Lavi, I...1547 Lavigne, C... 255, 256, 811 Lavric, M...2988 Law, A... 44, 1872 Law, K...2882 Law, SC...950 Lawrence, A...1272 Lawrence, P...2885 Lawrence Ford, T... 370, 2413 Lawrence-Ford, T... 1375, 2378 Lawson, EF... 1828, 2903 Laxer, RM.. 315, 1321, 1992, 2318 Layh-Schmitt, G...609 Lazaro, DM...2000 Lazaro, E... 1774, 2549 Lazaro, M...2493 Lazaros, G...1254 Lazo, F...1393 Lazzaro, A...1292 Le, B... 2105, 2106 Le, T... 96, 1060 Le Bars, M. 132, 1517, 2491, 2492, 2923 Le Cao, KA...950 Le CRI, R...2204 Le Devic, P...2324 Le Goff, B...1042 Le Gouellec, N...1792 Le Goux, P...2324 Le Guenno, G... 1774, 2549 le Guern, V...520, 521, 958, 2536, 2549 LE Hoang, P...2757 Le Jeunne, C.783, 1759, 1763, 1769 Le Quellec, A...............2777 Le-Guern, V................1925 Leal, GN...1300 Leal, M...1388, 1438, 2381 Leaman, D...1031 Leanderson, T...2952 Leandro, MJ..452, 989, 995, 1955, 2696 Leatherman, S... 2373, 2781 Leavitt, F... 1102, 1107 LeBlay, P Sr....391 Leboime, A... 622, 1137 Lebrun, A...2324 Lebwohl, M... 1563, 1851 Leccese, E...997 Leccese, P... 560, 2758 Leceta, J...1138 Leclair, V...682 Leclercq, S...2115 Lecompte, T...2866 Lecomte, P... 118, 2125 Ledbetter, J...1814 Ledbetter, L...186 Lederer, DJ...1797 Ledesma, C...1388, 1438, 2381 Ledesma-Colunga, MG.. 330, 333 Lee, A...2953 Lee, AT....................2955 Lee, CH...2262 Lee, CK.. 614, 702, 703, 812, 847, 2564 Lee, CK... 221, 1056 Lee, D...910 Lee, EB... 460, 849 Lee, EB...166, 1220, 2347 Lee, EY... 571, 1220, 1241, 1453, 1508, 2215, 2347 Lee, EJ...614 Lee, EJ...614 Lee, HS...2949 Lee, HP...323 Lee, H...2078 Lee, HS... 946, 1056, 2025, 2918, 2954 Lee, JH...1220 Lee, J... 60, 182, 587, 598, 1056, 1221, 2464 Lee, JJ...1074 Lee, J... 326, 347, 484 Lee, JJ...2288 Lee, JY... 1346, 1347 Lee, J...2320 Lee, J...1056, 2025, 2690 Lee, J...2025 Lee, J...342 Lee, JH...1241 Lee, JH...1056 Lee, JW...2149 Lee, JW...2753 Lee, J. 729, 750, 1800, 2698, 2944, 2946 Lee, K...2431 Lee, KA...1576 Lee, K...1224 Lee, KH...1241 Lee, KE...155, 533, 2266 Lee, M... 569, 588 Lee, MS...2262 Lee, R...763 Lee, SH...1453 Lee, SJ... 166, 2215 Lee, SJ...1508 Lee, SH...1056 Lee, SI...220, 2262, 2356 Lee, SW...2714 Lee, SY... 2149, 2576 Lee, SY...1048 Lee, SY...326 Lee, S...60, 182, 587, 598, 1221 Lee, SG... 2149, 2753 Lee, S...2590 Lee, SS...155, 533, 1056, 2266 Lee, SY...2922 Lee, SR...2825 Lee, SK... 1457, 2714 Lee, SW...1056 Lee, SY...1048 Lee, SJ...2679 Lee, S...571 Lee, TC... 320, 2318 Lee, WS...2262 Lee, WW...1458 Lee, YH...2537 Lee, YN...314 Lee, YC....................1857 Lee, YY...334
Lee, YJ... 1403, 2215 Lee, YY... 187, 1854 Lee, YC.......... 254, 1335, 1408 Leehan, KM................2930 Leese, J...2442 Lefevre, G. 1271, 1687, 1718, 2700 Leff, L...3016 Leffler, M...2278 Lefkowitz, EJ...2454 Legangneux, E...473 Léger, JM...1245 Legmann, P...1768 Legorreta-Haquet, M...1947 Leguy-Seguin, V... 255, 256 Lehane, PB...505 Lehman, AJ...248, 365, 379, 382, 383, 421, 426, 583, 943, 956, 1397, 1550, 1551, 1601, 2411, 2416, 2496, 2518 Lehmann, A...176 Lehner, PJ...869 Lehtimäki, L...927 Leinonen, M... 2283, 2507 Leipe, J... 131, 2845 Leirisalo-Repo, M...2477 Leirisalo-Repo, M... 2368, 2484 Leiss, H... 27, 634, 650 Leluc, O...140 Lemay, C... 64, 192 Lembke, W... 1491, 1511 Lemeiter, D... 335, 2357 Lemmers, H... 1222, 1223 Lems, WF. 817, 1386, 2127, 2398, 2502, 2558 Lems, WF...1451 Len, CA... 1900, 2712 Lencina, V... 887, 2441 Lendl, U...2414 Lenert, A...1243 Leng, J... 494, 1540 Leng, L...1861 Lenhartz, H...1323 Lenna, S...1720 Lensen, KJDF...354 Lenzi, M...2855 Leo-Summers, L...2857 Leon, EP...2151 Leon, F...1529 Leon, L... 482, 1431 Leonard, D... 2673, 2681 Leonardi, C... 1562, 1851 Leonardi Bertazzi, GR...733 Leong, JY...1308, 1309, 1618 Lepore, L...299 Lepore, N...937 Lepri, FR...1225 Lequerré, T... 1517, 2923 Lequerré, T...1471 Lerner, D...1991 Lerner, V...2859 Leroux, G.. 835, 1037, 1925, 2757 Lertratanakul, A...862 LeSage, D...727 Lescarbeau, R... 75, 1619 Leské, C...1864 Lespessailles, E...548, 1561, 1564, 1590 Lessard, C...985 Lessard, CJ...2535, 2543, 2978 Lester, S...778, 789, 2034, 2962 Lesuis, N...1350 Leszczynski, P...947 Letourneau, V...956 Letourneur, F...1137 Letzkus, M...305 Leu, JH...294 Leuenberger, L... 18, 2840 Leung, A...2268 Leung, YY... 374, 1582 Leung, YT...870 LeVan, T...2456 Levarht, EWN...454 Levarht, N...441 Levartovsky, D... 443, 700, 971 Levascot, A...335 Leverson, J...858 Levesque, MC...1452 Levi, M...2295 Levin, AM...1134 Levine, AB...679 Levine, DM...525 Levine, Y...1513 Levitan, E... 842, 2388 Levitsky, A... 2126, 2515 Levrini, G...2228 Levy, DM.. 1295, 1310, 1312, 1825 Levy, RA... 2643, 2868 Levy, S...880 Levy, Y...1846 Lew, R... 1523, 2139 Lewallen, D...195, 196, 199, 1802 Lewandowski, L...1296 Lewiecki, EM...2267 Lewis, CE... 207, 1083 Lewis, C...1083 Lewis, CE...200 Lewis, CE... 212, 973, 1276, 1286, 1821, 3007 Lewis, C...197 Lewis, DM.1798, 2535, 2543, 2930, 2978 Lewis, E...704 Lewis, J...1910 Lewis, JD...929, 1546, 1839 Lewis, M...1114 Lewis, MJ...869 Lexberg, S...944 Leyland, KM...201 Leyton-Mange, A...2246 Lheritier, K... 174, 2291 Lheritier, K.. 175, 931, 2297, 2298 Lheritier, K... 159, 930 Li, A...854 Li, D... 25, 37, 2794 Li, D...2685 Li, E... 374, 1582 Li, G...1853 Li, H...459 Li, H... 1209, 2872 Li, H...2978 Li, H... 66, 1803 Li, J......................25, 37 Li, J.......................1459 Li, J............ 1132, 1209, 2872 Li, K...964 Li, L...1514 Li, LC... 2334, 2442 Li, M...696 Li, P... 2829, 2939 Li, Q...1857 Li, Q...1528 Li, QK...2538 Li, QZ...413 Li, QZL...1606 Li, R...1502 Li, R... 66, 1803 Li, S...2683 Li, S...1548, 1554, 1556, 1559 Li, S...2996 Li, S... 1953, 2782 Li, S...1597 Li, SC...1321 Li, W...2974 Li, W...193, 194, 197, 1279 Li, XQ...672 Li, X...1176, 1190, 2136 Li, X...1949 Li, X...644 Li, X...2803 Li, X...1065, 2424, 2426, 2814 Li, Y...1949 Li, Y... 1463, 2177 Li, Y... 666, 2838 Li, Y...885 Li, ZG...2747 Li, Z...150, 665, 1463, 2165, 2177 Li, Z... 772, 1723 Liaaen Jensen, JC...532 Liakouli, V...768 Liang, G...2685 Liang, H...2114 Liang, KP... 886, 1410 Liang, K... 1586, 2099 Liang, MH...1857 Liang, P... 360, 442 Lianza, AC...1300 Liao, H... 1953, 2782 Liao, J...2674 Liao, KP...841, 898, 1370, 2889 Liao, K.. 96, 385, 1141, 1434, 1911 Liao, KP...818 Liao, W...2680 Liao, Z...1185 Liarski, VM...2839 Libanati, C... 1795, 2255 Libanati, C...2267 Licheva, RN...949 Lidove, O...255, 256, 2193, 2757 Lidtke, RH... 213, 2245 Lie, BA...880 Lie, E... 356, 504, 905, 944, 1164, 1383, 1804, 2035, 2524, 2832 Lieber, SB...2153 Liebergall, M...2234 Lieberman, S...1329 Liebl, H...1024 Liedmann, A... 130, 153 Lifermann, F...1864 Lightfoot, AP...2218 Ligozio, G...954 Likhodii, S...1289 Lilleby, V...1898 Lim, DH.. 614, 702, 703, 812, 847, 2564 Lim, H...2347 Lim, MK... 612, 2684 Lim, MJ...1508 Lim, MJ...2265 Lim, N... 1754, 1862 Lim, SS.899, 961, 1334, 1811, 2117, 2624, 2626, 2646 Lim, SY...2807 Lim, SK...2268 Lim, YH...1221 Lima, G... 1301, 1824 Lima, G...411 Lima, J...2635 Limal, N...1037, 1778, 1925 Limaye, V...2953 Limburg, PC...1626 Limone, B...1142 Limpers, A...1704 Lin, A...606 Lin, CJF...2267 Lin, C... 1795, 2254 Lin, D... 394, 2410 Lin, G...1405 Lin, H...427, 2005, 2244 Lin, J...183, 2226, 2246 Lin, JH... 66, 1087 Lin, J... 1803, 2050 Lin, LL...1210 Lin, N...97 Lin, P...1919 Lin, TS...1514 abstract author Index 2014 Program Book 317
abstract author Index 318 Lin, T... 1614, 1616 Lin, YY...323 Lin, Z...1185, 2303, 2591 Linares, LF...2588 Linares, LF...596 Linares Ferrando, LF... 1249, 2853 Lind-Albrecht, G...2129 Lindblad, S...501, 510, 1596 Lindblad-Toh, K...2673 Lindegaard, HM... 349, 1905 Lindquist, JH...891 Lindquist, LA...1800 Lindqvist, E...1379 Lindqvist, E...2329 Lindqvist, U...1549 Lindsey, S... 1836, 2191 Lindsley, CB...1316 Lindsley, H...2242 Lindström, U...42 Lineker, S...1933 Ling, N...1828 Ling, X...2268 Linghu, B...885 Linglart, A...257 Link, TM... 1024, 1176 Link, TM...1820 Lintermans, LL...2733 Linton, D...1932 Linton, MF... 843, 1437 Lioger, B...2779 Liossi, C...1331 Lioté, F...1925 Lioté, F.118, 165, 1543, 1565, 2125, 2962 Liozon, E...2779 Lippe, R...2414 Lippuner, K...2268 Lipsky, PE.. 674, 1949, 1951, 2690 Lipstein, EA...2317 Lipton, JM...2281 Lisignoli, G...35 Liss, DT... 1346, 1347 Lisse, JR...2205 Listing, J.. 491, 1837, 1838, 2027, 2618 Litinsky, I...971 Little, MA...1760 Littlejohn, G...2419 Littlejohn, GO...778 Litz, B......................895 Liu, B...1968 Liu, CC...178, 254, 1434 Liu, D...2354 Liu, F... 1024, 1801 Liu, H...2320 Liu, H... 439, 1976 Liu, H...1968 Liu, J...951 2014 Program Book Liu, J...997 Liu, J...46, 1075, 2036 Liu, L...2689 Liu, M...1124 Liu, MF... 324, 2344 Liu, ML...1208 Liu, N...97 Liu, N...2453 LIU, Q...66, 1087, 1803, 2050 Liu, S...2963 Liu, SH...1090 Liu, S...2906 Liu, S...122 Liu, S...1345 Liu, W...2237 Liu, Y. 315, 1812, 1896, 1898, 2285 Liu, Y...1363 Liu, Y...979, 2045, 2893 Liu, Y...2674 Liu, Z...1204 Liu, Z...2854 Liu-Ambrose, T...2334 Liu-Bryan, R...327 Llinares-Tello, F.. 1519, 1531, 2423 LLobet, JM...1674 Llorca, J...1103 Llorca, J...2452 Llorca, J.. 1367, 1415, 1787, 1788, 2203, 2459, 2461 Llorens, V...1251 Llorente, I...2412 Llorente, L... 411, 694 Llorente Cubas*, I...2144 Lloyd, TE...1265 Lluch Mesquida, P...814 Lo, GH...216, 1281, 1818, 2895 Lo, MS...314 Lo, Y... 2654, 2658 Lo, Y...254 Lo Monaco, A...2399 Lobo, F...95 Lobosco, S...1077 Locher, M... 1491, 1511 Locht, H...2500 Locke, C...951 Locke, J... 522, 2982 Lodato, C...147 Lodi, A...935 Loeb, V...2350 Loell, IM...1211 Loeschmann, PA...2414 Loeuille, D... 219, 540 Lofek, S...783 Loft, AG... 541, 629 Logeart, I...1558 Logeart, I... 581, 584 LoGrasso, P...1484 Lohani, S...997 Lohfeld, L...2884 Lohne, F...795 Lok-Charles, C...1690 Lomakina, O...2296 Lombardi, A...2268 Lommerse, J...997 Londoño, J...2608 Longo, AV...2672 Longo, D... 1614, 1616 Lood, C...1814, 2186, 2844 Looney, RJ...684 Loos, M...3018 Lopes, JB... 50, 51, 52, 73 Lopez, H...760 Lopez, I...91 Lopez, JA... 2276, 2280 Lopez, LR...16 López, P...2445 López de Figueroa, P...1008 Lopez de Padilla, C... 914, 2213 López Lasanta, M...59 Lopez Longo, F...2622 Lopez Longo, FJ.............1256 Lopez-Barrera, F... 330, 333 López-Bote, JP...2412 Lopez-Isac, E...753 López-Lasanta, MA..... 475, 1129, 2097, 2391, 2526 López-Longo, FJ... 1670, 2459 López-López, J...2412 López-Mejías, R. 1103, 2063, 2064 López-Mejías, R. 1787, 1788, 2203, 2452, 2459, 2461 Lopez-Olivo, MA...17, 427, 970, 1676, 2005, 2009, 2013, 2244, 2420 Lopez-Pedrera, C... 7, 1978 Lopez-Robledillo, JC...2276 Lopez-Zepeda, J...1984 Lorcerie, B...2866 Loredo-Alanís, S...1420 Lorente-Betoret, ML...2423 Lorenz, HM...1560 Lorenz, HM...940 Lorenz, H... 2491, 2492 Lorenzin, M................1291 Lorenzini, L...527 Lorenzini, S...184 Loricera, J. 814, 1250, 1791, 2775, 2776 Lories, R...1917 Lortholary, O...............2779 Losina, E.. 55, 65, 210, 900, 1809, 2235, 2859, 2862 Lottenburger, T... 349, 1905 Lotz, M... 1008, 1013 Lotz, MK...1016, 1021, 1885 Louder, A...2395 Louie, GH...608 Louie, JS...631 Louie-Gao, Q..... 974, 1874, 1875 Louis-Joseph, L...2024 Lourido, L... 93, 982, 1127 Louw, I...2493 Lovell, DJ...2291 Lovell, DJ...931, 2297, 2298 Lovell, D. 273, 276, 277, 930, 933, 2318 Low, C...477 Lowin, T.. 994, 1029, 1959, 1965, 1974 Loza, E...731, 2276, 2710 Lozada, C...2896 Lozano, I...1267 Lu, B. 254, 818, 1281, 1809, 1876, 2017, 2020, 2894 Lu, CC... 494, 1540 Lu, D...1653 Lu, J...1544 Lu, J...1618 Lu, L...2632 Lu, N.171, 172, 827, 923, 974, 1875, 2969 Lu, Q...2674, 2680, 2685 Lu, R...1604, 1922, 2688 Lu, S...609 Lu, X...54 Lubberts, E. 340, 1738, 1749, 1799 Luberto, F...785 Luca, N... 61, 2275 Lucas, M...2997 Luccioli, F...908 Lucena, J...237 Luciano, N...1772, 2931, 2981 Lueking, A...357 Luggen, M...2650 Lugonja, B...2183 Luijtens, K... 464, 1409 Luime, JJ... 120, 139, 1571, 1583, 2815 Lukas, C.121, 395, 590, 1140, 2385, 2397, 2587 Lukert, B...2242 Lukina, G...2524 Lumb, S...2873 Lunardi, C...747, 753, 776, 880 Lund, L...2892 Lund, MB... 724, 2703 Lund Hetland, M... 853, 1964 Lundberg, IE. 910, 912, 1211, 2726, 2953 Lundberg, K...2183 Lunt, M...271, 467, 1909, 2033 Luo, B...1132, 1209, 2872 Luo, C.370, 1375, 2378, 2413, 2528 Luo, F...964 Luo, M...2918 Luo, R...111, 1069, 1070 Luo, X...2683 Luo, Y...821
Luong, P...2570 Luqmani, R.372, 793, 794, 796, 909, 1760, 1761 Luster, AD...1041 Lutalo, P... 676, 1237 Lutalo, K...2695 Luther, S...1045 Luttringer, O...2295 Lux, A...834 Lux, J...2339 Lv, Q...1185 Ly, B...2928 Ly, KH...256, 1782, 1864 Ly, KH...783 Lübbeke, A...2248 Lyberg, T...398 Lyddiatt, A...1933 Lyden, AK...924 Lynch, JA... 210, 1801 Lynch-Jordan, A...1104 Lyons, J...404, 886, 1410 Lyons-Weiler, J...1887 Lystad, L...782 Lythgoe, M... 655, 2863 Lyu, R...2477 Løgstrup, BB...1441 M Ma, CB...1190 Ma, C...1646 Ma, J...2449 Ma, KM...2264 Ma, MH...2974 Ma, X...1463 Ma, Y... 394, 734 Maas, F...2831 Maas, M...1960 Mabille, C...466 Macahilig, C...667 Maccari, F...2204 Maccarone, M...58 MacCarter, D... 122, 2393 Macchioni, P...785, 790, 791, 798, 908, 2417 MacDermott, EJ... 317, 2904 MacDonald, AG... 41, 563 Maceiras Pan, F...2372 Macfarlane, GJ...41, 71, 563, 975, 1382, 1880, 2071, 2811 MacFarlane, L...178 Macfarlane, T...71 Macgregor, AJ...1330 Machado, KL...73 Machado, LG... 50, 51, 52, 73 Machado, P..... 2428, 2579, 2953 Machida, T...1948 Machiyama, T...1950 Macias, W...1483 Macias, WL...488 Maciuca, R...1645 Mackey, A...439 Mackey, D... 498, 1422 Mackey, M...679 Mackie, I...2865 Mackie, S.. 775, 880, 2767, 2772, 2773 MacLaughlin, E...1352 MacMullan, P...109 Macoritto, M...1619 Macovei, L...823 Madan, R...1273 Madar-Balakinski, N...971 Madaule, S...2779 Maddess, M... 1495, 1500 Maddison, P... 961, 2646 Maddox, J...916 Mader, R...138 Madhavan, R... 247, 251, 897 Madhok, R...757 Madhoun, H...1983 Madhoun, HM...708 Madsen, OR... 377, 1188 Maecker, HT...2688 Maeda, T...2462 Maeda, Y...1914 Maehlen, MT...356 Maejima, Y...805 Maeoka, A...1028 Maers, K...1032 Maeyama, K...2906 Magalhaes Martins, F...2428 Magallares, B...1113 Magan, T...2967 Maganti, R...1357 Magder, LS...1665, 1667, 1920 Magder, LS...687, 689, 697, 1652, 2635, 2647, 2648, 2667 Magee, A...718 Magee, K...1897 Maggio, MC...299 Magliano, DJ... 1277, 1278 Magliano, M...793 Maglione, W...879, 1675, 1689 Magner, R... 515, 518 Magni-Manzoni, S... 299, 2281 Magnusson, B... 282, 284, 930 Magrey, MN... 586, 1997 Maguin-Gaté, K... 337, 2360 Magy-Bertrand, N...2866 Mahadevan, U...1409 Mahajan, M...2277 Mahajan, V...2805 Mahé, E...2204 Maher, A...779 Maher, G...1503 Maheu, E... 1275, 2324 Mahgoub, EY... 100, 2487 Mahler, EAM... 976, 2249 Mahler, M...4, 15, 446, 1629 Mahmood, Z...996 Mahmoud, TG...2008 Mahoney, JM...750 Mahowald, ML...268 Mahr, A...1778 Maiburg, B...2572 Maier, R...616 Maier-Moore, J........ 985, 2543 Maiese, B...2623 Maijer, KI... 1960, 2463 Maillard, S...1331 Maillefert, JF... 2481, 2849 Mairon, N...505 Maisonobe, T...1037, 1262, 1270, 2778 Maixner, W...979 Maíz, O... 1251, 1252 Maiz Alonso, O... 1249, 2853 Maiz-Alonso, O...1240 Majithia, V... 1391, 2570 Major, BT... 838, 1052 Major, G...490 Mak, A...2657 Makino, H... 31, 82, 85, 678 Makino, S...1784 Makita, N...1461 Makol, A...1617 Makovey, J... 1280, 2241 Makowka, A...735 Makris, A...1466 Makris, U. 104, 1151, 1342, 1936, 2857 Maksimowicz-McKinnon, K...808 Maksymowych, W...2938 Maksymowych, WP.408, 586, 2573 Maksymowych, WP. 557, 562, 565, 566, 591, 852, 1191, 1903 Maksymowych, W..359, 360, 361, 362, 405, 855, 1893, 1975, 2577, 2613, 2615, 2912, 2985, 2986 Malaise, MG... 1018, 1025 Malaise, O... 1018, 1025 Malattia, C...299 Malcarne, VL...1089, 1338, 2335 Maldonado, M...1520 Maldonado-Ficco, H...1568 Maldonado-Garza, H...739 Maldonado-Velázquez, M...933, 1984 Maldonado-Velázquez, MDR. 1311 Maletta, KI...2319 Malfait, AM...922 Malik, S...2376 Mallari Moher, A...910 Mallen, C...179, 831, 2767 Malley, K...2211 Malloy, M...2319 Malm, D...1183 Malm- Green, S...2625 Malmström, V...993, 2726, 2797, 2874 Malochet-Guinamand, S...1448 Maloney, A...2873 Maloney, KM...997 Malouf, J...2267 Malspeis, S... 2017, 2887 Maly, MR...217 Malyavantham, K... 2540, 2541 Malysheva, O...1436 Mamani, M... 1388, 2381 Mamani, M...148, 1438, 2715 Mamas, M...1909 Mammen, AL... 912, 1265 Mamtani, R... 1546, 1839 Mamyrova, G... 1317, 1318 Man, A... 2713, 2721 Manapat-Reyes, BH...461 Manchanda, T...517 Manches, O...2732 Manckoundia, P...2849 Mandal, A...1136 Mandl, KD...1313 Mandl, L...115 Mandl, LA.. 187, 198, 1691, 1854, 2970 Mandl, P...906, 1389, 2589 Manero, J... 1670, 2853 Mangano, K...2047 Manger, K...940 Mangnus, L...1379 Maniaci, B...1009 Manickam, S...1680 Manicki, P...2587 Manion, K... 656, 2742 Manka, D...439 Mann, HF...136, 851, 2371 Manning, C...1914 Manning, J...737 Mannion, ML...302 Manno, A...1461 Manocha, S...1997 Manoussakis, MN...478 Mansfield, L...2883 Mansikka, H... 951, 1030 Mansiz Kaplan, B...151 Manske, S...2146 Mansour, L...1632 Mantel,... 1376, 2892 Manthena, S...551 Mantilla, R...1285 Mantilla, RD...84 Manzano, M...2715 Manzi, S... 672, 961, 1924, 2646, 2955 Manzo, A... 988, 2403 Mapp, P...2965 abstract author Index 2014 Program Book 319
abstract author Index Mara, C...288 Maracle, CX...2802 Maradiaga-Ceceña, M...1268 Maradit Kremers, H...1852, 2628, 2642 Marangoni, RG...966 Maravic, M...234 Marcantonio, G... 1495, 1500 March, L...208, 209, 1280, 2241 Marchesoni, A.. 2383, 2512, 2514 Marchi, G...527 Marciniak, S...1529 Marcos, AI....... 887, 2042, 2441 Marcos, J.. 406, 1388, 1438, 1637, 2381, 2670 Mardekian, J...2076 Marder, G...3 Marder, RL...1994 Marenco de la Fuente, J...2622 Marenco de la Fuente, JL...1670 Marengo, F...410 Marengo, MF... 887, 2441 Margaretten, M..698, 1084, 2048, 2049 Margolis, D...1839 Margolis, P...2318 Marhadour, T... 2161, 2606 Mari, K...1368 Maria, A...1726 Maria, NI... 1799, 2979 María Blanco-Madrigal, J...1787, 1788 Mariampillai, K... 1037, 1262 Marian, V...1810 Maricic, M..................919 Marie, I...255, 811, 2757 Marie, SKN... 2220, 2225 Mariette, X... 460, 2966 Mariette, X...8, 504, 520, 521, 1368, 1385, 1837, 1838, 2163, 2536, 2549, 2757, 2928 Marijnissen, R...1734 Marin, J...1585 Marini, R. 1622, 1636, 2659, 2660, 2661, 2662 Marino, G...1639 Marino, L. 406, 1388, 1438, 2381, 2715 Marion, S...991 Marion-Thore, S...2928 Mariz, HA...733 Markham, A...534 Markham, AJ...871 Marklein, B...339 Marks, E...1936 Markt, J...2014 Markus, R...1504 Markusse, IM...817, 1386, 1692, 2398, 2502 Markusse, I...2137 Marlet, J...1634 Marmarelis, E...772 Marotta, A.359, 360, 361, 362, 405, 408, 1903, 1975, 2985 Marotte, H...2136 Maroun, MC...1248 Marques, R...2102 Marques-Neto, JF... 2705, 2720 Márquez, A.. 776, 777, 1787, 1788 Marra, C...2120 Marra, CA... 116, 2118 Marras, C...668 Marras Fernández Cid, C...2622 Marras Fernández-Cid, C...2372 Marras Fernandez-Cid, C...1670 Marren, A...1908 Marrero, B... 315, 1812 Marroquín, M...2533 Marsal, S...59, 475, 1129, 1973, 2097, 2391, 2526 Marshak-Rothstein, A. 1794, 1813 Marshall, D... 41, 563, 2438 Marshall, D...2023 Marshall, L...855, 1893, 2577 Marshall, L.1847, 2418, 2498, 2503 Marshall, T...2392 Martel-Pelletier, J...205, 218, 926, 2231, 2250 Martikainen, J...2484 Martimianakis, T...1992 Martin, A...823 Martin, DA...1646 Martin, G...460 Martin, G...760 Martin, G... 1124, 1289 Martín, J. 745, 747, 753, 765, 776, 777, 880, 1787, 1788, 2452, 2459 Martin, JE... 747, 880 Martin, KR...975 Martin, L...2849 Martin, MA...1367 Martin, RS...2836 Martin, R...2365 Martin, R... 538, 819 Martin, S...775 Martin, T...1681 Martin, U...2438 Martin Lopez, M...680 Martín-Esteve, I...412 Martin-Hervas, C...595 Martín-Mola, E...351, 595, 605, 1603, 2400, 2513, 2522 Martin-Toutain, I...1634 Martincova, R...2824 Martinez, A. 406, 1388, 1438, 2381 Martínez, A...474 Martínez, A...1290 Martínez, C...2608 Martínez, C...2480 Martinez, D...2421 Martínez, H...1290 Martinez, L...3004 Martínez, O................2482 Martínez Costa, L...1252 Martinez de la Escalera, G.330, 333 Martínez Ferrer, A...1674 Martinez Rivera, JI...1426 Martínez Taboada, V.. 1670, 2622 Martínez-Cácerez, E...1267 Martinez-Cordellat, I...2119 Martinez-Costa, L...2853 Martínez-Galla, D...1650 Martínez-Hernández, E...2079 Martínez-Lavín, M... 894, 2079 Martinez-Martinez, LA.. 894, 2079 Martinez-Martinez, MU.1649, 1650 Martinez-Mora, C...1138 Martínez-Morillo, M...568 Martínez-Taboada, V...2776 Martinez-Taboada, VM...777 Martini, A... 933, 2291 Martini, A...931, 2297, 2298 Martini, A. 273, 276, 277, 278, 282, 284, 299, 928, 930, 1900, 2281 Martini, D.. 527, 1772, 2931, 2981 Martins, F... 1837, 1838 Martire, MV...2715 Martire, V...406 Martucci, E...1292 Martyanov, V...750 Marut, W...1704 Maruyama, S...1651 Marzan, K...2291 Marzan, K...273 Marzo-Ortega, H...544, 557, 586, 2589 Mas, L... 141, 406 Masayuki, Y...2214 Masetto, A...360, 442, 2518 Masi, AT... 2038, 2039 Mason, M...418, 2415, 2813 Mason, T II... 304, 2903 Mason, TG II...1321 Masotti, A...1228 Massaad, R...2268 Massarotti, E...............1924 Massarotti, E................254 Massarotti, M...908 Masseau, A...256 Massey, J...2460 Mastaglio, C...908 Masteller, E...1493 Masters, E...1094 Masters, ET... 1882, 2076 Masuda, I...2465 Masui, Y...966 Masuoka, S.. 232, 233, 1460, 2259 Mat, C...2854 Mata, C...814 Mata, D...1093 Mata-Arnaiz, C...2775 Mateo, I...680 Mateo, ML... 568, 1267 Mateos, J...93, 982, 1003, 1126, 1127 Mateus, C...2656 Mathai, SC...1678 Mathers, D...490 Mathew, S... 1395, 1830 Mathian, A...2779 Mathiesen, P...2953 Mathieu, A... 613, 2559 Mathieu, R...314 Mathieu, S... 564, 1448 Mathsson-Alm, L...447 Matsuda, F...805 Matsudaira, R...2728 Matsue, H...143 Matsui, K...1842 Matsui, Y...2021 Matsukawa, Y...1688 Matsuki, F... 1456, 2910 Matsukura, M...805 Matsumoto, AK...1356 Matsumoto, I...87, 2346, 2352 Matsumoto, S...1175 Matsumoto, T... 1610, 2170 Matsumoto, Y...2345 Matsumura, T...805 Matsuo, S... 82, 85, 1651 Matsushima, S...2214 Matsushita, M...1907 Matsushita, T...86 Matsutani, T...2727 Matsuura, M...1868 Matsuzaki, CN...2809 Mattan, Y...2234 Mattar, M...1162 Mattat, K...2552 Matteson, EL...258, 390, 419, 428, 438, 800, 838, 885, 1052, 1055, 1253, 1366, 1405, 1742, 1852, 2116, 2495, 2628, 2642 Mattey, D...1957 Matthews, K...322 Matthys, P...316 Mattocks, K...1934 Mattoo, H...2805 Mattox, D...1961 Matucci-Cerinic, M.351, 908, 1130, 1703, 2709, 2711, 2999 Matzko, C...1395 Maughn, K...279 Maurer, B...722, 967, 2953, 2998 Maurer, K...870 Maurier, F. 1776, 1778, 1792, 2849 320 2014 Program Book
Mautalen, C...2255 Mautalen, C...2268 Mauvais, FX...1326 Maverakis, E...1915 Mavi, B...2610 Mavragani, C....1047, 2087, 2090, 2100 Mavragani, CP...478 Mavria, G...768 Mawdsley, A...2707 Maxwell, J...2969 Maya, JJ...2764 Mayan, MD... 1003, 1034 Mayes, M...747, 754, 2999 Mayes, MD... 745, 751, 765 Mayes, MD...753 Mayman, DJ...1854 Maymo, J... 59, 1129 Maynard, JW...2148 Maz, M... 784, 1404 Mazieres, B...202 Mazilu, D...1539 Mazza, LF...2867 McAdams-DeMarco, M.. 44, 1872, 2148 McAlear, C...801, 804, 880, 1861, 2851 McAlindon, TE...216, 1281, 1818, 2894, 2895 McArdle, A...2218 McBain, H...3010 McCallum, R...1357 McCarthy, B...2240 McCarthy, EM... 1624, 2694 McCarthy, GM...779, 884, 1050 McChulloch, CE...1024 McClellan, W...899 McClinton, C...1446 McClory, D...1507 McClung, M...917 McClung, MR...2268 McClung, M...916 McColl, E...1530 McColm, J...677 McConnell, R... 49, 1422 McCormick, J...655 McCormick, J...779, 884, 2800 McCormick, N... 116, 2118 McCormick, S...2964 McCracken, C...2290 McCulloch, C...1190 McCulloch, CE...1276 McCune, WJ... 679, 704 McCurdy, DK... 972, 1076 McDermott, M...968 McDonald, B...793 McDonald, C...832 McDonald, M...2442 McDougall, D...1191 McDougall, J Jr....2624 McDuffie, J...977 McElhanon, K...2219 McElhone, K... 711, 712 McElroy, B...2330 McFadden, M...1570 McGarry, T... 1044, 1195 McGeachy, MJ...404 McGettigan, B...1757 Mcgill, R...2154 McGlynn, L...757 McGonagle, D... 1007, 2773 McGowan, D...2014 McGregor, JAG...1781 McGuinness, D...757 McGwin, G... 302, 1415 McGwin, J... 679, 684 McHugh, C...525 McHugh, G...984 McHugh, N...676 McHugh, NJ... 546, 1699 McInnes, IB...537, 539, 550, 953, 954, 1486, 1548, 1554, 1556, 1559, 1577, 2451, 2821 McKeown, T...2424 McKinney, C...2962 McMahon, MA... 3, 1647 McMorrow, D...95 McNally, E... 796, 909 McNamee, K...2359 McNinch, N...2277 McPhillips-Tangum, C...2011 McQueen, FM... 828, 1215 McWilliams, L...2520 Meacock, R...712 Meadows, A...1340 Meara, A... 1983, 2641 Mease, PJ...537, 545, 548, 549, 550, 558, 561, 852, 952, 953, 954, 1183, 1528, 1545, 1552, 1553, 1557, 1561, 1564, 1565, 1577, 1579, 1590, 1594, 1853 Meaux Ruault, N...2849 Mecchella, J...113, 1354, 2311 Mech, C... 369, 1507 Mecoli, C...2851 Medeiros, PB...2809 Medema, J...2237 Mediero, A..19, 22, 23, 24, 33, 34, 36, 2355, 2792, 2947 Medina, J...596 Medina Bornachera, D...2625 Medina Montalvo, S...1683 Medina Peralta, M...372 Medina-Chinchon, M...1393 Medina-Rodriguez, FG...1508 Medrano, M...2276 Medrano-Ramírez, G.. 1268, 1984 Medsger, TA Jr....363, 736, 1887, 1897, 2997 Meednu, N...2820 Meersseman, P...203 Mehdi, A...950 Mehta, J...1329 Mehta, K... 1081, 1082 Mehta, NN...1063, 2140, 2889 Mehta, N...1987 Mehta, RI...2655 Mehta, T... 1081, 1082 Mei, H...1951 Meijs, J... 1692, 1930 Meijs, J...1693 Meiners,... 2551, 2934 Meini, A...305 Meissner, Y...491 Mekinian, A.. 12, 811, 2145, 2779 Melguizo-Madrid, E...576 Meli, L...1901 Melia, LA...1502 Melikoglu, M...2043, 2749, 2751, 2752, 2759, 2854 Melikoglu, MA...1412 Melin, J...1844 Melissa, P...236 Mellado Narciso, LM...2190 Mellemkjær, L...848, 1837, 1838 Meller, S...2725 Mellins, ED... 1900, 2292 Mello, SBVD...2212 Melo Gomes, JA...2428 Melo-Gomes, J...282 Melton, MH...49 Melzer, M... 994, 998 Mempel, TR...1041 Ménard, HA...442 Mendelsohn, AM...294, 479, 539, 933, 1548, 1554, 1556, 1559 Mendelson, A...2899 Mendes, A...2656 Mendez, I...102 Menendez, M...802 Menéndez, P...346 Menet, C...1494 Menezes, PR...51 Meng, T...2414 Meng, X............. 1501, 1502 Mengi, A...2769 Menne, HJ........... 2612, 2940 Menon, B...633 Menon, I... 2369, 2370 Menon, S...458 Menor Almagro, R... 40, 1670 Menter, A... 1562, 1569 Menz, HB...2052 Menza, L...908 Meoni, L...45 Mera, A...814 Merayo-Chalico, J...1658, 1664, 2676, 2724, 2990 Mercado Velazquez, P...1716 Mercan, R... 2548, 2761 Mercer, L... 1837, 1838 Mercer, LK...1848 Merino, R...2276 Merino-Meléndez, L...2412 Merino-Meléndez*, L...2144 Merkel, PA... 236, 780, 787, 794, 801, 804, 808, 875, 880, 1754, 1766, 1781, 1860, 1861, 1862, 2851, 2854, 2999 Merle, S...2024 Merola, J...2226 Meroni, PL... 1708, 2383 Meroni, PL...2868 Merrien, D...1864 Merrihew, K... 1345, 2311 Merrill, JT. 666, 684, 707, 715, 866, 961, 1605, 1921, 1922, 2469, 2646 Merriman, ME...2959 Merriman, TR...21, 168, 778, 1136, 1219, 2958, 2959, 2960, 2961, 2962, 2964 Mery-Bossard, L...2204 Merz, EL...1338 Mesbah, R...2549 Mescam-Mancini, L...1270 Meshefedjian, G...1866 Mesquida, M...1249, 1250, 1251, 2853 Messas, E... 809, 811 Messemaker, T...2102 Messia, V... 1225, 1228 Messina, OD...1093 Messuti, L...1639 Metcalf, B... 1280, 2241 Metcalf, R...2034 Mettler, S...2129 Metyas, S...2070 Meune, C...730, 740, 1687 Meyer, A...1037, 1271, 1707 Meyer, MK... 80, 1516 Meyer, P...423 Meyer, R... 1149, 1832 Meyerhoff, J...417 Meyuhas, R...2350 Meza-Romero, R...1751 Micalizzi, C...321 Miceli-Richard, C...520, 521, 581, 2966 Michaelson, J...651 Michalowicz, BS...453 Michalska-Jakubus, M...1715 Michaud, K.108, 110, 480, 840, 890, 1067, 1452, 2456, 2519 Michel, BA...2450 Michelsen, B...1573 Michet, CJ III..419, 800, 838, 1366, 2116 Michet, CJ... 258, 390, 428 abstract author Index Michot, JM...8 2014 Program Book 321
abstract author Index Middleton, J...1957 Midtvedt, O...724 Miese, DF... 1173, 1177 Miese, F...1189 Mieszkalski, KL...2293 Miettunen, P... 61, 2275 Miguelez, R...596 Mihai, C... 722, 823 Mihali, E...2645 Mihaylova, D...928 Mihaylova, MK...949 Mikdashi, JA...2655 Miki, K...241 Mikkelsen, JG...2737 Mikkelsen, K... 398, 944 Mikkers, H...2102 Mikuls, TR...108, 167, 250, 348, 446, 462, 480, 840, 1067, 1372, 1391, 1392, 1470, 1474, 1475, 1523, 1620, 1904, 2014, 2139, 2454, 2456, 2494, 2781, 2782, 2891, 2921 Miles, A...673 Milicescu, M...823, 1538, 2497 Millán, A...1285 Millen, C...1156 Miller, A....................372 Miller, B...2191 Miller, C...2882 Miller, FW. 912, 1316, 1317, 1318, 2211, 2216, 2222, 2953 Miller, H...2525 Miller, J...307 Miller, KL...2313 Miller, M...1940 Miller, P...1795 Miller, P...1356 Miller, RE...922 Miller, R... 1495, 1500 Miller, RJ...922 Miller, SD...2359 Miller Kroouze, R...2008 Mills, SD...1089, 1338, 2335 Milne, C...2881 Milojevic, D... 273, 2286 Miloslavsky, E...1349 Miloslavsky, EM. 1754, 1766, 2886 Milward, M...2183 Mimori, T.. 805, 806, 1258, 1259, 1260, 2467 Mims, CC...2317 Mimura, T... 39, 1666 Min, C... 2021, 2727 Min, HK... 326, 347, 484 Mina, R...2320 Mincheva-Nilsson, L...1516 Minden, K. 270, 273, 284, 285, 289, 301, 2902 Minegishi-Takase, K. 123, 125, 133 Miner, J...1940 Miner, JN... 180, 2963 Minguez, E...2853 Minoia, F...2281 Minor, L...283 Minota, S... 1435, 1765 Minten, M...1843 Mintz, DN...187 Mintz, J...895 Miozzari, H...2248 Mira, JP...743 Mirabelli, G...908 Miranda, D...2671 Miranda, P... 1486, 2821 Miranda, V... 1739, 1969 Miranda-Carus, ME...605 Miranda-Filloy, JA...1787, 1788, 2452, 2459 Miranda-Limón, J...1984 Mirault, T... 809, 811 Misaki, K...145 Misharin, A... 343, 969 Mishima, M... 1258, 1259 Mishra, A Sr....1135 Misra, D...2969 Misra, R...89, 1272, 2173 Missler-Karger, B...2507 Mistry, N...1992 Mitchell, B...979 Mitchell, BD... 81, 2893 Mitchell, N...1845 Mitenko, E...2296 Mitera, T...316 Mitjavila, F.1655, 1657, 1659, 2620 Mitoma, H........... 1000, 1952 Mitra, A...1602, 1963, 2364 Mitri, G...2121 Mitsugi, N...1414 Mitsuhiro, T...133 Mitsui, H...631 Mittal, M... 551, 552, 586 Mittleman, B......... 1614, 1616 Mitton-Fitzgerald, E...1625 Miura, Y... 1456, 2462 Miura, Y...1028 Miwa, Y... 1028, 2509 Mix, C...319 Miyabe, C...1041 Miyabe, Y...1041 Miyahara, H...414 Miyake, S... 1746, 2728 Miyamoto, T...2470 Miyamura, T...1645 Miyanokoshi, M...1255 Miyara, M...1634 Miyasaka, N...82, 85, 2427, 2472 Miyata, T...805 Miyazaki, M...756 Miyazaki, T. 986, 1040, 1238, 2977 Miyazaki, T...1610 Miyazaki, Y...1541 Mizui, M...2846 Mizuno, T...329 Mizushima, I...1235 Mizushina, K... 146, 424 Mjaavatten, MD... 1383, 2035 Mlakar, L... 759, 769 Mlcoch, T...1159 Mo, X... 1204, 1983 Moallem, E... 636, 2350 Mobley, JA...1132 Mochida, Y...1414 Moder, K...1253 Moder, KG...1617 Modesto, C...2276 Modi, A...48 Modi, M...705 Modjinou, D...1224 Moericke, R... 174, 175 Moericke, R... 118, 2125 Moeser, A...1793 Moghadam-Kia, S. 736, 1266, 1348 Mogosan, C...1153, 1525, 1526 Mogun, H...1073 Mohammad, A...813 Mohasseb, DM...2056 Mohring, S...1470 mohsen Abdul Salam, M...1632 Moilanen, E... 927, 1011 Moilanen, LJ...927 Moilanen, T...1011 Moisio, K... 214, 215 Moisio, KC...211 Mok, CC.681, 716, 854, 1673, 2264, 2633 Mok, MY... 2654, 2658 Molad, Y...388 Molano, I...2741 Molano-González, N...84 Molberg, O...724 Molberg,...777, 2703, 2953 Molcard, S...2024 Moldovan, I... 681, 716 Molenaar, THE...2398 Molina, E...1066, 2026, 2374 Molina, J... 1519, 1531 Molina Molina, M... 1421, 1674 Molineros, J... 2089, 2841 Molitor, JA........ 453, 745, 1931 Moll Tuduri, C...814 Moller, I...2231 Molloy, E...837 Molloy, ES...779, 884, 2694 Molnar, M...910 Molta, CT...667, 1641, 2117 Moltó, A.. 585, 2324, 2554, 2556, 2557, 2574 Momohara, S..223, 226, 430, 495, 1061, 1123, 2465 Momtahen, T... 1522, 2795 Monach, P...1754, 1766, 1861 Monach, PA...780, 801, 804, 808, 880, 1786, 1862, 2851 Monfort, J... 777, 2231 Mongelli, F...278 Monguzzi, A...2239, 2433, 2443 Montagna, P... 1713, 1966 Montagnier-Petrissans, C...2199 Montastruc, JL...845 Monteagudo, I...2482 Montealegre, G...2285 Montealegre Sanchez, GA...315, 1812, 1896, 1898 Montecucco, C...483, 988, 1256, 2403, 2609 Montell, E...1290 Montes, A...455 Montesinos, MC...2355 Montestruc, F...2779 Montgomery, C... 1134, 2930 Montgomery, CG.2535, 2543, 2978 Montgomery, G...2959 Monti, G...2855 Monti, S...2609 Montiel Hernandez, JL...1426 Montilla, C... 40, 2622 Montilla Morales, CA.. 1670, 2853 Montilla-Morales, CA...74 Montilla-Morales, C. 59, 596, 2604 Moon, JY...166 Moore, K...320 Moore, K...24, 33 Moore, L...1933 Moore, O...1682 Moore, RA...250 Moore, S...3010 Moore, T...2730 Moore, TL...400 Moore, T...2139 Moore, T... 737, 2147 Moore, T...1429 Moorthy, LN... 1898, 1988 Moosig, F... 776, 777, 880 Moots, R...2493 Moots, R... 1062, 1339 Mor, A...2723 Mora, C...1656 Morado, IC...777 Moraes, JCB...957, 2151, 2304 Moraes-Fontes, MF... 2409, 2656 Moragues, C... 118, 2125 Morales, K...1299 Morales, M...410 Morales, MA...2217 Morales-Nebreda, L... 969, 3005 Moramarco, A...882 322 2014 Program Book
Moran, S...1760 Morange, S...140 Morardet, L...1926 Morehouse, C...719 Moreira, E...1588 Morejon, E...668 Morel, J...121, 393, 395, 473, 520, 521, 1140, 1385, 1490, 1837, 1838, 2385, 2536, 2587 Morel, L...645 Morel, N...2779 Moreland, L... 801, 880 Moreland, LW..363, 404, 804, 808, 886, 1344, 1348, 1410, 2051, 2851 Morell-Dubois, S...2700 Morella, K...1161 Morelos, M...694 Moreno, JV...2064 Moreno, J...2063 Moreno, M...40, 595, 1240, 2578, 2622 Moreno-Martinez, D...1699 Morf, H...1436 Morgan, AW...137 Morgan, AW.. 449, 775, 880, 2924 Morgan, C...2198 Morgan, GA... 1327, 2224 Morgan, L... 1116, 1337 Morgan, M...2494 Morgan, N... 1116, 1337 Morgan, R...1962 Morgan DeWitt, EM. 259, 262, 288, 2317, 2318 Morgan-DeWitt, E...2293 Mori, S...241 Mori, S...332 Mori, S...1912 Morina, P...156 Morinelli, TA...762 Morinobu, A... 1456, 2910 Morishima, Y...2418 Morishita, K... 2288, 2903 Morita, K...859 Morita, R...986, 1040, 1238, 2977 Moriyama, T...1939 Morlock, R...105, 901, 1165 Moroncini, G...1675 Morris, AE...2867 Morris, Q...290 Morris, R... 2211, 2222 Morrison, M...618 Morsley, K...372 Mortensen, JH...2209 Moruno Cruz, H...1683 Mosca, M. 527, 1772, 2432, 2656, 2708, 2755, 2931 Moser, S... 252, 266 Moser Sivils, K...1798 Mosher, DP...2115 Moshkovich, O...683 Moshref, M...1455 Moskowitz, RW...2896 Mosley-WIlliams, A...370, 1375, 2378, 2413 Mosquera, A...1121 Mossell, J...1352 Mota-Mondragón, BA...2079 Motojima, S...472, 1698, 2506 Moturu, S...110 Moulis, G...845, 2549, 2757 Moulton, V... 2677, 2682 Mount, DB...1136, 1219, 2958 Mountian, I...2475 Mountz, JD...1132, 1209, 2872 Moura, B...2324 Moura, RA..................995 Mouterde, G... 121, 1418 Mouthon, L. 743, 783, 1326, 1690, 1759, 1763, 1767, 1769, 1774, 1776, 1778, 1782, 1792, 1864, 2199, 2549, 2701, 2777, 2778 Moutsopoulos, HM...478, 1047, 2087, 2090, 2100 Movahedi, M...824, 1068, 2033 Movasat, A... 1670, 1683 Moxness, M...1504 Moy, E...1514 Moy, L...1495 Moy, LY...2354 Mpofu, S. 536, 537, 538, 550, 819, 953, 954 Mroczek, A...902 Mrowietz, U...485 Msihid, J...2795 Mudano, A...1051 Mueller, R. 131, 2366, 2913, 2914, 2971 Mueller-Lutz, A...1173 Muellershausen, F...910 Muench, GRA...2818 Mukherjee, M...741 Mulero, J... 2578, 2604 Mulero- Mendoza, J...40 Mulgund, M...426 Mulla, MJ...872 Mullan, R...1979 Mullen, M...2200 Muller, G...811 Muller, KE...2284 Muller, R...2565 Muller, S...831 Muller-Ladner, U... 2233, 2711 Municio, C...2175 Muniz, L...863 Munk, HL... 541, 629 Munn, A...2101 Muñoz, A...474 Muñoz, S...59 Muñoz, S...2625 MuÑoz Fernandez, S... 40, 2853 Muñoz-Calleja, C...2412 Muñoz-Elías, EJ.............2738 Muñoz-Fernández, S...1252 Muñoz-Monroy, OE...2079 Munro, J...307 Munroe, M...1605 Munroe, ME.866, 1604, 1922, 2880 Muntner,... 842, 2388 Murakami, A... 1258, 1259 Murakawa, M...1461 Muramatsu, Y... 1016, 1885 Muraoka, S.. 232, 233, 1460, 2259 Murasawa, A...135, 481, 1416 Murat, S...2769 Murata, M..................646 Murata, M........... 2510, 2925 Murata, M.S., T...2418 Muratore, F...785, 790, 791, 798, 882, 2766 Muratore, M... 908, 2239 Muroga, Y...329 Murooka, TT...1041 Murosaki, T... 1435, 1765 Murota, A... 1040, 2977 Murphy, A...935 Murphy, C... 779, 884 Murphy, E...797 Murphy, J...1467 Murphy, L...72, 888, 980, 1092 Murphy, M.359, 360, 361, 362, 405, 408, 1903, 2985 Murphy, SL... 924, 2333 Murray, A... 737, 2147 Murray, M... 109, 2312 Murray, SG... 1856, 2827 Murru, V...1627 Murtaugh, M... 1677, 1694 Murtaza, A...328 Murthy, V...1357 Mus, AM... 340, 1749 Muscal, E. 104, 1151, 1825, 1988, 2273 Muschter, D...1010 Musenge, E...423 Mussano, E...2040 Mussard, J... 938, 1196 Mustafa, A...1342 Musto, A...1472 Mutebi, A...549 Muth, T... 1057, 1078 Muthana, M...2798, 2817, 2875 Mutlu, G...969 Mutti, A...2976 Myasoedova, E...419, 838, 1055 Myasoutova, L...1508 Myklebust, G... 786, 795 Müller-Ladner, U...1064 Myoung, E...2290 Mysler, E... 1486, 2821 Myung, G... 1079, 2107 Mäkinen, H... 1365, 2812 Möller, I...132 Möller, I...1290 Møller, HJ...409 Møller, JM... 1171, 1188 Møller-Bisgaard, S...1171 N N. Amaral, T... 2705, 2720 Naderi, MY...2439 Nadkarni, A... 95, 1142 Naegeli, A...683 Naga, OS... 637, 1213 Nagaev, I...1516 Nagaeva, O...1516 Nagafuchi, H...2763 Nagahira, A...1461 Nagai, T... 87, 1696 Nagakura, T.......... 1868, 2274 Nagamine, M...332 Nagamine, R...2429 Nagamoto, T...145 Nagano, S...2458 Nagaoka, S...86, 87 Nagaraja, V...2717 Nagaraju, K... 1211, 2216 Nagasawa, Y... 1688, 2340 Nagasawa, Y...1906 Nagata, M...2529 Nagatani, K... 1435, 1765 Nagaura, T...267 Nahin, R... 896, 1106 Naides, SJ...407 Nair, A... 213, 2245 Nair, N...2460 Nair, RP...625 Naka, T...2363 Nakachi, S...859 Nakagawa, I.2, 5, 1179, 1628, 2638, 2864 Nakagawa, N...............1035 Nakahashi, S... 146, 424 Nakai, A...1035 Nakajima, A...457 Nakajima, A... 430, 495 Nakajima, H...143 Nakajima, T... 805, 806 Nakamura, H................849 Nakamura, H.429, 2159, 2389, 2651 Nakamura, K...756 Nakamura, M...1176 Nakamura, M...1028 Nakamura, T...329 Nakamura, T...2268 Nakamura, Y...332 Nakamura, Y...145 abstract author Index Nakanishi, K...2154 2014 Program Book 323
abstract author Index 324 Nakanishi, T... 496, 2128 Nakano, K... 2447, 2806 Nakano, K...2159 Nakano, M...1648 Nakano, T...143 Nakaoka, Y...805 Nakashima, H...1235 Nakashima, R... 806, 1260 Nakashima, Y...429, 2389, 2651 Nakashita, T...472, 1698, 2506 Nakayamada, S...805, 1541, 2691, 2806 Nakazono, K... 481, 1416 Nakken, B...2871 Nalesso, G...2951 Nalli, C...4, 15 Nalotto, L...671 Nam, EJ... 342, 593 Nam, JL.. 124, 137, 380, 449, 1740 Namour, F...1480 Nan, B...881 Nanki, T... 1218, 2762 Nantel, F...248, 365, 379, 382, 383, 421, 426, 583, 943, 956, 1397, 1550, 1551, 1601, 2411, 2416, 2496, 2518 Nantz, EP...488 Nanus, D...389 Napalkov, P...803 Naparstek, Y... 636, 2350 Narain, S...1647 Narayan, A...2538 Narazaki, M... 31, 678 Narbonne, V...2161 Naredo, E...132 Naredo, E...2589 Narita, I...805, 1235, 1416, 1648 Narula, N...................781 Narváez, J...412, 691, 695, 776, 777, 814, 1240, 1381, 1421, 1430, 1655, 1656, 1657, 1659, 1670, 1674, 2194, 2620, 2622, 2780 Narvaez, JA... 412, 1381 Nascimento, JJD...2225 Nash, P... 493, 550 Nash, P...537, 953, 1682 Nasmyth-Miller, C...2469 Nasonov, EL...459 Nasonov, E... 933, 2524 Nasrullayeva, G...1898 Nassif, C...2281 Nataf, H...2324 Nath, A...1679 Nath, S...415, 2089, 2841 Nathan, S...836 Nativ, S...2972 Natour, J...1588 Natter, MD... 1313, 2286 Natvig, B...1274 Nava-Zavala, A...1268 2014 Program Book Navarra, S... 681, 1673 Navarra, SV...716 Navarro-Compán, V...557, 576, 595, 2387, 2578, 2579, 2586, 2588, 2589, 2596, 2598, 2604 Navarro-Millan, I...1474 Navarro-Sarabia, F... 576, 2469 Navarro-Zarza, JE...1268 Navarta, DA... 141, 2987 Navid, F...609 Nayak, P...1069, 1070, 2420 Nayak, U...2956 Nayar, S... 531, 1045 Ndosi, M...3015 Nduaka, C...460, 487, 849, 2489 Neal, R...2629 Needell, S...2490 Neel, A...811 Neeman, N...1353 Neerinckx, B...1917 Negrete-López, R... 1420, 2251 Negueroles, R...2119 Neidhart, M... 1128, 2448 Neilson, B...889 Neira, O...959 Nel, H...950 Nel, L...1237 Nelson, AE...201 Nelson, JL...320 Nelson, S...1303, 1304, 1826 Nelson, SL...1294 Nelson,...104, 1151, 2045 Nemes, D. 1525, 1526, 1538, 2497 Nemkova, D... 1322, 1323 Nennesmo, I...1211 Neogi, T.. 172, 822, 826, 827, 923, 974, 1821, 2783, 2969, 3007 Neovius, M...42, 2018, 2525 Neri, R... 1256, 2217 Neria, E...2359 Nerome, Y...2274 Nes, PG...149 Nesher Peleg, S...3012 Netea, M... 1222, 1223 Neto, D...504 Neuhaus, J...1006 Neumann, T...1793 Neuville, S... 1018, 1025 Neveu, S...2324 Neville, C...682 Nevitt, M...207, 1083, 3007 Nevitt, MC............. 200, 210, 212, 973, 1024, 1276, 1286, 1288, 1820, 1821, 2783 Newkirk, M...1476 Newkirk, M...2883 Newman, ED...941, 1395, 1830 Newman, S...3010 Newmark, R...1557 Neyaz, Z...1679 Nezamzadeh, M...1063 Nezos, A.. 1047, 2087, 2090, 2100 Ng, B...2384 Ng, E...917 Ng, J................ 1236, 1756 Ng, LWK...1310 Ng, M...1467 Ng, N...904 Ng, WF...313, 522, 2982 Ngamjanyaporn, P...686 Ngcozana, T...2699 Ngian, G...1682 Ngian, GS...1705 Nguyen, C...1993 Nguyen, L...2996 Nguyen, MHV...242 Nguyen, M...2324 Nguyen, M...607 Nguyen, TDL...2998 Nguyen, T...2734 Nguyen, T...2273 Nguyen, USDT...193, 974, 1874 Nguyen, V...639 Nguyen, Y...657 Nguyen Huu, VA...2339 Ngwiri, T...2289 Ni, J...2683 Ní Gabhann, J... 1624, 2694 Ni Mhuiri, A...2327 Nicaise-Roland, P...12 Nicassio,... 1937, 3013 Nicco, C...1718 Nicholas, A... 1470, 2917 Nicholls, D...2419 Nicolai, R... 1225, 1228 Nicolaides, A...2637 Nicolas, P...2145 Nicoli, D...882 Niedermayer, D...58 Niederreiter, B...634, 650, 2907 Nielsen, CT...2091 Nielsen, MA...366 Nielsen, S...277, 282, 2903 Nieminen, R...927 Nierkens, S...1203 Nieto, C...2175 Nieuwenhuis, WP...........1174 Nieuwland, S... 1609, 1623 Niewerth, M... 301, 2902 Niewold, TB...1617, 2880, 2927 Nigil Haroon, N.. 2553, 2829, 2939 Nigon, D... 1140, 2028 Nigro, A...2758 Nigrovic, PA...314, 1744, 1988 Nihtyanova, SI...2997 Niinisalo, H...399 Niiro, H... 1000, 1952 Nijsten, TEC...139, 1571, 1583 Niki, Y...414 Nikiphorou, E...1406, 1841, 2135, 2810 Nikpour, M...720, 723, 1705 Nikpour, M...1682 Nilo DeMagaldi, E...........1273 Nilsdotter, A...106 Nilsson, J...1477 Ninaber, MK...1692 Ninaber, MK...1693 Ninet, J... 1778, 2866 Nirmala, N...305 Nirula, A... 549, 1557 Nisar, M...1358 Nishida, K...414 Nishikawa, A...2977 Nishikomori, R...143 Nishimi, S...1028 Nishimoto, N...2467 Nishimoto, T...759 Nishimura, K...2910 Nishina, N...1175 Nishino, A...429, 2389, 2651 Nishino, I...2223 Nishio, MJ... 122, 2393 Nishioka, J...496 Nishioka, M................2214 Nishioka, Y...496 Nishiwaki, A... 355, 1906 Nissen, MJ...2565 Nistala, K... 284, 931 Nistala, K... 1314, 2900 Nitiham, J... 2841, 2955 Nititham, J...520 Nitschke, L...1943 Nitta, H...267 Nitta, K...1939 Niu, J.66, 200, 207, 212, 923, 1083, 1286, 1384, 1803, 1821 Niu, J...1949 Nived, O... 961, 2646 Nivuori, M...1701 Noble, J...2466 Noble, P...197 Nocturne, G...520, 521, 2163 Noda, K... 338, 2214 Noda, K... 1000, 1952 Noda, S...748, 749, 752, 3003 Noel, D...1726 Noel, E...256 Noel, N...8 Noergaard, M...287 Nograles, K...631 Noguchi, A...5, 1179, 1628, 2638 Noguchi, S...2223 Nojima, T...1260 Nojima, Y...1666
Nolla, JM... 691, 695, 1381, 1421, 1430, 1655, 1656, 1657, 1659, 1674, 2194, 2620, 2780 Nomura, J...1197 Nonaka, I...2223 Nonaka, Y... 1868, 2274 Noordenbos, T...850 Noort, AR... 1960, 2802 Nordberg, LB...356 Nordgren, B...1085 Nordin, A...753 Nordlund, J...2980 Nordmark, G...2980 Nordsletten, L...1274 Nordström, D...2524 Nordström, DC...1524 Norheim, KB...2980 Norli, ES... 1383, 2035 Norman, G...4, 15 Norman, GL...2866 Norman, K...735 Noroozi Farhadi, P... 2211, 2222 Norris, JM. 446, 1904, 2019, 2880, 2891, 2921 Norscini, J...410 Northrup, A... 1495, 1500 Norton, K...2738 Norton, S.. 1406, 1841, 2135, 2810 Norvang, V...944 Noss, E...2455 Notarangelo, LD...314 Notarnicola, A...2228 Noth, I...432 Novakovich, E...2756 Novofastovski, I...138 Nowak, E... 2536, 2606 Nowatzky, J...2732 Nowell, B... 498, 1422 Nowling, TK... 661, 2741 Nozaki, T...355, 1688, 1906, 2340 Nugent, K...2807 Nugnes, M...142 Nuhaily, S...53 Numeric, P... 2024, 2155 Nummenmaa, E...1011 Nunes, E...1644 Nuñez, E...2276 Nunez, K...2332 Nunez Alvarez, C...1716 Núñez-Álvarez, C... 2533, 2867 Nuñez-Cornejo Piquer, C...2119 Nuño, L.. 1256, 1603, 2400, 2513, 2522 Nunokawa, T... 1762, 1773 Nur, M...1534 Nurminen, T...543, 544, 565, 566, 852, 1553 Nurmohamed, MT... 580, 2558 Nurmohamed, MT... 354, 2093 Nurmohamed, MT. 572, 573, 2053, 2400, 2583 Nurmohamed, M... 2491, 2492 Nutz, A...1490 Nwosu, LN...2965 Nygaard, H... 1383, 2035 Nüßlein, H... 2491, 2492 Nüßlein, H...940 O O Cuiv, P...618 O Dell, J...1470, 1523, 2139 O Neill, L... 2312, 2694 O Brien, SH...1320 O brien, S...1404 O Brien, WR...28 O Connell, PG... 1624, 2694 O Connor, K...2002 O Connor, L...917 O connor, L... 858, 2839 O Dell, AA...641 O Dell, J...108, 1953, 2373 O Dell, JR... 446, 462, 1904, 2781, 2782, 2891, 2921 O Doherty, C...2520 O Donnell, JL...1214, 1757, 1758 O Donnell, M...477 O Donoghue, J...1761 O Dwyer, T...2916 O Flynn, E...2614 O Hanlon, TP...2953 O Keefe, R...197 O Keeffe, A...961 O Leary, N...737 O Mahony, A...1972, 1975, 2803 O Malley, C... 919, 2037 O Malley, T...1608, 1631, 1924 O Neil, KM...1303, 1304, 1826 O Neil, L...2401 O Neill, C...1467 O Neill, L... 779, 884 O Neill, LA... 1044, 1979 O Neill, M...109 O Neill, T...2636 O Neill, TW...1284 O Reilly, D... 624, 2101 O Rielly, DD...623 O Rourke, C...1261, 1429, 2247 O Rourke, KS...2886 O Rourke, MA...2181 O Shea, A... 251, 897 O Shea, JJ...315 Oakley, S...490 Oates, J... 661, 1669 Oba-Shinjo, SM...2220 Ober-Blöbaum, JL...340 Oberle, EJ...2229 Oberst, A...1814 Obici, L...305 Obmolova, G...2743 OBrien, T...1237 Obry, A...2923 Ocal, L... 1711, 2627 Ocheltree, C...2784 Ochi, K... 223, 226 Ochiai, M...495 Ochoa, E...747 Ochs, W...491, 940, 2233 Oda, K...267 Oddis, CV.437, 910, 912, 914, 1266 Oddone, E... 891, 977 Odegard, J...2738 Odeh, M...2150 Odhiambo, J...2630 Odoit, S...473 Odom, E... 2010, 2011 Oelke, K...844 Oen, K...290, 292, 2288 Oeser, A... 843, 1442 Oeser, AM...1437, 1630, 1902 of Their Collaborators, OB...2086 Ofer-Shiber, S...388 Ogbonnaya, A...1165 Ogdie, A.. 104, 1063, 1151, 1361, 2140, 2305 Ogimoto, A...805 Ogollah, R...1114 Ogorzaly, S...1162 Ogunbambi, O...2396 Ogura, T... 146, 424 Oguro, N...1028 Oh, BR...2347 Oh, J... 1253, 1405 Oh, K...1028 Oh-Ishi, M...780 Ohara, RA...444, 937, 1962, 3006 Ohara, Y...2021 Ohashi, S...2260 Ohata, J...1645 Ohira, H...2653 Ohira, T...1890 Ohmura, K....... 2, 5, 1179, 2638 Ohmura, K........ 805, 806, 1260 Ohno, S... 87, 123 Ohrndorf, S... 130, 153 Oikonomopoulos, I...440 Oikonomou, D...2585 Øiestad, BE...1286 Ojeda, AF...792 Oka, H...2260 Oka, S...2457 Okada, A... 429, 2389 Okada, K...2465 Okada, M. 1645, 1842, 2021, 2727 Okada, T...2472 Okada, Y...625, 2918, 2954 Okafuji, I...143 Okamoto, A....... 87, 1218, 2762 Okamoto, A..................87 Okamoto, Y.877, 1255, 1264, 1640, 1710, 1939, 2991 Okamura, K... 513, 2133 Okamura, T...859 Okawa, J...2206 Okayama, A... 92, 2159 Okazaki, T...780 Okazaki, Y...746, 1257, 2692 Oksel, F...2157 Oku, K... 2, 5, 1179, 1628, 2638, 2677, 2864 Okubo, N...1890 Okuda, A...1958 Okun, M...951 Okura, C... 513, 2133 Okura, T...1610 Okuyama, A...1497 Olaleye, A...3010 Olazagasti, J...914 Oldroyd, A...224, 230, 231, 240 Olech, E...2469 Olejarova, M...129 Olejarova, M...136 Olenginski, TP...1395, 1830, 2322 Olferiev, M...1607 Olivas Vergara, OM...680 Olive, A... 59, 1129, 1240, 1670, 2622, 2853 Olivé Marqués, A... 568, 1267 Olivecrona, H...2283 Oliveira, CS...2643 Oliveira, G...1745 Oliveira, R...51 Oliveira, RM... 50, 52, 73, 235 Oliveira, S...931 Oliveira, S...1325 Oliver, A... 2010, 2011 Oliver, M...148 Oliver, P...2083 Oliver, S... 2328, 2331 Oliver, SJ...885 Olivieri, I...557, 560, 2758 Oliviero, F...1291 Olivotto, E...1292 Ollier, WE...2953 Olsen, IC...489, 905, 1274, 1913 Olsen, NJ...413 Olsen C, I...356 Olson, JC... 2318, 2319 Olson, L...858, 1499, 2839 Olszynski, W...248, 426, 583, 956, 1601, 2411 Omata, Y...2260 Ombrello, A... 816, 1227 Ombrello, MJ... 1900, 2852 abstract author Index 2014 Program Book 325
abstract author Index 326 Omdal, R...1169, 2652, 2980 Ometto, F...2408 Omma, A...422, 2523, 2627, 2750 Omouri, M...2779 On behalf of the BSRBR,.467, 1542, 1848 Onat, AM. 2157, 2523, 2562, 2611, 2616, 2744, 2750, 2769 Onda, A...1218 Oneata, R...823 Onel, K...1303, 1304, 1826, 2293 Onen, F... 601, 1230, 1584, 2562, 2595, 2611 Ong, HL...528 Ong, JP...1445 Ong, MS... 1313, 2286 Ong, RTH...2918 Ong, VH... 1703, 1714 Ongen, G...2043 Ongenaert, M...1494 Onida, F....................879 Onishi, S... 1610, 2170 Ono, K...2260 Onuma, K...815 Oomura, K.................2864 Oon, S...2842 Oparanov, BA...949 Opava, CH...1085 Oppermann, B...1830 Opris, D...1539 Orabona, C...316 Orban, I...928 Ordas, C...40 Ordi-Ros, J...668 Ordóñez, MC...1240 Oreiro, N...93, 1126, 2602 Oreiro-Villar, N...982, 1121, 1122, 1125 Orellana, C...358 Oren, A...2359 Oren, S...388 Orfanos, P...478 Organ, JM...1794 Origasa, H... 457, 2472 Origuchi, T.. 429, 805, 2389, 2651 Orlovsky, Y...2743 Orman, M...1247 Ormseth, M... 843, 1902 Ormseth, MJ... 1437, 1630 Ormseth, S...3013 Ormseth, SR...1937 Ørnbjerg, LM...2131 Ornetti, P...2849 Oros-Ovalle, C...1650 Orozco, C...2402 Orozco, MC. 887, 2381, 2441, 2575 Orozco-Barocio, G...1268 Orr, C...109, 2312, 2800 Ort, T...2743 2014 Program Book Ortega, R...2423 Ortego, N...1252 Ortego-Centeno, N.. 753, 776, 777, 1256, 1787, 1788, 2853 Ortiz, AM...2480 Ortiz, EC...2629 Ortiz Garcia, AM...1138 Ortiz Sanjuan, F. 1791, 2775, 2776 Ortiz Sanjuan, FM...2119 Ortiz-Fernández, L... 1787, 1788 Ortiz-García, AM...2144 Ortiz-Sanjuán, F..814, 1240, 1250, 1252 Ortiz-Santamaría, V...1240 Ortiz-Villalvazo, MA...1268 Ortmann, W...2955 Ortolan, A...1291 Orwoll, E...920 Osborn, T...1617 Osorio, J... 437, 1273 Ospelt, C.. 456, 1210, 1967, 2448, 2785 Ostendorf, PDB...130, 153, 1173, 1177, 1189 Ostenfeld, T...1761 Østerås, N... 1274, 3018 Ostergaard, M...132 Ostergaard, M...366, 409, 1188, 2171, 2589 Østergaard, M... 1181, 2912 Østergaard, M...349, 1171, 1180, 1183, 1891, 1964 Østergaard, O...2091 Østgård, R...1741 Osthoff, M...1705 Osting, V...2001 Ostrovrsnik, J...1790 Ostrowski, M...1888 Ostrowski, RA...1244, 1343, 1377, 1985 Oswald, M.................2280 Ota, SI... 1000, 1952 Ota, T...2458 Ota, Y... 877, 1710 Otaki, N...332 Otani, K...2214 Otawa, S...248, 365, 379, 382, 383, 421, 426, 583, 943, 956, 1397, 1550, 1551, 1601, 2411, 2416, 2496, 2518 Oto, Y...2214 Otomo, K...2846 Otsa, K... 58, 351 Otsuka, F...31 Otsuzi, CI...1298 Otten, MH... 293, 932 Otvos, JD...1630 Otvos, J...1902 Otvos, L...966 Oufnac, B...1836 Overman, RA...1835, 2263, 2316 Owen, C...1682 Owen, T.............. 860, 2820 Oyake, N...143 Oyoo, OG...1396 Ozaki, S... 82, 85, 780 Ozanich, A... 1346, 1347 Ozawa, Y...1414 Ozbalkan, Z... 422, 2746 Ozbek, S...2157 Ozdemir, M...2704 Ozdemir, O...1120 Ozdogan, H...1231, 1232, 1233, 2043, 2279, 2280, 2282 Ozen, G...119, 1423, 2769 Ozen, S... 930, 1231, 1900, 2279, 2280, 2282 Ozeri, D...2000 Ozgocmen, S...599 Özgör*, L...1943 Ozguler, Y. 2043, 2157, 2749, 2754 Özgür, MF...2523 Ozisik, L...2610 Ozkan, O...1574 Ozmen, M...603 Ozturk, MA... 2616, 2761 Ozturk Gokbakan, D...151 Oztuzcu, S...2744 Ozyazgan, Y... 2760, 2852 P Pablos, JL.134, 346, 660, 992, 1739, 1969, 1973, 2175, 2735 Pachas, W...2083 Pachman, LM...1327, 2224, 2953 Packham, J... 1542, 1848 Padeh, S...2899 Padley, R... 951, 1030 Padula, A... 560, 2758 Padyukov, L...2953 Paek, S...2440 Paget, SA... 1989, 1991 Pagnoux, C.801, 804, 808, 880, 883, 1776, 1778, 1782, 1864, 2851 Pagovich, OE...856 Pahau, H Sr..................154 Pain, C... 1322, 1323 Paiola, L...733 Paira, S...406, 1388, 2040, 2381 Paira, SO...1438 Pakozdi, A...1661, 1663, 1671 Palacios, G...2706 Palazzi, C... 560, 2758 Paller, A...1812 Palli, D...2432 Palm,... 776, 777, 880 Palmer, S... 322, 1512 Palmisano, M...2689 Palmou, N...1250 Palmsten, K...1877 Paltiel, AD...2235 Pamfil, C...2645 Pamuk, G... 79, 1725 Pamuk, O...2157 Pamuk, ON. 79, 1725, 2523, 2562, 2611, 2719, 2769 Pamukcu, M...1574 Pan, A...1873 Pan, F...926 Pan, W...2850 Pan, X...2420 Panaviene, VV... 277, 282, 933 Panayiotidis, P...1462 Panchal, S...1358 Pandya, J...2726 Pang, D...632 Pang, ES...1467 Pangan, AL...269, 552, 561, 562, 1545, 2581 Panicker, S...2844 Panico, B...1377 Panikkath, D...2807 Panikkath, R...2807 Panopolou, A...2474 Panopoulos, S...2709 Paolazzi, G...1256, 2512, 2514 Paolino, S. 1697, 1700, 1713, 1966 Pap, T... 2231, 2951 Papachristos, A... 1445, 1932 Papageorgiou, A... 2090, 2100 Papaioannou, TG...2709 Papalardo, E...6 Papapoulos, S... 918, 2254 Papapoulos, S... 917, 2268 Papastefanakis, E...1401 Papo, T...1925 Papo, T.. 1239, 1774, 1778, 1864, 2757 Papoila, AL...675 Papon, L...395 Papp, K...1569 Pappas, C...2851 Pappas, DA...515, 2367, 2415 Pappone, N...138 Pappu, R...667 Paramarta, JE... 561, 850 Paran, D... 443, 700, 971 Paraskos, J...180 Parasu, N... 1172, 1424 Pardeo, M... 1225, 1228 Pardo, D...2540 Parida, J...................1679 Parienti, JJ...2193 Parikh, M...2246 Parimi, N...1801 Paris, A...2110 Pariser, D...1569 Parish, MC...446, 1904, 2921
Parisi, F...738 Parisi, S... 908, 1256 Park, C...1817 Park, DJ...155, 533, 2266 Park, EH... 1216, 1217 Park, EJ...1221 Park, EK... 2149, 2753 Park, HJ...2714 Park, JL...1900 Park, JW...342 Park, JK... 1220, 2347 Park, JS...2714 Park, JE...946 Park, KS...220 Park, KS...326, 347, 484, 1364 Park, NY...2993 Park, S...2779 Park, SH...326 Park, SH...2078 Park, SH...155, 347, 484, 2440 Park, W...1508, 1509, 2265, 2825 Park, YH... 1194, 1817 Park, YB... 1457, 2714 Park, YW...2679 Park, YJ... 693, 1364 Parker, B...676, 686, 1699 Parker, M..................1755 Parkes, MJ...1284 Parks, C... 2211, 2222 Parlak, S...1119 Parma, A... 2201, 2708 Parmar, D V...1135 Parmeggiani, M...882 Parmer, P...2052 Parnes, M...2273 Parodis, I...670 Parra, ER...2702 Parra-Izquierdo, V...2608 Parra-Salcedo, F...1371 Paruolo, C...2040 Parvu, M. 1153, 1525, 1526, 1538, 2497 Pascal, S...1279 Pascart, T... 163, 511 Paschke, J...2912 Pascual, V...1611 Pascual Ramos, V...1984 Pascual-Ramos, V...461 Pascual-Ramos, V... 411, 1371 Pascual-Salcedo, D...1603, 2400, 2459, 2513, 2522 Paskins, Z...831, 2336, 2898 Pasma, A...2382 Pasoto, SG...2933 Pasquale, M...2395 Pasquali, JL...2866 Passo, MH...1161, 2317, 2318 Pasta, DJ... 888, 980 Pastan, S...899 Pastor-Asurza, CA...1393 Pastore, R...9 Pastula, C...1503 Patarroyo-Pinto, P...17 Patel, A...1346 Patel, DR... 868, 939 Patel, G...2006 Patel, H...1703 Patel, J...81 Patel, M...2226 Patel, P... 1236, 1756 Patel, R...1487 Patel, R...1372 Patel, Y... 880, 2396 Paterson, JM... 1833, 2309 Paterson, M... 2829, 2939 Pathak, R...2187 Patki, A...2454 Patnaik, A...1351 Pato, E... 1252, 2853 Patrikos, D..................557 Patsopoulos, N...2466 Patsouras, M...............1980 Patterson, SL...569 Pattier, S...1681 Pattison, J...1237 Patton, E...2004 Patzer, R...899 Pau, D...2481 Pauer, L...1094, 1108, 2080 Paul, A...2318 Paul, G...2272 Pauling, J...1694 Pauling, JD...1699 Paulissen, SMJ... 1738, 1799 Paulus, H...431 Paupitz, J... 1301, 1824 Pavelka, K.. 504, 2491, 2492, 2493 Pavelka, K...129, 136, 851, 1039, 1524, 2085, 2371, 2422, 2524, 2555, 2580, 2594 Pavenski, K...1780 Pavlov, A...138 Pavuluri, P...2001 Pawar, R...640 Pawaria, S...1813 Pay, S... 2157, 2750 Payette, MP... 502, 2210 Payne, AS...2206 Payne, J...1475, 2014, 2782 Paz, Z...2153 Pazzola, G... 777, 882 Pea, L...671 Pearce, A...755 Pearce, W...862 Pearson, M...2183 Pease, CT...775, 880, 2767, 2773 Peckham, DW...2738 Pecondón Español,...2622 Pecorini, G...1971 Pectasides, D...1254 Peddi, M...1676 Peddi, P...1676 Pedersen, JK...349 Pedersen, R...2503 Pedersen, S... 2613, 2986 Pedersen, SJ...591, 1188, 2589 Pedersen, TR.......... 489, 1913 Pedersen, TK...1867 Pedoia, V... 1176, 1190 Pedro, S.. 108, 110, 480, 890, 2519 Peeters, AJ...1386 Peeva, E... 1614, 1616 Pego-Reigosa, JM...1670 Pego-Reigosa, JM...2622 Pehlivan, Y.2157, 2523, 2744, 2750 Pei, J... 375, 2469 Peichl, P... 2491, 2492 Peiró, ME...814 Peiteado, D. 595, 605, 1603, 2400, 2513, 2522, 2853 Peláez-Ballestas, I...2251 Peliçari, KDO...1622 Peliçari, KO...1636, 2662, 2663 Pellecchia, L...523 Pellegrini, C...2944 Pellegrini, V.................194 Pellerito, R...1256, 2512, 2514 Pelletier, JP.. 396, 567, 1535, 1536 Pelletier, JP...205, 218, 502, 926, 2231, 2250, 2569 Pelletier, M...816 Pellett, F...625 Peloquin, C... 172, 822 Peloso,...250 Pelzek, A...448 Pena, CE... 1637, 2670 Peña, J...2255 Penatti, AE...2383 Pendegraft, RS...2213 Pendl, JD...2320 Pène, F...743 Peng, SL...................1927 Peng, Y...2839 Peng, Y... 657, 2844 Penmetsa, S...1764 Penserga, E... 2108, 2156 Pepper, RJ...1860 Pera, MA... 1637, 2670 Perales, M...1649 Peralta Ginés, C...596 Perandones, C...2672 Perard, L...1925 Perard, L...2757 Perazzio, SF... 1644, 2745 Perdan-Pirkmajer, K...514 Perdriger, A...520, 521, 2536 Pereira, B. 1413, 1418, 1428, 1448 Pereira, D...2625 Pereira, K...2720 Pereira, PVS...2745 Pereira, RMR..52, 235, 238, 1301, 1824 Pereira, RMR.. 50, 51, 1298, 2933 Pereira, RMR...863 Pereira, RM...73 Pereira da Costa, I...733 Pereira Da-Silva, J...2428 Pereira Gonçalves, M...2656 Peres, F...2705 Peres, FA.. 1622, 1636, 2663, 2720 Perez, A...2114 Perez, MO...2304 Perez, M...1263 Perez, S...1670 Perez Alamino, R. 370, 1375, 1600, 1643, 2378, 2413 Pérez Gómez, A...1683 Perez Riveros, P...530 Perez Venegas, JJ...59 Perez-Aso, M.22, 23, 33, 1729, 2355 Pérez-Barbosa, L............2251 Pérez-Esteban, S...3008 Pérez-Lorenzo, MJ... 346, 2735 Perez-Pampin, E... 455, 814 Perez-Ruiz, F... 177, 2962 Perez-Sanchez, C... 7, 1978 Pérez-Vicente, S... 99, 1367 Pérez-Yagüe, S...660 Pericelous, C...655 Perich-Campos, RA...1393 Pericleous, C...1201, 2863, 2865 Perka, C...29 Perl, A...2722 Perlat, A...2757 Perlman, HR...343, 969, 2908 Perna, A...668 Pernis, AB... 350, 2840 Perper, S... 858, 2839 Perrella, O...2855 Perretti, M...2875 Perricone, R...1472 Perrodeau, E...1864 Perruccio, A...2437 Perruccio, AV...2942 Perry, B...763 Perry, E...433 Pers, JO...2536 Pers, YM Sr....391 Pértega-Díaz, S...1125 Perthuiset, E...585 Pertuiset, E.1782, 1864, 2162, 2574 Peruzzo, L...1291 abstract author Index 2014 Program Book 327
abstract author Index 328 Peschken, C..... 2023, 2619, 2791 Peschken, CA...961, 1855, 2022, 2401, 2646 Pestaña, M...1656 Peter, HH... 2491, 2492 Peter, WF...3018 Peterfy, C...1521 Peterfy, CG... 1183, 1528 Peters, E...3014 Peters, M...2143 Peters, MA...497 Petersen, KK...1293 Petersen, NJ...2895 Peterson, A...895 Peterson, C...782 Peterson, ER...1797 Peterson, EJ...2172, 2213, 2843, 2905 Peterson, HJ... 1344, 1348 Peterson, L...545 Petersson, I...376 Petersson, IF...2525 Petersson, IF... 364, 367 Petitpain, N...845 Petri, C...2299 Petri, M...6, 672, 687, 689, 697, 870, 961, 1619, 1652, 1665, 1667, 1669, 1920, 2089, 2539, 2635, 2646, 2647, 2648, 2667, 2668, 2791, 2834, 2836, 2955 Petricca, L...999 Pettersson, G... 88, 987 Peykova, L...1419 Pezic, A...307 Pfeiffenberger, M...1006 Pfister, T...1928 Phadke, A...2216 Pham, A...2626 Pham, H...144 Pham, M...1685 Pham, T...140, 473, 1385, 2584 Phan-Chronis, K...492 Phee, H...2908 Phibbs, C...2781 Philips, R...659 Philipson, R...1761 Phillips, K... 745, 924 Phippard, DJ...1754, 1766, 1862 Phipps-Green, A...2959 Pialat, JB...1186, 1187, 1894 Pianta, A...983 Piantoni, S...1642 Picco, P...299 Picerno, V... 184, 908 Pickrell, D...2055 Pielberg, G...2673 Pierangeli, S...6 Pierangeli, SS...2863 Pieters, BCH...1049 Pietrogrande, M...2855 2014 Program Book Piette, JC...2779 Piette, JC... 8, 835, 1925 Piga, M... 613, 908 Pigatto, E...1707 Pignac-Kobinger, J...3004 Pikazis, D...478 Pike, VC...156 Pikwer, A...358 Pikwer, M... 358, 1477 Pilkington, C... 1325, 1331 Pillai, J...1429 Pillai, NE...2918 Pillai, S...2805 Pillebout, E...1792 Pillinger, MH...156, 176, 1224 Pilström, B...2507 Pimentel-Santos, F...557 Pina, T... 1249, 2853 Pina Murcia, T...814, 1240, 1250, 1256, 1787, 1788, 1791, 2203, 2452, 2459, 2775, 2776 Pinal-Fernandez, I...1265 Pincus, T. 69, 353, 417, 1157, 2078, 2111, 2310, 2379, 2568 Pineau, CA.1771, 2619, 2664, 2665, 2666, 2884 Pineda, L...2854 Pinedo-Villanueva, R...372 Pinhata, MM...2225 Pinkhasov, J...2848 Pintilie, S...823 Pinto, D...1900 Pinto, D...2897 Pinto-Tasende, JA...2602 Pintor-Iglesias, A...1126 Pioli, P...772 Pioltelli, P...2855 Pioro, M...1162, 1996, 2001 Piotto, D...2712 Piper, J... 796, 909 Piper, M...1358 Pipitone, N...790, 791, 798, 2228 Pires Marafon, D Jr.... 1225, 2901 Pirkmajer, S...514 Pirronello, F...2845 Pisal, D...951 Pisaneschi, E...1225 Pisetsky, DS... 404, 679 Pisoni, CN...2625 Pispati, A...949 Pistorio, A... 299, 1316 Pittman, JR...2882 Pitts, KR...16 Pitzalis, C...904 Piva, SR... 1091, 2326 Piwinski, J...830 Pizem, J...1789 Pizzino, G...744 Pizzo, AS...236 Pizzorni, C. 1697, 1700, 1713, 1966 Planck, SR... 1236, 1756 Plant, D... 1884, 2924 Plantinga, L...899 Plasencia-Rodriguez, C. 605, 1603, 2400, 2513, 2522 Plass, N... 315, 1896 Plata, A...74 Platas, J...32 Platt, A...180 Platt, H...2953 Platt, RW...2664, 2665, 2666 Playford, M...2889 Plenge, RM... 1219, 2960 Pleštilová, L... 1128, 2450 Pluma-Sanjurjo, A. 475, 2391, 2526 Poddubnyy, D...558, 2592, 2593, 2618, 2983 Podlusky, S... 725, 1929 Podojil, JR...2359 Pohle, S...345 Poiley, J...948 Poireaud, T...165 Poiroux, L...476 Pokroy-Shapira, E...388 Polachek, A...443 Pollock,...742 Pollock, R...623, 625, 2099 Polokoff, MA...1972 Polomat, K... 2024, 2155 Polomat, K... 1269, 2532 Polyak, JL. 1097, 1099, 1100, 1881, 2060, 2073 Poncet, C... 2491, 2492 Ponchel, F...1007, 1020, 1740 Pongratz, G...994, 998, 1974 Pons, A...1519, 1531, 2423 Pons-Estel, B...959 Pons-Estel, B...2040 Pons-Estel, GJ...959 Pons-Estel on behalf of GENLES, B. 2089 Ponsonby, AL...307 Ponte, C... 794, 796, 909 Pontiggia, L...2861 Poole, JL...2332 Poolman, R...3018 Poon, V...2309 Pope, CA...319 Pope, E...1321 Pope, JE...371, 386, 394, 492, 673, 745, 1065, 1074, 1387, 2380, 2410, 2469, 2619, 2814, 2884, 2999 Pope, R...344 Pope, RM... 2167, 2908 Popmihajlov, Z...250 Popov, JM...407 Popoviciu, H... 1538, 2497 Porru, G.............. 613, 2559 Portal-Nuñez, S...............32 Portela Hernandez, M...1984 Porter, B... 536, 538, 819 Porter, JC...1201 Porto, LC...2643 Possemato, N...2417 Postal, M. 1622, 1636, 2659, 2660, 2661, 2662, 2663 Potarca, A...1863 Potvin, J...................1026 Pouchot, J...202 Poudel, D...2187 Poulin-Costello, M... 386, 492 Poulsen, K...1156 Poulton, CJ...1781 Pounds, J Jr....1465 Pouplin, S...1413 Pourrat, J...1925 Powell, M...2668 Powers, T...1349 Poyraz, C...2760 Pozzi, MR...2768 Pozzuoli, A...1292 Prabhakaran, S...921 Prabu, A...676 Pradel, V... 140, 2584 Prado, M...1644 Pradsgaard, D...2287 Praestgaard, A...875 Prafioriti, A...531 Prahalad, S. 319, 1900, 2290, 2293 Praino, E...1701 Prajzlerová, K... 1039, 2085 Praprotnik, S...514 Prasad, N..................2603 Prasad, P... 211, 215 Prasad, P...2164 Prati, C................. 43, 559 Pratsidou-Gertsi, P...298 Pratt, AG...2460 Pratt, G...2013 Pratt, J... 2317, 2318 Predeteanu, D...1539 Pregnolato, F...2383 Preijers, F...2178 Preis, E...735 Prencipe, G. 311, 1225, 1228, 1901 Presby, M...608 Prescott, K.................1342 Presnell, S...1611 Price, D... 247, 251, 897 Price, LL... 216, 1116, 1281, 1336, 1337, 1818, 2065, 2337, 2338, 2858 Pricop, L...537, 550, 953, 954 Pridgen, W...1878 Prieto-Alhambra, D...372 Prihar, B...2001 Primdahl, J...2131
Prince, F...293 Prince Nelson, S...762 Prior, D...720 Prior, Y...981 Priori, R...2544 Pritchard, C...921 Prokopec, S...2787 Proost, P...316 Protogerou, AD...2709 Protogerou, AD... 1443, 2617 Proudman, S.720, 723, 1682, 1705, 2034, 2520, 2999 Provan, S...1440 Provan, SA... 2561, 2571 Prowse, P...2438 Pruhs, ZM...840 Pruijn, GJ...443 Przebinda, A...1922 Przepiera-Bedzak, H...1598 Psaradellis, E... 248, 1550 Psarelli, E...1062 Puar, R...1855 Puchner, A.27, 634, 650, 2358, 2907 Puéchal, X.. 520, 521, 1759, 1763, 1767, 1768, 1769, 1776, 1777, 1778, 1782, 1864, 2536, 2779 Pugliese, DM... 1395, 1830 Pugnet, G...845, 1768, 1778 Puig Sanz, L.539, 1548, 1554, 1556, 1559 Puig-Kröger, A... 605, 2175 Pullman-Mooar, SW...2140 Punaro, MG...1316, 1321, 1898, 2293 Punzi, L... 671, 1291, 1292, 1707, 2408 Puolakka, K... 2368, 2484 Purcaru, O... 1552, 2560 Purdue, E... 24, 1043 Puri, S... 1081, 1082 Pushparajah, DS...1359 Put, K...316 Put, S...316 Putrik, P.70, 101, 1058, 1059, 1164, 1373, 2113 Putt, ME...929 Putta, S...2873 Putterman, C. 640, 651, 664, 1608, 1631, 1924, 1941, 2180, 2649 Puvenna, V...2764 Puyraveau, M...556 Puzas, E...25 Puzenat, E...1690 Py, G...141 Pyatak, E...2325 Pyne, D...1661, 1663, 1671 Pyo, T...1509 Pyrkotsch, P...737 Pörings, AS...1965 Pødenphant, J...............349 Q Qaiyum, Z...604 Qazi, S...1248 Qi, J... 2303, 2591 Qi, M...1938 Qin, J...2738 Qin, Y...2114 Qizilbash, N...102 Qu, B... 1202, 1615 Qu, H... 1668, 1672 Qu, K...772 Quach, D... 524, 2446 Quach, HL...524, 2446, 2466 Quach, L...462 Qualls, C...2789 Quan, A...2001 Quang, C...2542 Quarta, E...2239 Quarta, L...2239 Quartarone, G...2243 Quartey, G...505 Quartier, P...2291 Quartier, P... 2297, 2298 Quartier, P.270, 273, 282, 284, 289, 316, 473, 1326 Quartuccio, L...1256, 2544, 2855 Queiro, R...59 Quemeneur, T... 1776, 1778 Querci, F... 2432, 2656 Quesada, A...74 Quevedo, V... 1670, 2622 Quilès, N...2204 Quinet, R...1465 Quinn, EK... 973, 2783 Quinn, S...2034 Quiñones, J...1393 Quinones, M.370, 1375, 2378, 2413 Quintana, R... 1388, 2381 Quintana, R...1438 Quintanar, M...1664 Quintanilla, MA...829 Quinteros, A...1388, 1438, 2040, 2381 Quinzanos, I... 2386, 2570 Quipourt, V...2849 Quirke, AM...433 Quismorio, A...2070 Quismorio, FP Jr....2629 R R Bernatsky, S... 961, 2646 Raaschou, P... 846, 1838 Raastad, J...186 Raber, S...459 Rabin, B...363 Rabinovich, CE... 273, 1321 Rabot, S...638 Raboud, J...2553 Rabusa, C... 720, 723 Racaza, G... 1287, 2108 Radbruch, A...2837 Radbruch, AH...1954 Rademacher, J...1712 Radfar, L. 1798, 2535, 2543, 2930, 2978 Radner, H... 1842, 2029 Radominski, SC...2469 Radominski, S...1508 Radstake, TRDJ. 336, 747, 753, 757, 1704, 2725 Radstake, T...1203, 1720, 2178, 2953, 2962 Radtke, D...677 Radvanski, DC...160 Raes, J...638 Raffeiner, B...908, 1160, 2408 Raffray, L... 1792, 2779 Raganelli, L...1225 Ragazzi, M...1160 Raggi, P... 1437, 1442 Raghavan, S...1351 Rahbar, MH... 569, 588 Rahimi, H... 934, 2353 Rahman, A...676, 711, 961, 2637, 2646, 2863, 2865 Rahman, P...248, 537, 539, 550, 583, 623, 624, 625, 626, 953, 956, 1124, 1289, 1548, 1550, 1554, 1556, 1559, 2101, 2411 Rahmani, B...1327 Rai, MK...2603 Rai, R...1507 Rai, S...1400 Raimondo, S... 610, 611 Raisch, D...2232 Raj, P...1606 Raja, R...1020 Rajakariar, R...1661, 1663, 1671 Rajendran, S...2774 Rakel, B...1117 Rakieh, C...449 Rakocevic, G...2330 Rakow, A...29 Ralston, P... 464, 468 Ramachandaran, R.. 169, 188, 189, 190, 191 Ramachandran, S.. 105, 901, 1165 Ramakrishna, J...2286 Raman, I...1606 Raman, SV...2790 Ramanan, A...276 Ramanan, AV...2830 Ramanathan, A...1319 Ramani, A...2362 Ramani, K...1032 Rambhad, G...2436 Ramentol, M...776 Ramires de Jesus, G...2643 Ramirez, D...1026 Ramirez, J...134, 445, 469, 1973, 2478, 2508, 2926 Ramirez, M...1026 Ramírez-Fernández, M...894 Ramiro, S...70, 101, 561, 574, 582, 1058, 1059, 1164, 1373, 2113, 2600, 2828 Ramkhelawon, B...24, 33 Ramonda, R...575 Ramonda, R... 908, 1291 Ramos, JG...2671 Ramos,... 1887, 2956 Ramos-Casals, M... 961, 2646 Rampakakis, E... 265, 365, 379, 382, 383, 421, 426, 943, 956, 1109, 1397, 1601, 2411, 2416, 2496, 2518 Ramsay, E...281 Ramsey-Goldman, R.. 1608, 1631 Ramsey-Goldman, R.672, 862, 961, 1924, 2089, 2646, 2791 Ranade, K...1755 Randall, T...2872 Randazzo, B... 1554, 1556 Randell, E...1289 Randhawa, D...642 Rangel-Moreno, J...860 Ranger, A...1920 Rannio, T...1365, 2812, 2911 Rantalaiho, V... 2368, 2484 Rantapää-Dahlqvist, S...90 Rantapää-Dahlqvist, SM...1379 Rantapää-Dahlqvist, S.. 447, 2084 Rantapää-Dahlqvist, SM...2098 Rao, DA...1744 Rao, V...1616 Rao, VR...1614 Raouf, J...1211 Rapecki, S...2873 Raschi, E...1708 Rasheed, H... 2962, 2964 Rashid, A...303 Rashkov, R...161 Rasker, J... 892, 893 Rasmussen, A...985, 1798, 2430, 2535, 2543, 2930, 2978 Rasmussen, S...1605 Rasmussen, TK...2737 Rastalsky, N... 802, 1349 Rat, AC... 2866, 3018 Rat,, AC... 202, 219 Ratanasrimetha, P. 726, 799, 2531 Ratnarajah, S...490 Rattan, S...1441 Ratz, T...563 Ratzlaff, C...2142 Rauch, C... 2491, 2492 Rauch, L...1965 Rauen, T...1033 abstract author Index 2014 Program Book 329
abstract author Index 330 Ravaud, P... 1778, 1864 RAVE-ITN Investigators, FT...1860 Raveendran, R...413 Raveendran, V...784 Ravelingien, I...958 Ravelli, A... 2297, 2298 Ravelli, A. 277, 278, 284, 299, 928, 1316, 1325, 1901, 2281 Ravenell, R...2001 Ravera, F...737 Ravindran, R...810 Ravindran, V...2774 Rawat, A...1306 Rawlings, D...2870 Ray, DW............. 1923, 2636 Ray, L...1840 Raya, E... 1670, 2622 Rayahin, J... 211, 215 Rayavarapu, S...2216 Raychaudhuri, S. 1602, 1963, 2364 Raychaudhuri, SK.1602, 1963, 2364 Raychaudhuri, S..625, 1744, 1900, 2918, 2954 Raynauld, JP...218, 396, 502, 567, 1535, 1536, 2210, 2250, 2569 Raza, K..... 389, 2183, 2463, 2874 Razawy, W...1749 Rebello, R...883 Rech, J... 1892, 2233 Rech, J...940, 1184, 2130 Recillas-Gispert, C...2533 Recknor, C... 2254, 2255 Reddy, D...2288 Reddy, SM...1580 Reddy, ST...334 Reddy, V...989, 995, 1955, 2696 Redecha,...872 Redlich, K...27, 2358, 2907 Redman, R...2014 Rednic, S.. 1153, 1525, 1526, 2645 Redondo, G...1093 Reed, AM...304, 320, 914, 1316, 2213, 2953 Reed, GW...515, 518, 1537, 2375 Reed, J...1328 Reed, M...2438 Reed, TJ...653 Reedquist, KA...1198 Reese, C...763 Regent, A... 783, 1769 Reggia, R... 671, 1532 Reginato, A...2321 Reginato, AM...1026 Reginster, JY...2267 Reginster, JY... 225, 2268 Regnault, V...2866 Rego-Pérez, I...1121, 1122, 1125, 1126 Reguiai, Z...2204 2014 Program Book Rehaume, L... 618, 632 Rehman, A...2038 Rehman, AA...2039 Rehman, MI...1501 Reich, H...2787 Reid, C...1936 Reid, IR... 1215, 2268 Reiff, A...933 Reijnierse, M... 1174, 1379 Reijnierse, M.540, 594, 1186, 1187, 1823, 1894, 2597, 2984 Reilly, P...551 Reiman, M...186 Reimold, A... 348, 2494 Reimold, AM...840 Reimundes, C...2672 Rein, C...2574 Reinhardt, A...1898 Reis, L...709 Reis, RC...237 Reiser, M...940 Reiseter, S...2703 Reiss, W...375 Reitberg, D...2896 Reitblat, T...949 Reixach, N...1021 Rejeski, WJ...3007 Reker, D...1019 Relaño, S...1126 Relaño-Fernandez, S.. 1121, 1122 Relic, B... 1018, 1025 Rell-Bakalarska, M...1180 Rémillard, MA...396, 502, 1535, 1536, 2569 Remmers, EF......... 1900, 2852 Remy, P...958 Remy Piccolo, V...284 Ren, P...644 Ren-Fielding, C...2246 Renaud, J...586 Renner, B...2182 Renner, JB...201, 978, 2046, 2941 Rennie, W...1994 Repa, A...1401 Repp, H...1146 Resch, H...916 Resche Regon, M...811 Resche-Rigon, M...1245 Reshiti, N...2913 Resick, P...895 Restrepo, JF...1066, 1133, 2026, 2374 Restuccia, G...785, 790, 791, 798 Reutermann, P...2027 Reveille, JD..6, 569, 588, 617, 754, 2089 Revicki, D...259, 260, 261, 549 Reyes, MA...1252 Reyes Llerena, G...959 Reyes-Lopez, AL... 330, 333 Reynisdottir, G...434 Reynolds, JA... 1923, 2636 Reynolds, K... 841, 898 Reynolds, R...451, 1474, 2453 Reynolds, RJ...2454 Rezaei, H...2126 Rezus, E...1525, 1526, 1538, 2497 Rharbaoui, F...1750 Rhead, B...2446 Rhéaume, M...883 Rhee, RL...875, 1781, 2701 Rhodes, B...676 Rhodes, C...815 Rhodus, NL...2535, 2543, 2978 Riancho, JA...228 Riancho-Zarrabeitia, L... 228, 814, 1240, 1249, 1250, 1251, 1252, 1791, 2775, 2776, 2853 Riba-Garcia, I...78 Ribeiro, ACM...957, 2151, 2809 Ribon, M... 938, 1196 Riccardi, A...523 Ricci, J...36 Ricci, M...2768 Riccieri, V...1130 Rice, L...758 Rice, P...1482 Rich, E...2210 Richard, D... 174, 175 Richard, D...159 Richard, MA...1690 Richards, H.536, 537, 538, 550, 819, 953, 954 Richards, JS... 1372, 2570 Richards, K...2878 Richardson, A...185 Richardson, B...2736 Richardson, BC...868 Richardson, C...729 Riches, PL...2962 Richette, P...164, 165, 2231 Richez, C...662 Richi, P... 1670, 2622 Richter, A...491 Richter, J... 357, 701 Richter, JG... 1057, 1078 Ricse, M. 1655, 1656, 1657, 1659, 2194, 2620, 2780 Rider, LG...2216 Rider, LG.. 912, 1316, 1317, 1318, 2211, 2222, 2953 Riebschleger, M...902 Riebschleger, MP...1988 Riecke, BF...2439 Riega-Torres, J...2251 Riegsecker, S...2879 Riemekasten, G.730, 735, 747, 753, 773, 1712, 2711, 2837 Riente, L...147 Riese, R...458, 508, 849, 2487 Rietschel, M...2003 Rietveld, L...2860 Rifkin, I...662 Rigamonti, F...2976 Rigante, D...299 Rigby, W... 1845, 2198 Rigby, WFC...442 Rigolet, A. 1037, 1262, 1270, 1271, 2778 Riis, BJ... 222, 2230 Riisbro, R...947 Rillo, O....................2040 Rillo, OL... 887, 1438, 2042, 2441, 2706 Rillo, OL...406, 1388, 2381 Rimar, D...2150 Rinaldi, M... 912, 1316 Rincheval, N... 1384, 1411 Ringold, S... 297, 2293 Riopedre, AM Sr....1093 Ripoll, VM...2865 Rischmueller, M... 778, 2962 Riso, N... 2409, 2656 Rispens, T...2400 Rist Bouillon, S... 520, 521 Ritchlin, CT...25, 37, 325, 539, 934, 1548, 1554, 1556, 1557, 1559, 1807, 2353, 2794 Rittberg, R...1981 Ritter, SY...2796 Riva, M...2768 Rivas, P...1103 Rivera, J...1139 Rivera, J...407 Rivera-Kweh, M...936 Rivero, M...2706 Riveros-Frutos, A. 568, 1240, 2622 Rivière, S...2757 Rivkin, G...2234 Riyazi, N...2398 Robbiano, C...278 Robbie, G...719 Roberts, C...737 Roberts, H...2798 Roberts, J...1854 Roberts, LJ II...1437 Roberts, L... 1156, 2419 Roberts, MS...1452 Roberts, M...2894 Roberts, ME...1619 Roberts, N...744 Roberts, VC...2430 Roberts, WN Jr...708 Roberts, WN...2001 Robertson, AAB...1044 Robertson, JM...2430 Robinson, D...2884 Robinson, DB...745, 1476, 1855,
2401 Robinson, ES...2206 Robinson, G...649 Robinson, G...546 Robinson, M... 247, 251, 897 Robinson, SM...2438 Robinson, WH. 348, 451, 452, 453, 815, 840, 1457, 1470, 1476, 2019, 2456, 2908 Robles, M...1285 Robles Perez, A...1421 Roblin, D...54 Roblot, P...1864 Robotham, M...2840 Robson, J... 794, 1761 Robson, M...1760 Robustillo Villarino, M...1674 Roccatello, D... 1627, 2855 Rocchetta, PA... 2512, 2514 Rocha, B... 93, 982, 1127 Rocha Muñoz, AD...........2671 Rocher, V...904 Rockette, H... 912, 1316 Roddy, E...2962 Roddy, E...172, 831, 1114 Roddy, J...1682 Rodere, M...1448 Rodrigues, I... 1172, 1424 Rodrigues, J..365, 382, 426, 1397, 2416, 2518 Rodriguez, ER...2786 Rodriguez, J... 59, 2097 Rodríguez, JM...2482 Rodriguez Amado, J...1426 Rodriguez Araya, TL... 597, 2190 Rodriguez de la Serna, A...1113 Rodriguez Gil, G... 887, 2441 Rodriguez Moreno, J...1656 Rodriguez Rodriguez, L...747 Rodriguez Rodriguez, N.1033, 2734 Rodríguez Valls, MJ Sr....1240 Rodriguez-Almaraz, E... 680, 1670 Rodríguez-Amado, J...2251 Rodriguez-Ariza, A...7 Rodriguez-Bellido, Z...1393 Rodríguez-Carrio, J...2445 Rodríguez-Cundín, P...2853 Rodríguez-Gómez, M...2372 Rodríguez-Gómez, M.. 1670, 2622 Rodríguez-Moreno, J...1430 Rodriguez-Muguruza, S. 568, 1267 Rodriguez-Olivo, J...1427 Rodriguez-Pla, A... 808, 1786 Rodríguez-Portales, JA...2268 Rodriguez-Reyna, TS...1716 Rodriguez-Rodriguez, L.. 90, 1139, 1431 Rodriguez-Rodriguez, L.. 482, 776, 1138, 2459 Rodríguez-Salvanés, F...3008 Roebuck-Spencer, T...1825 Roeleveld, DM... 1036, 1734 Roemer, F...207, 210, 1083, 1821 Roesch, SC... 1089, 1338 Roeterink, A... 575, 577 Roeven, M...2178 Roga, S...335 Roger, M...1215 Rogers, S...1493 Rogier, R...1733, 1734, 1816 Rogovski, O...700 Rohekar, G...2380 Rohrer, MD...2978 Roig, D...59 Roitg, I...473 Rojas-Villarraga, A...84 Rokutanda, R... 2021, 2727 Rolando, J...2881 Rollefstad, S.489, 1274, 1440, 1913 Román Acosta, S...1649 Roman Ivorra, JA...2119 Romanini, F...2715 Rome, K...2052 Romero, F...2853 Romero, J...2706 Romero Bogado, ML...1683 Romero Sanchez, C...2608 Romero-Díaz, J...961, 2533, 2639, 2646 Romo-Tena, J...2676 Ronday, HK... 817, 2502 Rood, J...1899 Rooney, T... 1483, 2822 Roorda, LD. 260, 261, 1451, 2053, 2054, 3018 Roos, EM...3018 Roppelt, H...1351 Rorick, MJ...415 Rosa, J.141, 410, 1388, 1438, 1585, 2072, 2381, 2402, 2987 Rosa, J... 1760, 1761 Rosado-Canto, R...1658 Rosales, Z...482 Rosario, MP...2480 Rosas, I... 437, 1273 Rosas, J... 596, 1519, 1531, 1670, 2622 Rosas Saucedo, J...694 Rosas-Gómez de Salazar, J...2423 Rose, A...2837 Rose, CD... 929, 2278 Rose, C...2779 Rose, K... 2211, 2222 Rose, S....................2140 Roselli, E... 88, 987, 2786 Rosemffet, MG.127, 128, 141, 2402 Rosen, A...1474, 2539, 2929 Rosen, C.626, 627, 628, 1575, 1850 Rosen, D...2873 Rosen, O...916 Rosenbaum, J...1919 Rosenbaum, JT...544, 615, 1236, 1756 Rosenberg, AM...290 Rosenberg, D...1928 Rosenberg, I...1983 Rosenthal, AK...1625 Rosenzwajg, M...2731 Rosenzweig, S...816 Roset, A...691, 695, 1657 Roskos, L... 719, 1496 Rosner, I...2150 Rosol, TJ...1473 Ross, JA...688 Rossello-Urgell, J...1786 Rossetti, M...1455 Rossi, C...2981 Rossi, D...908 Rossignol, J...2779 Rossini, P...908 Rotar, Z...788, 1789, 1790, 2041 Rotar,...514 Roth, B...1961 Roth, D... 669, 1641 Roth, J...932, 1199, 2988 Roth, K...2376 Roth, M...2995 Roth-Wojcicki, E... 2317, 2319 Rothenbuhler, A...257 Rothwell, S...2953 Rotman, G...2359 Rotondo, C...1701 Rottat, L...2701 Rouanet, S...2928 Roubey, R...3 Roubille, C...2250 Roujeau, JC...163 Rousseau, M...2201 Rousseau, V...845 Rouster-Stevens, KA...1303, 1304, 1316, 1826, 1988, 2290 Routledge, C...2460 Roux, C. 202, 234, 257, 1769, 2268, 2579 Roverano, S...2625 Rovin, BH...2835 Rovira, J...596 Rowell, L...2469 Rowland, CM...407 Rowshandel, J...2007 Royant, V...2757 Rozadilla, T...2620 Rozenbaum, M...2150 Rozenberg, S...585 Rozenblyum, EV... 1827, 1992 Rozo, C...350 Rozo, CT...2840 Rua Elorduy, MJ...2276 Rúa-Figueroa, I... 1670, 2622 Ruaro, B... 1697, 1700 Rubbert, C.................1173 Rubbert-Roth, A. 1486, 1845, 2821 Rubin, L...1780 Rubin, LA...1445 Rubinstein, T...............2649 Rubio Rivas, M...691, 1655, 1656 Rubio Romero, E...1250 Rubio-Pérez, N...933 Rucco, M...738 Ruddy, M............ 1495, 1500 Ruderman, EM... 1346, 1347 Rudrangi, R...1357 Rudwaleit, M. 543, 544, 852, 2560, 2589, 2593 Rueda-Gotor, J..1791, 2775, 2776, 2853 Ruetsch, C... 1149, 1832 Ruff, W...1, 856 Ruhlmann, V...1189 Ruivard, M... 1782, 1864 Ruiz, B... 730, 1130 Ruiz, N...1785 Ruiz Gutiérrez, L...1683 Ruiz Moreno, O...2853 Ruiz-Cano, MJ...731 Ruiz-Esquide, V.....134, 445, 469, 2478, 2508, 2926 Ruiz-Irastorza, G... 961, 2646 Ruiz-Limon, P... 7, 1978 Ruiz-Nodar, JM...829 Ruiz-Romero, C.93, 982, 1126, 1127 Ruiz-Zorrilla, A... 40, 596 Rullo, OJ...1076 Rumba-Rozenfelde, I.277, 284, 928, 2281 Rump-Goodrich, L...1957 Ruperto, N...2291 Ruperto, N...931, 2297, 2298 Ruperto, N... 273, 276, 930 Ruperto, N.277, 282, 284, 299, 912, 933, 1316, 2281, 2295 Rus, H...639 Rus, V...639 Rush, S...1084 Russell, AM...727 Russell, CB...1646 Russo, A...1093 Russo, D...957 Russo, G...2785 Russo, R...2279, 2280, 2282 Russo, RAG. 284, 1325, 1900, 2302 Ruta, S...1585, 2072, 2987 Rutgers, A...1775, 1956, 2733 Ruth, J... 937, 1962 Ruth, JH...444 Ruth, NM... 1161, 1825 abstract author Index 2014 Program Book 331
abstract author Index Rutkowska-Sak, L...928 Rutledge, M...2227 Rutten-van Molken, M... 96, 1141 Ruyssen Witrand, A...466, 1140, 2483 Ruyssen-Witrand, A... 351, 2028 Ruzehaji, N...1130 Ruzek, M... 951, 1030 Ruzickova, O...136 Ryals, M...674 Ryan, PC...1486 Rybak, D...2649 Rybak-Feiglin, A...2268 Rybakowska, P...1798 Rybicki, BA...1134 Rybin, D............. 1523, 2139 Rönnblom, L...2673, 2681, 2980 Rönnelid, J... 447, 1534 Röver, H...2129 Rødevand, E...944 S S.Akhavan, P...1833 Sa Leitao, D...1348 Saad, CGS...957, 2151, 2304 Saad-Magalhaes, C... 1325, 2281 Saadoun, D...8, 809, 811, 1245, 2731, 2757 Saag, KG. 49, 54, 64, 302, 498, 820, 842, 844, 919, 1422, 2268, 2388, 2471 Saas, P... 991, 2849 Saavedra, MA...710 Saavedra, MA...2671 Saavedra, MA...1984 Sabapathy, A...2640 Sabbadini, MG... 1242, 2202 Sabbatini, ARM..............527 Sabelli, M...2402 Sabnis, S...2436 Saccardo, F...2855 Sacchetti, C...2818 Sacchi, A...2324 Sackeyfio, A...1143 Sacksen, IA...742 Sacnum, M...2040 Sacnun, MP...1388, 1438, 2381 Sacre, K... 1239, 1925 Sada, KE... 31, 82, 85, 678 Sadatsafavi, M...116, 1770, 2118 Sadlonova, M...1389 Saegusa, J... 1456, 2910 Saeki, T...1235 Saeki, Y...1842 Saevarsdottir, S. 352, 358, 367, 376, 501, 510, 1596, 2018, 2524, 2890, 2966 Saevarsdottir*, S...364 Saez, L...747 332 2014 Program Book Saferding, V...27, 2358, 2907 Safford, M... 842, 2388 Sagalovskiy, I...2087 Sagar, H...718 Sagara, Y...2159 Sagawa, A...2505 Saggar, R...2697 Saggar, R...2697 Sagliani, J...2490 Sahhar, J... 1682, 1705 Sahin, A...2769 Sahin, K... 422, 2761 Sahin, S...2627 Sahinkaya, Y...2627 Sahl, S...1829 Sahni, S...2047 Sahu, R... 643, 2869 Said Nahal, R... 622, 1137 Saigusa, R...756, 1724, 3003 Saiki, O... 506, 1533 Sailler, L...1925 Sainz de la Maza, M...1251 Saito, K...805, 1541, 2806 Saito, K...402 Saito, M... 1016, 1885 Saito, M...1028 Saito, R...145 Saito, S...1950 Saito, S...470, 1398, 2479 Saito, T...1235 Saito, T...1414 Saitta, A...744 Sajuthi, S...2956 Sakai, R...1497 Sakai, Y...329 Sakamoto, K...1179 Sakamoto, N...1948 Sakatsume, M...1648 Sakellariou, G... 908, 2403 Sakellariou, G...2585 Saketkoo, LA...727, 1246, 1256, 1678, 1931, 2699, 2707, 2716 Sala-Icardo, L...1787, 1788, 2412 Salama, AD... 1760, 1860 Salama, S...883 Salas, A...406, 1388, 1438, 2381 Salas, AP... 1637, 2670 Salas-Heredia, E. 1519, 1531, 2423 Salazar, G... 745, 754 Salcedo, M... 887, 2441 Saldarriaga Rivera, LM...1785 Sale, J...1936 Sale, MM...2956 Saleh, L...2261 Saliba, L...845 Salinas-Encinas, D...1311 Salli, A...1119 Salmon, J... 18, 1072 Salmon, JE.. 872, 1647, 1877, 2840 Salt, EG...1167 Saltarelli, M...2237 Salts, S...1501 Salvador, G...445 Salvarani, C...776, 777, 785, 790, 791, 798, 880, 882, 885, 2228, 2417, 2757, 2766 Salvatierra, G...1388, 1438, 2381 Salvi, E...1130 Salzberger, W...650 Sambataro, D.531, 879, 1675, 1689 Sambataro, G... 879, 1689 Sammour, M...1926 Sampaio-Barros, PD...957, 2304, 2702 Sampalis, JS...248, 265, 365, 379, 382, 383, 421, 426, 583, 943, 956, 1109, 1397, 1550, 1551, 1601, 2411, 2416, 2496, 2518 Sampedro, J...2482 Samson, M... 1782, 2849 Samuels, J...81, 1224, 2246 Sánchez, A...474 Sanchez, MD...74 Sanchez Andrade, MA...2853 Sánchez Atrio, A... 1683, 2622 Sánchez Bursón, J Sr....2853 Sánchez Costa, J...1367 Sanchez Riera, L...53 Sanchez-Alonso, F...2511 Sánchez-Andrade, A...814 Sánchez-Barrioluengo, M...2423 Sánchez-Guerrero, J.. 3, 961, 2533, 2639, 2646 Sanchez-Mateos, P..... 605, 2175 Sánchez-Menéndez, M...1852 Sanchez-Nuñez, AL...2644 Sandbach, S... 1486, 2821 Sandberg, M...2018 Sandberg, MEC...352 Sander, DO... 130, 153 Sanders, T... 2336, 2898 Sandhu, A...503 Sandikci, SC...2746 Sandler, DS... 1346, 1347 Sandling, JK...2980 Sandoval Rios, M...1426 sang Yeob, L...2993 Sanges, S...1718, 1792, 2701 Sanghi, D III...1135 Sangle, S... 958, 1237 Sanint, J...568 SanJose, B...102 Sanmarti, R...134, 445, 469, 1973, 2478, 2508, 2511, 2926 Sanna, G...1627 Sansinanea, P... 1637, 2670 Santacatterina, M...1596 Santana, M...2077 Santaniello, A. 747, 753, 777, 1203, 1675 Santarelli, C................2077 Santiago, L...148 Santimaria, R...1491 Santini, E...2981 Santora, A... 920, 2268 Santos, L...2409 Santos, MJ... 1629, 2428 Santos-Gómez, M. 814, 1240, 1249, 1250, 1251, 1252, 1791, 2775, 2776, 2853 Santos-Ramirez, C.1519, 1531, 2423 Santos-Soler, G.. 1519, 1531, 2423 Sanz, J...595 Saporiti, G...879 Saracbasi, E... 2612, 2940 Sarano, J...2625 Saraux, A...2912 Saraux, A... 202, 520, 1186, 1187, 1368, 1894, 2161, 2536, 2606 Sari, I.601, 1230, 1584, 2562, 2595, 2611, 2616 Sarin, R...1915 Saritaş, F...2562 Sarkar, S...1810 Sarmiento, A...2903 Sarsour, K...803 Saruhan-Direskeneli, G...807 Sarver, C...727 Sarzi-Puttini, P... 142, 2443 Sarzi-Puttini, P...397, 1543, 2433, 2512, 2514, 2550, 2976 Sasaki, A...332 Sasho, T... 1016, 1885 Sassano, MF...1961 Sasso, EH.364, 367, 376, 2615, 2973 Sasu, M...823 Sato, EI... 959, 1898 Sato, E... 430, 495 Sato, H...232, 233, 1460, 2259 Sato, K...39 Sato, M...402 Sato, S.86, 748, 749, 752, 756, 966, 1724, 3003 Sato, S...1258, 1259, 1266 Sato, S...2653 Sato, T... 1435, 1765 Sato, T...780 Satoh, M...936 Satoh, T...143 Satorius, C... 1900, 2852 Satumtira, N... 607, 620 Satyanarayana, C...830 Sauer, B... 494, 1540 Saul, M... 404, 1410 Saunders, KC...418, 1537, 2813 Saura, C...445 Saurit, V... 959, 2040 Sautet, A...1012 Sauvageau, D. 396, 502, 567, 1535, 1536, 2569
Savasta, C...1999 Savel, C...1448 Saverno, K...2395 Savey, L...2731 Savjani, M...1810 Savolainen, E...399 Saw, WY... 2918, 2954 Sawada, T...2763 Sawalha, AH... 77, 881, 1002 Sawitzke, A...2231 Sawyer, L... 1527, 2501 Saxena, A...3, 534, 1605, 1829 Saxne, T...436 Sayani, A...688 Sayarlioglu, M...2157, 2270, 2523, 2616, 2750 Sayegh, F...2585 Saygin, C... 2704, 2754 Sayles, H...167, 348, 840, 1067, 1470, 1475, 2014, 2456 Sayre, EC.. 915, 1770, 1865, 2112, 2306, 2308, 2932 Sbreglia, C...2855 Scaglioni, V. 792, 1388, 1783, 2381 Scaini, P...2855 Scanu, A...1291 Scarabelli, M... 988, 2403 Scarafia, S... 148, 2715 Scaramuzzino, S...1140 Scarcia, M...768 Scardapane, A...2228 Scarpato, S...2855 Scarsi, M...1642 Scavone, J...1094, 1108, 2080 Schabbauer, G...2907 Schabert, VF...1165 Schaeverbeke, T...2912 Schaeverbeke, T.. 165, 1140, 1736 Schafer, P...955 Schafer, PH... 2355, 2689 Schaier, M...1863 Schall, TJ...1863 Schanberg, L...1296, 1313, 2292, 2293, 2294 Schaper, F...1626 Scharbatke, EC... 1560, 2915 Scharmga, A... 2136, 2143 Scharping, N...2870 Schau, T...945 Schauer, P...2247 Schaufelberger, C...1180 Scheel-Toellner, D. 389, 2183, 2874 Scheet, P...617 Scheffer, H.................2966 Scheinberg, MA...2836 Scheinecker, C...1022 Scheines, E...2040 Schelbergen, R... 1199, 2952 Schelbergen, RF...2948 Schenfeld, J...2037 Scher, JU... 1580, 1605 Scherer, P...966 Scherer, S...1900 Schett, G.. 940, 1184, 1892, 2130, 2233 Schett, GA. 548, 1192, 1561, 1564, 1565, 1579, 1590, 2589 Scheuern, A... 296, 312 Schiappapietra, B...278 Schiel, A...2706 Schiff, M...1520 Schiff, MH...2366 Schiff, MH...2913 Schikler, K...2291 Schikler, KN... 2271, 2903 Schiopu, E.. 745, 1927, 1962, 3006 Schiødt, M...525 Schlefman, A...2278 Schleich, DC... 1173, 1177 Schleinitz, N...1774 Schlereth, B...1511 Schlesinger, L...1473 Schlesinger, N...159, 160, 1686 Schlichting, DE...488, 1483, 2822 Schlichting, U...616 Schmajuk, G.112, 1084, 1856, 2048, 2049, 2123, 2124 Schmalzing, M...996, 1560, 2915 Schmeling, H........... 61, 2275 Schmid, A...2338 Schmidt, MFG...1006 Schmidt, T...103 Schmidt, TJ... 2306, 2308 Schmidt, WA...795, 796, 885, 909 Schmitz-Bortz, E... 2612, 2940 Schmunk, G...2738 Schneck, L...176 Schneeberger, E... 2402, 2575 Schneeberger, EE...410 Schneeweiss, S...2036 Schneider, F...770 Schneider, M. 357, 491, 701, 1057, 1078, 1189, 2233 Schneider, PDM...130, 153, 1173, 1177, 1730 Schneider, R.319, 1988, 2292, 2300 Schnitzer, TJ... 242, 925 Schoenfeld, S...1349 Schoindre, Y...1271, 2757, 2779 Scholey, J..................2787 Schollmeier, K...2833 Scholtes, V...3018 Scholtz, J...987 Scholz, B...2314 Scholz, J...................2783 Schouffoer, AA...1692 Schouffoer, AA... 1930, 2138 Schouffoer, A...1693 Schramm, C...2145 Schreiber, K...1358 Schreiber, S...485 Schreiter, J...1976 Schroeder, E...1006 Schroeder, HW Jr....706 Schroeder, J...485 Schroeder, LL... 1395, 1830 Schröder, A...345 Schueller-Weidekamm, C...2589 Schuldt, D...485 Schulert, G... 310, 1901 Schulman, E...394 Schulman, K...2121 Schulman, S...459 Schulte, M..................505 Schulte-Pelkum, J...1629 Schulz-Knappe, P... 357, 1730 Schulze-Koops, H...2493 Schulze-Koops, H..131, 497, 1131, 2845, 2913 Schumacher, HR Jr... 159, 250, 826 Schumacher, R...110 Schwab, P...840 Schwarting, A...1256 Schwartz, AV...1276 Schwartz, A...858, 1499, 2839 Schwartz, N...138 Schwartz, N...2649 Schwartz, S...2321 Schwartz, T... 1088, 2941 Schwartz, TA...201 Schwartzman, S...1567 Schwarz, C...1737 Schwarz, EM. 325, 934, 2353, 2794 Schwarz, T...1900 Schwarz, UI...386 Schwarzecker, B... 634, 650 Schwill, U...2027 Schüttrumpf, J...1750 Schönau, V...880 Sciascia, S... 14, 1627 Scioscia, C... 908, 2399 Scirè, CA... 908, 1256 Scofield, RH.985, 1798, 2535, 2542, 2543, 2930, 2978 Scolnik, M... 792, 1783 Sconfienza, L...184 Scott, B...920 Scott, BB...2268 Scott, C...1296 Scott, DL... 839, 2974 Scott, FI... 1546, 1839 Scott, FI IV...929 Scott, JR...924 Scott, JL... 637, 1213 Scott, S...2664, 2665, 2666 Scrivo, R...58 Scuccimarri, R... 1998, 2289 Scully, M...2743 Sebastiani, M...2855 Sébastien, J...1137 Secco, A.... 148, 406, 1388, 1438, 2381, 2625, 2715 Sedhom, M...2460 Sedky Abdou, M...1632 Sedlis, SP...156 Sedova, L... 1159, 2422 Seeger, JD...46 Seeliger, B...1793 Seelmann, D...2717 Segal, BM.. 745, 2535, 2543, 2978 Segal, NA...200, 207, 1083, 1276 Segarra-Linares, SL...2644 Segelmark, M...1863 Segurado, O... 376, 2973 Seguro, L...235 Seguro, LPC...238 Sehgal, N...1353 Sehnert, B...345 Sehra, S...2140 Sehra, ST...732 Seibold, JR...2999 Seishima, M... 1258, 1259 Sejer Hansen, M...1180 Sekhon, S...1507 Seki, S...1028 Sekicki, V...689 Sekine, H...1948 Sekine, H...2521 Sekiyama, J... 733, 2712 Seldin, MF...2955 Selga, D...1863 Seligman, V...2001 Sellam, J...1012, 1275, 2928 Sellas-Fernandez, A... 596, 2853 Selmi, C...1256 Selva, D... 1236, 1756 Selva O Callaghan, A...2953 Semanik, P... 2944, 2946 Semanik, PA... 68, 1800 Semb, AG. 489, 1274, 1440, 1913, 2561, 2571 Semenova, O...2396 Semerano, L...2357 Semeraro, A...2399 Senabre-Gallego, JM.. 1519, 1531, 2423 Sène, D...8, 520, 521, 835, 2757 Senécal, JL.................2210 Senel, K...1412 Senel, S...2616 Şenel, S...2562 Sengupta, R...2830 Şeniz, BN...2750 ŠEnolt, L...129 Senolt, L.. 136, 1039, 1128, 2085, 2371, 2450 Seo, P.. 801, 804, 808, 880, 1754, 1766, 1861, 2851 Seo, Y...2825 Sequeira, W... 681, 716, 717 Serada, S...2363 abstract author Index 2014 Program Book 333
abstract author Index 334 Serafim, AS... 796, 909 Serafin, DS... 1961, 2878 Sergeant, J...686 Seriolo, B... 1713, 1966 Sermon, J...1569 Sernissi, F.. 527, 1772, 2931, 2981 Seror, R... 2536, 2549 Serrallonga, M...1381 Servettaz, A...2081 Seshan, SV...2087 Sesseng, S...1822 Seta, N....................1469 Sethi, M...1475 Seto, Y...430 Setoguchi, K...87 Setoguchi, S...2292 Sève, P...2757 Sever, F...1247 Sevilla, R... 649, 997 Sevilla Pérez, B... 1787, 1788 Sewerin, DP. 130, 153, 1173, 1177 Seyahi, E. 1232, 2043, 2749, 2751, 2752, 2759, 2760, 2852 Seymour, M...1446 Sezen, M...2301 Sfikakis, PP.1443, 1462, 1612, 2617, 2709 Shaddick, G... 546, 2830 Shadick, N... 1141, 2103 Shadick, NA.....1335, 1369, 1370, 1408, 2889, 2973 Shafaie, N... 277, 928 Shafi, L.....................775 Shah, A... 369, 1507 Shah, A... 104, 1151 Shah, AA...741, 745, 1677, 1927 Shah, A...156 Shah, B...156 Shah, H...2315 Shah, K...2187 Shah, K... 1564, 1579 Shah, M...2277 Shah, N... 494, 1540 Shah, SJ... 725, 1929 Shah, SN...1882 Shah, U... 1829, 1854 Shahbazian, A...334 Shaheen, M...972 Shahidul Makki, M...1015 Shahrara, S... 1510, 2799 Shai, I...171 Shaik, IH...1810 Shaikh, S...2912 Shaikh, S...956, 1550, 1601 Shakil, H...2099 Shakoor, N... 213, 2245 Shakoory, B...2200 Shalev, V...2067 Shallom, G...1547 2014 Program Book Shamilov, R... 322, 1512 Shanahan, EM...2034 Shanahan, E...2034 Shang, Q... 374, 1582 Shanmugam, VK...1677 Shao, X...524, 2446, 2466 Shapiro, LS.1694, 2195, 2196, 2197, 2444, 2716 Shapiro, M...1846 Sharma, A...503 Sharma, A...113 Sharma, A...1760 Sharma, L...211, 214, 215, 2944 Sharma, S...503 Sharma, S...1813 Sharma, S...1888 Sharma, T... 1395, 1830 Sharma, TS...941, 1394, 2322 Shaughnessy, L...1409 Shaw, A...1940 Shaw, AT...1914 Shaw, JE... 1277, 1278 Shaw, M...2542 Shaw, Y...1452 Shaweesh, Y...2718 Shawi, M...248, 365, 379, 382, 383, 421, 426, 583, 943, 956, 1397, 1550, 1551, 1601, 2411, 2496, 2518 Shay, K... 948, 2826 Shay-Aharoni, H...388 Sheaff, M...1661, 1663, 1671 Shealy, D...439 Sheane, BJ...690, 1858, 2935 Sheen, DH...1508 Sheen, DH... 612, 2684 Shehwaro, N...1239 Shen, B... 832, 1229 Shen, H... 542, 1850 Shen, J... 374, 1582 Shen, L...2094, 2541, 2546 Shen, M... 832, 1229 Shen, N...310, 1202, 1615, 2850 Sheng, F...181 Shenoi, S... 275, 2903 Shenstone, B...778 Sheriff, M.248, 365, 943, 956, 1397, 1550, 2411, 2416, 2496 Sherrer, Y.. 370, 1375, 2378, 2413 Sherry, DD... 259, 262, 281 Sherwood, J...2951 Shesternya, P...1508 Sheth, H... 1344, 1348 Sheth, K... 1081, 1082 Sheth, T...1341 Shetty, A...1702 Shetty, N...353 Shetuni, B...750 Sheu, JH...323 Sheu, TR...25 Shewade, A... 505, 515, 518 Shewchuk, R... 1668, 1672 Shi, B... 344, 2167 Shi, J...454 Shi, K...241 Shi, L... 1463, 2177 Shi, L...870 Shi, L...1544 Shi, R...1211 Shi, XA...201 Shi-Wen, X...1728 Shiao, R...815 Shiau, AL... 324, 2344 Shiba, H...1784 Shibanuma, N...1035 Shibasaki, Y...2418 Shibata, A...1497 Shiboski, CH...525 Shiboski, S...525 Shida, H...2, 5, 1179, 1628, 2638 Shidara, K...430 Shields, AM...869 Shields, KJ...864 Shiels, P... 747, 757 Shiff, NJ...61 Shigematsu, K... 506, 1533 Shikano, K...232, 233, 1460, 2259 Shim, SC.. 612, 1056, 1458, 1508, 1509, 2684, 2922 Shima, Y...1695 Shimada, K...86, 87, 1762, 1773, 2457 Shimamura, S...2, 5, 1179, 1628, 2638 Shimbova, KM...949 Shimizu, H...2021 Shimizu, M...309 Shimizu, Y...430 Shimizu, Y. 2, 5, 1179, 1628, 2638, 2677 Shimojo, N...143 Shimonov, R...2234 SHIN, JH...2590 Shin, KC...1241 Shindo, E...232, 233, 1460, 2259 Shinjo, SK. 2212, 2220, 2221, 2225 Shintani, A...1437 Shiozawa, A...117, 1155, 2114 Shiozawa, K... 2510, 2925 Shiozawa, S... 2510, 2925 Shipley, JA...1699 Shipley, M...3010 Shir, Y...264, 265, 1109 Shirai, T...438 Shirai, Y...746, 762, 3002 Shiraiwa, H...1688 Shiraiwa, H... 355, 1906 Shirota, Y..................1950 Shiwen, X... 760, 1721 Shlomchik, M...1941 Shmerling, RH...2153 Sho, N...1696 Shock, A. 1942, 1943, 1944, 1945, 2873 Shoda, H... 859, 1454 Shoda, N...2260 Shoda, T...1784 Shoenfeld, Y...647 Shojania, K... 2120, 2884 Shojania, K...1144, 1865, 2932 Shoji, T...2472 Sholter, D. 248, 365, 379, 383, 583, 2411, 2518 Short, L...154 Shott, S...1112, 2058, 2073 Shpigelman, A...2150 Shrader, J...2330 Shrestha, A... 401, 2252 Shrestha, P...2187 Shu, GL...1942 Shu, J...371 Shudo, K...3003 Shufflebotham, J...1114 Shukla, A... 308, 2603 Shums, Z...2866 Shupak, R...1932 Siaton, B...2003 Sibbitt, W Jr.... 1764, 2789 Sibilia, J... 473, 811, 1140, 1681, 1707, 2204, 2536, 2757, 2928 Sibley, CH...2756 (SICCA), SSCCA...525 Siddiqui, I...2002 Siderovski, DP... 1961, 2878 Sidiropoulos, P...298, 1401, 2645 Sieber, J... 1944, 2693 Siebuhr, AS...368, 541, 629, 1293 Siegel, DL...1328 Siegel, J... 874, 2999 Siegel, R...1212 Siegel, S... 57, 1589 Siegert, E...735, 1712, 2837 Siegwald, E...704 Sieni, E...321 Sieper, J...2938 Sieper, J.. 536, 538, 544, 553, 562, 616, 819, 852, 1545, 2581, 2589, 2592, 2593, 2618, 2983 Sifuentes Giraldo, A...1240 Signorini, V...2656 Signorovitch, J... 1147, 1555 Siguenza, P...691 Sikara, M...1980 Sikes, D...1355 Sikora, K...283 Sikora, KA...83 Silacci, M...1491
Silva, CA.. 1298, 1300, 2151, 2809 Silva, CA... 1898, 2320 Silva, CAA...2221 Silva, DR...1588 Silva, KF...1300 Silva, MF...2320 Silva, MG...2212 Silva, T...863 Silva Fernández, L..... 1670, 2622 Silva-Fernandez, L...467 Silver, R... 745, 3002 Silver, RM... 762, 763 Silverfield, J...849 Silverman, E...933, 2300, 2619 Silverman, ED...1295, 1310, 1312, 1827 Silverman, GJ...387, 448, 1328 Silverman, MH...949 Silverman, SL... 1158, 2076 Sim, JH...2690 Simard, J...1071 Simard, JF...846, 1072, 1877 Simeón, CP...753 Simeon, CP...747 Siminovitch, KA...361 Simmons, K...1933 Simms, RW. 745, 2702, 2713, 2721 Simon, A.. 1231, 2279, 2280, 2282 Simon, D...1184, 1892, 2130 Simon, J...1795 Simon, T... 97, 1840 Simon, T...2519 Simon Campos, JA...459 Simonini, G...2901 Simonneau, G...2701 Simonsen, O...1293 Simos, P...1401 Sims, R...2699 Sindel, D...1115 Singer, NG...1303, 1304, 1826 Singh, A...2395 Singh, AG... 2628, 2642 Singh, A IV.................1135 Singh, A... 1031, 2879 Singh, F...1707 Singh, J. 47, 64, 118, 188, 192, 820, 842, 962, 1051, 1660, 2125, 2388 Singh, JA. 170, 189, 190, 191, 195, 196, 199, 1668, 1672, 1802 Singh, JA...169 Singh, N... 1329, 2189 Singh, R... 91, 767 Singh, RR.642, 659, 972, 2164, 2848 Singh, S...793, 796, 909, 1761 Singh, S...1306 Singh, S...89 Singhal, A...2856 Singla, S...1465 Sinibaldi, D...1486 Sinicato, NA...1622, 1636, 2659, 2660, 2661, 2662, 2663, 2720 Sinigaglia, L...2399 Sippl, N...2874 Sirajuddin, A...750 Siricilla, M...111 Siskind, L...661 Sisol, K... 851, 2422 Sitbon, O...2701 Siu, T...2354 Sivera, F... 99, 829 Sivils, KL.. 985, 2430, 2535, 2543, 2930, 2978 Sjöwall, C...1877 Skapenko, A... 1131, 2845 Skarpengland, T...1440 Skarstein, K...532 Skaug, L...1986 Skelton, A...2982 Skeoch, S... 1182, 1464 Skinner-Taylor, C...1425 Skriner, K... 339, 2530 Skrumsager, B...1492 Skwarek, M...1621 Slatkowsky-Christensen, B...1822 Sleeman, MA... 1486, 2821 Sleglova, O.. 129, 136, 1098, 2422 Sleptsova, T...2296 (SLICC), SLICC...865, 2631, 2791 Slight-Webb, S... 648, 2688 Slobodin, G...2150 Slocum, C...2002 Sloetjes, A...1199 Sloetjes, AW...20 Slomian, J...225 Sluka, K...1117 Smail, A... 1864, 1925 Small, A...1096, 1099, 1112, 2075 Small, BJ...1112, 2058, 2073 Small, BJ...1096 Smallwood, C...2272 Smargiassi, A...2015 Smearman, J...674 Smecuol, E...1285 Smerud, KT...1913 Smethurst, R... 2369, 2370 Smikle, M...6 Smith, CD...2619 Smith, CK...641 Smith, D...95 Smith, D...784 Smith, J...2051 Smith, K...985 Smith, M...2962 Smith, MD...778 Smith, M...1163 Smith, R...2896 Smith, S...2235 Smith, S...979 Smith, S... 1624, 2694 Smith, V...737, 1928, 1991 Smith, W...49, 1546, 1849 Smithson, GM..............2725 Smits, N... 260, 261 Smoktunowicz, N...2865 Smolen, J.....634, 650, 906, 1022, 1389, 2029 Smolen, JS...27, 58, 1054, 1131, 1407, 1847, 2358, 2387, 2475, 2495, 2498, 2517, 2907 Smolik, I...1476 Smrcka, A...860 Smrzova, A...1159 Smulders, YM...354 Smyth, G...1467 Snapir, A...728 Snapir, D...728 Snipes, K...2788 Snyder, KR...16 So, A...2962 So, A...157, 159, 1197 So, AK Sr....158 Soare, A....................823 Soares de Souza, S...2040 Sobanski, V...1706, 1718, 2700 Sobel, ES...645 Sode, J...2500 Sofat, N...2967 Sohn, DH...815 Sohn, J...2539 Sohn, MW...1800 Sohng, KY...2440 Soininen, P...399 Sokka, T...1365, 2812, 2911 Sokka-Isler, T...351 Sokol, R...718 Sokolove, J.348, 451, 452, 815, 840, 1470, 1476, 2019, 2456 Solaiman, M...2396 Solak, O...1111 Solans, R... 776, 777, 880 Solar-Cafaggi, D...1779 Solau-Gervais, E...1385 Soldal, DM...786 Soldano, S... 1713, 1966 Soler, V...674 Soler Palacios, B...2175 Solini, A...2981 Solis-Vallejo, E...1984 Solmaz, D.. 603, 1584, 2611, 2616 Solomon, DH... 841, 898 Solomon, DH... 2029, 2511 Solomon, DH...46, 178, 254, 818, 980, 1075, 1080, 1434, 1842, 2036, 2122 Solomon, D...96, 1809, 1911 Soloski, MJ...608 Solotkin, K...2623 Solow, EB... 840, 1342 Soltesz, E... 88, 987 Solus, JF...1442, 1630, 1902 Solyman, J...2070 Soma, K... 461, 1181 Sommerfleck, FA...2575 Son, CN...570, 1241, 2158 Son, HJ...1048 Son, MB...314 Song, GG...2537 Song, IH... 561, 1545 Song, JJ...1457 Song, J...68, 1800, 2944, 2946 Song, JS... 1216, 1217 Song, J...1968 Song, L...870 Song, M...539, 1554, 1556, 1559 Song, P...2177 Song, P... 1751, 1752 Song, ST...612, 1458, 2684, 2922 Song, YW.. 166, 1220, 2215, 2347 Soni, R... 1081, 1082 Sonmez, C...2548 Sonsuz, A...2752 Sontheimer, C... 657, 861 Sood, A...503 Sopeña, B...777 Sorensen, IJ...1188 Soriano, E. 1438, 2040, 2072, 2987 Soriano, ER...410, 792, 959, 1388, 1585, 1783, 2381, 2402 Soto-Hermida, A. 1121, 1122, 1125 Soubrier, M. 351, 564, 1413, 1418, 1428, 1448 Souda, P...91 Souers, A... 858, 2839 Souliotis, V...1612 Soussan, M...2145 Southwood, TR.271, 272, 286, 1982 Souza, B...237 Souza, R...2895 Souza II, D...1918 Sozeri, B...1230 Spaggiari, L...2228 Spainhour, JC...1669 Spalding, DM...1132 Spannow, AH...2287 Spargo, L...2520 Sparks, C... 1053, 1062 Sparks, JA...55, 818, 1876, 2008, 2017, 2887 Sparsa, A...1690 Spatz, M...997 Specker, C...1256 Specks, U.. 804, 808, 1754, 1766, 1861, 2851 Spector, TD...869 Spek, PJVD...2979 Spelling, NW...1298 abstract author Index 2014 Program Book 335
abstract author Index 336 Spellmeyer, D...2873 Spencer, CH... 1320, 2272 Spencer, D...404 Spencer, H... 1380, 2390 Spencer, J...2695 Spencer-Green, G...1502 Spengler, J...2183 Spiegel, LR...2288 Spieler, W...1508, 1528, 2233 Spiera, RF.. 781, 878, 1691, 1754, 1766, 1927, 1991 Spijkervet, FKL...2551 Spindler, AJ...2077 Spindler, W...141 Spindler, WJ...2077 Spira, A...2702 Spitz, R...1117 Spoorenberg, A...2831 Spotswood, H...874 Sprachman, M...769 Sprafka, M...2037 Spreafico, R...1455 Sprecher, M...1193 Springer, J...784 Springorum, HR...1010 Spruill, IJ...2956 Späth, T...1029, 1965, 1974 Späthling-Mestekemper, S...1154 Squadrito, F...744 Sreih, AG... 880, 1861 Srinivas, A...2227 Srinivasalu, H...283 Srinivasan, M...525 Srivastava, P...1272 Srivastava, R II...1135 Srivastava, R...318 St. Clair, W...1754 St. Claire, EW...1766 Stach, C...544, 565, 566, 1945 Staelens, F...1180 Staes, C...2313 Stagnaro, C... 2708, 2755 Stahl, E...2961 Stahl, EA.. 1136, 1219, 2958, 2960 Stamm, TA...1389 Stamm, TA...58 Stamp, LK...168, 173, 828, 1214, 1757, 1758, 2377, 2959, 2962, 2964 Stancati, A... 174, 175 Stancati, A...159 Stanczyk, J...2450 Stanevicha, V... 277, 282 Stanford, SM... 2818, 2871 Stange, R...2951 Stangl, H...1010 Stanley, R...2180 Starck-Schwertz, S...305 Starnes, C...2227 2014 Program Book Starr, AJ...672, 1307, 2269 Starr, M. 265, 365, 382, 956, 2411, 2496, 2518 Statnikov, A...81 Staud, R... 247, 251, 897 Stauffer, P...1236, 1756, 1919 Stavrakis, S...866 Stawiarz, L............. 501, 510 Ste-Marie, PA...264, 265, 1109 Stebbings, S...2377 Stebbins, C...1920 Steele, E... 1236, 1756 Steele, R...1089 Steen, S...761 Steen, VD...734, 745, 836, 1677, 1678, 1927, 1931, 2698, 2707, 2999 Steen Krogh, N...2562 Steenbeek, R...2104 Steengaard-Petersen, K. 409, 2737 Steenwijk, EC...2979 Steer, S...839 Steere, AC...983, 984, 1402, 1970 Stefanik, J... 207, 1083 Steffensen, R...2171 Stegeman, CA... 1775, 2733 Stehlik, C...2167 Stehman-Breen, C...918 Stein, CM...843, 1437, 1902 Stein, CM... 1442, 1630 Steiner, CW... 634, 650 Steiner, G...1022 Steinmetz, J...244 Steinsson, K... 961, 2646 Stel, A...1626 Stelekati, E...1899 Stengaard-Pedersen, K.. 349, 366, 1200, 1964, 2171 Stensballe, A...80 Stenzel, W. 1037, 1262, 1263, 1270 Stephanou, A...655 Stephenson, J...1143 Sterba, G Sr....1113 Sterba, Y...1315 Sterpka, J...1, 856 Steuer, A...2474 Steultjens, M... 572, 3018 Steup-Beekman, GM...2138 Stevens, A... 297, 2738 Stevens, AM...320 Stevens, JA...72 Stevens, RM... 548, 602, 1543, 1561, 1564, 1565, 1572, 1579, 1590, 2854 Stevens, W.. 720, 723, 1682, 1705 Stevens-Lapsley, J...1282 Stevenson, K...1114 Stevenson, M...1002 Stewart, C...2174 Stewart, KG...1321 Stewart, P...389 Sticherling, M...1184, 1892, 2130 Stifano, G... 758, 2702 Stigliano, E...1971 Stijnen, T...1823 Stiller, JL...201 Stillman, M... 2765, 2856 Stine, KC...2281 Stinson, WA...937 Stirnemann, J...1925 Stitah, S...885 Stocco, A...2273 Stock, A...651, 664, 1941 Stock, T...1478 Stoel, BC...2141 Stoffels, M...816 Stohl, W...857 Stoica, V...823 Stoilov, RM...949 Stojkovic, T...1262 Stok, K...2136 Stolfa, J...1159 Stoll, ML...1297 Stoll, T... 961, 2646 Stolshek, BS...1158 Stolwijk, C...574, 578, 2600, 2828 Stomp, W...1174 Stone, D...816 Stone, DU... 2535, 2543 Stone, DU...1798, 2930, 2978 Stone, JH.. 802, 1754, 1766, 2804, 2805 Stone, M...2189 Storgard, C...1165 Storti, K...2895 Stoustrup, P...1867 Stout, K...3017 Strand, V...2488 Strand, V...458, 2487, 2489 Strand, V...243, 249, 378, 418, 550, 1077, 1522, 1555, 1565, 1597, 2240, 2475, 2813, 2834 Strangfeld, A...491, 1837, 1838 Stratton, RJ... 760, 1721 Straub, R... 994, 998, 1010, 1029, 1959, 1965, 1974, 2349 Straus, WL...250 Strauss, H...176 Strauss, J...977 Strazza, M...2723 Street, R...3014 Strehl, C...1518 Strek, M...432 Stremnitzer, C... 322, 1512 Stringer, E...2288 Strippoli, R...311 Strle, K...1970 Strnad, D...2859 Strober, B...1562 Strobova, K...2116 Strom, BL...929 Struemper, H...669 Strusberg, I...2040 Strutton, G...632 Stryker, D...2290 Stuart, PE...625 Stuckey, D... 655, 2863 Studenic, P... 1389, 1407 study Group, TA... 356, 905 Study group, TA... 825, 846 Stummvoll, GH... 634, 650 Sturfelt, G...961 Sturfelt, GK...2646 Sturgess, A...1682 Sturm, MS...1320 Sturrock, RD... 41, 563 Stüdemann, K...301 Su, AI... 1016, 1885 Su, E...1854 Su, F......................1176 Su, JH......................323 Su, K...1620, 1953, 2782 Su, L...1743 Su, L... 961, 2646 Su, L...2177 Su, W...644 Su, Y... 759, 1731 Suárez, A...2445 Suarez-Almazor, ME...17, 111, 427, 970, 1069, 1070, 1676, 2005, 2009, 2013, 2244, 2420, 2895 Suarez-Farinas, M...631 Suarez-Fueyo, A...2735 Subedi, A...2187 Subesinghe, S...2044 Subra, JF...1864 Subramanian, V...641 Suchy, D...1159 Suda, A...87 Suda, M...2021 Suda, T... 1258, 1259 Sudano, D...2205 Sudini, K...1031 Suematsu, E...87 Suemori, K... 1610, 2170 Suen, SW...2948 Sugai, S...525 Sugano, T...1958 Sugawara, E... 2, 2638 Sugaya, M...749 Sugg, E...2878 Sugii, S...86, 87, 1762, 1773 Sugimoto, N...430 Sugimoto, T...2256 Sugiura, H...1175 Sugiyama, E...1001 Sugiyama, K... 1688, 1906
Sugiyama, K...678 Sugiyama, Y... 125, 133 Sugiyama M.D., Ph.D, N...2418 Suh, CH...1508, 1509, 1613 Suh, YS... 220, 2356 Sukhdeo, S... 1310, 1827 Suksaranjit, P...726, 799, 2531 Suliman, Y...2718 Sulli, A.737, 1697, 1700, 1713, 1966 Sullivan, B...1646 Sullivan, C...1830 Sullivan, KE...870 Sumida, H...748 Sumida, T...82, 85, 86, 87, 2346, 2352, 2467 Sumitomo, S...859 Sun, GH...803 Sun, G... 1124, 1289 Sun, H...2781 Sun, L.. 635, 654, 960, 2343, 2678 Sun, M...993 Sun, X... 665, 2747 Sun, X... 1814, 2844 Sun, Y...1387 Sun, YC...1005 Sun, Y...2343 Sunbul, M...1423 Sundel, RP...314 Sundman-Engberg, B...1180 Sung, C...1808 Sung, IH...2590 Sung, PJ...323 Sung, S...342 Sung, YK.. 1056, 1805, 2025, 2158 Sung Won, L...2993 Sunkureddi, P... 174, 175 Supp, G... 906, 1389 Suppiah, R...794 Suresh, L...2540, 2541, 2546 Suri, D...1306 Susic, G... 277, 282 Suta, M...1525, 1526, 1538, 2497 Suter, L...2235 Sutton, C...711 Sutton, E...676 Suyama, Y... 2021, 2727 Suzuki, E...1915 Suzuki, K... 470, 986, 1040, 1238, 1398, 1469, 1958, 2479, 2977 Suzuki, M...2345 Suzuki, T...429, 2389, 2651 Sveaas, SH...2561 Svendsen, A...349 Svenson, LW...2015 Svensson, F...206 Svensson, L... 88, 987, 2786 Svensson, M...2847 Svenungsson, E... 670, 1877 Svircev, J... 2105, 2106 Swaim, B...529 Swales, C... 38, 1446 Swart, JF...282 Swarup, I...198 Swearingen, C...370, 1375, 1580, 2378, 2413, 2528 Swearingen, CJ...156 Swedler, W...1510, 1702, 2799 Sweezie, R...1933 Sweiss, NJ... 1510, 2799 Swiatnicki, K...2059 Swift, S...3014 Swigris, JJ...1419 Swindell, W...751 Sy, A...804 Sy, T...2700 Sylvestre, MP...1866 Symmons, DP... 467, 1909 Symmons, DP...1068, 1542, 1848, 2392 Syngle, A... 1450, 3009 Syrbe, U...616 Szűcs, G...2477 Szabo, D...2284 Szabo, E...2553 Szczerba, B...1798 Szczygiel Cunha, J...2321 Szentpetery, A... 1578, 2614 Szklo, M...1363 Sznajd, J... 1760, 1761 Szodoray, P...2871 Szombati, I...1863 Sztajnbok, F...930 Szulc, P...62, 63 Szumski, A.. 855, 1558, 1893, 2577 Szumski, A...1581, 1847, 2498 Sørensen, GL... 541, 629 T Taams, LS...633 Tabara, Y...805 Tacang, A...913 Tachmazidou, I...1900 Tacla, M...................2809 Tada, K...1746 Tada, Y...749 Taddeo, A...1954 Taddio, A...2901 Tager, AM...1796 Tagliaferri, E...879 Tagoe, C... 401, 2252 Tahanan, A...588 Tahara, K...1255 Tahara, M...2352 Tahir, N...1487 Tak, P...450 Tak, PP...392, 1198, 1513 Tak, PP... 2448, 2816 Tak, PP... 1960, 2463 Tak, P...2912 Takagi, K...877 Takagi, K...232, 233, 1460 Takagi, N... 457, 2467 Takagishi, K... 513, 2133 Takahashi, H...805 Takahashi, H...329 Takahashi, M...332 Takahashi, M...805 Takahashi, N..471, 512, 516, 1488, 1489, 2504, 2516 Takahashi, R... 496, 2128 Takahashi, R...2509 Takahashi, S...2352 Takahashi, T...748, 749, 752, 756, 1724, 3003 Takahashi, Y...2363 Takai, C...2346 Takasaki, Y.. 87, 1746, 1907, 2728 Takayama, L.. 50, 51, 52, 73, 1824 Takayama, M... 1218, 2762 Takeda, A... 2021, 2727 Takehara, K...86, 1258, 1259 Takei, H...1497 Takei, M...355, 1688, 1906, 2340 Takei, S...143, 1868, 2274 Takemoto, T...471 Takemura, M................402 Takenaka, S... 146, 424 Takeno, M...123, 125, 2763 Takeshita, M...2977 Takeuchi, M...2852 Takeuchi, T...1784 Takeuchi, T...470, 746, 986, 1040, 1175, 1238, 1257, 1398, 1469, 1890, 1958, 2427, 2467, 2472, 2473, 2479, 2521, 2692, 2877, 2977 Takezaki, T... 1868, 2274 Takiguchi, M... 986, 2977 Takihara, T... 759, 769 Talaei, N...652 Talarico, R. 2201, 2217, 2656, 2755 Talathi, S...970 Talbert, J...1167 Talotta, R...397 Talpin, A...1137 Tam, A...1714 Tam, LS... 374, 1582 Tamai, M...429, 2389, 2651 Tamaki, H...1261 Tamaki, M...780 Tamaki, Z...756, 965, 3005 Tamayo, M...1121 Tambiah, J...102 Tamborrini, G...2565 Tambralli, A...1297 Tamirou, F...958 Tamura, M...1197 Tamura, N...1746, 1907, 2728 Tamura, N...805 Tamura, Y...746 Tan, BK...1777 Tan, CD...2786 Tan, FK... 747, 751, 765 Tan, JHT... 1308, 1309 Tan, L...2685 Tan, P...828 Tan, PK...2963 Tan, W... 1046, 2095 Tan-Koi, WC...1808 Tanaka, A...1952 Tanaka, C... 2510, 2925 Tanaka, E... 430, 495 Tanaka, K...2345 Tanaka, K...2521 Tanaka, K...2467 Tanaka, L... 1814, 2844 Tanaka, N...232, 233, 1460, 2259 Tanaka, S...414, 1454, 2260 Tanaka, S...1696 Tanaka, T...1695 Tanaka, Y...508 Tanaka, Y... 2510, 2925 Tanaka, Y. 1483, 1541, 1890, 2427, 2447, 2467, 2472, 2691, 2806 Tanaka, Y... 1610, 2346 Tandon, M... 526, 530 Tandre, K...2681 Tanemoto, K...805 Tang, D... 494, 1540 Tang, F...1949 Tang, H...1653 Tang, J...48 Tang, MW... 392, 1198 Tang, Q...2685 Tang, T...1641 Tang, WW...1591 Tang, X...1394 Tang, X... 2351, 2449 Tang, X Sr....66, 1087, 1803, 2050 Tani, C... 2432, 2656 Tani, C...2755 Taniguchi, A...223, 226, 430, 495, 1061, 1123 Taniguchi, T...1724 Taniguchi, T...748, 749, 752, 756, 1724, 3003 Tanino, M...2458 Tanner, S...1570 Tansey, M...2833 TAO, K...1087 TAO, Q...2582 Tao, S...1752 Taoufik, Y...2928 abstract author Index Tap, J...622 2014 Program Book 337
abstract author Index 338 Tapp, RJ...1277 Taraborelli, M...18 Taran, A...2208 Tarcha, EJ...2738 Targoff, I...1317 Targoff, IN... 1318, 2210 Tarhan, EF...603 Tarn, J... 522, 2982 Taroni, J...750 Tarp, S...2589 Tarp, U.....................349 Tarrant, TK... 1961, 2878 Tarriela, M...1728 Tas, SW... 1960, 2802 Tasaki, Y...309 Tascilar, EK...2043 Tascilar, K... 2749, 2754 Tashkin, D... 751, 2995 Tasse, J...1777 Tasset, C... 1480, 1481 Tatangelo, M...2814 Tatar, Z...1428 Tatebe, N...678 Tateishi, K...1035 Tatibouet, S...723 Tattersall, R...1444 Taufiq, F...2246 Tauro, L...1291 Taurog, JD... 607, 620 Tausche, AK...2962 Tavano, A...140 Tavares, R... 1172, 1424 Tavoni, A...1772, 2755, 2855 Taxter, A...279 Tay, T...720 Taylor, A...57, 1546, 1589, 1849 Taylor, A...519 Taylor, C.............. 737, 2147 Taylor, J...487 Taylor, J...2317 Taylor, J...672 Taylor, J... 775, 880 Taylor, JJ...2872 Taylor, K...2471 Taylor, KE...520, 525, 2841, 2955 Taylor, L...1063 Taylor, PC...488, 1446, 2822 Taylor, V... 655, 2863 Taylor, W...162, 826, 2573 Tchao, N... 1754, 1766 Tchetverikov, I...139, 1571, 1583, 2815 Tchetverikov, I...120 Teal, TH...873 Tebib, J... 2481, 2928 Tedeschi, SK...867 Tegla, C...639 Teglbjaerg, CS...917 2014 Program Book Teh, LS...712 Teh, LS... 676, 711 Tehlirian, C...666 Tehrani, R... 1244, 1985 Tejasvi, T...625 Tejedor, D...1290 Tekano, J...1870 Tekin, L...253 Tektonidou, M...958, 2617, 2868 Teku, G...761 Teleman, A...1549 Telliez, JB...1514 Telliez, JB... 1614, 1616 Tello-Winniczuk, N...1427 ten Cate, R... 293, 932 Tena, X...568 Tencer, T... 1595, 1597 Teng, CC... 494, 1540 Teng, GG... 1808, 1873 Teng, L... 1564, 1565 Tenner, C...176 Tenner, CT...156 Teo, YY... 2918, 2954 Teos, LY...529 Tepper, S... 2765, 2856 ter Haar, N. 1231, 2279, 2280, 2282 ter Wee, MM...2127 Terabe, K... 471, 2516 Teramura, T.......... 1016, 1885 Terao, C... 805, 806 Terkeltaub, R.... 1013, 1206, 2949 Terreri, MT... 1898, 2712 Terrier, B. 1759, 1763, 1767, 1768, 1769, 1774, 1776, 1778, 1782, 1792, 1864, 2549, 2731, 2777, 2778 Terry, K...849 Terry, KK...460 Terslev, L...2589 Teruya, J...2273 Terwee, C...260, 261, 3018 Terzioglu, E...2157 Tesoro-Cruz, E..............1947 Testi, A...1637 Tetreault, P...925 Tévar, MI...40 Tévar Sánchez, MI...2598 Tezcan, ME...2548 Thaci, D...1560 Thai, J...2782 Thakur, U..................2148 Thanou, A...707, 866, 1605, 1921 Thava, A...600 Thavaneswaran, A...542, 624, 630, 1568, 1576, 1587, 1592, 1593, 2605, 2607, 2935 Thawait, G...2148 the CA Investigators Group, F... 2294 the CARRA investigators, F...1315 the CARRA Registry Investigators, F. 2294 the Vasculitis Research Consortium, F...808 Theander, E...519, 589, 1549 Theek, C...357 Theiler, R...2971 Theis, JC...2897 Theis, KA... 72, 1092 Theodoridou, A...298 Theriault, C... 961, 2646 Therneau, TM... 1052, 1405 Thervet, E... 1792, 2549 Thévenin, F...540 Thibodaux, R...2191 Thiel, S...1200, 2171, 2299 Thiele, G... 1470, 1475 Thiele, GM...2456 Thiele, GM.. 348, 840, 1620, 2782 Thiele, K...1154 Thielman, N...1296 Thiolat, A...335 Thirunavukkarasu, K...461 Thiyagarajan, T... 661, 2741 Thomas, D...1502 Thomas, G.................1886 Thomas, H.................1503 Thomas, K...1355 Thomas, LW...1201 Thomas, M...2689 Thomas, R.154, 618, 632, 950, 2460 Thombs, BD...1089 Thompson, A...1641 Thompson, B...1444 Thompson, H...2396 Thompson, K...797, 961, 2646 Thompson, LF...2978 Thompson, PR...641 Thompson, SD...1900 Thompson, T................862 Thomsen, H... 1171, 1188 Thomson, J...757 Thomson, T...75 Thomson, W...272, 274, 295, 303, 1900, 2294 Thongprayoon, C..726, 799, 1253, 2531 Thorne, C...2912 Thorne, C. 365, 382, 383, 386, 421, 943, 1551 Thorne, JC...371, 394, 492, 1387, 1833, 2309, 2410 Thorp, LE... 213, 2245 Thullen, M...25 Thunem, C... 1383, 2035 Thurlings, RM...450 Thurman, J...2182 Thyberg, I...2435 Tian, H... 118, 2125 Tian, SY...1295 Tidwell, B...2121 Tigen, K...1423 Tijhuis, GJ... 2053, 2054 Tikly, M...423 Tillett, W...546 Tilley, J... 322, 1512 Tillmanns, S...2833 Tilson, HH...833 Timlin, H...1667 Timman, R...2382 Timoshanko, J...102 Timoshchenko, R... 1961, 2878 Timsit, MA...2606 Tin, D...371, 394, 1387, 2410 Tincani, A...4, 15, 18, 671, 1532, 1642, 2868 Ting, K...789 Ting, T...1104 Tiniakou, E...856 Tintinger, G...423 Tiple, A...1413 Tislow, J...836 Titcombe, P................2874 Titze, J...345 Tiwari, H...451 Tiwari, HK...2454 Tiziani, S...935 Tjensvoll, AB... 1169, 2652 Tkacz, J... 1149, 1832 Tng, H...2657 To, CH...2633 To, J...860 Tochimoto, A.877, 1264, 1710, 2991 Todd, J...373 Toder, K...1994 Todoerti, M... 483, 2609 Toellner, K...1045 Toenhake-Dijkstra, H.. 1222, 1223 Toepfer, D...2136 Toes, REM... 1515, 2102 Toes, REM... 454, 2392 Togo, O...2472 Toh, M...490 Tohma, S.82, 85, 86, 87, 1842, 2457 Toib, D...2293 Toktas, H...1111 Tokuhira, M........... 470, 1398 Tokunaga, T................2509 Toldos, O...660 Toledo Del-Rio, AP...733 Toledo-Garcia, A. 2195, 2196, 2197, 2444 Toloza, S...681, 716, 1673 Tolstykh, I... 1276, 1820 Tolusso, B...403, 999, 1639, 1971 Tomala-Haz, J...1311 Tomasson, G...787 Tomelleri, A...2202
Tomero, E... 1670, 2622 Tomiita, M............ 143, 2541 Tomita, U...1461 Tomizza, M... 1172, 1424 Tomobe, M...457 Tomsic, M.. 514, 788, 1524, 1789, 1790, 2041, 2524 Tongu, K...496 Toniolo, M...2565 Tonner, C.. 112, 1084, 2048, 2109, 2123, 2124, 2405 Tony, H...459 Tony, HP...497, 940, 996, 2915 Toole, J...1851 Toplak, N...1325 Topless, R...21, 168, 2959, 2961, 2962 Torene, R...305 Torgutalp, M... 509, 1432 Toribio, R...1888 Tormey, V...305 Torner, J...................1821 Torner, JC...212, 973, 1286 Tornero, J...59, 1129, 2097 Torok, KS...1321, 1324, 1897 Torralba, KD... 681, 716 Torralba, KMD...1993 Torras, J... 1657, 1659 Torre Salaberri, I. 1250, 1252, 2853 Torre-Alonso, JC... 59, 596 Torrealva, H...1393 Torrente, V...1670, 2276, 2622 Torrente-Segarra, V...474 Torres, B...2697 Torres, on behalf of the CAP study investigators, J...1928 Torres-Barrera, G...739 Torres-López, E...1425 Torretti, D...1830 Tortosa, R...59, 1129, 2097 Torun, T...2704 Tory, HO...2122 Tosun, B...1574 Tóth, E... 174, 175 Toth, M... 273, 2277 Totoson, P... 337, 2360 Totsuka, K...457 Touma, Z...685, 2634, 2640 Toupet, K...1726 Tourkina, E...763 Tournadre, A...1448 Tousseyn, T...316 Toussirot, E...991, 2204, 2779 Touzard, C... 2434, 3011 Tovar, JV...474 Townsend, AF...2442 Toyama, T.748, 749, 752, 756, 1724, 3003 Toyama, Y...1123 Toyoizumi, S...508 Toyoshima, Y...............1028 Toyota, Y...133 Tozkir, H.....................79 Trabattoni, D...397 Trachana, M...277, 282, 298, 928 Trad, M...2849 Tran, C...2164 Tran, M...1544 Tran, P...922 Tran, T...2790 Tran, TM... 607, 619 Tran, V...2386 Trapiella, L..................747 Trauzeddel, R...282 Travers, T...437 Treadwell, E...2378 Treadwell, EL...370, 1375, 2413 Treharne, G... 173, 2377 Trenkmann, M.92, 967, 1977, 2450, 2785 Tresadern, P...737 Tress, J...281 Treviño-Montes, D... 1420, 1425 Trevisani, VM...709 Treyvaud, MO...2984 Triclin, N...2193 Triedman, NA...2008 Trinder, S...1706, 1717, 1728 Triolo, G... 610, 611 Trisolino, G...1292 Trojanowska, M...764, 766, 1720 Trojanowski, M...2200 Troldborg, A...1200 Tropé, S...291 Trouillet, S...2779 Trouw, L...1515 Trouw, LA...2138 Trouw, LA...441, 454, 2392 Troxell, M...1236 Troyanov, Y...2210 Trujillo, E...555 Trujillo, MDM...555 Truong, D...2542 Truong, K..................1307 Trupin, L.98, 420, 1084, 1856, 2049, 2109, 2405 Trzcinska-Butkiewicz, B...1715 Tsai, FN...2166 Tsai, W.....................816 Tsalapaki, C... 1254, 1466 Tsang, K...28, 1732, 2796 Tsang, L...2461 Tsao, HW...2917 Tsao, PH...1809 Tse, D...1756 Tse, SM...2633 Tse, SM...269 Tseng, CH...2995 Tsoi, LC...625 Tsokos, GC.1033, 1725, 2675, 2677, 2682, 2734, 2846 Tsou,... 1962, 3006 Tsoukas, A...1771 Tsuboi, H...2352 Tsuboi, N...1651 Tsuchida, N... 125, 133 Tsuchiya, N...82, 85, 86, 87, 2457 Tsuda, T...2021 Tsuji, S...2389 Tsukamoto, H... 1000, 1952 Tsukamoto, M...1469 Tsukimi, Y...965 Tsumiyama, K... 2510, 2925 Tsuzaka, K...2529 Tsuzuki, H... 1000, 1952 Tu, K... 1833, 2309 Tu, S...1616 Tubach, F... 473, 1385, 1837, 1838 Tubery, A...2527 Tucker, K...2047 Tucker, LB. 292, 1303, 1304, 1825, 1826, 1870, 2288 Tuckwell, K...803 Tufan, A...2761 Tugal-tutkun, I...2852 Tugwell, P...1933 Tulio de Mello, M...709 Tunc, R...2854 Tuncay, F...1110 Tunceli, O... 901, 1143 Tuncer, T...1105 Turesson, C. 42, 358, 436, 501, 504, 510, 1477, 1596, 1804 Turgut Ozturk, B...2854 Turiel, M...2550 Turina, M...577 Turina, MC... 561, 850 Turk, S... 359, 361, 362, 405, 408, 1903, 2400 Turkiewicz, A...206 Turkmen, U...1111 Turner, JD...2463 Turner, R...1214 Turner, S...964 Turpin, R...2121 Turrent, A...11 Turrión Nieves, A...1683 Tuttle, P IV...400 Twilt, M...286, 287, 293, 2287 Tymms, K...2419 Tytus, S... 1172, 1424 Tzaribachev, N...933 Tzaribachev, N...1192 Tzioufas, AG...478, 1980, 2100 Tzontcheva, A...2938 Tälli, S...58 Töyrä Silfverswärd, S...435 U Ubara, Y...1235 Ubilla, B.. 1787, 1788, 2203, 2452, 2459, 2461 Ucar, E...1670 Uchida, K...1939 Uchino, K...2764, 2765, 2856 Uda, H... 506, 1533 Udata, C...1501 Ueda, A...123, 125, 133, 805 Ueda, S...719 Ueda, Y...646 Ueki, N... 1000, 1952 Ueland, T...2703 Ueng, J...1780 Ueno, K...309 Uetani, M... 429, 2389 Ugarte, A...2868 Ugarte-Gil, MF...1393 Ugurlu, S. 1232, 1233, 2043, 2749, 2751, 2752, 2759, 2760 Uhart, M...918 Uher, M.280, 851, 2371, 2422, 2580 Uhlig, T. 101, 356, 905, 944, 1164, 1373 Ukichi, T...2214 Ukyo, Y...2521 Ulasli, A...1111 Ulasli, M...2744 Ulmansky, R... 636, 2350 Ulrichts, H...1498 Umar, S...2879 Umeda, M...429, 2389, 2651 Umeda, N...2346 Umehara, H...525 Umekita, K... 92, 2159 Umemura, M...2509 Umicevic-Mirkov, M...2966 Uña, C...1093 Unal, AU...2769 Ungprasert, P...726, 799, 2531 Unizony, S...802, 1754, 1766 Unlu,Ozkan, F...2057 Unnebrink, K................269 Uno, M...2220 Unwin, R...78 Uppuluri, RR...2436 Urbanova, M...1159 Urbanova, Z...2422 Urbanski, G...1792 Urbonaviciute, V...1735 Uriarte, E............ 1670, 2622 Uribe, N...1654 Uribe Woolnough, L...1305 Urowitz, M...2646 abstract author Index 2014 Program Book 339
abstract author Index 340 Urowitz, MB...685, 690, 699, 865, 961, 1858, 1859, 2631, 2634, 2640, 2791 Urraro, T...2855 Urrego, C...40 Urruticoechea, A...474 Urso, K...1732 Ursu, S...932 Urtiaga, B...2063 Urtiaga, J...2063 Uruha, A...2223 Usategui, A...134, 660, 992, 1739, 1969 Usategui, R...74 Uslu, S...603 Ustek, D...2852 Ustun, I...2057 Utku, U...2270 Utset, T...679 Utset, TO...432 Utz, PJ...878, 2688, 2737 Uyanik, MS...79 Uziel, Y...931 Uziel, Y.277, 284, 1231, 2279, 2280, 2282, 2899 Uzunaslan, D... 2704, 2754 Uzunhan, Y...1037 V Vacca, A.............. 613, 2559 Vachon-Presseau, E...925 Vagelli, R...2201 Vaglio, A... 776, 880 Vagnani, S... 2432, 2656 Vaillancourt, J... 583, 1551 Vaiopoulos, AG...1462 Vakil-Gilani, K...547 Vaknin, I...2359 Valcov, R... 157, 158 Valdeolivas Casillas, N...1683 Valena, C...2768 Valentin, MA...885 Valentini, G... 523, 967 Valenzuela, A... 721, 2996 Valenzuela, G... 2253, 2471 Valera, I...767 Valero, JL...2119 Valesini, G...2544 Valiente, G... 1204, 2687 Valieva, S...2296 Valino-Seoane, I...1138 Valle-Oñate, R..............2608 Vallejo, AN...1897 Vallet, H...2757 Valls, E...1252 Valls Pascual, E... 1674, 2853 Valter, I...1795 van t Klooster, G... 1480, 1481 2014 Program Book van t Klooster, R...2141 van t Spijker, A...2382 van Adelsberg, J... 2795, 2824 van Aken, J...1930 Van Assche, G...804 van Baarsen, LGM...2448 van Beijeren Bergen en Henegouwen, D...1626 Van Beneden, K...1479 van Bijnen, ST...2178 van Bon, L...1203 Van Brunt, D...2621 van Brussel, M...1317 van Busschbach, J...2382 van Caam, A...1004, 1017, 1049, 2793 van de Laar, MA...2966 van de Loo, F...638, 1004, 2793 van de Loo, FA...1036 van de Loo, FAJ... 1049, 1816 Van De Sompel, A...1498 van de Venne, M...1358 Van De Vyver, C...203 Van De Wiele, T...638 van den Bemt, B... 500, 1843 van den Berg, R... 575, 577 van den Berg, R...540, 594, 2597, 2937 van den Berg, S...1735 van den Berg, W. 1004, 2348, 2793 van den Berg, WB...1199 van den Berg, WB...20, 76, 1017, 1036, 1733, 1734, 1816, 2948, 2950, 2952 van den Bergh, J...2143 van den Bersselaar, L.. 1036, 1733, 1734 van den Bos, T... 2053, 2054 Van den Bosch, F..557, 574, 1545, 2134, 2600, 2828, 2988 van den Bosch, M...........1199 van den Bosch, MH.. 20, 76, 2948 van den Broek, M...2502 van den Ende, CHM... 976, 2860 van den Ende, E... 204, 2249 Van den Eynde, B...316 van den Hoek, J... 2053, 2054 van den Hoogen, FHJ.76, 500, 1843 Van Denderen, CJ...572 van Denderen, JC...2558 Van der Aa, A...1481 van der Bijl, CMA...580 van der Burg, L...582 van der Esch, M...1451 van der Geest, KSM...1956 van der Heijde, D.2573, 2912, 2938 van der Heijde, DM.575, 577, 1174, 1181, 1379 van der Heijde, D...361, 540, 552, 553, 557, 565, 582, 584, 594, 905, 953, 954, 1164, 1186, 1187, 1387, 1552, 1553, 1822, 1890, 1894, 2137, 2387, 2560, 2561, 2571, 2579, 2586, 2588, 2589, 2592, 2597, 2600, 2601, 2828, 2937, 2984 van der Heijde, DM. 543, 544, 545, 562, 566, 574, 852, 2472 van der Helm- van Mil, AHM..1379 van der Helm- van Mil, AHM...454 van der Helm-van Mil, AHM...90, 1174 van der Horst, A...450 van der Horst, C...2802 Van der Horst - Bruinsma, IE..2583 van der Horst-Bruinsma, IE...580, 2558 van der Horst-Bruinsma, IE.572, 573 van der Kallen, J...490 van der Kleij, D...2400 van der Kraan, P. 1004, 2348, 2793 van der Kraan,...20, 76, 1017, 1049, 1199, 2948, 2950 van der Laken, CJ... 580, 2127 van der Laken, CJ... 354, 2093 van der Leeden, M...1451 van der Leij, C...1960 van der Lubbe, PA...1386 van der Maas, A... 500, 1843 van der Poll, T...833 van der Veer, E...2831 van der Vegt, B...2551 van der Ven, M...139, 1571, 1583 van der Ven, M...120 van der Weijden, MAC.. 580, 2558 van der Windt, D...1114 van der Zee-Neuen, A... 70, 2113 Van Deuren, R...1720 van Duivenvoorde, LM.. 620, 1916, 1973 van Erp, AE...2948 van Eyk, J...................815 van Gaalen, F... 575, 577 van Gaalen, F...594, 2579, 2597, 2937 van Geffen, EW.............1017 van Groenendael, JH...817 van Hagen,... 1799, 2979 van Hamburg, JP... 1738, 1749 van Herwaarden, N... 500, 1843 van Hijum, S...1816 van Hoogstraten, H... 1522, 2823 Van Hooser, A... 75, 1619 van Iersel, T...1493 van Krugten, M...2815 van Laar, JM...874 van Leeuwen, J... 260, 261 van Leeuwen, J...1749 van Lent, PL...20, 76, 1199, 2348, 2948, 2950, 2952 van Loosdregt, J...1455 van Marle, S...1493 Van Mater, H...2293 van Nies, JAB...454 van Nieuwenhuijze, AEM...1036 van Nimwegen, JF...2547 van Onna, M...2572 van Oosterhout, M. 575, 577, 2138 van Pelt, PA...107, 300, 1871 Van Praet, J...638 Van Praet, L................2988 van Riel, P...1837, 1838, 2524 van Riel, PLCM...2966 van Rietbergen, B...2143 van Rij, AM...2959 Van Rompaey, L...1494 van Roon, JAG......... 336, 2725 Van Rossum, MAJ... 293, 932 Van Roy, M...1498 van Royen-Kerkhof, A...933 van Royen-Kerkhof, A. 1316, 1317, 1325 van Schaardenburg, D.. 408, 2912 van Schaardenburg, D...359, 361, 362, 405, 450, 1903, 2104 van Sijl, A...1909 van Sijl, AM...354 van Steenbergen, HW.90, 454, 1379 van Suijlekom-Smit, LWA. 293, 300, 932 van Tok, MN... 620, 1916 van Tubergen, A...2143 van Tubergen, AM...2828 van Tubergen, A...574, 578, 579, 2572, 2592, 2600 van Tunen, J...1451 Van Veenendaal, M...290 van Vilsteren, M...2104 van Vollenhoven, R... 508, 2835 van Vollenhoven, R.464, 672, 1350, 1524, 1528, 2126 van Vollenhoven, RF...2525 van Vollenhoven, RF.364, 367, 376, 500, 961, 1843, 1845, 2515, 2517, 2524, 2646 Van Voorhis, D... 1158, 1882 van Weely, SFE... 572, 573 van Winkelhoff, AJ...441 van Zeben, D... 120, 2815 van Zoest, K.............1960 van Zuiden, GS...2547 Vandeloo, C...1077 Vandenhende, MA...811 Vandepapeliere, P...1609 Vanderburgh, S...1825 Vanderkooi, O...2275 Vankayalapati, H...1484 Vanstone, L...1507 Varela, CF...1783 Varela-Eirin, M...1034
Varga, J...727 Varga, J.. 725, 729, 745, 750, 965, 966, 1929, 3005 Vargas, AB...1436 Vargas, M...2967 Vargas-Guerrero, A...894 Vargas-Hitos, J...747 Vargas-Lebrón, C...2276 Varisco, V... 142, 2976 Varkas, G...2988 Varley, C... 230, 231 Varothai, NA... 553, 1545 Vasconcelos, C...958 Vasconcelos, O...2330 Vaseer, S...707 Vashisht, P...2927 Vasileiou, P...1254 Vassilopoulos, D... 1254, 1466 Vastert, B. 1231, 1325, 2279, 2280, 2282 Vastert, SJ...284 Vastesaeger, N... 2477, 2493 Vatankulu, B...2751 Vavrincova, P...273 Vayssière, B...1494 Vayssièrre, B...1480 Vazhappilly, S...2275 Vázquez, J...2853 Vázquez on behalf of RENACER Study Group, N...474 Vázquez Rodríguez, T.. 1670, 2622 Vázquez-Mosquera, ME.1121, 1122, 1125 Veale, D...2477, 2798, 2875 Veale, DJ...58, 109, 779, 884, 1044, 1195, 1977, 1979, 2181, 2312, 2800 Vedamurthy, D...1394 Veeramreddy, D...2275 Vega, G...1305 Vega, L...3008 Vega-Fernandez, P...1825 Vega-Morales, D.. 739, 1420, 1425, 1427, 2251, 2644 Veigl, D...1039 Vela, P...99, 814, 829, 2622 Vela Casasempere, P...1670 Velasco, T...2412 Velayudhan, J...1503 Velazco-Caspia, J...894 Vélazquez-García, A...710 Velez, S... 887, 2441 Velloso Feijoo, ML...1240 Veloso, E...406, 1388, 1438, 2381 Velozo, EJ...2040 Velsko, I...936 Vemuri, S...1840 Venables, P...433 Venalis, P...2726 Vencovsky, J... 851, 910, 1039, 1128, 1316, 1486, 2085, 2422, 2821, 2953 Vencovsky, MD, DSc, J... 280, 912 Venditti, C...908 Venkataramanan, V...2437 Venkatram, M...718 Venn, A... 208, 209, 229 Venning, M... 1760, 1863 Ventosa, J...1250 Venuturupalli, S...2978 Vera-Lastra, OL...1984 Verazza, S...299 Verbeek, S...2348 Verbruggen, G... 203, 2134 Verbruggen, N...2268 Veres, G...2284 Vergara, C...1702 Vergara, F...2402 Vergés, J...1290 Verheul, MK...2138 Verheul, MK...2392 Verheul, MK...441 Verhoeven, F... 559, 2360 Verma, I...1450 Vermeulen, S...2966 Vernet, N..................2928 Veroz Gonzalez, R... 597, 2190 Verrill, J...1345 Verrouil, E...202 Verschueren, K...1479 Versnel, MA... 1799, 2979 Verstappen, G...2934 Verstappen, S... 78, 2031 Verstappen, SM... 1382, 2032 Verstappen, SM...2392 Verweij, CL...2093 Vettori, S... 523, 967 Viallard, JF...1864 Viana, VDST...2221 Viana, VST... 2151, 2933 Vicedomini, L...523 Vicente, E...3008 Vicente-Rabaneda, E...2144 Vickers, KC...1437 Vickery, M...1299 Vidal, C...393 Vidal, E...783 Vidal, M...................1093 Videm, V...154 Vieillard, V...1263 Vieira, SM...1, 856 Viger, ML...2339 Vignaux, O...1768 Vihinen, M...761 Vij, R...432 Vijayan, R...2774 Viklicky, O...1863 Vila, D...148 Vila, LM...6, 681, 716, 2089 Villa, L... 912, 1316 Villa, N...1093 Villaggio, B... 1713, 1966 Villalba, A. 605, 1603, 2400, 2513, 2522 Villalba, JM...7 Villarreal, M...1766 Villarreal-Alarcón, M...739 Villeneuve, E..396, 502, 567, 1535, 1536, 2569 Villiger,...1193 Vina, ER...2968 Vincent, GR...1178 Vincent, S... 1495, 1500 Vinet, E...1866, 2664, 2665, 2666 Vinter, C...1777 Viola, S...299 Vis, M...139, 1571, 1583 Visconti, RP...763 Vishwanath, S...2546 Visscher, J...392 Vissing, R............ 1094, 1108 Vissink, A.. 441, 2547, 2551, 2934 Viswanathan, H...549 Vital, EM... 676, 1178 Vitali, C...531, 879, 1675, 1689 Vitielli, P...256 Vitolo, B... 988, 2403 Vittecoq, O...132, 395, 521, 1517, 2923 Vittecoq, O...520, 1140, 1471 Vitters, E... 1004, 2793 Vives, F...649 Vivino, FB... 525, 2545 Vizjak, A...1789 Vlachoyiannopoulos, P. 1928, 1980 Vlachoyiannopoulos, PG. 478, 2709 Vlahos, B...459 Vlamynck, E...2081 Vleugels, RA...2226 Vliet Vlieland, T... 976, 2860 Vliet Vlieland, T...2329 Vo Hoang, V...540 Voaklander, D...2023 Voelker, J...677 Voelker, K...1163 Vogel, U...................2500 Vogl, T...932, 1199, 2988 Vogler, LB...2290 Volin, M...1510 Volin, MV...2799 Volk, R...427, 2005, 2009, 2244 Volkmann, E... 2697, 2995 Volkov, A...647 Volkov, S...1510, 1702, 2799 Voll, RE... 345, 2833 Volpi, S...314 von Dalwigk, K...1022 von Kempis, J...2366, 2913, 2914 von Scheven, E...1828 von Spee-Mayer, C...2837 Vonk, MC...747 Vonortas, S...1212 Voorhees, JJ...625 Vora, SS... 2317, 2318 Vordenbäumen, DS... 130, 153 Vordenbäumen, S...357 Vorup-Jensen, T...1964 Vos, P...1733 Voskuyl, AE... 2104, 2127 Voskuyl, AE...354, 753, 2093 Voss, A...1633 Voss, J...1499 Vosslamber, S...2093 Vostretsova, K...915 Vougiouka, O... 928, 2281 Voulgarelis, M... 1047, 2090, 2100 Voulgari, PV... 592, 1170 Vradii, D...144 Vree Egberts, W...443 Vriezekolk, JE...204 Vroman, H...1738 Vsetecka, D...1617 Vulcano, A...1637 Vuolteenaho, K...1011 Vuong, TT...398 Vyse, S...869 Vyse, TJ...869 W Waagenaar, G...2572 Wada, J... 31, 678 Wada, Y...805, 1235, 1648 Wade, J...468 Wade, S...919 Wager, C...1920 Wagman, RB...2267 Wagman, RB...917 Wagman, R... 918, 2254 Wagner, C...2835 Wagner, C... 348, 1476 Wagner, F...1492 Wagner, S...497 Wagner-Weiner, L...2903 Wahba, K...110 Waheeduddin, S...53 Wahezi, D... 1315, 2903 Wahl, D...2866 Wahl, ER...420 Waimann, CA..127, 128, 406, 887, 1388, 2381, 2441 Waisberg, MG...2809 Waisman, G...410 Wakabayashi, H...678 abstract author Index 2014 Program Book 341
abstract author Index 342 Wakabayashi, K...2509 Wakasugi, K...1255 Wakazono, H...267 Wakefield, R...132 Wakefield, RJ...124, 137, 2772 Wakeland, E...1606 Wakiguchi, H...2274 Wakkee, M...1583 Wakura, D...1784 Walczak, H...869 Waldron, N...546 Wale, N...1614, 1616, 2873 Walgreen, B...1036, 1733, 1734 Walimbe, M...1276 Walitt, B... 896, 1106 Walitt, BT... 892, 893 Walker, D..................2438 Walker, H...1836 Walker, M...1246 Walker, S...1331 Walker, S...2475 Walker, U... 2711, 2971 Walker, UA...833, 1524, 2699 Walkup, M...3007 Wallace, CA... 275, 297 Wallace, CA... 273, 289 Wallace, D...681, 716, 1079 Wallace, DJ...672, 705, 961, 1673, 2646, 2834, 2880 Wallace, D...1869 Wallace, Z...1349, 2804, 2805 Wallenstein, G... 100, 2487 Wallis, BB...438 Walliser, J...2268 Walsh, D...1841, 2810, 2965 Walsh, DNE... 2328, 2331 Walsh, J...1570 Walsh, L...1031 Walsh, NE... 2006, 2327 Walter, JE...314 Walther, T...773 Waltman, BA...2841 Wamhoff, B...439 Wampler Muskardin, T...2927 Wan, J...2654 Wanat, KA...2189 Wand, H...878 Wang, A...2267 Wang, A...955 Wang, B...................1023 Wang, B...................1496 Wang, C... 263, 1116, 1336, 1337, 2065, 2337, 2338, 2858 Wang, CR... 324, 2344 Wang, D...960 Wang, ECY..................341 Wang, F...2851 Wang, FS...1005 2014 Program Book Wang, H...1941 Wang, H...2038 WANG, J...2582 Wang, J...2164 Wang, J...617 Wang, K... 66, 1803 Wang, L... 849, 1514 Wang, LC... 858, 2839 Wang, L...719 Wang, L...2957 Wang, L...1653 Wang, Q...984 Wang, Q...696 Wang, Q...1953 Wang, R...................1478 Wang, S... 2351, 2449 Wang, S...654 Wang, S...2632 Wang, SX...2237 Wang, T...2539 Wang, W...1889, 2816, 2919 Wang, W... 965, 3005 Wang, XY...2165 Wang, X...1185 WANG, X...2582 Wang, X...378 Wang, Y...2172, 2843, 2905 Wang, Y...1027 Wang, Y...218, 1277, 1278 Wang, Y...539, 1548, 1554 Wang, Y...327, 1013, 1206, 2949 Wang, Z...1209 Wang, Z...1953 Ward, MM...569, 588, 608, 617 Wardwell, PR...2362 Ware, C...638 Ware, MA...265 Waring, JF...1131 Warmington, K...1932 Warner, RL...808 Warrell, RP Jr....830 Warren, RB...2924 Warriner, AH...49 Warrington, KJ... 801, 808, 880 Warters, M...1987 Wasko, MCM...1395 Wassenberg, S...1154 Wasserman, S...2669 Watanabe, A...2472 Watanabe, H...678 Watanabe, H...2653 Watanabe, KS...678 Watanabe, R...1950 Watanabe, S...2906 Watanabe, T...2159 Watanabe, T...2, 5, 1179, 1628, 2638, 2864 Watanabe Duffy, KN...2288 Waterton, J... 1182, 1464 Watkins, A..................662 Watson, K...1909 Watson, KD.. 467, 676, 1542, 1848 Watts, G...2455 Watts, N...918 Watts, NB... 917, 2268 Watts, R...775, 880, 1760 Watts, RA... 794, 1758 Wax, SD... 666, 2838 Weaver, F... 2105, 2106 Weaver, J...48 Weaver, LK...2168, 2281, 2876 Webb, D...1395 Webb-Detiege, T...1465 Weber, U...2589 Webers, C...2600 Webster, A...1884 Webster, F...2437 Wechalekar, MD...2034 Wechsler, B...2757 Wedderburn, L...303 Wedderburn, LR.. 932, 1314, 2953 Wedderburn, LR...274, 295, 1900, 2900 Weel, AEAM. 120, 139, 1571, 1583, 2815 Wei, J...966 Wei, M...187 Wei, N...631 Wei, Y...665 Weichenthal, M...625 Weinberg, E...2416 Weinblatt, M.385, 1141, 1362, 2103 Weinblatt, M...1520 Weinblatt, M...1369, 1370, 1485, 1486, 2821 Weinblatt, ME...479, 1335, 1408, 2889, 2973 Weiner, HL...1748 Weinshilboum, RM...2957 Weinstein, A...1924 Weisleder, N...2219 Weisman, M...705, 1287, 3013 Weisman, MH.. 446, 569, 588, 617, 681, 716, 1079, 1673, 1904, 1937, 2019, 2880, 2891, 2921, 2978 Weiss, JE... 2271, 2318 Weiss, M...2269 Weiss, P............. 1299, 1895 Weiss, PF...279, 319, 2293 Weitoft, T...1534 Weitzman, D...2067 Weller-Heinemann, F...933 Weller-Heinemann, F...282 Welling, J...2699 Wells, A...122, 602, 1543, 1572 Wells, AU...2999 Wells, C...276 Wells, G... 962, 1051 Wells, GA...1660 Wen, J...651, 664, 1941 Wen, L...2266 Wen, ZH...323 Wendler, J...940 Wendling, D.43, 337, 473, 556, 559, 2360, 2554, 2556, 2557, 2568 Wener, MH...453, 742, 1638 Weng, CT...2344 Weng, H... 1495, 1500 Weng, H...2477, 2493, 2938 Weng, H...1528 Were, E...2289 Wermuth, PJ...771, 774, 1722 Werner, D...1892 Werner, SG...2129 Werth, V...1208 Werth, VP... 1646, 2206 Wessel, A...1212 Westfall, A.................1474 Westfall, M...1616 Westhovens, R. 260, 261, 316, 479 Westra, J... 441, 1626 Westrich, GH...1043 Wevers-de Boer, KVC...2138 Weyand, CM... 438, 1742 Whalen, E...2080 Whalen, E...1611 Wheeling, T...2037 Wherry, EJ...1899 Whibley, D...975 Whiskin, C...1507 Whitaker, JW...1889, 2816, 2919 White, CJ...156 White, D...66, 1286, 3007 White, DK...1083 White, DH...2959 White, D...1020 White, JC...1158 White, T...2115 White, V... 1236, 1756 White, W............ 1486, 1619 Whitehead, G...2442 Whitelegge, J...91 Whitfield, M...750, 772, 1723 Whitlock, KB...275 Whittaker, M...2044 Wichers, R...757 Wichuk, S. 855, 1893, 2577, 2613, 2986 Wichuk, S...591, 2615, 2985 Wick, J...2242 Wick, M...2589 Wicks, I...2842 Wicks, IP... 1036, 1467 Widdifield, J...1065, 1833, 2309, 2814 Wiebert, P.................2016 Wiederkehr, D...100, 1145, 2406
Wiemann, O...2129 Wiese, MD...2520 Wiesenhutter, C...1487 Wiest, C...998 Wigaard, E...786 Wigler, I... 443, 971 Wigley, FM...728, 741, 745, 964 Wiik, A...398 Wijarnpreecha, K...2531 Wijmenga, C...880 Wikberg, JES...1516 Wiland, P...1508 Wilbe, M...2673 Wilder, E...2246 Wilder, T...19, 2792, 2947 Wildt, M... 737, 761 Wiley, GB...2978 Wiley, K...1303, 1304, 1825, 1826 Wilkerson, J... 2211, 2222 Wilkinson, B...2488 Wilkinson, B... 487, 1181 Wilkinson, F...1699 Wilkinson, JM...2817 Wilkinson, J.................728 Willard, B... 987, 2765 Willems, W...1479 Willemsen, L...1733 Williams, A...1485 Williams, AE...1143 Williams, AS... 30, 341 Williams, D...1358 Williams, DA... 252, 924 Williams, F...1884 Williams, H...1182 Williams, JO...341 Williams, K...2962 Williams, K...1208 Williams, M...302 Williams, RO...2359 Williamson, D...895 Willig, J...1422 Willis, L...415 Willis, R... 6, 2650 Willis, W...1204 Willisch, A...596 Wilner, G...1043 Wilson, AG.2798, 2817, 2875, 2924 Wilson, D... 1236, 1756 Wilson, DR...2362 Wilson, F...2916 Wilson, G...662 Wilson, H... 549, 3013 Wilson, K...1142 Wilson, M...1467 Wilson, M...1869 Wilson, N... 53, 2842 Wilton, K...1852 Wimalasundera, S...2469 Wimmer, M...213 Wimmer, MA...2245 Winchester, R...2972 Windhager, R...1022 Windsor, W... 322, 1512 Wing, L...2309 Wingrove, J...2863 Wink, F...2831 Winkelmann, SJ...485 Winklehner, A...2998 Winkler, AR... 1614, 1616 Winkler, A...1352 Winn, D...1356 Winnier, DA...1133 Winter, E...2061 Winthrop, KL... 820, 1546 Winthrop, KL. 57, 844, 1589, 1849 Winzenberg, T...926 Wipf, P.....................769 Wirth, JR... 637, 1213 Wirth, W...210 Wise, BL...1801 Wishart, N...1499 Wisniacki, N...1920 Wisniewski, SR...404, 1410, 2997 Wisseh, S...2826 Witcher, J...677 Witcombe, D...461 Wither, J... 656, 2787 Wither, JE... 652, 2742 Withers, D...1045 Withers, M...1287 witko-sarsat, V...783 Witt, M... 131, 2845 Wittbrodt, E...2121 Witte, D...1303, 1304, 1826 Witte, T.. 747, 753, 776, 777, 880, 2771 Witteman, HO...682 Wittig, B...1064, 1560, 2915 Wittoek, R...203 Wluka, A... 1277, 1278 Wofsy, D... 963, 2838 Wohlfahrt, A... 254, 1335 Wojdyla, D...959 Wolbink, GJ...2400 Wolbink, G...2093 Wolcott, E...1337 Wolf, B...1669 Wolf, DC...1409 Wolf, J...1500 Wolfe, F.. 480, 892, 893, 896, 1106 Wolfe, J...252 Wolfe, K...793 Wolinsky, F...54 Wollenhaupt, J...2493 Wollenhaupt, J...849 Wollenhaupt, J...545, 1561, 1579 Wollenhaupt, J...548, 1564, 1590 Woller, S...2784 Wolover, L...1924 Wolska, N...1798 Won, S... 1056, 2025 Wong, A...1236 Wong, B...1493 Wong, CK...374 Wong, D. 1515, 1521, 2468, 2485, 2486 Wong, H...815 Wong, J...1163 Wong, JB...263 Wong, Q...525 Wong, R...952 Wong, R...2437 Wong, TY..................1277 Wong, WK...2999 Wong-Pack, M...2257 Woo, JMP...1076 Woo, JM...972 Woo, P....................1900 Woo, YJ...1457 Wood, E... 581, 584 Wood, R...325, 934, 2353 Wood, S...2489 Wood, SP...849 Wood, TA... 750, 1723 Woods, M...2869 Woods, R..................1491 Woodward, J................873 Woolf, C...2783 Wopereis, H...1816 Worthington, J...747, 753, 1884 Wouters, C...284, 316, 933, 2279, 2280, 2282 Wouters, H...1479 Wren, JD...2978 Wright, A...2897 Wright, F... 2798, 2875 Wright, J... 2859, 2862 Wright, N...54 Wright, NC...49 Wright, T.. 1303, 1304, 1305, 1826 Wrightson, H...2438 Wu, A...2721 Wu, B...1143 Wu, C.....................1181 Wu, CL... 324, 2344 Wu, C.....................2683 Wu, CC...2361 Wu, CY....................1496 Wu, G...2973 Wu, G... 451, 2454 Wu, HJ...2674 Wu, H... 1172, 1424 Wu, H... 1523, 2373 Wu, LC...911, 1204, 2686, 2687 Wu, L...1318 Wu, L...2689 Wu, M... 745, 751, 754 Wu, PW...862 Wu, Q...1132, 1209, 2872 Wu, R.....................2680 Wu, S...1009 Wu, X...1949 WU, X...66, 1087, 1803, 2050 Wu, Y...1619 Wu, Z...644 Wulffraat, NM...931, 2297, 2298 Wulffraat, N...107, 277, 282, 284, 1231, 1325, 2279, 2280, 2282 Wulffraat, NM...1871 Wunderler, N...2743 Wuttge, D...761 Wyatt, J...2772 Wyatt, P...1827 Wyman, BT...1181 Wysham, KD...2827 Wållberg Jonsson, S...2084 Wållberg-Jonsson, S...1376 Wähämaa, H... 993, 2797 Wöhner, M...1943 X Xenitidis, T...2208 Xia, Y...562 Xia, Y...640 Xiao, R...1895 Xibille-Friedmann, D...1426 Xie, F... 169, 498, 820, 842, 1148, 1546, 1839, 1849, 1910, 2388 Xie, W...2782 Xie, Z...1181 Xing, J...952 Xing, L... 934, 2820 Xu, B...1735 Xu, D... 696, 2224 Xu, H...2918 Xu, L......................1862 Xu, P... 418, 2813 Xu, R...821 Xu, S...1714 Xu, S...2563, 2566, 2567, 2601 Xu, Y...2582 Xu, Y...2794 Xu, Z... 294, 1529 Y Yılmaz, V...253 Yabe, Y... 471, 2516 Yabes, J...1897 Yachie, A...309 Yacyshyn, E...2884 abstract author Index 2014 Program Book 343
abstract author Index Yaffe, K...1288 Yagci, I...151, 2057, 2769 Yagoto, M...2345 Yagüe, J...2176, 2179, 2508, 2926 Yahia, M...2162 Yahini, B...3012 Yair, S...2350 Yair-Sabag, S...607 Yajima, N...2509 Yaksh, T...2784 Yalavarthi, S...77 Yalavarthi, S... 641, 2867 Yalcinkaya, Y...1711 Yamada, H...1958 Yamada, H...82, 85 Yamada, H...145 Yamada, M...2712 Yamada, S...486 Yamada, Y...2992 Yamagata, K...2447 Yamagata, K...82, 85 Yamaguchi, KI... 2021, 2727 Yamaguchi, Y...1719 Yamaji, K... 1746, 1907 Yamakami, LYS...2221 Yamamoto, A...2843 Yamamoto, K. 457, 859, 1454, 2472 Yamamoto, M... 805, 1235 Yamamoto, S...............1437 Yamamoto, T. 232, 233, 1460, 2259 Yamamoto, Y...402 Yaman, A...246 Yamanaka, H...1061 Yamanaka, H...223, 226, 430, 495, 805, 877, 1123, 1255, 1264, 1640, 1710, 1890, 1939, 2427, 2465, 2467, 2472, 2991 Yamanaka, R...678 Yamane, T... 2510, 2925 Yamano, Y...2159 Yamaoka, K...2447, 2691, 2806 Yamasaki, H...1610 Yamasaki, M...1433 Yamasaki, M...965 Yamasaki, S...1001 Yamasaki, Y...2274 Yamashita, M...987 Yamashita, N... 146, 424 Yamashita, T...756 Yamatou, T...143, 1868, 2274 Yamauchi, M...2256 Yamazaki, H...1235 Yan, M...1606 Yan, Q...2453 Yan, X...2012 Yan, X...2582 Yan, Z...525 Yanagida, T...1218 Yanai, R...2509 Yancey, P...1437 Yancy, WS Jr....977 Yanez, D...2839 Yang, D...1812 Yang, GY...750 Yang, JA...166, 1220, 1403 Yang, J...2114 Yang, J...2909 Yang, L...1619 Yang, M...2342 Yang, P...1647 Yang, P...1132, 1209, 2872 Yang, S...47, 169, 170, 820, 842 Yang, W...1349 Yang, Y....................2685 Yang, Y....................2255 Yang, Z...1742 Yang, Z...2689 Yano, K...1123 Yao, Q...832, 1229, 1243 Yao, R...2477 Yao, R...1528 Yao, Y...719 Yarkan, H... 601, 2595 Yasar Bilge, S...2750 Yashiro, M...2653 Yasuda, K...662 Yasuda, S...2, 5, 456, 1179, 1628, 2638, 2677, 2864 Yasuhiro, T...267 Yasui, T...2260 Yasui, T...1454 Yasukawa, M... 1610, 2170 Yasuoka, H... 746, 2692 Yau, M... 81, 979 Yau, MS...2893 Yazar, M.....................79 Yazdani, R...714 Yazdany, J. 112, 420, 679, 698, 903, 1084, 1353, 1668, 1672, 1834, 1856, 2048, 2109, 2123, 2124 Yazici, A... 2157, 2750 Yazici, H.. 2749, 2751, 2752, 2759, 2760, 2854 Yazici, Y...69, 370, 378, 1375, 1580, 1844, 2378, 2413, 2528, 2732, 2756, 2854 Ybañez García, D...1674 Ye, B...966 Ye, Y...1949 Ye, Y...2689 Yeasted, RE... 242, 925 Yeatts, P... 1236, 1756 Yee, A...446 Yee, CS................ 676, 711 Yee, K... 610, 611 Yeh, S...2290 Yeh, WS...1857 Yelin, E... 698, 2048 Yelin, EH.98, 888, 2049, 2109, 2235, 2405, 2421, 2791, 2827 Yen, EY...972 Yentür,...807 Yeo, JG...1308, 1309, 1618 Yeo, L... 389, 2874 Yeremenko, N... 850, 1973 Yerges-Armstrong, L...979 Yerges-Armstrong, LM...2893 Yerramreddy, V...1484 Yesil, N...422 Yeung, RSM...290, 2288, 2903 Yeung, RS...1900 Yildirim Cetin, G. 2157, 2270, 2523, 2750 Yildiz, F... 2523, 2750 Yildiz, M...2610 Yilmaz, H...1119 Yilmaz, N...2769 Yilmaz, S... 2157, 2750 Yilmaz, S... 2750, 2769 Yim, D...2253 Yin, D... 1501, 1502 Yin, F...644 Yin, J...2918 Yin, Y...645 Ying, J... 1294, 1303, 1304, 1825, 1826 Yip, P...606 Yiu, G...2737 Yo, N... 2510, 2925 Yoder, L...2697 Yokoe, I...1906 Yokogawa, N... 1762, 1773 Yokosawa, M...............2352 Yokota, K...39 Yokota, T...145 Yomogida, K...1751 Yoneda, T...1890 Yonemoto, Y... 513, 2133 Yong, W Sr....381 Yongfei, F...381 Yoo, B.571, 614, 702, 703, 812, 847, 2564 Yoo, DH.. 1056, 1241, 1508, 1509, 2025, 2158 Yoo, HJ...2347 Yoo, IS...612, 1458, 2684, 2922 Yoo, KD...1364 Yoo, S...719 Yoo, SJ...612, 1458, 2684, 2922 Yoo, WH...220, 1056, 2262, 2356 Yoon, BY... 1056, 2025 Yoon, BR...1458 Yoon, CH...693 Yoon, MJ...166 Yoshiaki, I...123 Yoshida, H...2345 Yoshida, K...1842, 2029, 2511 Yoshida, K... 338, 2214 Yoshida, K...1035 Yoshida, N...2801 Yoshida, N...2846 Yoshida, S...1123 Yoshida, S...1784 Yoshifuji, H...805, 806, 1260 Yoshihara, R... 2510, 2925 Yoshihide, A...966 Yoshikawa, M...1541, 2691, 2806 Yoshimi, R... 123, 125, 133 Yoshimoto, K...1469, 1958, 2877 Yoshimura, A.986, 1040, 1238, 2977 Yoshioka, R...1461 Yoshioka, Y...471 Yoshizaki, A...748, 756, 1724 Yoshizaki, K...1468 Yoshizawa, T... 646, 1027 You, X...1949 You, Y...539, 1556, 1559 Young, A.. 1406, 1841, 2135, 2810 Young, C... 243, 249 Young, D... 522, 2982 Young, F...2312 Young, J... 1833, 2309 Young, J...2419 Young, J...2354 Young, J...1114 Young, K...2169 Young, K...1470 Young, K...405 Young, KA... 2880, 2891 Young, N...2687 Young, NA. 911, 1204, 1473, 2219, 2686 Young, S. 1798, 2535, 2543, 2930, 2978 Young-McCaughan, S...895 Yourish, J...375 Youssef, H...676 Ytterberg, J... 2183, 2797 Ytterberg, SR...801, 804, 808, 880, 912, 1861, 2851 Yu, A...1024 Yu, A...856 Yu, F... 840, 2456 Yu, H...2354 Yu, M...1246 Yu, M...1587 Yu, N...1716 Yu, N...857 Yu, Q...2174 Yu, S...2114 Yu, SL...374 Yu, W...1046 Yu, Y... 1953, 2782 Yuan, J... 537, 550, 953 344 2014 Program Book
Yuan, JM...1873 Yuasa, M...2738 Yucel, AE...1574 Yudoh, K...780 Yue, Y... 1953, 2782 Yukawa, N... 806, 1260 Yukioka, M...241 Yule, D...529 Yun, H...49, 57, 169, 820, 842, 1546, 1589, 1839, 1849, 1910, 2375, 2388 Yun, J...1509 Yung, R...939 Yunis, E...1716 Yunoue, N...1541, 2691, 2806 Yurdakul, S.2043, 2751, 2752, 2759 Yurkovich, M...2932 Z Zaal, AI...2320 Zaal, KJ...315 Zacarias, A. 691, 695, 1656, 1659, 2194, 2620, 2780 Zacarias Crovato, A...1430 Zacariaz, J...410 Zaccara, E...879, 1675, 1689 Zadeh, A...2635 Zaenker, M...491, 945, 2027 Zagury, JF...3001 Zaid, M...1190 Zajonc, D...2164 Zakem, JM.................1465 Zakhem, G...3006 Zalevsky, J...2725 Zamora, N... 141, 2575 Zamora Medina, MDC...694 Zamout, P...2084 Zampeli, E...1443 Zampogna, G...1966 Zanchetta, JR...2268 Zanchetta, J...916 Zang, Y... 2169, 3004 Zanghi, J...1493 Zanola, A... 4, 15, 1642 Zapantis, E...13 Zarco, P...2586, 2588, 2598 Zarnitsky, C...2536 Zavada, J...129, 136, 851, 1837, 1838, 2371, 2422, 2555, 2580 Zazueta, BM...2469 Zazzetti, F... 887, 2441 Zbarskaya, O...618 Zbehlik, A...1354 Zea, A... 1670, 2622 Zea, A... 1600, 1643 Zécler, J...1269 Zeddou, M...1018 Zeft, A...319 Zeft, AS...1900 Zeggini, E...1900 Zelko, FA...1825 Zen, M...671 Zenasni, F...585 Zeng, L...2818 Zeng, R...1619 Zeng, X... 696, 1949 Zeng, X...181 Zengin, B... 601, 2595 Zeni, S...1708 Zenone, T... 255, 256 Zerbe, N... 1037, 1262 Zerbini, A...882 Zerbini, CAF...493 Zerbini, C... 1795, 2493 Zerbini, CAF...2268 Zernicke, J...2552 Zeuner, RA...485 Zevallos-Miranda, F...1393 Zha, W...1491 Zhai, G. 623, 624, 1124, 1289, 2101 Zhang, C...966 Zhang, F...206 Zhang, F...1202 Zhang, F...1949 Zhang, F... 1595, 1597 Zhang, H...2820 Zhang, H...960 Zhang, HZ...2972 Zhang, J.169, 842, 1148, 1839, 2388 Zhang, L...696 Zhang, L...696 Zhang, M... 1046, 2095 Zhang, M...2313 Zhang, N...1504 Zhang, P... 2303, 2591 Zhang, R... 461, 1181 Zhang, W... 18, 394, 734 Zhang, W...1289 Zhang, W...649 Zhang, W...179 Zhang, X... 150, 665 Zhang, X...687 Zhang, X...2047 Zhang, X... 1009, 1751 Zhang, X...1465 Zhang, X...1949 Zhang, X...1463 Zhang, Y... 244, 1577 Zhang, Y...2582 Zhang, Y...1116 Zhang, Y... 623, 624, 1124, 1289, 2101 Zhang, Y...1727 Zhang, Y... 211, 214, 215 Zhang, Y. 171, 172, 787, 822, 827, 923, 974, 1280, 1286, 1801, 1821, 1874, 1875, 2241, 2960, 2969 Zhang, Z...870 Zhang, Z... 610, 611 Zhang, Z...1620, 1953, 2782 Zhang, ZY...2818 Zhang-Hoover, J...649, 997, 1495 Zhao, L....................1949 Zhao, M...2739 Zhao, M...2674, 2680, 2685 Zhao, M...2591 Zhao, S...1053 Zhao, W... 77, 641 Zhao, X... 1013, 2949 Zhao, X...815 Zhao, Y...1544 Zhao, Z...2613 Zhao, Z...591 Zheng, L... 1463, 2177 Zheng, W...1825 Zhernakova, A...90 Zhi, X... 66, 1803 Zhiyi, Z... 118, 2125 Zhou, B...2835 Zhou, H... 294, 1529 Zhou, H...1653 Zhou, J...2657 Zhou, L...1493 Zhou, Q... 816, 1227 Zhou, S...901 Zhou, T...2582 Zhou, X... 617, 745, 753 Zhou, X...966 Zhou, Y...2517 Zhou, Y...1968 Zhou, Y... 463, 479 Zhu, B...687 Zhu, B...2680 Zhu, H...1606 Zhu, J...1459 Zhu, R...2970 Zhu, S...2850 Zhu, TY... 374, 1582 Zhu, Y...1009 Zhuang, Y...1529 Zhukov, O...407 Zielstorff, M... 649, 2354 Ziemek, J...758, 2713, 2721 Ziesmann, E...1933 Zignego, AL...2855 Zikou, A...1170 Zilberman-Rudenko, J...1212 Zingaro, G...1500 Zingg, M...2248 Zink, A.301, 491, 1154, 1837, 1838, 2902 Zisman, D...1547 Zitnik, R...1513 Ziza, JM... 256, 2779 Zobel, I...1280 Zochling, J...557, 1682, 2419 Zollars, E...1920 Zoma, A... 961, 2646 Zoma, AA...676 Zoratti, M...1566 Zou, H... 617, 2909 Zuber, Z...270 Zubrzycka-Sienkiewicz, A.948, 2826 Zuccoli, G...2228 Zuccotti, GV...142 Zucht, HD...1730 Zuckerman, A...459 Zuckerman, SH...488 Zufferey, F...1884 Zufferey, P... 157, 158 Zuily, S...2866 Zulian, F...1325 Zuliani, F...2855 Zummer, M...365, 421, 583, 956, 2411, 2619 Zuniga, J...1716 Zuo, X...1606 Zuo, Y...6 Zurakowski, D...314 Zwierska, I...1114 Zwingenberg, J...1959 abstract author Index 2014 Program Book 345
Abril, Andy, MD Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease A Barton, Jennifer, MD Rheumatoid Arthritis - Clinical Aspects III: Malignancies, Vaccinations, Pregnancy and Surgery Rheumatoid Arthritis - Clinical Aspects V: Mortality and Other Outcomes Burmester, Gerd, MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy IV: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Cardiovascular and Other Systems Disclosure: AbbVie, 2, 5, 8; BMS, 5, 8; Medimmune, 5; Pfizer Inc, 5, 8; Roche Pharmaceuticals, 5; Sandoz, 8; UCB, 2 Abstract Moderator disclosure Agarwal, Sandeep K., MD, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics II Disclosure: Adheron Therap., 5 Aliprantis, Antonios O., MD, PhD Biology and Pathology of Bone and Joint II: Cartilage Biology and Synovial Activation Allen, Kelli D., PhD Epidemiology/Public Health Anolik, Jennifer H., MD, PhD B cell Biology and Targets in Autoimmune Disease Aranow, Cynthia, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis Ardoin, Stacy P., MD, MS Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Central Nervous System and Other Clinical Aspects Askanase, Anca D., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarkers in Systemic Lupus Erythematosus Disclosure: Exagen, 2 Badley, Elizabeth M., PhD Innovations in Rheumatologic Care Baer, Alan N., MD Sjögren s Syndrome II: Insights into Pathophysiology Disclosure: UptoDate, 7 Baker, Nancy A., MPH, OTR, OTR/L ACR/ARHP Combined Abstract Session: Rehabilitation B Barnabe, Cheryl, MD, MSc Epidemiology and Public Health IV: Rheumatoid Arthritis Pathogenesis Barron, Karyl, MD Pediatric Rheumatology - Pathogenesis and Genetics Behrens, Edward M., MD Innate Immunity and Rheumatic Disease Bingham III, Clifton O., MD Rheumatoid Arthritis - Clinical Aspects II: Remission and De-escalation of Therapy Disclosure: **Missing Disclosure** Rheumatoid Arthritis - Clinical Aspects VI: Impact of Treatment and Other Interventions Disclosure: **Missing Disclosure** Binstadt, Bryce A., MD, PhD ACR/ARHP Combined Abstract Session: Pediatric Rheumatology Boackle, Susan A., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I: Pathways of Inflammation/ Injury Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis Boers, Maarten, MD, MSc, PhD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy III: Innovative Therapeutic Strategies in Rheumatoid Arthritis Disclosure: BMS, 5; GSK, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 5 Bombardieri, Stefano, MD Sjögren s Syndrome I: Clinical Perspectives Disclosure: GlaxoSmithKline LLC, 5 Bookman, Arthur A. M., MD Sjögren s Syndrome I: Clinical Perspectives Bradley, Laurence A., PhD Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes I: Research Perspectives Braun, Juergen, MD Spondyloarthropathies and Psoriatic Arthritis VI - Imaging and Biomarkers Bridges Jr., S. Louis, MD, PhD Rheumatoid Arthritis - Clinical Aspects IV: Promising Biomarkers Brown, Lin, MD Rheumatoid Arthritis - Clinical Aspects III: Malignancies, Vaccinations, Pregnancy and Surgery Bykerk, Vivian P., MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis - Early in Development Cairns, Ewa, PhD Rheumatoid Arthritis - Animal Models I Callahan, Leigh F., PhD Health Disparities/Social Determinants of Health Disclosure: **Missing Disclosure** Carter, John D., MD Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease C Chakravarty, Eliza, MD, MS Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Cardiovascular Disease and Pregancy Disclosure: UCB, 5 Charles, Julia F., MD, PhD Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis Christmann, Romy, MD, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics II Cid, Maria C., MD, PhD Vasculitis I Disclosure: GSK and Novartis, 5 Cidon, Michal, MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus Clancy, Robert M., PhD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis I: Pathways of Inflammation/ Injury Clowse, Megan E. B., MD, MPH Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Novel Therapies for Systemic Lupus Erythematosus Disclosure: UCB, 5 346 2014 Program Book
Cohen, Philip L., MD Innate Immunity and Rheumatic Disease Disclosure: Janssen Pharmaceutica Product, L.P., 2 Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy VI: Biomarkers and Predictors of Rheumatoid Arthritis Disease Response and Outcomes Disclosure: Amgen, 2; Merck Pharmaceuticals, 5; Pfizer Inc, 2 Conaghan, Philip G., MD, PhD Osteoarthritis - Clinical Aspects II: Osteoarthritis Risk Factors and Therapies Disclosure: Abbott Laboratories, 8; Novartis Pharmaceutical Corporation, 5; Pfizer Inc, 5; Roche Pharmaceuticals, 8 Criswell, Lindsey A., MD, MPH Genetics, Genomics and Proteomics II: Genetics of Autoimmunity Disclosure: Amgen-Medimmune, 5; Crescendo Biosciences, 5 Crofford, Leslie J., MD Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes I: Research Perspectives Cronin, Mary E., MD ACR Plenary Session II: Discovery 2014 Cronstein, Bruce N., MD Rheumatoid Arthritis Human Etiology and Pathogenesis I: Mechanisms of Joint Damage Disclosure: Arthritis Foundation, RRF, 6; CanFite Biopharma, 5; Gilead, Astrazeneca, Celgene,, 2; Multiple, 9; Regeneron, BMS, Eli Lilly, 5 Crow, Mary K., MD ACR Plenary Session III: Discovery 2014 Disclosure: Bristol-Myers Squibb, 5; Eisai, 5; GlaxoSmithKline, 5; Lilly, 5; Novo Nordisk, 2; Pfizer-CTI, 2; Takeda, 5 Crowson, Cynthia S., MS Epidemiology and Public Health I: Drug and Vaccine Safety Disclosure: Roche Pharmaceuticals, 2 Curran, Megan, MD Muscle Biology,Myositis and Myopathies D Dalbeth, Nicola, MBChB, MD Metabolic and Crystal Arthropathies II: Mechanisms of Disease Disclosure: AstraZeneca/Ardea, 2, 5; Takeda, 5; Teijin, 8 Dall era, Maria, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Lupus Nephritis Deal, Chad, MD Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Clinical Osteoporosis: Treatment and Safety Disclosure: Amgen, 5; Lilly, 5 Demoruelle, Kristen, MD Rheumatoid Arthritis - Clinical Aspects IV: Promising Biomarkers Denton, Christopher P., MD, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics I: Systemic Sclerosis, Advances in Therapy Disclosure: Actelion Pharmaceuticals US, 2, 5; Bayer, 5; CSL Behring, 2; Genentech and Biogen IDEC Inc., 5; GlaxoSmithKline, 5; Roche Pharmaceuticals, 5; Sanofi-Aventis Pharmaceutical, 5 Deodhar, Atul A., MD Spondyloarthropathies and Psoriatic Arthritis I - Novel Treatments Axial Spondyloarthritis Disclosure: Abbvie, Amgen, Janssen, Novartis, Pfizer, UCB, 5; Amgen, Abbvie, Novartis, Pfizer, UCB, 2 Domsic, Robyn T., MD, MPH Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis Dunlop, Dorothy D., PhD Epidemiology and Public Health III: Gout and Systemic Lupus Erythematosus E Edwards, N. Lawrence, MD Metabolic and Crystal Arthropathies I: Clinical Aspects Disclosure: Cymabay Pharmaceuticals, Crealta Pharmaceuticals, AstraZeneca Pharmaceuticals, Takeda Pharmaceuticals USA, 5 Elkon, Keith B., MD Systemic Lupus Erythematosus - Animal Models Fischer, Aryeh, MD Rheumatoid Arthritis - Clinical Aspects V: Mortality and Other Outcomes Flood, Joseph, MD ACR Plenary Session I: Discovery 2014 Disclosure: **Missing Disclosure** Gabay, Cem, MD, PhD Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Mechanisms of Joint Damage Disclosure: **Missing Disclosure** F G Gaffney, Patrick, MD Genetics, Genomics and Proteomics I: Epigenetic Mechanisms in Autoimmunity Genetics, Genomics and Proteomics II: Genetics of Autoimmunity Genovese, Mark C., MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy III: Innovative Therapeutic Strategies in Rheumatoid Arthritis Disclosure: Abbvie, 2, 5; Amgen, 2, 5; Covagen, 5; Crescendo, 5; Galapgos, 5; Gilead, 5; Lilly, 2, 5; Pfizer Inc, 2, 5; Principia, 5; Salix, 5; Sanofi- Aventis Pharmaceutical, 2, 5 Gensler, Lianne S., MD Spondyloarthropathies and Psoriatic Arthritis I - Novel Treatments Axial Spondyloarthritis Disclosure: AbbVie, 5; Celgene, 5; Janssen Pharmaceutica Product, L.P., 5; UCB, 5 Giles, Jon, MD, MPH Rheumatoid Arthritis - Clinical Aspects I: Cardiovascular Disease Risk Gilkeson, Gary S., MD Systemic Lupus Erythematosus - Human Etiology and Pathogenesis II: Pathogenic Targets, Genetic Variants and Apoptosis Gladman, Dafna D., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Central Nervous System and Other Clinical Aspects Disclosure: BMS, GSK, Eli Lilly, 5; GSK, 2 Goldstein, Barbara, MD, MMSc Rheumatoid Arthritis - Clinical Aspects VII: New Aspects of Monitoring Disease Gordon, Jessica K., MD, MSc Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics I Gravallese, Ellen M., MD Biology and Pathology of Bone and Joint I: Bone Remodeling in Inflammation and Arthritis H Hannan, Marian T., DSc, MPH Clinical Practice/Patient Care Haroon, Nigil, MD, PhD, DM Spondyloarthropathies and Psoriatic Arthritis IV - Clinical Aspects Axial Spondyloarthritis Disclosure: Abbvie, Amgen, Celgene, Janssen and UCB, 5 Hasson, Scott, PT, PhD Exemplary Abstracts Abstract Moderator disclosure 2014 Program Book 347
Abstract Moderator disclosure 348 Hetland, Merete Lund, DMSc, MD, PhD Rheumatoid Arthritis - Clinical Aspects VII: New Aspects of Monitoring Disease Higgs, Jay B., MD Imaging of Rheumatic Diseases: Ultrasound Hill, Catherine, MD, MBBS, MSc Epidemiology and Public Health II: Osteoarthritis, Sedentary Behavior and more Hummers, Laura K., MD, ScM Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics II: Approaches to Cardiac and Vascular Manifestations in Systemic Sclerosis Disclosure: **Missing Disclosure** Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics III: Updates in Predictors and Outcomes in Systemic Sclerosis Husni, M. Elaine, MD, MPH Orthopedics, Low Back Pain and Rehabilitation Disclosure: **Missing Disclosure** Pain: Basic and Clinical Aspects II/Orthopedics, Low Back Pain and Rehabilitation Disclosure: Abbvie, 5; Brigham and Women s hospital, 7; Bristol Myers Squibb, 5; Bristol- Myers Squibb, 5; Celgene, 5; Eli Lilly and Company, 5; Genzyme Corporation, 2; Janssen Pharmaceutica Product, L.P., 5; Novartis Pharmaceutical Corporation, 5; UCB, 5 Hyrich, Kimme, MD, PhD Rheumatoid Arthritis - Clinical Aspects II: Remission and De-escalation of Therapy Disclosure: Abbvie, 5; Pfizer Inc, 5 Imundo, Lisa F., MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Miscellaneous Pediatric Rheumatic Diseases Disclosure: HHoffman-LaRoche, Ltd, 2; UCB, 2 Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Systemic Lupus Erythematosus 2014 Program Book I Inman, Robert D., MD Spondyloarthropathies and Psoriatic Arthritis VI - Imaging and Biomarkers Disclosure: Abbvie, Amgen, Janssen, UCB, Pfizer, 5 Spondyloarthropathies and Psoriatic Arthritis - Pathogenesis, Etiology: From Genes to Cytokines Disclosure: Amgen, Janssen, UCB, Abbvie, Pfizer, 5 Jackson, Shaun, MD PhD B cell Biology and Targets in Autoimmune Disease J Johnson, Sindhu R., MD, PhD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics I: Systemic Sclerosis, Advances in Therapy Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Clinical Aspects and Therapeutics III: Updates in Predictors and Outcomes in Systemic Sclerosis Kalliolias, George D., MD, PhD Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II K Kalunian, Kenneth C., MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Novel Therapies for Systemic Lupus Erythematosus Kamen, Diane L., MD, MS Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Biomarkers in Systemic Lupus Erythematosus Kang, Insoo, MD T cell Biology and Targets in Autoimmune Disease Katz, Jeffrey N., MD, MSc Epidemiology and Public Health II: Osteoarthritis, Sedentary Behavior and more Kavanaugh, Arthur, MD Spondyloarthropathies and Psoriatic Arthritis III - Clinical Aspects Psoriatic Arthritis Disclosure: Abbvie, 2; Amgen, 2; Janssen Pharmaceutica Product, L.P., 2; ucb, 2 Kay, Jonathan, MD Rheumatoid Arthritis Small Molecules, Biologics and Gene Therapy V: Novel Therapies in Rheumatoid Arthritis - Late in Development Disclosure: AbbVie Inc., 2, 5; Amgen, 5; Ardea Biosciences, Inc., 2; AstraZeneca, 5; Bristol- Myers Squibb, 5; Crescendo Bioscience, Inc., 5; Eli Lilly and Company, 2, 5; Epirus Biopharmaceuticals, Inc., 5; Genentech Inc., 5; Hospira, Inc., 5; Janssen Biotech, Inc., 5; PanGenetics, B.V., 5; Pfizer Inc, 5; Roche Laboratories, Inc., 2, 5 Kermani, Tanaz A., MD Vasculitis III Klein-Gitelman, Marisa S., MD, MPH ACR/ARHP Combined Abstract Session: Pediatric Rheumatology Kloppenburg, M., MD, PhD Osteoarthritis Clinical Aspects II: Osteoarthritis Risk Factors and Therapies Disclosure: AbbVie Inc., 9; Arthritis and Rheumatology, 6; Dutch Arthritis Foundation, Pfizer, TI Pharma, 2; Leiden University Medical Center, 3; Pfizer Inc., 8 Koné-Paut, Isabelle, MD Miscellaneous Rheumatic and Inflammatory Diseases Disclosure: Novartis, Pfizer, SOBI, Abbvie, Chugai, 5 Krishnan, Eswar, MD Exemplary Abstracts Disclosure: **Missing Disclosure** L Lafyatis, Robert, MD Systemic Sclerosis, Fibrosing Syndromes and Raynaud s - Pathogenesis, Animal Models and Genetics I Disclosure: Shire, Sanofi, Regeneron, Roche/ Genentech, Biogen, Lycera, Novartis, Celgene, BMS, Amira, Celdara, Celltex, Dart Therapeutics, Idera, Inception, Intermune, Medimmune, Precision Dermatology, Promedior, Zwitter, PRISM, UCB, Actelion, EMD Serono, Ak, 5; Shire, Sanofi/Genzyme, Regeneron, Genentech, UCB, HGS, Precision Dermatology, Biogen, BMS, 2 Landewé, Robert B. M., MD, PhD Spondyloarthropathies and Psoriatic Arthritis V - Clinical Aspects and Treatment Lang, Bianca, MD Muscle Biology,Myositis and Myopathies Disclosure: **Missing Disclosure** Lassere, Marissa N., MD, PhD ACR/ARHP Combined Abstract Session: Epidemiology and Public Health Disclosure: **Missing Disclosure** Lazaro, Deana M., MD Education Lee, Yvonne C., MD, MMSc Epidemiology and Public Health IV: Rheumatoid Arthritis Pathogenesis Disclosure: Cubist, 1; Express Scripts, 1; Forest Laboratories, 2; Merck Pharmaceuticals, 1; Perrigo, 1 Pain: Basic and Clinical Aspects I Disclosure: Cubist, 1; Express Scripts, 1; Forest Laboratories, 2; Merck Pharmaceuticals, 1; Perrigo, 1 Pain: Basic and Clinical Aspects II/Orthopedics, Low Back Pain and Rehabilitation Disclosure: Cubist, 1; Express Scripts, 1; Forest Laboratories, 2; Merck Pharmaceuticals, 1; Perrigo, 1 Levy, Roger A., MD Antiphospholipid Syndrome Disclosure: A ACTION, 2; Inova Diagnostics, Inc., 8 Liao, Katherine, MD, MPH Health Services Research: Risk Assessment and Outcomes of Rheumatic Disease
Lim, S. Sam, MD, MPH Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Complications of Systemic Lupus Erythematosus Disclosure: GlaxoSmithKline, 2 Lo, Grace H., MD, MSc Osteoarthritis - Clinical Aspects I: Imaging in Osteoarthritis Losina, Elena, PhD Health Services Research: Improving Clinical Practice Lotz, Martin K., MD Pain: Basic and Clinical Aspects I Louie, Grant H., MD, MHS Rheumatoid Arthritis - Clinical Aspects I: Cardiovascular Disease Risk M Mahr, Alfred, MD, PhD Vasculitis III Makris, Una, MD Health Services Research: Improving Clinical Practice Malfait, Anne-Marie, MD, PhD Biology and Pathology of Bone and Joint II: Cartilage Biology and Synovial Activation Marder, Wendy, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Cardiovascular Disease and Pregnancy Markenson, Joseph A., MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy V: Novel Therapies in Rheumatoid Arthritis - Late in Development Disclosure: Amgen,BMS,IROKO,Anteres,Celgene, Abbvie,and PFizer, 8 Matsumoto, Alan K., MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy IV: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Cardiovascular and Other Systems Disclosure: Abbott Immunology Pharmaceuticals, 2, 5; Amgen, 2, 5; Ardea Biosciences, 2; Astellas, 2; AstraZeneca, 5; Auxillium, 2; Boehringer Ingelheim, 2; Bristol- Myers Squibb, 2; Cardinal Health, 5; Celgene, 2; Centocor, Inc., 2; Eli Lilly and Company, 2; Genentech and Biogen IDEC Inc., 2; Hoffmann- La Roche, Inc., 2; Horizon, 5; Human Genome Sciences, Inc., 2; Janssen Pharmaceutica Product, L.P., 2; Medac Pharma, 5; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2, 5; Regeneron, 2; Sanofi-Aventis Pharmaceutical, 2; Seikagaku, 2; Takeda, 2; Xoma Corporation, 2 Matteson, Eric L., MD, MPH ACR Plenary Session II: Discovery 2014 Disclosure: Ardea Biosciences, 2; Biogen Idec, 2; Celgene, 2; Centocor, Inc., 2; Genentech and Biogen IDEC Inc., 2; Mesoblast, 2; National Institutes of Health., 2; Novartis Pharmaceutical Corporation, 2; Pfizer Inc, 2; Roche Pharmaceuticals, 2; Sanofi-Aventis Pharmaceutical, 2 Maz, Mehrdad, MD Miscellaneous Rheumatic and Inflammatory Diseases McInnes, Iain B., PhD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy II: Novel Therapies in Rheumatoid Arthritis - Early in Development Disclosure: Elly Lilly, 5; Galapagos, 5; Pfizer Inc, 2, 5; Vertex, 5 McMahon, Maureen A., MD 2014 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship Disclosure: Glaxo Smith Klein, 8 Mease, Philip J., MD Spondyloarthropathies and Psoriatic Arthritis II - Novel Treatments Psoriatic Arthritis Disclosure: AbbVie, 2, 5, 8; Amgen, 2, 5, 8; Bristol-Myers Squibb, 2, 5, 8; Celgene, 2, 5; Covagen, 5; Crescendo, 2, 5, 8; Genentech and Biogen IDEC Inc., 2, 5, 8; Janssen Pharmaceutica Product, L.P., 2, 5, 8; Lilly, 2, 5, 8; Merck Pharmaceuticals, 2, 5; Novartis Pharmaceutical Corporation, 2, 5; Pfizer Inc, 2, 5, 8; UCB, 2, 5, 8 Michaud, Kaleb, PhD Epidemiology and Public Health I: Drug and Vaccine Safety Disclosure: National Data Bank for Rheumatic Diseases, 3; Rheumatology Research Foundation, 2 N Navarro-Millan, Iris, MD Systemic Lupus Erythematosus - Clinical Aspects and Treatment: Complications of Systemic Lupus Erythematosus Newman, Eric D., MD Quality Measures and Quality of Care Nguyen, Uyen Sa D.T., DSc, MPH Epidemiology/Public Health Nigrovic, Peter A., MD Rheumatoid Arthritis - Animal Models I O O Rourke, Kenneth S., MD Education Oddis, Chester V., MD ACR Plenary Session I: Discovery 2014 Disclosure: Genentech and Biogen IDEC Inc., 2 Late-breaking Abstracts Session Disclosure: Genentech and Biogen IDEC Inc., 2 Orange, Dana E., MD, MS Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II P Paget, Stephen A., MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Malignancy and Infection Disclosure: Crescendo bioscience, 5 Pap, Thomas, MD Rheumatoid Arthritis - Animal Models II Passo, Murray H., MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis Disclosure: Pfizer Inc, 2, 5 Perl, Andras, MD, PhD T cell Biology and Targets in Autoimmune Disease Disclosure: Pfizer Inc, 2 Perlman, Harris R., PhD Rheumatoid Arthritis - Animal Models II Disclosure: **Missing Disclosure** Peterfy, Charles, MD, PhD Imaging of Rheumatic Diseases: X-Ray, MRI and CT Disclosure: Amgen, 8; Spire Sciences, Inc., 1, 3, 4 Peterson, Erik J., MD Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes Piva, Sara R., PhD, PT Osteoarthritis Porter, Duncan, MD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy VI: Biomarkers and Predictors of Rheumatoid Arthritis Disease Response and Outcomes Disclosure: Pfizer Inc, 2; Roche Pharmaceuticals, 2 Abstract Moderator disclosure 2014 Program Book 349
Abstract Moderator disclosure 350 R Rauch, Joyce, PhD Antiphospholipid Syndrome Reiff, Andreas, MD Pediatric Rheumatology - Clinical and Therapeutic Aspects: Miscellaneous Pediatric Rheumatic Diseases Reveille, John D., MD Spondyloarthropathies and Psoriatic Arthritis IV - Clinical Aspects Axial Spondyloarthritis Disclosure: Abbvie, 5; Eli Lilly and Company, 5; UCB, 5 Richardson, Jan K., PT, PhD, OCS Osteoarthritis Ritchlin, Christopher T., MD, MPH Spondyloarthropathies and Psoriatic Arthritis Pathogenesis, Etiology: From Genes to Cytokines Disclosure: Abbott Laboratories, 5; Eli Lilly and Company, 5; Janssen Pharmaceutica Product, L.P., 2, 5, Novartis Pharmaceutical Corporation, 5; Regneron, 5 Rose, Jillian A., LCSW Health Disparities/Social Determinants of Health Ruderman, Eric, MD Spondyloarthropathies and Psoriatic Arthritis II - Novel Treatments Psoriatic Arthritis Disclosure: AbbVie, 5; Amgen, 2, 5; Celgene, 2, 5; Lilly, 5; Pfizer Inc, 5 S Salt, Elizabeth G., PhD ACR/ARHP Combined Abstract Session: Epidemiology and Public Health Disclosure: NIH, 2; Pfizer Inc, 5; SmithKLine Beecham, 1 Sawalha, Amr, MD Genetics, Genomics and Proteomics I: Epigenetic Mechanisms in Autoimmunity Schmidt, Wolfgang A., MD Imaging of Rheumatic Diseases: Ultrasound Disclosure: Esaote, 2; General Electric, 2; Siemens, 2 Shadick, Nancy A., MD, MPH Rheumatoid Arthritis - Clinical Aspects VI: Impact of Treatment and Other Interventions Disclosure: ABBVIE, 2; Amgen, 2; BMS, UCB, Crescendo Biosciences, 2; Genentech and Biogen IDEC Inc., 2; Merck Human Health, 3 Shahrara, Shiva, PhD Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis I Sharma, Leena, MD Osteoarthritis - Clinical Aspects I: Imaging in Osteoarthritis 2014 Program Book Shelef, Miriam A., MD, PhD Rheumatoid Arthritis - Human Etiology and Pathogenesis I: Mechanisms of Joint Damage Singer, Nora G., MD Pediatric Rheumatology - Pathogenesis and Genetics Disclosure: Abbott Immunology Pharmaceuticals, 5; Abbott, Lilly, Roche/ Genentech, UCB, HGS, GSK, Celgene, 9; genetech/orche, 5; Merck Human Health, 2; Pfizer, 9 Singh, Jasvinder A., MD, MPH Orthopedics, Low Back Pain and Rehabilitation Disclosure: **Missing Disclosure** Systemic Lupus Erythematosus - Animal Models Sivils, Kathy L., PhD Sjögren s Syndrome II: Insights into Pathophysiology So, Alexander, MD Metabolic and Crystal Arthropathies II: Mechanisms of Disease Disclosure: AstraZeneca, 8 Sokolove, Jeremy, MD Rheumatoid Arthritis - Human Etiology and Pathogenesis II: Citrullination, Autoantibodies and Genes Soriano, Enrique R., MD, MSc Spondyloarthropathies and Psoriatic Arthritis III - Clinical Aspects Psoriatic Arthritis Disclosure: Abbott Immunology Pharmaceuticals, 2, 5; Janssen Pharmaceutica Product, L.P., 2; Roche Pharmaceuticals, 2, 5; UCB, 2, 5 Spiera, Robert F., MD Vasculitis II Disclosure: Roche Genetch, 2 Suter, Lisa, MD Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes II: Clinical Perspectives T Tanner, S. Bobo, MD Osteoporosis and Metabolic Bone Disease - Clinical Aspects and Pathogenesis: Clinical Osteoporosis: Treatment and Safety Disclosure: Amgen, TEVA, Anteres, Celgene,Pfizer,Navitus, UCB, 5; Merck, Lilly, GSK, Pfizer,Novartis, UCB, Astra-Zeneca, 2; Pfizer Antares, BMS, 8 Taylor, Peter C., MD, PhD Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy I: Safety of Biologics and Small Molecules in Rheumatoid Arthritis - Malignancy and Infection Disclosure: UCB, 2; UCB, Pfizer, Merck, AstraZeneca, Abbvie, BMS, NovoNordisk, Celgene, Lilly, 5 Troum, Orrin M, MD Imaging of Rheumatic Diseases: X-Ray, MRI and CT U Unizony, Sebastian, MD Vasculitis II V Van den Bosch, Filip, MD, PhD Spondyloarthropathies and Psoriatic Arthritis V - Clinical Aspects and Treatment Disclosure: Abbvie, Celgene, Merck, Pfizer, UCB, 5; Abbvie, Janssen, Pfizer, UCB, 8 Varga, John, MD ACR Plenary Session III: Discovery 2014 Vazquez-Mellado, Janitzia, MD, PhD Metabolic and Crystal Arthropathies I: Clinical Aspects Vinet, Evelyne, MD Epidemiology and Public Health III: Gout and Systemic Lupus Erythematosus W Wallace, Daniel J., MD 2014 Rheumatology Research Foundation Edmond L. Dubois, MD Memorial Lectureship Warrington, Kenneth J., MD Vasculitis I White, Daniel K., PT, ScD, MSc ACR/ARHP Combined Abstract Session: Rehabilitation Y Yazdany, Jinoos, MD MPH Quality Measures and Quality of Care Yelin, Edward H., PhD Health Services Research: Risk Assessment and Outcomes of Rheumatic Disease Yunus, Muhammad, MD Fibromyalgia, Soft Tissue Disorders, Regional and Specific Clinical Pain Syndromes II: Clinical Perspectives Z Zeft, Andrew S., MD, MPH Pediatric Rheumatology - Clinical and Therapeutic Aspects: Juvenile Idiopathic Arthritis Disclosure: Merck Pharmaceuticals, 1; Novartis, 5; OPKO, 1
Enbrel (etanercept) Brief Summary SEE PACKAGE INSERT FOR FULL PRESCRIBING INFORMATION WARNINGS SERIOUS INFECTIONS AND MALIGNANCIES Patients treated with Enbrel are at increased risk for developing serious infections that may lead to hospitalization or death [see Warnings and Precautions and Adverse Reactions]. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids. Enbrel should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: Active tuberculosis, including reactivation of latent tuberculosis. Patients with tuberculosis have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent tuberculosis before Enbrel use and during therapy. Treatment for latent infection should be initiated prior to Enbrel use. Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric anti-fungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness. Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefits of treatment with Enbrel should be carefully considered prior to initiating therapy in patients with chronic or recurrent infection. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel, including the possible development of tuberculosis in patients who tested negative for latent tuberculosis infection prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, including Enbrel. INDICATIONS AND USAGE Rheumatoid Arthritis Enbrel is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis (RA). Enbrel can be initiated in combination with methotrexate (MTX) or used alone. Polyarticular Juvenile Idiopathic Arthritis Enbrel is indicated for reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis (JIA) in patients ages 2 and older. Psoriatic Arthritis Enbrel is indicated for reducing signs and symptoms, inhibiting the progression of structural damage of active arthritis, and improving physical function in patients with psoriatic arthritis (PsA). Enbrel can be used in combination with methotrexate (MTX) in patients who do not respond adequately to MTX alone. Ankylosing Spondylitis Enbrel is indicated for reducing signs and symptoms in patients with active ankylosing spondylitis (AS). Plaque Psoriasis Enbrel is indicated for the treatment of adult patients (18 years or older) with chronic moderate to severe plaque psoriasis (PsO) who are candidates for systemic therapy or phototherapy. CONTRAINDICATIONS Enbrel should not be administered to patients with sepsis. WARNINGS AND PRECAUTIONS Serious Infections Patients treated with Enbrel are at increased risk for developing serious infections involving various organ systems and sites that may lead to hospitalization or death. Opportunistic infections due to bacterial, mycobacterial, invasive fungal, viral, parasitic, or other opportunistic pathogens including aspergillosis, blastomycosis, candidiasis, coccidioidomycosis, histoplasmosis, legionellosis, listeriosis, pneumocystosis, and tuberculosis have been reported with TNF blockers. Patients have frequently presented with disseminated rather than localized disease. Treatment with Enbrel should not be initiated in patients with an active infection, including clinically important localized infections. Patients greater than 65 years of age, patients with co-morbid conditions, and/or patients taking concomitant immunosuppressants (such as corticosteroids or methotrexate), may be at greater risk of infection. The risks and benefits of treatment should be considered prior to initiating therapy in patients: with chronic or recurrent infection; who have been exposed to tuberculosis; with a history of an opportunistic infection; who have resided or traveled in areas of endemic tuberculosis or endemic mycoses, such as histoplasmosis, coccidioidomycosis, or blastomycosis; or with underlying conditions that may predispose them to infection, such as advanced or poorly controlled diabetes [see Adverse Reactions]. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with Enbrel. Enbrel should be discontinued if a patient develops a serious infection or sepsis. A patient who develops a new infection during treatment with Enbrel should be closely monitored, undergo a prompt and complete diagnostic workup appropriate for an immunocompromised patient, and appropriate antimicrobial therapy should be initiated. Tuberculosis Cases of reactivation of tuberculosis or new tuberculosis infections have been observed in patients receiving Enbrel, including patients who have previously received treatment for latent or active tuberculosis. Data from clinical trials and preclinical studies suggest that the risk of reactivation of latent tuberculosis infection is lower with Enbrel than with TNF-blocking monoclonal antibodies. Nonetheless, postmarketing cases of tuberculosis reactivation have been reported for TNF blockers, including Enbrel. Tuberculosis has developed in patients who tested negative for latent tuberculosis prior to initiation of therapy. Patients should be evaluated for tuberculosis risk factors and tested for latent infection prior to initiating Enbrel and periodically during therapy. Tests for latent tuberculosis infection may be falsely negative while on therapy with Enbrel. Treatment of latent tuberculosis infection prior to therapy with TNF-blocking agents has been shown to reduce the risk of tuberculosis reactivation during therapy. Induration of 5 mm or greater with tuberculin skin testing should be considered a positive test result when assessing if treatment for latent tuberculosis is needed prior to initiating Enbrel, even for patients previously vaccinated with Bacille Calmette-Guerin (BCG). Anti-tuberculosis therapy should also be considered prior to initiation of Enbrel in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent tuberculosis but having risk factors for tuberculosis infection. Consultation with a physician with expertise in the treatment of tuberculosis is recommended to aid in the decision whether initiating antituberculosis therapy is appropriate for an individual patient. Tuberculosis should be strongly considered in patients who develop a new infection during Enbrel treatment, especially in patients who have previously or recently traveled to countries with a high prevalence of tuberculosis, or who have had close contact with a person with active tuberculosis. Invasive Fungal Infections Cases of serious and sometimes fatal fungal infections, including histoplasmosis, have been reported with TNF blockers, including Enbrel. For patients who reside or travel in regions where mycoses are endemic, invasive fungal infection should be suspected if they develop a serious systemic illness. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. When feasible, the decision to administer empiric antifungal therapy in these patients should be made in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of antifungal therapy. In 38 Enbrel clinical trials and 4 cohort studies in all approved indications representing 27,169 patient-years of exposure (17,696 patients) from the United States and Canada, no histoplasmosis infections were reported among patients treated with Enbrel. Neurologic Events Treatment with TNF-blocking agents, including Enbrel, has been associated with rare (< 0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with Enbrel therapy. Prescribers should exercise caution in considering the use of Enbrel in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders [see Adverse Reactions]. Malignancies Lymphomas In the controlled portions of clinical trials of TNF-blocking agents, more cases of lymphoma have been observed among patients receiving a TNF blocker compared to control patients. During the controlled portions of Enbrel trials in adult patients with RA, AS, and PsA, 2 lymphomas were observed among 3306 Enbrel-treated patients versus 0 among 1521 control patients (duration of controlled treatment ranged from 3 to 36 months). Among 6543 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled and uncontrolled portions of clinical trials, representing approximately 12,845 patient-years of therapy, the observed rate of lymphoma was 0.10 cases per 100 patient-years. This was 3-fold higher than the rate of lymphoma expected in the general US population based on the Surveillance, Epidemiology, and End Results (SEER) Database. An increased rate of lymphoma up to several-fold has been reported in the RA patient population, and may be further increased in patients with more severe disease activity. Among 4410 adult PsO patients treated with Enbrel in clinical trials up to 36 months, representing approximately 4278 patient-years of therapy, the observed rate of lymphoma was 0.05 cases per 100 patient-years, which is comparable to the rate in the general population. No cases were observed in Enbrel- or placebo-treated patients during the controlled portions of these trials. Leukemia Cases of acute and chronic leukemia have been reported in association with postmarketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF-blocker therapy, patients with rheumatoid arthritis may be at higher risk (approximately 2-fold) than the general population for the development of leukemia. During the controlled portions of Enbrel trials, 2 cases of leukemia were observed among 5445 (0.06 cases per 100 patient-years) Enbrel-treated patients versus 0 among 2890 (0%) control patients (duration of controlled treatment ranged from 3 to 48 months). Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of leukemia was 0.03 cases per 100 patient-years. Other Malignancies Information is available from 10,953 adult patients with 17,123 patient-years and 696 pediatric patients with 1282 patient-years of experience across 45 Enbrel clinical studies. For malignancies other than lymphoma and non-melanoma skin cancer, there was no difference in exposure-adjusted rates between the Enbrel and control arms in the controlled portions of clinical studies for all indications. Analysis of the malignancy rate in combined controlled and uncontrolled portions of studies has demonstrated that types and rates are similar to what is expected in the general US population based on the SEER database and suggests no increase in rates over time. Whether treatment with Enbrel might influence the development and course of malignancies in adults is unknown. Melanoma and Non-melanoma skin cancer (NMSC) Melanoma and non-melanoma skin cancer has been reported in patients treated with TNF antagonists including etanercept. Among 15,401 patients treated with Enbrel in controlled and open portions of clinical trials representing approximately 23,325 patient-years of therapy, the observed rate of melanoma was 0.043 cases per 100 patient-years. Among 3306 adult rheumatology (RA, PsA, AS) patients treated with Enbrel in controlled clinical trials representing approximately 2669 patient-years of therapy, the observed rate of NMSC was 0.41 cases per 100 patient-years vs 0.37 cases per 100 patient-years among 1521 control-treated patients representing 1077 patient-years. Among 1245 adult psoriasis patients treated with Enbrel in controlled clinical trials, representing approximately 283 patient-years of therapy, the observed rate of NMSC was 3.54 cases per 100 patient-years vs 1.28 cases per 100 patient-years among 720 control-treated patients representing 156 patient-years. Postmarketing cases of Merkel cell carcinoma have been reported very infrequently in patients treated with Enbrel. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients Malignancies, some fatal, have been reported among children, adolescents, and young adults who received treatment with TNF-blocking agents (initiation of therapy at 18 years of age), including Enbrel. Approximately half the cases were lymphomas, including Hodgkin s and non-hodgkin s lymphoma. The other cases represented a variety of different malignancies and included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. The malignancies occurred after a median of 30 months of therapy (range 1 to 84 months). Most of the patients were receiving concomitant immunosuppressants. These cases were reported postmarketing and are derived from a variety of sources, including registries and spontaneous postmarketing reports. In clinical trials of 1140 pediatric patients representing 1927.2 patient-years of therapy, no malignancies, including lymphoma or NMSC, have been reported. Postmarketing Use In global postmarketing adult and pediatric use, lymphoma and other malignancies have been reported. Patients With Heart Failure Two clinical trials evaluating the use of Enbrel in the treatment of heart failure were terminated early due to lack of efficacy. One of these studies suggested higher mortality in Enbrel-treated patients compared to placebo [see Adverse Reactions]. There have been postmarketing reports of worsening of congestive heart failure (CHF), with and without identifiable precipitating factors, in patients taking Enbrel. There have also been rare (< 0.1%) reports of new onset CHF, including CHF in patients without known preexisting cardiovascular disease. Some of these patients have been under 50 years of age. Physicians should exercise caution when using Enbrel in patients who also have heart failure, and monitor patients carefully. Hematologic Events Rare (< 0.1%) reports of pancytopenia, including very rare (< 0.01%) reports of aplastic anemia, some with a fatal outcome, have been reported in patients treated with Enbrel. The causal relationship to Enbrel therapy remains unclear. Although no high-risk group has been identified, caution should be exercised in patients being treated with Enbrel who have a previous history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (eg, persistent fever, bruising, bleeding, pallor) while on Enbrel. Discontinuation of Enbrel therapy should be considered in patients with confirmed significant hematologic abnormalities. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 10 9 /L). While neutropenic, one patient developed cellulitis that resolved with antibiotic therapy. Hepatitis B Reactivation Reactivation of hepatitis B in patients who were previously infected with the hepatitis B virus (HBV) and had received concomitant TNF-blocking agents, including very rare cases (< 0.01%) with Enbrel, has been reported. In some instances, hepatitis B reactivation occurring in conjunction with TNF-blocker therapy has been fatal. The majority of these reports have occurred in patients concomitantly receiving other medications that suppress the immune system, which may also contribute to hepatitis B reactivation. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating TNF-blocker therapy. Prescribers should exercise caution in prescribing TNF blockers in patients previously infected with HBV. Adequate data are not available on the safety or efficacy of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF-blocker therapy to prevent HBV reactivation. Patients previously infected with HBV and require treatment with Enbrel should be closely monitored for clinical and laboratory signs of active HBV infection throughout therapy and for several months following termination of therapy. In patients who develop HBV reactivation, consideration should be given to stopping Enbrel and initiating anti-viral therapy with appropriate supportive treatment. The safety of resuming Enbrel therapy after HBV reactivation is controlled is not known. Therefore, prescribers should weigh the risks and benefits when considering resumption of therapy in this situation. Allergic Reactions Allergic reactions associated with administration of Enbrel during clinical trials have been reported in < 2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of Enbrel should be discontinued immediately and appropriate therapy initiated. Caution: The following components contain dry natural rubber (a derivative of latex), which may cause allergic reactions in individuals sensitive to latex: the needle cover of the prefilled syringe and the needle cover within the needle cap of the SureClick autoinjector. Immunizations Live vaccines should not be given concurrently with Enbrel. It is recommended that pediatric patients, if possible, be brought up-to-date with all immunizations in agreement with current immunization guidelines prior to initiating Enbrel therapy [see Drug Interactions]. Autoimmunity Treatment with Enbrel may result in the formation of autoantibodies [see Adverse Reactions] and, rarely (< 0.1%), in the development of a lupus-like syndrome or autoimmune hepatitis [see Adverse Reactions], which may resolve following withdrawal of Enbrel. If a patient develops symptoms and findings suggestive of a lupus-like syndrome or autoimmune hepatitis following treatment with Enbrel, treatment should be discontinued and the patient should be carefully evaluated. Immunosuppression TNF mediates inflammation and modulates cellular immune responses. TNFblocking agents, including Enbrel, affect host defenses against infections. The effect of TNF inhibition on the development and course of malignancies is not fully understood. In a study of 49 patients with RA treated with Enbrel, there was no evidence of depression of delayed-type hypersensitivity, depression of immunoglobulin levels, or change in enumeration of effector cell populations [see Adverse Reactions]. Use in Wegener s Granulomatosis Patients The use of Enbrel in patients with Wegener s granulomatosis receiving
immunosuppressive agents is not recommended. In a study of patients with Wegener s granulomatosis, the addition of Enbrel to standard therapy (including cyclophosphamide) was associated with a higher incidence of non cutaneous solid malignancies and was not associated with improved clinical outcomes when compared with standard therapy alone [see Drug Interactions]. Use with Anakinra or Abatacept Use of Enbrel with anakinra or abatacept is not recommended [see Drug Interactions]. Use in Patients with Moderate to Severe Alcoholic Hepatitis In a study of 48 hospitalized patients treated with Enbrel or placebo for moderate to severe alcoholic hepatitis, the mortality rate in patients treated with Enbrel was similar to patients treated with placebo at 1 month but significantly higher after 6 months. Physicians should use caution when using Enbrel in patients with moderate to severe alcoholic hepatitis. ADVERSE REACTIONS Across clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events [see Warnings and Precautions]. The most common adverse reactions with Enbrel were infections and injection site reactions. Clinical Studies Experience Adverse Reactions in Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, or Plaque Psoriasis The data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months. In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied. Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice. Infections Infections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents. In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS and PsO patients. Rates of infections in RA and PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza. In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/ Enbrel + MTX-treated groups). In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, septic arthritis, bronchitis, gastroenteritis, pyelonephritis, sepsis, abscess and osteomyelitis. In clinical trials in PsO, serious infections experienced by patients have included, but are not limited to, pneumonia, cellulitis, gastroenteritis, abscess and osteomyelitis. The rate of serious infections was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials. In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the US and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis [see Warnings and Precautions]. Injection Site Reactions In placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 15% of patients treated with Enbrel developed injection site reactions during the first 3 months of treatment. All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation. Injection site reactions generally occurred in the first month and subsequently decreased in frequency. The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given. Immunogenicity Patients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept. Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO. These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel. In PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6% 8.7% and were all non-neutralizing. The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed. The immunogenicity data of Enbrel beyond 120 weeks of exposure are unknown. The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of any antibody positivity in an assay is highly dependent on several factors, including assay sensitivity and specificity, assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of the incidence of antibodies to etanercept with the incidence of antibodies to other products may be misleading. Autoantibodies Patients with RA had serum samples tested for autoantibodies at multiple time points. In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%). The percentage of patients who developed new positive antidouble-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients). The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients. In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients [see Warnings and Precautions]. Other Adverse Reactions Table 3 summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA. Table 3. Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials Placebo Controlled a (Studies I, II, and a Phase 2 Study) Placebo (N = 152) Enbrel c (N = 349) Active Controlled b (Study III) MTX (N = 217) Enbrel c (N = 415) Reaction Percent of Patients Percent of Patients Infection d (total) Upper Respiratory Infections e Non-upper Respiratory Infections Injection Site Reactions Diarrhea Rash Pruritus Pyrexia Urticaria Hypersensitivity 39 30 15 11 9 2 1 1 50 38 21 37 8 3 2 3 86 70 59 18 16 19 5 4 4 1 81 65 54 43 16 13 5 2 2 1 a Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms. b Study duration of 2 years. c Any dose. d Includes bacterial, viral, and fungal infections. e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis, and influenza. In placebo-controlled PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group. Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II. Table 4. Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials (Studies I & II) Placebo (N = 359) Enbrel a (N = 876) Reaction Percent of Patients Infection b (total) Non-upper Respiratory Infections Upper Respiratory Infections c Injection Site Reactions Diarrhea Rash Pruritus Urticaria Hypersensitivity Pyrexia 28 14 17 6 2 1 2 1 27 12 17 15 3 1 1 1 1 a Includes 25 mg SC QW, 25 mg SC BIW, 50 mg SC QW, and 50 mg SC BIW doses. b Includes bacterial, viral and fungal infections. c Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis and sinusitis. Adverse Reactions in Pediatric Patients In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients [see Warnings and Precautions]. The types of infections reported in pediatric patients were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae. In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children. Postmarketing Experience Adverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure. Adverse reactions are listed by body system below: Blood and lymphatic system disorders: Cardiac disorders: Gastrointestinal disorders: General disorders: Hepatobiliary disorders: Immune disorders: Musculoskeletal and connective tissue disorders: Neoplasms benign, malignant, and unspecified: Nervous system disorders: Ocular disorders: Respiratory, thoracic and mediastinal disorders: pancytopenia, anemia, leukopenia, neutropenia, thrombocytopenia, lymphadenopathy, aplastic anemia [see Warnings and Precautions] congestive heart failure [see Warnings and Precautions] inflammatory bowel disease (IBD) angioedema, chest pain autoimmune hepatitis, elevated transaminases, hepatitis B reactivation macrophage activation syndrome, systemic vasculitis lupus-like syndrome melanoma and non-melanoma skin cancers, merkel cell carcinoma [see Warnings and Precautions] convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, paresthesias [see Warnings and Precautions] uveitis, scleritis interstitial lung disease Skin and subcutaneous tissue disorders: cutaneous lupus erythematous, cutaneous vasculitis (including leukocytoclastic vasculitis), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar) Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use. DRUG INTERACTIONS Specific drug interaction studies have not been conducted with Enbrel. Vaccines Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel. The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines. No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel. Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin [see Warnings and Precautions]. Immune-Modulating Biologic Products In a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) [see Warnings and Precautions] and did not result in higher ACR response rates compared to Enbrel alone. The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases). One patient with pulmonary fibrosis and pneumonia died due to respiratory failure. Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 10 9 /L). In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit [see Warnings and Precautions]. Cyclophosphamide The use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended [see Warnings and Precautions]. Sulfasalazine Patients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone. The clinical significance of this observation is unknown. USE IN SPECIFIC POPULATIONS Pregnancy Pregnancy Category B Pregnancy Surveillance Program There is a Pregnancy Surveillance Program that monitors outcomes in women exposed to Enbrel during pregnancy. Women who become pregnant during Enbrel treatment are encouraged to enroll. Patients or their physicians should call 1-800-77-AMGEN (1-800-772-6436) to enroll. Risk Summary There are no adequate and well controlled studies in pregnant women. Based on limited data, etanercept concentration in cord blood at the time of delivery showed that etanercept crossed the placenta in small amounts. Developmental toxicity studies have been performed in rats and rabbits at doses ranging from 60- to 100-fold higher than the human dose and have revealed no evidence of harm to the fetus due to Enbrel. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed. Human Data Three case reports showed that cord blood levels of etanercept at delivery in infants, born to mothers administered etanercept during pregnancy, were between 3 and 32% of the maternal serum level. Nursing Mothers Limited data from published literature show that etanercept is present in low levels in human milk and minimally absorbed by a breastfed infant. Caution should be exercised when Enbrel is administered to a nursing woman. The development and health benefits of breastfeeding should be considered along with the mother s clinical need for Enbrel and any potential adverse effects on the breastfed child from the drug or from the underlying maternal condition. Women who choose to continue Enbrel treatment while nursing are encouraged to enroll in Amgen s Lactation Surveillance Program. Patients or their physicians should call 1-800-77-AMGEN (1-800-772-6436) to enroll. Pediatric Use Enbrel has not been studied in children < 2 years of age with JIA. The safety and efficacy of Enbrel in pediatric patients with PsO have not been studied. Rare (< 0.1%) cases of IBD have been reported in JIA patients receiving Enbrel, which is not effective for the treatment of IBD [see Adverse Reactions (6.2)]. The clinical significance of infant exposure to Enbrel in utero is unknown. The safety of administering live or live-attenuated vaccines in exposed infants is unknown. Risks and benefits should be considered prior to administering live or live-attenuated vaccines to exposed infants. Geriatric Use A total of 480 RA patients ages 65 years or older have been studied in clinical trials. In PsO randomized clinical trials, a total of 138 out of 1965 subjects treated with Enbrel or placebo were age 65 or older. No overall differences in safety or effectiveness were observed between these patients and younger patients, but the number of geriatric PsO subjects is too small to determine whether they respond differently from younger subjects. Because there is a higher incidence of infections in the elderly population in general, caution should be used in treating the elderly. Use in Diabetics There have been reports of hypoglycemia following initiation of Enbrel therapy in patients receiving medication for diabetes, necessitating a reduction in anti-diabetic medication in some of these patients. Rx Only. This brief summary is based on ENBREL prescribing information v.53: 11/2013 2013 Amgen Inc., Thousand Oaks, CA 91320 All rights reserved. US License Number 1132 1998 2013 Immunex Corporation. All rights reserved. US Patent Nos. 7,915,225; 5,605,690; Re. 36,755. For more information please call 1-888-436-2735 or visit www.enbrel.com 60077-R5-V1 V53
IMPORTANT SAFETY INFORMATION SERIOUS INFECTIONS Patients treated with ENBREL (etanercept) are at increased risk for developing serious infections that may lead to hospitalization or death. Most patients who developed these infections were taking concomitant immunosuppressants such as methotrexate or corticosteroids or were predisposed to infection because of their underlying disease. ENBREL should not be initiated in the presence of sepsis, active infections, or allergy to ENBREL or its components. ENBREL should be discontinued if a patient develops a serious infection or sepsis. Reported infections include: 1) Active tuberculosis (TB), including reactivation of latent TB. Patients with TB have frequently presented with disseminated or extrapulmonary disease. Patients should be tested for latent TB before ENBREL use and periodically during therapy. Treatment for latent infection should be initiated prior to ENBREL use, 2) Invasive fungal infections, including histoplasmosis, coccidioidomycosis, candidiasis, aspergillosis, blastomycosis, and pneumocystosis. Patients with histoplasmosis or other invasive fungal infections may present with disseminated, rather than localized, disease. Antigen and antibody testing for histoplasmosis may be negative in some patients with active infection. Empiric antifungal therapy should be considered in patients at risk for invasive fungal infections who develop severe systemic illness, and 3) Bacterial, viral, and other infections due to opportunistic pathogens, including Legionella and Listeria. The risks and benefi ts of treatment with ENBREL should be carefully considered prior to initiating therapy in patients 1) with chronic or recurrent infection, 2) who have been exposed to TB, 3) who have resided or traveled in areas of endemic TB or endemic mycoses, or 4) with underlying conditions that may predispose them to infections such as advanced or poorly controlled diabetes. Patients should be closely monitored for the development of signs and symptoms of infection during and after treatment with ENBREL, including the possible development of TB in patients who tested negative for latent TB prior to initiating therapy. MALIGNANCIES Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with tumor necrosis factor (TNF) blockers, including ENBREL. In adult clinical trials of all TNF blockers, more cases of lymphoma were seen compared to control patients. The risk of lymphoma may be up to several-fold higher in RA and psoriasis patients. The role of TNF blocker therapy in the development of malignancies is unknown. Cases of acute and chronic leukemia have been reported in association with postmarketing TNF blocker use in RA and other indications. The risk of leukemia may be higher in patients with RA (approximately 2-fold) than the general population. Melanoma and non-melanoma skin cancer (NMSC) have been reported in patients treated with TNF blockers, including ENBREL. Periodic skin examinations should be considered for all patients at increased risk for skin cancer. Pediatric Patients In patients who initiated therapy at 18 years of age, approximately half of the reported malignancies were lymphomas (Hodgkin s and non-hodgkin s lymphoma). Other cases included rare malignancies usually associated with immunosuppression and malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants. NEUROLOGIC EVENTS Treatment with TNF-blocking agents, including ENBREL, has been associated with rare (<0.1%) cases of new onset or exacerbation of central nervous system demyelinating disorders, some presenting with mental status changes and some associated with permanent disability, and with peripheral nervous system demyelinating disorders. Cases of transverse myelitis, optic neuritis, multiple sclerosis, Guillain-Barré syndromes, other peripheral demyelinating neuropathies, and new onset or exacerbation of seizure disorders have been reported in postmarketing experience with ENBREL therapy. Prescribers should exercise caution in considering the use of ENBREL in patients with preexisting or recent-onset central or peripheral nervous system demyelinating disorders. CONGESTIVE HEART FAILURE Cases of worsening congestive heart failure (CHF) and, rarely, new-onset cases have been reported in patients taking ENBREL. Caution should be used when using ENBREL in patients with CHF. These patients should be carefully monitored. HEMATOLOGIC EVENTS Rare cases of pancytopenia, including aplastic anemia, some fatal, have been reported. The causal relationship to ENBREL therapy remains unclear. Exercise caution when considering ENBREL in patients who have a previous history of significant hematologic abnormalities. Advise patients to seek immediate medical attention if they develop signs or symptoms of blood dyscrasias or infection. Consider discontinuing ENBREL if significant hematologic abnormalities are confirmed. HEPATITIS B REACTIVATION Reactivation of hepatitis B has been reported in patients who were previously infected with hepatitis B virus (HBV) and received concomitant TNF-blocking agents, including ENBREL. Most reports occurred in patients also taking immunosuppressive agents, which may contribute to hepatitis B reactivation. Exercise caution when considering ENBREL in these patients. ALLERGIC REACTIONS Allergic reactions associated with administration of ENBREL during clinical trials have been reported in <2% of patients. If an anaphylactic reaction or other serious allergic reaction occurs, administration of ENBREL should be discontinued immediately and appropriate therapy initiated. IMMUNIZATIONS Live vaccines should not be administered to patients on ENBREL. JIA patients, if possible, should be brought up to date with all immunizations prior to initiating ENBREL. In patients with exposure to varicella virus, consider temporary discontinuation of ENBREL and prophylactic treatment with Varicella Zoster Immune Globulin. AUTOIMMUNITY Autoantibodies may develop with ENBREL, and rarely lupus-like syndrome or autoimmune hepatitis may occur. These may resolve upon withdrawal of ENBREL. Stop ENBREL if lupus-like syndrome or autoimmune hepatitis develops. WEGENER S GRANULOMATOSIS PATIENTS The use of ENBREL in patients with Wegener s granulomatosis receiving immunosuppressive agents (eg, cyclophosphamide) is not recommended. MODERATE TO SEVERE ALCOHOLIC HEPATITIS Based on a study of patients treated for alcoholic hepatitis, exercise caution when using ENBREL in patients with moderate to severe alcoholic hepatitis. ADVERSE EVENTS The most commonly reported adverse events in RA clinical trials were injection site reaction, infection, and headache. In clinical trials of all other adult indications, adverse events were similar to those reported in RA clinical trials. DRUG INTERACTIONS The use of ENBREL in patients receiving concurrent cyclophosphamide therapy is not recommended. The risk of serious infection may increase with concomitant use of abatacept therapy. Concurrent therapy with ENBREL and anakinra is not recommended. Hypoglycemia has been reported following initiation of ENBREL therapy in patients receiving medication for diabetes, necessitating a reduction in antidiabetic medication in some of these patients. Please see Brief Summary of Prescribing Information on the preceding pages. References: 1. Enbrel (etanercept) Prescribing Information, Immunex Corporation, Thousand Oaks, Calif. November 2013. 2. Data on fi le, Amgen; #1 Biologic for Rheumatologists: May 2, 2014. 3. Data on fi le, Amgen; TEMPO CSR 57599 3 yr Clinical: June 21, 2005. 2014 Amgen Inc., Thousand Oaks, CA 91320 All rights reserved. 81748-R1-V1
In moderately to severely active rheumatoid arthritis (RA) Help patients get back to many of the activities they love ACTIVE MOVEMENT ENABLE EXPLORE SUPPORT ENBREL ENBREL + MTX achieved signifi cant improvements in physical function vs MTX alone as measured by HAQ-DI by Week 2 and out to Year 3 1 * Whether your patients are practicing their putt, spending time with family, or walking their dog, ENBREL has been a symbol of change for your patients with moderate to severe RA. Since 1998, ENBREL was the first and is still the only FDA-approved soluble TNF receptor treatment for appropriate patients. Because of you, ENBREL is the #1 prescribed biologic by rheumatologists today. 2 ENBREL is indicated for reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in patients with moderately to severely active rheumatoid arthritis. ENBREL can be initiated in combination with methotrexate (MTX) or used alone. Prescription ENBREL is administered by injection. Important Safety Considerations: ENBREL suppresses the immune system and has been associated with serious and sometimes fatal infections, including TB and other opportunistic infections. Other serious and sometimes fatal adverse events including malignancies, neurologic events, hematologic events, congestive heart failure, hepatitis B reactivation, allergic reactions, lupus-like syndrome and autoimmune hepatitis have also been reported. ENBREL is contraindicated in patients with sepsis. Please see additional Important Safety Information and Brief Summary on preceding pages. *In the TEMPO study, mean HAQ scores at baseline, week 2, and year 3 were 1.7, 1.5, and 1.1 in the MTX arm (n = 228) and 1.8, 1.3, and 0.8 in the ENBREL + MTX arm (n = 231), respectively. 3 HAQ-DI = Health Assessment Questionnaire-Disability Index. 6-month total of IMS monthly NPA prescription data by rheumatologists. These data include only dispensed total scripts. Visit Booth #943 to see how you can help patients get back to many of the activities they love. Enbrel and the Enbrel logo are registered trademarks of Immunex Corporation.